<SEC-DOCUMENT>0000950170-25-022183.txt : 20250218
<SEC-HEADER>0000950170-25-022183.hdr.sgml : 20250218
<ACCEPTANCE-DATETIME>20250218160041
ACCESSION NUMBER:		0000950170-25-022183
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250218
DATE AS OF CHANGE:		20250218

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IDEAYA Biosciences, Inc.
		CENTRAL INDEX KEY:			0001676725
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				474268251
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38915
		FILM NUMBER:		25634732

	BUSINESS ADDRESS:	
		STREET 1:		5000 SHORELINE CT, SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-443-6209

	MAIL ADDRESS:	
		STREET 1:		5000 SHORELINE CT, SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Ideaya Biosciences, Inc.
		DATE OF NAME CHANGE:	20160609
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>idya-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-02-18T15:50:25.1665+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:idya="http://www.ideayabio.com/20241231">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_43ee73fe-c85b-4774-968b-97b304ed243e" name="dei:DocumentFiscalPeriodFocus" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad">FY</ix:nonNumeric><ix:nonNumeric id="F_fbb4715e-22bc-422d-b405-05d7e185daba" name="dei:AmendmentFlag" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad">false</ix:nonNumeric><ix:nonNumeric id="F_d7f428a3-5053-41f0-ac78-0f76a6fb3fa6" name="dei:EntityCentralIndexKey" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad">0001676725</ix:nonNumeric><ix:nonFraction id="F_a4436390-e215-4734-bf5f-6f7d9bb4566d" name="us-gaap:CommitmentsAndContingencies" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_db1f14ba-60eb-409c-bacf-2ea36e6fcc5e" name="us-gaap:CommitmentsAndContingencies" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_8b9de624-e845-40d7-a9f4-ea6904fdf1d8" name="us-gaap:PreferredStockValue" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_cd9a8961-a8bc-4fc1-85bb-4c42f207ee7a" name="us-gaap:PreferredStockValue" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_d3a6b20e-57d6-4e14-ab8d-c3cbd58018ea" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_cdf3bc15-99ed-4518-8a55-98939fdba747">P3Y</ix:nonNumeric><ix:nonNumeric id="F_338a4ed1-99c5-4700-8268-537e20e71a59" name="us-gaap:IncomeTaxExaminationYearUnderExamination" contextRef="C_8aa43324-1520-4534-b3e2-3a693540bf81">2020 2021</ix:nonNumeric><ix:nonNumeric id="F_3b792965-e65d-4647-ad8c-bd3fa5a2dc19" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad">http://www.ideayabio.com/20241231#PresidentAndCEOMember</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="idya-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="C_80a30d44-ed50-40c7-8625-d5e98146ade0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:PolymeraseThetaProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_83549ecb-3fd7-4381-8f30-327213eea05d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_847c9af8-88d2-45a3-91d6-dcdef630162c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">idya:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a14eee6-aa6b-4583-9df1-42b202346a23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">idya:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8aa43324-1520-4534-b3e2-3a693540bf81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b100a11-1b65-4fec-ae5b-2257a2c5399e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:JuneTwoThousandTwentyThreeSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b87a953-8e4e-49fe-b4a9-0b35f9a89796"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">idya:MarketableSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c32f180-89d2-481f-bc80-3f77774ec456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">idya:SanDiegoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c4ee195-6613-4c9b-a476-c2df7fdfea67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f3cffd2-a88d-4fe5-892e-4adcc9f5604d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_907e44ce-49c7-48a8-8a1c-69ad47564e17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_933a2b9d-bb76-4d41-8fb8-2901d19455b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_93b03c8e-0f95-4d58-98e5-1b1e2a78067e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_94217de2-f133-4daf-80d3-64910929d8e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_949ed0b5-4cbf-4fe7-81a6-07bd20fe4626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9597b477-72d9-47f9-a2b7-c96116c45490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_97b79519-0af1-4cce-8a6d-7911a10985ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99b1a732-1279-4f63-b48e-5b56395593f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c02d070-8681-4a68-9460-90f6386b903f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-11</xbrli:startDate><xbrli:endDate>2024-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c98a97a-3cca-48ab-963f-645540e482b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e083923-3902-4bc7-aab2-a290354677b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f7c598b-0376-4cd2-bb63-5b1ddcee4a82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9fb9e960-f425-4a31-bc47-44faa05f376c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a08caba6-5fab-4b48-87ef-fe485515b9e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0e7b3d3-6830-4717-90ea-44da053262f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1506248-4546-46fa-a347-9575de765d3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a17848a4-d1a9-4d09-81d7-b191ed14dfd6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">idya:IDE161Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a2a77a38-375b-46dc-9258-d476935d3c33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a37ca623-522c-4962-8cd1-5abe0ff44d5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:JuneTwoThousandTwentyThreeSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-26</xbrli:startDate><xbrli:endDate>2023-06-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a46184c7-01af-47bf-9f47-d0c0ccee58f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">idya:OrphanDrugCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a4955acc-673d-4246-a4cf-8af30b6dc428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a59c732f-c597-47eb-9ca9-3046723cbffb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a6ac4859-4009-41b4-9008-d4385ab189d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">idya:ExerciseOfOutstandingOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6b8d688-85fc-4f28-b94d-adbdcc815d1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-11</xbrli:startDate><xbrli:endDate>2024-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a702b98c-ab89-4793-9842-f4bec0373771"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7f64497-48a3-44cb-b7f9-5fe1d8d9ba6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aaa793d3-6d40-4eb9-8f53-fe79e2aded7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aab90a1f-cce5-40ae-a524-bb89f7b2708e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:PolymeraseThetaProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac598710-34a2-44e0-b556-f784f9ca8469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:JanuaryTwoThousandTwentyFourSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad7e94d4-33b0-49a5-8627-5b260d67b825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">idya:MarketableSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af24a5ec-af73-4d40-8dd3-8e064854bf7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b08e0fb2-11c2-4fdf-a73e-de1ec106e6a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b29be823-d29d-4c0b-b5d4-dab37fe7947c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3327635-f95d-42dd-9385-6f262bcd38d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3aa4c0b-2b97-4391-af57-fe7af6cf0a24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:WernerHelicaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b452a75e-2a3a-4c85-bb40-898b74dc7c1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">idya:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b6a91b55-3856-4d3e-9d9b-637a1fc4e083"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b82f7f69-7a56-4486-a04d-d1739f434a83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:JanuaryTwoThousandTwentyFourSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8560028-9f37-4ff3-9028-5dc8f0dd96db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b89b606e-379c-490c-b2c7-22e9477ad049"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:PolymeraseThetaProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b8fed8f4-659e-48c7-a3fc-ebd4660253a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">idya:IDE397Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b9f082f0-76fd-4961-ba1a-7e2f141962b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb829766-4720-419f-b5f8-c1559b6f88fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-11</xbrli:startDate><xbrli:endDate>2024-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bbfe6a5e-e0cb-482c-8581-bd5e60a751e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:PolymeraseThetaProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bccc40ef-fa48-4336-b831-e54faeed80cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">idya:MarketableSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf017758-6c8e-4dda-9992-6c460c60b3fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bfa82174-2a92-4b37-a2b1-ccf30e752c5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0a63604-9e4a-452e-bb59-d9e6b5170b43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-19</xbrli:startDate><xbrli:endDate>2024-01-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c19a5e53-23fd-4bc8-8462-f68e81fbfe48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3f56777-d0fc-4e30-8e99-35ce57f4b839"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c495f084-6fcb-44de-808b-4aa3452ff136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6ec1b34-88b5-403e-b14c-f9db680a80a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">idya:DarovasertibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c78e44e9-bd4d-4c0a-9c26-f931942fb9cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:GlaxoSmithKlineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:GlaxoSmithKlineCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-31</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cbbfcaff-64c2-4dd6-8836-3121afdff880"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cbd0ef8f-ad56-44d1-80e0-5de5d8d02ca8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cdf3bc15-99ed-4518-8a55-98939fdba747"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce651b87-a2ee-4952-8dab-aa55bb0ac861"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cec1db68-704c-4a32-8899-82a806f8d2c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">idya:TenPercentStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d0071ee7-da0d-4c80-b8f6-5f69ef5e6bea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenEmployeeStockPurchasedPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d007c432-86f1-4c3b-b319-24effed11e62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3d4e1da-83e6-4d41-ae1c-a616266a1832"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d400c976-b0bd-479d-aa74-c54c3f83c119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4a29fc9-5039-4781-aa51-00d8294b4d29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d536bcf1-3ec0-423d-b2dc-d793db2570c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">idya:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d61cade1-8268-42c8-9099-392bd152a976"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d65b61cb-05ca-4927-b54c-ce7d454a1633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d83f8cee-a2f2-4da8-9137-df95b7b83290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9ee7a65-84e7-461b-a9c8-917f6e54722e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:GlaxoSmithKlineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:GlaxoSmithKlineCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dcda7935-3db6-4964-a858-3e928a1e6238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:JuneTwoThousandTwentyThreeSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ddead929-9307-4f06-a8f6-718bdcb2cf0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3597327-9749-4444-867d-4367f5e1a23a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:MethionineAdenosylTransferase2AProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e499769c-c222-47df-bc66-3631881a62b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">idya:IDE161Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4f99219-ed58-4929-87e5-a993db32910d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-27</xbrli:startDate><xbrli:endDate>2023-10-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e56ae803-71fa-40b1-b315-c44f63fe65d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-27</xbrli:startDate><xbrli:endDate>2023-10-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6119aea-4ad7-47ff-8b8a-db55f4f12c97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e7bea947-3207-4f35-a41f-9c2f685e82c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e952c7de-9670-4b9f-bbd9-0381bf16deb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">idya:AmgenClinicalTrialCollaborationAndSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ea3cfd25-fdc0-4753-b6b9-64944718b206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb581dfe-56cb-4aba-ab2b-d96ee1f0e219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb642f77-00cf-4cd5-89ff-cfa0d9ff7eb3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb95813f-4508-41df-ad29-f6eec05c524e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ecf66199-2c61-4da1-b565-ea15c7525705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed5d8c12-9405-4e8a-b68f-e1da9fa98a3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ede69319-7140-4c54-a59f-e3cd00f2c014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eed81da0-8376-4317-a154-9ffbb5c0bf7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202307Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef560538-beca-4fdb-9d65-b2ca89c607d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef94d34b-8101-44d9-aaaf-b044579ff409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:WernerHelicaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f02efd60-1311-4d54-8d9c-b1359814dbc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f222b075-c12f-4efc-8c81-d8aea1803872"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f401e5c8-9543-480b-b6f2-bdab7d05f204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">idya:MarketableSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f605952c-8fcd-4667-9e72-9bc4842bb390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f7361d23-b930-48a8-9c1b-395215d1e86d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f7b6061f-1a70-4f34-9ba6-8614c500e543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:PolymeraseThetaProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa12496f-6344-415f-a910-de2c2bf8a71f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_faad213a-ce5c-4221-b05a-2e531d08f6d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fada0950-b58a-4dd1-87c9-557dfba92f85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb60d22d-1a0c-4b09-951c-98eeeac567e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd99da48-95e7-4823-8ffd-92a6ffd6af51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fdb1e9d4-d4ba-4bfd-94d7-8c22b58dd404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">idya:SanDiegoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe0af623-ced9-4295-b11c-a7901893dc7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0178d793-324f-4f5d-8dfc-49181bd85b1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_017e85c7-1596-4e8e-927b-df535668349a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">idya:NovartisInternationalPharmaceuticalsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_028bd853-e9b5-4c40-9a66-731769196cc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04d43460-4b81-4f83-b2c2-02fb5a312c66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_074141e9-fba5-404a-bcf9-4a845e4634ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07e35c69-dfae-4e28-83b9-c956215e0274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09973aa9-24e1-483b-99d4-30e070b0dbb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">idya:SanDiegoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d608e0d-30c3-491f-bc22-755d69e64cfd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:JanuaryTwoThousandTwentyFourSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e321b30-69e1-4345-9158-2fcb284b612c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f3b93c3-2bd5-4282-b511-d0be9bbb12b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f9012d2-5d2a-4197-80a8-0c4c3a822d34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_102bebb9-1268-4e37-90b3-15a47af627e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10a02746-ad3a-4e28-acc1-fe5727c8d092"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:PolymeraseThetaProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10ae45c4-8dc3-46cf-ab6d-19afaee6b186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12cb1aba-8889-4b3b-885c-40f700ad3c6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_14486222-86aa-41d5-ae07-15df550cdd49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_15a7a270-9ab0-4d62-adb8-a1a7678eee8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:WernerHelicaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_15cd159b-08a9-48df-9fa1-4e164fd62eb7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_15e27b17-950f-4151-a11c-4aba882b2d8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16c5e261-e767-47ab-9f42-00c92286082e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1707f298-031e-42ff-92b2-f2d35e7cb9fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1789f966-ab3e-40ee-add4-b0aaa08d3263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_17c6d71a-63e2-457f-a633-102c0bde4eb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1894684a-f942-4a64-aebe-705ed6473dad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:JiangsuHengruiPharmaceuticalsCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1995fabd-2822-4d7e-89fa-1b6e278a87fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">idya:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b2706bd-6978-4079-8e5c-6be28981766b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b812d03-ff06-4951-b51d-8d95f0881594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:WernerHelicaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ce730f4-285b-4d18-9b94-24f179a1f447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d6fd8be-e5c3-430b-802a-c42663370c20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-27</xbrli:startDate><xbrli:endDate>2023-10-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1fa75d5d-f291-49dc-801d-19a66aa48744"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenEmployeeStockPurchasedPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_20bb6b78-a1c7-4e02-a061-317ab08cbf4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">idya:CancerResearchTechnologyAndTheUniversityOfManchesterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21330ef1-face-41aa-bc1a-38277d6baec6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21782d2d-3573-4395-b36b-0736994720e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_21d37c85-a2fd-4198-8e25-eada4c1b7d75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_22bc9e4b-b2f2-40b0-b055-d6de85aad84e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22f94b97-85f3-4e83-8f04-ecf937a7a2ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">idya:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2378e96a-3247-479e-b4ea-c4f63e5949db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_251008aa-c1a9-42db-be7d-38cbbc1eb46d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_26c750d2-8712-4a4a-a85d-4f7f7ab0f46b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">idya:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27155058-a3b3-4ee4-8db6-19df70e8e552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_274ca130-dad0-4940-9133-f4b57bf70ddb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:WernerHelicaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28484219-22fe-452a-8a69-2ba6d3d5a00e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:WernerHelicaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29388ec7-4754-45f1-b582-afffea61e7ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a9cefda-dc1e-448e-84a6-0e063d36ae4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2c520ba2-7d16-4246-9088-3fdbb269e8a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d6346e6-95ec-4b03-b74c-67593a769fb2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:PolymeraseThetaProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2dd15ed5-ab2a-4718-85b6-49aa0ce8c31a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">idya:OrphanDrugCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f75efad-f0a6-4830-98d3-294b93ab7d63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenEmployeeStockPurchasedPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f896155-5fb2-43f9-9ec7-58dfaea72f5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3062bf66-4396-4633-bd29-bdc943e6d16c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:JanuaryTwoThousandTwentyFourSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_32a22686-66c0-40db-bd68-392be3f3a5cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_32b3ac20-7005-4029-b9d5-0a08c767ed8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34b68bd4-0003-4e5f-b72b-00f8d56f232d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3581a854-ba16-4bf6-95e9-e33f2a21a2e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35bd050f-8213-4ced-a848-8e723be54545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">idya:DarovasertibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_364b5f8f-7b5f-4a54-aaa4-7b2b4312be72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_364d998d-4e55-404f-9c33-0ee5538a29c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38305cf8-eda8-4b97-a281-f86a6e1d392c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenEmployeeStockPurchasedPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_39360529-0ce4-46c5-8c50-c0b69f139d2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_398ec6fa-698e-497a-9e5f-057cc0f5a06c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a8b018a-8ca5-43cb-9db1-a7f041be1845"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ccc9e3e-a98d-4222-a5ff-8d2e28d0cadc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:GlaxoSmithKlineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:GlaxoSmithKlineCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d9101a4-e405-4fd0-a74a-a22c9cf099bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ee2b473-d5b8-47db-8a39-4baf5b194b84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:WernerHelicaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3fb19a67-7108-4959-9367-f31f87dee14d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">idya:NovartisInternationalPharmaceuticalsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46c16141-586e-4130-9e68-98823b85e056"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">idya:IDE397Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4731288a-d1d1-4c3c-a9e6-91e059e7e20f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47b63c45-ebe3-463d-93fb-502e26c0ae49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49528f5e-068e-48f2-8643-656de2cfb1fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a13cb3d-0ae0-44c8-9454-9eb34da39ecb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-27</xbrli:startDate><xbrli:endDate>2023-10-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b10675f-0784-4fa3-8f18-4c914a58c0d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e5c2597-3aa6-4e75-84f5-fcacb80ec75e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e9c63ed-b84b-4dfc-8ce5-17fc94afdaed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:MethionineAdenosylTransferase2AProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51602dc5-8082-4af9-ae8d-664968b23422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_528a15eb-04d7-4a77-882c-7e2e6baa5a16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">idya:ExerciseOfOutstandingOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_532df7ab-49f7-48a9-8543-1497d27c4737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5461c8ef-2882-483f-a96f-317b9393242b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">idya:SanDiegoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54da252c-c145-4c7e-bec2-4a22f8d0c57c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">idya:IDE397Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_55abfe7d-fa2b-408a-b618-f79551bab538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_569cd832-f7fb-45d7-b394-66e1bc0a4298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenEmployeeStockPurchasedPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5855cfe6-054d-4ae0-825a-83a7de5b18e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b17504e-2e08-477e-af4e-e1ad86f5b6e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c35883b-fbec-4b73-845e-1e70a57f9790"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenEmployeeStockPurchasedPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c3703b4-36c2-48ab-aecf-7f7732bf9bb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:WernerHelicaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c8611d6-e1c9-4c75-8bf6-e818c66f5c44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:PolymeraseThetaProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d624162-e14b-4855-a956-1c0a4448424b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5eba0c16-aaa5-49a4-a81d-b173390ca4d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">idya:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">idya:NovartisInternationalPharmaceuticalsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_63980d6b-b6c2-4f34-9482-a0495f116793"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-11</xbrli:startDate><xbrli:endDate>2024-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6441389d-ead7-45d4-86d2-83922de15d96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_64b83c21-4b63-4ca9-9683-99ffc7d0f98b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:GlaxoSmithKlineCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_650406b3-09c1-4d06-8663-ecb638592c77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_651623b8-e9c1-43f9-a69b-5797bef8158e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_65d2c0cd-0252-4d0e-99da-bb88696b6445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_66c2d5d4-7a3c-49b2-bb70-145a6e9b9b23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">idya:CancerResearchTechnologyAndTheUniversityOfManchesterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67f86cd1-0ddf-496c-b21f-48df8bce456d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:BiocytogenPharmaceuticalsBeijingCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6814219a-6bb3-46e5-9d9a-753145524259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69622302-21de-4f4c-a022-d0681d928a7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-07-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6d1a7946-4210-4f48-afb5-2b7ec9271ed6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:BiocytogenPharmaceuticalsBeijingCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-31</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6fb07cd5-fdda-41ce-bad2-075ecef88512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_708a6a15-ace7-419f-8285-9848a72f3257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7415a7a9-5eb5-4ea2-a045-27af19dae8bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">idya:CancerResearchTechnologyAndTheUniversityOfManchesterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_750fdeba-ea50-4e26-8f84-b154ebcc6f75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">idya:DarovasertibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75dd9ba0-2dcb-4995-8704-30a44e45f791"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_761fc146-6272-4882-8bef-299b24f35235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76c3f127-e221-49fe-8e31-8bd88d9f4e1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77882837-0da6-42b6-aba3-1ef2b76bff1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77a77c54-3d7a-48df-b0a2-b2ee4ac11347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_77daf335-fcd4-483d-9de0-eb33d3d8f444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:WernerHelicaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_78c6497a-ce12-4868-8a73-d11183d394be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7997c4a8-f7da-4956-8da0-38a0332faec7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79faf38f-faf7-45d1-b17b-062ffafd4097"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a6bc497-f228-42bb-8d0a-1e9eedd0706f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7bcd1912-41e8-4474-944c-32f938bcc64c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7bf84ed4-93bd-4eeb-804c-d7cf2b19b16a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:WernerHelicaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7c297d4e-8a0d-4d1f-80dc-8cc368231084"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">idya:IDE161Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7cd721db-73ca-47d3-bf8c-9b912b4a5d53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d833bb0-e665-4cf0-b5ef-b88aee6558e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>idya:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_GBP"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:unit id="U_Vote"><xbrli:measure>idya:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Obligation"><xbrli:measure>idya:Obligation</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="border-top:1.5pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1200cfad-cff1-4145-842c-cea51b10b7b9" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_285b70d1-d87e-4cf1-8b3b-7c7c47bbf679" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e124e4bd-9c91-49b7-91a5-987714a7b79c" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_004140e2-4543-4bc8-af8f-a883aaf78773" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8a9506ca-447a-448f-b649-a364a07a2dec" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_0fc82ed9-0baf-4f7e-8161-f5a93907033e" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the transition period from </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                  </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                    </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f584e6e7-56a8-416f-861b-b2b24ef5fee5" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-38915</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b54dff6f-f641-4cb6-9cb0-f0a25221dc5b" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDEAYA Biosciences, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"/>
    <td style="width:50%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_166b30c0-6479-46f6-b94f-f91e0f52a9d4" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_73bcaea7-f29a-4541-bd7f-edbece6ff4fd" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">47-4268251</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:25.9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_f237e3fd-b58b-4909-b5bc-f88f25b56955" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5000 Shoreline Court</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;"><ix:nonNumeric id="F_8e84f01b-b9ad-4969-8416-03971b46cfbb" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 300</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_a279b063-94fb-4cda-9d4b-d5baf642fedf" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">South San Francisco</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;"><ix:nonNumeric id="F_5b75be0d-8420-407c-9891-66944910022a" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_350e30f5-edc5-4737-aa7d-9f40ed909cc3" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">94080</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d45c8529-8c01-4f73-90c8-186c799c62e8" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e4281d1c-7843-4519-9bfe-948c48c076a8" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">443-6209</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:45%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7pt;"><ix:nonNumeric id="F_825b8a3d-dc7f-4a19-9fd2-32fd34e202ea" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7pt;"><ix:nonNumeric id="F_632f0200-d783-45f5-b720-6c9f78df6612" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">IDYA</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7pt;"><ix:nonNumeric id="F_cc8978d7-0148-4d84-9b04-a2c37aa4ce4a" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d7bb1e5-07d0-4cda-95d5-4fad36580695" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:EntityWellKnownSeasonedIssuer"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9942d0b1-23ea-4752-a57c-d26e7d31923c" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:EntityVoluntaryFilers"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a4fa99be-00ae-4158-be05-8fb997c75a4f" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:EntityCurrentReportingStatus"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14b67083-f7fa-4d5f-9fd3-6438be94a44c" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:EntityInteractiveDataCurrent"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:55.84%;box-sizing:content-box;"/>
    <td style="width:1.06%;box-sizing:content-box;"/>
    <td style="width:20.1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:2.1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10.8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_7043f743-f057-4e8b-bcf5-fe85364e3bcc" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_06bb90ee-86e6-4b4c-8f42-254cbccaef2e" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_9e98e18e-7581-49e5-a82b-49b24cab7d93" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_0dbfe475-5164-4528-9293-fc50661bd04d" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  </span><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_e6d579de-3a7d-421e-9c51-bfc3feaace9f" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).  </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_bce4e0a2-4af4-43c7-aeb6-ad404aa8644d" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, based on the closing price of the shares of common stock on the Nasdaq Global Select Market on June 28, 2024, the last business day of the registrant&#8217;s most recently completed second fiscal quarter,</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of $35.11 per share, was $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1eee0472-0b80-4228-9ed6-b3baf8d502b9" contextRef="C_398ec6fa-698e-497a-9e5f-057cc0f5a06c" name="dei:EntityPublicFloat" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion. Shares of common stock held by each executive officer and director and by each other person who may be deemed to be an affiliate of the registrant, have been excluded from this computation. The determination of affiliate status for this purpose is not necessarily a conclusive determination for other purposes.</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 14, 2025, the registrant had </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a955d8ca-f5e7-4627-93dc-df1d18624d0d" contextRef="C_21782d2d-3573-4395-b36b-0736994720e9" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">87,537,391</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, $0.0001 par value per share, outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div><ix:nonNumeric id="F_ddd45e5f-f343-4c31-b6b2-8584ed283c2c" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true" continuedAt="F_ddd45e5f-f343-4c31-b6b2-8584ed283c2c_1"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:8pt;font-family:Times New Roman;"><ix:continuation id="F_ddd45e5f-f343-4c31-b6b2-8584ed283c2c_1"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the registrant&#8217;s definitive Proxy Statement relating to the 2025 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.66%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:82.52%;box-sizing:content-box;"/>
    <td style="width:1.04%;box-sizing:content-box;"/>
    <td style="width:5.78%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART I</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:1.5pt;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="margin-left:1.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safty_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART II</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchase of Equity Securities</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_selected_financial_data"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Reserved</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_mda"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_market_risk"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_disagreements_with_accountants"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosures</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign_jur"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART III</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_officers_corp_governan"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_beneficial_ownership"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_related_party_independence"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_accounting_fees"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART IV</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:8.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:8.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:4.3pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTE REGARDING</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORWARD-LOOKING STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts contained in this Form 10-K, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations and future results of anticipated products, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. The forward-looking statements in this Annual Report on Form 10-K are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of risks, uncertainties and assumptions described under the sections in this Annual Report on Form 10-K entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Annual Report on Form 10-K. These forward-looking statements are subject to numerous risks, including, without limitation, the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results and costs of developing our product candidates or any other future product candidates, and conducting preclinical studies and clinical trials, including our darovasertib Phase 2/3 clinical trials, IDE397 Phase 1/2 clinical trials, IDE849 Phase 1 clinical trial, IDE161 Phase 1 clinical trial, IDE705 (GSK101) clinical trial, IDE275 (GSK959) clinical trial, as well as the potential clinical utility and tolerability of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our clinical and regulatory development plans;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results and costs related to the research and development of our precision medicine target and biomarker discovery platform, including costs related to the development of our proprietary libraries and database of tumor genetic information and specific cancer-target dependency networks;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations about the impact of macroeconomic developments, such as health epidemics or pandemics, macro-economic uncertainties, social unrest, geopolitical hostilities, natural disasters or other catastrophic events, on our business, and operations, including clinical trials, manufacturing suppliers and collaborators, and on our results of operations and financial condition;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of companion diagnostics for biomarkers associated with our product candidates and any future product candidates, or the cost of coordinating and/or collaborating with certain diagnostic companies for the manufacture and supply of companion diagnostics;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of and costs involved in obtaining and maintaining regulatory approval (or certification in certain foreign jurisdictions) for any current or future product candidates and companion diagnostics, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the potential market size and size of the potential patient populations for darovasertib, IDE397, IDE849, IDE161, IDE705, IDE275, our other product candidates and any future product candidates, if approved for commercial use;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and amount of any option exercised, milestone, royalty or other payments we may or may not receive pursuant to any current or future collaboration or license agreement, including under the Collaboration, Option and License Agreement with an affiliate of GSK plc, GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED, or GSK;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including our Collaboration, Option and License Agreement with GSK, our Clinical Study Collaboration and Supply Agreement with Gilead Sciences, Inc., our Clinical Trial Collaboration and Supply Agreement with MSD International Business GmbH, our Clinical Trial Collaboration and Supply Agreements with Pfizer Inc., our Clinical Trial Collaboration and Supply Agreement with Amgen </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ii</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inc., our License Agreement with Novartis, our Option and License Agreement with Cancer Research Technologies Ltd. and the University of Manchester, our Option and License Agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd and our License Agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd.;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of commencement of future nonclinical studies and clinical trials and research and development programs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to acquire, discover, develop and advance product candidates into, and successfully complete, clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our intentions and our ability to establish collaborations and/or partnerships;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing or likelihood of regulatory filings and approvals for our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our commercialization, marketing and manufacturing capabilities and expectations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our intentions with respect to the commercialization of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the pricing and reimbursement of our product candidates, if approved;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the implementation of our business model and strategic plans for our business, product candidates and technology platforms, including additional indications for which we may pursue;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates, including the projected terms of patent protection;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our potential involvement in lawsuits in connection with enforcing our intellectual property rights;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our potential involvement in third party interference, opposition, derivation or similar proceedings with respect to our patent rights and other challenges to our patent rights and patent infringement claims;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our ability to obtain additional capital;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our future financial performance; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments and projections relating to our competitors and our industry, including competing therapies and procedures, as well as the competitive position of our product candidates.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not occur or be achieved, and actual results could differ materially from those projected in the forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Principal Risks Associated with Our Business</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business is subject to numerous risks and uncertainties, including those described in Part I, Item 1A, &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. You should carefully consider these risks and uncertainties when investing in our securities. The principal risks and uncertainties affecting our business include the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. We have incurred significant losses since our inception, and we anticipate that we will </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iii</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to incur significant losses for the foreseeable future, which, together with our limited operating history, makes it difficult to assess our future viability;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are early in our development efforts. Our business is dependent on the successful development of our product candidates, future product candidates, and companion diagnostics for biomarkers associated with our product candidates and future product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Collaboration, Option and License Agreement with GSK, if GSK terminates any development program under its collaborations with us, whether as a result of our inability to meet milestones or otherwise, any potential revenue from those collaborations will be significantly reduced or non-existent, and our results of operations and financial condition will be materially and adversely affected;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As an organization, we have never completed a clinical trial, and may be unable to do so for any of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The successful development of targeted therapeutics, including therapeutics involving direct targeting of an oncogenic pathway and synthetic lethality therapeutics, including our portfolio of synthetic lethality small molecule inhibitors, as well as any related diagnostics, is highly uncertain;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preclinical and clinical drug development is a lengthy and expensive process with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of any product candidates, which could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our business, financial condition, results of operations and prospects. Furthermore, results of earlier studies and trials may not be predictive of future trial results;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may find it difficult to enroll patients in our clinical trials given the limited number of patients who have the diseases for which our product candidates are being developed. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.583%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.583%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.803127325319387%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to successfully develop molecular diagnostics for biomarkers that enable patient selection and/or that demonstrate drug-target interaction, or experience significant delays in doing so, we may not realize the full commercial potential of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.583%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.583%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.803127325319387%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third parties for the manufacture of our product candidates for preclinical and clinical development and expect to continue to do so for the foreseeable future. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.583%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.583%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.803127325319387%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant competition in an environment of rapid technological and scientific change, and our failure to effectively compete may prevent us from achieving significant market penetration. Most of our competitors have significantly greater resources than we do and we may not be able to successfully compete;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.583%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.583%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.803127325319387%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to attract and retain senior management and key scientific and commercial personnel, our business may be materially and adversely affected;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.583%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.583%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.803127325319387%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends on our ability to obtain and maintain protection for our intellectual property and our proprietary technologies and to avoid infringing the rights of others; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.583%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.583%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.803127325319387%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our stock price may be volatile and you may not be able to resell shares of our common stock at or above the price you paid. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iv</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. Busi</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ness.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Overview</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are most likely to benefit from these targeted therapies. Our small molecule drug discovery expertise includes discovery and development of small molecule therapeutics. We are applying these capabilities and approach to develop a robust pipeline in precision medicine oncology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pipeline &#8211; Overview and Program Goals</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our clinical pipeline includes six potential first-in-class clinical-stage product candidates &#8211; darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). We own or control all commercial rights of three of these product candidates: darovasertib, IDE397, and IDE161, and own or control all commercial rights outside of greater China for IDE849. We are also advancing several development candidates, including IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor for which we are targeting an investigational new drug, or IND, filing in mid-year 2025; IDE034, a potential first-in-class B7H3/PTK7 topoisomerase-I-inhibitor-payload bispecific antibody drug conjugate, or BsADC, program for which we are targeting an IND filing in the second half of 2025; and IDE251, a potential first-in-class KAT6/7 dual inhibitor program for which we are targeting an IND filing in the second half of 2025. We also have multiple earlier-stage preclinical programs. We have established selective, value-accretive collaborations with leading pharmaceutical companies to support our clinical development activities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img42081897_0.jpg" alt="img42081897_0.jpg" style="width:652px;height:337px;"/></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Pfizer Agreements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Gilead CSCSA</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Hengrui Pharma License Agreement</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to GSK Collaboration, Option and License Agreement</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(5)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Merck CTCSA</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(6)</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Pursuant to Biocytogen Option and License Agreement</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All data and the status of each program are summarized below as of February 1, 2025, unless otherwise noted.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Darovasertib (GNAQ or GNA11 Mutations)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Darovasertib (IDE196) is our most advanced clinical-stage product candidate, which we in-licensed from Novartis. Darovasertib is a potent, selective small molecule inhibitor of protein kinase C, or PKC, which we are developing for genetically defined cancers having GNAQ or GNA11 gene mutations. PKC is a protein kinase that functions downstream of the GTPases GNAQ and GNA11. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have enrolled over 230 patients as of February 7, 2025, and have opened multiple clinical sites, including international sites, in our potential registration-enabling Phase 2/3 clinical trial, designated as IDE196-002. The purpose of the clinical trial is to evaluate darovasertib in combination with crizotinib, Pfizer&#8217;s investigational cMET inhibitor, in patients having metastatic uveal melanoma, or MUM, with human leukocyte antigen-, or HLA-A*02:01 negative, or HLA-A2(-), serotype, as part of a second Clinical Trial Collaboration and Supply Agreement, or the Second Pfizer Agreement, with Pfizer.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we announced the recommendation of a move-forward dose and the completion of the Part 2a dose optimization for the potential registration-enabling Phase 2/3 trial evaluating the combination of darovasertib and crizotinib in the first-line, or 1L, setting in patients with HLA-A2(-) MUM. We are targeting a median progression free survival, or PFS, readout for the Phase 2/3 registration-enabling trial of the darovasertib and crizotinib combination in 1L HLA-A2-negative MUM by year-end 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are enrolling additional HLA-A*02:01 positive, or HLA-A2(+), patients as an independent clinical strategy to address HLA-A2(+) MUM patients, in our ongoing Phase 2 clinical trial, designated as IDE196-001.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are targeting a median overall survival, or OS, readout from our Phase 2 clinical trial, designated as IDE196-001, in approximately 40 1L MUM patients in 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have enrolled 95 patients as of December 31, 2024 in our Phase 2 clinical trial, designated as IDE196-009, evaluating darovasertib as single-agent neoadjuvant and adjuvant therapy in patients having primary uveal melanoma, or UM, with ongoing enrollment and multiple clinical sites open. We are targeting a clinical data update in over 75 patients and regulatory update(s) in the first half of 2025, including vision data in plaque brachytherapy patients.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, we announced interim clinical data from the ongoing Phase 2 Company-sponsored trial and provided a regulatory update on a potential Phase 3 registration-enabling clinical trial in neoadjuvant UM patients based on a Type C meeting held with the U.S. Food and Drug Administration, or FDA. Based on the FDA meeting, we currently project approximately 400 patients will be randomized for treatment with darovasertib in the treatment arm or the control arm, with potential modifications pending further feedback from the FDA. We are currently finalizing the trial protocol for neoadjuvant UM and are targeting to initiate the study in the first half of 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also supporting evaluation of darovasertib as single-agent neoadjuvant and adjuvant therapy in primary UM in an ongoing investigator-sponsored clinical trial, or IST, captioned as &#8220;Neoadjuvant / Adjuvant trial of Darovasertib in Ocular Melanoma,&#8221; or NADOM, led by St. Vincent&#8217;s Hospital in Sydney with the participation of Alfred Health and the Royal Victorian Eye and Ear Hospital in Melbourne. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, we announced interim clinical data from the ongoing investigator-sponsored Phase 2 trial of darovasertib as neoadjuvant/adjuvant treatment in UM, which was included in an oral presentation at the American Society of Clinical Oncology, or ASCO, 2024 Annual Meeting, and preliminary clinical data from our Phase 2 trial of darovasertib for neoadjuvant UM. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE397 (MTAP Gene Deletion)</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDE397, our small molecule methionine adenosyltransferase 2a, or MAT2A, inhibitor, is being evaluated in a Phase 1/2 clinical trial. We have selected a move-forward Phase 2 expansion dose for IDE397 monotherapy, based on adverse event, or AE, profile and preliminary clinical efficacy observed, including multiple partial responses by RECIST 1. We are enrolling patients with an initial focus in MTAP-deletion urothelial cancer, or UC, and non-small cell lung cancer, or NSCLC. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2024, we announced clinical data for the IDE397 Phase 2 monotherapy expansion dose demonstrating preliminary clinical efficacy in heavily pre-treated MTAP-deletion UC and NSCLC patients.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are collaborating with Gilead Sciences, Inc., or Gilead, to clinically evaluate IDE397 in combination with Trodelvy (sacituzumab-govitecan-hziy), Gilead&#8217;s Trop-2 directed antibody drug conjugate, or ADC, in patients having MTAP-deletion UC, in our Phase 1 clinical trial pursuant to a Clinical Study Collaboration and Supply Agreement, or Gilead CSCSA, with Gilead. A first patient was dosed for the Phase 1 trial in June 2024. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, we reported the first preliminary clinical case study of the IDE397 and Trodelvy combination in MTAP-deletion UC at ENA 2024, including a partial response by RECIST 1.1 in a patient case report with a genetic co-alteration of MTAP-deletion and a FGFR3-TACC3 fusion, and rapid and deep first-evaluation molecular responses, or MRs, with ctDNA reduction of greater than 95% observed. The partial response reported at ENA 2024 has confirmed by RECIST 1.1. We are targeting a Phase 1/2 expansion in the first quarter of 2025 and a clinical data update for the Phase 1 trial in MTAP-deletion UC in 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2025, we expanded our clinical study collaboration and entered into a Clinical Study Collaboration and Supply Agreement, or the Second Gilead CSCSA, to evaluate the IDE397 and Trodelvy combination in MTAP-deletion NSCLC.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were collaborating with Amgen to clinically evaluate IDE397 in combination with AMG 193, the Amgen investigational MTA-cooperative PRMT5 inhibitor, in patients having tumors with MTAP-deletion, in an Amgen-sponsored clinical trial pursuant to our Clinical Trial Collaboration and Supply Agreement with Amgen, or the Amgen CTCSA. We and Amgen mutually agreed to wind down the IDE397 and AMG 193 clinical combination study in February 2025 and will not pursue dose expansion.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, we presented a preclinical poster presentation on the antitumor activity by combinatorial inhibition of MAT2A and PRMT5 in MTAP-deleted tumors at the EORTC-NCI-AACR Symposium, or ENA 2024. We are targeting to enable our wholly-owned clinical combination of IDE397 and IDE892, our potential best-in-class MTA-cooperative PRMT5 inhibitor development candidate, in the second half of 2025 in MTAP-deletion NSCLC.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE849 / SHR-4849 (DLL3 ADC program)</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we entered into an exclusive License Agreement, or the Hengrui Pharma License Agreement, with Jiangsu Hengrui Pharmaceuticals Co., Ltd., or Hengrui Pharma, pursuant to which Hengrui Pharma granted us an exclusive worldwide license outside of Greater China for IDE849 (SHR-4849), a potential first-in-class Phase 1 DLL3 TOP1i ADC. Under the terms of the Hengrui Pharma License Agreement, Hengrui Pharma is eligible to receive upfront and milestone payments totaling $1.045 billion, including a $75.0 million upfront fee, up to $200.0 million in development and regulatory milestone payments, plus commercial success-based milestones. Hengrui Pharma is also eligible to receive mid-single to low-double digit royalties on net sales outside of Greater China.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDE849 is currently being evaluated by Hengrui Pharma in an ongoing Phase 1 trial in China in small cell lung cancer, or SCLC, patients. In preliminary results from the trial, 8 out of 11 evaluable patients achieved partial response by RECIST 1.1. In January 2025, Hengrui Pharma selected expansion doses for the Phase 1 trial.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are planning on submitting a U.S. IND for the evaluation of IDE849 as a monotherapy in SCLC in the first half of 2025. We are also targeting to initiate the evaluation of IDE849 in combination with IDE161 and in neuroendocrine tumors, or NETs in the second half of 2025. A clinical data update is targeted in 2025.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE275 / GSK959 (WRN Program - High Microsatellite Instability)</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, GSK initiated a Phase 1 clinical trial for IDE275 (GSK959), following the submission of the GSK-sponsored IND and FDA allowance to proceed with the clinical trial. IDE275 (GSK959) targets the helicase domain of the Werner, or WRN, protein, for patients having tumors with high microsatellite instability, or MSI-High. GSK will lead clinical development for the Werner Helicase program.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We earned a $7.0 million milestone payment for the IND clearance of IDE275 (GSK959) in October 2024. We previously earned an earlier milestone of $3.0 million in October 2023 in connection with IND-enabling studies. We have the potential to earn up to an additional $10.0 million milestone payment upon initiation of Phase 1 clinical dose expansion.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE161 (HRD, including BRCA)</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDE161 is our potential first-in-class, small molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. We are progressing with enrollment of patients having tumors with homologous recombination deficiency, or HRD, into the Phase 1 expansion portion of the Phase 1/2 clinical trial. We selected an initial Phase 1/2 monotherapy expansion dose for IDE161 in endometrial cancer, based on AE profile and preliminary efficacy observed. In parallel, we are also continuing with Phase 1 dose optimization to confirm a move-forward expansion dose for the planned Phase 2 portion of the clinical trial. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, we entered into a Clinical Trial Collaboration and Supply Agreement, or the Merck CTCSA, with Merck (known as MSD outside of the United States and Canada). We are evaluating IDE161 in combination with Merck's anti-PD-1 therapy, KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (pembrolizumab), in patients with MSI-High, and microsatellite stable, or MSS, endometrial cancer. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, the first patient was dosed with IDE161 in combination with KEYTRUDA in the Company-sponsored Phase 1 clinical trial. We are targeting a Phase 1 expansion in MSI-High and MSS endometrial cancer in 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, we presented preclinical results on the IDE161 and ADC combination rationale as a poster at ENA 2024. We are targeting clinical combination(s) of IDE161 with TOP1i-ADCs in solid tumors in 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We received Fast Track Designations from the FDA in September 2023 for IDE161, specifically for the treatment of (i) adult, pretreated, platinum-resistant advanced or metastatic ovarian cancer patients having tumors with BRCA1/2 mutations and (ii) adult, pretreated, advanced or metastatic hormone receptor positive, or HR+, Her2- and BRCA1/2 mutant breast cancer patients.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE705 / GSK101 (Pol Theta Program - HR mutations, including BRCA, or HRD)</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enrollment is ongoing in the Phase 1 dose escalation portion of the GSK-sponsored study. IDE705 (GSK101) targets the helicase domain of the Pol Theta protein for patients having solid tumors with BRCA or other mutations associated with HRD. GSK is leading clinical development of IDE705 (GSK101). GSK is clinically evaluating IDE705(GSK101) in a GSK-sponsored dose escalation trial in combination with niraparib, the GSK small molecule inhibitor of poly-(ADP-ribose) polymerase, or PARP, in solid tumors.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2023, we earned a $7.0 million payment for a milestone based on acceptance of the IND by the FDA. An earlier preclinical development $3.0 million milestone payment from GSK was achieved in August 2022 in connection with ongoing IND-enabling studies to support the evaluation of IDE705 (GSK101). </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have the potential to receive an additional $10.0 million milestone payment upon initiation of Phase 1 clinical dose expansion.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE892 (MTA-cooperative PMRT5 inhibitor)</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we selected IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor, as a development candidate. IDE892 is a potent and selective MTA-cooperative PRMT5 inhibitor with favorable ADME properties, demonstrating robust MTAP deletion-specific pathway suppression and highly durable antitumor activity in combination with IDE397 IND-enabling studies.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to successful completion of ongoing IND-enabling studies for IDE892, we are targeting an IND submission in mid-year 2025. We are also targeting to enable our wholly-owned clinical combination of IDE397 and IDE892 in the second half of 2025 in MTAP-deletion NSCLC.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE034 (B7H3 / PTK7 BsADC program)</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2024, we entered into an Option and License Agreement, or the Biocytogen Option and License Agreement, with Biocytogen Pharmaceuticals (Beijing) Co., Ltd., (Biocytogen, HKEX: 02315), or Biocytogen, pursuant to which Biocytogen granted us an option for an exclusive worldwide license for a potential first-in-class B7H3/PTK7 topoisomerase-I-inhibitor-payload bispecific antibody drug conjugate, or BsADC, program, or the Option.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, we announced the selection of IDE034, a potential first-in-class B7H3/PTK7 topo-I-payload BsADC, as a development candidate and the exercise of the Option. Pursuant to the Biocytogen Option and License Agreement, we paid Biocytogen an upfront fee and exercise fee for the Option totaling $6.5 million.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the successful completion of ongoing IND-enabling studies for IDE034, we are targeting an IND submission in the second half of 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Biocytogen is eligible to receive total potential upfront, option exercise and milestone payments equal an aggregate of $406.5 million, including development and regulatory milestones of $100.0 million.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE251 (KAT6/7 inhibitor)</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we selected IDE251, a potential first-in-class KAT6/7 inhibitor, as a development candidate. IDE251 is an equipotent, highly selective, small molecule dual inhibitor of the lysine acetyltransferase (KAT) 6 and 7, both of which have been shown to support cancer cell survival.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the successful completion of ongoing IND-enabling studies for IDE251, we are targeting an IND submission in the second half of 2025. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Precision Medicine Research Platform</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have established a robust precision medicine research platform with capabilities for identification and validation of new targets and biomarkers, drug discovery and translational biology. Our approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are most likely to benefit from these targeted therapies.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We own or control all commercial rights in programs directed to targets identified in on our new target and biomarker discovery platform.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The drug discovery platform includes our proprietary chemical library, INQUIRE&#153;, structure-based drug design enabled by extensive structural biology and crystallography capabilities, and our proprietary content-based machine-learning engine, HARMONY&#153;, providing effective and efficient molecular design and structure-activity-relationship, or SAR, cycles.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Pipeline Programs (Defined Biomarkers)</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have initiated early preclinical research programs focused on pharmacological inhibition of several new targets, or NTs, for patients with solid tumors characterized by defined biomarkers based on genetic mutations and/or molecular signatures. We believe these research programs have the potential for discovery and development of first-in-class or unique-in-class or best-in-class therapeutics. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We own or control all commercial rights in our next-generation programs.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New Target and Biomarker Discovery Platform</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have invested significantly and continue to invest in capabilities for identification and validation of new precision medicine targets and biomarkers for patient selection. For targets of interest, we advance our research to discover therapeutic drugs and to further qualify relevant biomarkers.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We own or control all commercial rights in programs directed to targets identified in on our new target and biomarker discovery platform.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Scientific Rationale &#8211; Synthetic Lethality</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Synthetic lethality is emerging as an important therapeutic paradigm in the treatment of cancer. It was first defined by Calvin Bridges in 1922 based on the observation that certain combinations of gene mutations resulted in lethality despite the fact the single mutations in either gene were viable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cancer cells often contain genetic changes that lead to alterations in pathways such as DNA repair and metabolism. These changes endow the cancer cells with certain properties such as the ability to replicate by bypassing normal control mechanisms. However, removing these important regulators of cell function may also make these cancer cells more dependent on backup pathways that can then be targeted to achieve a therapeutic effect. We are using small molecule inhibitors against targets in DNA damage repair, or DDR, pathways or in tumor metabolism pathways, that have potentially less effects on the viability of normal cells, but are designed to result in lethality in cancer cells having specific underlying genetic alterations. Cancer targets based on synthetic lethality are ideal for precision medicine approaches because each product candidate inherently has a tumor-associated genetic biomarker to facilitate patient selection.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Darovasertib &#8211; PKC Inhibitor Clinical Candidate in Uveal Melanoma</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Darovasertib (IDE196) is our most advanced clinical-stage product candidate, which we in-licensed from Novartis. Darovasertib is a potent, selective small molecule inhibitor of PKC, which we are developing for genetically defined cancers having GNAQ or GNA11 gene mutations. PKC is a protein kinase that functions downstream of the GTPases GNAQ and GNA11.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have enrolled over 230 patients as of February 7, 2025 and have opened multiple clinical sites, including international sites, in our potential registration-enabling Phase 2/3 clinical trial, designated as IDE196-002. The purpose of the clinical trial is to evaluate darovasertib in combination with crizotinib, Pfizer&#8217;s investigational cMET inhibitor, in patients having MUM with human leukocyte antigen-, or HLA-A*02:01 negative, or HLA-A2(-), serotype, as part of the Second Pfizer Agreement with Pfizer.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we announced the recommendation of a move-forward dose and the completion of the Part 2a dose optimization for the potential registration-enabling Phase 2/3 trial evaluating the combination of darovasertib and crizotinib in the first-line, or 1L setting in patients with HLA-A2(-) MUM.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are enrolling additional HLA-A*02:01 positive, or HLA-A2(+), patients as an independent clinical strategy to address HLA-A2(+) MUM patients, in our ongoing Phase 2 clinical trial, designated as IDE196-001.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are targeting a median OS readout from our Phase 2 clinical trial, designated as IDE196-001, in approximately 40 1L MUM patients in 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also supporting evaluation of darovasertib as single-agent neoadjuvant and adjuvant therapy in primary UM in an IST, captioned as &#8220;Neoadjuvant / Adjuvant trial of Darovasertib in Ocular Melanoma,&#8221; or NADOM, led by St. Vincent&#8217;s Hospital in Sydney with the participation of Alfred Health and the Royal Victorian Eye and Ear Hospital in Melbourne.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have enrolled 95 patients as of December 31, 2024 in our Phase 2 clinical trial, designated as IDE196-009, evaluating darovasertib as single-agent neoadjuvant and adjuvant therapy in patients having primary UM with ongoing enrollment and multiple clinical sites open. In September 2024, we announced interim clinical data from the ongoing Phase 2 Company-sponsored trial and provided a regulatory update on a registrational trial based on a Type C meeting held with the FDA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, we announced interim clinical data from the ongoing investigator-sponsored Phase 2 trial of darovasertib as neoadjuvant/adjuvant treatment in UM, which was included in an oral presentation at the American Society of Clinical Oncology, or ASCO, 2024 Annual Meeting, and preliminary clinical data from our Phase 2 trial of darovasertib for neoadjuvant UM. <br/> <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ASCO 2024 Clinical Data from Investigator-Sponsored Phase 2 Trial</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>In our ongoing investigator-sponsored Phase 2 trial of darovasertib as neoadjuvant/adjuvant treatment in UM, 15 patients planned for enucleation with localized UM were treated twice daily with a 300 mg dose of darovasertib in the Phase 2 investigator-sponsored clinical trial as of May 14, 2024. An initial safety cohort of three patients was treated for one month, and the remaining 12 patients were treated in an expansion cohort for up to six months with darovasertib as neoadjuvant treatment prior to their primary intervention (enucleation, plaque brachytherapy or external beam radiotherapy, or EBRT) across three Australian centers. As of May 14, 2024, 13 patients had completed neoadjuvant darovasertib treatment, 11 patients received adjuvant darovasertib treatment after primary treatment of UM, with five patients completing the planned six months of therapy. As of May 14, 2024, 75% (nine out of 12 enucleation patients) had confirmed preservation of the eye, by conversion from planned enucleation to plaque brachytherapy or EBRT, and approximately 67% (eight out of 12 enucleation patients) observed greater than 30% tumor shrinkage (maximum tumor volume change) after six months. Median tumor shrinkage (maximum tumor volume change) in the 12 enucleation patients was approximately 47% after six months. The darovasertib monotherapy neoadjuvant treatment had a manageable AE profile with no drug-related serious adverse events, or SAEs, observed in the investigator-sponsored Phase 2 trial. Drug-related AEs in the trial were predominantly Grade 1 or Grade 2, and 20% of patients reported at least one drug-related Grade 3 AE.<br/><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company-Sponsored Phase 2 Trial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/> <br/>In September 2024, we provided a clinical data update in which we observed encouraging clinical activity in our Phase 2 Company-sponsored trial. Collectively with the IST trial, the clinical efficacy data from the Phase 2 Company-sponsored trial substantiate clinical proof of concept for the use of darovasertib in the neoadjuvant uveal melanoma setting. The Phase 2 Company-sponsored trial used a data cutoff date of August 15, 2024, with an enrollment cutoff date of May 13, 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>We evaluated 31 enucleation and 18 plaque brachytherapy UM patients who were treated with darovasertib neoadjuvant therapy in the Phase 2 Company-sponsored and IST trials. We observed approximately 59%, or 29 of the 49 total evaluable patients, with greater than or equal to 20% ocular tumor shrinkage by product of diameters and approximately 49%, or 24 of the 49 total evaluable patients, with greater than or equal to 30% ocular tumor shrinkage by product of diameters. We also observed an approximately 61% eye preservation rate in enucleation patients. We found evidence predicting visual preservation by reducing the amount of radiation associated with plaque brachytherapy. We observed a manageable AE profile from the Phase 2 Company-sponsored trial. In 38 patients, 11% of patients experienced a Grade 3 or higher AE and 5% of patients experienced a serious AE rate. We also observed a discontinuation rate of 3%. The most common AEs observed included diarrhea, nausea, vomiting and fatigue.<br/> <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are pursuing a clinical strategy for darovasertib to broadly address UM, alternatively referred to as ocular melanoma, in both primary and metastatic settings. Greater than 90% of UM patients have tumors harboring GNAQ or GNA11 mutations. There are no FDA-approved systemic therapies for primary UM, as either neoadjuvant or adjuvant therapies. There are likewise no FDA-approved therapies for patients having MUM with HLA-A*02:01 negative, or HLA-A2(-), serotype. These primary UM patients and HLA-A2(-) MUM patients collectively represent approximately 85% of all ocular melanoma patients. We have a separate, independent clinical strategy to address HLA-A*02:01 positive, or HLA-A2(+), MUM patients.<br/> </span><span style="color:#008000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The potentially addressable patient population for MUM is estimated to include an annual incidence of approximately 4,500 patients across the United States and Europe. (Neo)Adjuvant UM represents a significant expansion opportunity for darovasertib &#8211; with a potential annual incidence of approximately 12,000 patients aggregate in North America, Europe and Australia.<br/> <br/>We own or control all commercial rights in our darovasertib program in UM, including in MUM and in primary UM, subject to certain economic obligations pursuant to our exclusive, worldwide license to darovasertib with Novartis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Darovasertib &#8211; Potential Registration-Enabling Clinical Trial in First-Line HLA-A2(-) MUM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/> <br/>The protocol of the Phase 2/3 clinical trial design incorporates guidance and feedback following our Type C meeting with the FDA in March 2023. This protocol includes an integrated Phase 2/3 open-label study-in-study design in first-line MUM patients with an HLA-A2(-) serotype. The clinical trial design employs a Phase 2 portion with median progression free survival, or PFS, as a primary endpoint for potential accelerated approval. Patients enrolled in Phase 2 will continue on treatment within the same study and will be considered, together with additional enrolled patients, to evaluate OS as the primary endpoint of the Phase 3 confirmatory portion of the clinical trial to support a potential full approval.<br/> <br/>In the Phase 2 portion of the clinical trial, approximately 230 patients will be randomized on a 2:1 basis for treatment with the darovasertib and crizotinib combination in the treatment arm or investigators choice in the control arm, selected from (a) a combination of ipilimumab (ipi) and nivolumab (nivo), (b) PD1-targeted monotherapy or (c) dacarbazine. The treatment arm of the Phase 2 portion of the clinical trial includes a nested study to confirm the move forward combination dose for the integrated Phase 2/3 clinical trial &#8211; including cohorts at the Phase 2 expansion doses of (i) darovasertib 300 mg BID + crizotinib 200 mg BID and (ii) darovasertib 200 mg BID + crizotinib 200 mg BID. Under the nested study design, patients enrolled in the cohort at the move forward dose will be included within the Phase 2/3 registrational clinical trial. The Phase 2 portion of the clinical trial contemplates an efficacy and safety data set of approximately 200 patients randomized 2:1 with the treatment arm at the move forward dose to support a potential accelerated approval based on median PFS by blinded independent central review, or BICR, as a primary endpoint. Accelerated approval is intended to allow for earlier approval of drugs that treat serious conditions and fill an unmet medical need based on a demonstration of effectiveness on a surrogate endpoint.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patients enrolled in Phase 2 at the selected dose would continue on treatment and be included in the Phase 3 study analysis, supplemented by enrollment of approximately 120 additional patients into the Phase 3 portion of the clinical trial, with 2:1 randomization on the same basis as the Phase 2 portion. Efficacy data from the Phase 3 could support potential full approval using median OS as a primary endpoint.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we announced the recommendation of a move-forward dose and the completion of the Part 2a dose optimization for the potential registration-enabling Phase 2/3 trial evaluating the combination of darovasertib and crizotinib in the 1L setting in patients with HLA-A2(-) MUM.<br/> <br/>In May 2023, we expanded our relationship with Pfizer to support the Phase 2/3 registrational trial to evaluate darovasertib and crizotinib as a combination therapy in MUM by entering into Amendment No. 1 to the Second Pfizer Agreement. Under Amendment No. 1 to the Second Pfizer Agreement, Pfizer will provide us with a first defined quantity of crizotinib at no cost, as well as an additional second defined quantity of crizotinib at a lump-sum cost.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prevalence of HLA-A2*02:01 Negative Serotype in MUM</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data from darovasertib clinical trials in MUM demonstrate that approximately 70% of MUM patients with known HLA-A*02:01, or HLA-A2 status were HLA-A2(-). As reported at ESMO 2023, the HLA-A2 status was known in subsets of patients enrolled in clinical trials evaluating darovasertib. Prevalence of HLA-A2(+) and HLA-A2(-) in MUM patients was determined from a first data set of n=149 MUM patients treated with darovasertib as monotherapy or in a combination arm of a clinical trial, and separately in a second data set of n=118 MUM patients treated with the darovasertib and crizotinib combination. These data include 102 of 149 (68%) of patients in the all-treatment subset and 81 of 118 (69%) patients in the darovasertib and crizotinib combination treatment subset.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Darovasertib &#8211; Strategy for HLA-A*02:01 Positive MUM<br/> <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on clinical data from the Phase 2 clinical trial evaluating darovasertib and crizotinib in MUM as reported at ESMO 2023, and based on the darovasertib mechanism of action, we anticipate darovasertib will have clinical activity independent of HLA-A2 status in GNAQ/11-mutation cancers.<br/> </span><span style="color:#008000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are enrolling additional HLA-A2(+) MUM patients as an independent clinical strategy to address HLA-A2(+) MUM patients, in our ongoing Phase 2 clinical trial, designated as IDE196-001. This strategy demonstrates our commitment to fully address the high unmet medical need in MUM. Such clinical trial data from darovasertib and crizotinib combination treatment in HLA-A2(+) MUM could support publication and potential inclusion in NCCN Clinical Practice Guidelines in Oncology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Darovasertib &#8211; Orphan Drug Designation in UM and Fast Track Designation in MUM<br/> <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2022, the FDA designated darovasertib as an Orphan Drug in UM, including primary and metastatic disease. Under an Orphan Drug designation, darovasertib may be entitled to certain tax credits for qualifying clinical trial expenses, exemption from certain user fees and, subject to FDA approval of a New Drug Application, or NDA, for darovasertib in UM, eligibility for seven years of statutory marketing exclusivity during which the FDA is prohibited from approving a subsequent same drug for the same rare disease or condition except in limited circumstances, such as a subsequent drug that demonstrates clinical superiority. As an FDA-designated Orphan Drug, darovasertib may also be excluded from certain mandatory price negotiation provisions of the 2022 Inflation Reduction Act, if approved for a single indication only.<br/> <br/>In November 2022, the FDA granted Fast Track designation to our development program investigating darovasertib in combination with crizotinib in adult patients being treated for MUM. The Fast Track designation makes our darovasertib and crizotinib development program eligible for various expedited regulatory review processes, including generally more frequent FDA interactions, such as meetings and written communications, potential eligibility for rolling review of a future NDA and potential accelerated approval and priority review of an NDA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Darovasertib &#8211; Phase 2 Trials in Neoadjuvant and Adjuvant Therapy in Uveal Melanoma (UM)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are clinically evaluating the potential for darovasertib as neoadjuvant or adjuvant therapy, or both, also referred to as (neo)adjuvant therapy, in primary, non-metastatic UM patients. We previously reported preliminary clinical data in the neoadjuvant setting showing evidence of anti-tumor activity that we believe supports further clinical evaluation of darovasertib to determine its potential as a neoadjuvant therapy to either save the eye by avoiding enucleation, or to reduce the tumor thickness in the eye, enabling treatment with less radiation to preserve vision, and as an adjuvant therapy, to potentially extend relapse free survival. <br/> <br/>We have enrolled 95 patients as of December 31, 2024 in our Phase 2 clinical trial, designated as IDE196-009, evaluating darovasertib as single-agent neoadjuvant and adjuvant therapy in patients having primary UM with ongoing enrollment and multiple clinical sites open. The purpose of the clinical trial is to evaluate single-agent darovasertib as neoadjuvant treatment of primary UM prior to primary interventional treatment of enucleation or radiation therapy and also as adjuvant therapy following the primary treatment. An amendment to the study protocol was submitted to the FDA in July 2024 to enable dosing of darovasertib therapy up to 12 months.<br/><br/>We are additionally supporting evaluation of darovasertib as (neo)adjuvant therapy in primary UM in the ongoing NADOM IST. Pursuant to an as-amended protocol for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the NADOM study, UM patients who would otherwise undergo enucleation are instead treated with single agent darovasertib as neoadjuvant treatment for up to six months or maximum benefit. This reflects an increase in potential treatment duration versus the initial approach of one month neoadjuvant therapy, following which these patients will undergo a primary interventional treatment. Patients will subsequently be treated with darovasertib for up to six months as follow-up adjuvant therapy after the primary interventional treatment.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Darovasertib &#8211; Potential Registration-Enabling Clinical Trial in Neoadjuvant UM</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Type C meeting was held with the FDA for the clinical trial design of a potential Phase 3 registration-enabling clinical trial in neoadjuvant UM patients. For the potential Phase 3 clinical trial, we currently project approximately 400 patients will be randomized for treatment with darovasertib in the treatment arm or the control arm, with potential modifications pending further feedback from the FDA. Based on the currently targeted clinical trial design, there will be two cohorts enrolled, including plaque brachytherapy eligible UM patients and enucleation eligible UM patients. For the plaque brachytherapy cohort, the randomization will be darovasertib followed by plaque brachytherapy versus plaque brachytherapy alone. For the enucleation cohort, the randomization will be with or without darovasertib as neoadjuvant therapy. <br/> <br/>Based on FDA guidance and information provided in our FDA briefing book, we expect that time to vision loss will be the primary endpoint for plaque brachytherapy UM patients. Eye preservation rate will be the primary endpoint for enucleation UM patients for the target registrational trial design in neoadjuvant UM. The FDA briefing book noted an objective to exceed lower bound of 10% eye preservation rate with a 95% confidence interval for this primary endpoint. No detriment to Event-Free-Survival, or EFS, in the treatment arms will be a secondary endpoint.<br/> <br/>Pending ongoing discussions with the FDA, we are evaluating potential surrogate and composite endpoints to support earlier approval scenarios. The registrational study will enroll UM patients with a high risk for metastatic disease. Based on the FDA meeting, there is a potential for consideration of a broad indication label in neoadjuvant UM for subjects with low, intermediate and high risk for metastatic disease. We anticipate approximately two years of data maturity to initial readout for no detriment to EFS in the treatment arms for this high-risk patient population based on preliminary projections. 300mg BID darovasertib was noted in the FDA briefing book as the move-forward dose for the registrational trial. We are currently finalizing the trial protocol and are targeting to initiate the study in the first half of 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE397</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8211; MAT2A Inhibitor in Tumors with MTAP Deletion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDE397 is a clinical-stage, potent, selective small molecule inhibitor of methionine adenosyltransferase 2a, or MAT2A, which we are developing for patients having solid tumors with MTAP deletion. The prevalence of methylthioadenosine phosphorylase, or MTAP, gene deletion is estimated to be approximately 15% of human solid tumors. MTAP deletion in patient tumors is identified by commercial or institutional next generation sequencing, or NGS, panels or by MTAP immunohistochemistry, or IHC, assay with confirmation by NGS.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MTAP-null cells lack the ability to metabolize 5-methylthioadenosine, or MTA, which is an essential step in a biochemical pathway involved in salvaging the metabolite S-adenosyl methionine, or SAM. Increased levels of MTA partially inhibit the methyltransferase PRMT5 for which SAM is the methyl-donor substrate for methylation of various proteins. This partial inhibition of PRMT5 by increased levels of MTA renders MTAP-null cells more dependent on the activity of MAT2A, an enzyme that is responsible for the synthesis of SAM. Because of this enhanced dependence, loss of MTAP results in synthetic lethality when MAT2A is pharmacologically inhibited.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are enrolling patients into a Phase 1/2 clinical trial, designated as IDE397-001, to evaluate IDE397 for patients having certain tumors with MTAP gene deletion. We are proceeding with enrollment of MTAP-deletion patients into a monotherapy Phase 1/2 expansion cohort with an initial focus on high priority solid tumor types, including UC and NSCLC. We have selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion UC and NSCLC, based on AE profile and preliminary clinical efficacy observed, including multiple partial responses by RECIST 1.1.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company-Sponsored Phase 1/2 Monotherapy Expansion in MTAP-Deletion Urothelial and Lung Cancer</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2024, we announced clinical data for the IDE397 Phase 1/2 monotherapy expansion dose demonstrating preliminary clinical efficacy in heavily pre-treated MTAP-deletion UC and NSCLC patients. The patients evaluated had a median of two prior lines of therapy, ranging from one to seven prior lines of treatment. The reported Phase 1/2 clinical data were based on 18 evaluable MTAP-deletion patients, including seven UC patients, four adenocarcinoma squamous NSCLC patients, and seven squamous NSCLC patients at the expansion dose of 30 mg once-a-day, or QD, of IDE397. In the interim update for 18 evaluable patients, with a data analysis cutoff date of June 21, 2024, we reported an overall response rate of approximately 39% (one complete response and six partial responses by RECIST 1.1 evaluation), which included two unconfirmed partial responses (one UC patient that had a 100% tumor reduction in the target lesion at the last CT-scan assessment and one adenocarcinoma squamous NSCLC patient which were both confirmed in our October 2024 update). We also observed a disease control rate of 94%, including one complete response, six partial responses and ten stable disease by RECIST 1.1 evaluation. In addition, we observed tumor shrinkage in 14 of the 18 evaluable patients. 11 of the evaluable patients are still on treatment and five of the seven responses by RECIST 1.1 evaluation remain in response. We also reported a ctDNA molecular response, or MR, rate of 81%, representing 13 of 16 reportable patients with 50% or greater ctDNA reduction (several quality control failures of patient samples precluded the other patients from MR analysis).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regarding safety data, we also reported a favorable AE profile at the 30 mg QD expansion dose. Approximately 5.6% of patients experienced a Grade 3 or higher drug-related AE at the 30 mg QD dose, represented by one instance of Grade 3 asthenia, and no drug-related SAEs were observed. We observed no drug-related AEs leading to discontinuations, and one non-evaluable patient discontinued due to rapid clinical progression of cancer fatigue and drug-unrelated AEs in the first cycle of treatment. We anticipate that the favorable AE profile and dosing convenience of a 30 mg QD tablet has the potential to enable long-term dosing and combination development.<br/> <br/>In October 2024, we announced Phase 1 expansion data for IDE397 in MTAP-deletion UC and NSCLC patients in a late breaker abstract oral presentation at the 36th edition of the EORTC-NCI-AACR Symposium, or ENA 2024, in Barcelona, Spain. The patients evaluated had a median of two to three prior lines of therapy, ranging from one to seven prior lines of treatment. The reported clinical data were based on 27 evaluable MTAP-deletion patients, including 10 UC patients, nine adenocarcinoma NSCLC patients, and eight squamous NSCLC patients at the expansion dose of 30 mg QD of IDE397. In the update of 27 evaluable patients, with a data analysis cutoff date of August 22, 2024, we reported an overall response rate of approximately 33% (one complete response and eight partial responses by RECIST 1.1 evaluation). Nine of nine responses were confirmed by RECIST 1.1, including four UC patients, of which one was a complete response, three squamous NSCLC patients, and two adenocarcinoma NSCLC patients. Two patients were confirmed after the data cutoff date. We also observed an overall response rate by RECIST 1.1 evaluation by solid tumor type. For MTAP-deletion UC patients, the confirmed overall response rate was 40%, or 4 out of 10 patients, for MTAP-deletion squamous NSCLC patients, the confirmed overall response rate was approximately 38%, or 3 out of 8 patients, and for MTAP-deletion adenocarcinoma NSCLC patients, the confirmed overall response rate was approximately 22%, or 2 out of 9 patients. In addition, we observed a disease control rate of 93%, including one complete response, eight partial responses and 16 stable disease by RECIST 1.1 evaluation, reflecting 25 of 27 evaluable patients with stable disease or better. Of the 27 evaluable patients, 15 are still on treatment. The median duration of treatment has not been reached and is greater than 6.2 months. The median time to response is approximately 2.7 months. The median duration of response and median progression free survival data is still immature. Three UC patients were on treatment greater than 250 days, four squamous NSCLC patients were on treatment greater than 200 days, and three adenocarcinoma NSCLC patients were on treatment greater than 200 days. We also reported a ctDNA MR rate of 81%, representing 17 of 21 reportable patients with 50% or greater ctDNA reduction and approximately 33%, representing 7 of 21 reportable patients, with a deep 90% or greater ctDNA reduction (several quality control failures of patient samples precluded the other patients from MR analysis). All 17 MRs were rapid occurring at the first ctDNA sample analysis.<br/> <br/>We continued to report favorable AE profile at the 30 mg QD expansion dose. Approximately 18% of patients experienced a Grade 3 or higher drug-related AE at the 30 mg QD dose, and no drug-related SAEs were observed. No drug-related AEs leading to discontinuations were observed. We anticipate that the favorable AE profile and dosing convenience of a 30 mg QD tablet has the potential to enable long-term dosing and combination development, including with MTA-cooperative PRMT5 inhibitors and topoisomerase payload ADCs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are collaborating with Gilead to clinically evaluate IDE397 and Trodelvy (sacituzumab-govitecan-hziy), Gilead&#8217;s Trop-2 directed ADC combination, in patients having MTAP-deletion UC, in our Phase 1 clinical trial pursuant to the Gilead CSCSA, with Gilead.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A first patient was dosed for the Phase 1 trial in June 2024. The Phase 1 clinical trial is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of IDE397 in combination with Trodelvy in MTAP-deletion UC patients (NCT04794699). Pursuant to the Gilead CSCSA, we and Gilead retain the commercial rights to our respective compounds, including with respect to use as a monotherapy or combination agent. We are the study sponsor and Gilead will provide the supply of Trodelvy. IDE397 monotherapy or in combination with Trodelvy has not been approved by any regulatory agency, and the efficacy and safety of this combination has not been established.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, we reported the first preliminary clinical case study of the IDE397 and Trodelvy combination in MTAP-deletion UC at ENA 2024, including a partial response by RECIST 1.1 in a patient case report with a genetic co-alteration of MTAP-deletion and a FGFR3-TACC3 fusion, and rapid and deep first-evaluation MRs with ctDNA reduction of greater than 95% observed. The partial response reported at ENA 2024 has confirmed by RECIST 1.1. We are targeting a Phase 1/2 expansion in the first quarter of 2025 and a clinical data update for the Phase 1 trial in MTAP-deletion UC in 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2025, we expanded our clinical study collaboration and entered into the Second Gilead CSCSA to evaluate the IDE397 and Trodelvy combination in MTAP-deletion NSCLC.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were collaborating with Amgen to clinically evaluate IDE397 in combination with AMG 193, the Amgen investigational MTA-cooperative PRMT5 inhibitor, in patients having tumors with MTAP deletion, in an Amgen-sponsored clinical trial pursuant to the Amgen CTCSA. We and Amgen mutually agreed to wind down the IDE397 and AMG 193 clinical combination study in February 2025 and will not pursue dose expansion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, we presented a preclinical poster presentation on the antitumor activity by combinatorial inhibition of MAT2A and PRMT5 in MTAP-deleted tumors at the EORTC-NCI-AACR Symposium, or ENA 2024. We are targeting to enable our wholly-owned clinical combination of IDE397 and IDE892, our potential best-in-class MTA-cooperative PRMT5 inhibitor development candidate, in the second half of 2025 in MTAP-deletion NSCLC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are currently no FDA-approved therapies for patients with MTAP-deletion solid tumors, highlighting the unmet medical need. The priority MTAP-deletion solid tumor types for the IDE397 Phase 1/2 monotherapy program are UC and NSCLC. MTAP-deletion prevalence has been reported at over 15% in NSCLC and over 25% in UC, based on The Cancer Genome Atlas, or TCGA, database. We estimate that the MTAP-deletion annual incidence in the United States in NSCLC and UC is approximately 48,000 patients, based on the 2024 Surveillance, Epidemiology, and End Results database. In addition, there are several potential expansion MTAP-deletion solid tumor types that are also being considered for monotherapy and combination development, including pancreatic, head and neck, gastric, and squamous esophageal cancer, among others. Based on the TCGA database, MTAP-deletion prevalence in pancreatic, head and neck, gastric and squamous esophageal cancer represents an aggregate U.S. annual incidence of approximately 27,000 patients.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We own all rights, title, and interest in and to IDE397 and IDE892, including all worldwide commercial rights thereto.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE849 (DLL3) Program with Hengrui Pharma</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>In December 2024, we entered into the Hengrui Pharma License Agreement, pursuant to which Hengrui Pharma granted us an exclusive worldwide license outside of Greater China, for IDE849 (SHR-4849), a potential first-in-class Phase 1 DLL3 TOP1i ADC. DLL3 has been reported to be expressed in multiple solid tumor types, including in SCLC and Neuroendocrine Tumors at approximately 85% and 20-40%, respectively. DLL3 has limited extracellular expression in normal tissues, making it a promising therapeutic target in these tumor types, for which there remains significant unmet medical need.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDE849 has shown promising antitumor activity in preclinical studies, including tumor regression as a monotherapy in multiple models. IDE849 is currently being evaluated by Hengrui Pharma in an ongoing Phase 1 trial in China in SCLC patients. In the ongoing Phase 1 dose escalation, IDE849 has reached therapeutic dose levels where multiple partial responses have been observed as of the data cut-off date of December 10, 2024. Among 11 evaluable SCLC subjects treated at therapeutic dose</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">levels, 8 partial responses by RECIST 1.1 were observed, resulting in an overall response rate of ~73% (including both confirmed and unconfirmed responses, with all unconfirmed responses pending further evaluation). As of the data cut-off date, treatment related adverse events, or TRAEs were predominantly Grade 1 or 2. The Phase 1 dose escalation is ongoing with no reported drug-related discontinuations, and the maximum tolerated dose has not yet been reached. The most common TRAEs observed were white blood cell count decreased, anemia, neutrophil count decreased, nausea and platelet count decreased. In January 2025, Hengrui Pharma selected expansion doses for their Phase 1 trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>We are planning on submitting a U.S. IND for the evaluation of IDE849 as a monotherapy in SCLC in the first half of 2025. We are also targeting to initiate the evaluation of IDE849 in combination with IDE161 and in NETs in the second half of 2025. A clinical data update is targeted in 2025.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Hengrui Pharma License Agreement, Hengrui Pharma is eligible to receive upfront and milestone payments totaling $1.045 billion, including a $75.0 million upfront fee, up to $200.0 million in development and regulatory milestone payments, plus commercial success-based milestones. Hengrui Pharma is also eligible to receive mid-single to low-double digit royalties on net sales outside of Greater China.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE275 (GSK959) &#8211; WRN Inhibitor in Tumors with High Microsatellite Instability</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We discovered IDE275 (GSK959), our Werner, or WRN, Helicase inhibitor clinical development candidate and evaluated IDE275 (GSK959) in preclinical studies in collaboration with GSK. IDE275 (GSK959) targets WRN for patients having tumors with MSI-High.<br/>  <br/>WRN protein is a RecQ enzyme involved in the maintenance of genome integrity. Germline loss of function mutations in WRN lead to premature aging and pre-disposition to cancer. Microsatellite instability is a change in the DNA content of a tumor cell in which the number of repeats of microsatellites, short repeated sequences of DNA, differ as cells divide. MSI-High is present in about 15% of gastrointestinal tumor cancers, including in approximately 22% of stomach adenocarcinoma and 16% of colorectal cancer. Tumors with MSI-High are routinely assessed in multiple diagnostic profiling tests.<br/>  <br/>WRN is a protein having several functional domains, and we have shown that the helicase functional domain of WRN is responsible for this synthetic lethal interaction, as reflected in our publication in Cell Press &#8211; iScience, Werner Syndrome Helicase is Required for the Survival of Cancer Cells with Microsatellite Instability (March 2019).<br/>  <br/>We have demonstrated preclinical in vivo efficacy with tumor regression and PD response in a relevant MSI-High model. We have observed selectivity of our Werner Helicase inhibitor and validation of the synthetic lethal relationship to tumors with MSI-High over tumors with MSS based on a lack of in vivo pharmacological response in relevant MSS xenograft models.<br/>  <br/>We, in collaboration with GSK, received IND clearance for IDE275 (GSK959), a potential first-in-class WRN inhibitor, in October 2024 to enable first-in-human clinical evaluation of IDE275 (GSK959) for patients having tumors with MSI-High. GSK will lead clinical development for the Werner Helicase program. GSK is responsible for 80% of global research and development costs, and we are responsible for 20% of such costs. GSK holds a global, exclusive license to develop and commercialize the Werner Helicase Inhibitor DC.<br/>  <br/>In October 2023, we achieved and earned a $3.0 million milestone in connection with IND-enabling studies. In October 2024, we earned a $7.0 million milestone payment for the IND clearance of IDE275 (GSK 959). We have the potential to earn up to an additional $10.0 million milestone payment upon initiation of Phase 1 clinical dose expansion. We are also eligible to receive further aggregate late-stage development and regulatory milestones of up to $465.0 million. Upon commercialization, we will be eligible to receive up to $475.0 million of commercial milestones, 50% of U.S. net profits and tiered royalties on global non-U.S. net sales of the Werner Helicase Inhibitor DC &#8211; ranging from high single-digit to sub-teen double-digit percentages, subject to certain customary reductions.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE161 &#8211; PARG Inhibitor in Tumors with Homologous Recombination Deficiency</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are evaluating IDE161, a small molecule inhibitor of PARG, in a Phase 1/2 clinical trial, designated as IDE161-001 for patients having tumors with HRD and potentially other genetic and/or molecular signatures. PARG is a novel target in a clinically validated biological pathway. PARG functions as a regulator of DNA repair in the same biochemical pathway as PARP. PARG hydrolyzes PAR chains that are polymerized by PARP enzymes, completing the PAR cycle. Small molecule inhibitors of PARG result in a dose dependent increase in cellular PAR after DNA damage. PARG is a mechanistically distinct target relative to PARP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are progressing with enrollment of patients having tumors with HRD into the Phase 1 expansion portion of the Phase 1/2 clinical trial. The selection of an initial Phase 1/2 monotherapy expansion dose has been made in endometrial cancer. In parallel, we are also continuing with Phase 1 dose optimization to confirm a move-forward expansion dose for the planned Phase 2 portion of the clinical trial.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, we received Fast Track Designation from the FDA for IDE161 for the treatment of adult patients having advanced or metastatic ovarian cancer with germline or somatic BRCA 1/2 mutations who are platinum resistant and have received prior antiangiogenic and PARP inhibitor therapies and for the treatment of adult patients having advanced or metastatic HR+, Her2- breast cancer with germline or somatic BRCA 1/2 mutations who have progressed following treatment with at least one line of a hormonal therapy, a CDK4/6 inhibitor therapy and a PARP inhibitor therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under each Fast Track designation, the IDE161 development program in BRCA1/2 mutant (m) breast and ovarian cancers is eligible for various expedited regulatory review processes, including generally more frequent FDA interactions (e.g., meetings, written communications), potential eligibility for rolling review, accelerated approval, and priority review of a future NDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, we entered into the Merck CTCSA with Merck (known as MSD outside of the United States and Canada). We are evaluating the combination of IDE161 and Merck&#8217;s anti-PD-1 therapy KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (pembrolizumab) in patients with MSI-High and MSS endometrial cancer. Under the Merck CTCSA, Merck will provide KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to us, and we will sponsor the Phase 1 clinical combination trial.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, the first patient was dosed with IDE161 in combination with KEYTRUDA in the Company-sponsored Phase 1 clinical trial. The safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of IDE161 in combination with KEYTRUDA is being evaluated as an arm in IDE161-001 (NCT05787587), a Company-sponsored Phase 1 trial of IDE161 in solid tumors. We are targeting a Phase 1 expansion in MSI-High and MSS endometrial cancer in 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, we presented preclinical results on the IDE161 and ADC combination rationale as a poster at ENA 2024. We are targeting clinical combination(s) of IDE161 with TOP1i-ADCs in 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We entered into an exclusive license under the Evaluation, Option and License Agreement with Cancer Research Technologies Ltd., also known as Cancer Research United Kingdom, or CRT, and the University of Manchester, pursuant to which we hold exclusive worldwide license rights covering a broad class of PARG inhibitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2023, we incurred an obligation to pay milestone payments in an aggregate amount of &#163;750,000 to CRT based upon the achievement of certain milestones relating to first and second tumor histologies in connection with the Phase 1 portion of the IDE161-001 Phase 1/2 clinical trial in oncologic diseases. We will be obligated to make additional payments to CRT aggregating up to &#163;18.75 million upon the achievement of specific development and regulatory approval events for development of a PARG inhibitor in oncologic diseases, including an aggregate of up to &#163;1.5 million and up to &#163;2.25 million for the achievement of certain Phase 2 and Phase 3 development milestones, respectively, in each case as relating to first and second tumor histologies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We own or control all commercial rights in our PARG program, subject to certain economic obligations pursuant to our exclusive, worldwide license to certain PARG inhibitors, including IDE161, with CRT and University of Manchester.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE705 (GSK101) &#8211; Pol Theta Helicase Inhibitor in tumors with Homologous Recombination Deficiency</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We discovered IDE705 (GSK101), our DNA Polymerase Theta, or Pol Theta, Helicase inhibitor clinical development candidate, and evaluated IDE705(GSK101) in preclinical studies in collaboration with GSK. IDE705 (GSK101) targets the helicase domain of the Pol Theta protein for patients having solid tumors with BRCA or other mutations associated with HRD.<br/> <br/>Pol Theta is involved in a DNA repair process called microhomology mediated end joining, or MMEJ, that is utilized when homologous recombination mediated repair is compromised, as happens in the case of certain BRCA1 or BRCA2 mutations. The expression of Pol Theta is largely absent in normal cells, but tumor cells harboring double strand break repair defects, such as BRCA1 or BRCA2 mutations, show higher Pol Theta expression and synthetic lethality when Pol Theta is inhibited. Pol Theta is a large protein with two functional domains: a DNA polymerase domain and an ATP-dependent DNA helicase domain, sometimes referred to as an ATPase domain, linked by a RAD51 central region.<br/> <br/>GSK is evaluating IDE705 (GSK101) in combination with niraparib, the GSK small molecule inhibitor of PARP for the treatment of patients having tumors with BRCA or other HRD, in a GSK-sponsored Phase 1 clinical trial. GSK has dosed the first patient, and enrollment is ongoing in the dose escalation portion of this study.<br/> <br/>GSK is leading clinical development of IDE705 (GSK101) pursuant to the Collaboration, Option and License Agreement with GSK, or GSK Collaboration Agreement. GSK is responsible for all research and development costs for the Pol Theta program.<br/> <br/>We have the potential to earn up to an additional $10.0 million milestone payment upon initiation of Phase 1 clinical dose expansion. In August 2023, we achieved and earned a $7.0 million milestone based on acceptance of the IND by the FDA, for which payment was received in October 2023. An earlier preclinical development $3.0 million milestone payment from GSK was achieved in August 2022 in connection with ongoing IND-enabling studies to support evaluation of IDE705 (GSK101).<br/><br/>We have the potential to earn further aggregate late-stage development and regulatory milestones of up to $465.0 million. Upon commercialization, we will be eligible to receive up to $475.0 million of commercial milestones, and tiered royalties on global net sales of GSK101 &#8211; ranging from high single-digit to sub-teen double-digit percentages, subject to certain customary reductions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE892 &#8211; MTA-cooperative PMRT5 inhibitor</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we announced the selection of IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor. IDE892 was discovered through our iterative physics-based ligand design and optimization platform, and is a highly potent and selective MTA-cooperative PRMT5 inhibitor with best-in-class potential and favorable drug-like properties. IDE892 has demonstrated exceptionally selective antiproliferative activity in MTAP-deleted tumor cell models and durable complete responses in combination with MAT2A inhibitor IDE397 in challenging MTAP-deletion preclinical models.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDE892 enables a wholly-owned clinical combination between the PRMT5 and MAT2A mechanisms and delivers potentially greater efficacy in MTAP-deletion solids tumors through this rational combination approach, including favorable potency, selectivity, and synergistic combination potential with MAT2A inhibitor IDE397.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development of IDE892 is ongoing to support an IND filing to the FDA in mid-year 2025, subject to satisfactory completion of ongoing preclinical and IND-enabling studies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE034 (B7H3/PTK7) program with Biocytogen</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>In July 2024, we entered into the Biocytogen Option and License Agreement, pursuant to which Biocytogen granted us an option for an exclusive worldwide license</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">from Biocytogen to develop and commercialize products in connection with a potential first-in-class B7H3/PTK7 topoisomerase-I-inhibitor-payload BsADC program, or the Option. B7H3/PTK7 has been found to be co-expressed in multiple solid tumor types, including double-digit percent prevalence in lung, colorectal, and head and neck cancers, among others. Based on preclinical data, the potential first-in-class B7H3/PTK7 topoisomerase-I-inhibitor-payload BsADC program has the potential to be developed as a monotherapy agent and used in combination with multiple programs in our pipeline targeting DDR-based therapies, including our PARG inhibitor IDE161.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>In November 2024, we announced the selection of IDE034, a potential first-in-class B7H3/PTK7 topo-I-payload BsADC, as a development candidate and the exercise of the Option. Under the terms of the Biocytogen Option and License Agreement, we paid Biocytogen an upfront fee and an exercise fee for the Option totaling $6.5 million.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are targeting an IND submission to the FDA in the second half of 2025 for IDE034, subject to satisfactory completion of ongoing preclinical and IND-enabling studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>Pursuant to our exercise of the Option, Biocytogen is eligible to receive additional development and regulatory milestone payments and commercial milestone payments, as well as low to mid single-digit royalties on net sales. Total potential milestone payments equal an aggregate of $400.0 million, including development and regulatory milestone payments of up to $100.0 million. Our royalty obligations continue with respect to each country and each product until the later of (i) the date on which such product is no longer covered by certain intellectual property rights in such country and (ii) the 10th anniversary of the first commercial sale of such product in such country.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE251 - KAT6/7 inhibitor</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we announced the selection of IDE251, a potential first-in-class KAT6/7 inhibitor. IDE251 is an equipotent, highly selective, small molecule dual inhibitor of the lysine acetyltransferase (KAT) 6 and 7, both of which have been shown to support cancer cell survival. IND-enabling studies to support the potential clinical evaluation of IDE251 monotherapy in patients with breast and lung cancers with 8p11 amplification are ongoing, as well as additional opportunities in the setting of lineage addiction. Based on our biomarker evaluation, 8p11 amplification prevalence is projected to be approximately 15% in breast cancer and 17.5% in squamous NSCLC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDE251 selectively inhibits both KAT6 and KAT7 while sparing other structurally similar KAT molecules. KAT6 and KAT7 are mechanistically intertwined epigenetic modulators of cell identity and lineage commitment programs corrupted by oncogenic transformation. Dual KAT6/7 inhibition with IDE251 delivers robust and durable anti-tumor activity, superior to KAT6 inhibition alone, in preclinical tumor models with 8p11 amplifications, as well as in biomarker selected indications dependent upon lineage-specific transcription factor activity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are targeting an IND submission to the FDA in the second half of 2025 for IDE251, subject to satisfactory completion of ongoing preclinical and IND-enabling studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Next-Generation Precision Medicine Pipeline Programs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have initiated early preclinical research programs focused on pharmacological inhibition of several new targets, or NTs, for patients with solid tumors characterized by defined biomarkers based on genetic mutations and/or molecular signatures. We believe these research programs have the potential for discovery and development of first-in-class or unique-in-class or best-in-class therapeutics. Collectively, we believe these efforts will further advance our multi-pronged clinical and business strategy. We own or control all commercial rights in our next-generation NT programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New Target and Biomarker Discovery Platform</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since inception of the company, our core research has and continues to be focused on precision medicine oncology, with synthetic lethality as a central tenet. We have invested significantly and continue to invest in capabilities for identification and validation of new precision medicine targets and biomarkers for patient selection. For targets of interest, we advance our research to discover therapeutic drugs and to further qualify relevant biomarkers.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Precision Medicine Research Platform</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have established a robust precision medicine research platform with capabilities for identification and validation of new targets and biomarkers, drug discovery and translational biology. Our approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are most likely to benefit from these targeted therapies. Our small molecule drug discovery expertise includes discovery and development of small molecule therapeutics.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The drug discovery platform includes our proprietary chemical library, INQUIRE&#153;, structure-based drug design enabled by extensive structural biology and crystallography capabilities with over 200,000 chemical compounds, and our proprietary content-based machine-learning engine, HARMONY&#153;, providing effective and efficient molecular design and structure-activity-relationship, or SAR, cycles. We have deep research and development expertise in synthetic lethality &#8211; which represents an emerging class of precision medicine targets. We are applying these capabilities to develop a robust pipeline in precision medicine oncology.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">DECIPHER&#153; Dual CRISPER Synthetic Lethality Library &#8211; UCSD</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have constructed our DECIPHER Dual CRISPR library for synthetic lethality target and biomarker discovery in collaboration with the University of California, San Diego, and bioinformatics analysis and validation are ongoing. The DECIPHER 1.0 library is focused on DNA Damage Repair targets across various</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> tumor suppressor genes and oncogenes of interest that were selected based on their known prevalence and role in solid tumors, enabling evaluation of approximately 50,000 independent gene knockout combinations of DDR pathway related drug targets across known tumor suppressor genes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PAGEO&#153; Paralogous Gene Evaluation in Ovarian Cancer and Dep Map Consortium &#8211; Broad Institute</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have an ongoing strategic collaboration with the Broad Institute focused on synthetic lethality target and biomarker discovery. This collaboration will use the large-scale CRISPR paralog screening platform developed at the laboratory of William R. Sellers, M.D., Core Institute Member, Broad Institute, to evaluate functionally redundant paralogous genes across ovarian cancer subtypes and to generate novel target and biomarker hypotheses. Dr. Sellers, who also serves on our Scientific Advisory Board, is the principal investigator for the strategic collaboration. We have also become a member of the Broad DepMap (Cancer Dependency Map) consortium led by the Broad Institute to further enhance our efforts in bioinformatics and cell-based screening for synthetic lethality target and biomarker discovery and validation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Small and Medium Enterprise Status from the European Medicines Agency</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, we were granted Small and Medium Enterprise, or SME, status by the European Medicines Agency, or EMA. This enables us to have access to administrative, regulatory and financial support, including fee reductions for scientific advice and regulatory procedures across all our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Drug Discovery and Program Biomarker Discovery Platform</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also continuing to invest in our capabilities to advance our research on newly identified synthetic lethality targets of interest, including to enable discovery of therapeutic drugs and program relevant biomarkers. These investments include both additional research personnel and capital investments, which will enhance our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">capabilities broadly, including in target validation, biological assay development, protein synthesis, structural biology, computational chemistry, and analytical chemistry, among other core functional areas.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As examples of aspects of our drug discovery platform, we use our INQUIRE&#153; Chemical Library to enhance our synthetic lethality drug discovery platform. INQUIRE is a proprietary, expert-curated small-molecule library of over 200,000 chemical compounds, which we believe will enhance our hit discovery capabilities across a broad range of novel synthetic lethality targets and historically difficult-to-drug target classes, such as helicases and endonucleases.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use our HARMONY &#153; machine-learning engine to empower evaluation and decisions related to structure-activity-relationships analyses, empowering our drug-discovery platform.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our objective is to develop and commercialize innovative precision medicine drugs that indirectly or directly target the genetic drivers of cancer in order to provide therapies for defined patient populations. The principal components of our strategy are to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Continue to efficiently develop our clinical-stage product candidates: darovasertib, IDE397, IDE849, IDE161, IDE275 (GSK959) and IDE705 (GSK101). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are evaluating darovasertib in combination with crizotinib in a potential registrational clinical trial in patients having MUM. We are also evaluating darovasertib as monotherapy in a Phase 2 clinical trial in primary UM and plan to initiate a Phase 3 potential registrational clinical trial in neoadjuvant UM in the first half of 2025. We are currently evaluating IDE397 in a Phase 2 monotherapy expansion cohort in patients with MTAP-deletion solid tumor types, including UC, and NSCLC. We are also evaluating IDE397 in combinations with PRMT5 inhibitors and with Trodelvy (sacituzumab-govitecan-hziy), Gilead&#8217;s Trop-2 directed ADC. We plan to evaluate IDE849 in a Phase clinical trial as a monotherapy and in combination with IDE161 in SCLC and NETs. We are currently evaluating IDE161 in a Phase 1 expansion trial in HRD, endometrial cancer and in combination with KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Merck&#8217;s anti-PD-1 therapy in MSI-High and MSS endometrial cancer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Advance our preclinical pipeline of small molecule product candidates into clinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our pipeline includes multiple preclinical research programs, including IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor development candidate, IDE034, a potential first-in-class B7H3/PTK7 topo-I-payload BsADC development candidate, and IDE251, a potential first-in-class KAT6/7 inhibitor development candidate. We are continuing to invest in our earlier-stage preclinical programs and have established selective, value-accretive collaborations with leading pharmaceutical companies to support our clinical development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Broaden our pipeline of targeted therapies and apply our core capabilities to establish a leading franchise in the field of synthetic lethality. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are continuing our target identification and validation activities for advancing new synthetic lethality targets and associated biomarkers, with active programs for several next-generation synthetic lethality targets. We continue to invest in core functional capabilities, including in drug discovery, bioinformatics and translational biology.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaborate with leaders in the field of diagnostics to enable the identification of defined patient populations for our product candidates. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our precision medicine approach leverages the availability or development of companion diagnostics to identify patients for which our product candidates will be most effective.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaborate under our existing strategic partnerships and identify additional strategic collaborations to accelerate development timelines and maximize the commercial potential of our targeted product candidates. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have established selective, value-accretive collaborations with leading pharmaceutical companies to support our clinical development activities. We have entered into the Pfizer Agreements, as defined below, for the evaluation of darovasertib in combination with crizotinib in MUM. We are collaborating with Gilead to clinically evaluate IDE397 and Trodelvy (sacituzumab-govitecan-hziy), Gilead&#8217;s Trop-2 directed ADC combination, in patients having MTAP-deletion UC and NSCLC, in our Phase 1 clinical trial. We entered into the Merck CTCSA with Merck (known as MSD outside of the United States and Canada) to evaluate the combination of IDE161 with KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (pembrolizumab) in patients with MSI-High and MSS endometrial cancer in a Phase 1 clinical trial. We have entered into a strategic partnership and collaboration with GSK for our synthetic lethality programs targeting Pol Theta and Werner Helicase pursuant to the GSK Collaboration Agreement. We also entered into two in-licensing agreements for ADCs with topoisomerase-I-inhibitor-payloads to enable combinations with our synthetic</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lethality programs with Hengrui Pharma for IDE849 and Biocytogen for IDE034. We will selectively evaluate strategic collaborations for our targeted product candidates with biopharmaceutical partners whose research, development, commercial, marketing, and geographic capabilities complement our own.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our industry is very competitive and subject to change based on ongoing advances in technology. Although we believe that our approach, strategy, scientific capabilities, knowledge and experience provide us with competitive advantages, we expect to have substantial competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Many of our competitors have significantly greater financial, technical and human resources. Smaller and early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result, our competitors may discover, develop, license or commercialize products before or more successfully than we do. We face competition with respect to product candidates in our pipeline, and will face competition with respect to future product candidates, from segments of the pharmaceutical, biotechnology and other related markets that pursue targeted approaches to addressing activating genetic and other molecular alterations in cancer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For darovasertib, we are not aware of other companies actively developing clinical-stage therapeutics directed to PKC as a target for solid tumors. Exscientia is developing a PKC theta inhibitor in inflammatory diseases in Phase 1 studies. Varsity Pharma is preclinically evaluating a PKC inhibitor in CLL. Additionally, Windtree Therapeutics is advancing a preclinical-stage atypical PCK iota inhibitor, including both topical and oral formulations, for potential treatment of Basal Cell Carcinoma, or BCC. We are aware of other companies that are conducting research and development of potential therapies for primary UM or for MUM based on other targets and approaches. For example, Aura Biosciences is developing AU-011, a virus-like drug conjugate (VDC), as local treatment for early-stage choroidal melanoma. Immunocore is developing and commercializing Tebentafusp, also known under its branded name as Kimmtrak, for the treatment of adult patients with HLA-A*02:01-positive unresectable or MUM. iOnctura has initiated a Phase 2 trial for Roginolisib, an allosteric PI3K delta inhibitor, in 2L+ MUM. Novartis is developing DYP688, an ADC, with a GNAQ-11 inhibitor payload in a Phase 1/2 clinical trial in MUM. Additionally, Replimune has initiated a potentially registration-enabling trial for RP-2, an oncolytic immunotherapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For IDE397, Servier Pharmaceuticals, LLC, or Servier, is evaluating a small molecule MAT2A inhibitor, designated as S95035, in a Phase 1 trial. Insilico Medicine and Beigene have also initiated Phase 1 trials for their small molecule MAT2A inhibitors called ISM3412 and SYH2039, respectively. Additionally, Anagenex, Genhouse Bio, Hanmi, ScinnoHub and SK Biopharma have small molecule MAT2A inhibitors in preclinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For IDE849, our competitors include companies developing DLL3-targeting therapies using various therapeutic modalities, including bispecific T-cell engagers (BiTEs), antibody-drug conjugates (ADCs), chimeric antigen receptor (T-cell) therapies, and radiopharmaceuticals. Amgen received accelerated approval from the FDA in May 2024 for Tarlatamab (branded name Imdelltra), a DLL3-CD3 BiTE. Boehringer Ingelheim and Daiichi Sankyo are developing drugs with a similar mechanism of action, both in Phase 2 studies. We are aware of several companies developing DLL3 ADCs with topoisomerase-I-inhibitor-payloads in Phase 1 studies, including Zai Lab, Roche, Zhang Jiang, and Baili. In radiopharmaceuticals, Abdera initiated a Phase 1 clinical trial for ABD-147 at the end of 2024, and several other companies are pursuing preclinical development of DLL3-targeting radiotherapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For IDE161, 858 Therapeutics has initiated a Phase 1 clinical trial for its small molecule PARG inhibitor, ETX-19477. Danatlas received IND clearance for its PARG inhibitor, DAT-2645, in August 2024, and Evopoint received clearance from the NMPA in December 2024. Additionally, several companies are conducting preclinical research to develop PARG inhibitors, including Alivexis, Azkarra, FoRx, Nodus Oncology, Satya Pharma Innovations and SynRx.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For GSK101 (IDE705), Artios Pharma is developing a Pol Theta inhibitor, designated as ART-6043, in a Phase 1/2 study. Several other companies have initiated Phase 1 studies for Pol Theta inhibitors, including Moma Therapeutics, Repare Therapeutics, Varsity Therapeutics, Simcere, and SynRx. Additionally, Breakpoint Therapeutics and Danatlas have Pol Theta inhibitors in IND-enabling studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For GSK959 (IDE275), Novartis is evaluating a non-covalent Werner Helicase (WRN) inhibitor called HRO-761 in a Phase 1 trial. Roche is developing a covalent WRN inhibitor, designated as RG6457, in a Phase 1 trial. Additionally, several companies are conducting preclinical research to develop WRN inhibitors, including Eikon, Genhouse, Insilico, Nimbus, Puhe and Ryvu, among others.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For IDE892, we are aware of many companies developing PRMT5 inhibitors in both clinical and preclinical stages. The most advanced assets are currently in Phase 1/2 studies, including BMS-986504 from BMS, AMG-139 from Amgen, TNG462 from Tango, AZD-3470 from AstraZeneca, and BGB-58067 from Beigene. At least nine other companies have initiated Phase 1 clinical trials and more than fifteen companies are advancing preclinical PRMT5 inhibitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For BCG034, we are not aware of any other companies developing bispecific ADCs targeting both B7-H3 and PTK7; however, many companies are developing mono-antigen ADCs targeting either B7-H3 or PTK7. Merck and Hansoh are both evaluating B7-H3 ADCs in Phase 3 clinical trials. Several other companies have B7-H3 ADCs in earlier phases of clinical development, including Beigene, Duality, GSK, Innovent, Mabwell, MacroGenics, MediLink, and Minghui. Furthermore, Genmab, Kelun, and Day One are evaluating PTK7 ADCs in Phase 1 studies, and Lilly is advancing a preclinical PTK7 ADC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For IDE251, we are not aware of other companies developing therapeutics directed to both KAT6 and KAT7; however, there are several companies developing drugs directed to KAT6. Pfizer is developing a KAT6A inhibitor, designated as PF-07248144, in a Phase 1 trial. Menarini also recently initiated a Phase 1 study for a KAT6A inhibitor called MEN-2312. Olema Oncology received IND clearance for a KAT6A/B inhibitor in December 2024 and is expected to begin a Phase 1 trial soon. Additionally, Isoterix and Qubit are developing preclinical KAT6A inhibitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For our preclinical pipeline of synthetic lethality therapeutics, potential competition includes established companies, as well as earlier-stage emerging biotechnology companies. Multiple established companies have been involved with research and development in synthetic lethality, such as AstraZeneca (Lynparza), Pfizer (Talzenna), GSK (Zejula) and Roche. Additionally, several other early-stage companies are developing synthetic lethality therapeutics, including 858 Therapeutics, Artios, Breakpoint Therapeutics, Eikon, FoRx Therapeutics, Repare Therapeutics, Ryvu Therapeutics, Tango, Vividion and Xpose.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual property, including patents, trade secrets, trademarks and copyrights, is important to our business. We endeavor to establish, maintain and enforce intellectual property rights that protect our business interests.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our patent portfolio, including patents owned by or exclusively licensed to us, is built on a program-by-program basis with a goal of establishing broad protection that generally includes, for each product candidate compound and for selected alternative back-up compounds, claims directed to composition of matter, pharmaceutical compositions, and methods of treatment using such pharmaceutical compositions. For some programs, our portfolio may also include claims directed to methods of treatment involving biomarker-enabled patient identification or selection, methods of treatment involving particular dosing approaches, polymorphs, formulations and/or methods of synthesis. We are seeking and maintaining patent protection in the United States and key foreign jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of January 26, 2025, we own or exclusively in-license patents and patent applications, comprising approximately 59 distinct patent families, protecting our technology across our pipeline. Excluding applications that we are not currently prosecuting, our portfolio consists of approximately 18 issued U.S. patents, approximately 35 pending U.S. applications, 22 pending applications under the Patent Cooperation Treaty, or PCT, 55 issued foreign patents and approximately 203 pending foreign applications in approximately 50 foreign jurisdictions, including without limitation countries included in major markets in North America, Europe, and Asia, each having expiration dates ranging from 2035 to 2045. The nominal expiration of our patents and patent applications does not account for any applicable patent term adjustments or extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of January 26, 2025, as relating to our PKC program, including darovasertib, we own or have exclusively in-licensed from Novartis patents and patent applications comprising approximately six issued U.S. patents, approximately 33 issued foreign patents, approximately nine pending U.S. applications, approximately four pending</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PCT application, and approximately 33 pending applications in approximately 18 foreign jurisdictions which we are currently prosecuting, including without limitation countries included in major markets in North America, Europe, and Asia. These in-licensed patents and applications are directed to composition of matter, pharmaceutical compositions and methods of treatment, including treatment of UM. These solely owned or in-licensed patent applications, if granted, would expire between 2035 and 2045, without taking into account any applicable patent term adjustments or extensions. In addition, the PKC program portfolio includes two U.S. patent application and two PCT applications which are jointly owned with Pfizer directed to methods of treatment for certain combination treatments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of January 26, 2025, as relating to our MAT2A program, including IDE397, we own patents and patent applications comprising approximately four issued U.S. patents, approximately four issued foreign patent, approximately eight pending U.S. applications, approximately five pending PCT applications and approximately 50 pending foreign applications in approximately 28 foreign jurisdictions which we are currently prosecuting, including without limitation countries included in major markets in North America, Europe, and Asia. These solely owned or in-licensed patent applications, if granted, would expire between 2039 and 2044, without taking into account any applicable patent term adjustments or extensions. In addition, the MAT2A program portfolio also includes one pending PCT application directed to methods of treatment of cancer which is jointly owned with GSK pursuant to the GSK Collaboration Agreement; one pending US application, one pending PCT application, and two foreign applications directed to methods of treatment of cancer which is jointly owned with Amgen pursuant to the Amgen CTCSA; and one pending US application directed to methods of treatment of cancer which is jointly owned with Gilead pursuant to the Gilead CSCSA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of January 26, 2025, as relating to our PARG program, including IDE161, we own or have exclusively in-licensed from Cancer Research UK and University of Manchester, patents and patent applications comprising approximately three issued U.S. patents, approximately 14 issued foreign patents, approximately three pending U.S. application, and approximately 61 pending foreign applications in approximately 37 foreign jurisdictions which we are currently prosecuting, including without limitation countries included in major markets in North America, Europe, and Asia. These solely owned or in-licensed patent applications, if granted, would expire between 2035 and 2044, without taking into account any applicable patent term adjustments or extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 3, 2024, as relating to our Pol Theta program, GSK holds a global, exclusive license to develop and commercialize Pol Theta products arising out of the Pol theta program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our patent portfolio also supports programs in our synthetic lethality preclinical pipeline, including U.S. patent applications directed to composition of matter, pharmaceutical compositions and/or methods of treatment of cancer for each of our Pol Theta (HR), WRN (MSI-High), PRMT5, KAT6A/7, and certain next-generation SLT programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Strategic Relationships</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We own or control all commercial rights in our three most advanced programs, each of which are clinical-stage programs &#8211; darovasertib, IDE397 and IDE161. We have entered into strategic relationships for these programs &#8211; for example, to in-license certain intellectual property rights or to enable evaluation of combination therapies, such as through combination drug supply or clinical trial collaborations to evaluate combinations. For darovasertib, we have an exclusive license agreement with Novartis and separately, we have established clinical trial collaboration and supply agreements with Pfizer in support of our clinical evaluation of darovasertib in combination with crizotinib in MUM. For IDE397, we entered into the Gilead CSCSA and the Second Gilead CSCSA to clinically evaluate IDE397 in combination with Trodelvy, the Gilead Trop-2 directed ADC, in patients having MTAP-deletion UC and NSCLC, respectively. For IDE161, we have an exclusive in-license agreement with Cancer Research UK and University of Manchester, and we entered into the Merck CTCSA to clinically evaluate IDE161 in combination with KEYTRUDA, the Merck anti-PD-1 therapy, in patients with endometrial cancer.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into a strategic partnership and collaboration with GSK for our synthetic lethality programs targeting Pol Theta and Werner Helicase, pursuant to the GSK Collaboration Agreement. We own all commercial rights to our earlier next-generation synthetic lethality programs, including IDE892 and IDE251, for which our small molecule compounds are being discovered and/or developed internally with our own resources, supplemented by certain service providers, such as CROs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, in 2024, we entered into two in-licensing agreements for ADCs with topoisomerase-I-inhibitor-payloads to enable combinations with our synthetic lethality programs. Pursuant to the Biocytogen Option and License Agreement, we obtained an option to in-license IDE034, a preclinical B7H3/PTK7 bispecific ADC, and we subsequently exercised the option to obtain worldwide commercial rights to the molecule. We also entered into the Hengrui Pharma License Agreement for global development and commercial rights to IDE849, a DLL3-targeting ADC, outside of Greater China. Under the terms of the Biocytogen Option and License Agreement and the Hengrui Pharma License Agreement, Biocytogen and Hengrui Pharma provide development manufacturing services for the ADCs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have established collaborative relationships with other companies for access to their proprietary database of patient samples, and/or for their genetic screening services on their proprietary platform. We have established certain development manufacturing and service relationships with CMOs for darovasertib, IDE397, and IDE161, as well as our preclinical candidates IDE892 and IDE251. We have an agreement with STA Pharmaceutical Hong Kong Limited, or STA Pharmaceutical, and Yuhan Corporation for the synthesis of the API for darovasertib, and agreements with STA Pharmaceutical and Patheon Inc. for formulation and manufacturing of darovasertib drug product. We have an agreement with STA Pharmaceutical for the synthesis of the API, formulation and manufacturing of IDE397 drug product. We have an agreement with Pharmaron for the synthesis of the API, and with STA Pharmaceutical for the formulation and drug product manufacturing of IDE161, IDE892 and IDE251. We have established arrangements with CMOs as well for packaging, labeling and distribution of darovasertib, IDE397, and IDE161. We also have established clinical services relationship with CROs to support our conduct of clinical trials for our darovasertib, IDE397, and IDE161 programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to these existing strategic license relationships, existing and planned development manufacturing and service arrangements, and existing and planned clinical services arrangements, we have various existing agreements and relationships with service providers, such as CROs, which are enabling execution of various research and development activities for each of our pipeline programs. In particular, such agreements are directed to chemistry and compound synthesis, compound analysis and characterization, structural biology, computational biology, biological assay and model development, in vitro screening, in vivo screening, translational biomarker diagnostic development, bioinformatics, toxicology and formulation, among other activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also evaluate future strategic opportunities to accelerate development timelines and maximize the commercial potential of our product candidates. We plan to selectively evaluate strategic collaborations with biopharmaceutical partners whose research, development, commercial, marketing, and geographic capabilities complement our own.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreements with Pfizer</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">for Darovasertib</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2020, we entered into a Clinical Trial Collaboration and Supply Agreement with Pfizer, Inc., as amended in September 2020, April 2021, September 2021 and May 2023, or the Pfizer Agreement. Pursuant to the Pfizer Agreement, Pfizer supplies us with their MEK inhibitor, binimetinib, and their cMET inhibitor, crizotinib, to evaluate combinations of darovasertib independently with each of the Pfizer compounds, in patients with tumors harboring activating GNAQ or GNA11 mutations. Under the Pfizer Agreement, we are the sponsor of the combination studies and will provide darovasertib and pay for the costs of the combination studies. Pfizer will provide binimetinib and crizotinib for use in the clinical trial at no cost to us. The Pfizer Agreement provides that we and Pfizer will jointly own clinical data generated from the clinical trial and will also jointly own inventions, if any, relating to the combined use of darovasertib and binimetinib, or independently, to the combined use of darovasertib and crizotinib. We and Pfizer have formed a joint development committee responsible for coordinating all regulatory and other activities under the agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>In March 2022, we and Pfizer entered into a Second Clinical Trial Collaboration and Supply Agreement (as amended in May 2023), or the Second Pfizer Agreement, pursuant to which we are evaluating darovasertib and crizotinib as a combination therapy in MUM in a planned Phase 2/3 potential registration-enabling clinical trial. Pursuant to the Second Pfizer Agreement, we are the sponsor of the combination trial and we will provide darovasertib and pay for the costs of the combination trial; Pfizer will provide crizotinib for the planned combination trial at no cost to us for up to an agreed-upon number of MUM patients. We and Pfizer will jointly own clinical data from the planned combination trial and all inventions relating to the combined use of darovasertib and crizotinib. We and Pfizer have formed a joint development committee responsible for coordinating all regulatory and other activities under the Second Pfizer Agreement. <br/> <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separately, in March 2022, we and Pfizer also entered into a Third Clinical Trial Collaboration and Supply Agreement, or the Third Pfizer Agreement, pursuant to which we could, subject to preclinical validation and FDA feedback and guidance, evaluate darovasertib and crizotinib, as a combination therapy in cMET-driven tumors such as NSCLC and/or HCC in a Phase 1 clinical trial. Pursuant to the Third Pfizer Agreement, we would have been the sponsor of the planned combination trial, and we would provide darovasertib and pay for the costs of the combination trial; Pfizer would provide crizotinib for the planned combination trial at no cost to us. Pursuant to Amendment No. 1 to the Second Pfizer Agreement, as described below, we and Pfizer terminated the Third Pfizer Agreement.<br/><br/>In May 2023, we continued our relationship with Pfizer by entering into Amendment No. 4 to the Pfizer Agreement relating to the supply of crizotinib in support of this Phase 2 clinical trial, pursuant to which Pfizer will continue to provide us with an additional defined quantity of crizotinib at no cost.<br/> <br/>We also expanded our relationship with Pfizer in May 2023 under an Amendment No. 1 to the Second Pfizer Agreement to support the Phase 2/3 registrational trial to evaluate darovasertib and crizotinib as a combination therapy in MUM. Under the as-amended Second Pfizer Agreement, Pfizer will provide us with a first defined quantity of crizotinib at no cost, as well as an additional second defined quantity of crizotinib at a lump-sum cost. The Third Pfizer Agreement has been terminated by us and Pfizer under Amendment No. 1 to the Second Pfizer Agreement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we entered into Amendment No. 5 to the Pfizer Agreement for the supply of crizotinib in the Phase 1/2 clinical trial for Pfizer to provide us a defined quantity of crizotinib at defined costs.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exclusive License Agreement with Novartis for Darovasertib</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2018, we entered into a license agreement with Novartis to develop and commercialize Novartis&#8217; LXS196 (also known as IDE196), a Phase 1 PKC inhibitor, for the treatment of cancers having GNAQ and GNA11 mutations. We renamed Novartis&#8217; LXS196 oncology as IDE196, and which has a non-proprietary name of darovasertib. Under the license agreement, Novartis granted to us a worldwide, exclusive, sublicensable license to research, develop, manufacture, and commercialize certain defined compounds and products, including IDE196 and certain other PKC inhibitors, as well as companion diagnostic products, collectively referred to as the licensed products, for any purpose.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#008000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All inventions, know-how, data and results resulting from our activities under the license agreement, including activities relating to our own clinical trials, will be exclusively owned by us. All inventions, know-how, data and results resulting from Novartis&#8217; activities connected with Novartis&#8217; ongoing Phase 1 clinical trial for IDE196 will be exclusively owned by Novartis, and subject to the license to us. Ownership of all other inventions and know-how will be determined according to U.S. patent law, with Novartis&#8217; interest subject to the license to us.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We control the prosecution and maintenance of the patents exclusively licensed to us, with Novartis retaining step-in rights if we do not continue such prosecution and maintenance. If we fail to maintain or prosecute any exclusively licensed patent and Novartis exercises this step-in right, our license to the relevant patents will terminate in the relevant country. We have the first right to enforce any exclusively licensed patents, while Novartis retains the right to representation. If we do not bring an action to enforce any exclusively licensed patent, Novartis has the right to bring such action, and we will have the right to representation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We paid Novartis an upfront payment of $2.5 million and issued 263,615 shares of our Series B redeemable convertible preferred stock concurrently with the execution of the license agreement. Subject to completion of certain clinical and regulatory development milestones, we agreed to make milestone payments in the aggregate of up to $9.0 million, and subject to achievement of certain commercial sales milestones, we agreed to make milestone payments in the aggregate of up to $20.0 million. We also agreed to pay mid to high single-digit tiered royalty payments based on annual worldwide net sales of licensed products, payable on a licensed product-by-licensed product and country by country basis until the latest of the expiration of the last to expire exclusively licensed patent, the expiration of regulatory exclusivity, and the ten year anniversary of the first commercial sale of such product in such country. The royalty payments are subject to reductions for lack of patent coverage, loss of market exclusivity, and payment obligations for third-party licenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreement with Amgen for IDE397</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2022, we entered into the Amgen CTCSA to clinically evaluate IDE397 in combination with AMG 193, the Amgen investigational MTA-cooperative PRMT5 inhibitor, in patients having MTAP-null solid tumors, in a Phase 1/2 clinical trial. We and Amgen mutually agreed to wind down the IDE397 and AMG 193 clinical combination study in February 2025 and will not pursue dose expansion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Study Collaboration and Supply Agreement with Gilead for IDE397</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, we entered into the Gilead CSCSA to clinically evaluate IDE397 in combination with Trodelvy (sacacituzumab-govitecan-hziy), a Trop-2 directed ADC, in patients having MTAP-deletion UC, in a Phase 1 clinical trial. Under the mutually non-exclusive Gilead CSCSA, we will receive Trodelvy drug supply from Gilead and will sponsor the Phase 1 clinical combination trial evaluating ID397 and Trodelvy. Gilead will bear internal or external costs incurred in connection with its supply of Trodelvy. We will bear all internal and external costs and expenses associated with the conduct of the combination study. We and Gilead will jointly oversee clinical development of the combination therapy through a Joint Steering Committee responsible for coordinating all regulatory and other activities under the Gilead CSCSA. We and Gilead each retain commercial rights to its respective compounds, including with respect to use as a monotherapy agent or combination agent.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 12, 2025, we entered into the Second Gilead CSCSA with Gilead pursuant to which we and Gilead will collaborate on a portion of our Phase 1 study for the clinical evaluation of IDE397 in combination with Trodelvy, or the Combination Study, in certain patients with advanced solid tumors in lungs. Pursuant to the Second Gilead CSCSA, we are the sponsor of the Combination Study, and we will provide the IDE397 compound and pay for the costs of the Combination Study. Gilead will provide Trodelvy for the Combination Study at no cost to us. We and Gilead will jointly own clinical data from the Combination Study and all inventions relating to the combined use of IDE397 and Trodelvy. Each party retains commercial rights to its respective compounds, including with respect to use as a monotherapy or combination agent. We and Gilead will form a joint steering committee responsible for coordinating all regulatory and other activities under the Second Gilead CSCSA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreement with Merck for IDE161</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, we entered into the Merck CTCSA with Merck (known as MSD outside of the United States and Canada) to evaluate the combination of IDE161 with Merck&#8217;s anti-PD-1 therapy, KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (pembrolizumab), in patients with MSI-High and MSS endometrial cancer. Pursuant to the Merck CTCSA, we are the sponsor of the combination study, and we will provide the IDE161 compound and pay for the costs of the combination study. Merck will provide KEYTRUDA at no cost to us. We and Merck will jointly own clinical data from the combination. Each party retains commercial rights to its respective compounds, including with respect to use as a monotherapy or combination agent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exclusive Option and License Agreement with Cancer Research UK and University of Manchester for IDE161</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2017, we entered into the CRUK/Manchester Agreement with Cancer Research UK and University of Manchester, which was amended on April 24, 2019 and on March 3, 2020, for the development and commercialization of licensed products comprising pharmaceutical preparations of PARG inhibitors for all therapeutic uses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under this agreement, Cancer Research UK and University of Manchester have granted to us, and we have in turn granted to Cancer Research UK and University of Manchester, non-exclusive, sublicensable, royalty-free licenses to carry out non-clinical research during the research term, which ended with our exercise of our option described below. The non-clinical research was governed by a joint research committee comprised of representatives from each party. During the research term, no party was to undertake a drug discovery program in PARG inhibitors other than under this agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cancer Research UK also granted us the exclusive option to obtain an exclusive, sublicensable, worldwide, royalty-bearing license, under certain Cancer Research UK background intellectual property and Cancer Research UK&#8217;s interest in any intellectual property jointly developed under the agreement, to research, develop, manufacture, and commercialize licensed products, as well as a non-exclusive, sublicensable, royalty-free, freedom-to-operate license under related intellectual property. Cancer Research UK and University of Manchester retain certain rights under the licensed intellectual property for academic, non-commercial research and teaching.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2022, we exercised our option for an exclusive worldwide license covering a broad class of PARG inhibitors from Cancer Research Technology Ltd., or CRT, and the University of Manchester, and in connection therewith, paid a one-time option exercise fee of &#163;250,000.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following our option exercise, we gained sole control and responsibility for the research, development, manufacture, and commercialization of the licensed PARG inhibitors. Cancer Research UK also transferred its know how relating to the research, development or manufacturing of the licensed PARG inhibitors to us. We are obligated to develop a PARG inhibitor for the treatment of a cancer indication now that we exercised the option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#008000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each party is the sole owner of any intellectual property it develops solely under the agreement, and the parties will be joint owners of any jointly developed intellectual property. Each party grants the other a non-exclusive, fully-paid, royalty free, irrevocable, sublicensable, perpetual license to its rights in such jointly created intellectual property to make, use and sell inventions claimed in the joint patents, except for those joint patents exclusively licensed to us under the agreement following our exercise of the option.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will be obligated to make payments to CRT aggregating up to a total of &#163;19.5 million upon the achievement of specific development and regulatory approval events for development of a PARG inhibitor in oncologic diseases. We will also pay low single-digit tiered royalties, and potentially also sales-based milestones, to CRT based on net sales of licensed products. In addition, in the event we sublicense the intellectual property, we will also be obligated to pay CRT a specified percentage of any sublicense revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2023, we incurred an obligation to pay milestone payments in an aggregate amount of &#163;750,000 to CRT based upon the achievement of certain milestones relating to first and second tumor histologies in connection with the Phase 1 portion of the Phase 1/2 clinical trial in oncologic diseases.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of the clinical and regulatory milestones are related to and may be due and payable by us if certain milestones are achieved in connection with the IDE161-001 Phase 1/2 clinical trial. We will be obligated to make additional payments to CRT aggregating up to &#163;18.75 million upon the achievement of specific development and regulatory approval events for development of a PARG inhibitor in oncologic diseases, including an aggregate of up to &#163;1.5 million and up to &#163;2.25 million for the achievement of certain Phase 2 and Phase 3 development milestones, respectively, in each case as relating to first and second tumor histologies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaboration, Option and License Agreement with GSK for Pol Theta and Werner Helicase</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2020, we entered into the GSK Collaboration Agreement with GSK, pursuant to which we and GSK have entered into a collaboration for its synthetic lethality programs targeting MAT2A, Pol Theta and WRN. On July 27, 2020, we and GSK received Hart-Scott-Rodino Antitrust Improvements Act clearance, and the GSK Collaboration Agreement became effective.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>Pursuant to the GSK Collaboration Agreement, GSK paid us $100.0 million on July 31, 2020. As of December 31, 2024, GSK has made aggregate payments in the amount of $20.0 million for the achievement of certain development and regulatory milestones with respect to Pol Theta and WRN products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">GSK Collaboration - Pol Theta Program</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the GSK Collaboration Agreement, GSK holds a global, exclusive license to develop and commercialize Pol Theta products arising out of the Pol Theta program. We and GSK collaborated on preclinical research for the Pol Theta program, and GSK is leading clinical development for the Pol Theta program. GSK is responsible for all research and development costs for the Pol Theta program.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>We will be eligible to receive total development and regulatory milestones of up to $485.0 million, with respect to each Pol Theta product, including as applicable, for multiple Pol Theta products that target certain alternative protein domains or are based on alternative modalities. Additionally, we will be eligible to receive up to $475.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million of commercial milestones with respect to each Pol Theta product. We are also entitled to receive tiered royalties on global net sales of Pol Theta products by GSK, its affiliates and their sublicensees ranging from high single digit to sub-teen double-digit percentages, subject to certain customary reductions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>In June 2022, we announced the nomination of a Pol Theta Helicase Inhibitor development candidate, or DC, and in August 2022, we announced the achievement of an initial preclinical development milestone in connection with ongoing investigational new drug, or IND-enabling studies to support evaluation of Pol Theta Helicase Inhibitor DC, triggering a $3.0 million milestone payment, which we received in October 2022. An IND was submitted and was cleared by the FDA in August 2023 to enable clinical evaluation in combination with niraparib, triggering a $7.0 million milestone payment.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>We have the potential to achieve an additional $10.0 million development milestone upon initiation of Phase 1 clinical dose expansion, as well as potential further aggregate late-stage development and regulatory milestones of up to $465.0 million.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">GSK Collaboration - Werner Helicase Program</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the GSK Collaboration Agreement, GSK holds a global, exclusive license to develop and commercialize WRN products arising out of the WRN program. We and GSK are collaborating on ongoing preclinical research for the WRN program, and GSK will lead clinical development for the WRN program, with us responsible for 20% and GSK responsible for 80% of such global research and development costs. The cost-sharing percentages will be adjusted based on the actual ratio of U.S. to global profits for WRN products, as measured three and six years after global commercial launch thereof.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will be eligible to receive total development milestones of up to $485.0 million, with respect to each WRN product, including as applicable, for multiple WRN products that are based on alternative modalities. Additionally, we will be eligible to receive up to $475.0 million of commercial milestones with respect to each WRN product. We will be entitled to receive 50% of U.S. net profits and tiered royalties on global non-U.S. net sales of WRN products by GSK, its affiliates and their sublicensees ranging from high single digit to sub-teen double-digit percentages, subject to certain customary reductions. We will have a right to opt-out of the 50% U.S. net profit share and corresponding research and development cost share for the WRN program, and would be eligible to receive tiered royalties on U.S. net sales of WRN products by GSK, its affiliates and their sublicensees at the same royalty rates as for global non-U.S. net sales thereafter, with economic adjustments based on the stage of the WRN program at the time of opt-out.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, we earned a $3.0 million milestone from GSK in connection with IND-enabling studies for the Werner Helicase Inhibitor DC. In October 2024, we earned a $7.0 million milestone payment for the IND clearance of IDE275 (GSK 959). We have the potential to earn up to an additional $10.0 million milestone payment upon initiation of Phase 1 clinical dose expansion. We are also eligible to receive further aggregate late-stage development and regulatory milestones of up to $465.0 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">GSK Collaboration - General</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the GSK Collaboration Agreement, subject to certain exceptions, we and GSK will not, directly or through third parties, develop or commercialize other products whose primary and intended mechanism of action is the modulation of WRN or Pol Theta for an agreed upon period of time. We and GSK have formed a joint steering committee, joint development committees, and joint commercialization committees responsible for coordinating all activities under the GSK Collaboration Agreement. Ownership of intellectual property developed under the GSK Collaboration Agreement is allocated between or shared by the parties depending on development and subject matter.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>GSK&#8217;s royalty obligations continue with respect to each country and each product until the later of (i) the date on which such product is no longer covered by certain intellectual property rights in such country and (ii) the 10th anniversary of the first commercial sale of such product in such country.<br/>Each party has the right to sublicense its rights under the GSK Collaboration Agreement subject to certain conditions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>The GSK Collaboration Agreement will continue in effect on a product-by-product and country-by-country basis until the expiration of the obligation to make payments under the GSK Collaboration Agreement with respect to such product in each country, unless earlier terminated by either party pursuant to its terms. Either party may</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminate the GSK Collaboration Agreement for the other party&#8217;s insolvency or certain uncured breaches. We may terminate the GSK Collaboration Agreement if GSK or any of its sublicensees or affiliates challenge certain patents of ours. GSK may terminate the GSK Collaboration Agreement in its entirety or on a target-by-target basis upon 90-day notice to us. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Option and License Agreement with Biocytogen for IDE034</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2024, we entered into the Biocytogen Option and License Agreement with Biocytogen, pursuant to which Biocytogen granted us an option for an exclusive worldwide license to develop and commercialize products in connection with a potential first-in-class B7H3/PTK7 topoisomerase-I-inhibitor-payload BsADC program, or the Option. Under the terms of the Biocytogen Option and License Agreement, we paid Biocytogen an upfront fee and, upon our exercise of the Option, an exercise fee totaling up to $6.5 million.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, we announced the selection of IDE034, a potential first-in-class B7H3/PTK7 topo-I-payload BsADC, as a development candidate and the exercise of the Option. Pursuant to our exercise of the Option, Biocytogen is eligible to receive additional development and regulatory milestone payments and commercial milestone payments, as well as low to mid single-digit royalties on net sales. Total potential milestone payments equal an aggregate of $400.0 million, including development and regulatory milestone payments of up to $100.0 million. Our royalty obligations continue with respect to each country and each product until the later of (i) the date on which such product is no longer covered by certain intellectual property rights in such country and (ii) the 10th anniversary of the first commercial sale of such product in such country.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will have the right to terminate the Biocytogen Option and License Agreement for any reason or no reason upon ninety (90) days written notice to Biocytogen. Upon any termination of the Biocytogen Option and License Agreement after the exercise of the Option, the license granted to us will automatically terminate. We will have the right to sell any or all of the inventory of Licensed Products held by us as of the date of termination for a period of 12 months following such termination.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement with Hengrui Pharma for IDE849 (SHR-4849)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we entered into the Hengrui Pharma License Agreement with Hengrui Pharma, pursuant to which Hengrui Pharma granted us an exclusive worldwide license outside of Greater China to develop and commercialize SHR-4849, a novel DLL3-targeting topo-I-payload antibody drug conjugate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Hengrui Pharma License Agreement, Hengrui Pharma is eligible to receive upfront and milestone payments totaling $1.045 billion, including a $75.0 million upfront fee, up to $200.0 million in development and regulatory milestone payments, plus commercial success-based milestones. Hengrui Pharma is also eligible to receive mid-single to low-double digit royalties on net sales outside of Greater China.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Hengrui Pharma License Agreement will continue in effect on a product-by-product and country-by-country basis until the expiration of the obligation to make payments under the Hengrui Pharma License Agreement with respect to such product in each country, unless earlier terminated by either party pursuant to its terms. Either party may terminate the Hengrui Pharma License Agreement upon mutual agreement or for the other party&#8217;s insolvency or certain uncured material breaches. We may terminate the Hengrui Pharma License Agreement for any reason upon certain notice to Hengrui Pharma.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales and Marketing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to become a fully integrated, commercial stage biopharmaceutical company. This will enable us to realize our goal of delivering transformative medicines to patients in need. We currently hold worldwide commercialization rights for darovasertib, IDE397, and IDE161 and own or control all commercial rights outside of greater China for IDE849. We intend to retain significant rights in key markets. Considering our stage of development, we have not yet fully built our commercialization capabilities. We have begun planning for potential commercial operations, including for sales and marketing capabilities, subject to the results of our Phase 2/3 clinical trial for darovasertib.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to initiate commercial readiness activities in anticipation of regulatory approvals. To enable our delivery of any approved medicines to patients, we plan to build our own sales force to commercialize them in the United States and potentially in Europe and other selected foreign countries. We believe a moderately sized specialty sales force, supported by effective marketing and sales management organizations, would enable us to reach healthcare practitioners who specialize in the care of the patient populations for darovasertib and our other product candidates. We may also enter into distribution and other marketing arrangements with third parties for any of our approved medicines to support their safe and effective use.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently rely, and expect to continue to rely, on third parties for the manufacture of our product candidates and our biomarker diagnostics for preclinical and clinical testing, as well as for future commercial manufacture of any drugs and diagnostics that we may commercialize. We do not own or operate, and currently have no plans to establish, any manufacturing facilities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In general, we plan to establish agreements with contract manufacturing organizations, or CMOs, for synthesis of the active pharmaceutical ingredient, or API, manufacturing of drug product comprising such API, as well as packaging, labeling and distribution.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have also established supply arrangements with one or more CMOs for each of our small molecule development programs and with Biocytogen and Hengrui Pharma for our in-licensed ADCs in support of our current clinical development needs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our lead product candidates darovasertib, IDE397, IDE275 (GSK 959), IDE161, IDE705 (GSK 101) are each small molecules that can be manufactured in reliable and reproducible synthetic processes from readily available starting materials. We believe the synthetic chemistry is amenable to scale-up using standard manufacturing equipment and processes. We expect that the compounds being discovered and developed for our other pipeline programs and other future programs, can be produced at contract manufacturing facilities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In many cases, we anticipate that the biomarker diagnostic may be commercially available on an existing third-party diagnostic panel or assay. In cases where such biomarker diagnostic is not already commercially available, we generally expect to establish agreements with strategic partners for clinical supply of companion diagnostics for biomarkers associated with the targeted therapeutics we are developing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing. A new drug must be approved by the FDA through the NDA process before it may be legally marketed in the United States.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Drug Development Process</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of preclinical laboratory tests, animal studies and formulation studies in accordance with good laboratory practice, or GLP, regulations and other applicable regulations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an IND, which must become effective before clinical trials in humans may begin; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval by an independent institutional review board, or IRB, at each clinical site before each clinical trial may be initiated; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, regulations to establish the safety and efficacy of the proposed drug for its intended use; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an NDA; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA advisory committee review, if applicable; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current good manufacturing practice, or cGMP, regulations to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA review and approval of the NDA. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once a pharmaceutical product candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. The sponsor will also include a protocol detailing, among other things, the objectives of the first phase clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if the first phase lends itself to an efficacy evaluation. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. A clinical hold also may be imposed by the FDA at any time during a clinical trial due to safety concerns or non-compliance with specific FDA requirements, and the clinical trial may not continue until the FDA notifies the sponsor that the hold has been lifted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCP regulations, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. They must be conducted under protocols detailing the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND. An IRB at each institution participating in the clinical trial must review and approve each protocol before a clinical trial commences at that institution and must also approve the information regarding the clinical trial and the consent form that must be provided to each clinical trial subject or his or her legal representative, monitor the clinical trial until completed and otherwise comply with IRB regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The product candidate is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. Sponsors sometimes designate their Phase 1 clinical trials as Phase 1a or Phase 1b. Phase 1b clinical trials are typically aimed at confirming dosing, pharmacokinetics and safety in a larger number of patients. Some Phase 1b studies evaluate biomarkers or surrogate markers that may be associated with efficacy in patients with specific types of diseases. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> This phase involves clinical trials in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and appropriate dosage. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 3:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population, generally at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk-benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product labeling. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a clinical trial may move forward at designated check points based on access to certain data from the clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 clinical trial to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrent with clinical trials, companies may conduct additional animal studies and also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected AEs, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or laboratory testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of certain clinical trials of FDA-regulated products are required to register and disclose specified clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, clinical trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these clinical trials can be delayed until the new product or new indication being studied has been approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Review and Approval Process</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The results of product development, preclinical and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">assure and preserve the product&#8217;s identity, strength, quality and purity. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Under the Prescription Drug User Fee Act, or PDUFA, the FDA has agreed to certain performance goals in the review of NDAs through a two-tiered classification system, standard review and priority review. According to the current PDUFA performance goals for new molecular entity NDAs, the FDA endeavors to review and act on applications within ten months of the 60-day filing date under standard review, and within six months of the 60-day filing date under priority review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 clinical trial or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor to conduct Phase 4 testing, which involves clinical trials designed to further assess a drug&#8217;s safety and effectiveness after NDA approval, and may require testing and surveillance programs to monitor the safety of approved products which have been commercialized. The FDA may also place other conditions on approval including the requirement for a risk evaluation and mitigation strategy, or REMS, to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Marketing approval may be withdrawn for non-compliance with regulatory requirements or if problems occur following initial marketing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric Use</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even when not pursuing a pediatric indication, under the Pediatric Research Equity Act, or PREA, an NDA or supplement thereto must contain data that is adequate to assess the safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. In addition, any sponsor planning to submit an NDA or supplement subject to PREA must submit an initial pediatric study plan, or iPSP, to the IND early in development. The iPSP must contain an outline of the proposed pediatric trials the sponsor plans to conduct, including trial objectives and design, any deferral or waiver requests, and other information required by regulation. The FDA must then review the information submitted, consult with the sponsor, and agree upon a final plan. The FDA or the sponsor may request an amendment to the plan at any time. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separately, the FDA may issue a Written Request for pediatric studies relating to a drug product if it has determined that information related to the use of the drug in the pediatric population may produce health benefits. If the sponsor conducts the studies pursuant to the Written Request and submits the study reports within the specified timeline, the drug may be entitled to pediatric exclusivity. Pediatric exclusivity is a type of non-patent marketing exclusivity which, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing exclusivity. Sponsors may submit a proposal asking the FDA to issue a Written Request for this purpose.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Orphan Drug Designation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making the drug product available in the United States for the disease or condition will be recovered from sales of the product in the United States. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its designated orphan use are disclosed publicly by the FDA. Orphan drug designation conveys certain financial incentives, including opportunities for grant funding, tax credits for certain clinical trial costs and certain user-fee waivers. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other application to market the same drug for the same indication for seven years, except in limited circumstances, such as a subsequent product demonstration of clinical superiority to the product with orphan drug exclusivity. Competitors may receive approval of different drugs for the indication for which the orphan product has exclusivity or obtain approval for the same drug but for a different indication from that for which the orphan product has exclusivity. Our product candidates could also be blocked from approval if a competitor obtains approval of the same drug for the same rare disease or condition before we do.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may also be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2022, the FDA designated darovasertib as an orphan drug for the treatment of UM, including MUM, and we may seek orphan drug designation for additional product candidates in the future. Orphan drug designation does not guarantee that any product candidate will be approved for the designated rare disease or condition, if at all.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Expedited Development and Review Programs</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA offers a number of expedited development and review programs for qualifying product candidates intended to treat serious or life-threatening diseases or conditions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New drug products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for frequent interactions with the review team during product development and, once an NDA is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product may demonstrate substantial improvement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After an NDA is submitted for a product, including a product with a fast track designation and/or breakthrough therapy designation, the NDA may be eligible for priority review. A product is eligible for priority review if it has the potential to provide a significant improvement in the treatment or prevention of a serious disease or condition compared to marketed products. If the drug contains a new molecular entity, priority review designation means the FDA&#8217;s goal is to take an action on the marketing application within six months of the 60-day filing date, compared with ten months under standard review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will require the sponsor to perform one or more adequate and well-controlled post-marketing confirmatory trials to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. The FDA may withdraw approval of a drug or indication approved under the accelerated approval pathway if a trial required to verify the predicted clinical benefit fails to verify such benefit or if the applicant fails to conduct any required post-approval trial with due diligence. Recently, the Food and Drug Omnibus Reform Act, or FDORA, enacted as part of the year-end omnibus spending bill in December 2022, included several reforms intended to expand the FDA&#8217;s ability to regulate products receiving accelerated approval, including by increasing the FDA&#8217;s oversight over the conduct of confirmatory trials.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if a product qualifies for one or more of these expedited development and review programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. In November 2022, the FDA granted fast track designation to darovasertib in combination with crizotinib for treatment of adult patients with MUM, and in September 2023, the FDA granted two fast track designations to IDE161 for specific ovarian and breast cancer indications. We also expect to pursue breakthrough therapy designation and accelerated approval for darovasertib and may explore some of these opportunities for our other product candidates as appropriate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Post-approval Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. After approval, some types of changes to the approved product, such as adding new indications, certain manufacturing changes and additional labeling claims, are subject to further FDA review and approval. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations. In addition, the FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any drug products manufactured or distributed by us or our partners pursuant to FDA approvals will be subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, drug sampling and distribution requirements, complying with certain electronic records and signature requirements, and complying with FDA promotion and advertising requirements. The FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on the market and imposes requirements and restrictions on drug manufacturers, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), industry-sponsored scientific and educational activities, and promotional activities involving the internet. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing of a product or withdrawal of the product from the market, as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds on post-approval clinical trials, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Marketing Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity, or NCE. A drug is a new chemical entity if the FDA has not previously approved any other drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or an NDA submitted under Section 505(b)(2) of the FDCA, or 505(b)(2) NDA, submitted by another company for another drug that contains the same active moiety. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the NCE NDA holder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDCA alternatively provides three years of marketing exclusivity for a change to a previously approved drug, such as a new indication or condition of use, submitted in an NDA, or supplement to an existing NDA, if one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other types of non-patent exclusivity include seven-year orphan drug exclusivity and six-month pediatric exclusivity (each discussed above).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FDA Regulation of Companion Diagnostics</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are collaborating or expect to collaborate with strategic partners or CMOs to manufacture and supply </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diagnostics to identify patients with biomarkers associated with the targeted therapeutics we are developing. These diagnostics, often referred to as companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the FDCA, medical devices are classified into one of three classes &#8211; Class I, Class II or Class III &#8211; depending on the degree of risk associated with each medical device and the extent of control needed to provide reasonable assurances with respect to safety and effectiveness. Class I devices are those for which safety and effectiveness can be reasonably assured by adherence to a set of regulations, referred to as General Controls, which require compliance with the applicable portions of the FDA&#8217;s Quality System Regulation, or QSR, facility registration and product listing, reporting of AEs and malfunctions, and appropriate, truthful and non-misleading labeling and promotional materials. Class II devices are those that are subject to General Controls, as well as Special Controls, which can include performance standards, guidelines and postmarket surveillance. Most Class II devices are subject to premarket review and clearance by the FDA under Section 510(k) of the FDCA. Under the 510(k) process, the manufacturer must submit to the FDA a premarket notification, demonstrating that the device is &#8220;substantially equivalent&#8221; to a predicate device. To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics that do not raise different questions of safety or effectiveness than the predicate device. Class III devices</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">include devices deemed by the FDA to pose the greatest risk such as life-supporting or life-sustaining devices, or implantable devices, in addition to new devices deemed not substantially equivalent following the 510(k) process. The safety and effectiveness of Class III devices cannot be reasonably assured solely by General Controls and Special Controls. Therefore, these devices are generally subject to the premarket approval, or PMA, application process, which is generally more costly and time-consuming than the 510(k) process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Alternatively, a device might be the subject of a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">de novo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">classification request, which seeks marketing authorization and reclassification as a lower-risk Class I or Class II device for a new device that otherwise would automatically be regulated as a Class III device requiring a PMA approval. Specifically, medical device types that the FDA has not previously classified as Class I, II or III are automatically classified into Class III regardless of the level of risk they pose. The Food and Drug Administration Modernization Act of 1997 established a new route to market for low to moderate risk medical devices that are automatically placed into Class III due to the absence of a predicate device, called the &#8220;Request for Evaluation of Automatic Class III Designation,&#8221; or the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">de novo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">classification procedure. This procedure allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the use of a companion diagnostic is essential to the safe and effective use of a drug product, then the FDA generally will require approval or clearance of the diagnostic contemporaneously with the approval of the therapeutic product. In July 2014, the FDA issued a final guidance document addressing the development and approval process for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">companion diagnostic devices. According to the guidance, for novel product candidates such as ours, a companion diagnostic device and its corresponding drug candidate should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product labeling. The guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a drug generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption, or IDE, regulations. Thus, the sponsor of the diagnostic device will be required to submit an IDE application for clinical testing of the device and comply with the applicable IDE requirements. According to the guidance, if a diagnostic device and a drug are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE. In July 2016, the FDA issued a draft guidance document intended to further assist sponsors of therapeutic products and sponsors of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> companion diagnostic devices on issues related to co-development of these products. In December 2018, the FDA issued another draft guidance document to facilitate class labeling on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">companion diagnostic devices for oncology therapeutic products, under which a companion diagnostic&#8217;s labeling may identify a specific group or class of therapeutic products, rather than specific products, where scientifically appropriate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA generally requires sponsors developing companion diagnostics intended to select patients who will respond to a specific cancer treatment to obtain approval of a PMA for that diagnostic contemporaneously with approval of the therapeutic, though 510(k) clearance or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">de novo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> classification are also possible. The FDA&#8217;s review of an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> companion diagnostic in conjunction with its review of a cancer therapeutic involves coordination between the FDA&#8217;s Center for Drug Evaluation and Research and the FDA&#8217;s Center for Devices and Radiological Health. The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer than the 510(k) or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">de novo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> processes. PMAs must generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, the applicant must demonstrate that the diagnostic produces reproducible results when the same sample is tested multiple times by multiple users at multiple laboratories. As part of the PMA review, the FDA will typically inspect the manufacturer&#8217;s facilities for compliance with the QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the clinical trials are conducted and then the data submitted in an amendment to the PMA. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing. PMA approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional clinical trials or other data that may be expensive and time-consuming to generate and that can substantially delay approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a companion diagnostic is the subject of a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">de novo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">classification request in lieu of a PMA, the FDA is required to classify the device within 120 days following receipt of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">de novo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission. If the manufacturer seeks reclassification into Class II, the manufacturer must include a draft proposal for special controls sufficient to ensure a reasonable assurance of the safety and effectiveness of the medical device. The FDA may reject the reclassification petition if it identifies a legally marketed predicate device that would be appropriate for a 510(k) or determines that the device is not low to moderate risk or that general controls would be inadequate to control the risks and special controls cannot be developed. If the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">de novo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">request is granted, the new device may be legally marketed (in compliance with applicable regulatory controls), a new classification regulation for the device type will be established, and the device may serve as a predicate device for 510(k) submissions for future devices of the same type.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#8217;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulation Outside the United States</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that any of our product candidates, once approved, are sold in a foreign country, we would be subject to numerous and varying foreign laws and regulations regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization, or MA, commercial sales and distribution of our products, and may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals. The foreign regulatory approval process includes all of the risks associated with FDA approval set forth above, as well as additional country-specific regulation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. Approval by one regulatory authority does not ensure approval by regulatory authorities in other jurisdictions. The approval process varies from country to country, can involve additional testing beyond that required by FDA, and may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing, promotion, and reimbursement vary greatly from country to country.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-clinical Studies and Clinical Trials</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similarly to the United States, the various phases of non-clinical and clinical research in the European Union, or EU, are subject to significant regulatory controls.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-clinical studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. Non-clinical (pharmaco-toxicological) studies must be conducted in compliance with the principles of good laboratory practice, or GLP, as set forth in EU Directive 2004/10/EC (unless otherwise justified for certain particular medicinal products, e.g., radio-pharmaceutical precursors for radio-labeling purposes). In particular, non-clinical studies, both </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials of medicinal products in the EU must be conducted in accordance with EU and national regulations and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, or ICH, guidelines on Good Clinical Practices, or GCP, as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU member states, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory landscape related to clinical trials in the EU has been subject to recent changes. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. Unlike directives, the CTR is directly applicable in all EU member states without the need for member states to further implement it into national law. The CTR notably harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, which contains a centralized EU portal and database.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While the EU Clinical Trials Directive required a separate clinical trial application, or CTA, to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, much like the FDA and IRB respectively, the CTR introduces a centralized process and only requires the submission of a single application for multi-center trials. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CTR transition period ended on January 31, 2025, and all clinical trials (and related applications) are now fully subject to the provisions of the CTR.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Medicines used in clinical trials must be manufactured in accordance with Good Manufacturing Practice, or GMP. Other national and EU-wide regulatory requirements may also apply.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketing Authorization</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to market our future products in the EU and many other foreign jurisdictions, we must obtain separate regulatory approvals. More concretely, in the EU, medicinal product candidates can only be commercialized after obtaining a MA. To obtain regulatory approval of a product candidate under EU regulatory systems, we must submit a MA application, or MAA. There are two types of MAs:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Centralized MAs&#8221; are issued by the European Commission through the centralized procedure based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP of the European Medicines Agency, or EMA, and are valid throughout the entire territory of the EU. The centralized procedure is mandatory for certain types of medicinal products, such as (i) medicinal products derived from biotechnological processes, (ii) designated orphan medicinal products, (iii) advanced therapy medicinal products, or ATMPs (such as gene therapy, somatic cell therapy and tissue engineered products) and (iv) medicinal products containing a new active substance indicated for the treatment of certain diseases, such as AIDS/HIV, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases and other immune dysfunctions. The centralized procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;National MAs&#8221; are issued by the competent authorities of the EU member states, only cover their respective territory, and are available for products not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in an EU member states, this national MA can be recognized in another member state through the mutual recognition procedure. If the product has not received a national MA in any member state at the time of application, it can be approved simultaneously in various member state through the decentralized procedure. Under the </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decentralized procedure an identical dossier is submitted to the competent authorities of each of the member states in which the MA is sought, one of which is selected by the applicant as the reference member state.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In exceptional cases, the CHMP might perform an accelerated review of a MAA in no more than 150 days (not including clock stops). Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the PRIority MEdicines, or PRIME, scheme, which provides incentives similar to the breakthrough therapy designation in the United States. In March 2016, the EMA launched an initiative, the PRIME scheme, a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to optimize their product development plans and speed up their evaluation to help them reach patients earlier. Product developers that benefit from PRIME designation can expect to be eligible for accelerated assessment but this is not guaranteed. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated contact and rapporteur from the CHMP is appointed early in the PRIME scheme facilitating increased understanding of the product at EMA&#8217;s committee level. An initial meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, in the EU, a &#8220;conditional&#8221; MA may be granted in cases where all the required safety and efficacy data are not yet available. The conditional MA is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It is valid for one year and has to be renewed annually until fulfillment of all the conditions. Once the pending studies are provided, it can become a &#8220;standard&#8221; MA. However, if the conditions are not fulfilled within the timeframe set by the EMA, the MA ceases to be renewed. Furthermore, MA may also be granted &#8220;under exceptional circumstances&#8221; when the applicant can show that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. This may arise in particular when the intended indications are very rare and, in the present state of scientific knowledge, it is not possible to provide comprehensive information data on the efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. This may arise in particular when the intended indications are very rare and, in the present state of scientific knowledge, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. This MA is close to the conditional MA as it is reserved to medicinal products to be approved for severe diseases or unmet medical needs and the applicant does not hold the complete data set legally required for the grant of a MA. However, unlike the conditional MA, the applicant does not have to provide the missing data and will never have to. Although the MA &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually and the MA is withdrawn in case the risk-benefit ratio is no longer favorable.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the EU member states make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. MAs have an initial duration of five years. After these five years, the authorization may be renewed on the basis of a reevaluation of the risk-benefit balance.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Data and Marketing Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, new products authorized for marketing, or reference products, generally receive eight years of data exclusivity and an additional two years of market exclusivity upon MA. If granted, the data exclusivity period prevents generic or biosimilar applicants from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial MA of the reference product in the EU. The overall 10-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10 years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new chemical or biological entity, and products may not qualify for data exclusivity.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric Development</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EEA, MAAs for new medicinal products have to include the results of studies conducted in the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA&#8217;s Pediatric Committee, or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all EU member states and study results are included in the product information, even when negative, the product is eligible for six months&#8217; supplementary protection certificate extension (if any is in effect at the time of approval) or, in the case of orphan pharmaceutical products, a two year extension of the orphan market exclusivity is granted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Medicinal Products</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those in the United States. A medicinal product can be designated as an orphan if its sponsor can establish that: (1) the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2) either (a) such condition affects not more than five in ten thousand persons in the EU when the application is made, or (b) the product, without the benefits derived from the orphan status, would not generate sufficient return to justify the necessary investment; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized for marketing in the EU or, if such method exists, the drug will be of significant benefit to those affected by that condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, an application for designation as an orphan product can be made any time prior to the filing of a MAA. An EU orphan designation entitles a party to incentives such as reduction of fees or fee waivers, protocol assistance, and access to the centralized procedure. Upon grant of a MA, orphan medicinal products are entitled to a ten-year period of market exclusivity for the approved indication. During this market exclusivity period, competent authorities cannot accept another MAA, or grant a MA, or accept an application to extend a MA for a similar medicinal product for the same indication. The period of market exclusivity is extended by two years for orphan medicines that have also complied with an agreed PIP. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The orphan exclusivity period may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example because the product is sufficiently profitable not to justify market exclusivity, or where the prevalence of the condition has increased above the threshold. Additionally, MA may be granted to a similar product for the same indication at any time if (i) the applicant consents to a second orphan medicinal product application, (ii) the applicant cannot supply sufficient quantities of the product, or (iii) the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aforementioned EU rules are generally applicable in the European Economic Area, or EEA, which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to comply with EU and member state laws that apply to the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulation of Companion Diagnostics</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> diagnostic medical devices, or IVD MDs, were regulated by the EU Directive on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diagnostic medical devices (Directive No. 98/79/EC, as amended), or IVDD, which regulated the placing on the market, the CE marking, the essential requirements, the conformity assessment procedures, the registration obligations for manufacturers and devices, as well as the vigilance procedure. IVD MDs had to comply with the requirements provided for in the IVDD, and with further requirements implemented at national level (as the case may be).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulation of companion diagnostics is subject to further requirements since Regulation (EU) No 2017/746, or IVDR, became applicable on May 26, 2022 but there is a tiered system extending the grace period for many devices (depending on their risk classification) before they have to be fully compliant with the Regulation. The IVDR introduced a new classification system for companion diagnostics which are now specifically defined as diagnostic tests that support the safe and effective use of a specific medicinal product, by identifying patients that are suitable or unsuitable for treatment. Companion diagnostics will have to undergo a conformity assessment by a notified body. Before it can issue an EU certificate, the notified body must seek a scientific opinion from the EMA on the suitability of the companion diagnostic to the medicinal product concerned if the medicinal product falls exclusively within the scope of the centralized procedure for the authorization of medicines, or the medicinal product is already authorized through the centralized procedure, or a MAA for the medicinal product has been submitted through the centralized procedure. For other substances, the notified body can seek the opinion from a national competent authorities or the EMA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aforementioned EU rules are generally applicable in the EEA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare Reform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system that could affect our future results of operations as we begin to directly commercialize our products. In March 2010, the Patient Protection and Affordable Care Act, or ACA, was signed into law which substantially changed the way healthcare is financed by both governmental and private insurers in the United States and significantly affected the pharmaceutical industry. The ACA contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments and fraud and abuse changes. Additionally, the ACA increases the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; requires collection of rebates for drugs paid by Medicaid managed care organizations; imposes a non-deductible annual fee on pharmaceutical manufacturers or importers who sell &#8220;branded prescription drugs&#8221; to specified federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected, expands of eligibility criteria for Medicaid programs, creates a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research and establishes a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers, which will remain in effect through 2032, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. In addition, on March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory Medicaid drug rebate cap, beginning January 1, 2024. The rebate was previously capped at 100% of a drug&#8217;s average manufacturer price.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. On August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023), and replaces the Part D coverage gap discount program with a new discounting program (which began in 2025). The IRA permits the Secretary of the Department of Health</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and Human Services to implement many of these provisions through guidance, as opposed to regulation, for the initial years. CMS has published the negotiated prices for the initial ten drugs, which will first be effective in 2026, and has published the list of the subsequent 15 drugs that will be subject to negotiation, although the drug price negotiation program is currently subject to legal challenges. For that and other reasons, it is currently unclear how the IRA will be effectuated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare product candidates and services, which could result in reduced demand for our product candidates once approved or additional pricing pressures.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, similar developments may affect our ability to profitably commercialize our products, if approved. On December 13, 2021, Regulation No 2021/2282 on Health Technology Assessment, or HTA, amending Directive 2011/24/EU, was adopted. The Regulation entered into force in January 2022 and has been applicable since January 2025, with phased implementation based on the type of product, i.e. oncology and advanced therapy medicinal products as of 2025, orphan medicinal products as of 2028, and all other medicinal products by 2030. The Regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products, as well as certain high-risk medical devices, and provide the basis for cooperation at the EU level for joint clinical assessments in these areas. It will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the highest potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Healthcare Laws</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, and transparency laws and regulations with respect to drug pricing and payments and other transfers of value to physicians and other healthcare providers, as well as similar foreign laws in the jurisdictions outside the United States. If their operations are found to be in violation of any of such laws or any other governmental regulations that apply, they may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, the curtailment or restructuring of operations, exclusion from participation in governmental healthcare programs and imprisonment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data Privacy and Security Laws</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmaceutical companies may be subject to numerous federal, state, and foreign laws, regulations and standards which govern the collection, use, disclosure and protection of health-related and other personal information, and could apply now or in the future to our operations or the operations of our partners. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. These third-party payors are increasingly reducing reimbursements for medical products, drugs and services. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product and also have a material adverse effect on sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in many countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. In the EU, governments influence the price of products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Member states are free to restrict the range of pharmaceutical products for which their national health insurance systems provide reimbursement, and to control the prices and reimbursement levels of pharmaceutical products for human use. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed to by the government. Member states may approve a specific price or level of reimbursement for the pharmaceutical product, or alternatively adopt a system of direct or indirect controls on the profitability of the company responsible for placing the pharmaceutical product on the market, including volume-based arrangements, caps and reference pricing mechanisms. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. The downward pressure on healthcare costs in general, particularly prescription products, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may face competition for our product candidates from lower-priced products in foreign countries that have placed price controls on pharmaceutical products. In addition, there may be importation of foreign products that compete with our own products, which could negatively impact our profitability. Furthermore, there can be no assurance that our products will be considered medically reasonable and necessary for a specific indication, that our products will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available or that the third-party payors&#8217; reimbursement policies will not adversely affect our ability to sell our products profitably.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human Capital</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At IDEAYA, we view our employees as among our most valuable assets. Our ability to hire and retain highly skilled professionals remains an important element to our success in discovering and developing targeted therapeutics. Our employees are at the heart of our values of passionate commitment, fearless innovation, courageous integrity, respectful teamwork, objective decision-making and empowered accountability. We offer our employees a challenging work environment, ongoing skills development, attractive career advancement, and a culture that rewards entrepreneurial initiative and exceptional execution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have assembled a team of cancer biologists, drug discovery chemists, translational biologists and drug development professionals with broad experience at leading oncology organizations. Our team is led by our Chief Executive Officer, Yujiro S Hata. We are also guided by a renowned scientific advisory board made up of key scientific and clinical thought leaders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We established an internal human resources departments as part of our commitment to our human resources programs and our employee work experience, and we seek to hire and retain a highly qualified workforce in compliance with applicable federal and other laws and regulations. We draw from the largest pools of talent to help find the best people for our company. We believe the variety of experiences and perspectives of our employees bring to their work every day makes us stronger and more successful. As of December 31, 2024, females make up 45% of our workforce, 25% of our executive team, and 37.5% of our board of directors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had a total of 131 employees. Of these employees, 104 were primarily engaged in research and development activities and 27 were primarily engaged in general and administrative activities. Of our total employees, 98 hold biology, chemistry or other relevant scientific degrees, including 57 Ph.D&#8217;s. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Information</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were founded in June 2015 as a Delaware corporation. Our principal executive offices are located at 5000 Shoreline Court, Suite 300, South San Francisco, California 94080, and our telephone number is (650) 443-6209. Our website address is www.ideayabio.com.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We file electronically with the Securities and Exchange Commission (SEC) our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended. Our SEC filings are available to the public on the SEC&#8217;s website at www.sec.gov. At our corporate website, www.ideayabio.com, we make available free of charge a variety of information for investors, including copies of these reports, and any amendments to these reports, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The information on, or that can be accessed through, our website is not part of this report and is not incorporated by reference herein. We have included our website address as an inactive textual reference only. We also use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use IDEAYA Biosciences, Inc.&#174;, the IDEAYA logo, and other marks as trademarks in the United States and other countries. This Annual Report on Form 10-K contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Annual Report on Form 10-K, including logos, artwork and other visual displays, may appear without the &#174; or &#153; symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by any other entity.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Ris</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">k Factors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, growth prospects and stock price. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Many of the following risks and uncertainties are, and will be, exacerbated by the ongoing Ukraine-Russia conflict, the Israel Hamas conflict, or banking sector volatility and any worsening of the global business and economic environment as a result. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. We have incurred significant losses since our inception, and we anticipate that we will continue to incur significant losses for the foreseeable future, which, together with our limited operating history, makes it difficult to assess our future viability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are an early-stage biopharmaceutical company, and we have only a limited operating history upon which you can evaluate our business and prospects. We currently have no products approved for commercial sale, have not generated any revenue from sales of products and have incurred losses in each year since our inception in June 2015. In addition, we have limited experience as a company and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Six of our product candidates, IDE397, darovasertib (IDE196), IDE161, IDE705/GSK101 and IDE275/GSK959 (both being developed by GSK under the GSK Collaboration Agreement), and IDE849/SHR-4849 (licensed from Hengrui Pharma) are currently in ongoing clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have had significant operating losses since our inception. Our net losses for the twelve months ended December 31, 2024 and 2023 were $274.5 million and $113.0 million, respectively. As of December 31, 2024, we had an accumulated deficit of $622.8 million. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. One of our product candidates is in late-phase clinical trials, two product candidates are in mid-phase clinical trials, and five product candidates are in early-stage clinical trials being conducted by us. We have multiple other product candidates in preclinical development, as well as early-stage research programs. Our product candidates will require substantial additional development time and resources before we will be able to apply for or receive regulatory approvals and, if approved, begin generating revenue from product sales. Furthermore, we expect to continue to incur additional costs associated with operating as a public company. We also do not yet have a sales organization or commercial infrastructure and, accordingly, we will incur significant expenses to develop a sales organization or commercial infrastructure in advance of regulatory approval and generating any commercial product sales. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase as we continue to develop our product candidates and any future product candidates, conduct clinical trials and pursue research and development activities. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; deficit and working capital.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our operating results may fluctuate significantly, which will make our future results difficult to predict and could cause our results to fall below expectations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our quarterly and annual operating results may fluctuate significantly, which will make it difficult for us to predict our future results. These fluctuations may occur due to a variety of factors, many of which are outside of our control and may be difficult to predict, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and cost of, and level of investment in, research, development and commercialization activities, which may change from time to time; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and status of enrollment for our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of regulatory approvals, if any, in the United States and internationally; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of manufacturing, as well as building out our supply chain, which may vary depending on the quantity of productions, and the terms of any agreements we enter into with third-party suppliers; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">timing and amount of any option exercise, milestone, royalty or other payments we may or may not receive pursuant to any current or future collaboration or license agreement, including under the GSK Collaboration Agreement;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">timing and amount of any milestone, royalty or other payments due under any current or future collaboration or license agreement, including the License Agreement with Novartis, the Option and License Agreement with CRT and University of Manchester, the Option and License Agreement with Biocytogen Pharmaceuticals Co., Ltd.; and the License Agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">coverage and reimbursement policies with respect to any future approved products, and potential future drugs that compete with our products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenditures that we may incur to acquire, develop or commercialize additional products and technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of demand for any future approved products, which may vary significantly over time; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">future accounting pronouncements or changes in our accounting policies; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and success or failure of preclinical studies and clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or collaboration partners. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will require substantial additional financing to achieve our goals, and failure to obtain additional capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have invested a significant portion of our efforts and financial resources in research and development activities for our precision medicine target and biomarker discovery platform and our initial preclinical and clinical product candidates. Preclinical studies and clinical trials and additional research and development activities will require substantial funds to complete. As of December 31, 2024, we had cash, cash equivalents and marketable securities of $1.1 billion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that we will continue to expend substantial resources for the foreseeable future in connection with the research and development of our precision medicine target and biomarker discovery platform, clinical and preclinical product candidates, and any other future product candidates we may choose to pursue, and commercialization of potentially approved drug products, as well as other corporate uses. Specifically, in the near term, we expect to incur substantial expenses as we advance our synthetic lethality product candidates through preclinical studies, advance darovasertib, IDE397, IDE161 and IDE849/SHR-4849 through clinical development, seek regulatory approval, prepare for and, if approved, proceed to commercialization, and continue our research and development efforts. These expenses will include our cost sharing obligations with GSK for research and development for our WRN program. These expenditures will include costs associated with conducting preclinical studies and clinical trials, obtaining regulatory approvals, and manufacturing and supply, as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may arise. Because the outcome of any preclinical study or clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully develop and commercialize our product candidates or any future product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our existing cash, cash equivalents and marketable securities will allow us to fund our planned operations for at least 12 months from the date of the issuance of the financial statements included in this Form 10-K. However, our operating plans and other demands on our capital resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Such financing may result in dilution to stockholders, imposition of burdensome debt covenants and repayment obligations, or other restrictions that may adversely affect our business. If we raise additional funds through licensing or collaboration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">arrangements with third parties, we may have to relinquish valuable rights to our product candidates, or grant licenses on terms that are not favorable to us. Attempting to secure additional financing may also divert our management from our day-to-day activities, which may adversely affect our ability to develop our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future capital requirements will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results and costs of developing our product candidates or any other future product candidates, and conducting preclinical studies and clinical trials, including our ongoing clinical trials for IDE397, darovasertib, IDE161, and IDE849/SHR-4849; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results and costs related to the research and development of our precision medicine target and biomarker discovery platform, including costs related to the development of our proprietary libraries and database of tumor genetic information and specific cancer-target dependency networks; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates or any future product candidates, or any applicable diagnostics; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and characteristics of any additional product candidates we develop or acquire; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of coordinating and/or collaborating with certain diagnostic companies for manufacturing and supply of companion diagnostics for biomarkers associated with our product candidates and any future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current or future collaboration or license agreement, including under the License Agreement with Novartis or the Option and License Agreement with CRT and University of Manchester; Option and License Agreement with Biocytogen Pharmaceuticals Co., Ltd.; and License Agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd.; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and amount of any option exercise, milestone, royalty or other payments we may or may not receive pursuant to any current or future collaboration or license agreement, including under the GSK Collaboration Agreement; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current or future collaboration or license agreement, including under the License Agreement with Novartis or the Option and License Agreement with CRT and University of Manchester; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential delays in our ongoing clinical programs as a result of any public health outbreaks, epidemics or pandemics (such as the COVID-19 pandemic);</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of manufacturing our product candidates and any future products we successfully commercialize; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of commercialization activities, including the cost of building a sales force in anticipation of product commercialization and distribution costs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any product liability or other lawsuits related to our product candidates or future approved products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expenses needed to attract, hire and retain skilled personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with being a public company; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our intellectual property portfolio; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, receipt and amount of sales of any future approved products, if any. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to raise additional funds will depend on financial, economic and other factors, including the ongoing effects of the COVID-19 pandemic, the Ukraine-Russia conflict, the Israel-Hamas conflict, and closure of or liquidity issues at financial institutions, many of which are beyond our control. Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. Furthermore, we maintain the majority of our cash and cash equivalents in accounts with major U.S. and multi-national financial institutions, and our deposits at certain of these institutions exceed insured limits. Market conditions can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. If adequate funds are not available to us on a timely basis, we may be required to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay, limit, reduce or terminate preclinical studies, clinical trials or other research and development activities or eliminate one or more of our development programs altogether; or </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay, limit, reduce or terminate our efforts to establish manufacturing and sales and marketing capabilities or other activities that may be necessary to commercialize darovasertib, if approved, IDE397, if approved, IDE161, if approved, or any other future approved products, or reduce our flexibility in developing or maintaining our sales and marketing strategy. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have primarily financed our operations through the sale of equity securities and payments received under our collaboration agreements. We will be required to seek additional funding in the future and currently intend to do so through collaborations, public or private equity offerings or debt financings, credit or loan facilities or a combination of one or more of these funding sources. If we raise additional funds by issuing equity securities, our stockholders may suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, is likely to involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity securities received any distribution of our corporate assets. We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights or jointly own some aspects of our technologies or product candidates that we would otherwise pursue on our own.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are early in our development efforts. Our business is dependent on the successful development of our product candidates, future product candidates, and companion diagnostics for biomarkers associated with our product candidates and future product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current product candidates are in various stages of development and we are further developing our precision medicine target and biomarker discovery platform. We have no products approved for sale and our product candidates, IDE397, darovasertib and IDE161, are in various stages of clinical development and will require additional clinical development, regulatory review and approval in each jurisdiction in which we intend to market them, access to sufficient commercial manufacturing capacity, and significant sales and marketing efforts before we can generate any revenue from product sales. Our other product candidates have not been tested in clinical trials. The success of our business, including our ability to finance our company and generate revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of our product candidates, which may never occur. In the future, we may also become dependent on other product candidates that we may develop or acquire; however, given the current stages of development for our product candidates, it may be several years, if at all, before we have demonstrated the safety and efficacy of a product candidate sufficient to support approval for commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not previously submitted a new drug application, or NDA, to the FDA or similar approval filings to a comparable foreign regulatory authority, for any product candidate. An NDA or other relevant regulatory filing must include extensive preclinical and clinical data and supporting information to establish that the product candidate is safe and effective for each desired indication. The NDA or other relevant regulatory filing must also include significant information regarding the chemistry, manufacturing and controls for the product. We cannot be certain that our current or future product candidates will be successful in clinical trials or receive regulatory approval. Further, even if they are successful in clinical trials, our product candidates or any future product candidates may not receive regulatory approval. If we do not receive regulatory approvals for current or future product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approval to market a product candidate, our revenue will depend, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights, as well as the availability of competitive products, whether there is sufficient third-party reimbursement and adoption by physicians.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We plan to seek regulatory approval to commercialize our product candidates both in the United States and in select foreign countries. While the scope of regulatory approval generally is similar in other countries, in order to obtain separate regulatory approval in other countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy. Other countries also have their own regulations governing, among other things, clinical trials and commercial sales, as well as pricing and distribution of drugs, and we may be required to expend significant resources to obtain regulatory approval and to comply with ongoing regulations in these jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The clinical and commercial success of our current and any future product candidates will depend on a number of factors, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to raise any additional required capital on acceptable terms, or at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to develop and successfully utilize our precision medicine target and biomarker discovery platform; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">timely and successful completion of our preclinical studies and clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance of INDs by the FDA, or similar regulatory filing by a comparable foreign regulatory authority for the conduct of clinical trials of our product candidates and our proposed design of future clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether we are required by the FDA or a comparable foreign regulatory agency to conduct additional clinical trials or other studies beyond those planned to support approval of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to timely execute our ongoing clinical trials and enroll a sufficient number of patients on a timely basis to evaluate our product candidates in clinical development;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance of our proposed indications and primary endpoint assessments of our product candidates by the FDA and comparable foreign regulatory authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability or successful development of companion diagnostics for biomarkers associated with our product candidates or any other future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to make arrangements with third-party manufacturers for, or establish, commercial manufacturing capabilities, and to consistently manufacture our product candidates on a timely basis; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability, and the ability of any third parties with whom we contract, to remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with current good manufacturing practices, or cGMPs, or similar foreign requirements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to demonstrate to the satisfaction of the FDA and comparable foreign regulatory authorities the safety, efficacy and acceptable risk-benefit profile of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates, either as monotherapy or in combination with other drugs, or future approved products, if any; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timely receipt of necessary marketing approvals from the FDA and comparable foreign regulatory authorities;</span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual obligations and with all regulatory requirements applicable to our current product candidates or any future product candidates or approved products, if any; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of physicians, operators of hospitals and clinics and patients to use or adopt any approved products, as well as the willingness of physicians and other health-care providers to incorporate molecular diagnostics or genetic sequencing into their clinical practice; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully develop a commercial strategy and thereafter commercialize any approved products in the United States and internationally, whether alone or in collaboration with others; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability and level of coverage and adequate reimbursement from managed care plans, private insurers, government payors, such as Medicare and Medicaid, and other third-party payors for any of our product candidates that may be approved; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the convenience of our treatment or dosing regimen; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to compete with other approved therapies, if any; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance by physicians, payors and patients of the benefits, safety and efficacy of our product candidates or any future product candidates, if approved, including relative to alternative and competing treatments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient demand for any approved products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and enforce intellectual property rights in and to our product candidates; and </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to avoid third-party patent interference, opposition, derivation, intellectual property challenges, intellectual property infringement claims or similar proceedings with respect to our intellectual property rights. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our current or future product candidates. Even if regulatory approvals are obtained, we may never be able to successfully commercialize any products. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through the sale of products to continue our business or achieve profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In connection with the GSK Collaboration Agreement, if GSK terminates any development program under its collaborations with us, whether as a result of our inability to meet milestones or otherwise, any potential revenue from those collaborations will be significantly reduced or non-existent, and our results of operations and financial condition will be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have invested a significant portion of our time and financial resources in the development of multiple product candidates that are included in our strategic partnership and collaboration with GSK, under the GSK Collaboration Agreement entered into on June 15, 2020, or the GSK Collaboration Agreement. The programs currently included in the GSK Collaboration Agreement are the Pol Theta and WRN programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the GSK Collaboration Agreement, we will be eligible to receive from GSK future development and regulatory milestones of up to $475.0 million for the Pol Theta and $475.0 million for the WRN product, and commercial milestones of up to $475.0 million, with respect to the Pol Theta and WRN product. Additionally, we are entitled to receive 50% of U.S. net profits and tiered royalties on global non-U.S. net sales of WRN products by GSK, its affiliates and their sublicensees ranging from high single digit to sub-teen double digit percentages, subject to certain customary reductions. We are entitled to receive tiered royalties on global net sales of Pol Theta products by GSK, its affiliates and their sublicensees ranging from high single digit to sub-teen double digit percentages, subject to certain customary reductions. We have a right to opt-out of the 50% U.S. net profit share and corresponding development cost share for the WRN program, and would be eligible to receive tiered royalties on U.S. net sales of WRN products by GSK, its affiliates and their sublicensees at the same royalty rates as for global non-U.S. net sales thereafter, with potential positive economic adjustments based on the stage of the WRN program, as applicable, at the time of opt-out. There is no guarantee that we will be able to successfully continue to advance the Pol Theta and WRN programs and receive regulatory filing milestone payments related to any Pol Theta or WRN product. GSK may terminate the entire GSK Collaboration Agreement or any collaboration program on a target-by-target basis for any or no reason upon written notice to us after expiration of a defined notice period. The GSK Collaboration Agreement or any program under the GSK Collaboration Agreement may also be terminated by either party for the other party&#8217;s insolvency or certain uncured breaches. We may terminate the GSK Collaboration Agreement if GSK or any of its sublicensees or affiliates challenge certain of our patents. Depending on the timing of any such termination we may not be entitled to receive the option exercise fees, or potential milestone payments, as these payments terminate with termination of the GSK Collaboration Agreement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If GSK terminates its rights and obligations with respect to a program or the entire GSK Collaboration Agreement, then depending on the timing of such event:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the development of our product candidates subject to the GSK Collaboration Agreement may be terminated or significantly delayed;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our cash expenditures could increase significantly if it is necessary for us to hire additional employees and allocate scarce resources to the development and commercialization of product candidates that were previously funded by GSK;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we would bear all of the risks and costs related to the further development and commercialization of product candidates that were previously the subject of the GSK Collaboration Agreement, including the reimbursement of third parties; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in order to fund further development and commercialization, we may need to seek out and establish alternative collaboration arrangements with third-party collaboration partners; this may not be possible, or we may not be able to do so on terms which are acceptable to us, in which case it may be necessary for us to limit the size or scope of one or more of our programs or increase our expenditures and seek additional funding by other means.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events would have a material adverse effect on our results of operations and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">As an organization, we have never completed a clinical trial, and may be unable to do so for any of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need to successfully initiate and complete our own Phase 1 clinical trials and later-stage and pivotal clinical trials in order to obtain FDA or a comparable foreign regulatory body&#8217;s approval to market our product candidates. Carrying out clinical trials and the submission of regulatory filings is a complicated process. As an organization, we have not yet completed any clinical trials for any of our product candidates. We have limited experience in preparing, submitting and prosecuting regulatory filings, and have not previously submitted any NDA or other comparable foreign regulatory submission for any product candidate. In addition, we have had limited interactions with the FDA and cannot be certain how many additional clinical trials of darovasertib, IDE397 or IDE161 or how many clinical trials of any of our other product candidates will be required or whether the FDA will agree with the design or implementation of our clinical trials. We are required to comply with certain regulatory requirements, and the FDA may identify specific clinical or other development-related requirements that we must satisfy, as a condition to initiating or continuing our clinical trials; if we fail to meet such a requirement, the FDA may issue a clinical hold or designate other conditions on our clinical trials. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to regulatory submission of a marketing application for, and approval of, darovasertib, IDE397, IDE161, or any of our other product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our planned clinical trials, could prevent us from or delay us in commercializing darovasertib, IDE397, IDE161, or any other product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The successful development of targeted therapeutics, including therapeutics involving direct targeting of an oncogenic pathway and synthetic lethality therapeutics, including our portfolio of synthetic lethality small molecule inhibitors, as well as any related diagnostics, is highly uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successful development of targeted therapeutics, including therapeutics involving direct targeting oncogenic pathways and synthetic lethality therapeutics, such as our portfolio of synthetic lethality small molecule inhibitors, as well as any related diagnostics, is highly uncertain and is dependent on numerous factors, many of which are beyond our control. Our precision medicine target and biomarker discovery platform is based on new technologies and methods relating to drug target and biomarker identification, screening and validation, including Dual CRISPR genetic screening and bioinformatics and we have not, to date, sought regulatory approval for any therapeutics developed through our precision medicine target and biomarker discovery platform. As such, it is difficult to accurately predict the developmental challenges we or our collaboration partners may incur for our current and future product candidates as we proceed through product discovery, identification, preclinical studies and clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our precision medicine target and biomarker discovery platform is novel and may not be effective at identifying targets and/or biomarkers for product candidates. We therefore cannot provide any assurance that we will be able to successfully identify additional product candidates or biomarkers, advance any of these additional product candidates or diagnostics for their associated biomarkers through the development process.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, particular patient genetic alterations, such as mutations, deletions or fusions may not be functionally active genetic drivers of the disease. Further, whether a genetic alteration is functionally active may be difficult to ascertain from preclinical cancer models, may be tissue-type dependent and may vary from patient to patient within a specific indication. If that was the case, we would need to functionally validate such genetic alterations, for example, using </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">models, potentially across more than one tumor-tissue type and across multiple cell lines. If some of the genetic alterations are not functionally validated, this would reduce the size of our addressable patient population. Even if genetic alterations are preclinically validated, the relevance of these alterations may not translate into a human clinical setting, which could adversely impact our clinical trial results and our commercial opportunities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Targeted therapeutics that appear promising in the early phases of development may fail to reach the market for several reasons, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">research or preclinical studies may show our targeted small molecule inhibitors or antagonists to be less effective than desired or to have harmful or problematic side effects or toxicities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to accurately identify, validate or develop clinically relevant biomarkers for our targeted therapeutic product candidates; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trial results may show our targeted therapeutic small molecule inhibitors to be less effective than expected based on preclinical studies (e.g., a clinical trial could fail to meet its primary endpoint(s)) or to have unacceptable side effects or toxicities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to receive the necessary regulatory approvals or a delay in receiving such approvals. Among other things, such delays may be caused by slow enrollment in clinical trials, patients dropping out of trials, length of time to achieve trial endpoints, additional time requirements for data analysis, IND preparation, discussions with the FDA or similar foreign regulatory authorities, an FDA or similar foreign regulatory authority request for additional preclinical or clinical data, or unexpected safety or manufacturing issues; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing costs, formulation issues, pricing or reimbursement issues, or other factors that may make our targeted therapeutic small molecule inhibitors uneconomical; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">proprietary rights of others and their competing products and technologies that may prevent our targeted therapeutic small molecule inhibitors, or the diagnostics for biomarkers associated with such small molecule inhibitors, from being commercialized.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of these factors, it is more difficult for us to predict the time and cost of product candidate development, and we cannot predict whether the application of our precision medicine target and biomarker discovery platform will result in the identification, development, and regulatory approval of any products. The length of time necessary to complete clinical trials and to submit an application for marketing approval for a decision by a regulatory authority may be difficult to predict for targeted therapeutic small molecule inhibitors, in large part because of the limited regulatory history associated with them. The clinical trial requirements of the FDA and other comparable foreign regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the product candidate. The regulatory approval process for product candidates based on synthetic lethality is uncertain and may be more expensive and take longer than the approval process for product candidates based on other, better known or more extensively studied technologies. It is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in either the United States or other comparable regions of the world or how long it will take to commercialize our product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product candidate to market would adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we are successful in obtaining regulatory approval, commercial success of any approved products will also depend in large part on the availability of insurance coverage and adequate reimbursement from third-party payors, including government payors, such as the Medicare and Medicaid programs, and managed care organizations, which may be affected by existing and future healthcare reform measures designed to reduce the cost of healthcare. Third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost-effectiveness of a product, to qualify for reimbursement, which could be costly and divert our resources. If government and other healthcare payors were not to provide adequate insurance coverage and reimbursement levels for one any of our products once approved, market acceptance and commercial success would be limited.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if any of our products is approved for marketing, we will be subject to significant regulatory obligations regarding the submission of safety and other post-marketing information and reports and registration, and will need to continue to comply (or ensure that our third-party providers comply) with cGMPs, or similar applicable foreign requirements and GCPs for any clinical trials that we conduct post-approval. In addition, there is always the risk that we or a regulatory authority might identify previously unknown problems with a product post-approval, such as AEs, of unanticipated severity or frequency. Compliance with these requirements is costly and any failure to comply or other post-approval issues with our product candidates could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical and clinical drug development is a lengthy and expensive process with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of any product candidates, which could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our business, financial condition, results of operations and prospects. Furthermore, results of earlier studies and trials may not be predictive of future trial results.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before we can initiate clinical trials for our product candidates, we must submit the results of preclinical studies to the FDA or a comparable foreign regulatory authority along with other information, including information about product candidate chemistry, manufacturing and controls, diagnostics for biomarkers for our product candidates and our proposed clinical trial protocol, as part of an IND application or similar regulatory filing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining marketing approval from regulatory authorities for the sale of any products, we, or our collaboration partners must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. Clinical trials are expensive and can take many years to complete, and their outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. In addition, we may rely in part on preclinical, clinical and quality data generated by contract research organizations, or CROs, and other third parties for regulatory submissions for our product candidates. While we have or will have agreements governing these third parties&#8217; services, we have limited influence over their actual performance. Further, pursuant to our license agreement with Novartis, we have a right of reference to certain data from Novartis&#8217; Phase 1 clinical trial data for our regulatory filings for darovasertib.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If these third parties, including Novartis, fail to make data available to us, or, if applicable, make regulatory submissions in a timely manner, in each case pursuant to our agreements with them, our development programs may be significantly delayed and we may need to conduct additional studies or trials or collect additional data independently. In either case, our development costs would increase.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our clinical trial collaboration and supply agreements with Pfizer, Gilead and Merck for the supply of crizotinib, Trodelvy and KEYTRUDA respectively, support our plans to evaluate the safety and efficacy of darovasertib in combination with crizotinib, IDE397 in combination with Trodelvy, and IDE161 in combination with KEYTRUDA. If any of these strategic collaborators delay or fail to supply their compound in support of these combination trials, fail to sponsor or appropriately conduct the combination trial (in the case of Amgen), or we fail to reach an agreement with any of these strategic collaborators for the continued supply of their compound beyond the terms of the current supply agreements, the development programs as pertaining to these combinations may be significantly delayed, and our development costs may increase. In each case, this may require us to establish additional supply agreements and rely upon third parties for supply of such combination agents, or if such combination agents are commercially available, in the absence of a supply agreement, we may incur the cost of purchasing such combination agents and may be at risk of having insufficient supply. We may initiate clinical trials in which our product candidates, including darovasertib, IDE397 or IDE161, are combined with one or more other pharmaceutical agents that have not yet been approved by the FDA or comparable foreign regulatory authorities; in such situations, we may be relying on third parties for obtaining appropriate regulatory approvals and we may have no or limited influence over whether or not such regulatory approvals are achieved for such combination agents.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and our strategic collaborators also may experience numerous unforeseen events during, or as a result of, any preclinical studies or clinical trials that could delay or prevent us or our strategic collaborators from successfully developing our product candidates, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be unable to generate sufficient preclinical, toxicology, or other </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> data to support the initiation of clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or a comparable foreign regulatory authority disagreeing as to the design or implementation of our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in obtaining regulatory authorization to commence a clinical trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining IRB or ethics committee approval or positive opinion at each clinical trial site; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recruiting an adequate number of suitable patients to participate in a clinical trial, particularly if any public health outbreak, epidemic or pandemic leads to clinical site closures; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">having patients complete a clinical trial or return for post-treatment follow-up; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical sites deviating from clinical trial protocol or dropping out of a clinical trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">addressing subject safety concerns that arise during the course of a clinical trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adding a sufficient number of clinical trial sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining sufficient quantities of product candidate for use in preclinical studies or clinical trials from third-party suppliers; or </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accessing third-party products or product candidates for use in combination with our product candidates in preclinical studies or clinical trials, including third-party product candidates that have not yet been approved by the FDA or comparable foreign regulatory authorities. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and our strategic collaborators may experience numerous adverse or unforeseen events during, or as a result of, preclinical studies and clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon our development programs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our third-party contractors may fail to comply with regulatory requirements, fail to maintain adequate quality controls, or be unable to produce sufficient product supply to conduct and complete preclinical studies or clinical trials of our product candidates in a timely manner, or at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our investigators might have to suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risks; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of clinical trials of our product candidates may be greater than we anticipate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the quality of our product candidates or other materials necessary to conduct preclinical studies or clinical trials of our product candidates may be insufficient or inadequate;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or our strategic collaborators are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only moderately positive or if there are safety concerns, we may:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur unplanned costs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain marketing approval in some countries and not in others; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain marketing approval for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be subject to additional post-marketing testing requirements, which could be expensive and time-consuming; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have the treatment removed from the market after obtaining marketing approval. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and our strategic collaborators could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial or by the FDA or another comparable foreign regulatory authority. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs or other foreign regulatory authorities or ethics committees for reexamination, which may impact the costs, timing or successful completion of a clinical trial. For example, in recent years the FDA has issued draft guidance and launched programs aiming to reform and modernize the dose optimization procedures used by clinical trial sponsors during the development of oncology drugs. Although these efforts have not yet resulted in any formal changes to the FDA&#8217;s regulations or policies, changes in the FDA&#8217;s thinking with respect to dose selection and optimization could require us to change the design of our planned or ongoing clinical trials or otherwise conduct additional preclinical, clinical or manufacturing studies beyond those we currently anticipate, which could increase our costs and/or delay the development of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As another example, the regulatory landscape related to clinical trials in the EU recently evolved. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the EU Clinical Trials Directive required a separate clinical trial application, or CTA, to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application for multi-center trials. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR transition period ended on January 31, 2025, and all clinical trials (and related applications) are now fully subject to the provisions of the CTR. Compliance with the CTR requirements by us and our third-party service providers, such as CROs, may impact our developments plans.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, conducting clinical trials in foreign countries, as we may do for certain of our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the possibility that we could be required to conduct additional preclinical studies before initiating any clinical trials, the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with comparable foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or a regulatory authority concludes that the financial relationship may have affected the interpretation of the clinical trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of the marketing application we submit. Any such delay or rejection could prevent or delay us from commercializing our current or future product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our preclinical studies or clinical trials of our product candidates are delayed or terminated, the commercial prospects of our product candidates may be harmed, and our ability to ultimately generate revenues from any of these product candidates will be delayed or not realized at all. In addition, any delays in completing our clinical trials may increase our costs, slow down our product candidate development and regulatory approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business, financial condition, results of operations and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. If our product candidates and any future product candidates prove to be ineffective, unsafe or commercially unviable, our entire platform and approach would have little, if any, value, which would have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, the results of preclinical studies and clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed through preclinical studies and initial clinical trials. Furthermore, for some of our programs, in the future we intend to conduct basket trials, which will be designed to include multiple clinically defined populations under one investigational protocol, although each population is enrolled and analyzed separately. A basket trial design could potentially decrease the time to study new populations by decreasing administrative burden, however, these trials may not provide opportunities for accelerated regulatory pathways, and do not overcome limitations to extrapolating data from the experience in one disease to other diseases, because safety and efficacy results in each indication are analyzed separately. Accordingly, clinical success in a basket trial, or any trial in one indication, may not predict success in another indication. In contrast, in the event of an adverse safety issue, clinical hold, or other adverse finding in one or more indications being tested, such event</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">could adversely affect our trials in the other indications and may delay or prevent completion of the clinical trials. A number of companies in the pharmaceutical, biopharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials for similar indications that we are pursuing due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier studies, and we cannot be certain that we will not face similar setbacks. Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval of any products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Synthetic lethality represents an emerging class of precision medicine targets, and negative perceptions of the efficacy, safety or tolerability of this class of targets, including any that we develop, could adversely affect our ability to conduct our business, advance our product candidates or obtain regulatory approvals.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Aside from PARP inhibitors, such as Lynparza, Rubraca, Zejula and Talzenna, no synthetic lethality small molecule inhibitor therapeutics have been approved to date by the FDA or other comparable regulators. AEs in future clinical trials of our product candidates or in clinical trials of others developing similar products and the resulting publicity, as well as any other AEs in the field of synthetic lethality, or other products that are perceived to be similar to synthetic lethality, such as those related to gene therapy or gene editing, could result in a decrease in the perceived benefit of one or more of our programs, increased regulatory scrutiny, decreased confidence by patients and CROs in our product candidates, and less demand for any product that we may develop. Our substantial pipeline of synthetic lethality small molecule inhibitor product candidates could result in a greater quantity of reportable AEs or other reportable negative clinical outcomes, manufacturing reportable events or material clinical events that could lead to clinical delays or holds by the FDA or applicable regulatory authority or other clinical delays, any of which could negatively impact the perception of one or more of our synthetic lethality programs, as well as our business as a whole. In addition, responses by U.S. federal, state or foreign governments to negative public perception may result in new legislation or regulations that could limit our ability to develop any product candidates or commercialize any approved products, obtain or maintain regulatory approval, or otherwise achieve profitability. More restrictive statutory regimes, government regulations, or negative public opinion would have an adverse effect on our business, financial condition, results of operations, and prospects, and may delay or impair the development of our product candidates and commercialization of any approved products or demand for any products we may develop.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tissue-type agnostic basket trials are an emerging clinical approach that may result in delays in clinical development, additional regulatory requirements and delays in, or the prevention of, our ability to obtain regulatory approval or commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We initiated a Phase 1/2 tissue-type agnostic basket trial with darovasertib in June 2019, and may also utilize a basket trial approach in clinical trials for other product candidates. Basket trials allow us to evaluate the safety and efficacy of a product candidate in a variety of tumor types with a specific molecular profile. We believe that this clinical approach provides many benefits, however, there are limited precedents, and as a result, there a number of inherent risks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is limited precedent for the FDA and foreign regulatory authorities to review and grant tissue-type agnostic approvals. Furthermore, as clinical trials increasingly use classification of tumors by molecular profiling, the FDA or other regulatory authority may change or issue guidance or adopt a policy that adversely affects requirements for basket trials. In the event that such guidance or policy has an effect on any of our protocols or trials, as the case may be, it may result in the delay of clinical development, or require us to conduct additional preclinical studies or clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain a tissue-type agnostic approval for one or more of our product candidates, there is limited precedent for obtaining reimbursement. Third-party payors may reimburse at different levels across tumor tissue types and indicates, or not at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may find it difficult to enroll patients in our clinical trials given the limited number of patients who have the diseases for which our product candidates are being developed. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our and our collaboration partners&#8217; ability to enroll a sufficient number of patients who remain in the clinical trial until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patient eligibility and exclusion criteria defined in the protocol; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and nature of the patient population required for analysis of the clinical trial&#8217;s primary endpoints; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proximity of patients to clinical trial sites; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the design of the clinical trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that enrolled patients will not complete a clinical trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trial investigators&#8217; willingness to continue enrolling patients and patients&#8217; willingness to complete protocol assessments during any public health outbreak, epidemic or pandemic;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinicians&#8217; and patients&#8217; perceptions as to the safety of the product candidate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new therapies that may be approved for the indications we are investigating as well as any drugs under development; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain patient consents. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will be required to identify and enroll a sufficient number of patients for each of our clinical trials. Potential patients for any planned clinical trials may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for such trials. We also may encounter difficulties in identifying and enrolling patients with a stage of disease appropriate for our planned clinical trials and monitoring such patients adequately during and after treatment. We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible patients to participate in the clinical trials required by the FDA or a comparable foreign regulatory authority. In addition, the process of finding and diagnosing patients may prove costly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. As a result of any public health outbreak, competition for potential patients in our trials may be further exacerbated as a result of any clinical site closures. Since the number of qualified clinical investigators is already limited, we may conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, certain conditions for which we plan to evaluate our current development candidates are rare diseases, such as MUM, with limited patient pools from which to draw for clinical trials. For example, one of our product candidates, darovasertib, is currently being evaluated in a Phase 1/2 basket trial that we initiated in June 2019 to evaluate darovasertib in solid tumors harboring GNAQ/GNA11 hotspot mutations in MUM. The timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. The eligibility criteria of our clinical trials, once established, will further limit the pool of available trial participants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our clinical trials may be affected by any public health outbreak, epidemic or pandemic. Clinical site initiation and patient enrollment may be delayed. For example, as a result of the COVID-19 pandemic, several of our sites halted new enrollment for several months in 2020 before resuming enrollment. Some patients may not be able or willing to comply with clinical trial protocols, and data collected may be incomplete, if quarantines impede patient movement or interrupt healthcare services. Similarly, the ability to recruit and retain patients, and principal investigators and site staff who, as healthcare providers, may have heightened exposure to infectious diseases, may be delayed or disrupted, which may adversely impact our clinical trial operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If patients are unwilling to participate in our clinical trials for any reason, including the existence of other approved therapies or concurrent clinical trials for similar patient populations, if they are unwilling to enroll in a clinical trial with a placebo-controlled design, or we otherwise have difficulty enrolling a sufficient number of patients, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of our product candidates may be delayed. Our inability to enroll a sufficient number of patients for any of our future clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. In addition, we expect to rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will have limited influence over their actual performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot assure you that we will not experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our product candidates or any future product candidates may be associated with undesirable side effects or AEs that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As with most pharmaceutical products, use of our product candidates could be associated with side effects or AEs which can vary in severity from minor reactions to death and in frequency from infrequent to prevalent. Undesirable side effects or unacceptable toxicities caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or a comparable foreign regulatory authority. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of these or other side effects. Furthermore, certain of our product candidates may be co-administered with third-party approved or experimental therapies, such as darovasertib with crizotinib in the combination arms of our Phase 1/2 clinical trial or IDE397 with PRMT5 inhibitors in the combination arms of our Phase 1/2 clinical trial. These combinations may have additional side effects. The uncertainty resulting from the use of our product candidates in combination with other therapies may make it difficult to accurately predict side effects in future clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, only three of our product candidates, IDE397, darovasertib, and IDE161 have been tested in clinical trials, and they have been observed to be generally well tolerated, with certain drug-related SAEs and AEs being reported for darovasertib, as monotherapy and in combination with crizotinib, for IDE397, and for IDE161.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If unacceptable side effects arise in the further development of our product candidates, we, the FDA or comparable foreign regulatory authorities, or the IRBs at the institutions in which the clinical trials are being conducted could suspend or terminate our clinical trials or the FDA or a comparable foreign regulatory authority could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our clinical trials or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. Potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition, results of operations and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, even if we successfully advance our product candidates or any future product candidates into and through clinical trials, such trials will likely only include a limited number of patients and limited duration of exposure to our product candidates. Some adverse effects of our product candidates will not be uncovered until a significantly larger number of patients are exposed to the product candidate. Further, any clinical trials may not be sufficient to determine the effect and safety consequences of taking our product candidates over a multi-year period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our product candidates receives marketing approval and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may withdraw their approval of the product; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to recall a product or change the way such product is administered to patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to restrict the use of the product, including implementing a Risk Evaluation and Mitigation Strategy, or REMS, or to create a Medication Guide outlining the risks of such side effects for distribution to patients or similar risk management measures; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be sued and held liable for harm caused to patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the product may become less competitive; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues to us, which would adversely affect our business, financial condition, results of operations and prospects. In addition, if one or more of our product candidates prove to be unsafe, our entire technology platform and pipeline could be affected, which would have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to successfully develop molecular diagnostics for biomarkers that enable patient selection and/or that demonstrate drug-target interaction, or experience significant delays in doing so, we may not realize the full commercial potential of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A key component of our strategy includes the use of molecular diagnostics to guide patient selection and/or to confirm target engagement of our product candidates. In some cases, a diagnostic may be commercially available, for example, on a tumor-profiling panel. If not already commercially available, we may collaborate with diagnostic companies for the development of biomarkers associated with our product candidates. We may have difficulty in establishing or maintaining such development relationships, and we will face competition from other companies in establishing these collaborations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are also several risks associated with biomarker identification and validation. We, in collaboration with any diagnostic partners, may not be able to identify predictive biomarkers or pharmacodynamic biomarkers for one or more of our programs. We may not be able to validate potential biomarkers (e.g., certain genetic mutations) or their functional relevance preclinically in relevant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">models. Data analytics and information from databases that we rely on for identifying or validating some of our biomarker-target relationships may not accurately reflect potential patient populations. Potential biomarkers, even if validated preclinically, may not be functionally effective or validated in human clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we, in collaboration with these parties, are unable to successfully develop companion diagnostics for our product candidates, or experience delays in doing so, the development of our product candidates may be adversely affected. The development of companion diagnostic products requires a significant investment of working capital, and may not result in any future income. This could require us to raise additional funds, which could dilute our current investors or impact our ability to continue our operations in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are also risks associated with diagnostics that are commercially available, including that we may not have access to reliable supply for such diagnostics.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The failure to obtain required regulatory approvals or certification for any companion diagnostic tests that we may pursue may prevent or delay approval of our product candidates. Moreover, the commercial success of any of our product candidates may be tied to the regulatory approval or certification, market acceptance and continued availability of a companion diagnostic.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA regulates </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">companion diagnostics as medical devices that will likely be subject to and require prospective validation in clinical trials in conjunction with the clinical trials for our product candidates, and which will require regulatory clearance or approval prior to commercialization. We plan to collaborate with third parties for the development, testing and manufacturing of these companion diagnostics, the application for and receipt of any required regulatory clearances or approvals, and the commercial supply of these companion diagnostics. Our third-party collaborators may fail to obtain the required regulatory clearances or approvals, which could prevent or delay approval of our product candidates. In addition, the commercial success of any of our product candidates may be tied to and dependent upon the receipt of required regulatory clearances or approvals of the companion diagnostic.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if a companion diagnostic is approved, we will rely on the continued ability of any third-party collaborator to make the companion diagnostic commercially available to us on reasonable terms in the relevant geographies. Furthermore, if commercial tumor profiling panels are not able to be updated to include additional tumor-associated genes, or if clinical oncologists do not incorporate molecular or genetic sequencing into their clinical practice, we may not be successful in developing or commercializing our existing product candidates or any future product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, approval, clearance or certification of companion diagnostics may be subject to further legislative or regulatory reforms notably in the EU. On May 25, 2017, the new In Vitro Medical Devices Regulation, or IVDR, entered into force. The IVDR repeals and replaces the EU In Vitro Diagnostic Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EU member states, regulations are directly applicable, i.e., without the need for adoption of EU member states laws implementing them, in all EU member states and are intended to eliminate current differences in the regulation of medical devices among EU member states. The IVDR, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EU for in vitro diagnostic medical devices and ensure a high level of safety and health while supporting innovation. The IVDR became applicable on May 26, 2022. Following subsequent legislative changes, European institutions adopted a &#8220;progressive&#8221; roll-out of the IVDR to prevent disruption in the supply of in vitro diagnostic medical devices. Therefore, the IVDR applies since May 26, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">but there is a tiered system extending the grace period for many in vitro diagnostic medical devices (depending on their risk classification) before they have to be fully compliant with the Regulation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulation of companion diagnostics is subject to further requirements since the IVDR became applicable as it introduced a new classification system for companion diagnostics which are now specifically defined as diagnostic tests that support the safe and effective use of a specific medicinal product, by identifying patients that are suitable or unsuitable for treatment. Companion diagnostics will have to undergo a conformity assessment by a notified body. Before it can issue an EU certificate, the notified body must seek a scientific opinion from the EMA on the suitability of the companion diagnostic to the medicinal product concerned if the medicinal product falls exclusively within the scope of the centralized procedure for the authorization of medicines, or the medicinal product is already authorized through the centralized procedure, or a marketing authorization application for the medicinal product has been submitted through the centralized procedure. For other substances, the notified body can seek the opinion from a national competent authorities or the EMA. These modifications may make it more difficult and costly for us to obtain regulatory clearances, approvals or certifications for our companion diagnostics or to manufacture, market or distribute our products after clearance, approval or certification is obtained.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim, &#8220;topline&#8221; and preliminary data from our clinical trials may differ materially from the final data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may publicly disclose preliminary or &#8220;topline&#8221; data from our clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same clinical trials, or different conclusions or considerations may qualify such topline results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data is available. From time to time, we may also disclose interim data from our clinical trials. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and the value of our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically a summary of extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, financial condition, operating results and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be unable to obtain regulatory approval for our product candidates or any future product candidates. The denial or delay of such approval would prevent or delay commercialization of our product candidates and adversely impact our business, financial condition, operating results and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population. Approval policies or regulations may change, and the FDA or comparable foreign regulatory authorities have substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed. Neither we nor any collaborator or any future collaborator, is permitted to market any of our product candidates in the United States or abroad until we receive approval of an NDA from the FDA or similar regulatory approvals from comparable foreign regulatory authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to obtaining approval to commercialize a product candidate in the United States, we or our collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA, that such product candidates are safe and effective for their intended uses. Foreign regulatory authorities may require a similar demonstration before we can obtain approval to commercialize a product candidate abroad. Results from preclinical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA or comparable foreign regulatory authorities. The FDA or a comparable foreign regulatory authority, as the case may be, may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or may object to elements of our clinical development program.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA or a comparable foreign regulatory authority can delay, limit or deny approval of a product candidate for many reasons, including, but not limited to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may disagree with the design or implementation of our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negative or ambiguous results from our clinical trials, or results may not meet the level of statistical significance required by the FDA or a comparable foreign regulatory agency for approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA&#8217;s or the applicable comparable foreign regulatory agency&#8217;s non-approval of the formulation, labeling or specifications of our product candidates or any of our future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities could question the integrity of data obtained in our current or future clinical trials, for example, due to missed protocol procedures;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may disagree regarding the formulation, labeling and/or the specifications of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may only approve indications that are significantly more limited than what we apply for and/or with other significant restrictions on distribution and use; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may find deficiencies in the manufacturing processes or facilities of our third-party manufacturers with which we or any of our collaborators or any potential future collaborators, contract for clinical and commercial supplies; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the approval policies or regulations of such authorities may significantly change in a manner rendering our or any of our collaborators&#8217; clinical data insufficient for approval. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed pharmaceuticals may result in increased cautiousness by the FDA and comparable foreign regulatory authorities in reviewing new drugs based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our collaborators or any potential future collaborators, from commercializing any products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Of the large number of drugs in development, only a small percentage successfully complete the FDA or comparable foreign regulatory approval processes and are commercialized. The lengthy approval process, as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we eventually complete clinical trials and receive approval of an NDA or foreign marketing application for a product, the FDA or a comparable foreign regulatory authority may grant approval contingent on the performance of costly additional clinical trials, including Phase 4 clinical trials, and/or the implementation of a REMS, which may be required to ensure safe use of the drug after approval. The FDA or a comparable foreign regulatory authority also may approve a product candidate for a more limited indication or patient population than we originally requested, and the FDA or a comparable foreign regulatory authority may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may develop our product candidates and future product candidates in combination with other therapies, and safety or supply issues with combination-use products may delay or prevent development and approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may develop our product candidates in combination with one or more cancer therapies, both approved and unapproved. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product candidates or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. Combination therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop any of our product candidates for use in combination with other drugs or for indications other than cancer. Similarly, if the therapies we use in combination with our product candidates are replaced as the standard of care for the indications we choose for any of our product candidates, the FDA or similar regulatory authorities outside of the United States may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also evaluate our product candidates in combination with one or more cancer therapies that have not yet been approved for marketing by the FDA or a similar regulatory authority outside of the United States. We may be unable to effectively identify and collaborate with third parties for the evaluation of our product candidates in combination with their therapies. We will not be able to market and sell any product candidate we develop in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval. The regulations prohibiting the promotion of products for unapproved uses are complex and subject to substantial interpretation by the FDA and other foreign government agencies. In addition, there are additional risks similar to the ones described for our products currently in development and clinical trials that result from the fact that such cancer therapies are unapproved, such as the potential for serious adverse effects, delay in their clinical trials and lack of FDA or comparable foreign regulatory authorities approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA or a similar regulatory authority outside of the United States does not approve these other drugs or revokes approval of, or if safety, efficacy, manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination with any product candidate we develop, we may be unable to obtain approval of or market such product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Although we may apply for orphan drug designation for our product candidates, we may not receive the designation or we may be unable to obtain the benefits associated with such designation, including the potential for marketing exclusivity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. In the United States, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding, tax credits for certain clinical trial costs and user-fee waivers. If a drug with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug and indication for seven years, except in limited circumstances.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, the European Commission grants orphan designation on the basis of the EMA&#8217;s Committee for Orphan Medicinal Products opinion. A medicinal product may be designated as orphan if (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2) either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment; and (3) there exists no satisfactory method of diagnosis, prevention or treatment, of such condition authorized for marketing in the EU, or if such a method exists, the product will be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of significant benefit to those affected by the condition. In the EU, orphan designation entitles a party to financial incentives such as reduction of fees or fee waivers, protocol assistance, and access to the centralized marketing authorization procedure. Moreover, upon grant of a marketing authorization and assuming the requirement for orphan designation are also met at the time the marketing authorization is granted, orphan medicinal products are entitled to a ten-year period of market exclusivity for the approved therapeutic indication. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed Pediatric Investigation Plan, or PIP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we may apply for orphan drug designation for our product candidates, we may not receive the designation we apply for. Even if we received orphan drug designation for one or more of our product candidates, which we have received for darovasertib in UM, there is no guarantee that we will obtain approval or orphan drug exclusivity for the product. Even if we obtain approval and orphan drug exclusivity for any of our product candidates, that exclusivity may not effectively protect the product candidate from competition because different therapies can be approved for the same condition and the same therapy could be approved for different conditions. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to provide greater safety, greater effectiveness or a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. In the EU, during the exclusivity period, marketing authorizations may be granted to a similar medicinal product with the same orphan indication if: (i) the applicant can establish that the second medicinal product, although similar to the orphan medicinal product already authorized is safer, more effective or otherwise clinically superior to the orphan medicinal product already authorized; (ii) the marketing authorization holder for the orphan medicinal product grants its consent; or (iii) if the marketing authorization holder of the orphan medicinal product is unable to supply sufficient quantities of product. The European exclusivity period can be reduced to six years, if, at the end of the fifth year a drug no longer meets the criteria for orphan drug designation (i.e. the prevalence of the condition has increased above the orphan designation threshold or it is judged that the product is sufficiently profitable so as not to justify maintenance of market exclusivity). Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. While we may seek additional orphan drug designations for applicable indications for our current and any future product candidates, we may never receive such designations. Even if we do receive such designations, there is no guarantee that we will enjoy the benefits of those designations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek and fail to obtain fast track or breakthrough therapy designations for our current or future product candidates. Even if we are successful, these programs may not lead to a faster development or regulatory review process, and they do not guarantee we will receive approval for any product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product sponsor may apply for fast track designation. The sponsor of a fast track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once an NDA is submitted, the product candidate may be eligible for priority review. A fast track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted. The FDA has broad discretion whether or not to grant fast track designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Although the FDA has granted fast track designation to darovasertib in combination with crizotinib for treatment of adult patients with MUM and to IDE161 for treatment of adult patients with specific breast cancer or ovarian cancers and we may seek additional designation for other product candidates in the future, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may rescind the fast track designation if it believes that the designation is no longer supported by data from our clinical development program.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also seek breakthrough therapy designation for any product candidate that we develop. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Product candidates designated as breakthrough therapies by the FDA may also be eligible for priority review. Like fast track designation, breakthrough therapy designation is within the discretion of the FDA. Accordingly, even if we believe a product candidate we develop</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to drugs developed under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if a product candidate we develop qualifies as a breakthrough therapy, the FDA may later decide that the drug no longer meets the conditions for qualification and rescind the designation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may attempt to secure approval from the FDA through the use of the accelerated approval pathway. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw any accelerated approval we have obtained.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may in the future seek accelerated approval for our one or more of our product candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. If such post-approval studies fail to confirm the drug&#8217;s clinical benefit or are not completed in a timely manner, the FDA may withdraw its approval of the drug on an expedited basis. In addition, in December 2022, President Biden signed an omnibus appropriations bill to fund the U.S. government through fiscal year 2023 which included the Food and Drug Omnibus Reform Act of 2022, or FDORA. Among other things, the legislation introduced reforms intended to expand the FDA&#8217;s ability to regulate products receiving accelerated approval, including by increasing the FDA&#8217;s oversight over the conduct of confirmatory trials.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review or approval. Furthermore, if we decide to submit an application for accelerated approval for our product candidates, there can be no assurance that such application will be accepted or that any expedited review or approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for a product candidate would result in a longer time period to commercialization of such product candidate, if any, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face significant competition in an environment of rapid technological and scientific change, and our failure to effectively compete may prevent us from achieving significant market penetration. Most of our competitors have significantly greater resources than we do and we may not be able to successfully compete.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and pharmaceutical industries in particular are characterized by rapidly advancing technologies, intense competition and a strong emphasis on developing proprietary therapeutics. We compete with a variety of multinational biopharmaceutical companies and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors have developed, are developing or will likely develop product candidates and processes competitive with our product candidates. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments that enter the market. We believe that a significant number of product candidates are currently under development, and may become commercially available in the future, for the treatment of diseases and other conditions for which we may try to develop product candidates. Our competitors may obtain regulatory approval of their products more rapidly than we may or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. We believe that</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">while our precision medicine target and biomarker discovery platform and our scientific and technical know-how give us a competitive advantage in this space, competition from many sources remains. Our competitors include larger and better funded biopharmaceutical, biotechnological and oncology therapeutics companies, as well as universities and other research institutions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial opportunity and success will be reduced or eliminated if competing products emerge that are safer, more effective, or less expensive than the therapeutics we develop. Our competitors may develop drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than our products and these competitors may also be more successful than us in manufacturing and marketing their products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For darovasertib, we are not aware of other companies actively developing clinical-stage therapeutics directed to PKC as a target for solid tumors. Exscientia is developing a PKC theta inhibitor in inflammatory diseases in Phase 1 studies. Varsity Pharma is preclinically evaluating a PKC inhibitor in CLL. Additionally, Windtree Therapeutics is advancing a preclinical-stage atypical PCK iota inhibitor, including both topical and oral formulations, for potential treatment of Basal Cell Carcinoma, or BCC. We are aware of other companies that are conducting research and development of potential therapies for primary UM or for MUM based on other targets and approaches. For example, Aura Biosciences is developing AU-011, a virus-like drug conjugate (VDC), as local treatment for early-stage choroidal melanoma. Immunocore is developing and commercializing Tebentafusp, also known under its branded name as Kimmtrak, for the treatment of adult patients with HLA-A*02:01-positive unresectable or MUM. iOnctura has initiated a Phase 2 trial for Roginolisib, an allosteric PI3K delta inhibitor, in 2L+ MUM. Novartis is developing DYP688, an ADC, with a GNAQ-11 inhibitor payload in a Phase 1/2 clinical trial in MUM. Additionally, Replimune has initiated a potentially registration-enabling trial for RP-2, an oncolytic immunotherapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For IDE397, Servier Pharmaceuticals, LLC, or Servier, is evaluating a small molecule MAT2A inhibitor, designated as S95035, in a Phase 1 trial. Insilico Medicine and Beigene have also initiated Phase 1 trials for their small molecule MAT2A inhibitors called ISM3412 and SYH2039, respectively. Additionally, Anagenex, Genhouse Bio, Hanmi, ScinnoHub and SK Biopharma have small molecule MAT2A inhibitors in preclinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For IDE849, our competitors include companies developing DLL3-targeting therapies using various therapeutic modalities, including bispecific T-cell engagers (BiTEs), antibody-drug conjugates (ADCs), chimeric antigen receptor (T-cell) therapies, and radiopharmaceuticals. Amgen received accelerated approval from the FDA in May 2024 for Tarlatamab (branded name Imdelltra), a DLL3-CD3 BiTE. Boehringer Ingelheim and Daiichi Sankyo are developing drugs with a similar mechanism of action, both in Phase 2 studies. We are aware of several companies developing DLL3 ADCs with topoisomerase-I-inhibitor-payloads in Phase 1 studies, including Zai Lab, Roche, Zhang Jiang, and Baili. In radiopharmaceuticals, Abdera initiated a Phase 1 clinical trial for ABD-147 at the end of 2024, and several other companies are pursuing preclinical development of DLL3-targeting radiotherapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For IDE161, 858 Therapeutics has initiated a Phase 1 clinical trial for its small molecule PARG inhibitor, ETX-19477. Danatlas received IND clearance for its PARG inhibitor, DAT-2645, in August 2024, and Evopoint received clearance from the NMPA in December 2024. Additionally, several companies are conducting preclinical research to develop PARG inhibitors, including Alivexis, Azkarra, FoRx, Nodus Oncology, Satya Pharma Innovations and SynRx.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For GSK101 (IDE705), Artios Pharma is developing a Pol Theta inhibitor, designated as ART-6043, in a Phase 1/2 study. Several other companies have initiated Phase 1 studies for Pol Theta inhibitors, including Moma Therapeutics, Repare Therapeutics, Varsity Therapeutics, Simcere, and SynRx. Additionally, Breakpoint Therapeutics and Danatlas have Pol Theta inhibitors in IND-enabling studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For GSK959 (IDE275), Novartis is evaluating a non-covalent Werner Helicase (WRN) inhibitor called HRO-761 in a Phase 1 trial. Roche is developing a covalent WRN inhibitor, designated as RG6457, in a Phase 1 trial. Additionally, several companies are conducting preclinical research to develop WRN inhibitors, including Eikon, Genhouse, Insilico, Nimbus, Puhe and Ryvu, among others.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For IDE892, we are aware of many companies developing PRMT5 inhibitors in both clinical and preclinical stages. The most advanced assets are currently in Phase 1/2 studies, including BMS-986504 from BMS, AMG-139 from Amgen, TNG462 from Tango, AZD-3470 from AstraZeneca, and BGB-58067 from Beigene. At least nine other companies have initiated Phase 1 clinical trials and more than fifteen companies are advancing preclinical PRMT5 inhibitors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For BCG034, we are not aware of any other companies developing bispecific ADCs targeting both B7-H3 and PTK7; however, many companies are developing mono-antigen ADCs targeting either B7-H3 or PTK7. Merck and Hansoh are both</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">evaluating B7-H3 ADCs in Phase 3 clinical trials. Several other companies have B7-H3 ADCs in earlier phases of clinical development, including Beigene, Duality, GSK, Innovent, Mabwell, MacroGenics, MediLink, and Minghui. Furthermore, Genmab, Kelun, and Day One are evaluating PTK7 ADCs in Phase 1 studies, and Lilly is advancing a preclinical PTK7 ADC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For IDE251, we are not aware of other companies developing therapeutics directed to both KAT6 and KAT7; however, there are several companies developing drugs directed to KAT6. Pfizer is developing a KAT6A inhibitor, designated as PF-07248144, in a Phase 1 trial. Menarini also recently initiated a Phase 1 study for a KAT6A inhibitor called MEN-2312. Olema Oncology received IND clearance for a KAT6A/B inhibitor in December 2024 and is expected to begin a Phase 1 trial soon. Additionally, Isoterix and Qubit are developing preclinical KAT6A inhibitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For our preclinical pipeline of synthetic lethality therapeutics, potential competition includes established companies, as well as earlier-stage emerging biotechnology companies. Multiple established companies have been involved with research and development in synthetic lethality, such as AstraZeneca (Lynparza), Pfizer (Talzenna), GSK (Zejula) and Roche. Additionally, several other early-stage companies are developing synthetic lethality therapeutics, including 858 Therapeutics, Artios, Breakpoint Therapeutics, Eikon, FoRx Therapeutics, Repare Therapeutics, Ryvu Therapeutics, Tango, Vividion and Xpose.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development decisions and data from clinical trials of our competitors may adversely impact clinical development of our product candidates, and may additionally or alternatively have a material adverse impact on our financial condition or business prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, we also face competition more broadly across the market for cost-effective and reimbursable cancer treatments. The most common methods of treating patients with cancer are surgery, radiation and drug therapy, including chemotherapy, hormone therapy and targeted drug therapy or a combination of such methods. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Insurers and other third-party payors may also encourage the use of generic products or specific branded products. We expect that if our product candidates are approved, they will be priced at a significant premium over competitive generic, including branded generic, products. As a result, obtaining market acceptance of, and a gaining significant share of the market for, any of our product candidates that we successfully introduce to the market will pose challenges. In addition, many companies are developing new therapeutics, and we cannot predict what the standard of care will be as our product candidates progress through clinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, we may also develop diagnostics to enable relevant biomarker screening for clinical and commercial purposes in connection with our product candidates. If not already commercially available, we anticipate working in collaboration with diagnostic companies for this development, and we will face competition from other companies in establishing these collaborations. Our competitors will also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, coverage, reimbursement and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any products we may develop. Competing products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect to expand our development and regulatory capabilities and potentially implement sales and distribution capabilities, and as a result, we will need to increase the size of our organization, and we may experience difficulties in managing growth.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had 131 employees. We will need to continue to expand our managerial, operational, finance and other resources in order to manage our operations and clinical trials, continue our development activities, submit for regulatory approval and, if approved, commercialize our product candidates or any future product candidates. Our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">management and personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively execute our growth strategy requires that we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manage our preclinical studies and clinical trials effectively; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identify, recruit, retain, incentivize and integrate additional employees, including sales personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manage our internal development and operational efforts effectively while carrying out our contractual obligations to third parties; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to improve our operational, financial and management controls, reports systems and procedures.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no assurance that any of these increases in scale, expansion of personnel, equipment, software and computing capacities, or process enhancements will be successfully implemented, or that we will have adequate space in our laboratory facilities to accommodate such required expansion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we may not be able to market and sell any products effectively, if approved, or generate product revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we have filled the Chief Commercial Officer position in the fourth quarter of 2024, we currently do not have a marketing or sales organization. In order to commercialize any product, if approved, in the United States and foreign jurisdictions, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. In advance of any of our product candidates receiving regulatory approval, we expect to establish a sales organization with technical expertise and supporting distribution capabilities to commercialize each such product candidate, which will be expensive and time-consuming. We have no prior experience in the marketing, sale and distribution of pharmaceutical products, and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain, and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. Under our GSK Collaboration Agreement, GSK will be responsible for commercialization of any Pol Theta or WRN products. We may choose to collaborate with additional third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our product candidates. If we are not successful in commercializing products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to attract and retain senior management and key scientific and commercial personnel, our business may be materially and adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical, scientific and commercial personnel. We are highly dependent upon our senior management, particularly our President and Chief Executive Officer, as well as our senior scientists and other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of any products, initiation or completion of our planned clinical trials or the commercialization of our product candidates or any other product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition for qualified personnel in the biotechnology and biopharmaceutical fields is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and if we initiate commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output.</span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees and independent contractors, including principal investigators, consultants, collaborators, service providers and other vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk that our employees and independent contractors, including principal investigators, consultants, collaborators, service providers and other vendors may engage in misconduct or other illegal activity. Misconduct by these</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate: the laws and regulations of the FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies; manufacturing standards; U.S. federal and state healthcare fraud and abuse laws, data privacy and security laws and other similar non-U.S. laws; or laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third-parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our research and development activities and our third-party manufacturers&#8217; and suppliers&#8217; activities involve the controlled storage, use and disposal of hazardous materials owned by us, including the components of our product candidates and other hazardous compounds. We and any third-party manufacturers and suppliers we engage are subject to numerous federal, state and local environmental, health and safety laws, regulations and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment, and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#8217; facilities pending their use and disposal. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination, which could cause an interruption of our research and development efforts, commercialization efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research, product development and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials and pollution insurance to cover us for certain biological or hazardous waste exposure and contamination situations, this insurance may not provide adequate coverage against potential liabilities. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We attempt to distribute our technology, biology, execution and financing risks across a range of therapeutic classes, disease states, programs and technologies. Due to the significant resources required for the development of our broad portfolio of programs, and depending on our ability to access capital, we must make certain risk assessments and prioritize</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">development of certain product candidates. Moreover, we may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our organization is committed to a broad approach to precision medicine that seeks to maximize our integrated biomarker and small molecule drug discovery capabilities. Our current portfolio consists of multiple programs, extending across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. Together, these programs require significant capital investment. The directly targeted therapy programs are at various stages of preclinical and clinical development, and our synthetic lethality programs are in the target identification, validation, lead optimization, and clinical stages of development. We seek to maintain a process of prioritization and resource allocation to maintain an optimal balance between advancing and expanding our synthetic lethality and direct targeting programs. Because we have limited financial and managerial resources, we focus on specific product candidates, indications and discovery programs. As a result, we may forgo or delay pursuit of opportunities with other product candidates that could have had greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaborations, licenses and other similar arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, as our programs progress, we or others may determine: that certain of our risk allocation decisions were incorrect or insufficient; that we made platform level technology mistakes; that individual programs or our approach to synthetic lethality or precision medicine in general has technology or biology risks that were unknown or underappreciated; that our choices on how to build our organizational infrastructure to drive our expansion will result in an inability to manufacture our products for clinical trials or otherwise impede our manufacturing capabilities; or that we have allocated resources in such a way that large investments are not recovered and capital allocation is not subject to rapid re-direction. All of these risks may relate to our current or future precision medicine programs or companion diagnostics, and in the event material decisions in any of these areas turn out to have been incorrect or under-optimized, we may experience a material adverse impact on our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Public health outbreaks, epidemics or pandemics (such as the COVID-19 pandemic) may materially and adversely affect our business and operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The COVID-19 pandemic previously adversely affected, and the COVID-19 pandemic or other actual or threatened public health outbreaks, epidemics, or pandemics may in the future adversely affect, among other things, our research and development efforts, clinical trial operations, manufacturing and supply chain operations, administrative personnel, third-party service providers, and business partners. While the COVID-19 pandemic did not materially adversely affect our business operations during the twelve months ended December 31, 2024, economic and health conditions in the United States and across most of the globe continue to change rapidly and may materially affect us economically. A continuing widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from a future public health outbreak could materially affect our business and the value of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain, or deploy key leadership and other personnel, or otherwise prevent products from being developed, approved, or commercialized in a timely manner or at all, which may adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA and other government agencies to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies, including a prolonged government shutdown, or such as the European Medicines Agency following its relocation to Amsterdam and resulting staff changes, may cause significant regulatory delays and, therefore, delay our efforts to seek approvals and adversely affect our business, financial condition, results of operations, or cash flows. For example, over</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the last several years, the U.S. government has shut down several times, and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, in response to the COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. Even though the FDA has since resumed standard inspection operations, any resurgence of the virus or emergence of new variants or other health outbreaks may lead to inspectional or administrative delays. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA and other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our corporate headquarters is located in the San Francisco Bay Area, which in the past has experienced both severe earthquakes and wildfires. We do not carry earthquake insurance. Earthquakes, wildfires or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters or other facilities, that damaged critical infrastructure, such as our enterprise financial systems or manufacturing resource planning and enterprise quality systems, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, the third parties on which we depend, including suppliers, contract manufacturers and CROs are similarly vulnerable to natural disasters or other sudden, unforeseen and SAEs. If such an event were to affect our supply chain, manufacturing arrangements or interfere with a preclinical study or clinical trial, it could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine, potential changes in global trade policies, including tariffs, and other geopolitical tensions. Our business, financial condition and results of operations may be materially adversely affected by any negative impact on the global economy and capital markets resulting from the conflict in Ukraine, potential changes in global trade policies, including tariffs, or any other geopolitical tensions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the ongoing military conflict between Russia and Ukraine. In February 2022, a military invasion of Ukraine by Russian troops was reported. Following the invasion, the U.S. and global financial markets experienced volatility, which has led to disruptions to trade, commerce, pricing stability, credit availability and supply chain continuity globally. In response to the invasion, the United States, United Kingdom and European Union, along with others, imposed significant new sanctions and export controls against Russia, Russian banks and certain Russian individuals and may implement additional sanctions or take further punitive actions in the future. The full economic and social impact of the sanctions imposed on Russia (as well as possible future punitive measures that may be implemented), as well as the counter measures imposed by Russia, in addition to the ongoing military conflict between Ukraine and Russia and related sanctions, which could conceivably expand into the surrounding region, remains uncertain; however, both the conflict and related sanctions have resulted and could continue to result in disruptions to trade, commerce, pricing stability, credit availability and supply chain continuity in both Europe and globally, and has introduced significant uncertainty into global markets. Such risks and disruptions may negatively impact our supply chain, manufacturing arrangements, preclinical studies, clinical trials and our access to capital markets and ability to finance operations, which could have a materially adverse impact on our results of operations, financial condition and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, during the last few years, there have also been significant changes to U.S. and other countries&#8217; trade policies, export control laws, sanctions, legislation, treaties and tariffs, including, but not limited to, U.S. trade policies and tariffs affecting China. There is significant uncertainty about the future of trade relationships around the world, including potential changes to trade laws and regulations, trade policies, and tariffs. As an example, on February 1, 2025, the U.S. government announced a 25% tariff on product imports from certain countries, including Mexico and Canada, and 10% tariffs on product imports from certain countries, including China. Some foreign governments, including China, have instituted retaliatory tariffs on certain U.S. goods and have indicated a willingness to impose additional tariffs on U.S. products. Other countries, including Mexico, have threatened retaliatory tariffs on certain U.S. products. We cannot predict what additional actions may ultimately be taken by the United States or other governments with respect to tariffs or trade relations, what products may be subject to such actions (including subject to U.S. export control restrictions), or what actions may be taken by the other countries in retaliation. The imposition of additional tariffs or other trade barriers, together with any future downturns in the global economy resulting therefrom, could adversely affect our financial performance. Additionally, it is possible that government policy changes and uncertainty about such changes could increase market volatility and currency exchange rate fluctuations. As a result of these dynamics, we cannot predict the impact to our business of any future changes to the United States&#8217; or other countries&#8217; trading relationships or the impact of new laws or regulations adopted by the United States or other countries.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The commercial success of our partnered product candidates in our Pol Theta and WRN programs, which are part of the GSK Collaboration Agreement, will depend in large part on the development and marketing efforts of GSK. If GSK is unable to perform in accordance with the terms of the GSK Collaboration Agreement, our potential to generate future revenue from these programs would be significantly reduced and our business would be materially and adversely harmed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will have limited influence and/or control over GSK&#8217;s approaches to development and commercialization of any Pol Theta or WRN products. While we will have the right to receive potential milestone, profit share and royalty streams payable as GSK or its sublicensees advance development of such Pol Theta or WRN products, we are likely to have limited ability to influence GSK&#8217;s development and commercialization efforts. If GSK does not perform in the manner that we expect or fulfill its responsibilities in a timely manner, or at all, the clinical development, regulatory approval and commercialization efforts related to product candidates we have licensed to GSK could be delayed or terminated. Furthermore, GSK or its licensees may elect to devote greater resources to other programs that do not relate to us or our collaboration.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we terminate the GSK Collaboration Agreement, or any program thereunder due to a material breach by GSK, we have the right to assume the responsibility at our own expense for the development of the applicable product candidates. Assumption of sole responsibility for further development will greatly increase our expenditures, and may mean we need to limit the size and scope of one or more of our programs, seek additional funding and/or choose to stop work altogether on one or more of the affected product candidates. This could result in a limited potential to generate future revenue from such product candidates, and our business could be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties to conduct certain of our preclinical studies and all of our clinical trials and intend to rely on third parties in the conduct of all of our future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, it may delay or prevent us from seeking or obtaining regulatory approval or commercializing our current or future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently do not have the ability to independently conduct preclinical studies that comply with the regulatory requirements known as good laboratory practice, or GLP, requirements. We also do not currently have the ability to independently conduct any clinical trials. The FDA and regulatory authorities in other jurisdictions require us to comply with regulations and standards, commonly referred to as GCP, requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the clinical trial patients are adequately informed of the potential risks of participating in clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct GLP-compliant preclinical studies and GCP-compliant clinical trials on our product candidates properly and on time. The third parties with whom we contract for execution of our GLP-compliant preclinical studies and our GCP-compliant clinical trials play a significant role in the conduct of these studies and trials and the subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited ability to control the amount or timing of resources that they devote to our programs. Although we rely on these third parties to conduct our GLP-compliant preclinical studies and GCP-compliant clinical trials, we remain responsible for ensuring that each of our GLP preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. Further, some of these agreements may also be terminated by such third parties on short notice, or under certain circumstances, including our insolvency. If the third parties conducting our preclinical studies or our clinical trials do not adequately perform their contractual duties or obligations, experience significant business challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be difficult, costly or impossible, and our preclinical studies or clinical trials may need to be extended, delayed, terminated or repeated. As a result, we may not be able to obtain regulatory approval in a timely fashion, or at all, for the applicable product candidate, and our business, financial position, results of operations and prospects may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties for the manufacture of our product candidates for preclinical and clinical development and expect to continue to do so for the foreseeable future. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not own or operate manufacturing facilities and have no plans to build our own clinical or commercial scale manufacturing capabilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates and related raw materials for preclinical and clinical development, as well as for commercial manufacture of any future approved products. The facilities used by third-party manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit our NDA to the FDA. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with cGMP requirements or similar applicable foreign requirements for manufacture of drug products. If these third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or other comparable foreign regulatory authorities, including requirements related to the manufacturing of high potency compounds, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. These third-party manufacturers may be delayed in their manufacture or shipment of our product candidates due to public health outbreaks, heightened geopolitical conflict, increases in inflation and interest rates, or supply chain disruptions. For example, deterioration in the relationship between the United States and the PRC may impact international trade, government spending, regional stability and macroeconomic conditions. The impact of these potential developments, including any resulting sanctions, export controls or other restrictive actions that may be imposed against governmental or other entities in, for example, the PRC, may contribute to disruption of our PRC-based third-party suppliers and instability and volatility in the global markets, which in turn could adversely impact our operations and weaken our financial results. Additionally, our ability to audit these third-party manufacturers for compliance with cGMP requirements or similar foreign requirements (where applicable) and our specifications may be hindered or delayed due to a public health outbreak or geopolitical conditions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we have no control over the ability of third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we currently and may in the future rely on foreign contract manufacturing organizations, or CMOs, contract research organizations, or CROs and other foreign organizations and companies that conduct manufacturing or research for us. Such foreign entities may be subject to U.S. legislation, sanctions, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material or have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies. For example, in January 2024, there was Congressional activity, including the introduction of the BIOSECURE Act (H.R. 7085) in the House of Representatives and a substantially similar Senate bill (S.3558). The BIOSECURE Act was passed by the House of Representatives in September 2024. If these bills become law, or similar laws are passed, they would have the potential to severely restrict the ability of U.S. biopharmaceutical companies like us to purchase services or products from, or otherwise collaborate with, certain Chinese biotechnology companies &#8220;of concern&#8221; without losing the ability to contract with, or otherwise receive funding from, the U.S. government.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may be unable to establish or renew any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">breach of the manufacturing agreement by the third-party; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to manufacture our product according to our specifications; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to manufacture our product according to our schedule or at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">misappropriation of our proprietary information, including our trade secrets and know-how; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination or nonrenewal of the agreement by the third-party at a time that is costly or inconvenient for us. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us, particularly if the COVID-19 pandemic, geopolitical conflict and macroeconomic concerns continue or worsen.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval, and any related remedial measures may be costly or time-consuming to implement. We do not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture of our product candidates. If our current third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on, and in the future may rely on, third-party databases and collaborations with third parties to inform patient selection and drug target identification for our existing product candidates and any future product candidates and for the supply of biomarker companion diagnostics</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are using bioinformatics, including data analytics, biostatistics, and computational biology, to identify new target and biomarker opportunities. As part of this approach, we interrogate public and proprietary databases comprising human tumor genetic information and specific cancer-target dependency networks. We rely on these databases and data analytics for identifying or validating some of our biomarker-target relationships and access to these databases may not continue to be available publicly or through a proprietary subscription on acceptable terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our precision medicine targeted therapeutic product candidates also rely on the availability and use of commercially available tumor diagnostics panels or data on the prevalence of our target patient population to inform the patient selection and drug target identification for our product candidates. In cases where such biomarker diagnostic is not already commercially available, we expect to establish strategic collaborations for the clinical supply and development of companion diagnostics. If these diagnostics are not able to be developed, or if commercial tumor profiling panels are not able to be updated to include additional tumor-associated genes, or if clinical oncologists do not incorporate molecular or genetic sequencing into their clinical practice, we may not be successful in developing our existing product candidates or any future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We depend on third-party suppliers for key materials required for the production of our product candidates, and the loss of these third-party suppliers or their inability to supply us with adequate materials could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third-party suppliers for certain materials, such as starting reagents, required for the production of our product candidates and/or for certain materials and assays, such as diagnostics, for clinical and commercial use of our product candidates. Our dependence on these third-party suppliers and the challenges we may face in obtaining adequate supplies of materials involve several risks, including limited control over pricing, availability, quality and delivery schedules. As a small company, our negotiation leverage is limited and we are likely to get lower priority than our competitors that are larger than we are. We cannot be certain that our suppliers will continue to provide us with the quantities of these raw materials that we require or satisfy our anticipated specifications and quality requirements. Any supply interruption in limited or sole sourced raw materials could materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential commercialization of our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the facilities to manufacture our product candidates must be the subject of a satisfactory inspection before the FDA or other regulatory authorities approve an NDA or grant a marketing authorization for the product candidate manufactured at that facility. We will depend on these third-party manufacturing partners for compliance with the FDA&#8217;s requirements for the manufacture of our finished products. If our manufacturers cannot successfully manufacture material that conforms to our specifications and the FDA&#8217;s and other regulatory authorities&#8217; GMP requirements, our product candidates will not be approved or, if already approved, may be subject to recalls.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, certain of the third-party suppliers on which we rely are based in the PRC. The evolving trade dispute between the PRC and the United States has resulted in the imposition of significant tariffs on certain imports from the PRC. Any deterioration of the relationship between the United States and the PRC, or the imposition of more stringent export controls or tariffs applicable to our suppliers in the PRC, could adversely affect our ability to obtain the raw materials required for the manufacture of our product candidates, and therefore adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured the product candidates ourselves, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possibility of a breach of the manufacturing agreements by the third parties because of factors beyond our control; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possibility of termination or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified replacement third-party manufacturer; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possibility that we may not be able to secure a manufacturer or manufacturing capacity in a timely manner and on satisfactory terms in order to meet our manufacturing needs. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these factors could cause the delay of approval or commercialization of any products, cause us to incur higher costs or prevent us from commercializing any products successfully. Furthermore, if any of our product candidates are approved and contract manufacturers fail to deliver the required commercial quantities of finished product on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality and on a timely basis, we would likely be unable to meet demand for our products and could lose potential revenue. It may take several years to establish an alternative source of supply for our product candidates and to have any such new source approved by the FDA or any other relevant regulatory authority.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with our obligations under any of our in-license agreements, we could lose license rights that are important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current in-license agreements or any future in-license agreements provide or may provide that we must use reasonable efforts to obtain regulatory approval for a product candidate using the licensed compound. The agreements further impose or may impose an obligation to make various milestone payments and royalty payments, as well as other obligations on us. If we materially breach the terms of any in-license agreement and fail to cure such breach within the period allowed, then the licensor may terminate the license agreement. In addition, the licensor has or may have the right to terminate on our insolvency. If the agreement is terminated, then we will not be able to further develop or commercialize the licensed compound or any future related product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, any dispute with the licensor may result in the delay or termination of the research, development or commercialization of the licensed compound or any future related product candidates, and may result in costly litigation or arbitration that diverts management attention and resources away from our day-to-day activities, which may adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our existing collaboration arrangements and any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our product candidates or diagnostics associated with such product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the future, we may seek to enter into additional collaboration arrangements for the development or commercialization of certain of our product candidates or diagnostics for biomarkers associated with our product candidates. To the extent that we</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decide to enter into additional collaboration agreements in the future, we may face significant competition in seeking appropriate collaborators. Moreover, collaboration arrangements are complex and time-consuming to negotiate, document, implement and maintain and challenging to manage. We may not be successful in our efforts to prudently manage our existing collaborations or to enter new ones should we chose to do so. The terms of new collaborations or other arrangements that we may establish may not be favorable to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success of our collaboration arrangements, including our GSK Collaboration Agreement, will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include risks that:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may have significant discretion in determining the efforts and resources that they will apply to collaborations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in their strategic focus due to their acquisition of competitive products or their internal development of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a collaborator with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our current or future product candidates or that results in costly litigation or arbitration that diverts management attention and resources; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborations may be terminated, which may result in a need for additional capital to pursue further development or commercialization of the applicable current or future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may own or co-own intellectual property covering products that result from our collaboration with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes may arise with respect to the ownership or inventorship of any intellectual property developed pursuant to our collaborations; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a collaborator&#8217;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Commercialization of Our Product Candidates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we receive regulatory approval for any product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If one of our product candidates is approved, it will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, the FDA or similar foreign regulatory authorities may impose significant restrictions on a product&#8217;s indicated uses or marketing or impose ongoing requirements for potentially costly and time-consuming post-approval studies, post-market surveillance or clinical trials to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Similar requirements may apply in foreign jurisdictions. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, AE reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs or similar foreign requirements and GCP requirements for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our product candidates, including AEs of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension or withdrawal of regulatory approval, restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on product distribution or use, or requirements to conduct post-marketing studies or additional clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension of any of our ongoing clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal by the FDA or comparable foreign regulatory authorities to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of our product candidates; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The occurrence of any event or penalty described above may inhibit our ability to commercialize any future approved product and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if any of our product candidates is approved, our product labeling, advertising and promotion will be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. Similar requirements may apply in foreign jurisdictions. If we receive marketing approval for a product, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The incidence and prevalence of our target patient populations are estimations. If the market opportunities for our product candidates are smaller than we estimate, our business, financial position, results of operations and prospects may be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on various sources, including published literature and public or proprietary databases, to ascertain an estimate of the number of patients having particular genetic alterations, such as mutations, deletions or fusions, across various tissue-type specific indications. The determinable prevalence may vary depending on the source and quality of the underlying data and in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">some cases, insufficient data or poorly curated data may impact our ability to accurately estimate the prevalence of our target patient populations for each indication and in the aggregate across multiple indications both in the clinical trial setting, as well as in the commercial setting, if our product is approved. If the market opportunities for our product candidates are smaller than we estimate, our business, financial position, results of operations and prospects may be harmed. In addition, upon treatment with our product candidates, patients may have or develop resistance to our product candidates, reducing the addressable patient population and the duration of treatment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if our product candidates or any future product candidate obtains regulatory approval, they may fail to achieve the broad degree of physician and patient adoption and use necessary for commercial success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if our product candidates or any future product candidate receives FDA or other regulatory approvals, the commercial success of any product will depend significantly on the broad adoption and use of the resulting product by physicians and patients for approved indications. For a variety of reasons, including among other things, competitive factors, pricing or physician preference, reimbursement by insurers, the degree and rate of physician and patient adoption of any products, if approved, commercial success will depend on a number of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical indications for which the product is approved and patient demand for approved products that treat those indications; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the safety and efficacy of our product as compared to other available therapies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of companion diagnostics for biomarkers associated with our product candidates or any other future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the time required for manufacture and release of our products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of coverage and adequate reimbursement from managed care plans, private insurers, government payors (such as Medicare and Medicaid) and other third-party payors for any of our products that may be approved; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance by physicians, operators of hospitals and clinics and patients of the product as a safe and effective treatment; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">physician and patient willingness to adopt a new therapy over other available therapies for a particular indication; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">proper training and administration of our product candidates by physicians and medical staff; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient satisfaction with the results and administration of our product candidates and overall treatment experience, including, for example, the convenience of any dosing regimen; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of treatment with our product candidates in relation to alternative treatments and reimbursement levels, if any, and willingness to pay for the product, if approved, on the part of insurance companies and other third-party payors, physicians and patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of side effects;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitations or warnings contained in the FDA-approved labeling for our products or similar foreign requirements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of physicians, operators of hospitals and clinics and patients to utilize or adopt our products as a solution; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any FDA requirement for a REMS or similar foreign risk mitigation measures; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of our sales, marketing and distribution efforts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse publicity about our products or favorable publicity about competitive products; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential product liability claims. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot assure you that our current or future product candidates, if approved, will achieve broad market acceptance among physicians and patients. Any failure by our product candidates that obtain regulatory approval to achieve market acceptance or commercial success would adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The successful commercialization of any products will depend in part on the extent to which governmental authorities, private health insurers, managed care plans and other third-party payors provide coverage, adequate reimbursement levels and implement pricing policies favorable for any products. Failure to obtain or maintain coverage and adequate</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">reimbursement for products, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The availability of coverage and adequacy of reimbursement by governmental healthcare programs, such as Medicare and Medicaid, private health insurers, managed care plans and other third-party payors are essential for most patients to be able to afford medical services and pharmaceutical products such as our product candidates that receive FDA approval. Our ability to achieve acceptable levels of coverage and reimbursement by third-party payors for our products will have an effect on our ability to successfully commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. The process for determining whether a third-party payor will provide coverage for a product typically is separate from the process for setting the price of such product or for establishing the reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved products for a particular indication, or place products at certain formulary levels that result in lower reimbursement levels and higher cost-sharing obligation imposed on patients. One third-party payor&#8217;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service. As a result, the coverage determination process will often require us to provide scientific and clinical support for the use of our products to each payor separately and can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. We cannot be sure that coverage will be available for any product that we may develop. A decision by a third-party payor not to cover any of our product candidates could reduce physician utilization of our products once approved and adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assuming there is coverage for our products, if any, by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our products, pricing of other third-party therapeutics may limit the amount we will be able to charge for our products. These third-party payors may deny or revoke the reimbursement status of our products, if approved, or establish prices for our products at levels that are too low to enable us to realize an appropriate return on our investment. If reimbursement is not available, is decreased or eliminated in the future, or is available only at limited levels, we may not be able to successfully commercialize our products and may not be able to obtain a satisfactory financial return on our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of our products, if any. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products, and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face an inherent risk of product liability as a result of the planned clinical trials of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, and a breach of warranty. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of any products. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for any products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injury to our reputation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs to defend the related litigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a diversion of management&#8217;s time and our resources; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards to clinical trial participants or patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of revenue; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to commercialize any products. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of any products. Although we have obtained and intend to maintain product liability insurance covering our clinical trials, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient funds to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing any of our product candidates, we intend to expand our insurance coverage to include the sale of such product candidate; however, we may be unable to obtain this liability insurance on commercially reasonable terms or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our success depends on our ability to obtain and maintain protection for our intellectual property and our proprietary technologies and to avoid infringing the rights of others.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends in part on our ability to obtain and maintain patent, trademark, trade secret and other intellectual property protection for our product candidates and proprietary technologies, as well as our ability to operate without infringing upon the proprietary rights of others.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and our licensors have applied, and we intend to continue applying, for patents covering important aspects of our product candidates, proprietary technologies and their uses as we deem appropriate. However, the patent prosecution process is expensive, time-consuming and complex, and we may not be able to apply for patents on certain aspects of our current or future product candidates and proprietary technologies in a timely fashion, at a reasonable cost, in all jurisdictions, or at all. If we cannot adequately obtain, maintain and enforce our intellectual property rights and proprietary technology, competitors may be able to use our technologies or the goodwill we have acquired in the marketplace and erode or negate any competitive advantage we may have and our ability to compete, which could harm our business and ability to achieve profitability and/or cause us to incur significant expenses. Failure to obtain, maintain and/or enforce intellectual property rights necessary to our business and failure to protect, monitor and control the use of our intellectual property rights could negatively impact our ability to compete and cause us to incur significant expenses. The intellectual property laws and other statutory and contractual arrangements in the United States and other jurisdictions we depend upon may not provide sufficient protection in the future to prevent the infringement, use, violation or misappropriation of our patents, trademarks, data, technology and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other intellectual property rights and products by others, and may not provide an adequate remedy if our intellectual property rights are infringed, misappropriated or otherwise violated by others.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our patent applications cannot be enforced against third parties practicing the inventions claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the invention as claimed. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our actual or potential future collaborators or licensors will be successful in protecting our product candidates and proprietary technologies by obtaining and defending patents. These risks and uncertainties include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the United States Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other requirements during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patent applications may not result in any patents being issued; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained or licensed patents that will limit, interfere with or eliminate our ability to make, use and sell our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other parties may have designed or may design around our claims or developed technologies that may be related or competitive to our platform, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent applications, either by claiming the same methods or devices or by claiming subject matter that could dominate our patent position; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any successful opposition to any patents owned by or licensed to us could deprive us of rights necessary for the practice of our technologies or the successful commercialization of any product candidates that we may develop;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">because patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we or our licensors were the first to file any patent application related to our product candidates and proprietary technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an interference proceeding can be provoked by a third-party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications for any application with an effective filing date before March 16, 2013; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely in part on our portfolio of issued and pending patent applications in the United States and other countries to protect our intellectual property and competitive position. The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. It is possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. If we fail to timely file for patent protection in any jurisdiction, we may be precluded from doing so at a later date. And although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in any of our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Moreover, should we become a licensee of a third-party&#8217;s patents or patent applications, depending on the terms of any future in-licenses to which we may become a party, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain or enforce the patents, covering technology in-licensed from third parties. Therefore, these patents and patent applications may not be prosecuted, maintained and/or enforced in a manner consistent with the best</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interests of our business. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and it may not provide us with adequate proprietary protection or competitive advantages against competitors with similar products or services. Accordingly, we cannot provide any assurances about which of our patent applications will issue, the breadth of any resulting patent, whether any of the issued patents will be found to be infringed, invalid or unenforceable or will be threatened or challenged by third parties, that any of our issued patents have, or that any of our currently pending or future patent applications that mature into issued patents will include, claims with a scope sufficient to protect our products and services. The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. We cannot offer any assurances that the breadth of our granted patents will be sufficient to stop a competitor from developing, manufacturing and commercializing a product or technologies in a non-infringing manner that would be competitive with one or more of our products or technologies, or otherwise provide us with any competitive advantage. Further, our patents or the patent rights that we license from others, may be challenged in the courts or patent offices in the United States and abroad. Once granted, patents may remain open to opposition, interference, re-examination, post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review, nullification or derivation action or similar proceedings in court or before patent offices in the United States or foreign jurisdictions for a given period after allowance or grant, during which time third parties can raise objections against such patents. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, all of which could limit our ability to stop others from using or commercializing similar or identical product candidates, or limit the duration of the patent protection of our product candidates. In addition, defending such challenges in such proceedings may be costly. Further, there can be no assurance that we will have adequate resources to enforce our patents. Thus, any patents that we may own may not provide the anticipated level of, or any, protection against competitors. Furthermore, an adverse decision may result in a third-party receiving a patent right sought by us, which in turn could affect our ability to develop, manufacture or commercialize our products or technologies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection for our patent rights is uncertain, and we cannot ensure that:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any of our pending patent applications will issue as patents;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any of the patents we own or license will be found to ultimately be valid and enforceable if subject to challenge; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we were the first to make the inventions covered by each of our patents and pending applications;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we were the first to file patent applications for these inventions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we will be able to successfully manufacture and commercialize our products on a substantial scale, if approved, before relevant patents we may have expire;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any patents issued to us or our licensors will provide a basis for an exclusive market for any commercially viable products we may develop or will provide us with any competitive advantages; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we will develop or in-license additional proprietary technologies that are patentable; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of others will not have an adverse effect on our business; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others will not develop, manufacture and/or commercialize similar or alternative products or technologies that do not infringe our patents;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors do not conduct research and development activities in countries where we do not have enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our commercial activities or products will not infringe upon the patents of others.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to enforce patent rights also depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products and services. Such proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product or service. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. If we initiate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lawsuits to protect or enforce our patents, or litigate against third-party claims, such proceedings would be expensive and would divert the attention of our management and technical personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where we obtain licenses from or collaborate with third parties, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties, or such activities, if controlled by us, may require the input of such third parties. We may also require the cooperation of our licensors and collaborators to enforce any licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Moreover, if we do obtain necessary licenses, we will likely have obligations under those licenses, and any failure to satisfy those obligations could give our licensor the right to terminate the license. Termination of a necessary license, or expiration of licensed patents or patent applications, could have a material adverse impact on our competitive position, business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of our patents and patent applications may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products, services and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, our owned and in-licensed intellectual property rights may be subject to a reservation of rights by one or more third parties. For example, the research resulting in certain of our owned and in-licensed patent rights and technology was funded in part by the U.S. government. As a result, the government may have certain rights, or march-in rights, to such patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the government to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise by the government of such rights could harm our competitive position, business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we rely on a combination of contractual provisions, confidentiality procedures and patent, trademark, copyright, trade secret and other intellectual property laws to protect the proprietary aspects of our products, brands, technologies, trade secrets, know-how and data. These legal measures afford only limited protection, and competitors or others may gain access to or use our intellectual property rights and proprietary information. Our success will depend, in part, on preserving our trade secrets, maintaining the security of our data and know-how and obtaining, maintaining and enforcing other intellectual property rights. We may not be able to obtain, maintain and/or enforce our intellectual property or other proprietary rights necessary to our business or in a form that provides us with a competitive advantage.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to obtain sufficient patent or other intellectual property protection for our product candidates or proprietary technologies or if we lose any patent or other intellectual property protection for our product candidates or proprietary technologies, our business, financial condition, results of operations and prospects could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation for patents covering our product candidates, our business may be materially harmed, and in any case, the terms of our patents may not be sufficient to effectively protect our product candidates and business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents have a limited term. In most countries, including the United States, the expiration of a patent is generally 20 years after its first effective non-provisional filing date. However, depending upon the timing, duration and specifics of FDA marketing approval of darovasertib, IDE397, our other product candidates or any future product candidates, one or more of any U.S. patents we may be issued or have licensed may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA-approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration, and our competitive position, business, financial condition, results of operations, and prospects could be harmed, possibly materially.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If there are delays in obtaining regulatory approvals or other additional delays, the period of time during which we can market our product candidates under patent protection could be further reduced. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. Once the patent term has expired, we may be open to competition from similar or generic products. The launch of a generic version of one of our products in particular would be likely to result in an immediate and substantial reduction in the demand for that product, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent application process to maintain patent applications and issued patents. In addition, periodic maintenance fees, renewal fees, annuity fees and various other government fees on issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime of the patent and/or applications and any patent rights we may obtain in the future. While an unintentional lapse of a patent or patent application can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance with these requirements can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our products or services, we may not be able to stop a competitor from marketing products or services that are the same as or similar to our products or services, which would have a material adverse effect on our business, financial condition and results of operations. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by others, and the patent protection, prosecution and enforcement for some of our product candidates may be dependent on our licensors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently are reliant upon licenses of certain intellectual property rights and proprietary technology from third parties that are important or necessary to the development of our proprietary technology, including technology related to our product candidates. For example, we rely on our exclusive license agreement with Novartis for the clinical development of darovasertib and our option and license agreement with CRT for the clinical development of PARG inhibitors. These licenses, and other licenses we may enter into in the future, may not provide adequate rights to use such intellectual property rights and proprietary technology in all relevant fields of use or in all territories in which we may wish to develop or commercialize technology and product candidates in the future. Licenses to additional third-party proprietary technology or intellectual property rights that may be required for our development programs may not be available in the future or may not be available on commercially reasonable terms. In that event, we may be required to expend significant time and resources to redesign our proprietary technology or product candidates or to develop or license replacement technology, which may not be feasible on a technical or commercial basis. If we are unable to do so, we may not be able to develop and commercialize technology and product candidates in fields of use and territories for which we are not granted rights pursuant to such licenses, which could harm our business, financial condition, results of operations and prospects significantly. Third-party patents may exist which might be enforced against our current or future product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some circumstances, we may not have the right to control the preparation, filing, prosecution and enforcement of patent applications, or to maintain the patents, covering technology that we license from third parties. In addition, some of our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agreements with our licensors require us to obtain consent from the licensor before we can enforce patent rights, and our licensor may withhold such consent or may not provide it on a timely basis. Therefore, we cannot be certain that our licensors or collaborators will prosecute, maintain, enforce and defend such intellectual property rights in a manner consistent with the best interests of our business, including by taking reasonable measures to protect the confidentiality of know-how and trade secrets, or by paying all applicable prosecution and maintenance fees related to intellectual property registrations for any of our product candidates. We also cannot be certain that our licensors have drafted or prosecuted the patents and patent applications licensed to us in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. This could cause us to lose rights in any applicable intellectual property that we in-license, and as a result our ability to develop and commercialize product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current licenses impose, and our future licenses likely will impose, various royalty payments, milestones, and other obligations on us. If we fail to comply with any of these obligations, we may be subject to liability, including the payment of damages, and the licensor may have the right to terminate the license. Termination by the licensor would cause us to lose valuable rights, and could prevent us from developing and commercializing our product candidates and proprietary technologies. Furthermore, if any current or future licenses terminate, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the freedom to seek regulatory approval of, and to market, products similar or identical to our planned products. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in product candidates that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize product candidates, we may be unable to achieve or maintain profitability. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties (potentially including our competitors) to receive licenses to a portion of the intellectual property rights that are subject to our existing licenses. Any of these events could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may fail to comply with any of our obligations under existing or future agreements pursuant to which we license or have otherwise acquired intellectual property rights or technology, which could result in the loss of rights or technology that are material to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are party to various agreements that we depend on to operate our business, including intellectual property rights relating to darovasertib, in particular, our agreement with Novartis. Our rights to use currently licensed intellectual property, or intellectual property to be licensed in the future, are or will be subject to the continuation of and our compliance with the terms of these agreements. These agreements are complex, and certain provisions in such agreements may be susceptible to multiple interpretations which could lead to disputes, including but not limited to those regarding:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of rights granted under the license agreement; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which our proprietary technology and product candidates infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the sublicensing of patent and other rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ownership of inventions and know-how resulting from the creation or use of intellectual property by us or our counterparties, alone or jointly; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope and duration of our payment obligations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the priority of invention of patented technology;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rights upon termination of such agreement; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope and duration of exclusivity obligations of each party to the agreement. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The resolution of any contractual interpretation dispute that may arise, if unfavorable to us, could have a material adverse effect on our business, financial condition, results of operations and prospects. Such resolution could narrow what we believe</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to be the scope of our rights to the relevant intellectual property or technology, increase what we believe to be our financial or other obligations under the relevant agreement or decrease the third-party&#8217;s financial or other obligations under the relevant agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, if disputes over intellectual property rights that we have licensed or acquired from third parties prevent or impair our ability to maintain our current license agreements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. If we fail to comply with our obligations under current or future license agreements, these agreements may be terminated or the scope of our rights under them may be reduced and we might be unable to develop, manufacture or market any product that is licensed under these agreements. We are generally also subject to all of the same risks with respect to protection of intellectual property that we may license as we are for intellectual property that we own, which are described herein. If we or any of our current or future licensors fail to adequately protect this intellectual property, our ability to commercialize product candidates could suffer.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become subject to third-party claims alleging infringement, misappropriation or violation of such third-party&#8217;s patents or other intellectual property rights and/or third-party claims seeking to invalidate our patents, which could require us to spend significant time and money and, if successfully asserted against us, could delay or prevent us from developing, manufacturing and selling our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends significantly on our ability to develop, manufacture or commercialize our products and product candidates without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. However, our research, development and commercialization activities may nonetheless be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Claims by third parties that we infringe their intellectual property rights may result in liability for damages or prevent or delay our developmental and commercialization efforts. We cannot assure you that our operations do not, or will not in the future, be found to infringe existing or future patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates or impair our competitive position. As the biotechnology industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our product candidates. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, reexaminations, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review proceedings and post-grant review proceedings before the USPTO and/or corresponding foreign patent offices, and companies in the industry have used these proceedings to gain a competitive advantage. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. For example, we are aware of an international patent application published as PCT WO 2017/096165 A1. If a patent issues from such patent application with claims similar to those published, our ability to commercialize a product candidate for our MAT2A program may be adversely affected if we do not obtain a license under such patent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history and can involve other factors such as expert opinion. Our analysis of these issues, including interpreting the relevance or the scope of claims in a patent or a pending application, determining applicability of such claims to our proprietary technologies or product candidates, predicting whether a third-party&#8217;s pending patent application will issue with claims of relevant scope, and determining the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. We do not always conduct independent reviews of pending patent applications of and patents issued to third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, patent applications in the United States and elsewhere are typically published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Certain U.S. applications that will not be filed outside the United States can remain confidential until patents issue. In addition, patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived. Furthermore, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our product candidates or the use of our product candidates. These applications may later result in issued patents, or the revival of previously abandoned patents, that will prevent, limit or otherwise interfere with our ability to make, use or sell our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result, we may be unaware of third-party patents that may be infringed by commercialization of darovasertib, IDE397 or our other product candidates, and cannot be certain that we were the first to file a patent application related to a product candidate or proprietary technology. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant product revenue and against whom our own patent portfolio may thus have no deterrent effect. We may be unaware of one or more issued patents that would be infringed by the manufacture, sale or use of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we may be required to indemnify future collaboration partners against claims of infringement, misappropriation, or other violations of intellectual property rights. We are not aware of any threatened or pending claims related to these matters, but in the future litigation may be necessary to defend against such claims. If a patent infringement suit were brought against us, we could be forced, including by court order to stop or delay development, manufacturing and/or sales of the product or product candidate that is the subject of the suit. As a result of patent infringement claims, or in order to avoid potential claims, we may choose to seek, or be required to seek, a license from the third-party and would most likely be required to pay license fees or royalties or both. These licenses may not be available on commercially reasonable terms, or at all, in which event our business would be materially and adversely affected. Even if we were able to obtain a license, we may be unable to maintain such licenses and the rights may be nonexclusive, which could give our competitors access to the same intellectual property.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although no third-party has asserted a claim of patent infringement against us as of December 31, 2024, others may hold proprietary rights that could prevent darovasertib, IDE397, our other product candidates or any future product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to our product candidates or proprietary technologies could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe or attorney&#8217;s fees and costs of litigation to the party whose intellectual property rights we may be found to be infringing, and require us to obtain a license to manufacture or market darovasertib, IDE397, our other product candidates or any future product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be time-consuming and a substantial diversion of management and employee resources from our business. Even if we believe such claims are without merit, we cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Even if such licenses are available, we could incur substantial costs related to royalty payments for licenses obtained from third parties, which could negatively affect our gross margins, and the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us. In addition, we cannot be certain that we could redesign our product candidates or proprietary technologies to avoid infringement, if necessary, or on a cost-effective basis. If we were to challenge the validity of any such third-party U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. We will have similar burdens to overcome in foreign courts in order to successfully challenge a third-party claim of patent infringement. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing darovasertib, our other product candidates or any future product candidates, until the asserted patent expires or is held finally invalid or not infringed in a court of law. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity or the disclosure of confidential information, and the perceived value of our product candidates or intellectual property could be diminished correspondingly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, our collaborators or any third parties with which we collaborate in the future, may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability. Further, collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. Also, we may be obligated under our agreements with our collaborators, licensors, suppliers and others to indemnify and hold them harmless for damages arising from intellectual property infringement by us. Any of the foregoing could harm our competitive position, business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties, including our competitors may currently, or in the future, infringe, misappropriate or otherwise violate our issued patents or other intellectual property rights or those of our licensors. To prevent infringement or unauthorized use, we may be required to file lawsuits or initiate other proceedings to protect or enforce our patents or other intellectual property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rights, which can be expensive, time-consuming and unsuccessful. However, the steps we have taken, and are taking, to protect our proprietary rights may not be adequate to enforce our rights as against such infringement, misappropriation or violation of our intellectual property rights. In certain circumstances it may not be practicable or cost-effective for us to enforce our intellectual property rights fully, particularly in certain developing countries or where the initiation of a claim might harm our business relationships. We may also be hindered or prevented from enforcing our rights with respect to a government entity or instrumentality because of the doctrine of sovereign immunity. Our ability to enforce our patent or other intellectual property rights depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products or technologies. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product or technologies. Thus, we may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Any inability to meaningfully enforce our intellectual property rights could harm our ability to compete and reduce demand for our products and product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in a patent infringement proceeding, a court or administrative tribunal may decide that a patent we own or in-license is not valid, is unenforceable and/or is not infringed. If we or any of our collaborators or potential future collaborators, were to initiate legal proceedings against a third-party to enforce a patent directed at one of our product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. Similar mechanisms for challenging the validity and enforceability of a patent exist in foreign patent agencies. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and could result in the revocation, cancellation, or amendment of our patents or those of our licensors. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. A court may decide that a patent or other intellectual property right of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims or other intellectual property narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents or other intellectual property do not cover the technology in question.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we could lose at least part, and perhaps all, of the patent protection on an affected product candidate. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO, or equivalent actions brought in foreign jurisdictions, may be necessary to determine the priority of invention with respect to our patents or patent applications or those of our licensors. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. An unfavorable outcome could require us to cease using the covered technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. These and other uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">common stock. Any of the foregoing could harm our business, financial condition, results of operations and prospects. Even if our patents or other intellectual property rights are found to be valid and infringed, a court may refuse to grant injunctive relief against the infringer and instead grant us monetary damages and/or ongoing royalties. Such monetary compensation may be insufficient to adequately offset the damage to our business caused by the infringer&#8217;s competition in the market. An adverse result in any litigation or administrative proceeding could put one or more of our patents or other intellectual property rights at risk of being invalidated or interpreted narrowly, which could adversely affect our competitive business position, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims that we or our employees, consultants, advisors or other third parties have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be subject to claims that our employees or consultants have wrongfully used for our benefit or disclosed to us confidential information of third parties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is common in the biotechnology and biopharmaceutical industries, in addition to our employees, we engage the services of consultants, advisors and other third parties to assist us in the development of our product candidates. Many of these individuals, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or biopharmaceutical companies including our competitors or potential competitors. Some of these employees, consultants and contractors, may have executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment or engagement. Although we try to ensure that individuals working for or collaborating with us do not use the intellectual property rights, proprietary information or know-how of others in their work for us, and do not perform work for us that is in conflict with their obligations to another employer or any other entity, we may become subject to claims that we, our employees, consultants, advisors or other third parties have, inadvertently or otherwise, misappropriated the intellectual property, including know-how, trade secrets or other information proprietary to their former or current employers or clients. We may also be subject to claims that patents and applications we have filed to protect inventions of our employees, consultants, advisors or other third parties, even those related to one or more of our product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, which could adversely affect our competitive position, business, financial condition, results of operations, and prospects. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property rights.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also be subject to claims that our former employees, contractors or collaborators, or other third parties have an ownership interest in our current or future patents, patent applications, or other intellectual property rights, including as an inventor or co-inventor. We may be subject to ownership or inventorship disputes arising, for example, from conflicting obligations of employees, consultants or others who were or are involved in developing our products or product candidates. Although it is our policy to require our employees and our personnel who may be involved in the development of intellectual property to execute agreements assigning such inventions, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. The assignment of intellectual property may not be self-executing and despite such agreement, such inventions may become assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. We may be subject to claims that former employees, consultants, advisors or other third parties have an ownership interest in our patents or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property rights, and other owners may be able to license their rights to other third parties, including our competitors. Such an outcome could have a material adverse effect on our business. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and scientific personnel.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may face claims by third parties challenging ownership interest in or inventorship of intellectual property rights we regard as our own, based on claims that our agreements with employees, consultants, advisors or other third parties obligating them to assign intellectual property to us are ineffective or in conflict with prior or competing contractual obligations of assignment, which could result in ownership disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial value of such intellectual property. In the future litigation may be necessary to defend against these and other claims challenging inventorship or ownership and it may be necessary or we may desire to obtain a license to such third-party&#8217;s intellectual property rights to settle any such claim; however, there can be no assurance that we would be able to obtain such license on commercially reasonable terms, if at all. If we fail in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. A court could prohibit us from using technologies, features or other intellectual property rights that are essential to our products or technologies, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of another person or entity, including another or former employers. An inability to incorporate technologies, features or other intellectual property rights that are important or essential to our products or product candidates could have a material adverse effect on our business, financial condition, results of operations, and competitive position, and may prevent us from developing, manufacturing and/or commercializing our products or technologies. In addition, we may lose valuable intellectual property rights or personnel. Such an outcome could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees. Any litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to develop, manufacture and/or commercialize our products or services, which could materially and adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to patent protection, we also rely on other intellectual property rights, including protection of copyright, trade secrets, know-how, technology and/or other proprietary information that is not patentable or that we elect not to patent. Trade secrets can be difficult to protect, and some courts are less willing or unwilling to protect trade secrets. To maintain the confidentiality of our trade secrets and proprietary information, we rely heavily on confidentiality agreements with third parties, and confidential information and invention assignment agreements with employees, consultants, advisors and appropriate third parties. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes and we may not enter into such agreements with all employees, consultants and third parties who have been involved in the development of our intellectual property rights. Although we generally require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to contractual measures, we try to protect the confidential nature of our proprietary information using commonly accepted physical and technological security measures. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. In addition, such security measures may not provide adequate protection for our proprietary information, for example, in the case of misappropriation of a trade secret by an employee, consultant, customer or third-party with authorized access. Our security measures may not prevent an employee, consultant, advisor or other third-party from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. Therefore, we may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by such employees, consultants, advisors or third parties, despite the existence generally of these confidentiality restrictions. These agreements may not provide meaningful protection against the unauthorized use or disclosure of our trade secrets, know-how or other proprietary information in the event the unwanted use is outside the scope of the provisions of the contracts or in the event of any unauthorized use, misappropriation, or disclosure of such trade secrets, know-how, or other proprietary information. There can be no assurances that such employees, consultants, advisors or third parties will not breach their agreements with us, that we will have adequate remedies for any breach, or that our trade secrets will not otherwise become known or independently developed by third parties, including our competitors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products that we consider proprietary. We may not be able to obtain adequate remedies in the event of such unauthorized use. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. Even though we use commonly accepted security measures, trade secret violations are often a matter of state law in the United States, and the criteria for protection of trade secrets can vary among different jurisdictions. If the steps we have taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. Because from time to time we expect to rely on third parties in the development, manufacture, and distribution of our products and provision of our services, we must, at times, share trade secrets with them.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Trade secrets will over time be disseminated within the industry through independent development, the publication of journal articles and the movement of personnel skilled in the art from company to company or academic to industry scientific positions. Though our agreements with third parties typically restrict the ability of our advisors, employees, collaborators, licensors, suppliers, third-party contractors and consultants to publish data potentially relating to our trade secrets, our agreements may contain certain limited publication rights. In addition, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Despite employing the contractual and other security precautions described above, the need to share trade secrets increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position, business, financial condition, results of operations, and prospects would be harmed. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. The exposure of our trade secrets and other proprietary information would impair our competitive advantages and could have a material adverse effect on our business, financial condition and results of operations. In particular, a failure to protect our proprietary rights may allow competitors to copy our technology, which could adversely affect our pricing and market share. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to make precision medicines that are similar to ours but that are not covered by the claims of the patents that we own or have exclusively licensed; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or have exclusively licensed; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our pending patent applications or those that we may own in the future will not lead to issued patents;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of others may harm our business;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may choose not to seek patent protection for some of our proprietary technology to maintain certain trade secrets or know-how, and a third-party may subsequently file a patent covering such trade secrets or know-how;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices we may set.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, the EU and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private payors. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an increase to the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and an extension the rebate program to individuals enrolled in Medicaid managed care organizations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishment of a Center for Medicare and Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since its enactment, there have been judicial, executive and congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the U.S. Supreme Court&#8217;s decision, President Biden issued an executive order initiating a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2032, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional action is taken by Congress. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The American Rescue Plan Act of 2021 was also signed into law, which eliminated the statutory Medicaid drug rebate cap, beginning January 1, 2024. The rebate was previously capped at 100% of a drug&#8217;s average manufacturer price.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law, which among other things, includes prescription drug provisions that have significant implications for the pharmaceutical industry and beneficiaries, including extending enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plan year 2025, allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs (beginning in 2026), imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if their drug prices increase faster than inflation (first due in 2023), and redesigning Medicare Part D to reduce out-of-pocket prescription drug costs for beneficiaries (which began in 2025). CMS has published the negotiated prices for the initial ten drugs, which will first be effective in 2026, and has published the list of the subsequent 15 drugs that will be subject to negotiation, although the drug price negotiation program is currently subject to legal challenges. For that and other reasons, it is currently unclear how the IRA will be effectuated. The implementation of cost containment measures, including the prescription drug provisions under the IRA, as well as other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved. Complying with any new legislation and regulatory changes could be time-intensive and expensive, resulting in a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally-mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. These reforms could reduce the ultimate demand for our product candidates or put pressure on our product pricing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved. In markets outside of the United States and EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 13, 2021, Regulation No 2021/2282 on Health Technology Assessment, or HTA, amending Directive 2011/24/EU, was adopted. The Regulation entered into force in January 2022 and has been applicable since January 2025, with phased implementation based on the type of product, i.e. oncology and advanced therapy medicinal products as of 2025, orphan medicinal products as of 2028, and all other medicinal products by 2030. The Regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products, and provide the basis for cooperation at the EU level for joint clinical assessments in these areas. It will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the highest potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States, the EU or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under any U.S. federal healthcare program, such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. federal civil and criminal false claims and civil monetary penalties laws, including the civil False Claims Act, which prohibit, among other things, including through civil whistleblower or qui tam actions, individuals or entities from knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. Pharmaceutical manufacturers can cause false claims to be presented to the U.S. federal government by engaging in impermissible marketing practices, such as the off-label promotion of a product for an indication for which it has not received FDA approval. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Health Insurance Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Federal Food Drug or Cosmetic Act, or FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the government information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (nurse practitioners, certified nurse anesthetists, physician assistants, clinical nurse specialists, anesthesiology assistants and certified nurse midwives), and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical sales representatives;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">similar healthcare laws and regulations in the EU and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Actual or perceived failures to comply with applicable data protection, privacy and security and AI/ML laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory environment surrounding information security, data collection and privacy is increasingly demanding. We are subject to numerous U.S. federal and state laws and non-U.S. regulations governing the protection of personal and confidential information of our clinical patients, clinical investigators, employees and vendors/business contacts, including in relation to medical records, credit card data and financial information. Outside the United States, an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, in Europe, the European Union General Data Protection Regulation, or GDPR, went into effect in May 2018, implementing more stringent requirements in relation to our use of personal data. The GDPR applies to any company established in the European Economic Area, or EEA, as well as to those outside the EEA if they collect and use personal data in connection with the offering of goods or services to individuals in the EEA or the monitoring of their behavior. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EU and the United States remains uncertain, and the efficacy and longevity of current transfer mechanisms between the EEA, and the United States remains uncertain. Case law from the Court of Justice of the European Union, or CJEU, states that reliance on the standard contractual clauses &#8211; a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism &#8211; alone may not necessarily be sufficient in all circumstances and that transfers must be assessed on a case-by-case basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 10, 2023, the European Commission adopted its Adequacy Decision in relation to the new EU-US Data Privacy Framework, or the DPF, rendering the DPF effective as a GDPR transfer mechanism to U.S. entities self-certified under the DPF. The DPF also introduced a new redress mechanism for EU citizens which addresses a key concern in the previous CJEU judgments and may mean transfers under standard contractual clauses are less likely to be challenged in future. We expect the existing legal complexity and uncertainty regarding international personal data transfers to continue. In particular, we expect the DPF Adequacy Decision to be challenged and international transfers to the United States and to other jurisdictions more generally to continue to be subject to enhanced scrutiny by regulators. As a result, we may have to make certain operational changes and we will have to implement revised standard contractual clauses and other relevant documentation for existing data transfers within required time frames.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, from January 1, 2021, companies have had to comply with the GDPR and also the UK data protection regime, which imposes separate but similar obligations to those under the GDPR. The UK GDPR mirrors the fines under the GDPR (e.g., fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover). On October 12, 2023, the UK Extension to the DPF came into effect (as approved by the UK Government), as a UK GDPR data transfer mechanism to U.S. entities self-certified under the UK Extension to the DPF. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, HIPAA imposes privacy, security and breach reporting obligations with respect to individually identifiable health information upon &#8220;covered entities&#8221; (health plans, health care clearinghouses and certain health care providers), and their respective business associates, individuals or entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. While we do not believe that we are currently acting as a covered entity or business associate under HIPAA and thus are not directly regulated under HIPAA, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, certain states govern the privacy and security of health-related and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. By way of example, the California Consumer Privacy Act, as amended by the California Privacy Rights Act, collectively, the CCPA, requires covered businesses that process the personal information of California residents to, among other things: (i) provide certain disclosures to California residents regarding the business&#8217;s collection, use, and disclosure of their personal information; (ii) receive and respond to requests from California residents to access, delete, and correct their personal information, or to opt out of certain disclosures of their personal information; and (iii) enter into specific contractual provisions with service providers that process California resident personal information on the business&#8217;s behalf. Additional compliance investment and potential business process changes may also be required. Similar laws have passed in other states and are continuing to be proposed at the state and federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any person, including any of our employees, clinical trial collaborators or those with whom we share such information, negligently disregards or intentionally breaches our established controls with respect to clinical subject, clinical investigator or employee data, or otherwise mismanages or misappropriates that data, we could be subject to significant monetary damages, regulatory enforcement actions, fines and/or criminal prosecution in one or more jurisdictions. In addition, a data breach could result in negative publicity which could damage our reputation and have an adverse effect on our business, financial condition or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we use artificial intelligence, including machine learning, and automated decision-making technologies, or collectively, AI Technologies, in our business. We have recently adopted an AI Acceptable Use Policy, however, if the models underlying the AI Technologies we use are incorrectly designed or implemented; trained or reliant on incomplete, inadequate, inaccurate, biased or otherwise poor quality data, or on data to which we do not have sufficient rights or in relation to which we and/or the providers of such data have not implemented sufficient legal compliance measures; used without sufficient oversight and governance to ensure their responsible use; and/or adversely impacted by unforeseen defects, technical challenges, cybersecurity threats or material performance issues, the performance of our products, services and business, as well as our reputation, could suffer or we could incur liability resulting from the violation of laws or contracts to which we are a party or civil claims. The regulatory framework for AI Technologies is rapidly evolving as many federal, state, and foreign government bodies and agencies have introduced or are currently considering additional laws and regulations. Additionally, existing laws and regulations may be interpreted in ways that would affect the operation of AI Technologies. As a result, implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or market perception of their requirements may have on our business and may not always be able to anticipate how to respond to these laws or regulations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is possible that new laws and regulations will be adopted in the United States and in other non-U.S. jurisdictions, or that existing laws and regulations, including competition and antitrust laws, may be interpreted in ways that would limit our ability to use AI Technologies for our business, or require us to change the way we use AI Technologies in a manner that negatively affects the performance of our products, services, and business and the way in which we use AI Technologies. We may need to expend resources to adjust our products or services in certain jurisdictions if the laws, regulations, or decisions</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are not consistent across jurisdictions. Further, the cost to comply with such laws, regulations, or decisions and/or guidance interpreting existing laws, could be significant and would increase our operating expenses (such as by imposing additional reporting obligations regarding our use of AI Technologies). Such an increase in operating expenses, as well as any actual or perceived failure to comply with such laws and regulations, could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our stock price may be volatile and you may not be able to resell shares of our common stock at or above the price you paid.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading price of our common stock could be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors include those discussed in this &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K and others such as:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results from, and any delays in our clinical trials, including those for darovasertib, IDE397, IDE161, or any other future clinical development programs, including public misperception of the results of our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by academic or other third parties challenging the fundamental premises underlying our approach to treating cancer and/or biopharmaceutical product development; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements of regulatory approval or disapproval of our current or any future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure or discontinuation of any of our research and development programs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing setbacks or delays of or issues with the supply of the materials for our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements relating to, or results from, our GSK Collaboration Agreement or other collaborations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements related to our Biocytogen Option and License Agreement or Hengrui Pharma License Agreement;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements relating to future licensing, collaboration or development agreements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in the commercialization of our current or any future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">public misperception regarding the use of our therapies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquisitions and sales of new products, technologies or businesses; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">quarterly variations in our results of operations or those of our future competitors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in earnings estimates or recommendations by securities analysts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by us or our competitors of new products, significant contracts, commercial relationships, acquisitions or capital commitments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments with respect to intellectual property rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our commencement of, or involvement in, litigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in financial estimates or guidance, including our ability to meet our future revenue and operating profit or loss estimates or guidance; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">major changes in our board of directors or management; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">new legislation in the United States relating to the sale or pricing of pharmaceuticals; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA or other U.S. or comparable foreign regulatory actions affecting us or our industry; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product liability claims or other litigation or public concern about the safety of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">market conditions in the biopharmaceutical and biotechnology sectors, particularly as a result of the volatility in the market caused by the COVID-19 pandemic, as well as adverse geopolitical and macroeconomic developments, such as the ongoing Ukraine-Russia conflict, the Israel-Hamas conflict, and related sanctions, instability in the global banking system, actual and anticipated changes in interest rates, economic inflation and the responses by central banking authorities to control such inflation; and </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic and geo-political conditions in the United States and abroad. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the stock markets in general, and the markets for biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility. In particular, the market prices of securities of smaller biotechnology have experienced dramatic fluctuations that often have been unrelated or disproportionate to the operating results of these companies. These broad market fluctuations may adversely affect the trading price or liquidity of our common stock. Furthermore, the trading price of our common stock may be adversely affected by third-parties trying to drive down the market price. Short sellers and others, some of whom post anonymously on social media, may be positioned to profit if our stock declines and their activities can negatively affect our stock price. In the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of our stockholders were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of our management would be diverted from the operation of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">An active, liquid and orderly market for our common stock may not be maintained, and you may not be able to resell your common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to our initial public offering, or IPO, in May 2019, there was no public market for shares of our common stock. Our stock currently trades on the Nasdaq Global Select Market, but we can provide no assurance that we will be able to maintain an active trading market on the Nasdaq Global Select Market or any other exchange in the future. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses, applications, or technologies using our shares as consideration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. As of December 31, 2024, we have outstanding a total of 86.5 million shares of common stock. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares purchased by affiliates. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock. In addition, as of December 31, 2024, approximately 99.5 million shares of common stock that are either subject to outstanding options or reserved for future issuance under our existing equity incentive plan will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Risks</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our information technology systems, or those of our collaborators, CROs or other contractors or consultants, may fail or suffer security breaches, which could adversely affect our business. Security breaches, loss of data or financial assets, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information, preclinical and clinical trial data, health-related information and personal information, or collectively, Confidential Information. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such Confidential Information, including both our own and that of third parties. We have established physical, electronic and organizational measures to safeguard and secure our systems to prevent a data compromise, and rely on commercially available systems, software, tools, and monitoring to provide security for our information technology systems and the processing, transmission and storage of digital information. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our Confidential Information. Our internal information technology systems and infrastructure, and those of our current and any future collaborators, contractors and consultants and other third parties on which we rely, are vulnerable to attack, damage and interruption from computer viruses, malware (e.g. ransomware), malicious code, misconfigurations, &#8220;bugs&#8221; or other vulnerabilities, natural disasters, terrorism, war, telecommunication and electrical failures, hacking, cyberattacks or intrusions over the Internet, phishing attacks and other social engineering schemes, attachments to emails, human error, fraud, denial or degradation of service</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attacks, sophisticated nation-state and nation-state-supported actors, employee theft or misuse, persons inside our organization, or persons with access to systems inside our organization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The risk of a security breach or disruption or data loss, particularly through cyberattacks or cyber-intrusion, including by computer hackers, foreign governments and cyber-terrorists, has generally increased as the number, level of persistence, intensity and sophistication of attempted attacks and intrusions from around the world have increased. Emerging and evolving cybersecurity threats such as the attack on SolarWinds and the Log4j vulnerability reported in December 2021 pose unique challenges and involve sophisticated threat actors.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the pervasive use of mobile devices that access Confidential Information increases the risk of data security breaches, which could lead to the loss of Confidential Information, including both our own and that of third parties. As a result of the continuing hybrid working environment, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on industry-accepted security measures and technology to securely maintain all confidential and proprietary information on our information systems. We have devoted and will continue to devote significant resources to the security of our information technology systems, but they may still be vulnerable to these threats. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. There can also be no assurance that our programs, and our future collaborators&#8217;, contractors&#8217; and consultants&#8217; cybersecurity risk management programs and processes, including policies, controls or procedures, will be fully implemented, complied with or effective in protecting our systems, networks and Confidential Information.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and certain of our service providers are from time to time subject to cyberattacks and security incidents. While we do not believe that we have experienced any significant system failure, accident or security breach to date, if</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss of clinical trial data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Moreover, if a computer security breach affects our systems or results in the unauthorized release of personally identifiable information, our reputation could be materially damaged. In addition, such a breach may require notification to governmental agencies, the media or individuals pursuant to applicable privacy and security laws. We would also be exposed to a risk of loss, including financial assets, litigation and potential liability and significant incident response, system restoration or remediation and future compliance costs, all of which could materially adversely affect our business, financial condition, results of operations and prospects. We maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruption or breach of our systems.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we engage in future acquisitions or strategic collaborations, it may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may evaluate various acquisitions and strategic collaborations, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased operating expenses and cash requirements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the assumption or incurrence of additional indebtedness or contingent liabilities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the issuance of our equity securities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of key personnel, and uncertainties in our ability to maintain key business relationships; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if we undertake acquisitions, we may incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our programs may require the use of intellectual property rights held by third parties to which we do not have rights. In such a case, the growth of our business will depend in part on our ability to acquire, in-license or use these rights. However, we may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates on reasonable terms and conditions or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The acquisition or licensing of intellectual property rights for pharmaceutical products is very competitive. If we seek to acquire or license additional intellectual property rights, we may face substantial competition from a number of more established companies, some of which have acknowledged strategies to license or acquire products, and many of which have more institutional experience and greater financial and other resources than we have. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities, as may other emerging companies taking similar or different approaches to product licenses and/or acquisitions. In addition, a number of established research-based pharmaceutical and biotechnology companies may acquire products in late stages of development to augment their internal product lines, which may provide those companies with an even greater competitive advantage. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us or may interfere with our acquisition or licensing of rights from others. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have collaborated with U.S. academic institutions and may in the future collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. These institutions may provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have on reasonable terms, we may have to abandon development of that program and our competitive position, business, financial condition, results of operations, and prospects could suffer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in patent law in the United States or in other countries could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our patent rights may be affected by developments or uncertainty in the United States&#8217; or other jurisdictions&#8217; patent statutes, patent case law, USPTO rules and regulations or the rules and regulations of other jurisdictions&#8217; patent offices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are a number of recent changes to U.S. patent laws that may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. For example, on September 16, 2011, the Leahy-Smith America Invents Act, or Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#8220;first to file&#8221; system in which the first inventor to file a patent application is typically entitled to the patent. Third parties are allowed to submit prior art before the issuance of a patent by the USPTO, and may become involved in post-grant proceedings including opposition, derivation, reexamination, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. In addition, the U.S. Congress may pass additional patent reform legislation that is unfavorable to us.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future. Similarly, statutory or judicial changes to the patent laws of other countries may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting and defending all current and future patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights. For example, some foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, some countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, on June 1, 2023, the European Union Patent Package (EU Patent Package) regulations were implemented with the goal of providing a single pan-European Unitary Patent and a new European Unified Patent Court (UPC) for litigation involving European patents. As a result, all European patents, including those issued prior to ratification of the EU Patent Package, now by default automatically fall under the jurisdiction of the UPC. It is uncertain how the UPC will impact granted European patents in the biotechnology and pharmaceutical industries. Our European patent applications, if issued, could be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">challenged in the UPC. During the first seven years of the UPC&#8217;s existence, the UPC legislation allows a patent owner to opt its European patents out of the jurisdiction of the UPC. We may decide to opt out our future European patents from the UPC, but doing so may preclude us from realizing the benefits of the UPC. Moreover, if we do not meet all of the formalities and requirements for opt-out under the UPC, our future European patent applications and patents could remain under the jurisdiction of the UPC. The UPC will provide our competitors with a new forum to centrally revoke our European patents, and allow for the possibility of a competitor to obtain pan-European injunction. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize our technology and product candidates and, resultantly, on our business, financial condition, prospects and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We employ reputable professionals and rely on such third parties to help us comply with these requirements and effect payment of these fees with respect to the patents and patent applications that we own, and if we license intellectual property we may have to rely upon our licensors to comply with these requirements and effect payment of these fees with respect to any patents and patent applications that we license. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If securities or industry analysts do not continue to publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We incur significant costs as a result of operating as a public company, and our management devotes substantial time to new compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We incur significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Exchange Act and regulations regarding corporate governance practices. The listing requirements of the Nasdaq Global Select Market and the rules of the Securities and Exchange Commission, or SEC, require that we satisfy certain corporate governance requirements relating to director independence, filing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules and regulations will increase our legal and financial compliance costs and make some activities more time-consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including D&amp;O insurance, on acceptable terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company, we are subject to Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, and the related rules of the SEC, which generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. Additionally, as a result of our ceasing to be an emerging growth company and being deemed a large accelerated filer as of January 1, 2024, commencing with our Annual Report on Form 10-K for the year ended December 31, 2023, our independent registered public accounting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">firm is required to issue an opinion on the effectiveness of our internal control over financial reporting. We expect to incur significant expenses and devote substantial management effort toward ensuring compliance with the auditor attestation requirements of Section 404. Furthermore, we will also have to file a more expansive proxy statement and be subject to shorter filing deadlines, which will require additional time and expense as well. It may require significant resources and management oversight to maintain and, if necessary, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard. As a result, management&#8217;s attention may be diverted from other business concerns, which could adversely affect our business and operating results. To comply with these requirements, we may need to hire more employees in the future or engage outside consultants, which would increase our costs and expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to provide the reports required by these rules, we must conduct reviews and testing of our internal controls. During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal control over financial reporting, we may not detect errors on a timely basis and our audited financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we are required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. In order to report our results of operations and financial statements on an accurate and timely basis, we will depend on CROs and contract manufacturing organizations, or CMOs, to provide timely and accurate notice of their costs to us and on GSK to provide timely and accurate reports of cost sharing under the GSK Collaboration Agreement. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from the Nasdaq Global Select Market or other adverse consequences that would materially harm to our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to maintain effective internal controls, our business, financial position, results of operations and prospects could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company, we are subject to reporting and other obligations under the Exchange Act, including Section 404, which require annual management assessments of the effectiveness of our internal control over financial reporting. As a result of our ceasing to be an emerging growth company and being deemed a &#8220;large accelerated filer&#8221; as of January 1, 2024, commencing with our Annual Report on Form 10-K for the year ending December 31, 2023, our independent registered public accounting firm is required to formally attest to the effectiveness of our internal control over financial reporting pursuant to Section 404.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of its testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act of 2002. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources, which further increases as a large accelerated filer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States. Any failure to maintain effective internal controls could have an adverse effect on our business, financial position, and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we sell shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, our stock price may decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may from time to time issue additional shares of common stock at a discount from the current trading price of our common stock. As a result, our stockholders would experience immediate dilution upon the purchase of any shares of our common stock sold at such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its stock ownership by certain stockholders over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes (such as research and development tax credits) to offset its post-change taxable income may be limited. As a result of such ownership changes, our ability to utilize certain NOLs and other tax attributes may be permanently limited if such attributes will expire unused. We have experienced ownership changes in the past, and we may experience ownership changes in the future due to subsequent shifts in our stock ownership (some of which may be outside our control). As a result, even if we attain profitability, we may be unable to use a material portion of our NOLs and other tax attributes to offset future taxable income.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent changes in control or changes in our management without the consent of our board of directors. These provisions include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the required approval of at least 66 2/3% of the shares entitled to vote at an election of directors to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the requirement that a special meeting of stockholders may be called only by our chief executive officer or president or by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the costs of maintaining adequate D&amp;O insurance coverage increase significantly in the future, our operating results could be materially adversely affected. Likewise, if any of our current D&amp;O insurance coverage should become unavailable to us or become economically impractical, we may need to decrease our coverage limits or increase our self-insured retention or we may be unable to renew such insurance at all. If we incur liabilities that exceed our coverage or incur liabilities not covered by our insurance, we would have to self-fund any indemnification amounts owed to our directors and officers and employees in which case our results of operations and financial condition could be materially adversely affected. Additionally, a lack of D&amp;O insurance may make it difficult for us to retain and attract talented and skilled directors and officers to serve our company, which could adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation provides for an exclusive forum in the Court of Chancery of the State of Delaware and in the U.S. federal district courts for certain disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any state law derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, any action to interpret, apply, enforce, or determine the validity of our amended and restated certificate of incorporation or amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. The choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees and result in increased costs for investors to bring a claim.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future. Since we do not intend to pay dividends, your ability to receive a return on your investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1B. Unre</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">solved Staff Comments.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity.</span></p>
  <div><ix:nonNumeric id="F_fc327759-af26-4301-b57f-fc3504f522e9" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true" continuedAt="F_fc327759-af26-4301-b57f-fc3504f522e9_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity Risk Management and Strategy</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF). This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the NIST CSF as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.</span></p><div><ix:nonNumeric id="F_1a0721a8-c5b4-45c0-9205-8bb4013fe55c" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk management program is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a64a12f2-25a8-41a1-91b6-c9c57b0e6b80" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into our overall risk management program, and shares common methodologies, reporting channels and governance processes that apply across the risk management program to other legal, compliance, strategic, operational, and financial risk areas.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Key elements of our cybersecurity risk management program include but are not limited to the following:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk assessments designed to help identify material risks from cybersecurity threats to our critical systems and information;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a security team principally responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a documented set of cybersecurity policies and procedures that specifies the manner in which security controls are implemented;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_091ec5fb-ea10-497e-9298-1a3a3a767ed4" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security processes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity awareness training of our employees, including incident response personnel, and senior management; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_51e839bd-8a76-4689-83a0-6469e69b034d" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a third-party risk management process for key service providers based on our assessment of their criticality to our operations and respective risk profile,, suppliers, and vendors who have access to our critical systems and information.</span></ix:nonNumeric></span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that our cybersecurity risk management program and processes, including our policies, controls or procedures, will be fully implemented, complied with or effective in protecting our systems and information.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face risks from cybersecurity threats that, if realized, are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_810fb6bf-e0bc-49e6-a868-c5f499362790" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For more information, see the section titled &#8220;Risk Factor&#8212; Our information technology systems, or those of our collaborators, CROs or other contractors or consultants, may fail or suffer security breaches, which could adversely affect our business. Security breaches, loss of data or financial assets, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity Governance</span></p><div><ix:nonNumeric id="F_fd56092b-7b63-4adb-913c-f9e857075c91" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true" continuedAt="F_fd56092b-7b63-4adb-913c-f9e857075c91_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9268d4a8-7360-498c-9260-ded91734c6c8" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee, or the Committee, oversight of cybersecurity risks, including oversight of management&#8217;s implementation of our cybersecurity risk management program.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Committee is composed of members of our board of directors with diverse expertise, including risk management, public accounting, biotechnology, chief executive officer roles, and multiple public company directorships, which has prepared them to oversee our cybersecurity risks.</span></p><div><ix:nonNumeric id="F_8c137812-6142-4e9f-84e2-74b477ae1b2e" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee receives quarterly reports from management on our cybersecurity risks. In addition, management updates the Committee where it deems appropriate, regarding any cybersecurity incidents it considers to be significant or potentially significant.</span></p></ix:nonNumeric></div></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_fc327759-af26-4301-b57f-fc3504f522e9_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_fd56092b-7b63-4adb-913c-f9e857075c91_1"><div><ix:nonNumeric id="F_cf7856b9-c11f-4e68-b20e-410948970679" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2cfbf585-b877-41bd-8f32-d26a01535f59" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee reports to our full board of directors regarding its activities, including those related to cybersecurity.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The full board of directors also receives briefings from management on our cybersecurity risk management program. Board members receive presentations on cybersecurity topics from our Senior Vice President, or SVP, Head of Finance and Investor Relations, Senior Vice President, General Counsel, internal security staff and external experts as part of the board of directors&#8217; continuing education on topics that impact public companies.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_ec23686f-ec6c-4246-a2bb-256cc438a792" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d523b56-e882-4f5c-aada-28d133f7d2b5" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9bc934ec-7695-4fff-a675-d238207fc753" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Andres Briseno, our SVP, Head of Finance and Investor Relations and, Douglas Snyder, our Senior Vice President, General Counsel, are primarily responsible for assessing and managing our material risks from cybersecurity threats.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Mr. Briseno and Mr. Snyder have primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0544803a-100e-468a-817c-2ea0d35bdb4b" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true" continuedAt="F_0544803a-100e-468a-817c-2ea0d35bdb4b_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Briseno has served in a number of significant leadership roles at our company since 2016, including oversight of investor relations, business operations and corporate developments, and was appointed as SVP, Head of Finance and Investor Relations in 2023.</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_0544803a-100e-468a-817c-2ea0d35bdb4b_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Mr. Snyder has served in a number of significant leadership roles in various companies in the healthcare industry, and provided an oversight to legal and compliance teams with his broad legal background. Prior to joining our company, Mr. Snyder served in senior leadership and operations roles across healthcare field, including biotechnology, pharmaceuticals and the FDA</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Further, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our management team&#8217;s experience includes monitoring the cybersecurity landscape for new risks and best practices, developing and executing cybersecurity strategies, overseeing related governance policies, testing compliance with applicable technical standards, remediating known risks and leading employee training programs.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the information technology environment.</span></p></ix:continuation></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Prop</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">erties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our corporate headquarters are located in South San Francisco, California, where we lease and occupy office and laboratory space.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2023, we entered into a lease agreement for approximately 44,000 square feet of laboratory and office facilities at 5000 Shoreline Court, South San Francisco, California. The lease term is 120 months, and we have an option to extend the lease term for a total of two consecutive five-year periods. The lease commenced in August 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, we amended our 5000 Shoreline Court facility lease agreement to expand the size of the original premises by adding approximately 11,321 rentable square feet of additional space. The amendment to the lease term commenced in January 2025. Our lease at 7000 Shoreline Court, South San Francisco, California, expired in September 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, we entered into a lease agreement for approximately 5,700 square feet of space at 11710 El Camino Real, San Diego, California for corporate office space. The lease commenced in December 2023 and expires in March 2028. We have an option to renew the lease for three years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe our existing facilities are sufficient for our needs for the foreseeable future. To meet the future needs of our business, we may lease additional or alternate space, and we believe suitable additional or alternative space will be available in the future on commercially reasonable terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Legal Pro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ceedings</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safty_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Mine S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">afety Disclosures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Market for </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Information</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock trades on the Nasdaq Global Select Market under the symbol &#8220;IDYA.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 14, 2025, we had 8 record holders of our common stock. Since many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividend Policy</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid any cash dividends on our common stock and do not anticipate paying cash dividends in the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Authorized for Issuance under Equity Compensation Plans</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information about our equity compensation plans is incorporated by reference to Item 12 of Part III of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sale of Unregistered Securities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Proceeds from the Sale of Registered Securities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_selected_financial_data"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 6. Reserved</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_mda"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sis of Financial Condition and Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K, our actual results could differ materially from the results described, in or implied, by these forward-looking statements. Please also see the section of this Annual Report on Form 10-K titled &#8220;Note Regarding Forward-Looking Statements.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are most likely to benefit from these targeted therapies. Our small molecule drug discovery expertise includes discovery and development of small molecule therapeutics. We are applying these capabilities and approach to develop a robust pipeline in precision medicine oncology. <br/> <br/>Our clinical pipeline includes six potential first-in-class clinical-stage product candidates &#8211; darovasertib (PKC), IDE397 (MAT2A), IDE849(DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). We own or control all commercial rights of three of these product candidates: darovasertib, IDE397, and IDE161, and own or control all commercial rights outside of greater China for IDE849. We are also advancing several development candidates, including IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor for which we are targeting an investigational new drug, or IND, filing in mid-year 2025; IDE034, a potential first-in-class B7H3/PTK7 topoisomerase-I-inhibitor-payload bispecific antibody drug conjugate, or BsADC, program for which we are targeting an IND filing in the second half of 2025; and IDE251, a potential first-in-class KAT6/7 dual inhibitor program for which we are targeting an IND filing in the second half of 2025. We also have multiple earlier-stage preclinical programs. We have established selective, value-accretive collaborations with leading pharmaceutical companies to support our clinical development activities.</span><span style="color:#008000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#008000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Darovasertib &#8211; PKC Inhibitor Clinical Candidate in Uveal Melanoma</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#008000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Darovasertib (IDE196) is our most advanced clinical-stage product candidate, which we in-licensed from Novartis. Darovasertib is a potent, selective small molecule inhibitor of protein kinase C, or PKC, which we are developing for genetically-defined cancers having GNAQ or GNA11 gene mutations. PKC is a protein kinase that functions downstream of the GTPases GNAQ and GNA11.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have enrolled over 230 patients as of February 7, 2025, and have opened multiple clinical sites, including international sites, in our potential registration-enabling Phase 2/3 clinical trial, designated as IDE196-002. The purpose of the clinical trial is to evaluate darovasertib in combination with crizotinib, Pfizer&#8217;s investigational cMET inhibitor, in patients having metastatic uveal melanoma, or MUM, with human leukocyte antigen-, or HLA-A*02:01 negative, or HLA-A2(-), serotype, as part of the second Clinical Trial Collaboration and Supply Agreement, or Second Pfizer Agreement, with Pfizer.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we announced the recommendation of a move-forward dose and the completion of the Part 2a dose optimization for the potential registration-enabling Phase 2/3 trial evaluating the combination of darovasertib and crizotinib in the first-line, or 1L setting in patients with HLA-A2(-) MUM.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are enrolling additional HLA-A*02:01 positive, or HLA-A2(+), patients as an independent clinical strategy to address HLA-A2(+) MUM patients, in our ongoing Phase 2 clinical trial, designated as IDE196-001.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are targeting a median overall survival, or OS, readout from our Phase 2 clinical trial, designated as IDE196-001, in approximately 40 1L MUM patients in 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have enrolled 95 patients as of December 31, 2024, in our Phase 2 clinical trial, designated as IDE196-009, evaluating darovasertib as single-agent neoadjuvant and adjuvant therapy in patients having primary uveal melanoma, or UM, with ongoing enrollment and multiple clinical sites open. We are targeting a clinical data update in over 75 patients and regulatory update(s) in in the first half of 2025, including vision data in plaque brachytherapy patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, we announced interim clinical data from the ongoing Phase 2 Company-sponsored trial and provided a regulatory update on a potential Phase 3 registration-enabling clinical trial in neoadjuvant UM patients based on a Type C meeting held with the U.S. Food and Drug Administration, or FDA. Based on the FDA meeting, we currently project approximately 400 patients will be randomized for treatment with darovasertib in the treatment arm or the control arm, with potential modifications pending further feedback from the FDA. We are currently finalizing the trial protocol for neoadjuvant UM and are targeting to initiate the study in the first half of 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also supporting evaluation of darovasertib as single-agent neoadjuvant and adjuvant therapy in primary UM in an ongoing investigator-sponsored clinical trial, or IST, captioned as &#8220;Neoadjuvant / Adjuvant trial of Darovasertib in Ocular Melanoma,&#8221; or NADOM, led by St. Vincent&#8217;s Hospital in Sydney with the participation of Alfred Health and the Royal Victorian Eye and Ear Hospital in Melbourne.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, we announced interim clinical data from the ongoing investigator-sponsored Phase 2 trial of darovasertib as neoadjuvant/adjuvant treatment in UM, which was included in an oral presentation at the American Society of Clinical Oncology, or ASCO, 2024 Annual Meeting, and preliminary clinical data from our Phase 2 trial of darovasertib for neoadjuvant UM.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We own or control all commercial rights in our darovasertib program in UM, including in MUM and in primary UM, subject to certain economic obligations pursuant to our exclusive, worldwide license to darovasertib with Novartis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE397 &#8211; MAT2A Inhibitor in Tumors with MTAP Deletion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDE397, our small molecule methionine adenosyltransferase 2a, or MAT2A, inhibitor, is being evaluated in a Phase 1/2 clinical trial. We have selected a move-forward Phase 2 expansion dose for IDE397 monotherapy, based on adverse event, or AE, profile and preliminary clinical efficacy observed, including multiple partial responses by RECIST 1. We are enrolling patients with an initial focus in MTAP-deletion urothelial cancer, or UC, and non-small cell lung cancer, or NSCLC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>In July 2024, we announced clinical data for the IDE397 Phase 2 monotherapy expansion dose demonstrating preliminary clinical efficacy in heavily pre-treated MTAP-deletion UC and NSCLC patients.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are collaborating with Gilead Sciences, Inc., or Gilead, to clinically evaluate IDE397 in combination with Trodelvy (sacituzumab-govitecan-hziy), Gilead&#8217;s Trop-2 directed antibody drug conjugate, or ADC, in patients having MTAP-deletion UC, in our Phase 1 clinical trial pursuant to a Clinical Study Collaboration and Supply Agreement, or the Gilead CSCSA, with Gilead. A first patient was dosed for the Phase 1 trial in June 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, we reported the first preliminary clinical case study of the IDE397 and Trodelvy combination in MTAP-deletion UC at ENA 2024, including a partial response by RECIST 1.1 in a patient case report with a genetic co-alteration of MTAP-deletion and a FGFR3-TACC3 fusion, and rapid and deep first-evaluation molecular responses, or MRs, with ctDNA reduction of greater than 95% observed. The partial response reported at ENA 2024 has confirmed by RECIST 1.1. We are targeting a Phase 1/2 expansion in the first quarter of 2025 and a clinical data update for the Phase 1 trial in MTAP-deletion UC in 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2025, we expanded our clinical study collaboration and entered into a Clinical Study Collaboration and Supply Agreement, or the Second Gilead CSCSA, to evaluate the IDE397 and Trodelvy combination in MTAP-deletion NSCLC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were collaborating with Amgen to clinically evaluate IDE397 in combination with AMG 193, the Amgen investigational MTA-cooperative PRMT5 inhibitor, in patients having tumors with MTAP deletion, in an Amgen-sponsored clinical trial pursuant to our Clinical Trial Collaboration and Supply Agreement with Amgen, or the Amgen CTCSA. We and Amgen mutually agreed to wind down the IDE397 and AMG 193 clinical combination study in February 2025 and will not pursue dose expansion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, we presented a preclinical poster presentation on the antitumor activity by combinatorial inhibition of MAT2A and PRMT5 in MTAP-deleted tumors at the EORTC-NCI-AACR Symposium, or ENA 2024. We are targeting to enable our wholly-owned clinical combination of IDE397 and IDE892, our potential best-in-class MTA-cooperative PRMT5 inhibitor development candidate, in the second half of 2025 in MTAP-deletion NSCLC.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We own all right, title and interest in and to IDE397 and the MAT2A program, including all worldwide commercial rights thereto.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE849 (DLL3) Program with Hengrui Pharma</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we entered into an exclusive License Agreement, or the Hengrui Pharma License Agreement, with Jiangsu Hengrui Pharmaceuticals Co., Ltd., or Hengrui Pharma, pursuant to which Hengrui Pharma granted us an exclusive worldwide license outside of Greater China for IDE849 (SHR-4849), a potential first-in-class Phase 1 DLL3 TOP1i ADC. Under the terms of the Hengrui Pharma License Agreement, Hengrui Pharma is eligible to receive upfront and milestone payments totaling $1.045 billion, including a $75.0 million upfront fee, up to $200.0 million in development and regulatory milestone payments, plus commercial success-based milestones. Hengrui Pharma is also eligible to receive mid-single to low-double digit royalties on net sales outside of Greater China.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDE849 is currently being evaluated by Hengrui Pharma in an ongoing Phase 1 trial in China in small cell lung cancer, or SCLC, patients. In preliminary results from the trial, 8 out of 11 evaluable patients achieved partial response by RECIST 1.1. In January 2025, Hengrui Pharma selected expansion doses for the Phase 1 trial.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are planning on submitting a U.S. IND for the evaluation of IDE849 as a monotherapy in SCLC in the first half of 2025. We are also targeting to initiate the evaluation of IDE849 in combination with IDE161 and in neuroendocrine tumors, or NETs, in the second half of 2025. A clinical data update is targeted in 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We own or control all commercial rights outside of greater China for IDE849.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE275 (GSK959) - WRN Inhibitor in Tumors with High Microsatellite Instability</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#cc00cc;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, in collaboration with GSK, received IND clearance for IDE275 (GSK959), a potential first-in-class WRN inhibitor, in October 2024 to enable first-in-human clinical evaluation of IDE275 (GSK959) for patients having tumors with high microsatellite instability, or MSI-High. GSK will lead clinical development for the Werner Helicase program. GSK is responsible for 80% of global research and development costs, and we are responsible for 20% of such costs. GSK holds a global, exclusive license to develop and commercialize the Werner Helicase Inhibitor DC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, GSK initiated a Phase 1 clinical trial for IDE275 (GSK959), following the submission of the GSK-sponsored IND and FDA allowance to proceed with the clinical trial. IDE275 (GSK959) targets the helicase domain of the Werner, or WRN, protein, for patients having tumors with MSI-High.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We earned a $7.0 million milestone payment for the IND clearance of IDE275 (GSK959) in October 2024. We previously earned an earlier milestone of $3.0 million in October 2023 in connection with IND-enabling studies. We have the potential to earn up to an additional $10.0 million milestone payment upon initiation of Phase 1 clinical dose expansion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also eligible to receive further aggregate late-stage development and regulatory milestones of up to $465.0 million. Upon commercialization, we will be eligible to receive up to $475.0 million of commercial milestones, 50% of U.S. net profits and tiered royalties on global non-U.S. net sales of the Werner Helicase Inhibitor DC &#8211; ranging from high single-digit to sub-teen double-digit percentages, subject to certain customary reductions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE161 &#8211; PARG Inhibitor in Tumors with Homologous Recombination Deficiency</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDE161 is our potential first-in-class, small molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. We are progressing with enrollment of patients having tumors with homologous recombination deficiency, or HRD, into the Phase 1 expansion portion of the Phase 1/2 clinical trial. We selected an initial Phase 1/2 monotherapy expansion dose for IDE161 in endometrial cancer, based on AE profile and preliminary efficacy observed. In parallel, we are also continuing with Phase 1 dose optimization to confirm a move-forward expansion dose for the planned Phase 2 portion of the clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, we entered into a Clinical Trial Collaboration and Supply Agreement, or the Merck CTCSA, with Merck (known as MSD outside of the United States and Canada). We are evaluating the combination of IDE161 with KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (pembrolizumab) in patients with MSI-High and microsatellite stable, or MSS, endometrial cancer. Under the Merck CTCSA, Merck will provide KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to us, and we will sponsor the Phase 1 clinical combination trial.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, the first patient was dosed with IDE161 in combination with KEYTRUDA in the Company-sponsored Phase 1 clinical trial. We are targeting a Phase 1 expansion in MSI-High and MSS endometrial cancer in 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>In October 2024, we presented preclinical results on the IDE161 and ADC combination rationale as a poster at ENA 2024. We are targeting clinical combination(s) of IDE161 with TOP1i-ADCs in solid tumors in 2025.</span><span style="color:#cc00cc;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We received Fast Track Designation from the FDA in September 2023 for IDE161, specifically for the treatment of (i) adult,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">109</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pretreated, platinum-resistant advanced or metastatic ovarian cancer patients having tumors with BRCA1/2 mutations and (ii) adult, pretreated, advanced or metastatic hormone receptor positive, or HR+, Her2- and BRCA1/2 mutant breast cancer patients.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We entered into an exclusive license under the Evaluation, Option and License Agreement with Cancer Research Technologies Ltd., also known as Cancer Research United Kingdom, or CRT, and the University of Manchester, pursuant to which we hold exclusive worldwide license rights covering a broad class of PARG inhibitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2023, we incurred an obligation to pay milestone payments in an aggregate amount of &#163;750,000 to CRT based upon the achievement of certain milestones relating to first and second tumor histologies in connection with the Phase 1 portion of the IDE161-001 Phase 1/2 clinical trial in oncologic diseases. We will be obligated to make additional payments to CRT aggregating up to &#163;18.75 million upon the achievement of specific development and regulatory approval events for development of a PARG inhibitor in oncologic diseases, including an aggregate of up to &#163;1.5 million and up to &#163;2.25 million for the achievement of certain Phase 2 and Phase 3 development milestones, respectively, in each case as relating to first and second tumor histologies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We own or control all commercial rights in our PARG program, subject to certain economic obligations pursuant to our exclusive, worldwide license to certain PARG inhibitors, including IDE161, with CRT and University of Manchester.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE705 (GSK101) &#8211; Pol Theta Helicase Inhibitor in tumors with Homologous Recombination Deficiency</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enrollment is ongoing in the Phase 1 dose escalation portion of the GSK-sponsored study. IDE705 (GSK101) targets the helicase domain of the Pol Theta protein for patients having solid tumors with BRCA or other mutations associated with HRD. GSK is leading clinical development of IDE705 (GSK101). GSK is clinically evaluating IDE705(GSK101) in a GSK-sponsored dose escalation trial in combination with niraparib, the GSK small molecule inhibitor of poly-(ADP-ribose) polymerase, or PARP, in solid tumors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2023, we earned a $7.0 million payment for a milestone based on acceptance of the IND by the FDA. An earlier preclinical development $3.0 million milestone payment from GSK was achieved in August 2022 in connection with ongoing IND-enabling studies to support the evaluation of IDE705 (GSK101). We have the potential to earn up to an additional $10.0 million milestone payment upon initiation of Phase 1 clinical dose expansion.</span><span style="color:#cc00cc;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have the potential to earn further aggregate late-stage development and regulatory milestones of up to $465.0 million. Upon commercialization, we will be eligible to receive up to $475.0 million of commercial milestones, and tiered royalties on global net sales of GSK101 &#8211; ranging from high single-digit to sub-teen double-digit percentages, subject to certain customary reductions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE892 - MTA-cooperative PMRT5 inhibitor</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we announced the selection of IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor. IDE892 was discovered through our iterative physics-based ligand design and optimization platform, and is a highly potent and selective MTA-cooperative PRMT5 inhibitor with best-in-class potential and favorable drug-like properties. IDE892 has demonstrated exceptionally selective antiproliferative activity in MTAP-deleted tumor cell models and durable complete responses in combination with MAT2A inhibitor IDE397 in challenging MTAP-deletion preclinical models.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to successful completion of ongoing IND-enabling studies for IDE892, we are targeting an IND submission in mid-year 2025. We are also targeting to enable our wholly-owned clinical combination of IDE397 and IDE892 in the second half of 2025 in MTAP-deletion NSCLC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE034 (B7H3/PTK7) program with Biocytogen</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2024, we entered into an Option and License Agreement, or the Biocytogen Option and License Agreement, with Biocytogen Pharmaceuticals (Beijing) Co., Ltd., (Biocytogen, HKEX: 02315), or Biocytogen, pursuant to which Biocytogen granted us an option for an exclusive worldwide license for a potential first-in-class B7H3/PTK7 topoisomerase-I-inhibitor-payload bispecific antibody drug conjugate, or BsADC, program, or the Option.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, we announced the selection of IDE034, a potential first-in-class B7H3/PTK7 topo-I-payload BsADC, as a development candidate and the exercise of the Option. Under the terms of the Biocytogen Option and License Agreement, we paid Biocytogen an upfront fee and an exercise fee for the Option totaling $6.5 million.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the successful completion of ongoing IND-enabling studies for IDE034, we are targeting an IND submission in the second half of 2025.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Biocytogen is eligible to receive total potential upfront, option exercise and milestone payments equal an aggregate of $406.5 million, including development and regulatory milestones of $100.0 million.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IDE251 - KAT6/7 inhibitor</span><span style="color:#cc00cc;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#cc00cc;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we announced the selection of IDE251, a potential first-in-class KAT6/7 inhibitor. IDE251 is an equipotent, highly selective, small molecule dual inhibitor of the lysine acetyltransferase (KAT) 6 and 7, both of which have been shown to support cancer cell survival. IND-enabling studies to support the potential clinical evaluation of IDE251 monotherapy in patients with breast and lung cancers with 8p11 amplification are ongoing, as well as additional opportunities in the setting of lineage addiction. Based on our biomarker evaluation, 8p11 amplification prevalence is projected to be approximately 15% in breast cancer and 17.5% in squamous NSCLC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDE251 selectively inhibits both KAT6 and KAT7 while sparing other structurally similar KAT molecules. KAT6 and KAT7 are mechanistically intertwined epigenetic modulators of cell identity and lineage commitment programs corrupted by oncogenic transformation. Dual KAT6/7 inhibition with IDE251 delivers robust and durable anti-tumor activity, superior to KAT6 inhibition alone, in preclinical tumor models with 8p11 amplifications, as well as in biomarker selected indications dependent upon lineage-specific transcription factor activity.</span><span style="color:#cc00cc;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#cc00cc;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the successful completion of ongoing IND-enabling studies for IDE251, we are targeting an IND submission in the second half of 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Next-Generation Precision Medicine Pipeline Programs</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have initiated early preclinical research programs focused on pharmacological inhibition of several new targets, or NTs, for patients with solid tumors characterized by defined biomarkers based on genetic mutations and/or molecular signatures. We believe these research programs have the potential for discovery and development of first-in-class or unique-in-class or best-in-class therapeutics. Collectively, we believe these efforts will further advance our multi-pronged clinical and business strategy. We own or control all commercial rights in our next-generation NT programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New Target and Biomarker Discovery Platform</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the inception of the company, our core research has and continues to be focused on precision medicine oncology, with synthetic lethality as a central tenet. We have invested significantly and continue to invest in capabilities for identification and validation of new precision medicine targets and biomarkers for patient selection. For targets of interest, we advance our research to discover therapeutic drugs and to further qualify relevant biomarkers. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prospectus Supplement - At-the-Market Facility</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 26, 2023, we filed a new Registration Statement on Form S-3 (File No. 333- 272936) under the Securities Act as an automatic shelf registration statement as a &#8220;well-known seasoned issuer,&#8221; as defined in Rule 405 under the Securities Act. On June 26, 2023, we also entered into an Open Market Sales Agreement, or the June 2023 Sales Agreement, with Jefferies LLC, or Jefferies, relating to an at-the-market offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, par value $0.0001 per share, having aggregate gross proceeds of up to $250.0 million through Jefferies as sales agent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From January 1, 2024 through January 17, 2024, we sold an aggregate of 6,115,516 shares of our common stock for aggregate net proceeds of $215.9 million at a weighted average sales price of approximately $36.39 per share under the at-the-market offering pursuant to the June 2023 Sales Agreement with Jefferies as sales agent.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 19, 2024, we entered into a new Open Market Sales Agreement, or the January 2024 Sales Agreement, with Jefferies, relating to an at-the-market offering program under which we may offer and sell, from time to time at our sole discretion, shares of common stock having aggregate gross proceeds of up to $350.0 million through Jefferies as sales agent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, pursuant to the January 2024 Sales Agreement, we sold an aggregate of 4,066,866 shares of our common stock for aggregate net proceeds of $164.0 million at a weighted average sales price of approximately $41.28 per share under the at-the-market offering pursuant to the January 2024 Sales Agreement with Jefferies as sales agent. As of December 31, 2024, approximately $182.1 million of common stock remained available to be sold under the ATM facility.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">111</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequent to December 31, 2024, from January 1, 2025 through January 6, 2025, the Company sold an aggregate of 984,000 shares of our common stock for aggregate net proceeds of $25.1 million at a weighted average sales price of approximately $26.00 per share under the at-the-market offering pursuant to the January 2024 Sales Agreement with Jefferies as sales agent. As of January 6, 2025, approximately $156.6 million of common stock remained available to be sold under the ATM facility.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may cancel our at-the-market program at any time upon written notice, pursuant to its terms.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2024 July Public Offering and Sale of IDEAYA Common Stock</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 11, 2024, we completed an underwritten public follow-on offering. The offering consisted of 8,355,714 shares of common stock at an offering price to the public of $35.00 per share, including 1,127,142 shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants to purchase 285,715 shares of common stock at a public offering price of $34.9999 per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, we received aggregate gross proceeds of approximately $302.4 million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $283.8 million, after deducting underwriting discounts and commissions and other offering expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2023 October Public Offering and Sale of IDEAYA Common Stock</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 27, 2023, we completed an underwritten public follow-on offering. The offering consisted of 5,797,872 shares of common stock at an offering price to the public of $23.50 per share, including 797,872 shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants to purchase 319,150 shares of common stock at a public offering price of $23.4999 per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, we received aggregate gross proceeds of approximately $143.7 million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $134.6 million, after deducting underwriting discounts and commissions and other offering expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2023 April Public Offering and Sale of IDEAYA Common Stock</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 27, 2023, we completed an underwritten public follow-on offering. The offering consisted of 8,858,121 shares of common stock at an offering price to the public of $18.50 per share, including 1,418,920 shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants to purchase 2,020,270 shares of common stock at a public offering price of $18.4999 per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, we received aggregate gross proceeds of approximately $201.3 million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $188.7 million, after deducting underwriting discounts and commissions and other offering expenses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Corporate Update</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have any products approved for sale and have not generated any product revenue since inception. We have funded our operations primarily through the sale and issuance of common stock and the upfront payment and certain milestone payments received from GSK. As of December 31, 2024, we had cash, cash equivalents and marketable securities of $1.1 billion, consisting primarily of money market funds, U.S. government securities, commercial paper, and corporate bonds.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception in June 2015, we have devoted substantially all of our resources to discovering and developing our product candidates. We have incurred significant operating losses to date and expect that our operating expenses will increase significantly as we advance our product candidates through preclinical and clinical development; seek regulatory approval, and prepare for, and, if approved, proceed to commercialization; acquire, discover, validate and develop additional product candidates; obtain, maintain, protect and enforce our intellectual property portfolio; and hire additional personnel. Certain program costs that contribute to our operating expenses have been and/or will be reimbursed by GSK pursuant to the GSK Collaboration Agreement, including 100% of costs we incur for research we perform in connection with the Pol Theta program and 80% of the aggregate program costs incurred by us and GSK for research each of us performs for the Werner Helicase program. We also incur costs in accordance with the Gilead CSCSA and Second CSCSA. Gilead bears internal or external costs incurred in connection with its supply of Trodelvy. We bear all internal and external costs and expenses associated with the conduct of the combination study. We also incur costs in accordance with the Merck CTCSA. Merck provides KEYTRUDA for the study at no cost to us. We bear all internal and external costs and expenses associated with the conduct of the study. We also entered into two in-licensing agreements for ADCs with topoisomerase-I-inhibitor-payloads to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">112</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enable combinations with our synthetic lethality programs with Hengrui Pharma for IDE849 and Biocytogen for IDE034. See Note 10. Significant Agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our net losses were $274.5 million and $113.0 million for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, we had an accumulated deficit of $622.8 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to generate product revenue will depend on the successful development, regulatory approval and eventual commercialization of one or more of our product candidates, ourselves, or for some programs, in collaboration with our strategic partners.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings, or other capital sources, including potential collaborations with other companies or other strategic transactions. Adequate funding may not be available to us on acceptable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our cash, cash equivalents, and short-term and long-term marketable securities will be sufficient to fund our planned operations for at least twelve months from the date of the issuance of our Annual Report on Form 10-K filed February 18, 2025</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These funds will support our efforts through potential achievement of multiple preclinical and clinical milestones across multiple programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of Operating Results</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaboration Revenues</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not generated any revenue from product sales, and we do not expect to generate any revenue from product sales unless and until we are able to initiate a registrational clinical trial, obtain regulatory approval and commercialize one of our product candidates in the future. Our revenue consists exclusively of collaboration revenue under the GSK Collaboration Agreement, including amounts that are recognized related to previously received upfront payments and amounts due and payable to us for research and development services. The amount of revenue recognized related to the GSK Collaboration Agreement, including as related to the previously received upfront payment or to certain development milestone payments, may vary considerably by period and certain components thereof may generally decrease year-over-year as we satisfy remaining performance obligations, for example, relating to the Pol Theta and WRN R&amp;D Services. Since December 31, 2023, we have fully recognized the contract liabilities related to the upfront payment and reimbursements for the research and development performance obligations under the GSK Collaboration Agreement. There are no remaining contract liabilities as of December 31, 2024 as we concluded all the research and development performance obligations under the GSK Collaboration Agreement. The future revenue recognition will be contingent on additional milestones earned, profit sharing and royalties on any net product sales under our collaborations. We expect that any revenue we recognize or generate under the GSK Collaboration Agreement will fluctuate from period to period due to period to period variability in milestone payments and other payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Substantially all of our research and development expenses consist of expenses incurred in connection with the discovery and development of our product candidates. These expenses include certain payroll and personnel-related expenses, including salaries, employee benefit costs and stock-based compensation expenses for our research and product development employees, fees to third parties to conduct certain research and development activities on our behalf including fees to CMOs and CROs in support of manufacturing and clinical activity for darovasertib, IDE397, IDE849, IDE275 (GSK959), IDE161, IDE705 (GSK 101), and consulting costs, costs for laboratory supplies, costs for product licenses and allocated overhead, including rent, equipment, depreciation, information technology costs and utilities. We expense both internal and external research and development expenses as they are incurred.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into various agreements with CMOs and CROs. Our research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments made to CMOs and CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">113</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs of certain activities, such as preclinical studies, are generally recognized based on an evaluation of the progress to completion of specific tasks. Nonrefundable payments made prior to the receipt of goods or services that will be used or rendered for future research and development activities are deferred and capitalized as prepaid expenses and other current assets on our balance sheet. The capitalized amounts are recognized as expense as the goods are delivered or the related services are performed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not allocate our internal costs by product candidate, including internal costs, such as payroll and other personnel expenses, laboratory supplies and allocated overhead. With respect to internal costs, several of our departments support multiple product candidate research and development programs, and therefore the costs cannot be allocated to a particular product candidate or development program. The following table summarizes our external clinical development expenses by program:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:54.76%;box-sizing:content-box;"/>
    <td style="width:1.98%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:18.639999999999997%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.98%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:18.639999999999997%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External clinical development expenses </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Darovasertib</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,335</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,829</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">IDE397</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,629</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,985</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">IDE161</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,743</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,104</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel related and stock-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,543</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,948</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development expenses </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">:</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,423</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,642</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">294,673</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,508</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:1.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.3895030152644585%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">External clinical development expenses include manufacturing and clinical trial costs. These expenses are primarily for services provided by external consultants, CMOs and CROs.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.3895030152644585%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDE397 includes costs from the Amgen CTCSA</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.3895030152644585%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other research and development expenses include $75.0 million upfront payment under the Hengrui Pharma License Agreement for IDE849 and $6.5 million of upfront and option license exercise fees under the Biocytogen Option and License Agreement for IDE034.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are focusing substantially all of our resources on the development of our product candidates. We expect our research and development expenses to increase substantially during the next few years, as we seek to initiate and/or advance clinical trials for our product candidates, complete our clinical program, pursue regulatory approval of our product candidates and prepare for a possible commercial launch. Predicting the timing or the cost to complete our clinical program or validation of our commercial manufacturing and supply processes is difficult and delays may occur because of many factors, including factors outside of our control. For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. Furthermore, we are unable to predict when or if our product candidates will receive regulatory approval with any certainty.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of payroll and personnel-related expenses, including salaries, employee benefit costs and stock-based compensation expense, professional fees for legal, patent, consulting, accounting and tax services, allocated overhead, including rent, equipment, depreciation, information technology costs and utilities, and other general operating expenses not otherwise classified as research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We anticipate that our general and administrative expenses will increase, as a result of increased personnel costs, including salaries, benefits and stock-based compensation expense, patent costs for our product candidates, expanded infrastructure and higher consulting, legal and accounting services associated with maintaining compliance with our Nasdaq stock exchange listing and requirements of the Securities and Exchange Commission, or the SEC, investor relations costs and director and officer insurance policy premiums associated with being a public company.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Income and Other Income, Net</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income and other income, net consists primarily of interest income earned on our cash, cash equivalents and marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">114</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A discussion regarding our financial condition and results of operations for fiscal year 2024 compared to fiscal year 2023 is presented below. A discussion regarding our financial condition and results of operations for fiscal year 2023 compared to fiscal year 2022 can be found in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K filed with the SEC on February 20, 2024.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the Years Ended December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our results of operations for the periods indicated (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"/>
    <td style="width:1.3%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.200000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.3%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.200000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.3%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.020000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.68%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">% Change</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,000</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,385</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(16,385</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(70</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">294,673</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,508</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">165,165</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">128</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,302</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,306</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,996</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333,975</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,814</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,161</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(326,975</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(134,429</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(192,546</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income and other income, net</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,498</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,468</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,030</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(274,477</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(112,961</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(161,516</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaboration Revenue</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration revenue decreased by $16.4 million, or 70%, during the year ended December 31, 2024 compared to the year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We completed all performance obligations related to the upfront payment under the GSK Collaboration Agreement as of December 31, 2023 for the Pol Theta and WRN programs. Future collaboration revenue recognized under the GSK Collaboration Agreement is related to milestone payments as they are earned.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, we earned a $7.0 million milestone payment for the IND clearance of IDE275 (GSK 959), a potential first-in-class WRN inhibitor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses increased by $165.2 million, or 128%, during the year ended December 31, 2024 compared to the year ended December 31, 2023. The increase in research and development expenses was primarily due to $75.0 million upfront payment under the Hengrui Pharma License Agreement for IDE849, $6.5 million in upfront and option exercise fees under the Biocytogen Option and License Agreement for IDE034, increases of $64.1 million in fees paid to CROs, CMOs and consultants related to the advancement of our lead product candidates through preclinical and clinical studies, $15.6 million in personnel-related expenses, including salaries, benefits and stock-based compensation, to support our growth, and $4.0 million in costs for laboratory supplies, facilities and information technology costs to support our research and development programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses increased by $11.0 million, or 39%, during the year ended December 31, 2024 compared to the year ended December 31, 2023. The increase in general and administrative expenses was primarily due to increases of $7.0 million in personnel-related expenses, including salaries, benefits and stock-based compensation and $4.0 million in consulting and legal services.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Income and Other Income, Net</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income increased by $31.0 million, or 145%, during the year ended December 31, 2024 compared to the year ended December 31, 2023, primarily due to higher interest rates and investment balances.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">115</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources; Plan of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sources of Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have funded our operations primarily through the sale and issuance of common stock and the upfront payment and certain milestone payments received from GSK. As of December 31, 2024, we had cash, cash equivalents and marketable securities of $1.1 billion, consisting primarily of money market funds, U.S. government securities, commercial paper, and corporate bonds.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material Cash Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred net losses since our inception. For the years ended December 31, 2024 and December 31, 2023, we had net losses of $274.5 million and $113.0 million, respectively, and we expect to incur substantial additional losses in future periods. As of December 31, 2024, we had an accumulated deficit of $622.8 million. Based on our current business plan, we believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our planned operations for at least the next 12 months from the issuance date of this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not generated any product revenue. We do not expect to generate any meaningful product revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates, and we do not know when, or if, it will occur. We expect to continue to incur significant losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for our product candidates, and begin to commercialize any approved products. We are subject to all of the risks typically related to the development of new product candidates, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. Moreover, we expect to incur additional costs associated with operating as a public company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will continue to require additional capital to develop our product candidates and fund operations for the foreseeable future. We may seek to raise capital through private or public equity or debt financings, collaboration or other arrangements with corporate sources, or through other sources of financing. Adequate additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategies. We anticipate that we will need to raise substantial additional capital, the requirements for which will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, timing, rate of progress and costs of our drug discovery, preclinical development activities, laboratory testing and clinical trials for our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and scope of clinical programs we decide to pursue;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope and costs of manufacturing development and commercial manufacturing activities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we acquire or in-license other product candidates and technologies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost, timing and outcome of regulatory review of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;	</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain collaborations on favorable terms, if at all;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with being a public company; and	</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost and timing associated with commercializing our product candidates, if they receive marketing approval.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will continue to require additional capital to meet operational needs and capital requirements associated with such operating plans. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments or engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to others rights to our product candidates in certain territories or indications that we would prefer to develop and commercialize ourselves.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">116</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2023, we entered into a lease agreement for approximately 44,000 square feet of laboratory and office facilities at 5000 Shoreline Court, South San Francisco, California. The lease term is 120 months, and we have an option to extend the lease term for a total of two consecutive five-year periods. The lease commenced in August 2024. In May 2024, we amended our 5000 Shoreline Court facility lease agreement to expand the size of the original premises by adding approximately 11,321 rentable square feet of additional space. The amendment to the lease term commenced in January 2025. Our lease at 7000 Shoreline Court, South San Francisco, California, expired in September 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, we entered into a lease agreement for approximately 5,700 square feet of space at 11710 El Camino Real, San Diego, California for corporate office space. The lease commenced in December 2023 and expires in March 2028. We have an option to renew the lease for three years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We enter into contracts in the normal course of business with third-party contract organizations for preclinical and clinical studies and testing, manufacture and supply of our preclinical and clinical materials and providing other services and products for operating purposes. These contracts generally provide for termination following a certain period after notice, and therefore, we believe that our non-cancelable obligations under these agreements are not material.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Notes 5. Operating Leases, 6. Commitments and Contingencies, 7. Income Taxes and 10. Significant Agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adequate additional funding may not be available to us on acceptable terms or at all. See the section of this Annual Report on Form 10-K titled &#8220;Part I, Item 1A. &#8211; Risk Factors&#8221; for additional risks associated with our substantial capital requirements.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Off-Balance Sheet Arrangements</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not entered into any off-balance sheet arrangements as defined in the rules and regulations of the SEC.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary Statement of Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the primary sources and uses of cash, cash equivalents, and restricted cash for each of the periods presented below (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.673%;box-sizing:content-box;"/>
    <td style="width:1.72%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.943%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.72%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.943%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash (used in) provided by:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(247,584</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(115,224</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(502,559</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(158,456</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">677,551</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">362,717</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (decrease) increase in cash, cash equivalents and restricted cash</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(72,592</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,037</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Flows from Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in operating activities was $247.6 million for the year ended December 31, 2024. Cash used in operating activities was primarily due to the use of funds in our operations to develop our product candidates resulting in a net loss of $274.5 million, adjusted for net non-cash charges of $15.3 million and changes in net operating assets and liabilities of $11.5 million. Our non-cash charges consisted of $34.7 million in stock-based compensation, $2.4 million in depreciation and $1.4 million of the amortization of right of use assets, partially offset by $23.2 million accretion of discounts on marketable securities. The net change in our operating assets and liabilities consisted primarily of cash inflows from $8.3 million in accounts payable and $10.8 million in accrued and other liabilities due to CRO fees in support of research and manufacturing activities, partially offset by cash outflows of $6.2 million in prepaid and other assets and $1.4 million in lease liabilities.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in operating activities was $115.2 million for the year ended December 31, 2023. Cash used in operating activities was primarily due to the use of funds in our operations to develop our product candidates resulting in a net loss of $113.0 million, adjusted for net non-cash charges of $10.9 million and changes in net operating assets and liabilities of $13.2 million. Our non-cash charges consisted of $18.5 million in stock-based compensation, and $2.5 million in depreciation and amortization of right of use assets of $1.5 million, partially offset by $11.6 million accretion of discounts on marketable securities. The net change in our operating assets and liabilities consisted primarily of decreases of $13.8 million in contract liabilities due to revenue recognized under the GSK Collaboration Agreement, $2.0 million in prepaid and other assets, and $1.9 million in lease liabilities, partially offset by $1.6 million accrued and other liabilities due to CRO fees in support of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">117</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">research and manufacturing activities, $2.6 million in accounts payable, and $0.2 million in accounts receivable from GSK for estimated program costs under the GSK Collaboration Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Flows from Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in investing activities was $502.6 million for the year ended December 31, 2024, which consisted primarily of $1.2 billion used to purchase marketable securities and $3.9 million used to purchase property and equipment, partially offset by $692.6 million provided by maturities of marketable securities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in investing activities was $158.5 million for the year ended December 31, 2023, which consisted primarily of $596.0 million used to purchase marketable securities and $2.4 million used to purchase property and equipment, partially offset by $439.9 million provided by maturities of marketable securities.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Flows from Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities was $677.6 million for the year ended December 31, 2024, which consisted primarily of $274.4 million of net proceeds from our follow-on offering, $9.4 million of proceeds from issuance of pre-funded warrants, $379.9 million of proceeds from ATM offering, $12.5 million of proceeds from exercise of common stock options and $1.4 million of proceeds from ESPP purchase.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities was $362.7 million for the year ended December 31, 2023, which consisted primarily of $281.2 million of net proceeds from our follow-on offering, $42.2 million of proceeds from issuance of pre-funded warrants, $28.6 million of proceeds from ATM offering, $9.6 million of proceeds from exercise of common stock options, and $1.2 million of proceeds from ESPP purchase.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported revenue recognized and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates. For more detail on our critical accounting policies, refer to Note 2 to the financial statements appearing elsewhere in this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licenses of intellectual property:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> If a license to our intellectual property is determined to be distinct from the other promised goods or services identified in an arrangement, we recognize revenue from non-refundable, upfront fees allocated to the license at the point in time when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other goods or services, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress toward satisfying the performance obligation for purposes of recognizing revenue from non-refundable, upfront fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of progress and related revenue recognition.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Customer options for additional goods or services: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a contract contains customer options that allow the customer to acquire additional goods or services, including a license to our intellectual property, the goods and services underlying the customer options are evaluated to determine whether they are deemed to represent a material right. In determining whether the customer option has a material right, we assess whether there is an option to acquire additional goods or services at a discount. If the customer option is determined not to represent a material right, the option is not considered to be a performance obligation. If the customer option is determined to represent a material right, the material right is recognized as a separate performance obligation. We allocate the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until the option is exercised.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">118</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone payments:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> At the inception of each arrangement or amendment that includes development, regulatory or commercial milestone payments, we evaluate whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 prescribes two methods to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. Whichever method is used, it should be consistently applied throughout the life of the contract; however, it is not necessary for us to use the same approach for all contracts. If it is probable that a significant revenue reversal would not occur when the uncertainty associated with the milestone is resolved, the associated milestone value is included in the transaction price. Milestone payments that are highly susceptible to factors outside our influence, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. If there is more than one performance obligation, the transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. We recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability or achievement of each milestone and any related constraint, and if necessary, adjust our estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalties:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upfront payments and fees are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. We do not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contractual cost sharing payments received from a customer or collaboration partner are accounted for as variable consideration. We include an expected value in the transaction price. Contractual cost sharing payments made to a customer or collaboration partner are accounted for as a reduction to the transaction price if such payments are not related to distinct goods or services received from the customer or collaboration partner.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contracts may be amended to account for changes in contract specifications and requirements. Contract modifications exist when the amendment either creates new, or changes existing, enforceable rights and obligations. When contract modifications create new performance obligations and the increase in consideration approximates the standalone selling price for goods and services related to such new performance obligations as adjusted for specific facts and circumstances of the contract, the modification is accounted for as a separate contract. If a contract modification is not accounted for as a separate contract, we account for the promised goods or services not yet transferred at the date of the contract modification (the remaining promised goods or services) prospectively, as if it were a termination of the existing contract and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. We account for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. In such case the effect that the contract modification has on the transaction price, and on the entity&#8217;s measure of progress toward complete satisfaction of the performance obligation, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) at the date of the contract modification (the adjustment to revenue is made on a cumulative catch-up basis).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upfront payment contract liabilities resulting from our license and collaboration agreements do not represent a financing component as the payment is not financing the transfer of goods and services, and the technology underlying the licenses granted reflects research and development expenses already incurred by us. As such, we do not adjust our revenues for the effects of a significant financing component.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Determination of the timing of satisfaction of performance obligations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize revenue from the MAT2A R&amp;D Services, Pol Theta R&amp;D Services and WRN R&amp;D Services over time, as GSK simultaneously receives and consumes the benefits provided by our performance as we perform. We measure our progress toward complete satisfaction of the MAT2A R&amp;D Services, Pol Theta R&amp;D Services and WRN R&amp;D Services</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">119</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">based on the costs incurred as a percentage of the estimated total costs to be incurred to complete the performance obligations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated total costs to be incurred to complete the MAT2A R&amp;D Services, Pol Theta R&amp;D Services and WRN R&amp;D Services may evolve and be updated throughout the performance period with the consultation with GSK through the joint development committee. The change in the estimated total costs and/or the timing of completion may materially impact an amount of subsequent revenue recognition and/or its timing. MAT2A R&amp;D Services and Pol Theta R&amp;D Services are completed. The expected timing of completing the WRN R&amp;D Services may be updated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See the section titled &#8220;Summary of Significant Accounting Policies&#8212;Recent Accounting Pronouncements&#8221; in Note 2 to our financial statements included elsewhere in this Annual Report on Form 10-K for additional information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_market_risk"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7A. Quantitative and Qualita</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tive Disclosures About Market Risk.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Rate Sensitivity</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates or exchange rates. As of December 31, 2024, we had cash, cash equivalents and marketable securities of $1.1 billion, consisting of bank deposits, interest-bearing money market funds, investments in U.S. government securities, commercial paper, and corporate bonds, for which the fair value would be affected by changes in the general level of U.S. interest rates. Even if the fair value of certain government securities, commercial paper, and corporate bonds is affected by changes in U.S. interest rates, the principal of such instruments will be due to us upon maturity.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. Because our investments are primarily short-term in duration and our holdings in U.S. government treasury bonds mature prior to our expected need for liquidity, we believe that our exposure to interest rate risk is not significant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we are seeing, and expect to continue to see, record inflation due to geopolitical and macroeconomic events, such as the ongoing Ukraine-Russia conflict and related sanctions, the Israel-Hamas conflict, and the banking sector volatility, we do not believe that inflation, or exchange rate fluctuations have had a significant impact on our results of operations for any periods presented herein.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8. Financial Statemen</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ts and Supplementary Data</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial statements required to be filed pursuant to this Item 8 are appended to this report. An index of those financial statements is found in Item 15 of Part IV of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_disagreements_with_accountants"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9. Changes in</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Disagreements with Accountants on Accounting and Financial Disclosure.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">121</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9A. Controls and P</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rocedures</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, with the participation of our principal executive officer and principal financial and accounting officer, evaluated the effectiveness of our disclosure controls and procedures at the end of the period covered by this Annual Report on Form 10-K. Based upon such evaluation, our principal executive officer and principal financial and accounting officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no changes in our internal control over financial reporting that occurred during the quarter ended December 31, 2024 that have materially affected, or are reasonably likely to materially effect, our internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management&#8217;s Report on Internal Control Over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Under the supervision of and with the participation of our principal executive officer and principal financial and accounting officer, our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2024 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in &#8220;Internal Control&#8212;Integrated Framework&#8221; (2013). Based on this assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The effectiveness of our internal control over financial reporting as of December 31, 2024 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report, which is included under &#8220;Item 8. Financial Statements and Supplementary Data&#8221; of this Annual Report.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9B. Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Information</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Trading Plans</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>During the three months ended December 31, 2024, no Section 16 officers or directors </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_223fe026-c06f-4fe7-9c00-40b86fd8f3dc" contextRef="C_eb642f77-00cf-4cd5-89ff-cfa0d9ff7eb3" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_af0991a3-0130-4b99-886d-1cdaa1a748b8" contextRef="C_eb642f77-00cf-4cd5-89ff-cfa0d9ff7eb3" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_01a8ef09-f2f4-4d6f-b6f5-d6334337c959" contextRef="C_eb642f77-00cf-4cd5-89ff-cfa0d9ff7eb3" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_6b0acaad-b3bf-46bd-9df1-089e4622e123" contextRef="C_eb642f77-00cf-4cd5-89ff-cfa0d9ff7eb3" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> contracts, instructions or written plans for the purchase or sale of our securities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Study Collaboration and Supply Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 12, 2025, we entered into the Second Gilead CSCSA with Gilead pursuant to which we and Gilead will collaborate on a portion of our Phase 1 study for the clinical evaluation of our IDE397 compound in combination with Gilead&#8217;s Trop2-ADC, Trodelvy, or the Combination Study, in certain patients with advanced solid tumors in lungs. Pursuant to the Second Gilead CSCSA, we are the sponsor of the Combination Study, and we will provide the IDE397 compound and pay for the costs of the Combination Study.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gilead will provide Trodelvy for the Combination Study at no cost to us. We and Gilead will jointly own clinical data from the Combination Study and all inventions relating to the combined use of IDE397 and Trodelvy. Each party retains commercial rights to its respective compounds, including with respect to use as a monotherapy or combination agent. We and Gilead will form a joint steering committee responsible for coordinating all regulatory and other activities under the Second Gilead CSCSA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">122</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Second Gilead CSCSA will continue in effect until the later of (i) the completion of the patient monitoring period for the separate arm of the study evaluating the combination therapy, or the Gilead Arm, in accordance with the study protocol and (ii) our provision to Gilead of the final version of the final study report for the Gilead Arm, unless earlier terminated by either party pursuant to its terms. We or Gilead may terminate the Second Gilead CSCSA for the other party&#8217;s insolvency, upon uncured material breach or for other specified reasons with certain notice and other requirements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Second Gilead CSCSA contains various representations, warranties, covenants, dispute resolution mechanisms, indemnities and other provisions customary for transactions of this nature.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing is only a summary description of the terms of the Second Gilead CSCSA, does not purport to be complete and is qualified in its entirety by reference to the Second Gilead CSCSA, which will be filed as an exhibit to our Quarterly Report on Form 10-Q for the fiscal quarter ending March 31, 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosure_regarding_foreign_jur"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9C. Disclo</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sure Regarding Foreign Jurisdictions that Prevent Inspections</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">123</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Part III</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_officers_corp_governan"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 10. Directors, E</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">xecutive Officers and Corporate Governance.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f9ee59aa-6554-4c55-9b26-8825d38ab7a6" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> insider trading policies and procedures applicable to our directors, officers and employees, that we believe are reasonably designed to promote compliance with insider trading laws and regulations and the Nasdaq stock exchange listing standards. A copy of our policy is filed with this Annual Report on Form 10-K as Exhibit 19.1.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The other information required by this item will be contained in our definitive proxy statement to be filed with the SEC in connection with the Annual Meeting of Stockholders within 120 days after December 31, 2024, or the Proxy Statement, and is incorporated in this Annual Report on Form 10-K by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 11. Executive Compe</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nsation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be contained in the Proxy Statement and is incorporated in this Annual Report on Form 10-K by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_beneficial_ownership"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 12. Security Ownersh</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ip of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be contained in the Proxy Statement and is incorporated in this Annual Report on Form 10-K by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_related_party_independence"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 13. Certain Relatio</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nships and Related Transactions, and Director Independence.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be contained in the Proxy Statement and is incorporated in this Annual Report on Form 10-K by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_accounting_fees"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 14. Principal Accou</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nting Fees and Services.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be contained in the Proxy Statement and is incorporated in this Annual Report on Form 10-K by reference.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">124</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Part IV</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 15. Exhibits, Financial </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statement Schedules.</span></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following documents are filed as part of this report:</span></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FINANCIAL STATEMENTS</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following documents are included on pages F-1 through F-31 attached hereto and are filed as part of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:95%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="independen"><a href="#reportofindependentaccountingfirm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accou</span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">nting Firm (PCAOB ID 238)</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audited Financial Statements:</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:13.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:13.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheet"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Balance Sheets</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:13.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:13.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_operations_comprehensive_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:13.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:13.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_redeemable_convertible_prefer"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Stockholders&#8217; Equity</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:13.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:13.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Cash Flows</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:13.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:13.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_tostatements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Financial Statements</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> FINANCIAL STATEMENT SCHEDULES</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All schedules to the financial statements are omitted as the required information is either inapplicable or presented in the financial statements.</span></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBITS</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The exhibits listed in the accompanying Exhibit Index are filed as part of, or incorporated by reference into, this report.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">125</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit Index</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Exhibits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:9.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:45.18%;box-sizing:content-box;"/>
    <td style="width:8.3%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7%;box-sizing:content-box;"/>
    <td style="width:1.06%;box-sizing:content-box;"/>
    <td style="width:8.34%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td rowspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit Description</span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Herewith</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;display:none;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;display:none;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;display:none;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;display:none;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312519158427/d746735dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Certificate of Incorporation.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/28/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;3.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312519158427/d746735dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/28/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reference is made to Exhibits </span><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312519158427/d746735dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">3.1</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;through </span><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312519158427/d746735dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">3.2</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312519144721/d637842dex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Common Stock Certificate.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/13/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="idya-ex4_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Common Stock.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;4.4</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312523122115/d488081dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of April 2023 Pre-funded Warrant.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;4/27/2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;4.5</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312523265158/d560299dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of October 2023 Pre-funded Warrant.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;10/27/2023</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">   </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4.6</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312524177726/d807091dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of July 2024 Pre-funded Warrant.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/11/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312519122586/d637842dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement by and between IDEAYA Biosciences, Inc. and Novartis International Pharmaceutical, Inc. dated as of September 19, 2018.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/26/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2(a)&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312519122586/d637842dex102a.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Evaluation, Option and License Agreement by and among IDEAYA Biosciences, Inc., Cancer Research Technology Ltd. and University of Manchester dated as of April 28, 2017</span><span style="color:#0070c0;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/26/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2(a)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312519122586/d637842dex102b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment #1 to Evaluation, Option and License Agreement by and among IDEAYA Biosciences, Inc., Cancer Research Technology Ltd. and University of Manchester dated as of April 24, 2019.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/26/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;10.2(c)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000156459020012501/idya-ex102c_1874.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment #2 to Evaluation, Option and License Agreement by and among IDEAYA Biosciences, Inc., Cancer Research Technology Ltd. and University of Manchester dated as of March 3, 2020.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:11.5pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:11.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/24/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2(c)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3(a)#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312519144721/d637842dex105a.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2019 Incentive Award Plan.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/13/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5(a)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3(b)#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312519144721/d637842dex105b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Stock Option Grant Notice and Stock Option Agreement under the 2019 Incentive Award Plan.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/13/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3(c)#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312519144721/d637842dex105c.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2019 Incentive Award Plan.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/13/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5(c)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3(d)#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312519144721/d637842dex105d.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2019 Incentive Award Plan.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/13/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5(d)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312519144721/d637842dex106.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/13/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;10.5(a)#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312519122586/d637842dex104a.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2015 Equity Incentive Plan, as amended.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.25pt;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="margin-left:7.25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/26/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4(a)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;10.5(b)#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312519122586/d637842dex104b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Stock Option Agreement under the 2015 Equity Incentive Plan.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.25pt;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="margin-left:7.25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/26/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.25pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:7.25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">126</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:9.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:45.18%;box-sizing:content-box;"/>
    <td style="width:8.3%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7%;box-sizing:content-box;"/>
    <td style="width:1.06%;box-sizing:content-box;"/>
    <td style="width:8.34%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;10.5(c)#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312519122586/d637842dex104c.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Early Exercise Stock Option Agreement under the 2015 Equity Incentive Plan.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.25pt;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="margin-left:7.25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/26/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4(c)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.25pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="margin-left:7.25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;10.5(d)#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312519122586/d637842dex104d.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Stock Purchase Right Grant Notice and Restricted Stock Purchase Agreement under 2015 Equity Incentive Plan</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.25pt;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="margin-left:7.25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/26/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4(d)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;10.6(a)#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312523063052/d438859dex993a.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2023 Employment Inducement Award Plan.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;S-8</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;3/7/2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.3(a)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6(b)#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312524194956/d871726dex991c.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to the 2023 Employment Inducement Award Plan.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-8</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/6/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1(c)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6(c)#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312523063052/d438859dex993b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Stock Option Grant Notice and Stock Option Agreement under the 2023 Employment Inducement Award Plan.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-8</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;3/7/2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.3(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312519144721/d637842dex107b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement by and between IDEAYA Biosciences, Inc. and Yujiro Hata.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/13/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000156459021056989/idya-ex102_169.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Employment Agreement by and between IDEAYA Biosciences, Inc. and Michael White.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/15/2021</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;10.9#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000095017023006456/idya-ex10_10.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement by and between IDEAYA Biosciences, Inc. and Darrin Beaupre.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;3/7/2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;10.10</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;10.10#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000095017023041394/idya-ex10_5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Employment Agreement, dated as of July 1, 2023 by and between IDEAYA Biosciences, Inc. and Andres Ruiz Briseno.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;8/10/2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;10.5</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;10.11#&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000095017024120675/idya-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement by and between IDEAYA Biosciences, Inc. and Douglas Snyder.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;11/4/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;10.12#&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="idya-ex10_12.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement by and between IDEAYA Biosciences, Inc. and Stu Dorman.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000095017024017093/idya-ex10_13.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Non-Employee Director Compensation Program.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/20/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312519144721/d637842dex1014.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement for Directors and Officers.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/13/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312519122586/d637842dex1015.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease Agreement by and between IDEAYA Biosciences, Inc. and ARE-SAN FRANCISCO NO. 17, LLC dated as of August 26, 2016.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/26/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312519122586/d637842dex1016.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Letter Agreement Amendment to Lease Agreement by and between IDEAYA Biosciences, Inc. and ARE-SAN FRANCISCO NO. 17, LLC dated as of January 27, 2017.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/26/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312519122586/d637842dex1017.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to Lease Agreement by and between IDEAYA Biosciences, Inc. and ARE-SAN FRANCISCO NO. 17, LLC dated as of May 31, 2018.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/26/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000156459019043225/idya-ex1011_86.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amendment to Lease Agreement by and between IDEAYA Biosciences, Inc. and ARE-SAN FRANCISCO NO. 17, LLC dated as of September 30, 2019.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/13/2019</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">127</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:9.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:45.18%;box-sizing:content-box;"/>
    <td style="width:8.3%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7%;box-sizing:content-box;"/>
    <td style="width:1.06%;box-sizing:content-box;"/>
    <td style="width:8.34%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19(a)&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000095017024120675/idya-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Option and License Agreement by and between IDEAYA Biosciences, Inc. and Biocytogen Pharmaceuticals (Beijing) Co., Ltd., dated as of July 30, 2024.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/4/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19(b)&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="idya-ex10_19b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to Option and License Agreement by and between IDEAYA Biosciences, Inc. and Biocytogen Pharmaceuticals (Beijing) Co., Ltd., dated as of December 12, 2024.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20(a)&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000156459020024653/idya-ex104_335.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreement by and between IDEAYA Biosciences, Inc. and Pfizer Inc. dated as of March 11, 2020.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/12/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20(b)&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000156459020053546/idya-ex101_656.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1 to Clinical Trial Collaboration and Supply Agreement by and between Pfizer Inc. and IDEAYA Biosciences, Inc. dated as of September 23, 2020.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/12/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20(c)&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000156459021026023/idya-ex101_489.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 2 to Clinical Trial Collaboration and Supply Agreement by and between Pfizer Inc. and IDEAYA Biosciences, Inc. dated as of April 8, 2021.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/10/2021</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20(d)&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000156459021056989/idya-ex101_117.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 3 to Clinical Trial Collaboration and Supply Agreement by and between Pfizer Inc. and IDEAYA Biosciences, Inc. dated as of August 9, 2021.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/15/2021</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20(e)&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000095017023041394/idya-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 4 to Clinical Trial Collaboration and Supply Agreement by and between Pfizer Inc. and IDEAYA Biosciences, Inc. dated as of May 12, 2023.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/10/2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20(f)&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="idya-ex10_20f.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 5 to Clinical Trial Collaboration and Supply Agreement by and between Pfizer Inc. and IDEAYA Biosciences, Inc. dated as of December 16, 2024</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21(a)&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000156459020039719/idya-ex103_470.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Collaboration, Option and License Agreement by and between GlaxoSmithKline Intellectual Property (No. 4) Limited and IDEAYA Biosciences, Inc. dated as of June 15, 2020.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/12/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.65pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;10.21(b)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000156459022010922/idya-ex1018_64.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1 to Collaboration, Option and License Agreement by and between GlaxoSmithKline Intellectual Property (No. 4) Limited and IDEAYA Biosciences, Inc. dated as of October 23, 2020.</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/18/2022</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:7.5pt;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="margin-left:7.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21(c)&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000095017022008946/idya-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 2. to Collaboration, Option and License Agreement by and between GlaxoSmithKline Intellectual Property (No. 4) Limited and IDEAYA Biosciences, Inc. dated as of January 31, 2022.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/10/2022</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22(a)&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000095017022008946/idya-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreement by and between Pfizer Inc. and IDEAYA Biosciences, Inc. dated as of March 9, 2022.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/10/2022</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22(b)&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000095017023041394/idya-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1 to Clinical Trial Collaboration and Supply Agreement by and between Pfizer Inc. and IDEAYA Biosciences, Inc. dated as of May 10, 2023</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/10/2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">128</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:9.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:45.18%;box-sizing:content-box;"/>
    <td style="width:8.3%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7%;box-sizing:content-box;"/>
    <td style="width:1.06%;box-sizing:content-box;"/>
    <td style="width:8.34%;box-sizing:content-box;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000095017022023207/idya-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreement by and between Amgen Inc. and IDEAYA Biosciences, Inc. dated as of July 26, 2022.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/8/2022</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000095017024017093/idya-ex10_23.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Clinical Study Collaboration and Supply Agreement by and between Gilead Sciences, Inc. and IDEAYA Biosciences, Inc. dated as of November 29, 2023</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/20/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25(a)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000095017023041394/idya-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease Agreement by and between DW LSP 5000 Shoreline, LLC and IDEAYA Biosciences, Inc. dated as of June 1, 2023.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/10/2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25(b)&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="idya-ex10_25b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to Lease Agreement by and between DW LSP 5000 Shoreline, LLC and IDEAYA Biosciences, Inc. dated as of May 10, 2024.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.26</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000095017024017093/idya-ex10_25.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Office Lease Agreement by and between AAT TORREY 13-14, LLC and IDEAYA Biosciences, Inc. dated as of November 14, 2023</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/20/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.27&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="idya-ex10_27.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Option and License Agreement by and between IDEAYA Biosciences, Inc. and Jiangsu Hengrui Pharmaceuticals Co., Ltd., dated as of December 27, 2024.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.28&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000095017024054466/idya-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreement by and between IDEAYA Biosciences, Inc. and MSD International Business GmbH, dated as of March 8, 2024</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/7/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.29</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000119312524011346/d581989dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Open Market Sales Agreement by and between IDEAYA Biosciences, Inc. and Jefferies LLC, dated as of January 19, 2024.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/19/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="idya-ex19_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading Compliance Policy</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="idya-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#power_of_attorney"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Power of Attorney (included on signature page to this Annual Report on Form 10-K).</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="idya-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="idya-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="idya-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">129</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:9.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:45.18%;box-sizing:content-box;"/>
    <td style="width:8.3%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7%;box-sizing:content-box;"/>
    <td style="width:1.06%;box-sizing:content-box;"/>
    <td style="width:8.34%;box-sizing:content-box;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1676725/000095017024017093/idya-ex97.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Policy for Recovery of Erroneously Awarded Compensation.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;10-K</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">    </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/20/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;97</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded with the Inline XBRL document)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#134; Portions of this exhibit have been omitted pursuant to Regulation S-K, Item 601(b)(10) or certain schedules and attachments to this exhibit have been omitted pursuant to Regulation S-K, Item 601(a)(5). Such omitted information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># Indicates management contract or compensatory plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* The certification attached as Exhibit 32.1 that accompanies this Annual Report on Form 10-K is not deemed filed with the SEC and is not to be incorporated by reference into any filing of IDEAYA Biosciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-K, irrespective of any general incorporation language contained in such filing.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16. For</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 10-K Summary.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">130</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEX TO THE FINANCIAL STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:94%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#reportofindependentaccountingfirm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(PCAOB ID </span><span><ix:nonNumeric id="F_ad8aa836-1320-4744-9d9b-db6a5b9b5faf" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">238</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheet"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Balance Sheets</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_operations_comprehensive_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_redeemable_convertible_prefer"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Stockholders&#8217; Equity</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Cash Flows</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_tostatements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Financial Statements</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="reportofindependentaccountingfirm"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="margin-left:5.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Board of Directors and Stockholders of IDEAYA Biosciences, Inc.</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d5c27f50-2526-4e8d-8b11-23086c8caa99" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying balance sheets of IDEAYA Biosciences, Inc. (the "Company") as of December 31, 2024 and 2023, and the related statements of operations and comprehensive loss, of stockholders&#8217; equity and of cash flows for each of the three years in the period ended December 31, 2024, including the related notes (collectively referred to as the "financial statements"). We also have audited the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control - Integrated Framework </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control - Integrated Framework</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (2013) issued by the COSO.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis for Opinions</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's management is responsible for these financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management&#8217;s Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audits of the financial statements included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Definition and Limitations of Internal Control over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Critical Audit Matters</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued Research and Development Expenses Related to Contract Research Organizations</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described in Notes 2 and 4 to the financial statements, the Company has entered into various agreements with contract research organizations (CROs). The Company&#8217;s accrued research and development expenses as of December 31, 2024 was $20.0 million, of which a portion relates to open agreements with CROs. The Company&#8217;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, management will adjust the accrual accordingly. Management&#8217;s process involves reviewing open contracts and purchase orders, communicating with applicable personnel to identify services that have been performed, and estimating the level of service performed and the associated costs incurred based on vendor estimates for the services when the Company has not yet been invoiced or otherwise notified of actual costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal consideration for our determination that performing procedures relating to accrued research and development expenses related to CROs is a critical audit matter is a high degree of auditor effort in performing procedures related to the Company&#8217;s accrued research and development expenses related to CROs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. These procedures included testing the effectiveness of controls relating to accrued research and development expenses, including controls related open agreements with CROs. These procedures also included, among others, testing research and development expenses related to CROs, on a sample basis, by obtaining and inspecting source documents, such as underlying agreements with CROs, purchase orders, invoices received, and information received from certain third party service providers.</span></p>
  <p style="margin-left:5.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7f1e32e5-22c4-47f4-99cc-c46f4e06d763" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PricewaterhouseCoopers LLP</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8a19b563-c2dc-4903-a6a5-0d0e5efadc40" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Jose, California</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 18, 2025</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2017.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDEAYA Biosciences, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheet"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Balance</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Sheets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:53.609%;box-sizing:content-box;"/>
    <td style="width:2.36%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:18.836%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:2.36%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:18.836%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_942247fc-391c-498a-a740-fdba3fb6c567" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,378</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73ad4007-3113-45ff-9a94-3fd61043d414" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,018</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa8877af-e671-410d-99d3-c965f06a5ccc" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">591,941</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b169ca0f-d5a2-43df-ab13-bf75ec243c11" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">368,096</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa76fadc-d669-4968-ac20-88a2f66d1bfd" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:ReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea6d83f0-3734-437c-bfca-edf8c1905cfd" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:ReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e68ba48b-0090-492e-8870-cad37aaf068e" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,391</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5338298d-844c-41ad-8248-9c5165fd1a5d" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ff50180-974e-4348-92f0-86b236bf922e" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">689,713</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b25ddf46-e72b-460b-ad9a-0c875d96fdc9" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">532,632</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82510c51-c08d-4e8b-8901-27bc984ac9ce" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">805</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d03823b6-f9c1-4931-b282-610d835b9084" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">757</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5e9c9ec-f141-486e-82b0-9fe6bc972681" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">405,832</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e4125a6-f49c-4a0d-858c-31928cb65892" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,492</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07cd3245-8250-422e-a787-b4624893f2f2" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,966</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3b617c8-f92c-4d25-949e-2e3fab0d7667" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,164</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0c60728-9e89-468e-a2eb-93940b09fd13" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,775</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87502054-0e93-4835-9ab7-540898300b97" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,246</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1774230-911a-4329-88c9-9034e66e0190" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dae76a36-8489-405b-a34b-e8201539b967" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,124,091</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4f23a03-a693-49ea-b5c2-3bf85c2a9e21" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">649,316</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and Stockholders&#8217; Equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f056fa42-e885-47c2-b65b-2153007704f2" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,421</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6660b9b-e85a-442c-9adc-f7f6f72ed930" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,598</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a309b5b5-2303-4707-9ff7-ed71b2fd05a6" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,352</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_965c5614-070b-409a-bd98-d55d5f3d7436" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,756</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a87236c4-55d5-4701-8b43-14f503cd8e4c" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">298</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efe410b2-5445-45fd-ab48-21bd1a9cee1d" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,747</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3895a109-21fe-4d2d-a021-358890907a5e" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,071</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20eb0c98-db95-4a63-b9c0-aceecd04c59a" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,101</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term operating lease liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53fce149-b612-4cde-95fc-3d1cd734fb68" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,873</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b7cf583-51f3-4c13-9118-0611e7f9f758" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,125</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_116b0850-6006-4839-9cd2-e21bbe6a69f4" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,944</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cc9de67-04ab-43bc-b7dd-911372fd81af" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,226</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="font-size:9pt;"><span style="-sec-ix-hidden:F_a4436390-e215-4734-bf5f-6f7d9bb4566d;"><span style="-sec-ix-hidden:F_db1f14ba-60eb-409c-bacf-2ea36e6fcc5e;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (Note 6)</span></span></span></span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Preferred stock, $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0dc1053-8cfa-45d4-8b97-262a75ff884f" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_0ab33a1c-ba1f-4807-8f3d-fd5d88e97ea0" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;par value, </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a74f2dc-dda2-4e93-9116-29c89d13a85f" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_cd2fa7eb-cc17-4e5c-935c-c9b9647495d9" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;shares authorized as of December 31, 2024 and December 31, 2023; </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef3dbc84-b89f-4516-9e38-55f430fc2bf4" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_bbf1105e-307c-4ecc-b8fe-e9fb2754f14c" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_da02a650-80ae-4fb6-992e-cab389a31cdb" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_82148dd4-eb4e-4059-8ed9-ef3b8ebd522e" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding as of December 31, 2024 and December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;"><span style="-sec-ix-hidden:F_8b9de624-e845-40d7-a9f4-ea6904fdf1d8;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;"><span style="-sec-ix-hidden:F_cd9a8961-a8bc-4fc1-85bb-4c42f207ee7a;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43240f2d-540f-47be-9e44-70e13a7f353e" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_c8731961-2340-44f4-af3a-1d9898f60fe9" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;par value, </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f24abd84-cead-4d91-84db-88e2d14d51d1" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_efeb7e0a-6b01-419f-aaf0-3171aa016dc7" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">300,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;shares authorized as of December 31, 2024 and December 31, 2023; </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c472744f-c89f-4bc8-9d99-9c6cd4ef06e7" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b0a98cc9-b820-4ad1-9507-dbab9e71aac7" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">86,503,509</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;and </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f98ebce-4d53-4569-abc0-0730e479de0c" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c9263377-c92d-49c4-9b1f-72ff3a0ec336" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">65,039,369</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding as of December 31, 2024 and December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d646e103-a4d8-489b-b870-0518707a3130" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cd2ec24-87f1-414a-b3b7-0dbe8186bcea" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ba33dea-6609-452e-8220-c574b2b4234f" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,681,167</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aac25bd3-ce8f-4052-b68a-83216c025b48" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">968,885</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10b43fb3-bc46-4b9d-a4b0-2a8b36457176" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">812</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85ccc905-7d08-4d8f-b837-2d4a207ab59a" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">562</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91bc8ede-c284-4888-8bab-45214e16ad5c" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">622,841</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29f454b0-7ab0-4c51-b199-e6eafcaf0db0" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">348,364</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a833497-52bb-4f80-80bd-156ac559922b" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,059,147</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69014bc1-a401-4db5-877f-cdf6a9941ab9" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">621,090</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8966ddb-1b0c-485c-8515-5cd2ea8ef50a" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,124,091</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_119f0faa-4212-44f4-b80f-2b4b975c978a" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">649,316</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDEAYA Biosciences, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_operations_comprehensive_loss"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statements of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Comprehensive Loss</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.863%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.764000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.764000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.764000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70ffdd70-e81b-4de7-aaa2-02a409a094a8" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb4b231e-eee5-4e33-90d0-efcfbc213d02" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,385</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f65f8cea-6f36-4bfc-9d59-a48d9c6cb861" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,931</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad1357ac-510c-4a34-8a71-9b3b2da7144a" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77b120f2-10b0-409c-b05e-7884c4a9239b" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,385</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a166775f-6247-49ce-ae1e-1aa06d216025" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,931</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_882b81f1-c96b-4c22-887f-406b500fa4e2" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">294,673</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b64d7982-9697-4a24-a12c-188ade7f7193" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,508</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_108e7438-f4a9-490a-bc8c-bbde0e7dddfb" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,536</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d50c012a-f7a2-4af1-90d4-969d8439f391" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,302</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bd76de2-edbd-4e73-85f0-43427d5201d9" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,306</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a455789-a60a-403a-a12c-d1334f2663fc" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,897</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da347b30-b058-48ad-b1ee-16fa6f68c415" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">333,975</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb13dfa1-38e2-47b7-94c8-41d48aa91d2e" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,814</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5901c8ee-0563-42c6-bf5c-a10efb4432e6" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,433</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e4e3014-89ef-4d43-abe2-6eef096498b7" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">326,975</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5c5485c-a14f-4618-85a1-cc5a1704318f" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">134,429</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e0b6881-7900-4511-9180-f05451856874" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62,502</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income and other income, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e52aa6c-a2ed-4a5e-9974-377a15bfdaaf" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,498</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_169ff44c-71dc-40f6-a8a1-5f26b3098850" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,468</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba7d6721-f467-4341-97fd-e30c04c17765" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,847</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91217756-22ea-41af-ac73-368e1ee5dae0" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">274,477</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a5a0350-0298-4533-aa05-e60ae5aa6980" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">112,961</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94ece008-2f7d-4141-89dd-2b27618f52a6" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">58,655</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gains (losses) on marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2c24abd-937d-4813-9503-62521a64de07" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">250</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2ee5160-ba5f-49d1-9d0f-328397a03cd5" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,433</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f5584a1-5fbe-4c78-86b2-d2c64ec7914b" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,159</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4df818a5-e44b-4d80-95ec-c0a33edec422" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">274,227</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7542a57b-bc57-4537-b532-3a9049b7e806" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">109,528</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be2caf41-c4be-49a0-aa75-57dd63a1a945" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">60,814</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27307e98-a710-4f37-aeaf-0167988a98d4" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-"><ix:nonFraction id="F_f0caba62-72b4-4dec-b21a-80424abf544f" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">3.36</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_515b92a9-c811-42bb-a604-cfc840b25ba8" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b90061c0-2232-45ef-a2c0-f18e5db12edf" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.96</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38b9affc-383c-4f64-9635-8a81c8e9a6cf" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_27f6d108-d110-4f61-87d5-7ec47e5bd970" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.42</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average number of common shares outstanding<br/>&#160;&#160;&#160;&#160;used in computing net loss per share, basic and diluted</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2381f0c7-2c63-4aba-b537-58a7f89177f7" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_07d7b007-c773-4bc1-9d04-79009db886fc" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">81,678,069</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b754dc43-49df-4a89-81bd-6d338e62bb2d" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5b5dc0fc-ee80-4f15-9525-2219d08998bd" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">57,519,929</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0f3570d-6382-42a3-a87d-2b385e8a7010" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d0e10406-1792-4a12-8ba0-d16ee1477637" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">41,444,696</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDEAYA Biosciences, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_redeemable_convertible_prefer"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statements of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Stockholders&#8217; Equity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(in thousands, except share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.667%;box-sizing:content-box;"/>
    <td style="width:1.36%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.982%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.562%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.562%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.562%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.562%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.742%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Paid-In</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Comprehensive</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stockholders'</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Income (Loss)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2021</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abd5835d-49c7-44dc-9643-2743bd2de774" contextRef="C_3d9101a4-e405-4fd0-a74a-a22c9cf099bd" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">38,533,045</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15747893-6baa-45aa-98e8-7d305de91a31" contextRef="C_3d9101a4-e405-4fd0-a74a-a22c9cf099bd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0533e5d5-3756-432d-8224-5b7f5c21fb87" contextRef="C_15cd159b-08a9-48df-9fa1-4e164fd62eb7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">478,970</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cce7f3d1-9b29-42ee-b4c3-2b4ca93f87f4" contextRef="C_eb581dfe-56cb-4aba-ab2b-d96ee1f0e219" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">712</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2dc4774f-8dc0-4b25-999d-4b2f36bf9fe7" contextRef="C_aaa793d3-6d40-4eb9-8f53-fe79e2aded7a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">176,748</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59f9c539-a0e9-4b1d-9ab0-8a04245c7158" contextRef="C_6fb07cd5-fdda-41ce-bad2-075ecef88512" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">301,514</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon follow-on public offering, net of<br/>&#160;&#160;&#160;&#160;issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1f783c7-5d3f-4921-8b06-ada4fd130c94" contextRef="C_a1506248-4546-46fa-a347-9575de765d3e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,761,905</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85793e98-decf-4f8e-bfa2-b830fef8aca7" contextRef="C_a1506248-4546-46fa-a347-9575de765d3e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0020916-ee5d-4330-a4a5-d5a1b0acf107" contextRef="C_47b63c45-ebe3-463d-93fb-502e26c0ae49" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,080</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dccdc9d2-144b-4bb6-9f86-ad8cd8f06882" contextRef="C_94217de2-f133-4daf-80d3-64910929d8e1" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,081</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock related to at-the-market offering program,<br/>&#160;&#160;&#160;&#160;net of issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60b3ae80-02ec-4a96-ae41-6da2b65f5326" contextRef="C_79faf38f-faf7-45d1-b17b-062ffafd4097" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">601,844</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c191c77b-3df6-48e8-8146-26857972d063" contextRef="C_3581a854-ba16-4bf6-95e9-e33f2a21a2e8" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,842</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02844538-1af2-4c0c-a0c4-01bc9bbbd092" contextRef="C_ef560538-beca-4fdb-9d65-b2ca89c607d8" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,842</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2de61c6b-1646-4262-8dd6-98f800ca5da3" contextRef="C_fd99da48-95e7-4823-8ffd-92a6ffd6af51" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">214,643</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbe2d06e-653d-4acc-9658-9bd9f926f88e" contextRef="C_fb60d22d-1a0c-4b09-951c-98eeeac567e1" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,448</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e328e3ac-159b-47da-8108-5fda32079caa" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,448</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock purchase plan (ESPP) purchase</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_953cc608-d488-4596-98d7-3aaed9b492ae" contextRef="C_fd99da48-95e7-4823-8ffd-92a6ffd6af51" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">81,742</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4507b7a-28b2-48ab-bd7c-9a9142a7ca39" contextRef="C_fb60d22d-1a0c-4b09-951c-98eeeac567e1" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">755</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b65c1d72-a5b2-4f2a-ad1b-88953eba029a" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">755</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03cc3a21-ee00-41ef-ae64-9fad82d1e2b3" contextRef="C_fb60d22d-1a0c-4b09-951c-98eeeac567e1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,629</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86f02063-2eba-4aa4-a1f7-61e8534ca70f" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,629</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5a0a66c-7ff8-42a9-b6cc-ecee090e18f5" contextRef="C_1707f298-031e-42ff-92b2-f2d35e7cb9fd" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,159</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a105e678-82ea-479a-a962-7f90220cae5e" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,159</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fa7bb32-96c1-421a-928c-bbcd58aef997" contextRef="C_b8560028-9f37-4ff3-9028-5dc8f0dd96db" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">58,655</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cda611c-7689-4a3a-bfa1-44b27f7b38e5" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">58,655</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96bca776-2414-460c-9bc1-acd01ad0ed82" contextRef="C_77882837-0da6-42b6-aba3-1ef2b76bff1b" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">48,193,179</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e429b35b-0d69-4e14-b8de-5958d977e28b" contextRef="C_77882837-0da6-42b6-aba3-1ef2b76bff1b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2daed2b7-6c39-497b-9704-c2cdc4906316" contextRef="C_028bd853-e9b5-4c40-9a66-731769196cc4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">587,724</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_252de9ff-ad62-415c-9ce6-585f52e83a65" contextRef="C_51602dc5-8082-4af9-ae8d-664968b23422" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,871</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4247812-1b13-43c3-a9c4-c43df2537f32" contextRef="C_4731288a-d1d1-4c3c-a9e6-91e059e7e20f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">235,403</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb0bd431-1e11-4561-a1b9-ec104b10be09" contextRef="C_ce651b87-a2ee-4952-8dab-aa55bb0ac861" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">349,455</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon follow-on public offering, net of issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_942a6237-f27b-4f33-b7f5-9104ca625c82" contextRef="C_faad213a-ce5c-4221-b05a-2e531d08f6d7" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">14,655,993</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_378c227b-0035-40a7-be3c-0abe76eee299" contextRef="C_faad213a-ce5c-4221-b05a-2e531d08f6d7" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ffb5edd-dc37-43c5-abca-a41f818a7d08" contextRef="C_12cb1aba-8889-4b3b-885c-40f700ad3c6e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,120</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ed1f380-38f5-4a74-a3aa-b522dbce2533" contextRef="C_7cd721db-73ca-47d3-bf8c-9b912b4a5d53" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,122</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of pre-funded warrants for the purchase of common stock</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b78b6232-2649-4797-aa3d-342737619691" contextRef="C_32a22686-66c0-40db-bd68-392be3f3a5cc" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,182</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71fb6051-a8a8-42f1-a687-fcc92714c41b" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,182</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock related to at-the-market offering program,<br/>&#160;&#160;&#160;&#160;net of issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e270669-241a-4e33-ad1c-21d3b52cacec" contextRef="C_ede69319-7140-4c54-a59f-e3cd00f2c014" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,188,705</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3476d59-d41c-48b8-b4cd-01219af2d795" contextRef="C_fada0950-b58a-4dd1-87c9-557dfba92f85" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,598</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_653675c5-c3c8-4153-a52e-4de4909c72ec" contextRef="C_b29be823-d29d-4c0b-b5d4-dab37fe7947c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,598</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03bc7d8a-6622-45c5-9976-62418908a4ae" contextRef="C_074141e9-fba5-404a-bcf9-4a845e4634ea" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">931,012</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8eea4381-ec17-4067-80e1-3f194fe034e8" contextRef="C_32a22686-66c0-40db-bd68-392be3f3a5cc" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,559</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d4a0820-6de3-4331-aa38-35881c930f48" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,559</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock purchase plan (ESPP) purchase</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b14cbfb-b53f-44d3-b389-a0aab7e4eac1" contextRef="C_074141e9-fba5-404a-bcf9-4a845e4634ea" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">70,480</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0609ee7f-d623-441a-ae0a-052ea2b01b45" contextRef="C_32a22686-66c0-40db-bd68-392be3f3a5cc" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,213</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b15b7638-4b1e-42e6-8b22-f3bd2b515725" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,213</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b29590bd-fa05-4044-9cab-eababe4251b7" contextRef="C_32a22686-66c0-40db-bd68-392be3f3a5cc" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,489</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c519b082-23ee-47fc-81b6-ece42fc303ba" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,489</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive gain</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87923c16-76e2-4ef2-9c84-8d2d244df759" contextRef="C_d3d4e1da-83e6-4d41-ae1c-a616266a1832" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,433</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6e804af-6e85-411a-844a-802a5c4eabdc" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,433</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da1d7ded-bcc7-4eed-93a8-6bf805018d0b" contextRef="C_39360529-0ce4-46c5-8c50-c0b69f139d2e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">112,961</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db199e8a-d337-4e84-b4b3-f0bb788a425c" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">112,961</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_898b50f9-eaf0-4078-976e-aae8db6cbd2b" contextRef="C_b9f082f0-76fd-4961-ba1a-7e2f141962b2" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">65,039,369</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_766ed3e4-7cbc-4334-b63d-55a36eb2bc83" contextRef="C_b9f082f0-76fd-4961-ba1a-7e2f141962b2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd5e55b2-b274-452b-8b09-b335cab046f9" contextRef="C_af24a5ec-af73-4d40-8dd3-8e064854bf7c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">968,885</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c86e55fc-10d5-4c84-8c12-426c5788a4d5" contextRef="C_f222b075-c12f-4efc-8c81-d8aea1803872" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">562</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cc9a257-3ed2-4cf9-8c90-976e4443b8a4" contextRef="C_d007c432-86f1-4c3b-b319-24effed11e62" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">348,364</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73fa3fa3-abe0-40b2-a363-729d28d9ae2f" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">621,090</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon follow-on public offering, net of issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba81a60a-bb37-403a-a8ca-b0386d3c1311" contextRef="C_0f3b93c3-2bd5-4282-b511-d0be9bbb12b0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,355,714</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10b158ac-996d-4e17-a42d-16efb5f63ed8" contextRef="C_0f3b93c3-2bd5-4282-b511-d0be9bbb12b0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_641395da-6b90-4793-8892-3862e289c39d" contextRef="C_77a77c54-3d7a-48df-b0a2-b2ee4ac11347" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">274,349</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc6e8689-37e2-4a4c-9b52-591cecf14b52" contextRef="C_32b3ac20-7005-4029-b9d5-0a08c767ed8d" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">274,350</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of pre-funded warrants for the purchase of common stock</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_edeed76d-b696-4fe1-9c80-47fca91f7370" contextRef="C_77a77c54-3d7a-48df-b0a2-b2ee4ac11347" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,400</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b801ef2a-b988-45f9-9820-43d6d6631845" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,400</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of pre-funded warrants</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_822d74bd-3d04-4e7c-ae23-108ee55a0e26" contextRef="C_65d2c0cd-0252-4d0e-99da-bb88696b6445" name="idya:AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,749,993</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock related to at-the-market offering program,<br/>&#160;&#160;&#160;&#160;net of issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df0fc906-3a61-43e6-b65f-db1a601961e0" contextRef="C_f605952c-8fcd-4667-9e72-9bc4842bb390" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,182,382</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a5e165b-1837-4acb-8254-b6dbc84b3da1" contextRef="C_f605952c-8fcd-4667-9e72-9bc4842bb390" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2121202b-132f-43c6-abea-9f3af92a61a5" contextRef="C_c3f56777-d0fc-4e30-8e99-35ce57f4b839" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">379,865</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5977d0b4-6d60-46fb-9ca8-8c5721563582" contextRef="C_933a2b9d-bb76-4d41-8fb8-2901d19455b0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">379,866</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe3f0ead-9fd5-49ea-819c-3bba27468f32" contextRef="C_65d2c0cd-0252-4d0e-99da-bb88696b6445" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,118,695</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_784affd0-998f-4ac1-84e9-0b82b0680fab" contextRef="C_ea3cfd25-fdc0-4753-b6b9-64944718b206" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,483</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d7f1fd4-c96e-490f-a31f-0966007c9684" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,483</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock purchase plan (ESPP) purchase</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5adbcdef-fac8-4d07-8332-19793b29a923" contextRef="C_65d2c0cd-0252-4d0e-99da-bb88696b6445" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">57,356</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96cbbdae-4c2e-41a3-aee4-73b0863f6e3e" contextRef="C_ea3cfd25-fdc0-4753-b6b9-64944718b206" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,439</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a14b4825-e79b-4234-979a-9e8806f40a39" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,439</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d47c2d5-e303-4cca-bd51-7204dd5ad83f" contextRef="C_ea3cfd25-fdc0-4753-b6b9-64944718b206" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,746</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d02f788d-cff4-493b-9ca6-786834ec08cd" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,746</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive gain</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25054031-23ca-4dc6-bc35-50e572088766" contextRef="C_21330ef1-face-41aa-bc1a-38277d6baec6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">250</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16e122f4-75c9-4fca-90a2-7bc57a7305a9" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">250</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;">
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b912cba-5dbd-4d2d-beb5-8ae0f9c384d7" contextRef="C_a59c732f-c597-47eb-9ca9-3046723cbffb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">274,477</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efb5e469-bb72-4e37-8bf9-b085c023270b" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">274,477</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1908dab-d2fe-4d5e-a1c6-db48852f982f" contextRef="C_76c3f127-e221-49fe-8e31-8bd88d9f4e1e" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">86,503,509</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a7026f9-badc-45d9-a0ce-0dcd10081272" contextRef="C_76c3f127-e221-49fe-8e31-8bd88d9f4e1e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91437ce0-0294-4f0e-8f46-de8a96102a18" contextRef="C_a4955acc-673d-4246-a4cf-8af30b6dc428" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,681,167</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0b7ceb1-f68e-463a-bdda-1eced22de8b3" contextRef="C_7d833bb0-e665-4cf0-b5ef-b88aee6558e7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">812</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87b20a5f-1680-44e3-b79a-32ae35aef088" contextRef="C_8c4ee195-6613-4c9b-a476-c2df7fdfea67" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">622,841</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0e0bec2-7f0a-448e-ad75-6e0cb5c7bfcc" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,059,147</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDEAYA Biosciences, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statements of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.743%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.724%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.281%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.724%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.521%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.724%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from operating activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce25e6c8-57f7-435c-8b2d-50849b4ec38e" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">274,477</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec90b025-8a00-4f90-9bcb-317393954f96" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">112,961</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5b37ef8-eb76-4d57-825b-7db21862f6da" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">58,655</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in<br/>&#160;&#160;&#160;&#160;&#160;operating activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ca5a3aa-9624-4efd-89e9-7e8c2f8f813d" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,387</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_233dc159-e553-4ac4-9cac-38456fc88b27" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,476</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f03d466f-47e7-42e6-8541-f609bc729e7f" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,101</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net amortization (accretion) of premiums (discounts) on <br/>&#160;&#160;&#160;&#160;&#160;marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76031451-e281-4420-83db-49d27e23c443" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,233</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7071f2d-c8bf-4934-86c9-099b95c23d13" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,553</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cecd06ef-8894-4e26-8ba4-2fa8370c9a48" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">695</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e83464e5-51d7-4fb3-bcdf-1c1763f04b23" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,746</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0915b808-a057-49ac-8ad5-84e82ae291c4" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,489</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b0914e6-81b7-4778-b614-c1f64ecc27b9" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,629</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of right of use assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_006370f6-f522-407b-b417-514edb62deec" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,447</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a61ecd6d-a39b-445f-812e-3d7e17907ac8" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,532</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d16ab440-28b6-4230-b732-51e02c9c2d3f" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,414</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in assets and liabilities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51a608bb-fd0e-4475-96e8-99ea0d8632e2" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64734d3d-acc8-4f85-9e15-86fefb9c9458" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">193</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c44a71aa-462c-437e-8e11-5da48af7c13a" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">892</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54ace939-5dc4-4430-815e-c59a4b1d2dfb" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,174</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b956994-a1bf-4e50-96af-5a0b218166ca" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,045</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3039826e-7410-4db0-8c1d-363480dccc76" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,119</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_783eb46b-a3f4-4912-aacb-a5085d8f2c54" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,280</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20faacaa-b882-4f8a-898e-fc0451e1dc7b" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,635</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afad2341-0049-4d82-b9d2-561222922994" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,864</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued and other liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70a9a842-3d1b-4263-accf-ac6564ecae7d" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,794</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c00a1f51-18d6-4cd1-8f25-05029391dba9" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,635</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_525eee8f-ab0b-4163-9ae9-d94c6c49ac7c" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,572</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a9c2948-57df-4ea3-ba32-bb0adeec9710" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9be6f06-bd60-41fc-be37-738501088b89" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">13,753</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab48b5d7-4bbf-4b95-a827-f14f2afa23fe" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">46,479</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9f77658-0d39-4601-9d47-a4712604a28b" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="idya:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,369</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d2efcf8-7f27-4b16-9db8-11ca5a8d9395" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="idya:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,872</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a4efeaa-6641-477f-9644-490b2c09f732" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="idya:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,699</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2dc184b2-7d5a-407f-a396-ac8e31832b9f" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">247,584</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23e1b200-ddd4-4884-a9b5-c76f10b4ab0c" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">115,224</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_143e5676-0e7f-43a8-bbf4-d9dcfe787b84" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">87,175</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from investing activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca4065a4-8dfd-4a71-85ab-b4a4c82a0648" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,857</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd9422f6-2ede-47bc-ba31-ce856b61e8de" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,368</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ae68c2b-4814-45ff-90b2-004e6311fb1d" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,443</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6638c79-d2e8-4ba5-89eb-1e74ffc1ed8b" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,191,309</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ead8b96c-615c-4c1b-ba2e-8275364ec0e6" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">595,980</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_663143db-fd28-4a53-92ad-ea314d632019" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">255,808</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maturities of marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6a0cb51-1562-411a-bbdf-4982ed924c8b" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">692,607</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f73d1ecb-e953-4513-b451-292289626899" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">439,892</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d216216-7814-467c-8c98-113ff4aa62b9" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">225,847</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b62aa5d6-a137-49ec-b834-479d698c8c09" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">502,559</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef79af9c-1f2e-4aeb-9fcc-8a699e8f470d" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">158,456</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22bfada6-9469-4c21-a575-9be6698d3115" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">33,404</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from financing activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock in public offering, net of issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3a3ab3c-4a9f-4476-9ccc-30cb1a4e7472" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">274,350</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d2f91b5-a671-4c04-8e04-45bede20e4ac" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,165</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9d7fa02-6736-4bb6-abc0-83f5b70b57c0" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,105</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuances of pre-funded warrants</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e255180a-f2ef-429d-9b21-73c607311bfa" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,400</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9d5ca19-fc11-4dbb-bdf9-312eef142825" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,182</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e71489de-2fe7-477b-b0c4-8a1c7ee29872" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_600fe333-8900-431f-aa19-27f50d5ac85f" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="idya:ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">379,879</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63702039-a0b9-4b6b-aa19-eba75b6c0620" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="idya:ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,598</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d66adf1-8eeb-489f-9245-fc0c20e0a6dd" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="idya:ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,857</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of common stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d937ca0c-8b48-4496-b3b1-9c32ff835116" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,483</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ce17b35-4584-4dcb-a15d-f795bd0d20fa" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,559</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7bfd2d6-677d-47bd-86fd-49bb5381c236" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,448</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from ESPP purchases</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36220957-e361-4f8b-971c-3904e0f9c1ed" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,439</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e824d756-8d32-4a19-8a1f-54ac684ce1aa" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,213</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d44619ea-6b15-4701-974c-8e41e9fa352a" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">755</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c0a2821-ab58-4928-98e9-a6af7e39fa99" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">677,551</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4d85c55-2349-443c-a083-df236f7c597c" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">362,717</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79280e5e-f30e-4881-ade2-5501ce59048d" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,165</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (decrease) increase in cash, cash equivalents and restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d40c68be-730f-494c-a5f7-0cb807db625c" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">72,592</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38a12d91-f2f4-477c-94ed-d64c8238abb6" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,037</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36184e3a-0053-4390-ae56-93d05fdcdc13" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">23,414</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash, at beginning of period</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_980205f0-a0bb-4d14-b89c-df9480ce6c30" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,775</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89d0bb26-c75e-4c22-b763-477be4e8dcc3" contextRef="C_ce651b87-a2ee-4952-8dab-aa55bb0ac861" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,738</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5feab512-d35b-4c15-95c3-0d6d053d39bb" contextRef="C_6fb07cd5-fdda-41ce-bad2-075ecef88512" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,152</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash, at end of period</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb80aa6b-c8a1-4245-91c6-2c6c77125104" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,183</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ae5f015-4510-4683-996b-82002ca820db" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,775</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc636307-d4b5-4e19-b1bd-62cf66fb661d" contextRef="C_ce651b87-a2ee-4952-8dab-aa55bb0ac861" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,738</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reconciliation of cash, cash equivalents and restricted cash</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_224a4a04-f1b5-4b17-b0bc-3f4dcecbf7f7" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,378</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_805b4b11-0caf-4dcd-860b-e0a4551d36a0" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,018</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_525048e1-e3b6-48dd-b4b4-8eddb68ee8d0" contextRef="C_ce651b87-a2ee-4952-8dab-aa55bb0ac861" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,632</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f106adc9-a532-4727-84ac-fb6654013f92" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">805</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02a258f5-3975-4c7f-8393-0444e655eebf" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">757</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0480845f-1cc3-459b-bdc5-6d9ef0b03164" contextRef="C_ce651b87-a2ee-4952-8dab-aa55bb0ac861" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52f1dd56-b81f-4003-ac75-c0dd0e26712e" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,183</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24faee44-8906-4cf1-909f-91c17b9866ce" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,775</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f522614-9cb1-4489-b4a8-aa298294dd8a" contextRef="C_ce651b87-a2ee-4952-8dab-aa55bb0ac861" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,738</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure of cash flow information:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for interest</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e17333d-0de3-42b0-ac45-0124ce5cbac1" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d596f0ff-c96a-4f7d-8d63-f1139e164d4a" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23229960-c38a-4883-9966-91ee0ec16d09" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental non-cash investing and financing activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use asset obtained in exchange for a new operating lease liability</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2cd8d45-337a-4abf-b702-e1f609e3c1fd" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,976</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fd2a5c9-f343-472a-8134-8e01c051d0c5" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,294</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14dce24c-0828-42c5-971b-1e3ac5471fab" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment in accounts payable and accrued<br/>&#160;&#160;&#160;&#160;liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22a3f9e3-f2cb-4b88-95f5-60851d4f36a7" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,479</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d6936cd-000f-4951-9052-c49ddfca58f9" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d90c7f3-97e0-4c78-87a3-c8ba9d7cbf30" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">384</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unpaid offering costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_868a478d-20e2-439c-8eb0-6e850f1168c7" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="idya:UnpaidOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6adbbf53-e7ff-499a-9fda-e066f38135f8" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="idya:UnpaidOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00f962e0-fe23-4a78-8684-15a76b7e40be" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="idya:UnpaidOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unpaid at-the-market offering program costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f0ebe1c-c7c8-41c4-b3bc-4bd9b0287480" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="idya:UnpaidAtTheMarketOfferingProgramCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_783d0991-a2b6-40f4-bec3-6ffbcb5f38e3" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="idya:UnpaidAtTheMarketOfferingProgramCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2931bd1d-3f84-412e-910b-4430f253e62d" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="idya:UnpaidAtTheMarketOfferingProgramCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDEAYA Biosciences, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="notes_tostatements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Financ</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ial Statements	</span></p>
  <div><ix:nonNumeric id="F_047f46bb-b014-41bf-8b12-a7841b9d771b" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true" continuedAt="F_047f46bb-b014-41bf-8b12-a7841b9d771b_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Organization</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Description of the Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDEAYA Biosciences, Inc. (the &#8220;Company&#8221;) is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The Company is headquartered in South San Francisco, California and was incorporated in the State of Delaware in June 2015. To date, the Company has been primarily engaged in business planning, research, development, recruiting and raising capital.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Follow-On Offering</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 11, 2024, the Company completed an underwritten public follow-on offering. The offering consisted of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8ea72d0-c2da-40af-a574-f6af419cf1c3" contextRef="C_9c02d070-8681-4a68-9460-90f6386b903f" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,355,714</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_384eab77-8420-40ad-bc34-59321a772b2e" contextRef="C_5b17504e-2e08-477e-af4e-e1ad86f5b6e1" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (&#8220;common stock&#8221;), at an offering price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11c752d6-17e8-4c38-81d7-549947d0ca44" contextRef="C_5b17504e-2e08-477e-af4e-e1ad86f5b6e1" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">35.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b780e195-1524-43c5-86fc-f6ca33f7cdca" contextRef="C_63980d6b-b6c2-4f34-9482-a0495f116793" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,127,142</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3d00edc-fbd9-40bd-873e-8acabd9bc94b" contextRef="C_5b17504e-2e08-477e-af4e-e1ad86f5b6e1" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">285,715</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_505f3349-f295-40dd-a331-b062f6c9ae06" contextRef="C_532df7ab-49f7-48a9-8543-1497d27c4737" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">34.9999</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, the Company received aggregate gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77b55240-df4c-437a-ba12-b978afb6b2a2" contextRef="C_a6b8d688-85fc-4f28-b94d-adbdcc815d1b" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">302.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0daf3e1c-d7b0-49d3-a43e-721bd5d5ea91" contextRef="C_a6b8d688-85fc-4f28-b94d-adbdcc815d1b" name="idya:NetProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">283.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering expenses.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 27, 2023, the Company completed an underwritten public follow-on offering. The offering consisted of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d49ab2c3-ec34-4f4b-89b2-2414a41a3b15" contextRef="C_e4f99219-ed58-4929-87e5-a993db32910d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,797,872</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at an offering price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a9a93f8-f2dd-46af-8433-50ea7606e376" contextRef="C_17c6d71a-63e2-457f-a633-102c0bde4eb4" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">23.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e89a3f7-2a9f-4c35-9906-d081f1346a1c" contextRef="C_4a13cb3d-0ae0-44c8-9454-9eb34da39ecb" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">797,872</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6dacbec-f476-4f4d-83bf-ecdcf1005388" contextRef="C_17c6d71a-63e2-457f-a633-102c0bde4eb4" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">319,150</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64a9fdac-002f-4599-82cf-414f72f04965" contextRef="C_a0e7b3d3-6830-4717-90ea-44da053262f8" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">23.4999</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, the Company received aggregate gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5effc8b8-8dee-405b-ad7d-5d0ec6d5458d" contextRef="C_e56ae803-71fa-40b1-b315-c44f63fe65d8" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">143.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1076e596-7f56-4578-9404-d8819b18833b" contextRef="C_e56ae803-71fa-40b1-b315-c44f63fe65d8" name="idya:NetProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">134.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering expenses.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 27, 2023, the Company completed an underwritten public follow-on offering. The offering consisted of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a90fb1c6-1a81-42cd-b773-89c4bfaf535c" contextRef="C_07e35c69-dfae-4e28-83b9-c956215e0274" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,858,121</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at an offering price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48f1907c-e4af-4b7c-ae24-4a4d8341e7e0" contextRef="C_d400c976-b0bd-479d-aa74-c54c3f83c119" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">18.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3f9f14a-c0a4-40e8-bfde-ee99e8131710" contextRef="C_e6119aea-4ad7-47ff-8b8a-db55f4f12c97" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,418,920</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad203082-7f63-4236-9823-91fe28ba8741" contextRef="C_d400c976-b0bd-479d-aa74-c54c3f83c119" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,020,270</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf65c3a9-f37a-4b37-b2e5-2773f945c2dd" contextRef="C_e7bea947-3207-4f35-a41f-9c2f685e82c3" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">18.4999</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, the Company received aggregate gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2ad24c2-ebe2-4efc-9a06-c5cd3005f579" contextRef="C_7997c4a8-f7da-4956-8da0-38a0332faec7" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">201.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20a3f371-f8f9-4087-97e7-c2af9758e82c" contextRef="C_7997c4a8-f7da-4956-8da0-38a0332faec7" name="idya:NetProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">188.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering expenses.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At-the-Market Offering</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 26, 2023, the Company filed a new Registration Statement on Form S-3 (File No. 333- 272936) under the Securities Act as an automatic shelf registration statement as a &#8220;well-known seasoned issuer,&#8221; as defined in Rule 405 under the Securities Act. On June 26, 2023, the Company also entered into an Open Market Sales Agreement (the &#8220;June 2023 Sales Agreement&#8221;), with Jefferies LLC (&#8220;Jefferies&#8221;), relating to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of our common stock, having aggregate gross proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d00b8d6c-4a85-4230-9169-764f41b411ea" contextRef="C_a37ca623-522c-4962-8cd1-5abe0ff44d5e" name="idya:SalesOfCommonStockAggregateOfferingPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">250.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million through Jefferies as sales agent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From January 1, 2024 through January 17, 2024, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc131812-40c5-4bc0-8109-16cd296b0b9c" contextRef="C_dcda7935-3db6-4964-a858-3e928a1e6238" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,115,516</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock for aggregate net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_261397d8-7bd7-48d5-bbe5-c1cd50ca2a5a" contextRef="C_dcda7935-3db6-4964-a858-3e928a1e6238" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">215.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million at a weighted average sales price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_503bee54-39d9-4eb5-abdd-cfd2bfb71cde" contextRef="C_8b100a11-1b65-4fec-ae5b-2257a2c5399e" name="idya:SharesIssuedWeightedAverageSalesPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">36.39</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share under the at-the-market offering pursuant to the June 2023 Sales Agreement with Jefferies as sales agent.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 19, 2024, the Company entered into a new Open Market Sales Agreement (the &#8220;January 2024 Sales Agreement&#8221;), with Jefferies, relating to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of common stock having aggregate gross proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60401f35-345f-4162-ba68-c7dfdbce4fd3" contextRef="C_c0a63604-9e4a-452e-bb59-d9e6b5170b43" name="idya:SalesOfCommonStockAggregateOfferingPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">350.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million through Jefferies as sales agent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_047f46bb-b014-41bf-8b12-a7841b9d771b_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, pursuant to the January 2024 Sales Agreement, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00b6e87f-4e13-45cf-a8f3-fa5b977cd0ee" contextRef="C_ac598710-34a2-44e0-b556-f784f9ca8469" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,066,866</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock for aggregate net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd3c64a4-21a9-4b76-b463-007a68f99500" contextRef="C_ac598710-34a2-44e0-b556-f784f9ca8469" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">164.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million at a weighted average sales price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60f492c1-4484-406a-bed8-dc56e6eb7a81" contextRef="C_3062bf66-4396-4633-bd29-bdc943e6d16c" name="idya:SharesIssuedWeightedAverageSalesPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">41.28</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share under the at-the-market offering pursuant to the January 2024 Sales Agreement with Jefferies as sales agent. As of December 31, 2024, approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a33528e-3711-441e-9de0-b9d7230998f0" contextRef="C_3062bf66-4396-4633-bd29-bdc943e6d16c" name="idya:CommonStockRemainingAvailableToBeSaleAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">182.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of common stock remained available to be sold under the ATM facility.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may cancel its at-the-market program at any time upon written notice, pursuant to its terms.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has incurred significant losses and negative cash flows from operations in all periods since inception and had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82dfb81c-d1d7-499b-97a7-65acf52caf91" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">622.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has financed its operations primarily through the sale and issuance of common stock and the upfront payment and certain milestone payments received from GSK.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, none of the Company&#8217;s product candidates have been approved for sale, and the Company has not generated any revenue from commercial products since inception. Management expects operating losses to continue and increase for the foreseeable future, as the Company progresses clinical development activities for its lead product candidates. The Company&#8217;s prospects are subject to risks, expenses and uncertainties frequently encountered by companies in the biotechnology industry as discussed under Risks and Uncertainties in Note 2. While the Company has been able to raise multiple rounds of financing, there can be no assurance that in the event the Company requires additional financing, such financing will be available on terms which are favorable or at all. Failure to generate sufficient cash flows from operations, raise additional capital or reduce certain discretionary spending would have a material adverse effect on the Company&#8217;s ability to achieve its intended business objectives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had cash, cash equivalents and marketable securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac847aa3-5e5b-416f-b8d5-6fbcc05e029f" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="idya:CashCashEquivalentsAndMarketableSecurities" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion. Management believes that the Company&#8217;s current cash, cash equivalents and marketable securities will be sufficient to fund its planned operations for at least 12 months from the date of the issuance of these financial statements.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div><ix:nonNumeric id="F_7d285788-4fa0-4539-aa76-246d7e49d029" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_7d285788-4fa0-4539-aa76-246d7e49d029_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8af901bc-9798-43d8-b0e0-30ec8984a15f" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial statements and accompanying notes have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;).</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_18a28408-1774-48e6-80d7-d7a1dff8a827" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include useful lives of property and equipment, determination of the discount rate for operating leases, accruals for research and development activities, revenue recognition, stock-based compensation, and income taxes. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bb56694c-1495-48bd-8e91-f7940ff6a8cd" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cf5dc78-edc0-4502-9bb8-087032a3f1a2" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_5ee9284d-087d-44a1-9d30-0455c0ecba3a" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable and operating segment. Financial information about the Company&#8217;s operating segment and geographic areas is presented in Note 13 of the financial statements.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_29c71d7d-46c7-432c-bca9-a1a4f9a3ea86" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="idya:RisksAndUncertaintiesPolicyTextBlock" escape="true" continuedAt="F_29c71d7d-46c7-432c-bca9-a1a4f9a3ea86_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company operates in a dynamic and highly competitive industry and is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturers, contract research organizations and collaboration partners, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company believes that changes in any of the following areas could have a material</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_7d285788-4fa0-4539-aa76-246d7e49d029_1" continuedAt="F_7d285788-4fa0-4539-aa76-246d7e49d029_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_29c71d7d-46c7-432c-bca9-a1a4f9a3ea86_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse effect on the Company&#8217;s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials and collaboration activities; regulatory approval and market acceptance of the Company&#8217;s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company&#8217;s ability to attract and retain employees necessary to support its growth.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Products developed by the Company require approvals from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that the products will receive the necessary approvals, or that any approved products will be commercially viable. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval, it could have a materially adverse impact on the Company. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company may require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs which would materially and adversely affect its business, financial condition and operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c7990150-b6b8-4d9a-9329-7bcce9c5d469" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. Substantially all the Company&#8217;s cash, cash equivalents and marketable securities are held by three financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s investment policy addresses credit ratings, diversification, and maturity dates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company invests its cash equivalents and marketable securities in money market funds, U.S. government securities, commercial paper, and corporate bonds. The Company limits its credit risk associated with cash equivalents and marketable securities by placing them with banks and institutions it believes are creditworthy and in highly rated investments and, by policy, limits the amount of credit exposure with any one commercial issuer. The Company has not experienced any credit losses on its deposits of cash, cash equivalents or marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b8621fc-f563-416e-a0d3-92e214a2db5a" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents that are readily convertible to cash are stated at cost, which approximates fair value. The Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less at the date of purchase to be cash equivalents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_01d33524-6c2f-49eb-bf43-06eda5941a52" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash as of December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> consisted of cash balances held as security in connection with the Company&#8217;s facility lease agreements in South San Francisco, California and San Diego, California. The balances are classified as long-term assets on the Company&#8217;s balance sheet.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_45adc29f-811f-428b-908c-460729104879" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:MarketableSecuritiesPolicy" escape="true" continuedAt="F_45adc29f-811f-428b-908c-460729104879_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">securities are investments in marketable securities with maturities greater than three months at the time of purchase. The Company determines the appropriate classification of its investments in marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable securities as available-for-sale. After consideration of the Company&#8217;s risk versus reward objectives and liquidity requirements, the Company may sell these securities prior to their stated maturities. The Company classifies highly liquid securities with maturities beyond 12 months as long-term marketable securities in the balance sheet. These securities are carried at fair value as determined based upon quoted market prices or pricing models for similar securities. Unrealized gains and losses, if any, are excluded from earnings and are reported as a component of accumulated other comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income and other income (expense), net on the statements of operations and comprehensive loss. Realized gains and losses, if any, on available-for-sale securities are included in interest income and other income (expense),</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_7d285788-4fa0-4539-aa76-246d7e49d029_2" continuedAt="F_7d285788-4fa0-4539-aa76-246d7e49d029_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_45adc29f-811f-428b-908c-460729104879_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">net. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5eb8274c-ad38-427f-99a1-236e55f75146" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying amounts of the Company&#8217;s certain financial instruments, including cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities and market interest rates if applicable. Refer to Note 3 for details on the fair value of marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6e9aa122-b000-40ce-98e6-f13af762693c" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which is generally between </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d3a6b20e-57d6-4e14-ab8d-c3cbd58018ea;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4f7c6061-793e-4dc5-9a2f-547a4772c26a" contextRef="C_4e5c2597-3aa6-4e75-84f5-fcacb80ec75e" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Leasehold improvements are stated at cost and amortized over the shorter of the useful lives of the assets or the lease term. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations and comprehensive loss in the period realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2848e7ac-d688-4730-95fe-8fd1758120ee" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:PropertyPlantAndEquipmentImpairment" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount of the asset or asset group to the future net cash flows which the asset or asset group is expected to generate. If such asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group exceeds the fair value of the asset or asset group. There have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfa63d63-f99b-4ae6-b844-82ea1e3a4493" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_978d2c8b-f453-4be4-a0da-f2e13b088ecc" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such impairments of long-lived assets for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d7b61219-5d1c-4f91-8034-e27ccfc26207" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if an arrangement is a lease, or contains a lease, at its inception. Operating leases are included in right-of-use (&#8220;ROU&#8221;) assets, lease liabilities, and long-term lease liabilities on the Company&#8217;s balance sheet.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ROU assets and lease liabilities are recognized based on the present value of the future lease payments over the lease term at commencement date. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The ROU asset also includes any lease payments made to the lessor at or before the commencement date, minus lease incentives received, and initial direct costs incurred. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company combines lease and nonlease components.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9642acfa-f6c4-4e50-be1a-cebaa0bbdea4" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="idya:CloudComputingArrangementsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cloud Computing Arrangements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes certain implementation costs incurred under a cloud computing arrangement that is a service contract. Costs incurred during the application development stage related to the implementation of the hosting arrangement are capitalized and included within prepaid expenses and other current assets, and other non-current assets on the accompanying balance sheets. Amortization of capitalized implementation costs is recognized on a straight-line basis over the term of the associated hosting arrangement when it is ready for its intended use. Costs related to preliminary project activities and post-implementation activities are expensed as incurred.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_964b97df-df66-44cc-b1f3-7539460047cb" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true" continuedAt="F_964b97df-df66-44cc-b1f3-7539460047cb_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company follows Accounting Standards Codification Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 606&#8221;). Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_7d285788-4fa0-4539-aa76-246d7e49d029_3" continuedAt="F_7d285788-4fa0-4539-aa76-246d7e49d029_4"><div><ix:continuation id="F_964b97df-df66-44cc-b1f3-7539460047cb_1" continuedAt="F_964b97df-df66-44cc-b1f3-7539460047cb_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company applies the five-step model to contracts when (1) parties have approved the contract and are committed to performing respective obligations, (2) the Company can identify each party&#8217;s rights regarding the goods or services to be transferred, (3) the Company can identify the payment terms for the goods or services to be transferred, (4) the contract has commercial substance, and (5) it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines the performance obligations by assessing whether each promised good or service is distinct. Goods or services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligations when (or as) the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the &#8220;variable consideration constraint&#8221;) that a significant reversal of recognized revenue is not probable.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licenses of intellectual property:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> If a license to the Company&#8217;s intellectual property is determined to be distinct from the other promised goods or services identified in an arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license at the point in time when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other goods or services, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress toward satisfying the performance obligation for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Customer options for additional goods or services: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a contract contains customer options that allow the customer to acquire additional goods or services, including a license to the Company&#8217;s intellectual property, the goods and services underlying the customer options are evaluated to determine whether they are deemed to represent a material right. In determining whether the customer option has a material right, the Company assesses whether there is an option to acquire additional goods or services at a discount. If the customer option is determined not to represent a material right, the option is not considered to be a performance obligation. If the customer option is determined to represent a material right, the material right is recognized as a separate performance obligation. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until the option is exercised.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone payments:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> At the inception of each arrangement or amendment that includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 prescribes two methods to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the expected value method to estimate the amount of variable consideration related to the reimbursement of Pol Theta and WRN program costs which is consistently applied throughout the life of the contract: however, it is not necessary for the Company to use the same approach for all contracts. If it is probable that a significant revenue reversal would not occur when the uncertainty associated with the milestone is resolved, the associated milestone value is included in the transaction price. Milestone payments that are highly susceptible to factors outside the Company&#8217;s influence, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. If there is more than one performance obligation, the transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalties:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upfront payments and fees are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contractual cost sharing payments received from a customer or collaboration partner are accounted for as variable consideration. The Company includes an expected value in the transaction price. Contractual cost sharing payments made to a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_7d285788-4fa0-4539-aa76-246d7e49d029_4" continuedAt="F_7d285788-4fa0-4539-aa76-246d7e49d029_5"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_964b97df-df66-44cc-b1f3-7539460047cb_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">customer or collaboration partner are accounted for as a reduction to the transaction price if such payments are not related to distinct goods or services received from the customer or collaboration partner.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contracts may be amended to account for changes in contract specifications and requirements. Contract modifications exist when the amendment either creates new, or changes existing, enforceable rights and obligations. When contract modifications create new performance obligations and the increase in consideration approximates the standalone selling price for goods and services related to such new performance obligations as adjusted for specific facts and circumstances of the contract, the modification is accounted for as a separate contract. If a contract modification is not accounted for as a separate contract, the Company accounts for the promised goods or services not yet transferred at the date of the contract modification (the remaining promised goods or services) prospectively, as if it were a termination of the existing contract and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. The Company accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. In such case, the effect that the contract modification has on the transaction price, and on the entity&#8217;s measure of progress toward complete satisfaction of the performance obligation, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) at the date of the contract modification (the adjustment to revenue is made on a cumulative catch-up basis).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upfront payment contract liabilities resulting from the Company&#8217;s license and collaboration agreements do not represent a financing component as the payment is not financing the transfer of goods and services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company. As such, the Company does not adjust its revenues for the effects of a significant financing component. Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liability in the Company&#8217;s balance sheets. If the related performance obligation is expected to be satisfied within the next twelve (12) months, this will be classified and included within current contract liability.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1dec748-302f-4ae1-b1e3-4830754c25e0" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of compensation costs, employee benefit costs, costs for contract manufacturing organizations (&#8220;CMOs&#8221;), costs for contract research organizations (&#8220;CROs&#8221;), costs for clinical trials, costs for sponsored research, consulting costs, costs for laboratory supplies, costs for product licenses, facility-related expenses and depreciation. All research and development costs are charged to research and development expenses as incurred and included within the statements of operations and comprehensive loss. Payments associated with licensing agreements to acquire exclusive licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternate commercial use are also expensed as incurred. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_76eb1cc8-0955-4c1d-9dd7-d7d893766449" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="idya:AccruedResearchAndDevelopmentExpensesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Research and Development Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into various agreements with CMOs and CROs. The Company&#8217;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CMOs and CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. Management&#8217;s process involves reviewing open contracts and purchase orders, communicating with applicable personnel to identify services that have been performed, and estimating the level of service performed and the associated costs incurred based on vendor estimates for the services when the Company has not yet been invoiced or otherwise notified of actual costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14dbb7fc-daee-4bb8-bbcc-5c6f3897c7c4" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for stock-based compensation arrangements with employees and non-employees in accordance with ASC 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Compensation. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for stock-based compensation arrangements using a fair value method which requires the recognition of compensation expense related to all stock-based awards. The fair value method requires the Company to estimate the fair value of stock option awards on the date of grant using an option pricing model. The Company uses the Black-Scholes option pricing model to determine the fair value of options granted, which is expensed on a straight-line basis over the vesting period. Generally, the stock options granted by the Company to its employees have a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2bfa8fa-0660-403a-a287-d56157599290" contextRef="C_93b03c8e-0f95-4d58-98e5-1b1e2a78067e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term and vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_82ca6b8e-20e5-4690-b970-ecb9c0dca863" contextRef="C_93b03c8e-0f95-4d58-98e5-1b1e2a78067e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year period with </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fdab4132-e59c-4532-9f73-7b7401e944b3" contextRef="C_9597b477-72d9-47f9-a2b7-c96116c45490" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year cliff vesting.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_7d285788-4fa0-4539-aa76-246d7e49d029_5" continuedAt="F_7d285788-4fa0-4539-aa76-246d7e49d029_6"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_86d95657-ab93-4b72-8ea8-6522eeb8c3ac" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method whereby deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are currently in effect unless such rate is expected to be different when the deferred item reverses. Valuation allowances are established where necessary to reduce deferred tax assets to the amounts expected to be realized. Deferred tax assets and liabilities are classified as noncurrent on the balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that has a greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf30acab-930a-49a6-8eb0-ee4e19f26e71" contextRef="C_97b79519-0af1-4cce-8a6d-7911a10985ed" name="idya:RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized" unitRef="U_pure" scale="-2" decimals="INF">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits in interest expense and other expense, respectively.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a62f0163-20e5-49d8-982d-8273583c2054" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive Income and Loss</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive income and loss include net loss and certain changes in stockholders&#8217; equity that are excluded from net loss, primarily unrealized gains and losses from the Company&#8217;s marketable securities.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_70411431-3afd-45b9-9752-49f02174c015" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss per Share Attributable to Common Stockholders</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. Pre-funded warrants are included in the calculation of basic and diluted earnings per share. For purposes of the diluted net loss per share calculation, stock options, restricted stock and restricted stock that is subject to repurchase at the original purchase price are considered to be potentially dilutive securities. The Company considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of early exercised shares subject to repurchase do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_7ec32e0a-ffe8-4960-86f7-cfc54f7edf99" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true" continuedAt="F_7ec32e0a-ffe8-4960-86f7-cfc54f7edf99_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) under its accounting standard codifications (&#8220;ASC&#8221;) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New Accounting Pronouncements Adopted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) under its accounting standard codifications (&#8220;ASC&#8221;) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. These amendments enhance interim disclosure requirements, require disclosure of the title and position of the chief operating decision maker (&#8220;CODM&#8221;), require disclosure of significant segment expenses that are regularly provided to the CODM, clarify circumstances for disclosure of more than one segment profit or loss measure and require that a public entity that has a single reportable segment provide all disclosures required by ASC 280 and amendments. This ASU update is effective for fiscal years beginning after December 15, 2023 for the Company&#8217;s annual report, and interim periods within fiscal years beginning after December 15, 2024. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company adopted this ASU for the annual report for the fiscal year beginning </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1e37055a-f4e2-4c05-b05f-2e6a1a1cdfeb" contextRef="C_eed81da0-8376-4317-a154-9ffbb5c0bf7e" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and evaluated the impact of the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_51bf1380-2091-4ab2-9f0a-9fdff7269773" contextRef="C_eed81da0-8376-4317-a154-9ffbb5c0bf7e" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adoption </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the ASU. It did </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d397e36-c1bb-48ee-8581-cb37d2650d03" contextRef="C_eed81da0-8376-4317-a154-9ffbb5c0bf7e" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t result in a material impact on the Company's financial statements and related disclosures. See Note 13. Segment Information.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New Accounting Pronouncements, Not yet Adopted</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative, which modifies the disclosure or presentation requirements related to variety of FASB Accounting Standard Codification topics. The effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K is effective. If by June 30, 2027, the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_7d285788-4fa0-4539-aa76-246d7e49d029_6"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_7ec32e0a-ffe8-4960-86f7-cfc54f7edf99_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the associated amendment will be removed from the Codification and will not become effective for any entities. The Company is currently evaluating the effect of adopting this ASU.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 14, 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which amends the guidance in ASC 740, Income Taxes. The ASU is intended to improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The ASU&#8217;s amendments are effective for public business entities for annual periods beginning after December 15, 2024. Entities are permitted to early adopt the standard &#8220;for annual financial statements that have not yet been issued or made available for issuance.&#8221; Adoption is either prospectively or retrospectively; the Company will adopt this ASU on a prospective basis. The Company is currently evaluating the impact of the ASU, but does not expect any material impact upon adoption.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 2024, the FASB issued ASU 2024-03 - Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The ASU requires more detailed disclosures about the types of expenses in commonly presented expense captions such as cost of sales, selling, general and administrative expenses and research and development expenses. This includes separate footnote disclosure for expenses such as purchases of inventory, employee compensation, depreciation, and intangible asset amortization. Public business entities are required to apply the guidance prospectively and may apply it retrospectively. The ASU's amendments are effective for public business entities for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Public business entities are required to apply the guidance prospectively and may apply it retrospectively. The Company is currently evaluating the effect of adopting this ASU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_ea225c5e-1852-4f76-8bb1-ed96d8711823" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="idya:FairValueMeasurementsAndMarketableSecuritiesTextBlock" escape="true" continuedAt="F_ea225c5e-1852-4f76-8bb1-ed96d8711823_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Fair Value Measurement and Marketable Securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2e5f6ef7-165b-4bb5-b21b-3eaede15a6f5" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="idya:FairValueMeasurementsAndMarketableSecuritiesPolicyTextBlock" escape="true" continuedAt="F_2e5f6ef7-165b-4bb5-b21b-3eaede15a6f5_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Observable inputs, such as quoted prices in active markets for identical assets or liabilities at the measurement date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_2e5f6ef7-165b-4bb5-b21b-3eaede15a6f5_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs which reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_ea225c5e-1852-4f76-8bb1-ed96d8711823_1" continuedAt="F_ea225c5e-1852-4f76-8bb1-ed96d8711823_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as consider counterparty credit risk in its assessment of fair value.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b0a9eb60-ba70-4a79-b163-0372587b3edd" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" escape="true" continuedAt="F_b0a9eb60-ba70-4a79-b163-0372587b3edd_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, financial assets measured and recorded at fair value are as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.986%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.002%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.562999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.681999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.521999999999998%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.222000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0300be4b-72ac-4b58-992b-1c7d2115da50" contextRef="C_04d43460-4b81-4f83-b2c2-02fb5a312c66" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">552,008</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47d66659-5486-47de-82e0-1b9523d3ebae" contextRef="C_04d43460-4b81-4f83-b2c2-02fb5a312c66" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,214</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_674ca26e-de5f-4fb3-933e-ce5a13b551e6" contextRef="C_04d43460-4b81-4f83-b2c2-02fb5a312c66" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2576e78d-43a7-4b0e-ab8d-07b2b59b6203" contextRef="C_04d43460-4b81-4f83-b2c2-02fb5a312c66" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">552,869</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ca5cf9d-94df-4c52-8bc7-d7da4211872d" contextRef="C_16c5e261-e767-47ab-9f42-00c92286082e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">363,197</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efc434b0-87ab-42fc-b2d1-92dda692ae36" contextRef="C_16c5e261-e767-47ab-9f42-00c92286082e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">357</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e7f0f03-027c-4f15-accd-ce609e6f745e" contextRef="C_16c5e261-e767-47ab-9f42-00c92286082e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">419</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afe22e20-7c7e-4f84-bbbd-5e96d7d7a6fd" contextRef="C_16c5e261-e767-47ab-9f42-00c92286082e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">363,135</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7071fbb0-f62c-4812-8085-4ee06e265449" contextRef="C_ed5d8c12-9405-4e8a-b68f-e1da9fa98a3b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,109</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b168a8b-835b-4e2c-8af2-ff3b5a2d7470" contextRef="C_ed5d8c12-9405-4e8a-b68f-e1da9fa98a3b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48045723-0b14-40a3-ba85-014e79c2126b" contextRef="C_ed5d8c12-9405-4e8a-b68f-e1da9fa98a3b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e2f43e0-e3ae-440b-83dc-a86a49bf3c25" contextRef="C_ed5d8c12-9405-4e8a-b68f-e1da9fa98a3b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,122</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Subtotal</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ce67f6e-74ef-4fbe-a284-d7babb457228" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,004,314</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41ffc4de-0170-4c96-b6d0-8f87ddd8d344" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,592</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_018cfeb8-51ff-4d2d-9403-6507b4358a16" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">780</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa817f8c-f942-49cd-80d3-231451c124e6" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,005,126</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bd741cf-6d95-41bb-8833-d3196bdc99b2" contextRef="C_f7361d23-b930-48a8-9c1b-395215d1e86d" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,626</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5014cfd2-99b8-490a-87ff-6503d5c6d1ac" contextRef="C_f7361d23-b930-48a8-9c1b-395215d1e86d" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,626</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4626521-84ab-4e6b-9590-ecc02bce922b" contextRef="C_d83f8cee-a2f2-4da8-9137-df95b7b83290" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,399</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f63d5d54-0463-48c9-bf69-6f30d7e759ec" contextRef="C_d83f8cee-a2f2-4da8-9137-df95b7b83290" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,399</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total value of assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28883b15-b1d3-4a0f-9e8e-37747aa61297" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:InvestmentOwnedAtCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,081,339</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81c15ecc-4b0b-4df4-9fe0-3d61a416edc0" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,592</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4c9e9e0-7700-4ece-89b8-75315c97eebf" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">780</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35139051-88f1-4c52-a486-cdd188325fbb" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,082,151</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3c6d7ed-36bc-4c85-ac4c-9e3dc76ba94d" contextRef="C_2f896155-5fb2-43f9-9ec7-58dfaea72f5d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,379</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f76ffc61-ed6d-4631-b899-454af2a72aae" contextRef="C_2f896155-5fb2-43f9-9ec7-58dfaea72f5d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9572f42-ade5-43a0-9df1-4db43a7d8566" contextRef="C_2f896155-5fb2-43f9-9ec7-58dfaea72f5d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,378</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in marketable securities, current</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_182d5137-ed02-4d38-9f0e-c821a7f27a2a" contextRef="C_8b87a953-8e4e-49fe-b4a9-0b35f9a89796" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">591,089</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f25de3e3-fc6d-4c01-a774-3672c6829c04" contextRef="C_8b87a953-8e4e-49fe-b4a9-0b35f9a89796" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">928</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18584b34-e8f3-4842-aea2-7a74172521e5" contextRef="C_8b87a953-8e4e-49fe-b4a9-0b35f9a89796" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce2bcd4f-7944-46b9-a871-c1afc1eba3c5" contextRef="C_8b87a953-8e4e-49fe-b4a9-0b35f9a89796" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">591,941</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in marketable securities, non-current</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac21e0c7-1dab-4155-87f7-70e24a06ba2e" contextRef="C_ad7e94d4-33b0-49a5-8627-5b260d67b825" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">405,871</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e528a597-a0ce-4a00-babc-526f66a8d40f" contextRef="C_ad7e94d4-33b0-49a5-8627-5b260d67b825" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">664</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fcd94dd-a496-46eb-b0aa-b231509feb7c" contextRef="C_ad7e94d4-33b0-49a5-8627-5b260d67b825" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">703</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b42f9e7-3ffe-43ae-a21a-89e85a77dd75" contextRef="C_ad7e94d4-33b0-49a5-8627-5b260d67b825" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">405,832</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total value of assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0777f34-8404-4e2a-b315-1165e7b5ca18" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:InvestmentOwnedAtCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,081,339</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50fda0ac-93e3-4b85-adbc-97bf2e9d4a50" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,592</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b12b64e-6dd4-4181-9580-7abb6127bf89" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">780</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3dabb627-1e51-4cbc-844b-aa65c455f763" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,082,151</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03ce6fb1-2ff2-4753-bdcb-0246c508e0d3" contextRef="C_b08e0fb2-11c2-4fdf-a73e-de1ec106e6a4" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of commercial paper was included in cash and cash equivalents on the balance sheet due to securities with purchase dates within 90 days of maturity dates.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s short-term marketable securities mature in one year or less.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s long-term marketable securities mature between one and three years.</span></div></div></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b0a9eb60-ba70-4a79-b163-0372587b3edd_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023, financial assets measured and recognized at fair value are as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:30.58%;box-sizing:content-box;"/>
        <td style="width:1.36%;box-sizing:content-box;"/>
        <td style="width:9.1%;box-sizing:content-box;"/>
        <td style="width:1.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.38%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.38%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.38%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.38%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c107c73-f072-465a-a8e8-588a73410584" contextRef="C_102bebb9-1268-4e37-90b3-15a47af627e2" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">412,679</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c4dabd9-2605-4e26-9638-ce1936e4ac18" contextRef="C_102bebb9-1268-4e37-90b3-15a47af627e2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">591</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a84789f-2e87-4119-beaf-6d2dd0a6a11b" contextRef="C_102bebb9-1268-4e37-90b3-15a47af627e2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd96dae5-3094-41f5-b054-c3014155f4ce" contextRef="C_102bebb9-1268-4e37-90b3-15a47af627e2" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">413,135</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df928b0f-1bc9-4709-96d3-3e6cdbf8e1a4" contextRef="C_27155058-a3b3-4ee4-8db6-19df70e8e552" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,983</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09930194-f3be-4b14-a14d-a91fbd0ee397" contextRef="C_27155058-a3b3-4ee4-8db6-19df70e8e552" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">197</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56b523f0-014f-461e-88b3-988d5b029a87" contextRef="C_27155058-a3b3-4ee4-8db6-19df70e8e552" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c255008-75f0-4964-9937-f09c8d820440" contextRef="C_27155058-a3b3-4ee4-8db6-19df70e8e552" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,148</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f46ef29-635f-4463-8224-75f269d424fb" contextRef="C_d61cade1-8268-42c8-9099-392bd152a976" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126,601</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9de8607a-75fd-4012-8c4f-9249a3ef9621" contextRef="C_d61cade1-8268-42c8-9099-392bd152a976" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0d51988-952c-452a-b26b-f5af546a4332" contextRef="C_d61cade1-8268-42c8-9099-392bd152a976" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f22c920-0031-42f2-bd8e-30d1060b08ae" contextRef="C_d61cade1-8268-42c8-9099-392bd152a976" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126,543</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Subtotal</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c0454fb-b35c-49b2-95be-dac0426cac6b" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">593,263</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b15cc20b-27d3-43f9-9997-e22052bc76a3" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">788</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29f801ff-e693-409e-b792-456c3e7d7e98" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">225</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a0497c0-3f64-463d-8ba5-b3a24b914d67" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">593,826</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae1bc0d3-d7e9-48fd-ae99-bbe4e0c6c04a" contextRef="C_cbd0ef8f-ad56-44d1-80e0-5de5d8d02ca8" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,300</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eacef13c-9230-4bca-a661-5e67d854211c" contextRef="C_cbd0ef8f-ad56-44d1-80e0-5de5d8d02ca8" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,300</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_934be7b9-70a2-4e54-a116-b0c029fb8570" contextRef="C_708a6a15-ace7-419f-8285-9848a72f3257" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">480</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ed2f0b6-178a-43dd-9b85-84dfd8ec68a3" contextRef="C_708a6a15-ace7-419f-8285-9848a72f3257" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">480</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total value of assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d4a77ae-cb46-495a-80e5-88bc3e926795" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:InvestmentOwnedAtCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">632,043</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4cdedac-af5a-4370-97a0-e5b82e32a751" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">788</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc5996ae-7614-414b-954d-698791db371b" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">225</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f600eac-0cc6-496c-b328-ae77c15cd84d" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">632,606</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2195f51d-aad4-4368-82ed-0477082d8e85" contextRef="C_34b68bd4-0003-4e5f-b72b-00f8d56f232d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,055</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e42f05b3-b2a3-4698-8a2f-497cbaae6a93" contextRef="C_34b68bd4-0003-4e5f-b72b-00f8d56f232d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_823f48a3-0504-433a-bd4d-2ecffeed7c71" contextRef="C_34b68bd4-0003-4e5f-b72b-00f8d56f232d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_865c7ff5-2d7b-45ae-8dba-4fc0cb49f06b" contextRef="C_34b68bd4-0003-4e5f-b72b-00f8d56f232d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,018</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in marketable securities, current</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8905e8e2-7b7d-4993-9a24-2334a5217829" contextRef="C_bccc40ef-fa48-4336-b831-e54faeed80cb" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">368,043</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fb607ce-359e-46fd-bff2-c318bf356753" contextRef="C_bccc40ef-fa48-4336-b831-e54faeed80cb" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">227</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f4954d2-5412-410e-89ed-29ff923a99f8" contextRef="C_bccc40ef-fa48-4336-b831-e54faeed80cb" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">174</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cf28005-8585-42cf-b664-3231cdcfd98c" contextRef="C_bccc40ef-fa48-4336-b831-e54faeed80cb" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">368,096</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in marketable securities, non-current</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c97c0eed-a91f-4d27-96c6-2c2754cc1ea1" contextRef="C_f401e5c8-9543-480b-b6f2-bdab7d05f204" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,945</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0be25175-0ce5-4a35-bb69-f75f0af8b436" contextRef="C_f401e5c8-9543-480b-b6f2-bdab7d05f204" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">557</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b88dde88-cd02-44f4-88a3-7e84e9840c3b" contextRef="C_f401e5c8-9543-480b-b6f2-bdab7d05f204" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc12e577-c2e7-4821-86af-2f6ed5caf1c8" contextRef="C_f401e5c8-9543-480b-b6f2-bdab7d05f204" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,492</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total value of assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0c4a313-c0f2-4c00-842a-d07d26989916" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:InvestmentOwnedAtCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">632,043</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8816331-e999-453e-970d-a57b226fafde" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">788</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d77dfd5f-3384-4194-8734-01507ad0438f" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">225</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf2c3f6a-ba91-4495-8653-332a05275305" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">632,606</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c734cdf-e017-48ef-9f31-84561bbca0bb" contextRef="C_251008aa-c1a9-42db-be7d-38cbbc1eb46d" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">37.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of U.S. government securities and $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20d9b401-081e-4f0a-a147-3972b6406abf" contextRef="C_83549ecb-3fd7-4381-8f30-327213eea05d" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">80.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of commercial paper were included in cash and cash equivalents on the balance sheet due to securities with purchase dates within 90 days of maturity dates</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s short-term marketable securities mature in one year or less.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s long-term marketable securities mature between one and three years</span></div></div></ix:continuation></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ea225c5e-1852-4f76-8bb1-ed96d8711823_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, all marketable securities had a remaining maturity of less than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bdb6e773-3b57-474c-bd27-29cce2ba2f21" contextRef="C_7a6bc497-f228-42bb-8d0a-1e9eedd0706f" name="idya:MarketableSecuritiesRemainingMaturityPeriod" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_f9cddc40-08f0-4082-8c13-a057d8ec0105" contextRef="C_75dd9ba0-2dcb-4995-8704-30a44e45f791" name="idya:MarketableSecuritiesRemainingMaturityPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ef77357-94a2-414d-b691-3aef7384d20f" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_36e8b12a-7d31-4e62-8181-9d0f45ebea5d" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> financial liabilities measured and recognized at fair value as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers available evidence in evaluating potential other-than-temporary impairments of its marketable securities, including the duration and extent to which fair value is less than cost, and the Company&#8217;s ability and intent to hold the investment. As of December 31, 2024 and December 31, 2023, the Company held certain securities in an unrealized loss position. These unrealized losses were considered to be temporary as the Company expects to recover the entire amortized cost basis on the securities in unrealized loss positions based on the creditworthiness of the underlying issuer, and the Company neither intends to sell these securities nor considers it more likely than not that the Company would be required to sell any such security before its anticipated recovery. As a result, the Company did not consider any of these investments to be other-than-temporarily impaired at December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_f21cb7e9-1e13-4d5a-ae69-a9007da52613" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Balance Sheet Components</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_023f6036-975d-458b-bf05-1d1b7f146442" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.79%;box-sizing:content-box;"/>
        <td style="width:1.34%;box-sizing:content-box;"/>
        <td style="width:17.584%;box-sizing:content-box;"/>
        <td style="width:1.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.302000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.302000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Life</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In Years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><ix:nonNumeric id="F_c371b3b1-1fe5-46d8-b1be-e806cf368993" contextRef="C_1995fabd-2822-4d7e-89fa-1b6e278a87fd" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9f35fef-88ee-4440-a185-7ba9d2ff9623" contextRef="C_1995fabd-2822-4d7e-89fa-1b6e278a87fd" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,513</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_305bcaaf-c57f-41ed-a63b-b5dc0742ccb7" contextRef="C_d536bcf1-3ec0-423d-b2dc-d793db2570c0" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,455</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><ix:nonNumeric id="F_aa940907-1610-401d-a039-33a6afd96d30" contextRef="C_c19a5e53-23fd-4bc8-8462-f68e81fbfe48" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2891de9-c44a-439e-86eb-3d4630d43286" contextRef="C_c19a5e53-23fd-4bc8-8462-f68e81fbfe48" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">503</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a71457f-0761-4627-a1b8-d0f899237b94" contextRef="C_2378e96a-3247-479e-b4ea-c4f63e5949db" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">261</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><ix:nonNumeric id="F_4703dc86-1a1b-404c-8f12-384a434fed66" contextRef="C_9fb9e960-f425-4a31-bc47-44faa05f376c" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e69ddcc0-5ea8-4e53-b61b-dd11fc577a0b" contextRef="C_9fb9e960-f425-4a31-bc47-44faa05f376c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">231</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65bae4b6-08d3-4b7c-bf4a-e4a6aab7d6b6" contextRef="C_14486222-86aa-41d5-ae07-15df550cdd49" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">231</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><ix:nonNumeric id="F_d9f3b61e-6fe5-433e-8ada-f5e31ef1121f" contextRef="C_1789f966-ab3e-40ee-add4-b0aaa08d3263" name="idya:PropertyPlantAndEquipmentUsefulLifeDescription"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of useful<br/>life or lease term</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cb6df7b-2127-497c-86bf-936e447ddf5d" contextRef="C_651623b8-e9c1-43f9-a69b-5797bef8158e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,913</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1064b052-a550-4a9d-b040-b8f75601da9d" contextRef="C_1ce730f4-285b-4d18-9b94-24f179a1f447" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,321</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><ix:nonNumeric id="F_103b1c1b-e8f4-44d1-8670-32fe6b6ee71b" contextRef="C_c495f084-6fcb-44de-808b-4aa3452ff136" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38a7436e-a968-492b-a45b-4f7b4b1e56d8" contextRef="C_c495f084-6fcb-44de-808b-4aa3452ff136" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,517</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf3c8170-04d0-47fd-8c60-33abe7e49c8d" contextRef="C_d65b61cb-05ca-4927-b54c-ce7d454a1633" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">507</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0212906b-3593-4a68-b653-a7742726c60d" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,677</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f07c004-0e3e-41b6-b547-92ab2a302eb6" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,775</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23707035-c014-4162-90b3-93bcd9da0fb0" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,711</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c6defd6-8902-4eb4-aa97-ad3945a238a7" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,611</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10711804-c7a1-4d9f-a807-e5b79f5a1314" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,966</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecefc666-def8-4fe5-9293-158d1ff65f2b" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,164</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98e46306-319e-4dba-9cf1-fb6fe4cf10a0" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43f33b95-c7fc-40c7-b199-35751083f2f5" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89fd2945-19c7-499b-beeb-29a09b030d59" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024, 2023 and 2022, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58758dcc-f1f8-4b59-846b-4b6aaea3c7a9" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true" continuedAt="F_58758dcc-f1f8-4b59-846b-4b6aaea3c7a9_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:63.847%;box-sizing:content-box;"/>
        <td style="width:1.66%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.417%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.66%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.417%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71c269ba-ebf2-45f9-b876-028ec32d451a" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="idya:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,956</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bc231b2-592a-4a02-863c-1ca4a9b1874f" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="idya:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,676</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued salaries and benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59840193-8d39-49b9-974d-90430f3f8a69" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,233</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21914c70-d483-4f58-adc1-f3f9e31e4d9a" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,974</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Legal and professional fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_741a3aa4-be44-4e5b-8bc8-5c49a50c0a24" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,213</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67a3d37d-add7-4bb9-a4ec-f979ea69309c" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">959</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c3008b1-453b-4df6-9578-00a533ea7888" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">950</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7031b67-ee9d-40ed-b8f2-3b397675c892" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f58444de-0c39-44b0-9285-1112ebb85671" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,352</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc71d166-c9f0-451f-acbe-d92b6288e610" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,756</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_58758dcc-f1f8-4b59-846b-4b6aaea3c7a9_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_4ab202ec-9bd7-4525-b6fb-fdbe0d3aee5b" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true" continuedAt="F_4ab202ec-9bd7-4525-b6fb-fdbe0d3aee5b_1"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Operating Leases</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2023, the Company entered into a lease agreement for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27582a0c-fdc9-4d9a-9f1b-e3809706ea47" contextRef="C_8a14eee6-aa6b-4583-9df1-42b202346a23" name="idya:OperatingLeasesAreaLeased" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">44,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of laboratory and office facilities at 5000 Shoreline Court, South San Francisco, California. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2ae0f5ad-1933-4cc7-b627-659446c1a543" contextRef="C_847c9af8-88d2-45a3-91d6-dcdef630162c" name="idya:OperatingLeaseCommencementDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The lease term is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8bd00d88-25cf-455b-a0bb-0a8743e238f7" contextRef="C_8a14eee6-aa6b-4583-9df1-42b202346a23" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120 months</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_af3f4c52-090b-47c4-b5c3-24b80389dbe2" contextRef="C_847c9af8-88d2-45a3-91d6-dcdef630162c" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company has an option to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_661fa099-669b-49de-bef5-a2c9aedfbe9d" contextRef="C_26c750d2-8712-4a4a-a85d-4f7f7ab0f46b" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extend the lease term</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for a total of two consecutive five-year periods</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This lease agreement commenced in August 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, the Company amended its 5000 Shoreline Court facility lease agreement to expand the size of the original premises by adding approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53ea7772-5e8a-4066-8054-064ffa32f1a2" contextRef="C_22f94b97-85f3-4e83-8f04-ecf937a7a2ac" name="idya:OperatingLeasesAdditionalAreaLeased" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">11,321</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> rentable square feet of additional space. The lease term for the expanded premises will not begin until the landlord makes certain improvements and offers to deliver possession of the expansion premises to the Company. The lease term for the expanded premises has not yet commenced as of December 31, 2024.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_4ab202ec-9bd7-4525-b6fb-fdbe0d3aee5b_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's lease at 7000 Shoreline Court, South San Francisco, California, expired in September 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Company entered into a lease agreement for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18e260ce-e54b-4dba-8374-b56fec363875" contextRef="C_fdb1e9d4-d4ba-4bfd-94d7-8c22b58dd404" name="idya:OperatingLeasesAreaLeased" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">5,700</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of space at 11710 El Camino Real, San Diego, California for corporate office space. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9e3d9e3-9f0b-4ee1-adb9-27c56d3c8c8c" contextRef="C_8c32f180-89d2-481f-bc80-3f77774ec456" name="idya:OperatingLeaseCommencementDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The lease term commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c1c309c4-1d0a-4108-a27e-e8a496caffd3" contextRef="C_09973aa9-24e1-483b-99d4-30e070b0dbb0" name="idya:OperatingLeaseCommencementMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8afb2456-7dcf-4372-8422-65ec0121d8da" contextRef="C_5461c8ef-2882-483f-a96f-317b9393242b" name="idya:LeaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 2028</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has an option to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb450fa7-71ad-4081-b0b0-138c24e35699" contextRef="C_5461c8ef-2882-483f-a96f-317b9393242b" name="idya:LesseeOperatingLeaseExistenceOfOptionToRenew" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">renew the lease</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f082339b-4b3c-4bcc-823e-376a41a06400" contextRef="C_fdb1e9d4-d4ba-4bfd-94d7-8c22b58dd404" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_08df0f95-9de2-4d91-8e35-914df5dccb4c" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future minimum lease payments under operating leases included on the Company's balance sheet are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.28%;box-sizing:content-box;"/>
        <td style="width:3.72%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:38%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b83fc48-ce78-4468-b1ee-c80907eac40e" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">386</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b34ff4a-8f5b-41ba-9700-1c6d488bb66f" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,705</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08bca3c7-7028-498e-bb86-692ebe5e8f3e" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,389</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26f3d9ad-11c7-4dba-8c78-457d22feb88c" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,224</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63a68aa6-c3d2-49b9-99e7-07bf88b57430" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,263</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9218055a-8aca-4427-bce5-3d95f3debaa9" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="idya:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,790</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total future minimum lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49c75f30-1bcf-4ca4-bb15-770436a6aad8" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,757</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfb2a4e4-a26f-4050-a654-e3ab51ec690d" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,586</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f01ba43c-b279-4180-9754-0319827ea21c" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,171</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_05d907d4-da25-43bb-9933-cd016867ce5d" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="idya:OperatingLeasesDisclosuresTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes other information about the Company's operating leases:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.74%;box-sizing:content-box;"/>
        <td style="width:2%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:20.6%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.22%;box-sizing:content-box;"/>
        <td style="width:22.44%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><ix:nonNumeric id="F_e5a94bd0-2dd8-4c6d-ad83-3e1c1e6d7f0d" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.4</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><ix:nonNumeric id="F_163f6ab4-6e21-4cdc-b1da-71436562b344" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e7cea99-dcb1-4a0e-a865-1d1769c35763" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">12.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c31e3a7e-13ed-4200-bed3-8eb8703d80d1" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">8.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease costs were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9756db9a-fbb9-4b77-bf20-d9067af52d53" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fac5a83a-2c58-40e0-89aa-f4d163291cd8" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_221180a6-9578-4847-8034-e3d6ab2d18de" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024, 2023 and 2022, respectively. Variable lease costs were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a153858f-b554-4ecf-b6da-256df81bf24b" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a83e3f1-9250-45d8-b7e8-b3c89ae744aa" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4fdfac3-3738-4398-8104-53a7a8f5728d" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024, 2023, and 2022, respectively. Variable lease costs represent additional costs incurred, related to administration, maintenance and property tax costs incurred, which are billed based on both usage and as a percentage of the Company's share of total square footage.</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024, 2023 and 2022, cash paid for amounts included in the measurement of lease liabilities and included within cash used in operating activities in the statement of cash flows was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_234cb812-738b-4407-b7ef-8262df40d082" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cdda98b-b2f7-4cee-bc3e-ff6ae5444fc4" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f61f902-e278-4950-b3f0-d736c284cdd5" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_7fc66d88-cc99-4d6e-a0b2-144301ccf0ac" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_7fc66d88-cc99-4d6e-a0b2-144301ccf0ac_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may be involved in litigation related to claims that arise in the ordinary course of its business activities. The Company accrues for these matters when it is probable that future expenditures will be made and these expenditures can be reasonably estimated. As of December 31, 2024, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company&#8217;s financial position, results of operations or cash flows.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company enters into standard indemnification arrangements in the ordinary course of business with vendors, clinical trial sites and other parties. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_7fc66d88-cc99-4d6e-a0b2-144301ccf0ac_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incurred </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs to defend lawsuits or settle claims related to these indemnification agreements. Accordingly, the Company has not recorded a liability related to such indemnification agreements as of December 31, 2024.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_2fee3df8-0f05-47d8-84a0-927901a23918" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_2fee3df8-0f05-47d8-84a0-927901a23918_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Income Taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4db07650-b2ea-4a22-8fb1-005e5d1d16b9" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_30050818-1400-41ab-bc69-5b3774a98314" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_20f96056-7165-42bb-b5f1-f8ecd76839c2" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> provision for income taxes was recorded for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, December 31, 2023 and December 31, 2022. The Company has incurred net operating losses only in the United States since its inception. The Company has not reflected any benefit of such net operating loss carryforwards in the financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3ce87b78-6309-4b1c-a569-e314658296cb" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The provision for income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.342%;box-sizing:content-box;"/>
        <td style="width:1.24%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.312999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.24%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.312999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.24%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.312999999999999%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84721032-379e-45e6-af9b-3d880ad98b35" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aef348d0-121b-40c7-bde9-2ad75b154715" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0746568-e8a6-4c7d-baf5-b3cddea0fb45" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58087cbc-2800-4dbd-a8f7-af09bc2a0bc0" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3">1.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d44cab2-5843-4481-9128-2cab5b5b94d6" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3">1.3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b6ea878-4174-4770-8797-03e90f6fce75" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3">1.9</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17fc6e75-26b7-4ba6-aadb-69f530f16d09" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-">25.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a642768c-4b74-4323-a32e-ec3458d2557c" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-">29.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09743046-36e8-4dab-b02e-a205d56bef43" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-">23.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22eb25af-4446-4e74-af03-1f3ca6cc4f69" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e60c8e5-9f68-4184-9fd9-6db9564678b0" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36c3d856-f477-4443-9ad1-ea8fd5cc3239" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cdd9b49-523b-4bd0-89cb-1a9986d3382f" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d934f446-739d-4e0c-9fc5-71b02fb7d74d" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" sign="-">8.3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e91bfd65-18ee-4902-a4ea-0bcc608ea729" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" sign="-">4.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other permanent differences</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9d17894-f153-45b2-9855-780ba010d33c" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de0da4f7-4d2c-4b64-a134-e77beab04c95" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="3" sign="-">0.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fea1ccd-d9a2-41fb-af05-e8f5e4794e16" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="3" sign="-">0.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 162(m) limitation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68e3f21c-2e41-476d-acda-75b7345f4852" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="idya:EffectiveIncomeTaxRateReconciliationSection162MLimitation" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af909175-adb1-4953-b0a8-9b171cfb2b93" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="idya:EffectiveIncomeTaxRateReconciliationSection162MLimitation" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08e1e547-db51-4525-b6e2-ece58f506a22" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="idya:EffectiveIncomeTaxRateReconciliationSection162MLimitation" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70a1fc20-1935-4045-be60-61880f4f7f78" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3">0.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a295e37-aa12-4b96-a52a-900652704334" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3">0.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_896b58d9-6b7e-40c9-b2b6-54c9328acf07" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3">0.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2c62cb67-2f87-42a1-9996-d4658c326936" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The tax effects of temporary differences and carryforwards of the deferred tax assets are presented below (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:60.328%;box-sizing:content-box;"/>
        <td style="width:1.82%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.017%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.82%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.017%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bf6760a-a686-4d7b-a012-e15d9756781e" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,524</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_580bc05f-d8d9-4e3e-8c5e-0d79f223f77c" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,717</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credit carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_477428d7-496a-4530-beee-54528dfb8b98" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,868</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a30f0ab0-0380-4265-b6c4-8cff71e26438" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,997</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d3f3da6-914a-4c4d-856e-4bd21da31e1f" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="idya:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,074</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f8bd430-896f-4157-854c-3acb46607e20" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="idya:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">610</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9be1ade3-775a-43aa-99de-276a90c6a68c" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,365</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e270526-44c3-43a6-9461-4ac54222de19" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,096</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55fe3568-2c8e-4ddc-a39c-14fbbb52b762" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,401</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c40291d-fb26-4055-973f-db9da4fea2bd" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,593</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b782ce1-15e7-4ff5-a359-00d8b5ee9fd5" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,468</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_007a2159-f222-4506-8c58-ca8d68dd1c57" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,257</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research &amp; development expenditures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1efe972-1406-4e15-aaf8-ea44586f1627" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,271</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f45f74a-51fb-4e34-8fe3-feedf42aa2ec" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,267</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_421c6e15-91b1-4386-8eed-9342d46e81fa" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">168,971</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe56f997-d999-4242-8cc1-6be7cd02025c" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,537</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd647a38-b587-4b61-870b-b5e0bb661fab" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164,876</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52401a10-8aac-48f2-bbc5-caada2ccb2f3" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,888</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b402c2d-7b7f-4847-9246-16704003477f" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,095</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e00132a0-850b-4f17-857c-8268d3df0f82" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">649</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b14d4f87-4ff4-4cf3-b936-439a31532e3c" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="idya:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,990</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60d84e4b-5001-4845-a533-97d2ea0468e9" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="idya:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">477</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b71fd086-c90d-47e2-a324-b792477dbe61" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aecc9063-6c9c-4094-b53f-8e67d8acd1a6" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d312ea2-fa90-4e4b-b689-db67ea7e4089" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d92c7d0-fca4-44c4-9b71-75aeffe4f91d" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_2fee3df8-0f05-47d8-84a0-927901a23918_1"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on the Company&#8217;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#8217;s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b67ca9c-e692-435d-8e03-f2f28165ecdf" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">69.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_449a929f-8cad-4f74-9ef1-047af1c5ef26" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">32.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bbb70e3-7935-456d-bfb2-b76414b837f5" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during 2024, 2023, and 2022, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_d78ef02c-6eb4-4c25-ba32-e2416fd87c3d" contextRef="C_9f7c598b-0376-4cd2-bb63-5b1ddcee4a82" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">147.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e4d9206-14a0-472e-b75d-83ed02bc55ec" contextRef="C_22bc9e4b-b2f2-40b0-b055-d6de85aad84e" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">135.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million available to reduce future taxable income, if any, for federal income tax purposes as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023, respectively. The Company had net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87e92b05-245a-4c5a-99db-06cf7f685438" contextRef="C_bf017758-6c8e-4dda-9992-6c460c60b3fe" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5">93.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37733c58-537b-4f4f-8b81-29be57b8de42" contextRef="C_364b5f8f-7b5f-4a54-aaa4-7b2b4312be72" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5">89.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million available to reduce future taxable income, if any, for state income tax purposes. If not utilized, the federal carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66227a45-d724-43b0-bdd7-bccb720e8fcf" contextRef="C_9f7c598b-0376-4cd2-bb63-5b1ddcee4a82" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5">11.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the state carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be23f1e5-d415-419a-affa-e0538ab913d1" contextRef="C_bf017758-6c8e-4dda-9992-6c460c60b3fe" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">93.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_71acabec-2863-49c0-b01d-020706cd4a4f" contextRef="C_10ae45c4-8dc3-46cf-ab6d-19afaee6b186" name="idya:TaxCreditCarryForwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9dd0b4bf-7234-47bb-aab7-f1d424d3c4f8" contextRef="C_364d998d-4e55-404f-9c33-0ee5538a29c1" name="idya:TaxCreditCarryForwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2036</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. The federal net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_3c4837a3-fe13-4651-b6b4-0877284cb8e3" contextRef="C_9f7c598b-0376-4cd2-bb63-5b1ddcee4a82" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5">135.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million arising after December 31, 2017 do not expire.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also had federal and state research and development credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07285f70-6bc3-4fd1-8d98-261c2c59b204" contextRef="C_9f7c598b-0376-4cd2-bb63-5b1ddcee4a82" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5">19.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e3bc040-2c70-4572-8984-0d1da0d2dfc5" contextRef="C_bf017758-6c8e-4dda-9992-6c460c60b3fe" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5">10.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_713df2af-775c-4b8b-bba1-0f8bd4d2d3a6" contextRef="C_22bc9e4b-b2f2-40b0-b055-d6de85aad84e" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5">12.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b9ec81f-d515-40e3-9d0d-ac81a6edddf6" contextRef="C_364b5f8f-7b5f-4a54-aaa4-7b2b4312be72" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5">6.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023, respectively. The Company had Orphan Drug Credits (&#8220;ODC&#8221;), related to the orphan drug designation of darovasertib in 2022, of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97877b6d-184b-4648-bc3b-e896b92abd90" contextRef="C_2dd15ed5-ab2a-4718-85b6-49aa0ce8c31a" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f24bef27-c2f7-4bcc-9cd0-5f6edba7b392" contextRef="C_a46184c7-01af-47bf-9f47-d0c0ccee58f3" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. The federal credits will expire starting in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d26a20f9-ec8f-44bb-b496-f1e13539532f" contextRef="C_10ae45c4-8dc3-46cf-ab6d-19afaee6b186" name="idya:TaxCreditCarryForwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if not utilized, and the state research credit can be carried forward indefinitely.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Tax Reform Act of 1986 limits the use of net operating loss carryforwards in certain situations where changes occur in the stock ownership of a company. The annual limitation may result in the expiration of net operating losses and credits before utilization. The Company performed a Section 382 analysis through December 31, 2024. The Company has not experienced ownership changes in the current year. Subsequent ownership changes may affect the limitation in future years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Related to unrecognized tax benefits noted below, the Company accrued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fa9d511-9007-477c-80d4-5107bdc17c1d" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7d8ac238-5f6d-4c2f-a880-e4bf8814ffb0" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3af41468-7898-4a99-86d9-6e458814c5ed" contextRef="C_ce651b87-a2ee-4952-8dab-aa55bb0ac861" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> penalties or interest during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, December 31, 2023 and December 31, 2022. The Company does not expect its unrecognized tax benefit balance to change materially over the next 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf85dece-ba9b-4c83-ba20-09cff2027110" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3550319e-8f7b-453a-9130-0345114f850a" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5">3.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized tax benefits as of December 31, 2024 and December 31, 2023, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd3d3840-2ed5-40ee-b93c-ada321a04a5c" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits (in thousands).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:72.675%;box-sizing:content-box;"/>
        <td style="width:2.501%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:22.825%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance as of January 1, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef809957-15ef-4d63-abf0-95e47e792c34" contextRef="C_ce651b87-a2ee-4952-8dab-aa55bb0ac861" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,962</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase related to prior year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20c4c2fd-c81b-4435-a9cd-eddd914eec32" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">372</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7fb1fee-7bbf-4d06-b543-58c1c06ad929" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,488</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43956ef2-5591-453d-bc15-eb8d9717ce1c" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,822</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Decrease related to prior year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6910e84e-45f0-4951-9fd4-09df2b06f6c1" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72c568dc-54a3-4b14-936c-093e068bb49e" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,290</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d2a82bc-43b4-4cb8-a4f7-5857d923ce7e" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,927</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company files income tax returns in the U.S. federal jurisdiction and in the states of Arizona, California, New Jersey, North Carolina, Pennsylvania, Texas, Utah and Wisconsin. For jurisdictions in which tax filings have been filed, all tax years remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any net operating losses or credits.</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is under audit in California for tax years </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_338a4ed1-99c5-4700-8268-537e20e71a59;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2020-2021</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_5efa5253-11ea-4f3b-af26-dd73779a5560" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_5efa5253-11ea-4f3b-af26-dd73779a5560_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company&#8217;s certificate of incorporation authorized the Company to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb110e91-c6a6-4ddd-a3d8-5a57f3d4f8c4" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3648c1c8-2bd3-47da-a307-f3dff849d39a" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">300,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8915f7c2-9703-4c16-823a-6571528d7df2" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_28dda432-ae8e-4a63-8a54-174d1466139d" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_430e32ab-0272-4d09-b66f-bf2cbaf4c424" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:CommonStockVotingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each share of common stock is entitled to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e4782ba-0075-4e17-850c-00e4b1017686" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="idya:NumberOfCommonStockVotingRightsHeldPerShare" unitRef="U_Vote" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vote.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Company&#8217;s board of directors. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0abbc197-b6e1-44b3-b5cb-fd189ef40ef8" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:DividendsCommonStock" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> dividends have been declared to date.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 11, 2024, the Company completed an underwritten public follow-on offering. The offering consisted of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7d6f498-9211-48db-a6a4-df50fee5c9c3" contextRef="C_9c02d070-8681-4a68-9460-90f6386b903f" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,355,714</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at an offering price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8155150-ebf6-4ad4-9796-d405c74fc3a1" contextRef="C_9e083923-3902-4bc7-aab2-a290354677b9" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">35.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bb1b836-bcf4-4f04-bb50-b4ec0effc421" contextRef="C_63980d6b-b6c2-4f34-9482-a0495f116793" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,127,142</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbe31618-8e6a-440a-b406-c46cc6ce1258" contextRef="C_5b17504e-2e08-477e-af4e-e1ad86f5b6e1" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">285,715</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c18cd204-0107-4060-90fe-79f55c6ced10" contextRef="C_5b17504e-2e08-477e-af4e-e1ad86f5b6e1" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">34.9999</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, the Company received aggregate gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58c9e980-6866-4f8c-b6fa-d7761c445752" contextRef="C_a6b8d688-85fc-4f28-b94d-adbdcc815d1b" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">302.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d86ac40e-5367-488b-a2dc-d5f1673136e8" contextRef="C_a6b8d688-85fc-4f28-b94d-adbdcc815d1b" name="idya:NetProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">283.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 27, 2023, the Company completed an underwritten public follow-on offering. The offering consisted of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22688874-155a-45ea-a42c-78edfdff8bfc" contextRef="C_e4f99219-ed58-4929-87e5-a993db32910d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,797,872</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at an offering price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f81ffc01-c281-4f7d-97df-075325018e5e" contextRef="C_d4a29fc9-5039-4781-aa51-00d8294b4d29" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">23.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05f7c63e-c292-4ed6-b115-314c4c56069c" contextRef="C_4a13cb3d-0ae0-44c8-9454-9eb34da39ecb" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">797,872</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d762d65-b761-4abb-adb9-8fafb81bae56" contextRef="C_17c6d71a-63e2-457f-a633-102c0bde4eb4" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">319,150</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27f7ca65-610d-4c40-8bc5-4cb899dc97cf" contextRef="C_17c6d71a-63e2-457f-a633-102c0bde4eb4" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">23.4999</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, the Company received aggregate gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3675798-5528-4f56-ba91-cdd92c7298d1" contextRef="C_e56ae803-71fa-40b1-b315-c44f63fe65d8" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">143.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24b5a4fc-31ec-4f37-82cf-f1b9f33e1b4e" contextRef="C_e56ae803-71fa-40b1-b315-c44f63fe65d8" name="idya:NetProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">134.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering expenses.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 27, 2023, the Company completed an underwritten public follow-on offering. The offering consisted of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cab3c7c-849d-4151-ac80-8f4611ae9264" contextRef="C_07e35c69-dfae-4e28-83b9-c956215e0274" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,858,121</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at an offering price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d413959-68d3-4634-abb1-8a859707951c" contextRef="C_7bcd1912-41e8-4474-944c-32f938bcc64c" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">18.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_720b8ea3-9ef2-4b32-9193-8e3821b11414" contextRef="C_e6119aea-4ad7-47ff-8b8a-db55f4f12c97" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,418,920</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_445807f1-d1e2-46a3-b051-ad42c2c3cd90" contextRef="C_d400c976-b0bd-479d-aa74-c54c3f83c119" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,020,270</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74ef83cc-bbfa-40a5-9490-907020ad6eb1" contextRef="C_d400c976-b0bd-479d-aa74-c54c3f83c119" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">18.4999</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, the Company received aggregate gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3589f9c2-7538-4a86-b45f-3bcd98792cfd" contextRef="C_7997c4a8-f7da-4956-8da0-38a0332faec7" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">201.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c1bfec3-2bef-4296-bcb1-948e4763b85b" contextRef="C_7997c4a8-f7da-4956-8da0-38a0332faec7" name="idya:NetProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">188.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering expenses.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_67545a54-d34a-4308-90df-f3edefc153e1" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" escape="true" continuedAt="F_67545a54-d34a-4308-90df-f3edefc153e1_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, the following aggregate warrants to purchase shares of the Company&#8217;s common stock were issued and outstanding:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:22.324%;box-sizing:content-box;"/>
        <td style="width:2.521%;box-sizing:content-box;"/>
        <td style="width:21.904%;box-sizing:content-box;"/>
        <td style="width:3.161%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:17.363%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:26.465%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Issue Date</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Expiration Date</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise Price per Share</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Shares subject to Outstanding Warrants</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><ix:nonNumeric id="F_b6d9ca13-abf9-4eca-b264-bc843d28eed2" contextRef="C_bb829766-4720-419f-b5f8-c1559b6f88fb" name="idya:ClassOfWarrantOrRightsIssueDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">July 11, 2024</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">None</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38554083-55fd-4ca7-8d1b-3aaca26c4d2d" contextRef="C_69622302-21de-4f4c-a022-d0681d928a7a" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_533f9b09-c9a9-410b-97ba-e0911b5b2ddc" contextRef="C_69622302-21de-4f4c-a022-d0681d928a7a" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">285,715</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><ix:nonNumeric id="F_df7fef88-c00b-482b-941c-ece1fd5a7fb1" contextRef="C_1d6fd8be-e5c3-430b-802a-c42663370c20" name="idya:ClassOfWarrantOrRightsIssueDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 27, 2023</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">None</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bd08f36-8050-4d2f-81e7-0ea5400df5d1" contextRef="C_fa12496f-6344-415f-a910-de2c2bf8a71f" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d5838cd-a071-45d1-b2e3-18666302f54d" contextRef="C_fa12496f-6344-415f-a910-de2c2bf8a71f" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">319,150</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><ix:nonNumeric id="F_917aae1f-a632-4b1b-a88d-ab16ecef40b5" contextRef="C_650406b3-09c1-4d06-8663-ecb638592c77" name="idya:ClassOfWarrantOrRightsIssueDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 27, 2023</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">None</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e479c294-d497-4769-a219-7cad3acb678a" contextRef="C_5855cfe6-054d-4ae0-825a-83a7de5b18e1" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e453748-e511-43ad-93eb-404fa56268cb" contextRef="C_5855cfe6-054d-4ae0-825a-83a7de5b18e1" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">270,270</ix:nonFraction></span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_5efa5253-11ea-4f3b-af26-dd73779a5560_1"><div><ix:continuation id="F_67545a54-d34a-4308-90df-f3edefc153e1_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) In September 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_605c1290-0c25-41c4-8865-bbc5d952fd04" contextRef="C_0178d793-324f-4f5d-8dfc-49181bd85b1e" name="idya:CommonStockSubjectToOutstandingPreFundedWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,750,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock subject to outstanding pre-funded warrants were cashless exercised and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2da8a04-9f80-4c8a-ad20-f00bbfdcb4af" contextRef="C_3a8b018a-8ca5-43cb-9db1-a7f041be1845" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,749,993</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were issued.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The warrants are classified as a component of Stockholders&#8217; Equity within Additional Paid-in-Capital. The warrants are classified as equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, are indexed to the Company&#8217;s common stock and meet the equity classification criteria. The warrants will not expire until they are fully exercised.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ff4548ba-4d07-4a33-8e8f-345d2bf294a6" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="idya:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" escape="true" continuedAt="F_ff4548ba-4d07-4a33-8e8f-345d2bf294a6_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had reserved common stock for future issuance as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.673%;box-sizing:content-box;"/>
        <td style="width:1.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.403%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.26%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.403%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of outstanding options under the 2015, 2019 and 2023 Plans</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cfc81ca-05f8-4d39-bbb8-3e7f2ea0e795" contextRef="C_a6ac4859-4009-41b4-9008-d4385ab189d1" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,737,595</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_772cf725-bb47-4bac-b915-ee835b371727" contextRef="C_528a15eb-04d7-4a77-882c-7e2e6baa5a16" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,269,975</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for grant under the 2019 Plan</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfcf3ff4-2882-4590-986e-9babd23be39f" contextRef="C_2a9cefda-dc1e-448e-84a6-0e063d36ae4d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,910,589</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_412c4e69-cdbe-47d2-b58f-5d096fa5e5bc" contextRef="C_cbbfcaff-64c2-4dd6-8836-3121afdff880" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">964,622</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for grant under the 2023 Inducement Plan</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e31e0c78-8065-4081-b3a4-a8cffe571749" contextRef="C_15e27b17-950f-4151-a11c-4aba882b2d8a" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">593,592</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df461a58-eb8e-490d-8c01-82e0c614556d" contextRef="C_6814219a-6bb3-46e5-9d9a-753145524259" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">524,300</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available under the Employee Stock Purchase Plan</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b5881db-4f1f-4bd2-a7c9-25130ea416e2" contextRef="C_2c520ba2-7d16-4246-9088-3fdbb269e8a6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,911,011</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe8c5e55-03e8-4522-b6a6-a75f01995808" contextRef="C_f02efd60-1311-4d54-8d9c-b1359814dbc8" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,317,974</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants issued and outstanding</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_538554b7-cf98-495a-a50e-19610bc93a7b" contextRef="C_ecf66199-2c61-4da1-b565-ea15c7525705" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">875,135</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e30759e-6073-4aae-9e35-a852cd7c5cef" contextRef="C_fe0af623-ced9-4295-b11c-a7901893dc7c" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,339,420</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b835426-5660-44a5-bf90-fcec54e8027b" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,027,922</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91261ec3-a654-476d-9551-2e8c784b51ed" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,416,291</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <div><ix:continuation id="F_ff4548ba-4d07-4a33-8e8f-345d2bf294a6_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_c27df491-c8c9-427f-9468-c12f740b982b" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_c27df491-c8c9-427f-9468-c12f740b982b_1"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2023 Inducement Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 24, 2023, the Company adopted the IDEAYA Biosciences, Inc. 2023 Employment Inducement Award Plan (the &#8220;2023 Inducement Plan&#8221;), pursuant to which the Company reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81140a40-7e13-44bb-9e6d-afb20a531bbc" contextRef="C_0f9012d2-5d2a-4197-80a8-0c4c3a822d34" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company as an inducement material to the individual&#8217;s entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The 2023 Inducement Plan was approved by the Company&#8217;s board of directors without stockholder approval in accordance with such rule. Options granted under the 2023 Inducement Plan have a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_99029a07-856c-4ee9-aed1-c966a82afb65" contextRef="C_907e44ce-49c7-48a8-8a1c-69ad47564e17" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and generally vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12bc15f3-64ab-43e9-b18d-773dbedb6bae" contextRef="C_907e44ce-49c7-48a8-8a1c-69ad47564e17" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year period with </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_beb188b6-508d-4b4b-9e16-f15afb779aab" contextRef="C_bfa82174-2a92-4b37-a2b1-ccf30e752c5b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year cliff vesting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 25, 2024, the Company amended the 2023 Employment Inducement Award Plan, increasing the number of shares available for issuance by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f53a13f8-fe85-416e-b925-4fb04f196515" contextRef="C_9c98a97a-3cca-48ab-963f-645540e482b5" name="idya:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the number of shares available for issuance under the 2023 Inducement Plan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5dfec47c-e40c-496b-90ed-9979afc39642" contextRef="C_49528f5e-068e-48f2-8643-656de2cfb1fd" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">593,592</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2019 Incentive Award Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2019, the Company&#8217;s board of directors adopted and the Company&#8217;s stockholders approved the 2019 Incentive Award Plan (the &#8220;2019 Plan&#8221;), under which the Company may grant cash and equity-based incentive awards to the Company&#8217;s employees, consultants and directors. Following the effectiveness of the 2019 Plan, the Company will not make any further grants under the 2015 Equity Incentive Plan (the &#8220;2015 Plan&#8221;). However, the 2015 Plan continues to govern the terms and conditions of the outstanding awards granted under it. Shares of common stock subject to awards granted under the 2015 Plan that are forfeited or lapse unexercised and which following the effective date of the 2019 Plan are not issued under the 2015 Plan will be available for issuance under the 2019 Plan.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options granted under the 2019 Plan may be either incentive stock options (&#8220;ISOs&#8221;) or nonqualified stock options (&#8220;NSOs&#8221;). ISOs may be granted only to Company employees (including officers and directors who are also employees). NSOs may be granted to Company employees, directors and consultants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2019 Plan is subject to an annual increase on the first day of each year beginning in 2020 and ending in 2029, equal to the lesser of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66fc1fa0-4616-47ee-b0e7-d435c5bcabf2" contextRef="C_a2a77a38-375b-46dc-9258-d476935d3c33" name="idya:ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the shares outstanding on the last day of the immediately preceding fiscal year, and such smaller number of shares as determined by the Company&#8217;s board of directors. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_941dc3c8-bcbc-45a3-8ba3-b225cc5f7b86" contextRef="C_93b03c8e-0f95-4d58-98e5-1b1e2a78067e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options granted under the 2019 Plan have a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f5966889-e31e-4d8c-a58f-e924b25e5286" contextRef="C_93b03c8e-0f95-4d58-98e5-1b1e2a78067e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years (or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9e4b5000-84b3-4eca-9544-68d240158ea0" contextRef="C_cec1db68-704c-4a32-8899-82a806f8d2c7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if granted to a 10% stockholder) and generally vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_75210e08-9ef3-42e5-b5a1-eeb33d2dbd5d" contextRef="C_93b03c8e-0f95-4d58-98e5-1b1e2a78067e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year period with </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_46bf4225-9ff0-417e-83b1-489c98f446d7" contextRef="C_9597b477-72d9-47f9-a2b7-c96116c45490" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year cliff vesting.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the number of shares available for issuance under the 2019 Plan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30728ae9-5118-4433-9778-d1160866c75d" contextRef="C_5d624162-e14b-4855-a956-1c0a4448424b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,910,589</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_c27df491-c8c9-427f-9468-c12f740b982b_1" continuedAt="F_c27df491-c8c9-427f-9468-c12f740b982b_2"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2015 Equity Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2015, the Company established its 2015 Plan which provides for the granting of stock options to employees, directors and consultants of the Company. Options granted under the 2015 Plan may be either ISOs or NSOs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2019 Employee Stock Purchase Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2019, the Company&#8217;s board of directors adopted and the Company&#8217;s stockholders approved the 2019 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP provides eligible employees with the opportunity to acquire an ownership interest in the Company through periodic payroll deductions up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57653990-08c1-4bdd-9325-8e8b352f937a" contextRef="C_2f75efad-f0a6-4830-98d3-294b93ab7d63" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of eligible compensation. The offering period is determined by the Company in its discretion but may not exceed </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_55e16302-19de-4468-8d05-216af860f5ae" contextRef="C_d0071ee7-da0d-4c80-b8f6-5f69ef5e6bea" name="idya:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months. The per-share purchase price on the applicable exercise date for an offering period is equal to the lesser of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b33d8a76-4118-422d-92a2-a32726a1f664" contextRef="C_38305cf8-eda8-4b97-a281-f86a6e1d392c" name="idya:ESPPDiscountedPurchasePricePercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the fair market value of the common stock at either the first business day or last business day of the offering period, provided that no more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b86621e-218b-4c45-9754-39a58155b90a" contextRef="C_38305cf8-eda8-4b97-a281-f86a6e1d392c" name="idya:ESPPMaximumSharesPurchasablePerPeriodPerEmployee" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock may be purchased by any one employee during each offering period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ESPP is intended to constitute an &#8220;employee stock purchase plan&#8221; under Section 423(b) of the Internal Revenue Code of 1986, as amended. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd41d27b-0bbe-4ee2-a4cc-2f0cd6f559bd" contextRef="C_a702b98c-ab89-4793-9842-f4bec0373771" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">195,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were initially reserved for issuance under the ESPP, subject to an annual increase on January 1 of each year, beginning on January 1, 2020, equal to the lesser of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d8365b4-e048-41e6-b14f-423e7deae78e" contextRef="C_569cd832-f7fb-45d7-b394-66e1bc0a4298" name="idya:ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the shares outstanding on the last day of the immediately preceding fiscal year and such smaller number of shares as may be determined by the Company&#8217;s board of directors, provided, however, that no more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d8e04b9-b5b7-47f0-ae27-49c68cde9665" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="idya:MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,500,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares may be issued under the ESPP.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the number of shares available for issuance under the ESPP was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd977400-c4f4-4a62-8f21-547fe90c4272" contextRef="C_2f75efad-f0a6-4830-98d3-294b93ab7d63" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,911,011</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For the years ended December 31, 2024, 2023, and 2022 the Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fe8d4f2-c276-4d6a-99b6-4277a4b254fe" contextRef="C_d0071ee7-da0d-4c80-b8f6-5f69ef5e6bea" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd192c31-7d86-47d1-91e6-4b2f59ba8d21" contextRef="C_5c35883b-fbec-4b73-845e-1e70a57f9790" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d4a5c15-e5af-4c5d-b3a8-469bf88c25fc" contextRef="C_1fa75d5d-f291-49dc-801d-19a66aa48744" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million respectively, of compensation expense related to employee participation in the ESPP.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f58d3033-1942-4461-a567-bce0af981c3a" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense recorded related to awards granted to employees and non-employees was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.642%;box-sizing:content-box;"/>
        <td style="width:1.619%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.834%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.619%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.834%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.619%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.834%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a391ac6d-17e3-4bfa-80b0-9d8b83b0a616" contextRef="C_78c6497a-ce12-4868-8a73-d11183d394be" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,115</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15d8d68e-e645-4530-a40c-aa6b0beda73b" contextRef="C_b6a91b55-3856-4d3e-9d9b-637a1fc4e083" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,826</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4fea05a-ce75-45a0-a766-1431da4b651e" contextRef="C_8f3cffd2-a88d-4fe5-892e-4adcc9f5604d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,050</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d4dfc9d-7236-4733-892c-62e335ab4d53" contextRef="C_1b2706bd-6978-4079-8e5c-6be28981766b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,631</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0bc778d-1ba3-4f7f-84b9-15d9eed511fb" contextRef="C_a7f64497-48a3-44cb-b7f9-5fe1d8d9ba6e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,663</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05d98571-0baf-4855-a925-710b53eaa16c" contextRef="C_a08caba6-5fab-4b48-87ef-fe485515b9e7" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,579</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df0a8190-8bf9-44f6-a6a6-fa741289d947" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,746</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c5c60cb-4422-481c-bbf8-4d07869a1c7c" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,489</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_816c21c4-7915-4bff-aab1-e5b612674112" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,629</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Arial;"><ix:nonNumeric id="F_c38713c1-03ac-4080-ab09-5e3fdfe1140e" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Activity under the Company&#8217;s 2015 and 2019 Plans and 2023 Inducement Plan is set forth below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:37.6%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.68%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.68%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate    <br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance, January 1, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18eb1b36-9b6e-49ef-9ae7-c978dfd29dd0" contextRef="C_4b10675f-0784-4fa3-8f18-4c914a58c0d5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,269,975</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e0ee23b-b961-479d-97f2-0918f22f922e" contextRef="C_4b10675f-0784-4fa3-8f18-4c914a58c0d5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">15.53</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><ix:nonNumeric id="F_624d83a1-f458-4e69-96e9-097f9901cc69" contextRef="C_21d37c85-a2fd-4198-8e25-eada4c1b7d75" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.82</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb1ecd74-e642-48f2-ab6f-1732d4acb0ef" contextRef="C_4b10675f-0784-4fa3-8f18-4c914a58c0d5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-1">128.49</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04f10dc3-7fb8-4b84-9601-973f0054e9a5" contextRef="C_55abfe7d-fa2b-408a-b618-f79551bab538" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,247,538</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04d9d257-dfd1-44d1-a909-0c62c56c5fb2" contextRef="C_55abfe7d-fa2b-408a-b618-f79551bab538" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">41.88</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fc3d063-3f25-4e97-96b2-d1cdc853713e" contextRef="C_55abfe7d-fa2b-408a-b618-f79551bab538" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,118,695</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da8a2c41-697b-498f-9767-09d30317c84a" contextRef="C_55abfe7d-fa2b-408a-b618-f79551bab538" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.16</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options canceled</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ed826dc-bcdd-4771-bf8a-035139c6fd8f" contextRef="C_55abfe7d-fa2b-408a-b618-f79551bab538" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">661,223</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da6dd12f-a96f-4a28-b38f-26981d8b0801" contextRef="C_55abfe7d-fa2b-408a-b618-f79551bab538" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">29.57</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance, December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1cd689b-fe6e-4232-a56b-e185fa6e79c9" contextRef="C_ddead929-9307-4f06-a8f6-718bdcb2cf0c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,737,595</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6baa338-e81a-432d-bb31-a8d0ddfde769" contextRef="C_ddead929-9307-4f06-a8f6-718bdcb2cf0c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">26.06</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><ix:nonNumeric id="F_12ff022c-fe5d-4961-942c-d19f84ae5516" contextRef="C_55abfe7d-fa2b-408a-b618-f79551bab538" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.89</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40fd4290-5b26-4bc2-bf1f-5232699a865c" contextRef="C_ddead929-9307-4f06-a8f6-718bdcb2cf0c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-1" format="ixt:num-dot-decimal">43.01</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercisable as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84dea0ea-4d98-4577-a1b7-75f108aac43f" contextRef="C_ddead929-9307-4f06-a8f6-718bdcb2cf0c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,185,690</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d82e30f8-04c5-491b-bb0c-810d136b41d9" contextRef="C_ddead929-9307-4f06-a8f6-718bdcb2cf0c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.63</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><ix:nonNumeric id="F_9cfc0fcd-5ae7-4364-a725-d98dcf40f5d0" contextRef="C_55abfe7d-fa2b-408a-b618-f79551bab538" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.62</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8f42a0b-841a-4ea1-99e9-10b9969ffe4c" contextRef="C_ddead929-9307-4f06-a8f6-718bdcb2cf0c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-1" format="ixt:num-dot-decimal">31.04</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vested and expected to vest as of<br/>&#160;&#160;&#160;December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db1b95c2-97a1-4697-a5ba-21878210fabd" contextRef="C_ddead929-9307-4f06-a8f6-718bdcb2cf0c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,737,595</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e464b65-0f79-4090-9fee-616d2910c4f7" contextRef="C_ddead929-9307-4f06-a8f6-718bdcb2cf0c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">26.06</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><ix:nonNumeric id="F_c57af64b-5e92-47db-85ed-3f1693fc535b" contextRef="C_55abfe7d-fa2b-408a-b618-f79551bab538" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.89</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3983e64-844b-4ce1-8061-5b93361d89f3" contextRef="C_ddead929-9307-4f06-a8f6-718bdcb2cf0c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-1" format="ixt:num-dot-decimal">43.01</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_c27df491-c8c9-427f-9468-c12f740b982b_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant-date fair value of options granted during the years ended December 31, 2024, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6e0913b-bfa9-4a42-a0aa-9e08617f0e08" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">29.93</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd09f81d-da43-4102-a6ac-b603a60d27f1" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">13.98</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28b3587a-55a9-44ea-8d40-41a37dbd1019" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively. The aggregate intrinsic value of options exercised for the years ended December 31, 2024, 2023, 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e8599bf-80e9-49c0-89d7-c81e6a7e296e" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">32.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_425c0e77-22b4-455b-b7da-b19493542dc4" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cf45095-068d-4a66-aa76-1742dab9de5c" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. Intrinsic values are calculated as the difference between the exercise price of the underlying options and the fair value of the common stock on the date of exercise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and December 31, 2023, the total unrecognized stock-based compensation expense for stock options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7d54c24-7863-4c1d-bd73-7e7f243dad12" contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">90.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4af6d59-4e1c-48c3-a33f-9d8abba2b7b5" contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">41.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58d8ccd1-1e5f-44f8-82ca-defe099955a8" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.63</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5650d4b0-2161-48e6-80c5-86e70c674e5a" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.59</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Black-Scholes Assumptions</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24650691-69b4-443c-a5fe-1cedef505c7b" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair values of options were calculated using the assumptions set forth below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:37.852%;box-sizing:content-box;"/>
        <td style="width:1.7%;box-sizing:content-box;"/>
        <td style="width:19.016%;box-sizing:content-box;"/>
        <td style="width:1.7%;box-sizing:content-box;"/>
        <td style="width:19.016%;box-sizing:content-box;"/>
        <td style="width:1.7%;box-sizing:content-box;"/>
        <td style="width:19.016%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><ix:nonNumeric id="F_255345f9-e94b-4959-964f-5504d142fffc" contextRef="C_97b79519-0af1-4cce-8a6d-7911a10985ed" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_3c26d0d0-3579-47da-8d5c-a5ea87dde343" contextRef="C_7a6bc497-f228-42bb-8d0a-1e9eedd0706f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><ix:nonNumeric id="F_2b057fc2-207b-4832-8895-31e1bb2e4db9" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><ix:nonNumeric id="F_a3f6f47e-a5da-4b8d-b608-9eeef24725bb" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb326032-8f5f-41b3-8c12-4c0aa8eb72e4" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">76.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99210ad7-7bdc-4cb7-be48-1c3577338fc6" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">81.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64a23747-5a12-4604-b9b4-4322b2df952a" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">81.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eec63890-d55e-4818-a7b5-7b3037f7e998" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">86.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d222937f-1b4b-4d71-a648-5634e6cefe3f" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">86.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e03a594a-29a7-42e7-9fcb-7c9a9446494b" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">89.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b0dbd7c-352e-4316-b03b-14b391d08297" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6dd8e6b3-d756-4aee-a528-a37f59db7bcc" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4433110f-3326-47ba-8279-8ddd9c337e6e" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb09d136-59a2-43f2-845f-82830f67f473" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f4d4f2e-6f01-4e98-9829-d69b1fce88d1" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5f89dc2-f719-4cf6-94a0-5213d2ee3802" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d8ca389-63f5-4ef2-9907-f129a755eb7f" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e73aa34-877c-4ace-9c7b-a29011fa145b" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45b088ce-7f6c-42ee-b13c-8da7d4f4e080" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The expected term represents the weighted-average period the stock options are expected to remain outstanding and is based on the options&#8217; vesting terms and contractual terms.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The expected volatility is based on the Company&#8217;s historical stock price volatility. The historical stock price volatility is calculated based on a period of time commensurate with the expected term assumption for each grant.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-Free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The risk-free rate assumption is based on U.S. Treasury instruments whose term was consistent with the expected term of the Company&#8217;s stock options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Dividend Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has not paid and does not anticipate paying any dividends in the near future. Accordingly, the Company has estimated the dividend yield to be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04c3e5ff-b7d2-4e87-83a1-2d54e9393743" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_6727c40e-7871-4bd9-8481-f197d8fa5773" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for forfeitures as they occur.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the Company&#8217;s common stock is determined based on the market price on the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_844c441e-d0df-47ff-ad62-6049ced8846c" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true" continuedAt="F_844c441e-d0df-47ff-ad62-6049ced8846c_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Significant Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">GSK Collaboration, Option and License Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2020, the Company entered into the Collaboration, Option and License Agreement (the &#8220;GSK Collaboration Agreement&#8221;), with an affiliate of GSK plc, GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED (&#8220;GSK&#8221;), pursuant to which the Company and GSK have entered into a collaboration for its synthetic lethality programs targeting MAT2A, Pol Theta and Werner Helicase (&#8220;WRN&#8221;). On July 27, 2020, the Company and GSK received Hart-Scott-Rodino Antitrust Improvements Act clearance, and the GSK Collaboration Agreement became effective.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the GSK Collaboration Agreement, GSK paid the Company $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c3e18ed-d7b4-4cfc-b2e5-a9211b3a4f91" contextRef="C_c78e44e9-bd4d-4c0a-9c26-f931942fb9cd" name="idya:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million on July 31, 2020. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, GSK has made aggregate payments in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5d99eb3-94ca-49b9-9719-d796ab928595" contextRef="C_d9ee7a65-84e7-461b-a9c8-917f6e54722e" name="idya:DevelopmentAndRegulatoryMilestonePaymentToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the achievement of certain development and regulatory milestones with respect to Pol Theta and WRN products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">GSK Collaboration - Pol Theta Program</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the GSK Collaboration Agreement, GSK holds a global, exclusive license to develop and commercialize Pol Theta products arising out of the Pol Theta program. The Company and GSK collaborated on preclinical research for the Pol</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_844c441e-d0df-47ff-ad62-6049ced8846c_1" continuedAt="F_844c441e-d0df-47ff-ad62-6049ced8846c_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Theta program, and GSK is leading clinical development for the Pol Theta program. GSK is responsible for all research and development costs for the Pol Theta program.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will be eligible to receive total development and regulatory milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8003a83a-d11e-4b99-a165-d76b4743b01a" contextRef="C_80a30d44-ed50-40c7-8625-d5e98146ade0" name="idya:DevelopmentAndRegulatoryMilestonePaymentToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">485.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, with respect to each Pol Theta product, including as applicable, for multiple Pol Theta products that target certain alternative protein domains or are based on alternative modalities. Additionally, the Company will be eligible to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1b38e9e-4b75-4d78-9f6a-91475ed30f53" contextRef="C_80a30d44-ed50-40c7-8625-d5e98146ade0" name="idya:CommercialMilestonePaymentToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">475.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of commercial milestones with respect to each Pol Theta product. The Company is also entitled to receive tiered royalties on global net sales of Pol Theta products by GSK, its affiliates and their sublicensees ranging from high single digit to sub-teen double-digit percentages, subject to certain customary reductions.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2022, the Company announced the nomination of a Pol Theta Helicase Inhibitor development candidate (&#8220;DC&#8221;), and in August 2022, the Company announced the achievement of an initial preclinical development milestone in connection with ongoing investigational new drug (&#8220;IND&#8221;)-enabling studies to support evaluation of Pol Theta Helicase Inhibitor DC, triggering a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e7d8264-36eb-4fbd-8cb2-b5bf2b702ba4" contextRef="C_f7b6061f-1a70-4f34-9ba6-8614c500e543" name="idya:MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment, which the Company received in October 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An IND was submitted and was cleared by the FDA in August 2023 to enable clinical evaluation in combination with niraparib, triggering a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f262b159-2c4c-4ba4-a984-4a93769ca1d7" contextRef="C_10a02746-ad3a-4e28-acc1-fe5727c8d092" name="idya:MilestonePaymentReceivedClinicalEvaluation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has the potential to achieve an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aff19281-239c-4c53-abb7-1b3008a302c1" contextRef="C_b89b606e-379c-490c-b2c7-22e9477ad049" name="idya:AdditionalPaymentOfDevelopmentMilestoneToAchieve" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone upon initiation of Phase 1 clinical dose expansion, as well as potential further aggregate late-stage development and regulatory milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f99dbab-3917-4ab6-845e-02f2bc24ff48" contextRef="C_bbfe6a5e-e0cb-482c-8581-bd5e60a751e6" name="idya:DevelopmentMilestonePaymentToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">465.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">GSK Collaboration - Werner Helicase Program</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the GSK Collaboration Agreement, GSK holds a global, exclusive license to develop and commercialize WRN products arising out of the WRN program. The Company and GSK are collaborating on ongoing preclinical research for the WRN program, and GSK will lead clinical development for the WRN program, with the Company responsible for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8519932-8b60-44d2-8b1a-5c112ece19c4" contextRef="C_28484219-22fe-452a-8a69-2ba6d3d5a00e" name="idya:DevelopmentCostsSharingPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and GSK responsible for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7dcc78b-0a07-47ba-b96c-286f5acfac1b" contextRef="C_ef94d34b-8101-44d9-aaaf-b044579ff409" name="idya:DevelopmentCostsSharingPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of such global research and development costs. The cost-sharing percentages will be adjusted based on the actual ratio of U.S. to global profits for WRN products, as measured three and six years after global commercial launch thereof.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will be eligible to receive total development milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b03eae25-d2f1-4ae8-8ce7-f614d486a976" contextRef="C_1b812d03-ff06-4951-b51d-8d95f0881594" name="idya:DevelopmentMilestonePaymentToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">485.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, with respect to each WRN product, including as applicable, for multiple WRN products that are based on alternative modalities. Additionally, the Company will be eligible to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9399999a-a141-491d-8ef7-1c1aeb997b8e" contextRef="C_1b812d03-ff06-4951-b51d-8d95f0881594" name="idya:CommercialMilestonePaymentToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">475.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of commercial milestones with respect to each WRN product. The Company will be entitled to receive </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fefae537-a83f-45ca-b3c6-41eeaa605e0e" contextRef="C_28484219-22fe-452a-8a69-2ba6d3d5a00e" name="idya:PercentageOfProfitShare" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of U.S. net profits and tiered royalties on global non-U.S. net sales of WRN products by GSK, its affiliates and their sublicensees ranging from high single digit to sub-teen double-digit percentages, subject to certain customary reductions. The Company will have a right to opt-out of the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_802eb252-cf44-456c-8ec4-4e24939e44bb" contextRef="C_28484219-22fe-452a-8a69-2ba6d3d5a00e" name="idya:PercentageOfProfitShare" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% U.S. net profit share and corresponding research and development cost share for the WRN program, and would be eligible to receive tiered royalties on U.S. net sales of WRN products by GSK, its affiliates and their sublicensees at the same royalty rates as for global non-U.S. net sales thereafter, with economic adjustments based on the stage of the WRN program at the time of opt-out.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, the Company earned a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80cd813e-ff9d-4092-afa4-f45d075578c4" contextRef="C_7bf84ed4-93bd-4eeb-804c-d7cf2b19b16a" name="idya:MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone from GSK in connection with IND-enabling studies for the Werner Helicase Inhibitor DC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, an IND was cleared by the FDA to enable clinical evaluation, triggering a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8f1d468-3459-44e0-aa61-28c3f11802c6" contextRef="C_274ca130-dad0-4940-9133-f4b57bf70ddb" name="idya:MilestonePaymentReceivedClinicalEvaluation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has the potential to earn up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ea88544-0268-41ed-a000-6b7524707fdc" contextRef="C_4e5c2597-3aa6-4e75-84f5-fcacb80ec75e" name="idya:EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone upon initiation of Phase 1 clinical dose expansion, as well as potential further aggregate late-stage development and regulatory milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19917227-f47b-454c-a1ab-e67a16e33c59" contextRef="C_5c3703b4-36c2-48ab-aecf-7f7732bf9bb6" name="idya:DevelopmentMilestonePaymentToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">465.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">GSK Collaboration - General</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the GSK Collaboration Agreement, subject to certain exceptions, the Company and GSK will not, directly or through third parties, develop or commercialize other products whose primary and intended mechanism of action is the modulation of WRN or Pol Theta for an agreed upon period of time. The Company and GSK have formed a joint steering committee, joint development committees, and joint commercialization committees responsible for coordinating all activities under the GSK Collaboration Agreement. Ownership of intellectual property developed under the GSK Collaboration Agreement is allocated between or shared by the parties depending on development and subject matter.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_844c441e-d0df-47ff-ad62-6049ced8846c_2" continuedAt="F_844c441e-d0df-47ff-ad62-6049ced8846c_3"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GSK&#8217;s royalty obligations continue with respect to each country and each product until the later of (i) the date on which such product is no longer covered by certain intellectual property rights in such country and (ii) the 10th anniversary of the first commercial sale of such product in such country.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each party has the right to sublicense its rights under the GSK Collaboration Agreement subject to certain conditions.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The GSK Collaboration Agreement will continue in effect on a product-by-product and country-by-country basis until the expiration of the obligation to make payments under the GSK Collaboration Agreement with respect to such product in each country, unless earlier terminated by either party pursuant to its terms. Either party may terminate the GSK Collaboration Agreement for the other party&#8217;s insolvency or certain uncured breaches. The Company may terminate the GSK Collaboration Agreement if GSK or any of its sublicensees or affiliates challenge certain patents of the Company. GSK may terminate the GSK Collaboration Agreement in its entirety or on a target-by-target basis upon </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b50c8ecf-ba75-42fc-bc84-2225cb7db106" contextRef="C_3ccc9e3e-a98d-4222-a5ff-8d2e28d0cadc" name="idya:NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90-day</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> notice to the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Novartis License Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2018, the Company entered into a License Agreement with Novartis to develop and commercialize Novartis&#8217; LXS196 (also known as IDE196), a Phase 1 PKC inhibitor, for the treatment of cancers having GNAQ and GNA11 mutations. The Company renamed Novartis&#8217; LXS196 oncology as IDE196, and which has a non-proprietary name of darovasertib. Under the license agreement, Novartis granted to the Company a worldwide, exclusive, sublicensable license to research, develop, manufacture, and commercialize certain defined compounds and products, including IDE196 and certain other PKC inhibitors, as well as companion diagnostic products, collectively referred to as the licensed products, for any purpose.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid Novartis an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bed24b04-64a5-4d50-b9f3-12724dea9086" contextRef="C_017e85c7-1596-4e8e-927b-df535668349a" name="idya:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5e357be-c470-40da-b8d9-5b85a382222a" contextRef="C_5eba0c16-aaa5-49a4-a81d-b173390ca4d4" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">263,615</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its Series B redeemable convertible preferred stock concurrently with the execution of the license agreement. Subject to completion of certain clinical and regulatory development milestones, the Company agreed to make milestone payments in the aggregate of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4ef4e61-9efe-4c11-8f41-53472322b616" contextRef="C_3fb19a67-7108-4959-9367-f31f87dee14d" name="idya:DevelopmentAndRegulatoryMilestonePaymentToBePaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and subject to achievement of certain commercial sales milestones, the Company agreed to make milestone payments in the aggregate of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70e1c525-ba7e-4da8-a253-58a1adb4a80f" contextRef="C_3fb19a67-7108-4959-9367-f31f87dee14d" name="idya:CertainCommercialSalesMilestonesPaymentToBePaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company also agreed to pay mid to high single-digit tiered royalty payments based on annual worldwide net sales of licensed products, payable on a licensed product-by-licensed product and country by country basis until the latest of the expiration of the last to expire exclusively licensed patent, the expiration of regulatory exclusivity, and the ten year anniversary of the first commercial sale of such product in such country. The royalty payments are subject to reductions for lack of patent coverage, loss of market exclusivity, and payment obligations for third-party licenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pfizer Clinical Trial Collaboration and Supply Agreements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2020, the Company entered into a Clinical Trial Collaboration and Supply Agreement with Pfizer, Inc. (as amended in September 2020, April 2021, September 2021 and May 2023 (the &#8220;Pfizer Agreement&#8221;). Pursuant to the Pfizer Agreement, Pfizer supplies the Company with their MEK inhibitor, binimetinib, and their cMET inhibitor, crizotinib, to evaluate combinations of darovasertib independently with each of the Pfizer compounds, in patients with tumors harboring activating GNAQ or GNA11 mutations. Under the Pfizer Agreement, the Company is the sponsor of the combination studies and will provide darovasertib and pay for the costs of the combination studies. Pfizer will provide binimetinib and crizotinib for use in the clinical trial at no cost to the Company. The Pfizer Agreement provides that the Company and Pfizer will jointly own clinical data generated from the clinical trial and will also jointly own inventions, if any, relating to the combined use of darovasertib and binimetinib, or independently, to the combined use of darovasertib and crizotinib. The Company and Pfizer have formed a joint development committee responsible for coordinating all regulatory and other activities under the agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2022, the Company and Pfizer entered into a Second Clinical Trial Collaboration and Supply Agreement (as amended in May 2023 (the &#8220;Second Pfizer Agreement&#8221;), pursuant to which the Company is evaluating darovasertib and crizotinib as a combination therapy in MUM in a planned Phase 2/3 potential registration-enabling clinical trial. Pursuant to the Second Pfizer Agreement, the Company is the sponsor of the combination trial and the Company will provide darovasertib and pay for the costs of the combination trial, and Pfizer will provide crizotinib for the planned combination trial at no cost to the Company for up to an agreed-upon number of MUM patients. The Company and Pfizer will jointly own clinical data from the planned combination trial and all inventions relating to the combined use of darovasertib and crizotinib. The Company and Pfizer have formed a joint development committee responsible for coordinating all regulatory and other activities under the Second Pfizer Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separately, in March 2022, the Company and Pfizer also entered into a Third Clinical Trial Collaboration and Supply Agreement (the &#8220;Third Pfizer Agreement&#8221;), pursuant to which the Company could, subject to preclinical validation and FDA feedback and guidance, evaluate darovasertib and crizotinib, as a combination therapy in cMET-driven tumors such as NSCLC and/or HCC in a Phase 1 clinical trial. Pursuant to the Third Pfizer Agreement, the Company was the sponsor of the planned combination trial, and the Company would provide darovasertib and pay for the costs of the combination trial. Pfizer would provide crizotinib for the planned combination trial at no cost to the Company. Pursuant to Amendment No. 1 to the Second Pfizer Agreement, as described below, the Company and Pfizer terminated the Third Pfizer Agreement.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_844c441e-d0df-47ff-ad62-6049ced8846c_3" continuedAt="F_844c441e-d0df-47ff-ad62-6049ced8846c_4"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2023, the Company continued its relationship with Pfizer by entering into Amendment No. 4 to the Pfizer Agreement relating to the supply of crizotinib in support of this Phase 2 clinical trial, pursuant to which Pfizer will continue to provide the Company with an additional defined quantity of crizotinib at no cost.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expanded its relationship with Pfizer in May 2023 under an Amendment No. 1 to the Second Pfizer Agreement to support the Phase 2/3 registrational trial to evaluate darovasertib and crizotinib as a combination therapy in MUM. Under the as-amended Second Pfizer Agreement, Pfizer will provide the Company with a first defined quantity of crizotinib at no cost, as well as an additional second defined quantity of crizotinib at a lump-sum cost. The Third Pfizer Agreement has been terminated by the Company and Pfizer under Amendment No. 1 to the Second Pfizer Agreement.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we entered into Amendment No. 5 to the Pfizer Agreement for the supply of crizotinib in the Phase 1/2 clinical trial for Pfizer to provide us a defined quantity of crizotinib at defined costs.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cancer Research UK and University of Manchester Exclusive Option and License Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2022, the Company exercised its option for an exclusive worldwide license covering a broad class of poly (ADP-ribose) glycohydrolase (&#8220;PARG&#8221;), inhibitors from Cancer Research Technology Ltd. (&#8220;CRT&#8221;), and the University of Manchester, and in connection therewith, paid a one-time option exercise fee of &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d7c7374-26e6-44a0-8afb-c8212b81d7ef" contextRef="C_7415a7a9-5eb5-4ea2-a045-27af19dae8bb" name="idya:PaymentOfOneTimeOptionExerciseFee" unitRef="U_GBP" decimals="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company will be obligated to make payments to CRT aggregating up to a total of &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f13c487a-e61d-499e-91a1-a39e9a1c43ce" contextRef="C_7415a7a9-5eb5-4ea2-a045-27af19dae8bb" name="idya:PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents" unitRef="U_GBP" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of specific development and regulatory approval events for development of a PARG inhibitor in oncologic diseases. The Company will also pay low single-digit tiered royalties, and potentially also sales-based milestones, to CRT based on net sales of licensed products. In addition, in the event the Company sublicenses the intellectual property, it will also be obligated to pay CRT a specified percentage of any sublicense revenue.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2023, the Company incurred an obligation to pay milestone payments in an aggregate amount of &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e7c8415-d3be-497b-921f-80b866481d1a" contextRef="C_20bb6b78-a1c7-4e02-a061-317ab08cbf4f" name="idya:MilestonePaymentsRelatingToFirstAndSecondTumorHistologies" unitRef="U_GBP" decimals="0" format="ixt:num-dot-decimal">750,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to CRT based upon the achievement of certain milestones relating to first and second tumor histologies in connection with the Phase 1 portion of the Phase 1/2 clinical trial in oncologic diseases.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will be obligated to make additional payments to CRT aggregating up to &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_161e2a25-227f-4c0d-9f38-a91141a51f56" contextRef="C_66c2d5d4-7a3c-49b2-bb70-145a6e9b9b23" name="idya:AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent" unitRef="U_GBP" scale="6" decimals="-4" format="ixt:num-dot-decimal">18.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of specific development and regulatory approval events for development of a PARG inhibitor in oncologic diseases, including an aggregate of up to &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_925843f1-6f81-4cce-a1e2-4c4dfe63ccc8" contextRef="C_66c2d5d4-7a3c-49b2-bb70-145a6e9b9b23" name="idya:DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies" unitRef="U_GBP" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and up to &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed855863-8f3b-4bde-bc3f-1050ebee99eb" contextRef="C_66c2d5d4-7a3c-49b2-bb70-145a6e9b9b23" name="idya:DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies" unitRef="U_GBP" scale="0" decimals="2" format="ixt:num-dot-decimal">2.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the achievement of certain Phase 2 and Phase 3 development milestones, respectively, in each case as relating to first and second tumor histologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amgen Clinical Trial Collaboration and Supply Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2022, the Company entered into a Clinical Trial Collaboration and Supply Agreement with Amgen Inc.(the &#8220;Amgen CTCSA&#8221;), to clinically evaluate IDE397 in combination with AMG 193, the Amgen investigational MTA-cooperative PRMT5 inhibitor, in patients having MTAP-null solid tumors, in a Phase 1/2 clinical trial. Under the mutually non-exclusive Amgen CTCSA, the Company will provide IDE397 drug supply to Amgen, who will be the sponsor of the Phase 1 clinical combination trial evaluating IDE397 and AMG 193. Each party will pay for fifty percent (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a475eee-2c1b-4af5-a79b-4a43baf78a1f" contextRef="C_e952c7de-9670-4b9f-bbd9-0381bf16deb8" name="idya:PayForExternalThirdPartyCostPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%) of the external third-party costs of the combination study. Each party will be responsible for its own internal costs and expenses in support of the combination study. The Company and Amgen will jointly oversee clinical development of the combination therapy through a Joint Oversight Committee responsible for coordinating all regulatory and other activities under the Amgen CTCSA. The parties will jointly own collaboration data and combination-related intellectual property, if any, arising from the combination clinical trial. The Company and Amgen each retain commercial rights to its respective compounds, including with respect to use as a monotherapy agent or combination agent. The Company and Amgen mutually agreed to wind down the IDE397 and AMG 193 clinical combination study in February 2025 and will not pursue dose expansion.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Gilead Clinical Study Collaboration and Supply Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Company entered into a Clinical Study Collaboration and Supply Agreement with Gilead Sciences, Inc. (&#8220;Gilead&#8221;), (&#8220;Gilead CSCSA&#8221;), to clinically evaluate IDE397 in combination with Trodelvy (sacacituzumab-govitecan-hziy), a Trop-2 directed ADC, in patients having MTAP-deletion urothelial cancer, in a Phase 1 clinical trial. Under the mutually non-exclusive Gilead CSCSA, the Company will receive Trodelvy drug supply from Gilead and will sponsor the Phase 1 clinical combination trial evaluating ID397 and Trodelvy. Gilead will bear internal or external costs incurred in connection with its supply of Trodelvy. The Company will bear all internal and external costs and expenses associated with the conduct of the combination study. The Company and Gilead will jointly oversee clinical development of the combination therapy through a Joint Steering Committee responsible for coordinating all regulatory and other activities under the Gilead CSCSA. The Company and Gilead each retain commercial rights to its respective compounds, including with respect to use as a monotherapy agent or combination agent.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_844c441e-d0df-47ff-ad62-6049ced8846c_4"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 12, 2025, the Company entered into an additional Clinical Study Collaboration and Supply Agreement with Gilead, or the Second Gilead CSCSA, pursuant to which the Company and Gilead will collaborate on a portion of the Company&#8217;s Phase 1 study for the clinical evaluation of our IDE397 compound in combination with Trodelvy, or the Combination Study, in certain patients with advanced solid tumors in lungs. Pursuant to the Second Gilead CSCSA, the Company is the sponsor of the Combination Study and the Company will provide the IDE397 compound and pay for the costs of the Combination Study. Gilead will provide Trodelvy for the Combination Study at no cost to the Company. The Company and Gilead will jointly own clinical data from the Combination Study and all inventions relating to the combined use of IDE397 and Trodelvy. Each party retains commercial rights to its respective compounds, including with respect to use as a monotherapy or combination agent. The Company and Gilead will form a joint steering committee responsible for coordinating all regulatory and other activities under the Second Gilead CSCSA.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Merck Clinical Trial Collaboration and Supply Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, the Company entered into a Clinical Trial Collaboration and Supply Agreement (&#8220;Merck CTCSA&#8221;), with Merck (known as MSD outside of the United States and Canada) to evaluate the combination of IDE161 with Merck&#8217;s anti-PD-1 therapy, KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (pembrolizumab), in patients with high microsatellite instability (&#8220;MSI-High&#8221;) and microsatellite stable (&#8220;MSS&#8221;) endometrial cancer. Pursuant to the Merck CTCSA, the Company is the sponsor of the combination study, and the Company will provide the IDE161 compound and pay for the costs of the combination study. Merck will provide KEYTRUDA at no cost to the Company. The Company and Merck will jointly own clinical data from the combination. Each party retains commercial rights to its respective compounds, including with respect to use as a monotherapy or combination agent.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Biocytogen Option and License Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2024, the Company entered into an Option and License Agreement (the &#8220;Biocytogen Option and License Agreement&#8221;), pursuant to which Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (&#8220;Biocytogen&#8221;), granted us an option for an exclusive worldwide license from Biocytogen to develop and commercialize products in connection with a potential first-in-class B7H3/PTK7 topoisomerase-I-inhibitor-payload BsADC program (the &#8220;Option&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Biocytogen Option and License Agreement, the Company paid Biocytogen an upfront fee and, upon the Company&#8217;s potential exercise of the Option, an exercise fee totaling up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecda83c4-0c53-45da-a8b2-83264429f216" contextRef="C_6d1a7946-4210-4f48-afb5-2b7ec9271ed6" name="idya:PaymentOfOptionExerciseFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Option is exercisable by the Company within a specified time period after the Company obtains all data and results from certain non-GLP toxicology studies specified in the Biocytogen Option and License Agreement, which the Company will conduct at its own cost. Subject to the Company&#8217;s exercise of the Option, Biocytogen will be eligible to receive an option exercise fee, development and regulatory milestone payments and commercial milestone payments, as well as low to mid single-digit royalties on net sales. Total potential milestone payments equal an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_189358fe-824b-461e-9453-61e1e46f46bc" contextRef="C_67f86cd1-0ddf-496c-b21f-48df8bce456d" name="idya:AggregatePotentialMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">400.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, including development and regulatory milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_adb6a0eb-071a-4873-bf01-0b30fb9f2941" contextRef="C_67f86cd1-0ddf-496c-b21f-48df8bce456d" name="idya:DevelopmentAndRegulatoryMilestonePaymentToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Hengrui Pharma License Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, the Company entered into an exclusive License Agreement (the &#8220;Hengrui Pharma License Agreement&#8221;) with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (&#8220;Hengrui Pharma&#8221;), pursuant to which Hengrui Pharma granted the Company an exclusive worldwide license outside of Greater China, for IDE849 (SHR-4849), a potential first-in-class Phase 1 DLL3 TOP1i ADC. Under the terms of the Hengrui Pharma License Agreement, Hengrui Pharma is eligible to receive upfront and milestone payments totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e995e9e8-9ca1-4f59-b8e0-0effe654e908" contextRef="C_1894684a-f942-4a64-aebe-705ed6473dad" name="idya:TotalMilestonePaymentToBeReceived" unitRef="U_USD" scale="9" decimals="-6" format="ixt:num-dot-decimal">1.045</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion, including a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce00a065-81dd-4e89-bd90-ed3a1bc523be" contextRef="C_1894684a-f942-4a64-aebe-705ed6473dad" name="idya:UpfrontFeePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront fee, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ddfd232-621d-456d-bdcd-64feeba6bd99" contextRef="C_1894684a-f942-4a64-aebe-705ed6473dad" name="idya:DevelopmentAndRegulatoryMilestonePaymentToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">200.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in development and regulatory milestone payments, plus commercial success-based milestones. Hengrui Pharma is also eligible to receive mid-single to low-double digit royalties on net sales outside of Greater China.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_e40856dd-f0cc-47e6-8193-50d7add41b3d" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:RevenueFromContractWithCustomerTextBlock" escape="true" continuedAt="F_e40856dd-f0cc-47e6-8193-50d7add41b3d_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Revenue Recognition</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes revenue in accordance with ASC 606 for the GSK Collaboration Agreement (see No. 10, Significant Agreements).</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disaggregation of Revenue</span></p><div><ix:nonNumeric id="F_a72acbd1-0d8d-4054-97f5-15b785410bbe" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:DisaggregationOfRevenueTableTextBlock" escape="true" continuedAt="F_a72acbd1-0d8d-4054-97f5-15b785410bbe_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents revenue disaggregated by research program (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_e40856dd-f0cc-47e6-8193-50d7add41b3d_1" continuedAt="F_e40856dd-f0cc-47e6-8193-50d7add41b3d_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a72acbd1-0d8d-4054-97f5-15b785410bbe_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.32%;box-sizing:content-box;"/>
        <td style="width:1.98%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:17.7%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.98%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:17.7%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.98%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MAT2A</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bb3b7f2-fe33-4da2-8ecb-b5a9f0ed83db" contextRef="C_4e9c63ed-b84b-4dfc-8ce5-17fc94afdaed" name="idya:CollaborationRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,722</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_319f6071-c30e-4f68-8114-4950f4cb3012" contextRef="C_e3597327-9749-4444-867d-4367f5e1a23a" name="idya:CollaborationRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,756</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pol Theta</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d244e91-bcf0-4ea6-9a58-37c350384a12" contextRef="C_2d6346e6-95ec-4b03-b74c-67593a769fb2" name="idya:CollaborationRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,002</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76033997-d658-4941-95cb-09cc85988e30" contextRef="C_5c8611d6-e1c9-4c75-8bf6-e818c66f5c44" name="idya:CollaborationRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,894</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">WRN</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd088813-133d-4763-84d5-bf0bf4f879cc" contextRef="C_15a7a270-9ab0-4d62-adb8-a1a7678eee8e" name="idya:CollaborationRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70278ce3-96c9-4a59-b825-5e0ab8618edb" contextRef="C_77daf335-fcd4-483d-9de0-eb33d3d8f444" name="idya:CollaborationRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,661</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79de0c30-df10-4fbe-89b5-8d8ab4081f8b" contextRef="C_3ee2b473-d5b8-47db-8a39-4baf5b194b84" name="idya:CollaborationRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,281</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total collaboration revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29336a45-f71b-40de-87f6-9c50ab2c2750" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="idya:CollaborationRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef011d85-0c04-49a0-a848-fa7c3421e071" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="idya:CollaborationRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,385</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b999f70-7af3-4378-8239-718165c80312" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="idya:CollaborationRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,931</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company identified the following </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24249284-2402-451b-89c0-2394cd69ffa5" contextRef="C_64b83c21-4b63-4ca9-9683-99ffc7d0f98b" name="idya:NumberOfPerformanceObligations" unitRef="U_Obligation" decimals="INF" format="ixt-sec:numwordsen">six</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> performance obligations associated with the GSK Collaboration Agreement:</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preclinical and Phase 1 Monotherapy clinical research and development services under the MAT2A program (&#8220;MAT2A R&amp;D Services&#8221;)</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preclinical research services and the related license to IDEAYA-owned technology under the Pol Theta program (&#8220;Pol Theta R&amp;D Services&#8221;)</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preclinical research services and the related license to IDEAYA-owned technology under the WRN program (&#8220;WRN R&amp;D Services&#8221;)</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material right associated with the option to license IDEAYA-owned technology under the MAT2A program (&#8220;Option&#8221;)</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(v)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material right associated with the option to license to IDEAYA-owned technology under the MAT2A program to the extent necessary for preclinical activities in preparation for the MAT2A Combination Trial (&#8220;Preclinical MAT2A License&#8221;)</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(vi)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material right associated with the supply of MAT2A product for the MAT2A Combination Trial (&#8220;MAT2A Supply&#8221;) </span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to the Pol Theta and WRN programs, the Company identified two promises: (1) granting of the license to develop and commercialize Pol Theta and WRN products, respectively, and (2) the preclinical research services. The Company determined that these two promises are not distinct within the context of the contract.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized revenue related to amounts allocated to the MAT2A R&amp;D services as the underlying services were performed over the period through the delivery of the Option data package, which is generated from its conduct of the dose escalation portion of the MAT2A Phase 1 monotherapy clinical trial. The Company used its internal research and development capability and also engaged third-party clinical research organizations (&#8220;CROs&#8221;), for which the Company acted as a principal. The Company delivered the Option data package to GSK. Accordingly, the performance obligation related to the MAT2A R&amp;D services was fulfilled.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized revenue related to amounts allocated to the Pol Theta R&amp;D Services and WRN R&amp;D Services as the underlying services were performed over the period through the completion of the Pol Theta and WRN preclinical research programs, respectively. Within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6309977b-a229-404a-b61f-f049a82b4cf2" contextRef="C_aab90a1f-cce5-40ae-a524-bb89f7b2708e" name="idya:ReimbursementPeriodOfCostsIncurred" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days from the end of each calendar quarter, GSK reimbursed the Pol Theta program costs incurred by the Company. Within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7f8bf027-da16-4ccf-9120-3c716b3fbe43" contextRef="C_eb95813f-4508-41df-ad29-f6eec05c524e" name="idya:ReimbursementPeriodOfCostsIncurred" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days from the end of each calendar quarter, the Company and GSK determined the amounts of WRN program costs incurred by both parties and the net amount owed by GSK to the Company or by the Company to GSK, which was paid within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_37314290-60ab-44b3-933e-45480ead375b" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="idya:ReimbursementPeriodOfCostsIncurred" format="ixt-sec:durday"><ix:nonNumeric id="F_75ca8316-12b8-4122-939c-44ffbc3e97a4" contextRef="C_15a7a270-9ab0-4d62-adb8-a1a7678eee8e" name="idya:ReimbursementPeriodOfCostsIncurred" format="ixt-sec:durday"><ix:nonNumeric id="F_eab738ef-54cb-4ac8-814b-ebc4f7f70d90" contextRef="C_15a7a270-9ab0-4d62-adb8-a1a7678eee8e" name="idya:DeterminationPeriodOfCostsIncurred" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days from such determination by a reimbursing party. The Company used its internal research capability and could also engage third-party CROs in transferring the Pol Theta R&amp;D services and WRN R&amp;D services, for which the Company acts as a principal. The Company completed Pol Theta R&amp;D services during December 2022. Accordingly, the performance obligation related to the Pol Theta R&amp;D services was fulfilled. The Company completed WRN R&amp;D services during December 2023. Accordingly, the performance obligation related to the WRN R&amp;D services was fulfilled.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company completed all performance obligations related to the upfront payment under the GSK Collaboration Agreement as of December 31, 2023. Since December 31, 2023, the Company has no accounts receivable and no contract liabilities related to the GSK Collaboration Agreement. Because the Company completed all performance obligations, future collaboration revenue recognized under the GSK Collaboration Agreement is only related to milestone payments as they are earned.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Pol Theta product, the Company achieved and earned a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b25168a-4683-47f0-be48-186d233ceb23" contextRef="C_10a02746-ad3a-4e28-acc1-fe5727c8d092" name="idya:MilestonePaymentReceivedClinicalEvaluation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million payment for a milestone in August 2023 based on acceptance of the IND by the FDA. An earlier preclinical development $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f9d5b42-3abc-4267-bfd3-351e58e7586c" contextRef="C_f7b6061f-1a70-4f34-9ba6-8614c500e543" name="idya:MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment from GSK was achieved in August 2022 in connection with ongoing IND-enabling studies to support evaluation of GSK101. The Company has the potential to receive an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7be2a354-ed7f-4d54-913f-bd1cefe048ea" contextRef="C_b89b606e-379c-490c-b2c7-22e9477ad049" name="idya:AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment upon initiation of Phase 1 clinical dose expansion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_e40856dd-f0cc-47e6-8193-50d7add41b3d_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the WRN product, the Company achieved and earned a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f080e3e0-672e-4b5b-8abf-391c98cb6a5e" contextRef="C_274ca130-dad0-4940-9133-f4b57bf70ddb" name="idya:MilestonePaymentReceivedClinicalEvaluation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million payment for a milestone in October 2024 based on the acceptance of the IND by the FDA. An earlier preclinical development $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d5d00b0-9d4a-46da-b6d8-637b148873c1" contextRef="C_7bf84ed4-93bd-4eeb-804c-d7cf2b19b16a" name="idya:MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million payment from GSK was achieved in October 2023 in connection with IND-enabling studies for the Werner Helicase Inhibitor DC. The Company has the potential to receive an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57923a38-06ee-4ad5-abb3-a3c23a74a0b0" contextRef="C_b3aa4c0b-2b97-4391-af57-fe7af6cf0a24" name="idya:AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment upon initiation of Phase 1 clinical dose expansion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Significant judgments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In applying ASC 606 to the GSK Collaboration Agreement, the Company made the following judgment that significantly affect the timing and amount of revenue recognition.</span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(i) Determination of the transaction price, including whether any variable consideration is included at inception of the contract</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction price is the amount of consideration that the Company expects to be entitled to in exchange for transferring promised goods or services to the customer. The transaction price must be determined at inception of a contract and may include amounts of variable consideration. However, there is a constraint on inclusion of variable consideration in the transaction price, if there is uncertainty at inception of the contract as to whether such consideration will be recognized in the future.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The decision as to whether or not it is probable that a significant reversal of revenue will occur in the future, depends on the likelihood and magnitude of the reversal and is highly susceptible to factors outside the Company&#8217;s influence (for example, the Company cannot determine the outcome of clinical trials; the Company cannot determine if or when the counterparty will initiate or complete clinical trials; and the Company cannot determine if or when an regulatory agency provides any approval). In addition, the uncertainty is not expected to be resolved for a long period and finally, the Company has limited experience in the field. Therefore, at inception of the GSK Collaboration Agreement, development and regulatory milestones were fully constrained and were not included in the transaction price based on the factors noted above.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company constrains estimates of other variable consideration, such as reimbursable program costs, to amounts that are not expected to result in a significant revenue reversal in the future. The Company re-evaluates the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e184d64f-efd7-47ad-b95a-a046cef2f4fd" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Net Loss Per Share Attributable to Common Stockholders</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7e246c7-c1d3-4f8d-b320-5ebb4c62c0e1" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:54.091%;box-sizing:content-box;"/>
        <td style="width:1.4%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.902000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.4%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.902000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.4%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.902000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7a6865e-3fb7-43ef-b43f-e45dd661b53a" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">274,477</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76d8dca1-a97a-4bbd-b265-2895dc92b609" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">112,961</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67108300-6512-4e45-9ae9-b9acd5a7382c" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">58,655</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used in computing net loss per share <br/>&#160;&#160;&#160;attributable to common stock, basic and diluted </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30269d97-26fb-48c7-b60a-9771d5a0fc11" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7d80a458-b40f-4027-90b2-b299e9a44335" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">81,678,069</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bcc1d51-e60a-4934-95d0-dc1789a1a3fa" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_22f08a56-525c-41ef-8a1d-594dcc63f919" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">57,519,929</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b1db535-e52a-43ef-bc18-31e3ea053b17" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4530e811-668f-4476-acba-b0f12573c004" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">41,444,696</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders, basic and<br/>&#160;&#160;&#160;diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc68c207-9fb0-4a1f-965b-cf0b94ae6e25" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_cdcba9d4-d81b-42cb-925c-22f35c3e1515" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">3.36</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3075692-e932-4f61-a2e0-875025234793" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_065ff17d-6fc8-4a99-89d2-18fcab64f53c" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.96</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e551de3c-3d2e-4e95-8182-56a8d0473483" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_cd9013e6-5e31-4888-805d-18b0de68e91c" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.42</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) The shares underlying the pre-funded warrants to purchase shares of the Company's common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the years ended December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Arial;"><ix:nonNumeric id="F_2af500a6-3bd9-4ba4-aeee-c7149d4d7629" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:54.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.38%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_208f127c-9478-449c-aa5e-30e5cbc65c22" contextRef="C_0e321b30-69e1-4345-9158-2fcb284b612c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,737,595</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9925c8eb-fe3e-429a-a860-037532817c95" contextRef="C_761fc146-6272-4882-8bef-299b24f35235" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,269,975</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4d51568-c0c2-413c-b70e-bad8a0a1b40b" contextRef="C_949ed0b5-4cbf-4fe7-81a6-07bd20fe4626" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,097,263</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12d33bd3-3bc9-446d-bf2b-b2e6e1357fd8" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. Segment Information</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company operates and manages its business as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d55681f2-cc8e-48dc-95a0-01ac6c0df60f" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c84d50c1-d7ba-4c65-ad11-dbf553e82398" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating and reportable segment, which is the business of research and development for oncology-focused precision medicine. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_3b792965-e65d-4647-ad8c-bd3fa5a2dc19;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">President and CEO. The Company&#8217;s measure of segment profit or loss is net income. For purposes of evaluating performance and allocating resources, the CODM reviews the financial information and evaluates net income against comparable prior periods and the Company&#8217;s forecast. All of the Company's long-lived assets are located in the United States.</span></span></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1ab6d26-a608-489d-a035-c374d341c93d" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="idya:SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the significant expense categories included within net income presented on the Company's statements of operations and comprehensive loss, see below for disaggregated research and development expenses:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.692%;box-sizing:content-box;"/>
        <td style="width:1.78%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.517%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.78%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.517%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.78%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.937000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External clinical development expenses </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Darovasertib</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_886dc366-3806-424f-a732-1681884a3a97" contextRef="C_35bd050f-8213-4ced-a848-8e723be54545" name="idya:ExternalClinicalDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,335</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65e74421-e916-4fcc-92a1-a16359f68107" contextRef="C_c6ec1b34-88b5-403e-b14c-f9db680a80a0" name="idya:ExternalClinicalDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,829</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2dd9cbff-475e-48e3-8d4f-d66eb889a7d2" contextRef="C_750fdeba-ea50-4e26-8f84-b154ebcc6f75" name="idya:ExternalClinicalDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,433</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">IDE397</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bda5e3b6-569c-46bb-ab2e-0277cba29ff0" contextRef="C_b8fed8f4-659e-48c7-a3fc-ebd4660253a2" name="idya:ExternalClinicalDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,629</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc27938b-e85f-41c8-b004-90fa5e5f7d3e" contextRef="C_54da252c-c145-4c7e-bec2-4a22f8d0c57c" name="idya:ExternalClinicalDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,985</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca9dfa7a-3164-4ded-9cc1-2f3d1c7eaba6" contextRef="C_46c16141-586e-4130-9e68-98823b85e056" name="idya:ExternalClinicalDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,426</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">IDE161</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e850df9-6b18-479c-889b-80fbfc2ef56a" contextRef="C_e499769c-c222-47df-bc66-3631881a62b1" name="idya:ExternalClinicalDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,743</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff0f72ab-5621-4ab5-956f-b108cccb013a" contextRef="C_7c297d4e-8a0d-4d1f-80dc-8cc368231084" name="idya:ExternalClinicalDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,104</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb20379e-66e7-467b-aec8-b9934e6ff7b2" contextRef="C_a17848a4-d1a9-4d09-81d7-b191ed14dfd6" name="idya:ExternalClinicalDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,749</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel related and stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_758e51fc-322e-47eb-9241-f3824f54361c" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="idya:PersonnelRelatedAndStock-BasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,543</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7d051a0-1eb6-4c25-8cc3-63facf7ec491" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="idya:PersonnelRelatedAndStock-BasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,948</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9198b3e6-7a86-4e93-8ab7-1dafb684e007" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="idya:PersonnelRelatedAndStock-BasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,717</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development expenses </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">:</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64a1f060-6e7d-42f6-acdb-c89a0a360d9b" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158,423</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8f1ad2f-df3e-429b-ba92-63664b145a1e" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,642</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1623d6e3-60ed-4daa-b1b6-1b6062ee0de9" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,211</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f12714fc-c739-4a79-94a2-96ecf96c91ba" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">294,673</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a29df52-d258-4b42-b594-d801527abced" contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,508</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f2703dc-de74-46df-9140-8b60bbdcfa26" contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,536</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">         (1)          External clinical development expenses include manufacturing and clinical trial costs. These expenses are primarily for services provided by</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                        external consultants, CMOs and CROs.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">         (2)          IDE397 includes costs from the Amgen CTCSA</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">         (3)          Other research and development expenses include manufacturing and clinical trial costs for preclinical and earlier clinical stage programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                       These expenses are primarily for services provided by external consultants, CMOs and CROs.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aaca54fe-961c-40c7-9fa5-b5193279a915" contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. Subsequent Events</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">At-the-Market Offering</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequent to December 31, 2024, from January 1, 2025 through January 6, 2025, the Company raised aggregate net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6817d24d-d7a7-40fe-af64-082e011d0d1b" contextRef="C_b82f7f69-7a56-4486-a04d-d1739f434a83" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under the at-the-market offering pursuant to the January 2024 Sales Agreement with Jefferies as sales agent. As of January 6, 2025, approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71e571dd-17cc-4dc3-94ca-43179cf173b8" contextRef="C_0d608e0d-30c3-491f-bc22-755d69e64cfd" name="idya:CommonStockRemainingAvailableToBeSaleAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">156.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of common stock remained available to be sold under the ATM facility.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commencement of Expansion Premises Office Lease - South San Francisco</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company commenced the First Amendment to the Lease Agreement by and between DW LSP 5000 Shoreline, LLC and the Company in January 2025. The Company added approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_496ddac6-6ea0-4aed-b8d9-401cc1dba41a" contextRef="C_b452a75e-2a3a-4c85-bb40-898b74dc7c1d" name="idya:OperatingLeasesAdditionalAreaLeased" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">11,321</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> rentable square feet of additional space to expand the size of the original premises.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Study Collaboration and Supply Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 12, 2025, the Company entered into the Second Gilead CSCSA with Gilead pursuant to which the Company and Gilead will collaborate on a portion of the Phase 1 study for the clinical evaluation of IDE397 in combination with Trodelvy, or the Combination Study, in certain patients with advanced solid tumors in lungs. Pursuant to the Second Gilead CSCSA, the Company is the sponsor of the Combination Study, and the Company will provide the IDE397 compound and pay for the costs of the Combination Study.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.56in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Signa</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized, in South San Francisco, California on February 18, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:50.0%;border-collapse:separate;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.22%;box-sizing:content-box;"/>
    <td style="width:2.18%;box-sizing:content-box;"/>
    <td style="width:88.6%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">IDEAYA Biosciences, Inc.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Yujiro Hata</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Yujiro Hata</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="power_of_attorney"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Powe</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">r of Attorney</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Yujiro Hata and Andres Briseno, and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution, for him in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed by the following persons in the capacities and on the dates indicated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:30%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:44%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:18%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Signature</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Yujiro Hata</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Director</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;February 18, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Yujiro Hata</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Andres Ruiz Briseno</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Senior Vice President and Head of Finance and Investor Relations</span></p><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;February 18, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Andres Ruiz Briseno</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Terry Rosen, Ph.D.</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chairman of the Board of Directors</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;February 18, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Terry Rosen, Ph.D.</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Garret Hampton, Ph.D.</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:5pt;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 18, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Garret Hampton, Ph.D.</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Susan L. Kelley, M.D.</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;February 18, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Susan L. Kelley, M.D.</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Catherine Mackey, Ph.D.</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 18, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Catherine Mackey, Ph.D.</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:3.6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Scott Morrison</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;February 18, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Scott Morrison</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jeffrey Stein, Ph.D.</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;February 18, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jeffrey Stein, Ph.D.</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Wendy Yarno</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;February 18, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Wendy Yarno</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:9.9pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:9.9pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>idya-ex4_3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<html>
 <head>
  <title>EX-4.3</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 4.3</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">											       </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DESCRIPTION OF THE REGISTRANT&#x2019;S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	IDEAYA Biosciences (&#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, $0.0001 par value per share (&#x201c;common stock&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Description of Capital Stock</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	The following summary describes our common stock and the material provisions of our amended and restated certificate of incorporation (the &#x201c;certificate of incorporation&#x201d;), our amended and restated bylaws (the &#x201c;bylaws&#x201d;), the amended and restated investors&#x2019; rights agreement (the &#x201c;investors&#x2019; rights agreement&#x201d;), each as amended from time to time, to which we and certain of our stockholders are parties, and of the Delaware General Corporation Law (the &#x201c;DGCL&#x201d;). Because the following is only a summary, it does not contain all of the information that may be important to you. For a complete description, you should refer to the full text of our certificate of incorporation, bylaws and investors&#x2019; rights agreement.  We encourage you to read those documents and the DGCL carefully.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	The certificate of incorporation authorizes 300,000,000 shares of common stock, $0.0001 par value per share.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Voting Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting shares are able to elect all of the directors. In addition, the affirmative vote of holders of 66-2/3% of the voting power of all of the then outstanding voting stock is required to take certain actions, including amending certain provisions of our amended and restated certificate of incorporation, such as the provisions relating to amending our amended and restated bylaws, the classified board and director liability.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dividends</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidation</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	In the event of our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rights and Preferences</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate in the future.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fully Paid and Nonassessable</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	All outstanding shares of common stock are fully paid and non-assessable.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Undesignated Preferred Stock</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Under our certificate of incorporation, our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock, $0.0001 par value per share, in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. No shares of preferred stock are outstanding, and we have no present plan to issue any shares of preferred stock.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Certain holders of unregistered common stock purchased in private placements, or their permitted transferees, are entitled to rights with respect to the registration of such shares under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). These rights are provided under the terms of (i) an investors&#x2019; rights agreement between us and the holders of certain of these shares, or the investors&#x2019; rights agreement, which include demand registration rights and piggyback registration rights, and (ii) a stock purchase agreement between us and the holder of certain of these shares, or the stock purchase agreement, which include Form S-3 registration rights. All fees, costs and expenses of underwritten registrations will be borne by us and all selling expenses, including underwriting discounts and selling commissions, will be borne by the holders of the shares being registered.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	The demand, piggyback and Form S-3 registration rights will expire, with respect to any particular stockholder party to the investors&#x2019; rights agreement, upon the earliest of (i) three years after the consummation of our initial public offering, (ii) when that stockholder can sell all of its shares under Rule 144 of the Securities Act during any 90-day period or (iii) upon the consummation of an acquisition. The Form S-3 registration rights will expire, with respect to the stockholder party to the stock purchase agreement, when such stockholder can sell all of its shares under Rule 144 of the Securities Act during any 90-day period.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anti-Takeover Effects of Provisions of Our Amended and Restated Certificate of Incorporation, Our Amended and Restated Bylaws and Delaware Law</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Some provisions of Delaware law and our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us by means of a proxy contest or otherwise; or removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that might result in a premium over the market price for our shares.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware Anti-Takeover Statute</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	We are subject to Section 203 of the DGCL, which prohibits persons deemed &#x201c;interested stockholders&#x201d; from engaging in a &#x201c;business combination&#x201d; with a publicly-held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#x201c;interested stockholder&#x201d; is a person who, together with affiliates and associates, beneficially owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#x2019;s voting stock. Generally, a &#x201c;business combination&#x201d; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors, such as discouraging takeover attempts that might result in a premium over the market price of our common stock.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Undesignated Preferred Stock</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	The ability to authorize undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of us. These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management of our company.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Special Stockholder Meetings</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Our amended and restated bylaws provide that a special meeting of stockholders may be called by our board of directors, or by our President or Chief Executive Officer.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Requirements for Advance Notification of Stockholder Nominations and Proposals</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Elimination of Stockholder Action by Written Consent</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Our amended and restated certificate of incorporation and our amended and restated bylaws eliminate the right of stockholders to act by written consent without a meeting.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Classified Board; Election and Removal of Directors; Filling Vacancies</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders, with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the shares of common stock outstanding will be able to elect all of our directors. Our amended and restated certificate of incorporation provides for the removal of any of our directors only for cause and requires a stockholder vote by the holders of at least a 66-2/3% of the voting power of the then outstanding voting stock. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of the board, may only be filled by a resolution of the board of directors unless the board of directors determines that such vacancies shall be filled by the stockholders. This system of electing and removing directors and filling vacancies may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Choice of Forum</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for: any state law derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the DGCL; or any action asserting a claim against us that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is governed by the internal affairs doctrine. Similarly, our amended and restated certificate of incorporation provides that the U.S. federal district courts are the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. The enforceability of similar choice of forum provisions has been challenged in legal proceedings, and it is possible that, in connection with such actions or any future actions, a court could find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable. Although our amended and restated certificate of incorporation contains the choice of forum provision described above, it is possible that a court could find that such provisions are inapplicable for a particular claim or action or that such provisions are unenforceable.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amendment of the Certificate of Incorporation and Bylaws</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue undesignated preferred stock, would require approval by a stockholder vote by the holders of at least a 66-2/3% of the voting power of the then outstanding voting stock.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	The provisions of the DGCL, our amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitations of Liability and Indemnification Matters</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Our amended and restated certificate of incorporation contains provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by Delaware law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.981%;box-sizing:content-box;"></td>
    <td style="width:3.001%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:91.018%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">any breach of the director&#x2019;s duty of loyalty to us or our stockholders;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the DGCL; or</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">any transaction from which the director derived an improper personal benefit.</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Each of our amended and restated certificate of incorporation and amended and restated bylaws provide that we are required to indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. Our amended and restated bylaws also obligate us to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under Delaware law. We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by our board of directors. With specified exceptions, these agreements provide for indemnification for related expenses including, among other things, attorneys&#x2019; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. We believe that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain directors&#x2019; and officers&#x2019; liability insurance.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. Further, a stockholder&#x2019;s investment may be adversely affected to the extent that we pay the costs of settlement and damages.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nasdaq Global Select Market Listing</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Our common stock is listed on the Nasdaq Global Select Market under the symbol &#x201c;IDYA.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transfer Agent and Registrar</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	The transfer agent and registrar for our common stock is American Stock Transfer &amp; Trust Company, LLC. The transfer agent and registrar&#x2019;s address is 6201 15th Avenue, Brooklyn, New York 11219.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>3
<FILENAME>idya-ex10_12.htm
<DESCRIPTION>EX-10.12
<TEXT>
<html>
 <head>
  <title>EX-10.12</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.4in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.12</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDEAYA BIOSCIENCES, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EMPLOYMENT AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Employment Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is entered into between IDEAYA Biosciences, Inc., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and Stu Dorman (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and, together with the Company, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) effective as of December 1, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company desires to assure itself of the services of Executive by engaging Executive to perform services as an employee of the Company under the terms hereof; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Executive desires to provide services to the Company on the terms herein provided effective as of the Effective Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW, THEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in consideration of the foregoing, and for other good and valuable consideration, including the respective covenants and agreements set forth below, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employment.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company shall employ Executive upon the terms and conditions provided herein effective as of the Effective Date.  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Position and Duties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Effective as of the Effective Date, Executive: (i) shall serve as the Company&#x2019;s </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Commercial Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with responsibilities, duties, and authority usual and customary for such position, subject to direction by the Chief Executive Officer of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CEO</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); (ii) shall report directly to the CEO or the CEO&#x2019;s designee; and (iii) agrees promptly and faithfully to comply with all present and future policies, requirements, rules and regulations, and reasonable directions and requests, of the Company in connection with the Company&#x2019;s business.  At the Company&#x2019;s request, Executive shall serve the Company and/or its subsidiaries and affiliates in such other capacities in addition to the foregoing as the Company shall designate.  In the event that Executive serves in any one or more of such additional capacities, Executive&#x2019;s compensation shall not automatically be increased on account of such additional service.  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Principal Office</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive shall perform services for the Company at the Company&#x2019;s offices located in South San Francisco, California, or, with the Company&#x2019;s consent, at any other place in connection with the fulfillment of Executive&#x2019;s role with the Company; provided, however, that the Company may from time to time require Executive to travel temporarily to other locations in connection with the Company&#x2019;s business.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exclusivity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except with the prior written approval of the CEO (which the CEO may grant or withhold in his or her sole and absolute discretion), Executive shall devote Executive&#x2019;s best efforts and full working time, attention, and energies to the business of the Company, except during any paid vacation or other excused absence periods.  Notwithstanding the </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.12</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foregoing, Executive may, without violating this Section 1(d), (i) as a passive investment, own publicly traded securities in such form or manner as will not require any services by Executive in the operation of the entities in which such securities are owned; (ii) engage in charitable and civic activities; or (iii) engage in other personal passive investment activities, in each case, so long as such interests or activities do not materially interfere to the extent such activities do not, individually or in the aggregate, interfere with or otherwise prevent the performance of Executive&#x2019;s duties and responsibilities hereunder.  Executive may also serve as a member of the board of directors or board of advisors of another organization provided (i) such organization is not a competitor of the Company; (ii) Executive receives prior written approval from the Company&#x2019;s CEO; and (iii)  such activities do not individually or in the aggregate interfere with the performance of Executive&#x2019;s duties under this Agreement, violate the Company&#x2019;s standards of conduct then in effect, or raise a conflict under the Company&#x2019;s conflict of interest policies.  For the avoidance of doubt, the CEO has approved Executive&#x2019;s continued service with those organizations set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, such approval to continue until the earlier to occur of (a) the CEO&#x2019;s revocation of such approval in his or her sole and absolute discretion, or (b) such time as such service interferes with the performance of Executive&#x2019;s duties under this Agreement, violates the Company&#x2019;s standards of conflict or raises a conflict under the Company&#x2019;s conflict of interest policies.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The period of Executive&#x2019;s employment under this Agreement shall commence on the Effective Date and shall continue until Executive&#x2019;s employment with the Company is terminated pursuant to Section 5.  The phrase &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; as used in this Agreement shall refer to the entire period of employment of Executive by the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation and Related Matters</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  During the Term, Executive shall receive a base salary at the rate of $500,000 per year (as may be increased from time to time, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Annual Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), subject to withholdings and deductions, which shall be paid to Executive in accordance with the customary payroll practices and procedures of the Company.  Such Annual Base Salary shall be reviewed by the CEO, and, as applicable, the Board of Directors of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and/or the Compensation Committee of the Board, not less than annually.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="width:100%;display:inline;" id="ole_link1"><font id="ole_link2"></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive shall be eligible to receive a discretionary annual bonus based on Executive&#x2019;s achievement of performance objectives established by the Board, its Compensation Committee and/or the CEO, such bonus to be targeted at forty percent (40%) of Executive&#x2019;s Annual Base Salary (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Annual Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Any Annual Bonus approved by the Board, the Compensation Committee of the Board and/or the CEO shall be paid at the same time annual bonuses are paid to other executives of the Company generally, subject to Executive&#x2019;s continuous employment through the date of approval.  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive shall be entitled to participate in such employee and executive benefit plans and programs as the Company may from time to time offer to provide to its executives, subject to the terms and conditions of such plans.  Notwithstanding the foregoing, nothing herein is intended, or shall be construed, to require the Company to institute or continue any particular plan or benefit.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.12</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company shall reimburse Executive for all reasonable, documented, out-of-pocket travel and other business expenses incurred by Executive in the performance of Executive&#x2019;s duties to the Company in accordance with the Company&#x2019;s applicable expense reimbursement policies and procedures as are in effect from time to time.  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vacation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive will be entitled to paid vacation in accordance with the Company&#x2019;s vacation policy, as in effect from time to time.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Awards.     </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial Equity Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In connection with entering into this Agreement, promptly following the commencement of your employment with the Company, subject to the terms and conditions of the Company&#x2019;s 2023 Employment Inducement Award Plan, and subject to the approval of the Board or the Compensation Committee of the Board, Executive will be granted an option to purchase one hundred seventy thousand (170,000) shares of the Company&#x2019;s common stock (the &#x201c;Stock Option&#x201d;), with an exercise price per share equal to the closing trading price of a share of the Company&#x2019;s common stock on the date of grant.  Subject to Executive&#x2019;s continued employment with the Company through the applicable vesting date, 25% of the shares underlying the Stock Option will vest on the first anniversary of the date of the Effective Date and 1/48th of the total number of shares initially underlying the Stock Option will vest on the last day of the month of each monthly anniversary thereafter.  The Stock Option will be subject to the terms and conditions of the Company&#x2019;s 2013 Employment Inducement Plan and the Company&#x2019;s standard form of stock option agreement. </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Executive shall be eligible for such future grants of stock options and other equity awards as may be determined by the Board or its Compensation Committee. </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Covered Terminations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding anything to the contrary in any agreement evidencing the Stock Option, or any future stock option or other equity award, the unvested portion of the Stock Option, or such future stock option or other equity award, shall not terminate upon the date of a Covered Termination (as defined below) but instead shall remain outstanding and eligible to vest in accordance with Section 6 hereof until the three month anniversary of such Covered Termination.  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">        </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At-Will Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company and Executive acknowledge that Executive&#x2019;s employment is and shall continue to be at-will, as defined under applicable law.  This means that it is not for any specified period of time and can be terminated by Executive or by the Company at any time, with or without advance notice, and for any or no particular reason or cause.  It also means that Executive&#x2019;s job duties, title, and responsibility and reporting level, work schedule, compensation, and benefits, as well as the Company&#x2019;s personnel policies and procedures, may be changed with prospective effect, with or without notice, at any time in the sole discretion of the Company (subject to any ramification such changes may have under Section 6 of this Agreement).  This &#x201c;at-will&#x201d; nature of Executive&#x2019;s employment shall remain unchanged during </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.12</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive&#x2019;s tenure as an employee and may not be changed, except in an express writing signed by Executive and a duly-authorized officer of the Company.  If Executive&#x2019;s employment terminates for any lawful reason, Executive shall not be entitled to any payments, benefits, damages, award, or compensation other than as provided in this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notice of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  During the Term, any termination of Executive&#x2019;s employment by the Company or by Executive (other than by reason of death) shall be communicated by written notice (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notice of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) from one Party hereto to the other Party hereto (i) indicating the specific termination provision in this Agreement relied upon, if any, (ii) setting forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive&#x2019;s employment under the provision so indicated, and (iii) specifying the Date of Termination (as defined below).  The failure by the Company to set forth in the Notice of Termination all of the facts and circumstances which contribute to a showing of Cause (as defined below) shall not waive any right of the Company hereunder or preclude the Company from asserting such fact or circumstance in enforcing their rights hereunder. The failure by the Executive to set forth in the Notice of Termination all of the facts and circumstances which contribute to a showing of Good Reason (as defined below) shall not waive any right of the Executive hereunder or preclude the Executive from asserting such fact or circumstance in enforcing their rights hereunder.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  For purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Date of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the date of the termination of Executive&#x2019;s employment with the Company specified in a Notice of Termination.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deemed Resignation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Upon termination of Executive&#x2019;s employment for any reason, Executive shall be deemed to have resigned from all offices and board memberships, if any, then held with the Company or any of its affiliates, and, at the Company&#x2019;s request, Executive shall execute such documents as are necessary or desirable to effectuate such resignations.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consequences of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments of Accrued Obligations upon all Terminations of Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Upon a termination of Executive&#x2019;s employment for any reason, Executive (or Executive&#x2019;s estate or legal representative, as applicable) shall be entitled to receive, within 30 days after Executive&#x2019;s Date of Termination (or such earlier date as may be required by applicable law): (i) any portion of Executive&#x2019;s Annual Base Salary earned through Executive&#x2019;s Date of Termination not theretofore paid, (ii) any expenses owed to Executive under Section 3, (iii) any accrued but unused paid time-off owed to Executive, (iv) </font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any Annual Bonus earned but unpaid as of the Date of Termination, and (v) any amount arising from Executive&#x2019;s participation in, or benefits under, any employee benefit plans, programs, or arrangements under Section 3, which amounts shall be payable in accordance with the terms and conditions of such employee benefit plans, programs, or arrangements.  Except as otherwise set forth in Sections 6(b) and (c), the payments and benefits described in this Section 6(a) shall be the only payments and benefits payable in the event of Executive&#x2019;s termination of employment for any reason.  </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.12</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severance Payments upon Covered Termination Outside a Change in Control Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If, during the Term, Executive experiences a Covered Termination outside a Change in Control Period (each as defined below), then in addition to the payments and benefits described in Section 6(a), the Company shall, subject to Executive&#x2019;s delivery to the Company of a waiver and release of claims agreement substantially in the form of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereto, with any such changes to applicable law as the Company deems necessary (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Release</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that becomes effective and irrevocable in accordance with Section 11(d), provide Executive with the following:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.8575102053935906%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company shall pay to Executive an amount equal to Executive&#x2019;s Annual Base Salary multiplied by 0.75.  Such amount will be subject to applicable withholdings and payable in a single lump sum cash payment on the first regular payroll date following the date the Release becomes effective and irrevocable in accordance with Section 11(d). </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.8575102053935906%;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the period commencing on the Date of Termination and ending on the nine month anniversary thereof or, if earlier, the date on which Executive becomes eligible for comparable replacement coverage under a subsequent employer&#x2019;s group health plan (in any case, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-CIC COBRA Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), subject to Executive&#x2019;s valid election to continue healthcare coverage under Section 4980B of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and the regulations thereunder, the Company shall, in its sole discretion, either (A) continue to provide to Executive and Executive&#x2019;s dependents, at the Company&#x2019;s sole expense, or (B) reimburse Executive and Executive&#x2019;s dependents for coverage under its group health plan (if any) at the same levels in effect on the Date of Termination; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if (1) any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A under Treasury Regulation Section 1.409A&#x2011;1(a)(5), (2) the Company is otherwise unable to continue to cover Executive or Executive&#x2019;s dependents under its group health plans, or (3) the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments over the Non-CIC COBRA Period (or remaining portion thereof).</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severance Payments upon Covered Termination During a Change in  Control Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If, during the Term, Executive experiences a Covered Termination during a Change in Control Period, then, in addition to the payments and benefits described in Section 6(a), the Company shall, subject to Executive&#x2019;s delivery to the Company of the Release that becomes effective and irrevocable in accordance with Section 11(d), provide Executive with the following:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.8575102053935906%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company shall pay to Executive an amount equal to the sum of Executive&#x2019;s Annual Base Salary and Executive&#x2019;s target Annual Bonus.  Such amount will be subject to applicable withholdings and payable in a single lump sum cash payment on the first regular payroll date following the date the Release becomes effective and irrevocable in accordance with Section 11(d). </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.12</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.8575102053935906%;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the period commencing on the Date of Termination and ending on the twelve month anniversary thereof or, if earlier, the date on which Executive becomes eligible for comparable replacement coverage under a subsequent employer&#x2019;s group health plan (in any case, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CIC COBRA Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), subject to Executive&#x2019;s valid election to continue healthcare coverage under Section 4980B of the Code and the regulations thereunder, the Company shall, in its sole discretion, either (A) continue to provide to Executive and Executive&#x2019;s dependents, at the Company&#x2019;s sole expense, or (B) reimburse Executive and Executive&#x2019;s dependents for coverage under its group health plan (if any) at the same levels in effect on the Date of Termination; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if (1) any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A under Treasury Regulation Section 1.409A-1(a)(5), (2) the Company is otherwise unable to continue to cover Executive or Executive&#x2019;s dependents under its group health plans, or (3) the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments over the CIC COBRA Period (or remaining portion thereof).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.8575102053935906%;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cause any unvested equity awards, including any stock options, restricted stock awards and any such awards subject to performance-based vesting, held by Executive as of the Date of Termination, to become fully vested and, if applicable, exercisable, and cause all restrictions and rights of repurchase on such awards to lapse with respect to all of the shares of the Company&#x2019;s Common Stock subject thereto. </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Other Severance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The provisions of this Section 6 shall supersede in their entirety any severance payment provisions in any severance plan, policy, program, or other arrangement maintained by the Company except as otherwise approved by the Board.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Requirement to Mitigate; Survival</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive shall not be required to mitigate the amount of any payment provided for under this Agreement by seeking other employment or in any other manner.  Notwithstanding anything to the contrary in this Agreement, the termination of Executive&#x2019;s employment shall not impair the rights or obligations of any Party. </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definition of Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  For purposes hereof, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean any one of the following: (i) Executive&#x2019;s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii) Executive&#x2019;s attempted commission of, or participation in, a fraud or act of dishonesty against the Company; (iii) Executive&#x2019;s intentional, material violation of any contract or agreement between Executive and the Company or of any statutory duty owed to the Company; (iv) Executive&#x2019;s unauthorized use or disclosure of the Company&#x2019;s confidential information or trade secrets; or (v) Executive&#x2019;s gross misconduct. The determination that a termination of Executive&#x2019;s employment is either for Cause or without Cause shall be made by the Board or its Compensation Committee, in each case, in its sole discretion.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.12</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definition of Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  For purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean any of the following types of transactions: (i) the direct or indirect sale or exchange in a single or series of related transactions by the stockholders of the Company of more than fifty percent (50%) of the voting stock of the Company; (ii) a merger or consolidation in which the Company is a party; or (iii) the sale, exchange, or transfer of all or substantially all of the assets of the Company (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), wherein the stockholders of the Company immediately before the Transaction do not retain immediately after the Transaction, in substantially the same proportions as their ownership of shares of the Company&#x2019;s voting stock immediately before the Transaction, direct or indirect beneficial ownership of more than fifty percent (50%) of the total combined voting power of the outstanding voting securities of the Company or the successor entity, or, in the case of a Transaction described in (iii), the corporation or other entity to which the assets of the Company were transferred, as the case may be.  Notwithstanding the foregoing, a transaction shall not constitute a Change in Control if: (i) its sole purpose is to change the state of the Company&#x2019;s incorporation; (ii) its sole purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#x2019;s securities immediately before such transaction; (iii) it constitutes the Company&#x2019;s initial public offering of its securities; or (iv) it is a transaction effected primarily for the purpose of financing the Company with cash (as determined by the Board in its discretion).  Notwithstanding the foregoing, a &#x201c;Change in Control&#x201d; must also constitute a &#x201c;change in control event,&#x201d; as defined in Treasury Regulation &#167;1.409A-3(i)(5).</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definition of Change in Control Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  For purposes hereof, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in  Control Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the period commencing three months prior to a Change in Control and ending 12 months after such Change in Control.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definition of Covered Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  For purposes hereof, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Covered Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the termination of Executive&#x2019;s employment by the Company without Cause or by Executive for Good Reason, and shall not include a termination due to Executive&#x2019;s death or disability.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definition of Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  For purposes hereof, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean that Executive has complied in all material respects with the &#x201c;Good Reason Process&#x201d; (hereinafter defined) following the occurrence of any of the following events, without Executive&#x2019;s prior written consent: (i) a material reduction of Executive&#x2019;s Annual Base Salary (unless pursuant to a salary reduction program applicable generally to the Company&#x2019;s senior management employees); or (ii) relocation of Executive&#x2019;s principal place of employment to a place that increases Executive&#x2019;s one-way commute by more than by more than seventy-five (75) miles as compared to Executive&#x2019;s principal place of employment immediately prior to such relocation; or (iii) a material reduction in Executive&#x2019;s job title and primary duties, responsibilities and authorities, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that a change in job position (including a change in title) shall not be deemed a &#x201c;material reduction&#x201d; in and of itself unless Executive&#x2019;s  new duties are materially reduced from the prior duties. </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definition of Good Reason Process</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  For the purposes hereof, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Good Reason Process</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean that (A) Executive has reasonably determined in good faith that a </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.12</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Good Reason&#x201d; condition has occurred; (B) Executive has notified the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first time the Executive becomes aware of the occurrence of such condition; (C) Executive has cooperated in good faith with the Company&#x2019;s efforts, for a period not less than 30 days immediately following the Company&#x2019;s receipt of such notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cure Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), to remedy the condition; (D) notwithstanding such efforts, the Good Reason condition continues to exist; and (E) Executive terminates Executive&#x2019;s employment with the Company within 30 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assignment and Successors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company shall assign its rights and obligations under this Agreement to any successor to all or substantially all of the business or the assets of the Company (by merger or otherwise).  This Agreement shall be binding upon and inure to the benefit of the Company, Executive, and their respective successors, assigns, personnel, and legal representatives, executors, administrators, heirs, distributees, devisees, and legatees, as applicable.  None of Executive&#x2019;s rights or obligations may be assigned or transferred by Executive, other than Executive&#x2019;s rights to payments hereunder, which may be transferred only by will, operation of law, or as otherwise provided herein</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Miscellaneous Provisions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restrictive Covenant Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  On or before the Effective Date, Executive shall enter into the Company&#x2019;s standard form Proprietary Information and Invention Assignment Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual Property Assignment Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; together with any other confidentiality agreement between Executive and the Company, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restrictive Covenant Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  The Restrictive Covenant Agreements shall survive the termination of this Agreement and Executive&#x2019;s employment with the Company for the applicable period(s) set forth therein.  Notwithstanding the foregoing, in the event of any conflict between the terms of the Restrictive Covenant Agreements and the terms of this Agreement, the terms of this Agreement shall prevail.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-Solicitation of Employees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  For a period of one year following Executive&#x2019;s Date of Termination, Executive shall not, either directly or indirectly (i) solicit for employment by any individual, corporation, firm, or other business, any employees, consultants, independent contractors, or other service providers of the Company or any of its affiliates, or (ii) solicit any employee or consultant of the Company or any of its affiliates to leave the employment or consulting of or cease providing services to the Company or any of its affiliates; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the foregoing clauses (i) and (ii) shall not apply to a general advertisement or solicitation (or any hiring pursuant to such advertisement or solicitation) that is not specifically targeted to such employees or consultants.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement shall be governed, construed, interpreted, and enforced in accordance with its express terms, and otherwise in accordance with the substantive laws of the State of California, without giving effect to any principles of conflicts of </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.12</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">law, whether of the State of California or any other jurisdiction, and where applicable, the laws of the United States, that would result in the application of the laws of any other jurisdiction.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Validity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect.  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement may be executed in several counterparts, each of which shall be deemed to be an original, but all of which together will constitute one and the same Agreement.  Signatures delivered by facsimile shall be deemed effective for all purposes.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The terms of this Agreement, together with the Restrictive Covenant Agreements, are intended by the Parties to be the final expression of their agreement with respect to the employment of Executive by the Company and supersede all prior understandings and agreements, whether written or oral, regarding Executive&#x2019;s service to the Company.  The Parties further intend that this Agreement, together with the Restrictive Covenant Agreements, shall constitute the complete and exclusive statement of their terms and that no extrinsic evidence whatsoever may be introduced in any judicial, administrative, or other legal proceeding to vary the terms of this Agreement or the Restrictive Covenant Agreements.  Notwithstanding the foregoing, in the event of any conflict between the terms of the Restrictive Covenant Agreements and the terms of this Agreement, the terms of this Agreement shall prevail.    </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendments; Waivers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement may not be modified, amended, or terminated except by an instrument in writing signed by Executive and a duly authorized representative of the Company.  By an instrument in writing similarly executed, Executive or a duly authorized officer of the Company, as applicable, may waive compliance by the other Party with any specifically identified provision of this Agreement that such other Party was or is obligated to comply with or perform; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that such waiver shall not operate as a waiver of, or estoppel with respect to, any other or subsequent failure.  No failure to exercise and no delay in exercising any right, remedy, or power hereunder shall preclude any other or further exercise of any other right, remedy, or power provided herein or by law or in equity.  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:33.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:33.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.933%;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dispute Resolution</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  To ensure the timely and economical resolution of disputes that arise in connection with this Agreement, Executive and the Company agree that any and all controversies, claims and disputes arising out of or relating to this Agreement, including without limitation any alleged violation of its terms, shall be resolved solely and exclusively by final and binding arbitration held in San Francisco, California through JAMS in conformity with the then-existing JAMS employment arbitration rules, which can be found at </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">https://www.jamsadr.com/rules-employment-arbitration/</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The arbitration provisions of this Agreement shall be governed by and enforceable pursuant to the Federal Arbitration Act.  In all other respects for provisions not governed by the Federal Arbitration Act, this Agreement shall be construed in accordance with the laws of the State of California, without reference to conflicts of law principles. The arbitrator shall: (a) provide adequate discovery for the resolution of the dispute; and (b) issue a written arbitration decision, to include the arbitrator&#x2019;s essential findings and conclusions and a statement of the award.  The arbitrator shall award the prevailing Party attorneys&#x2019; </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.12</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:33.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fees and expert fees, if any.  Notwithstanding the foregoing, it is acknowledged that it will be impossible to measure in money the damages that would be suffered if the Parties fail to comply with any of the obligations imposed on them under Section 8(a), and that in the event of any such failure, an aggrieved person will be irreparably damaged and will not have an adequate remedy at law.  Any such person shall, therefore, be entitled to seek injunctive relief, including specific performance, to enforce such obligations, and if any action shall be brought in equity to enforce any of the provisions of Section 8(a), none of the Parties shall raise the defense, without a good faith basis for raising such defense,  that there is an adequate remedy at law.  Executive and the Company understand that by agreement to arbitrate any claim pursuant to this Section 8(h), they will not have the right to have any claim decided by a jury or a court, but shall instead have any claim decided through arbitration.  Executive and the Company waive any constitutional or other right to bring claims covered by this Agreement other than in their individual capacities.  Except as may be prohibited by applicable law, the foregoing waiver includes the ability to assert claims as a plaintiff or class member in any purported class or representative proceeding.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enforcement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If any provision of this Agreement is held to be illegal, invalid, or unenforceable under present or future laws, such provision shall be fully severable; this Agreement shall be construed and enforced as if such illegal, invalid, or unenforceable provision had never comprised a portion of this Agreement; and the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid, or unenforceable provision or by its severance from this Agreement.  Furthermore, in lieu of such illegal, invalid, or unenforceable provision there shall be added automatically as part of this Agreement a provision as similar in terms to such illegal, invalid, or unenforceable provision as may be possible and be legal, valid, and enforceable.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Withholding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company shall be entitled to withhold from any amounts payable under this Agreement any federal, state, local, or foreign withholding or other taxes or charges which the Company is required to withhold.  The Company shall be entitled to rely on an opinion of counsel if any questions as to the amount or requirement of withholding shall arise.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whistleblower Protections and Trade Secrets</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding anything to the contrary contained herein, nothing in this Agreement prohibits Executive from reporting possible violations of federal law or regulation to any United States governmental agency or entity in accordance with the provisions of and rules promulgated under Section 21F of the Securities Exchange Act of 1934 or Section 806 of the Sarbanes-Oxley Act of 2002, or any other whistleblower protection provisions of state or federal law or regulation (including the right to receive an award for information provided to any such government agencies).  Furthermore, in accordance with 18 U.S.C. &#167; 1833, notwithstanding anything to the contrary in this Agreement: (i) Executive shall not be in breach of this Agreement, and shall not be held criminally or civilly liable under any federal or state trade secret law (x) for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, or (y) for the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (ii) if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose the trade secret to Executive&#x2019;s attorney, and </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.12</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may use the trade secret information in the court proceeding, if Executive files any document containing the trade secret under seal, and does not disclose the trade secret, except pursuant to court order.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive represents and warrants that Executive&#x2019;s acceptance of employment with the Company has not breached, and the performance of Executive&#x2019;s duties hereunder will not breach, any duty owed by Executive to any prior employer or other person.  Executive further represents and warrants to the Company that (a) the performance of Executive&#x2019;s obligations hereunder will not violate any agreement between Executive and any other person, firm, organization, or other entity; (b) Executive is not bound by the terms of any agreement with any previous employer or other party to refrain from competing, directly or indirectly, with the business of such previous employer or other party that would be violated by Executive entering into this Agreement and/or providing services to the Company pursuant to the terms of this Agreement; and (c) Executive&#x2019;s performance of Executive&#x2019;s duties under this Agreement will not require Executive to, and Executive shall not, rely on in the performance of Executive&#x2019;s duties or disclose to the Company or any other person or entity or induce the Company in any way to use or rely on any trade secret or other confidential or proprietary information or material belonging to any previous employer of Executive.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Golden Parachute Excise Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Best Pay</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Any provision of this Agreement to the contrary notwithstanding, if any payment or benefit Executive would receive from the Company pursuant to this Agreement or otherwise (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) would (i) constitute a &#x201c;parachute payment&#x201d; within the meaning of Section 280G of the Code and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Excise Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), then such Payment will be equal to the Reduced Amount (as defined below).  The &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reduced Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; will be either (A) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (B) the entire Payment, whichever amount after taking into account all applicable federal, state, and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes), results in Executive&#x2019; s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (A) of the preceding sentence, the reduction shall occur in the manner (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reduction Method</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that results in the greatest economic benefit for Executive.  If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pro Rata Reduction Method</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Notwithstanding the foregoing, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A (as defined below) that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows:  (1) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for Executive as determined on an after-tax basis; (2) as a second priority, Payments that are </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.12</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">contingent on future events (</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">., being terminated without cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (3) as a third priority, Payments that are &#x201c;deferred compensation&#x201d; within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting Firm</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The accounting firm engaged by the Company for general tax purposes as of the day prior to the Change in Control will perform the calculations set forth in Section 10(a).  If the firm so engaged by the Company is serving as the accountant or auditor for the acquiring company, the Company will appoint a nationally recognized accounting firm to make the determinations required hereunder.  The Company will bear all expenses with respect to the determinations by such firm required to be made hereunder.  The accounting firm engaged to make the determinations hereunder will provide its calculations, together with detailed supporting documentation, to the Company within 30 days before the consummation of a Change in Control (if requested at that time by the Company) or such other time as requested by the Company.  If the accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it will furnish the Company with documentation reasonably acceptable to the Company that no Excise Tax will be imposed with respect to such Payment.  Any good faith determinations of the accounting firm made hereunder will be final, binding and conclusive upon the Company and Executive.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The intent of the Parties is that the payments and benefits under this Agreement comply with or be exempt from Section 409A of the Code and the Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Effective Date, (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith.  Notwithstanding any provision of this Agreement to the contrary, if the Company determines that any compensation or benefits payable under this Agreement may be subject to Section 409A, the Company shall work in good faith with Executive to adopt such amendments to this Agreement or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Company determines are necessary or appropriate to avoid the imposition of taxes under Section 409A, including, without limitation, actions intended to (i) exempt the compensation and benefits payable under this Agreement from Section 409A, and/or (ii) comply with the requirements of Section 409A; however, this Section 11(a) shall not create an obligation on the part of the Company to adopt any such amendment, policy or procedure or take any such other action, nor shall the Company (A) have any liability for failing to do so, or (B) incur or indemnify Executive for any taxes, interest or other liabilities arising under or by operation of Section 409A.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separation from Service</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding any provision to the contrary in this Agreement:  (i) no amount that constitutes &#x201c;deferred compensation&#x201d; under Section 409A shall be payable pursuant to Section 6 unless the termination of Executive&#x2019;s employment constitutes a &#x201c;separation from service&#x201d; within the meaning of Section 1.409A-1(h) of the Department of Treasury Regulations (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Separation from Service</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); (ii) for purposes of Section 409A, Executive&#x2019;s </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.12</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">right to receive installment payments shall be treated as a right to receive a series of separate and distinct payments; and (iii) to the extent that any reimbursement of expenses or in-kind benefits constitutes &#x201c;deferred compensation&#x201d; under Section 409A, such reimbursement or benefit shall be provided no later than December 31</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">st</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the year following the year in which the expense was incurred.  The amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent year.  The amount of any in-kind benefits provided in one year shall not affect the amount of in-kind benefits provided in any other year.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specified Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding anything in this Agreement to the contrary, if Executive is deemed by the Company at the time of Executive&#x2019;s Separation from Service to be a &#x201c;specified employee&#x201d; for purposes of Section 409A, to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A, such portion of Executive&#x2019;s benefits shall not be provided to Executive prior to the earlier of (i) the expiration of the six-month period measured from the date of Executive&#x2019;s Separation from Service with the Company or (ii) the date of Executive&#x2019;s death.  Upon the first business day following the expiration of the applicable Section 409A period, all payments deferred pursuant to the preceding sentence shall be paid in a lump sum to Executive (or Executive&#x2019;s estate or beneficiaries), and any remaining payments due to Executive under this Agreement shall be paid as otherwise provided herein.  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Release</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding anything to the contrary in this Agreement, to the extent that any payments due under this Agreement as a result of Executive&#x2019;s termination of employment are subject to Executive&#x2019;s execution and delivery of the Release, (i)  if Executive fails to execute the Release on or prior to the Release Expiration Date (as defined below) or timely revokes Executive&#x2019;s acceptance of the Release thereafter, Executive shall not be entitled to any payments or benefits otherwise conditioned on the Release, and (ii) in any case where Executive&#x2019;s Date of Termination and the Release Expiration Date fall in two separate taxable years, any payments required to be made to Executive that are conditioned on the Release and are treated as nonqualified deferred compensation for purposes of Section 409A shall be made in the later taxable year.  For purposes of this Section 11(d), &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Release Expiration Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the date that is 21 days following the date upon which the Company timely delivers the Release to Executive, or, in the event that Executive&#x2019;s termination of employment is &#x201c;in connection with an exit incentive or other employment termination program&#x201d; (as such phrase is defined in the Age Discrimination in Employment Act of 1967), the date that is 45</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">days following such delivery date.  To the extent that any payments of nonqualified deferred compensation (within the meaning of Section 409A) due under this Agreement as a result of Executive&#x2019;s termination of employment are delayed pursuant to this Section 11(d), such amounts shall be paid in a lump sum on the first payroll date following the date that Executive executes and does not revoke the Release (and the applicable revocation period has expired) or, in the case of any payments subject to Section 11(d)(ii), on the first payroll period to occur in the subsequent taxable year, if later.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee Acknowledgement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive acknowledges that Executive has read and understands this Agreement, is fully aware of its legal effect, has not acted in reliance upon any representations or promises made by the Company other than those contained in writing herein, and has entered into this Agreement freely based on Executive&#x2019;s own judgment.  </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.12</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Signature Page Follows</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Parties have executed this Agreement as of the Effective Date.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">			</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDEAYA BIOSCIENCES, INC.</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:30pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:/s/ Yujiro S. Hata</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name:  Yujiro S. Hata</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title: 	President and Chief Executive Officer</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:30pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXECUTIVE</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:30pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:/s/ Stu Dorman</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="margin-left:6.667%;text-indent:35.714%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name: Stu Dorman</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Address:</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[             ]	</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[             ]	</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|US-DOCS\157183142.1||</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.12</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PERMITTED OUTSIDE ACTIVITIES</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[[ ]]</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.12</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RELEASE OF CLAIMS</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	This Release of Claims (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Release</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is entered into as of _________________, 20__, between [__________] (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and IDEAYA Biosciences, Inc., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and, together with Executive, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), effective eight days after Executive&#x2019;s signature hereto (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), unless Executive revokes his acceptance of this Release as provided in Paragraph 1(c), below.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.537%;text-indent:13.68%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.3219067748786717%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive&#x2019;s Release of the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive understands that by agreeing to this Release, Executive is agreeing not to sue, or otherwise file any claim against, the Company or any of its employees or other agents for any reason whatsoever based on anything that has occurred as of the date Executive signs this Release.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;text-indent:14.451%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.7362277688064245%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On behalf of Executive and Executive&#x2019;s heirs and assigns, Executive hereby releases and forever discharges the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Releasees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; hereunder, consisting of the Company, and each of its owners, affiliates, divisions, predecessors, successors, assigns, agents, directors, officers, partners, employees, and insurers, and all persons acting by, through, under or in concert with them, or any of them, of and from any and all manner of action or actions, cause or causes of action, in law or in equity, suits, debts, liens, contracts, agreements, promises, liability, claims, demands, damages, loss, cost or expense, of any nature whatsoever, known or unknown, fixed or contingent (hereinafter called &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), which Executive now has or may hereafter have against the Releasees, or any of them, by reason of any matter, cause, or thing whatsoever from the beginning of time to the date hereof, including, without limiting the generality of the foregoing, any Claims arising out of, based upon, or relating to Executive&#x2019;s hire, employment, remuneration or resignation by the Releasees, or any of them, including Claims arising under federal, state, or local laws relating to employment, Claims of any kind that may be brought in any court or administrative agency, any Claims arising under the Age Discrimination in Employment Act (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADEA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), 29 U.S.C. &#167; 621, et seq.; Title VII of the Civil Rights Act of 1964, as amended by the Civil Rights Act of 1991, 42 U.S.C. &#167; 2000 et seq.; the Equal Pay Act, 29 U.S.C. &#167; 206(d); the Civil Rights Act of 1866, 42 U.S.C. &#167; 1981; the Family and Medical Leave Act of 1993, 29 U.S.C. &#167; 2601 et seq.; the Americans with Disabilities Act of 1990, 42 U.S.C. &#167; 12101 et seq.; the False Claims Act , 31 U.S.C. &#167; 3729 et seq.; the Employee Retirement Income Security Act, 29 U.S.C. &#167; 1001 et seq.; the Worker Adjustment and Retraining Notification Act, 29 U.S.C.  &#167; 2101 et seq. the Fair Labor Standards Act, 29 U.S.C. &#167; 215 et seq., the Sarbanes-Oxley Act of 2002; the California Labor Code; the employment and civil rights laws of California; Claims for breach of contract; Claims arising in tort, including, without limitation, Claims of wrongful dismissal or discharge, discrimination, harassment, retaliation, fraud, misrepresentation, defamation, libel, infliction of emotional distress, violation of public policy, and/or breach of the implied covenant of good faith and fair dealing; and Claims for damages or other remedies of any sort, including, without limitation, compensatory damages, punitive damages, injunctive relief and attorney&#x2019;s fees.  </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.12</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;text-indent:14.451%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.7362277688064245%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the generality of the foregoing, Executive does not release the following claims:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.8465159749385585%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.8465159749385585%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Claims for workers&#x2019; compensation insurance benefits under the terms of any worker&#x2019;s compensation insurance policy or fund of the Company;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.8465159749385585%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Claims to continued participation in certain of the Company&#x2019;s group benefit plans pursuant to the terms and conditions of COBRA;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.8465159749385585%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Claims to any benefit entitlements vested as the date of Executive&#x2019;s employment termination, pursuant to written terms of any Company employee benefit plan;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.8465159749385585%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Claims for indemnification under any indemnification agreement with the Company, the Company&#x2019;s Bylaws, California Labor Code Section 2802 or any other applicable law; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.8465159749385585%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(vi)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive&#x2019;s right to bring to the attention of the Equal Employment Opportunity Commission claims of discrimination; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that Executive does release Executive&#x2019;s right to secure any damages for alleged discriminatory treatment.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;text-indent:14.451%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.7362277688064245%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with the Older Workers Benefit Protection Act of 1990, Executive has been advised of the following:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.8465159749385585%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive has the right to consult with an attorney before signing this Release;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.8465159749385585%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive has been given at least [twenty-one (21)   OR   forty-five (45)] days to consider this Release;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.8465159749385585%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive has seven (7) days after signing this Release to revoke it, and Executive will not receive the severance benefits provided by that certain Employment Agreement between the Parties (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employment Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) unless and until such seven (7) day period has expired.  If Executive wishes to revoke this Release, Executive must deliver notice of Executive&#x2019;s revocation in writing, no later than 5:00 p.m. on the 7th day following Executive&#x2019;s execution of this Release to [             ].</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;text-indent:14.451%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.7362277688064245%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXECUTIVE ACKNOWLEDGES THAT EXECUTIVE HAS BEEN ADVISED OF AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS:</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.12</font></p></div>
  <p style="margin-left:7.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BEING AWARE OF SAID CODE SECTION, EXECUTIVE HEREBY EXPRESSLY WAIVES ANY RIGHTS EXECUTIVE MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.537%;text-indent:13.68%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.3219067748786717%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive Representations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive represents and warrants that:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;text-indent:14.451%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.7362277688064245%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive has returned to the Company all Company property in Executive&#x2019;s possession;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;text-indent:14.451%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.7362277688064245%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive is not owed wages, commissions, bonuses or other compensation, other than wages through the date of the termination of Executive&#x2019;s employment and any accrued, unused vacation earned through such date, and any payments that become due under the Change of Control Agreement;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;text-indent:14.451%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.7362277688064245%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the course of Executive&#x2019;s employment Executive did not sustain any injuries for which Executive might be entitled to compensation pursuant to worker&#x2019;s compensation law or Executive has disclosed any injuries of which Executive is currently, reasonably aware for which Executive might be entitled to compensation pursuant to worker&#x2019;s compensation law; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;text-indent:14.451%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.7362277688064245%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive has not initiated any adversarial proceedings of any kind against the Company or against any other person or entity released herein, nor will Executive do so in the future, except as specifically allowed by this Release.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2.537%;text-indent:13.68%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.3219067748786717%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The provisions of this Release are severable.  If any provision is held to be invalid or unenforceable, it shall not affect the validity or enforceability of any other provision.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2.537%;text-indent:13.68%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.3219067748786717%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Choice of Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Release shall in all respects be governed and construed in accordance with the laws of the State of California, including all matters of construction, validity and performance, without regard to conflicts of law principles.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2.537%;text-indent:13.68%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.3219067748786717%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Integration Clause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Release and the Employment Agreement contain the Parties&#x2019; entire agreement with regard to the separation of Executive&#x2019;s employment, and supersede and replace any prior agreements as to those matters, whether oral or written. This Release may not be changed or modified, in whole or in part, except by an instrument in writing signed by Executive and a duly authorized officer or director of the Company.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.12</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:2.537%;text-indent:13.68%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.3219067748786717%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Execution in Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Release may be executed in counterparts with the same force and effectiveness as though executed in a single document.  Facsimile signatures shall have the same force and effectiveness as original signatures.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2.537%;text-indent:13.68%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.3219067748786717%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intent to be Bound</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Parties have carefully read this Release in its entirety; fully understand and agree to its terms and provisions; and intend and agree that it is final and binding on all Parties.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.12</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	IN WITNESS WHEREOF, and intending to be legally bound, the Parties have executed the foregoing on the dates shown below.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> EXECUTIVE						IDEAYA BIOSCIENCES, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">						</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">__________________________				__________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">							By:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">							Title:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">						           </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: ______________________			Date: _____________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">|</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>4
<FILENAME>idya-ex10_27.htm
<DESCRIPTION>EX-10.27
<TEXT>
<html>
 <head>
  <title>EX-10.27</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:36.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:37.963%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSE AGREEMENT</font></p>
  <p style="margin-left:6.48%;text-indent:7.739%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.546%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSE AGREEMENT </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is entered into as of December 27</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), by and between Jiangsu Hengrui Pharmaceuticals Co., Ltd., organized under the laws of the People&#x2019;s Republic of China, having an address at No. 7 Kunlunshan Road, Lianyungang, Jiangsu Province 222047, China and its Affiliates (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hengrui</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and IDEAYA Biosciences, Inc., organized under the laws of Delaware, having an address at 5000 Shoreline Court, Suite 300, South San Francisco, California 94080 U.S.A. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ideaya</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Hengrui and Ideaya may be referred to herein individually as a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or collectively as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;.</font></p>
  <p style="margin-left:36.88%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:37.963%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RECITALS</font></p>
  <p style="margin-left:6.48%;text-indent:7.745%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.611%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whereas</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Ideaya is a precision medicine biotechnology company that focuses on discovering, developing, and commercializing targeted therapeutics for patients to treat cancer;</font></p>
  <p style="margin-left:6.48%;text-indent:7.742%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.583%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whereas</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Hengrui is a biotechnology company that possesses intellectual property relating to certain antibody-drug-conjugates; and</font></p>
  <p style="margin-left:6.48%;text-indent:7.739%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.546%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whereas</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Ideaya desires to obtain from Hengrui, and Hengrui desires to grant to Ideaya, an exclusive license to develop and commercialize products containing such antibody-drug- conjugates, all under the terms and conditions set forth herein.</font></p>
  <p style="margin-left:6.48%;text-indent:7.746%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.63%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Now</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Therefore</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in consideration of the foregoing premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Ideaya and Hengrui hereby agree as follows:</font></p>
  <p style="margin-left:36.867%;font-size:10pt;margin-top:12.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:37.963%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AGREEMENT</font></p>
  <p style="margin-left:36.853%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:37.963%;text-align:center;" id="article_1__definitions"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 1 DEFINITIONS</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:11.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.1</font><div style="width:100%;display:inline;" id="x_1__acceptance__means__with_respect_to_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acceptance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to an IND for a Licensed Product, that [***]</font></div></div>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:7.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have passed since such IND has been submitted to the FDA, unless the FDA notifies the sponsor that the investigations described in the IND are subject to a clinical hold, or on earlier notification by FDA that the clinical investigations in the IND may begin.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADC(s)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a compound consisting of an Antibody conjugated to a drug(s).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.3</font><div style="width:100%;display:inline;" id="x_3__affiliate__means__with_respect_to_a"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any party, any entity that, now or in the future, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with such party, but for only so long as such control exists. As used in this Section 1.3, &#x201c;control&#x201d; means (a) to possess, directly or indirectly, the power to direct the management or policies of an entity, whether through ownership of voting securities, by contract relating to voting rights, or corporate governance; or (b) direct or indirect beneficial ownership of fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:3.7pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.4</font><div style="width:100%;display:inline;" id="x_4__alliance_manager__has_the_meaning_s"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Alliance Manager</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 3.7(f).</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.5</font><div style="width:100%;display:inline;" id="x_5__antibody__means_a_molecule_comprisi"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Antibody</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a molecule comprising or containing: (a) one or more immunoglobulin variable domains; (b) fragments, variants, modifications, or derivatives of such immunoglobulin variable domains irrespective of origin or source; or (c) the nucleic acid consisting of a sequence of nucleotides encoding (or complementary to a nucleic acid encoding) the foregoing molecules in clause (a) or (b). The molecules described in clause (a) or (b) can be fused to any immunoglobulin constant domains, for example, CH1, CH2, CH3, or CL, or a combination thereof.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.6</font><div style="width:100%;display:inline;" id="x_6__api__means_active_pharmaceutical_in"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">API</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means active pharmaceutical ingredient. For clarity, drug delivery vehicles, adjuvants, and excipients shall not be deemed to be APIs, except in the case where such delivery vehicle, adjuvant, or excipient is recognized by the FDA as an active ingredient in accordance with 21 CFR 210.3(b)(7).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.7</font><div style="width:100%;display:inline;" id="x_7__applicable_laws__means_the_applicab"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicable Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the applicable provisions of any and all national, supranational, regional, state, and local laws, treaties, statutes, rules, regulations, administrative codes, guidance, ordinances, judgments, decrees, directives, injunctions, orders, permits of or from any Governmental Authority having jurisdiction over or related to the subject item, including the</font></div></div>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:7.574%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. Food, Drug and Cosmetic Act (21 U.S.C. &#167;301 et seq.), Prescription Drug Marketing Act, the Generic Drug Enforcement Act of 1992 (21 U.S.C. &#167;335a et seq.), U.S. Patent Act (35 U.S.C. &#167;1 et seq.), Federal Civil False Claims Act (31 U.S.C. &#167;3729 et seq.), and the Anti-Kickback Statute (42 U.S.C. &#167;1320a-7b et seq.), all as amended from time to time, together with any rules, regulations, and compliance guidance promulgated thereunder.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.8</font><div style="width:100%;display:inline;" id="x_8__arising_ip__has_the_meaning_set_for"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arising IP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 8.2.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.9</font><div style="width:100%;display:inline;" id="x_9__bla__means__a__a_biologics_license_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BLA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) a Biologics License Application as defined in the United States Federal Food, Drug, and Cosmetic Act, 21 U.S.C. &#167; 301 et seq., as amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions, and modifications thereto), or (b) any corresponding foreign application in the Territory, including, with respect to the EU, an MAA filed with the EMA pursuant to the Centralized Approval Procedure or with the applicable Regulatory Authority of a country in Europe with respect to the mutual recognition or any other national approval procedure.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.10</font><div style="width:100%;display:inline;" id="x_10__business_day__means_a_day_other_th"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business Day</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a day other than Saturday, Sunday or any other day on which commercial banks located in the State of New York, U.S. or Beijing, China are authorized or obligated by Applicable Laws to close.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.11</font><div style="width:100%;display:inline;" id="x_11__calendar_quarter__means_each_respe"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Calendar Quarter</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means each respective period of three (3) consecutive months ending on March 31, June 30, September 30, and December 31.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.12</font><div style="width:100%;display:inline;" id="x_12__calendar_year__means_each_respecti"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Calendar Year</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means each respective period of twelve (12) consecutive months ending on December 31.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.13</font><div style="width:100%;display:inline;" id="x_13__change_of_control__means__with_res"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change of Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to a Party, (a) any acquisition, assignment, transfer, or other disposition, of all or substantially all of such Party&#x2019;s business or assets by or to a Third Party, (b) any reorganization or combination, whether by operation of law or otherwise, including a consolidation and merger, of such Party with or into any other entity, (c) any change in the shareholding of such Party in which the shareholders of such Party immediately prior to such change own less than fifty percent (50%) of such Party immediately after such change, (d) any circumstances in which a Third Party obtains the power, directly or indirectly, to </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">direct or cause the direction of the management or policies of such Party, or (e) the effectuation by the Party of a transaction or series of related transactions in which fifty percent (50%) or more of the voting power of the Party is transferred.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.14</font><div style="width:100%;display:inline;" id="x_14__claim__has_the_meaning_set_forth_i"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Claim</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 10.1.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.15</font><div style="width:100%;display:inline;" id="x_15__clinical_supply_agreement__has_the"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical Supply Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 5.4.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.16</font><div style="width:100%;display:inline;" id="x_16__cmc__means_chemistry__manufacturin"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CMC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means chemistry, manufacturing, and control.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.17</font><div style="width:100%;display:inline;" id="x_17__cmo__means_contract_manufacturing_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CMO</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means contract manufacturing organization.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.752%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.18</font><div style="width:100%;display:inline;" id="x_18__combination_product__means___a__a_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Combination Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means: (a) a pharmaceutical product that consists of a Licensed Compound and at least one other API that is not a Licensed Compound; or (b) any combination of a Licensed Product and another pharmaceutical product that contains at least one other API that is not a Licensed Compound, where such products are not formulated together but are sold together as a single product and invoiced as one product. The other API(s) in clause (a) and the other pharmaceutical product(s) in clause (b) are each referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Product(s)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.19</font><div style="width:100%;display:inline;" id="x_19__commercial_supply_agreement__has_t"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial Supply Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 5.5.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.20</font><div style="width:100%;display:inline;" id="x_20__commercialization__means_the_condu"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the conduct of all activities undertaken in support of the promotion, marketing, sale and distribution (including importing, exporting, transporting, customs clearance, warehousing, invoicing, handling, and delivering Licensed Products to customers) of Licensed Products, including: (a) sales force efforts, detailing, commercial strategy, advertising, medical education, planning, marketing, sales force training, and sales and distribution (including pricing and reimbursement activities), (b) post-approval clinical trials, and (c) data generation efforts (e.g., RWE, HEOR studies, etc.). &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialize</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercializing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; have correlative meanings.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.21</font><div style="width:100%;display:inline;" id="x_22__commercial_milestone_payment__has_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercially Reasonable Efforts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to the efforts to be expended, or considerations to be undertaken, by a Party or its Affiliate with respect to any objective, activity, or decision to be undertaken hereunder, [***].</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.22</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial Milestone Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 6.3(a).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.23</font><div style="width:100%;display:inline;" id="x_23__confidential_information__of_a_par"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; of a Party means all Know-How, materials, or other proprietary scientific, marketing, financial, or commercial information that is disclosed by or on behalf of such Party or any of its Affiliates or otherwise made available to the other Party or any of its Affiliates, whether made available orally, in writing, or in electronic form, whether before, on, or after the Effective Date. The existence and terms of this Agreement are the Confidential Information of both Parties, and the Licensed Know-How is the Confidential Information of Hengrui.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.24</font><div style="width:100%;display:inline;" id="x_24__confidentiality_agreement__means_t"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidentiality Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Mutual Nondisclosure Agreement between Hengrui and Ideaya, dated as of July 30, 2024.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.25</font><div style="width:100%;display:inline;" id="x_25__control__or__controlled__means__wi"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Controlled</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any materials, Know-How, Patents, or other Intellectual Property, the legal authority or right (whether by ownership, license, or otherwise, but without taking into account any rights granted by one Party to the other Party </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pursuant to this Agreement) of a Party to grant access, a license, or a sublicense of or under such materials, Know-How, Patents, or other Intellectual Property to the other Party, or to otherwise disclose proprietary or trade secret information to such other Party, without [***].</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.26</font><div style="width:100%;display:inline;" id="x_26__cover__means__with_respect_to_a_va"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cover</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to a Valid Claim in a country and a Licensed Product, that such claim (for clarity, with respect to Valid Claim of a patent application, if such pending claim were to issue in an issued patent without modification) would be infringed, absent a license, by the use, offer for sale, sale, or importation or other Exploitation of such Licensed Product in such country.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.27</font><div style="width:100%;display:inline;" id="x_27__cro__means_any_third_party_contrac"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CRO</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Third Party contract research organization.</font><font id="x_28__data__means_any_and_all_scientific"></font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.28</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all scientific, technical, or test data pertaining to any Licensed Compound or Licensed Product that is generated by or on behalf of Hengrui or its Affiliates or, to the extent such data is Controlled by Hengrui, by or on behalf of its licensees, or by or on behalf of Ideaya or its Affiliates or, to the extent Controlled by Ideaya, its Sublicensees, including research data, clinical pharmacology data, CMC data (including analytical and quality control data and stability data), pre-clinical data, clinical data, clinical study reports, or submissions made in association with an IND or MAA with respect to any Licensed Compound or Licensed Product.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.29</font><div style="width:100%;display:inline;" id="x_29__develop__means_to_research_or_deve"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Develop</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means to research or develop (including clinical, nonclinical, and CMC development), analyze, test, and conduct preclinical, clinical, and all other regulatory trials for a Licensed Compound or Licensed Product, as well as all related regulatory activities and any and all activities pertaining to new indications, pharmacokinetic studies, and all related activities including work on new formulations, new methods of treatment, and CMC activities including new manufacturing methods. &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Developing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; have correlative meanings.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.30</font><div style="width:100%;display:inline;" id="x_30__development_milestone_payment__has"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development Milestone Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 6.2(a).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.31</font><div style="width:100%;display:inline;" id="x_31__development_plan__has_the_meaning_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 3.2(a).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.32</font><div style="width:100%;display:inline;" id="x_32__direct_license__has_the_meaning_se"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Direct License</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 12.5(b).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.33</font><div style="width:100%;display:inline;" id="x_33__distributor__means__with_respect_t"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Distributor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to a country, any Third Party that is used by pharmaceutical manufacturers generally in such country on a non-exclusive basis, and without any license grant or other right from Ideaya or any of its Sublicensees under any Intellectual Property, to distribute finished, packaged pharmaceutical products to pharmacies, managed care organizations, governmental agencies, and other group purchasing organizations (e.g., pharmaceutical benefits managers) and the like in such country. For clarity, a Distributor of a Licensed Product in a country shall not include any person or entity that has been granted a right, whether by license or otherwise and whether express or implied (including by subcontract or agency), by Ideaya or its Affiliates to Manufacture any such Licensed Product.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.34</font><div style="width:100%;display:inline;" id="x_34__divisional_specified_patent__has_t"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Divisional Specified Patent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 8.4(a)(iii).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.35</font><div style="width:100%;display:inline;" id="x_35__dll3__means_delta_like_ligand_3_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DLL3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Delta-like ligand 3.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.36</font><div style="width:100%;display:inline;" id="x_36__documents__means_all_materials_and"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all materials and documents that arise from any Development, Manufacture, or Commercialization of any Licensed Compound or Licensed </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Products.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.37</font><div style="width:100%;display:inline;" id="x_37__ema__means_the_european_medicines_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EMA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the European Medicines Agency or any successor entity thereto.</font><font id="x_38__eu__means_all_countries_that_are_o"></font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.38</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EU</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all countries that are officially recognized as member states of the European Union or the European Economic Area at the Effective Date and any country that becomes a member state of European Union or the European Economic Area at any particular time. For clarity, countries that are officially recognized as member states of European Union or the European Economic Area as of the Effective Date but subsequently cease to be member states will continue to be treated as member states of European Union or the European Economic Area in connection with this Agreement. Without limiting the foregoing, the following are included in the definition of &#x201c;EU&#x201d;: the United Kingdom, Switzerland, Iceland, Liechtenstein and Norway. For clarity, as of the Effective Date, European Union consists of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain and Sweden.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.39</font><div style="width:100%;display:inline;" id="x_39__executive_officers__has_the_meanin"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive Officers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 13.1.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.40</font><div style="width:100%;display:inline;" id="x_40__exploit__means_to_make__use__sell_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exploit</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means to make, use, sell, offer for sale, or import, including to research, Develop, Manufacture, Commercialize, register, hold, or keep (whether for disposal or otherwise), transport, distribute, promote, market, or otherwise dispose of, or to have any of the foregoing performed. &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exploiting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exploitation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; have correlative meanings.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.41</font><div style="width:100%;display:inline;" id="x_41__export_control_laws__means__a__all"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Export Control Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) all applicable trade, export control, import, and antiboycott laws and regulations imposed, administered, or enforced by the U.S. government, including the International Emergency Economic Powers Act (50 U.S.C. &#167;&#167; 1701&#x2013;1706), Section 999 of the Internal Revenue Code, the U.S. customs laws at Title 19 of the U.S. Code, the Export Control Reform Act of 2018 (50 U.S.C. &#167;&#167; 4801-4861), the Export Administration Regulations (15 C.F.R. Parts 730-774), the U.S. customs regulations at 19 C.F.R. Chapter 1, and the Foreign Trade Regulations (15 C.F.R. Part 30); and (b) all applicable trade, export control, import, and antiboycott laws and regulations imposed, administered or enforced by any other country, except to the extent inconsistent with U.S. law.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.42</font><div style="width:100%;display:inline;" id="x_42__fcpa__means_the_u_s__foreign_corru"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FCPA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Foreign Corrupt Practices Act (15 U.S.C. Section 78dd-1, et. seq.), as amended.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.43</font><div style="width:100%;display:inline;" id="x_43__fda__means_the_united_states_food_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the United States Food and Drug Administration or any successor entity thereto.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.44</font><div style="width:100%;display:inline;" id="x_44__field__means_any_and_all_uses_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Field</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all uses.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.45</font><div style="width:100%;display:inline;" id="x_45__first_commercial_sale__means__on_a"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">First Commercial Sale</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, on a Licensed Product&#x2013;by&#x2013;Licensed Product and country-by-country basis, the first sale by Ideaya or any of its Affiliates or Sublicensees to a Third Party of a Licensed Product in a given country in the Territory, after Regulatory Approval has been granted with respect to such Licensed Product in such country. Any sale of Licensed Product by Ideaya to its Affiliate or Sublicensee will not constitute a First Commercial Sale. [***].</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.46</font><div style="width:100%;display:inline;" id="x_46__fte__means_the_equivalent_of_one__"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FTE</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the equivalent of [***] working full time for [***] (consisting of a total of [***] hours per year (or such other number as may be agreed by the JSC)) of scientific or </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">technical work (or scientific managerial work) undertaken by a Party&#x2019;s employees, as applicable.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.47</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Generic Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to a Licensed Product in a particular regulatory jurisdiction, any pharmaceutical product that (a) (i) contains the same API as the Licensed Compound in such Licensed Product and is approved by the Regulatory Authority in such country; (ii) is a biologic product (A) for which the licensing, approval, or marketing authorization relies in whole or in part on a prior licensing, approval, or marketing authorization granted such Licensed Product, (B) that is &#x201c;biosimilar&#x201d; to such Licensed Product, as the term &#x201c;biosimilar&#x201d; is defined in 42 U.S.C. &#167; 262(i)(2), or (C) that has been licensed by the FDA or other Regulatory Authority outside of the United States by reference to such Licensed Product, as set forth at 42 USC 262(k)(4) or other analogous applicable Law outside of the United States; or (iii) is approved by the Regulatory Authority in such country as a substitutable generic for such Licensed Product; and (b) is sold in such jurisdiction by a Third Party that is not a Sublicensee or Distributor and did not purchase such product in a chain of distribution that included any of Ideaya or its Affiliates, Sublicensees or Distributors.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.48</font><div style="width:100%;display:inline;" id="x_48__governmental_authority__means_any_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governmental Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any national, international, federal, state, provincial, or local government, or political subdivision thereof, or any multinational organization or any authority, agency, or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power, any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.49</font><div style="width:100%;display:inline;" id="x_49__greater_china__means_the_mainland_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Greater China</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Mainland China, Hong Kong, Macao, and Taiwan.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.50</font><div style="width:100%;display:inline;" id="x_50__hengrui_know_how__has_the_meaning_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hengrui Know-How</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 8.2.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.51</font><div style="width:100%;display:inline;" id="x_51__hengrui_platform__means_technology"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hengrui Platform</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means technology Controlled by Hengrui to the extent relating to [***].</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.52</font><div style="width:100%;display:inline;" id="x_52__hengrui_representative__has_the_me"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hengrui Representative</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 10.2.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.53</font><div style="width:100%;display:inline;" id="x_53__icc__has_the_meaning_set_forth_in_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ICC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 13.2(a).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.54</font><div style="width:100%;display:inline;" id="x_54__icc_rules__has_the_meaning_set_for"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ICC Rules</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 13.2(a).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.55</font><div style="width:100%;display:inline;" id="x_55__ideaya_know_how__has_the_meaning_s"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ideaya Know-How</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 8.2.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.56</font><div style="width:100%;display:inline;" id="x_56__ideaya_patent__has_the_meaning_set"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ideaya Patent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 8.4(c).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.57</font><div style="width:100%;display:inline;" id="x_57__ideaya_representative__has_the_mea"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ideaya Representative</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 10.1.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.58</font><div style="width:100%;display:inline;" id="x_58__ind__means_an_investigational_new_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IND</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an investigational new drug application, clinical trial authorization or equivalent application filed with the applicable Regulatory Authority, which application is required to commence human clinical trials in the applicable country.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.59</font><div style="width:100%;display:inline;" id="x_59__indemnitee__has_the_meaning_set_fo"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnitee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 10.3.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.60</font><div style="width:100%;display:inline;" id="x_60__indemnitor__has_the_meaning_set_fo"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnitor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 10.3.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.61</font><div style="width:100%;display:inline;" id="x_61__indirect_tax__has_the_meaning_set_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indirect Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 7.3(c).</font><font id="x_62__information__means_any_information"></font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.62</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any information, Inventions, concepts, compounds, compositions, formulations, formulas, practices, procedures, processes, methods, knowledge, know-how, trade secrets, technology, techniques, designs, drawings, correspondence, computer programs, documents, apparatus, results, strategies, regulatory documentation, information and submissions pertaining to, or made in association with, filings with any Government Authority or patent office, data, including pharmacological, toxicological, non-clinical and clinical data, analytical and quality control data, manufacturing data and descriptions, patent and legal data, market data, financial data or descriptions, devices, assays, chemical formulations, specifications, material, product samples and other samples, physical, chemical and biological materials and compounds, and the like, in written, electronic, oral or other tangible or intangible form, now known or hereafter developed, whether or not patentable, but excluding any Patents.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.63</font><div style="width:100%;display:inline;" id="x_63__initial_licensed_know_how__means_s"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial Licensed Know-How</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means such Know-How and related materials Controlled by Hengrui existing as of the Effective Date that are necessary or reasonably useful for Development of the Licensed Compound in the Field in the Territory as and to the extent set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 1.63</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.64</font><div style="width:100%;display:inline;" id="x_64__initiate__or__initiation__means__w"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initiate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initiation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to a clinical trial, the first dosing of the first subject in such clinical trial.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.65</font><div style="width:100%;display:inline;" id="x_65__intellectual_property__means_all_w"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all worldwide intellectual property or industrial property rights created, arising under or recognized by any laws or Governmental Authority, including (a) Patents, (b) Know-How, (c) trademarks, service marks, logos, product names and slogans, symbols, trade dress, trade names, d/b/a&#x2019;s, domain names and other indicia of origin, all applications and registrations for the foregoing, and all goodwill associated therewith and symbolized thereby, including all renewals of same, (d) published and unpublished works of authorship whether or not copyrightable, including computer software programs, databases and other compilations of information, copyrights in and to the foregoing, together with all common law rights and moral rights therein, and any applications and registrations therefor, including extensions, renewals, derivatives, translations, adaptations and combinations of the above and (e) any other similar intellectual property or industrial property rights anywhere in the world.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.66</font><div style="width:100%;display:inline;" id="x_66__inventions__means_all_inventions__"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all inventions, whether or not patentable, discovered, made, conceived, or conceived and reduced to practice, in the course of activities performed under this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.67</font><div style="width:100%;display:inline;" id="x_67__joint_inventions__has_the_meaning_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Joint Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 8.2.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.68</font><div style="width:100%;display:inline;" id="x_68__joint_know_how__has_the_meaning_se"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Joint Know-How</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 8.2.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.69</font><div style="width:100%;display:inline;" id="x_69__joint_patent__has_the_meaning_set_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Joint Patent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 8.2.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.70</font><div style="width:100%;display:inline;" id="x_70__jsc__has_the_meaning_set_forth_in_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">JSC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 3.7(a).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.71</font><div style="width:100%;display:inline;" id="x_71__know_how__means_all_data__regulato"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Know-How</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all Data, Regulatory Filings, Information, Inventions, and Documents.</font><font id="x_72__knowledge__means__with_respect_to_"></font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.72</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Knowledge</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to a matter that is the subject of a given representation or warranty of Hengrui,[***].</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.73</font><div style="width:100%;display:inline;" id="x_73__licensed_compound__means__a__the_a"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensed Compound</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) the ADC Controlled by Hengrui or its Affiliates and designated as &#x201c;SHR-4849&#x201d;, which Antibody is conjugated to a drug that is designed to bind, interact with, inhibit, or otherwise modulate topoisomerase, as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 1.73</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and [***].</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.74</font><div style="width:100%;display:inline;" id="x_74__licensed_know_how__means_any_and_a"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensed Know-How</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all Know-How Controlled by Hengrui as of the Effective Date or at any time during the Term that is necessary or reasonably useful to Exploit any Licensed Compound or Licensed Product in the Field in the Territory, including, for clarity, the Initial Licensed Know-How and any and all Hengrui Know-How or Hengrui Sole Inventions.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.75</font><div style="width:100%;display:inline;" id="x_75__licensed_patents__means_any_and_al"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensed Patents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all patents and patent applications Controlled by Hengrui as of the Effective Date or at any time during the Term that (a) claim the composition of matter of, or the method of making or using, any Licensed Compound or Licensed Product in the Field in the Territory, or (b) otherwise are necessary or reasonably useful to Exploit any Licensed Compound or Licensed Product in the Field in the Territory, including, for clarity, any patents and patent applications Controlled by Hengrui that claim, or that otherwise that are necessary or reasonably useful to Exploit any, Hengrui Know-How or Hengrui Sole Inventions; in each case including all continuations, continuations-in-part, divisionals, reissues, reexaminations, extensions, term restorations, registrations, re-instatements, amendments, or corrections thereof, including those set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 1.75</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and any and all foreign equivalents of any of the foregoing.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:3.7pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.76</font><div style="width:100%;display:inline;" id="x_76__licensed_product__means_one_or_mor"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensed Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means one or more pharmaceutical products containing a Licensed Compound (alone or with one or more other active ingredient(s)), in any forms, presentations, delivery systems, dosages, strengths, and formulations; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Licensed Product excludes any pharmaceutical products containing (a) any other proprietary compound of Hengrui or its Affiliates (other than the Licensed Compound); or (b) any proprietary compound licensed to Hengrui or its Affiliates by a Third Party.</font><font id="x_77__licensed_technology__means_the_lic"></font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.77</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensed Technology</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Licensed Know-How and Licensed Patents, including Hengrui&#x2019;s interest in the Joint Know-How, Joint Inventions, and Joint Patents.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.78</font><div style="width:100%;display:inline;" id="x_78__losses__has_the_meaning_set_forth_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Losses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 10.1.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.79</font><div style="width:100%;display:inline;" id="x_79__manufacture__and__manufacturing__m"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacture</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; mean activities directed to manufacturing, processing, filling, finishing, packaging, labeling, quality control, quality assurance testing and release, post-marketing validation testing, stability testing, inventory control and management, storing and transporting the Licensed Compound or the Licensed Products, but excluding Development or Commercialization.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.80</font><div style="width:100%;display:inline;" id="x_80__maa__means_a_marketing_authorizati"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MAA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a marketing authorization application or equivalent application, including a BLA or NDA and any necessary Pricing and Reimbursement Approvals, and all amendments and supplements thereto, filed with the applicable Regulatory Authority in any country or jurisdiction.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.81</font><div style="width:100%;display:inline;" id="x_81__major_biopharmaceutical_company__m"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Major Biopharmaceutical Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a company headquartered in U.S., EU or Japan that is primarily involved in the research, development, manufacturing, and marketing of biotechnology-based pharmaceutical products, having annual sales of pharmaceutical products of at least [***] (or its equivalent in another currency) in the year prior to the grant of a sublicense under Section 2.2.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.82</font><div style="width:100%;display:inline;" id="x_82__major_market__has_the_meaning_set_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Major Market</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 4.2.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.83</font><div style="width:100%;display:inline;" id="x_83__nda__means_a_new_drug_application_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NDA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a New Drug Application (or similar application), as defined in the Federal Food, Drug, and Cosmetic Act, as amended, and applicable regulations promulgated thereunder by the FDA (or an equivalent foreign agency).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.752%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.84</font><div style="width:100%;display:inline;" id="x_84__net_sales__means__with_respect_to_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Licensed Product, [***] for sales or other disposition of such Licensed Product by or on behalf of Ideaya or its Affiliates or Sublicensees (or Sublicensee&#x2019;s Affiliates) (each a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selling Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) to Third Parties (other than Sublicensees and their Affiliates), less the following deductions to the extent included in the gross invoiced sales price for such Licensed Product or otherwise directly paid or actually incurred by a Selling Party and not otherwise recovered by or reimbursed to the Selling Parties, as applicable, with respect to the sale of such Licensed Product:</font></div></div>
  <p style="margin-left:19.8%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.528%;text-align:justify;" id="xa__discounts__including_cash_and_quanti"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.85</font><div style="width:100%;display:inline;" id="x_85__party_vote__has_the_meaning_set_fo"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Party Vote</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 3.7(e).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.86</font><div style="width:100%;display:inline;" id="x_86__patents__means__a__all_national__r"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) all national, regional and international patents, certificates of invention, applications for certificates of invention, priority patent filings, and patent applications, or (b) any renewals, divisions, continuations (in whole or in part), or requests for continued examination of any of such patents, certificates of invention and patent applications, and any and all patents or certificates of invention issuing thereon, and any and all reissues, reexaminations, extensions, divisions, renewals, substitutions, confirmations, registrations, revalidations, revisions, and additions of or to any of the foregoing.</font><font id="x_87__phase_1_clinical_trial__means_a_hu"></font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.87</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1 Clinical Trial</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a human clinical trial of a Licensed Product in any country conducted in a small number of volunteers designed or intended to establish an initial safety profile, pharmacodynamics, or pharmacokinetics of a Product and that would satisfy the requirements of 21 CFR 312.21(a) or foreign equivalent.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.752%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.88</font><div style="width:100%;display:inline;" id="x_88__phase_2_clinical_trial__means_a_hu"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2 Clinical Trial</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a human clinical trial of a Licensed Product in any country to determine initial efficacy and determine the appropriate dose range and that would satisfy the requirements of 21 CFR 312.21(b) or foreign equivalent.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.89</font><div style="width:100%;display:inline;" id="x_89__phase_3_clinical_trial__means_a_pi"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 3 Clinical Trial</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a pivotal human clinical trial of a Licensed Product in any country with a defined dose or a set of defined doses of a Licensed Product designed to ascertain efficacy and safety of such Licensed Compound or Licensed Product for the purpose of submitting applications for Regulatory Approval to the competent Regulatory Authorities and that would satisfy the requirements of 21 CFR 312.21(c) or foreign equivalent.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.90</font><div style="width:100%;display:inline;" id="x_90__platform_patents__means_all_licens"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Platform Patents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all Licensed Patents, excluding any Product Patents, to the extent Covering the Hengrui Platform (or any improvements thereto), including those Licensed Patents identified as such in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 1.75</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and any Patents issuing thereon, any divisional, continuation, continuation-in-part, reissue, reexamination, utility model, parent or extension thereof, any Patent that claims priority to or shares priority or a common specification therewith, and any foreign counterparts of any of the foregoing.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:11.9pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.91</font><div style="width:100%;display:inline;" id="x_91__pmda__means_the_pharmaceuticals_an"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PMDA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Pharmaceuticals and Medical Devices Agency of Japan or any successor entity thereto.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.92</font><div style="width:100%;display:inline;" id="x_92__pricing_and_reimbursement_approval"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pricing and Reimbursement Approval</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to a Licensed Product, the approval, agreement, determination, or decision of the applicable Regulatory Authority establishing the price or level of reimbursement for such Licensed Product, as required in a given country or jurisdiction prior to reimbursed (or insurance-covered) sale of such Licensed Product in such jurisdiction.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.93</font><div style="width:100%;display:inline;" id="x_93__production_cell_line__has_the_mean"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Production Cell Line</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 6.6.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.94</font><div style="width:100%;display:inline;" id="x_94__product_infringement__has_the_mean"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product Infringement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 8.5(b)(i).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.95</font><div style="width:100%;display:inline;" id="x_95__product_patents__means__a__all_lic"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product Patents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) all Licensed Patents identified as Product Patents in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 1.75</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and (b) any other Licensed Patents that relate solely to the Licensed Compound(s) or Licensed Product(s) (</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, do not relate to compounds or products that are not Licensed Compound(s) or Licensed Product(s)), including any Patents filed pursuant to the last sentence of Section 8.4(a)(iii).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:3.7pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.96</font><div style="width:100%;display:inline;" id="x_96__regulatory_approval__means_any_and"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Approval</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all approvals, licenses, registrations, permits, notifications, and authorizations (or waivers) of any applicable Regulatory Authority, including Pricing and Reimbursement Approvals, that are necessary for the manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale, or other Commercialization of a Licensed Product in a given country or regulatory jurisdiction.</font><font id="x_97__regulatory_authority__means_any_ap"></font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.97</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any applicable Governmental Authority responsible for granting Regulatory Approvals for Licensed Products, including the FDA, the EMA, and any corresponding national or regional regulatory authorities.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.98</font><div style="width:100%;display:inline;" id="x_98__regulatory_filings__means_any_regu"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Filings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any regulatory application, submission, notification, communication (including meeting minutes), correspondence, registration, briefing documents, and other filings made to, received from, or otherwise conducted with a Regulatory Authority in order to Develop, Manufacture, or Commercialize a Licensed Compound or Licensed Product in a particular country or jurisdiction, including any IND, MAA, or Regulatory Approval.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.99</font><div style="width:100%;display:inline;" id="x_99__royalty_bearing_licensed_product__"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty-Bearing Licensed Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 6.4(a).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.100</font><div style="width:100%;display:inline;" id="x_100__royalty_floor__has_the_meaning_se"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Floor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 6.4(f).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.101</font><div style="width:100%;display:inline;" id="x_101__royalty_term__has_the_meaning_set"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 6.4(b).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.102</font><div style="width:100%;display:inline;" id="x_102__sanctions__means_economic_or_fina"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sanctions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a) the U.S. government, including those administered by OFAC or the U.S. Department of State, or (b) the United Nations Security Council, the European Union, any European Union member state or the United Kingdom.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.103</font><div style="width:100%;display:inline;" id="x_103__sec__means_the_u_s__securities_an"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Securities and Exchange Commission, or any successor</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">entity.</font></p>
  <p style="break-after:column;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x200b;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x200b;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:0.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.711767489152648%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.104</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selling Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 1.84.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:0.667%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.711767489152648%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.105</font><div style="width:100%;display:inline;" id="x_105__sigma__means_sigma_aldrich__shang"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sigma</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;	means	Sigma-Aldrich	(Shanghai)	Co.,	Ltd.	and	Sigma-Aldrich</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:7.565%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Shanghai) Trading Co., Ltd., Merck KGaA companies, with a principal place of business at 15- 18F, No.3, Building C, The New Bund World Trade Center (Phase II) Lane 227 Dongyu Road, Pudong New District Shanghai 200126, China.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.106</font><div style="width:100%;display:inline;" id="x_106__sole_inventions__has_the_meaning_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sole Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 8.2.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.107</font><div style="width:100%;display:inline;" id="x_107__specified_patent__means_patent_ap"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specified Patent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means [***].</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.108</font><div style="width:100%;display:inline;" id="x_108__sublicense_agreement__has_the_mea"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sublicense Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 2.2.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.109</font><div style="width:100%;display:inline;" id="x_109__sublicense_fees__means_all_non_cr"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sublicense Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all non-creditable, non-refundable upfront licensee fee or Development milestone payments received by Ideaya or its Affiliates, in consideration for the grant, under Section 2.2, of a sublicense under the Licensed Technology, pursuant to any Sublicense Agreement executed on or before [***] and all non-creditable, non-refundable upfront payments received by Ideaya or its Affiliates in consideration for the assignment or transfer of all or substantially all of the rights under the Licensed Technology to a Third Party, but for clarity excluding in connection with any Change of Control of Ideaya (such agreement assigning or transferring such rights an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assignment Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); provided that [***].</font><font id="x_110__sublicensee__means_a_third_party_"></font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.110</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sublicensee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Third Party or an Affiliate of Ideaya to which Ideaya grants a sublicense under Section 2.2, under the Licensed Technology, to Develop, Manufacture or Commercialize any Licensed Compound or Licensed Product in the Field in the Territory, as the case may be, other than a Distributor. In no event will Hengrui or any of its Affiliates be deemed a Sublicensee. Notwithstanding the foregoing, a party appointed by Ideaya or its Affiliates to distribute, market, or sell Licensed Product, where such party makes royalty or other payments (other than the purchase price of Licensed Product) to Ideaya or its Affiliates, will be deemed to be a Sublicensee.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.111</font><div style="width:100%;display:inline;" id="x_111__territory__means_worldwide_other_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Territory</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means worldwide other than Greater China.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.112</font><div style="width:100%;display:inline;" id="x_112__term__has_the_meaning_set_forth_i"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 12.1.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.113</font><div style="width:100%;display:inline;" id="x_113__third_party__means_any_entity_oth"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any entity other than Ideaya or Hengrui or an Affiliate of Ideaya or Hengrui.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.114</font><div style="width:100%;display:inline;" id="x_114__transferred_materials__has_the_me"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transferred Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 5.3.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.115</font><div style="width:100%;display:inline;" id="x_115__tri_party_agreement__has_the_mean"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tri-Party Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in Section 6.6.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.116</font><div style="width:100%;display:inline;" id="x_116__u_s___means_the_united_states_of_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the United States of America, including its territories and possessions.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.117</font><div style="width:100%;display:inline;" id="x_117__valid_claim__means__a__a_claim_of"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Valid Claim</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) a claim of an issued and unexpired patent that has not been revoked or held unenforceable or invalid by a court or other governmental agency of competent jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken within the allowable time period), and that has not been lapsed, been revoked, cancelled </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or abandoned, been donated to the public, finally disclaimed, denied, or held finally invalid or unenforceable by a court of competent jurisdiction in an unappealed or unappealable decision and which has not been held unenforceable through disclaimer or otherwise (b) a claim of a pending patent application that has been pending for no longer than [***] from its filing date and that was filed and has been pending and is being prosecuted in good faith and has not been lapsed, been revoked, cancelled or abandoned, been donated to the public, finally disclaimed, denied, or held finally invalid or unenforceable by a court of competent jurisdiction in an unappealed or unappealable decision and which has not been held unenforceable through disclaimer or otherwise.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:12.3pt;font-family:Times New Roman;margin-bottom:0;margin-right:38.38%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 2 GRANT OF LICENSES</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.1</font><div style="width:100%;display:inline;" id="x_1_licenses_to_ideaya___subject_to_the_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licenses to Ideaya.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the terms and conditions of this Agreement,</font></div></div>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:7.556%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hengrui hereby grants to Ideaya, effective as of the Effective Date and during the Term, an exclusive (even as to Hengrui), royalty-bearing, non-transferable (except as set forth in Section 14.5), license, with the right to grant sublicenses solely as provided in Section 2.2, under the Licensed Technology to Exploit the Licensed Compound and Licensed Products in the Field in the Territory.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.752%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.2</font><div style="width:100%;display:inline;" id="x_2_sublicensing___ideaya_will_have_the_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sublicensing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Ideaya will have the right to grant sublicenses, through multiple tiers, under the licenses granted in Section 2.1 to its Affiliates and to Third Parties, provided that Ideaya will notify Hengrui of the grant of such sublicense and the identity of the applicable Sublicensee in writing, and provide to Hengrui a copy of such sublicense (which may be redacted for financial terms to the extent not relevant to Hengrui&#x2019;s rights or obligations hereunder), in each case, no later than [***] following the grant of such sublicense agreement (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sublicense Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and, with respect to the grant by Ideaya of any such sublicense to a Third Party in respect of the U.S., Japan or the EU to any such potential Sublicensee that is not a Major Biopharmaceutical Company at the time of the proposed sublicensing, Ideaya will obtain the written consent of Hengrui prior to entering into a Sublicense Agreement for the U.S., Japan or EU with such Third Party, such consent not to be unreasonably withheld, conditioned, or delayed. Ideaya will ensure that each sublicense granted under the licenses granted in Section 2.1 will be in writing and comply with all terms and conditions of this Agreement applicable to such Sublicensee and will require further sublicenses to comply with the terms and conditions hereof, in the same manner and to the same extent as Ideaya is bound hereby, and Ideaya shall remain responsible for the performance of this Agreement by the Sublicensees. Without limiting the foregoing, each Sublicense Agreement will contain the following provisions: (a) a requirement that the sublicensee comply with Article 11 with respect to the other Party&#x2019;s Confidential Information; (b) requirements consistent with this Section 2.2 and the relevant terms of this Agreement; and (c) if such sublicense contains a right to Commercialize the Licensed Products, such Sublicense Agreement will also contain the following provisions: (i) a requirement that the Sublicensee submit applicable sales or other reports to Ideaya to the extent necessary or relevant to the reports required to be made or records required to be maintained by Ideaya under this Agreement and (ii) the audit requirement set forth in Section 7.4 (</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">mutatis mutandis</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). For clarity, any attempted sublicense by Ideaya in violation of this Section 2.2 shall be void.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.1pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.3</font><div style="width:100%;display:inline;" id="x_3_no_implied_licenses___except_as_expr"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Implied Licenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as expressly set forth in this Agreement, neither Party will acquire any license or other intellectual property interest, by implication or otherwise, under or to any Intellectual Property Controlled by the other Party.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.4</font><div style="width:100%;display:inline;" id="x_4_disclosure_and_transfer_of_licensed_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosure and Transfer of Licensed Know-How</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__promptly_after_the_effective_date__b"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Promptly after the Effective Date (but in no event later than [***] after the Effective Date), to the extent not already in Ideaya&#x2019;s possession, Hengrui will transfer to Ideaya the Initial Licensed Know-How. As reasonably requested by Ideaya, Hengrui shall provide to Ideaya, reasonable access to personnel of Hengrui or its Affiliates familiar with the Licensed Compounds and Licensed Know-How, and shall facilitate transfer of supplier relationships to Ideaya. In addition, Hengrui will use good faith efforts to provide to Ideaya on an ongoing basis, any Data arising from Hengrui&#x2019;s conduct of any clinical trial of any Licensed Product, in each case promptly, but no later than [***] following Ideaya&#x2019;s reasonable request, provided that any such Data that is raw data may be subject to further quality control review after such provision to Ideaya. </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding anything to the contrary, Hengrui shall not be required to reduce to tangible embodiments any Know-How that does not already exist in such tangible embodiments in fulfillment of any of its obligations hereunder (including this Section 2.4 and Section 5.2).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__such_access_will_be_provided_by_tele"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Such access will be provided by teleconference, by electronic means, or in- person at Hengrui&#x2019;s or its contractor&#x2019;s facilities. At least [***], upon Ideaya&#x2019;s reasonable request, Hengrui will provide to Ideaya or its permitted designee any material additional Licensed Know-How generated since the last such disclosure.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.504%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.463%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__with_respect_to_the_licensed_know_ho"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to the Licensed Know-How transfer contemplated by Section 2.4(a), Hengrui will provide Ideaya with electronic copies of, and if reasonably requested by Ideaya, physical access to the originals of, any and all documents, electronic records and databases, samples, and other tangible materials included in the applicable Licensed Know-How. For clarity, Licensed Know-How shall include all material preclinical study reports that was generated by or on behalf of Hengrui or its Affiliates prior to the Effective Date, for any Licensed Compound or Licensed Product or incorporated (including any Data therein) in any Regulatory Filing for any Licensed Compound or Licensed Product.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="xd__hengrui_s_provision_of_any_licensed_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hengrui&#x2019;s provision of any Licensed Know-How or access to its personnel, and conduct of any of its other obligations contemplated under this Section 2.4 shall be (i) at no cost or expense for the initial [***] FTE hours (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FTE Cap</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); and (ii) at a charge to Ideaya of [***] per FTE hour thereafter.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;" id="xe__each_party_will_provide_the_other_pa"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Party will provide the other Party with copies of Data that have been or are generated by or on behalf of such Party and its Affiliates in relation to Licensed Compound or Licensed Products. Hengrui will provide all Information (including all Data) under Sections 2.4 and 5.2 in the original language of such Information. Upon reasonable request by Ideaya and acceptance by Ideaya of the fee quote provided by Hengrui with respect thereto, Hengrui will provide the translation of any such documents into English at Ideaya&#x2019;s sole cost and expense. For clarity, notwithstanding such disclosure, any such Data will remain the Confidential Information of the disclosing Party for purposes of this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.5</font><div style="width:100%;display:inline;" id="x_5_license_grant_back_to_hengrui___in_p"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License Grant Back to Hengrui</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In partial consideration for the rights granted to Ideaya hereunder, Ideaya hereby grants to Hengrui, an irrevocable, perpetual, non-terminable, exclusive (even as to Ideaya), royalty-free, fully paid-up, freely transferable license, with the right to freely grant sublicenses through multiple tiers, under any rights Controlled by Ideaya in Arising IP to Exploit the Licensed Compounds and Licensed Products in the Field in Greater China. Hengrui shall remain fully liable for any action or inaction by any of its sublicensees that would be a breach of the terms of this Agreement as if committed by Hengrui. Hengrui will ensure that each sublicense granted under the license granted in this Section 2.5 will be in writing and comply with all terms and conditions of this Agreement applicable to such sublicensee and will require further sublicenses to comply with the terms and conditions hereof, in the same manner and to the same extent as Hengrui is bound hereby, and Hengrui shall remain responsible for the performance of this Agreement by all sublicensees.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:36.867%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:37.963%;text-align:center;" id="article_3__development"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 3 DEVELOPMENT</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:11.75pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.1</font><div style="width:100%;display:inline;" id="x_1_general___as_between_the_parties___1"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As between the Parties, Ideaya will be solely responsible, at its own expense, for the pre-clinical and clinical Development of such Licensed Compound and Licensed Products containing such Licensed Compound in the Field in the Territory. As between the Parties, Hengrui will be solely responsible, at its own expense, for the pre-clinical and clinical Development of such Licensed Compound and Licensed Products containing such Licensed Compound in the Field outside of the Territory.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.2</font><div style="width:100%;display:inline;" id="x_2_development_plans_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__development_plan___an_initial_develo"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. An initial development plan for Ideaya&#x2019;s intended Development activities is set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 3.2(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (as amended in accordance with this Agreement, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and Ideaya will conduct such Development of the Licensed Compound under this Agreement in accordance with such Development Plan. Ideaya will be responsible for updating the Development Plan annually and will provide the JSC with each updated Development Plan that also includes a report on Ideaya&#x2019;s Development activities.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__conflict___if_the_terms_of_a_develop"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conflict</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the terms of a Development Plan contradict, or create inconsistencies or ambiguities with, the terms of this Agreement, then the terms of this Agreement will govern.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.3</font><div style="width:100%;display:inline;" id="x_3_conduct_of_development_activities___"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conduct of Development Activities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party will perform all Development activities in compliance with all Applicable Laws, including good scientific and clinical practices under the Applicable Laws of the country in which such activities are conducted.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.4</font><div style="width:100%;display:inline;" id="x_4_development_diligence___ideaya_will_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development Diligence</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Ideaya will use Commercially Reasonable Efforts (but in no event less than such efforts that Ideaya would use for its Development activities with respect to its other programs) to Develop a Licensed Product pursuant to the Development Plan, and if such Development is successful, file at least one MAA for such Licensed Product in the Field in the Territory following the Effective Date. Without limiting the generality of the foregoing, Ideaya shall use Commercially Reasonable Efforts to Initiate a clinical trial of a Licensed Product in the Territory [***].</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.5</font><div style="width:100%;display:inline;" id="x_5_use_of_contractors___each_party_may_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Contractors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party may perform its activities under this Agreement through one or more contractors, including distributors, in its reasonable discretion, provided that each contractor will be bound by a written agreement that is consistent with the terms and conditions of this Agreement, including terms regarding the confidentiality and non-use of Confidential Information no less stringent than those set forth in Article 11 and terms requiring assignment to such Party of all Intellectual Property that is necessary or useful for or otherwise related to the Development, Manufacture, or Commercialization of Licensed Compound or Licensed Products developed by each contractor in the course of performing any such work that are consistent with the terms and conditions of this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:3.7pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.6</font><div style="width:100%;display:inline;" id="x_6_conduct_of_regulatory_activities__ri"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conduct of Regulatory Activities; Right of Reference; Pharmacovigilance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__conduct_of_regulatory_activities___i"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conduct of Regulatory Activities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Ideaya will be solely responsible, at its own expense, for (i) all regulatory activities related to Licensed Products in the Field in the Territory, including all Regulatory Filings and all communications with Regulatory Authorities, and (ii) preparing, filing, obtaining, and maintaining Regulatory Approvals for Licensed Products </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the Field in the Territory. Subject to Applicable Laws, Ideaya (or its Affiliate or other Sublicensee) will be the holder of all Regulatory Approvals for Licensed Products in the Field in the Territory. Without limiting the following, Ideaya shall use Commercially Reasonable Efforts to conduct all such regulatory activities, which shall include seeking Regulatory Approval in each of the Major Markets.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__right_to_reference_regulatory_materi"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Right to Reference Regulatory Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party hereby grants to the other Party a right of reference to all Regulatory Materials filed by such Party for Licensed Products solely for the purpose of seeking, obtaining and maintaining Regulatory Approvals for, and the Commercialization of, Licensed Products in such other Party&#x2019;s respective territory.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__pharmacovigilance_and_drug_safety_ag"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmacovigilance and Drug Safety Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Before the receipt of regulatory approval for the commencement of any clinical trials in or for the Territory, the Parties will enter into a mutually acceptable drug safety data exchange agreement setting forth the Parties&#x2019; respective obligations in detail regarding pharmacovigilance and the exchange of global drug safety data for regulatory reporting and will revise such agreement for post-marketing surveillance purposes at an appropriate time before the receipt of approval of an MAA of a Licensed Product in the Territory.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.7</font><div style="width:100%;display:inline;" id="x_7_governance_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__formation__purposes_and_principles__"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Formation; Purposes and Principles</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Within [***] after the Effective Date, the Parties will form a joint steering committee (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">JSC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) to review and oversee certain activities of the Parties relating to the Development and Commercialization of the Licensed Compound and Licensed Products, to ensure coordination of Development and Commercial activities in and outside of the Territory, and to facilitate information sharing between the Parties with respect thereto. The JSC will be in existence from the date of its formation until the Parties mutually agree to disband the JSC.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:19.87%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:8.320229626856358%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__specific_responsibilities___the_jsc_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specific Responsibilities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The JSC will:</font></div></div>
  <p style="margin-left:26.467%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.63%;text-align:justify;" id="xi__coordinate_and_facilitate_communicat"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font id="xiii__review_and_discuss_development_of_"></font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xiv__review_and_discuss_any_material_ame"><font id="xc__membership___the_jsc_will_be_compose"></font><font id="xv__review_and_discuss_regulatory_develo"></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Membership</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The JSC will be composed of a total of three (3) (or such other number agreed by the Parties) representatives appointed by each Party. Each individual appointed by a Party as a representative to the JSC will be an employee of such Party with sufficient seniority within the applicable Party to provide meaningful input and make decisions arising within the scope of the JSC&#x2019;s responsibilities and have knowledge and expertise in the Development of compounds and products similar to the Licensed Compound and Licensed Products under this Agreement. Each Party may replace any of its JSC representatives at any time upon written notice to the other Party, which notice may be given by e-mail, sent to the other Party. Each JSC representative will be subject to confidentiality obligations no less stringent than those in Article 11.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:3.7pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="xd__meetings___the_jsc_will_hold_meeting"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Meetings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The JSC will hold meetings [***] during the Term for so long as the JSC exists, unless the Parties mutually agree in writing to a different frequency. Either Party may also call a special meeting of the JSC by providing at least [***] prior written notice to the other Party if such Party reasonably believes that a significant matter must be addressed prior to the next scheduled meeting. The JSC may meet in person or by audio or video conference as its representatives may mutually agree. Other representatives of the Parties (including relevant Alliance Managers), their Affiliates, and, only with the advance, written consent (not to be </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:3.7pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;" id="xe__decision_making___each_party_s_repre"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unreasonably withheld, delayed, or conditioned) of both Parties, Third Parties involved in the Development of Licensed Compound and Licensed Products may be invited by the members of the JSC to attend meetings as observers; provided, however, that such representatives are subject to confidentiality obligations no less stringent than those set forth in Article 11.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Decision-Making</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party&#x2019;s representatives on the JSC will collectively have one (1) vote (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Party Vote</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) on all matters before the JSC, and no action or decision will be taken by the JSC without a unanimous Party Vote (i.e., the affirmative Party Vote of each Party). If the JSC is not able to reach agreement with respect to a matter at a duly called meeting of the JSC, either Party may refer such matter to the Executive Officers for resolution, and the Executive Officers will attempt to resolve the matter in good faith. If the Executive Officers fail to resolve such matter within [***] after the date on which the matter is referred to the Executive Officers (unless a longer period is agreed to by the Parties), then the Executive Officer of Ideaya will have final decision-making authority on all matters relating to the Licensed Compounds and Licensed Products in the Territory, and Hengrui will have final decision- making authority on all matters relating to the Licensed Compounds and Licensed Products outside of the Territory; [***]. Either Party may submit for resolution, pursuant to Section 13.1, to the Executive Officers any such disputes that are unable to be resolved under this Section 3.7(e) in accordance with such final decision-making authority. Notwithstanding the foregoing or anything contained herein, neither the JSC nor a Party through exercise of its final decision-making authority will have the right or authority to amend or waive any of the terms or conditions of this Agreement or otherwise determine any matter outside the authority of the JSC or that expressly requires mutual agreement of the Parties under this Agreement, or to increase or materially change the other Party&#x2019;s obligations under this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.1pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;" id="xf__alliance_managers___each_party_will_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Alliance Managers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party will appoint an individual, who is an employee of such Party, to act as a project manager (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Alliance Manager</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) who will be responsible for (i) providing a single point of communication within the Parties&#x2019; respective organizations and between the Parties with respect to this Agreement, including any issues that may arise that it may be possible to resolve without (or prior to) escalation to the JSC, and (ii) implementing and coordinating activities and facilitating the exchange of information between the Parties. The Alliance Managers will be responsible for facilitating the flow of information and otherwise promoting communication, coordination and collaboration between the Parties. Each Party may replace its Alliance Manager at any time upon written notice to the other Party.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.8</font><div style="width:100%;display:inline;" id="x_8_audits_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;margin-top:3.7pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:7.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.706953553812739%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa___if_a_regulatory_authority_desires_t"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a Regulatory Authority desires to conduct an inspection or audit of any Ideaya facility or any Affiliate or Third Party facility under contract with Ideaya with regard to the Development of a Licensed Product, then Ideaya will notify Hengrui as soon as practicably possible after receipt of such notification of such audit or inspection and provide copies of any materials provided to it by the applicable Regulatory Authority to the extent relating to such Licensed Product; provided that Ideaya will not be required to notify Hengrui of audits or inspections that are of a routine nature or to the extent they do not relate to Development of such Licensed Product, except where such audits result in communications or actions of such Regulatory Authority which have an impact upon such Licensed Product. In addition, if a Regulatory Authority conducts an unannounced inspection or audit of any Ideaya facility or any Affiliate or Third Party facility under contract with Ideaya with regard to Development of a Licensed Product, then Ideaya will notify Hengrui as promptly as practicable after, but in any event within [***] of, commencement of such audit or inspection. Ideaya will cooperate, and will use reasonable efforts to cause the contract </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;margin-top:3.7pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:7.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.706953553812739%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">facility to cooperate, with such Regulatory Authority and Hengrui during such inspection or audit. Following receipt of the inspection or audit observations of such Regulatory Authority, Ideaya will promptly provide Hengrui with a copy of the inspection or audit report to the extent relating to such Licensed Product and also provide Hengrui with copies of any written communications received from Regulatory Authorities with respect to such facilities in a timely manner after receipt, to the extent such written communications relate to Development of such Licensed Product, and will prepare the response to any such observations. Ideaya will provide Hengrui with a copy of any proposed response to such communications and will consider in good faith including Hengrui&#x2019;s reasonable comments with respect to such proposed response. Ideaya agrees to conform its activities under this Agreement to any commitments made in such a response.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__if_a_regulatory_authority_desires_to"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a Regulatory Authority desires to conduct an inspection or audit of any Hengrui facility or any Affiliate or Third Party facility under contract with Hengrui, in each case with regard to any Hengrui clinical trial Information provided to Ideaya under this Agreement that Ideaya has submitted to such Regulatory Authority in order to obtain Regulatory Approval of the Licensed Product or Manufacture of Licensed Compound or Licensed Product supplied to Ideaya under this Agreement, then Hengrui will notify Ideaya as soon as practicably possible after receipt of such notification of such audit or inspection and provide copies of any materials provided to it by the applicable Regulatory Authority to the extent relating to such Licensed Product; provided, that Hengrui will not be required to notify Ideaya of audits or inspections that are of a routine nature or to the extent they do not relate to the Exploitation of such Licensed Product in the Territory, except where such audits result in communications or actions of such Regulatory Authority which have an impact upon such Licensed Product in the Territory. In addition, if a Regulatory Authority in the Territory conducts an unannounced inspection or audit of any Hengrui facility or any Affiliate or Third Party facility under contract with Hengrui, in each case with regard to any Hengrui clinical trial Information provided to Ideaya under this Agreement that Ideaya has submitted to such Regulatory Authority in order to obtain Regulatory Approval of a Licensed Product or relates to any Licensed Compound or Licensed Product supplied to Ideaya under this Agreement, then Hengrui will notify Ideaya within [***] of commencement of such audit or inspection. Hengrui will cooperate, and will use reasonable efforts to cause the contract facility to cooperate, with such Regulatory Authority during such inspection or audit. Following receipt of the inspection or audit observations of such Regulatory Authority, Hengrui will promptly provide Ideaya with a copy of the inspection or audit report to the extent relating to such Licensed Product and also provide Ideaya with copies of any written communications received from Regulatory Authorities with respect to such facilities in a timely manner after receipt, to the extent such written communications relate to any Hengrui clinical trial Information provided to Ideaya under this Agreement that Ideaya has submitted to such Regulatory Authority in order to obtain Regulatory Approval for a Licensed Product or Licensed Compound or Licensed Product supplied to Ideaya under this Agreement, and will prepare the response to any such observations. Hengrui will provide Ideaya with a copy of any proposed response to such communications and will consider in good faith including Ideaya&#x2019;s reasonable comments with respect to such proposed response. Hengrui agrees to conform its activities under this Agreement to any commitments made in such a response.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.48in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:36.893%;text-indent:-0.053%;padding-left:0.013%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:38.009%;text-align:center;" id="article_4__commercialization"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 4 COMMERCIALIZATION</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:11.75pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.1</font><div style="width:100%;display:inline;" id="x_1_general___as_between_the_parties__id"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As between the Parties, Ideaya will be solely responsible, at its own expense, for all aspects of the Commercialization of Licensed Products in the Territory, and Hengrui will be solely responsible, at its own expense, for all aspects of the Commercialization of Licensed Products outside the Territory, including: (a) developing and executing a commercial launch and pre-launch plan; (b) negotiating with applicable Regulatory Authorities regarding the price and reimbursement status of Licensed Products; (c) marketing and promotion activities; (d) booking sales and distribution and performance of related services; (e) handling all aspects of order processing, invoicing and collection, inventory and receivables; (f) providing customer support, including handling medical queries, and performing other related functions; (g) medical affairs activities (e.g., medical education, non-registrational data generation, etc.); and (h) conforming its practices and procedures to Applicable Laws relating to the marketing, detailing, and promotion of Licensed Products.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.2</font><div style="width:100%;display:inline;" id="x_2_commercialization_diligence___with_r"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialization Diligence</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. With respect to any Licensed Product for which Regulatory Approval has been obtained in a country, Ideaya will use Commercially Reasonable Efforts (but in no event less than such efforts that Ideaya would use for its Commercialization activities with respect to its other programs) to Commercialize such Licensed Product in such country, including that if Regulatory Approval is obtained in any of the United States, Japan, United Kingdom, France, Germany, Spain or Italy (each a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Major Market</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), Ideaya shall itself or through a Sublicensee use Commercially Reasonable Efforts to market and promote such Licensed Product in such country.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.3</font><div style="width:100%;display:inline;" id="x_3_promotional_materials___the_parties_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Promotional Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Parties will each be responsible for filing their own trademarks for Licensed Products in their respective territories, and shall discuss granting each other mutual licenses under copyrights embodied in marketing content to commercialize the Licensed Product in their respective territories.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:33.707%;text-indent:30.869%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:33.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 5 MANUFACTURE AND SUPPLY</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:11.75pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.1</font><div style="width:100%;display:inline;" id="x_1_responsibility___as_between_the_part"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Responsibility</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As between the Parties, except as otherwise set forth in this Agreement, Ideaya, itself or through its Affiliates or CMOs, will be responsible for the Manufacture and supply of Ideaya&#x2019;s and its Affiliates&#x2019; and Sublicensees&#x2019; requirements for Licensed Compound and Licensed Products for Development and Commercial use in the Territory.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:7.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.706953553812739%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.2</font><div style="width:100%;display:inline;" id="x_2_manufacturing_technology_transfer___"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing Technology Transfer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Promptly after Ideaya&#x2019;s written request, to the extent not already in Ideaya&#x2019;s possession, Hengrui will commence a technology transfer to Ideaya or its permitted designee of all Licensed Know-How relating to the Manufacture of the Licensed Compound or Licensed Product, including facilitating contracting with Hengrui&#x2019;s current CMOs, as reasonably necessary for Ideaya or its permitted designee to be able to implement the Manufacturing process used by Hengrui (or its Affiliate or CMO) to Manufacture the applicable Licensed Compound or Licensed Product (including API and linker payload materials for manufacture, and any intermediate materials or compounds). Hengrui will use good faith efforts to complete such Manufacturing technology transfer as soon as reasonably practicable. In addition to such Manufacturing technology transfer, Hengrui will use good faith efforts to provide reasonable assistance from and access to Hengrui employees with relevant knowledge related to such Manufacturing technology. [***].</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.3</font><div style="width:100%;display:inline;" id="x_3_transfer_of_existing_materials___pro"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transfer of Existing Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Promptly after Ideaya&#x2019;s written request, and in accordance with the Clinical Supply Agreement, Hengrui will transfer to Ideaya from Hengrui&#x2019;s then-existing stock (which, for the avoidance of doubt, excludes any stock that is reasonably necessary or useful for Hengrui&#x2019;s Development activities outside the Territory) of the Licensed Compound and Licensed Product in the Control of Hengrui or any of its Affiliates (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transferred Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). For clarity, the Transferred Materials will include any molecules or compounds used in the manufacture by Ideaya or its permitted designee of such Licensed Compound. The Transferred Materials will be delivered by Hengrui [***] to an address Ideaya designates in writing. Title and risk of loss will be transferred to and borne by Ideaya upon delivery of the Transferred Materials by Hengrui to a carrier designated by Ideaya. Upon request by Ideaya made reasonably prior to the shipment of the Transferred Materials by Hengrui, Hengrui will provide Ideaya the applicable documentation required for Ideaya to conduct its final release for the Transferred Materials in accordance with Applicable Laws.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.4</font><div style="width:100%;display:inline;" id="x_4_clinical_supply_agreement___in_accor"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical Supply Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In accordance with a clinical supply agreement to be negotiated and executed promptly after the Effective Date (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical Supply Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and an associated quality agreement, Hengrui will supply the specific quantity of clinical trial materials to Ideaya for use in clinical trials of Licensed Products, as requested by Ideaya in a forecasted order submitted to Hengrui reasonably in advance of (but in any event, at least [***] prior to) the delivery date. Ideaya will reimburse Hengrui&#x2019;s reasonable documented fully burdened cost of Manufacturing such quantity of clinical trial material provided under the Clinical Supply Agreement, as mutually agreed in writing in advance.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.5</font><div style="width:100%;display:inline;" id="x_5_commercial_supply_agreement___upon_t"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial Supply Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon the written request of Ideaya, the Parties will enter into good faith negotiations for a supply agreement governing the supply of Licensed </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product by Hengrui or one of its Affiliates to Ideaya for Commercialization in the Field in the Territory following Ideaya&#x2019;s receipt of the first Regulatory Approval in the Territory (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial Supply Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and an associated quality agreement. The terms of any such Commercial Supply Agreement will be negotiated in good faith by the Parties based upon reasonable and customary terms typically associated with supply of pharmaceutical products for Commercialization in the Territory.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:7.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.706953553812739%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.6</font><div style="width:100%;display:inline;" id="x_6_ideaya_manufacturing_in_greater_chin"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ideaya Manufacturing in Greater China</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding anything to the contrary herein, in the event Ideaya or any of its Affiliates elects to engage a CDMO to Manufacture Licensed Compound and Licensed Products on its behalf in Greater China, Ideaya shall, or shall cause its applicable Affiliate to, provide notice to Hengrui thereof offering Hengrui the right to assume such Manufacturing obligations. Upon receipt of such notice, Hengrui and Ideaya shall negotiate in good faith to agree on such a Manufacturing arrangement in Greater China on commercially reasonable terms; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Ideaya and its Affiliates shall have the right to engage a Third Party to undertake the Manufacture of Licensed Compound and Licensed Products on its behalf in Greater China if Ideaya or its applicable Affiliate provides credible evidence to Hengrui that Hengrui&#x2019;s Manufacturing capabilities do not meet Ideaya&#x2019;s requisite quality standards, as assessed by the quality assurance function of Ideaya or its applicable Affiliate, and Hengrui agrees in writing and in good faith that Hengrui&#x2019;s Manufacturing capabilities do not meet such standards.</font></div></div>
  <p style="margin-left:43.573%;text-indent:0.114%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:44.685%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:43.573%;text-indent:0.114%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:44.685%;text-align:center;" id="article_6"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 6 </font><font id="payments"></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PAYMENTS</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1</font><div style="width:100%;display:inline;" id="x_1_upfront_payment___in_partial_conside"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upfront Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In partial consideration for Ideaya&#x2019;s rights in and to the Licensed Technology licensed hereunder and other rights granted hereunder, within [***] of the Effective Date, Ideaya will pay to Hengrui a one-time non-creditable and non-refundable upfront fee in the amount of Seventy-Five Million U.S dollars ($75,000,000).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:11.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.2</font><div style="width:100%;display:inline;" id="x_2_development_and_regulatory_milestone"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development and Regulatory Milestone Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__development_and_regulatory_milestone"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development and Regulatory Milestones</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In partial consideration for Ideaya&#x2019;s rights in and to the Licensed Technology licensed hereunder and other rights granted hereunder, Ideaya will pay to Hengrui the one-time development milestone payments (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development Milestone Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) set forth in the table below upon the first achievement of each milestone event (whether by or on behalf of Ideaya, its Affiliates, or Sublicensees):</font></div></div>
  <p style="font-size:10pt;margin-top:0.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:7.62%;border-spacing:0;table-layout:auto;width:85.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:75.66%;box-sizing:content-box;"></td>
    <td style="width:24.34%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:41.05pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;text-indent:98pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:18.147%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Development Milestone Event</font></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;text-indent:1.25pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.227%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.213%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Development Milestone Payment (in US$)</font></p></td>
   </tr>
   <tr style="height:27.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.35pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.987%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(i)	[***]</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:1.25pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.227%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.222%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:27.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.35pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.987%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(ii) [***]</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:2.15pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.4%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.213%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:27.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.35pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.987%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(iii) [***]</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:2.15pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.4%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.213%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:13.7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.35pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.987%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(iv) [***]</font></p><p style="margin-left:0.987%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:2.15pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.4%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.213%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:27.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.35pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.987%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(v) [***]</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:2.15pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.4%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.213%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:27.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.35pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.987%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(vi) [***]</font></p><p style="margin-left:5.053%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:2.15pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.4%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.213%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:27.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.35pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.987%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(vii)  [***]</font></p><p style="margin-left:5.053%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:2.15pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.4%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.213%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:13.7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.35pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.987%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:2.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.387%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.213%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$200,000,000</font></p></td>
   </tr>
  </table>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.583%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Development Milestone Payment above is payable one time only, regardless of the number of times the corresponding event is achieved by a Licensed Product and regardless of the number of Licensed Products to achieve such event. Under no circumstances will Ideaya be obligated to pay Hengrui, pursuant to this Section 6.2, more than Two Hundred Million U.S. dollars ($200,000,000).</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:3.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.593%;text-align:justify;" id="if_any_development_milestone_event_set_f"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any Development Milestone Event set forth in (ii) through (vii) occurs without any one of the preceding Development Milestone Events set forth in (i) through (iii) occurring, such non- occurring Development Milestone Payment set forth in (i) through (iii) would be deemed to be achieved and paid at the same time as the trigger and payment for the first of the applicable subsequent Development Milestone Event set forth in (ii), (iii), (iv), (v), (vi), or (vii).</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notice and Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Ideaya will notify Hengrui promptly, but in no event later than [***], after Ideaya becomes aware of the achievement of any milestone event set forth in Section 6.2(a). Thereafter, Hengrui will submit to Ideaya an invoice for the corresponding milestone payment set forth Section 6.2(a). Within [***] of Ideaya&#x2019;s receipt of any such invoice, Ideaya will remit the applicable milestone payment to Hengrui.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.3</font><div style="width:100%;display:inline;" id="x_3_commercial_milestone_payments_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial Milestone Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__commercial_milestones___in_partial_c"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial Milestones</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In partial consideration for Ideaya&#x2019;s rights in and to the Licensed Technology licensed hereunder and other rights granted hereunder, Ideaya will pay to Hengrui the one-time commercial milestone payments set forth below upon the first achievement of aggregate annual Net Sales of Royalty-Bearing Licensed Products in the Territory exceeding the values indicated below in a Calendar Year (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial Milestone Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). For clarity, the milestone payments in this Section 6.3(a) will be additive such that if multiple milestone events for the Licensed Compound specified below are achieved in the same Calendar Year, then the Commercial Milestone Payments for all such milestone events will be payable after the end of such Calendar Year.</font></div></div>
  <p style="font-size:10pt;margin-top:0.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:9.889%;border-spacing:0;table-layout:auto;width:79.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:61.46%;box-sizing:content-box;"></td>
    <td style="width:38.54%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:33.85pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;text-indent:20.85pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:2.08%;text-indent:-1.844%;padding-left:1.773%;font-size:12pt;margin-top:2.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Calendar Year Net Sales of all Royalty-Bearing Licensed Products in the Territory (in US$)</font></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;text-indent:37.65pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:4.613%;text-indent:-2.667%;padding-left:2.36%;font-size:12pt;margin-top:2.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Commercial Milestone Payment (in US$)</font></p></td>
   </tr>
   <tr style="height:19.45pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.35pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.987%;text-indent:0;font-size:12pt;margin-top:2.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:0.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.013%;text-indent:0;font-size:12pt;margin-top:2.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:19.45pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.35pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.987%;text-indent:0;font-size:12pt;margin-top:2.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:0.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.013%;text-indent:0;font-size:12pt;margin-top:2.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:19.45pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.35pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.987%;text-indent:0;font-size:12pt;margin-top:2.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:0.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.013%;text-indent:0;font-size:12pt;margin-top:2.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:20.15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.35pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.987%;text-indent:0;font-size:12pt;margin-top:2.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:0.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.013%;text-indent:0;font-size:12pt;margin-top:2.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:19.45pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.35pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.987%;text-indent:0;font-size:12pt;margin-top:2.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:0.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.013%;text-indent:0;font-size:12pt;margin-top:2.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:19.45pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.35pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.987%;text-indent:0;font-size:12pt;margin-top:2.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:0.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.013%;text-indent:0;font-size:12pt;margin-top:2.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:19.45pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.35pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.987%;text-indent:0;font-size:12pt;margin-top:2.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:0.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.013%;text-indent:0;font-size:12pt;margin-top:2.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
   </tr>
  </table>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:13.75pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.546%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Commercial Milestone Payment above is payable one time only, regardless of the number of times the corresponding event is achieved by the Licensed Products. Under no circumstances will Ideaya be obligated to pay Hengrui, pursuant to this Section 6.3, more than [***].</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__notice_and_payment___ideaya_will_not"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notice and Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Ideaya will notify Hengrui promptly, but in no event later than within [***] after Ideaya becomes aware that the Licensed Products have achieved any commercial milestone event set forth in Section 6.3(a), whether sold by Ideaya, its Affiliates, or </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sublicensees. Ideaya will pay to Hengrui the applicable Commercial Milestone</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:3.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment within [***] after the end of the Calendar Year in which such commercial milestone event is achieved.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.4</font><div style="width:100%;display:inline;" id="x_4_royalty_payments_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__royalty_rate___in_partial_considerat"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In partial consideration for Ideaya&#x2019;s rights in and to the Licensed Technology licensed hereunder and other rights granted hereunder, subject to the remainder of this Section 6.4, Ideaya will make quarterly royalty payments to Hengrui, on aggregate annual Net Sales of all Licensed Products sold in the Territory during the applicable Royalty Term for each Licensed Product in each country (such Licensed Product in such country, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty-Bearing Licensed Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div>
  <p style="font-size:10pt;margin-top:0.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:7.62%;border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:80.32%;box-sizing:content-box;"></td>
    <td style="width:19.68%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:33.85pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;text-indent:159.45pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:2.867%;text-indent:-38.66%;padding-left:26.653%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Annual Net Sales of All Royalty-Bearing Licensed Products in the Territory</font></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;text-indent:0.2pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.04%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.019%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Royalty Rate</font></p></td>
   </tr>
   <tr style="height:33.85pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.35pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.987%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:0.2pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.04%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:47.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.35pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.987%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:0.2pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.04%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:47.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.35pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.987%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:0.2pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.04%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:47.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.35pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.987%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:0.2pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.04%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:47.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.35pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.987%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:0.2pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.04%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:33.85pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.35pt;border-left:0.5pt solid #000000;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.987%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:0.2pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="margin-left:0.04%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
   </tr>
  </table>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:13.65pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__royalty_term___royalties_will_be_pai"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Royalties will be paid on a Licensed Product&#x2013;by&#x2013;Licensed Product and country-by-country basis in the Territory from the First Commercial Sale of such Licensed Product in such country until the later of: (i) expiration of the last-to-expire Valid Claim of the Licensed Patents Covering the composition of matter or method of use in an approved Indication in such country of such Licensed Product in such country, and (ii) [***] after the First Commercial Sale of such Licensed Product in such country (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font><font id="xc__generic_competition___if_one_or_more"></font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:13.65pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Generic Competition</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If one or more Generic Products to a Licensed Product is launched in a country in the Territory during the Royalty Term for such Licensed Product in such country, and the unit volume of all Generic Products to such Licensed Product that are sold by Third Parties in such country is equal to or exceeds [***] of the combined unit volume </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:13.65pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of such Licensed Product and such Generic Product sold in such country for any Calendar Quarter, the royalties applicable to such Net Sales in such country will be reduced by [***] of the royalties otherwise payable under Section 6.4(a), as applicable, for such Calendar Quarter. Determinations of unit volume will be based on a mutually acceptable calculation method and using market share data provided by a reputable and mutually agreed upon provider, such as IQVIA.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="xd__third_party_licenses___subject_to_se"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third Party Licenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject to Section 6.6., if Ideaya, its Affiliates, or Sublicensees obtains a license from a Third Party under such Third Party&#x2019;s Patents, which Ideaya, its Affiliates or Sublicensees determine in good faith are necessary to manufacture, use, import, offer to sell, or sell a Licensed Compound or Licensed Product in the Field in the Territory (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Necessary Third Party License</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), then Ideaya will have the right to credit [***] of all royalty payments made by Ideaya, its Affiliates, or Sublicensees to such Third Party pursuant to such Necessary Third Party License against any payments owed to Hengrui hereunder with respect to such Licensed Product; provided that (i) Ideaya shall provide written notice to Hengrui promptly after commencing negotiations with such Third Party and (ii) any such credits not exhausted in any Calendar Quarter may be carried forward into future Calendar Quarters, provided that such carried forward credits never reduce the royalties due to Hengrui in any Calendar Quarter below the Royalty Floor.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;" id="xe__know_how_royalty___on_a_country_by_c"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Know-How Royalty</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On a country-by-country and Licensed Product&#x2013;by&#x2013; Licensed Product basis in a Calendar Quarter, in the event that none of the manufacture, use, importation, offer to sell, or sale of the Licensed Products is Covered by any Valid Claim of a Licensed Patent in such country, then the royalties applicable to such Net Sales in such country for such Licensed Product will be reduced by [***] of the royalties otherwise payable under this Section 6.4, as applicable, for such Calendar Quarter.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;" id="xf__maximum_amount_of_royalty_reduction_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maximum Amount of Royalty Reduction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In no event will the royalties payable to Hengrui under Section 6.4 be reduced by more than [***] in any Calendar Quarter during the Royalty Term for a Licensed Product as a result of the reductions set out in Sections 6.4(c) to 6.4(e) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Floor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Credits for deductions not exhausted in any Calendar Quarter may be carried forward into future Calendar Quarters, provided that such carried forward credits never reduce the royalties due to Hengrui in any Calendar Quarter below the Royalty Floor.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.752%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.5</font><div style="width:100%;display:inline;" id="x_5_sublicensing_payments___in_partial_c"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sublicensing Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In partial consideration for Ideaya&#x2019;s rights in and to the Licensed Technology licensed hereunder and other rights granted hereunder, Ideaya will pay to Hengrui an amount equal to [***] of any Sublicense Fees received by Ideaya or its Affiliates pursuant to any Sublicense Agreement or Assignment Agreement, in each case, executed on or before the [***], which amount shall be paid to Hengrui promptly after, but in any event within [***] of, receipt of the applicable Sublicense Fees; provided that in no event will Ideaya be obligated to pay more than [***] pursuant to this Section 6.5.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.6</font><div style="width:100%;display:inline;" id="x_6_tri_party_agreement_and_cell_line_co"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tri-Party Agreement and Cell Line Costs</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Parties shall cooperate to promptly execute an agreement with Sigma confirming Ideaya&#x2019;s use (by itself or by or through its third-party contract research organization or contract manufacturing organization) of the [***] cell line to express the Licensed Compound pursuant to the terms of this Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tri-Party Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). To the extent the Tri-Party Agreement has</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:3.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not been executed prior to the completion of the Manufacturing technology transfer contemplated by Section 5.2, the Parties will cooperate in good faith to determine an alternative solution for Ideaya to obtain such rights. To the extent any amount is payable to Sigma under the Tri-Party Agreement in connection with the transfer by Hengrui to Ideaya of the cell line engineered to produce the Licensed Compound (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Production Cell Line</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the Parties shall each bear [***] of the cost, and, notwithstanding the terms of the Tri-Party Agreement, Ideaya shall pay such amounts when due to Sigma, and upon Ideaya&#x2019;s use of the Production Cell Line to express the Licensed Compound for GMP activities, Ideaya shall invoice Hengrui for its share of such cost. To the extent any amount is payable to Sigma in connection with the transfer of the Production Cell Line by Ideaya to a Third Party under the Tri-Party Agreement or any separate agreement between Ideaya, Sigma, and/or such Third Party, as between the Parties, Ideaya shall solely bear such costs.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:33.267%;text-indent:31.777%;font-size:10pt;margin-top:12.3pt;font-family:Times New Roman;margin-bottom:0;margin-right:33.25%;text-align:left;" id="article_7__payment__records__audits"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 7 PAYMENT; RECORDS; AUDITS</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.752%;font-size:0;margin-top:11.75pt;justify-content:flex-start;margin-bottom:0;margin-right:7.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.1</font><div style="width:100%;display:inline;" id="x_1_payment__reports___royalty_payments_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment; Reports. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty payments due by Ideaya to Hengrui under Section 6.4 will be calculated and reported for each Calendar Quarter. Ideaya will pay all royalty payments due under Section 6.4 within [***] after the end of each Calendar Quarter and will include with each payment a report setting forth, on a country-by-country and Licensed Product&#x2013;by&#x2013; Licensed Product basis, (a) the amount of gross sales of the Licensed Products in such Calendar Quarter, (b) the amount of Net Sales of the Licensed Product in such Calendar Quarter (including reasonable information supporting the determination of Net Sales), (c) a calculation of the royalty payment due on such sales, including the application of any reduction made in accordance with Sections 6.4(c) to 6.4(e), and any Commercial Milestone Payment due on such sales, and (d) the exchange rate for such country.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.2</font><div style="width:100%;display:inline;" id="x_2_exchange_rate__manner_and_place_of_p"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange Rate; Manner and Place of Payment. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All references to dollars and &#x201c;$&#x201d; in this Agreement will refer to U.S. dollars. All payments under this Agreement will be payable in U.S. dollars. When conversion of payments from any currency other than U.S. dollars is required, such conversion will be at an exchange rate equal to the weighted average of the rates of exchange for the currency of the country from which such payments are payable as published by </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Wall Street Journal</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Eastern U.S. Edition, during the Calendar Quarter in which the applicable sales were made. All payments owed under this Agreement will be made by wire transfer in immediately available funds to a bank and an account designated in writing by Hengrui.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.3</font><div style="width:100%;display:inline;" id="x_3_taxes_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__taxes_on_income___each_party_will_be"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Taxes on Income</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party will be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the activities of such Party under this Agreement.</font><font id="xb__withholding_tax___the_parties_agree_"></font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Withholding Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Parties agree to cooperate with one another and use reasonable efforts to avoid or reduce tax withholding or similar obligations in respect of royalties, milestone payments, and other payments made by Ideaya to Hengrui under this Agreement. To the extent Ideaya is required to deduct and withhold taxes on any payment to Hengrui, Ideaya will deduct those taxes from such payment, pay the amounts of such taxes to the proper Governmental Authority in a timely manner, and promptly transmit to Hengrui an official tax certificate or other evidence of such withholding sufficient to enable Hengrui to claim such payment of taxes. Hengrui will provide Ideaya any tax forms that may be reasonably necessary in order for Ideaya not to withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__indirect_tax___each_party_will_provi"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indirect Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party will provide the other with reasonable assistance to enable the reduction, credits, or recovery, as permitted by Applicable Laws, of withholding taxes, tariffs, or sales, use, value added or similar taxes (each an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indirect Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or Indirect Tax. For clarity, Hengrui will bear any Indirect Taxes imposed by the applicable tax authorities in Greater China on payments made under this Agreement. In the event any tax authority outside of Greater China imposes any Indirect </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax on payments made under this Agreement and such imposition does not result from the actions of either Party (such as changing such Party&#x2019;s location or jurisdiction), the Parties shall discuss in good faith a reasonable allocation of such Indirect Tax to be borne by each Party. Notwithstanding the foregoing, if as a result of any action by Hengrui, including assignment, any change in Hengrui&#x2019;s tax residency, or any failure on the part of Hengrui to comply with Applicable Laws (including filing or record retention requirements), incremental taxes are imposed that were not otherwise applicable, then Hengrui shall be solely responsible for the amount of such incremental taxes.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.752%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.4</font><div style="width:100%;display:inline;" id="x_4_records__audit___ideaya_will_keep__a"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Records; Audit</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Ideaya will keep, and will have its Affiliates and Sublicensees keep, complete and accurate records pertaining to the sale or other disposition of Licensed Products in sufficient detail to permit Hengrui to confirm the accuracy of Commercial Milestone Payments and royalty payments due hereunder. Such records will be kept for [***] following the end of the Calendar Quarter to which they pertain, or such longer period as may be required under Applicable Law. Hengrui will have the right to have an independent, certified public accountant reasonably acceptable to Ideaya audit records of Ideaya, its Affiliates or Sublicensees to confirm Net Sales, royalties, and Commercial Milestone Payments for a period covering not more than [***] following the Calendar Quarter to which they pertain. Such audits may be conducted during normal business hours upon reasonable prior written notice to Ideaya, and not more than once per Calendar Year. Any such auditor will not disclose Ideaya&#x2019;s Confidential Information to Hengrui, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by Ideaya or the amount of payments by Ideaya under this Agreement, and will enter into a customary confidentiality agreement with Ideaya. Any amounts shown to be owed but unpaid will be paid within [***] after the accountant&#x2019;s report. Any overpayment by Ideaya revealed by an audit will be credited against future payments owed by Ideaya to Hengrui (and if no further payments are due, will be refunded by Hengrui to Ideaya within [***] after the accountant&#x2019;s report). Hengrui will bear the full cost of such audit unless such audit discloses an underpayment by Ideaya of more than [***] of the amount of royalties or other payments due under this Agreement for the audited period, in which case, Ideaya will bear the reasonable cost (including any fee paid by Hengrui to such auditor) of such audit.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.1pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.5</font><div style="width:100%;display:inline;" id="x_5_late_payments___in_case_of_a_delay_o"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Late Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In case of a delay of any undisputed payment under this Agreement, Ideaya will pay Hengrui interest on any payments that are not paid on the date on which such payments are due under this Agreement at a monthly interest rate equal to [***] plus the U.S. prime interest rate, as reported by </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Wall Street Journal</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Eastern U.S. Edition, for the first Business Day of each month (starting with the month in which such payment was first due), or the maximum applicable legal rate, if less, calculated based on the total number of days payment is delinquent.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:34.6%;text-indent:31.281%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:35.648%;text-align:left;" id="article_8__intellectual_property"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 8 INTELLECTUAL PROPERTY</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:11.8pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.1</font><div style="width:100%;display:inline;" id="x_1_background_ip___all_right__title_and"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Background IP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All right, title and interest in and to the Know-How and Patents, and any other Intellectual Property Controlled by a Party or its Affiliates prior to the Effective Date or discovered, generated, acquired or otherwise Controlled by a Party or its Affiliates during the Term outside the scope of this Agreement will, in each case, be solely owned by such Party and its Affiliates.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.752%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.2</font><div style="width:100%;display:inline;" id="x_2_ownership_of_arising_ip___to_the_ext"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ownership of Arising IP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. To the extent allowed under each Applicable Law of the applicable jurisdiction, ownership of Inventions will be determined in accordance with U.S. patent law. If U.S. patent law is not allowed and a different Party is considered owner or inventor of a given Invention under national patent law, such Party will assign, or cause to assign, the Invention to the rightful owner as determined under U.S. patent law. Hengrui will solely own any Patents and Know-How made, developed or generated solely by Ideaya or jointly by Ideaya and Hengrui under this Agreement to the extent (a) Covering (or in the case of Know-How, solely relating to or embodied in) the composition of matter of SHR-4849 or (b) Covering (or in the case of Know-How, solely relating to or embodied in) the Hengrui Platform and not relating solely to the Licensed Compound or Licensed Product (</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, relate to compounds or products that are not Licensed Compounds or Licensed Products) (and, for clarity, any such Patents and Know-How will automatically be included in Licensed Patents and Licensed Know-How). Except for Patents to the extent Covering, and Know-How solely relating to or embodied in, the composition of matter of SHR-4849 or the Hengrui Platform that are governed by the foregoing sentence, (a) each Party will solely own any Intellectual Property relating to the Licensed Compound or Licensed Product made, developed or generated solely by it or its Affiliates, or its or their respective employees, agents, or independent contractors (Inventions therein, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sole Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;; Ideaya&#x2019;s Know-How therein, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ideaya Know-How</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;, and Hengrui&#x2019;s Know-How therein, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hengrui Know-How</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) under this Agreement (and, for clarity, any Hengrui Sole Invention and Hengrui Know-How will automatically be included in Licensed Patents and Licensed Know-How); and (b) the Parties will jointly own any Intellectual Property that is made, developed or otherwise generated jointly by employees, agents, or independent contractors of one Party or its Affiliates together with employees, agents, or independent contractors of the other Party or its Affiliates (Inventions therein, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Joint Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;; Know-How therein, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Joint Know-How</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Sole Inventions, Ideaya Know-How, Hengrui Know-How, Joint Inventions, Joint Know-How, and Patents claiming any of the Sole Inventions or Joint Inventions are collectively &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arising IP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;. All Patents claiming Joint Inventions will be referred to herein as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Joint Patents.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; Except to the extent either Party is restricted by the licenses granted to the other Party under this Agreement, each Party will be entitled to practice, license, assign, and otherwise exploit the Joint Inventions, Joint Know-How, and Joint Patents without the duty of accounting to the other Party or seeking consent from the other Party. References in this Section 8.2 to generation of Intellectual Property by a Party or its Affiliates will include generation by either Party&#x2019;s or its Affiliates&#x2019; respective employees, agents, or independent contractors.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:3.7pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.3</font><div style="width:100%;display:inline;" id="x_3_disclosure_of_inventions_and_know_ho"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosure of Inventions and Know-How</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party will promptly disclose to the other Party (a) its Sole Inventions and Know-How that arise in the performance of activities under this Agreement and (b) Joint Inventions and Know-How, including any invention </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:3.7pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disclosures or other similar documents submitted to it by its employees, agents, or independent contractors describing such Inventions, and will promptly respond to reasonable requests from the other Party for additional information relating to such Inventions and Know-How.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.4</font><div style="width:100%;display:inline;" id="x_4_patent_prosecution_and_maintenance_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent Prosecution and Maintenance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:19.87%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:8.320229626856358%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__licensed_patents_other_than_joint_pa"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensed Patents other than Joint Patents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:23.293%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.559419235419364%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;" id="xi__as_between_the_parties__hengrui_will"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As between the Parties, Hengrui will have the sole right to control the preparation, filing, prosecution, and maintenance (including any interferences, reissue proceedings, reexaminations, patent term extensions, applications for supplementary protection certificates, oppositions, invalidation proceedings, and defense of validity or enforceability challenges) of all Licensed Patents (other than Product Patents and Joint Patents) at its sole cost and expense and by counsel of its own choice.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:23.293%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.559419235419364%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;" id="xii__subject_to_this_section_8_4_a___as_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to this Section 8.4(a), as between the Parties, Hengrui will have the first right, but not the obligation to control the preparation, filing, prosecution, and maintenance (including any interferences, reissue proceedings, reexaminations, patent term extensions, applications for supplementary protection certificates, oppositions, and invalidation proceedings) of all Product Patents (excluding, for clarity, any Joint Patents) at its sole cost and expense and by counsel of its own choice.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:23.293%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.559419235419364%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;" id="xiii__hengrui_will_consult_with_ideaya_a"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hengrui will consult with Ideaya and keep Ideaya reasonably informed of the status of all Product Patents in the Territory and will promptly provide Ideaya with all material correspondence received from any patent authority in connection therewith. In addition, Hengrui will promptly provide Ideaya with drafts of all proposed filings and correspondence to any patent authority with respect to such Product Patents in the Territory sufficiently in advance of any applicable filing deadlines for Ideaya&#x2019;s review and comment prior to the submission of such proposed filings and correspondences. Hengrui will confer with Ideaya and consider in good faith and incorporate Ideaya&#x2019;s reasonable comments in relation to such filings and correspondences, so long as Ideaya provides such comments within [***] (or a shorter period reasonably designated by Hengrui if [***] is not practicable given the filing deadline) of receiving the draft filings and correspondences from Hengrui. In addition, Hengrui will confer with Ideaya and file, at Ideaya&#x2019;s reasonable request, continuation or divisional applications of the Specified Patent such that the continuation or divisional application(s) relate solely to the Licensed Compound (or the complementarity determining region sequences contained in the Antibody portions thereof) or Licensed Product (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Divisional Specified Patent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), including claims covering the genus of the antibody hu100 (subject to Claim 1(i) of the Specified Patent) used in the Licensed Compound and Licensed Product, and such Divisional Specified Patents shall thereafter be deemed Product Patents.</font><font id="xiv__in_the_event_that_hengrui_desires_t"></font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:23.293%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.559419235419364%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that Hengrui desires to abandon or cease prosecution or maintenance of any Product Patent in the Territory, Hengrui will provide reasonable prior written notice to Ideaya of such intention to abandon (which notice will, to the extent possible, be given no later than [***] prior to the next deadline for any action that must be taken with respect to any such Product Patent in the relevant patent office). In such case, upon Ideaya&#x2019;s written election </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:20%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided no later than [***] after such notice from Hengrui, Ideaya will have the right to assume the prosecution and maintenance of such Product Patent at Ideaya&#x2019;s expense. For clarity, if Ideaya does not provide such election within [***] after such notice from Hengrui, Hengrui may, in its sole discretion, continue or discontinue prosecution and maintenance of such Product Patent.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:23.293%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.559419235419364%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;" id="xv__for_clarity__hengrui_will_have_the_s"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For clarity, Hengrui will have the sole right to control the preparation, filing, prosecution, and maintenance (including any interferences, reissue proceedings, reexaminations, patent term extensions, applications for supplementary protection certificates, oppositions, invalidation proceedings, and defense of validity or enforceability challenges) of all Licensed Patents, Joint Patents and Patents claiming any Hengrui Sole Invention in Greater China at its sole cost and expense and by counsel of its own choice.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:19.87%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:8.320229626856358%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__joint_patents_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Joint Patents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:23.293%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.559419235419364%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;" id="xi__subject_to_this_section_8_4_b___as_b"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to this Section 8.4(b), as between the Parties, Ideaya will have the first right, but not the obligation, to control the preparation, filing, prosecution, and maintenance including any interferences, reissue proceedings, reexaminations, patent term extensions, applications for supplementary protection certificates, oppositions, invalidation proceedings, and defense of validity or enforceability challenges of Joint Patents that are filed in the Territory by counsel of its own choice. Hengrui shall have the sole right, but not the obligation, to control the preparation, filing, prosecution, and maintenance, including any interferences, reissue proceedings, reexaminations, patent term extensions, applications for supplementary protection certificates, oppositions, invalidation proceedings, and defense of validity or enforceability challenges of any Joint Patents in Greater China.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:23.293%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.559419235419364%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;" id="xii__ideaya_will_consult_with_hengrui_an"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ideaya will consult with Hengrui and keep Hengrui reasonably informed of the status of the Joint Patents and will promptly provide Hengrui with all material correspondence received from any patent authority in connection therewith. In addition, Ideaya will promptly provide Hengrui with drafts of all proposed material filings and correspondence to any patent authority with respect to the Joint Patents sufficiently in advance of any applicable filing deadlines for Hengrui&#x2019;s review and comment prior to the submission of such proposed filings and correspondences. Ideaya will confer with Hengrui and consider in good faith Hengrui&#x2019;s comments prior to submitting such filings and correspondences, so long as Hengrui provides such comments within [***] (or a shorter period reasonably designated by Ideaya if [***] is not practicable given the filing deadline) of receiving the draft filings and correspondences from Ideaya.</font><font id="xiii__in_the_event_that_ideaya_desires_t"></font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:23.293%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.559419235419364%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that Ideaya desires to abandon or cease prosecution or maintenance of any Joint Patent in any country, Ideaya will provide reasonable prior written notice to Hengrui of such intention to abandon or cease prosecution or maintenance of any Joint Patent (which notice will, to the extent possible, be given no later than [***] prior to the next deadline for any action that must be taken with respect to any such Joint Patent in the relevant patent office). In such case, upon Hengrui&#x2019;s written election provided no later than [***] after such notice by Ideaya, Ideaya will assign its rights and title in such Joint Patent to Hengrui and Hengrui will acquire all rights and title in such Joint Patent at its expense. If Hengrui does not provide such election within [***] after such notice, Ideaya may, in its sole discretion, continue or discontinue prosecution and maintenance of such Joint Patent.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.504%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.463%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__ideaya_s_solely_owned_patents___as_b"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ideaya&#x2019;s Solely Owned Patents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As between the Parties, Ideaya will have the first right, but not the obligation, to file, prosecute and maintain all Patents claiming Sole Inventions that are solely owned by Ideaya (each, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ideaya Patent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), at Ideaya&#x2019;s sole cost and expense. In the event that Ideaya desires to abandon or cease prosecution or maintenance of any Ideaya Patent that Covers any Licensed Compound or Licensed Product, Ideaya will provide reasonable prior written notice to Hengrui of such intention to abandon (which notice will, to the extent possible, be given no later than [***] prior to the next deadline for any action that must be taken with respect to any such Ideaya Patent in the relevant patent office). In such case, upon Hengrui&#x2019;s written election provided no later than [***] after such notice from Ideaya, Hengrui will have the right to assume the prosecution and maintenance of such Ideaya Patent at Hengrui&#x2019;s expense and upon any such assumption, such Patent shall constitute a Licensed Patent and not an Ideaya Patent for purposes of this Agreement. For clarity, if Hengrui does not provide such election within [***] after such notice from Ideaya, Ideaya may, in its sole discretion, continue or discontinue prosecution and maintenance of such Ideaya Patent.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="xd__cooperation_of_the_parties___each_pa"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cooperation of the Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party agrees to cooperate fully in the preparation, filing, prosecution, and maintenance of Patents in the Territory under this Section 8.4 and in the obtaining and maintenance of any patent term extensions, supplementary protection certificates and their equivalent with respect thereto, at its own cost. Such cooperation includes:</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.565%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) executing all papers and instruments, or requiring its employees or contractors, to execute such papers and instruments, so as enable the other Party to apply for and to prosecute patent applications in any country as permitted by this Section 8.4; and (ii) promptly informing the other Party of any matters coming to such Party&#x2019;s attention that may affect the preparation, filing, prosecution, or maintenance of any such patent applications.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;" id="xe__create_act___without_limiting_sectio"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CREATE Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Without limiting Section 8.4(d), neither Party shall have the right to make an election under the Cooperative Research and Technology Enhancement Act of 2004, 35 U.S.C. 103(c)(2)-(c)(3) (the &#x201c;CREATE Act&#x201d;) when exercising its rights under this Section 8.4 without the prior written consent of the other Party. With respect to any such permitted election, the Parties shall coordinate their activities with respect to any submissions, filings, or other activities in support thereof. The Parties acknowledge and agree that this Agreement is a &#x201c;joint research agreement&#x201d; as defined in the CREATE Act.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;" id="xf__patent_marking___to_the_extent_requi"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent Marking</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. To the extent required by Applicable Law, Ideaya shall, and shall cause its Affiliates and Sublicensees to, use Commercially Reasonable Efforts to mark the Licensed Products (or the applicable product insert or packaging) sold under this Agreement with the number of each issued Licensed Patent or Joint Patent, as applicable, that applies to the Licensed Products.</font><font id="xg__common_interest___all_information_ex"></font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Interest</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All information exchanged between the Parties regarding the prosecution, maintenance, enforcement or defense of Patents under this Article 8 will be deemed to be Confidential Information of the Party that controls the prosecution, maintenance or defense (as applicable) of the applicable Patent.  In addition, each Party acknowledges and agrees that, with regard to such prosecution, maintenance, enforcement and defense, the interests of the Parties as collaborators, licensors or licensees are to, for their mutual benefit, obtain patent protection and plan patent defense against potential patentability/invalidity challenges or infringement activities by Third Parties, and as such, are aligned and are legal in nature. Each Party agrees and acknowledges that it has not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning Patent Rights under this Article 8, including privilege under the common interest doctrine and similar or related doctrines. Notwithstanding anything to the contrary in this Agreement, to the extent a Party has a good faith belief that any information required to be disclosed by such Party to the other Party under this Article 8 is protected by attorney-client privilege or any other applicable legal privilege or immunity, such Party shall not be required to disclose such information unless and until the Parties have agreed upon a procedure (which may include entering into a specific common interest agreement, disclosing such Confidential Information on a &#x201c;for counsel eyes only&#x201d; basis or similar procedure) under which such Confidential Information may be disclosed without waiving or breaching such privilege or immunity. The Parties shall in good faith cooperate to agree upon any such procedures.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.5</font><div style="width:100%;display:inline;" id="x_5_infringement_by_third_parties_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Infringement by Third Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__notice___each_party_will_notify_the_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party will notify the other Party within [***] of becoming aware of any alleged or threatened infringement by a Third Party of any of the Licensed Patents or Joint Patents in the Territory, including any declaratory judgment, opposition, or similar action alleging the invalidity, unenforceability, or non-infringement of any of the Licensed Patents or </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Joint Patents.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:19.87%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:8.320229626856358%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__enforcement_right_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enforcement Right</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:23.293%;font-size:0;margin-top:3.7pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.559419235419364%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;" id="xi__as_between_the_parties__ideaya_will_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As between the Parties, Ideaya will have (A) the sole right, but not the obligation, to bring and control any action or proceeding with respect to infringement or challenge (and defend to the extent such defense is in connection with an enforcement action initiated by Ideaya) of any Ideaya Patent, and (B) the first right, but not the obligation, to bring and control any action or proceeding with respect to infringement or challenge (and defend to the extent such defense is in connection with an enforcement action initiated by Ideaya) of any Product Patent or Joint Patent in the Field in the Territory with respect to a Licensed Product by a Third Party product (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product Infringement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), in each case at its own expense and by counsel of its own choice. Hengrui will have the right, at its own expense, to be represented in any action under subsection (B) by counsel of its own choice, and Ideaya and its counsel will reasonably cooperate with Hengrui and its counsel in strategizing, preparing, and litigating any such action or proceeding. If Ideaya fails to bring an action or proceeding with respect to Product Infringement of any Product Patent or Joint Patent in the Territory within (X) [***] following the notice of alleged infringement or declaratory judgment or (Y) [***] before the time limit, if any, set forth in the appropriate laws and regulations for the filing of such actions, whichever comes first, Hengrui will have the right, but not the obligation, to bring and control any such action at its own expense and by counsel of its own choice, and Ideaya will have the right, at its own expense, to be represented in any such action by counsel of its own choice, and Hengrui and its counsel will reasonably cooperate with Ideaya and its counsel in strategizing, preparing, and litigating any such action or proceeding.</font><font id="xii__except_as_otherwise_agreed_by_the_p"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:23.293%;font-size:0;margin-top:3.7pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.559419235419364%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as otherwise agreed by the Parties as part of a cost-sharing arrangement, any recovery or damages realized as a result of such action or proceeding with respect to Product Patents or Joint Patents in the Territory will be used first to reimburse the Parties&#x2019; reasonable and documented out-of-pocket legal expenses relating to the action or proceeding, and any remaining compensatory damages relating to Licensed Products or Joint Patents (including lost sales or lost profits with respect to Licensed Products) and punitive damages will be retained by the Party that brought and controlled such action or proceeding, and in the case that Ideaya brought and controlled such action or proceeding, such remaining compensatory damages for the Territory will be deemed to be Net Sales subject to royalty payments to Hengrui in accordance with the provisions of Section 6.3. Ideaya will have the sole right to retain any recovery or damages realized as a result of any action or proceeding solely in relation to any Ideaya Patent, and any such amounts will not be treated as Net Sales for the purposes of this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:23.293%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.559419235419364%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;" id="xiii__for_clarity__hengrui_will_have_the"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For clarity, Hengrui will have the sole right to bring and control any action or proceeding with respect to infringement or challenge (and defend to the extent such defense is in connection with an enforcement action initiated by Hengrui) of (A) any Platform Patents or any other Licensed Patents (other than Product Patents) worldwide, and (B) any Licensed Patents or Joint Patents in Greater China, in each case of (A) and (B), at its own expense and by counsel of its own choice.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__cooperation___in_the_event_that_a_pa"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cooperation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the event that a Party brings an action in accordance with this Section 8.5, the other Party will cooperate fully, including, if required to bring such action, being named as a party to such action or furnishing of power of attorney.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.6</font><div style="width:100%;display:inline;" id="x_6_infringement_of_third_party_rights__"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Infringement of Third Party Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If any Licensed Compound or Licensed Product used or sold by Ideaya, its Affiliates, or Sublicensees becomes the subject of a Third Party&#x2019;s claim or assertion of infringement of any Intellectual Property in a jurisdiction within the Territory, Ideaya will promptly notify Hengrui, and the Parties will promptly meet to consider the claim or assertion and the appropriate course of action and may, if appropriate, agree on and enter into a &#x201c;common interest agreement&#x201d; wherein the Parties agree to their shared, mutual interest in the outcome of such potential dispute. Absent any agreement to the contrary, and subject to claims for indemnification under Article 10, each Party will defend itself from any such Third Party claim that is brought against such Party at its own cost and expense, provided, however, that the provisions of Section 8.5 will govern the right of the Parties to assert a counterclaim of infringement of any Licensed Patent or Joint Patent.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.7</font><div style="width:100%;display:inline;" id="x_7_consent_for_settlement___neither_par"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consent for Settlement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Neither Party will unilaterally enter into any settlement or compromise of any action or proceeding under this Article 8 that would in any manner alter, diminish, or be in derogation of the other Party&#x2019;s rights under this Agreement without the prior written consent of such other Party, which will not be unreasonably withheld, conditioned or delayed.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rights Under Tri-Party Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the event of any conflict between the provisions of this Article 8 and the Tri-Party Agreement, the Parties agree that this Article 8 shall govern with respect to rights of the Parties under to file Patents claiming the Production Cell Line expressing the Licensed Compound.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:28.253%;text-indent:32.351%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:23.361%;text-align:left;" id="article_9__representations_and_warrantie"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 9 REPRESENTATIONS AND WARRANTIES</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:11.75pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.1</font><div style="width:100%;display:inline;" id="x_1_mutual_representations_and_warrantie"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mutual Representations and Warranties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party represents and warrants to the other that, as of the Effective Date: (a) it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof, (b) it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate or partnership action, and (c) this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement, instrument or understanding, oral or written, to which it is a Party or by which it may be bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.2</font><div style="width:100%;display:inline;" id="x_2_additional_hengrui_representations__"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Hengrui Representations, Warranties, and Covenants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.	Hengrui represents, warrants, and covenants, as applicable, to Ideaya that, as of the Effective Date:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__hengrui_is_the_sole_owner_of_the_ent"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hengrui is the sole owner of the entire right, title, and interest, or exclusive licensee (with the right to grant sublicenses of the scope contemplated herein), in and to all patents, patent applications, and other Intellectual Property within the Licensed Technology, free and clear from any mortgages, pledges, liens, security interests, conditional and installment sale agreements, encumbrances, charges, or claims of any kind;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__hengrui_has_the_full_and_legal_right"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hengrui has the full and legal right and authority to grant the licenses granted by it under this Agreement, without the requirement to obtain the consent of any Third Party; and Hengrui has not granted as of the Effective Date, and will not grant during the Term, any right to any Third Party under the Licensed Technology that would conflict with the rights granted to Ideaya hereunder;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__exhibit_1_75_lists_all_patents_contr"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 1.75</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> lists all Patents Controlled by Hengrui as of the Effective Date that would be infringed, absent a license or other right to practice granted under such Patents, by the Exploitation of the Licensed Compound in the Field in the Territory;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="xd__the_inventorship_of_each_licensed_pa"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inventorship of each Licensed Patent is properly identified on each patent and patent application; all official fees, maintenance fees and annuities for the Licensed Patents have been paid and all administrative procedures with Governmental Authorities have been completed for the Licensed Patents such that the Licensed Patents are subsisting and, to Hengrui&#x2019;s Knowledge, the claims included in any Licensed Patents that are issued are valid and enforceable, and no claim or action has been brought or, to Hengrui&#x2019;s Knowledge, threatened by any Third Party alleging that the Licensed Patents are invalid or unenforceable, and no Licensed Patent is the subject of any interference, opposition, cancellation, or other protest proceeding;</font><font id="xe__hengrui_has_not_received_any_written"></font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hengrui has not received any written notice from a Third Party asserting or alleging that the Development of any Licensed Compound or Licensed Product conducted by Hengrui prior to the Effective Date infringed any Patents or misappropriated any Intellectual </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property of any Third Party in the Field in the Territory; and except as disclosed in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 9.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to Hengrui&#x2019;s Knowledge, the Exploitation of the Licensed Compounds and Licensed Products in the Field in the Territory will not infringe the issued Patents of any Third Party in the Territory that, if issued with the published or currently pending claims, would be infringed by the Exploitation of the Licensed Compounds and Licensed Products in the Field in the Territory;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;" id="xf__to_hengrui_s_knowledge__no_third_par"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to Hengrui&#x2019;s Knowledge, no Third Party is infringing or misappropriating or has infringed or misappropriated the Licensed Technology with respect to the Licensed Compound in the Field in the Territory;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;" id="xg__the_licensed_know_how_has_been_kept_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Licensed Know-How has been kept confidential or has been disclosed to Third Parties only under terms of confidentiality, and to Hengrui&#x2019;s Knowledge, no breach of such confidentiality has been committed by any Third Party; and the Licensed Technology does not include any trade secrets that have been misappropriated from any Third Party or obtained in breach of any contractual obligation of Hengrui or its employees to a Third Party;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;" id="xh__exhibit_1_63_lists_all_material_know"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 1.63</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> lists all material Know-How Controlled by Hengrui existing as of the Effective Date that are necessary or reasonably useful for Development of the Licensed Compound in the Field in the Territory; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;" id="xi__to_hengrui_s_knowledge__all_tangible"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to Hengrui&#x2019;s Knowledge, all tangible information and data provided by or on behalf of Hengrui to Ideaya on or before the Effective Date in contemplation of this Agreement was and is true, complete, and correct (as of the Effective Date) in all material respects;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font><div style="width:100%;display:inline;" id="xj__except_as_disclosed_in_exhibit_9_2__"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">except as disclosed in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 9.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there are no agreements in effect as of the Effective Date between Hengrui and a Third Party under which rights with respect to any material Licensed Technology are licensed to Hengrui in the Field in the Territory; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(k)</font><div style="width:100%;display:inline;" id="xk__hengrui_has_disclosed_to_ideaya__i__"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hengrui has disclosed to Ideaya (i) true, complete, and correct copies (as of the Effective Date) of written documents in Hengrui&#x2019;s possession and Control as of the Effective Date containing all material adverse information known to Hengrui with respect to the safety and efficacy of the Licensed Compounds or Licensed Products, and (ii) all material information of which it is aware or that is in its possession and Control as of the Effective Date that is material to evaluating the Product Patents filed within the Territory, including Information relating to the novelty, validity or sufficiency of such Product Patents and any challenges thereto, including any freedom to operate searches, analyses, opinions, or reports.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.3</font><div style="width:100%;display:inline;" id="x_3_mutual_covenants_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mutual Covenants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.504%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.463%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__each_party_represents__warrants_and_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Party represents, warrants and covenants to the other Party that it is not debarred or disqualified under the U.S. Federal Food, Drug and Cosmetic Act, as may be amended, or comparable laws in any country or jurisdiction other than the U.S., and it does not, and will not during the Term, employ or use the services of any person who is debarred or disqualified, in connection with activities relating to any Licensed Compound or Licensed Product. In the event that either Party becomes aware of the debarment or disqualification or threatened debarment or disqualification of any person providing services to such Party, including the Party </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.463%;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">itself or its Affiliates, Sublicensees, or other licensees, that directly or indirectly relate to activities contemplated by this Agreement, such Party will immediately notify the other Party in writing and such Party will cease employing, contracting with, or retaining any such person to perform any such services.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.504%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.463%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hengrui covenants for itself and for its Affiliates, heirs, successors, agents, and assigns, and any person or entity claiming by, through or under it, that Hengrui will not, and it will cause its Affiliates, and will include provisions in its agreements with licensees (other than Ideaya) requiring such licensees, not to, nor will any person, organization, or any other entity acting on behalf of or with the authorization of Hengrui or its Affiliates, directly or indirectly, conduct any activities, including any research, Development, manufacturing, or Commercialization activities, relating to any compound or product that contains an ADC that contains a mono-specific Antibody that is designed to bind, interact with, inhibit, or otherwise modulate [***], other than a combination product (for clarity, &#x201c;combination&#x201d; shall not mean an ADC) consisting of any compound (other than the Licensed Compound or Licensed Product) Controlled by Hengrui in combination with (but not conjugated to) a [***], which [***] is Controlled by a Third Party, in any country in the Territory, during the Term.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__ideaya_covenants_for_itself_and_for_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ideaya covenants for itself and for its Affiliates, heirs, successors, agents, and assigns, and any person or entity claiming by, through or under it, that Ideaya will not, and it will cause its Affiliates, and will include provisions in its agreements with Sublicensees requiring such Sublicensees, not to, nor will any person, organization, or any other entity acting on behalf of or with the authorization of Ideaya or its Affiliates, directly or indirectly, conduct any activities, including any research, Development, manufacturing, or Commercialization activities, relating to any compound or product that contains an ADC that contains a mono-specific Antibody that is designed to bind, interact with, inhibit, or otherwise modulate [***], other than a Licensed Compound or Licensed Product or a combination product consisting of a Licensed Compound or Licensed Product together with any compound Controlled by Ideaya other than a [***], in any country in the Territory during the Term.</font><font id="xd__hengrui_agrees_and_covenants_for_its"></font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hengrui agrees and covenants for itself and for its Affiliates, heirs, successors, agents, and assigns, and any person or entity claiming by, through or under it, that Hengrui will, and it will cause its Affiliates, and will include provisions in its agreements with licensees (other than Ideaya) requiring such licensees, not to, directly or indirectly, actively promote, market, distribute, import, sell, have sold, or otherwise Commercialize any Licensed Compound or Licensed Product in countries in the Territory. Without limiting the foregoing, Hengrui and its Affiliates will not engage in any advertising or promotional activities relating to any Licensed Compound or Licensed Product for sale in the Territory; and Hengrui and its Affiliates will not actively solicit orders or Licensed Compound or Licensed Product from any prospective purchaser for sale in the Territory; and Hengrui will include provisions in its agreements with licensees (other than Ideaya) requiring such licensees not to so engage or solicit. If Hengrui or its Affiliates or licensees (other than Ideaya) receives any order from a prospective purchaser for sale in the Territory, Hengrui will promptly refer that order to Ideaya. Hengrui and its Affiliates will not and will not authorize its licensees (other than Ideaya) to knowingly accept any such orders. Notwithstanding anything to the contrary, it is understood that materials used in the advertisement and promotion of Licensed Compound or Licensed Product outside the Territory </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may be accessible to persons in the Territory (such as advertisement or Internet sites or other digital uses), and such use shall not be a breach of the terms of this Agreement provided that: (i) the media chosen is not primarily directed to persons residing in the Territory or chosen with the primary intent of communicating with persons residing in the Territory; and (ii) in the case of a periodical or other distributed materials, is not primarily distributed to persons in the Territory.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;" id="xe__ideaya_agrees_and_covenants_for_itse"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ideaya agrees and covenants for itself and for its Affiliates, heirs, successors, agents, and assigns, and any person or entity claiming by, through or under it, that Ideaya will, and it will cause its Affiliates, and will include provisions in its agreements with Sublicensees requiring such Sublicensees, not to directly or indirectly, actively promote, market, distribute, import, sell, have sold, or otherwise Commercialize any Licensed Compound or Licensed Product in countries outside of the Territory. Without limiting the foregoing, Ideaya and its Affiliates will not engage in any advertising or promotional activities relating to any Licensed Compound or Licensed Product for sale outside the Territory; and Ideaya and its Affiliates will not actively solicit orders or Licensed Compound or Licensed Product from any prospective purchaser for sale outside the Territory; and Ideaya will include provisions in its agreements with Sublicensees requiring such Sublicensees not to so engage or solicit. If Ideaya or its Affiliates or licensees (other than Hengrui) receives any order from a prospective purchaser for sale outside the Territory, Ideaya will promptly refer that order to Hengrui. Ideaya and its Affiliates will not and will not authorize its licensees (other than Hengrui) to knowingly accept any such orders. Notwithstanding anything to the contrary, it is understood that materials used in the advertisement and promotion of Licensed Compound or Licensed Product in the Territory may be accessible to persons outside the Territory (such as advertisement or Internet sites or other digital uses), and such use shall not be a breach of the terms of this Agreement provided that: (i) the media chosen is not primarily directed to persons residing outside the Territory or chosen with the primary intent of communicating with persons residing outside the Territory; and (ii) in the case of a periodical or other distributed materials, is not primarily distributed to persons outside the Territory.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.4</font><div style="width:100%;display:inline;" id="xb__hengrui_covenants_for_itself_and_for"><font id="x_4_compliance___each_party_covenants_as"></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party covenants as follows:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__in_the_performance_of_its_obligation"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the performance of its obligations under this Agreement, such Party will comply and will cause its and its Affiliates&#x2019; employees and contractors to comply with all Applicable Laws. Without limiting the foregoing, any transfer of Know-How to the other Party under this Agreement (including with respect to the termination provisions) will be made in full compliance with the FCPA, Export Control Laws, Sanctions, or any other Applicable Laws, which may require specific, prior authorization from a Governmental Authority.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__it_and_its_and_its_affiliates__emplo"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It and its and its Affiliates&#x2019; employees and contractors have not, directly or indirectly as of the Effective Date, and will not, in connection with the performance of their respective obligations under this Agreement, directly or indirectly through Third Parties, pay, promise or offer to pay, or authorize the payment of, any money or give any promise or offer to give, or authorize the giving of anything of value to a public official or entity or other person for purpose of obtaining or retaining business for or with, or directing business to, any person, including either Party.</font><font id="xc__it_and_its_affiliates__and_their_res"></font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It and its Affiliates, and their respective employees and contractors, in </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">connection with the performance of their respective obligations under this Agreement, will not cause any Ideaya Representatives or Hengrui Representatives, as applicable, to be in violation of the FCPA, Export Control Laws, Sanctions, or any other Applicable Laws or otherwise cause any reputational harm to the other Party.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="xd__it_will_immediately_notify_the_other"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It will immediately notify the other Party if it has any information or suspicion that there may be a violation of the FCPA, Export Control Laws, Sanctions, or any other Applicable Laws in connection with the performance of this Agreement or the Development, Manufacture, or Commercialization of any Licensed Product.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;" id="xe__such_party_will_have_the_right__upon"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Such Party will have the right, upon reasonable prior written notice and during the other Party&#x2019;s regular business hours, to reasonably audit the other Party&#x2019;s books and records in the event such Party can provide reasonable evidence proving that a suspected violation of any of the representations, warranties, or covenants in this Section 9.4 needs to be investigated.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.5</font><div style="width:100%;display:inline;" id="x_5_disclaimer___except_as_expressly_set"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclaimer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as expressly set forth in this Agreement, ALL OTHER REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:36.867%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:37.963%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 10 INDEMNIFICATION</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:11.8pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.1</font><div style="width:100%;display:inline;" id="x0_1_indemnification_by_hengrui___hengru"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification by Hengrui</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Hengrui will defend, indemnify, and hold harmless Ideaya and its Affiliates and their respective directors, officers, employees and agents (each, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ideaya Representative</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) from and against any and all liabilities, expenses, and losses, including reasonable legal expenses and attorneys&#x2019; fees (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Losses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), to which any Ideaya Representative may become subject as a result of any claim, demand, action, or other proceeding by any Third Party (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Claim</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) to the extent such Losses arise out of: (a) the Development, Manufacture, Commercialization, use, handling, or storage of any Licensed Compound or Licensed Product by Hengrui or its Affiliates or licensees (other than Ideaya, its Affiliates or Sublicensees), (b) the gross negligence or willful misconduct of any Hengrui Representative, or</font></div></div>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:7.583%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) the breach by Hengrui of any warranty, representation, covenant, or agreement made by Hengrui in this Agreement; except, in each of subsection (a), (b), and (c), to the extent such Losses are (i) subject to Ideaya&#x2019;s obligations pursuant to Section 10.2 or (ii) subject to the Parties&#x2019; indemnification obligations under the Clinical Supply Agreement or Commercial Supply Agreement.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.2</font><div style="width:100%;display:inline;" id="x0_2_indemnification_by_ideaya___ideaya_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification by Ideaya</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Ideaya will defend, indemnify, and hold harmless Hengrui and its Affiliates and their respective directors, officers, employees, and agents (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hengrui Representative</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) from and against any and all Losses to which any Hengrui Representative may become subject as a result of any Claim to the extent such Losses arise out of:</font></div></div>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:7.556%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) the Development, Manufacture, Commercialization, use, handling, or storage of any Licensed Compound or Licensed Product by Ideaya or its Affiliates or Sublicensees in the Territory, (b) the gross negligence or willful misconduct of any Ideaya Representative, or (c) the breach by Ideaya of any warranty, representation, covenant, or agreement made by Ideaya in this Agreement; except, in each of subsection (a), (b), and (c), to the extent such Losses are (i) subject to Hengrui&#x2019;s obligations pursuant to Section 10.1 or (ii) subject to the Parties&#x2019; indemnification obligations under the Clinical Supply Agreement or Commercial Supply Agreement.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.752%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.3</font><div style="width:100%;display:inline;" id="x0_3_procedure___a_party_that_intends_to"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Procedure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. A party that intends to claim indemnification under this Article 10 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnitee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) will promptly notify the indemnifying Party (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnitor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) in writing of any Claim in respect of which the Indemnitee intends to claim such indemnification, and the Indemnitor will have sole control of the defense or settlement thereof. The Indemnitee may participate at its expense in the Indemnitor&#x2019;s defense of and settlement negotiations for any Claim with counsel of the Indemnitee&#x2019;s own selection. The indemnity arrangement in this Article 10 will not apply to amounts paid in settlement of any action with respect to a Claim, if such settlement is effected without the consent of the Indemnitor, which consent will not be unreasonably withheld or delayed. The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any action with respect to a Claim will only relieve the Indemnitor of its indemnification obligations under this Article 10 if and to the extent the Indemnitor is actually prejudiced thereby. The Indemnitee will cooperate fully with the Indemnitor and its legal representatives in the investigation of any action with respect to a Claim covered by this indemnification.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.4</font><div style="width:100%;display:inline;" id="x0_4_insurance___ideaya__at_its_own_expe"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insurance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Ideaya, at its own expense, will maintain product liability and other </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">appropriate insurance (or self-insure) in an amount consistent with sound business practice and reasonable in light of its obligations under this Agreement during the Term. Ideaya will provide a certificate of insurance (or evidence of self-insurance) evidencing such coverage to Hengrui upon request.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.5</font><div style="width:100%;display:inline;" id="x0_5_limitation_of_liability___except_fo"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitation of Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. EXCEPT FOR LIABILITY FOR BREACH ARTICLE</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:7.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.706953553812739%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HEREOF OR A PARTY&#x2019;S WILLFUL MISCONDUCT OR FRAUDULENT OR INTENTIONALLY WRONGFUL ACT, NEITHER PARTY WILL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY</font></div></div>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:7.528%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LICENSE GRANTED HEREUNDER; provided, however, that this Section 10.5 will not be construed to limit either Party&#x2019;s indemnification obligations under this Article 10.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:39.187%;text-indent:-0.065%;padding-left:0.013%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:40.296%;text-align:center;" id="article_11__confidentiality"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 11 CONFIDENTIALITY</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.1</font><div style="width:100%;display:inline;" id="x1_1_confidential_information___except_t"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, the Parties agree that, during the Term and for [***] thereafter (or, for any trade secret, for so long as such trade secret constitutes a trade secret under Applicable Law), the receiving Party will keep confidential and will not publish or otherwise disclose and will not use for any purpose other than as expressly provided for in this Agreement any Confidential Information of the other Party under this Agreement, and both Parties will keep confidential and, subject to Sections 11.2 through 11.5, will not publish or otherwise disclose the terms of this Agreement. Each Party may use the other Party&#x2019;s Confidential Information only to the extent required to accomplish the purposes of this Agreement, including exercising its rights or performing its obligations. Each Party will use at least the same standard of care as it uses to protect proprietary or Confidential Information of its own (but no less than reasonable care) to ensure that its employees, agents, consultants, contractors, and other representatives do not disclose or make any unauthorized use of the Confidential Information of the other Party. Each Party will promptly notify the other Party upon discovery of any unauthorized use or disclosure of the Confidential Information of the other Party. Notwithstanding the definition of &#x201c;Confidential Information&#x201d; in Article 1, all Confidential Information included in the Licensed Know-How and relating to the Licensed Compound or Licensed Products in the Field will be Confidential Information of both Parties during the Term.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.2</font><div style="width:100%;display:inline;" id="x1_2_exceptions___the_obligations_of_con"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exceptions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The obligations of confidentiality and restriction on use under Section 11.1 will not apply to any information that the receiving Party can prove by competent written evidence: (a) is now, or hereafter becomes, through no act or failure to act on the part of the receiving Party, generally known or available to the public; (b) is known by the receiving Party at the time of receiving such information, other than by previous disclosure of the disclosing Party, or its Affiliates, employees, agents, consultants, or contractors; (c) is hereafter furnished to the receiving Party without restriction by a Third Party who has no obligation of confidentiality or limitations on use with respect thereto, as a matter of right; or (d) is independently discovered or developed by the receiving Party without the use of Confidential Information belonging to the disclosing Party.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.3</font><div style="width:100%;display:inline;" id="x1_3_authorized_disclosure___each_party_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Authorized Disclosure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party may disclose Confidential Information belonging to the other Party as expressly permitted by this Agreement or if and to the extent such disclosure is reasonably necessary in the following instances:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__filing__prosecuting__or_maintaining_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">filing, prosecuting, or maintaining Licensed Patents and Joint Patents as permitted by this Agreement;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__regulatory_filings_for_licensed_prod"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory filings for Licensed Products that such Party has a license or right to Develop hereunder in a given country or jurisdiction;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:19.87%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:8.320229626856358%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__prosecuting_or_defending_litigation_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prosecuting or defending litigation as permitted by this Agreement;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="xd__complying_with_applicable_court_orde"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complying with applicable court orders or governmental regulations, </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">including regulations applicable to the public sale of securities;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;" id="xe__in_the_case_of_ideaya__disclosure_to"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the case of Ideaya, disclosure to its and its Affiliates, employees, consultants, contractors, and agents, and to Sublicensees, in each case on a need-to-know basis in connection with the Development, Manufacture, or Commercialization of Licensed Compounds or Licensed Products in accordance with the terms of this Agreement, in each case under written obligations of confidentiality and non-use at least as stringent as those herein;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:3.7pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;" id="xg__disclosure_to_potential_and_actual_i"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the case of Hengrui, disclosure to its and its Affiliates, employees, consultants, contractors, and agents, and to licensee, in each case on a need-to-know basis in connection with the Development of Licensed Compounds or Licensed Products outside of the Field and Territory in accordance with the terms of this Agreement, in each case under written obligations of confidentiality and non-use at least as stringent as those herein; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disclosure to potential and actual investment bankers, investors, lenders, investors, acquirors, licensees, and other financial or commercial partners (and their attorneys and agents) solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition, or collaboration, in each case under written obligations of confidentiality and non-use at least as stringent as those herein, but may be of shorter duration (except for trade secrets which will be maintained as confidential as long as they are trade secrets) to the extent such shorter duration is reasonable and customary in the case of investment bankers, investors, lenders, or financial partners and their attorneys and agents.</font></div></div>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.574%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that a Party is required to make a disclosure of the other Party&#x2019;s Confidential Information pursuant to Section 11.3(c) or (d), it will, except where impracticable, give reasonable advance notice to the other Party of such disclosure and use efforts to secure confidential treatment of such Confidential Information at least as diligent as such Party would use to protect its own confidential information, but in no event less than reasonable efforts. Any information disclosed pursuant to Section 11.3(c) or (d) will remain Confidential Information and subject to the restrictions set forth in this Agreement, including the foregoing provisions of this Article 11. Notwithstanding the foregoing, the Parties will take all reasonable action to avoid disclosure of Confidential Information hereunder.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.4</font><div style="width:100%;display:inline;" id="x1_4_securities_filings___the_parties_ag"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Filings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Parties agree that the press release set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 11.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> may be released on or after the Effective Date. Except with respect to such press release, notwithstanding anything to the contrary in this Article 11, in the event either Party proposes to file with the Securities and Exchange Commission or the securities regulators of any state or other jurisdiction a registration statement or any other disclosure document that describes or refers to the terms and conditions of this Agreement or any related agreements between the Parties, such Party will notify the other Party of such intention and will provide the other Party with a copy of relevant portions of the proposed filing at least [***] prior to such filing (and any revisions to such portions of the proposed filing a reasonable time prior to the filing thereof), including any exhibits thereto that refer to the other Party or the terms and conditions of this Agreement or any related agreements between the Parties. The Party making such filing will cooperate in good faith with the other Party to obtain confidential treatment of the terms and conditions of this Agreement or any related agreements between the Parties that the other Party requests to be kept confidential or otherwise afforded confidential treatment, and will only disclose Confidential Information that it </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is reasonably advised by legal counsel is legally required to be disclosed. No such notice will be required if the description of or reference to this Agreement or a related agreement between the Parties contained in the proposed filing has been included in any previous filing made by the either Party in accordance with this Section 11.4 or otherwise approved by the other Party or disclosed in a prior press release by the Parties or other prior public disclosure made by a Party in accordance with the terms of this Article 11.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.5</font><div style="width:100%;display:inline;" id="x1_5_publications_and_promotional_materi"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Publications and Promotional Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__as_between_the_parties___i__ideaya_o"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As between the Parties, (i) Ideaya or its Affiliates or Sublicensees will have the sole right to publish academic, scientific or medical peer reviewed publications (including, for clarity, presentations) that relate to the Licensed Compound or Licensed Product in the Territory, other than any publication of Data resulting from clinical trials conducted by Hengrui or its Affiliates or licensees with respect to Development of Licensed Product for Regulatory Approval outside of the Territory, and (ii) Hengrui or its Affiliates or licensees will have the sole right to publish Data resulting from clinical trials conducted by Hengrui or its Affiliates or licensees with respect to Development of Product for Regulatory Approval outside of the Territory.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__each_party_will_submit_to_the_other_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Party will submit to the other Party for such other Party&#x2019;s review any proposed academic, scientific or medical peer reviewed publication by such Party or its Affiliates or licensees that relates to the Licensed Compound or Licensed Product or any Confidential Information of such other Party. Ideaya will also submit to Hengrui for its review any proposed academic, scientific or medical publication or public presentation that contains Licensed Know- How or Joint Know-How that has not been previously publicly disclosed or otherwise approved by Hengrui to be publicly disclosed, for the purposes of determining whether any portion of the proposed publication or presentation should be modified or deleted so as to preserve the value of such Licensed Know-How and Joint Know-How. Hengrui will also submit to Ideaya for its review any proposed academic, scientific or medical publication or public presentation that contains Licensed Know-How (relating to Exploitation of Licensed Compound or Licensed Product in the Territory) or Joint Know-How that has not been previously publicly disclosed or otherwise approved by Ideaya to be publicly disclosed, for the purposes of determining whether any portion of the proposed publication or presentation should be modified or deleted so as to preserve the value of such Licensed Know-How or Joint Know-How. Each Party will consider all comments provided by the other Party in good faith, including comments regarding the potential adverse impact on Exploitation of Licensed Compound or Licensed Product.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__written_copies_of_any_proposed_publi"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written copies of any proposed publication or presentation required to be submitted hereunder will be submitted to the applicable Party within a reasonable time period before submission for publication or presentation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Review Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The Party receiving such submission will provide its comments with respect to such publications and presentations within [***] of its receipt of such written copy. The Review Period may be extended for an additional [***] in the event such receiving Party can, within [***] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="xd__each_party_will_comply__and_will_cau"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Party will comply, and will cause its Affiliates or licensees to comply, to the extent applicable, with (i) standard academic practice regarding authorship of scientific </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">publications and recognition of contribution of the other Party in any publication governed by this Section 11.5, including International Committee of Medical Journal Editors standards regarding authorship and contributions, and (ii) standard pharmaceutical industry accepted guidelines regarding promotional materials, including Pharmaceutical Research and Manufacturers of America (PhRMA) guidelines.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.6</font><div style="width:100%;display:inline;" id="x1_6_prior_confidentiality_agreement___a"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior Confidentiality Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of the Effective Date, the terms of this Article 11 will supersede any prior non-disclosure, secrecy or confidentiality agreement between the Parties (or their Affiliates) relating to the subject of this Agreement to the extent it applies to each Party&#x2019;s rights and obligations relating to each other. Any information disclosed pursuant to any such prior agreement will be deemed Confidential Information for purposes of this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.7</font><div style="width:100%;display:inline;" id="x1_7_equitable_relief___given_the_nature"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equitable Relief</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Given the nature of the Confidential Information and the competitive damage that a Party would suffer upon unauthorized disclosure, use, or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages may not be a sufficient remedy for any breach of this Article 11. In addition to all other remedies, a Party will be entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Article 11.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:36.867%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:37.963%;text-align:center;" id="article_12__term_and_termination"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 12</font></p>
  <p style="margin-left:6.747%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:7.815%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TERM AND TERMINATION</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:11.8pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">12.1</font><div style="width:100%;display:inline;" id="x2_1_term___this_agreement_will_commence"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement will commence on the Effective Date and unless terminated earlier as provided in this Article 12 will continue until the expiration of all Royalty Terms in the Territory (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Upon expiration of the Royalty Term for a Licensed Product in a particular country (to the extent, for clarity, that the Agreement has not been terminated earlier as provided in this Article 12), the licenses granted by Hengrui to Ideaya under Section 2.1, with respect to such Licensed Product (and corresponding Licensed Compound) and such country will become non-exclusive, fully paid-up, royalty-free, perpetual, and irrevocable.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">12.2</font><div style="width:100%;display:inline;" id="x2_2_termination_by_mutual_agreement___t"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination by Mutual Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Parties may terminate this Agreement at any time upon mutual written agreement, in its entirety or, subject to the Parties&#x2019; agreement with respect to the effects of termination, with respect to one or more Licensed Products or countries.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.3</font><div style="width:100%;display:inline;" id="x2_3_termination_for_cause_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination for Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__material_breach___each_party_will_ha"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Breach</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party will have the right to terminate this Agreement upon written notice to the other Party if such other Party materially breaches this Agreement and has not cured such breach or such breach is not curable within [***] after notice of such breach from the non-breaching Party, provided that, if such breach is not reasonably capable of cure within such [***] period but is capable of cure, the breaching Party may submit a reasonable cure plan prior to the end of such [***] period, in which case, if the other Party agrees to such plan (such agreement not to be unreasonably withheld, conditioned or delayed), the other Party will not have the right to terminate this Agreement during an additional [***] period, so long as the breaching Party is using best efforts to implement such cure plan throughout such additional [***] period.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__disputed_breach___unless_and_until_t"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disputed Breach</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Unless and until the Parties have completed the dispute resolution procedures set forth in Article 14, then provided the Party alleged to be in breach continues to comply with its other obligations under this Agreement, including all payment obligations, during the pendency of any dispute, then the non-breaching Party will not have the right to terminate this Agreement under Section 12.3(a). It is understood and agreed that during the pendency of such dispute, all of the terms and conditions of this Agreement will remain in effect and the Parties will continue to perform all of their respective obligations.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.504%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.463%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__bankruptcy___to_the_extent_permitted"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bankruptcy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. To the extent permitted under Applicable Law, each Party will have the right to terminate this Agreement in its entirety upon written notice to the other Party if such other Party makes a general assignment for the benefit of creditors, files an insolvency petition in bankruptcy, petitions for or acquiesces in the appointment of any receiver, trustee, or similar officer to liquidate or conserve its business or any substantial part of its assets, commences under the laws of any jurisdiction any proceeding involving its insolvency, bankruptcy,</font></div></div>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:3.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.62%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reorganization, adjustment of debt, dissolution, liquidation, or any other similar proceeding for the release of financially distressed debtors or becomes a party to any proceeding or action of the type described above and such proceeding is not dismissed within [***] after the commencement thereof.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">12.4</font><div style="width:100%;display:inline;" id="x2_4_termination_by_ideaya_for_convenien"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination by Ideaya for Convenience</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Ideaya will have the right to terminate this Agreement for any reason or no reason upon [***] written notice to Hengrui in its entirety.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.5</font><div style="width:100%;display:inline;" id="x2_5_effects_of_termination___upon_termi"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effects of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon termination of this Agreement, the following will</font></div></div>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">apply:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:19.87%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:7.463%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:9.3136153750156%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__upon_termination_of_this_agreement_p"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon termination of this Agreement pursuant to Section 12.2 or 12.4 or by</font></div></div>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:7.528%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hengrui pursuant to Section 12.3, the license granted to Ideaya in Section 2.1 will automatically terminate, and all other rights and obligations of the Parties under this Agreement will terminate (except for those rights that survive pursuant to Sections 12.5(a), 12.6 and 12.7).</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__sublicense_survival____upon_an_early"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sublicense Survival</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon an early termination of Ideaya&#x2019;s license rights under this Agreement pursuant to Section 12.3 by Hengrui (and such early termination is not due in whole or in part to the actions or omissions of the applicable Third Party Sublicensee), (i) Ideaya will provide written notice to Hengrui within [***] following the notice of termination that it desires to have any Third Party Sublicensee to become a direct licensee of Hengrui of substantially identical scope as the sublicense granted by Ideaya or its Affiliates and on terms substantially identical to this Agreement (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Direct License</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), (ii) during a period of [***] (or [***] if the [***] additional cure period in Section 12.3(a) applies) following the date of delivery of notice of termination of this Agreement pursuant to Section 12.3, Ideaya will respond, or will cause such Third Party Sublicensee to respond, promptly to Hengrui&#x2019;s reasonable requests for true and correct information and documentation to enable Hengrui to confirm the compliance of such Sublicensee with all Applicable Laws and this Agreement, and (iii) if such Third Party Sublicensee is then not in material breach of the terms of this Agreement in regard to such sublicense, and is then in compliance with all Applicable Laws at the date of delivery of notice of termination of this Agreement, and if such Third Party Sublicensee agrees in writing to assume all applicable obligations of Ideaya under this Agreement, taking into consideration any differences in scope or territory between this Agreement and the applicable sublicense agreement, then (y) the Direct License will become effective, upon the effective date of termination of this Agreement, and such sublicense will terminate effective upon the effective date of the Direct License, and (z) Hengrui and such Third Party Sublicensee will promptly enter into a written agreement reflecting terms of the Direct License. Notwithstanding the foregoing, provided Ideaya and such Sublicensee have complied with the obligations to provide information under clause (ii) above, Hengrui has not completed its inquiries or review of information set forth above by the effective date of termination of this Agreement, such Direct License will automatically become effective upon the effective date of termination, subject to Hengrui&#x2019;s right to terminate such Direct License in accordance with the terms thereof, and if Ideaya disputes Hengrui&#x2019;s determination that any such Sublicensee was in material breach of the terms of this Agreement in regard to such sublicense, or was not in compliance with all Applicable Laws at the date of delivery of notice of termination of this Agreement, then the Parties may submit such dispute for resolution pursuant to Article 13, and this Agreement will not be terminated with respect to such Sublicensee during the pendency of such dispute resolution.</font></div></div>
  <p style="margin-left:6.48%;text-indent:15.49%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.528%;text-align:justify;" id="for_clarity__upon_any_existing_sublicens"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For clarity, upon any existing sublicense becoming a Direct License between Hengrui and such Third Party Sublicensee, any sales of products following the effective date of termination of this Agreement by such Third Party Sublicensee that would have been </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensed</font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.528%;text-align:justify;"><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Products </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under this Agreement will be considered Net Sales, and will be subject to the royalty obligations under the applicable Direct License.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__except_in_the_event_of_termination_o"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except in the event of termination of this Agreement by Hengrui pursuant to Section 12.3, Ideaya and its Affiliates and Sublicensees will have the right to sell any or all of the inventory of Licensed Products held by Ideaya and its Affiliates and Sublicensees as of the date of termination for a period of [***] following such termination, so long as such sales are made in the normal course consistent with Ideaya&#x2019;s past practice and the applicable terms of this Agreement and Ideaya continues to comply with all of its payment, reporting and audit obligations hereunder with respect to the Licensed Products.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="xd__each_party_will_immediately_pay_or_c"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Party will immediately pay or cause to be paid to the other Party all sums which at the date of termination are due and payable to the other Party under this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;" id="xe__notwithstanding_anything_to_the_cont"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding anything to the contrary herein, if any clinical trial of a Licensed Product has been initiated at the time of termination, the terms of this Agreement will continue to apply as necessary to accomplish a safe and orderly wind-down of such clinical trials, at the cost and expense of Ideaya.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;" id="xf__subject_to_any_rights_retained_by_an"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to any rights retained by any applicable Sublicensee under Section 12.5(b), and subject to any payment obligations set forth in Section 12.5(f)(iii) and (iv):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:23.293%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.559419235419364%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;" id="xi__with_respect_to_all_regulatory_filin"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to all Regulatory Filings and all other regulatory documents necessary to further Develop and Commercialize the Licensed Products, as they exist as of the date of such termination, Hengrui shall determine in its sole discretion which of these shall be, at the reasonable cost and expense of Hengrui (i) assigned to Hengrui, and Ideaya shall provide to Hengrui a copy of the applicable documents and filings, together with the raw and summarized data for any preclinical and clinical studies of the Licensed Products or (ii) withdrawn or inactivated.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:23.293%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.559419235419364%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;" id="xii__to_the_extent_not_already_in_hengru"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent not already in Hengrui&#x2019;s possession, Ideaya shall, at Hengrui&#x2019;s reasonable cost and expense, provide to Hengrui the tangible embodiments of all Know- How Controlled by Ideaya to the extent necessary for the Development, Manufacture and Commercialization of the Licensed Products in existence as of the date of such termination. Ideaya shall reasonably cooperate with Hengrui to assist Hengrui with understanding and Exploitation of the Know-How provided to Hengrui under this Section 12.5(f). Effective upon such termination date, Ideaya hereby grants to Hengrui a royalty-bearing, perpetual, worldwide, transferable, non- exclusive, freely sublicensable (through multiple tiers) right and license under such Know-How solely for Developing, Manufacturing and Commercialization the Licensed Products in the Field; provided that the applicable portions of such license will be contingent on payment by Hengrui to Ideaya of any and all payments payable, as a result of the grant of such license, by Ideaya or its Affiliates to any Third Party that Controls any such Ideaya Technology.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:23.293%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.559419235419364%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;" id="xiii__to_the_extent_ideaya_owns_any_trad"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent Ideaya owns any trademarks or trade names (whether registered or unregistered, including applications therefor) or domain names that pertain specifically to the Licensed Product that Hengrui reasonably believes would be necessary or </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:20%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reasonably useful for the Commercialization of a Licensed Product (as then currently marketed, but not including any marks that include any corporate name or logo of Ideaya), Ideaya shall, at Hengrui&#x2019;s reasonable cost and expense, assign (or cause its Affiliate to assign) to Hengrui all of Ideaya&#x2019;s (or such Affiliate&#x2019;s) right, title and interest in and to such trademark, trade name or domain name.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:23.256%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.463%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.559419235419364%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;" id="xiv__the_foregoing_subsections_12_5_f__i"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing subsections 12.5(f)(i), (ii), and (iii) will be royalty- bearing, and the Parties shall negotiate in good faith and mutually agree on a fair and reasonable royalty rate to be paid by Hengrui to Ideaya for the grant of a license and right of reference to Hengrui under the Ideaya Technology Controlled by Ideaya or its Affiliates as of the effective date of such termination that is necessary or reasonably useful for Hengrui to Develop, Commercialize and otherwise Exploit the Licensed Compounds and Licensed Product in the Field in the terminated portions of the Territory, which royalty rate shall account for the duration of the Term, the commercial viability of the Licensed Compounds and Licensed Product in the Field in the terminated portions of the Territory, the scope of the Ideaya Technology subject to the foregoing grant of rights and the amount and extent of Ideaya&#x2019;s investments in such Ideaya Technology. If the Parties fail to reach an agreement on such royalty rate after [***] of negotiations, such royalty rate shall be determined through binding arbitration in accordance with Section 13.2.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">12.6</font><div style="width:100%;display:inline;" id="x2_6_confidential_information___upon_ter"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon termination of this Agreement, except to the extent that a Party obtains or retains the right to use the other Party&#x2019;s Confidential Information, each Party will promptly return to the other Party, or delete or destroy, all relevant records and materials in such Party&#x2019;s possession or Control containing Confidential Information of the other Party, pursuant to the other Party&#x2019;s request; provided that such Party may keep one copy of such materials for archival purposes only subject to continuing confidentiality obligations or to the extent such Confidential Information is electronically archived in the ordinary course of the receiving Party&#x2019;s business. Any such Confidential Information retained by the receiving Party pursuant to this Section 12.6 will remain subject to the obligations of non-disclosure and will not be used for any purpose other than to comply with Applicable Law.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:3.7pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">12.7</font><div style="width:100%;display:inline;" id="x2_7_survival___expiration_or_terminatio"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Survival</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Expiration or termination of this Agreement for any reason will not relieve the Parties of any obligation or right that has already accrued prior to such expiration or termination. Except as set forth below or elsewhere in this Agreement, the obligations and rights of the Parties under the following provisions will survive expiration or termination of this Agreement: Article 1 (as applicable), Article 6 (with respect to any payment obligations incurred prior to the date of notice of termination or expiration), Article 10, Article 11 (excluding Section 11.5), Article 13, and Article 14 and Sections 2.3, 2.5, 3.7(f) (solely with respect to any outstanding decisions and disputes at the time of termination or expiration), 7.1 through 7.2 (with respect to any payment obligations incurred prior to the date of notice of termination or expiration), 7.3, 7.4 through 7.5 (with respect to any payment obligations incurred prior to the date of notice of termination or expiration), 8.1, 8.2, 9.5, 12.5 (as applicable), 12.6, 12.7, and 12.8.</font><font id="x2_8_exercise_of_right_to_terminate___th"></font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">12.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise of Right to Terminate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The use by either Party of a termination right provided for under this Agreement will not give rise to the payment of damages or any other form of compensation or relief to the other Party with respect thereto; provided that termination of this Agreement will not preclude either Party from claiming any other damages, compensation, or relief that it may be entitled to upon such termination.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:37.307%;text-indent:24.843%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:38.38%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 13 DISPUTE RESOLUTION</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:11.8pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">13.1</font><div style="width:100%;display:inline;" id="x3_1_resolution_by_executive_officers___"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Resolution by Executive Officers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If a dispute as to matters arising under or relating to this Agreement or either Party&#x2019;s rights and obligations hereunder arises, either Party may refer such dispute to the officer designated by the Chief Executive Officer of Ideaya and the officer designated by the Chief Strategy Officer of Hengrui (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive Officers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), who will meet in person or by telephone within [***] after such referral to attempt in good faith to resolve such dispute. If such matter cannot be resolved by discussion of such officers within such [***] period, or such other time period as the Parties may agree to in writing, such dispute will be resolved in accordance with Section 13.2.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.2</font><div style="width:100%;display:inline;" id="x3_2_arbitration_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arbitration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__any_dispute_arising_under_or_relatin"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any dispute arising under or relating to this Agreement that is not resolved as provided in Section 13.1, may be submitted by either Party for resolution through binding arbitration in accordance with the Rules of Arbitration of the International Chamber of Commerce (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ICC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) as then in effect (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ICC Rules</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Notwithstanding the foregoing, the Parties acknowledge and agree that the following disputes may be resolved by a competent court under the Applicable Laws: (i) disputes with respect to determining the validity, enforceability or infringement of any patent, (ii) any dispute relating to antitrust matters, and (iii) any other dispute that is not permitted under applicable law to be resolved by arbitration despite the existence of this Section 14.3.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__the_arbitration_will_be_conducted_by"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The arbitration will be conducted by a panel of three (3) arbitrators, none of whom will be a current or former employee or director, or a then-current stockholder, of either Party, their respective then-current Affiliates, or any Sublicensee. Each Party will be entitled to appoint a co-arbitrator, and the two co-arbitrators so appointed will nominate the third arbitrator, who will act as the President of the Tribunal, within [***] of their appointment. If any Party or the co-arbitrators fail to make the appointment as provided herein, the ICC Court of Arbitration will make the appointment in accordance with the ICC Rules. The place of arbitration will be Hong Kong, and the arbitration and all communications and documents relating thereto will be conducted in English.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__document_production_in_the_arbitrati"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Document production in the arbitration will generally be conducted in accordance with the latest IBA Rules on the Taking of Evidence in International Arbitration.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="xd__the_award_will_be_final_and_unappeal"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The award will be final and unappealable, and judgment upon the award may be entered in any court of competent jurisdiction. The arbitrators will have no authority to award punitive or any other non-compensatory damages. The arbitrators will, unless they deem otherwise in the circumstances, order that all or part of the costs incurred by the prevailing Party</font></div></div>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:3.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in connection with the arbitration, including reasonable attorneys&#x2019; fees, be paid by the non- prevailing Party.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;" id="xe__except_to_the_extent_necessary_to_co"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except to the extent necessary to confirm or enforce an award or to accomplish the purpose of this Agreement, including to exercise its rights and to perform its </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obligations under this Agreement or as may be required by Applicable Law, the existence, content, or results of an arbitration will be Confidential Information of each of the Parties, and neither a Party nor an arbitrator may disclose such Confidential Information without the prior written consent of the other Party, provided, however, each Party may disclose the content of the award to its Affiliates, Sublicensees and the licensees, employees, agents, consultants, contractors and other representatives who have a legitimate need to know the content of the award or as otherwise permitted under Article 11.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">13.3</font><div style="width:100%;display:inline;" id="x3_3_payment_tolling___during_the_penden"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment Tolling</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. During the pendency of any dispute resolution proceeding between the Parties under this Article 13, the obligation to make any payment, or portion thereof, under this Agreement from one Party to the other Party, which payment, or portion thereof, is the subject, in whole or in part, of a proceeding under this Article 13, will be tolled until the final outcome of such dispute has been established. Any portion of a payment which is not in dispute will be paid in accordance with the terms of this Agreement.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:37.133%;text-indent:25.228%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:38.185%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:37.133%;text-indent:25.228%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:38.185%;text-align:left;" id="article_14__general_provisions"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 14 GENERAL PROVISIONS</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:11.75pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">14.1</font><div style="width:100%;display:inline;" id="x4_1_governing_law___this_agreement_will"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement will be governed by and construed in accordance with the laws of the State of New York, U.S., without giving effect to any rules of conflict of laws that would result in the application of the laws of any other jurisdiction.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">14.2</font><div style="width:100%;display:inline;" id="x4_2_entire_agreement__modification___th"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entire Agreement; Modification</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement, including the exhibits, is both a final expression of the Parties&#x2019; agreement and a complete and exclusive statement with respect to all of its terms. This Agreement supersedes all prior and contemporaneous agreements and communications, whether oral, written, or otherwise, concerning any and all matters contained herein. This Agreement may only be modified or supplemented in a writing expressly stated for such purpose and signed by the Parties to this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">14.3</font><div style="width:100%;display:inline;" id="x4_3_relationship_between_the_parties___"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Relationship Between the Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Parties&#x2019; relationship, as established by this Agreement, is solely that of independent contractors. This Agreement does not create any partnership, joint venture, or similar business relationship between the Parties. Neither Party is a legal representative of the other Party, and neither Party can assume or create any obligation, representation, warranty, or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever.</font><font id="x4_4_non_waiver___the_failure_of_a_party"></font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">14.4</font><div style="width:100%;display:inline;" id="x4_5_assignment_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement will neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. Any waiver by a Party of a particular provision or right will be in writing, will be as to a particular matter and, if applicable, for a particular period of time and will be signed by such Party.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.204%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:7.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.681229549748838%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assignment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.504%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.463%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__neither_this_agreement_nor_any_right"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred by either Party, whether by merger, consolidation, divesture, restructure, sale of stock, sale of assets, or otherwise, without the prior written consent of the other Party (which consent will not be unreasonably withheld, delayed or conditioned), except that: (i) either Party may assign or otherwise transfer this Agreement and its rights and obligations hereunder, without the other Party&#x2019;s consent in connection with a Change of Control of such Party, to the successor of the Party in such Change of Control, provided that the assignee will expressly agree to be bound by the assigning Party&#x2019;s obligations under this Agreement; (ii) either Party may assign or otherwise transfer this Agreement and its rights and obligations hereunder without the other Party&#x2019;s consent to an Affiliate of such assigning Party, provided that the assigning Party will remain liable and responsible to the non-assigning Party for the performance and observance of all such duties and obligations by such Affiliate; and (iii) either Party may assign or otherwise transfer this Agreement and its rights and obligations hereunder without the other Party&#x2019;s consent in connection with the sale, transfer or other disposition of all or substantially all of such Party&#x2019;s assets to which this Agreement relates, provided that the assignee will expressly agree to be bound </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.463%;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by the assigning Party&#x2019;s obligations under this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__as_soon_as_practicable_upon_the_entr"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As soon as practicable upon the entry by a Party to a definitive agreement that effects a Change of Control of such Party, such Party will provide written notice to other Party setting forth the name of the Third Party acquirer or the entity with or into which such Party will be merged or consolidated, as the case may be and such other details as the other Party may reasonably request in connection with such Change of Control.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__in_the_event_of__i__a_change_of_cont"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of (i) a Change of Control involving either Party, or (ii) the acquisition by either Party of all or substantially all of the business of a Third Party (together with any entities that were Affiliates of such Third Party immediately prior to such acquisition, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acquiree</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), whether by merger, sale of stock, sale of assets or otherwise (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acquisition</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the Intellectual Property of the Third Party acquirer in a Change of Control, or the Acquiree, as applicable, that existed prior to the effective date of such Change of Control or Acquisition (or that is developed thereafter without any use of Intellectual Property of such Party or any of its Affiliates existing prior to the Change of Control or Acquisition or acquired or developed thereafter) will not be included in the Patent Rights, Know-How, or other Intellectual Property rights licensed or transferred hereunder by such Party to the other Party, or otherwise subject to this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:15.529%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.991558156703723%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="xd__the_rights_and_obligations_of_the_pa"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The rights and obligations of the Parties under this Agreement will be binding upon and inure to the benefit of the permitted successors and permitted assigns of the Parties specified above, and the name of a Party appearing herein will be deemed to include the name of such Party&#x2019;s permitted successors and permitted assigns to the extent necessary to carry out the intent of this section. Any assignment not in accordance with this Section 14.5 will be null and void.</font><font id="x4_6_severability___if__for_any_reason__"></font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">14.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication will not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Agreement. All remaining portions will remain in full force and effect as if the original Agreement had been executed without the invalidated. unenforceable, or illegal part.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">14.7</font><div style="width:100%;display:inline;" id="x4_7_notices___any_notice_to_be_given_un"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any notice to be given under this Agreement must be in writing and delivered either in person, by (a) air mail (postage prepaid) requiring return receipt, (b) internationally-recognized overnight courier, or (c) email confirmed thereafter by any of the foregoing, to the Party to be notified at its address(es) given below, or at any address such Party may designate by prior written notice to the other in accordance with this Section 14.7. Notice will be deemed sufficiently given for all purposes upon the earliest of: (i) the date of actual receipt;</font></div></div>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.583%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) if air mailed, [***] after the date of postmark; (iii) if delivered by overnight courier, the [***] after dispatch; or (iv) if sent by email, the date of confirmation of receipt if during the recipient&#x2019;s normal business hours and followed up via delivery pursuant to subsection (i), (ii), or (iii) above.</font></p>
  <p style="margin-left:13.147%;text-indent:-22.228%;padding-left:6.667%;font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;margin-right:50.194%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If to Ideaya, notices must be addressed to: IDEAYA Biosciences, Inc.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:19.813%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="margin-left:13.147%;text-indent:-15.947%;padding-left:6.667%;font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;margin-right:38.38%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with a copy (which alone will not constitute notice) to: IDEAYA Biosciences, Inc.</font></p>
  <p style="margin-left:19.813%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:38.38%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.147%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If to Hengrui, notices must be addressed to:</font></p>
  <p style="margin-left:19.813%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:40.259%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jiangsu Hengrui Pharmaceuticals Co., Ltd. [***]</font></p>
  <p style="font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.147%;text-indent:-15.947%;padding-left:6.667%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:38.38%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with a copy (which alone will not constitute notice) to: Jiangsu Hengrui Pharmaceuticals Co., Ltd.</font></p>
  <p style="margin-left:19.813%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="x4_8_force_majeure___each_party_will_be_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.752%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">14.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Force Majeure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party will be excused from liability for the failure or delay in performance of any obligation under this Agreement by reason of any event beyond such Party&#x2019;s reasonable control, including Acts of God, fire, flood, explosion, earthquake, pandemic flu, or other natural forces, war, civil unrest, acts of terrorism, accident, destruction or other casualty, any lack or failure of transportation facilities, any lack or failure of supply of raw materials, or any other event similar to those enumerated above. Such excuse from liability will be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the Party has not caused such event(s) to occur. Notice of a Party&#x2019;s failure or delay in performance due to force majeure must be given to the other Party within [***] after its occurrence. All delivery dates under this Agreement that have been affected by force majeure will be tolled for the duration of such force majeure. In no event will any Party be required to prevent or settle any labor disturbance or dispute.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.752%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">14.9</font><div style="width:100%;display:inline;" id="x4_9_rights_in_bankruptcy___all_rights_a"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rights in Bankruptcy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All rights and licenses granted under or pursuant to this Agreement by one Party to the other Party are, and will otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws, licenses of right to &#x201c;intellectual property&#x201d; as defined under Section 101 of the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws. The Parties agree that a Party that is a licensee of such rights under this Agreement will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party to this Agreement under the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws, the other Party will be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and same, if not already in its possession, will be promptly delivered to it (a) upon any such commencement of a bankruptcy or insolvency proceeding upon its written request therefor, unless the bankrupt Party </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.463%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">elects to continue to perform all of its obligations under this Agreement, or (b) if not delivered under (a) above, following the rejection of this Agreement by or on behalf of the bankrupt Party upon written request therefor by the other Party.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">14.10</font><div style="width:100%;display:inline;" id="x4_10_designation_of_affiliates___each_p"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designation of Affiliates</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party may discharge any obligations and exercise any rights hereunder through delegation of its obligations or rights to any of its Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party&#x2019;s obligations under this Agreement, and will cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any breach by a Party&#x2019;s Affiliate of any of such Party&#x2019;s obligations under this Agreement will be deemed a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such Party&#x2019;s Affiliate.</font><font id="x4_11_interpretation___the_headings_of_c"></font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">14.11</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interpretation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The headings of clauses contained in this Agreement preceding the text of the sections, subsections, and paragraphs hereof are inserted solely for convenience and ease of reference and will not constitute any part of this Agreement, or have any effect on its interpretation or construction. All references in this Agreement to the singular will include the plural where applicable. Unless otherwise specified, references in this Agreement to any Article will include all Sections, subsections, and paragraphs in such Article, references to any Section will include all subsections and paragraphs in such Section, and references in this Agreement to any subsection will include all paragraphs in such subsection. The word &#x201c;including&#x201d; and similar words means including without limitation. The word &#x201c;or&#x201d; means &#x201c;and/or&#x201d; unless the context dictates otherwise because the subjects of the conjunction are mutually exclusive. The words &#x201c;herein,&#x201d; &#x201c;hereof,&#x201d; and &#x201c;hereunder&#x201d; and other words of similar import refer to this Agreement as a whole and not to any particular Section or other subdivision. All references to days in this Agreement mean calendar days, unless otherwise specified. Ambiguities and uncertainties in this Agreement, if any, will not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. This Agreement has been prepared in the English language and the English language will control its interpretation. In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral, or other communications between the Parties regarding this Agreement will be in the English language.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">14.12</font><div style="width:100%;display:inline;" id="x4_12_further_actions___each_party_agree"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further Actions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as necessary or appropriate in order to carry out the purposes and intent of this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.537%;text-indent:7.764%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.274814632528381%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">14.13</font><div style="width:100%;display:inline;" id="x4_13_counterparts__electronic_or_facsim"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Counterparts; Electronic or Facsimile Signatures</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement may be executed in any number of counterparts, each of which will be an original, but all of which together will constitute one instrument. This Agreement may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SIGNATURE PAGE FOLLOWS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.94in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:6.48%;text-indent:7.72%;font-size:10pt;margin-top:3.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.333%;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In Witness Whereof</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Parties have caused this License Agreement to be executed and entered into by their duly authorized representatives as of the Effective Date.</font></p>
  <p style="font-size:10pt;margin-top:1.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:7.083%;border-spacing:0;table-layout:auto;width:74.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:52.28%;box-sizing:content-box;"></td>
    <td style="width:47.72%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:33.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.</font></p></td>
    <td style="padding-top:0in;text-indent:25.8pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.773%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">IDEAYA BIOSCIENCES, INC.</font></p></td>
   </tr>
   <tr style="height:25.9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:5.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:	/s/ Frank Jiang</font></p></td>
    <td style="padding-top:0in;text-indent:25.8pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.773%;text-indent:0;font-size:12pt;margin-top:5.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:	/s/ Yujiro Hata</font></p></td>
   </tr>
   <tr style="height:25.9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Frank Jiang</font></p></td>
    <td style="padding-top:0in;text-indent:25.8pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.773%;text-indent:0;font-size:12pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Yujiro Hata</font></p></td>
   </tr>
   <tr style="height:19.45pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:2.5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:0.467%;text-indent:0;font-size:12pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Chief Strategy Officer</font></p></td>
    <td style="padding-top:0in;text-indent:25.8pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:4.773%;text-indent:0;font-size:12pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.44in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.893%;text-indent:0.078%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:41.981%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 11.4 PRESS RELEASE</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.43in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1.26in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:6.72%;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.815%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors</font></p>
  <div class="item-list-element-wrapper" style="margin-left:9.87%;display:flex;margin-top:13.6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:12.935%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.697991789637191%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.87%;display:flex;margin-top:0.35pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:8%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.697991789637191%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DLL3 highly expressed in Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NETs), respectively 85% and 20-40%</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.87%;display:flex;margin-top:0.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:14%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.697991789637191%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rational combination opportunities with IDEAYA&#x2019;s DNA Damage Repair (DDR) clinical pipeline, including Phase 1 PARG inhibitor IDE161</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.87%;display:flex;margin-top:0.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.697991789637191%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Targeting US IND filing for SHR-4849 in H1 2025</font></div></div>
  <p style="margin-left:6.627%;font-size:10pt;margin-top:10.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.815%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SOUTH SAN FRANCISCO, CALIFORNIA and SHANGHAI, China, December 29, 2024 /PRNewswire/</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:7.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has entered into an exclusive license agreement for SHR-4849, a novel DLL3-targeting Topo-I-payload ADC program with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma, SHA: 600276), an innovative global pharmaceutical company headquartered in China focused on unmet clinical needs. Under the terms of the agreement, IDEAYA will develop and commercialize SHR-4849 worldwide outside of Greater China.</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#34;There is significant unmet medical need in DLL3-expressing solid tumors, and we are excited by the opportunity to develop SHR-4849, which has monotherapy potential in SCLC and NETs. SHR-4849 is competitively well positioned with first-in-class potential in the DLL3 topo-I-payload ADC field, a therapeutic area that has demonstrated preliminary monotherapy clinical validation in SCLC,&#34; said Yujiro</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">S. Hata, Chief Executive Officer and Founder, IDEAYA Biosciences. &#x201c;In addition, SHR-4849 accelerates IDEAYA&#x2019;s strategic objective to develop wholly-owned rational clinical combinations of topo-payload based ADCs with our PARG inhibitor IDE161, where we observe enhanced preclinical combination efficacy versus evaluated topo-payload ADCs alone,&#34; said Daniel A. Simon, Chief Business Officer, IDEAYA Biosciences.</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Frank Jiang, Chief Strategy Officer and Board Director, Hengrui Pharma, said &#34;SHR-4849 is a novel DLL3 targeting ADC showing encouraging early clinical signals in small-cell lung cancer with a manageable safety profile. We are delighted to partner with IDEAYA to support the development of this ADC globally, which furthers our goal of delivering innovative medicines for the benefit of patients around the world.&#34;</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SHR-4849 has shown promising antitumor activity in preclinical studies, including tumor regression as a monotherapy in multiple models. This drug is currently being evaluated in a Phase 1 clinical trial for advanced solid tumors in China (NCT06443489). In the ongoing Phase 1 dose escalation, SHR-4849 has reached therapeutic dose levels where multiple partial responses have been observed as of the data cut-off date of December 10, 2024. Among 11 evaluable small cell lung cancer (SCLC) subjects treated at therapeutic dose levels, 8 partial responses by RECIST 1.1 were observed, resulting in an overall response rate of ~73% (including both confirmed and unconfirmed responses, all unconfirmed responses were pending further evaluation). As of the data cut-off date, treatment related adverse events (TRAEs) were predominantly Grade 1 or 2, and the Phase 1 dose escalation is ongoing with no reported drug-related discontinuations, and the maximum tolerated dose has not yet been reached. The most common TRAEs</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1.26in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">observed were white blood cell count decreased, anemia, neutrophil count decreased, nausea and platelet count decreased.</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDEAYA is targeting to file a US IND for SHR-4849 in the first half of 2025.</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DLL3 has been reported to be expressed in multiple solid tumor types, including in SCLC and Neuroendocrine Tumors at approximately 85% and 20-40%, respectively, based on the Human Protein Atlas database. DLL3 has limited extracellular expression in normal tissues, making it a promising therapeutic target in these tumor types, for which there remains significant unmet medical need.</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the agreement, Hengrui Pharma is eligible to receive upfront and milestone payments totaling $1.045 billion, including a $75m upfront fee, up to $200m in development and regulatory milestone payments, plus commercial success-based milestones. Hengrui is also eligible to receive mid- single to low-double digit royalties on net sales outside of Greater China. The upfront and projected research and development costs, including potential milestone payments, does not change the earlier provided IDEAYA guided cash out runway of at least 2028.</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:12.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">About IDEAYA Biosciences</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:11.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality &#x2013; which represents an emerging class of precision medicine targets.</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:12.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">About Hengrui Pharma</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.944%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) is an innovative global pharmaceutical company focused on unmet clinical needs, with a strong track record of scientific and technological innovation. Since its first innovative drug approval in 2011, Hengrui Pharma has invested more than $5.4 billion in R&amp;D and set up 14 R&amp;D centers in Lianyungang, Shanghai, the U.S., and Europe. It has 9 major manufacturing sites and a global R&amp;D team of more than 5,000 professionals. Hengrui Pharma has independently established a number of leading technology platforms such as its ADC platform, proteolysis targeting chimera (PROTAC), molecular gels, bi/multi-specific antibodies, and AI molecular design, which provide a strong foundation for innovative R&amp;D. Hengrui strives for continued innovation and collaboration with global partners to serve a healthy China and benefit patients around the world.</font></p>
  <p style="font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:12.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This press release contains forward-looking statements, including, but not limited to, statements related to</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.944%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) the timing of a potential IND filing, (ii) potential development strategies, (iii) the estimated potential addressable market and (iv) the potential therapeutic benefits of IDEAYA therapeutics. Such forward- looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1.26in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">      </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.27</font></p></div>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.944%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Annual Report on Form 10-K dated February 20, 2024 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:70.509%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor and Media Contact IDEAYA Biosciences Andres Ruiz Briseno</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:38.38%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SVP, Head of Finance and Investor Relations </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investor@ideayabio.com</font></p>
  <p style="font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:23.361%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SOURCE IDEAYA Biosciences, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd. Sources</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 AACR. Abstract 3146/27</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rojo, F., at al., International Real-World Study of DLL3 Expression in Patients with Small Cell Lung Cancer. Lung Cancer. 2020;147:237&#x2013;243</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tanaka, K., at al., Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer. Lung Cancer. 2018 Jan:115:116-120</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yao, J., at al.,DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. The Oncologist, 2022, 27, 940&#x2013;951</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ali, G., at al., Prevalence of Delta-Like Protein 3 in a Consecutive Series of Surgically resected Lung Neuroendocrine Neoplasms. Front. Oncol. 11:729765.</font></p>
  <p style="margin-left:6.48%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Song, H., at al., Expression of Notch receptors and their ligands in pancreatic ductal adenocarcinoma. Exp Ther Med 16: 53-60, 2018</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.67in;min-height:0.61in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19(B)
<SEQUENCE>5
<FILENAME>idya-ex10_19b.htm
<DESCRIPTION>EX-10.19(B)
<TEXT>
<html>
 <head>
  <title>EX-10.19(b)</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">     </font></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                  										</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    Exhibit 10.19(b)</font></p></div>
  <p style="margin-left:0.013%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.028%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AMENDMENT NUMBER ONE TO OPTION AND LICENSE AGREEMENT</font></p>
  <p style="margin-left:7.587%;text-indent:7.84%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.546%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Amendment Number One to Option and License Agreement (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment No. 1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is entered into as of December 12, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment No. 1 Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), by and between Biocytogen Pharmaceuticals (Beijing) Co., Ltd., organized under the laws of China, having an address at No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, China 102609 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Biocytogen</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and IDEAYA Biosciences, Inc., organized under the laws of Delaware, having an address at 5000 Shoreline Court, Suite 300, South San Francisco, California 94080 U.S.A. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ideaya</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Biocytogen and Ideaya may be referred to herein individually as a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or collectively as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:7.839%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:7.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">W</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Parties entered into the Option and License Agreement, effective on July 30, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); and</font></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:7.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:7.528%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whereas</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Parties desire to amend, pursuant to Section 15.2 of the Agreement, certain terms of the Agreement in accordance with this Amendment No. 1 effective as of the Amendment No. 1 Effective Date.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.587%;text-indent:7.847%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:7.62%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Now Therefore</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the Parties, the Parties, intending to be legally bound, agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 2.1 of the Agreement shall be deleted in its entirety and replaced with the exhibit set forth in Attachment 1 to this Amendment No. 1.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:7.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of any discrepancies or conflicting terms between this Amendment No. 1 and the Agreement, the terms of this Amendment No. 1 shall control.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:13.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Agreement and this Amendment No. 1 constitutes and contains the complete, final and exclusive understanding and agreement of the Parties and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements, whether oral or written, between the Parties respecting the subject matter hereof and thereof.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Amendment No. 1, and all claims arising under or in connection therewith, will be governed by and interpreted in accordance with the substantive laws of the State of Delaware, without regard to conflict of law principles thereof.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Amendment No. 1 may be executed in two counterparts, each of which will be an original and both of which will constitute together the same document. Counterparts may </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.65in;min-height:0.78in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">     </font></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                  										</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    Exhibit 10.19(b)</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be signed and delivered by facsimile or PDF file, each of which will be binding when received by the applicable Party.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:7.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.2155241455442765%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except for the matters set forth in this Amendment No. 1, all other terms of the Agreement shall remain unchanged and in full force and effect.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.65in;min-height:0.78in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">     </font></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                  										</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:80%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    Exhibit 10.19(b)</font></p></div>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.306%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, authorized representatives of the Parties have duly executed this Amendment No. 1 to be effective as of the Amendment No. 1 Effective Date.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:52%;box-sizing:content-box;"></td>
    <td style="width:48%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">IDEAYA BIOSCIENCES, INC.</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">/s/ Yuelei Shen</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">/s/ Douglas Snyder</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: Yuelei Shen</font></p><p style="font-size:12pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: CEO</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: Douglas Snyder</font></p><p style="text-indent:-9.168%;padding-left:6.667%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:20.62%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Senior Vice President, General Counsel</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br> </font></p>
  <p style="font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br> </font></p>
  <p style="margin-left:9.587%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.65in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.13in;z-index:-3;min-height:0.93in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.013%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.028%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ATTACHMENT 1</font></p>
  <p style="margin-left:0.013%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.028%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.013%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.019%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.1</font></p>
  <p style="font-size:10pt;margin-top:1.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.013%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.019%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OPTION PERIOD STUDIES</font></p>
  <p style="font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.306%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.65in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.56%;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20(F)
<SEQUENCE>6
<FILENAME>idya-ex10_20f.htm
<DESCRIPTION>EX-10.20(F)
<TEXT>
<html>
 <head>
  <title>EX-10.20(f)</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.20(f)</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment No. 5 to Agreement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#x201c;Amendment No. 5&#x201d;)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment No. 5 Date: 			</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dec 16, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name of Original Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: 	Clinical Trial Collaboration and Supply Agreement (the &#x201c;Original Agreement,&#x201d; and together with any previous amendments which may be described below, the &#x201c;Agreement&#x201d;)</font></p>
  <p style="text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date of Original Agreement: 	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 11, 2020</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:	Pfizer Inc. (&#x201c;Pfizer&#x201d;) and </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ideaya Biosciences,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Inc.  (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ideaya&#x201d;)</font></p>
  <p style="text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, the parties hereto desire to amend, among other things, certain terms of the Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW, THEREFORE, in order to accommodate the desired amendment(s), the parties hereby agree as follows:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Defined Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.   Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Agreement.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment(s) to the Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Appendix B of the Agreement is revised to read, in its entirety, as set forthing in Appendix B of this Amendment No 5.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ratification of the Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as expressly set forth in Article 2 above, the Agreement shall remain unmodified and in full force and effect.  The execution, delivery and effectiveness of this Amendment No. 5 shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of the parties to the Agreement, nor constitute a waiver of any provision of the Agreement.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Amendment No. 5 may be executed in any number of counterparts, each of which shall be an original instrument and all of which, when taken together, shall constitute one and the same agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES IMMEDIATELY FOLLOWING ON NEXT PAGE</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.20(f)</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the duly authorized representatives of Pfizer and </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ideaya</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> have executed this Amendment No. 4 as of the date first above written.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49%;box-sizing:content-box;"></td>
    <td style="width:51%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ideaya Biosciences, Inc.</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">&#160;/s/ Yujiro Hata</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Print Name:	Yujiro Hata</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:	President and Chief Executive Officer</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">&#160;12/17/2024				</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;(Duly authorized)</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Pfizer Inc.</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">&#160;/s/ Arati Rao</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Print Name:	Arati Rao</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: Thoracic Oncology TA Development Head</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">&#160;&#160;12/24/2024</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;(Duly authorized)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.20(f)</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix B&#x2013; Supply Schedule</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Supply of Compounds &#x2013; Phase I/II Study combo with IDE196</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ideaya</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pfizer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are entering into this Supply Schedule to define each Party&#x2019;s clinical supply chain responsibilities with respect to the IDEYA Study pursuant to the Clinical Trial Collaboration and Supply Agreement dated March 11, 2020, as amended by Amendment No. 1 to Agreement dated September 23, 2020, Amendment No. 2 to Agreement dated April 8, 2021, Amendment No. 3 to Agreement dated August 9, 2021, Amendment No 4 to Agreement dated May 10, 2023, and Amendment No. 5 to Agreement dated November XX, 2024.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Supply Schedule is to be used for contracting purposes between </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ideaya</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pfizer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and defines the responsibilities not covered in the Quality Agreement for the binimetinib Drug Product (&#x201c;Binimetinib Compound&#x201d;) and the crizotinib Drug Product (&#x201c;Crizotinib Compound&#x201d; and each a &#x201c;Pfizer Compound&#x201d;), clinical packaging/labeling, release, storage/distribution /control/disposal, import/export, and Interactive Response Technology (IRT), regulatory, forecast planning activities for the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ideaya</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Compound(s)/ binimetinib or Compound(s)/crizotinib and Ideaya combination clinical trials.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon approval, it will serve as the standard of operation between both parties for these clinical supply activities.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ideaya will provide Pfizer written orders [***] days before delivery of the binimetinib Drug Product. Pfizer will provide Ideaya with binimetinib [***]. Pfizer is providing [***].</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ideaya will provide Pfizer written orders [***] days before delivery of the crizotinib Drug Product. Pfizer will provide Ideaya with [***].</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delivery timelines and Compound quantities are based on the Phase I/II study plan in place at the time of the Effective Date. Compound quantities are subject to modification based on Study conduct (due, for example, to the addition of Study sites or countries, patients with durable responses, etc). If the quantity of compounds set forth in this Agreement are not sufficient to complete the Study, Ideaya shall so notify Pfizer and the Parties shall discuss in good faith regarding additional quantities of Compounds to be provided and the schedule on which such additional quantities may be provided.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As specified in the Collaboration Agreement, the Parties agree that Pfizer shall provide each Pfizer Compound for use in the Study at no cost to Ideaya.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following are estimates of the demand for the supply of the Pfizer Compound for the Study. The supply chain teams from Pfizer and Ideaya will meet regularly to review demand and supply requirements and adjust the delivery schedule to ensure continuous supply for the Study.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Study Assumptions</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.20(f)</font></p></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The source of the Compounds to be provided by the Parties during the Term may change.  In such event, the supplying Party will ensure that all Compounds supplied by such Party will be from an approved source and the table above will be updated as applicable Regulatory Authorities approve the change to the Manufacturing Site.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.20(f)</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The responsibilities of both parties are summarised in table below:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CLINICAL SUPPLIES TABLE OF ROLES AND RESPONSIBILITIES</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Documentation will be transferred between the Clinical Supply Chain contacts or designee.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Supply Schedule is binding on the final date of approval.  The Supply Schedule can be reviewed at any time by mutual consent of each party to determine if changes will be considered minor or major.  Any minor changes to the content of the Supply Schedule will be documented in the Revision History box and no re-routing for signatures will be required.  A major change will necessitate the document to be revised, re-routed for signatures and be assigned the next sequential version number.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS HEREOF, Ideaya and </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pfizer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereby approves this Supply Schedule, Version 1 as of the dates set forth below:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:12.298%;box-sizing:content-box;"></td>
    <td style="width:37.133%;box-sizing:content-box;"></td>
    <td style="width:4.779%;box-sizing:content-box;"></td>
    <td style="width:12.298%;box-sizing:content-box;"></td>
    <td style="width:33.493%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ideaya Biosciences, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Pfizer, Inc.</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br>Signature</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Yujiro Hata</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signature</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Patrick Furcolo</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Yujiro Hata</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Patrick Furcolo</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Senior Director, Global Clinical Supply</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/17/2024</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">06-Jan-2025</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25(B)
<SEQUENCE>7
<FILENAME>idya-ex10_25b.htm
<DESCRIPTION>EX-10.25(B)
<TEXT>
<html>
 <head>
  <title>EX-10.25(b)</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.25(b)</font></p></div>
  <p style="font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Execution Version</font></p>
  <p style="font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FIRST AMENDMENT TO LEASE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5000 Shoreline Court</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.739%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THIS FIRST AMENDMENT TO OFFICE LEASE (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is made as of May 10, 2024</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, by and between </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DW LSP 5000 SHORELINE LLC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a Delaware limited liability company (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Landlord</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDEAYA BIOSCIENCES, INC.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a Delaware corporation (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tenant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:37.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:37.407%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RECITALS</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.738%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to that certain Lease dated June 1, 2023</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Tenant leased from Landlord and Landlord leased to Tenant certain premises (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Original Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) containing approximately 43,966 rentable square feet of space located on the third (3</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rd</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and first (1</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">st</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) floors in the building known as 5000 Shoreline Court, San Francisco, California (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Building</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).   Capitalized terms used but not defined herein are used herein with the meanings ascribed to them in the Lease.  All references herein to the &#x201c;Lease&#x201d; shall mean the Original Lease as amended by this Amendment, unless the context clearly indicates otherwise.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.738%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Landlord and Tenant desire to amend the Lease to expand the Premises to include, in addition to the Original Premises, the Expansion Premises (as defined below), upon the terms set forth hereinbelow. </font></div></div>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:37.407%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.74%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledge, Landlord and Tenant hereby agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.738%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recitals</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The foregoing recitals are true and correct and are incorporated as part of the agreement of the parties.</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.802%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.738%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expansion of Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font></div></div>
  <p style="margin-left:0.92%;text-indent:6.802%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expansion Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Landlord hereby agrees to lease to Tenant and Tenant hereby agrees to lease from Landlord the remaining rentable area of the third (3</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rd</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) floor of the Building shown on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to this Amendment containing approximately 11,321 rentable square feet of gross leasable area (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expansion Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Effective as of the Expansion Commencement Date (as defined below) and continuing through the Lease Term for the Original Premises (such period being the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expansion Term</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the Expansion Premises shall be added to and leased by Tenant as part of the Premises under the Lease.  Landlord shall install the Tenant Improvements (as defined on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> attached hereto and made a part hereof) to initially prepare the Expansion Premises for Tenant&#x2019;s occupancy thereof for office use, in accordance with the terms of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	(b) 	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expansion Commencement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Expansion Term shall begin on the date (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expansion Commencement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that Landlord offers to deliver possession of the Expansion Premises to Tenant following Substantial Completion (as defined on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) of the Tenant Improvements to be constructed by Landlord pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Expansion Commencement Date is estimated to occur on November 1, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Estimated Expansion Commencement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  If Landlord is unable to deliver possession of the Expansion Premises to Tenant on or before the Estimated Expansion Commencement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACTIVE\1608352630.1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.25(b)</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date for any reason whatsoever, then this Amendment shall not be void or voidable, and Landlord shall not be liable to Tenant for any loss or damage resulting therefrom. Notwithstanding the foregoing, if delivery of possession of the Expansion Premises to Tenant shall occur after the date that is sixty (60) days after the Estimated Expansion Commencement Date (other than by reason of Force Majeure or Tenant Delay) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expansion Premises Outside Delivery Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and such delay actually delays Tenant&#x2019;s occupancy of the Expansion Premises, then Tenant shall receive a day for day credit against Base Monthly Rent applicable to the Expansion Premises for each day of delay in delivery beyond the Expansion Premises Outside Delivery Date until the occurrence of the delivery of the Expansion Premises to Tenant (or if applicable, the Critical Expansion Premises Outside Delivery Date), and if delivery occurs on or after the date that is sixty (60) days following the Expansion Premises Outside Delivery Date (other than by reason of Force Majeure or Tenant Delay) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Expansion Premises Outside Delivery Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and such delay actually delays Tenant&#x2019;s occupancy of the Expansion Premises, then Tenant shall receive a two (2)-day credit against Base Monthly Rent applicable to the Expansion Premises for each day of delay in delivery beyond the Critical Expansion Premises Outside Delivery Date until the delivery of the Expansion Premises to Tenant.  If any portion of the delay in delivery is due to any Tenant Delay (as defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), then the delivery date shall be deemed (for the purposes of calculating the Expansion Commencement Date) the date the Expansion Premises would have been delivered but for such delays by Tenant.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	(c) 	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Premises Square Footage</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Effective as of the Expansion Commencement Date, the Premises shall contain a total of 55,287 rentable square feet of gross leasable area. Except as expressly set forth in this Amendment, Tenant&#x2019;s lease of the Expansion Premises shall be on all of the terms and conditions set forth in the Lease that are in effect immediately before the Amendment Effective Date.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	(d)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expansion Premises Base Rent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Commencing on the Expansion Commencement Date, Tenant shall pay Base Monthly Rent for the Expansion Premises in the amounts shown below:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:28.58%;box-sizing:content-box;"></td>
    <td style="width:25.1%;box-sizing:content-box;"></td>
    <td style="width:25.1%;box-sizing:content-box;"></td>
    <td style="width:21.22%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="padding-bottom:1pt;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease Year</font></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="padding-bottom:1pt;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Annual</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"> <br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Base Rent</font></p></td>
    <td colspan="2" style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="padding-bottom:1pt;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Base Monthly<br>Rent</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$923,793.60</font></p></td>
    <td colspan="2" style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$76,982.80</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</font></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$956,126.38</font></p></td>
    <td colspan="2" style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$79,677.20</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</font></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$989,590.80</font></p></td>
    <td colspan="2" style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$82,465.90</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</font></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$1,024,226.48</font></p></td>
    <td colspan="2" style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$85,352.21</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</font></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$1,060,074.40</font></p></td>
    <td colspan="2" style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$88,339.53</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</font></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$1,097,177.01</font></p></td>
    <td colspan="2" style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$91,431.42</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</font></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$1,135,578.20</font></p></td>
    <td colspan="2" style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$94,631.52</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</font></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$1,175,323.44</font></p></td>
    <td colspan="2" style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$97,943.62</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</font></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$1,216,459.76</font></p></td>
    <td colspan="2" style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$101,371.65</font></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</font></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$1,259,035.85</font></p></td>
    <td colspan="2" style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$104,919.65</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Amendment, the term &#x201c;Lease Year&#x201d; with respect to the Expansion Premises shall mean each consecutive twelve (12)-month period during the Lease Term commencing on the Expansion Commencement Date (the partial month following the Expansion Commencement Date (if such date is not the first day of a month) shall be deemed to be included in the first Lease Year), except that the last Lease Year shall end on the expiration date of the Lease Term.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, provided that Tenant is not then in default of the Lease, as amended hereby, after the expiration of applicable notice and cure periods, then during the first (1</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">st</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) through the twenty-first (21</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">st</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) full calendar months of the Expansion Term (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expansion Abatement Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), Tenant shall not be obligated to pay any Base Monthly Rent otherwise attributable to the Expansion Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACTIVE\1608352630.1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.25(b)</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">during such Expansion Abatement Period (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expansion Abatement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Landlord and Tenant acknowledge that the aggregate amount of the Expansion Abatement shall equal $1,640,888.38.  Tenant shall be required to pay Tenant&#x2019;s Share of Operating Expenses for the Expansion Premises as provided herein attributable to the Expansion Abatement Period, as well as for utilities and other services.  Tenant acknowledges and agrees that the foregoing Expansion Abatement has been granted to Tenant as additional consideration for entering into this Amendment, and for agreeing to pay the rental and performing the terms and conditions otherwise required under the Lease, as amended hereby.  If Tenant shall be in default under the Lease, as amended hereby, and shall fail to cure such default within the notice and cure period, if any, permitted for the cure pursuant to the terms and conditions of the Lease, and Landlord shall have terminated the Lease by reason of such uncured default, then Tenant shall pay Landlord unamortized portion of the Expansion Abatement, such amortization to be computed over a period of the number of full calendar months of the Expansion Term with interest at the lesser of (i) ten percent (10%) per annum or (ii) the maximum rate permitted by applicable law.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		(d)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expansion Premises Additional Rent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  During the Expansion Term, Tenant shall pay additional charges for Operating Expenses on account of the Expansion Premises in accordance with Article 8 of the Lease, except that Tenant&#x2019;s Share for the Expansion Premises shall be 8.11%.  Effective as of the Expansion Commencement Date, Tenant&#x2019;s Share for the Original Premises (31.49%) together with the Expansion Premises (8.11%) shall be 39.60%.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		(e)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Early Occupancy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Landlord shall use commercially reasonable efforts to permit Tenant, or any agent, employee or contractor of Tenant, to enter, use or occupy the Expansion Premises not less than thirty (30) days prior to the Expansion Commencement Date. Such entry, use or occupancy shall be subject to all the provisions of the Lease, as amended hereby (other than the payment of Base Monthly Rent and Additional Rent on account of Operating Expenses, Real Estate Taxes and utilities), including, without limitation, Tenant&#x2019;s compliance with the insurance and indemnity requirements of the Lease. Said early possession shall not advance the Expansion Commencement Date.  During such early access to the Expansion Premises, Tenant agrees that it shall not in any way materially interfere with the progress of the Tenant Improvements by such entry. Should such entry prove a material impediment to the progress of the Tenant Improvements, in Landlord&#x2019;s reasonable judgment, Landlord may demand that Tenant forthwith vacate the Expansion Premises during the period of time that the Tenant Improvements would be materially impeded, and Tenant shall promptly comply with this demand.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.738%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tenant&#x2019;s Estoppel</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Tenant hereby certifies and acknowledges that, as of the Amendment Effective Date, (a) to Tenant&#x2019;s knowledge, Landlord is not in default in any respect under the Lease; (b) Tenant does not have any defenses to its obligations under the Lease, and (c) there are no offsets against Rent.  Tenant acknowledges and agrees that: (i) the representations herein set forth constitute a material consideration to Landlord in entering into this Amendment; (ii) such representations are being made by Tenant for purposes of inducing Landlord to enter into this Amendment; and (iii) Landlord is relying on such representations in entering into this Amendment.    </font></div></div>
  <p style="margin-left:0.92%;text-indent:6.802%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.738%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Security Deposit</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Landlord is currently holding FirstCitizensBank Irrevocable Standby Letter of Credit No. SVBFS001791 dated June 2, 2023 in the amount of $615,524.00 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Existing Letter of Credit</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) as the Security Deposit under the Lease. In addition to the Existing Letter of Credit, within ten (10) days of the execution hereof, Tenant, as additional security for the performance of the obligations of Tenant under the Lease, as amended hereby, shall provide to Landlord either (x) an amendment to the Existing Letter of Credit to increase the amount of same by $153,965.60 (two (2) months&#x2019; Base Rent payable with respect to the Expansion Premises), or (y) a clean, irrevocable letter of credit in the amount of $769,489.60 substantially in the form of the letter of credit attached to the Lease as Exhibit M, and otherwise in accordance with the terms and conditions of the Lease, including but not </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACTIVE\1608352630.1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.25(b)</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limited to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.5</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Accordingly, as of the date hereof, the amount specified as &#x201c;Security/Letter of Credit&#x201d; in  </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section M</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Summary shall be amended to mean $769,489.60.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.738%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Brokerage.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Tenant represents and warrants that, other than CBRE, Inc. and Jones Lang LaSalle (together, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Brokers</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), it has had no dealings with any broker or agent in connection with this Amendment.  Tenant shall indemnify and hold Landlord harmless from and against any and all costs, expense or liability for any compensation, commissions, and charges claimed by any broker or agent (other than the Brokers) with respect to this Amendment or the negotiation thereof arising from a breach of the foregoing warranty.  Landlord shall be responsible for payment of the brokerage commissions due to the Brokers in connection with this Amendment pursuant to a separate written agreement. The terms of this Section shall survive the expiration or earlier termination of the Lease.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.469%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.669%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ratification</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as set forth herein, the terms of the Lease are hereby ratified and confirmed, including without limitation the provisions of Section 10.1 of the Lease concerning Landlord&#x2019;s liability, which are expressly incorporated herein.  The representations and warranties set forth in Section 15.10 of the Lease are hereby restated and confirmed as of the date hereof by the persons executing this Amendment on behalf of Tenant with respect to the Lease as amended hereby.  </font></div></div>
  <p style="margin-left:0.92%;text-indent:6.802%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.469%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.669%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successors and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective legal representatives, successors, and assigns.  </font></div></div>
  <p style="margin-left:6.387%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.469%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.669%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Miscellaneous</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Amendment shall be deemed to have been executed and delivered within the State of California, and the rights and obligations of Landlord and Tenant shall be construed and enforced in accordance with, and governed by, the laws of the State of California.  Each party has cooperated in the drafting and preparation of this Amendment and, therefore, in any construction to be made of this Amendment, the same shall not be construed against either party.  Except as expressly amended by this Amendment, all other terms, conditions and provisions of the Lease are hereby ratified and confirmed and shall continue in full force and effect.</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.802%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.469%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.398%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.669%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Counterparts; Execution</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Amendment may be executed in counterparts, which, when taken together, shall constitute one and the same instrument.  Any facsimile or electronic (e.g., email, pdf, DocuSign or comparable format) transmittal of original signature versions of this Amendment shall be considered to have the same legal effect as execution and delivery of the original document and shall be treated in all manner and respects as the original document.  In case any one or more of the provisions contained in this Amendment shall for any reason be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Amendment, and this Amendment shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein.</font></div></div>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.213%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[SIGNATURE PAGE FOLLOWS ON NEXT PAGE]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACTIVE\1608352630.1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.25(b)</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.802%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the parties have executed this Amendment to be effective as of the Amendment Effective Date.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:47.587%;font-size:10pt;margin-top:7.85pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LANDLORD</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:47.587%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DW LSP 5000 SHORELINE LLC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</font></p>
  <p style="margin-left:47.587%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a Delaware limited liability company</font></p>
  <p style="margin-left:47.587%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:47.587%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By: Divco West Real Estate Asset Management, Inc., a Delaware corporation, its Agent</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:47.587%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.759%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> /s/ Chris Pong	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:47.587%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.759%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Chris Pong	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:47.587%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.759%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Authorized Signatory	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:47.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:29.167%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TENANT</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.733%;text-indent:11.249%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDEAYA BIOSCIENCES, INC.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:40.733%;text-indent:11.249%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a Delaware corporation</font></p>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:47.587%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.759%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> /s/ Yujiro Hata	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:47.587%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.759%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Yujiro Hata	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:47.587%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:7.759%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> President and Chief Financial Officer	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Signature Page to First Amendment to Lease]</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.25(b)</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expansion Premises</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img34507759_0.jpg" alt="img34507759_0.jpg" style="width:624px;height:406px;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.25(b)</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT B</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Work letter for construction obligations</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> forms a part of that certain First Amendment to Lease by and between </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DW LSP 5000 SHORELINE LLC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a Delaware limited liability company, as Landlord, and IDEAYA BIOSCIENCES, INC., a Delaware corporation, as Tenant, to which this Exhibit is attached.  If there is any conflict between this Exhibit and said Amendment, this Exhibit shall govern. All capitalized terms referred to in this Exhibit shall have the same meaning provided in the Lease as amended by the Amendment, except where expressly provided to the contrary in this Exhibit.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Defined Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  All defined terms referred to in this Exhibit shall have the same meaning as defined in the Lease to which this Exhibit is a part, except where expressly defined to the contrary.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each of the following terms shall have the following meaning:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Construction Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; &#x2013; The final, complete plans and specifications for the construction of the Tenant Improvements consisting of all architectural, engineering, mechanical and electrical drawings and specifications which are required to obtain all building permits, licenses and certificates from the applicable governmental authority(ies) for the construction of the Tenant Improvements.  The Construction Plans shall be prepared by duly licensed and/or registered architectural and/or engineering professionals selected by Landlord in its sole and reasonable discretion, and shall be in substantial compliance in all respects with all applicable laws, rules, regulations, building codes for the city and county where the Building is located. Landlord hereby approves HPC and DGA as architectural professionals (the parties acknowledging that Landlord intends to engage DGA for the preparation of the Construction Plans).  In the event Tenant requests that Landlord retain DGA as the architect for the Tenant Improvements, Landlord agrees to use commercially reasonable efforts to retain DGA for the Tenant Improvements.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Force Majeure Delays</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; - Any delay, other than a Tenant Delay, by Landlord in completing the Tenant Improvements by the Estimated Expansion Commencement Date set forth in the Amendment by reason of (i) any strike, lockout or other labor trouble or industrial disturbance (whether or not on the part of the employees of either party hereto), (ii) governmental preemption of priorities or other controls in connection with a national or other public emergency, civil disturbance, riot, war, sabotage, blockade, embargo, inability to secure customary materials, supplies or labor through ordinary sources by reason of regulation or order of any government or regulatory body, or (iii) shortages of fuel, materials, supplies or labor (not arising from Landlord&#x2019;s failure to exercise prudent practices in ordering in advance long lead items), (iv) lightning, earthquake, fire, storm, tornado, flood, washout explosion, or unseasonable inclement weather or any other similar industry-wide or Building-wide cause beyond the reasonable control of Landlord, or (v) any other cause, whether similar or dissimilar to the above, beyond Landlord&#x2019;s reasonable control.  The time for performance of any obligation of Landlord to construct the Tenant Improvements under this Exhibit or the Amendment shall be extended at Landlord&#x2019;s election by the period of any delay caused by any of the foregoing events. Landlord shall use commercially reasonable efforts to keep Tenant reasonably apprised of any events that may materially delay the date of Substantial Completion.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Space Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; - That certain Space Plan to be attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B-2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, reflecting the Tenant Improvements to be constructed by Landlord.  Landlord and Tenant hereby approve of the Space Plan.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.25(b)</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Spec Buildout Sheet</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; - That certain list of specifications identified on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B-3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> attached hereto, with respect to the Tenant Improvements to be constructed by Landlord.  Landlord and Tenant hereby approve of the Spec Buildout Sheet.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Substantial Completion</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#x201d; &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Substantially Complete</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#x201d; &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Substantially Completed&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2011; The terms Substantial Completion, Substantially Completed and Substantially Complete shall mean when the last of the following has occurred (or would have occurred but for Tenant Delays): (a) Landlord has delivered to Tenant a written notice stating that the Tenant Improvements have been Substantially Completed substantially in accordance with the Construction Plans, except &#x201c;punch list&#x201d; items which may be completed without materially impairing Tenant&#x2019;s use of the Expansion Premises or a material portion thereof for the Permitted Use and such work as Landlord is required to perform but cannot complete until Tenant performs necessary portions of construction work it has elected or is required to do; (b) the acquisition of a temporary or permanent certificate of occupancy or its legal equivalent allowing occupancy of the Expansion Premises; (c) all base building systems are operational and fully-commissioned to the extent of serving the Expansion Premises; and (d) delivery of a certificate of substantial completion from the architect on behalf of the contractor confirming the matters set forth in the foregoing clause (a).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tenant Delay</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; - Any incremental delay incurred by Landlord in Substantially Completing the Tenant Improvements due to (i) a delay by Tenant, or by any person employed or engaged by Tenant, in approving or delivering to Landlord any plans, schedules or information, including, without limitation, the Construction Plans beyond the applicable time period set forth in this Exhibit, if any; (ii) a delay in the performance of work in the Expansion Premises by Tenant or any person employed by Tenant; (iii) any changes requested by Tenant in or to previously approved work or in the Space Plan, Spec Buildout Sheet, or Construction Plans; (iv) Tenant&#x2019;s requests for materials and finishes which are not readily available, and/or delays in delivery of any materials specified by Tenant through change orders; (v) the failure of Tenant to pay as and when due under this Exhibit all costs and expenses to construct the Tenant Improvements to the extent Tenant is required to pay for such costs in this Exhibit; (vi) interference with the construction of the Tenant Improvements, or (vii) the acts or omission of Tenant or its employees, agents or contractors (including without limitation the failure to timely deliver plans, insurance certificates or other items required by the Lease).  Notwithstanding anything to the contrary contained herein, no delay under clauses (ii), (iii), (iv), (vi) or (vii) shall constitute a Tenant Delay unless Landlord has given to Tenant reasonably detailed written notice of such delay by email to: [</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">        </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Tenant fails to correct the cause thereof within one (1) business day after receipt thereof.  In the event of Tenant Delay, the Expansion Commencement Date shall be accelerated so that each date shall be deemed to be one day earlier than the actual date thereof for each day of Tenant Delay.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tenant Improvements</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; - The improvements to be installed by Landlord in the Expansion Premises substantially in accordance with the Space Plan and the Spec Buildout Sheet.  The type and quality of materials to be used by Landlord to construct the Tenant Improvements will be consistent with the Landlord&#x2019;s standard building improvements for the Building, except as described to the contrary in the Space Plan and/or the Spec Buildout Sheet (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Standard Specifications</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Construction of the Tenant Improvements</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Landlord shall construct the Tenant Improvements in accordance with this exhibit and the Lease pursuant to a construction contract to be executed by Landlord and its contractor(s).  The construction contract for constructing the Tenant Improvements and the contractor(s) to perform the work shall be approved and/or selected, as the case may be, by Landlord, at its sole and absolute discretion without the consent of Tenant.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		2.1	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Construction Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Landlord shall cause to be prepared the Construction Plans for the Tenant Improvements that are consistent with and are logical evolutions of the Space Plan, the Spec Buildout Sheet, and the building standards, and deliver the same to Tenant for Tenant&#x2019;s approval (which</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.25(b)</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall not be unreasonably withheld, conditioned or delayed).  Tenant shall notify Landlord in writing within five (5) business days after receipt of Construction Plans or any preliminary plans that (i) Tenant approves of such plans; or (ii) Tenant disapproves the plans because they vary in design from the Space Plan or the Spec Buildout Sheet approved by Landlord and Tenant in the particular instances specified by Tenant in such notice (including, without limitation, the specific changes requested by Tenant), but such disapproval shall constitute a Tenant Delay (subject to the terms of such definition) unless the plans materially deviate from the Space Plan or the Spec Buildout Sheet or changes in such Space Plan or the Spec Buildout Sheet.  The failure of Tenant to provide such written notice within said five (5) business day period shall be deemed an approval by Tenant of such plans.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.2	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Construction</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Landlord shall construct the Tenant Improvements substantially in accordance with the Construction Plans. The construction contract for constructing the Tenant Improvements and the contractor(s) to perform the work shall be approved and/or selected, as the case may be, by Landlord at its sole and absolute discretion without the consent of Tenant. The parties anticipate that the Tenant Improvements will be &#x201c;turnkey&#x201d; condition and Substantially Completed by the Estimated Expansion Commencement Date, subject to Tenant Delays and Force Majeure Delays.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	2.3	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tenant&#x2019;s Responsibility</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Tenant shall be solely responsible for the suitability for the Tenant&#x2019;s needs and business of the design and function of the Tenant Improvements. Except as included in the Tenant Improvements, Tenant shall be responsible for procuring or installing in the Premises any trade fixtures, equipment, furniture, furnishings, telephone equipment or other personal property (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personal Property</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) to be used in the Premises by Tenant, and the cost of such Personal Property shall be paid by Tenant. In furtherance of the foregoing, Tenant shall be responsible for the procurement and installation of any and all equipment on the equipment list attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B-1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equipment List</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Landlord, at its cost, shall provide the utility capacity and distribution to the locations within the Premises required for the equipment on the Equipment List.  In addition, Landlord agrees to provide up to Four Hundred Fifty Thousand Dollars ($450,000.00) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">N2 Allowance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) toward the cost of the installation of the N2 system and related equipment to be installed in the Premises to service the Existing Premises and the Expansion Premises (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">N2 System</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Tenant will provide the N2 System at Tenant&#x2019;s cost, and Landlord will install the N2 System as part of the Tenant Improvements pursuant to a separate bid obtained by Landlord from its general contractor (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">N2 Cost Estimate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  In the event that the N2 Cost Estimate exceeds the N2 Allowance, the difference (the &#x201c;Over-Allowance Amount&#x201d;) shall be paid to Landlord within thirty (30) days of Landlord&#x2019;s request for the same.  The parties shall reconcile the Over-Allowance Amount against actual incremental costs incurred by Landlord to install the N2 System, within thirty (30) days following Substantial Completion of the Tenant Improvements.  Landlord shall provide documentation reasonably requested by Tenant to substantiate the reconciled amounts.  At the expiration or sooner termination of the Lease Term, the N2 System shall be surrendered to Landlord as part of the realty and shall then become Landlord&#x2019;s property.  Tenant shall conform to the Building&#x2019;s wiring standards in installing any telephone equipment and shall be subject to any and all rules of the site during construction.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	3.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment of Construction Costs</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except for the Over-Allowance Amount, Landlord shall pay for the costs to construct the Tenant Improvements based on the</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Space Plan and Spec Buildout Sheet approved by the parties as provided above. Any additional costs due to changes in the Tenant Improvements reflected in the Space Plan, the Spec Buildout Sheet, or in the Construction Plans requested by Tenant or as a result of any Tenant Delay shall be paid by Tenant as provided in Section 4 below.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Work</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If Tenant at any time desires any changes, alterations or additions to the Tenant Improvements, Tenant shall submit a detailed written request to Landlord specifying such changes, alterations or additions (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tenant Change Request</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Without limiting the generality of the foregoing, Landlord agrees to reasonably cooperate with Tenant with respect to any Tenant Change Request that would not materially and adversely affect the value of the Project or Landlord's ability to re-lease the space upon</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.25(b)</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expiration or earlier termination of the Lease for office, laboratory or research and development purposes (as applicable), and would not increase the cost, or cause a delay in the performance of the work, unless such increase in cost or delay is economically offset by Tenant, and if such delay causes a delay in Substantial Completion, such delay is agreed in writing by Tenant to constitute a Tenant Delay. Upon receipt of any Tenant Change Request, Landlord shall promptly, and within ten (10) business days after Landlord&#x2019;s receipt of the Tenant Change Request (unless such Tenant Change Request requires third party review, in which case such ten-business-day deadline shall not apply), notify Tenant of whether the matters proposed in the Tenant Change Request pursuant to the standard set forth in the preceding sentence are approved by Landlord (which approval shall not be unreasonably withheld, conditioned or delayed) or are disapproved.  If Landlord disapproves the Tenant Change Request, Landlord shall promptly notify Tenant in writing of such disapproval and the specific reasons for such disapproval, with particularity.  If Landlord approves the Tenant Change Request, Landlord&#x2019;s notice to Tenant regarding such approval shall specify (A) Landlord&#x2019;s reasonable estimate of the number of days of Tenant Delay, if any, which shall be caused by such Tenant Change Request if implemented (including, without limitation, delays due to the need to obtain any revised plans or drawings and any governmental approvals), and (B) Landlord&#x2019;s reasonable estimate of the increase, if any, which shall occur in the cost for the items or components affected by such Tenant Change Request if such Tenant Change Request is implemented (including, but not limited to, any costs of compliance with laws or governmental regulations that become applicable because of the implementation of the Tenant Change Request).  If Landlord approves the Tenant Change Request, Tenant shall notify Landlord in writing, within five (5) business days after receipt of such notice (if any) from Landlord, that Tenant approves and wishes to proceed with the Tenant Change Request (including the estimated delays and cost increases, if any, described in Landlord&#x2019;s notice, if any), in which event Landlord shall cause such Tenant Change Request to be incorporated into the Tenant Improvements, and Tenant shall be responsible for all actual delays and all actual costs or cost increases reasonably resulting from or attributable to the implementation of the Tenant Change Request, as a Tenant Delay.  If Tenant fails to notify Landlord in writing of Tenant&#x2019;s approval of and desire to proceed with such Tenant Change Request within said five (5) business day period, then such Tenant Change Request shall be deemed to be withdrawn and shall be of no further force or effect.  The incremental cost of such changes and the additional costs as a result of any other Tenant Delay, including the cost to revise the Construction Plans, obtain any additional permits, construct any additional improvements required as a result thereof, the cost for materials and labor, the cost for any construction supervisory or administrative fee payable by Landlord to its property manager, and all other additional costs incurred by Landlord from resulting delays in completing the Tenant Improvements, shall be paid by Tenant to Landlord upon completion of such changes and receipt by Tenant of invoices substantiating the additional costs.  Such additional costs shall be Additional Rent, payable within thirty (30) days after Tenant&#x2019;s receipt of notice from Landlord (along with any applicable invoices).  If Landlord does not receive such payment within said thirty (30) day period, Landlord shall have the right, in addition to any other rights or remedies available under the Lease, at law or in equity, to discontinue all or any portion of the work until it receives said payment; in which case the commencement or completion of such work shall not be deemed a waiver of Tenant&#x2019;s obligation to pay for same or any additional costs or expenses incurred as a result thereof. Any delay caused as a result of such a change or request for a change shall constitute a Tenant Delay (subject to the terms of such definition).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:2.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	5.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tenant&#x2019;s Lease Default</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding any provision to the contrary contained in the Lease, if a default by Tenant under the Lease or this Exhibit, beyond applicable notice and cure periods, has occurred at any time on or before the Substantial Completion of the Tenant Improvements, then (i) in addition to all other rights and remedies granted to Landlord pursuant to the Lease, Landlord shall have the right to cease the construction of the Tenant Improvements (in which case, Tenant shall be responsible for any delay in the Substantial Completion of the Tenant Improvements caused by such work stoppage), and (ii) all other obligations of Landlord under the terms of this Exhibit shall be forgiven until such time as such default is cured pursuant to the terms of the Lease.</font></p>
  <p style="text-indent:2.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.25(b)</font></p></div>
  <p style="text-indent:2.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	6. 	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warranties</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Landlord shall use commercially reasonable efforts to cause the Tenant Improvements to be completed in a good and workmanlike manner and free of defect, and in good condition and repair and in compliance with all applicable laws. To Landlord&#x2019;s knowledge, Landlord has not received a notice of violation of Hazardous Materials laws in the Expansion Premises. In the case of defects in the Tenant Improvements first discovered after the Expansion Commencement Date, Tenant shall be deemed to have waived any claim for correction or cure thereof on the date that is eleven and a half months after the date of Substantial Completion thereof if Tenant has not then given notice of such defect to Landlord.  With respect to items as to which Tenant has given adequate and timely notice hereunder, Landlord shall cause Landlord&#x2019;s contractor so to remedy, repair or replace any incomplete, defective or malfunctioning aspects of the Tenant Improvements, as applicable, which materially affect Tenant&#x2019;s use of, access to or occupancy of the Expansion Premises, such action to occur as soon as practicable during normal working hours and so as to avoid any unreasonable interruption of Tenant&#x2019;s use of the Expansion Premises. The foregoing shall constitute Landlord&#x2019;s entire obligation with respect to all incomplete, defective or malfunctioning aspects of the Tenant Improvements.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.25(b)</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B-1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equipment List</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">[See attached]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.25(b)</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B-2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Space Plan</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img34507759_1.jpg" alt="img34507759_1.jpg" style="width:624px;height:400px;"></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.25(b)</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B-3</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Spec Buildout Sheet</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">[See attached]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>8
<FILENAME>idya-ex19_1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html>
 <head>
  <title>EX-19.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDEAYA BIOSCIENCES, INC.<br>INSIDER TRADING compliance POLICY</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Adopted: April 4, 2019)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Effective as of: May 28, 2019)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Amended as of: October 30, 2024)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Insider Trading Compliance Policy (this &#x201c;Policy&#x201d;) of IDEAYA Biosciences, Inc. (the &#x201c;Company&#x201d;) consists of seven sections:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section I provides an overview; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section II sets forth the Company&#x2019;s policies prohibiting insider trading; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section III explains insider trading; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section IV consists of procedures that have been put in place by the Company to prevent insider trading; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section V sets forth additional transactions that are prohibited by this Policy; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section VI explains Rule 10b5-1 trading plans and provides information about Section 16 and Rule 144; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section VII refers to the execution and return of a compliance certificate.</font></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I.	</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUMMARY</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preventing insider trading is necessary to comply with securities laws and to preserve the reputation and integrity of the Company as well as that of all persons affiliated with the Company.  &#x201c;Insider trading&#x201d; occurs when any person purchases or sells a security (e.g., stock) while in possession of &#x201c;inside information&#x201d; relating to the security.  As explained in Section III below, &#x201c;inside information&#x201d; is information that is both &#x201c;material&#x201d; and &#x201c;non-public.&#x201d;  Insider trading violates several laws, including civil and criminal laws.  The penalties for violating insider trading laws include imprisonment, disgorgement of profits, civil fines, and criminal fines of up to $5 million for individuals and $25 million for corporations.  Insider trading is also prohibited by this Policy, and violation of this Policy may result in Company-imposed sanctions, including removal or dismissal for cause.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy applies to all officers, directors, employees and consultants of the Company and extends to all activities within and outside an individual&#x2019;s duties at the Company.  Individuals subject to this Policy are responsible for ensuring that their immediate family members (</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, spouses, children, stepchildren, parents, grandparents, stepparents, siblings, mothers-in-law, fathers-in-law, sons-in-law, daughters-in-law, brothers-in-law or sisters-in-law) and members of their households also comply with this Policy.  This Policy also applies to any entities controlled by individuals subject to this Policy, including any corporations, partnerships or trusts, and transactions by these entities should be treated for the purposes of this Policy and applicable securities laws as if they were for the individual&#x2019;s own account. Notwithstanding the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foregoing, this Policy, including, without limitation, the pre-clearance policy, blackout periods and prohibited transactions, does not apply to venture capital entities or other institutional investors, and the related transactions in the Company&#x2019;s equity securities by such entities, that may be affiliated with a director of the Company or for Company equity securities that a director may be deemed to have beneficial ownership of by virtue of such affiliation.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy extends to all activities within and outside an individual&#x2019;s Company duties.  Every officer, director, employee and consultant must review this Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Questions regarding the Policy should be directed to the Company&#x2019;s General Counsel (the &#x201c;Compliance Officer&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">II.	</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STATEMENT OF POLICIES PROHIBITING INSIDER TRADING</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No officer, director, employee or consultant, or any immediate family member or any member of the household of any such person, shall purchase or sell any type of security while in possession of material, non-public information relating to the security, whether the issuer of such security is the Company or any other company.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, no officer, director or employee, or any consultant listed under &#x201c;Applicable Consultants&#x201d; on Schedule I, or any immediate family member or any member of the household of any such person, shall purchase or sell any security of the Company during the period beginning at market close on the last trading day of any fiscal quarter of the Company and ending at market close on the second full trading day following the public release of earnings data for such fiscal quarter or during any other trading suspension period declared by the Company, whether or not the Company or any of its officers, directors or employees, or any applicable consultants, is in possession of material, non-public information.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, from time to time, the Company may impose a blackout period in connection with non-routine events outside of the financial reporting cycle. These events may include consideration of major strategic transactions (e.g., acquisitions, dispositions, joint ventures), product developments, interim earnings or sales releases, significant legal proceedings and other circumstances that potentially implicate material non-public information.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These prohibitions do not apply to:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchases of the Company&#x2019;s securities from the Company or sales of the Company&#x2019;s securities to the Company, or the surrender to or withholding by the Company of the Company&#x2019;s securities (</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to cover withholding obligations upon the vesting or settlement of equity-based awards);</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exercises of stock options or other equity awards or vesting of equity-based awards that do not involve a market sale of the Company&#x2019;s securities (note that the &#x201c;cashless exercise&#x201d; of a Company stock option </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">does</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> involve a market sale of the Company&#x2019;s securities, and therefore would not qualify under this exception);</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">bona fide</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gifts of the Company&#x2019;s securities; or</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchases or sales of the Company&#x2019;s securities made pursuant to any binding contract, specific instruction or written plan entered into while the purchaser or seller, as applicable, was unaware of any material, non-public information and which contract, instruction or plan (i) meets all requirements of the affirmative defense provided by Rule 10b5-1 (&#x201c;Rule 10b5-1&#x201d;) promulgated under the Securities Exchange Act of 1934, as amended (the &#x201c;1934 Act&#x201d;), (ii) was pre-cleared in advance pursuant to this Policy and (iii) has not been amended or modified in any respect after such initial pre-clearance without such amendment or modification being pre-cleared in advance pursuant to this Policy.  For more information about Rule 10b5-1 trading plans, see Section VI below.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the purposes of this Policy, a &#x201c;trading day&#x201d; is a day on which national stock exchanges are open for trading.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No officer, director, employee or consultant shall directly or indirectly communicate (or &#x201c;tip&#x201d;) material, non-public information to anyone outside the Company (except in accordance with the Company&#x2019;s policies regarding the protection or authorized external disclosure of Company information) or to anyone within the Company other than on a need-to-know basis.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">III.	</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXPLANATION OF INSIDER TRADING</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Insider trading&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> refers to the purchase or sale of a security by someone who is in possession of &#x201c;material,&#x201d; &#x201c;non-public&#x201d; information relating to the security.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Insider</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; refers to employees, officers, directors and consultants of the Company and anyone else within the Company who has material, non-public information about the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Securities&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> includes stocks, bonds, notes, debentures, options, warrants and other convertible securities, as well as derivative instruments.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Purchase&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;sale&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are defined broadly under the federal securities law.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Purchase&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> includes not only the actual purchase of a security, but any contract to purchase or otherwise acquire a security.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Sale&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> includes not only the actual sale of a security, but any contract to sell or otherwise dispose of a security.  These definitions extend to a broad range of transactions, including conventional cash-for-stock transactions, conversions, the exercise of stock options, and acquisitions and exercises of warrants or puts, calls or other derivative securities.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is generally understood that insider trading includes the following:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading by insiders while in possession of material, non-public information;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading by persons other than insiders while in possession of material, non-public information, if the information either was given in breach of an insider&#x2019;s fiduciary duty to keep it confidential or was misappropriated; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">communicating or tipping material, non-public information to others, including recommending the purchase or sale of a security while in possession of such information.</font></div></div>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">What Facts are Material?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The materiality of a fact depends upon the circumstances.  A fact is considered &#x201c;material&#x201d; if there is a substantial likelihood that a reasonable investor would consider it important in</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">making a decision to buy, sell or hold a security, or if the fact is likely to have a significant effect on the market price of the security.  Material information can be positive or negative and can relate to virtually any aspect of a company&#x2019;s business or to any type of security, debt or equity.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Examples of material information include (but are not limited to) information about the results of clinical trials; communications sent to or received from the U.S. Food and Drug Administration; dividends; corporate earnings or earnings forecasts; mergers, acquisitions, tender offers or dispositions; major new products or product developments; important business developments such as major contract awards or cancellations; management or control changes; significant borrowing or financing developments including pending public sales or offerings of debt or equity securities; defaults on borrowings; bankruptcies; and significant litigation or regulatory actions.  Moreover, material information does not have to be related to a company&#x2019;s business.  For example, the contents of a forthcoming newspaper column that is expected to affect the market price of a security can be material.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A good general rule of thumb:  </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When in doubt, do not trade.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">What is Non-public?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information is &#x201c;non-public&#x201d; if it is not available to the general public.  In order for information to be considered public, it must be widely disseminated in a manner making it generally available to investors through such media as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dow Jones</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business Wire</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reuters</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Wall Street Journal</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Associated Press</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">United Press International</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a broadcast on widely available radio or television programs, publication in a widely available newspaper, magazine or news website, a Regulation FD-compliant conference call, or public disclosure documents filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) that are available on the SEC&#x2019;s website.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The circulation of rumors, even if accurate and reported in the media, does not constitute effective public dissemination.  In addition, even after a public announcement, a reasonable period of time must lapse in order for the market to react to the information.  Generally, one should allow two full trading days following publication as a reasonable waiting period before such information is deemed to be public.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Who is an Insider?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Insiders&#x201d; include officers, directors, employees and consultants of a company and anyone else within the Company who has material, non-public information about a company.  Insiders have independent fiduciary duties to their company and its stockholders not to trade on material, non-public information relating to the company&#x2019;s securities.  All officers, directors, employees and consultants of the Company should consider themselves insiders with respect to material, non-public information about the Company&#x2019;s business, activities and securities.  Officers, directors, employees and consultants may not trade in the Company&#x2019;s securities while in possession of material, non-public information relating to the Company, nor may they tip such information to anyone outside the Company (except in accordance with the Company&#x2019;s policies regarding the protection or authorized external disclosure of Company information) or to anyone within the Company other than on a need-to-know basis.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individuals subject to this Policy are responsible for ensuring that their immediate family members and members of their households also comply with this Policy.  This Policy also applies to any entities controlled by individuals subject to the Policy, including any corporations,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">partnerships or trusts, and transactions by these entities should be treated for the purposes of this Policy and applicable securities laws as if they were for the individual&#x2019;s own account.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">D.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading by Persons Other than Insiders</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insiders may be liable for communicating or tipping material, non-public information to a third party (&#x201c;tippee&#x201d;), and insider trading violations are not limited to trading or tipping by insiders.  Persons other than insiders also can be liable for insider trading, including tippees who trade on material, non-public information tipped to them or individuals who trade on material, non-public information that has been misappropriated.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tippees inherit an insider&#x2019;s duties and are liable for trading on material, non-public information illegally tipped to them by an insider.  Similarly, just as insiders are liable for the insider trading of their tippees, so are tippees who pass the information along to others who trade.  In other words, a tippee&#x2019;s liability for insider trading is no different from that of an insider.  Tippees can obtain material, non-public information by receiving overt tips from others or through, among other things, conversations at social, business, or other gatherings.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">E.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Penalties for Engaging in Insider Trading</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Penalties for trading on or tipping material, non-public information can extend significantly beyond any profits made or losses avoided, both for individuals engaging in such unlawful conduct and their employers.  The SEC and Department of Justice have made the civil and criminal prosecution of insider trading violations a top priority.  Enforcement remedies available to the government or private plaintiffs (e.g., the Company&#x2019;s stockholders) under the federal securities laws include:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEC administrative sanctions;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">securities industry self-regulatory organization sanctions;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">civil injunctions;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">damage awards to private plaintiffs;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disgorgement of all profits;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">civil fines for the violator of up to three times the amount of profit gained or loss avoided;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">civil fines for the employer or other controlling person of a violator (</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.e.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, where the violator is an employee or other controlled person) of up to the greater of $1,425,000 or three times the amount of profit gained or loss avoided by the violator;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">criminal fines for individual violators of up to $5,000,000 ($25,000,000 for an entity); and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">jail sentences of up to 20 years.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, insider trading could result in serious sanctions by the Company, including dismissal.  Insider trading violations are not limited to violations of the federal securities laws.  Other federal and state civil or criminal laws, such as the laws prohibiting mail and wire fraud</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the Racketeer Influenced and Corrupt Organizations Act (RICO), also may be violated in connection with insider trading.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Size of Transaction and Reason for Transaction Do Not Matter</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The size of the transaction or the amount of profit received does not have to be significant to result in prosecution.  The SEC has the ability to monitor even the smallest trades, and the SEC performs routine market surveillance.  Brokers and dealers are required by law to inform the SEC of any possible violations by people who may have material, non-public information.  The SEC aggressively investigates even small insider trading violations.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">G.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Examples of Insider Trading</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Examples of insider trading cases include actions brought against corporate officers, directors, employees and consultants who traded in a company&#x2019;s securities after learning of significant confidential corporate developments; friends, business associates, family members and other tippees of such officers, directors, employees and consultants who traded in the securities after receiving such information; government employees who learned of such information in the course of their employment; and other persons who misappropriated, and took advantage of, confidential information from their employers.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following are illustrations of insider trading violations.  These illustrations are hypothetical and, consequently, not intended to reflect on the actual activities or business of the Company or any other entity.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading by Insider</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An officer of X Corporation learns that earnings to be reported by X Corporation will increase dramatically.  Prior to the public announcement of such earnings, the officer purchases X Corporation&#x2019;s stock.  The officer, an insider, is liable for all profits as well as penalties of up to three times the amount of all profits.  The officer also is subject to, among other things, criminal prosecution, including up to $5,000,000 in additional fines and 20 years in jail.  Depending upon the circumstances, X Corporation and the individual to whom the officer reports also could be liable as controlling persons.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading by Tippee</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An officer of X Corporation tells a friend that X Corporation is about to publicly announce that it has concluded an agreement for a major acquisition.  This tip causes the friend to purchase X Corporation&#x2019;s stock in advance of the announcement.  The officer is jointly liable with his friend for all of the friend&#x2019;s profits, and each is liable for all civil penalties of up to three times the amount of the friend&#x2019;s profits.  The officer and his friend are also subject to criminal prosecution and other remedies and sanctions, as described above.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">H.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prohibition of Records Falsification and False Statements</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13(b)(2) of the 1934 Act requires companies subject to the 1934 Act maintain proper internal books and records and to devise and maintain an adequate system of internal accounting controls.  The SEC has supplemented the statutory requirements by adopting rules that prohibit (1) any person from falsifying records or accounts subject to the above requirements and (2) officers or directors from making any materially false, misleading, or incomplete</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">statement to any accountant in connection with any audit or filing with the SEC.  These provisions reflect the SEC&#x2019;s intent to discourage officers, directors and other persons with access to the Company&#x2019;s books and records from taking action that might result in the communication of materially misleading financial information to the investing public.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IV.	</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STATEMENT OF PROCEDURES PREVENTING INSIDER TRADING</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following procedures have been established, and will be maintained and enforced, by the Company to prevent insider trading.  Every officer, director, employee and consultant is required to follow these procedures.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Clearance of All Trades by All Officers, Directors and Certain Employees and Consultants</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To provide assistance in preventing inadvertent violations of applicable securities laws and to avoid the appearance of impropriety in connection with the purchase and sale of the Company&#x2019;s securities, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all transactions in the Company&#x2019;s securities (including without limitation, acquisitions and dispositions of Company stock, the sale of Company stock issued upon exercise of stock options) by the officers or directors, or any employees or consultants listed on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule I</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (as amended from time to time by the Compliance Officer), must be pre-cleared</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by the Company&#x2019;s Compliance Officer.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Pre-clearance is not required for exercises of stock options or other equity awards or vesting of equity-based awards that do not involve a market sale of the Company&#x2019;s securities (the &#x201c;cashless exercise&#x201d; of a Company stock option does involve a market sale of the Company&#x2019;s securities, and therefore would not qualify under this exception). As part of the pre-clearance process, the individual requesting pre-clearance must confirm that he or she is not in possession of material, non-public information.  Pre-clearance does not relieve anyone of his or her responsibility under SEC rules.  For clarity, transactions in the Company&#x2019;s securities pursuant to a Rule 10b5-1 plan, which was approved in advance of entering into the plan, are considered pre-cleared.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of a disagreement regarding a proposed transaction, the Compliance Officer is required to report the proposed transaction to the Audit Committee of the Board of Directors.  If the Compliance Officer has determined to withhold clearance of a proposed transaction and the individual requesting pre-clearance disagrees with such decision, in order to receive clearance for the proposed transaction such individual must receive clearance from at least two of the three following persons: (i) the Chairman of the Board of Directors, (ii) the President or Chief Executive Officer of the Company and (iii) the Chairman of the Audit Committee of the Board of Directors.  The Compliance Officer and the Audit Committee may obtain the advice of outside legal counsel with respect to such request.  The individual requesting pre-clearance may not in any event engage in the proposed transaction until request has been finally resolved to the satisfaction of the Compliance Officer or, if applicable, the Chairman of the Board of Directors, President or Chief Executive Officer, or Chairman of the Audit Committee.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Black-Out Periods</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, no officer, director or employee, or any consultant listed under &#x201c;Applicable Consultants&#x201d; on Schedule I, or any immediate family member or any member of the household of any such person, shall purchase or sell any security of the Company during the period beginning at market close on the last trading day of any fiscal quarter of</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company and ending at market close on the second full trading day following the public release of earnings data for such fiscal quarter or during any other trading suspension period declared by the Company,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> except for:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchases of the Company&#x2019;s securities from the Company or sales of the Company&#x2019;s securities to the Company;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exercises of stock options or other equity awards or vesting of equity-based awards that do not involve a market sale of the Company&#x2019;s securities (the &#x201c;cashless exercise&#x201d; of a Company stock option </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">does</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> involve a market sale of the Company&#x2019;s securities, and therefore would not qualify under this exception);</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">bona fide</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gifts of the Company&#x2019;s securities; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchases or sales of the Company&#x2019;s securities made pursuant to any binding contract, specific instruction or written plan entered into while the purchaser or seller, as applicable, was unaware of any material, non-public information and which contract, instruction or plan (i) meets all requirements of the affirmative defense provided by Rule 10b5-1, (ii) was pre-cleared in advance pursuant to this Policy and (iii) has not been amended or modified in any respect after such initial pre-clearance without such amendment or modification being pre-cleared in advance pursuant to this Policy.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exceptions to the black-out period policy may be approved only by the Company&#x2019;s Compliance Officer or, in the case of exceptions for directors, the Chairperson of the Board of Directors or Chairperson of the Audit Committee of the Board of Directors.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company, through the Board of Directors, the Company&#x2019;s disclosure committee or the Compliance Officer, may recommend that some or all officers, directors, employees, consultants or others suspend trading in the Company&#x2019;s securities because of developments that have not yet been disclosed to the public.  Individuals affected by such an event-specific blackout will be notified by the Company that they are subject to the blackout.  Subject to the exceptions noted above, all those affected should not trade in our securities while the suspension is in effect, and should not disclose to others that we have suspended trading.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-Termination Transactions</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With the exception of the pre-clearance requirement, the insider trading laws continue to apply to transactions in the Company&#x2019;s securities even after termination of service to the Company.  If an individual is in possession of material, non-public information when his or her service terminates, that individual may not trade in the Company&#x2019;s securities until that information has become public or is no longer material.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">D.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information Relating to the Company</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Access to Information</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Access to material, non-public information about the Company, including the Company&#x2019;s business, earnings or prospects, should be limited to officers, directors, employees and consultants of the Company on a need-to-know basis.  In addition, such information should not be communicated to anyone outside the Company under any circumstances (except in</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accordance with the Company&#x2019;s policies regarding the protection or authorized external disclosure of Company information) or to anyone within the Company on an other than need-to-know basis.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In communicating material, non-public information to employees or consultants of the Company, all officers, directors, employees and consultants must take care to emphasize the need for confidential treatment of such information and adherence to the Company&#x2019;s policies with regard to confidential information.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inquiries From Third Parties</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inquiries from third parties, such as industry analysts, investors or members of the media, about the Company should be directed to the General Counsel at [       ] or [       ].</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">E.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitations on Access to Company Information</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following procedures are designed to maintain confidentiality with respect to the Company&#x2019;s business operations and activities.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All officers, directors, employees and consultants should take all steps and precautions necessary to restrict access to, and secure, material, non-public information by, among other things:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining the confidentiality of Company-related transactions;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conducting their business and social activities so as not to risk inadvertent disclosure of confidential information (e.g., review of confidential documents in public places should be conducted so as to prevent access by unauthorized persons);</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restricting access to documents and files (including computer files) containing material, non-public information to individuals on a need-to-know basis (including maintaining control over the distribution of documents and drafts of documents);</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">promptly removing and cleaning up all confidential documents and other materials from conference rooms following the conclusion of any meetings;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disposing of all confidential documents and other papers, after there is no longer any business or other legally required need, through shredders when appropriate;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restricting access to areas likely to contain confidential documents or material, non-public information;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">safeguarding laptop computers, mobile devices, tablets, memory sticks, CDs and other items that contain confidential information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">avoiding the discussion of material, non-public information in places where the information could be overheard by others such as in elevators, restrooms, hallways, restaurants, airplanes or taxicabs.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personnel involved with material, non-public information, to the extent feasible, should conduct their business and activities in areas separate from other Company activities.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">V.	</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADDITIONAL PROHIBITED TRANSACTIONS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has determined that there is a heightened legal risk and/or the appearance of improper or inappropriate conduct if the persons subject to this Policy engage in certain types of transactions.  Therefore, officers, directors, employees and consultants shall comply with the following policies with respect to certain transactions in the Company securities:</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Short Sales</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Short sales of the Company&#x2019;s securities evidence an expectation on the part of the seller that the securities will decline in value, and therefore signal to the market that the seller has no confidence in the Company or its short-term prospects.  In addition, short sales may reduce the seller&#x2019;s incentive to improve the Company&#x2019;s performance.  For these reasons, short sales of the Company&#x2019;s securities are prohibited by this Policy.  In addition, as noted below, Section 16(c) of the 1934 Act absolutely prohibits Section 16 reporting persons from making short sales of the Company&#x2019;s equity securities, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.e.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, sales of shares that the insider does not own at the time of sale, or sales of shares against which the insider does not deliver the shares within 20 days after the sale.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Publicly Traded Options</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A transaction in options is, in effect, a bet on the short-term movement of the Company&#x2019;s stock and therefore creates the appearance that an officer, director, employee or consultant is trading based on inside information.  Transactions in options also may focus an officer&#x2019;s, director&#x2019;s, employee&#x2019;s or consultant&#x2019;s attention on short-term performance at the expense of the Company&#x2019;s long-term objectives.  Accordingly, transactions in puts, calls or other derivative securities involving the Company&#x2019;s equity securities, on an exchange or in any other organized market, are prohibited by this Policy.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hedging Transactions</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain forms of hedging or monetization transactions, such as zero-cost collars and forward sale contracts, allow an insider to lock in much of the value of his or her stock holdings, often in exchange for all or part of the potential for upside appreciation in the stock.  These transactions allow the insider to continue to own the covered securities, but without the full risks and rewards of ownership.  When that occurs, the insider may no longer have the same objectives as the Company&#x2019;s other stockholders.  Therefore, such transactions involving the Company&#x2019;s equity securities are prohibited by this Policy.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">D.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchases of the Company&#x2019;s Securities on Margin; Pledging the Company&#x2019;s Securities to Secure Margin or Other Loans</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchasing on margin means borrowing from a brokerage firm, bank or other entity in order to purchase the Company&#x2019;s securities (other than in connection with a cashless exercise of stock options under the Company&#x2019;s equity plans).  Margin purchases of the Company&#x2019;s securities are prohibited by this Policy.  Pledging the Company&#x2019;s securities as collateral to secure loans is prohibited.  This prohibition means, among other things, that you cannot hold the Company&#x2019;s securities in a &#x201c;margin account&#x201d; (which would allow you to borrow against your holdings to buy securities).</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VI.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULE 10b5-1 TRADING PLANS, SECTION 16 AND RULE 144</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Plans</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 will protect directors, officers, employees and consultants from insider trading liability under Rule 10b5-1 for transactions under a previously established contract, plan or instruction to trade in the Company&#x2019;s stock (a &#x201c;Trading Plan&#x201d;) entered into in good faith and in accordance with the terms of Rule 10b5-1 and all applicable state laws and will be exempt from the trading restrictions set forth in this Policy.  The initiation or revocation of, and any modification to, any such Trading Plan will be deemed to be a transaction in the Company&#x2019;s securities, and such initiation, revocation or modification is subject to all limitations and prohibitions relating to transactions in the Company&#x2019;s securities.  Each such Trading Plan, and any modification or revocation thereof, must be submitted to and pre-approved by the Company&#x2019;s Compliance Officer, or such other person as the Company&#x2019;s Board of Directors may designate from time to time (the &#x201c;Authorizing Officer&#x201d;), who may impose such conditions on the implementation and operation of the Trading Plan as the Authorizing Officer deems necessary or advisable.  The Authorizing Officer may prescribe certain forms of Trading Plans to which employees&#x2019; Trading Plans must conform.  The Authorizing Officer may also require that Trading Plans be arranged with a specified broker.  However, compliance of the Trading Plan to the terms of Rule 10b5-1 and the execution of transactions pursuant to the Trading Plan are the sole responsibility of the person initiating the Trading Plan, not the Company or the Authorizing Officer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading Plans do not exempt individuals from complying with Section 16 short-swing profit rules or liability.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 presents an opportunity for insiders to establish arrangements to sell (or purchase) Company stock without the restrictions of trading windows and black-out periods, even when there is undisclosed material information.  A Trading Plan may also help reduce negative publicity that may result when key executives sell the Company&#x2019;s stock.  Rule 10b5-1 only provides an &#x201c;affirmative defense&#x201d; in the event there is an insider trading lawsuit.  It does not prevent someone from bringing a lawsuit.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A director, officer, employee or consultant may enter into a Trading Plan only when he or she is not in possession of material, non-public information, and only during a trading window period outside of the trading black-out period.  Although transactions effected under a Trading Plan will not require further pre-clearance at the time of the trade, any transaction (including the quantity and price) made pursuant to a Trading Plan of a Section 16 reporting person must be reported to the Company promptly on the day of each trade to permit the Company&#x2019;s filing coordinator to assist in the preparation and filing of a required Form 4.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reserves the right from time to time to suspend, discontinue or otherwise prohibit any transaction in the Company&#x2019;s securities, even pursuant to a previously approved Trading Plan, if the Authorizing Officer or the Board of Directors, in its discretion, determines that such suspension, discontinuation or other prohibition is in the best interests of the Company.  Any Trading Plan submitted for approval hereunder should explicitly acknowledge the Company&#x2019;s right to prohibit transactions in the Company&#x2019;s securities.  Failure to discontinue</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchases and sales as directed shall constitute a violation of the terms of this Policy and result in a loss of the exemption set forth herein.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Officers, directors, employees and consultants may adopt Trading Plans with brokers that outline a pre-set plan for trading of the Company&#x2019;s stock, including the exercise of options.  Trades pursuant to a Trading Plan generally may occur at any time.  However, the Company requires a cooling-off period of at least 30 days between the establishment of a Trading Plan and commencement of any transactions under such plan.  Subject to the terms of the Trading Plan, an individual may adopt more than one Trading Plan.  Please review the following description of how a Trading Plan works.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Rule 10b5-1, an individual&#x2019;s purchase or sale of securities will not be &#x201c;on the basis of&#x201d; material, non-public information if:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">First, before becoming aware of the information, the individual enters into a binding contract to purchase or sell the securities, provides instructions to another person to sell the securities or adopts a written plan for trading the securities (i.e., the Trading Plan).	</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Second, the Trading Plan must either:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">specify the amount of securities to be purchased or sold, the price at which the securities are to be purchased or sold and the date on which the securities are to be purchased or sold;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">include a written formula or computer algorithm for determining the amount, price and date of the transactions; or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prohibit the individual from exercising any subsequent influence over the purchase or sale of the Company&#x2019;s stock under the Trading Plan in question.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third, the purchase or sale must occur pursuant to the Trading Plan and the individual must not enter into a corresponding hedging transaction or alter or deviate from the Trading Plan.</font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revocation of and Amendments to Trading Plans</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revocation of Trading Plans should occur only in unusual circumstances.  Effectiveness of any revocation, modification or amendment of a Trading Plan will be subject to the prior review and approval of the Authorizing Officer.  Revocation is effected upon written notice to the broker.  Once a Trading Plan has been revoked, the participant should wait at least 90 days before trading outside of a Trading Plan and at least 90 days before establishing a new Trading Plan.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A person acting in good faith may amend a prior Trading Plan so long as such amendments are made outside of a quarterly blackout or other black-out period and at a time when the Trading Plan participant does not possess material, non-public information.  Plan amendments require a cooling-off period of at least 30 days between the amendment of a Trading Plan and commencement of any transactions under such amended plan.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Trading Plan shall include provision for suspension or revocation in certain circumstances, such as the announcement of a merger or the occurrence of an event that would cause the transaction either to violate the law or be expected to have an adverse effect on the Company.  The Authorizing Officer or administrator of the Company&#x2019;s stock plans is authorized to notify the broker in such circumstances, thereby insulating the insider in the event of suspension or revocation.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Discretionary Plans</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although non-discretionary Trading Plans are preferred, discretionary Trading Plans, where the discretion or control over trading is transferred to a broker, are permitted if pre-approved by the Authorizing Officer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Authorizing Officer of the Company must pre-approve any Trading Plan, arrangement or trading instructions, etc., involving potential sales or purchases of the Company&#x2019;s stock or option exercises, including but not limited to, blind trusts, discretionary accounts with banks or brokers, or limit orders.  The actual transactions effected pursuant to a pre-approved Trading Plan will not be subject to further pre-clearance for transactions in the Company&#x2019;s stock once the Trading Plan or other arrangement has been pre-approved by the Authorizing Officer.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reporting (if Required)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If required, an SEC Form 144 will be completed and filed by the individual/brokerage firm in accordance with the existing rules regarding Form 144 filings.  A footnote at the bottom of the Form 144 should indicate that the trades &#x201c;are in accordance with a Trading Plan that complies with Rule 10b5-1 and expires ____.&#x201d;  For Section 16 reporting persons, Forms 4 should be filed before the end of the second business day following the date that the broker, dealer or plan administrator informs the individual that a transaction was executed, provided that the date of such notification is not later than the third business day following the trade date.  A similar footnote should be placed at the bottom of the Form 4 as outlined above.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercises of options for cash may be executed at any time.  &#x201c;Cashless exercise&#x201d; option exercises are subject to trading windows.  However, the Company will permit same day sales under Trading Plans.  If a broker is required to execute a cashless exercise in accordance with a Trading Plan, then the Company must have exercise forms attached to the Trading Plan that are signed, undated and with the number of shares to be exercised left blank.  Once a broker determines that the time is right to exercise the option and dispose of the shares in accordance with the Trading Plan, the broker will notify the Company in writing and the administrator of the Company&#x2019;s stock plans will fill in the number of shares and the date of exercise on the previously signed exercise form.  The insider should not be involved with this part of the exercise.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trades Outside of a Trading Plan</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During an open trading window, trading in the Company securities not pursuant to an approved Trading Plan is allowed as long as the trading instructions in the approved Trading Plan continue to be followed.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Public Announcements</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may make a public announcement that Trading Plans are being implemented in accordance with Rule 10b5-1.  It will consider in each case whether a public announcement of a particular Trading Plan should be made.  It may also make public announcements or respond to inquiries from the media as transactions are made under a Trading Plan.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prohibited Transactions</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transactions prohibited under Section V of this Policy, including among others short sales and hedging transactions, may not be carried out through a Trading Plan or other arrangement or trading instruction involving potential sales or purchases of the Company&#x2019;s securities.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16:  Insider Reporting Requirements, Short-Swing Profits and Short Sales (Applicable to Officers, Directors and 10% Stockholders)</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reporting Obligations Under Section 16(a):  SEC Forms 3, 4 and 5</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16(a) of the 1934 Act generally requires all officers, directors and beneficial owners of more than ten percent of our outstanding stock (each, a &#x201c;10% stockholder&#x201d;) (collectively, &#x201c;Sec. 16 insiders&#x201d;), within 10 days after the Sec. 16 insider becomes an officer, director, or 10% stockholder, to file with the SEC an &#x201c;Initial Statement of Beneficial Ownership of Securities&#x201d; on Form 3 listing the amount of the Company&#x2019;s stock, options and warrants which the Sec. 16 insider beneficially owns.  Following the initial filing on Form 3, changes in beneficial ownership of the Company&#x2019;s stock, options and warrants must be reported on Form 4, generally within two business days after the date on which such change occurs, or in certain cases on Form 5, within 45 days after fiscal year end.  A Form 4 must be filed even if, as a result of balancing transactions, there has been no net change in holdings.  In certain situations, purchases or sales of Company stock made within six months </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">prior</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the filing of a Form 3 must be reported on Form 4.  Similarly, certain purchases or sales of Company stock made within six months </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">after</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> an officer or director ceases to be an insider must be reported on Form 4.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recovery of Profits Under Section 16(b)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the purpose of preventing the unfair use of information which may have been obtained by a Sec. 16 insider, any profits realized by any officer, director or 10% stockholder from any &#x201c;purchase&#x201d; and &#x201c;sale&#x201d; of Company stock during a six-month period (so called &#x201c;short-swing profits&#x201d;) are subject to recovery by the Company.  When such a purchase and sale occurs, good faith is no defense.  The Sec. 16 insider is liable even if compelled to sell for personal reasons, and even if the sale takes place after full disclosure and without the use of any inside information.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The liability of an insider under Section 16(b) of the 1934 Act is only to the Company itself.  The Company, however, cannot waive its right to short swing profits, and any Company stockholder can bring suit in the name of the Company.  Reports of ownership filed with the SEC on Form 3, Form 4 or Form 5 pursuant to Section 16(a) (discussed above) are readily available to the public, and certain attorneys carefully monitor these reports for potential Section 16(b) violations.  In addition, liabilities under Section 16(b) may require separate disclosure in the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company&#x2019;s annual report to the SEC on Form 10-K or its proxy statement for its annual meeting of stockholders.  No suit may be brought more than two years after the date the profit was realized.  However, if the Sec. 16 insider fails to file a report of the transaction under Section 16(a), as required, the two-year limitation period does not begin to run until after the transactions giving rise to the profit have been disclosed.  Failure to report transactions and late filing of reports require separate disclosure in the Company&#x2019;s proxy statement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Officers and directors should consult the attached &#x201c;Short-Swing Profit Rule Section 16(b) Checklist&#x201d; attached hereto as Attachment A, in addition to consulting the Compliance Officer prior to engaging in any transactions involving the Company&#x2019;s securities, including without limitation, the Company&#x2019;s stock, options or warrants.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Short Sales Prohibited Under Section 16(c)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16(c) of the 1934 Act prohibits insiders absolutely from making short sales of the Company&#x2019;s equity securities.  Short sales include sales of stock, which the insider does not own at the time of sale, or sales of stock against which the insider does not deliver the shares within 20 days after the sale.  Under certain circumstances, the purchase or sale of put or call options, or the writing of such options, can result in a violation of Section 16(c).  Insiders violating Section 16(c) face criminal liability.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compliance Officer should be consulted if you have any questions regarding reporting obligations, short-swing profits or short sales under Section 16.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 144 (Applicable to Officers, Directors and 10% Stockholders)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 144 provides a safe harbor exemption to the registration requirements of the Securities Act of 1933, as amended, for certain resales of &#x201c;restricted securities&#x201d; and &#x201c;control securities.&#x201d;  &#x201c;Restricted securities&#x201d; are securities acquired from an issuer, or an affiliate of an issuer, in a transaction, or chain of transactions, not involving a public offering.  &#x201c;Control securities&#x201d; are </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">any</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> securities owned by directors, executive officers or other &#x201c;affiliates&#x201d; of the issuer, including stock purchased in the open market and stock received upon exercise of stock options.  Sales of Company securities by affiliates (generally, directors, officers and 10% stockholders of the Company) must comply with the requirements of Rule 144, which are summarized below:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Current Public Information.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The Company must have filed all SEC-required reports during the last 12 months.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Volume Limitations.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Total sales of Company common stock by a covered individual for any three-month period may not exceed the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">greater</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of: (i) 1% of the total number of outstanding shares of Company common stock, as reflected in the most recent report or statement published by the Company, or (ii) the average weekly reported volume of such shares traded during the four calendar weeks preceding the filing of the requisite Form 144.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Method of Sale.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The shares must be sold either in a &#x201c;broker&#x2019;s transaction&#x201d; or in a transaction directly with a &#x201c;market maker.&#x201d;  A &#x201c;broker&#x2019;s transaction&#x201d; is one in which the broker does no more than execute the sale order and receive the usual and customary commission.  Neither the broker nor the selling person can solicit </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or arrange for the sale order.  In addition, the selling person or member of the Board of Directors must not pay any fee or commission other than to the broker.  A &#x201c;market maker&#x201d; includes a specialist permitted to act as a dealer, a dealer acting in the position of a block positioner, and a dealer who holds himself out as being willing to buy and sell Company common stock for his own account on a regular and continuous basis.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notice of Proposed Sale.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  A notice of the sale (a Form 144) must be filed with the SEC at the time of the sale.  Brokers generally have internal procedures for executing sales under Rule 144 and will assist you in completing the Form 144 and in complying with the other requirements of Rule 144.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you are subject to Rule 144, you must instruct your broker who handles trades in Company securities to follow the brokerage firm&#x2019;s Rule 144 compliance procedures in connection with all trades.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VII.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXECUTION AND RETURN OF CERTIFICATION OF COMPLIANCE</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After reading this Policy, all officers, directors, employees and consultants should execute and return to the Company&#x2019;s Compliance Officer the Certification of Compliance form attached hereto as Attachment B.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SCHEDULE I</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDIVIDUALS SUBJECT TO PRE-CLEARANCE REQUIREMENT AND</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TRADING BLACK-OUT PERIODS</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(as of January 30, 2025)</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attachment A</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Short-Swing Profit Rule Section 16(b) Checklist</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note:  ANY combination of PURCHASE AND SALE or SALE AND PURCHASE within six months of each other by an officer, director or 10% stockholder (or any family member living in the same household or certain affiliated entities) results in a violation of Section 16(b), and the &#x201c;profit&#x201d; must be recovered by IDEAYA Biosciences, Inc. (the &#x201c;Company&#x201d;).  It makes no difference how long the shares being sold have been held or, for officers and directors, that you were an insider for only one of the two matching transactions.  The highest priced sale will be matched with the lowest priced purchase within the six-month period.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	If a sale is to be made by an officer, director or 10% stockholder (or any family member living in the same household or certain affiliated entities):</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	1.	Have there been any purchases by the insider (or family members living in the same household or certain affiliated entities) within the past six months?</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	2.	Have there been any option grants or exercises not exempt under Rule 16b-3 within the past six months?</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	3.	Are any purchases (or non-exempt option exercises) anticipated or required within the next six months?</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	4.	Has a Form 4 been prepared?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Note:  If a sale is to be made by an affiliate of the Company, has a Form 144 been prepared and has the broker been reminded to sell pursuant to Rule 144 under the <br>Securities Act of 1933, as amended?</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchases And Option Exercises</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	If a purchase or option exercise for Company stock is to be made:</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	1.	Have there been any sales by the insider (or family members living in the same household or certain affiliated entities) within the past six months?</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	2.	Are any sales anticipated or required within the next six months (such as tax-related or year-end transactions)?</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	3.	Has a Form 4 been prepared?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Before proceeding with a purchase or sale, consider whether you are aware of material inside information which could affect the price of the Company stock.  All transactions in the Company&#x2019;s securities by officers and directors must be </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pre-cleared</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by contacting the Company&#x2019;s Compliance Officer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attachment A</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ATTACHMENT B</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF COMPLIANCE</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RETURN BY [_________] </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">[insert return deadline]</font></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TO:	Douglas Snyder, General Counsel</font></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FROM:	__________________________</font></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RE:	INSIDER TRADING COMPLIANCE POLICY OF IDEAYA BIOSCIENCES, INC.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have received, reviewed and understand the above-referenced Insider Trading Compliance Policy and undertake, as a condition to my present and continued employment with (or, if I am not an employee, affiliation with) IDEAYA Biosciences, Inc., to comply fully with the policies and procedures contained therein.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">___________________________	_______________<br>SIGNATURE	DATE</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">___________________________<br>NAME</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">___________________________<br>TITLE</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attachment B</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>9
<FILENAME>idya-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="margin-left:73.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">       </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Exhibit 23.1</font></p></div>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No.333-231784, 333-237362, 333-254617, 333-263657, 333-270334, 333-277189 and 333-281301) and Form S-3 (No. 333-254606, 333-238849 and 333-272936) of IDEAYA Biosciences, Inc. of our report dated February 18, 2025 relating to the financial statements, and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">/s/ PricewaterhouseCoopers LLP</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">San Jose, California</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">February 18, 2025</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>10
<FILENAME>idya-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Exhibit 31.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Yujiro Hata, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of IDEAYA Biosciences, Inc.; </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45%;box-sizing:content-box;"></td>
    <td style="width:4%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:50%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 18, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Yujiro Hata</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Yujiro Hata</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>11
<FILENAME>idya-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 											 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Andres Ruiz Briseno, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of IDEAYA Biosciences, Inc.; </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45%;box-sizing:content-box;"></td>
    <td style="width:4%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:50%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 18, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Andres Ruiz Briseno</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Andres Ruiz Briseno</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Senior Vice President and Head of Finance and Investor Relations</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>12
<FILENAME>idya-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Yujiro Hata, President and Chief Executive Officer of IDEAYA Biosciences, Inc. (the &#x201c;Company&#x201d;), hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Annual Report on Form 10-K of the Company for the period ended December 31, 2024 (the &#x201c;Report&#x201d;) fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48%;box-sizing:content-box;"></td>
    <td style="width:4%;box-sizing:content-box;"></td>
    <td style="width:48%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 18, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Yujiro Hata</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Yujiro Hata</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Andres Ruiz Briseno, Senior Vice President and Head of Finance and Investor Relations of IDEAYA Biosciences, Inc. (the &#x201c;Company&#x201d;), hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Annual Report on Form 10-K of the Company for the period ended December 31, 2024 (the &#x201c;Report&#x201d;) fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48%;box-sizing:content-box;"></td>
    <td style="width:4%;box-sizing:content-box;"></td>
    <td style="width:48%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 18, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Andres Ruiz Briseno</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Andres Ruiz Briseno</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Senior Vice President and Head of Finance and Investor Relations</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img34507759_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img34507759_0.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ,%!*,# 2(  A$! Q$!_\0
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MM+MO^$6M?LTTU_>>)9O"^J:5%%-'J>C6MW#);+^GVG_\%2_V1?%7_!/GQO\
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M_9]^*/@ZQ\#>![WXI^)_&GP^U?P/I&M:C\-O#MC\3;G0];\,W#^/]'OK"_\
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M>7)2IU*LK?#3ISG*T8R:^9_V;/B[_P %5?\ @M-XW_:H_:+_ &7?^"A&E?\
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M_@NK\:O&W[/G_!(S]N[XH?#J\OM,\96/P3N_".CZQI=Q<6>J:%_PM#Q'X?\
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M._A[_P $E?\ @HUH_P#P4,^-7P9UO]GOQ)X7\5_L^ZAX0_9\^'?C#X@^%I?
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M^,O WCOPAH'C7X<R:S\7?AI\%-0\*1>(M3U30M2\;Z9X7^&7B#XGZGXCN9_
M^KZ#K6LV6D+:ZE)J=N?L#_DQ\;OA'^R!\3/^"=?Q2_9T_P""7W_!OG^UE!^U
M5K7P:E@\6_%W]HG]CVXT[Q'\$8_"UK8:G\3KC2?C7\7=6UWQGXO^.FM:59ZS
MHGP\^'_P?D/B3Q;J^K$Z)I<;6$'A+4/T(^)7[/'[1GBKPY_P:2W&D?LZ?'Z9
M_P!FW4?A99_M%6LOP7^)5K?? 23PO\,/V>_#.LS?&>RN?#,5U\+[.VUCPOKU
MLM]XVBT2RN4TRZN+6>:VC,M>SEN%P^*S-9?C5".7U>//#?"4*E#VN#HQRC,L
MVSW#\10R_%U<17Q^(R6KA\/EB^O8K&8FE*=.NZ=95UF,JCPU:@LOJ8R49/,G
MP'XG8R>&Q4W4Q:QN!X0HXC))8VA1I4LKPN<X?,JE9X7#X/#4<=A:[IRA2AAY
MY8>H_%CXD?\ !6G_ ()0?ME_\$Z7_:&_X*)V7_!0G]G+]N;]IGP]^RM\4_ W
MBC]F#X3? +4OAWXW^(5QHVE^%O&?@&_^'L^K:@MG83:CJ6K_ -DKJNEZ,EKH
M,^DZAH>LW6O6.L^&_P"L>OY\?^"ZOP7^,7Q=^)__  1HU#X3_"?XE_$^P^%W
M_!5W]G7XB_$R]^'G@3Q3XUM/AW\/M$U-9-:\=^.KGPWI6IP^$?!ND1@OJGB?
MQ ^GZ)IZ?-=WT*\U_0=7B8#$U,3E^80Q%.DJF7<79IEF#JJDJ5:KE"X6X&S;
M#0JN/+&O2P^9YQG-##8AP=14XO"3JU%A(QIZ8FC2I8C!SI.=\5D6$Q.*3JU*
ME-XY9UQ'@YU%3E*4*%6I@\)@'6ITHTXS:A7<.:JY2_AS^&7[>_B[]A?_ (+Q
M_P#!<+4?"G[#7[9_[:[?$C7_ -EBROK#]CSX1:G\6+_X>+X8^%33V]YX\M]-
M4G1+/Q*=<FA\/S3$"^FT75T0'[*Q']'7[ W_  4M\<?MO^-_'G@WQ1_P3H_;
M]_8OMO!7A&W\46OC+]KWX':G\*O"7BZYN-7M]*/AGPKJ6I,O]J>(H(YVU2:Q
M@C<1Z;;7$\KQ[8UD^*?^";'P2^,_@7_@MO\ \%T/BOXW^$7Q/\&_"WXN7_[(
MS_"CXE>*O /BOP]X ^)R>&OAYKMEXC?X>^,=7TFS\.^-%T"]FBM-:;PWJ.I#
M2KJ6.WOC!*ZH?Z)9 3&X R2C  =2<'BO,X6OA^"."88BG*K.GP-EE%X>;E0J
M87$/ 5Z5-3Y.6HJN%Q#CB?9U$G.451J+V;:,,Q3K<2\9/#MX?FXNJ57B$E6C
MBZ4<-E52I*"J)TU3KT(O!<])M0Y95H/VR=OXU_\ @CQ\6O\ @N)_P5.T:Q_:
M8\4_\%%_"GP=^!'[/?[5VK?"O7O &G?LQ?!O6_%W[3?ACPMXQTCQ9\2M/\2:
MU:^%/#^A^ ;.P^'7B?2?AKX&UCP[HNI7T^JV6J:WJMM8:Y8Q^(M4^D?BH/\
M@K!\2?&'QX^*G[7W_!6?X,_\$0OA9IGQ/\6Z#^S%\!+CPU^QU\1)]9^$F@21
M1^$/C1\2_BIXS^*IGOKSQ='+)'K7@D>)K6WM[_3+V:/2O"-M/;6$_MW_  ;-
M?!'XW? ;_@G9\2_!'QI^$WQ+^"7CR_\ VP/VB/$VD^%OB]\/_%?P\\0SZ%K:
M>$!H'B6+P]XOTK1M6NO#^IR6T[:?JD-JUAJ"VUP+2YE\J3;^"O[#/PQ^"/P
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MG"^PSB%2=2/UFI4K5Y49.;HN>8QPT,7B[?6*,JOYI_\ !$/XC>---_X))?\
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M #QJ/^'L7_!++_I)9^P!_P")D?LZ_P#SQJ^_Z* /@#_A[%_P2R_Z26?L ?\
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M7_!++_I)9^P!_P")D?LZ_P#SQJ^_Z* /@#_A[%_P2R_Z26?L ?\ B9'[.O\
M\\:C_A[%_P $LO\ I)9^P!_XF1^SK_\ /&K[_HH ^ /^'L7_  2R_P"DEG[
M'_B9'[.O_P \:C_A[%_P2R_Z26?L ?\ B9'[.O\ \\:OO^B@#X _X>Q?\$LO
M^DEG[ '_ (F1^SK_ //&H_X>Q?\ !++_ *26?L ?^)D?LZ__ #QJ^_Z* /@#
M_A[%_P $LO\ I)9^P!_XF1^SK_\ /&H_X>Q?\$LO^DEG[ '_ (F1^SK_ //&
MK[_HH ^ /^'L7_!++_I)9^P!_P")D?LZ_P#SQJ/^'L7_  2R_P"DEG[ '_B9
M'[.O_P \:OO^B@#X _X>Q?\ !++_ *26?L ?^)D?LZ__ #QJ_$7]O*\_8O\
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M]@#_ ,3(_9U_^>-7W_10!\ ?\/8O^"67_22S]@#_ ,3(_9U_^>-1_P /8O\
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M1^SK_P#/&H_X>Q?\$LO^DEG[ '_B9'[.O_SQJ^_Z* /@#_A[%_P2R_Z26?L
M?^)D?LZ__/&H_P"'L7_!++_I)9^P!_XF1^SK_P#/&K[_ ** /@#_ (>Q?\$L
MO^DEG[ '_B9'[.O_ ,\:C_A[%_P2R_Z26?L ?^)D?LZ__/&K[_HH ^ /^'L7
M_!++_I)9^P!_XF1^SK_\\:C_ (>Q?\$LO^DEG[ '_B9'[.O_ ,\:OO\ HH ^
M /\ A[%_P2R_Z26?L ?^)D?LZ_\ SQJ/^'L7_!++_I)9^P!_XF1^SK_\\:OO
M^B@#X _X>Q?\$LO^DEG[ '_B9'[.O_SQJ/\ A[%_P2R_Z26?L ?^)D?LZ_\
MSQJ^_P"B@#X /_!6'_@ED01_P\L_8 YXX_;)_9U!_,?$?(^HYKP3]G/]LO\
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ME_TDL_8 _P#$R/V=?_GC5]_T4 ? '_#V+_@EE_TDL_8 _P#$R/V=?_GC4?\
M#V+_ ()9?])+/V /_$R/V=?_ )XU??\ 10!\ ?\ #V+_ ()9?])+/V /_$R/
MV=?_ )XU'_#V+_@EE_TDL_8 _P#$R/V=?_GC5]_T4 ? '_#V+_@EE_TDL_8
M_P#$R/V=?_GC4?\ #V+_ ()9?])+/V /_$R/V=?_ )XU??\ 10!\ ?\ #V+_
M ()9?])+/V /_$R/V=?_ )XU'_#V+_@EE_TDL_8 _P#$R/V=?_GC5]_T4 ?
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M1^SK_P#/&H_X>Q?\$LO^DEG[ '_B9'[.O_SQJ^_Z* /@#_A[%_P2R_Z26?L
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M'&49+1IALVGO&4HR76,HR<91:Z2C).,D]5)--)IGP!_P]B_X)9?])+/V /\
MQ,C]G7_YXU'_  ]B_P""67_22S]@#_Q,C]G7_P">-7W_ $4 ? '_  ]B_P""
M67_22S]@#_Q,C]G7_P">-1_P]B_X)9?])+/V /\ Q,C]G7_YXU??]% 'P!_P
M]B_X)9?])+/V /\ Q,C]G7_YXU'_  ]B_P""67_22S]@#_Q,C]G7_P">-7W_
M $4 ? '_  ]B_P""67_22S]@#_Q,C]G7_P">-1_P]B_X)9?])+/V /\ Q,C]
MG7_YXU??]% 'P!_P]B_X)9?])+/V /\ Q,C]G7_YXU'_  ]B_P""67_22S]@
M#_Q,C]G7_P">-7W_ $4 ? '_  ]B_P""67_22S]@#_Q,C]G7_P">-1_P]B_X
M)9?])+/V /\ Q,C]G7_YXU??]% 'P!_P]B_X)9?])+/V /\ Q,C]G7_YXU'_
M  ]B_P""67_22S]@#_Q,C]G7_P">-7W_ $4 ? '_  ]B_P""67_22S]@#_Q,
MC]G7_P">-1_P]B_X)9?])+/V /\ Q,C]G7_YXU??]% 'P!_P]B_X)9?])+/V
M /\ Q,C]G7_YXU'_  ]B_P""67_22S]@#_Q,C]G7_P">-7W_ $4 ? '_  ]B
M_P""67_22S]@#_Q,C]G7_P">-7H'PM_X*$_L"_''QWH7PM^"G[</[('Q@^)O
MBC^T_P#A&?AU\+?VEO@O\0/'?B+^Q-'U#Q%K/]A>$?"?C75_$&K_ -D>'](U
M77=3_L_3[C[!H^F:AJ=UY5E97,\7U_10 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% 'Q1^WY\+_ !K\5_@-HVD>"/ 4WQ9N?"7Q^_9B^+'B3X26
MM_X3T^]^)W@3X0_M _#KXD>-O!^FR>/-;\->![S5[GP[X:O]1T71_%_B+0O#
MNO:OIECHFJZOIUMJ#W</P9\'_P!@OQ=XED_8P\/?&7]GGPAX<^&_PZ^.'[8W
M[6?BS3=8B^$VO>(OAG)?_M(>+OBG^Q'^RSJ5QH&K^(&&C>!+3XUS?$C4+#X6
MZKX@^&7A3Q]^SMH'ART\37GAR_T8>)?W*HJL/)X:G*G!*2><_P!OPE.[J4,S
M67Y9@*5;#U4U4HK#?V-EF-PL:<HO#8_#5*]%QCC<?3Q2K1C7BX5%>$L'4R^M
M3NU3KX2I_:"G1K03Y9PJ0S3'4J\6N7%4JE"&*C66 P'U;\$?VU?V,OVNO'/_
M  4 \6?M(_L]^&9(]#^)_P"R;\!OV$O%_CB+Q]X3\.7GA[X+_%+X@_M;:E^T
MA\0/#6D:CK]MJLWCGX!:AK'[-WQ.\-K<:7'+XEM+C7_#_@N76=8&M6-CX!IO
M[,__  4S^$WP]_X)V_!WX-_#GXI>"O#/[//PG_8ZT+QPO@KXW>#;3P5I\OA_
M]H:U@_:6\%^*= TK]JKX/^&[UM)_9WTNWC@UOQ5\._VO="\:6FN-H'PQ\.?"
M7QIH>J>-?$']-M%9\J]IA:MDY8/$QQ%*-G&G.G3ABW1P5:G3=-5,'1QN99KF
M<87C7>/S;,:L\1*G7C2I[5:GM:6*I.$(_6\-2PTJB<Y5:#C+ 1Q.(PCJSJ1P
MU?,<+E668#,'2@J.(PF PR]C"O!UY?CW_P $[];^/'Q+^#/[27CKXO>*-;_:
M,\#>';WQ;^R_^SY:^'_'FB:Y8_M*?"?]G._^(/AJW^/%IXGU/5_#WA9OBE^T
MEJWB&\\)>,?$]]XBTSPU=7?P\T#5(?$%IHDC:L_P[\-_V3?CLVE> /C=\1?^
M";'BW1=8TS]H&U\4_%+]B7P_J7[#D'PSL?AAIG[&WQL_9O\ @UX:^"%AHW[3
M.L_#3XD)\'[OQGH&G_$#XC?&W7_A=XY\>-X@U7Q/X5\$:'X4\'>"?AEX5_IF
MHJ*]&GB:6-IU4Y?VCEF7Y=C)M\TJLL'-UJ^-M).#QF/Q-3$U:DZL:L<#'&8R
MCE$,OIXS%K$*51.I3G&G&"P^89GC,*HRK<]"ACZ+PF'P'MO:^U>&P."CAJ%J
M<J/]H2PF&J9I'&0P^&HT/YI_ 7['W[9/A[Q7^S5\.;/]EA? WCG]FG]G3X3W
M6A_MRQZG^SG\0/"7Q8_;8\._L4ZE^SKI_C#XT:AJ?Q^T']I[3_V>O@KIVN:E
MX2M_!'@KX,ZUXD^,?C2>#Q#JE]X4^'^B:I%\2_T;_P""5_[-GQV_99^$_P <
MOAY\=="\*:5?ZU^T]\3/B%X2UCPWXZU7XAWWCW0O&.F>%+K5/B/XK\0ZU:6.
MJW/B?QOXNMO$7B#6I=7L=-UJ\U2]O]0U'2=.-W!$WZ>T5W2Q526/S/,6HO$9
MM@LPP6+3<Y4W',L]RKB#$8BFISE.&*^M9/@L+&JYR4LNITL)6A56$R^>#Y*^
M'CB:65TJLY..3XK XK!\D:5-Q> R;.LEHX>:ITXP>$]CG^98R.&C&%/#YAB*
M^(P2PL,9F%'&%? '_!2S_DW7X<_]G_\ _!)W_P!>F_L;U]_US_B;PGX5\::=
M;:/XQ\,^'_%FD6?B#PGXLL]+\3:-IVO:=:^*O 7BK1O'7@7Q-;6.J6UU;0>(
M/!?C;PYX>\8^$]9BB74?#GBK0M&\0Z/<V>KZ78WD',;G04444 ?@G_P47_9\
M_:=\5_&SXO\ B[]G+X ?'/6/&'Q7_9Y\&?"O0?B%\+/B!^R'XM_9G^,,N@3?
M%%K'X/\ _!0K]FS]LC6[:TNOA!X6U3QUJ-X_C3]G_P (>)?B9K_P\\=>-- L
M]<TSQ)HWAG0]3ZKP3\._VGO@<_Q__9_O_P!@BP_:?B^-W[:VJ?M+:3\>=>\6
M_L^?\,V2^&/'WQ$\$?$C^U_BCH7CWXDVWQUL?B1^S9#HG_"&_"K1?#_P7\9V
M>IR?#/X,WV@>-/#UBVM7OP^_<*BL\/"6%<W2K5%*I1Q>&G*2I2D\-C,VR[.Z
MF'@W3?L:<,PRO"5(>P5*3Y:E2I*>*J2Q)6*?UN,(5$HQI8C"XRDJ;E%0QV$R
MK&9+1QDKN3KU5E^88RCR8EUZ"5:,8T8T<-A*6'_E \;?\$Y/^"F%K\,OCW\8
M8= ^%WQ%^+W_  4(_9C_ &Y_A?\ M-_ +P=H_A[P!\1_AYXF_:0^&/CWXB?L
M^67Q%^/7C3]IW7_A1\=_^&7O'>E>$OV2O E]X#\&_#VPT3X?_$G7O$:S^)?#
M^EWVNV_U]^U#H_[:'Q^\:_L5_$OP3^QS_P %$/@"W[.&H_&'2/&TGPK^)?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCWVJZ_K^DV5LUR.\^4.V\1_L_P#[./Q8\5Z#\5]<^%_PR\7>.] U*PU+P_\
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M#*P#*RD,K*PR&4C(((((()!!R*6NT^9VW"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HI&945G=E1%4LS,0JJJC+,S' "@ DDD  9/%>;Z[\7_AQX?#"
M\\5:=<SA)66VTAWUF=GB#9@?^S$NHK69V78HO9;9 Q!=T3+@ ])HKP8?%OQ5
MXC51X ^&'B'489X&>WU?Q&\&A:;YBL?FC+/+:WD.T9 75[25V.Q4#!0Z'PU\
M<?$YD_MWQMHG@JPN+>+-AX3T][R]BE&WS(VN[EHKJUD(!+3V>O7*;R0D8CP
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M^!WA'0/!VDQ?M<W.C^#K/PE+IFBZ9IM[K7BF[U@ \0_9<U7]JGQQ_P % ?\
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M<C@$CX^_9]_X*N?L.?M):QXE\)_#_P",^DVWC[P5XHU_P+XR^&_BJQU?P?\
M$KPSXV\*7PTSQ-X;UCX9>*M/T7XF:7=Z-J*SV5S/K/@S2[5KBUNX$E^T6UQ#
M']J1Z+\)?'VO:'XU31OA]XP\5>$)#=>'?%#Z7X>USQ+X3GOK*[L7ETG5Y;>Y
MU?P]<W6GWM_8R_9I[*>2UNKVTD!BFGC91H9A1A2C3QL,7;$<U:>.H4XUI8:7
M*I4Z<\###485:3YIPG+"S516I34'>NM*^9\(9GB,=7Q7#6(X>Y\H=++L-PMF
MF+KY;A\ZHNI*GB\7A>*:^>9GB<#C8^RP^)P]+/\ #U,)4]ICL/.O34<L?HU%
M?.NN_L^WMY\3T^*7A?X]?M!>!+VZUO1-4\1>!],\=:?XM^%GB.RTJ/3[.]T'
M_A ?BAX=\>:3X-TW7-,L6MM0D^&1\#:@E_=7.O6M[#K<]S>SO\?Z_P#M0>'?
M'5O=> /AQ\(OB9\*+F/2(+VPO?B)XB^'7Q7T.XDE:+6=1L8KWP=XK\"^,+.%
M#'<VNFW6N> ;I(EFB-_>S"(2*6.JT(U9XK XF$(8CV4)X6$LP]K2ES>SQ$:.
M%C+%1BDHJM"6&O2G-<LJM)2JHH\+X',ZV H9#Q1DF)Q&*REX[%8?/<12X2>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\6:Q<R0RQS>*_P!H31X=+^)^D:79.MTMOIWA7PY;![6Z%M-(TMK:7</Y/?\
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M]&,MGJ.F7>E^)O"GBCP_JULT9DMKRUDOM(UO1M3LYG0O%)<V5[;2LI,D3D$
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M#(\<6%GY$6GVWQ&UZT/BSXH3VHA"016=U\0=<\3WL"J66*"=5::8J9G^*O\
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M0?BO;:OIUN9M0OX?'4+>5%:6B&5EDU6[.LSQV_DJYN9(KG1X8U4RF2,9>/\
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MO"NF?&;X@>&H9H[+2XK"2Y\/7/C*[UJYOYYK71SJ>V+?YUHOB+XN'Q)XCL?
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M\?0>(9(-4^(/C[PK\-;VQTOQQ_PD.AZ!SVD?\%4/AG%X ^-7C/XH_L\?M0_
MC7?@U\#_  9^T-;_  K^)6@_!+6_B'\7_AM\1]4UOPS\/)O@X_P:^.WQ9\ >
M(_$_C/QSHG_"O]'\%>(/'OA/Q5#XNUGPW::OI.EZ;K^FZI/\S_&?_@G/^UU\
M3_BE\=_VG+#X@_!G3_C7^T1\)OCI^QMXN^&5_P"*_&TGP;\-?L4^)?AOXCTS
MX&Z9X?\ %MM\*1XIU+XU^"/C<\?QH\3Z_?>"-/TO4-*^+7Q5^%<-_J6D^%?A
MQXDA[#Q'_P $@_!]I\,O@I\+OA!XG\6_#":_^)G[/GB_]J_XT7?QP^+'QB^.
M^O\ A?\ 9=T;Q3\1?@YX/^#WC7]I&'XZ?8- \/\ [4,7P^\:6?@W58O#G@/1
M?"D7C6YTKPZFOZM#9S3"->>&GSSA1Q%3"Y'AIR<(5OJ6-QSSBEF.-P]%8FC'
M&0RO"T^'\YS##/$3P\L97SGAG+<7BKX3/\!G5E34,$Z'OU)5>(L35YU6]G6P
M>68CARMEN$K_ +FG4PV)SA5N+<GRJ*C2E.GA<@XAS.I@*4<?EF8_3UC_ ,%.
MOV6-2^)/PY^%]AK7B>XUSXO_ +& _;J^%VIC1M/A\.^._@Z;?4=2_L+0-2N-
M;AEF^)W_  C^D:IXI3P;<VEJ)O#6EZQJUOJLT.A:XNFX/PY_X*=_##XJ>,M*
MT;P;\"/VFM2^&^H:MX;\(7W[0,/A#X;7GPD\,?$SQ3\ ] _:/TWX:^+++2_B
MUJ/QAT/5D^'WBC0+.[\<7/PF/P8@\::K9>#Q\4)-8NK>*7\W$_X(M?'^+P!\
M8? 4?QI\"S:O\.?A7_PA?[ 'QCU76=<OOB/X*UKPA\>/VB?BY\,XOC1I^E_#
M#P[X;TCPK+\//CWJ?[,_Q(T_X=)K%OK_ ,&[KQ39:1H^E'6;;3;+M? W_!,G
M]J7PU\8_@OXED\*_LH^$]=^'6F?"K1?%'[9/PC^*/Q:^'?QT^('P@\!_ _0O
M 6K_ +,GQ<^ WA[X-Z3\.?VA/#MYXETZ_P##GAGXM?%?XI7.H^%_AI+H7B#1
M/AUH_P 0_"NF1S8U:N)J4<WQ%&A[%SPF$K9!AI35:</KV><3N=3,:LHT*LL1
ME?#D<EEB\M6#PU6-?#4\;A\1F>9UUP7G+QL(X?&1P^%G+%8?#X;$4L3BW[-?
M6LQP7#/!U5/"0@^58',.)L1Q#2PN*<Y3K4ZE3+ZN$RK X2KQ7E'V!=_\%<_@
M;)X+TCXH^$_@K^TW\1?A+IWP&^#O[27QU^*'@GP;\-KOPM^RQ\+/C?X-M/B-
MX2OOC79:U\6]"\7ZWXBTGX=71^(/CCP;^S_X7^.7BCP5X)2U\3Z_I5IH^O>%
M[O7?3/A__P %-OV8_B=J7Q#T7PA=^,;_ %SX7?MAZ!^Q1XNT9](T6+4;;XD>
M+-:_L'PIXWLHAXD>/4?@]XFO8=2&A^-K65[B_?0?$5C'H?\ :^A:GIUM^??@
M7_@G7^W3\!_V;?&'[*WPAO\ ]EWQ'X7_ &HOV4_V??@C\?/B3XV^(?Q,T?6_
M@!\5/A_^R;X _8]^*?Q&^$G@K3_@IK]E^T/X-USX;_#;PEKWP_\ !GC+Q1^S
M]?V'C;2M0;Q%K$FA>+98?"NAI7_!'_XD^!_B+^SO\2?AIX_\!>'=2^&O[:_C
M#XA_%S2;G4_$MQI_Q9_9';XZ>(OCG\(M U&XC\'BYN?CI\(/$5TG_")_:XX/
M"FG6?Q+^-&D)XIN8?$%CJ%>W7I81<3/"8>:EPX^(\#AHYA*I>NLIEQKE.%SB
M;C+ZNW1P?#<L3_9N+=*#QF%Q>/S?_:,3E-# 8C#'.=/AN6+PB=7B+ZICI/+]
M%AZ<Z7 ^;X[*YPFU-5:N.XGITJ&-H*HWAL3A<LRKV6&H9Q6S"G^K'CW]L'X/
M_#C]J;X'?LA>(I/$?_"U?C_X6\=>*/!MW8:7:7/@_2_^$)TO4-=M?#_B[66U
M.&]T3Q'X]T+PQ\1]8^'EE'I%]:>(;+X3_$;SK_3;G1+.WU3XKLO^"QOPDM_A
MW)\7O'G[,G[6GPJ^%FM_ SX\?'[X2>.O&6E_LWZOI/QU\*?L[>"]2^(OCO0/
MA]8?#/\ :6^(7B+PWXVO?!&CZKXC\*Z'\:]$^$EOK5EIU]$^IV5]9W-I%QO[
M0_\ P36^/?QD_:.^*7[7^@_'N;PK\7_#/QE_91\2_LO?#FT\1V=I\%;WX3_L
MQQVFM/X7^.=Q-\&==^(VD>)O'GB+XL?M<^'K^\^''B"]TG3_  5\4?#PNX=>
MFAUG2!\D6O\ P0R\=?#GX%/X=^#<_P #!\8_BS^P-^UK^QS^T7??$'QI\5-?
M\)1>+/C;X+UFZ^'?Q9^!WB'6?!7C#7OA\;;X@BR\*_%WPOX7\+> M#\<_#?Q
M$OB&^T[6/$OPE\#^&]<\FFZGU.A5K>YB9TL\YXKFG!4JN7ULRX<Q56C2I5:^
M&Q4JU;#Y#B<)"6+>#Q>%>98_#.CC:^!RKN5.A];G"%2,\)[?AV:E4;HUH1C5
M6'XHPT:R<Z5>A3A">8X*O]7I5,72KO+L-5A5P=+'9K^J_BC_ (*#0_"[]G;X
MP?M*_'[]D3]K+]G[PC\*+;P6=+\)^.8?V9O&WQ%^,FK_ ! U^T\)>%?"WPA\
M/? +]IGXS6.I^)]5\6:OX;\,VFE>-=:\"F]U?Q/H\>GS7ENNK7.E_=7@_P 6
M>'O'OA+POXZ\(ZK:Z[X3\:>'=$\6>&-;L95FLM8\/>(M-MM8T75+.9"4EM=0
MTV\MKNWD4E7BF1@2"*_#'P]_P3-^-'BS0OAG\([CX5? 7]@GX.>&/CKX,^/'
MQ%US]D#]KCXG_M$_%#XE^(?ACX#\<V7PVTZVM/VAOV)OAMX+\(P>'?BAJG@3
MQ[/=7-OXO%TOA-8K2QTW4X+/43^EW[!O[/\ X^_94_9?\ _LW>//%.F^-K;X
M*:AXV^'WPL\46FHW.HZK?_L_Z'XW\0Q?L^V/C)Y?#'A.SM_'OAGX.-X,\)>,
MX-$TR7P^^OZ#>7FBWL]A=PI#WN%&^8N4HPE"MERRRG2UIU,!' 4WF.*Q-:56
MM?'5LSQ-.E1P<?8.CAL'6Q;I?[54P>4^9"5?V66N<%SSI8E9FTTW#'5ZLIX+
M#4:2C%T\+@\%@JU7$8V-3&4J^*S7#Y>ZE&IE\,3F_P!A4445S'2%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 45YSK?Q;^''A_"W_BW2I)294\C3))-:G22
M'[\<\>D1WIM').U?M?D*S9 ;Y6*^?Q_'#5_$;)'\/?AIXF\013>9;+JFI>7I
M6F6U_@^6LT\"7]BT"!HI9?M.JZ;(58H3#D2T ?0U5+Z_L-+M9;[4KVTTZRA
M,UW?7,-I:PAF"J9;BX>.*,,Q"@NXRQ ') KY0UGQ#\6SXD\.V'CI+C0]/UZ"
M\A@TKP+.5U%;F""[=?)F759+>>^D>. RI?:M<Z3;6K">6W5O,CDS/AK\,O"'
MB7Q1XPL/%,>L:E/H5S"^GV-]K-HT<VG:DLMP7N)_#MU-%)?65PZB]73]7-K#
M<7(BG@6?S(U /:]>^/'PTT(SQ+K4FN7<$D<9M- M9+_S?, ;?;Z@YMM&G1 1
MO,6ILP8E I=65?,_'/QV^)>F^&M7\1^#_A!J#V.E-87"7OBV>XTV.]TZ_O;:
MRCFCLUBM/WF;N*X9K+4=3BBMT>23]SNFC^B]#\'^%O#(7^P/#^D:5(L"VS7-
MG8V\=[+"I!"7-_L-Y=9(#,US/*S, S,6YJ7Q5H4'BCPSXA\-W+>7!K^BZIH\
MDH'S0C4;*:T$Z$<K) 91-$ZX=)$5T(900 >(67@KXL^-+6UU'Q!\5X]+TN[6
MWU'3K?P1;R0I<Z??Q+/L.H0IH=P(_(:(6IN3K"%7:1FSGSNCT/X ?#?1Y#<7
M.GWWB*Z^T_:EN?$%^]T5;"DQ26EE'I^G74+.#(ZWMG<M(SN'=H]J*G[/6N2Z
MU\*/#=O=Q1VNH^&TN/"FH:<CB1M+.A2FVTRPG9>MU#H)TE[C//FR-G/4^UT
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M->C5C"I2JTYIPJ4ZD8SA).,DFF@HHHJC **** "BBB@ HHHH **** "BBB@
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MQ2_X)_M\!OBW;>&_!/PTU3P]>?$OXR_M@_!GQGX7\>^#?A%\.?&]M<_%"_\
M@]K7@WPYX$\0:=J3^!=(\??$72DT7PMH=WKG]7_[07QW^&W[,/P1^*/[0GQA
MUM_#GPQ^#_@O6_'?C768K#4-5GL]$T.U>YN/LNF:5:WNI7]Y<N([2RL[*TGG
MN+J>&)$);( /Q)_X)O6'[6O[2_\ P5*_;A_;8_;._9<\6_LIZ[\#/@%\(OV
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M@KH?A/XL? /4X?$_@SX8^-=3\%>"K4^&]'^%WQ!LO ^@_#GX:>&(;/P9-?\
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M/^(M+\1Z7I=[;^(_#/P^^*L=C?")+B&*UDL+*66WU"SOM/LOWGK&T?P[X?\
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M^-EA<PIXFE[;%4Z%'#9A*$8O,<)3AA,=]8PT8TE]3^ ?$?[0.F>&/&M_\<O
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M9^/$NM +X!^'GB[Q7BX>VGNY;;[!IMO(P MW-U:1ZNNV0[G=+W^S3'&H8O\
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MG\2/VT[.^^(7A_PSXAO?!&I>.=$\1?M(^*#XVN-$-CX=U":"2:6W80S#T#Y
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M>H_&3P%X3\7_  S\?:]X7\=^.[+3;/P[\-OVQ_!?AZX^&'PYDU;2=!O?$O\
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M#Q8LG]C^'?#WP^T^XABN+2\UVY%]JL>-H>WDC\J],<LK;G*7OABT,4>$,@D
M9V?M Z/#HOP^T3Q-H&G);R?##QCX8\8:;I6CVL-JMQ%;:HME<Z;'' D4<5C,
MVIK?7\*A(IDLB9 S!2/H*VN8+RVM[RUE2>VNH(KFWFC.4F@GC66&5#W22-U=
M3W!!H \!/P0UCQ&KO\1?B3XF\0+<&WNY-)TMTTW2+74%7]Z8;>X^VV4D$>^6
M*WDMM*TF3RV,@CA+M$/G?5)(/#NA7'@75;35KN35/'[^!=)NM&\-Z1<02^*)
M8HQX?/B'Q=K=W++I]I;O T26&D6EM<?V/!(WVE8+N=X_T-KQK]H#0IM=^$OB
MT6<TEKJ.B6<?B?3[V"-9;JTD\.SQZI=R6:."&NI]*M]0LH@ 7)NR(BLI1U /
M3O#[:FVAZ0=:A:WU<:;9KJD+203%;]($2[/FVTLT#AYE=U:.61=K#YB<UKUS
MWA+7XO%7A;PYXEA011Z_HFEZN(<Y-NVH64-T]L_)*RVTDK02HQWQRQNCX=6
MZ&@#YV_:&']@V'@7XFQ#RF^'?C32[S5KI5+SKX4U:>"WUS3[10#_ *1K-Y:Z
M)IBL<X2XD"J[L@KZ(!! ((((!!!R"#R""."".AKC/B+X<?Q=X%\5^'88X9+S
M4M$O4TS[0@D@CUF"(W6BW$L99 ZVNK065R5WIGRL!T/S#G?@?XE3Q7\*/!&K
MI-/<,NBQ:3/<7(*W-U/H,DNB27TZ-AT?438#45#JI:*[CD"A76@#U:O"OVC-
M'N[_ .%^I:UI:P+KG@74M)\=Z)=W)Q%IMWX>NQ)>:HSC#1M8:)/JUPDBM&4=
M S.J!C4/Q1_:7^#WPE%Q;>(_%-MJ.OVTXM9/"7AF2TUOQ1'<M")T@NM,ANHE
MTMY(VC,;:Q<:?&_FQ;7(D4UV7A7Q/8_%SP/J&H)X8\4:#HVO6^IZ3;6?C;28
M]%O=8TN[L5A&JPZ='>W=TFC:C'=21V<MZMG=7444ES':?8Y;.YN0#M=#U>S\
M0:+I&O:<Q?3];TO3]7L78 ,]GJ5I#>VS, 2 6AF0D D G@D<U2\1>+O"GA"V
MBO/%GB?P]X7LYW,<%WXBUK3=$MII%V;HXI]2N;:*1U\Q,HCEAO3(^89^7O O
MPP_:BM_"6A^%?$/Q<\#^ [#08Q:P2> ?",GBOQ!JFE2%G%C?ZOXS:#2](FTY
M)/L6GR:/H-P(K>&$M/,R*U=/8_LE?"1]437_ !LOBWXL^(8;GSX-9^*'BK4?
M$<L,8=I!8C3+7^RO#\^FJ[%EL;O1[BW480((QLH [/XI'0OB7\$/'%QX:FM/
M'6FWOAC6=2T/_A%Y8/$<&O:OX7DFU'3['2FTN2YCU.Y;Q!HL5@MO9R22O>QM
M;)B==HO_  ]\0>-_%_PA\/:W<:/<>#_'][H/D7&G>.]&U"-K/7M.FFTR>\U?
M18;K2M2%EJ<UF^JVMNMU9W+6%[:N71B17IVGZ?8:38V>EZ796FFZ9IUK;V.G
MZ=I]M#9V-A96L2P6MG9VEND=O:VMM B0V]O!&D4,2+'&BHH MT ?(%E\"/CE
MXJN[C4OBE^TEXMT^.^>:23PQ\'H(O!ECI96YFDL;?3/$DT<M_/9P0O''*+O1
M%O[F-!%?:C?2)]KD]#T;]F/X*Z;>3:MJG@Z#QUX@O((X=2\0_$J]O_B#JNIO
M&!_I5U_PE5QJ=A%=/CYI;"QL@!E41$.VO?** *UE96>G6=II^GVEM86%A;06
M5C8V4$5K9V5G:Q)!;6EI;0)'#;VUO"B0P00HD4,2)'&BHH LT44 %%%% !11
M10 4444 %%%% !17(:YX_P#!?ARY-AK'B72;;5 AD318[E;W7YT"ALVN@6 N
M=9NSM((6UL9F(9< [AGQZ[_:6\*WNJS^'?!.CZQXO\00PM.UC#%+;R6T4<R0
M32:IH.FVNO?$32H899H%FN;GP#]E@,\0GFB:1 X![%X\\70^!/"6M>+9](UC
M7H=%MXKB32M!AMI]3N5FNH+3,*WEU96J0VQN!=7UQ/=11VEA!<W3;_)\MOB;
M5OBQ\;_B^^@R^"_AGH_AY=%US2/$&D:J-0UCQE?>?9S*]U:P^)?#R:-X*TB7
M4-,EO-"US1?$&KF.XL=0O[*61&"74;/BE\;/B[>W.H^"M7\"3^%/"NKZ5=V7
MBO6Y8;:ULO#FB:I8PK<7VI>*;RW\9V<>F3:9?7#HWB#P/X,N;VXLM1TG399-
M7MI+>#W/]E'QE=^+_A7%_:8>/5=%US5;'489;6:P>WO+R5=9U*QAL[F>>XBL
M=!UO4M7\*V!E<LT'AX!F>1))' +"Z3^T9XM .H^(?#GP[L9&5DBTNPM[O5EC
M)826FK:6+GQ)%-A&!2_\/_$719VD4$0VZHPN."^)OP8G\->%;SQQ_P )IKWB
M#Q5HUW9SP7_B2[BN=)T5-2GBT:YU2"?56U+Q#9Z=H+WT/B>2UNO%-U90G15,
M$=O@,OV96-XBT2T\3>']<\.7^[[#K^CZEHMX4QO%KJEG-93LF> ZQ3L4/9@#
MD8H Y_1OB+X2UKX>V_Q/M]7LSX/?PW<>*+O58)A?6]AIVGVDUUK"W!LEFD-S
MHS6M[::E:)$;NVO;*YLY;=+J%X%UO"/B[PYX[\.:5XN\(ZK;ZWX=UNW:YTS4
M[99HX[B..:6VF5H;F*"ZMKBVNH)[6[M+J""ZM+J":VN88IXI(U^9_P!ECP?I
M\/P,UGX6>(;FYUZSL-5\4>%_$6D7K1P6]C:^)+&WU+5_#=D;**TOH[.W.NWU
MG>W%Q=W5Z^NG6Y+:]MK9;33].^E_#GASPQX \,Z=X<\.:=I_AOPOX>LC!964
M!$%G96J,\\\\\\[L\L\\SS7NH:A>S2W=]>37-_?W,]W<3SR %W6_$&@^&;"3
M5?$FMZ1X?TN)E274M;U*STJPC=@S*DEY?S6]NC,J.55I 2%8@$*<>26O[0G@
M#7KZ\TGX?1^(_BEJVGSVD%]:^ ="N+^PLQ?-<+:7%WXLUB30_!%M:W!M+GR+
MB?Q/''.MO.\!D2&5D^=OVLO$WPN\0Z?X/U8W<'C4Z-=^)]!E7PWI=MXPL]'D
MU[1QJ6D:Q<W?VVQ\/1/I/CWPEX)&J:9J&OZ:=0T*YUC3KSS-.N[VVG\#^'_Q
M,_:/\*BXF\&>!=<^*FOW-]-X;L]5O])TV+PQHND:CK-YK!M=1\/> $.GVXMO
M$DGB"STC5I?B6V@>%M(@N-"B\/>'K7[,;D _5/P=XJTSQOX6T'Q;HZW,>G>(
M-,MM2M[>]2&*_LS.@,^GZA%;SW,$.HZ=<"6QU"&&YN(H;RWGBCGF1!(U_6->
MT/P[:-J'B#6=*T.P4A6O=8U&STRT5B0 K7-[-!""20 "^22/6OR$U_QQ^UGX
M.TSQ)X0-WI>CW^F:S=ZKXF\*:$LME/X;3XK:RGB"PUZS\5:59V&F6.CVWB3Q
M5=:)#&GQ#U:6ROH[EKW3AH.GPZE7H6G^"_#FA_##4OB1\2_B5>0?'GPPFI6>
ML^$M>^(N@VL5YKO@CQ NM3^$)+?PXND:CXIU'Q=X8M+73_(U35?$S31>)HI;
M669S9W* 'VYKO[0OP\TBYCT^QEU?Q)JDXW6NGZ-IZ6KZ@A"LLFD7OB.YT#2]
M=#*2RQZ#?:I<$*0L#.T:R8G_  GWQM\5 +X1^&UMX:M)0PBU?Q>+_P"0D$>7
M?Z3K#>"=;TF="&VSV.C^+[/>%<I-$0K^U^&M \+:'81_\(IH6CZ'87T<5WLT
MC2;;25N1,@D2>XA@M[:1YG5PSM<IY^YF\W#[JZ*@#YO'PG^)WBG+^//BKJ=K
M:S!2^C^%)9(GLG!RT=OK%E9^$]$U:S;+ VGB?X?ZT&POG2S*-E4_@1I-O\._
M%/Q)^%,-RSV=AJ[^+-%@:&V1S;:Y+]JU"9FL;2RLH-L.H:!%]AM+6ULK>03+
M96L48E%?3E?/?C63_A%OC=\.?$?FM%9^++"\\'W\%I"HEN;A9@EC)>.2BRQ/
M?ZMHQ+,S2Q0Z5E5<111$ ^A**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /F:?XYV$WQ@^,W@X^#;;4=,^ O@OX5:A/XQ34+,ZG+X[
M^+4_C&?4O ]G975JD>EP:%X.T7P+XGUO69-7A,FG^-+1/[,N(K%IFC_9\\4>
M$['PNVEWGB:U'B?6=;O=7U&RU'S+.=;J^FMM-LX8;JZ6.#4'O4M[.XC,$TDC
M7.H?9MGG?*WSO^T5^S FB>*=;^*'PF^+WQG^'?B_XR_$KP]J?Q"\(:%XAT'Q
M7X,^(FK6O@_3O!<3WOA/XB>&_&+:8[^%?#&A>%HG\(7GAV6QM8]-BL9+6.UM
MH#9^(T7[5<GC:P-C^SQ\/?BEX.NTBUOQ7IK_ !*O_AWXS?5=/TN'1X+7PQK4
MOAC7_!5SIJV]G87,&BZKXJ\*W,E_>:HXU5[< 6_BX;%8S"4<7/-,-B)2IX[%
M.G6P='ZZJV#K8NO+!>SH8*G+&2EAL']6H8A5,(IJ<7*,Z\%*HOTS.<AX<X@S
M3A^AP-G>3TZ>+X6R*GC,OXBS'_5:66\19;P_E5+B=8W-N*,70X:I4LZXC_MG
M,\HEA.()8>6%JJE6P^5XB5'!3]>_:U_8@^ G[8OAJ*T^)7@WPM9_$?0M/ET[
MX=?'>U^''PH\5?&+X56=]JNF:CXBT[X?>*?B9X#\=)X>T;QQ9::_A;QYI=C9
M0Q^)/"6JZQI336=S<VVI6?Q5^U;^P+^WG^U5)X5T*\_X*'Z#\&-&^'7@WXTR
M?#_Q_P#!?]F30--^("?%/XH>!U^$&C^(_B)H/Q&\>?$[PYXBM/#/PH\7?&72
M8]>^$>K?L]^,;;4OB#O\/WVB?8Q?#[2^*_Q)^&G[/0\.2>+_ (@?$7X76/B*
MQNYK35;CP+X[\>_##PPVG_8Q<VGBGQ3H'AK6/!/A"[D-]FT;Q?XETU-4BLKV
M?3Y)X[*XD'J7A+Q7X_U7PWH?BO2+CP+\5O"/B;2-*\0>%O$O@[68K:'Q%X<U
MRTAU/2?$-IJ3!]"OM-U'3+JVOM-FTA)X+ZTEAEAG=)5F;T:>,PE6O5PM+$X>
MIBJ$82KX:%:G+$4(U$I0=:@I>UI*:DG%SC&Z:L?&8OAWB# 95E^?8W),VPF1
M9O4Q%'*LZQ&78NEE&:5<)4J4L52R[,YTE@L=4P]2E4A6AAJ]65.4)*:5CR+_
M ()Z_L9^$_\ @GO^QC\ OV._!?B.Y\8Z1\%/"5[I5[XQNM(C\//XO\7>)_$N
MN>._'_BN#PY%J6LQ^&K#Q)X[\4^(]:TSPT-;UP^'M.OK71FUO6&L6U*Z_)/_
M ((MZ?X]_:+_ &W_ /@LC_P49^*.BVNG_P#"=_M5I^Q'\!;:>T>2[T+X.?L:
MQZEX8U6]\-:W;W6J>'M8\+_$#5=:\*7&OZGX1US5_#VJ_$CP+XLFM;A%MD0_
MLY\9OVK/ 7P!^&?C[XH_$[PS\3+'2/AYX0\0>,-0T?PWX$UGQCXF\10>'K"2
M^ETCP7H>@175]X@UC46066FQ&*RLFNG$E_?:?8)+>Q^E_!2Y^&NJ?"?P#XE^
M#WA:U\&_#7QSX<LOB3X3\/VW@*\^%TMO8_$T-\0)[[5OA[JFB>&]:\)>)=;U
M#Q+>:YXKT;Q#H.D^);?Q-J6K'Q+8P:\^HH.D\8]1K\5_^#@K]IWQ;^RM_P $
MM_CIXL^'/Q!\:?"3XF?$/7?AC\&? OQ6\#V?CK^U/AI<^/\ Q]H<7C3QW<>)
M/A[:7/B'P+;>%_A7IOC_ %>R\6PRV$D'B"VT31M*O#XCUK1+2[_:BB@#^3K3
M_P!D'X??MM:3\7)_^";W_!=32OC)#^T=^S]H_P %_P!I;X3_ !KTO]G3]HKQ
MQ\;_ ()>'++XAZ/H/P^^*?B_P%HOP<_:3^&K+X8^*GC+PA>_%3Q=I?BSX^V/
MA_7+>)O&5S;Z+X4L='^1/^"DNB?M9?LM_P#!-_7?^"<OQ?\ V5O#6A>)_P#@
MI'^W3X?\,M^T#^QA\7I?C'H>MR?%S]H%_C/JG@?PG\"/&'ACX5?'Z75?AO\
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M0^$F\&77AOX*>)_#?[,_P_UCXS?L]^$M7G6S^('Q-\1:_J6O_#A;W4VN]/\
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MKX6_M4_M+?M!2?&_]K7]F#X^WGPJ^(W@GXU?&76?CU#X[ATC5_"7Q?T_X/\
M[6OQ0U?XF^"O WPU\*?%/6_A)^U>UIXLNGUZ'4]0U#4=<$@^T?CA^PE^T/\
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M)XBT&PO_ .S_ !9XUU/Q?9>*/"&BZ58Z[XAELOAQKM]8:'>ZD-"LM2_HDHH
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M0VMK:PQ6]M;6\20V]O;PHL<,$$,:K'%##&JQQ11JJ1HJHBA0  #+UCPYX?\
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MQ;XC^'_A?0?"FI^*8-/&H2:3=ZIJ?AVRL9=3N;/^U[Z2RU&>2:Z07"E9RD4
MCZ/7_AYX(\4><VN>&-)O+BX='GOEMA9ZG*T8PF_5;$VVI%0H"E/M6QE 5E(
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M]O1J4?:PIUJF'J2I^TC'GC3Q%&M0G*-U&M2J4I-3A******LYPHHHH ****
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MQ$\*>/;,3(4TWQ_H$VD75K8J?WD%OJ_AUY;K4[]U'[BZU22&+S2%G C_ 'B
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M!OPVUSQAX/NOA1K.J76O>"/!4FOV6IR>&]!TFPQ?V3/VK/VM]7_;J_X+#?\
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M+\*II_C/4/A>GPE'AG_0)K^;K]H'XB?\%T? 'P;^)7@O]I3_ ()G_P#!/_\
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M<2ZIX!C'Q?N?A7XC^!.N:=IT5U\-K:[UW2M5\/ZGI6KQ7FC^)["'2<+X@_\
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MZZOV>/VLOV<_VK?#MWXC^ 7Q<\'_ !#&C3_V?XQ\,Z=J267Q"^&OB&)(6O\
MP;\6/AKJRV'CWX5^.M&DGCMM>\$?$'P[X<\4Z)=L+;4])M9B%(!2C\;_ !>\
M->(;'PIXIA\':G+-ITM[!JMF88)-3$4=S<NLKWVN^&[6R(@LKZ,S?V3&BO;!
MDMIX?-N%]1^'OQ B\>6)NETQ]-?^S['4T477VR"2TO\ 4==TJ,"9K>SE6Y@O
MO#NI17436WDJ!"]O=74<I=?SN^!/[0WBS]I_X_?MUF3X9>!/&'P%_9O^+EI^
MSAX%\3VFO7%KXJNO''@7PU(G[0.C^)(-0$VGZ?>^"O%EY;3:)>Z#+#=RZ3XA
M@BDMK;5;![V]^QOV>;<VVEO&ZE)O^$6T43J7+XFB\>_%F!@/F9%"B%5Q'A"0
M7P6=F8 ]!^*'P4^#_P ;='BT#XP?"_P#\3M'MG:6RL?'7A31/$\>FW#%&^V:
M4^KV5U+I5\KQ1217VG26MY#+%%+%.DD:,O+>-/@GJ.H^"/!O@SX2_%OXA_L_
M1^ (;6T\-7GP_@\$>(X)=+L=/&F6/A[Q)I'Q4\(>/[#7= M[9(PD*#3M8B>*
M.2TURUD4/7L6J:[HFB1I+K6L:5I$4A"I)JFH6EA&['. CW<T2L3@X )/!]*X
M34?C1\+]+G:WN?%^GRR+C+:=!J&L0<HK\7.DV=[;, K#<5E(5@R-AT91QU<O
MP=:5><J$(5L13C2K8F@Y8;&3IPDI0A]<PTJ6*BH22E#DK1<6KQ:/H\OXMXCR
MVEEF%H9K7Q&79/C*^89=DF:PH9WP[A\9BJ4Z&*Q'^KF<TL?D5:>)HSG2Q/M\
MNJQKP?+5C-6MRVJW/[0'P]^$^B#2=)\)_M)?%72KI+?Q%)<:O#\ +;Q+H[7&
MHR-JFC6G]F?$K1K;Q-:V?]DV;:+>ZAH6@:S=_P!HZHFM>&8#:Z*'V_QVL?#_
M ,)+[XM_&OP/XT^ MAH=ZECXGT'QG%H7B_5=#,NL6FAVFJM<_"#6_B-I-]X<
MO[R^M;B#6;:_VV.F2/J'B&UT**UOEM?&_$/QVU"\\5:\VB>.=:T;PPDE@F@Q
MV'@GPQK+3JME%'J4L[:_?Z+>6T;7\<D]JLLEU-+%<$/%9"!8FIIX_P#CGJD<
M5YX5U'QAKNEW#NMMJ4GPWT"UMIECE^SR.DNGV^M6S>5<+-%-Y=S*(VA8,VX2
M)'/U2O3;>'Q]>,8X3ZO0P^)C2Q>&A5A&U/%5IRC3S/$U4TO:JIF:59<S;C5E
M[5;_ -OY3BZ<*6<<*956K5^(/[8S3.<DKXWA[.\3@*]9U,;D6786C6QG ^28
M*49U/[/G@^!Y2RVK[&,(5\#16 E]3?#?XL?"[XQ^'_\ A+/A+\1O _Q-\,BY
M:R?7O 7BK1/%NDP7R1132Z?=7VA7M];VNHP131-<:?<O%>6WF*)X(V(%>@5\
M#:AX)^/?B?0/&/AYM(ETW3O'4-Y'XNET&/PQ\/\ 7-8EU.R%A<W[>)- 'AOQ
M+!K36<4<$>NZ;JMOK-B(K<P7]M)%"R^-?"?X._MQ_"GXN3:5I'Q"^*GB+X#G
MX97I%A\5OB)\//B?<6OQ&G\4:2FB0Z#XF\6Q:_\ %Q8-%\+6&NC55\0^)-2T
M?53K^EM#.VI:5,8\IXG'X:6"A6PBQD:\X4,1B<#S0]A5G*25:6$K.;A@XP2E
M5J_7*M2DWR*E4]V4N_#Y)PGG='B7%9;Q!4X<JY7AJ^:93DO%*HXC^U,!AZ-*
M53+</Q#ET</'%\1U,1.=' X+_5O X/'4HK$5,9@;5:-']7J*^7X-(_:>G,0;
MQ5HMGYGWVN[7PT4@&TG]Y]B\/WKL<@+^Y249.<X!(T/^$9_:7_Z*'X/_ / *
MT_\ F&KTSX8^D**^7I])_:?@\T+XHT:\,9(0VEKX8"SCC!C-[H-FRYR>)EB.
M!TS@5F7$7[4Z+'Y%RDC9(DP?AZW;(8"2RMPBY!&T-*V67H%+$ ^M**^.+FZ_
M:JM%5IFG(8,5%MI_@B_;Y0"P9;"SN60\_+Y@4.01&6((&"WC[XY:7'+>>*]1
M\8Z%I5NZK<ZG%\-O#]W;0B20P0L\NH0:);*)KEH(8S+=1AS,-I9_+CE /N6B
MOA/1_P!HQ='\=^#=*\2?$/6=3TC7&UX7=GJ'@30-*9UT[29)H7@G\-W.NS.L
M-S+#/<"2XT^0)"BPI?":2)/J#3_C)\,M2E$,'B_3H'/_ $$XK[1H^A.?.U>U
ML8@..I?!/'7B@#TRO./B!\0H? PT^$:9+JE[J=EK^HV\"SM;Q_9?#5E!J&J?
MO4MKMC.EG,US#')'!;216UR);VWD$*3=EI>NZ)K:-)HNLZ5J\:$AY-+U&TOT
M0@@$,UI-*JD%E!!(P2,]17SW^T#<-:ZKX-E6WGNBWACXOVYCMTWR*MYX,CM'
MN&&1B"T2=KNZ?_EG;0S2 $K@@#G\;_%[Q1X@U+PMX43P5IK0645W+J\\L=U-
MIFY+:<P[[35_$-G<S@7,$#.FEW,0\\,Z6Y*2+HO\&?%7B8L_Q#^*&OZK;W5O
M&+W0]!C32=+6ZA\ORFC5B^FS0QA"6;_A';2>>5A,SI(K&3GOA?-=W?Q7\3:3
M8^!]&^'D'@#3M)T?5].353J>H:WIVO:0=1TJ_BGM+%+*>X26TL&U)Y;RYN@G
MV=KRYDO7:)?J>@#RK3/@E\+],MIK8>$M/U$75D;&[DUDSZN]Q&\8CFE"7\LU
MM:7$PRSS:?!9E"["$11D(.4_9PO;B/P/JG@[4+F2[U3X=>,/$OA"^NYE\N2]
M>VU![\WD<><"S%Q?W6GV3Q@0M%IQ6,ML9C] 5\[>'C_PBW[1?CC13YOV/XA^
M#]$\76K,2ME;7VB33:.VFVL98*U_?O\ \)!KE\\:,S1+$;B0;;9" ?1-%%%
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M1))+.L:;BQ5OINVMK>RMK>SM(8[>UM((K:VMX5"106\$:Q0PQ(N%2.*-%1%
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M+W_@I;H_A3PYK<G[('[7-QK7PU\$?%7P[\.OB)HOPV\<_%#PS\/?B[X"\/\
MQ*\"^*;[X5^/M/D^*?PMF\3^ /%_AKQ=IHUWPQX4\0VFFZUIE_+;V4\D3+\B
M:Q_P0/\ V7?!6HWOB7]BSXZ?ME_\$^?%5[=OJ]\W[,O[1WC>3P3XEUI9/.M7
M\9^ OBO<_$?3]5T"*585N?"WAZ_\(Z5>6EO#9,(H(U  /W)KX[_:B_X)\?L0
M_MJZ7?Z;^U/^RU\%?C3<W^EQZ*/%?BSP/I ^(^DZ9'<6]TEMX7^*FE0Z;\2O
M!_[VUA5IO"GBO1KA[<26CRM:3SPR?)/[,/A3_@H]^S5X\^-&@_M2?MD_#_\
M;@^&PL/A?!\'+N;X%^&_@/\ $/P?>*GC6]\;:7XH'@J:^TK6KC4-)N?"LMGK
MVN>(M>FO].\*ZAJTT.@:E<:A#KOZM^%M8N?$'A_2]9O-/&E7&H6YN&L5NOMJ
MPH99%A9;K[/:^<D\"QW"-Y$9"RA2"5W$ _%5?^")L7P/1+G_ ()V?\%!?VZ?
MV%$T:T:U\%_":'XJ']JC]E+PQY\?EWMQ_P ,\?M-0^/(K^>ZR\JM#X]TQ;:X
M?SH$1H+(6GSO^T9^Q5_P6R_:)N/V<?V:?VBOBW^PC^TI^Q=H?[6_[-?Q&_:&
M^(?A3P=\4/@#^T%\7_@U\&_'\GQ/\3^&?BE\))=4\<?!2\T+Q%JOAWPI$FC_
M  Z\0Z;?CQ%IWAO-@-*_M[Q#IW]*-% !7\K/Q6O?VM/^"PWQ)_X*\_LL_!W]
MJ;]E#_AF_P""/Q\^#7P"\!?LT_'+X0Q>)/%5UX__ &;F^$OQ'^,?B+7/%_PX
M^)&A>//#'PZU/]H719_"UQJ7CWX9?&WPMXYT31]:\$Z)H_@Z^M=<N8?ZIJ_,
MO]H[_@C9_P $Q/VK/$$WC3XP?L;_  E/Q$NO$NL^--0^*7PQL]9^!'Q6UKQC
MK]TM_JGBGQ/\3/@=J_P[\;>+];N=25M2:\\6ZYKA_M"XO;O:9M1U!KH _"KP
MC^QW^V!^S=^V)X3_ &D_VG_^">G@+5_!/_"_?A+\4/BUK/\ P2V\*^$M?^!>
MC^%?@3\'_P!H/3?@M;>$?V<[C6_"'[6/C3QO/^TU^T3+\>OC/XOB^'WBV34+
M[X5_#NTT#P]=6F@WMUXB\^_92_X*;_L]CQQ_P<!_\%%?#GQT^%6@_M._&;XC
M6O[/_P"Q+^S_ .-I4\-_%KQYH_[*7P@7X1_LV^*O!WPD^(8TOXJ7^G?'KXO>
M-]('C7PJ?"-I_P (QXE\/ZC%XPTK1GL)K33?V N?^"6O[;WP,AN[C]A?_@L9
M^UGX5MIKB?4[GX:?MS^'/ 7[>7@'4&L;>]_L#PAX>\5^.K#P?\7/A?X426>"
MRO;O0O&7B/4A9117$MMJLME:6H^ ?V9/V?/^"B7_  3E_8?^%7[ ?[4W_!*O
M]G#_ (*G?LL?#.3Q=XFU7Q?^S]\9?"'CWQ%:Q>*?BCXW^*&JR>)/V:?VO/AQ
MX*;XJ^/[;Q%XQU2_T9? FJ6ULEG-IUM;#[>=0DL0#E_!7[1R?#KP9^RU^Q]^
MW)_P2E^ OQ[_ &$="_;S\+_\$D_V0/CSXT\3_ GXJZF/&GPI\5#]CRU^)'Q#
M^!/Q9TG5_$\OBGXG?$SX+_&/XM:GJ_A;2/#CZ!\-[G1-%FC\=7FG_P#"Q_'?
M] ?[%W_!,W]AW_@GCJ/Q@U3]C;X$:?\ !&X^/-]X3U#XI0Z3XV^)GB?3/$%Q
MX&D\72^$TT_1?'GC3Q5H_A&ST5O'?BI;?3O!ECX>T^2+4UAN;6>'3],CLOY*
MOVGOV@O^")_[+OA/XM?M2?L_?"[]L#_@D9_P5#\"?#?XE>+_ -GKX3^//V?O
MB?\ !WQ%K/Q%O_!EYX=\$Z3'\(/B?X6^,G['$7PSUS4];L=&\3V/@9=%U&X^
M'#Z_9Z7-'I$EE%<?VR_L_:;\6=&^ WP2T?X^>(K;Q?\ '72OA%\-M-^-/BVR
ML-$TNS\4?%FQ\&Z+:_$;Q%::9X9L=,\.:=;:WXPBUG4X+#P_INGZ):17*6^E
M6-I81V\$8!\S_P#!43X,?M%?M&_\$^/VM/@!^RE??#[3_CE\:O@_K_PL\-R_
M%"_O]*\'W'AOQW+9^&OBCI=QJFFZ/KUSINNZU\*=2\;:/X,OY-/%C9^-+[P_
M<ZIJ.C:9'>:S8?SM>-E_9(\$_#SP9\-_^"G?_!M[\??V?-&^'WAKP7X8TK]H
M[]ESP_X*_:RTOP?\,OAEH=KX7T3Q=\5/VMOV/;OX4_';P;#HFEZ1I]S<:6=&
MO]0F6&+4&L%N[:SA/[K?MH?\%/OA=^R[\4/%/[+NF>$?C#XU_:9N?V0/B/\
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M?"_PH\5IXG\/QZGX2\8ZB/B/]OO]DK]E_P#:._X)T?$?]K:+X._#[5_VU_\
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKP'XG?'FQ\":E-X?\
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MQ#;:9\D>[)_T;1-(\ W<K[0BF^\9J6)DES)[!X(\%Z7X"T/^P=(O-<OX'O\
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M?:O864NB6<L%E?W>G?N/\/?!UE\// 7@KP%ILLEQ8>"O"?A[PK:7,W^ONH-
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M:6_9_P#^&FO^&_\ ]LC_ (QT_P"%R?#K_A>W_*>#XC?$3_DD7_"1_P#"P/\
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M)JC6TL4:V:/I;MJ]Q9(S1216QA1R/'/Q(\.:4GVB+?!IOA;[ OEQ1O;R=$\
MN;$5,/BL9A:N(A3AS0KRKTJ+I*"A+#X/&?6,'0;C#DJ*CAZ:J*4YR_>M55X^
M&XJE[+)\)F^1<.9YE^48G%8CV&(RJCE6/S*.->(GB*.;\1<.O)N),U4:V(^L
M82>8YMBYX.='#T*+6 A/!5.0?XQ?!6/P1X7^(GQ$U.W^$7@_7]7LH-.L/CI'
M:?#ZYANK^_EU^R\,W-EXQFLFMM;U#P-\-?#>FZ;8PSS#6;'7;5=&;4;/4H'F
MY?P]_P $[OV3OB(FH_$;1?"G_"O/&FMS:<#\8_V:O&NO? WXB:]+9:-ID>L7
M-S\5/@MK'A/Q7K5DWB0ZU:QVTVO7%@+.!K41F&XNHY>A\0_""&6UU*RMKW[5
MX>U"&\CN+36;>&_T[4-#FN/$MW'_ &M%$AMI[.7PWX2&NWT,ME<1NM]I5L;<
MM,KI[]X&_9Y\*:%^SW:?!_PFM]\%++6-OB.[O_@=%I?PMUW1/$&I^(8/&%Y>
M:7)H.EII]M?SWB1:;K?VC3+JVUS3A>:;JMK=6%[/;,[YA2DW;#8JE'"MI+GP
MV(GC(17NZNM0]CB)7U<J;P[LFJZ;E&5'@_&TJ<>?.\AQM;/U&<JBPV=Y1A>'
M,56E>JW3CEV:?VCE%-Q4J<:6-IYS'GG&655*<:6(^7_$GP=_;2^!$FB-\'OV
MV+OXCZ5K6MVGAK1/ 7[5_P (_"OQ5TS3)=02065K9^,_AOJ7P.^+VH R1.9O
M$?CWXG>.KRSN+F(RV=_8QQ:>GC'[0W@G5?BS]C'[?'_!)#X9?M0C1]*;3/#W
MQ:_9YUWX9?&/QYX7L+6ZGO9M5TJ+XUZ7\ ?B3\(#!<376J:?8_"SXF>/?$\%
MS</_ &1<WNI7+J?K^W\$_&KPWXFC\'VGQ8?X]^*?"&C:_P"-_!>K_&G3_"OA
M(6LU_;VFCZ#X7\::I\'/ ^@V=^FGZE:6^K+XAM/!$6N-;ZD\D]EJ @4W/M_P
MR\?_ !?U#1?%UW\<_@Q:_"_4?"4"744_@'QV?C7X>\:6<=MJ%QJ%SX,BTCPG
MX8^(=S=6:V,.W0M6^'.F:SJ$VIV-GH=OK%V+F.$ACH\U"G7PV,PM6O2G5Y:N
M'E5I4534W..)QN$>)P%"2C#FBJN*BJBE&--RFW!/$<*U50S3&Y7G?#F>X#*\
M=AL#[7!9O1P&89E+%O#PP]?)^&N((Y+Q9FM"5;$>QK3P615I825&O5Q4:.%A
M'$3_ !BT?6_V8/!4E]#\ ?\ @JC^UU^P-XB?2]*M=(^#O[<'B#Q!XO\ AFMW
MI4<,4NE:-X4_X*:^#M<^(WB+2;*"RN[&ZL/V;OV@?"^@QFW:;0]:.B6R1SUO
MV#]>^)O[?/A_X/ZW^U%I'AO4)_B#\'[O]J76-7^'.E>,_A&_@[7?%'C;4M ^
M$FDMX3U#Q]\0+BQU^X\%M+XOFTO5]?UG2XK:]L)LS7%E;K+^EGBGX_?LQ?M+
M^"O&/P^\'Z[X,^(GC#4+"QT35_A=XQ\+76D>/+/3?$=_'I3#Q+\+OB-HFB>,
M].T>^#SZ7-)J_AR&Q>YG6QN-TDODMVWA+]E_X;_#GQ+K=O\ "N"Z^%5[J'A'
MP)9+<>"]NCZ;J6E^#+;4= TS3+W1+(VUC-:^'[5H%LH+;['%:VVJP6$:?8+*
MRM;??#8K"XVE'$8/$T,70DY*-;#5J=>E)Q=I*-2E*<&XM-22E=-6>IY>=9#G
MG#>85<IXBR;-L@S6C"E4K99G678S*LPHTZ].-6C.K@L=1H8FG"M2E&I2E.FH
MU*<HS@W%IG*+^S3\?? 'DO\ !C]K7Q[/IUH9;A_"GQQTK2OBC#K,NV06^E-X
MPN8;;5/"^AP%T,2:%H4MY'%;PVXG>,R;J-]\9_VS_A7IUS=?$S]FCPY\8+#3
M[+4-4U+Q%^SIXMN/M,5O90F:#2M%^'?B^*[\9>*M>OU_=6Z6:Z59M<QLA\I9
MH,^WZ[XC^)7@-IEDUC0?'D%G9MJ>I)=:6^D:O9V"EXX7DDTMHM,M!?W %G8I
M/'>WMY<AWMK:2WMKZ6WZBP^*?E6<-WXN\(>)?":20FXFNY;.;5-(MH2 R>9J
M%M!#.960ES"-/\Q0K @D '<\D^.?BOK'[6M_\/M6^.7BO5F^!N@_#ZYT'QEX
M7_9X^'$=CXZ^(/Q N='\4^';RR\*_%?QY');V,A\6+:77AUO /PS:WL)4\21
MVVL^-?$4=O+ITGL7PD^)_P 7=%^+^N?![]HN;PE'XC\>Z%_PM/X-7G@Z"YM_
M#7]@:=!INC_$'X26U[J%O;7GB#Q+\,-4DTGQ!=:_<[;SQ9HGC9=8M])T"PTF
M71=,^E](\9^%->:&/2/$.DWMQ<)YL-G'>PI?O'MW;Q83-'>A-N6W- !@$YX.
M/!?VGOACX:^*-K\'++5M6\1Z!XB\)_&SP=XV\$:UX3U1-(UBQUW28-4L95N;
MH6UQ<3>&[W3]5N+'Q!I]NULU[!<VZ&XC=(\@'U!17D">'_B]H(<Z3XVT+Q=!
MG]W9>+M%DTZ>&)6=MD>J:)*TUU<.K!#+>1^5N"[4B0%6'^)'B717">+_ (9^
M);*,MM74?"\EOXMT_:KJCW-S]C^S7-A 0WF(DT<EPRX41M)E0 ?.G[3W_!,?
M_@GU^V8NN3_M,?L@? GXI>(?$<=I#J_Q O\ P-IGA_XM3PV*Q1VD5O\ &+P@
MGA_XIZ=%%%!# (]-\86B/;Q1VT@>!%C'YL^&/^" VC_LO>/OBG\8/^":'[?G
M[7O[$/Q)^*__  B%AKNA^(;KX??M;? A_#'@/1M6T/P=X9U/X8_'?PS?>-?%
M=MX0T_6=1M?!FI>*_C)J^L>$[34M4M=&O8$NK=K']U-$^)_@'Q RQ:=XHTP7
M+2");*_E;2;YIC_RRCL]42SN9G!R/W,<BD@[6(!-=X"",@Y!Y!'0CUH _"3Q
M!X@_X+M_!71M;\+_ !0_9G_8+_X*K?"F_P!/_P"$26Q^%?Q!U3]CGXW>+=,N
MI(K?4O$?Q.\#_'JR^(W[.FI6U_IC727_ (/\+^+-'LKFXG6&.2&TMF%_N_\
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M&)%CBBBC4)'''&@"1QQH J(H"JH"J  !7\_GP8_9\_X*D_'+_@I=^RI\;_\
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M6SX@>._$'[6O_!./X)?#+X'^(OVEI_@_\3]6_;S^*/PL\ ^)_#_AKQ_HFE?
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M8I'I\DMY#80&(+]6^/\ 0SXC\%^)M%2,RS7NCW@M(P0-]]!&;JP4DAL WL$
M; SMSM(;!'SY\!]9V:JL+K+&->L9H[N>X$8EU+7K,RW4DD:QMM%I9QVNM*C*
M 'DN"Y597F) /5=)^'GP\TRP_P"$@,Z:I:6UG-.VM->0) ;&*,F82S:)'9)J
M%K''&5"7YOWVIM9Y)=S-YQ\4? BWGP^OO$%IHUKINI+JNDZAI^CVUA!"=-T<
M3-86FEBV@C6-;^Z;4%U'6& =VNY&LVEEM;&V*^HZIX;L_$GB*Z32)9M%329[
M6[UW4=/ %OK'B"-[;4--T_4--DW:9JJZ=&EMJ&IW%U;->@S:99VE_#_IZ1:&
MMW6K?V/JND>)K*-;:]T^[M8_$^B13W.GV\DL#I#=ZAI;?:=4T9X)2MP)HSJ^
MGVHA\^YU.W "@ M?#373XD\!^%M7=Y)9I]*AMKJ:4EGGO=-9],OKAF8!CY]W
M9SS G)PXR6/)[FOESX.^)M \ >$_$5MXH\0V6G:58W^G:W9WVI742(UAXBT^
MR^RV]LR7$RW,B/%"D]M91EX;^YEB9"\BU+IW[5/@WQ?<WUE\+/"WC[XFSV4T
M=K)?Z'X8U#3_  _!<RPB54U#5=8BM+K3H]PE@,TVE,GG0OM#0O#-* ?3U8?B
M?7[3PIX;\0^*+^&\N;#PWH>K:_>V^GPI<7\]IH]A<:C<PV-O)+!'/>2PVSI;
M0O-"DLS(C2QJQ<?/NHS_ +5WC"73/[&L?AO\(=(DN8AK2ZS>3>-O&%K;AL3-
MH\NGPW'A2^5HV=HX[^WT^8S1PYE2)ID.F_[/<?B6.5?BG\1O'/Q%BO;>2WU/
M0WU ^&O!U\LFX-*OAO279M/N"CR1^;INJ6NV-RL21X4@ \R?XHZC\<KGP,O@
MY_A;X.U:?5[#Q!X,U#Q!XV7Q3\1+6&&Q/B"Y@?P=X)C6'0QK/AZPU"Q\0:-J
M_C6$W6E/J&G7EHTT+QQ_;%? ?@SX5:!\-_VF4\&^ ]&T+PQI^F^'K/X@:3]I
MU*[U'4M0\/Z@W_"+>(;)9;M+W53<)=+?C3TOM4EC,4=Q-MCC5B_WY0!\V^*Y
M8?!?[0'@WQ+++':Z9XU\-:IX?U2:64065D=/,+WFJWCR/Y7VF_U$?#G1+9F"
M&*WM[AT=8S>%_2F^+WPW^WZ?IUOXJL=1FU/5;31+6YT:"_UO25U>_N8;*RTZ
M\UW1[2^T73;JZO;BWLX8M1U"U9[N>&V'[^6-&Y3]H'X87/Q.\#BSTF2[A\0Z
M!J5IKND?8)M.M;V_2W<+JFB6U[JEM<V=E=:IIS3#2KV98X=/\06^BZE/*(+*
M16\W^'GPK_9SLM1TWQM-JLWBCQKH5Y;2'4_BGXGEF\6>'=:5X8[6#6?#.HR:
M78Z-X@LKJ>V:S-WX?@U&UOI+.\T^82O9W+ 'UW1110 4444 %>>?%C1)/$/P
MY\6Z9$[I,=*?4(1'"9Y)IM&FAUF&U2,/&2UY)8+:!@Q,9F\P1RE/*?T.B@#S
MOX2ZVWB#X<>$M1<.)5TJ/39C)+YTDDVC2RZ/+<2.0"7NWL3=$-EE$P!9B-Q]
M$KYZ^!B-X>U'XD?#Z2.2)?#?BAK_ $XW4F+NYTS5$:"UE$#;?W'V33;&\\Z)
M?+<ZHC' DC+_ $+0 4444 %%%% !1110 4444 %%%% !1110 4454U"^M=+L
M+W4[Z4066G6ES?7DQ#,(;6TA>XN)2J@LPCBC=R%!8XP 3@4 >!Z&!XL^/_B?
M62L5UI_@#0+;0;&ZB8H;?5+T.LT<J$JTTB27/BBT=MIC3RD&<B)F]#\4?"3X
M:^,OM;^(O!>A7MS? B\U&&T_LS6+E3OW)-K6E-8ZLZ,9'+1M>E&9BS*6YKYE
M_9(\2#Q'KWQA\0:EXITZYU+Q'XL@AM_#?VVRCOX9=%CU";5M5@TH,MTMAJ-W
MJ<DD%Q!$+-VAND0M]G/E_;U 'SP?@/J'A\%OAG\5?''@@(!'9Z3?30>+O">F
MP98E++PUJ+6D!E;=@W%]=WTA"IG)7)3^T_VD?"F[[=X:\#_%*PC CMVT'5W\
M)>(Y0"-]YJLFK0Q:&F%8E+/2-.G=Q%L\P/(IKZ(HH ^$?%_CD_&;XV_ CX87
MG@KQIX4NO"'B>Z^+GBB'Q!HJ6BQ6_A/3-0'A>^TW4#<>;>:%>^)DDT>[NFL;
M>WN;EH8XR[1J&^[JX+P'\1_#/Q(7Q9/X6N'OK'PCXPO_  5=ZBK6\ECJ&J:9
MIFCZE>SZ5/;SSBYT^(ZQ'9+<N(C-<VMRT,;VOV>XG[V@ HHHH **** "O%/&
M_P"SK\&?B%J%CK'B3P-IK:OIUPUU;ZIH\U_X=O))Y+BTN9)-0?0;K3H]78R6
M4'EMJ\=\ULIE^RF!IY6?VNB@#Q_X>?!S2OAWK^OZ[:>(/$6O2ZQ#':6<?B*\
M6_ET73U-N7TRRNMD;'3U-E9?98#&A@\J5I)+F:X>4?*'[0/[*6NW'CWXJ_M.
M?#SXZ?$7X:?$/Q!X)\(^$+S0=/TCP%XU^&^N^&? \&JOX>@\3>$_&7ABYUF.
M?2=>\5>(]9ANO!_C3PI=1"ZFD$TUQ=W"-^A]5[NTM+^WFL[ZVM[RTN$,<]K=
MPQW%O/&2"4F@F5XI$) )5U920..*Y,9@<-CZ<*>)C4:I556I3HU\1A:U&LH3
MIJI1Q&%JT:]*?LZM2FY4ZD7*G4G"5XRDG]!PYQ1G7"F*Q6+R6OA:<\?@:F69
MAALPRK*<\RW,,OJ8G"XR6#S#*,\P.995C\.L9@L'BX4\7@ZT:6*PF&Q--0K4
M*<X_G'#X=^,WA/X;?#K7_A]\+](^.7B.>QM!\0-;^%?QIMO@WXN@O3I]G<3O
MHO@_Q_:>)/ EU.]S<74<^A:K\1O#UUH@BLK9]6UEY+G4(\'QO\1['X6>#]*^
M*_Q9UK7?@EI^J7TVESV7QQT--(U7PUK]^=3OA'K?C3P#/\1/A9#<7HL+V\?Q
M&WC>WT>=O)^U7L=Q=PQ2_>&I?!SP+>W/V^QL+KPWJ@=9(]4\,7T^D7D#+]TV
MPB,EK;X."##;(<@9.!BN/USX8?$B;0;_ ,.Z=\3)=9TG4EEMKJR\4V2O<-8S
MR(9X'UR*._U2?S80\$J.R6\D+R0^2D<K;<Y8;%0E6GA\PJ+FHQIT,/BZ-'$X
M3#U(*"5;]W'"YA7E)1DZBK9C-2E4E).-HI=5'.\AKT,MPN;\)8*2P^95L9FV
M;Y!F699+Q#G&%Q$\14EE]\96SSA#*Z5!UJ4,'/+.#,/*E2PU*G5CB'*K*?D7
MP8\<^'?B#\-+;XD6/AC5O&/@;QA'?MH_BGP1KMMXANM;L;/4;_1;R>ZN="U9
M)M0L;N6SDFE6_O9($MCY<D#*)EKJ/ACJ'A<?$'5=4?59K+2-(TR6ST8>++E+
M;4!?ZU=0SRLUW<F))[IHUO'=#([*FKHBF5FWUT_B#]DOX#:WX;G\,:;X.N?A
MU;36ZQC5?@QXG\4_!+Q%#=13B\@U1=>^$^L^#]1FU2&_5+_[5>37(N+E3]LC
MN89)89.'A_9[^,7@#P#JWAOX:_'9_BEJT*3W'A*;]L/PPGQADT>Y<6BIIC^,
MO VH?"OQM<:2$MYS'?\ B"]\7>(;:ZOIKI]1O88;>QC?ML;3E%5,+"M!85U*
ME;"UDIO%03<Z,,+74+4ZEDJ%3ZU-N;<*T:48JK.5EW#&-IUJF"S[$Y7BIY['
M"X3+\\RZI/#4\AQ-6G##YEB<\RJ6*=3%X+GJ2S7"+(L-!8>C'$9=6QM>L\OH
M3?ML_M:>%/V1?@SI_CC4=?\ AOI7C+XE^/?"7P2^",?Q6\;Z7\/OAOK/Q@^(
MK7R>&1XS\9:G=6T.D>"O#6D:5XA^(7CFXTTWOB23P+X-\20^#M'\0>+)-$T'
M4_ /'?[#WQM_:9^$6I>%_C#_ ,%)OC]=6/Q"31-9UNP_9S^&7['_ ( ^#^W3
MO$%AXLTJT\ VGCO]G[XY?%NU\*I>:?IT"C7_ (]>,-4U;3+417VN3Q7M]'<Y
MOCCP?X^'PE^)'AW]I/\ 9D\&:GI]U81036_P?^(6G_%WX7?%.,V5SJ%_::U\
M//C1HG@;Q%HESL6:PT[0)4\6Z;/J0$]QXALM/5+@?-W[ W[+'['NA_M-_P#"
MV_V8M$^*_P"SKJW@+PUXLN?'WP6T#PS\4?V>/A;XQLO&!O?#&@M\2/@I>V>A
M_!_QG)I]I;Q>,?#'B;P;I-W%INLQ6KKKEZ;%!&0S'"3EAJ<ZCP];%QG+#X?%
MPGA<14=+F]I"%&O&G.<Z:A*4HP4FZ:]M'FHN-1O%\&<0X>EG6+P^"AG&6</U
M<-3S?..'\5AL^RC!0QJH/!8G$9AE57%X?#X7%2Q-"A3KXB5&,,=4_LVO[+,J
M=7"4_P!1_B'X9\*?!A/B#^TCJ.JS6OA[X8?#SQEXZU'060)96EAX2\%:E/?^
M7J,L\S6FDVVBV-P+738;18=."0PV<D.G6L.GK6UGQEXFN/V0]'\8_%G2]'M/
MB!XB^#O@RX\;:9HNF7":)I7Q$\7^'M&M-9&AZ3K%QJU_!INB^*-6N;C3K2_O
M-0O[6RLHUNKRXGBDN&ZWXY_&"+X:^%/ >H:/HMAXWO/B=\8/@]\)=$TIKY4T
MR_LOB7X[T70_%&LO>007ZS6OACP!+XL\8"*.VN8M0_L%;*8PVUS-=0<?^T)K
M-Y_PFOP0\*:F;;1? &J^+Y_$'BKQ7JI-OH@N?"T<%WIOA6_U1[F/3].37[>X
MU)(XM62$ZG>QZ='H]R]S:7MNU4/]IS*O&&,CRX3 0E4PS7)34Z\JE6-1UF^2
MM7G3PT:=##TTZE-5'.?N8B#C>*PDL!P9EU;$9%"E6SKB/,98;/JV*IRQ57"Y
M#@L'AJV68;+5%5\'A88O.*E;%X^LY4<RQ%&CA<.HU<FQG,VP_9'^$\WA;0;:
M^T&?PYXPM_#UA8ZSXH\#:QJ/AK4KC5&TU8-7NO\ 0+C^SKI;J[DN7*WMA=QO
M&XA=9("\;_)WQWTGXE?LVW/A74M*^,^L^.;GQ!J6I7FF>&]?\%0ZA>KIGA"Y
M'BW6M8U?7[.6XN+BVTRZOH=4UJ^2.TU&=C!?FVNK;2Y9M._5RO"/C#/\&/$N
MC>(_#?CAOAIXG\0>&-"U3Q!;>%/%&N:=;:KI\MOI+ZI%._V47GB;0+6\MX('
MNM1TS3Y;EM-9I8[>]CVP2]A\F?&GPQ^,OBGQCHVG7;> M1U#P[=>+;CX;0>(
M/!EY_:L&I7&D>&?!UUJ#V/AS6K;2O$ @?P)X4UJZM/M=F-[ZUJ$MZ;)[2[MA
M]Y:/\9/A[J[^0VO1Z/>J#Y]EX@BET>2U<$_NI[JZ5=-\U@,K'%?2LQ(4#?E1
MX+^S!X0'A_PM\(] ;R2_ACX7S>/]81+86[/X@^,FLW%_H4DYV(SZAH.@Z/XC
MT*<N9'6UN[=&V0BTW_66K^'M!U^,1:WHVEZLB*RQ_P!H6-M=M"'!#&!YXW>!
M^<AX61U;#*P8 @ \M^%LD7B'Q)\2_'"2V]Q!J7B./P[IDL)\R-M.\-VL<$=W
M;2_,IM]3@GL9G*.5DFMRY50$S[57C?P\C\-^#?#GB?5;86^D>'+OQ?K4FE0I
M<7-R)+;3F@\/P):BYEN+NZN]3O-(N;BVMHS)-,]S%!;QD"-!Y3\1]<^.GPV^
MU?%NX\8:/J7@+3+7SKSX3WFA6%OJ,UUK5_-8Z3IT7B72]&O=4\_39M4TM+BY
MBFFB9-+GN9(+F.299 #U7QE;IXA^*/PWT K-)!H$6J^-]2C63RXE2T,5IHEP
MPZN\&M1PKM .8II%.%9C7CGAC]G?X7? +Q[H^L_!B3QIX7FU2WN]!U#X>3_$
M_P"(_B#X1:3IWB.:SMH/$=G\./$7B/6O"WA'4%US3=$LK-/"-GX8_MU5GM)E
MG^S->Z?T-OXM\3^'O%'B[Q7XP\#ZEH&J:MI_AW1](NF2;7/#?ARSAA9]5:^U
M[3DB@N[>2Z>VO%M[.,7%W<6ILV>P):X7T33]7\%:WX=U73_#?BG3=8\1ZC&=
M26ZN[J&WUG4_$%F([S3+V2RN5MK@1VU[;68M;:WMTM;&VABM;9(8XU YZV$P
MN(JX>O7P]&K7PLI3PU:I3A*KAY3Y>=T:C7/2]HH1510E%5%%1FI))'L9?Q#G
MN4X'-LKRS.,RP&69]1HT,\RW"XW$4<OSBEAG6EA89G@H5%AL=]4E7KU,'+$T
MJDL)4JU*N'E2J3E)^":CX8_:5T;Q_I/A#Q/XX^"GQ ^$GQ#\:7]W??9O OC#
MP%\8](T6S675+:WEU >./&_A#QV^E26^BVEY?1:-\/8K?2DE>STR.*VM].??
M^)?[20T+6]=^&'B'X)?M >'9]?U5?!'A'QX_P\A\7?#'Q=/KKP:=:ZE;^,?A
MGKOCN'P3IEXMY*EK<?%BR^'T\5S"8;RTM7> 2^P:?-:^,/B3IVMP,\MAX5\(
M6]W:*793:ZKXO@2X1VC!*,MUH,@4D!6\R$$DK&E.^(#B^\5^ M+FO8;/2-'O
M;SQKX@FE9$6W@T&$MI4TKN55;:6[-U;S%F5%#+(0SQQJ>=8*M1@HX3'8BG;$
M^WDL6Y8^,J<E%5,-S5YK$QI:.=)QQ*E2J2WE12HGL/B;+<PQ%2MG_"^4XOFR
M6.5TIY!"EPE6H8NA.I/"YRJ.586635<=:4,-CEB,FJTL?A::E*-',9SS)\AX
M;TOX,W5UK_PXU34/ ^H^,?AR[C7M-AUG3+7Q;IFAZA96FOZ1J&MVEA?0:Y:6
M!T?6+-8+O452"5$,L<A+LQK^'_#DUS\6=(DMKC6%\->&M#O=9TW3M<O;F_:"
M74EDTN(16MS&K:,;F.:#4K:SF,MZMO;0W%U)!=SS6-EA>+_V?O@S\9OB;X=\
M=?%'X/>!_$%_:6UOJ_@G6/$/A72)/%^G:OX/O;>32];.O/91^(]'NKFUU>5K
M+1[?4HXSIVF1-K5N;F.&QT_G+OX:?%#XD^,O%?Q9^%/[1WC?X2W4^JQ^&$\+
MR^#?A[\0?A3XGTKPMN73]9U+PWXD\/VGC.TO[M;V2WN+OPG\1O"3W,$$<5[%
M-+! ]N3KYA05><\%'%QC62PT,#7I+$U*$G*\JM/'2PF'ISI>XI<N,J*JG*<5
M3:5*1ALKX1S.KE6'P_%%7AVK5RZ<\XQ/%64XVIDV#S.A"BE2P.,X5H\0YQC<
M+F$OK-2DZO#>%G@)1H8:M4QD)U,=3^U**\'^+'C;X\>")] NOAM\#=&^-V@-
M8W!\71:3\5=(^'GC^TU)'@%JOA/PKXUT)/!&N6-S%]IDF?7?BWX3N+.40VZ1
MWR%[JG^/?VD/A'\'_#W@?Q'\;_$]M\$[7QU:1RVJ_$F2TTRQ\.ZB+'3[V_T+
MQAXLTFZUKP#X=U32GU&*RN9KKQ:VC7MY!=_V)JVK6MN]U53S+!T7B5B*D\+#
M"*FZ^(QE&OA,'%57%0Y,=B*=+!UKRG&#]A7J<LVH2M)I&.%X*XCS&GDTLGP5
M#/\ $\05,93RO*.'<SROB#B.K+ PK5<3]:X6R;&XWB3+%&AAZV)IO-,JP2KX
M6E/$T'4HPE->JZWX4\,^)$*:]H.E:KF-HUEO+*"6YB1@ P@NRGVFW8A1\\$T
M;C PPP*\JUKX5KX7T?5+_P"&NJ>+]$U*WMY;C3_#^EZXUSH][?; B"XT_6C=
M1S;L[G9[D.%#>6"XC4>NZ!XAT#Q7HNF^)/"VN:/XE\.ZS:QWVD:]H&IV6LZ+
MJME+GRKS3=4TZ>YL;ZUDP?+N+6>6)\':YQ4/BG7K?PMX:\0>);I#);Z!HNIZ
MQ+$K;7G33K.:[^SQG#$RSF(0Q*%9FD=5568A3VQE&<8SA)2C)*491:E&49*Z
ME%JZ:::::;33NCYFM1JX>K5P^(I5*%>A4G1K4:T)4JM&K2DX5*56G-1G3J4Y
MQE"<)Q4H23C))IH^:?A?\1OC+XFLO$EW#IFD>+5\*^*[SP=K.F:B%\+Z[%K.
MD16TFIPVER;2STEH85NH \L\4LGFR 1J51U;U<?%RUTL*GC;PGXK\&NHQ/>W
M.F2:QH2R@J#'!J^D+<&XY;A_L42D8)P6 -/]GO09]#^$WA9[V8W6I>(8+CQ9
MJ-](@CGOI?$EQ)J=G<7*#A+E=)FTZVF3AE>W*N X85[20""",@\$'H1Z&F9G
M-Z%XP\*^)@/[ \0:3JLAC\YK:TO8'O8H\XWSV)=;RW&>/W\$9]N1725P6M?"
M_P"'^OF1]1\*:3Y\KM*]Y8V_]EWKS,V\S27FFM:7$LA?YB99) QR'#*2#SDO
MPV\3:4"?!GQ-\3:4G_/AXBCM?%U@JHI$=O:#4E2>PA&0&97N7QDX)"; #V"B
MOA7]H_XR?MG_  F\/Z&OP&_9L^'O[5/Q#N]>22^\!VOQBL/@?))X(M](UR:]
MU6V\2>.=-U;0;?6I==M-!TR*"[=+.*TU+4K^-;V;3(-.U#\Y?!'_  <4?LCZ
MCX+^)/BWXF?#GXO> -/^$L]WX;\9^._!MEH7[07P#;XI6VG)?CX1^&_C/\$]
M3\61:YXXW7FBV]Y:2>$--MM-'B'1[N]GCLYYI[< ]S_8V+?'_P#X*<_\%&?V
MI;B&QU7PO\$8/AY^P-\&_$]K.KW=@O@)3X\_:2\"ZK#&"D<^C_&!]!UBSS*T
MHL];5I8XC*%K]<?%/A/PMXXT'4O"OC7PUX?\8>%]9MWM-8\-^*=&T[Q!H.JV
MC_?M=2T?5K:[T^^MW_CANK>6-NZFO\^+PC\"OVVO!?[)/[8?_!03X ?\%GKB
M#QCK'[,WQ@^._P 3/V'?@+XA;1?$'A?QUXU@U&S\>?$3QMX/_P"%E:S<>"_&
M^G_#W2K7XS7'Q7A^&NC_ !OTK6-.C\'^']<T[2?#%EKVO_H;^P7_ ,%2?V3O
MVF/^"A_["/PM_8ST?_@L7\,;_P 1:]\;O$OQJA_;D_:'^//Q:^ /Q,_9WT?]
MDWX[ZO%J$FB?%[]L']I?1['Q/HWQPTWX+:UX6\7>'?#?@^P@M_\ A(=*NO$L
MAU;3-#OP#]\OA5_P3#_X)V>#OVU8OVU?@A\-O OACXY_!;P3XE^ $_A7X9:C
MH%C\-/AEK?B[3/#_ (GU._?X6Z# =)^'7Q=E^'7BFTTWS]+C\-SW_P -/B,T
MFK:'J=OK>A:K;_I]7\[?_!L8OQC\;_\ !.?QC^U7\<_'>K_$'QU^W/\ M??M
M#?M12:QK\LDNL6NF37WACX$VFG72&TL+6TM//^!EWJ>@Z?I-C9:+IWAK4]&L
MM(L;&P@@LK?^B2@ K\Z'OA\7O^"EUOIOV/5+CP[^R'\"[V]:]DTV\M[#2_BY
M\</[.@@CAU.2%K*\M]7^%5U= 00313/?Z5=!A,-+D$/Z+U^!'["O_!5[]AOQ
M]X\_:5U6X^,]M_PGWC7X[>(8YK#4O#.NZ5XQT#PMX=O/^$5\(^#/&?P[N;,?
M%7PIK?A#4$\0Z+?R>,_ 7ABUC@BBN8FDTWRM2N@#\7%^#7_!1/\ ;]_;9^)_
M_!-?_@J9\>_VA_V;O@W^U_\ %;]I+X^>,?@2TGP(USX%_%WX!_LS#]D;5_V;
M_@M_P3^^-NL_"*\\1GQ/X8\<7'B3XB?&.Q\*3:#XCNO@[\-=,^('Q5^'.E?%
MOXD?%#Q)=^N_\%5?V=_VR_V+_BI=?L[_ /!/']JS_@I+KVC_ /!1SP%\?/C=
M8_!SX6WMK\=/CAX?_:E_9^?]C#X3Z3XD\0?MH_%:U\2?M.>"/V>_%_PAU;P3
M\/=?UWQ5\<=(_P"%,WO@S2=8MO''BOPYXDC^$%Q[G_P4[_X)H?M2?\%%_P!N
MKX8?M,?LC_M<?!WQ_P##'3?A[X9^#UA8>*/B?XVT'XD?\$Z/$.J>,M+USQW^
MU5^R3;?L[>(_@_K<GQ<LK#P[X<U:/3OBWX\U[6?$WB#4-8\#^,!J?PPB^'>A
M_"@\"?\ !$3]O7X9?\%3/AI\>?#/[4=MXX_9_P#A#\4O 'Q0\._M<_M'_&'X
MY_M"_P#!0+5_@I8Z5XGT[QS^P%J \?ZWJ?PL3X#:]<>,?BE')>>'=%\!:O:R
M?$OPS\5=5\4_$+QO\.K#P-:@'Z6?M7>!/C)^U=^PE^R]^Q=^T9(?AY^T%^VA
M\*O!_@C]J?2= N/#.HS>&-1'P:LY_P!I,>&;SP[-K7@N^U/P#XTUW^W?#USI
M)UKPA/<>'H+JSEN]*%M-)\=?'CXR?M >$?V'_P!BA?VC_P!@.P_8KN?V1/BW
M_P $^_B+\1/B5KWQ7_97\ _"3P-XO^$OQ3^$_AWQQ\*OV$OA_P#LV?&+]H#Q
M)J>K?'?PG>?$C]F/X=^!?B7#^SE\,=%^$?Q>UFR^(WQ0T;P;;>)-.N?TJ^+W
MQA\/>#_VE_C;\;_$UAK_ (K\&?L2?LY&[F\%>$[33;[QKK/Q1^(T,NMZ+HG@
M&WUW5?#V@WOBSXB^&)U\ ^'M+U/Q!HNG7OBAM+M]6UW2;-VN8.4_:M^-'[)W
M[4WPAN?@7\3_ (G:?^R_X\U#QAX$\5^ ++]M/X)^*/ASX6U'XA_#;QKHOB[1
MM#N?!GQWMOAEX'_:%\$:]>:-+X3\;^&?AYX[U2S\4^$=8\06?AWQ;I&J_8O$
M&E@'H7[*G_!1OP3^U-\4?B1\%-8^"/Q7^#GB;PGXP\?>!=#OO'4WPV\;?#KX
MFZC\-O#OPXU_XD>'O#/Q#^$?CGXA^#'\7^!;'XJ^%K7Q7X6U#5(K6]NAXF@\
M!ZYX]C\!?$:3PAA?L^^#O@3^R'^V=^UC\,])\$?"CX%V'[1WA[X??M-?#JX\
M,>$_ WPOT#QSI'P[\%Q_#;XX:-;KX=T_1K;6]:^$NNZ3H7Q-\<:GK1;48M.^
M/^FW\<D^GV6JW%C^"?A[X,?!G_@@E\-_A1_P48_X*$>&_!6AZOX.^)GQ&\$_
M#;X3?\$V_$GQ/\6^!?C-\<OVGK#XE>.];^+GB7P?X]OOV8/@%H=CX$^%5U\8
M/A_\'OAC:_"_2]#^&WPLTRPA'Q4^*7C"3X9^&_ W]4OQB^"'[.O[:7P53P;\
M9/ GAKXO?"'QYH,&O:7'K$.I:==6]CXD\.W5K9^*?"/B*PFT7QEX#\22>'-?
MOK?3_%7A;5?#GBW2+74[R.SU*PDGG! /YG/^"0=]\8/VW?\ @HM=_MD?&_QW
M\0?B'IWA7X*>-/VE_!G@#XBZ_'JUA^R5KO[:GB34/^&:_AQ\'=$M8XM,\)?#
M?QY_P3ZG\ >(-7A2!]=\0?$6T\7^(-6U;4'U*<O]M_MV?\$M?C#^T+_P4XL_
MVV],_9W_ &!_VM?A)%_P3PM_V0]/^$'[9?C_ ,=>#[KP1\88_P!H'Q?\6[3X
MY>%XO#W[*G[1%B;CPUX9UJ/POHE[H>M> O'1D\2>*%TSQ3X6AM8+O6_S0_X)
M0^-O@%JGA/\ ;8_::B_X*EZK_P $X?@UKW[4ES\)_@E\/=-US_@GGX!TS2_V
M7/@;X,\$>"?@3IWB35?VQ?V<_C5\0IH/!&J>)_%OPE\,W%WXET>PGA\,0I!I
MOVR^,$'Z?_\ #3/['G_2T=_YL%_P0H_^@9H \:_9R^&WBSX-?\$9O@1\(/'O
MQ)UKXR^.OA3_ ,%F?A?\-O&GQ?\ $AU(^(OBMXL\#?\ !S)H?A?Q'\2=?.LZ
MUXDU@ZUXYUC2[SQ/JIU;Q%KVI&^U2<WVM:I=>;?3_K)_P2=_Y19?\$T_^S /
MV-__ %G7X<U^4'QJ_:R_X)A_!/\ 8I^&WP-^&O\ P5"_9@^/FKV?_!1_]C7X
M_>*_%WBS]K']DO7?B9XEU'XA_P#!8_X)?M<?M _$+Q-I?P=?X>>"=+\/^&+G
MQ5\1O&NLS>%_A]X6\*^!_A[H-S?7]O9Z1H.H:F/U?_X)._\ *++_ ()I_P#9
M@'[&_P#ZSK\.: /O^BBB@#S_ ,1^*=2M+L:/;Z9?:*MW/'9IXOU6"*;0+87$
MMM");=M.EU!_MSM<^7I\&O1Z)837B".6Z<A+>X\\\8:=\&=>\<_![X'>*H[S
M4_%OAR&Y^/OP_P!#C.MK;0_\*8U7POX;7Q1X@N]+\G2I7T[7OB3H5UI6G>(W
M-OJ^N(^L:?9W&H>'&N+'K]-\5^(/&/\ PEEEI_A+PY=:7HOB37?!MXNM^*KZ
MV;43IICBN)6LK?P9JL"VMW;W,>89+J1@6EB;>BK))Y]\*O"/@?6OB?XM^+5K
MXFN/$?Q&\(>$M(_9H\4V%IJ:ZEX7\(GP9K>J?$.YL],EG\.:+J$_B?7;7Q[X
M9/C2_>[O=/E7P[X;TZWL].U32-<EU'AQRE4CA\/&&%J+$8FE&K#%<LHO#TFZ
M]=TZ+:=:MR4N6FE=4ISC7G&4*4HOZKA5T<+5S?.*U?/<)+)\DQ]? 8K(?:T:
M]/.,;&&5Y4L7F%.G4CEV7_6<=[;&5)^SEC:%"IE>'JT<3CJ-:G]*T445W'RH
M45B7?B7PYI^H0:3?Z_HEEJMR8%MM,N]5L;;4+AKF3RK806<TZ7,IN)08X!'&
MQED^2/<W%;= !7FMYJLOA#7);#3[.[\0VNMSS:LV@:1$9M:T6YNY6-Y?H)/)
MTU-$U.]$US))JNHZ8\.J27ILY=16X-MI_7V?B;PYJ%_-I6G^(-$OM4MS,+C3
M;/5;"YOX#;2>5<":SAN'N(C!*1','C7RI#L?:W%<MI]IXUTFXUJ6#0O"E_)J
MFMZE?OJ-UXMU6QO+JT:YDBT>*YMH?!&H1PG3]&BL-/6*.]N(P+=I ^^63(!W
M\$C300S/!+;/+%'(]M.83/;LZ!F@F-O+/;F6(DQR&">:$NI,4LB;7:6O/?A9
MX\_X69X)T[QC_97]B?;]3\4:=_9WV[^TO*_X1OQ7K?ACSOMGV.P\S[;_ &/]
MN\O[*GV;[3]FWS^3]HE]"H **** "BN*\2?$KX=>#KZ+3/%_C_P5X5U*>TCO
MX-/\2>*M"T.^FL99I[>*]BM-3O[6XDM)+BUN8([A(S"\UO/$KEX9%7G_ /A>
MWP0_Z+)\*O\ PX?A'_Y<4 >JT5Y5_P +V^"'_19/A5_X</PC_P#+BC_A>WP0
M_P"BR?"K_P .'X1_^7% 'JM%96B:]H?B;2[76_#>LZ5X@T6]\[[%J^B:C9ZK
MI=W]FN);2X^RW]A-<6EQ]GN[>>UF\J5_*N(989-LD;JNK0 4444 %%%% !11
M10 4444 %%%86N>)_#?AB".Y\2>(-%T""9BD,NLZI9::D\@P/+@-Y-#Y\I+*
MJQ1;Y&9E55+, 0#=HKP?6?VAO ]A='3-'M/$?BG62@:/2=+TA["^E63:()K2
MR\12:+J6M6DK/&?/\,V&O.8F+PP3,!&V2/&7QX\6 CPSX!TKPC9R?+#J?BB6
M\=)HV#,SNNIIX=\2:'>(K1;4N/AUXCLO,\Q?-G"$  ^CJ\[O?BW\,;"\U#3)
M/'GA>YUG2[F6SU'0-*U>TUOQ%9WEN\D<]I-X=T:2_P!;6Z@DAECFM_L!FCDC
M='174BOF77=%\<W/Q'\-^!?B=X\\2RZ9XLL0=-N?"DD\K2ZM-_:]P-"NM,L=
M&L_"FJ:1I5CH%Q>ZOK>M^ /*B75-*-S)81VES>W/MOA7]G#X,>$)+ZXT[P-I
M-Y=ZI/!=ZI/K,9U2WOKRVDFFM[LZ-<Y\/6,UO+/-+;C2M(T^&WDD:2"*)V+$
M QY_VB-'U*X>Q\!^%/$OC6Z626 W%M9W4&G6EQ& ?(UFWTRRU_Q?X?=RT>U]
M9\'6< 617DE0$9C%U^T;XL ,%CX=^&]C+'S]IFT^YUVUD?E);6Y,?CG3-7MU
M&"UMJ/A_PE>G<1(8) 8T^B(+>"UACM[:&*WMX4$<,$$:0PQ(O"I'%&JHB*.
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M_P# ;]H/]H']H;3OBOXW\>_#RXT7X??".^^&'A#0E\!7OAK1O'\_@C4_B?\
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M2W65XHYI%2)P#SS]EC_DB7A[_L9?BA_ZM7QM7T+7SU^RQ_R1+P]_V,OQ0_\
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M        8IU '@9^!?\ ;E\FH?$#QWXF\8S07C75I:H4T72X4F*&\MEL4FU
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M>LVCW'AKPQ9*\[V&L:V@G34+#4(29;N!Y8XXY4T_3X&AMD\F\5>#]/\ A?\
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M\<RM>"[MY"VQ8KWPJC6LRJGF,\*[G5$"2?0M?"WP.^/OPSLM5^(<OCW6-1\
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M&TLH-/\ ^"B?@7XU_LHZGF>*.>32?V7?B+X;M+V"=[#PYJVC:M.\EKF>&_\
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M;\.^)=0BM] U;XT?$OQ=JMII_A:\\1Z?%K&L>%?!'A71O'OQ.U_2]&N-9M_
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M%":AXA&_XD_$CQ'XL+@_:=,M8HK/0+O?N+"ZT/6IO$FD13QARD5]X=TWPQ*
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MOA3?:;:3AA%K/C));=K1BNZ&6]T*^NO"-M?6,JE&6\\,>+/$ D#@Q1/$&G4
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M-$LMORK%HQB7Y8@3[[7SCX:!\)_M">,]#(=+#QWX?L?$EG\JK:6\]J\SVEA
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M!\._!WBZX@C:.TU'7/#^FWNKZ>KQO$S:7K4EO_:VE2F*22(3Z=>VLPCDD19
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M$EYXEU3119_VQK]O!--%HMKHMCJFLV.G>';IY]5>^O%U/6HM'U'2K33T]DH
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M3]0Z .:\9:"?%'A/Q'X=28VTVLZ+J.GVMV"5>RO;BUD2QOHF )2:QO#!=PN
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MEX!^&4?ERGXB>.=(M-6LW($DWA/0IHM5\07%OR&:?3I1I5XJ* "D<C.ZHIR
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M3>&;2#XF>#K?P_<QB:VUC4]9\.)!J6G0S6[)<B";0#,+>1)@&22,N =;\=O
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MA_6M:T"XU/P?/K=MHGBNTO-1\/ZAIFJQZ?9Z%K%]KLL=O=HLMQH]LLP,6\@
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M/;FXFM_LK21K& 3?"[Q5+XW^'?@WQ3=-&=1U?P_ITNM1Q1O"EKXA@A6S\1V
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MP%J6EVM]J[K<BTO9+=K.VFG(0 ^]**** "BBB@ HHHH **** "BBB@ HHHH
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MOP$^&NMF66+2)]!NY9UG:[T"\ELBA7=F*"QG%YI%O"Q(8K;Z=$RE%\MD&X,
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M("1UWKGW'3K"UTK3['2[&(066FV=K86<*_=AM;.!+>WB'M'#&B#V%> ^)_\
MBJOVB/ &@#<UE\/_  KK?C6_1DWV=W=ZO+%I%K:RD@A-1TF[CT'6+,?(ZPW,
MKJ75F5?HJ@#SOQG\)/AC\0UG/C7P'X6\17-Q;"T;4]0T>S;6XK=2I6.TUV*.
M+6;';M 5[*_MW5<JK!20?&-4_9QU_P ,6XG^ _Q?\=_#6XL[5K?3?"NM:M<>
M/OAY%'L(,,.@^+3K$NG22L2S7T<U\;<G?;V08"OJNB@#Q;X3I\?K/[3IWQF/
MPTU:WBM6.F^)/!-[KMMJMQ=0W$<8BUK0]1T2TTQOML#S70OM+O+".S-O#:MI
M-PUW)<V>KX4^+F@>+_'_ (Z^'-CHWBJPUOP ;7^U;[5M'2VT._CO#B"71]2@
MO+H3+("'B2^AT^>YAWSV<-Q#!<20^H32Q6\4L\\B10PQO+-+(P2.**-2\DCL
M2 J(BEF8D *"2<"O!/V<XIM0\%ZSX\NXIX;SXF^-?%'C-K:[4BYL+&XU%],T
MS326W$6UM:::L]HF]U6*[W;M[O0![HE_82WDNGQ7MI)?P0174]BES"]Y#:S3
M7%O#<RVRN9HX)KBTNH(IG18Y)K:XB1B\,BK;KYQ^(G[*GP;^(^N)XHO]#N_#
M?B87+WD^O^"KQ?#6I7UY+<_:IKW4&M;>2WO-0FE,AEU.:W;4G$KDW>\1O'2@
M^"7Q3\)1Q#X=?M&^.Y(8V:XN=+^+>EZ)\3[?4IXU<P6BZP\&@:]HM@Y*QSBP
MO)W5<RQHSHB  ^FZ*^:8_'7[1_A(Q)XV^#GAOQ]8*TMQJ'B#X.^+5M[BSL4/
MRQ0>"?':Z?J>IZEL!<06.O2),S+%&P8%C:L/VI_A']LL-)\7WOB/X5^(-17?
M#H'Q4\*:YX,NXH2ZQK<W&I7UI)X;CMG=\+<#76B 5V=U52U 'T916;I.LZ1K
M^GV^K:%JNFZUI5VI:UU/2;ZUU+3[E58HS6]Y9RS6TRJZLI,<C ,"I.016E0
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MS!AM_<I(">A(()[2N<UWPAX8\3(5UW0M-U)BH47$]LBWL:J00L-]%Y=["#M
M80SH&7*-E"5/+_\ "M8--^;PIXC\0^&#&/\ 1[*&]?4=%C?C,DVF7S,UT_ _
MUUV5P2""#B@#TNBOEOXA?$OXH?!>U\.2:M8:%\43XH\9:1X2T>PTZX7POXGO
M+C6IA;6\J(]J^AH$NFM;58&.W[1?0?:-1AAW2IW%E\8=5:.1-9^#/Q?T:_@E
M,4MI'H.C:[;L/+BD$UKJF@^(+_3[F!C(8PRS)*LD4BO$@"LP!WOB'QKI?AK5
M_#NBWUKJUQ=>)O[7-BVF:>^HK"NBVL%W>-<V]L[Z@P,,ZF);&RO7.R0R)$B;
MSL?V_HG]E?VW_:MC_9&/^0A]HC^S;_.^S>3YF[_CY^U?Z)]FQ]H^U_Z+Y7VC
M]W7C$>KZGXY^)7P[U.T\%^-M!T_PI#XQGU:\\5:&-%M]FL:/!I]FMI(]W.MU
M,;I51[>,_: DGGI$]O#=2V_H2^%91XXDU@I'_8)LH]46R+1F+_A,SOTU]9%O
MM+BX704CM1+N6+>[S>6]T3,@!=\.^-=+\3:OXBT:PM=7M[GPT-(-ZVJ:?)IJ
MS+K=K->6;6UM=.FHIB&!C*M]8V4B[XS&DB-O'7U\WZCKGBOP%\4O&NHP?#SQ
M)XIT3Q?_ ,(=*NI:'!<77V2TT?2CIUX\<5K8WD-Q>":2Z"6%Y=Z7*?LT,C2)
M:WL%R.P_X6]_U2_XP?\ A%?_ 'SH ]@HKQ__ (6]_P!4O^,'_A%?_?.C_A;W
M_5+_ (P?^$5_]\Z /8**\BM_B3XCU>Y%KH'PL\9@B/?/<>*H8/"D$1+;5,3W
M3745YM&6>*.>*?H%C()=7ZCI7Q3UBQO&N?$.F>&U6&26*S\*:>-0U2[14+_8
MOM6LW=C#:WTN##%<V^H0P++L9I8XB\B@'HNM:[H?AO3IM7\1:SI6@:3;%!<:
MIK6HVFE:= 9&"1B:]OIH+:(NY"('E7<Q"KDD"N/NOBMX'ANWTZSU?^V]35=R
M6&A6\VIR3X )6WNH5&G2NI959%O=ZN0C -D#XZN?AQ\2OV@O"7A^[L+*R\):
M%<:UINLV?C+QY\0+CQ[XOFTNQG,N(/"'AK38/#,9N)(S:ZIX>\1>*;I[0BXT
MZZCM[RV+P_;_ (*\*6G@WPUHN@P?9+BZT[2-*T_4M7MM+L])EUV^T^PAM+C5
M[NTLE$,=S?RQR74D8>587G:-)&49(!R=UXK^(NK+"/"?@5+"*=EQJ7C.[^P"
MV4Y!%WH=N\.I*>5;?;7%SM =#$6VFG7G@GQ;XFM+NR\5^,Y;?3M0MY;:[T?P
MQ:164:Q3Q-#<11ZM/&+JX@FC=XW@OK.XC9"0P<,RUZK10!B>&?#^G^$_#?A_
MPKI F72O#.B:5X?TQ;B7S[A=/T:PM].LA/-M7SIA;6T0EEVKYC[GVC.!MT5X
M]>>.?'DOC[Q5X,T#P=X7NXO#.A>'/$%O<ZUXVU'1[SQ%I_B8:O;02V-K9^#-
M9@T\Z=J_AW6--NDN;FY6<&PNC-9+<&( 'L-%>!VGB1OBWXIN_":MKOA?1_!N
MF65[\0?#DL_]E>(KO7M:O]8LM&\,:C>Z5=3-;Z)!9:!>:]>RZ-JAM_%&G:OX
M;>"_N- NM0M=1\D\&_M!_#OX/^"K_P"''B&\\4:[XK^$U[K_ (9E\/>'_"NM
MZSJLGAC0_$U[I7A.]>_CM(?#EG#)X6_L><RZMK>FJ41P/WCP12@&#^RMXFTW
MP+\2/BC^S;/9:]::AX:U36?$&CWFMRVLG]IZ/8:I%HVD-YKRPW9EG\ 2?#^?
M2X(+.:WEL+#4[OS+2&.WAF^E=&^-?A77/C+XL^!]II_B"/Q9X.\/VWB34]0N
M+73D\.SV-U!X9N(XK"[BU6;4I;L)XJT\/'<:3:PAH;T+.PC@:X^,/"NJ:+XK
M_:PTKXT'P'J_AG2M:@T?3M+USQ%JRW#:GJ-SX>U+P)-?Z2/#<^J^$'FN)->\
M#:%=:1/XEO+^SB9M6MK2>2]N/[*_2^@ KR3Q+\=/A9X6FU:SO?%4&IZEH4&I
M7&M:5X6L=3\8:EHJ:/%--J7]NVOABRU9O#ZV26\S7<VNG3;:T6-Y+N:")'D7
MUNOCCXE>-?$'P??X_'P[X1L_&IU"T\'_ !1M_#H^W1 :-XCM#X!\=74UO8VT
M\]];:1<^#K7Q!K*VOD+;6_B:;5+V[CABN* -K2?VI;76_&?A;0+?X:>--'\-
MZ_KDGAF\\5^*VT[19M*UZ6/3!I=C_P ([:S:O>2'5+CQ%X7$(U*[T2Z6QUN/
M44M)X(XEN_JVOQG^ ?P"^+/AV'Q7;>,/!QT>\U3X8ZO\1OA"NI/I=YXAL/B'
MX1U3P;JFBW^DV<%S>ZEX2U.22\TO3M?MKVWT?6[N"6#398G^PWD-K^OWAO7K
M'Q3X=T#Q/IA=M-\1Z+I>O:>T@ <V.KV,&H6A<*2 Y@N(RP!(!S@D<T ?GU\)
M/AI\.=/^)OQ6TWXR>"]&\2ZS9_$[5] T#QEX]U^X\=:E<Z9<Z=8^(O!5IXPM
M]:O]3T>RGU[PEJ5I+X:U>Y@BGU>[TW6-!U'[+K6G6=E>8OP7\86OPC^(7CNW
MFUS1=/L?%$/PS^(#?#^XU_3X-2UEOB7X:MKWQ!%X8T>>XCQXR\*:V+>2R\,V
M,-OJ?B?PYJHMHK.]N5\)K!Z_\6;*V\-?%/XFZ;)8:-:Z9\?O@5(+&[NKR1]7
MUOXM?#?4&T+18-*MI;\&WEL?#WC'0M1/V*S6;.@1:KISQ76FZK+<?//Q0^''
MA;X/_%#P5J=SX6T]O$&H_P#"Q=.MO$FH27U_#XW\0ZOX2NY/A9XHL-+FN7TG
M1_%V@^+;5-*\2IIUG8V&GZIJ6B^*-.M+(:II8TD ^B/A)):>$?B[X6UF*31+
M32_VH/A5<^-7,9U"?6=9^(_AK7+OQC.22&L;*U/@?XB2JRJQCGD\.LB&V>",
MZM]=^*- L_%?AKQ%X6U$NNG^)="U?0+YH\&06>L:?<:=<E,\;Q#<N5SQNQGB
MOA3XZ:GX:^"?BCX0:GH7B[P?INB>%_BCH.JZKHUU-H^H>,O!VA:S::AX9^([
MZ!I")<ZU/X9\7:+JSZGXBL=-TY[G3O$NFP:Q8Q33ZE&^B_H10!\M_"4Z;?:]
MX.\:ZEH^FIXM^(?PNG\)>-]7N-)L[;5[CQS\*M5M="\2:==7GEF[NY-2N9M8
MAG2XE<W&G>"-+68"/3K2*"/PR6\-^*O@_=2>7FR;X@_L[ZW<W,S1W+KH9E\0
M^ K^[WND<LMYI?@*:2T9@TDDOC1$7=-=J%Z;PO9Z+H?C#XG:9K]Q)IFF^ O&
M2_&;0]2U.^BL]+TS1/B)X0URTU^]N+J?R;6+2X_$T'Q0N[K[2ZV]IYT=U+()
M+835)\59=%U7X=^+/$/A"WM;_4?#2^$OC9I^JVVF7K:+XDN/"TVG^)M,N-)\
M206G]D>(+C6_#_A+^PI9-'U&^GM=+OM/CU VMGJ%@TX![U-##<PRV]Q%%/;S
MQ20SP31K+#-#*I26*6)PR212(S))&ZLKJQ5@02*_,+X/>-?BAX8TCXF? [PE
M\*=3^..K>$?%^N>#-8\2^)-7TCPGX9B\,:-:1>$/#6FS0:I-<+=6DFA: TL.
MD#4K<Q6MWLAN+L%9KG].+*\M=1L[34+&>.ZLKZV@O+.YA;=%<6MS$D]O/$W\
M4<T3I(C=U8'O7Q]=Z#K7AS]J'XA:CX6?6;GQ'XQ^''A/XC:99W;):^$=:M?"
M%R? /C'P)/<2R"!-4U2T/@G6=*UE(C<Z#J8@>^E&B7-SIVL@'R;\$O#/QBD\
M?_$;X+I\75^$4BZ_+K6H_P#"/Z+)XFEUJ_U3[??7>@>'_%^NW-OJMO-I*V.L
M-%MU.2\N9[;Q#J!?5FL;V>OI#]G31K[X8_'KXO\ PW;4_&?B[0_$VAZ7XQTS
MQMXLU234GU+7_",]AH'CJ.6?[/'!<ZM+JWBS3X[MXY9+VTT_2M+AU.6Y>:UD
M3YCO_&?C;Q!\5_#&J> _A?J.LV?C[29]!M]<U;5KCP]H>LZQK/C._P#C?)-X
M4\336NFZ5X=^('P_O[_7M!L;JYU#Q');W>ERPC0KMD;2[WWZ#76TV3X">/=>
MM;B]\5>$_B=J=[K5Z;JVT'0]1^&O[2MUK.F1_$<+)#<*=-TO6M7\)6<]B)V;
M1K^TETB[F2QU#2-=< ^V/B)X5'CCP'XP\(!X(IO$?AS5]*L[FY4M%8ZE=64T
M>F:B=J2.KZ;J!M;^&6-&EAFMHY8@9$6N+\'>+M#^(.E>$I=7TP7DGQ3^%BZK
MJNF7-S/J?A5H=)-A:>)O#4NA7MS=Z5!>0WOC6?3M5W6:WNLVEK_9^JSW\&@V
MT-C[-7S3X.TF_M_$6L^'=->TDN_A?\:M:UF.SB5+.27P!\6M"O?%$T1#E8_L
MNG:[XRU,6J0%?/D\$16L,?RB-P"UHOB"\D^)G@'Q-=P3VS^/O#/C/X7^*(+5
M7.D0^.?A=KNI:MI,41EW2QQM!!\5WL3)/,\UHL#(TJI).WO&MZ-IGB/1=7\/
M:U:K?:-KVEW^C:M9-)-"MYIFJ6DMC?VK2V\D-Q$MQ:SRQ&2"6*9 Y:*1'"L/
MGSXG:7#X:TCQCXEM;VTO+OP1X\\&?'*#1+"Z2+5M$\/V\=EHWC26ZMOGDCL_
M$.@:-\1YK.Y,:Q7M[=:Q$KRM9W$2?2] 'Y^_"[PS=?%?PAH7A7Q#;^$Y_&'P
M'\%+X O=!NX8=?\ "<VO:-XZU_PT_AKQEID[ZG::C8ZIH_PJ\,ZGJ(:,SV5U
MJ>F>+- AMKBWT5K?V']E;5@GA7QSX"DT>/PU+\-OB=XOT>Q\,N6_M+1_#OB&
M_/C/1(-07>T$HM7\0:CHME?:>!I5_:Z*EQILES;%;J?YQ\7?#/11^U!X]\&>
M(_'7C/P+X(^(VG>&?B)9Z3\.O$-QH6GZCJ6NW'_")ZJ?'F_3)H$36_&.EW$<
M%T9I+9=1\2:39PW,.I>(#%:>@?!3PKX=^"G[0GBSP5X4AL](\!_$#2;K1_#]
MK-=ZKJ>JZCXQ^%>D>$]9U5I+S4)+@Q&6U^(/B<O"C0V;#0',"(RHDH!]T7-M
M!>6UQ9W423VUU!+;7$,@RDT$\;131..Z21NR,.X)%> ?L\74]AHOB?P+?/,U
MYX,\17EO&;@[I[NSN+J]TV_UB9B=Q.M^-]!\;:E$=BJ]K-;RAG:1]OT-7SC9
M*/"/[16I6Z[8[#XC:%!=GYF4W&M1Z=/)96D,6=C1:59^!?%NJ73JJE;SQ@KL
MY>X8, ?1U%%% !1110 4444 ?#GQN\.?%3XC?#'XJVGQ"\*>%],MO#WCZ\M_
MA6=,U)EO-:\,7K7_ (:T7Q)XE*:CJUK8)9-KFE>)9,W>GSR7.B7)OO#VDI96
M,E]\G6,.N>$?V;+/XI/XQTSQ9J&J>./"_P 0_#USXPOX[;7+3QIX2U/3-<NM
M2T4:MJES=^)7M]7U#QUX/\0:6ANI=1FGM/$]K;V DUN.Y_7GQ+H=OXF\.Z_X
M;NW>*UU_1M4T6YEC!,D4&J64]E++'AD/F1I.70AT(=00RG!'QU^SG\#?@O>Z
M!JNJZM\,O"]_XPL?$%_9Z^=<LI]>M[2]OH[/Q''86.F^();_ $ZS'A^/68_#
M?VG3[.W,EUHMV9)&N_M9(!]GZ/JVG:_I.EZ[H]U'?:1K6G6.K:7?1!UBO-.U
M*VBO+&ZC65$D$=Q;313()$1PK@.BMD#1J&VMK>SMX+2T@AM;2UABMK:VMHD@
MM[:W@18H8((8E6.&&&-5CBBC54C151%"@ 34 %%%% !17G'Q \=3>"WT&*.R
ML'37KJ\LO[5U;4QINEZ5<6\,<\!O7,$GF1W2&X"_O[8(T&-[&0 <9X+^*LUU
MX@U[3O&.K:#964&FV&HZ7JD45SHGA^:)IGMYVL;W7UM+J\6XGD,*22GRWETR
M[:S,L(=E />J*\7USX^_#716DAAU6ZU^[BN/LS6N@6,EWE@64RPWMTUEI5U#
MN 59+74)_,W*T2R(2PQ1\1?BYXC8CPA\+&TJVCND5M1\:74EHLUI-N\B=-/E
MDT.X!"+YL[6-QJZ1@B-0[-&T@!]!5SVM^+?"_AO<->\0:/I,@MGO%MK[4+:"
M\FMH_,S):V3R"[N]S121QI;03232J88D>7"5XY'\-/BKXB,1\;_%6YL[:.5T
MFTWP; ;!+NQE $T3W\,&B@2N-R*+S2]3CC4Y^<,R5T&A? 7X:Z&8I9-'FUV[
MAF>87?B"[DOB^[&(Y["$6FD7$:D$@3Z;(Q+$NSX7: 95]^T%X5EN'T[PAI'B
M3QOJKVSS6EOHVE7,4$TB!F>&4W,:ZI$(HT:26>#1[N-$Y&_#;:3:]\??%R_\
M23PMH?P_TZZ@66WO_$-T+W5('C(#QR0-%--"\[!MD5YX60QQXS+DK(WO5AIV
MGZ5:QV.EV%EIME$6,5I86L%G:QER68QV]O''$A9B6;:@R22<FKE 'SR?@EKO
MB,2O\1/B9XEUV.Z6&>72-(==,TFWOU WM%#/]LL);=%:2.$P:-I<GS&7$99H
MZ[S1?@_\-M"5OLGA+2[J1UB#S:Q&^MR,T0XEC&K/>16LCMEI#9QVZLQ^X%55
M7TJB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#"UKPOX;\1J%U[0=(U<
MK#)!')J&GVMU/!%*"'%M<2QM/:L<EE>WDBD1\2(RN P\<N/@BFA:T=>^'.I-
MX8N$M$@@LDNKLQ>>#-YMQ=7FJ1^)5NX)Q*BO8-IL<"B")D<.9&;Z HH ^8]'
M\&?'#P-%?77AS6/#6O6]]=WNM7OA_6MSWMUJ^I.JW+MJ8M[%[NY")#*US+K>
MG6\TB.QM5+%)-;_A='B;PUYL?Q%^&7B'2(K2*-;K6M""ZII,EU+L:-8Y)3%I
MT4+1O@F/7[^5)E,+(7WB/Z&HH \RT/XR?#77\+:^*].LYO)BEDM]9,FBO&TN
MT>0)=32UM;FXC=MCI97%T,AF1GC <^EHZ2(DD;K)'(JNCHP9'1@&5T925964
M@JP)!!!!(-<3K_PU\!^)VEDUKPMI-S<3S"XGO8(#IVHSS8(W3ZEIKV=_,"#\
MR2W+HY +*2JD>(>,_P!FVTNM%U+3?!NO:_I]CK-PHUOP]<ZU=1Z3?::K-*EI
M%]B-C=2O!,L8B34[^=98FD$MRK F4 WO@J#XB\7_ !D^(S>88=<\80^&-)+L
M);>?2?"%BEK::QI;AF$=EK=A=Z89HU\K=>:;))+")29)/HFOAKP%\/\ XT_"
MO6@?"MIJVJ^'+>VGAE\$ZGKENOAJWAN9H'AO-(2XU=X;/42+6[+PV-_J$< N
MXY+JU5YE@'L</Q_L=-DMK;QUX*\6^"KF[N#'')=6+W>GK;JRH]V9YXM,OIXX
MF+&5+'2[U@B@Q&5G"  ^@J*XSP_\1/ _B@PIH?B?2;RXN'>."Q>Y%GJ<K1KN
M?9I=^+7464+\P<6NQ@&*L=K8[.@#QK]H#7)]"^$GC$V,;SZGKE@GA72[6&4P
MW5U>>*+B+1"EI(K(R7,-K>W5W$Z.KH;8NAWJH/I'A;0;?PMX9\/>&K5S);>'
M]$TO1896&UIH],LH+)9G&6/F3"'S9"68EW8LS$DGYU^*GBG3-?\ B1\,?#ES
M#.OA?P;X]F\1^*]:;RQ!8>(= T(7O@^W@BMYY+^[CN-3U&XMKU19^7;20"XN
M0+40W#_36GZC8:M:17^F7EM?V4V_RKFTF2>%S&[1RH'C9@)(I4>*:-B)(I4>
M*15=&4 %VBBB@ KYA\6:#HOQ,_:$T'0/$&AZ9K_AWX;^"=3UF>#5+*TU337U
M[Q-+!8SZ1J>G7L$]M)NTV70-<L'F1]MQI[21".2#<_T]7SK\!A_PD&J?%;XF
M.-P\:>-6L-)N5):'4/"WA:W:W\.ZA&2Q596M-1?3;E$!"R:4J^9(%41@":M^
MRO\ !^YO[C6O"VEZU\+?$D\9B7Q'\*?$6J^![^VA9666&VL=,G_X1^.*96*S
M*=%?>ORDX+ T&^'W[1OA NW@;XTZ'X[TZ(+;Z?X<^,OA1#-!;!B3->>.?!1T
M[6]2OU!"B:\TB1'^\Z$*J5]-44 ?'^I_M+>._AS<QV/QD^ 7C32TN)X[#2_$
M7PUOM-^(.@Z[>->?88I(X_,T6ZT1-1EVRZ9I>I33:Y)'-!'+8I*Y"_36A>,/
M#OB+PO9>,].U*)?#E]8/J2:E?J^F1V]K$9%N'OEU!;=[%K22*:.Z6Z6+R'BD
M#X"YKIJ\$_:7N5/PCUSP_';P7VH^-KW1O!FD:=<-(D>I7VLZE 9+(/"R3+-+
MIMMJ#6YA/F_:$B"8)W* >]T5Y_;^!I/#WPZL/ /P_P!:;P4^BZ-IND:!K<6E
MV6MOIRZ<UONGFTW5C);:BU\D,T=]]IE$\INY[A+J*\\NY3P+1T_;3\&[UU=O
M@_\ &+3+:[+@I=ZCX(\9:I9RR-'''#<0Z/9^$=,>".-9YUGT^]*-<&*&YOMG
MR 'U[17R@W[5>F^%];@\*_%WX:>/OAMXB71F\1:I);6VG_$+PQI.AF6:VBU6
M;7/!5UJ.H263WD2V$DJ^'D^RWL]O%=+%&YF7VCP7\7_A=\1!;KX*\>^%O$-U
M=0/<Q:79:O:#7%@C#%Y+G0+B2'6K,(J,SK=V$#*@WLH7!H ^<=!\=2_#3XP?
M';Q?\4?"'C?P[I?BO6- L]$\5PZ1<:YX+M_!G@;2KG2M*NCJ5B)+NVO=9FN=
M0UNZTJUL;J:%KH1LA>$R2_3GAGXF_#_QB88_#7B_0=4NIXDGCTV._BM]7\F3
M/ERR:-=FWU6&-]K!&FLT#%'"DE& [FO,_%'P;^%WC);G_A(? ^A74UXZ/>7M
MI;-H^IW;1LK)]IU;19-/U.<*R@A9;MU'(QAFR <)^T8\NK^'/"WP\M3(9_B+
MXUT#1+S[,YCO++1;6_M[R[UNW?(PNCZL-!FN=K;S:RR[4E^:)OH2.-(D2*)$
MCBC18XXXU")&B *B(B@*J*H"JJ@!0   !7S!J'[-<MGK&A^(_ _Q0\9:#JWA
MFZO9_#UOXD:W\;Z#HEOJ-D]AJ&FZ1H^I&SBLK6_MV07$DLE],)[>TO(R+FT@
MD7<;7_VC/"P/]K>!O!7Q*LQ*0MSX.\03^&-5M[*, O=ZA:>(H9;>]O2H9EL=
M&B E8K'$0^%8 ^AJ^3_V8])BO=;^/_Q.6,A?'WQC\1:;I-U%-//8ZIX5\"W-
MUH^C:I9O<R32,+J_O-=6;9(+9'A6"TBM[:&*"-WC;]J;PUX7\&^++W5M"\:>
M _%MEH.LMX9TKQIX2U&!-:\1P:=<-I5O9R:='JD;V%QJ:V\7]H7ZV-EY#&>9
MXH5D*>K_  +\%'X>?!_X=^$)+:6SO=*\+Z=)K%M,_F20^(-40ZQXC4MM7@Z]
MJ&HLJD$HA5"S%=Q /5Z*** "BBB@ HHHH \W^(OPB^''Q9M]*M?B'X5LO$L>
MB7,UUI+7$]_9W%C+<^1]J6&[TR[LKL6UY]EM?MEFTS6EW]FM_M,$OD1;?!]8
M_8Z\*VJF;X5_$/XI?"*]MU:32[7P[XPU?4_#5G?2"%9[VXT?5;R35+MKJ.".
M.Z@A\1V,4Z(D;#R4$1^P** .#2'QOX6^'UXBWC_%#QWI6D:M/837<&B^$F\4
MZL&N[C2;*YCM/LNBZ3&=]IITMPGDP^5";N3$LCUYG\"[;Q'X9\"^.?$WQ$\,
MZCX6U_5_'?CSQEK^EQN_B6Y,*SA3+HUMH<-[?W]F]OIS+H]A96MQ=Z@JI/IE
MO<1:A9^=]$44 >4^"_CE\)/B'JL^A>#O'FA:UK-NBR/I4<TUI?R(UO'=,UM:
MZA!:37GV>*51>"T2<V,R36UX(+FWGAC]6KQGQI^SQ\$?B ]Q-XJ^&GA>\O;R
M\DU"]U6PLF\/ZW>WDSM)-<7NN^'9=*UB\>:1VDF%S?2K+(S/(K.23QY^!_Q"
M\-,9/AE^T'\0-)A>Y%Q-HOQ'MM,^*VC-#$H%OI=A/K2Z?XAT:Q  BD:VUN>8
MQD,"95#$ [[XY^)$\*_"?QMJC27$3S:/)H\$MFI>\MY=?EBT07MK&$D9Y=-2
M_?4CB*18XK.2:5##%)CI_A[X=D\)^!_"OAVX6);W3-$L8=4,./*FUF2%;C6K
ME-K.N+O59KRZ.UV3,QV$KBOD7XG0?M2:A<> [#Q5\-_!'COP[I'C>S\4ZY=?
M"G6[O3[BZTO1EF,FD7VA>.KNV9I+_1YM65;>WOK^UOK]K"TCOM/O?LJ7WK^G
M_M2?"P7=EI?C1O%?PEUO4)72TTCXK^$]6\'M+&C;/M7]LS177AA+-FR%N'UY
M4^4EMJC) /HRBL31/$WAOQ+:)?\ ASQ!HFOV,@0I>Z)JMAJMHXE:18BES8W$
M\+"1H950AR':*0+DHV-N@#YW^/ZCQ$?AK\+T,<H^('CJQ;6M/E4.FH>#O"P7
M5_$T04D@RVP?3KZ/?&\:_9FD8 HIKZ(KYXM'7Q;^TEJTHD\[3_A/X%L=.-NZ
M<V7BKQF[WRWUO(<C9>>&7FLIT7#>9:C>V%53]#T %%%% 'QS\18D^(/[5_P;
M\&-:66IZ3\,=!U[XGZV&O3%/8ZB5CL-&+VT<L4DLUGKL_@O5K53YBLCNQ1K=
M+U#]C5\;_LY+'XX^*W[0GQE<:1=V]_XIL/ASX8U&S>5[S^Q_"UG'?7;S9_<)
M%J-CJ/A))%B8O]JT62.:.-X3)<?9% !1110 4444 %%%% !1165K&O:'X>M3
M?:_K.E:'9+G=>:QJ-GIEJNW&[-Q>S00C&1G+\9&>HH \0\7^']93QO:Z#\+?
M$FL>"=<\3+<>*_&U];)I>L>&;#3(+FWLVU5O#/B'2M4L_P#A)?$ET)K"S.A7
M?A\74EOJ.O\ B!M8;2H;&^]WTZVN++3[*TN]1NM7NK:U@@N-5OHK&"\U&>*-
M4EO;J'3+/3].BGN7!FECL;&TM$=RL%O#&%1?B[XH>.?#=WXZ_MCP_P#%[QQI
MMCXB\'Z1X9OO#'PT\/>&;36/$K:3JOB#4M(UGP_\0/'4:6$T,*^)=1MWL?!*
MW6JW Q<)>?NTC3Q6#PW\9[/X@R7_ (.\=?$+P'>^(KC2M/\  MK\0+_Q%XP&
MH:9=:#]@\4S>+$^(WD?V;-!XBT/1KFVN[+P=JKP:AXNL;"SAN[&"S2P /U(K
MQSQ)^T'\&/"E]#I.J?$+0KG69]0;2DT+PXUWXQ\0)J*':UI<:#X0M=<UBUF#
M?NPMU90@R QJ3("H\3E_96UWQL]S-\7?BIXK\5VU[?6NJ'09=9OM4L-)U&W+
M,[Z5 (O#O@1K24NT:V=U\*RD,6Y(V\N5HD]D\,_L\_"/PM;/;6?A"POH9Y1<
MW5KJJ)=:/=787:MZ_A:-+?PC;W:KM59['0+1UV1L"'16 !XU?_M;:OK2RQ?"
MOX(>.O&-U;W5]I]]'K5Q8^'[JPNX(U:T:3P]HZ^+?%,<%V[IB76M'\.VD<;Q
MR3WT$)FGM]CX1Z9^T#XA^(^E?$OXM>'O"OA*-? 6O>$[W1M&A6WN"+GQ!I.L
M:')YJ^*O%EQJ;(MM>/*+]/#QTEKBXMX+6[:[GF;ZQMK:VLX(K6SMX+6V@01P
MV]M%'!!"@Z)%#$JQQH.RHH ["IZ ,FVT+2;36M4\0VUE'#K.MV6DZ=JM\C2A
M[VTT*34Y-*CFC+F#=9MK&HA9TB6>2.=(IY98K:U2'PKXS>%/%6C1/\0/@E\+
M/AUXP^+.H:WHL&LWGBVQLENY= L-,O[5;NRU*YUOPZ8=2L9DT>W1QJL1DTV.
M2-H;E[6R$'T710!\C_M>^ O$_BCPOX#\6^#+M+;Q%\-_B'X?UZ+[3?WT%DNG
M7]W!IES>-80'['>W>F7\FDWQGNO(N++18=>&GW:374EI??4>@ZQ:>(M#T;Q!
MI[%K#7=*T[6+)F!#-::G9PWMLS @$$PSH2" 0>PJ#Q/H5OXG\-Z_X;NW>.VU
M_1M3T:>6,LLL,6I64UFTT3HR.DL(F\V)T='21%='5E##RG]GG7;G5_AW#8:@
MJQ:MX9U?4=$U.VC $%A-/Y'B&UTFW"@#R]"TS7;'0F]+C3)T;:Z,B@'N5>*?
M$>WMM/\ 'WPK\07GV?\ LK7+CQ5\)?$44T&]+G3?'6CKK.E+/*B&0*_B;P7I
M&C6P+ +)XBE4%$GF:O:Z\N^-.EWVI_#'Q8^D[SKF@V=MXS\/+'$)I)?$7@34
M;/QGH-LJ'J+S5M"L[.3 ;]S/(/+D!,;@')Z*NJ3>%?A5JJQ7>JZUX \6_P#"
M$^(GBMY);^_M[6;5OA9K]]+'#$62Q_M,Z=XTO9A&ELNG:4FH%ULHQ+6W\$T.
ME>'/$'@=HIXC\./'/BCPA:K/()6&@R747BOP;&C8'[NW\$>*/#5JHZ9@8@(I
M$:=;8^)9]6M8;OPIX;GO]/UKPA'XOT'Q%=W^CZ3X5U/4-319M,T._GMKK5/%
MEC?7T4MO?W>J1>"]2TNVTZ1Y$O+W4XUTJ3B=(GM=+^-NJM926T^D?%'X?:?X
M@L[RUO(I[:YU_P"'&JC0M<FC$;NCRWN@^,/"$*/&0'AT"4J)/)G,0!X]^VSI
M6HV7P[\*_%7P^=&M?$?P?\?>'/$MMJ>JQ2S/!I>J7L.A75E:P)!-'=1W6NWG
MAB]U&UN7MH9;#29W6X-Q#!;7/SK\?/A)\0O$OPC3XA>+_CSJ_P 3K_8=?\(:
M)HNA6'A/PA93:/H6L>)-:O7L;5A+>7UAX6T+7H[29]/TC5K.]$D-X SWT+_H
MW\4/!R?$'X<^./!!33S-XH\+:WH]C+JMN+FQL]5N[">/1]3FB\J9@VE:I]CU
M*":&-KFVN+2*YM=MS%$P^#;_ %KQ-XL^&'PX\6>!?$5G;/XT\!Z_XO\ &6J:
MSH4-SX?\*_$+2+33_AQX[\:7NA_V?<0P:'XBO?%7BFQ\6/;Z)=Z59>7=>/H+
M&XA@UY=5 )-/^"?P1\6?!J#P]X)\#Z#X7^(?CP^"]-36-6AU'Q)J&G0>(8H?
M$4'C+P[/XEN[F_CT'6_"FD:OJ>F/I,^GNKQ:CHEZ;76M,UFSMOLGX >-F^(G
MP8^''BV>YO+V_P!0\,6-GK5Y?Q)#=7?B+0C)X?\ $EU(D9*;;C7M+U&:&10G
MG0/'+Y4)<Q)\%?LV^!_'MOJ5G$/&[^)?&GPO\3?$'1]'T36_ML_AW1$^'%KH
M_A;6_"FC^(9[V[N9/"WC;2OB+HDVDW,>AV,/ABZTUM1L-,N]]_!J'U3^S3XG
MM[O7?CQX,CF\1RRZ%\3[GQI#:Z[8K81>'K#XH6G]O7?A"R@%]>!)O#'C.P\:
MZ?J9M%72[N[QJUA<7/\ :=PMN >C^)HVT+XR?#S7XHY4@\;>'_%?PTU&YCEC
M$<>JV5N/'WA&>:&16$HM;+0?'EM#@8,^KQJQP0DE6V\4:KJ&A?"WQ'J[I''?
M:Q+X'^(NF*F-+&L:C!J/A6\B>TE8HQMOB1INGZ):I.'>.VU.[B92\C1M?^.E
MO)%\/+_Q/;6HNM0^'6J:#\2K)/,:*0Q>!]7M=<UR"!E=,RZGX7MM=T?8VX2Q
MZC)&%+NI$LVEZ(EOXI\+I;>(O$<6JS3_ !1T:PT;1KVTLD?^TM/UF'3]%\<7
MK67@A_$=YXTL[CQ#IMC>>)-*O8O[3AO;JWATFVDUF4 A^!5P\7P\L?"UQ<QW
M-_\ #G5==^&EZ41D=8?!&K76B:#-.K*I$NI>%;?0-9W?-OCU*-V=G9L>1?M9
MW%[X-M_AK\7](L=4U#5/!&O^)?"CI;72VFD6&D_%3PCJGADZWKLAL[G;!I/B
MFV\(2VK32P6DL\AL)2+F^L[JS];\.M_8'QG^(7A]I9A:^-_#WACXD:9"]NJP
M-JVF1GP%XP$%PJ_/]GT[2/AW/-&[%EFU1I%50[-)8^//@-_B9\'?B'X*M[6:
M^U'5_#=Y+HEG!=V]B]WXDTAH];\,VS7=V\5K#!-X@TW38[EKF:"W:V:5)IX(
MV:9 #X#_ &F?B+\'O#FA^%)/A3\1] U;Q-X6\3>!?$R^&_#MU=:EI6IZOX&@
MATG2_$L.JZ19ZEH-GJ]MH$EQH^I17&HVO]MZ5]@:66ZN?#.G6D\OQ5\0^,_C
M7\$$T/P?^SWXMT[P+X4\(V6H:1\2/&6O:7X2U!= T'2K34EN-/\ #SJS:YI>
MLV6E:;<1P6.IZGIU_<QV%U"GGZ?9:A;>D>#KKX=:A\"M%\,ZGX?\"^"+KQYH
M_@:^UC6O#T&@Z/IGB?P#=ZEHMYX\U.]UNQMM-CAU/POHMEK?A_Q^LP@.@:U:
M17TD.G:5J6EB+SGX)?%_1K?X=>&OA+)XEL=5DDUCPQX7\4Z1:SR20>"EMOB/
M8:+J.KZ?KTJ+I&N>"?%_A:%M2FO-+OM330?%&H#SMVC>)+>/1 #]%/A=XR3X
MA?#CP/XW$FG/-XG\+:+J]_'I-P+FPL]6NK"%]9TR&3SIW5M*U;[;ID\$TKW-
MK<6DMK=8N895'&Z_:6=E\9=,M]5AM[_P]\6_AQK7@O6-)O\ 3K:\TV_U3P/>
M7&N:38W@N%ECN(=7\,^,/'R7EE-$;>XM=)6.=;A2BP<Y^SMY'A<_%3X. Z/:
M_P#"J_B3K)T#1](^WN--^'WQ# ^('@P7MS?#_2+Q?[<UK2Y/+8F Z08',XCC
MU"_Z_P"-I;2_#&B^-T>[1OAKXU\,>-;EK-=\BZ!%=R>'?&TCH70/%#X#\1>*
M)W4L%/EC<54%@ ='JWB+POXAT+0[&Y@N-6\._$N:^\)[_L\EO D-_P"']?N[
MF'5HKO[+=V27,>E76BF)X/M4>JW=K9RPQN[%,KX)ZC?7WPQ\+6NK,&USPS;W
MO@7Q PG6Y,FO> =3O/!FKW+2K][[=?:'-?QDYW0W43JSHZNWBOCOX@^!OA[X
M9^)WAOQ%XP\.Z+KG@OQJOQ"\(:)J&KV=GKNMQ7&IZ-\4K*VTO3!*VI7D%_XF
MO-<\*[;2"8+8Q2Q7"16#D5W7P;\4^'M9\5_$9?"NHZ?J?A;Q@?"_Q=\*7MF\
MT9NK'Q;IUQX5\01FSNQ%=V\]KXJ\!:I?:I;S6T%S8ZAKIM[Z&"X=85 ,7XU6
M6G:1\4_@?XKU5M(@\-^+K_Q3\"?&MO/I*WFH^);+XAZ,VK>#-%EN([*>YCTR
MU\8>%HCYJW-LVGW&KR2I)%87FLN?E37++6O FM_##XQ:OXYU^R\.^$_$3:WH
M-CJ-W-X@T[QAX&\9_$+4K'Q#JLUW+>0I#\0]'\#>+I4U9QIMS)XA\'V>D:O9
MW\,VB^(+;3ONKX\>"]=\>?"OQ/HGA.Y:R\96BZ9XF\&7D*6ANX?%?A'5K'Q-
MH<-E<7UU96NG76I7NE1Z0NJ374,.G1ZA)=SB:"*6WE^:+KX9?M'?%;X;:+\+
MO$_ASX5?"GP':Z3IGAVZCU&\U#Q[\0;&VT'3(M/LM6TEM#N+/PHDERL:HL:Z
MM:7:0/<PSR?9I9;6[ /O:OG']H$/H+^ OB+"F6\(:_(FH2B-W:WT.0V?B74V
MB$>YS=ZE'X03PI9*L<KL_BB6*-<S,K^Z>&].U'1_#N@:3J^L2^(M6TO1=+T[
M5/$$]N+.;7-1LK&"VO=8FM%GN5M9=3N8I;V2W6XN! \YB$\H7S&YKXIZ+)K_
M ,/O%%C;VHOKV#3AK.EV+?<O-9\.7,'B'1;63D9BN-6TNSAE!R#&[!E8$J0#
M&^'OP]UWP=XE^)'B#5/B3XF\;Z9X[UZ+6M T'7;B[N-.\"V7VC5KN32- -QJ
ME_"+&5M52",6=KID$=AINF6WV:1K?SV]8KS'X-ZU'KOPU\*W$=V]\=/L9/#T
MM]* )M0?PS=3Z -4E4!<?VQ'IT>KQ,%6.6WOH9X1Y$L1/IU !115+4=2T_2;
M22^U2]M=/LXBH>YNYHX(0SL$CC#R,H:25R(XHES)+(RQQJSL%(!=HKSNT^*7
M@_4-8TW1M/O+F\GU2\GT^&Y2SF@LHKRWMIKEH)9+T6LK.ZP^7']F@N 7EB+%
M8B\J>B4 %?.'@AQX2^-_Q$\+2LT5CXET]_%NEI)L2"*)-0.M7UX\F%S=:UK_
M (R\70('+L;#P<"I1+:7/K>O_$7P/X8\Y=;\4:1:3V\BQ3V*7(O=3B=P2H?2
M[ 76HJ,#+.;78N1N8;ES\K?$'6? OQ9UZ'4=%\'>/_&EWI*V^FWEEIVG:);Z
M#JEA9SZO_9>H7-Y=>'_$OB#3I+1]:U5],GM5\.W<2:E<-<RQRHB1@'UOI/C3
MPAK^IWNC:%XHT#6M5TZ(S:A8:3JUCJ-S9(LJ0O\ :X[.>8V[QRR1))'+MDC,
MT)=%$T1?I'=(T>21UCCC5G=W8*B(H+,[LQ"JJJ"68D  $D@"OS[N?@3\4=:\
M46>J6EIK?@#2H]'N=#32]'\;7=_#-8W,ZW5Q+KVIWOBS4-<U SM::);/8Q7E
MM92)I=O.VFN;9XI/5O /[+FFZ'X>TG1?%_BCQ#K]OHMW?2Z9I$6KNVDV=G>W
MT]_-9^9/9179$T]Q(TLEB-,DP0#)-*&N7 /8=<^,OPUT ,MSXJT^]G\B6:.W
MT4R:T\K1[P+?SM,2YL[>XD=-B1WMU:@%E>1XXCY@XA?C/XH\3[(_AU\,=?U:
M*ZAE%IK>O%-+TF.YA#/(LLB,^FRQJJD*K>(+*:65EB1?,94?U#0/AQX%\,&)
M]$\+Z3:SP3-/!>S6_P#:&I0RN%!,6J:BUWJ,:@*-D:72QH2Q1%+L6[:@#YEU
M7P/\;?'@L+KQ/KGAKP];6%[8ZW8:%HYDBNK+5M/?RX7&JI9:I/93&%[B=+N'
M4]9@AN'B(L'"A8.E@^"&G:QJUSKGQ#U2Z\9WEQ L44%Q+=6,=@P=&Q%<:5<:
M9'-$FV18H(M.T^U032,;5I3YA]UHH PM%\+^&_#BE=!T'2-(+0QP22:?I]K:
MSSQ1 !!<W$4:SW3# 9GN))9'?,CLSDL=VBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDD<<T<D,T:2Q2H
M\<L4B*\<D;J5>.1&!5T=25=&!5E)!!!(I]% 'ENO_!?X:^($;S_#%EIMQY#P
M176@@Z+) 7+,)Q;6/E:=<7",Q*R7UE=\!4=6C4(.-'P=\8>&54_#WXI:]IUO
M9VS1:?H?B)$U72UDE9C,&P#IUM$[222HT?AV>6*4[@Q=C(/H2B@#X2N#XU\/
M:7XET[5M'\3GQ5XGU*^NSKFE:QK&EV&HWNL10VQTW_A&I-,CTS6KE[DO'!)H
MMJ\Q-U!;P7-I%;+*/8O GQ:\!^&M$TKPEK2ZQX0U+2;2&WNK3Q!I%W; WTQ:
MXO6B:!;IXK<WDL[12Z@EFQCVF15<E:^BZI7^FZ=JML]EJEA9:E9R$&2TO[6"
M\MG*YVEX+B.2)B,G!9"1DXH IZ3XC\/Z\)3H>N:/K'D!#.-+U*SOS '^YYRV
MLTIA+<X$@4D@C&0:V:\3UC]G[X<:I,MS9V6I>'+I;AKDW'A_4I+<L[$,JI!?
MIJ-G:QQL-T2V-M:["< [0H7&/@#XS>&OG\*_%%?$,+W$EQ<6'C*UDF<I&J^1
M;07]S_;URPF&Z.98)M&B#A90P:1C$ >A_%?Q*?"'PX\8Z_'=K87=KHMS;:9>
MNP1+76=5*:1HD\C[X]D4>KWUDTCAU*1AF4Y %0_"#PTOA#X9>"]!^R_8IK?0
M[:\OK,?=M=4UAI-9U:W3Y5Q'#J>H7<<0VKB-5&!C%?*/QE\0_&CQ'::+X)U[
MPKX6T^!K^+6_$5A'-J%^?$&BPRNEC:P6^D7.NR6]FL]IJ+7KS&68WAT65$LT
M@D%[[?\ #?\ :%T'Q9:3P^,[2U^'?B"'5+JQBTK4=5^WV=W96MK:S+JQUE;&
MSTW3DNKB2[MDTW4)XK^&2SQ*&:>$, ?0]%5;*^LM2M8;[3KRUO[*X4M!>65Q
M%=6LZJS(S0W$#R12*'5D)1V 964G((%J@ KYW^(2CQ9\;?A%X)#13V7A>'5O
MBEK]BV/.C^P;M+\'ZK"2Q"_9/$,5Q;RAHF:2.\(CDB96+?1%?._PKE7Q9\5/
MC1X\$D5S8Z9K5E\,M"8H!<:>WA:WC/BJT$F3YMK?:L;#4H&4*F)-N'9#(P!]
M$445SOB_7X_"OA7Q'XEDC$ZZ#HFIZLMMN"M=RV-G-<06<9R"9KR:..U@1<O)
M-*D<89V4$ \7^%)'BCXI?&7QV9!<6MEK5M\/M&+1A7L#X>AAB\0VT4Q&9[34
M9;/0M9MV4F(&\D*%@^1=\:_LN_ ;X@:FNL^)?AUI,FIEV>XN](N-3\-R7S.D
MBE]0'AV^TM;Z7>ZR_:+A7N6>*-7F:$/$^M^S[H#Z!\)O"8N)3<WNN6LGB>\O
MG!6XOO[?F?4-.FO 53_2XM%DTNSN,HC%[4F1?,+D^ST ?/\ \=M:\5>!?A19
M:7\._$,VF^.=3U;PCX*\%ZKK*0>(M0O]5GO+<&"\EUR/4%U'4=4TG3]12XOK
MVUU&ZFFEFN%B-XZ7,.+%K?[57@^*./6?!'PV^,5JGV:TAN_!GB>X^'WB5XXD
MB2?5M8T[Q;;7/AN:YN<23/::1J=A;K.S"&*WMPD8U/'9'BGXY_"CP8&22S\*
M:;K/Q/UVRFBWI*L4G]C>%;ZWD) BN=,\00NS$ART-V555)\Q/H:@#YJC_:F^
M'^E2);?$?0OB'\'[J6[6PM3\1?!6K6&EZE= 8F.F>(=%37-!N+2%LYO)]0M(
MFCQ, (R2/=?#OBWPKXOM)+_PEXF\/^*+&&7R);WP[K.FZW:138W>3)<Z9<W,
M*2[>?+9P^.<8K>DC25'BE1)(Y$:.2.10Z2(X*NCHP*LC*2K*P(8$@@@U\S^/
M?V2?@WXTNK?6-,T:X^''B>R8RV7B7X:2P^$[Z.8><Z2S6=G;G2KB4SRB:6\^
MPQZK)Y:1+J,<8VT ?2D]O!=0R6]U!#<V\J[98)XTFAD7(.V2*161UR <,I&0
M#CBIJ\Y\'^&I_AAX,O\ 3M2\;^*?&]II#:MJUOKOC_4H-1URVTWRC>O8ZEKM
MMI\5SJ%M:3K=S1WMW;7-W;6TXLH5-C965I#S'P8^('C7Q=\*;?QW\2O#EAH6
MJNFKWHT_PE!JVM&_T;3M_D7UCHUN-6U=[V_,%U]BT:REUB]O(ULWM?,N;Y;*
M$ ]MHKY[TC]J?X$:IK-]X=NO'=IX7US3I[N&[T[QUIVK^!WA%K,\:2/<^*;#
M2K&,WL(CO+2TENTU!K:XA%Q9V]SYMO'[U97MEJ5I;W^G7=K?V-W$LUK>V5Q%
M=6ES"XRDUO<0/)#-$XY62-V1AR": +5%%% !1110!ROB;QUX)\%FQ'C'QCX5
M\)G5#<#3!XF\0Z1H1U$V?V<78L1JEY:F[-J;NU^T"W\PP?:;?S=OG1[NDMKF
MWO+>"[M)X;JTNH8KFVN;:5)[>YMYT66&>":)FCFAFC99(I8V9)$971BI!/Q'
M\2M*T[XR_M,:=\.]0N++5/#7@3P5:1>(='ETF&:\T_4/%-Q+XMU+4;6\O+.:
MW=5A\*?#+2[R.3[1;&R\5SVGEL+O4();MI^R3J?@7QA>^,_@[\4-3\$S7NE+
MI]YHBZ!X<BL]1E$[S&2=K32F\,6\046T4,9\ 7TD @DF24WER]TH!]JT5\II
MXK_:@\$I&OB3P1X3^)%A;VLC7.H^&[B]T>]WIO9 )+"+7-2UN\=0%\NP^&?A
MZT9MJ[X"=S:FD_M2^!WO%TGQAX?\;^ =:6V$\^GZSX>GU=X1D+(TUOX5?7-8
MTNV4[F%QXET;P_B-=TT4#%4(!],45ROACQSX+\:PR3^$/%GAWQ-'"J/<?V'K
M.GZG):>8!M2]AM+B6:RE!.UX;J.&:.0-'(BR*RCQ6'QQX_\ [9^*/CJQU"'6
MOAUX)\7R>&9/!L^D6D-^=&\*Z)I \<>(_#>MVB17USJFF:_/KW_$HU1=6@UB
M/0I=(TP:/>SPW3@'TI56]LK+4K2XL-1M+6_L;N)H;JRO;>*ZM+F%QAX;BWG2
M2&:)QPT<B,C#@@UQ.J_$WPKIEW+I\#ZMK]];0VMS?V_A;0M6\1+I5M>0QW-O
M-K-]I=I<:9HWFV<L=_%;ZG>VEW<6$B7MM;S6S+(>B\+^(]-\7^&]"\5:/]J_
MLGQ%I-AK.FF]M)[&Z:RU&VCNK9IK6X5)8F:&5&'#1R*5DADEA>.5P#PCQC^R
M'^S_ .,C//+X!L?#.IR6_D0:KX)GN/"DUDP*D7-OINE20^'I;H;<&6_T6]W;
MF9U9CN'IWPP^'$'PN\.1^%[+Q=XV\6Z=:F)-.D\;ZM8:Q>Z59P0K!!IFGW-E
MI.E-'IT$:(EO:S+.MLB)#;F*!5B'H]% 'P;\,?&/QQ^%[^-M=^+?[/?C/4KG
MQIXKN]?GUCX::AX7\:WUI!/%"FG:"/"NF>(+K5/[,TAVOFM]0;4+B4072P/;
MN\/FR^Z^'_VG_@7K\US92?$#2O"^K6"(VHZ-X]2Z\!ZC83/C=:2IXK@TFWN;
MJ%CMFCT^YO50AF#M&-]>^USOB/PAX3\8VD=CXN\,>'O%%E"[2PVGB+1M.UJV
MAE8 -+#!J5M<QQ2$*H,D:J_RK\W P :&FZSI&LQM-I&JZ;JL*+ SRZ;?6M]&
MJW,*7%LS26LLJJMQ;R)/ 20)8726,LC!CQGQ<\71^ _AGXW\6/=I82Z1X>OW
ML;R0;H[?5;N/[!HTD@')C_M6ZLQ)M#/L+%$=]J-Y1:_LC?!S1?$MGXK\&6OB
MSX>:M;&]%RW@;QIXAT2'5(;V/!L[Y#>W4D5A!<);WL>GZ7+IMG//:V\5_!>V
M(ELY9OVGOA_\1_BAX0T'P/X'DTN'0]=\4Z5:_$&XN9575+3PO)=01S:AI=O<
MSVMA?1:5YDVK7UE)<)J$[6%DFDI-<ED(!J?LL>%CX4^ WP]AF2R%_P"(-)?Q
MKJ,ME:+:":Y\:W<_B:!+I=B22W6G:;J=AH[RR[V6+388(W^SPP*OT%3(HHH(
MHX88XX888TBBBB18XHHHU"1QQQH B1H@"HB@*J@*H  %<OX[TSQ'K/@OQ3I7
MA#5TT'Q5?Z#JEMX<UF5FCAT[6Y+24:9<W$B6U[)%;)>>3]IEBL[J:* R20V\
MTJI&P!U=%?'FJ?"C]HU=$TRYT_Q_X#USQ0ZV2:KIFK:U^T%X6T.P#6KRZA_9
M^M^&?BY<SZRT&HK#;VKW_A+2GO;*26ZD;36C&F3?.?C3]D[]JOQO?WUS?^.O
MA596-Z8V&AV_B3XAZKIUJZQJ)Y+>Z\6>&?$FO/+>W7G:A=S7NM7<KWMS*8GA
MMTM[>  _2[6/%WA3P[N_X2#Q/X>T+:,M_;&M:;IFT?NN6^VW,&!^_@Y.!^^B
M_P">B9\UUW]HOX*>'E1[_P"(.C7*2.L44FAQZAXFADD:0Q!$G\.66JP$B4&-
MR9 L;@K(4*G'P3I/['G[4^BB,6GC;X'W*1)+&D>M:/!XCB"3LK2AHO$/PEU2
M-RS(C;G1F5DC*D%$*^N^"_@E^V=HE];6+_&CX2^#/#TAN3?7/@OX=>$KR^@+
M022Q&VT,_#'PE8WAN+U+:*Y,VM67DP/)=K]JEMX[2< ^JO _QC\-_$#Q'JOA
MO0])\4P2Z1ID6JSZGJVD1:?I4UO//%!;QV[O>O?&:Y$IN+83V$$4]O#/)%*Q
MB9:]:KYZ^#?PS^)7@KQ;\2-?^)7CK2_B+<>)E\)P:#XDM=(B\-ZH;32-/O(=
M3MM4\,Z?9IHFDJEQ+:164FG:EJLFHPVQN[YK*<BV'T+0!P'Q!\'ZSXSL--L-
M(\9ZQX.6VU$W&J2Z.U[#/JVG/9W4#6"WNEZKHFJ:=/'=26M[;WMKJ&Q#;207
M%E=1W ,'!:'^SC\/M*U!]8U&37_$NL2*BRZIJNI1:?>W 5%C*:A<^%[/P]<:
MY&R*JE?$<VLMM +.TA:1O6_$?B[PIX/M8K[Q;XG\/>%K&>7R(+SQ'K6FZ):S
M38W>3%<:G<VL,DNWYO+1R^.<8KS#P_\ M"?#SQ=XA\/:%X1'BGQ):>(M2U32
M(?%UAX1UVU\#6.HZ7I>I:JUK=^*]8L]+TRZEOHM*NK;3DT235VN;LQH1'"S3
MH >HZ#X5\,>%H&M?#/AW0_#]N^/,AT72K'3(Y2/XI5LH(1*Y/)>3<[-EF)))
MKQK]H.PNX='\-^+=+@>74_#6MQI#L 9I)+F:SUGP[8!#PPU7XD^&?A]I\@;<
M#!/*IBFW>2_T)7'_ ! T6Z\0>"_$>EZ<J'5I-,FN]":3[D/B+3"NJ>';D\$C
M[+K=G87(*X8&(%2K $ '2Z??6FJ6%EJ=A,MQ8ZC:6U]9W"9V3VEW"EQ;S+D
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MM[N2>>_U333XCU">["B]DN?$DTNM+'>E4C#7-G:WMMI\C%=V+-0S.P+M[#0
M4444 >(_M$:Q<Z9\*M?T_3HX;G5_%TECX+TJPF;:FIS^([I+.^T]3LD+2W.B
M_P!J"% C>9*J1DHK%U]6\/:+:^&] T/P[8EVLM T?3-%LS(<R&UTJR@L;<N>
M<N8H$+'/WLUX=\1B/%7QH^#W@9?)N;/PZVJ?%+Q!:-S<6G]DJ^G^#=6AX<(D
M>O)>V$SNJ$I>>5%(&=U/T30!QNN_#KX?>*+B6[\3>!/!OB*[F01S76N^&-$U
M>XE11;JJ2SZA8W$LB!;.T4*[$ 6MN ,01;?G/X"?#KP5IWQ?^.7C_P &Z+9^
M']*@UB+X<:=I6C!M/T>VN]$AT^7Q;MT:!DTZ,SZG9Z5=V,MK:6\=O%<W<4.[
M[1<,WU!XJUZ#PMX9\0^);E?,@T#1=4UB2('#3+IUE-=^0F.6DG,0AC1<L\CJ
MB LP!\U_9\T&;0OA+X4>\E%UJ?B&WG\6ZE?%/+FOY_$MQ)JEI<72<!+M-)GT
MZUG4*I#VQW OO8@'+_$L_M0Z/XD35_A9)\-?&'A>X5H9?"/B/3;[0M2TQ?,T
M\+<1:Y'KP35+E@EZYG=M/MK:*61/['OYOLSP\EJO[4'B3X<Q:>?C?\"O&W@E
M=5N&MM.U/PCK'AKXCZ-,8)+6"XGOY]+U#3KK1@TU[;FTLY[6YN[M9&2U6XEA
ME5?KVOG77Q_PE?[1W@O2-A:R^''@[6?%<\PP]M)J>O21:0VDW,?S8O+9)/#F
MOV32(H18FDMYA(DL; '2>#/VA_@E\0'B@\+?$KPQ=WMQ=BQMM*U&\?P[K=W=
M'&V*ST/Q'%I.L798G:CVUC+&[957+ @>S5Y!X_\ @%\'?BC.MWXX\ Z)K&H!
M@S:K +S1-9FP%"I=:SH%UI>J7<2!1L@NKR:%,ML1=[[O(/&?P.7X;>!?$%S\
M)_B/\1/ [6FE7%AX<\-?\))>:WX8AU35I/[.T>QLK'5)'O;>ZN]4O;#3K74I
MM2O9[",PF"&1X(E !2_9>G_X3GQ+\6/BZ=2N-6LO$OB[78_#TMW9K976EZ?=
MW]O:0:7*@9VEBD\!^%/A5J%O(3$RBXDC>.8+'<R_9=>*_L]>&X/#'PD\(VEO
M/<7<-Y81:C9WEZB1WUUH<D45KX2>_2(+&M]!X.M/#UE="-(T\ZU<I#"N(4]J
MH *S-7T31M?LWT[7M(TS6]/D(,ECJ]A:ZE9R$="]K>130.1V+(<5IT4 ?/\
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MV@:5/JVH3W6HW45E8P)$C16MM]INYHK:.YU*\L+$W,UO:&Z%W=6D$_Q9\?\
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MPSA[J6:0SQ).S&50XZRB@!D<<<*+%%&D4:*%2.-51$4=%5% 55'8  "GT44
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M R+[EI>BZ-H<+VVBZ3IFD6\DGFR0:786NGPR2E0ID>*TBA1I"H"[V4MM &<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '*:_X&\'^*!.=>\-Z1J,]Q''%+>R
MV<4>I^7$5,:1:K (M2@";0H\BZC.S='GRV93XSXF_9VT9K#63X&UC7O#-[JE
MD=/ET^'7+R+2+K3[@+#J%C<31H^LE+NW,N#)J4T2SE,QK'S'](T4 ?G)K?P
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M)_$>GQHY,95(EW. ?0E?GW\2_$OQ*T33?C_HEGX"C\2V'Q!\5:A87?C?P_K
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M%!'%##%&%CBBBC54CC151$4*H"@"I:** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;0FTG%K<_2"BBBNDX HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGC'4?CIX%^&UQHWQ2MO$%WX9;P]XB\->/-=U>>.#PUXE\*ZD=4 \*V]O:/\
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M/M6$D]PMK!::OXD^*>DWFIW%G$&C:%)+J4N;<+U7Q7M_&'QEU[3M1^*G@O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_S9
M_P#@M!_RL^_"#_LLW[ W_I)\,J_TF*_S9_\ @M!_RL^_"#_LLW[ W_I)\,J
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M<K+LK[*]Y66EVWNV?:7_  <%_P#!,R'_ ()F^$O^"8?[27[-EM-'I_P0\)^
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M+:]T;X@6>AVT4/\ 9EQI'CKQ(L,?]I:Q&NA!_>]1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^FQ4?\*Y_P""IO\ T>1^P!_XK3_:*_\ IL5 'W_17P!_PKG_ (*F_P#1Y'[
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M (K3_:*_^FQ4 ??]%? '_"N?^"IO_1Y'[ '_ (K3_:*_^FQ4?\*Y_P""IO\
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M%? '_"N?^"IO_1Y'[ '_ (K3_:*_^FQ4?\*Y_P""IO\ T>1^P!_XK3_:*_\
MIL5 'W_17P!_PKG_ (*F_P#1Y'[ '_BM/]HK_P"FQ4?\*Y_X*F_]'D?L ?\
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M ?\ BM/]HK_Z;%1_PKG_ (*F_P#1Y'[ '_BM/]HK_P"FQ4 ??]%? '_"N?\
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M_"N?^"IO_1Y'[ '_ (K3_:*_^FQ4?\*Y_P""IO\ T>1^P!_XK3_:*_\ IL5
M'W_17P!_PKG_ (*F_P#1Y'[ '_BM/]HK_P"FQ4?\*Y_X*F_]'D?L ?\ BM/]
MHK_Z;%0!]_T5\ ?\*Y_X*F_]'D?L ?\ BM/]HK_Z;%1_PKG_ (*F_P#1Y'[
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M_P"FQ4?\*Y_X*F_]'D?L ?\ BM/]HK_Z;%0!]_T5\ ?\*Y_X*F_]'D?L ?\
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MAZ1_&3:?\HA/^#A'_M(+\-/_ %I[P)094TTY)Z-.'_I<3]5/B[_R5C_@Y_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#\3/BM_P &]W_!*WXT_%'XD_&/XA_
M?Q/K'C_XL^/O&/Q,\<ZO;_&KXPZ5!JGC#QWXBU'Q3XFU&#2],\:VFFZ;#?:U
MJM[<QV&GVMM8V:2K;VEO#;QQQKP/_$-'_P $??\ HW;Q;_X?GXW_ /S>5R?Q
M<_X+^Z-X%_:K^/7[)7PR_8%_; _:4^('[/OB'4M&\8W'P'\-6?CU?L&G3V-K
M)XD?1M @U/6M+T.2\U&TLTO-4M;>(7<T5N9/-EC5OJ?_ ()_?\%E/V8_V_?B
M!XR^!VB>&OBG\ ?VC_ 5O=7NO_ 7X^^'++PEXWN]/TXQ+J]]X<6TU34H-4_L
M-KBW&M:/?KHOBC3XI3?R>'VTF*745#3]XE>\K63^)[.UNOFCH/V3_P#@C3^P
M;^Q!\4X?C'^S'X#^(GPS\<#3+K1-1N+3XX_%[5]#\1:%>[6N-$\4^%]>\8:E
MX<\2Z7Y\<%];6NLZ9>+8:G:V>JV!M=2L[6ZBZ!/^"17[",?P7_:2_9^7X5:X
M/A;^UI\2-*^+/QST'_A9?Q$-UXI\<Z+XLT_QMI^J66M'Q*=8\-P0^(M+LKQM
M-\/7NFZ?+'$UI+;-:R21-\K_ +;?_!?3]F#]DCX]77[*W@/X8?&C]K7]HK2G
M2V\2> ?@)H=AK-GX7U=K9;V3POJFL27<VH7WBNULY(KG4M&\+^'?$0T8-+9Z
MY=Z9JMM<:='U/["__!:?P7^V-^T);_LM>+_V2OVI?V6_C-J/@[Q%XZT;3/C7
MX/L](\/ZIH?A463:NL5_>W6B^(X[]$O[>2V0^$'L)E$JR:E;S""*X!6J6YO>
MVO=O6RU3WO:^S[['V[K7_!/[]EOQ!K'[6&O:IX%U.?4_VV?AKX-^$?[1<Z^-
M/%\*^,? G@'P)>?#;POI6GPPZTD/A.>Q\(7]UITNI>%TTG4;V5Q?WES-?(EP
M*NG_ /!._P#92T[X\_LU_M*6G@'5(_B]^R3\'8/@-\"_$1\;>,GM/"WPRM?"
M7B[P1#HE]H+ZVVB>)+E?#GCCQ)9'6/$5AJ6K-)>QW;7ANK2UFA^(O^"H?_!<
MO]GO_@EW\3_AS\(/'WPW^('Q9\<>//!5W\0+[2_ &H>&;(^$/#)UJ?0=!NM9
M;7[ZV,LWB.^TKQ)]AM[=0T,.A2S7#!+NV)_7WX5_$KP?\9?AM\/OBY\/=6BU
MWP+\3O!GAOQ[X/UB'&S4O#?BS1K37-&NR@9_*DEL+Z!IH&8R6\WF02 21L "
M:DDF[I.Z3ONK)6]+67FEY'H5%%%!(4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\>'_  3F^)'P
M[^&?_!PO_P %@-5^(_CWP7\/]+O](\1V-CJ7C?Q3H?A2PO+X?$;X<W)L[2\U
MZ^L+>XNA;PRSFWAD>80Q22E-B,PY+X]?$7X<?M;_ /!S/^Q)K_[$NNZ%\1;G
MX,?#[2_^&C_BO\*KFUUGPB;+PY_PL^X\6VNM^,= :XT36DM/A]XBT'X>7NM"
M_N[:75/$.D?#\WCZEIJ:7;?J;^T?_P &Y_["'[47QV^)_P"T+\1O%O[05GXX
M^+/BN\\8>)K/PUKWP<M_#\&J7R0I-'I=OKOP0\0:O'9@0)L34-;U*XY;?=."
M /T@_8M_8'_9N_8)^'][X _9_P#!MCI*ZQ<PW/B7QC?>'? =AX\\6M:(R:='
MXK\0^"O!W@X:]#I8EN3IB7]E*;)KR\,#+]HD!#3FBM5=R<5'6UE[J3?GU_X8
M_EJ_X(/_ !?^ O[%_P"VQ_P4H^#?[<_BOP=\%OVQO$OQBGGTWXB_&[4],\(#
MQSX97Q'XNU;Q-IOAWQYXLFL=-A_X2G5]3T#Q];VRZI:_\+'TG5M US21KD&@
M1R6/U+^R+_P5U_;#^)?_  6'C_8:^,_B[]C+X@?!6SL_B]XKT_XB?  MXLAL
M?#>C_#?Q+XZ\)1K\3(O&.H:%;:]INE6VFV/C^WBTQ5L[M-5TV22((9%_8C_@
MH+_P25_9&_X*2V.B?\+UT77/#7BW0(#8V?Q1^%NG?#+1OBG+HZR--;^'[KQM
MXQ^&_CK4WT&RN);FYLM*B\FUM[B]O)D3?<2$^5_LN?\ !#?]B3]D?X2?&#X5
M_#*W\>:EJ?QH^'/C'X6:_P#&GQ=%\)+SX\>'O"/CO0]0\/\ B&R\'?$;P_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img34507759_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img34507759_1.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ,$!+,# 2(  A$! Q$!_\0
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M!XRE@<1*=6JJ>'I.&(KT(VJ5HIQK0G?EC5=/^HBBOYV/V9/^"E?QU_X*)_\
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M?Q9;:=#J^I:*R:WIFD?L-^(=-L[HW>EW+K%::S?QF!H7,P=FC3]J_A1\"O\
M@X!T[_@G%^U#X5^.?[;/PEU#_@HNGBV[\9_LM_%/X6?#KX(ZYX/;PEX?\->%
M[RW^$7B_0/$?[.?@#P-$WCW7].\7:)_PDUWX+U'5O#$OB#1]=_M^YL-+ET%^
M[,85,KAF3QE*K3K95[18O"1@YXM3H8F&'Q5*E0C>5:OA5*K7J4*=ZU2EAJT<
M-3KXGV.'K<N!K4<QEECPE6G4P^;.E]6QKDHX.%*OA:F)P^)Q%9_P<-74*=&%
M=Q<(U<10=7V=%U*U+^@BBOXDO^">O_!T5)X;_P"">W[7%_\ \%&-:M+S]O\
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M$/\ :D_[&_\ 9S_]:%^&M?+$?_!$K_@K!\5_V<] T&U_X.%_VB-.T+QC\*=
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MXG>++/P[JVJ7GC[Q+97NFZ3KVCQ7-CHTNB:]I-AMU?4O#J2^'96_$[_@D/\
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MLK/1])U"T\-6WA)O 5VS0Z<E^WB?=.;.+XA;_@B_^V%^RS\7?CSXP_X)/_\
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MAM-*\>6W@.X\5:HDOA_5IK:SN]=\"GQVK7$^FZ/>6?BFQU?1M+U:U\Z\$_\
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MT"SN[7PSX?TZ;]3?BC_P1V_:7^%/[5OQV_:V_P""6?[?#_L5ZM^U7J\/BO\
M:2^!OC[X$>%/CY\&?'7Q%#WLMQ\2_#-KKVK:9>>!?$=[?:CJFNZO':Z?JUUJ
M^O:SJKKKVE^'KC_A&SK? G_@@K\)]'^!?[<_@[]L7XZ^/_VQ_P!HC_@H_96]
ME^U+^TWK.@:)\.]=DMO#SO=?#>Q^$O@BRG\4>'?AUI_PQU:/2M=\-6*R:QI#
M:KX?\.VAT>S\&^'O#G@S1/F,#@YTN&H9=B8+%5:?AYBN%,?A*M66"698[$9=
MA,#7I8:EELJ6!=#$9CAY<183-L9.E7P6.IX3%XC!XO,:V/I'TE6M;/%BJ=>=
M*G5XYP'$6'QE!5,2\%@</FKS*G6Q<L=.6.C7P.7N.15<IP3K8?'81U\LPV.P
M632HUJ?\X/Q"T7P1^RU^QQX _9)_X+$_\$ M:^$?P8^%.A_#S0M0_P""DW_!
M/JS^$_C#7H+SPEKGA[2M&^+'B#QUX9T"[O\ P/J_Q*N[2QE\?:QXK^,G_"2>
M.;KQ+JD*^!K?6[ZRT:#^^GX/^,_!/Q&^$WPP^(/PT\42>-_AUXX^'O@SQ=X"
M\9RW%U=S>+?!OB/P[IVK^&?$LUU?0V][<3ZYHUY9:E-->V\%W)+<NUS!%.9(
MU_G UG_@B/\ \%-OB-^S_I_[!_QD_P""SM]XK_83MM#\*^ =;\.^'_V/OAUX
M<_: \8?!KPI/I0T_X5:A\6KCQAK%]IL2:5I%EI,GC.YE\3ZIJT-MY/B;2-?T
M.]U+P]=_6G[</PD^/_P;^(?_  1B^"?["7Q+^,'PR^%_PR_:&\ _"OXD? WX
M=^#/$&O^!O&O[)WPXT'P9<^+-5^,OQ6>\_L3P1X:^&?P^\!7?AS2=.\3I>ZM
M\3O$GQ)M--T)UU6PGE;ZB%6GC:U2AB,52IUL]XLR>GAL;4I+ )T\TG4R[&YM
MQ'@:#KY?@:N%<\HA&IE5:5*&%H9G+%4HX/"9?BJOF4<*KT9J/L7E?#^?8C%0
MG56+PM!9=A*6:4<NR;'5(T\TQ2QL\'F*5+'X:7-7JY9[*I#%5\?0I_NA7\NW
MA[_@@-_P3Q_;,_:E_;Z_:-^,W[6OB;]M?3OC7\?;\^.?@C\*/C'_ ,(5\.O@
M3\0O"5K<6^F> OB=%\&OB)J.K>*?BA\*='UB+1O#,'C6Y\+3^%-"OKBWO_!%
MS<:O+?M_437\]?Q _P"".7[4_P %_P!J;]H;]J#_ ()8?\% 4_8UB_:[\11^
M-_VB?@7\1_@#X3^/_P +=9^)TTNJ7&J?%'P(_B'5K&[\':WJ%_J^I:[>Z.-,
MU!=1US5M26?7XO"R:/X4TGP^2$<=&O/#>T4LKS' QQ$(4:M6C4Q&,R?&4Z$X
M5ZE.-/"XB>6QJ2Q5%3Q6$Q^%RVK#V5!8FO2]#VE9X&IAZ6)5-/,LNQM3#SG5
MHPKT\+0S+#2G"M0A.<J^'6/<EA*SA@\9A)XVG5<\3#!TJGXI6$WQI_9;\)_\
M''7_  1JT[XN?%#X_?LZ_LU_L!>)OCE^S=K7Q1UV3Q7XU^%/A;QE\&-'\1>(
MOA')KYA26?26T/QQ9P:3HMNMCH\#^#=5UO1]#TNX\5ZU;5_3M_P1_P#$GA>X
M_P""//[ .OV5Y8)X>TK]B3X,P:K=J\0L[2[\+_#/3-+\6"Y<'RT>PUG2M7BU
M#>08[B"X$V'5P,O_ ()Z_P#!*;P+^Q=X8_:-UOXM_%3Q+^V+^TM^V=K=QKG[
M7'[0OQ3T#3=$F^*\#6&JZ1I_@C1_A_87VL:/X*^&>BZ3KFL6>G>#[?5-7CC3
M5+JR6^B\.6'ACP[X;_-.S_X(.?MR?"GX5?$#]B/]EK_@K?XI^#W_  3<^(NI
M>,88_@IK_P"SEX/^('QI^%_PY^(=_J%_X\^$_P /_CC?>*M.UTZ%XH?5]7C;
M7=N@W6D'4[F[BTB_U"[\0W?B7/'X6K7P6-P?M%B,ZS#@SAK)ZV=5:];%9;B<
MYR6IQ9[:>9+$TJ&9.G3PO%."PD,QI8>O5S2EP_B\1B\-A\;CL+'$<M&E0>84
M,Q47A,MP^=9S7_LFE0HT\=2RS-L'PLJF(RU4JCR^C6JYGPWF&.GDTJ]#"X.7
M$&%HX;%SH9?B6OYW?@'87WAO_@C%_P $)_B'XH1K7X8P_P#!?CPEXIFN;X;-
M-LO"7_"ROB!8+>7/FXABL(KWPKXP1Y9 L*OYZE@9#N_JG_X.CM1TRP_X(??M
MCP:A)$LNK7G[/FEZ3#(1YEUJLG[2OPBNX8;9#\TD\=M9W5T50%A!;3R?=1B/
MKOXP_P#!(7]DGXL_\$U-*_X)=+I&N>$?@3X/\%>&?#_PX\1Z+<V3^/\ P1XR
M\&WRZ]H7Q7M=5:RAL[[QQ=^*VO\ Q%XNN6LK2U\5RZ_XGT^\@M[#7;J)?S_M
M/^"*7[:O[0GBKX ^%O\ @IQ_P4_N_P!LS]E;]F;QWX8^(WA7X$>'_P!FSP=\
M';WXU>+_  +'/%X*U?X_^,].\2Z]J/B:QTN&0V>MZ#>)XDD\56ES?37GB"RU
MR]O]<ONO'X;#YAB\?@8UZF'PM?BCA[&1S2M3]IAZO#V59)P9P[B*L,-3E];P
M^=1P?!]3$QPLJ=3#5L7FN#JPQ<%2S".&YLLC6RN5+.73AB,74P&<8FME-.-.
M%6AG^-XEXJXJPV%]O*V$Q.35,7Q5# 5,1STZ^$PV5XN?U6NL3@Z<OG/]A+P[
MXC\!?\')?Q0T+XBQS0>)-;_X(H?L[/X<^WDB>6W\.:G^SKX8\5Q6OF_.2/%W
MAKQ,;A(S_KK.\9P2CL/>/^"A$]OK'_!QI_P0FT#1G6?Q#X;^&G[<WBKQ-!;+
MYEU8>$M6^#?B+3=)OK]8P6@T^]U'0]?LK6><K"]U'/%&3*2K?</_  4/_P""
M7'B?]JKXV? ;]LO]EG]I;6?V,?VYOV<-&U_P;X*^-6G?#_0OBGX2\;?"[Q(+
M^;5/A9\4OAUKU_I5CXB\/)>ZIJ]SH5V]]/!H,OB'7[N70=;OI=&N-$Y[]A+_
M ()8?%#X)_M2_$7]O[]N/]K"]_;8_;5\<?#RT^#7A/QC:_#/1O@_\,?@;\&X
M-0BUBZ\!?#+X?:)JFJV2W&JZO$UWJ7BN1=)O)[>ZU&'^RQJNO^,->\5=$Z\L
MVS'(,PS*-/!SX<SGC[.)4\/!0IXV?$N-\0LSR>EA7!UY5(QQ'&^&HYG]9A@6
MJ.6X^"<U7P=3&:.BL)DF,R>E*6,IXWA/@SA?#5J<I8>MAZ>199PED.98C,(5
M%[-5(X/AS%8S"?5*N(CB:V-P#<:-2GCJ6%_8;Q'X@TCPEX>U[Q5X@NFL=!\,
MZ-JGB#6[U;:[O6L](T:QGU+4KI;/3X+J_NVM[.VFF%M96MS=SE/*MH)IG2-O
MY3?"W_!(+]FO]LY-6_X*/_\ !$+_ (*:?M,_L,Z9^TQXO\2>,O$-Q\'+;QQ+
M^S]X_P#%OA_Q?K^C^+;K5OV?_%][\&/&>ESR>,K7Q']H\/\ B[5+[P=ITDD=
MUX3\$:?H4EI%>?UCRQ13Q203QQS0S1O%-#*BR12Q2*4DCDC<%7C="5=&!5E)
M4@@D5_,E'_P0E_;!_9$\?_%+7?\ @C]_P5+\7_L2_!GXM>*KSQKJ_P"RS\1?
M@3X$_:'^$W@[Q1K$[2ZQJ'PVE\?7&J:9X2L7@BT[2[.UA\!3^)SI&EZ=INL^
M.M9LM-TRWL_.C"V82K5H5HJ.!]GEV.P,_98G"XJ>*ISQN%Q[^L4IULMS"E3P
M56G[",XX?%Y8GC<-BJ6(H5LN]!R;P/LJ52BV\;"KC,'C8^UPV+PT,/6IT*V%
MC["=.CF.!J5:Z]I7E^_PF-K4L-4PU2-2.+3]AG]M3_@IA^RS_P %,/!W_!)K
M_@J-X[^%'[4%[\>/@]XO^,G[,'[5GPK\,6/@CQ#JECX)3Q3?ZIX3^*'A/1?#
M_A'P_;'_ (1_P/XB=9K;PU'JFD:U:Z?#<>*_B!;>)?[1\._)_P#P;X?\$^/V
M+_C[<_\ !5/X^_M ?LU?!CX]?$>^_P""G7[3WP=LM1^-7PZ\)_%+3_#O@/PO
M/HGB6'3/#.B>.-)US2/#]SJVJ_$3Q WB'5-*L[74M<LTTO3]1NI[+2[2"/\
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M7_P2*_:6_P""5O\ PUMY_P#PT1^T!/\ '3_A>_\ PH7RO^$/\_XG_"OXD?\
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MB+1-=XSX-_\ !'W]I/X@?M?? _\ ;/\ ^"H?[=Z?MJ^+_P!E=M5U']F3X/\
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M_ 'XA_ W_A2O_"O?[1_X3'_A/!XX'_"4?\+'_P"$XL/^$>_LK_A,_P#D"?\
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M?P^^%G_!0;X'?MF_#?Q];>%_A?\  /\ X)[Z1_P3[\%_LSCP'-J5O'X,\/\
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MKB\:?"Z^^'7B[X>ZI%+9Q1GPWH/@Z::\U'6IM;N*_P!#_P#8!_X(M77[#_\
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M_C3X%&@_%G3-)TW4+80>']'\9?!.;Q!)X>;2]8U/Q%XD&J0ZQ>?WU?%;X7>
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M_:*_^E/U]_44 ? /_"QO^"IG_1F_[ /_ (LK_:*_^E/T?\+&_P""IG_1F_[
M/_BRO]HK_P"E/U]_44 ? /\ PL;_ (*F?]&;_L _^+*_VBO_ *4_1_PL;_@J
M9_T9O^P#_P"+*_VBO_I3]??U% 'P#_PL;_@J9_T9O^P#_P"+*_VBO_I3]'_"
MQO\ @J9_T9O^P#_XLK_:*_\ I3]??U% 'P#_ ,+&_P""IG_1F_[ /_BRO]HK
M_P"E/T?\+&_X*F?]&;_L _\ BRO]HK_Z4_7W]10!\ _\+&_X*F?]&;_L _\
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M?K[^HH ^ ?\ A8W_  5,_P"C-_V ?_%E?[17_P!*?H_X6-_P5,_Z,W_8!_\
M%E?[17_TI^OOZB@#X!_X6-_P5,_Z,W_8!_\ %E?[17_TI^C_ (6-_P %3/\
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MX!_X6-_P5,_Z,W_8!_\ %E?[17_TI^C_ (6-_P %3/\ HS?]@'_Q97^T5_\
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M5,_Z,W_8!_\ %E?[17_TI^C_ (6-_P %3/\ HS?]@'_Q97^T5_\ 2GZ^_J*
M/@'_ (6-_P %3/\ HS?]@'_Q97^T5_\ 2GZ/^%C?\%3/^C-_V ?_ !97^T5_
M]*?K[^HH ^ ?^%C?\%3/^C-_V ?_ !97^T5_]*?H_P"%C?\ !4S_ *,W_8!_
M\65_M%?_ $I^OOZB@#X!_P"%C?\ !4S_ *,W_8!_\65_M%?_ $I^C_A8W_!4
MS_HS?]@'_P 65_M%?_2GZ^_J* /@'_A8W_!4S_HS?]@'_P 65_M%?_2GZ/\
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M17_TI^C_ (6-_P %3/\ HS?]@'_Q97^T5_\ 2GZ^_J* /@'_ (6-_P %3/\
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MMK6+6+S]W*^ ?^"3_P#RBS_X)J?]F _L;_\ K.OPYI&P?\+&_P""IG_1F_[
M/_BRO]HK_P"E/T?\+&_X*F?]&;_L _\ BRO]HK_Z4_7W]7P;^W_^V!XE_8W^
M'?PY\9:#X+\':KIWCKXHVW@#Q9\4/BSXC\<>#O@7\!/#LG@SQEXK;XD_&7Q9
M\/?AK\5=?T#PO?:KX7TOP!I-_>>'M(\+KXM\9: OB7QGX9L")KK.I5A1C&52
M7*IU:%"+[U<36IX>C#UG6JP@F[).5VTKLNG3G5<E!7<*5:M+5*U+#T9UZTK;
MR<:5.<E"*E4FTH4XSG*,73_X6-_P5,_Z,W_8!_\ %E?[17_TI^C_ (6-_P %
M3/\ HS?]@'_Q97^T5_\ 2GZ\*\#?\%!/VB/C[=_#/X<?LX? G]FSQ=\8=<^!
M>J?M"_$K7]6_:Y'B7]FC1?A]/\5_&7PC^%-]\)/C1\&/A!\3[[XO6WQXU7X>
M>,?%7A.]N?!O@.X\">"-*DN/B'H^F^.@OP\FZ/QM_P %(_$_PT^-_P"R)\&?
MB1^S?J/@>]^+OA;X>:G^UG?7GQ+\->(XOV,?%?Q\\0W?PL_9H\)ZWJ/A+3]8
M\-?$Z#XS?'W0O%7PKTKQ#HFNZ#::>FD6_B:ZM/L]^VG6G3"C4J5\-AHI*OC<
M?6RS!4JDHTI8O'4*^9X6=##JJX>UD\7D^88.GRW]KBZ5##4^:MF&70Q>,IQA
M3Q5:<E&G@,!3S/'3<HN.#P=;"Y?C:%3$RBVJ4L3@\VRW$X6E)^UQ=+&498:%
M6\E'U+_A8W_!4S_HS?\ 8!_\65_M%?\ TI^C_A8W_!4S_HS?]@'_ ,65_M%?
M_2GZ\[^(_P#P47U#P/\ L%?M._MG1_#3PO'>_L^?&C]HSX16WA+Q1\0;O0/"
M>L1? K]J_P 6?LSV_B[Q+XYM_!^JW?A;2-9MO#:>.=;2V\+ZZWAZWGN=+@DU
M<6JZA/ZW^PW^U;K/[5_AGQ[XEU#Q?^QIXTL?"NNZ1H=EJ?['/[1_B3]HO0;:
M[NM/N;_4+'QKJOB'X0_";_A&=72%M.GTK3[.#6_M]G<7-Q<36/D0I=8T6L0I
MRI/F5/!8/,9/X?\ 9,>Z:PM6TK.]3VD/<MSPN^>,7&25U+4N7G:CS9CF.4Q\
M\?E4YPQ]!=_82IS7.KTZBBYTY3A:3R/^%C?\%3/^C-_V ?\ Q97^T5_]*?H_
MX6-_P5,_Z,W_ & ?_%E?[17_ -*?K[A\4^(;7PCX9\0^*K[3]?U:R\-:'JNO
M7>E^%/#^L>+/$^I6^D6,]_-8>'?"WAZSU#7O$>N7<=NUOI6AZ-8WFJ:K?206
M5C;3W,\<;?$O@W]OKPMXU^$/P"^+.F_!WXM_:?CIHOQ=\6+\*K+2;+Q/\7?!
MWA3X-Z9XC'B>\O\ PEX.O/$,/B'61XRM/!'P\_L?PSJFH6D'B;XCZ$[ZT^E6
MMW?M%2K3I4ZU6I.,(8>"J57)V:@XUIIPC\55VH5+QI*<E+V<&E*M151)IU:-
M!->UKJJZ47IS*A*A"JW)VC!0EBJ"O.4;\]XW4)N,'_"QO^"IG_1F_P"P#_XL
MK_:*_P#I3]'_  L;_@J9_P!&;_L _P#BRO\ :*_^E/UX9?\ _!7_ ."]OIO[
M'4D'@MK/Q+^US\&_AG\>;#P-XX^,/P1^%WBCP=X$^*OB?PIX,\+Z18P?$+QU
MH&G_ !)^)-[XB\3W=O9^"_!E_<6][#X1\16Z>(8_$>I> /#GCC[+^$G[2>N>
M-/"WQV\9?%7X _%S]GS0_@GX^\:>%[=_'.BSZ_J7Q*\'^#K2*]_X6AX T+P9
M:ZUKNN>%]=MWE_L.TT_3;[6-0FMY;:SM+FXVQ'318=XIN*PRJXZ@Z[E%4O:Y
M9B'A,?#G;47]6Q,9TJDD^7FIU>5R5*HX7RS^L3PCA..*IT<'B*F&E"4<13I9
MA1IXC!2G1DE4@\3AZU&O2A**FZ->A4<5"O2<_)_^%C?\%3/^C-_V ?\ Q97^
MT5_]*?H_X6-_P5,_Z,W_ & ?_%E?[17_ -*?KZ@^%'QX^&?QM\*:UXU^'5UX
MOU+0?#]_=Z7J1U[X7_%'P)K)OK+3[75)X=.\,>/O!WACQ-K*FSO+<V\^C:1?
MV]Y<N]A:2SW\,UM'XC^S'^V)'^U#'X7U?PW\"_B_X(\):_>?M5:-JWB#XA:3
M9Z'/X&\5?LQ?'CPY\#4\&>.-%BNKN[\/^+/BG+J7BCQGX2T&[E74=-T+P!XH
MLM>M[/6+.6T@5_W_ -7M/VRH+$RAR3]R@U>%6I+EY*<*JO[%U)1]O:2H\[BT
MG&$I4HUX\KHSQ,L'"IS1498J&&QF,G0BV]:D,/@,74G%?#[%PE:I.G"?&_\
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MG_1F_P"P#_XLK_:*_P#I3]'_  L;_@J9_P!&;_L _P#BRO\ :*_^E/U]_44
M? /_  L;_@J9_P!&;_L _P#BRO\ :*_^E/T?\+&_X*F?]&;_ + /_BRO]HK_
M .E/U]_44 ? /_"QO^"IG_1F_P"P#_XLK_:*_P#I3]'_  L;_@J9_P!&;_L
M_P#BRO\ :*_^E/U]_44 ? /_  L;_@J9_P!&;_L _P#BRO\ :*_^E/T?\+&_
MX*F?]&;_ + /_BRO]HK_ .E/U]_44 ? /_"QO^"IG_1F_P"P#_XLK_:*_P#I
M3]'_  L;_@J9_P!&;_L _P#BRO\ :*_^E/U]_44 ? /_  L;_@J9_P!&;_L
M_P#BRO\ :*_^E/T?\+&_X*F?]&;_ + /_BRO]HK_ .E/U]_44 ? /_"QO^"I
MG_1F_P"P#_XLK_:*_P#I3]'_  L;_@J9_P!&;_L _P#BRO\ :*_^E/U]_44
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/'?CNZT3PY8/J^FKHGVZQ!)(_P \5^$7[27_  7U^ /[--K^SU\/-:_9C_;
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M4D[TZN)P4G'&8:G55Z<\1AG&7MZ$9NK34*CE!*G-Q^HJ***#4**** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ,OAJX>M3KTI>E2E*47\F;]%("& 92"I ((((((R""."".01P12UF;A1110
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M1\*Y_&GC\:?>OXDMM+L_$?[/WQ5O;Y/#_AWQ#>VOAWPU)K<MJMK<P!^[T?\
MX*0_L^:E\2Y/A_J&C?%WPKH;_&;Q_P#L]Z3\9_$_P\NK'X':Y\8/AIIGBO6?
M%7@ZT\?6E_?II<D&G^!_%LEAK/BC3/#_ (=U.XT673K+5YM2O=*L[_)5:;BI
M^T@H.G6J\\IQA%4L/B,/A*M24IN*C!8K%X;#0E)I5<1B*5"DYU:D8NY1E&G*
MK*+]E&5.#J)-P4ZN Q&:QCS*Z<HY7A,5F55)WHX##UL96]GAZ<JB^^J*_-R#
M_@JA^S)'X.\1_$3Q)H?QU\!> [3X$?$_]ICX<^+?'_P=\2^%-(^/7P4^#_AF
M'QCXX\6_!TZB%N]2O[/PK=Z?XETKP1XSM/ _Q \0^&+^/Q7H7A74/"]IJFLV
M%OQ!_P %,?A'X2\.?%[6/%'P8_:CT#Q#\#/AWX=^,OQ&^'%_\)+7_A.]+^"G
MB:'X@O8_%W3K>U\57/AK7_!=G<?"[QKI^M?V)XFOO$>BW^EP0ZCX>MTU;29;
MZZO[A2==.AR0E4FJR=*4(PGB*=93C-1E&>'GA,9'%TY)5,)]3Q;Q,:2PM=TZ
MHTZF(E3AAX2KRJUHT*2HIU?:U9SP=.E"FX<RJ>WJYCEU'#.#<<37S# T,.ZE
M;%X>%3]&**\K^"WQ6M/C9\.?#_Q*T_P3\0O &F^)8#>Z9X?^*&@V?AKQ:=-D
M"R6&J7&DV.K:U#!8ZK:R17NG.U\9I;65'FA@D)C7U2M*M*I0J2I5H2IU8.TZ
M<U:<)63<9Q>L9*]I1E:497C)*2:7/0KT<32A7P]2%:C5CS4JM.2G3J0;:4Z<
MU>,Z<K7A.+<)Q:E"4HM-E%%%9FH4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!Y=\6-=.A^&KF[2?R'T^TU'Q!Y@59#
MG0;1[NRB,;_*?M6KOIEJ"V0&E'![?D"26)9B69B2S$Y)).22>Y)Y)]:_07]J
M?Q*;3P[>Z=%(PDU:_P!,\/1A6V@VE@H\1:TW7+?Z3)X=MW  7&58?WOS4O/&
MG@[3I+B+4/%GAFQEM-4M-#NX[S7M+M9+76[^V6]L='N$GND:'5+RS9;NTT^0
M+=W%LRSPPO$0Y_0N$:"IX.OB)64L364(7M>5.CRP376SK5G#3>7*MVD_YZ\7
M,>\3G.!RZG>4<NP4JU5*[Y*V-DIR4DMK8>A0G=])OHFSI:^EOV3OBW\+O WB
MGQEX6\9ZQ<^%_''C/4-)@\,RZMIMU#X=\2>%?"WAV[UIY-/\06\=UIL%]H.H
M:MXPN->AUF[TB2UTN.SO8;62QBN-0D^/H?'?@>XL[K48/&7A2?3[&9K:]OX?
M$6D26=G<+<V]FT%U=)>-!;S+>7EI:M%*Z.+FZMX"HEGB5M[X0?$Y?"G[05MX
MTT:_^'/B+1_"G@/Q1X.OH=5U/Q!=S:#XP\1>(O#LD]E=WG@/0O'&J^$+N;2O
M#TZ2ZOJ_@[5K:WAM;[2&.E+JMW>KZ/$-)XG*:ZI*I5DO95H0H)3=2,:L(-M*
M,G*E#G4Y.-K.,?>2NG\]X>8J.7\5X*IB7A\/2G'%86M7QLG1AAY2P\II1G*=
M.$,14E"&'@JK::KN*@YR@U^YNEZMI6MV46I:+J>GZOIUQN\B_P!+O;;4+*;8
MQ5_*NK22:"3:P*MLD;:P(.",5>=$D1XY$62.1622-U#HZ."K(ZL"K*RDAE((
M()!!!K\#/VC_ (U:K\4?''C'Q-X6;Q'\(+_PIH-E\"]*\=_"/6]:US4_%'CO
MXVW7P]_XJWP#JO@O1=,\0>,=3\+/K?A'P=HL>H>&[G6=+\=VOC;P8FFZ8T/B
M2TU;[Z^*/[1_A#P'X OM>^!_QH\/>-?&L&N>$/#NF_"OQGXBMO%$]I>^)O$^
ME:+JC^+-+O;C3_B]X?O=#TJZU+6IK/7_ !#9-;W&F_V7_94M[>6NGS?G%7 U
MZ2P:DG[7&QYJ=)IQFDZKHT^:]OXDHMQ_NV;W/Z-PN>8+%RS=TYIX;)ZBI8C&
M1G&I0G*.$ABZ_LW!R;6&A4C&KO[ZE&-W%H_G._X.9/#OAOXR_M%_\$HO^"<_
M@S2SI6G_ +0GQ^UCXQ_&WP]X9N+S2M(N?AM\*$L+"+4=3\):=+#X<U6^E\-^
M(OB]>P:U?:7)J%H/#"0R7GV+:D/ZM@!0%4 *H   P  ,  =@!P!7\U?QV^/O
MQW_:K_X+,?M2_M0:%96][;?L$_"OX+_LFZ%K?@7X1>/OC2_P^D^+?C/4M7\<
M^//#'P9\+:CJOC+QCXB\/Z+J?Q8\'>(;70YKVYM'OH?$]Y87'A[0Y-$D^POA
MW\8?^"HOCA/AKJ7B3X<>&_ (\=_''X3>%?$.B7?@'7+(^!?ANO[.'B7XC_&3
M7=3;4[75I=&M4^*=CI'@GPQK.K:KJVGWNIW$?@Z+4;/7;N*^;[3@^/+_ &AA
M70KQQ-/$2C7J2II4%2P]7*L*YQJJ34Z4*^<4[58ITJJH9C["=6668]8?\6\3
ML1_:^+R^OAL7A7@,+ED*]&%6I.E7J5<=A\5F4U3I5*<6ZTL!@:52KAD_K.&C
M+!RQE+#QS/+'B_V3KU7X1_!S7OC)J7BBTTKQ+IOA6U\+:5H]S+=:CX>NO$!U
M/4/$%UJL=C;6Z6WB#019V]C!H%\VH22-=22OJ.FM;HJV]RLW\]WBK]JS_@H%
M;^'/CS=Z?\.O%&E>,?"'B?P;I/P[\'Q_L??'/7]*U'X?:I\6?@CX?U7XIQ_$
M7PY!XM3Q)JT?A?QA\7H[_P"&_A+X>>,/$VFZ-X"LO'TVDV&EZ;-'XY_I+_88
M^-7PZ\*_"+2W^*WC.U\'?$/QUJ6A:IK)\<:)X@\!Z?'>:AHOASPSH&D6^K>,
M=$\.V&F2>(M4MI-6T?P7J+:/XBTW7O%MQH%]X;T_Q1/?6#]^99E6GD7]I9>J
MU.52>"M>$95Z-/$TZN)C*M3C[:%)QA0E0Q5*LXU<)BG5P&*IT<?A<9AL-XG!
MO#6#Q6?8.CG53!5<'5P^+FL/+$SI.O66%R^=*BK_ %>I*HUFU"K0]C*7MOJ]
M6K2=3#^RJUM3X<?"+XN?LY?%#Q)\2[GX1M\6K'7?"VF^&OM'PK\;^'O^$@T>
MU75EN=<U"3PM\1(/ D6JW%]!9>&B+32O$[RVEGH-VEK;ZMJ%_#!7C?QXU>U^
M/O[0G@C2I_#6M>!-)U:W\"_#RZL?B7X>OO"7Q!OVU36?&>G>*XO#VBWZVRW?
MA@:!X_MK\ZI]MU[3-<\0^%XH+33K*'1_[8U']A[&_L=3M+?4--O+34+"[B6:
MTOK&XAN[2YA;[LMO<V[R0S1-_#)&[*>Q-,U'3--UBRGTW5]/LM4TZZ3R[FPU
M&T@OK*Y3(;9/:W,<L$R9 .V2-AD XR*^!CF,WBYXVM3C4Q$HSM.+=&U:5-TX
MUG&"Y7*.DG&*A&33ONV?OE3AZ@LJHY+A*\\-EU.I1YJ%2$<8Y82GB(UYX.-2
MO)U(PJ)2IJK.56K2C).$ER11S/Q&\?>&?A3\/?'?Q0\:WXTOP;\-_!OBCQ[X
MMU-@"NG>&?!^B7WB'7KXAF12+32].NK@AG0$1X+*.1_/I_P;#>&_$/BS]A'X
MN?ML^/\ 3H[;XE_\%$?VR/VCOVI?$MT3(]PFF7WC>Z\"Z9H44LR12MHFE:]X
M2\8:CH2.@'V;Q!+-"1:SP1QZW_!RW\4X/V>/^"4'Q8\+?#2VUO2OB/\ M0>)
M_ O['WPO\,^#]9UC1])U>]^,6IWD_C;0%\':7J%IX?U)_$7PI\/?$31?+?2I
M)Y;K4K8O(54BOU<_8X_9K\1_L<_LL?L\_LU^$-2\(:]X=^!_P?\  GPZ6RO-
M)N_#M_J6L:#X>L;7Q'KT_BC1Y+_3YY-9\2#5M<F)\"1W>H3:A))?7[WKSWT_
MG'T)XW^V9XNM[GXD>'] ENX+;3? W@V;4[^Y>9%M/[4\<:HB&TOIY&$-M>Z1
MIGA#3KR* LL_V/Q7%/,HANK)I?SZT?XT:3+X+\+>-/%WACQQX%L?&=UIMKX6
M.N^"/&B:9XED\0ZO%IWA6'POXBD\-VNA^)-0UZSO=*U4Z+H]W=:UHT.H-::[
M8:?>Z?J,%M]?_'?X)_&36OB)J7C;QG\,M;\6>$-4\?\ ]J^+K#X=WMCXVT_5
M/A_<:$_PZ&CP>&SJWA+QIJ.N:7X*N;3Q-I M_"]WI^G_ !*\.Z;KD\.J6-JL
M%[TO[4GQ8^!?Q5^%>L^%?A\EM8_%SQ'K_AEVT76?!NI?#;XF:9<>"-?M_&5E
M>:]I?C+1?#OBF/PQ9>)_!^BZ=KNK6EGJB6MA>1:AH$.JW[Z'%=_9X3-JN I9
M5@L!3I8J-2DI8GEO4G[?$55)T^6#BX5*%W%\[<9QDME%2/QG-^%,-GN+XHSO
M/L3BLKGA\6Z.6QJ\N%HO!9?A5"%=U*T*D:^'QUE-2HQ4Z$X2;<Y3E2/ *[;0
M?B/XY\-1K;Z-XGU6"R7 &FSS_P!HZ40&#8.DZBMWIQR1R?LN[!(!Y-<35BU:
M%+JW>X#FW2>)IP@#.85D4R*@+*"Q0$#+ 9/-?;XBG2J4IJK0AB(QC*2ISIQJ
M<S2;LHR3O)VLK*[=C\2R_$XK#8JC+"8VM@*DZE.F\31KU,.Z<932<YU*<X-0
MA?FE=V23;/OSP+XB^(>L:.=1TFTTV]NK?$=_:Z+>PZ1J27'V:"YED&B)J$5C
M]E)G"JRZ/=SRS1RHBC9@=Q#\9-3T1C!XLM[G2)DC,TW]NZ5-##';Q[5EN%N;
M2*POVB5W"L\?AVZB7='F<'_6?*^F_MP?LR^ ?%_PM^ ?Q!UGP59_$;XB_P#"
M17OPY\+:OJNBP>,O%9TB5]2U>XT/P[JRQ7EY_9L-Q(TU_97<EI:6UH[75U:[
M85EU_CWXLTG64CNM FU(Z9=V%II\$.I7=[=R6\\EU<W>IPPM=7^H11PM#::;
MA-/F^P;6PJ^:)L_D-+"5JV-I82I3G1JU:\*4H2@Z<J?/*/-[DDN51C+F2:TC
M;HT?UUBLVP6#R3$YK0Q-+&X;"8"KB:=:G7C7CB50ISC"U:$I*<JU6G[)S3=Z
MCDF^9.WVQH/Q0T;7HO-LDAU2/!9I_#.HV?B)(T7&7N+2U>'5[4X.3'/IBNO(
M/09[2Q\1:'J4GDV>IVDMQQ_HK2>1=C) YM+@17*G)VD&($-\IPP(K\3(9I;>
M5)H)9()HV#1S0NT<L;#D,DB%71@>05((]:]"T[XL_$#3S )/$=YK%O Z.EIX
MCV>(+?"#"QJ-66[EAC Z+;S0X."I# $?38C@^O&[PN+I5%NH5H2I2].:'M$W
MY\L%Z;GYGE_C!@I\L<TRG$8=Z*57!5J>)@W_ #>RK?5YPCW2J59)+3F>A^Q5
M%?F[X?\ VH=2M/+35]&NH"G2X\-ZU<V]ONSDO)HFNIK=C*#WCMY[!#P%*@8/
MT)X3^/\ )JVA6GB2^\/^*K/P[?27WV#7-:\':K'IU[:Z?J%UIEUJ4^N^"CXU
MT30M*CNK.=X[[Q;_ ,(NDMFJ7^U;":.[KYW&Y7CLOY7BJ/)&4G&$U.$XS:5[
M1<)-[:V:32W2/T3)>*<CX@YUE>-]O4I052M1G1KT:E*+DHIS56G"-G)J*E&4
MHMZ)L^GJ*\>\+_'3X<>+[[4]+T'Q)HNN7^B"%M:B\+:YHOC%-($\5O-%_:A\
M+W^J7&F,\5W:2B/4K:SE\F[MIC&(IT<^GV&L:5J@SIVHV=X?FREO<122)M(#
M"2(-YL97(W*Z*1D$C!&?//H=]C2HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K\</V\?\ @E+HG[=7QB^*7Q#\9ZEH6F1:C^QUX?\ @K\%]:?6_&,]
MYX,^,V@?$_XB_$&+Q!X]^&]D+'X?_%#X27RZ]X3T[Q1X$\<7'B?2?&FC0>*?
M"NL>&+?2M3>\OOV/K\Q?C]K_ .T?\9_VL_%_[,WP4_:9UK]DG1O@_P#LI>#O
MC_=^-O"OP]^#GQ!UOXC>/_B]\0OBWX#\%:+XGMOC9X#^(.C6GP@^'$/P4UC5
MOB!I?@NQ\)^/O%=UXY\/VVE_$WP/;Z-,-<Y:_(JN%DW4A5@LUE0KTW33PK_U
M>SF.*Q2=32-6AE\L;/"SC&I.GC5AJD(.4$UUT9U(8/,E>DL'4611Q\:T)5(5
M80XOX;K9=AYTXQFZE'$Y[2RBAC*3A*E5P-3$T\1;#SJR7QA\-?\ @F=\:8?C
M;\9_B!\9/V4?V(]8N_VC/$BZEXP^-?P]_; _:%\/>/O@[X;\;?LQ?#;X"?$3
MPG\,/@K<_L:)X!\867A2Y\.^,F^'\^O?$OP0^O>']8T@ZO%X1O[>6VM^I^)7
M['?_  4E^.W[)&I_LC_%./\ 8WA\ ^!?@C\,_A5HFE:-\4?BK-8_M5>+?AS\
M4_@GXAL_B#\3=8D_9UM=<_9:\/3_  X^%_BW16^'_@"+]H6XE\5_%"XEN?%<
MND^ =&N_$O+^(_VH_P!KW4/A)^T_^W'HW[4&@IX/_8^^*OAGP+:?LU?#?P#\
M)=9^ W[0G@[P#X3^$VJ_&#7=6\;^)/"/BGX\P>+_ (V7WCWQ5J?[.NI_#SXP
M^$O"OA_P\_P;N]<\)_$9=2\4-XE^5_%'_!5[]K[P?9_%'X:^,?&&B>&_B1=?
MMC_\%"Y_V<?&=MX.\&RV_P 2OV1OV?=/_;[\%6/A";3=0\//I$_C_P#9U^-/
M[/OPRB\;W]AI_P#:%_X \;?!6]\2ZKK>I>-?&#7NN*K4\ORNG*44\+7X=R!8
M3#4J2G+,,FP/#]*EPI6I8*K&.'G6PG#?$6;YO2CB:5+$^RHYMF7$M*>:9;E+
MI1E6"JX[,8/#QY<1E>8YS"=?$UIJ.59A#&8K&\28">,A4GBH_6,WX4P&3UIX
M:M6H2Q<<IPV0XN&"Q..Q)]M>&/\ @EC=_$/Q1\ 8/BQ\!/A+^S#\(?@[J7[1
MFJ:U\.?V1_V]OVQ-;USQ=K/Q?\+_  <T70/$!^)^@_"7]D/QU;6Z-X!UK3?%
MO@2ZU6]\)WFG1>'M1;^W+NYN=/T;[[T[]DNS\#?M&?LK^-OA-I'@?P+\"?V;
MOV2?VCOV;=*^'VF-J-AJ&D'XH>-/V2=:^'=MX6TJ#2KG2I/#.@Z!\ ?%%EKU
MWJ&O6>JP7M_X=^QV&MK?:M>Z5^+=_P#M+_MFZ9^SY^R/XH@_:!_X*IS^)/VC
MOVF/A_\ #WQE#XA_91_X)T6'QX'A7_ACG]I+XV:S%^S;X+M?V9M/^'&M^$-?
M\<^$/!E]XD\0?$72?$?B/3O"_A&\M_#-]HTMUK#:QQ?[5G[;/[7WP5\3^)/"
MF@?M#?\ !1?3];\)_L9_LU^._A59^(OV8?V!C9:[^TK^T'^T)^UA\-_">G_M
M]>([[]GO1_ OP6\!>)M:\"_![X>VVI^ ?'?P)\.Z7X5M=>UN[\2P^+;BY\0S
M>EB\)6PV.KX6<T\32S#^Q*E*C+$5?K.,QG#..R^\(.,JF*E1RW'XC 4%&,JM
M/%UJ=# T)T%&WFX'%4<PP>6XJE4YJ.(RRGFF#J8E4J'U; 8[B.-%4YU)*G0P
ML)9E;%8ARG&B\/3GBL57G7YY2^E/AA_P3?\ V[?V>?V9_'?[*7PGU#]EGQ+X
M9_:I_9O^$/PE^//Q*\8_$3XG:1K7[/\ \3?"_P"S?X4_94^)7Q"^$_@NQ^"6
MN67[0WA/6/A?X$\':UX&\%>,/$_P O-.\>Z1JG]OZY=>'_%;KX8Z'Q__ ,$?
M?B/<^/?!7Q'^%/Q!\!>#_$'A3]O?X%_%C7XM2O\ Q)<V_P 3?V*OAEXB_9.\
M<7_PL\7SV_A.22/XM^&_B)^S#I/C;X:7J0ZEH>G/?>(_#S>)]$L/B;XLO--K
M>"_VB?VM_%O[5O[6VG^(?BI^V[I?AKX&_%KQ/X1\.^%OAE\"?V.=5_8AT>R\
M,_LI_##XG2:'XW^+/BSX,:G^TM+>OX[\4:[<75Q8>/K:=Y;WPSIMO-::9)=V
MX^3/A_\ \%</VP]8^&WP"^'OBSQ'X0\._M33_LJ_V-\9'U/PAX=N_"=U\3OC
ME^T7_P $V/A1^S%^V3#I%II^A2R^ [OX3?M?^(OB=K'@K0+KP]X#G^(&F_$/
MX870$GP\2ZTGCR&I4JYKA,WRI-9PL@X7SW#U)2HQG4RC.J6*\1>'<(I*?U+F
MHPX$Q.41A"I"4<+G&(P-;$U\LQN-Q^!WS&O'&2P.!S&$EAXYKGU/#TZE*?LL
M+F>&I8'AK.J]6C%3QT/:/'Y;CIRJ49T*6/RK 8BG##9G##X;&_U=45^ O[7G
MCC]LS]EM_@G\(=/_ &X_VA?CA/\ %?\ :R\%>&I=;^"OP+_8K\1_MUZ#\,-7
M_9/_ &JOB!JWA.]\$ZK\#M-_9RU/POK/Q2^!^B^)_"?BY?@AX9\5V_@W2?B#
MX=GU[Q!=Z*FIS>E_M9?'/X_?!S]CS]C6^\/?%;]M_3_&OQ9_:7\%_#CXC>,8
M/@-^RUXA_;AU/P9XB\*_&CQ9>:)!\';+X%^(?V>++Q=;W7A?PY9LOA[X/N\/
MA#2I+K,FMW&H:K<DN114XU(34LVR;)HI<T&\5G,\'3I3O5C3BL/@ZN-I4L;5
M;3C*%66%ABJ:A.>L(2DZL6G3E1X?SSB2K&7O.&7Y#ALUQ>*C^Z]HI8K$4,HQ
M$\'2BY1FZN'C7J8>4JJH_M?17\[/[+'[2W[87[73?L[_  4LOVF_BM\)/#/Q
M6TW]N'XY:!^TI>?"S]E>+]K?QQ\$OV<OBW\$_@U\./ /C_X?7WPO\=_LV?##
MXG/XT^,OB-_BYIL'P1L/%^AZ)\-?#?AO5_!?PO\ B!XC\8VOA[2_9W_:&_;;
M_;>\2?%?X2:7^U:/V;O%7['?PS\3Z9XG^(WPU^$/P9\2:9^TK\9M$_:T_;-_
M9ETCQ_XW\/?%_P '?$2U\,?!*73?V-D\7>)/ GPEO? 7BV[\0_$WQ'HFC_%O
MP[8>#]':ZSKU(X; PS*JW'!U,%6S&-7EGSK!818ZEF-6KA^7ZS0JY;F67XG)
ML;@:]&GF$,SCRTL)6PD:N+IS3:J2J13M[+&K+Y2=W3>+J8Q8;"0I3CS0K4<?
MAG_:V#QE%U,%4RSEJ3Q-/$U*6%J?T*45_*)X/_X+ ?M9>-=/_:7URXU70_#-
M_P#'+]B+]D[QM^Q%X7LO"GAO4])^#G[3GQ9^"W[,5UX\CNM1N]#.J^/_  X?
M'O[:?PQ\>V&G>-KC7X[?P;\,?%\D-I;Z6-2@?^CW]E#QSXF^)_[+7[-?Q*\:
MZ@NK>,OB'\ ?@YXY\6ZJEG9:<FI^)O%OP[\.:_KVH)I^FV]IIUBM[JNH7=RM
MGI]I:V5J)!!:V\,"1QKU_5YMYPE*+>28W!9?C;*HDL5C<=Q5E\:-.3IJ/M*-
M;A#,:M:G5=*J\#C,FS&A3KX'-<-B'G6J*A5RZC4C)3S3!5<?AVH^XJ%#+N&<
MQJJ51VA4E37%.$P,Y8:5>C#,LOSC!3JQJ8&];WZBBBN<T"OF3P]\%_%.D_MD
M?%S]H:YO] ?P7X^_9J_9[^#>CZ7!=:BWBBV\3_";XG?M,>-/$=_J=E)I4>DP
MZ#>Z7\9O"]OHEU:ZW>:A<ZA8:]%?:7IMM:Z?=:I]-U^-W[-?_!2+2/VE?^"G
M?Q[_ &</!7QG^#6K?"'X7_"7Q7H/ACX9:#XL\$:O\6-3^+_P?^+5GX&^,7CO
MQ/I5K?R^-/#>CVNLZEJ/@7PUX4U&RM(;S2/!$WQ.B.HZ!X\\,W=O-%QK9KE^
M7TW_ +9B*&>XS#W35*%#*<@S+'9A4K22=D\'"IA:$4I2GC<5A8M0H^VKT3%5
MWA,HS/$54W@:N(X<R[$J"3JSKX[BO)/[,IT;N*O#,J&&Q>)O)-9=A,<XJI44
M*53]D:***H HHHH **** /YG/^"<O_*/;]A#_LS3]E__ -4CX'K[+KY/\.>"
M_P#@W&\'>'M!\(^$?^"B_P ,_"WA3PMHVE^'/#'ACPY_P7L_:9T/P]X<\/:'
M8P:9HN@Z#HNF?M\VNFZ/HVCZ;:VVGZ7I>GVUO8Z?8V\%I:00P0QQKL_V=_P;
MS_\ 237P9_XT ?M3_P#TP"M%-))6>B2_+_@_T] ],_9D^!8_:?\ @3_P6^_9
MM/BA/! ^/W[1OBWX,_\ "92:#_PE*>%/^%F?\$H_V"O!O_"1OX:&L>'O^$@3
M1?[9_M%M%_M_1/[3%N;+^UM/\[[7%U/PW_X)%>*OA7I_BC7_ (?_ !C_ &</
MA1\25^,/[/GQM^&'AGX ?L9ZS\&OV2?!_CGX%:1\0O"NJ^)?$W[-,/[4'B[6
M/%7C;XS>!OB9K/@GXF^-?#GQH^'MW?:-X3^%<UGIL6H>!9KCQ%]G_L ^%?V%
M?#GPQ^(NH?L"_%;PE\:OASXR^+^H>)?B?\0_"W[5GC']L>75_C);?#CX9^$+
MVV\3?%[QW\6?C-XCC\0:5\+_  I\*]-B\)W/BZ&#1?#5MX=N;31K.#4UN+W[
MKK./N576IMTZOM<NKJI%M3C5RG,:6:Y?.,OLO#9A0I8A)6C5<%3K*I1<J;)V
MJ4Y4:B4Z4\/F6$G3DO<J87.,#/+<SP]1*W/2QF J5,+5A*Z]E.:ARN<F_P 5
M_&__  24\7_$CPGXWF\6?M->'5^+_P 4? O[:^D>/_&>B_ 74;3P%/XZ_:_\
M7_LV:_8^(O#'PZNOC?>:[HWA#X3^'OV:?#'A*W\&ZE\2M>UOQNNJ76NWGCWP
MY>0-:WGN_C']E7]N+Q1\3_@O\?+7]KG]E72/C;\)?AU^T5\(I]2/["OQ:U#X
M8^(/ 'Q[\0?L[^*HFM/ +_\ !02V\3Z%XU\'ZU\ 8#_PD-S\3_$.@>(--\42
M6;>"]'N-'%_JGZ8T5$*<*3PWLH^RC@\NHY3@Z=-RA2P>78?!8K+:.%PE*+5/
M#0IY?C,1@8RHQA4^J2AAW-TJ-&-,>KJ2E:4JN,QN85IR2<Z^,S#&U<QQE>O)
MJ]9UL=6JXMPJ.5.G7J2G2A!L_&WPQ_P1S^'6@:K\.[75/B@?'GP[\(>$_P!F
M3PAXM\"^/?AMIFNCXI:=\!_!/[:GA+QR?%]_#XET_0RGQMNOVRM:UG6M-M?"
M(T;PRGA6XT:TT[6;#Q1$?#/*_#K_ ()$>/O@7I;:C\(?VMH]<^(MMJW[3WA&
MU\1?M!?"/Q7\3=%UW]FK]I.'X*VA^#_CM/ GQ]^#GQ)U_P"(?PYLOV>_A=;^
M'_V@='^*GACQ)KCV/B/4/%/A35-8\22:E8_MY16D7R8G&XRFH4L3F-'%X?&5
M:,(495L/CZ668?%X>U*,(TZ%?#91@L).C2C3IK!O'8.,8X7-<TI8QU6Z\<MC
M7;K+)X82GEOM6YO"QP+SR6&<92;E.I"IQ'FU:5:HYU:N(J8/$UIU*^4Y34P/
MYUZ)^PSXPT']@P?L=_\ "\M"\:>*)]2US6-;\?\ QB^#,/QO^%GBVW\4?&34
M_BUXB^%?B_X%_%GXA^+]8\1_ &^TO6+[X/6?@75/C3<^/]$^%2:;8Z5\7K?Q
M;I=IXO3P7X8_\$R?C!\#M,^''BGX-_M$?!SP7\7/AE\5/C)XQ\(^'&_9L\?:
ME^R/X#^&OQO^'G@+P-XJ^"/PF_9]7]J:Q\<?#3PE9ZQ\,_#'Q/TIM(^/5UHM
MI\0M4\?3Z;X.TGPQXOMO#/AS]CJ*J52<ZV.Q$I2]MF22QM2+<)5H+$X/&>S3
MAR^QI?6,#AY^SH>SA;ZQ!15/&XV.(F*4:>&HK6GA*E:K0C+WE"K7H5L-5J/F
MNYSE1KU(\T^9I\DXM5*-&5/\B?A!_P $=_V??"OB[3/%GQSDT#]I8Z?^SU\'
M?@[+H7C?P--I?AF^\9> OC%^T?\ '#X@_$;4/"Z>,=:\+:QHOQ*\:_M"SOIW
MPW\1Z%KMEX&L?"%G /$GBEM6GDLO5/AU_P $N/V8?#6M_&_QE\0?"'AWXI_$
M+XS_ !;_ &C_ (D+XZU;1-0L=8\"Z5^T9)XHTS6?#W@ZWOO$?B+3?#^O:/X%
M\6ZSX$D\?^&;3PYKFMZ-J&J));:=:ZM?Z?+^D5%85J5*O3Q-&I2I>QQ>"S'+
MZ]"%.%*A+!YOB<+B\RHPH4E"E1^MU\%AG5J484ZOLZ;H1G&A4JTYZ4JE2C&C
M&E4J0^KYAE>:49J<_:QQ^2Y9CLHRNNZK?M9_5,!F.,I0I3G*C.K66+JTZF,I
M4<13_&3QW_P2Y^,_QN^#D?P*^/?[7/@_QEX)^'/[+WQU_9O_ &?M1\(_LU7G
M@CQ7H>I_&GX'ZO\ L[0_&3XZ7US\>O%.C?%KQCX/^%>NZUI,7AWX>Z%\!/!F
MO:WXB\3^(KK2M/\ M?A72?!/J&@?\$L_A?\ #'3OVV/!WP"U?P=\&?A?^VS^
MSS_PJOQ;X&T3X1Z;>3^"OBFG@7Q?\-1\5_#?BBV\4Z+JMQX/NO"/B6P-[\#K
MN-/"]GXIT6^\7>$-?\(:KXX\>GQ'^I=%:XJ4L:\;/%2=:IF5#%8;,:TV_;YA
M1QCQ,\1#&UXVK8KGJ8NK7A*O.I*CB(87$4)4ZV"P4\.9?-Y54RZIET:>$>48
MG"XO*H4J-)4<NKX.KEM7#2P6'<'0PT*3RG!4_8TJ<:,\,L3A*E.6%Q^/HXGF
M?!7AP>#O!GA#P@+W^TO^$4\+>'_#7]H_9OL?V_\ L+2K33/MOV3S[K[+]J^R
M^?\ 9_M-SY'F>5Y\VWS&Z:BBM*]>KB:];$UY<];$5:E>M/EC'GJU9RJ5)<L%
M&$>:<F^6,8Q5[125D<F$PM# X7#8+"T_98;!X>CA</2YIS]G0P].-*C3YZDI
MU)\E.$8\U2<IRM>4I2;;****R.@**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ I&945G8A552S,3@*JC)))X  !)/84M<WXM
MNA;:#>KYR6[WJIIL<[LL:0F_<6TD[R.52-+>!Y;AY&951(F8L,9H _-S]I'Q
M(=9\7:=IZ,#%IVFOJ4R@G*W_ (EN#JARN<+LT8:% %/S@0#>2Q)/X'6'_!*S
MPY<_'"Q^*_B[XDZ1J^AZ'\>]6^-^F^&/#GPRE\&^(_$<NIZS^TQXNM=+^*?C
MZT^(.H2_$#6/#WBO]HV6'P]XC;PYH=I:>!/!T?@V\\-7\OB?4]?M/V0\:Z]8
M^)_%OB+7]+DAETK5-6N[C2)+=TD@DT?S#'I+0R1DQR1G3DM2CHS(ZX96*D$_
M!_QH^!/QN\:>-+CQ!\,/C%'X#T>_\:_LX>)M:TC5[GQIKB:KI/PI\:>)-6\=
M^'-)MK'Q#I%AX)L_$NB7_ARZ*:3%J.G^,]6T.XT7QAIEMI&J7VH7/ZS@<''!
MX3*ZL<.ZV)P-.FZ:C**G3GC)4J>+JTH59PHRJTH5:M:$JDHS@J;5*I3J24C^
M4<VSJOF>=\1P680P>!SG%2I5IU*?M:=7#8*HZ6!A*I&G4KTDJ,8^]1<8MM>T
MM!<T/DN?_@D]H.D?#_X6>$?!7Q)\*&_^&VBWD6H0?%CX-O\ %[X:?$3Q/K45
M[8Z_K7CCX9:G\3-"BU30&LM2N-0\.^##XF_L_P />*]+\+:[]NU*RT*30]2^
ML/V1?V3)OV6;KXY,?&/AWQ?:_&#XN^-?BI:MI'@GQ)X.U+1#XT\;>,O&<VA:
MP=3^*?COPSJB:.?%B:1I=QX+\)_#+33;:=)>7V@7E_J$D]OY]=_LX_'V3X0_
M!?PG#XFT1O&7@+XH-XQUU[CXM_$"YT--+%W=M$LGB&^\!WOC'QTH6XN-5&BR
MR_#S4++4]02QTWQS;:)I4]EX@^G/V</A-J'P2^#'@3X=:WXBN_%GB31-#T\>
M*?$=[/;W<FK^)Y;*V_MR[BO8-'T&2^M'OTF6SOK_ $N#5KRU6*YU9IM1EN9G
MZ,JP>'P%+$X7"8;ZGAL-&$*"=2I5]O\ VG4IYKC*5)5G*4*>&QB<*CA.=&G4
MI4Z.'<:'+"/EYOFF/S%5JN.S'Z[6KXVI*K%T<+"I55"OCJ%/%U*N&YH7J1HT
MJ\*:J2YHX_VEY-5)3]KN+>"ZC\FYACGBWPR^7*BNHEMYDN+>50P.V6WN(HIX
M)5Q)#-''+&RR(K#C/C%XRTWP]X.U#XL_%/Q+XEU[0?@5X:\:?$E+SQ3XIUK7
MAH-KHG@_53X@UI+G7=0O)FN8O"Z:O9I)=7,EO;P7M[*L:3SR3UJW_B-(;B:Q
MTK3-2\0:E;NL=Q;:;'!%:V3M&LF+_5]1GLM)MY(TEMI)K".\N-9%O<PW4&EW
M$#%Q\:_MZ? O]IW]J[]D;XV_LX? JP\ ^'OB;\8/#-IX.TK5-:\<ZHFCC1K_
M %W29?&&FW<__"'6DD":WX.M]>T.2X97CMDU%KCR[H1BWEO%JBJ=3$2H4ZU;
M#4ZE6C*5*,YQG3BYQ4)N+Y)<T5JI*SWL99//&3Q5#+:6/Q&#PF:8G#X3&0I8
MJI1I5:.(JPHS=:C"<56@J<W[LH34EHD[V/SX_P"""'A'QOJ_['GQO_:O\1"U
MC^+?[:/[0/QA^,S:MJMC=WUC+':ZG>^'M&%W8Q7>GZCJ&DV_CBU\;W\=O#J5
MG+=6&I>3:75MO2Y/Z 7?Q>_:3L#\-H]3\.W\%QXQC_9@:>'1/@-\1]=M=-U#
MQOIGC2X^-^E>-M5T[4]53P-8^&I/#EI>_P!NZC80P>%Y=3\.^$=8C&H>([?Q
M%%^C/[('[ _@']E;]E3X&?LZZ5J>K75[\+/A]HGA_6O$$>IM?1:UXH,!OO%.
MIV\=Y86J1Z7=^(KS4IM*MHK*PE@TPVD=R)+P7%Q-T7Q+^$?Q%\+::=5\ Z)8
M?$5(&GEO](?6?^$9UU+.*WEF5]*@FT[5+#6+LR(L/V-[_3)9-X:V$\I%N?(R
MO,L!2P4,/4JSIU6LME-U%/W)82MB:V,C2E#F@EF#Q+IXB3M)QHT96;@DOL^(
M>&\]K9OF.-I9?0QV&Q-?%K"^PJ4N>CAYPA1P490JJ%3FPM&A148QC.,6JD83
MC[5RE^4\OQ/_ &MM?^,FM^!/#NARV7A:T^.>AZ3)XDU#X:^+O#V@:;\)AX;^
M,E_JDEGXP\2^#[O2M:UB6\\&^ XII=)LO$'AR6Z\3:>UE\1M+N?'5AX3\"?=
MNIWE[8>-?@O?1Z!H6NZ/I7Q>\.^)_$;>*=?N/#/AG1+/P-I/B'Q[H&MZUK%O
MX?\ $XLHX/'?A?PA9:;>7>E?V;INNW^DZMJ>HZ-8:?<:O8^#Q?M/Z#8>(!H7
MCGP/X[^',UY/8IIEOXRT2YT368(98+%=1D\3Z3J<-C'HL]AJ5V]K#::5J/B:
M34;1+>^@9)+^UL6^@=!\3^&O%5G_ &AX8\0Z'XCL"(S]MT'5K#5[3$J>9$?M
M.GW%Q#B5/GC^?YT^9<CFO14</CLOE@X8OVW/0]A5Q,)QG4DW1A2E.S;M&2AS
M.+<G)SJ2E.<JCD_F9U<=DN=8+-*^2K!/!XBABJ6#K4:E*C*5&HJL>:7+'W^=
MJTHQCR.,$H+DL>Q?'O\ :!T3QEXQ^'OA3X?>'?%_PA\<QZA>?%7QYXM\'>+/
M D:^)? MAI&N^&[/2M5\=_!/X@>(X-1\/^(O&.JZ?JUMI'B^_P!+U/6O^$1:
M_L_#<Z:1K5YX=^M/@-\2]8\0?LQ>%?C'/\?]#^(-S:_#I/&_CG6+G3/!/B31
MM(C.C3>*-1T6>#P-/X)FL=:\-6##1;I]5UUY#-IMQ-JEL]Y+-.GP$L<:L[+&
MBM(09&55#.1G!<@ L1DXW9QD^M<MXD\(V/BKPWIOA'6)XY_#^BKX3M]%B/AW
MP1+K^D:3X.UC1]8TSP]IOCZZ\*W'Q%M/#\ZZ+;Z)?Z5%XN6WE\,W%[X=MQ:Z
M3.MM'\UBN%:JPV&H86K1J3A6K5,16JP=*<XU51C34.7VKY*4:<FX.HDY2<HV
M<FC](ROQ5PTLRS+&YKA<;0HUL'@J& P>%K+%4*53#/%3Q$ZO.\,E5Q52M!1K
M1HRE&E3C2FVH1D_S*_;S_:G_ .&X?^"HW_!%[]FGXE?#*X\+^'_@AKFO_P#!
M07X[>$O#OB/_ (39;>?P;HT4WP>M[Z"_T?P?'Y%C\0?!?B#P_K>FRMJ7V[3_
M !-'"J74#/#J']:O@7X[_"7XCZ%X?\2>%?&EC+I'BV"&[\+3:[9:MX.N?$EI
M<R-%;7F@Z9XQT_0=4U:SN9%VV]W86<]M.2GE2N'3=_#/^P;<ZU^U+_P5 _X*
MP_M7:#+!+8?#C2=$_8U^"FLWL\\6DPW'AN.6U\4G3+ZTBN;J#39/%/PXT?Q7
M=WULDUP8O&2SZ>DD,OD)_3#=_M(_$KP)^S=I_P ,- \.^"_'FHQ>"_!GPDTZ
MRL=!\;?#/Q1X+L=831/AXOB$>'K6Q^)OPS\8:7X$TS49/&6L2V/QA\!M_P (
M_P"&;Z&QTP:U=6>CIXV.RAJ%*M@,/B*M.OBL52BXJ52$:5&K&A1;M%RBZTXU
M9\TY<KBXI+1M_99%Q=&5;%8//L?EN%KX++,JQ53VLX8:O5Q.-PM3'8R$5*I&
MG.&#I5,+0]G1I.HJBJ2G)N22_9.N?\2^$O"OC/3SI'B_PUH'BK2C()?[-\1Z
M/I^MV E"LJRBTU*WN8!*JLP601AU#$!ADU^2O['5_P""?!=Q\7X]?\2?%[PK
MX7\&W_PY^&/A:ZT]/B5'\-/#USX4\"6/BRZU-Y-!L+[X<IK>I6_Q)\.VFJ:E
MXT@*>(Y=/T?0%LKY=$:!^^TC]M#X@CQK\0_^$6O_  !\6_A)HOBE-"\ ZY/*
M^F>(_%%I8>']#7Q'JM[XW\)Q3>#S:6OC2;Q'IFE6FD?#VY<Z=H\ U'5_[2OK
MF#1^&.68JICJ^!PJ]O6PSJ<SBU3O[&2C.47.22M-I1O)-NUMSW)\3970R/ 9
MWFDOJ&#S*GAG"-6,\0T\73E5I0G&A3FY7I)SG:#44GS629Y!X[L_#EA\1_B1
M9>#K!=*\*:?XRO\ 1=%TM+R]NHK!_#=GI_AG7[>WBO+F[33K,^+-&U^:PTVP
MD2PMK"6V,-M:2236L/-53T^&Z@LK:._N!>ZCY2R:E?!"AU#4YOWVI:@X9G<S
M7]\\]Y,\CR2R33O)+))(S.V5XO\ %&C^!_"?BCQKXBNDLO#_ (0\.ZUXHUR]
MD("6FC^']-N=6U.Z<D@!+>RM)Y6)( "$DXK]5PM)X;"4*4Y.3HT*<)SE)R;E
M""4Y.3;;O)-[Z+R/Y4S3$K,<UQV+HTHTX8S&UZM"C3A&$84ZM63HTH0@HI<L
M'&*22;:N]6S\!?A\3^U;_P '!?Q9\:/G4/ G_!/;]G72_AWX?G'[RQ@^*/Q(
MLYEU&1(COB2]6U\=?$G1KJ=_*G^T>#[58T=+:.5?Z'2[E!&7<HIRJ%F**<8R
M%SM!QQD#..*_ O\ X-]_!NOZ]^SI\>OVQ?&]F\'C?]MC]I7XD?%2>YE!:2?P
MOHNN:GI.G0+<.!)/;V?C6\^(RVK;(XEMY8Q#&J')_?*N7*H\^%^LSC[^,KUL
M;[R3<8UIOV%KZKEP\:,4]]#U>*:KHYI_9M*H_99/@<)DON2:C.>#I1>-YDFD
MU/,9XJHX[<SO:X5D^%?A5\8/COXQ6?X6ZXGA?PK\-[>^O/$=]=>'(?%2>.M5
MUN\\0^#=-\/6.A:CXV^&MA<6?AG6?"_BN_\ $%Q+XUT;4K"_T[PS<:?'JFF:
MG<66H_3'P7_9Y;XP>'?$_B:X\8ZSX6GTKQ"GAW0+.WTS2-4T*\%KH^F:IJ&J
M:Q:W-M;:S>B:;7!IUM;:7XCT1;6?1C/-)=+<36U>E>%/AG^U-^SLNKVWPRT;
MX1?%GPGKGB=_$>MZ1-<:AX&\8WEY+I5G83R:(UY*/#VD17W]E6GVP:YXA\57
M%O?WE[JULT\3'1V\3.L\CR5<)@<1['&4<1&G4=2/(FJ;;E[*M)^RCRU%%2]H
MX\T>96M>_P!KP9P/4]MA<WSS+GC<HQ>73KX=4)^V<)UXQ5-XK!PBL544\/*I
M.G]6C4<)NE-7ER\OY[PS_$+2/&/Q=\">)E\.7?BCP!KGAWPUI.E:/I>OZ7)/
MJ^O^"_#WB33K351J]Q<&>^U:^\36%I;Q:%)J&CK$81I&O^)(KB+4YOWE\$^%
MK+P-X-\*>"]-DDFL/"?AS1?#EI/*JK-<6^BZ=;:='<SA,*;BX6W$\[#[TTCL
M2223^6?AWPIXKU']I/2_B/\ &3P[K7@"'7_&5OXI\4R^)(YK7P5H4/@>#6]6
M\":-;>.)=(T?PKK6N:=K$'@[0_[2%[/J.N:3HD2:8C:3IR&#VG_@J7^U78?L
MA?\ !-[]KW]IS3M;M+;4?!/P'\7/\.M7@N5FM)_B1XWL%\$?"9[>XM9#Y\%W
M\0?$_A<"2UERUN[RQRHH\U?G,[QM;$T\NHUJM.M5I8>56O.E4A5@ZU>H]'.F
M^1RC2A3;C'W82E*,6XV9^C\$Y+A,NQ/$6,P>$Q&#PN*S&GA<#1Q6'K8:M'!X
M+#P]]4\1^_5.KB:]=0G5M4JPI0J5$IR:7X]_\$1/AYX5_:]_:S_X+%?\%+?%
M6FC7[#XU?MGZE^SO\!?%*WUU9ZC:?"3]FC2+?PU8>)/!VNZ5<VFL:1;^+M(U
M'P7:7=[I.HVYEE\)&RCD,=O/YO[-_'SQ#<_!O7_ NC^&=8U/7?[;LO$FJ7ND
M>,KB'Q6FGZ9HSZ+9VN?$EY /B&EWJ5]K4LEC=:EXSNDG@TG5;:"&06Y-G\_?
M\$'/V>Y/V9O^"1O[#?PZO],&E^(=;^#.F_%[Q7!)"8=0/B/XYZCJ7Q?O8M9W
MHDSZKID/C2TT2Y%QNEMETN*RW&.UC Y[]KCQY>W_ ,3?B/JFA6]SK&IZ';Z!
M\*_ >G:=87&I_P#"1>*X8Y?[(T:VL89K8W&JZE\3O&6H^"\37FFV]Q?V=E8&
M\M@$NWPR3#TL3CHK$\KPM"E5Q&(4W:'LX1LKMM))U)P5[J][=3OXVS'%Y;D=
M1Y:ZD<TQV)PN R^5&+=;V]:JIRY$E)R:P]*L[6:32;5D?1WAK]JI[=4AUK3M
M:T_&U3/I-]#KMF$XX72O$)2]C5.BB/Q#DI\AR0&'O7A;]H3PSKB(HUKP[/.S
ML@M;Z\D\)ZD%#$(S1:V&TFXFD4!FBLM8D7)(3IMK\?\ 5=3^)G@"^^'WACXH
M_##6-"\2^,]2M]"_M"TU#2FT!KVW\,ZSXAU?4X+34+G3O&-OID47A_4EMI=0
M\*6=E<S-#9VFHW-TES'!WM?4KA_)<RINOE]:I2BW:]*3J4XRLFXRA53FI)23
M<54CRW2LE9'Y6_$'C3AS$QP6?X/#XFHHJ?)BJ,</B9TN:4(U*=;".%)PFX2C
M&I*A4YG%N[:E?]I+?QGHSQQ27IN](695:*34[9XK613@;HM1A,^FR)DC#I>%
M2#N!*AB.FM[FWNXUFM;B&YA;!66WECFC8$ @J\;,IR"",'D$'H17XI:-XG\1
M^'G$FA:]J^D,&#$:=J%U:1N1VEBAE2*9".&25'1@2&4@XKXL_P""C?\ P5*_
M:"_8R^'GP*M/@WX*\ _%WX[?M$?M)?##X ?#;PEXLL=5TJ?5[OQA<WSW<PO?
M VH>'=3N)C<VVE>'K>YN/[3>TU'Q/87*VEPZ*%\3,.&<3@:-3$QQ%"M1I1YI
MMJ5*I:Z2M!\\6VVDE[1-MI).Y]OP_P")N6YWC<-EU3+L;@\9BZBI45&5+%8=
MRLY/FJIT:L4DI-OZNXJ*;;6Q_4-17S[:ZW\7O#201^(_"6I7RJB2W>I>$-3T
MOX@>'H5*A)&G@U4> _B,LOF*T@TW1O#7BLPPR6Y34;V4W:PZ'A;X[^$?$T-G
M+8:KH>K1WL,,]L^DZO#;7EQ'<HDD+1Z!XB71=9!\N12\2P3S*0P"%L+7SD:=
M22E*,)2C!)SE&+DH)WLY.-U%.SM>U[.VS/T6>)P]*=.G5KTJ52LW&C3JSC3G
M5<;<RI0FXRJ.-U=03M=7W1[E17.Q^*M":1(+B]_LZXD(5;?5H9]*E9S_  1_
M;XH(YCTP8'E1\J49@RD] CI(BR1NLB. R.C!T93T*LI(8'L02*@W'4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7Q-^TW^R_P#LA?M,>*;>/XY:CJ-CX[\ ?#'Q'_;,G@#]HSXK
M?L_>-6^ OC?4%3Q9H?Q+N?@M\3OAQX@\5_ OQ3JW@UQJN@^/Y-6^'UWJGA^_
M=+5+ZUOW'VS7X??MM_LY?M-_%K]K;X^^)O@M\6OB]\#_  TW_!,^R\&W&L^!
M?@Q\/_B1HGQ>\5GXE?'R_7X5Q:O\2/ ?B^TMO$ME8:E8W7]C^"KBQ\5M:>*;
M&YG1HY])>O+S7$RPF'EB(8>G7J8;!Y_C:3J0G.-*MEO"V>YG1O[*%6LH8JK@
MH9=65"G5Q%3#XVM1P]'$5ZM/#U?3RW#QK_6&\5+#.-?AS#I0ER2K0S?C+AK(
M,0HMN*Y\+A,VQ&94G.4*,*V!IU<35P^&A6Q-'Z1NOV1_^":_B[Q=H_QXL)_!
M,.DZ)XV^!6A3Z'X%_:.\:>%_V:?$OQ5\'VWPZTG]FF/X@_ ;P7\4-)_9T^(G
MQ3T"RNOA#IGP>G\=> -?\7M;+\);7P\UTND?#U=/\_'A+_@C-^T7X<U[2=,^
M*?[)GQ9T7]EKQ1^TY^T%XSO?"'[5.C^(+_X$:G^TG'\7!^U!XW\?>)_"GQ8D
MUOP%X0\9CXI?%&;Q18>+=5T[P+X;GEM;O2--T&X\#>$Y?#GYK?!3PI\4] ^%
MOA;]B_6_@-^T7IGQA\=_MW?\$T_VF-%U*Z_9^^,"?".Q^"7P<\(_L%?$CXI^
M+O%GQT_X0S_A3G@?5?!$_P !?B7X!U?X>^,?'&A_$I_'VEZ7H-CX0NSXCT.X
MOO!_&?PW^)?QI_8$^$/P@^%G[+7[3^C?'+]FG_@GE_P4#\'_ !UU;QC^R1\?
M_A)>ZU:_$?\ 97^(_P -/"W[-WP^UGXD?#'P?<_'WQ+\3OC5K?PU\>:/X<^#
M;_$30Y&^$L6K:A?V6IS^$8=;^BS/ X?ZM5HU:]+&4Y8K$2Q&$Q"C6IK&X?A+
MA//<?F52#<Z=:GE?$>-S+(<?6:BEB^'IX>6-HYCE]?#1\3(:]6MA<'BY4Y97
M7G'*J=.=-SHPH9=C,QS_ "O 89-0C.C4QN34OK.6TG*$88;,ZDI8:6!QJK/]
M^=1L?^"<?[<'PI^#.@^$OC]\/OB?\._A+\4]&T3X'^,/V8?VU?%_@K7?#'Q@
MT7X4>,_"6G>%/"?QE_9F^-?A+QW<^-&^#WB7QQ9WW@]?&EYJ&L^$K[6-1U;2
MKZW@>\AX3Q#H?_!)_P"%'BSQW^RE\6OC_P#!I_BU^T/\)/!O[,GCSX1?M-?M
MR>)/B5^T#\5_A=KWB/XJ:W\//AW?VG[0/QT\6?&;Q!<ZQKG[0'Q%@\%W]M<R
M^*[^S\4Z3X>T+5)='\->"M,T+\U?C'K=SXP_;D^"O[;'PV_9J_:UT+]G?X;>
M-_V3?!_Q@UY?V&?VLO#_ ,2OB!XO\&> ?VZ'F\6V7[.3_!*U_:+\3>%O@]I7
MQ6\(^$K[XG+\)I_#5W?_ !1MO#NBZ[J<7A;65TCV3P?\1O&2?\%%/CI\4=.\
M9?MK?"7X0_&WQU^REXC\)>"8_P#@DY^U3XZ\+_%K1[#X.>!?"VN2>,_BQK7[
M,6H:M^SW-;:M:7/A/Q39^-=5\ ZCX'CL)_$6M6NCQ)-J P<9XU*6*=2^9Y_C
ML#FF&Q3G7K5Z:P=%8?'XM\DI5Y9[1JXK'8.<<-F%2KE4HTO9UZM/&2HW%1R_
MV=#"J%*A@.#LASS+,1AXK#X7"XB69XCZQE6%A!^RH0X4Q,,)@L7&>(RY8;..
M>O?!>VP6'J_IAI?_  3D_9>T/QKK7CS1%_:.T?5O$^IZ=K7B[0]*_;@_;<T[
MX<>-M8TWP7X>^'BZMXZ^$5G^T/#\*?&^I:EX.\*>'M&\27WBSP9K%UXL73(;
M[Q1+J^I//>2Z^M?\$[OV,/$5W9ZAKOP(\.ZK?V/[*,G[$$5[>ZWXQFNY_P!E
MQM2\/ZS;?"S4;EO$GG:M#I.L>&-&U;P]XNU5[SQ[X:U.&\O_  _XITV[U;5Y
M;[[2HK!>[&4(Z0E1I8>4%I&6'H9=F&44*$HK1T:.4YMFN5TJ37)3R[,\PP4(
MK#8W$TJFE-*C*$Z*5*=-35.=-*$H*IBL)CJBA*-G%3QV7X#&346N;%8+"8B5
MZV&HSA^>@_X);_L=-X>BT6XT'XZW>MQ?%#2/C(/BU-^V1^V,G[14GQ \/?#K
MQ5\(_#VI3?M,6OQYMOV@9=&T#X9^.?&'@K1O!K_$D^"].T3Q-KD5MX?2XU2^
MN)_HC2OV7O@_IOA/X0^#;RS^('C+3/@3\0Q\5?AEJWQ1^-OQM^+_ (YT?QZE
MIXPT^#7M:^)?Q3^(?C'XB^.19Z=X\\4:9I^E>//%/B;1=-TN]LM-L-.MK'0]
M!M],^@Z*OVE3FC+VD^:-;!XF,N:7-'$9?[%8"O%WNJV!6'H?4ZJ]_#>PH^QE
M#V<.4Y8J$Z:BE3J8;&8*I3LN2>#S"GBJ6/PDX_#+#8ZECL;3QE"2=+$T\9BH
M5H3CB*JG\/\ C;_@G1^R7XXBU1Y?!'C;P3K.I_&+QQ\>XO&'P?\ CK\>?@GX
M^\._%'XH:+I^@?%+6? _CSX2_$OP;XM^'^C?%&RTRWO/B5X'\$ZQH'@/QWXE
MEO\ QKXI\-:IXSU+4/$%SA>-/^"8/[%7C;PM\.?!DWPP\3^#/#OPP^'%[\&]
M$L_A#\;?CM\$[GQ%\']5O1JFM_"SXIZO\(_B5X+UGXS> M?UEKO7=>\.?%K4
M/&ECK&OZOXCUV_2?5O%/B6\U;[]HK.,8PA3IQBHTZ*PT:4(I*%.."P,LLP<:
M<5[L(87+9U,OP\8I1HX&I4PE-1P\Y4W;G.4YU93E*I4^L>TJ.3=2;Q>-698I
MRFWS2>)S%+,*[;;JXY+%S<L0E47QYK7[ 7['^O\ B[1_'.I?!#P^WB3P[XOT
MWQWX>N++6/%VDZ=H/B71O@+<?LR:1<:)X?TGQ#8^'M)TS3/@C<+X-L/#MAI5
MOX<M)[+2/%D&DIXUT/1O$=C],>!/!'A?X9^!_!OPW\$:9_8G@OX?^%/#O@CP
MCHWVW4-2_LCPOX4TBST'0-,_M'5[N_U6_P#L&E6%I:_;=3OKW4+KRO/O;NYN
M9)9GZNBG'W9XVI'W9YC7P^)S"<=)X_$X2G7I87$8V2L\57PU+%8FGAZM=U*E
M&GB*\*<HQK5%++V5-O#2=.'-@\-+!81\D;X7!SE3G/"89VO0PTIT:,Y4*7+2
ME*E3DX-PBT4444%A7S!X7U/]D;Q)^U#XU;P5XV^#FO?M:_#GX<P>#/B-X/\
M"WQ(T#4_BGX&^'7B/7=/\7VD/CGX8:1XBGO_  W:ZUK4FFZG9^(/$'ABSU&^
M2XMH+;5)+&Y2"3Z?K\7OV;;OPQ\1_P#@HU\2M4@^!OQE_9_\._LYI^TSX"^$
M.D:Y^R7^TIX%\,?'#QA\;OB/\/\ QM^TU^TMXF_:,\5?"/2/@1K.A^-_&?@G
M0=-^"/@7PI\4]=U?Q;HUOXM^*6K17L.J>#]!\ S0][,L-%)*=+!9QBH5X^Y7
MPUL!/ U)4:MG-0Q=#,:N68JCAH5<37PN/K*K"EE,<VQN#6(5-8"LZC4HU,=E
M.'E0J*,Z%;_;8XVBYTVU&57"XW 83&X6==TJ%'$8>%>E6GFM/*\NS']H:***
MH84444 %%%% 'Y=_\$K/^48'_!.#_LPO]C__ -9[^'E?>E?!?_!*S_E&!_P3
M@_[,+_8__P#6>_AY7WI0!\!?LX?$SP3\%O%?_!9OXP_$K61X<^'7PI_;&TKX
MC^//$!LM0U+^Q/!W@G_@D]_P3H\2>)=6_L[2;6^U74#I^C:;>78LM-LKR_NC
M%Y%G:SW$D<3]]XK_ ."DOPP\#?!7XI_''Q=\"_VL/#_A_P"">F0^*_BAX=U+
MX,>1XL\+_#6Y\&:_X]MOBPD?_"2GPUXC\ /X>\-:P;R]\)>)]?US1-6M7T#Q
M#H.D:TKV">>?L[>#=7^(OB?_ (+-^ ?#_C"Y^'NN^-?VR=&\+:/XYL_#OAKQ
M?<>$=3UW_@E%_P $Y=,LO$2>%/&6G:OX3\3+I-Q<QWDOA_Q)IE[HNL11/IVH
MP-:W$F.'^'?_  2KU3PK^SC^W1\ [OXI?!CX?Z9^V;\#=3^"NG^#OV7/V;-?
M^!'[-/P7N]4\"?$?P;JWQ7\(_LXZS^T'\5-/3XB>,YOB#!?_ !#;PKXY\ :!
MXITKP+X#T9]+M=9TG5/&6O%)<TL:JL_91CAL)/!2MS*IB/KDOK=%Q2;5\*H-
M5*DH0A>2A&K4ES8?6U/_ &#5VGB\13QZLVZ>%E2P\<-7@]$G3JRQ,YTXQKSK
MN%)-X:-)PQWV)>_MR_!;PWKG[,OA'XCZ;\1_A-X[_:QU_P 6>'OA?X%^(7@Z
M33_$=A-X1FLK"YU+Q[_8M]KVB^"M$UK7=>\$^%?#&JZKK M]=\7_ !'^'_A>
MS)UOQ-:62\IXJ_X*&_!W0_']O\+/"G@+XY_%WXA2Z[\>M#G\*_"KX?6NNZE8
M?\,V:M\*M"^*VK77]L^(?#MLVD:5J_QI^'UCILUG<7=YK4VKR_8+*5;*X9/(
M_P!JK_@E[X>_:R\=?$?XG^,?CE\1_#'CQ?@W\,OAO^S'J'@K6?B%X6\/?LZ>
M,_A=XUOOB_HOQ8UOP1X8^*6@>%/CUK5U\<;#X9?$2[\.?$#3+30([?X.^ ]!
MM8H;FWO_ !#=\%XU_P""-WP8^-OC[5O$W[27B+1?C)X4UU/VU;F\\&'X>W/A
M6YTGQ%^V+K/[.&IR^*_!OBV'QYK6J>$O$/PQM?@/JVG:'JMC;3:AJR_$!YUN
M]#'AV6W\1Y)U76K<\4J<<!Q-B::IV]E+%T<3D\>$\!3J5)NO6KXS"QSROFU2
MM1P.#I5:V P=+&4HT*N/Q'.^?DRQQ2O5QV3T,QYM:N'PE3)\_P 1GV.]G%PH
MPI8?.*O#>6Y71P^(S'%5J.$S3,<32A3QM#"8/Z!T/_@IK^S7XQU#X>1_#O3O
MC/\ $SP[X[^'WP-^*6I>./ OP@\6ZQX:^&'@C]I+7-7\-?!G6/BC;36MEXL\
M/#Q1K?A_7;;5[73?"^NW?P\L](O]=^)T/@SP[#_:[>U_$K]KCX3_  N^&OQO
M^*FN6WC35?#/P%^(.B_"[Q5#X9\-/J^KZ_XWU]OAW9Z=HW@:R^UVZ>(V;7OB
M=X>\*W-R+FSMK/Q-:Z]I=U+$VBW<H_.KQ=_P2>^)GC1?@';Z]^T+^S]>ZA\$
M_A]\%_A]HOQ<T_\ 8?T+P!^T?\,+3X/ZRD]UJ/[*WQA^$WQO\ /\!K3XD>'[
M'2;3Q=X"UWPU\6?A=:^*(M5UG0O!-EX%U9OA5:_4_P 8/V#S\6/V&_B1^R%<
M?$'PQ'KOQ2\8ZS\1_%?CWQG\+I_B%X(UCQIXI_:''[1GBV#Q%\)V\?>%+GQ%
MX'USQ!-?^%9?";?$32Y8O"5S%IZ:SBU17WQ"A"..]@Y5[5L[HX&,4J<Y4X9A
M@7DN-G5JOD]G5RV&8PJ825"-55J^$K5Z]-X:KA\36$O/$8&&*<:%&3R66.JV
M=:C3A4P>+6=4J:I.GB9XBACG@94:T:?L*V%CBX4J4*LJ%0]E^'_[6GA#QIXV
M\ ?#;Q!\-?C7\(/'OQ/MOB?J/@KPK\7/!-CX=U+6-'^$5E\/[SQAK8?1_$'B
M.QMM-C/Q)\/VFF27-Y%<:C>0ZM%';*E@9)><T_\ ;6\):]\6?B;\)_"/P6_:
M-\:/\'_&U]\.O'OQ"\,_#K2[KX::1XRT[P#X=^)%WHD?B"\\5V&I7TZ>'O%O
MAV)9+/0YH)-5U6"P25F6:2+Y#\(_\$Y/C]\+_$'P7\<_!/XN?L!_ WQ=\&KO
MX\0VGA_X2?\ !-GQ[X$^"?B70_CQHOPAT[6KG5_A=X;_ &_=,U=/'^EW7PCT
MZ1?&T7Q#>QU/1[VVT:Z\)12Z/#JMWTWPY_X)O>)?AY^V3X__ &LSX@_8F\6Z
MM\2OC!:?%K6_$/BK]@K6M0_:;\,M/\)? WPJ\0^$OAG^TT/VLX_^$/T&\M?!
MU[J.@I??"?Q*V@V_BG6='OH_$2227]Q'+*IF/LE5A0P#R3%..+G2G4]GGSQO
M#T<$JF'A-UZ^ A@*W$4\3"G/#SJ8C"8:5*M3C*EA\4ZC]G@H3A"5?&RQ3<Z"
MG&"C@H+.$X>UE&%.&(K5*63RHSBL33A0Q%95HJM&I[#[0^''[6'P5^+>H? C
M3OAYKNI^))/VC/@+J7[2WPWN+71+Z.S/PATV3X;V_P#;_B:>>.+_ (1B\U&\
M^*GA6PTC1-56'5M1O(_$$-O:-_PC.MM9?2%?#G[)G[$6A?LK>/?CUXVL_'E]
MXXB^*/B.2T^&FAWOA]-$M_@A\%5\=_$CXNZ;\%=$GCUK58M<TK1/BK\:OBQJ
M^EZY#8^&?)\&:CX#\!2:'+;_  ZT_6=4^XZTE*G4A2J0I5*$ZL:M:I0J5(5'
MAE7Q6(K87"2G!<LZ^!P%3!X+'5J<ZM#$YCA\9B\)..#KX>E3FTH5*]-S56G2
MJ*C1KJ/(\5&C1I4JV+Y-'"CB\7#$XG!4YPI5X9?5PD,90H8U8BC HHHJ"@HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *^7_VM](\.^,?@G\3OA]XMCO)O"WC?X9^.O!OB&WT_4[[1=0GL/B#
MH5U\/&CT[5]+GM=2TS4$MO$]_=V>HZ?<VU_8S6:W=G/%/"LL?U!7P?\ M7^*
M2UO;Z!#N O\ 6$\Q\$!K3PU:,#&&S@I)JFOW)9><OI\;$@KM7ORO#?7,PPF'
M:YHSK1=1;WI0_>54_6G"2/!XHS-Y/P_FV81ER5:&$J1H2O9QQ->V'PS7I7JT
MW;?0_D,_X<A_%[X W;:G_P $^O\ @I%^TE^SO8VTSWMG\+_B#.GQ3^&,TZN9
M;6Q;1[>_\,:'#86\C.B3Z[X-\:W@MWDBE-P99I).E7XJ?\%ZOV8$#_$KX!_L
MT_M^^"M-'VF_UWX)^+)?A/\ %:YLT^60/I>M:=H.D7%\502+I_A;X7Z[+YLI
M6*6XC^6#][J*_3UE=&G_ +I6Q6"?2.'KR=)/I_L]=5L.ETM&G'30_F%\48W$
M66:X3+,Y6SGC\%3ABG'JGF&">#Q[;WYIXF;3U=]C\$_#G_!P)^SEX6\0V_@O
M]L#X _M1_L6>+7RMQ_PMCX6:UJ_AF.:-E2=+2\T&T'C74(XV;S$NH/AX+6:W
M F24%XXV_1SPK^W;^RW\:_!DFM? 'X\>!?BG<7<EK:7%I\.M13Q;XU\*V%YY
MC7WB+5_AQIT-UXZL4TC3X;N]@@OO"V;B]BM;:6 032RQ_5/B_P $^#/B#HES
MX9\>^$?#'C?PW>_\?GA_Q?H&E>)=$N\*R#[3I.LVE[83X1W7][;O\KLO1B#^
M3OQS_P""$7_!-GXU7,VM6'P;O?@5XK,AN+?Q7^SYXEN_AQ-IMRK"2"ZTWPJT
M.M?#FQGM)E6>WE@\%(R.HR60!1,H9M14N2MA,9&S_BPGA*RT_P"?E-U:,GN]
M:5)>:W6D*W">+E%U<)FN35.97>%K4<VP6ZU=#%+"XN$7L_\ :L2[;1EJC]+O
MAI\7/@OX[MQI/PR^('@OQ!-IQDBN_#^D:[92>(]+G(:[GCUWP[/.GB/3-1E$
MC7UVNM6%O?S^<U]<!_/,S_8OP,TH7GBJZU)U!32--E:-B,[+J^86T>#C S;?
M;1U!],C-?R5>,O\ @EO^TU\.['3;O]GS_@J+X0^+>CV.G7>H>#?AO^W!X;\)
M?%#1UT+1Y9Y+EM&^*UQ<>,?$_A?2]+N+6Z:74_A_X3T"72)[>>6"]LI(IL=?
M\ _^"C?_  5S_P"">?B3Q,O[2/[#NC_M5? OQJNA)X.?]E+XKW?C2_\ "$GA
M_P .6UQJVI^&(]8U?XV?%'Q%H6H:!&GB@^'/$Z>%M(TA;[4=5T74-.T)ETVQ
M\[,,QQ,<%7I5L#7HRE!0=2FH5J,8RDXR<I4)U>2#4*D$YN+<HN/*K2M]'P_P
M]EDLZP6+PN>X'$4:%26(>'Q4JF"Q;G2AS4E&&.I87VM1594ZLE2C.$81D_:N
M7*I?VN45_/Y^SQ_P<Q?\$L?C==Q>'O'/Q'\>?LL^.#.MG<>$_P!I'P#J'A>&
M"]5%:<2^,_"-SXW\":99HQ/D7'BCQ'X;N9HMCRV%M*YMU_<KX;_$_P"&WQC\
M':1\0_A'\0?!/Q1\ Z_')+H?C;X>>*=#\9^$]7CAD:&=M-\0^';[4=)O?(G1
MX)Q;W<A@F1X90DB,H^2C.$_AE&5MTFKKU6Z^:/V&I2JTK>TISA?9RBTGU]V6
MTEYIM'0:]X<\/>*=.ETCQ/H.C>(])GSYVF:]I=CJ^G391HSYMEJ$%Q;291W0
M[XCE'93PQ!^7]?\ V)?@7?WEUJO@^P\2_"/6[W'VO5/A3XDO?"R70C:5X([G
M0Y%U'PQ-;6YE98K4Z((!#':VY0PV-@EK]<T52;C)2BW&2VE%N,H^DHM27R:,
MIQC4A*E4C&I2G;GI5(QJ4YVVYZ<U*$O246?G[>_LR?'SPV[_ /")_%3P1\0]
M/(S%8?$CPU?>$]8MPF2D">)_!;:G9W:L&,9FO/"37&R.!I9IYQ<SW/QK^V-\
M;OBO^R'^SC\;?C;X]^ _BVWB^&GPZ\3>)M.U?PQJOA_QMX2DU:RL)$T4:OJ5
MC<VNI:/IUQK-WI-G)<:IX?@ D>],L4=C;Q7UW^YE?D7_ ,%Q/V=OVH_VM/\
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M&M-U[5)04^>$;2JKDY8)06U7Y.7OA:#]K_\ X.!?^"?GP$\N+4_!7["OP?\
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M5V"MZ5+\2/B)X4,:^,O"5O+;/*L$=] 7LHW9E9D\R^LIM=TPSN$<I"XTYI
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MT:+Y6N>,7H?H[17R_P"&?VE/"NKQP)-K>CQ7;1QB2RUR"]\+W)D*+Y@&HO\
MVMX>8K(2 TFHV*R[1MCBW[4]KL?'>D7<"7,T=U:VLG":A&L6J:1*P&<1:OH\
MM_9$$!BIFD@)"-P,IO\ &K8;$8:7)B*%6C+M5IR@WZ<R5UYJZ/LL%F67YE3]
MKE^.PF-IV3<L-B*591OTFJ<I.#Z.,DI)Z-)G:T52LM2T_4H_.T^^M+V+ .^U
MN(IU .0-QB=MIR""&P0P*D @@7:Q.T**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "ORN_;7_X*%_$[]EGXC^/?"G@7X"?"?XG
M>$O@U^RQ+^UI\7?$_P 2/VI)O@'KUMX$M/$_CK0KSPW\+_#4WP&^)OA[QYXS
M%GX U:^L[3Q9\0?A9H=S?7VD:5<:]8Q7,^J6OZHU\/?$?]@7X!_&C]K73_VJ
M?C;\.?A!\9K[PQ\%O!_PL^'GA;XI_!GP9X_N_AQX@\+?$;QE\0)OB-X,\6^+
M4UF;P]K.K'Q18Z5);Z'H>EWMN?#]I?MKUWYD-G8Y\M26+P*514<-[3'_ %VI
M*FJT8P629J\"Y45.E6K1_MG^S+T:%?#3J_PZN*PN%EB,13Z(3PT,%F<ZE*5?
M%QIY0\NHPJ.C*K-\49 LVA&NXSH4&^&GGMJ^)I8B%!I5</A,9CH83"UOAOPK
M_P %B-8\0?%#1M&N?@G\%;;X7^*?VGO&G[+WANVTO]K>?4_VO%\0^&;7Q1)9
M>./$W[(VH_L\^'[31_ \\OAF6_\ %-SHOQU\5:UX(\(3W'C&^T?4-,TC5H[7
MU+X5?\%5;;XE? 74/BK<? F]\.^/]17]@Z?X:?"(_$6'5;GXAZ7_ ,% _"?P
M?N_A+X@B\4)X)L'T;P_HWQ&\>_$GX>^)=17PSJYM[;X&>,_%R0+:SC2=-OI_
MP2J\':'XXA^-7P^\<^&? G[1*?M8_''X]ZC\:--^#NDR:]XP^#O[16LZ^/BA
M^S%\0Q:^+M,UGQGX1N?">N6EOX:\1WWB:"/PQ\0_!?P_^(UGX2EA\.3^$-5F
M^'O_  2YTSP!XO\ V!?&%O\ &2>^N/V*?V;/ OP,\1Z4/A^EGH_Q^\4_!GX6
M>*/AG\!?B5XDMO\ A-+J7PO:?">3XJ_''Q7I?@F*X\2G4-<^(FFR_P#"5Z?/
MX,M+S5>C!5*2P=66,P\W7=;A-JFJJEB:>#IY#CLRXPHX65/V>#K9CB,VPN!X
M?RS'8MX? TLPS>IB'E7]BY9+.,7QXR%6&+S#ZK6C7H0EG]/+.2C[+#XF2XGQ
M6#X>Q.+=>K+&8'!SX?K8?-<9AJ:S#&0P>!ITG6GG688C+\!U?@C]O[QE\;_'
MW[9?PC_9^^!OA3Q+\2/V9/$GAVR^&S?%;XTZM\+OAS^T#X17QGXQ^%/Q1\6V
M/C3PQ\%_BYKG@>7X7?&;X1_&OX97^AQ>!/'!U/5O!GAO4;G5=!T_QW;OH?QU
MX;_X*_?M%ZYX8_96UCQ!^S1^P_\ "/4_VL_V=]7_ &I_ B?'#_@IMXE^&?A&
MP^$\47P57PYI-UXPU+]@F\DU+XL:K=?%Z<ZSX'TGP]<Z'H&E>%WU.T\<^(7U
M5[#2?I+]EO\ X)0>!/V3?B%\#?BY\._BGXMO?B7X6^#_ ,5?A=^TQXA\27?Q
M \2:9^TYJOQAU+PQ\0O%_P 0;7PEXI^*_B#PU\#]?G^._AV]^*D5AX)T_5-)
M:'QCXQ\+7%O-)JEIXCT[CIO^"6_Q%\,^'OV)]/\ AK\9OV9=9UC]D/\ 8V@_
M8_O9OVH?V*-=_:(\)^/=.B_X4_*WQ%\.^$] _:O^"=U\-?$4EU\([9?L,OB7
MQY NFZ_>V!O7DMH[V?"A"5*OEE/$U7B(4U3P^;UL.H_5ZT\/PYQSAWCL'*K2
MPN*=+'Y]A.!,PK1J87"U</B,VS+#4,'#*L+5CA]JO)+^U94.:%.6)5?)H5[/
M%PPM?-,DG/!XYT^;"SK8++ZN>T*52DU&M0PV#J5:U3'U&ZGV)\?/VG/B5\.=
M9^ /PD^$/P=\&_&']I']H'3_ !=XAT7P3K_QEU#X:?"#PEX)^&&A^'=3^*?C
M[Q9\9-/^$GQ*\3'PKH&L>,_ W@WPR?#OP6U_Q!XN\2>./#)F\/\ AW0O^$AU
MOP]\'V/_  5S^(7C3XF^#/@QX!^ W[-_A/XHOX=\81?%KPM^U/\ MR2?L^GP
MC\5OA[\>O&'[/GB[X7_"Z\\.?LQ?&P?&UQXI\&77B+PQXBM[?P,WB3P9XA\'
MZL= TN]UN;2].^Y?CU^S/\8?B#J7[/OQ@^$7QD^'7PN_:B_9_P!#\7^&+/QG
MXC^"FO>//@AXZ\(_%+0?"]C\5_ _B#X-Z=\:/ _C+2?"VO\ B7P+X#\;^$3H
MGQOC\1^"]:\$:!97OB#Q=HLOB'3M>\4_9S_X)?\ @7X/_%E/C=\4O%'A7]H7
MXC:KX)\4+XQUOQE\'/#EDU]\:?B!^T#X[_:$\<?%7P7'?:YXH7X?Z(VM>-H?
M"'@GP)8G5=2\)>#O"?ABUU#X@>*M2LYM1N.C#\BSBF\3R/*(8S-IXF,'4O6C
M3RO&RR>C@W:.(645\6L-3Q<L2Z>=1S:6%<:E/(_KTXXU^>/#]1X9.?$#IY!3
MH*KR*@J4\ZHPX@K8CE:H_P!KT,N:JX>-)O*)96L>J5.KGJR^$O$D_P""LOQ#
M'A7]LWXH/\$/V9+SX;_L@P_MCOJ'A70_VY;_ %C]J/Q(/V2/B#XX^&S7_B']
MGH?LKVFF_#OP]\1-=\%K>VFMW/Q9\2KX>T/Q'H-Z;37[F\2P;Z!@_;K^-WB/
MQ?XW\2?#;]D9?B!^RI\/?C'X_P#@+XD^-%C\;H--^*O_  FWPN&M^'OB'XUT
MSX"77PMET:]^!O@KXKZ#J7PM\1^-Y_C=9>/X;_2->\5:3\(=9\(:=::MJL.H
M?\$ROA_<_LJ_M>_L^V&M^#M(^(7[6M_^V?/K7[0-G\(-$3QEH&F?M=?%WXE?
M%*+1-4@A\16^M^-+#X;Q>/=,\.1Q7?C;1K?Q5'X2L=26V\,+<6^FZ73?]@[X
M^Z1XI\;^#/AY^UUI_P /?V2O'_QN\;_M#:Y\*-&^"NHR?&Q/&?Q'O]1\:^/O
MAW:?'L?&6T\.+\"?&_QBU?6/B3XJ\'S_  0G\:ZA8:]XB^'-M\1['PIJ=O\
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M****R-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF\!>+_ OAB'X6^%+_P .ZI#XS\,ZSJ%OXAO/%\]CXAU.P_X2/2/%&DR^&?\
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M:KXP^(_B_P (&U\*Z9JLFK>"?&<_A_5/&^MZ8EDFO>)OL$]R^HS-;E<!\3O
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOV@OA_IWB>PLOC?X*\0_M#^!/&'CS3-$^&_C5Y/&>D:!\+_B-9PZ+=ZMX?\
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MX2?M$?"WX+3WWCCP#;^#4UGP-H^IZQ\*_&7QC^#WQ:^%:>%O'.K:9HNFZ/\
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MLGQ7X=T'Q5I#R)<?V;XATG3]<TUIE21(Y_L>I6]U;&58YI427R]X26158*[
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MT^XO]5NK/2-%TNWL-"T2TN]4U.YL]%TS3[.:_NVM_.=U(         !@ #@
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M+>^!;Z]:XC>/S]2E\)7.CQZU-")',*ZY#J=NHDFB>"2WN+B&78\;:UJGP?\
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M-8%A<-@-'XGT>:Q5G'5(]6\/2ZK9;9!PLMWIFG)&^YG.S:@_+G6M*^*_P_\
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MLX?'SPSJ_CO]F/\ 9SM[?5_AE\1/V;?$.LZ]X8O-)N[%TLO"-B-0\4Z5XO\
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M^4YC*6 K*CB52P]5XC#5N2-51G1BOK$)*$HS;5.T8M-M'XB_'+_@AU_P3?\
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M'?BMHOB&-38/9:TVWD^&-3M-6F+#.7DT>9[+7+6-AM91/IY9<L'(5&>O$Q.
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MC3]N/X\:U\<OV,?%7@Z^^(/Q/^*'[3'QK_:+_:/_ &G/B7X3\8_ 7]DCXN>
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M]OJUTW1]%T?3;6VT[2]+TZVM['3[&W@M+2"&WACC7:^Q_P#!O9_TDZ\(?^-
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M\(>"M(LMPM;Z31-=TBTUC7/%WB3PAI<":EI^H2W&BOXA73=-6YC;7_#V3/\
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MIRB6.""[_L_5-/']#_AOXR>,[;X)^'?C'\3_ (<V'ARUN/ACI7Q$\9Z5X/\
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MQ.Z@D$'!.<$'H:LU0@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/^)WB'P+XCT*]\'^!_&OP]EFU2PEL;70=(\7:SX!UV6/3=:DO?\ A7&H([>
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M9-QCHU*T=6VG=6N_YG:Z6VW7444UW2)'DD=8XT4N[NP1$11EF=F(554 DL2
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M@+BYN]-^WZ9?]CX]\4?$WXA^(? ]MJ_BOQ!)\,?#']NZ_>>!_%'BC1/'#_\
M"<)#INF>"=0T77X/A?X*\72:7HNEZAXXFU&/QUXM\=W=SJE[X9NK%K2YT9[Z
M7RL?PW4EC,%2PN'Y,*Z5"GB<1"HF^>,FJU64)S;4G!)QY8<LI;ZMGU61>)&'
MAD^=XG-,P=7-8XK&XC*\OK4)1C["=.#P6%A6HTE&4%7<XU.>LZM.DKKW4F_V
M,\"?%[X8?$VUAN_ ?CKPWXE$TFJP_8['4H5U>"?0M4N=$UJVO=#NC;ZSI]SI
M.L6=UIFI6U]86\]E?6\MM<1QRJ5KPO\ ;-UZ.S^&FA^%Q*ID\8^-M$BN+:)P
M+P:9X6%QXS:_5%S*EA;Z_H/AO3]0N=HMP=7M=.FD634[=)?B3X8_M1^&_@Y^
MRQX/T7XP?#'X?ZEJ%GX9U+Q+)X)TOXA_#S7?&,?C_P 0?VQXVUC0M:^&/Q*N
M/AKX@\5^,K;Q%JNN6>H3?"=/B-+XZOUDUKP2-4.O?V=I_P Z>#/'>@/X7\ :
M'KGQE'CG6=&\+MIUC<^)/BK_ ,)C=S2QV^FKXIGTM+O6I["*)[_2(7O8M!L+
M'2[!;2*UL[+3["WAM(N#),JJ8C,G-ITZ6 Q$*LXUHRC4FJ<W.,>6UN9*,95$
M[147=NS5_>XVXKP^ X<5&$HXG%YYE]>C3J8&I"KAZ"J48TZ]:513<HTFJE2-
M"2O*4H2M\$W'U&OQX_X+L_&O4/A#_P $Y?BQX=\-B[G\<_M"ZQX5_9R\$Z=I
MX>2_UB^^)-_(?$^D6EI"?M-[-J?P]T;QEI\5K;J[S3W4,;H\3NC?K WC;P8E
MY;:>_BWPPM_>ZI>:'9V+:]I2WEWK6GO#'?Z/;6QNQ-/JEC)<VZ7FGQ(]W;//
M"LT*&5 WXH?MCW?AC]HK_@M-_P $G/V1_%NIPVWPQ^#'B'6_VU?C&)+>^U#2
MEC\#37^K?#FT\20:?:W_ )-E=Z[\,;GPY<+=P16JV'Q $NJ3VVFW*W(^VSK$
M.AE>)J4KRG5@J%+D]YRG7Y8^Y:]Y*G4]HK7?+RR6C5_Q/@O+XXWB?*J>(2IX
M?#UWC\3*LU"G"C@.>LW4<[)0E6HQH2OIS2<96L[?UR_LG?!KQ=^R;^R[^SI^
MSKIGASPYXGT#X$_!'X7_  N^U>'M6.A>(;^;P3X,T?PY>W4&A:Q!-X?U#4;[
M4;&?4M2U2\\=:1'J4US>Z@+>*Y=+2?XV^(D&H6?[0I^*?QP\!>/O#O@>/XA-
MK&IPW?AY]4T#1]*\'7/AFY^'_B*RUS1=2O\ PE<:O<0_#/PV-6TJ'7_$NIW.
M@^-OB+I=EX>74;JU@T']9?#7C3P=XS@GN?"'BSPUXJMK5XX[JX\-Z[I>N0VT
MDL2S11W$NF75TD,DD+I*B2LK/&ZNH*L">EK\PPV(^JNNI4E45:C/#U$W*%2$
M93A*3IR5U"HG!*\H35KIQ:;/Z@S++EF<<#4IXJ=">!QE+,,/*$85J%:I3IU:
M<(XBF^656A*%:3Y:5:C/FY)QJ)Q1^2/[4?Q1^"GQM\.?"G7?@?J^@^*?$5WX
M[M/B!?:CI*MX9GU/POH^AZCX;ED\9B\L[#Q4NGW,7BV/4O"MS+HFHIJ^H:%_
M94?E:'>:W>VWCM?KIXG^ WP=\7WEWJ>M?#[P]_:^H2R3:CKNCV\OAGQ#J,DK
M%Y&U'Q!X:FTC6K\/(S2E;N^F3SB9MOF'?7Y1>*+#2-*\;^/]*\.37K>&=&\:
M:[X?T&VU*[_M"^L+?PS.GAO5+2;47C6YOXSXCTG6[JRN+Z6\U 6%U:07U]=W
M,,DS?9\*8O#<M7!4:>)51J6)J2J2ISHQLZ=/EBX\C3=X_8;E9MM*-E^+^*V4
MYBJN%SG%XC+98>\,NH4\/3KTL7-M5L1S5(S=:$X1Y:G_ "_2I\T8QC)S<A_A
MV:RM];TZXU&3RK2WN%GD;8T@+1 O$K*BLVTRA-Q X7/(-?>'P^^)/PBCTW3=
M#E6\LM7L[7S+G6-)U)VU2Z$\\SO=74N@RZ9XAGMS.TL5O!+I<\$$2+9JTHC8
M-^>M?AI\&T?]IO\ X+]_&GQU'))>>"/^"??[+/ASX4:9/!(YLHOBS\:)+G6+
MV0>6QB:9O#/B+Q_X?U%92'6\\+VT2P$VIF3P_%#'X/ASA_'<58N56HLMH0IP
MPD90C'$3G4DJ5*,Y1;IRJU:D:;FU42;C[KM9^EX)8K'9EG$>$L-AL.J&+G7S
M"OCFJGMZ*A3H46Y14G"K3BHP<8)4Y13J2YGJ?U!?&C7XM8\0A+/5;[6-,MH+
M:VTV]U 1K<O:Q0_:95(6RL9FC6^OKF />QO>,]JWFRN%0CRW2M=UK0IOM&C:
MMJ.E39^9["\N+4OD8(D$,B"16'RLD@967Y6!'%9KR22;?,D>38H1-[LVQ 20
MB[B=J@L2%&!DDXR35&PBU+Q!XW\+^!=&%[%<:U9>)-<UG6++PO>>-3X9\-^'
M]/CA;6;GPOH^MZ/K^IQ3^*=9\*Z*J:4+J15U2:61(EB$J_P#Q!G^;>(?'%#$
M\.TL;AL7B*.%P.54(XE4,50AAZ$J^(YL12J0A3@J[Q>(=3VD8QI6G/E::7]Q
M9;EV#X;R&I2S.="K1IU*N(QE1TG4HSE5J1IT[4YQ<IR<%1IJ/*VYZ13NK^P:
M?\7_ !1;2127T>FZF\1!%T+7^R-2 '.?[1T)]-FDDS\WFW0N6+@.VY@"/7_#
M_P"T7%'MBU)M:L>BC[5'9>)[//&7EF4Z!JT2$%@0)=1D0A& E ='^6_%.C7_
M (.U#1;#5=1\-W[Z_-=6UC;:3J&IVOB2Q?3[*XO;VX\3>#?%.B>'->\/VC)'
M;QV;I'JS2SWD2W M86@N;G$NM0L+$PB^OK.S-PS) +JYAMS.ZC<R0B9T\QE7
MYF5-Q Y( KT9<>>*'!>/_LK-<97JXBE3A4E@<WAA\S<Z<DW"?UNE.>*J0:C)
M\U/&V:3;>ARKA[A3/,/]<PE"$*4Y.*KX.57"\LE92C[&:5&+3:5I4-&]-S]*
M-"^,&BZRT:6USHVIER,)INJK9ZB0< A=$\01:5>RR*QY2UDN@5RRNQVA^^M_
M%VA32BVGO#IMX5W-9:M%+IMR@)(4E;I8XV#X.QHY'5]KA&)1POY2=>E=+I?C
M#Q1HJF/3=<OX(&"!K22;[58N(PP0/8W8GLW"!F"AX& #,!P2#]UE'T@:;489
M]D$XO3GQ&4XB,T^_+@\8X.-M]<=*^VEKOP,9X<SNY9?F,6NE/&4W%KUK4%*_
MRPZ/U95E=5=&5T=0R.I#*RL,AE8$AE(((()!'(IU?G7H7QOU[2\+>Z=:72EM
MTEQI%Q=>&KUSSU332VB$9.0)-#E53G P6!Z'6?C]K%W)9R:7J7B&P6UCD(BE
M_L>1VEF>'*3S16B0:@MLD3>3+=6"&3SG#PHX\Q_TW*O%7@7-87AGE' 5%%SG
M0S6$\!."2;:]K67U6I*R=HT<14DWHDVTG\MC.$<_P;M+ 3Q$6U%5,(XXB+;=
ME[D'[:*ONYTXI;MVN?>=%?(7A/\ :$UFZN;:SO8+'6/-N+>#9);R:5JC?:9X
M[=766T-Y8W#H\JMY,.GPLX!&^,'>OU)9^(=%OCLM]2MO-RJFVG<VEV&; 4-:
M70AN5))"C,0RV5'S @?=X3&83,,/2QF Q6'QN$K)RHXG"UJ>(H55&3C)TZU*
M4Z<^6491ERR=I1<79IH^?K4*V'JSHXBE4H5J;M.E6A*G4@VDTI0FE)7335UJ
MFFM&;-%%%=)D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:]H>IWFH:;INLZ3J&H:4ZQZI866HV=W>::[EU1-0M8)I)[-W,;A5N(XRQ1P
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MV:5=-UN_EM-9A>PNX[.YM[JWM/V(_8>_9[B_9<_8U_9H_9]&DVEY/\-?AGX
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M>F>'/"?A7_@F3_P3\USQ!K=^T4<TPM-,TJQNKR<0PRS-'"RPQ22E$;Z)O_\
M@IU\!/#OAKQIKGCWP!^T;\+];\*^!?#WQ0T/X=?$GX,:WX2^(GQ0^'/BGQ[X
M6^&.C>*_AGX?O[OR-;,7CKQOX-\/>*/"6K:EH'Q ^'=YXN\*_P#"R?"/A"/Q
M-H#ZE\7B:?LL;C,(JCKUL-4Q'/RQ;JU(T(XRO.I[-.<W.6&P&/QGLXN=1X;
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M0FBOS7UG_@J+\%=/T7X7ZYHWP>_:D\9V_P 5_BCXO^!.C6?A;X/(^JZ!\=_
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MUG\@0"]TK_A(-)OK+<]RSV_VUH?BGPSXF6X;PYXAT37A9LB7@T?5;'4FLY)
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M(+?5+BTT&&^NHM(TRTO!+92-?^*+JX6^@N+*-;BXM;Q;;Y\\%_%\ZQXM\<>
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M]5?Q)X@\/V\-KJ5V)[*Q>&>9Y;NWDB,8 +CIJX#X:_$+PUX=^,_CNX\</?\
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M\Q690QE5)4Z]6EFSB\PH*O24*U+#UN51CAJ-2G0P\.:GAJ=&$I1=8&I/+J^
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M/B[\%[E?V:?BOKWC;3CIG[,7B;P7XA^)7A[4K+X1:?8:G\5/%7@+]ICPO?\
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MX=N]+LM$O-"TB^T?3HK6&PTR_P!/M;ZRM(K*)8;18+>[BFB3[-$B)"P7<BJ
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MQ%=Z-I.G>)?$FK:1H.B1ZW<76H:=HVB:?I^FZ-)>7<.CVMC:7$MNWI^E>)]
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M!QT(ZU0-Y-N=1.'V.\;&/1M2E3?&Q1P)(YF1MK J2K$9!&<B@#6HK)^US_\
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MTE%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M")'4D$$JRH",@D<'H2*LT4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<+XYOEM[;3K8@-NN
MI-5FB;&R:VT&(Z@(&ZMNN+]=/MX\#F251D9 /=5\R_'>?Q[=6>I6_P .;G0;
M;Q#;II&GVK>(OM+V1C%W'KVK;%MX)PDTL-OI-F6=1E;H!GC4B6.H1YIQC9N[
M2LMWWMYV,ZU14J52HY1CRQ;YINT4[:<SULKVN0*"% 9BY  +-RS$#EB>Y)Y/
MN:6ODS_A=7QI\&?+\2_@G?7ME%\UQKW@.Y;4;6.!3AIVLDEU9$! +$7>J:?C
M(W)&"*[7PO\ M-_!WQ.RP'Q,/#EZ3AK'Q7;/HKQ-NVE)+Z1IM'5U;AD&I,PY
M., D?01KTM(\W(]E&HG3>G2TTKV\FSX6>#Q*3FH>VCNYT)1KQ]6Z3ER[_:2/
M?J*JV5_8ZE;1WFG7EI?VDPS%=65Q#=6TH]8YX'DB<>ZL15JMM]CEVW"BBB@
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MR2AP(QL<!4([*:);<031*0MO(QERS,[03 K.SNY9WVMY=S(6+.X@QDL15T
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M(8+J5?+BU.Q6432Z'JLL<<DIL+E@WD7 CGETF[==0MH)]MQ9WGRU^PQ^P?\
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MVSZS?Q1X!P1!9@7(DXY(74?[-1@",B7G(R#\XHBQHD:#:D:JB = J@*H'T
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M>[/:O$W[,GA'5Y_M^A^(_&GA?4HT7RY[?Q%J6IM.\;.RV^HZU?W3>/7T:1F
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MTVXX2G0QG#^&HU*DU)W>,IYOC\113C3I4Z>1XR6(KT:4_;4?ZT:\X^(WQ?\
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M(_6*OUK,Z48.$)1^K8*GCEAJ]2I1Q$H0J8^O0PGL*5&6*HNCB9/ZTW&$I]6
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M+T=87U?4H;:XGCFET_2DN+=]1O$1K>Q6>%KF2(2H6P]/^)7PYU:>TMM*\?\
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M9\1/%WA;P]!I<%EH.G>(OBE\0?@AXTTB;2['2=9@L_ M_K$K67B7P_HD>O\
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MN;A"%.+<\1B,2^6G2C"E3C&>)G3HTJ4(4</AH4,+0IT\/0HTX%%%%9@%%%%
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ML]O<Z=X<OSX@\'Z4L$I#&/0_#^D.\8$8FC*Q/'Y+9?L=?\%L?V3&^V?LB_\
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MTGXF^)KCP=\"+>.\TSQ5X4UGX[6-IJO@J;V[X+?LU?#KX*WNL^*[&3Q!X_\
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M?!+Q+XD\.^.=)^+7BWQ'XPM_&OP1U7X0>(=0DU672-=OM6T.UT[3K+E_$O\
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M25(\PHIN)KGR6]+NFN4.N7$.Y=EG:Z;IZ1\YNPDSB6,)@@/<7]M;D#E&M6(
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MVVWW;>K?J=VVP4444@/(_C.CR>%K..-&DD?5G1$12SN[:!KRJB*H+,S,0%4
MDD@ $FOI%?%6B!0#<760 #_Q*M6Z@?\ 7C7BOCK0KC7],L;>W>)?LNK074RR
ML5,L,EI>Z<T43>7(HE+7Z,#( @57);(4'5_X4UX8_P"A;U#_ ,'UK_\ (U?H
MW"\D\LLG=QQ%:,O)M0DE_P" R3T[H\[$K]Z_-)K[K?FCU;_A*]#_ .?BZ_\
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MB6[L/NXKN;9TDMX)(E"1R0Q/&@ 4(C(K(H P %4@  8&,#BO%_BK_P 3W7_
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M5A&L*R(LBNHMU'%*DR"1"=I+##*5961F1T96 *LCJR,",AE(J2OISF"BBB@
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M-2^'MO\ #S7?$^F_#OXE_"32_B!??VW\-]>\;KXELOAI\6_&GA%M)MO&MOX
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MT,EZMY+;QYQF.TDME  5"F 1ZA10!Y2-&^*V@I_Q)?&%IXBMX@2EEX@MBDY
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M[6@Z;Y'5Q;OF=:ICY?@#\*O^"<W_  4>T:X\-_\ "UOVQ?#OB;1;O]E;XL?
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MT\7W5S<M;)X5^+'@N]^%'C1Q#$\LUOH]C\0=-^"MQKMREO#->0#PKJWQ9O\
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M<FE&ZYW)::IK0^<O^#;C]H;]IG]LCPQ^UO\ M!?M-7OP[\6ZEX&^)VB?LR^
M_B3\.M-U31='\91_#RQOO$WCO4;33+YH;)='OIO%G@C4=)O=(T;PU:WOVB\D
MNO#]CJBW\ES_ $>>(?$^KZ=K5CHVAZ&=?NIK*6^GLH9)([MH@TPC-NR1S* B
MVER\@>)V<^3'& T@S^5/_! ;]F5/V5_^"3/[(/@RZL_LOBCX@^ %^/?C626
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M4S"K-?+/QAC7QC\9_@G\/1^]M=.O;_X@:[ WS1&UTH9TOSE&?EFFT_4+0A@
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MQ;<"4P>,OV;=2O?@I?6$\I+F]M_"GA<K\,;N]2;;/'<ZQX"U.19%')1I$?\
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M4;C3(X;+PC>Z));RR:1J=T+E[B?Q?KJSQJEH\1MEMH&9Y4E^TJ(C%+U.A_\
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MXYY.^5N?[N!VYP.@]HHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7C7Q7\-=2\-?#BW75-0UN^TRTU*WNKVQL9X-&CO(KR[FM9[RXLK69]UM%#+
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M]SKM];6EI-):WFM:YJE]I.E10V-N++PWI-S8^&]/<336&D6TMU=//Z;J_P
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M%-D ,G@?\(7XT.!Z#))QZDGN: /:Z*** "BBB@ HHHH **** "BBB@ HHHH
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ML6TI6]YI>ZNE[NR:_P" =F$]K/$T84ISBYU()N+:Y4VN9V[*-VO)>IUGP_\
M VC?#/P5H7@CPZ+AM*\/6<EM:O=.LEU<237$][=7-PZ)&C375Y<SSR;$1%:0
MJJJB@#7974_.K*?]H$9_/K6]00#P1D>AKPJ=3DOI>]KZZZ7_ ,S[BI3Y[:VM
M?I?>WIV[G/T5L-:PM_!M/^S\OZ#C]*@>Q'\#GV#C/_CPQ_Z":W5:#WNO5?Y7
M,'1FMK/T_P G;]3.HJP]M,G\&X>JG=^GWOTJ @@X(((Z@C!'X&M%)/9I^C,V
MFMTUZH2BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** +MDN9&;^ZN/Q8_X _Y%:=5;-=L.<<NQ/X#@?AQD
M?7-6JXZKO.7D[?=I^=SLI*T%YZ_?_P "QSGC'Q#!X1\)>)_%5UM^S^&_#^L:
M[,'.%=-*T^XOC'QR3)Y'EJJ_,S,%4%B!7PG^RQH%SI?PIM-:U$L^K>-]8U;Q
M;J$TN/-E:]G%G:R,PXVW%I8PWRJN%4WCG:&9Z]8_;3\376D?!F7PUIKXU?XC
M^)-"\$V2J?WOE7ERVH7Q"@$F*:VTXZ=,0IPNH*!AV0CH=!T>T\/:'HV@6 VV
M6B:7I^DV@(P?LVG6L5I#D9/S&.%2W))8DDD\GMRZ%ZDY_P D4EZR>_W1:^9X
MF?5N6C1H)ZU)N<O\--62?DY33]8_?>:TMV<2"/RY!)YOF0L\#M)C&YWA:-G)
M!Y#E@>XI;<7UDZO97\T."V[!:)V4G<(TDM'ME1-P!;?%/NYW!CS4]%>E.A2J
M?'3C)][6E_X$K/\ $^?HXS%8?2C7J07\O->'_@$KP_ W;;QKXBM&A6YMX=3C
MDGMEF8&!)8(&GCCN65U-@A$5N7N(_P#1[B625#"0H96'HMKXET>[P!=K Y_@
MN@8,?\#;]SGV$A->.T5S2R^@]G.+\I77W23T^=_,]"GGF,BUSJE42WO!Q;\[
MQ:2?I&WD>]&YMAY0-Q #<,4@S+&/.<*7*Q?-^\8*"Q5-QV@G&!FIJ^8]7T5]
M3DM[F#5M4TJ\M%D%O+8RVSP_O599!-8W]K?6,WF A7E:V%RJ(JPSQ<YS--U/
MXM:$56.]T#6[>"/]U%]IOM%=SE1(CB2WUC32TA+2*D>E6NTY O(R0#Q5<#6@
MWR+VD>C6DOG%O\F[[GL8?.<)6BO:R]A4ZQE=QO>VDU&UGO[RC;KW?U?17C^G
M_$#6XD0ZII2NHRC!"K3NY)"OYEB;E/*XZFQBPC*7,;!@-B\^*W@W2-+O-9\0
MZBN@Z=IT<;ZA>WH,MI:M),EN$>6U$\BGS9$0&6"('<"*Y9TZD/CA*/\ BBTO
MO:L>C2Q%"M_"K4ZEKIJ$XR:MW2=_P\STBBJ&E:IIVN:;8:SI%[;ZEI6J6EO?
MZ=?VDJS6M[9742S6US;RH2LD,T3K)&ZG#*P-7Z@V$95=65U#*P*LK ,K*1@A
M@<@@C@@C!'6N'UKX;>"]>+27NA6L=PW_ "\V)>PF#=G/V5HHI7'K/%+SSC(!
M'<T4)M:IV?=":35FDT]T]4_D>0V/PBL],EE:P\3>((;9I8Y8[.4V%S"I,C-<
MK*)K0[Q.NQ5: 6LL)7=YDFYA6I<^";Q,FUNX)P.BRJ\#D>@P94)[<LH/7CI7
MI5%=%/%5Z>BJ-KM+WE][U^YG#6RS!5]945"7\U)NF_FHVB_647;H?FUXAQJ_
M[67AZRU:TU"'3_A;X,O=3<KIU]>PRZUJQDA68-96]R$LX[:^L[A;V416Z7&G
M2*\P;RE;ZWLM3T[4D,FGWUI>H/O&UN(IMAS@K((V9HV!X9'"LK95@",5[+<6
M=I=J%N[6VNE4Y"W$$4Z@C."!*K 'D\CU-<IJ?P_\+ZJ_G7-ABXQ@7:L)+R,#
MA1;7EREQ=6:J,!5LY;=0 !C  'S6<Y/4S7$/%?6.2KR1@H2A>FE%MJS3YE=R
M=])=.UCW,LQ5/+</#"QI.5*#;YN9<[O:[>BBWHWIRJ_17N<G15B;X?:M:*W]
MC^(KLJ/]7;W[F[B0#H99=1CU34+MRO&Q-2TY"WS%P,!<&XM_&>E<W^B6^IPC
MGS].=K&X91]YS:SSZCI=N@/4WGB2V;N$*DE?EJ^09E0NU25:*UO1DI/_ ,!?
M++[DSVZ>9X6I9.;IO^^K+_P)71K45SJ^)]+10VH&YT<;S&9-5MVM[+>" 435
MXS/HL[ D!EM]1F*Y&[;D9WHI8IXUE@ECFB<;DEB=9(W7U5T)5A[@D5Y%2E4I
M/EJTYTY=IQ<7^*1W1G":O"49+>\6G^3)**IW$TOFQVMML$\B/*\C_,EO C(A
M<H.7ED9]L$;%$?9,Y<B$QO#_ &38.=US"+]S_'J!-Y@GEC%'/O@MPQ^\MM%"
MAP!LPH FVU[J_97=OO7YCN[Z+UN[?+9FE7R1=SGQM^UWI=DG[S3OA%X%N[V<
M'YHEUWQ#"L3<XV^8UCK>G,B?,4ETZ1]P=-J>FV?B:_LM6U.TT*UTV2TFDOM6
MGAG:WLTCCAFBM(@D\VH6$,!ETN/3+B&VBMY[IY)[E?LTTL;.V7\&/ RZ3K?Q
M(^(=SJ3:GJ/Q%\0B]0M:&W73-,M3<36NF6\K3.]S%;F^-H\\EO92.+"%9+<&
M,.WLT\%6P.%K8VLDH5\*Z.&=US.>)<82O&]XVP_MFF]))II]#@EB(8BM3P]-
MOFIUE4JZ:*-).2L]G>K[-=T]T>_4445XIZ 4444 %%%% !6+XDURU\,^'M=\
M1WV39Z#I&I:Q= $!F@TVSFNY$4GC>ZPE$]68"MJOF']K?Q%<:3\);C0M/W-J
MGCK7-(\*644;8F=+F<W]VJC.2D\%@;"0D;<7JJ<%UST82@\3BL/AU_R]JP@[
M=(N2YGIKI&[^1E7JJC1JU7M3A*7S2T7S=D4?V7=(N;7X8)XDU$A]7\?>(-<\
M8:E)@AFDOKQK2'DY.R2&R6[12S;3=L=Q)-?1E8'A308/"WAGP_X;M2#!H.C:
M;I,;J,>:+"TBMFF/ .Z9HVE<D L[L3R36_7[Y1IJE2ITTDE"$8V6VB2?XGX7
MB:KKXBM6;O[2I.:OV<GR[ZZ*RU"F21QS(8Y8TEC;ADD171AZ%6!4_B*?16AA
MML<Q>>#]#NP^+9K1GR2;1]D9)ZDVD@EL6/.?FMCS7FVH?!72FOO[5TF=])U9
M9X[E-8T2\U+PGKPFA#"-GUWP]<0W3( Q5HDABB=25=67 'N%%<.)RW 8Q)8G
M"4*O*[Q<Z<6X2_F@[7C+16DK--)IW1Z&&S7,<)_ Q=:":LXN;E%K^5J5UR^2
MLM^[/R _X*)?L,ZE_P %%+3]F[]E3XQ?'_QGI/@/PY^T'X,^.][X6_L'PKXD
M7QSH_P .;+7;*^\(:M?I#HGB"YT[4M#U[7X1K.N:KJ5UI]R(]4ETW6FL?)C_
M '5;2KF!56.-&C10JK#@*JJ,*JH0A 4  *JX &!Q7QS\)+0>.?VJ_B!XI<"?
M3?A-X/TSP?IDB_<CUOQ TUQ>29YS+"@\0V$H7! \O=C"AOO"O%="EAY3I475
ME3C-V=:M5KSOHG^\K3G/ENO=BI<J6RU;?V6'K5L1AZ-:NJ:JU*<925.G"E'W
MM8^Y!**?*U?35W\DN)9'0X=60^C*5/Y$ TVNV=$<;7574]F 8?D0:I2:;:2<
M[#&?6-BO_CIW+_X[0;'+45MRZ.>3#,#Z+(,'_OI<_P#H KC?&FJ/X+\)^*/%
MEY8W=[:^&/#VL^()[6PBDN[N[AT;3KG4)+6TM[=)IYKJX6W,-O!%"\TLSI''
M&[LJD _&WQEK\?Q2_;?^*_B-&%UI7PG\.6GPYTJ0DND%W:7,ME<NA'R1W%MX
MF3XJ:;(JDMY+KYFUCL3V&OF;]E[1M83PGXH\:>)T;_A*?'OC77M4UJ66-H9G
MNM.OKC3M5+Q.!)&MSXM3Q5J\:R9<+JW)9=K'Z9K:*LEYZ_?_ ,  J&XMK>[@
MEMKN"&ZMIE*36]Q$DT$J'JDL4BM'(I[JRD'TJ:BJ \,\4?LX_"+Q2;B67PO'
MH=Y<@"2[\,7$VB1LPP/,GTBW+>'K]R!@G4M&O01G(.3GG?#OPM^./PGF>?X+
M?M!>)M%M 5,>@^($%UIK^628T>T>/5O!<*89HW-M\.4F*L"LH917TK12<4]U
M^GY <KHW[8G[7/P]/E?$GX.^%_BKI%N=KZYX N;K2-4>(KQ+);61\0:CJ=RK
M<M%I_P .M'A?E5,8^>O8_!?_  4M^ FNWW]C>-=,\>?##6HD N;?Q!X=EUJW
MCG!VO%Y'A9]7\36<<;!MUQKWA;0X552TACZ#AJPM>\+^&O%5H+#Q/X?T7Q%9
M*Q=;36]+LM5MT?!'F1Q7T$Z1R 'B1 KKU# U+IKHW\]?\@/TG\#_ !4^&GQ,
MM6O/A]X]\(^,X8A_I"^'-?TS5;BS; )BU"SM;F2\T^=,CS+>^@MYXR0)(U)Q
M7?5^%&L?LL_"N_NHM0TB+7_"6HVY\RSO-!UJ69M/F4EHYM,A\01:[;Z0T;8*
M?V/%IY7'R%&):NCT>X_;"^%Z+'\/?CY)XWT>#_4^'OB9'+JEQY"8*0OK_B&#
MQMJETX \M(;'4/"MH(R(D:VC1"LN$O)_/_.P'[:45^1^C?M_?'CP(#%\;_V>
MVU.QBQYOB7X>27=I$D,6!+<O81WOCW1%$BD2"36?&'A105<FVB4[(OIGX>?\
M%!?V8?'\<:R^-IO EX\@C>V\>V']DV$#%<C[1XMTVXUGP)"20R".3Q2L^Y2&
MA7*Y@#[7HK)T/7]"\3Z9;:WX:UK2?$.C7JE[/5M#U*SU;3+M <%[:_L)KBUG
M4'@M%*X!XS61XPN[Z.RTW2=+N'L]1\3:S::%!?1[1+8VC0W6J:Y>6LCAXXM1
MM_#FEZQ)I$LL5Q!'JXL&N+:X@$D+@$4GBFZU&[NK+PCI=OKS:=<7%KJ6J7NI
MR:1X>MKVTF>VN]*AU2WTS6;C4=6M+E)8+VVT_3;BTTV>VN[+5-0L=2A6QE\+
MU7Q7KGB/7/%.E:]8Z38W/@?QEJ'A>V&D7%Y=07%G>^ ?A'XX26>XO8;:2:YA
MG\97%@TL=I9Q30V4,PM87D=:^FM.T^STFPLM+TZW2TL-.M+>QLK6/=Y=O:VL
M206\*%BS%8XD5 79F.,LS,23\E3?\C]\9?\ LK/_ +P?]G"@#Y6^-/[8G[8=
ME^W-H/PD^'OAR/0OV>-#^,?Q&^'GQ/\ B7;? ;XL?$6T\.:3I'P0_8F^(7P_
MG\3^// W@'Q]X6\!GQ/K/QS^-,\6L_$:]^&W@:X\/^"('E\=Z9<^&M7@U7X%
M_:*_;W_X*JZ5XK^ +?L\_LG:QXJ\ ?%+]C'X)?'WQSXEL_@?\2?'FF^!OBMX
ME\/_ !;N?B#\+8=6T&6."[\0R:W<_!A])\-2++K.CZ'8>*+W48C_ &QI[1_U
M&+X6B1M2MA%9-8:Q(&U(R+/)=7,7EQ1F"2.5I+613'"D)+ICRF8",)B*O'E5
M54*H"JH"JJ@!54#   X  X ' ' K2C.%+"4:$J,*N(HU<IJ+%SG5<\0\'3S&
MGF:Q5)S<)1S:6.I5O9T'AZ&"J8+#*C1J4Z<::IM/$4ZK3]C&A7HSH+EBN:>(
MPM>C4A.,$KTXT)X><JU.M7E0J25.O1J5<14J_@;\)OVJ_P#@J?XX^*/[.GPU
MO_A"=/\  /Q=^$SS_$#]H/7?V;_C?X;TKX/_ !FDTK]M2^M--\5^"?B7X/\
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M^>6G_'I:_P#7O#_Z+6NS\16(^RF<:%H2^6]I_IJS#[;!B[C.+=/['&<9R/\
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M L"5&:["N=IK1JS[,[4TTFFFGJFG=-=TUN%(RJPPRAA[@'K]:6B@96>TA;D
MH?\ 9.!^1R/R JL]BX^XX;GH1M./KR">W;UK2HJU4G':3?D]?SV^1FZ4']E+
MTT_+0Q&@F3K&V/4#</S&?UJ*N@IC1QO]]%;W(Y_/K^M:JN^L5\G;\'?\S-T%
M]F7R?^:_R,*BM1[*(CY2RGMSD?B#S^M5VLI1]TJWMDJ3^?'_ (]6BJP?6WKI
M^.WXF;I372Z[K7\-_P "G13VBD3[Z,H]2#C\^GZTRM$T]FGZ:F;36C5GV844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 9.!U/ HJ>W3?
M,@[ [C]%YY^IP/QI-V3?9-C2NTN[2^]FNB[%51_"H'Y#%.HHK@._8^ ?CO=?
M\)Y^U#\(O <1\_3?AQHM_P#$#6UC.Y;?4KN5)-.2YC^Z7AGTOP\\;/Q'%JY,
M9W2.K>_5\.:=\7O!WA7]HSXW>*/B*VLZ%=Z]K47AOPW>W>BW\EHN@>'Y3I9F
MD:".6Z6*^@TO1+F!HK1X1"GFO*3(,?7'ASQWX,\7QB3PQXHT+7,C)BT_4K6>
MYCX!Q-:+)]J@8 @E9H48=Q7LX#DC2MSQYY2<G&ZYDM(JZWLTKKUW/DL[]M/%
M<SIU%1ITXPC4<)>SDW[TFI6M=.7*]=XGY8_MC:#_ ,%+[[]I/7[_ /9(NO&F
MG_#>3]F>_L?#.HW?B+]GV/X.0_%H?#K]KU+BTUCPUXWOKSXJ_P#"SKCXIZA^
MR!J'@WQ!:>%YOA?;^']&\86OBW68[(ZQHVK?*^KZ)_P6</AKQGX?\%:1\<;:
MWUGX7_%W4?A+K7Q$\>?L>7GQ"\&ZIHW@+]O+2?AGX*^+>I>%O':>&]3^+'B;
MQQXX_8QU;0-:\)KXB\ 1Z+X$,GQ#^(&CZQI/C"3Q%_1#17<HV5:+?-&O@ZV#
MG&25HQK5YXA5Z323I8JC4DE1KP:E&E&=&2G3Q.,CB>"6,DU0MA\+&5"I1J1G
M&BE.I[+#O#.%9\S56G5IR<ZL9IMUE2KP<*N&PLJ'\^>D)_P60MOV>OB!X&U[
MP3\<-3^+?B/X0_#B'X>?$;3O$W[&2:CX,\7>&?VO_CU>>/+;Q%I)_:,T2)/'
M'B_]D_4?@G!I5II?C+QCX5:YTR31]7^,VG^-8M<\3WGT+\3- _X*2/XH_9D7
MX:/\6$TFQ^#'PHL_'-S<:[^S?IGAO3/B+:W^M_\ #0[?M)Z-K7COQIXLUO7_
M !'X$_X173O@5)\!O%?Q&\.^'OBK#K]_XS\4Q^$Y(?$6H?L/16&8X?\ M*=2
M<ZU?"RK5J5:I]1G'#1DZ,<TA&G[.,'3C0G'-)>UHPA&G6E@LOE5C.5";K%'&
M>PH3P\<+@Y1E&O&$ZE%SK4%7>2M^QK.?M$Z2R6$:4IRG.,<QS:,I36-:I_@Y
MH'P'_P""O/AG2/#]_+\>M6\6>)/#7[.7[+EE/IVJZCX%BTGQ9^T#XA_:4\7:
M]^T;=:H+CQ%>QQ:=\/O@4?#.A:T]PMWIOB:"2)/A/>MJUM?Z8_7_  .\,_\
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MUI_QZ6O_ %[P_P#HM:V_$]NO]GSS?V9<EHUMQ]JN=1\UX<74?"QF[N=ZKN+
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MLJ"07*X?#,RJP0N QQ]XJ#EL'TV$1>?\/#&1O/B.T,^"2?-_X1/QX%R">#Y
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M'7\3GZ*W7BC?[Z*WOCG_ +Z&"/P-5FLHS]UF7ZX8?D<'_P >K15XO=-?BO\
M/\#-T9K:S_!_CI^)ET5;:RE'W2K_ $.T_DV!_P"/57:-T^^C+]0<?@>A_ UH
MIQEM)/ROK]SU,W&4=TU\M/OV&44451(4444 *JEF51U8A1]2<#]:W@   .@
M ^@XK)M$W3 ]D!8_R'ZD'\*UZYJ[O)+LK_?_ ,,CIH+1ON[?)?\ #_@%?.?Q
M#SKWQ#TZQ0HUKX6TRVN[HM\WDZA?7/VB.-4"O'OGL8XE(=H9A%)(XW1 )/\
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M+^&]?\27F/LV@Z/J.K3*6V^8EA:2W/DJ<$F28QB*-5#,\CJJ*S, ?Q!^(?\
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M QW,S'JQ)/XG-9T%[S?96^;_ . CMKNR2[MO[O\ AQ****Z3F"BBB@ HHHH
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MMH/$OA^60VSW1*+9*JQ)(L1),WA:(9W-D\\#!YR=ON]9=W8337*W5O/;QO\
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MV \7^-_C1\6)<3IK?BG_ (1C0KKK_P 2;1D1E5'.=R2V'_"/JQ1O+W6F%^Z
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MI&S*&Y7@L!GYAQW'6K%9'B"0Q:'JS*Q21K"ZBB95WMYT\30P!5XR6FD11D@
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M=JS*K?+\LD<@6/R\^47$^IZ7*;.XACMQ>F620V[(/-@5$&89Y3RPP-RKG\\
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M6\>UL6A:=X+B.5I8M]M)"\G?UOA*OM:*]SD4+06M[J,5KLK;VZZWU.',\/\
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M"JK-\?\ PU!T_:T_9.'U;#>Q_([X5?\ !-7XB^!_BC^QU\1O&/Q[^%_CJ/\
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MZLG-\-\3?$O_  A_P^\8^)5?9-I/A_49[-LA?^)A) UOIJY/3??S6R9'/S<
MG /2_LC^#&\%? 7P3!<1B/4/$5M/XPU$[2KR2>(Y/ME@TH8!O.CT0:5!)O\
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MCL 00>017@W[1_B-/#7P:\:W'F;+C5=/7P[:KN"M+)KTT>G7"H>YCT^:]N&
MY,<#XYK:52,:<JB:DHQE*Z::=DWNNYR4Z,YUZ=!J493J0IVDFFN>25VG9JU[
MZGFO[)]K<ZW:?$CXHZC&RWWCWQE=M#YA+,MC8/-=[8CC:(5N]7N+0"/ _P")
M>J$!8HP/KNO-O@]X6/@OX8^"O#DD?E7-EH5K/J$>TJ4U34]VJ:HA!PQ\O4+V
MYC#,%9@H)5"=B^DU-"#A2IQ?Q<J<N_-+WI>OO-E8NHJN)K3C;EY^6%MO9TTJ
M=/\ \DC$****U.<3:H8L% 9@ 6P-Q"DE03U(4LQ / +''4T,JLI5@&5@596
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MGTR)EZL8K4W[IPFZ0_,7[>*_B1G2\YQ?+_X''FC^(?4JLG:C.CB/*C4BY_\
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M3RM"N0CS*6?8K5U7AS]H7PKK.G:3?ZGI&O>'QJ]E;ZA!]I@M;V VUW&D]M+
M]G<M>7T4\$B313V6GS6\L3*\4LBLI/J4J]&O'FI585(MM7C)/5)-IK=-)IM-
M7LT]FCDG3G3=IPE%VOJNFU^UKH]]HKG-'\7^&-?*II&NZ;>3D _9%N4BOT!&
M1YFGSF*]BSSQ+;H<@CJ#CHZU("BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R+W0-%U%C)>:99R
MS=KD0K%=KEBQVW</EW*!F)+!90&).[.36O10!Q<_@X!VET[5[^T=@%"7HCUB
M*., @)!+>8U.WP=H#PZDCHFX1-&["1?*/B+\'+3Q]8Z;I?BSPY8>(-+TW6[3
M7HETK4;O3IEO-/CN8HY)K26XM+C43<174T<EK=:Y-:*LDC) TD=N!]%T4TVK
MV;5]'9M779DRA&5G*,9-:IM)M/NF]4_-'@-[I=E;8\\WVE%B0BZG:R6RR$[0
MA\^Y6WTV%2Q\ME36+Z:-S$&4K,K"G+H]VD0N(FM[FUY!NX)A]E#C&81<3"*&
M289^Y"\NX LA9<,?HD@$$$ @@@@C((/!!!X((X(/6N:NO"&@W%Q]KBM7TZ]W
M!OM>DW$^FS9&WEA:O'#)D(H)EB<CEE(8[JZX8[$0WDIKM-7_ !5G][9YE;)L
M%5UC"=%]Z4W;_P !GSQ7I%(\+FMY[<J)X982RAE$L;Q[E(R&7<!N4@@AAD$$
M$'!J&O7G\'ZG;2W$UEJ\-ZMSM+V^JVGD%F0Y61[C2&M+>>0_\M#?:7>I,Q+S
M1R<HW.W_ (<NH,FXT"[9 <&XT>X@OFDD;G.Q$LWAMU&6 AT"24E?)+;G24]=
M/,8/2I"47WBU)>K3LUZ+F/+K9#6CK0K0J+^6HG3EZ)KFBWZ\B.#HK9.F6LLA
MBMM1B$HP6@NXY;6=<Y!1+:9(]1N9(W5HY/LVG.B.""^%D*57TR]4C9$9]P9E
M$!$LFQ#\SO O^D1*.I,T,9 *L1AE)ZX8BA4^&I&_9OE?W2LSRZN QE"[J8>H
MDMY17/%>LH.45\VBA30Z$L RDIC> P)3(W#<,Y7(Y&<9'(XIQ!!((P1D$'@@
MCJ#GICO7GOA'P_I?CO7?$+7?B"/P]?)-:3:/=/);J]]]I:YS;I ;K3[ZZ-OI
M\6E.4L[Y$@,K">-_/A*QB<0L.H-QYN:35KVLDM6M'>UUI^)I@,#+'2JQC-4U
M3@I<SBY)RE*T8NS5KI2=]?AV=]/'?V?B/%?B_P",WQ3?$L7B#Q?_ ,(WHD_4
M-HGAJ%8H)(CW2YMI=-\P@[3+:D ?*:^I*XG4O &J_!71;>+2IO#A\/W.I7*6
MUC:63VTC7US#=:A-(EG#%:^69Q;2[I&U&^97,:+&5*J.T0L44N KE5+JIW*&
MP-P5B 2 <@$@9'.!TJ<)5A4I\L;\T=9W5O>G*4G9ZIZWZ[&F:8:K0KJ4U%4Y
MI0H\LN:U.C"%.*:M%IJ/+?2UV[-CJ1E5AAE##*G# $94AE.#W5@&4]00".0*
M6BNL\P*0  D@ %L;B  3@8&3U.!P,]!Q2T4 %%%% 'A/[2OB-?#7P9\92B3R
M[G6+2'PY:*" 97UNXCM+N,9(Z:6U_*0,DK$V!W'9_";PN?!GPV\%^&Y(?(N=
M.T&S;4(L8*:I>J=0U4'W_M*[NLUX5^T)*OBOXC?!'X6+^\BU'Q.GBS6H@<L=
M.TIGC0!1S^]LHM?7>WRH8PVUP& ^N*PA[U>K+I3C"DO5^_/\XI^AV5?W>#PU
M/K6G5Q,O\*M1IZ?]N56O\0445^)?[1'_  4\_:'^'/Q>^+WP*^#'[)L'Q=^)
M?PG^+'@'X9VVBW/BG6M!M?B+<_&/X8^/?C+\)T\'ZH/#]Q81SZCX*^''B#3/
M&NH7\_\ 9'@C7Y8+Z_EN-&M;IJOVL?K-#"VJ>UQ%O9R5.HZ*<L5@\'3A.LHN
ME"K6Q..PU'#T935;$3G)4(5/9U.2*&#KXBCBJ]&,)4\%0JXK%-U:5-T<+0H5
ML17Q4U4G&V&P]*A.6(KNU+#IP=:<(SBS]M**_$C]KK_@JM\3/V>OC;XT^"O@
MCX(> O'_ (LT6Y^&_A?P[X!NOB;>67QCU;6/B)I'@/6+3XL2^ X_#L6G']G2
M/7?&R_!*S^((\56D=]\==/'A*66RAN7EM*'CG_@J/^T)\++;XEZKX]_9G\+:
M=H?@KXJS?!O2]5N_'%]HVE7_ (G\/?L9_$K]ISX@:SK>J067B:;1/#'@7Q#X
M(L/#?BR[.C7']A>$;S5?%%I-XCN--%A)%/$T:U3$TJ<N:IA,HQ^>5UM%99EF
M84\KQN(A4DU2J^QQM;#494Z<Y5+XF@^6TGRD\)7IX?"XF<>2EC<51P6'4G:M
M/$U\MI9Q3I2PS_VBG)Y=5EB;5*4'R4,3&SG1G$_<:BORB_9I_P""B'B#XZ?M
M6Z1^SI=0_LZZEH=U^S=X>^-</Q!^$OQKT[QI8>.[_6_$GBS0UNOA;HWB/_A#
M/'?BOX?/9^&4U>/QAI?P_P!7\,Q"_:U'BZ\MX]+U/7?U=K6$E4A[2-W'VV-P
M^JE%^UR_'XO+,2G&24DHXO!8B$6TE.$8U(WA.+?(I)MQ3NXPP\WU7+BL)A\;
M1LUH[T,32<K-\LG*#]Z,DBODKXJ1+XY_:%^#_@-HUGTWPM:7WCS6XV42P,4E
M9["&[A;*.OVC1;6 HX*F/5B'5D?:?K6OEKX/J/%WQG^-GQ(QFSL;ZS^'6B2K
MS')#HR6_]L%6ZE99]-TN\0C(<7C$84*#E6][V5/^>I%R_P -/WW?R;BE\SNP
MC]G]8K[.CAYJ#[5*S5"-O-*I*2Z+EN]K/ZXMM9U2S(\B^N%4=(W<RQ?]^I=\
M8Z8R%!QQFHM5\;>.;=))=,3P]<Q1>7*([FQU$WCQ1H1<PA;>^\J[FE^:2V$8
MTX>8L=L[[7>X%&BG4P]&I\5.-W]I+EE]ZLW\[BH8[%X=KV=>HHK[$I<\/_ )
M\T5ZI)^9=TSXQ7:[D\1>#M6M#$%,USI0:^C5'RRSM:S);RPVRA95,S32%OLT
MS[(W:.W/>Z;\1O!>J>6L.O6=O-(%Q!J)DTV4,S!/+'VY((Y6\PB)6@DECE<@
M0R2!E+>:U!<6UO=QF&Z@AN(FSF.>-)4.59"=KAADJS+G&<,1G!-<<\N@_@J2
MB^TDI+\TU^)ZE+/ZT;*M0IU%U<).G+UUYXM^245T\SZ%CD25$EB=)(Y$62.2
M-@Z2(X#(Z.I*LC*0RLI(8$$$@TZOF2TT7^R96N/#^IZIH,Y+.197;RVDLC;#
MFYLKS[1!,A:*(O&!&'VG#*TDC-U=EXP\;Z?\MR=%\10J-Q::.71-0D &-@DM
M4N[ NR@$,;2%&F+DF&%TC@Y9X'$0VBIKO!W_  =G]R9ZE'.<%5LI3E1EVJQ=
MK_XH<T;>;<?1'N%%>76_Q2L(B$US0];T@CE[F*W35].1>FXW.G-)< '#,H>Q
M1BIC7 GD$ [+2_%/AS6E4Z7K>FWC-M'DQW<0N5+,R('M9&2YC+LC!!)$I?:=
MN0*Y90E!VG&47VDFOS/1IU:55<U*I"HN\)1DOG9NWHS?HHHJ308T:/\ >16^
MH!/Y]15=[.)ONY0^QR/R.?T(JW15*4H[-K\ONV)<8RW2?RU^_<RWLI!]PJX_
M[Y/Y'(_6J[12I]Y& '4X)'YC(_6MRBM%6DMTI?@_PT_ S="+V;7XK\=?Q.?H
MK;>"*3[R#/J.#^8Q^N:K/8J?N.1[,,_J,'^=:*M%[WC^*_#7\#-T9K:TOP?X
MZ?B9M%6FM)EZ ./]D_T.#^6:K,K*<,I4^C @_D:U4HRV:?H]?N,G&4=TUZH2
MBBBF(***?&N]T3^\P'X=S^ R:-@2N[+=Z(U[=-D*#N1N/U;G],X_"IJ**X&[
MMM[MM_>=Z5DEV27W'C'QLU2"WT#3=&FD*1:SJ:R7ZA3(6T;2D%UJ3+$F]IGC
M9[1UC:&6)R"C;9&A#_A=H_\ P6F^'DZ>$M,M_P!FSXXQSZW\&?B-\?T2>\\!
M:D++X)> _@S\)?CAX>\;:G?>$?$7BC2=+OO'G@KXP>&[>#0-=U#1KG0/%-EJ
MVC:O=>7<^&-0\2?N!XLN5U/QY=1X5H?#FCVEB%;#8O\ 5R=0GE4-G:RV(M8B
MRA?DFD3?('D2'Y^\)_LK_LP^ K#6]*\#?LY? CP;I?B6S\=Z=XCT[PK\(O '
MA^QU_3_BBGAR/XEZ?K5II7A^T@U2Q^(<?@_PC%XXL[Z.>V\5Q>%?#<6NQ7\>
MA:6MKZ>"HUE3JS51052C5]A[BDHUXT,9"G[6#M*<*F+EE]55HU8+#8?"8ZA+
M"8VIF6'Q.4_.X_%8+^T*$,90J8C#T*U!8F%*HZ=2>'E"<JRI5.;EC42G%J$J
M;=6:IOZQAX4*M+&?$WA'_@J+HOC'XB_"7X1Z=^SI\6(_B/\ $_X2>!/CU?:!
MJ>N_#KPA!X&^$7C#XG>,?A=J7B?7M0^)7B?P$L^I^%=4\.Z'JEWX2L[<^)-=
MTWQ;9KX8L=7O--O;8_3W[&7[5EI^V-\(Y?C#I?PQ\=_"W0[CQ+?Z-H&F_$#3
M[JPU/Q#I%K8:7?VGBK3?.T^RM;[0]374C%8ZCI$^KZ/=O:3M8:Q>HK%/3_%_
M[.G[/GQ!\0^&_%OCWX%?!SQMXK\'7_@S5?"/B;Q;\,O!7B/Q!X7U/X<W>O7_
M ,/=1\.ZSK&B7FHZ+>^!+[Q3XFO?!MUIUS;3^&+OQ%KMSHCV,VK7[W&S\+O@
MM\'/@=H^J>'?@K\)OAG\(/#^N:Y=^)]:T+X7> _"WP_T?5_$M_#;6U]XAU33
M/">E:39:AKE[;V5G!=ZM=P37]S#:6T4UPZ01*GL573EB\54I1E2PD_;_ %7#
M2DJDZ+E++70<ZUH.4:<*690E"2J2<Z\*SJSC.G0P/ST'36!P].<7+,(QP/UG
M$1?+0J2ITLR6/]G2;;A&O6JY;.C=MPIX>K"T&YSQ/IE?)7PG9?&W[0/QD\?$
M^=8^&H[+P'HDGWH?W,@BU"2W8YR1+HLDQ=2%*:HQ7<LF1]'>-?$</A'PCXE\
M3SX*:#HFI:FJ''[Z:UM9)+:W&2!NN+@10("0"\B@D9S7YM:[\;-3_9%_8\C^
M-.SX>PZGX[^*_A+2[WQ9\9?&5Q\._A+X#L?'GB_3/!2^-_BAXUM=)UB70/"N
ME11/=Q3+9)#J.MZOHND7&I:/;:G+JMAYN,Q-'#SPSKR<(2Q&'I)J,I)U\9B:
M. P<'RI\JJ8K%4J;J3Y:5)2=6M.G2A.<>W"49RPV-J07O.E*"[^SHTYXW%R4
M;.4W##8:;Y(*56I?V=*$ZDXPE^IE%?@]\,/^"I_[4_Q@C^%>J^&?V0-,T;1_
MC'^T-\$O@IX5M]8\77ESJ-C8^-_V3_%'[3_Q4UV[::/P_/>S_#"U\/Q>'[JU
MNM'\.2W%E<OK%O::A>JNA#BM?_X+6^,K'X5?$OXCVOPX_9\TC5/ OA/]FG5;
M?X:^+_CS<^'_ (DS#X\Z[^R=IUU\3=6TKQ#X5\->"="^ VF_\--:KX=TCQ]X
MG^)/A>"\\9_"C6;!Y)K'4?$5S\/.QRM+ P<9JIF.$HX_!TY1<:E;!XC"Y;C*
M%=1E9J-6CFV!<(OW[SK*45]4Q;H84L%B*[Q*I1A-8/$TL)B)QJTW2IXFKF&,
MROV7M>;V<I4\=E^+H5G"4HTY4E>7[ZA[7^A:GQP&YD2V"JYN'6 (P#*YE81[
M6!X*MNP0>""0:X;X:>*I/'/PY\ ^-IGT>27QAX+\+>*)7\/:K8ZYH#R:_H=C
MJKMH>M:7?:GINL:0S79.FZII^I:A8W]F8;JTO;J"6.>3O]$OX8_%OAW2Y!$7
MU!]1G3S)Q&ZC3K)[D>5%Y;F>1I3'\FZ(+$LTV]C%Y;WBXSP<L33JV53#3JTI
MI24H^TI2<&E*-XR3FK*2;BUJG;4PP<5C)X94[N.(]G*+:<9>SJ)2YFI).+4'
M=IJZM9J^A[-I6DZ9H=A!IFD6%EIEA;^88;/3[6"SM4>:5YYY%M[:..)9+BXD
MEN)W"!I9Y9)9"TCLQT:**^6W/T5*RLMEHBA?-Q&GN6/X<#^;5G59NVW3-Z*
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MW.I>*KYW)+3/JMTRV4[,0"S3Z3:Z=*Q(^\Q +* S8'[5M]>77@GPYX#TMO\
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M058$@@@@D&N!^*WB5O"'PW\:^(HI!%<Z;X>U!K&0G;MU&YA-GIIS_P!?]Q;
M <DG Y(KZPN=*TV[!^T65O(3U?RU27\)4VR#\'%?(?[1/P ^)/Q-%EI?@GQ9
MHNG>"K@:?'XE\*ZLLT%Q?-:ZK#?&\M-5BT_4)GEA$,+16KS6$+-%\\CM@MTO
M,*<H27).,W%J.S5VFD[W3LGOH>?'(JT*]-^UI5**G%S;YHR<%).2Y+25VKI>
M]:^[2+_[,/A'_A#O@CX(LY(S'>ZOI[>)[_<NQVG\0R'4;82(>5D@TV6PM&#8
M8&W^8*V5'OM7H] FL+:WM;:.$V]M!%;PQV_[I(XH8UCC1(I&)1%10J('D*J
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:)H7C&X\83.]S-ONM%U*VL$N%A:;; ]]9A_+2]F68VL<#+9LK(@+RQ_0-O\
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M21A+.YO]/"<Q0QW O;*.0<*XT_5$OK1<#Y"(8X<IP"K88<[<>$=9B#EI-/\
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MA,PH8NM.,XQC>..PU.M@L0JBG64<75E#$*E2PF&PWX1>$?VM_P#@H3K7B_\
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MHHHKN("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M64%6 WI[FWMK::\GFCBM8()+F:=F'E1V\49EDF9AD>6D:ERPR-H)K$ZS\O\
MX^2+\4_VQ_A[X#B*W.E>!;32)M7A),EN)H/.\9ZLDV,HJW>GC2-,E4 -YN(F
M8.0$^YZ^!/V5WD^(OQ=^,OQEO8W!O[ZXM=,2903!'XCU2?4O(C;)"2:9IFEZ
M=8@@EQ!<E-Q5WW??=? <2XCVN8*BG[N&I0A;ISU%[23[:QE!.W\MGJ?2Y53Y
M,,YM:U9RE?\ NQ]Q?BI/YA1117SQZ84444 %1RQ13H8YHXYHVQNCE19$;!R,
MJX*G!Y&1UJ2B@"@-.AB8O937>G/_  _8;F2&%<\-BR8R6!+?Q[[1MQY.6YHT
M:TET?5[C5U>RN)I+5+6'.EVEM,F999;JXN;BV$1N;FZ#01O*D5L5CMPA#A\)
M?HKHHXO$X=WH5ZM)]>2<E?6]G9ZJ_1Z/7NS*="C4_B4X3]8IG9V_BF,X%U:L
MO^W P<?78^T@#CH['KQVJ71;C3;87A-_%)->:A>7>94-L8H;BYFG@M%,K-N6
M#SG8XDV-<2W$J1Q^:5KAZ*]BAQ)F%*RJ^RQ"[U(<D_E*DX+YRC)LX:F58:>L
M.>D_[LN:/W3N_NDD=WXMNEA\.:@4GBB:]2#2X)G=%C6;6+F#3(6$C$(I#WBE
M68[5(#-\H-;]O#%;V\%O  L,$,4,(!R!%$BI& >X"*!GOUKQG4+5K^S>R-Q)
M#%)+;RR(H22"?[-<1W*P7=O*K17-I*\2I<V[@":$O&64,35*WMKW3LFQCALV
M!+;_  ]=W7AY/4[=$_T_P_<S'M+>VS[C@,R*2:]K#\3X2I98BE4H2;U<6JL$
MM-6TH3[Z*$GH<%7*:\+NG.%5=G>$O2SNO_)D>\T5X_:^,M;L2%O9A<1#^'6]
M--G*J=I;KQ%H!N]&B3L5_L.!@?O;0RUT]IXWAF57GTJ]: \?;M&>WU^R;G!\
MF&PD_MV0 \,3H2 'CL<>U0S#!8FRHXFE-NUHN7)-WVM"?+-_)'!4PV(I?'2G
M&V[Y;I>K5TM^YW-%8VG>(=#U65H-/U2RN;I%+2V2SHE_ !U^T6$I2\MRO\2S
MP1LIX(!K9KL, HHHH ***IW-]!:,JRELN"0%7=P#C)Y&,GI]#45*E.E!U*LX
MP@K7E)V2NTEKYMI%1C*<E&$7*3V25WIJ7**RO[8L_P#IK_WQ_P#94?VQ9_\
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MH9044D@NA.%R:GCU2TETK^UHKFU>S-L]TMVDR26GDH&8R^>C&-HE"DM(KE<
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M7>)-0\V;QQ\-[^YN;+[/XEU*^N[O3[?4[;6-/U'5-(&:^X?^#QV_O[']C/\
M9'GL+^]M9IOVC=:5[BRN9;">:,_"[Q#(@:19!CYDC8-*60.B2,,+@ ']>?\
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M_'MS8:39GQ'9>!O#U]::[XQND7PWH]S!J6JV\B_GYI_[1W_!7SQCX5^(.O\
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M].T[5-1T>UUV&72UL;ZU;48!>2W%@8-/DW36L\TT<>HQR"6R\NX=@L"H'/!
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MNJ/=J***^F/*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"EB4#!2>* .ZHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ IKHDB-'(BNC@JZ.H9&4C!5E8$,"."""".M.HH X+
M5OAEX)U<M)+H=O8W#G<;G1VDTF5GY_>2K8-!!<OSUNH9P< ," !5W1_ OAW2
M-'BT3[$FI6T4US.)]5BMKF\:2ZN)+@LTZ6\(5HO,$,+0QQ,D4<8)9PSMV%%
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M<Z"E)VN^>HMDHI64TDDHI))6LO4\W_X5S:?]!.X_\!X__BZ/^%<VG_03N/\
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MT%-1M9:QBUMOMN?;SVX9=H<@-C.]GDX#!AA7<J#E5.2"0,@8)##^27_@N/\
M\$%/CU^V_P#M:?"[]K_]C?Q;X"\!?$K2/#>DZ=X]F\7^(-8\*SR^+/ -[#>?
M#WQOH.I:!HVLW4VMV6FO'I5S<7?V5K0>&-!GMI))%E\S]ZKGXD_M)6W[+UYX
MJ\/"S\4_'!9@FG6_B_PQX8^'T$\5QXI@TJXW>'K/XA:WX;.J6'AZ2]O])TZX
M^($$.LZO;:?97[Z/]L=!ZO\ LP_%.7X@_"F]UKQKXN.O>)O#7BCQ'X6\:7.I
M^"1\-=4T/7/#]VGVC0-=\-1:_P")+"'4M*@GMEFO=&UN]T/58Y8;[3Y&@N,F
M)49P4VW_  I*G+1^])_:3M;HUT7ST-*.-P]:5*,*CE+$4G7A%J*M"+BFDUN[
MR[MZ'\@__!T9^V]\3?"O[*W[)_\ P3WU.]T9OC_\:/#G@SQY^U!I'@O4KW6+
M 'PQ;:99Z1X<T6Z%KIUU=Z7XX^)\.IZ]8QWEE;7,\/@S3[B6QB$\(?[U^'7_
M  25_:9^!W_!#JX_87_9:E\!^&OVFOVF-&LM;_:5\8>.O$-[X;BT^T^(.F!_
MB'H6GZGH^AZUJ%W=Z%X=@T3X7Z7%/:I;PV-SK.HQO#= >;_/O^R/I>N?\%FO
M^#AKQ;\;O'4P\3_ GX-?$?Q=\6()V:0:-IOP<^"&MG0?@CH!FD$T-M:ZWKD7
MA>YO86:.+4VG\3W<H!8H/ZI/^"U2_M*Z#^RE)^V?^R3\2]4^&_Q\_8JUF[^(
M$\'A7Q3_ &QX7^(7P/N7T]_'WAOX@>%Y;5M#\2VR:?H]GXD2VU2S:6U31]2@
MTJZ2XU@X\;$YQE^%S7+LFKXF%/&YI1Q6(P\)2@I*G@U'VGNMW?/S::-Z-K1'
M=RRY7*SY5:[Z*^WW]._39E?_ (-^?^"2_P 0/^"77P5^+^D?&Z_\ ZQ\:OC%
M\0+?5=:U#X=ZC-JVBZ/X$\*Z+:6?@OPM'J=UI.CW\D\>IZEXQUJ_C>!88I-1
MM(5,K1F5_P"A#[&O_/23_OY+_P#'*_+?_@D%_P %!]$_X*5_L>^"?VAH([#2
M/'5IJ>J?#_XP^%M--T=,T'XGZ!9Z;?:S!H[7;M.VE:GINK:/XBTQ9R\UM8:Q
M'87+?:+-UC_52O4)/PK_ ."\G_!*_P 5_P#!3_\ 9.\,_#[X4W_@W1_C?\,_
MB;IGC?P#KGC.XN])T>32M0L=2T3QQX>U75M/T[6+V&QUK2KVSOFA@L'BEU70
MM,D;R@A=?I7_ (([_LU?M)_L??L$_";]FS]J3Q'X1\5>/_A/=^)_#GA[5?!>
ML:AK^DK\-O[8FO\ P3ITFJZGI^EW5Q=:587DNGK%]BA@L;"WL-/M5%M:Q*OZ
M=RQ),NR0$KN5L!W0Y4Y'*,IQD<C.#T((XIR(L8(0;06+$9)^9CDGDGJ>PX]!
M0 ZBBOD'XH_\$]_V!OCCX[UWXH_&K]A_]D#XP?$WQ1_9G_"2_$7XH_LT_!CX
M@>._$7]B:/I_AW1O[=\7>+/!6K^(-7_LCP_I&E:%IG]H:A<?8-'TS3],M?*L
MK*V@B /KZBO@'_AT_P#\$L_^D:G[ /\ XAO^SK_\[FC_ (=/_P#!+/\ Z1J?
ML _^(;_LZ_\ SN: /OZBO@'_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN:/^'3_
M /P2S_Z1J?L _P#B&_[.O_SN: /OZBO@'_AT_P#\$L_^D:G[ /\ XAO^SK_\
M[FC_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN: /OZBO@'_ (=/_P#!+/\ Z1J?
ML _^(;_LZ_\ SN:/^'3_ /P2S_Z1J?L _P#B&_[.O_SN: /OZBO@'_AT_P#\
M$L_^D:G[ /\ XAO^SK_\[FC_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN: /OZB
MO@'_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN:/^'3_ /P2S_Z1J?L _P#B&_[.
MO_SN: /OZBO@'_AT_P#\$L_^D:G[ /\ XAO^SK_\[FC_ (=/_P#!+/\ Z1J?
ML _^(;_LZ_\ SN: /OZBO@'_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN:/^'3_
M /P2S_Z1J?L _P#B&_[.O_SN: /OZBO@'_AT_P#\$L_^D:G[ /\ XAO^SK_\
M[FC_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN: /OZBO@'_ (=/_P#!+/\ Z1J?
ML _^(;_LZ_\ SN:/^'3_ /P2S_Z1J?L _P#B&_[.O_SN: /OZBO@'_AT_P#\
M$L_^D:G[ /\ XAO^SK_\[FC_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN: /OZB
MO@'_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN:/^'3_ /P2S_Z1J?L _P#B&_[.
MO_SN: /OZBO@'_AT_P#\$L_^D:G[ /\ XAO^SK_\[FC_ (=/_P#!+/\ Z1J?
ML _^(;_LZ_\ SN: /OZBO@'_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN:/^'3_
M /P2S_Z1J?L _P#B&_[.O_SN: /OZBO@'_AT_P#\$L_^D:G[ /\ XAO^SK_\
M[FC_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN: /OZBO@'_ (=/_P#!+/\ Z1J?
ML _^(;_LZ_\ SN:/^'3_ /P2S_Z1J?L _P#B&_[.O_SN: /OZBO@'_AT_P#\
M$L_^D:G[ /\ XAO^SK_\[FC_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN: /OZB
MO@'_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN:/^'3_ /P2S_Z1J?L _P#B&_[.
MO_SN: /OZBO@'_AT_P#\$L_^D:G[ /\ XAO^SK_\[FC_ (=/_P#!+/\ Z1J?
ML _^(;_LZ_\ SN: /OZBO@'_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN:/^'3_
M /P2S_Z1J?L _P#B&_[.O_SN: /OZBO@'_AT_P#\$L_^D:G[ /\ XAO^SK_\
M[FC_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN: /OZBO@'_ (=/_P#!+/\ Z1J?
ML _^(;_LZ_\ SN:/^'3_ /P2S_Z1J?L _P#B&_[.O_SN: /OZBO@'_AT_P#\
M$L_^D:G[ /\ XAO^SK_\[FC_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN: /OZB
MO@'_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN:/^'3_ /P2S_Z1J?L _P#B&_[.
MO_SN: /OZBO@'_AT_P#\$L_^D:G[ /\ XAO^SK_\[FC_ (=/_P#!+/\ Z1J?
ML _^(;_LZ_\ SN: /OZBO@'_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN:/^'3_
M /P2S_Z1J?L _P#B&_[.O_SN: /OZBO@'_AT_P#\$L_^D:G[ /\ XAO^SK_\
M[FC_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN: /OZBO@'_ (=/_P#!+/\ Z1J?
ML _^(;_LZ_\ SN:/^'3_ /P2S_Z1J?L _P#B&_[.O_SN: /OZBO@'_AT_P#\
M$L_^D:G[ /\ XAO^SK_\[FC_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN: /OZB
MO@'_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN:/^'3_ /P2S_Z1J?L _P#B&_[.
MO_SN: /OZBO@'_AT_P#\$L_^D:G[ /\ XAO^SK_\[FC_ (=/_P#!+/\ Z1J?
ML _^(;_LZ_\ SN: /OZBO@'_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN:/^'3_
M /P2S_Z1J?L _P#B&_[.O_SN: /OZBO@'_AT_P#\$L_^D:G[ /\ XAO^SK_\
M[FC_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN: /OZBO@'_ (=/_P#!+/\ Z1J?
ML _^(;_LZ_\ SN:/^'3_ /P2S_Z1J?L _P#B&_[.O_SN: /OZBO@'_AT_P#\
M$L_^D:G[ /\ XAO^SK_\[FC_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN: /OZB
MO@'_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN:/^'3_ /P2S_Z1J?L _P#B&_[.
MO_SN: /OZBO@'_AT_P#\$L_^D:G[ /\ XAO^SK_\[FC_ (=/_P#!+/\ Z1J?
ML _^(;_LZ_\ SN: /OZBO@'_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN:/^'3_
M /P2S_Z1J?L _P#B&_[.O_SN: /OZBO@'_AT_P#\$L_^D:G[ /\ XAO^SK_\
M[FC_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN: /OZBO@'_ (=/_P#!+/\ Z1J?
ML _^(;_LZ_\ SN:/^'3_ /P2S_Z1J?L _P#B&_[.O_SN: /OZBO@'_AT_P#\
M$L_^D:G[ /\ XAO^SK_\[FC_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN: /OZB
MO@'_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN:/^'3_ /P2S_Z1J?L _P#B&_[.
MO_SN: /OZBO@'_AT_P#\$L_^D:G[ /\ XAO^SK_\[FC_ (=/_P#!+/\ Z1J?
ML _^(;_LZ_\ SN: /OZBO@'_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN:/^'3_
M /P2S_Z1J?L _P#B&_[.O_SN: /OZBO@'_AT_P#\$L_^D:G[ /\ XAO^SK_\
M[FC_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN: /OZBO@'_ (=/_P#!+/\ Z1J?
ML _^(;_LZ_\ SN:/^'3_ /P2S_Z1J?L _P#B&_[.O_SN: /OZBO@'_AT_P#\
M$L_^D:G[ /\ XAO^SK_\[FC_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN: /OZB
MO@'_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN:/^'3_ /P2S_Z1J?L _P#B&_[.
MO_SN: /OZBO@'_AT_P#\$L_^D:G[ /\ XAO^SK_\[FC_ (=/_P#!+/\ Z1J?
ML _^(;_LZ_\ SN: /OZBO@'_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN:/^'3_
M /P2S_Z1J?L _P#B&_[.O_SN: /OZBO@'_AT_P#\$L_^D:G[ /\ XAO^SK_\
M[FC_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN: /OZBO@'_ (=/_P#!+/\ Z1J?
ML _^(;_LZ_\ SN:/^'3_ /P2S_Z1J?L _P#B&_[.O_SN: /OZBO@'_AT_P#\
M$L_^D:G[ /\ XAO^SK_\[FC_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN: /OZB
MO@'_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN:/^'3_ /P2S_Z1J?L _P#B&_[.
MO_SN: /OZBO@'_AT_P#\$L_^D:G[ /\ XAO^SK_\[FC_ (=/_P#!+/\ Z1J?
ML _^(;_LZ_\ SN: /OZBO@'_ (=/_P#!+/\ Z1J?L _^(;_LZ_\ SN:/^'3_
M /P2S_Z1J?L _P#B&_[.O_SN: /OZBO@'_AT_P#\$L_^D:G[ /\ XAO^SK_\
M[FOM[PGX3\*^ O"OAKP+X%\->'_!?@GP7X?T;PGX.\'>$]&T[PYX5\)^%?#F
MG6VC^'O#7AKP]H]M9Z1H7A_0M(L[32]&T;2[.UT[2].M;:QL;:"V@BB4 Z"O
MXA/^"X7[7]M_P3X_X+.>"OB#9?#'PKX^^$/[17[!_@7P3^V1\&[C3-,L-+_:
M-^'_ (@^*/QS\!ZN?%\Z6FS5O'6C>"_"GA?1?"/BS65O-1T[1_"^C>$I+K_A
M$1<:4_\ ;W7\[O[>_P#P64T;_@GG_P %5OA+^SU\?]-L+S]DWXQ?LL?#CQ5K
M/BNWT5+WQ)\'?B-J?Q@^._AB7QX1:6L^I>(O!>J:3X;\/:9XPT!4NK_2K;2[
M7Q)X7B:\MM9T/Q0%T[W=ES>Z[J]FUY>:W77MK8_ #P/I'[)^J^$8M)_8?_X*
MG?L:V'[+%YK-_P"-=&_8K_X*\?!3P?X[F_9U\3:]YEQKUK\.;SXL^!OB!I<]
MX9[FX$]Y\.3IMEK9?=K^O^-=3677KCRW]H;]O[X,?LD^$?'%_P#"#]K*W_;I
M_;O\=_"76OV=O"'Q7^&WPIL?@=^R)^PK\#?$RHOC+P[^R[\/-(T;P_H+>//$
M5JJ6%GXO\$Z1IFCP133ZO>30:I#K&E>+_P#1)\.7O@KQAX?T/Q9X3N?#/B;P
MOXFTG3]>\.^(M!?3-6T37=$U:TBOM+U?2-4L3/9:CINHV4\-W97MI-+;W-O+
M'-#(\;JQVO[)TK_H&:?_ . 5M_\ &Z"O:=TVET;C=^KY+M=^]];G^6)_P7)_
MY.'_ &5_^T;W[$G_ *JZOQ:K_3=U[]IWX[I_P<*0?LG#XAZB?V=_^&++OXA_
M\*M?3=!DT(>,X--U.6'7A<OI+:R+F-X8F2$:G]D&P 6^,@_#/_!/[]N3]JWX
MKZ?_ ,$#IOB'\8M:\42?M3_$?_@I9H_[0+W^C^%(S\3M-^#5OJS_  QM-<%G
MH%L+>/P@T$)TXZ.-->78OVY[OG(M$EV-5-J*7*G:*^TUIRN2^R];1?7<_@(K
M_;PK^*7]M7_@H+^V-\-_^"9/[2_QH\$?'+Q!X=^*/@S_ (+5_';]F_PQXQL]
M%\'R:EH_P0\+Z9XYFT#X>6T5UX=N+%M'TR73+!X)Y[275&-LGG7\@+AO[6J#
M.K)RY;I*SDM[](OLNZ"BBB@Q"BBB@ HHHH **** "BBB@#S?XB?";X9_%2'2
MX/B1\/? WCZ'1FO9-)C\:^$= \5II<M^ENMY)IR:[I]^MBUTMI;+=M;K&;E+
M>%)O,6-%%F/P'X8@T_P]IB>'?#HT_P )36=SX6LTT6PAL?#MUI]K)8Z?<:)8
MP0Q6FDS65E/<6=G-I\%LUK;3R1VXC5BI[X@'J*:8T/50?S_QIJ4]5*I/V:^"
M$=$MF[OS=]//<R5&E&K*LJ4)59\O-*77E48KH]HQMZ76S/&O&/P.^%WQ!O\
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MAU?6_%&NZ7"%#KHUU83R/FY\I?W&KVSZT**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***_EC_X+5_M"_MGZ)_P4C_X)X_LA_LP_M6>,_P!F+0/VGM*@\,>)=>\,
M^']#\4VMCK.M?$>3P];>*+KP_JOV*75YM,L65%T^'7M'2Y1 C74+'S %1CS.
MUTM&[OLM]C^IRBOY!OVK/C%_P5W_ ."('B'X/_M#?'']L6P_X*'_ +&OB_XB
M:;\./BGX;\3_  O\,_#?QWX?U#6+'4=6MY=&:QGUW5M+OY]$T37Y_#.LP>.+
M_P ./K>GQZ5XK\,+%J&EW$GNW_!23_@II^U]\8?VNO@)_P $T?\ @E)KOAWP
MS\6/B[\/?#?Q<^('Q^\1:;I=Y:>#O OC'PP_CC18+%?$>B>(+#P_IUC\//(\
M:>)]>'AO6_$=VFO^&?#_ (,MK?Q$9X;X'R-VLTTTWS7:22WO=)JVG3J?U!T5
M_,)H7[%'_!:_X">.? ?B>+_@L[\._BM>6GBGPIJ7Q'^$'Q>\,Z+H&FZYX.?6
M;)_%.C>&[OQ%IOCIS>:CHHU&UT6YCT7P8[W30M!JVC2!;F#V/_@X&_;T^-O[
M,_PP_9Y_9K_8_P#%FI^'OVOOVN?C'X>\*^ Y_#2:?<^)M+\(Z7JVFV-Z^G1Z
MA::A;65]XO\ &^N^#/"&G37=J([W3+GQ8MM)YNGS-$"Y;M)23OVOI;=NZ6G^
M3/Z&**_GX_X(-_MS_''X[>%/VD_V0?VSO%MUXC_;._8U^,/BGPIXYU#6OL,>
ML^*_ ]YKVH:?8ZP'LK'3+;5T\,>+M-\0^&I-2L;%+<>')O ES*[/K$4DW] ]
M FFFT^G])_-:A1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^-#_@X2^)][^SU_P %3_\
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MWM%%"2TT73_VS_-_>PN^[^]A_P /,?CO_P!"G\)/_!#XQ_\ F]H_X>8_'?\
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M?_F]H_X>8_'?_H4_A)_X(?&/_P WM%%"2TT73_VS_-_>PN^[^]A_P\Q^._\
MT*?PD_\ !#XQ_P#F]H_X>8_'?_H4_A)_X(?&/_S>T44)+31=/_;/\W]["[[O
M[V'_  \Q^.__ $*?PD_\$/C'_P";VC_AYC\=_P#H4_A)_P""'QC_ /-[110D
MM-%T_P#;/\W]["[[O[V'_#S'X[_]"G\)/_!#XQ_^;VC_ (>8_'?_ *%/X2?^
M"'QC_P#-[110DM-%T_\ ;/\ -_>PN^[^]A_P\Q^._P#T*?PD_P#!#XQ_^;VC
M_AYC\=_^A3^$G_@A\8__ #>T44)+31=/_;/\W]["[[O[V'_#S'X[_P#0I_"3
M_P $/C'_ .;VC_AYC\=_^A3^$G_@A\8__-[110DM-%T_]L_S?WL+ON_O8?\
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M_P W]["[[O[V'_#S'X[_ /0I_"3_ ,$/C'_YO:/^'F/QW_Z%/X2?^"'QC_\
M-[110DM-%T_]L_S?WL+ON_O8?\/,?CO_ -"G\)/_  0^,?\ YO:/^'F/QW_Z
M%/X2?^"'QC_\WM%%"2TT73_VS_-_>PN^[^]A_P /,?CO_P!"G\)/_!#XQ_\
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M_P"'F/QW_P"A3^$G_@A\8_\ S>T44)+31=/_ &S_ #?WL+ON_O8?\/,?CO\
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=_P#!#XQ_^;VBBBA)::+I_P"V?YO[V%WW?WL__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img42081897_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42081897_0.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 9N#&P# 2(  A$! Q$!_\0
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M4W_Q5 'WU17P+_PTUXP_Y^I/_ J;_P"*H_X::\8?\_4G_@5-_P#%4 ??5%?
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MZD_\"IO_ (J@#[ZHKX%_X::\8?\ /U)_X%3?_%4?\-->,/\ GZD_\"IO_BJ
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M !5'_#37C#_GZD_\"IO_ (J@#[ZHKX%_X::\8?\ /U)_X%3?_%4?\-->,/\
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M_P"!4W_Q5'_#37C#_GZD_P# J;_XJ@#[ZHKX%_X::\8?\_4G_@5-_P#%4?\
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M*H_X::\8?\_4G_@5-_\ %4 ??5%? O\ PTUXP_Y^I/\ P*F_^*H_X::\8?\
M/U)_X%3?_%4 ??5%? O_  TUXP_Y^I/_  *F_P#BJ/\ AIKQA_S]2?\ @5-_
M\50!]]45\"_\-->,/^?J3_P*F_\ BJ/^&FO&'_/U)_X%3?\ Q5 'WU17P+_P
MTUXP_P"?J3_P*F_^*H_X::\8?\_4G_@5-_\ %4 ??5%? O\ PTUXP_Y^I/\
MP*F_^*H_X::\8?\ /U)_X%3?_%4 ??5%? O_  TUXP_Y^I/_  *F_P#BJ/\
MAIKQA_S]2?\ @5-_\50!]]45\"_\-->,/^?J3_P*F_\ BJ/^&FO&'_/U)_X%
M3?\ Q5 'WU17P+_PTUXP_P"?J3_P*F_^*H_X::\8?\_4G_@5-_\ %4 ??5%?
M O\ PTUXP_Y^I/\ P*F_^*H_X::\8?\ /U)_X%3?_%4 ??5%? O_  TUXP_Y
M^I/_  *F_P#BJ/\ AIKQA_S]2?\ @5-_\50!]]45\"_\-->,/^?J3_P*F_\
MBJ/^&FO&'_/U)_X%3?\ Q5 'WU17P+_PTUXP_P"?J3_P*F_^*H_X::\8?\_4
MG_@5-_\ %4 ??5%? O\ PTUXP_Y^I/\ P*F_^*H_X::\8?\ /U)_X%3?_%4
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M]2?^!4W_ ,51_P -->,/^?J3_P "IO\ XJ@#[ZHKX%_X::\8?\_4G_@5-_\
M%4?\-->,/^?J3_P*F_\ BJ /OJBO@7_AIKQA_P _4G_@5-_\51_PTUXP_P"?
MJ3_P*F_^*H ^^J*^!?\ AIKQA_S]2?\ @5-_\51_PTUXP_Y^I/\ P*F_^*H
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M^?J3_P "IO\ XJ@#[ZHKX%_X::\8?\_4G_@5-_\ %4?\-->,/^?J3_P*F_\
MBJ /OJBO@7_AIKQA_P _4G_@5-_\51_PTUXP_P"?J3_P*F_^*H ^^J*^!?\
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MIKQA_P _4G_@5-_\51_PTUXP_P"?J3_P*F_^*H ^^J*^!?\ AIKQA_S]2?\
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M4W_Q5;OC+X^>*O#6MM907UQ*@C1]TEU+GD9[-0!]NT5\"_\ #37C#_GZD_\
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M7C#_ )^I/_ J;_XJC_AIKQA_S]2?^!4W_P 50!]]45\"_P##37C#_GZD_P#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %?G_^U)_R7;Q-_P!NO_I+%7Z 5^?_ .U)
M_P EV\3?]NO_ *2Q4 >4T444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!V.I_\DOT;_K]E_\
M9JXZNQU/_DE^C?\ 7[+_ .S5QU !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 =C
MX%_Y OBO_L'G^M<=78^!?^0+XK_[!Y_K7'4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M '8_%;_D;G_ZX1?^@UQU=C\5O^1N?_KA%_Z#7'4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '8_";_D=K7_ *YR?^@&N.KL?A-_R.UK_P!<Y/\ T UQU !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 =CX)_Y%OQ;_ ->B_P S7'5V/@G_ )%OQ;_UZ+_,
MUQU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5V7A7_ )$/Q=_NV_\ Z&:XVNR\*_\
M(A^+O]VW_P#0S0!QM%%% !1110 4444 %%%% !70Z7\//%6N6,=[IWAG6+^S
MDSLN+6PEDC;!P<,JD'D&N>K[S\*>)KKP7^R_IVMV,<,EW8Z.LT:3J3&6']X
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M0IYK>:L>\[L-U'.>:^2==^%>OZ+\09/!D<":IK:LB!+ ED?<@?(+!<  \D@
M8/;FG]IQ7_#ATYCCZ*]YB_8Q\=R6BS-=Z)%(5W&W:YDW@^F1&5S^.*\HU+P!
MK>B^,(/#&IV9T_5IIXX%2<_+EV"JVX9!7GJ,TNO+U#I<YVBO;+C]D3Q[#KT6
MFH--N$>+S7OHYW%O%R0%8L@8MQT53U%8?Q*_9U\7?"_2%U345L[[3MP22XT^
M5G$))P-X95(!/&<$9^HI7TN.S;L>7U9T[3[C5M0MK&TB:>[N95AAB7J[L0%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\3?]NO\ Z2Q4 >4T444 %%%=3\./AUJOQ0\2KHFD/;Q71B:9I+IRL:JN,DD
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M44 %%%% '8^!?^0+XK_[!Y_K7'5V/@7_ ) OBO\ [!Y_K7'4 %%%% !1110
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MTPK>WCE8VG8JBX4L2Q )P #T!II-NR$W;4PZ*^@/^&*?''_05\/_ /@1/_\
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M$^+EY9V.F6\MKH-BYD3SP!)/(1C>0,X &0!GN<^@QU5.,.MT:JW.Y]+/\?\
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MMZ=/IMXHW>7.N-PZ;E/1AP>02.*R:G?8>VX445Z]XC_9_/A_X-V7CW^W1/\
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M.=A:$$,N<\%B.:\Y;XR>$;S]H/PUX@M(#HGA;2+4V2O]G(^4)* PCC!(7+@
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M\AG:P>VDC,*"-P06V[.-P'RD^U,;XR>$?^&8AX3_ +5/_"0?8?(^Q_9I?O\
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M[=?_ $EBK] *_/\ _:D_Y+MXF_[=?_26*@#RFBBB@ KW7]C7_DKDW_8,F_\
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MP&0'CM325E'R-JK?M)R_O?J>#>!_!=W\/?VDM$\/WKK-/9ZG&HE0$+(I&Y6
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M93>/J*,!W.V)PQ'MEA^8I?VQ[J:#X4Z'%'+)''-J$2RHK$!P(78!AW&0#SW
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M1KGR)LH0/E?!^5@<].1BM_\ 8IN)%^)6KPAR(GTIV9>Q(EBP?PR?SKM/!?\
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M-C!<M;>7%)'%M(53N:23(&=W3'XUZ$_[)/@;Q3HMS-X.\83WUS'\JS&Z@NX
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M10 5]R76I7>C_LCVMY874UE=PZ';M'<6\ACD0_)R&!R/PKX;K[^\+^+_ /A
MOV;M%\0?9/MWV'1X)/L_F>7OX48W8..OH:4_X4KNW],(?Q8V5_\ AT<A^R'X
MG\8>)-+UM_$%W?:CI<9C^QW5^6=F<[MX61N6 PO<XJ#X'+9I^T9\3EL-GV8%
ML>7TW>:-_P#X]NKA/%W[:>NZQIDEKH>B0:#-("INI+@W,B@CJGR* ?<@U/\
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M?S%?9CU5%/\ WS4/Q&_Y,VT7_KSL/_0DK.IHI1OM)#C[W)+JTQNB?\F2S_\
M7K/_ .E;5Y+\-?@]X7U+P>GBSQOXL30M'FDDB@MK8@W$I0X8C(8_\!56.,'B
MO6M$_P"3)9_^O6?_ -*VJC\/? /@WX>? R+Q[K/AU/%E_-")WBD02HBL^U5"
MME5"\;F()'/TK6KI7JR?E^;".L(17=_H<[XF_9Q\):M\-[WQ;\/_ !)=ZK!9
MQR321WP4B14&7481&1@.<,.>.F<UUW[$:F3PQXL4=6N8A_XXU>@>!M>M?%7P
M1US4+7PC#X/M)[:Z\NPA10DJ^5_K1B- 0W3..W6O/_V(U+>&/%@7[QN8@/\
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M.1SUK._;'LYS\6(I1#(8SI<3!PIQ@.X)S[''YUZ%KG_)D]M_UZP_^E0K&/\
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M7XFRE9M_@95%%%60%%%% '8_";_D=K7_ *YR?^@&N.KL?A-_R.UK_P!<Y/\
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M3^=G:6.XMM7^]Z=JX2BI:3L5<****8@HHHH **** "BBB@ KLO"O_(A^+O\
M=M__ $,UQM=EX5_Y$/Q=_NV__H9H XVBBB@ HHHH ]9_9V^$>E?%WQ%J=EJ]
MU>6MM:6HF7[$R*[,7 Y+*PQC/:O9#^RU\*3K#:.OC*^&L [?L']IVAG!QG!C
M\O=TYZ5RG[$/_(Y>(O\ KP7_ -&"NO\ &?[+NN^,OC%>>)GU>PLM'GNHYQY;
M2-<@*JC&W:%!RO7=QU]JT:5X+HUK]YC&3]_NGI]R/%_CM\ [KX.W%I=0WO\
M:6BWCM'%,R;)(G'.QQT/'(8=<'@=_)J^J/VQOB5HVK:;IWA33;N._O;>[^TW
M;0L&6 JK($)'&XECD=L<]:VO#_PS^'_P)^&UIXA\;Z;%K&J72H)$N(%N/WC#
M<(8HV^7@ Y8^AYQ@5C#X7)O1,Z);J*6K/CVBOLJZ\ _#C]H+X=W^J>$-'BT3
M4[7>D30VRVKI,%#!)$3Y65ACGG&>#G-<9^S[\,_"]K\-=9^('B?3%UO['YS1
M6<BB1$2)<M\AX+$Y^]P  >*K^;FTLKD]K=78^:*]B_9S\.?#[Q#J&M+X\N;2
M%(HHS:)>WQM$8DMO(8,N2,+QGOTKWSX*ZKX ^,6EZI<Q_#;1=*FT]U5XFL+>
M57# E2K^6O/RG(QQQSS7(_ NQ\&?$KXL^.+VW\+6(T7R+<VEC>V,)6$XVN0@
MW*I)4GY?6K6DN5KH3+X>9=TOQ/G'XB6>BZ?XXUNV\.S"?1(KEEM9%<N"GLQ^
M\,Y /< <GK7.U]"_#OX5:!XV_:+\7:7?V\::/IEQ=31Z?!^[1PLP14PN,(-W
M08Z =*].\7>(_A!X1UV?P[XB\ KHT8RBZE)H<:P2C'WHY(\R-UZ@?E6,?=IQ
M?=&L_P"))=F?*_PU^&^J?%3Q(=%TF:U@NA TY>\=E0*I /*JQS\P[56\?>![
M_P"'/BJ\T#4Y+>:\M0A=[5F:,[D##!(!Z$=J^BOV._$WAH7-YH4>D?\ %1EI
M[E-3^SQG_1OW8\OS"=XYYVXQWZU8_:<^(7@6!O$?AN?PSYOB]HH0NK?88."0
MC*?.W>9PO'3VZ553W;6[!"-W)/I_GN?)=%?;VC?#OX=1?!GPKX@\2:/IMI;6
M5E;7UU=+;*CW#>5C;(RC=(&9@=N?F( YZ5XSXJ\:?";QA\1?"5S!HG]B>&X!
M,-4B2R%OOX_=Y6 DMR.W.#527+/D\R/L<YX/17U]I?Q8^!=[KUIHMKX,M9!<
M3+;QWKZ)!Y6YC@$ECYF,D<[:Y?\ : ^'GA/X3_$+P?K\&EK_ &)=W#/?:5&H
M>-A&R%MJ,<88-C:2%X[9I=5?9AO=+=:GFNH?L_\ B/3?AE'XYENM-.DO!'<"
M%99#/L=E5>-FW/S#^*D^ &B>#=>\;36_CB>W@TH6;O']JNS;1M,&3 +AE_A+
M'&>U?9&K>,?"EI\&8_$-UH?G>$FM(9ETK[)$V(F90B^43LX)4XS@8XKP/X4R
M>"_BA^T-?3Z=X8M8?#S:6S1Z;>64(19%\L%_*7<@.2>GK[TXNU1JW?Y:!;]V
MI?T]CR#XT:7X8T?XA:C:^#YXY]#18_+:&<SQAB@+!7).X9[Y/>N'KW;QU\++
M;Q9^TY=^$])MX=)T^1XF=;2)8TAB$"/(54# /7''4UZUXOO/@Q\"9+/0M0\+
M0:I>M&)&!L8[R95.0'=Y2.I!X!_ #%1'2";>Y4OB:2V/B^BOK7XU?!SP;XK^
M%[^.O!5K!8-#!]KQ:)Y<,\(/S@Q]%91D\ ="#[:/PA^&G@CQ%^SSI=_XCTNP
MA0":>[U/RDCGV1W#D@S8W ;5VG!SC@5?23>EK?C_ ,,3VMK<^.:*^X/A^GP<
M^,-OJNC:-X5LX_L:;6:6P2&9XSP)$D'S]>Y(;U%?/?AOP]X-^'_QNU;2?&[-
M<:#IKS)$71W#L"#%O6,9.5/(QC/7BE]I1?57#[+:Z:'D=6M+C674K1'4,C3(
MI4]""PXKZ^\)_$CX)^,O%%KX<L?!-K'/=OY4-S/HMNL3MC@;@2XS[BO(_P!H
M7X9Z7\-?BAI4>BQFWT[4%CN%MMQ81,)-K!2>=O (Y[GMBM*>E2%]FR)ZPG;=
M([S]L#P7X?\ #'A7P]-H^AZ=I4TEVR/)96D<+.OEYP2H&>?6OE>OL']MS_D3
MO#7_ %^O_P"BZ^/JY8?%/U_1&S^&/I^K"BBBMB KL;[_ ))7IO\ V$7_ /06
MKCJ[&^_Y)7IO_81?_P!!:@#CJ*** "BBB@"YI.KWN@ZE;ZAIUS)9WMNX>*>%
MMK(WJ#7M>G_ME^/;.SCAEM]&OI%7!N+BU<.WN=DBKGZ 5X113N[6%;6YUWCS
MXJ>)?B-K5OJFL7Y:>U/^BK;KY26_(/R <@Y Y))X'/%>B:+^V)X]TG3XK69-
M*U1XQM^TWMN_FM]2CJ"?PKPVBDM%9#>KNSL?B-\6/$GQ2OX[C7;Q7BASY%I
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M #].:]E^+_[+_P#PJGP;)KW_  DPU39-'#]G-CY.=QQD-YC=/3%/_8]\%_\
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M,G )QUKP;]GSP7_PG'Q6T6TD3?:6LGVVYXR-D>&P?8MM7_@5?1OB/XP?V?\
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M?YBOTE^%W_(BZ9_VT_\ 1KU^;5C_ ,?UO_UT7^8K])?A=_R(NF?]M/\ T:]
M'54444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7Y__M2?\EV\3?\ ;K_Z2Q5^@%?G_P#M2?\ )=O$
MW_;K_P"DL5 'E-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 =CJ?_)+]&_Z_9?_ &:N.KL=
M3_Y)?HW_ %^R_P#LU<=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '8^!?^0+X
MK_[!Y_K7'5V/@7_D"^*_^P>?ZUQU !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!V/Q6_
MY&Y_^N$7_H-<=78_%;_D;G_ZX1?^@UQU !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!V
M/PF_Y':U_P"N<G_H!KCJ['X3?\CM:_\ 7.3_ - -<=0 4444 %%%% !1110
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MSNJJ20GES.,X'\6!53]F"WN=-^!NHZAI*KK^J7-S-(=*EN%CC#C"^7DC"EE
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M,_.0"N,="3UXKYB\3^*-4\9:Y<:QK%T;S4K@J99]BINVJ%'"@ < =!79Z/\
MM&?$?0[&.SM?%%P8(QA?M,,4[ >F^1&;]:CE3C%/>);?O2:V?_ _R/I/Q1I\
M7P5_9;N-!U6ZCEOI+.6S54;AYIV8E4SU"[F/T4FL[P7_ ,F7W?\ V#;[_P!'
M2U\I^+O'6O\ CR^6[U_5;C4YE&$\UL(F<9VH,*N<#H!FM2S^+_B[3_!;^$[?
M5S'X?>-XFL_L\1^5V+,-Y3=R2>_>G-N<*B>\O^#_ )B5HN-NAZQ^Q+_R/VN?
M]@W_ -JI76^"?!F@^+OVH/'C:U;PW[V)\ZVL[A0R,QVJ7*GAMN1P>/FSV%?-
M7@GXA>(/AUJ$U]X>U#^S[J:+R9'\F.7<F0<8=2.H':FMX^\0_P#"72>)UU6:
M'7I)/->]AQ&Q;&#PH P1P1C!':JNN>$NR:^]F?*^62[M/[C[LM=2^)?_  L(
MV$7A[0[#P5#+@7K3%II(A_<"N-K'T*8'J>M>'_MB_P#)2O"'_7L/_1U>6ZC^
MTA\2-4MUAG\43B-65_W-O#$20<@$H@)''(/!Z'-<WXR^)7B3X@:E:7^OZE]O
MN[5=D,GDQQ[!G=T10#SZU,=)PD_LNY;UC-=U8^F_VW/^1.\-?]?K_P#HNOCZ
MNP\;?%OQ9\1K.UM?$6K'48+5S)$GV>*+:Q&,_(@SQZUQ]9QBXN3[O]$BF]$N
MP4445H2%=C??\DKTW_L(O_Z"U<=78WW_ "2O3?\ L(O_ .@M0!QU%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXOD_1J%:FYU%M^KT_(4KU%"F][_\$^>_CEJB:Q\7O%=S&<I]ODB!_P!SY/\
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M_ I?\*/^&N/!W_/>#_P*7_"OSRHH_L.C_._P#_6C$?\ /N/XGZ&_\-<>#O\
MGO!_X%+_ (4?\-<>#O\ GO!_X%+_ (5^>5%']AT?YW^ ?ZT8C_GW'\3]#?\
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M1_PUQX._Y[P?^!2_X5^>5%']AT?YW^ ?ZT8C_GW'\3]#?^&N/!W_ #W@_P#
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M4?V'1_G?X!_K1B/^?<?Q/T-_X:X\'?\ />#_ ,"E_P */^&N/!W_ #W@_P#
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M?^ S?XU]Q44 ?#O_  ROXH_Z:?\ @,W^-'_#*_BC_II_X#-_C7W%10!\._\
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MQK[7HH ^*/\ AEWQ-ZO_ . S?XT?\,N^)O5__ 9O\:^UZ* /BC_AEWQ-ZO\
M^ S?XT?\,N^)O5__  &;_&OM>B@#XH_X9=\3>K_^ S?XT?\ #+OB;U?_ ,!F
M_P :^UZ* /BC_AEWQ-ZO_P" S?XT?\,N^)O5_P#P&;_&OM>B@#XH_P"&7?$W
MJ_\ X#-_C1_PR[XF]7_\!F_QK[7HH ^*/^&7?$WJ_P#X#-_C1_PR[XF]7_\
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M5?W9/_ 9O\:^ZZ* /A3_ (94\5?W9/\ P&;_ !H_X94\5?W9/_ 9O\:^ZZ*
M/A3_ (94\5?W9/\ P&;_ !H_X94\5?W9/_ 9O\:^ZZ* /A3_ (94\5?W9/\
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M0*J4XJ*NM;_?V^9,8MRT>GY?\ ]UHKX D_:0_;D73#XI_P"&?/#(\,A/M?\
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MR2BBBI&%%%% !1110!QVF_\ )4-8_P"O*+^8KL:X[3?^2H:Q_P!>47\Q78T
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M !ZC^S\5_P ^V']KX#_GZCZ&HKYY_P"&X/ O_0)\1?\ @-!_\>H_X;@\"_\
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M$7_@-!_\>H_X;@\"_P#0)\1?^ T'_P >H_L_%?\ /MA_:^ _Y^H^AJ*^>?\
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M&M__ (_1_9^*_P"?;#^U\!_S]1]%T5\Z?\-T^ _^@1XC_P# :W_^/T?\-T^
M_P#H$>(__ :W_P#C]']GXK_GVP_M? ?\_4?1=%?.G_#=/@/_ *!'B/\ \!K?
M_P"/T?\ #=/@/_H$>(__  &M_P#X_1_9^*_Y]L/[7P'_ #]1]%T5\Z?\-T^
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M^*_Y]L/[7P'_ #]1]%T5\Z?\-T^ _P#H$>(__ :W_P#C]'_#=/@/_H$>(_\
MP&M__C]']GXK_GVP_M? ?\_4?1=%?.G_  W3X#_Z!'B/_P !K?\ ^/T?\-T^
M _\ H$>(_P#P&M__ (_1_9^*_P"?;#^U\!_S]1]%T5\Z?\-T^ _^@1XC_P#
M:W_^/T?\-T^ _P#H$>(__ :W_P#C]']GXK_GVP_M? ?\_4?1=17'^K'UKYY_
MX;I\!_\ 0(\1_P#@-;__ !^F2_MS> Y% &D^(NO_ #[0?_'Z/[/Q7_/MA_:^
M _Y^H^@:*^>?^&X/ O\ T"?$7_@-!_\ 'J/^&X/ O_0)\1?^ T'_ ,>H_L_%
M?\^V']KX#_GZCZ&HKYY_X;@\"_\ 0)\1?^ T'_QZC_AN#P+_ - GQ%_X#0?_
M !ZC^S\5_P ^V']KX#_GZCZ&HKYY_P"&X/ O_0)\1?\ @-!_\>H_X;@\"_\
M0)\1?^ T'_QZC^S\5_S[8?VO@/\ GZCZ&HKYY_X;@\"_] GQ%_X#0?\ QZC_
M (;@\"_] GQ%_P" T'_QZC^S\5_S[8?VO@/^?J/H:BOGG_AN#P+_ - GQ%_X
M#0?_ !ZC_AN#P+_T"?$7_@-!_P#'J/[/Q7_/MA_:^ _Y^H^AJ*^>?^&X/ O_
M $"?$7_@-!_\>H_X;@\"_P#0)\1?^ T'_P >H_L_%?\ /MA_:^ _Y^H^AJ*^
M>?\ AN#P+_T"?$7_ (#0?_'J/^&X/ O_ $"?$7_@-!_\>H_L_%?\^V']KX#_
M )^H^AJ*^>?^&X/ O_0)\1?^ T'_ ,>H_P"&X/ O_0)\1?\ @-!_\>H_L_%?
M\^V']KX#_GZCZ&HKYY_X;@\"_P#0)\1?^ T'_P >KT/X2?'#0OC-_:O]BVFH
MVO\ 9OE>=]OCC3=YF_;MV.V?]6<YQU%95,'B*47.<&DC6CF6$Q$U3I5$Y/H>
MAT445QGI!1110 4444 %%%% !1110 4444 %%%% !1110 5SVA_\E-U'_L'K
M_P"A+70USVA_\E-U'_L'K_Z$M '<T444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %?6?[!G_ #//_;C_ .W%?)E?6?[!G_,\_P#;C_[<
M5Y.:_P"YS^7YH]_(?^1C2^?_ *2SZSHHHK\]/UX**** "BBB@ HHHH ****
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M!=5^JW7Y>9^J9-QIE><25)2]G4?V9=?1[/\ !^1ZW1117RQ]Z%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'?"C_D44_P"N\O\
MZ%78UQWPH_Y%%/\ KO+_ .A4 =C1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 07W_'C<?]<V_D:YSX7?\B+IG_;3_P!&O71WW_'C<?\ 7-OY
M&N<^%W_(BZ9_VT_]&O0!\$?M1?\ )49?^N!_]'2UY%7KO[47_)49?^N!_P#1
MTM>15^D9?_NM/T/QG-_]_J^H4445Z!Y 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5^E'[-/_ "3"S_[9_P#H
MB*OS7K]*/V:?^286?_;/_P!$15\OGOP4_5GW'"W\6KZ(]6HHHKX\_10HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF::5_P!AB_\ _1@K&G[U6K![1BFOG)H;D_8T9]9-I_\ @-_S/M.N)^-'Q?\
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M+Y7*F^7XFTEZN]OQL?N?6!X^\=:-\,_!>M>*_$-U]BT31[62\NY]I8K&@R<
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M*D\6XK[XHK12?-3F]7"_WN_O>NK,G%<LXK:5ON5M/31(*_/;]JSX6^-/A?\
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MT#)Z] ?S<\2?%?XR^(/VV?#7Q]'[,7Q%@@T?3S8G03I=ZS2Y@GBW>=]EP/\
M7YQL/W?>OV(HJ8WC/GOJMO*ZL_P;^\<K2BX6T:L_/6YXY^S)\<O$WQX\)ZKJ
MWBCX7:_\*KRSO?LL6F^($D66Y3RU;S4\R&([<L5^Z1E3SZ>QT45;:;T1*NMP
MHHHJ1A1110 4444 %%%% !1110!Q7Q"_Y"GA?_K^'\A7YQ_%W_DK'C7_ +#=
M[_Z/>OT<^(7_ "%/"_\ U_#^0K\X_B[_ ,E8\:_]AN]_]'O7TV1?Q)^A\1Q3
M_!I>K_(Y*BBBOLC\Y"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KZS_8,_YGG_MQ_P#;BODROK/]@S_F>?\ MQ_]N*\G-?\ <Y_+\T>_D/\
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MDY/Y-MH****S+"N.^%'_ "**?]=Y?_0J[&N.^%'_ "**?]=Y?_0J .QHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (+[_CQN/^N;?R-<Y\+O
M^1%TS_MI_P"C7KH[[_CQN/\ KFW\C7.?"[_D1=,_[:?^C7H ^"/VHO\ DJ,O
M_7 _^CI:\BKUW]J+_DJ,O_7 _P#HZ6O(J_2,O_W6GZ'XSF_^_P!7U"BBBO0/
M("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS6/@KXSTVQMI+K4+KP_>6\%M$N7DD:W=50#N22!BOS._9$_:.^-_[*OP9M?
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M_&YF."MQI[1\?Q?;(0/T)KU;]CB1Y/V4?A$SDLW_  B^GC).>! @'Z5\Z?\
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MD%%"3E%5)_%!<GJ]N;_P#3YDUDE)PAM-\WHEJU_X'KZ(^5?V8?\ E*U^T/\
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M\A3PO_U_#^0K=KNPF,J8.3E32=^YY689=2S&,856U;M;]4S\\_\ AE/XI_\
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M1/SS_P"&4_BG_P!"O_Y4+7_X[1_PRG\4_P#H5_\ RH6O_P =K]#**/[<Q/\
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M1/SS_P"&4_BG_P!"O_Y4+7_X[1_PRG\4_P#H5_\ RH6O_P =K]#**/[<Q/\
M+'[G_F'^K&#_ )Y?>O\ Y$_//_AE/XI_]"O_ .5"U_\ CM'_  RG\4_^A7_\
MJ%K_ /':_0RBC^W,3_+'[G_F'^K&#_GE]Z_^1/SV'[)OQ5(R/"W_ )4;3_X[
M1_PR;\5O^A5_\J-I_P#':_12/_5K]*=1_;F)_EC]S_S#_5C!_P \OO7_ ,B?
MG3_PR;\5O^A5_P#*C:?_ !VC_ADWXK?]"K_Y4;3_ ..U^BU%']N8G^6/W/\
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M7_RHVG_QVC_ADWXK?]"K_P"5&T_^.U^BU%']N8G^6/W/_,/]6,'_ #R^]?\
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MT*O_ )4;3_X[7Z+44?VYB?Y8_<_\P_U8P?\ /+[U_P#(GYT_\,F_%;_H5?\
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M ,,I_%/_ *%?_P J%K_\=H_X93^*?_0K_P#E0M?_ ([7Z&44?VYB?Y8_<_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5^E'[-/_),+/\ [9_^B(J_->OT+^!,_B*+X>V
MT6VL9K79'EKMF#[O)C]#TQC]:^7SWX*?JS[CA;^+5]$>YT5QWVSQS_SX:1_W
MV_\ \51]L\<_\^&D?]]O_P#%5\>?HIV-%<=]L\<_\^&D?]]O_P#%4?;/'/\
MSX:1_P!]O_\ %4 =C17'?;/'/_/AI'_?;_\ Q5'VSQS_ ,^&D?\ ?;__ !5
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M_P#/AI'_ 'V__P 50!V-%<=]L\<_\^&D?]]O_P#%4?;/'/\ SX:1_P!]O_\
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M<_\ /AI'_?;_ /Q5 '8T5QWVSQS_ ,^&D?\ ?;__ !5'VSQS_P ^&D?]]O\
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MH^U>,?\ GSTO_OM_\: .JHKE?M7C'_GSTO\ [[?_ !H^U>,?^?/2_P#OM_\
M&@#JJ*Y7[5XQ_P"?/2_^^W_QH^U>,?\ GSTO_OM_\: .JHKE?M7C'_GSTO\
M[[?_ !H^U>,?^?/2_P#OM_\ &@#JJ*Y7[5XQ_P"?/2_^^W_QH^U>,?\ GSTO
M_OM_\: .JHKE?M7C'_GSTO\ [[?_ !H^U>,?^?/2_P#OM_\ &@#JJ*Y7[5XQ
M_P"?/2_^^W_QH^U>,?\ GSTO_OM_\: .JHKE?M7C'_GSTO\ [[?_ !H^U>,?
M^?/2_P#OM_\ &@#JJ*Y7[5XQ_P"?/2_^^W_QH^U>,?\ GSTO_OM_\: .JHKE
M?M7C'_GSTO\ [[?_ !H^U>,?^?/2_P#OM_\ &@#JJ*Y7[5XQ_P"?/2_^^W_Q
MH^U>,?\ GSTO_OM_\: .JHKE?M7C'_GSTO\ [[?_ !H^U>,?^?/2_P#OM_\
M&@#JJ*Y7[5XQ_P"?/2_^^W_QH^U>,?\ GSTO_OM_\: .JHKE?M7C'_GSTO\
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M*_:O&/\ SYZ7_P!]O_C1]J\8_P#/GI?_ 'V_^- '545ROVKQC_SYZ7_WV_\
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M 'V_^- '545ROVKQC_SYZ7_WV_\ C1]J\8_\^>E_]]O_ (T =517*_:O&/\
MSYZ7_P!]O_C1]J\8_P#/GI?_ 'V_^- '545ROVKQC_SYZ7_WV_\ C1]J\8_\
M^>E_]]O_ (T =517*_:O&/\ SYZ7_P!]O_C1]J\8_P#/GI?_ 'V_^- '545R
MOVKQC_SYZ7_WV_\ C1]J\8_\^>E_]]O_ (T =517*_:O&/\ SYZ7_P!]O_C1
M]J\8_P#/GI?_ 'V_^- '545ROVKQC_SYZ7_WV_\ C1]J\8_\^>E_]]O_ (T
M=517*_:O&/\ SYZ7_P!]O_C1]J\8_P#/GI?_ 'V_^- '545ROVKQC_SYZ7_W
MV_\ C1]J\8_\^>E_]]O_ (T =517*_:O&/\ SYZ7_P!]O_C1]J\8_P#/GI?_
M 'V_^- '545ROVKQC_SYZ7_WV_\ C1]J\8_\^>E_]]O_ (T =517*_:O&/\
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M4?;/'/\ SX:1_P!]O_\ %4 =C17'?;/'/_/AI'_?;_\ Q5'VSQS_ ,^&D?\
M?;__ !5 '8$9&",BFI#'&<HBJ?\ 9 %<C]L\<_\ /AI'_?;_ /Q5'VSQS_SX
M:1_WV_\ \50!V-%<=]L\<_\ /AI'_?;_ /Q5'VSQS_SX:1_WV_\ \50!V-%<
M=]L\<_\ /AI'_?;_ /Q5'VSQS_SX:1_WV_\ \50!V-%<=]L\<_\ /AI'_?;_
M /Q5'VSQS_SX:1_WV_\ \50!V-%<=]L\<_\ /AI'_?;_ /Q5'VSQS_SX:1_W
MV_\ \50!V-%<=]L\<_\ /AI'_?;_ /Q5'VSQS_SX:1_WV_\ \50!V-%<=]L\
M<_\ /AI'_?;_ /Q5'VSQS_SX:1_WV_\ \50!V-%<=]L\<_\ /AI'_?;_ /Q5
M'VSQS_SX:1_WV_\ \50!V-%<=]L\<_\ /AI'_?;_ /Q5'VSQS_SX:1_WV_\
M\50!V-%<=]L\<_\ /AI'_?;_ /Q5'VSQS_SX:1_WV_\ \50!V-<=\*/^113_
M *[R_P#H5'VSQS_SX:1_WV__ ,53?A+O_P"$17?C/VB3&/K_ (YH [.BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @OO^/&X_P"N;?R-<Y\+
MO^1%TS_MI_Z->NCOO^/&X_ZYM_(USGPN_P"1%TS_ +:?^C7H ^"/VHO^2HR_
M]<#_ .CI:\BKUW]J+_DJ,O\ UP/_ *.EKR*OTC+_ /=:?H?C.;_[_5]0HHHK
MT#R"SINFWFL7T-EI]I/?7DS;8K>VC:21SZ*H!)/TKI_^%.>/O^A'\2?^"BX_
M^(KK?V3?^3@/"OUN/_2:6OL?X_\ QZ_X49:Z+-_87]M_VD\J;?M?V?R]@4Y_
MU;YSN]NE>/C,95P]:%"E#F<E?\7_ )'TF7991Q6&J8FO4<5%]K]$?GQKG@3Q
M+X9MQ/K'AW5=)ASCS+ZREA7/IEE%85?H1\)?VL/"_P 6=4BT&]T^70]5N@5C
MM[IUF@G/]Q7P,DCLRC/09/%>,_M??L_Z;X)BM_%_AJT6QTV>807MC"N(X9&R
M5D0?PJ<8(' .W'6HI9A-5E0Q,.5O;L77RBE+#RQ6"J\\8[JUFOZ^6A\NT5Z#
M\,_@3XR^+"M-H6F9T]'\M]0NI!% K8Z9/+'UV@XR,UZ1=?L+_$*WMWECO] N
M749$,5U*&;V&Z(#/U->A4Q="C+EG-)GCT<OQ6(ASTJ;:[GSM16IXE\,ZIX/U
MNZTC6;*33]1M6VRP2XRO&0<C@@@@@C@@UV-U^SW\0K/0K#6)/#<QT^^,*V\D
M<\,C2&4@1_(KEADL.HXSSBMG5II)N2L]M=_0YE0JN4HJ#O'?1Z6WOVL>=45[
M!\0OV6_&/PS\%MXEUB;2VLXS&LMO;7#O-$7(4 @H%."0#AC7-_#+X(^+OBU,
M_P#8&G;K.)]DM_<OY=O&V,XW'ECTX4$C(XYK..)HS@ZD9KE6[-IX/$4ZD:4J
M;YGJE;4X.BOH>^_89^(=I:R317F@WLBKD007<H=O8;XE7/U(KQ6\\#Z[IOBY
M/#%WIDUMKS7"6JV<V%8R.0% ).,$D8;."#G.**6*HUW:G--E5\#B<,DZU-I,
MPJ*[WQU\"_'/PUTF/5/$>A-I]@\HA$PN89AO() (C=B. >3Q7,>%O"VJ>-=>
MM-%T6T:^U.Z)6&!65=V%+'EB , $\GM6D:M.I%SA)-+K<PJ4*M*:IU(-2?1I
MIF3179>.?@_XO^&]QIUOXBT9[&?42RVL:3Q3F4J5! $;-SEEX[YKT3PS^QA\
M1_$5BMU/#IVAAAE8M3N6$A!'4K&KX^AP?:LY8JA&"J.:L^MS:&!Q52HZ4:;Y
MENK/3U['A-%>R?$+]D_Q[\.]%FU:Y@LM6T^W4O<2Z7,TAA4=69756P.Y .!R
M<"O+?#OAW4_%FLVNDZ/92ZAJ-TVR*WA&68]?H !DDG@ $FJIUZ5:+E3DFD16
MPM?#R4*L&F]O,S:*^B+/]ACXA7-I'-)>Z#:R,H)MYKJ4NI]"5B*Y^A(KQ_XC
M?#G6OA;XFDT/78HH[Q8UF5H)-Z2(V<,I],@]0#Q6=/%4*LN2G--FM; 8K#P]
MI5IM+S.7HKT_X7_LY>-?BQ9_;M)LH;/2\E5U#49#%$[#J%P"S?4*1D$9S72>
M+OV-OB)X3TF74$BT_7(X@6DATJ=WE"@9)".B%OHN3[43Q>'ISY)S284\OQ=:
MG[6G3;CWM_5SPRBK^AZ'?>)-:L])TVW-SJ%Y*L$$(8*7<G &20!^)KT:W_9A
M^(TGBJP\/W&A"RO+R-IUDEN8WA2-2 SN\;-@ LO'4Y& :VG5ITW:<DO^ <].
MA5JING!NUMEWT7W]#RJBO=+W]D'X@:'XHT^P6QL=<5P+B5K&[41I&' 8-YHC
MYYZ '-?2/[0/[/\ IFO_  WN+3P3X+TB+7Q/$T365M;VLFP-\_SG:,8[$UYU
M7,Z%-T^5W4G;1[:I7?\ 71GKX?)<5657FBXN"O9IZZ-V7GHOO1\(^$?"NH>-
MO$NG:%I:+)?WTHAB#MM4$]23V  )/L*[[XM?LW^*O@WHUIJFLSZ;=V=Q/]G#
MZ?,[E'*E@&#HO4*>1GI6=IWA3QS\(?BOH-FNF?9/%J312V=H\D<JRER54%E8
MKAN5/S#OR*]'_:8\3?%W5O#.EP>/_#VGZ%I'VO="=/=&$LP1L!B)I",*6P.!
MUZXJZM:;JT_92CROSW]._P C.AAJ2H5O;PESQVT=EZ]OF<S\._V5?%WQ-\&P
M>)=+O='@L9S((X[N>593L8J>%C8=0>]>.2(8Y&1AAE.#7Z(_LC?\F^Z)_OW7
M_H^2OF3PU^QU\0?&-BVIF/3]$BF8O%%JLSI*ZGD-M1&*_1L'VKFI8^V(K0K2
M2C%V7XG?B,IOA,/4PT7*<U=_<ON/!Z*[+XF_"7Q)\)-8CT_Q#:+%YP+6]U V
M^&=1P2C>W&00",CCD5QM>S"I&I%3@[IGS=6E.C-TZBLUT844459D%%%% !11
M10 4444 %%%% !1110 4444 %%%% !7Z4?LT_P#),+/_ +9_^B(J_->OTH_9
MI_Y)A9_]L_\ T1%7R^>_!3]6?<<+?Q:OHCU:BBBOCS]%"BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH MQ_ZM?I3J;'_JU^E.H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** &R?ZMOI52K<G^K;Z54H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"6W_U
MA^E6*KV_^L/TJQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %17'^K'UJ6HKC_5CZT
M5Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KGM#_P"2FZC_ -@]?_0EKH:Y[0_^
M2FZC_P!@]?\ T): .YHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.^%'_(HI_U
MWE_]"KL:X[X4?\BBG_7>7_T*@#L:*** "BBN?USXA>%O#.O:3H>L>)='TK6]
M78IIVFWU_%#<WK @$0QLP:0Y('R@]:.M@Z7.@HHKGM!^(GA3Q5KNK:)HOB?1
M]7UG2'\O4=.L+^*>XLFR1MFC5BT9R",,!R#1UL'2YT-%5M1U*TT?3[F_O[J&
MRL;6)II[FXD$<44:@EG=B<*H ))/  KDA\</AR=+T34QX_\ "YTW7)S:Z5>?
MVS;>3J$P;88X'WXE<-\NU"3GB@/,[:BBN>L?B+X4U3Q??>$[/Q/HUWXIL8_.
MN]#@U")[VWC^4[Y( V]5^=.2 /F'J*.M@\SH:*;)(L4;.[!$499F.  .I)K$
M\'^._#7Q$TEM4\*^(=*\3:8LK0&]T>]BNX1(N-R;XV(W#(R,Y&10!NT45SGC
M3XD>$?AO9Q7?BWQ3HOA:UE;;'/K6H0V:.?0-(R@FD/?8Z.BL'P?X^\,?$+3C
MJ'A;Q'I/B6P5MINM'OHKN('TW1L1FMZJVW$%%%%( HHHH **** "BBB@ HHH
MH **** "BBB@ HK'\7>,-#\ ^';W7_$FK6>A:)9*&N=0OYEAAB!8*-S,<#+$
M >I(%3>&_$ND^,=!L=;T+4;75](OHA-:WUG*LL,R'HRL#@B@#2HHHH **\E^
M!G[2WA;]H'6?'FF>';/5;2Y\&:N^C:A_:<,<:R3*SKOB*2/N0F-N6VGIP*]:
MHZ)][/Y/5"OOY77W:,****!A1110!!??\>-Q_P!<V_D:YSX7?\B+IG_;3_T:
M]='??\>-Q_US;^1KG/A=_P B+IG_ &T_]&O0!\$?M1?\E1E_ZX'_ -'2UY%7
MKO[47_)49?\ K@?_ $=+7D5?I&7_ .ZT_0_&<W_W^KZA1117H'D'KO[)O_)P
M'A7ZW'_I-+7MG[?W_(+\&?\ 7:Z_]!BKQ/\ 9-_Y. \*_6X_])I:^@_VWO"&
MO>+--\)+H>B:CK+02W)E73[22<Q@K'@ML!QG!Z^E?/8YJ.8X=OM^LC[7*XN6
M48E)7=W^2/BS1=0N-)UBQO;1F6ZMIXYHF7J'5@5Q^(%?HW^TY;Q7WP#\5?:,
M +;1RC/]]94*_J!7RY\"_P!E?Q7XA\6:9J7B329]#T"TF6XE6^7RYI]IR(Q&
M?F&2!DD 8SCFO;?VV/B#:Z#\-U\,QS*=3UF5"85/S) C!F<^@+*JCUY]#6.9
M5(8C$4*5)WDGK;IJORLV:9+2J83"XFOB(VBUUZZ/OWNEYGC?P0^.7CW3O <'
M@KP)X175M0MYY)&U!E>5(TD8L RC"H<YPS-CCI7M_P %KWX\)XRCC\?6$4WA
MV:-]\S-9J\# $J5$+;CDX'(/7M6U\']/7X>_LTV-_P"'M-6]U-M(;5/)5<M=
M7+1E\'')YPOK@ "O,?V<?C!\5?BG\3%;5)GE\+0B4WB1V,44$3;#L0/MWYW%
M?EW$^O&:YZS5>5?V5.*4;W<M^NW9]CIP\7A8855ZLVY6Y8QM9+327=:Z^5SG
M?V^-+@@\6>%M01 MQ<V<L,C#J1&X*Y_[^&OIS3_$EGX/^"NF:]?1M+;:;HD%
MTR*,L=L"X ]ST_&OG#]O[_D+>"_^N%U_Z%%7L_Q _P"34[W_ +%J+_T2E<E3
MWLNH)_S/\V=E-\F<XF2Z07Y1/C_QO^T3XY^+EO=^'K^YMSIFIW41BL8;91Y6
M'!1%<#<1G&<DGC\*^S/&6K6?[-OP+:32+.*0Z7!';VT3C"RSNP7>^,9RQ+MW
M/-?G1X?U!=*U[3;UQE+:YCF8>H5P?Z5^B'[37A6[^(GP1U*+186O[E?)OH(H
M?F:55(8[0.IV$D#OVKTLSI4Z/L*45:#EK^"U^5]3R<EQ%;$/$UYR<JBA[M_^
MWG9?.VAX!\%_VNO&>I_$C2],\37=OJ6E:I=+:[1;)$UNSG:A0H!D;BN=V[BN
MY_;C\.I8Z5X7\9V0\C5K"^6V^T(,-M(:1"3_ ++)Q_O&OG+]G_X?ZQXN^+6@
MQ6EE.(M.OXKF]F:,A;=(W#$,>Q.W ![FOI;]O#7H+7X>Z'I&]?M5YJ/GB/OY
M<<;!C^;K^=/$TZ='&T/8))];=O\ AKCP5:KB<LQ7UN3:2TOW^?G;T/0/B!:P
M_'+]G.[GM$WR:CI:W]NBGE9T D"?7<I4_C7S[^PCX-_M#QEK?B25,Q:;;"VA
M8CCS)3R0?4*I'_ Z]*_8=\:#7/AQJ'AV9PT^CW)**?\ GC+EA_X^)/S%>B>
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M'_R.]?/^M?MM>+&^(@N[&."W\+P7&S^RGA5GFB#8+/)C<'(R1M( XX..??\
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M%% !1110 4444 <=IO\ R5#6/^O*+^8KL:X[3?\ DJ&L?]>47\Q78T %%%%
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MG?WLZ[_A<'CS_H=O$7_@VN/_ (NE_P"%P>/?^AV\1_\ @VN/_BZY"BCV-/\
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MCW_H=O$?_@VN/_BZY"BCV-/^5?<'UBM_._O9U_\ PN#Q[_T.WB/_ ,&UQ_\
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M3_E7W!]8K?SO[V=;_P +=\=?]#IXB_\ !K/_ /%T?\+=\=?]#IXB_P#!K/\
M_%UR5%'L:?\ *ON#ZQ6_G?WLZW_A;OCK_H=/$7_@UG_^+H_X6[XZ_P"AT\1?
M^#6?_P"+KDJ*/8T_Y5]P?6*W\[^]G7#XO>.UZ>-?$0_[BL__ ,72_P#"X/'O
M_0[>(_\ P;7'_P 77(44>QI_RK[@^L5OYW][.O\ ^%P>/?\ H=O$?_@VN/\
MXNC_ (7!X]_Z';Q'_P"#:X_^+KD**/8T_P"5?<'UBM_._O9U_P#PN#Q[_P!#
MMXC_ /!M<?\ Q='_  N#Q[_T.WB/_P &UQ_\77(44>QI_P J^X/K%;^=_>SK
M_P#A<'CW_H=O$?\ X-KC_P"+H_X7!X]_Z';Q'_X-KC_XNN0HH]C3_E7W!]8K
M?SO[V=?_ ,+@\>_]#MXC_P#!M<?_ !='_"X/'O\ T.WB/_P;7'_Q=<A11[&G
M_*ON#ZQ6_G?WLZ__ (7!X]_Z';Q'_P"#:X_^+H_X7!X]_P"AV\1_^#:X_P#B
MZY"BCV-/^5?<'UBM_._O9U__  N#Q[_T.WB/_P &UQ_\71_PN#Q[_P!#MXC_
M /!M<?\ Q=<A11[&G_*ON#ZQ6_G?WLZ__A<'CW_H=O$?_@VN/_BZ/^%P>/?^
MAV\1_P#@VN/_ (NN0HH]C3_E7W!]8K?SO[V=?_PN#Q[_ -#MXC_\&UQ_\77V
MA^S#X\L/BU\&[KPW/XCU*]\36,$MOJ]RLLRWEM]HDG,+I<,.7\L95E8[=HZ8
MQ7P!7T]X%\#^(O#?PC\!?$KPCJ-OH.D:2UYJ_C6*"5X[K6;2UNF98PH4K(PA
MCF10[(/G R 21XV:4:?L8I*SOI]S_KUL?29#B*WUF3;<DHNZ\KK;^MKGI&J:
MQXT_9U\=6TFIWMY>_ VTB\_5?$NOW9U&_AGD5D1!\YF*^<8% 6,@;R>F2/7-
M6TK1OCMX$TB]TKQ'KFFZ1=LE_:ZAX?O)=.GF3:P 8X#;#NR5('*J>U9/P]\>
M>#OVK/A?<WHT6XNO#=U<FUFT_6X(P9&B9'!*H[C ;:1SU%>,:MJWB']CWQCJ
MOB[Q=JLNH?"2\D;2- \,Z%(99+"1R)8B8I1'&B+'!,ORNQ!<  @DCY;E=1\M
MK5%^/_!/N^94H\U^:E+\/_M?QN='\*/C9XY\(>((]$^/4%AX8U#Q!=6]GX5A
MLXA.;V7>4F5F@:4)@R6PS(4'SG&<''<?&[P3XM2UN?&/P^OM6O/&EE#%#8>'
MY-3\O2;C,FV1I;=W6-F$<DC LPY1.X KH?BU\,;'XE>&9I8K*R;Q58VEPWA_
M5+P$-IUXZ Q3*P!*%9$B;(!(V#@XKR3X'_$K7/A?XUTOX-?$O5;WQ3X_U=IM
M2MM6M7\^S2V\EF6-I)-D@8?9Y>!&1\R\\G"5JG[VFDFMUTM_EWU&TZ?[BJVX
MO:76_F^]]M#NO@G\;;+QI,G@S7[R&/XHZ79M/KND06TBI;,KJK8D ,3 &2/[
MCM][V../\;Z%XX^!.M:+K'A34]8\2>"Y+AKOQC>>*-4-^=,L(61VDMDD<.#Y
M37!*QJY/EH,9 !U?CO\  '6-?M6UCX3SZ9X+\>WE\KZCKS226\MS:E'WQ,\:
M.QS((6P1C]WUX%:/P5^/7A+]IC2?%&AVFEZD\.F0166J1:Q#$L=RLZRHRKLD
M?<I$3YSCAA[X:LE[6FKQZKM_70/>;5&J[2^R^_\ 2^+UT.@T/Q;X1_:3^'NI
M-X4\2ZE_9+W(M)-4T=I].NHI8S'*51V57&04!(&"&(]:\LM?B5XG_9Z\:ZE!
M\2[MK/X/0(;+0_$.H.VH7]W=L4=$E,;/*?D6Y^9T4?(!GH#7^(GAF\_9E\8V
MGQ#T.6'1/@SHUJ#K/A716*SW=Y,7@6982%C;YI;7):13B(\$@ ^O:2W@S]IC
MX8Z'K&HZ NJ>'[X_;K:RUF!"\;KOC#%59@&P7'!/#46C35[7IO[T_P#,+SJO
MEORU8_<U^=K_ #N)\4_"-[XT\.6^O>&M6UBVUO2[2:^TBST[4&M+;4+@HKPQ
MW2959(RR(-KD##N"1DUQ'P0^,_B&/5K;P-\85L]#^)VIS2W.F:19P^8DU@L6
MX2&2(R1*=T-SPSAOD''*YXSP)XN\6?LQ^-K/P_\ %77;GQ4GCC48;#PQ'I,I
MN(]/"2['$WG"+8I^TV_W _$;=,#/K/QX^#MSX^T.[U;PB+#1_B9##%;Z5XDN
M&:.6TC$P:1!(BLRAHWG7@'_6$=\T<L8?NYZQ>TOZZ7W!2E.]:G=26\?ZZVVU
M]3G_ (W>#_B/X7GF\6?"B?4O$'B;4+E+>YT35M45M,M[7RR6DA@ED1$??'$,
M@Y^=^.3CJ?AK\6/"_P <-!UG1])UJ6;6=.MH[36OL4,UK)93RHZGRY&4#<&C
MDPR%L%0<],\C^SU\7)E\03?!SQ1=7^L?$3PW8O=ZKK!Q)9W ,J%?+D9A(Q"W
M$0^:-?NMZ#.5\8O@WJO@74M*\8?#*>P\&Z-ILLVK>+[>S=X)M7@B9)0@54*R
M,%%R '91F7KR2#E3?LJFCZ/OZ_H"FTO;TM8OXH]O3SOO^ W6M0\5?LW>-M/G
MN]3U#4O@E';FZUWQ'XCO6U*^M;J3S(HXH_F,WEEQ:_*D; &1SD?,1Z=-'X=_
M:*^'NEZGH/B?7++0[F=KBWU+P_=S:;/+Y9DB9&)57V;MV5(Y*J>PK*^&?Q*\
M%?M;?#75;B/0[JY\._;OL%S8:[!&/-DC$4P.U'<%070CG.5/%>5>*-5OOV._
M'6I^+=7NI&^#5XJ:1HGA306WR65VZ)*TAAD\N-5)@NB2LA.91QR<'*ZCY;6J
M+\?^#^%A<RIQYT^:E+\/_M?QNS<\!_&?Q)\+?$EWH'QKD@T&TU&[CL?!TRQF
M[FU%$=DD:5X3)AL/:DM)LR9">S8[GXX>#/%C6DWB_P  7NJW/C/3[>."PT$Z
MEY6E7.92)&F@9UC=Q')(0S,.43^Z!6MXQ\#Z!\:_!>G:N^DVMQJ?]GM=Z'=:
MC&/,L9IHU9'!&=I#+&21G[@QG%>4?!'X@>(OA'XUTSX/_%'6;SQ7X[U^275K
M#5+.0W%G%9^2P$3R2>7(&#6LYP(R/G7GDX%:?[R"]Y;KI_PW?4;O3_=5&W%[
M2ZI^;[WVT.X^!7QBG\3,O@CQO+;V?Q<TVVDO-:T6U@;R[>(RCRF$J[HFS%-;
MG"R,<N<@$$#EOBEH'Q+^%6O6FK_#N;4/$^C:E<S7?B/_ (2/4ENH]-@1E9?L
ML<LBF-=LD^5C#<1H,<#.S^T!\"]>\5PG7/A==Z=X0^(%U=QC4-?DDDMY;FS6
M)E,+21H[$;EMS@C'[L<\"KWP%^,>E?%S3=?\'S07]UK/A.*#2==N+]$\F\G*
MR12/$P<LZLT$ARRJ<,..2 :)>V@KKJNW_ OL'O-JA4;3^S+O_P &V_X&[X>\
M8>#OVD/ &J/X3\0W[:4UQ]BEU+2?/T^YAE01R%4=T5U.UDR0,$,1GK7EZ^/=
M<_9O\<:C:_$"_FB^#,,*VVB^)-5D;4=1NK^0)*8Y60O,0,78!:,*%C49^[FK
M\1_!NH_LY^,++Q]X9GM] ^#NBVJS:YX7T=F2:\NG9XO-6$J(V.'M@2TB\1>P
MSZKX;O\ P3^U1\*]%UV]\/\ ]I>';R:2XMK+6X$+QR122P%RJLR@\/C!/#?A
M1:--<RUIO[T_\PYIU'RM\M6/W-?Y7^=R3QAX0LOC!X9T/Q!HOB'7]/B%H;_3
MCH>HRV"7HE1'B\Y."P^5<!\8W,.,FN$^#/QNUK3]2M?!7QG%CH'Q+U2Y:72]
M)L[<R)/9% $<R0F2)29([@89P?D'&"">/M?B%J?[(7C#4+'XA7]WKOAOQ5?F
M#P?IVAMYZ:3:P2,OE2+*8A&-EQ;* A<?NVZ8&?8_C;\'4\?Z/>:KX?M]/T_X
MC0VJV^D>(;G<DEGARW$BJS*,/)T!^^:.6,/<GK%[/^OQ!2E-NI3TG'XH_P!=
M;;>NIS7QR\'_ !#\.W,WB[X4R:AKOB>^GCMI]#U/4E.EP6HBPTL5O+(B))NB
MBY!S^\?CYC74?!OXJ:5\4-%NM'DO(W\::#;P6GB>SM[=XA8W[*R2QJY&Q@)8
MI@&C9A\N02"">._9Z^*5YIOB"7X+^,+V^USXD>'K*2^U/6@1)97$;R))&$E8
MK(S".YA7YHU *,,D $T/CG\!?%K:M::Y\(-4TWP-///<7OB:5)I;:35&+(\;
M-Y<;[V!-Q][',GN<'*F_8U-'T?\ GY6V!2:7MZ5VNL>S\O.^Y3\1_P#">?L^
M>,M.>SNKW6O@[#$M_P"(?$'B6^_M"]M'+.CI'N?S2@5(2%2-N78]SCU5E\-_
MM$_#G3]2\/\ B/6+30[R9IK?4]!N9M-N)/+=XF4DJKA=P8$$<[0?2L_X5?%3
MPA^U5\.=6O+31[R30&NWTNZL=:@C4RLJ1R'Y4=P5Q(O?.0>*\E\67.I?LB^/
M-1\9:A>,OP5D5--TKPEH3%I;2YDC1VD\EPD:J9([AB1(3F0<<G!RNH^5JU1?
MC_P?PL+F5*/.GS4I?A_]K^-S6T#XV:A\"=<US2/C5>1Z)X=-Q]D\&W\L;WUU
MJ5K"SJ\L[P^8WF;&M6+2!"QD8X)W8]%^,?PZUG5([CQ5X3U36U\5Z;98TW1+
M?5#!IMW,K,R^? 65'R6P2Q&0JC/%:5WX3\$_M >#_#'B+6?#=MJ]K=6"7^G+
MJL"M);I<1I)@@$@,0$S@D97J:\9^%'Q7USX$>*M)^%'Q7U:_\7>./$5XM[I^
MJ:>_VBTAMI<0QQR22F-P1)!,Q"HPPX.220!+G]^"M);KH_3]1M^S7LZCO![/
MJO7[_=TZ:G??!'XT?V]-;>!/'<UK8_%^UAEN-5T2UMF,<*;]\1$JAH3F&2!L
M+(3EB#@@@<U\8?"OQ=^'^L#4O@^EYXMDUNXN)]5M?$6II/;V&&#1+:I-*@B4
M^9*-J9X1!Q@9Z+X\_ O4O%EK<Z[\-Y--\+?$>YGB$WB*1W@EDMU38T9D1';D
M+&,8Z**M?L\_&2V\>P:MX,N#J%QXJ\#QV^DZ]J%TJ^3=WBAXI987#%G5I()&
MRZH2&4X!) 5TE[:FDUU3V_X:^P-.36'JMI_9DMW_ ,&V^ECHO"/COP?^T%X&
MU:?PEKES<:5(\FFRZAIZ365Q!+Y:L?+9T5E8+(A# =^O%>1R>,?&'[//CVZA
M\87$G_"CK%!%:^)M7F.H:C-<2(KA9"K-,P$K2H"8\!549P 37^)GPL\1_!GQ
M;8^,_ FH6?A7X3Z!;IJ>O^&]-E>*6^>)W:=DB">6[/"L2#<ZYV ' &:]=\*Z
MSX._:@^$^F:U<:&U_P"&M4=Y([#6H4WAHIGBRRJS+G<C$8)X(^E%H4US+6#^
M]?\ !"\ZKY'[M2.OD_UY;_,F\2>#='^-WAOP_JUCXE\1:1IDUNM[:7'AW49=
M.-S%,BLC2  ,1MP0& (R>*\T^%/[0&H^&[JR\(?'%['PW\1]7OT72M+L[5ID
MGM9=D<+&2#S(U+3+,OS."-H) &">0NOB)JG[&7B36KCXAZA>:YX+UZZDA\)Z
M1H+>?_95K"[%8F28Q+&!%)"H",_W".P)]U^+?P;TGXA6%_JMKI>G+X[@T]X-
M%URZ4B2QG4.T#AP"RA)6WY )!R<&GRQ@E&>L'L_Z_$%*51N=/2<=U_7II^)S
M'QH\ >,]);4?&GPVO=8U;QA(\4</A^]U7&DB/:L;L+>1TC!VC=U^\2>IKU:O
M"_@5\:9_#GBRQ^!_C2ZU'7OB7IL4TM_K4>V6QF# W,>V5V60D0RQKS&.5(Y
M!/NE<]92C:$NFS[KI\NQU8=PG>I#KNNSZ_/N%%%%<QUA1110 4444 %%%% !
M1110 4444 %%%% !1110 5SVA_\ )3=1_P"P>O\ Z$M=#7/:'_R4W4?^P>O_
M *$M '<T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)E.&$CLZ*2#P=I;!!!P017SS^POXUUCPC_P2S^(FMZ;/(-1T:/7)+!EZPL(
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ML9EFB8C(R.Q'<$9!'H37V3H_[>GA:32XFU7P_K%OJ6W]Y'9B*6'=[,SJ<?\
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MQ!+)CA9(8$!/U$I_E7PK1653*\+5FYN-F^QO1SW'4*:IQE=+NCT?4OC"]_\
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MHZM9W;"BBBMSF"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]*/V:?\
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M6O?[CX0\"R_MJZ7\/=)^%T/@/P=X<DTZT328_B'/JT4\*VT:"-94M$=G,NT
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MN=_T.BAK44>^GWZ&A^R*\<G[+'PB,6-G_"*:8/E&.1:Q@_KFOE7]H#_E+?\
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MG]O?_H?_ (0_^ ]U_P#(E>J_MK?LGVG[6GPMAT2+4AH?B;2;G[?HVJ,I*13
M8*/CG8XP"1R"%8 [<'Q7P_X^_;N\!Z6GAZ_^%'@_Q_/9QK!%XFCUF"W%Q@8$
MDJ-<1LQZ9Q''GTSS2I^[!P>]V_5.WXK;T2+J>]*,EM:WI9O\'>_K<ZG]A?\
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MS_/KV3-JEG6]MT<8KSO'3;SZ?BS&_P"".T,=OX7^,T42+'$GBG:B(,*H",
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M3U_TK<N>PD2O;_\ @E_\);SP?^S[=>/=?W3^+?B+>2:]?74J_O&A9F\D$^C
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M7OB=H&FQM/J%WH5R;>&,9:21%\Q4'NQ0#\:\'_X)&_$C2O%G[).F^'+:>/\
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M *_A_(5^6U?69#_R]^7ZGP'%7_+C_M[_ -M"BBBOK#X$**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OJ3]FO
MXL7GP9LO"VG>+;N\U31O']\ECX4L]/"R+ISQW+0W!G#E-BO+.C#89"0"2 <
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MOO<?-[-X*\:Z'\7O"T;*^GIK:V41U31Q<)<W.C7$J?-;SKPR.C*Z$,JG,;<
M@@+2"NES4W^'_#=[:AK4ERM\M5=>Z[_/M?0R/C/\&+;Q]8W6MZ):V-G\1K:T
M%OHVOW196LV#,RD,H; !=_X3]XUR'P#^+EYI_B8_!CQE=WNN?$K0[22\U/68
MPKV,Z.ZRQA)"5D)$5Q"IS&O*MR0 3QGPS&M?L>:Q9?#V]TZ_\7^%=5N/[8O_
M !_<(]E8Z2)%$)BER)$&W[.K;FE7_7#@8RWIOQL^%.E?M0?#2TMO#OBRSL+:
M6]2[CU[3(TO4F$8DC9 R2*"-Q()W'!3&/1M**]G4=X/:7;]?D)-R?M:2M46\
M>_Z7V][7L<O\:_V?_&3:O#J_P7U;2_ E[J$]Q=>))WFEB?4I&96B8[8Y,E2U
MP?X?]9W[=S\*_BIX1_:J^'&L7=GI-\V@/<R:5=V>L1(C2D1QNW$<CC:1*O?.
M0>*Y/X/_ !F@\%VEYX&\>VT?@6U\*)!HNE:[XCO!9IXD2 -"]S LRH,8CB<A
M'DQYZ9;H6I?'KX&7[?$32_B]H=W<7,WA2QC>/P?I]DQ;5)(I99-HD1OE9O,"
M_P"J<_+WZ :O^[JNS6S_ *^770$^6]6BKI_%'M_EUZ>\<_XJDU?]D?QG?>+K
MN]V?!! ECIOA/16+SVUQ*BLS^7($0*95G<GS2?W@XYP/:;[P9X%_:(\(^%O$
M&O>'(=8L;FR34-/CU)/WD$=Q&CX(5B Q 3."1E>M0?"CXP:9\5-"L8-;L[3P
MSXQD626[\&:A=K)J%FJR,JM)"ZI( R;) 2@^61>H()\5UC2_%G[)/C;Q1XB\
M.^%]9^+<7CS4)KQ[#2[:6!=$6.5Y$C+(D^\-]I*@[8_]2>#G"EI5'R[5%^/S
MV\[WU"\:<>9>]2>_6WRW[*UM"]\,_C%KGP(\5:/\*_BWJM[XN\<>([V.ZT_4
M]+VS6D-M,1!''(\GE.")(9F(",,.,$DD#O/CA\"+WQ-'?>(_AR=.\,_$RZEB
M#>(IW>-S"JA&0LJ/U157[O:NK\26GASX]?#GQ%I_A[Q%I=]'?VTVF#6=,DCO
M1:R,GJC_ 'E#JVW<#R.F:\B^$GC:^_9XU2V^$WB?2[B/PCH<4C+\2]6D:RL+
MN28FX$8$BF,,&F:+_7,28SP/N@3<G[2FK36Z[_UV!Q4$J55W@]GU3]?O][0[
MG]GSXV6OCYM5\$W/]H7'BWP5%#INNZA<(GD7=VFZ&62%@VYE:2&1@61#AAP#
MD#S_ .(OPE\4?!GQ-9^*_AWJ5CX4^$^@P)J_B#PY9RNL]\T+M)<M&A0JS/ D
M:#=(H)4 X'-=5^T-^SG;?M,:1X:NM%\7Q>'K:W\R[2^L+0727R3*A5@RRH",
M+D-D@[JUOA+^T19^/=-^S>.-(@^&7B6YO?LEIX9\07P2\O8F5 DL<4J1.ZN[
M/&,(06C8 DY $^7]Y25UUCV_K7T!KF_=5G9KX9=_\K:;OWC<\+ZQX/\ VI/A
M'I^K7.BRWOAC5F=UL-7C57W0S/'EE1V'WHR1ACQCZ5V-?.?Q0^%.M_"/XMZM
M\<O#T6H>-)6$5M'X&TRS=&PT"6[.)4,G3:9#B+OC/>OHRN:M&*2<'>+_  ?5
M?EKU.RA*4FXU%:2_%='\]=.@4445S'6%%%% !1110 4444 %%%% !1110 44
M44 %%%% !7/:'_R4W4?^P>O_ *$M=#7/:'_R4W4?^P>O_H2T =S1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<=\*/^113_ *[R_P#H5=C7'?"C_D44_P"N\O\
MZ%0!V-%%% !117@?[<'Q_P!>_9G_ &>]7\=^&K'3M0UBUNK6WBAU5)'M\2RA
M&++&Z,< G&&'/Y5$YJ"N_+\78J,7)V1[Y17P='\;?VY;/PO:^*7^%'PXU_1Y
M+9+UK+1[B=+R2%D#_('NS\VT] &.> #7T!^R'^U5HG[6OPQ?Q/IFGS:)J=E<
MFQU31YY/,:UG"AL*^!O0@@AL#N" 0:VY7>2ZK==NGYF7,K)]'L^G?\CW&BO$
M/@CKWQTU3XH?$:U^)OAO1-(\$6UWM\*WNFS(\UW#YC@&0+*Y'[L1D[E0[B<#
M'3V^H6L5+OK_ ,.6])./;^M HHKXH^+GQ$\5:5_P5%^#/A*S\2:M:^%M1\-7
M,UYHD-[(ME<2!+\AY(0=C,#''\Q&?D'I3BN:<8=[_@F_T';]W.I_*K_BE^I]
MKT45D^+O$MKX,\*ZSX@ODEDLM*LYKZ=(%!D:.)"[!02 3A3C)'UJ)24(N4MD
M.,7)J,=V:U%>=_ #XY:!^T=\+=*\>^&;74++1]2>9(H-5B2.X4QRM&VY4=UZ
MH<88\8KT2M)1<79D)J2N@HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% $%]_QXW'_7-OY&N<^%W_(BZ9_VT_\
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M6A%QDH)..QXKQV)E&495&U+>[N%%%%=)Q!1110 4444 %%%% !1110 4444
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MI'.[CZ_HHA[DG);O3[][>H2]Z*@]M_\ APHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X
M[3?^2H:Q_P!>47\Q78UQVF_\E0UC_KRB_F*[&@ HHHH **** "BBB@ HHHH
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MG_#*?PL_Z%?_ ,J%U_\ ':/^&4_A9_T*_P#Y4+K_ ..T?VYAOY9?<O\ ,/\
M5C&?SQ^]_P#R)^>=%?H9_P ,I_"S_H5__*A=?_':/^&4_A9_T*__ )4+K_X[
M1_;F&_EE]R_S#_5C&?SQ^]__ ")^>=%?H9_PRG\+/^A7_P#*A=?_ !VC_AE/
MX6?]"O\ ^5"Z_P#CM']N8;^67W+_ ##_ %8QG\\?O?\ \B?GG17Z&?\ #*?P
ML_Z%?_RH77_QVC_AE/X6?]"O_P"5"Z_^.T?VYAOY9?<O\P_U8QG\\?O?_P B
M?GG17Z&?\,I_"S_H5_\ RH77_P =H_X93^%G_0K_ /E0NO\ X[1_;F&_EE]R
M_P P_P!6,9_/'[W_ /(GYYT5^AG_  RG\+/^A7_\J%U_\=H_X93^%G_0K_\
ME0NO_CM']N8;^67W+_,/]6,9_/'[W_\ (GYYT5^AG_#*?PL_Z%?_ ,J%U_\
M':/^&4_A9_T*_P#Y4+K_ ..T?VYAOY9?<O\ ,/\ 5C&?SQ^]_P#R)^>=%?H9
M_P ,I_"S_H5__*A=?_':/^&4_A9_T*__ )4+K_X[1_;F&_EE]R_S#_5C&?SQ
M^]__ ")^>=%?H9_PRG\+/^A7_P#*A=?_ !VC_AE/X6?]"O\ ^5"Z_P#CM']N
M8;^67W+_ ##_ %8QG\\?O?\ \B?GG17Z*K^R;\*BH)\+=O\ H(W?_P =I?\
MADWX4_\ 0J_^5&[_ /CM']N8;^67W+_,/]6,9_/'[W_\B?G317Z+?\,F_"G_
M *%7_P J-W_\=H_X9-^%/_0J_P#E1N__ ([1_;F&_EE]R_S#_5C&?SQ^]_\
MR)^=-%?HM_PR;\*?^A5_\J-W_P#':/\ ADWX4_\ 0J_^5&[_ /CM']N8;^67
MW+_,/]6,9_/'[W_\B?G317Z+?\,F_"G_ *%7_P J-W_\=H_X9-^%/_0J_P#E
M1N__ ([1_;F&_EE]R_S#_5C&?SQ^]_\ R)^=-%?HM_PR;\*?^A5_\J-W_P#'
M:/\ ADWX4_\ 0J_^5&[_ /CM']N8;^67W+_,/]6,9_/'[W_\B?G317Z+?\,F
M_"G_ *%7_P J-W_\=H_X9-^%/_0J_P#E1N__ ([1_;F&_EE]R_S#_5C&?SQ^
M]_\ R)^=-%?HM_PR;\*?^A5_\J-W_P#':/\ ADWX4_\ 0J_^5&[_ /CM']N8
M;^67W+_,/]6,9_/'[W_\B?G317Z+?\,F_"G_ *%7_P J-W_\=H_X9-^%/_0J
M_P#E1N__ ([1_;F&_EE]R_S#_5C&?SQ^]_\ R)^=-%?HM_PR;\*?^A5_\J-W
M_P#':/\ ADWX4_\ 0J_^5&[_ /CM']N8;^67W+_,/]6,9_/'[W_\B?G317Z+
M?\,F_"G_ *%7_P J-W_\=H_X9-^%/_0J_P#E1N__ ([1_;F&_EE]R_S#_5C&
M?SQ^]_\ R)^=-%?HM_PR;\*?^A5_\J-W_P#':/\ ADWX4_\ 0J_^5&[_ /CM
M']N8;^67W+_,/]6,9_/'[W_\B?G317Z+?\,F_"G_ *%7_P J-W_\=H_X9-^%
M/_0J_P#E1N__ ([1_;F&_EE]R_S#_5C&?SQ^]_\ R)^=-%?HM_PR;\*?^A5_
M\J-W_P#':/\ ADWX4_\ 0J_^5&[_ /CM']N8;^67W+_,/]6,9_/'[W_\B?G3
M17Z+?\,F_"G_ *%7_P J-W_\=H_X9-^%/_0J_P#E1N__ ([1_;F&_EE]R_S#
M_5C&?SQ^]_\ R)^=-%?HM_PR;\*?^A5_\J-W_P#':/\ ADWX4_\ 0J_^5&[_
M /CM']N8;^67W+_,/]6,9_/'[W_\B?G317Z+?\,F_"G_ *%7_P J-W_\=H_X
M9-^%/_0J_P#E1N__ ([1_;F&_EE]R_S#_5C&?SQ^]_\ R)^=-%?HM_PR;\*?
M^A5_\J-W_P#':/\ ADWX4_\ 0J_^5&[_ /CM']N8;^67W+_,/]6,9_/'[W_\
MB?G317Z*M^R;\*@I(\+=O^@C=_\ QVJW_#*?PL_Z%?\ \J%U_P#':/[<PW\L
MON7^8?ZL8S^>/WO_ .1/SSHK]#/^&4_A9_T*_P#Y4+K_ ..T?\,I_"S_ *%?
M_P J%U_\=H_MS#?RR^Y?YA_JQC/YX_>__D3\\Z*_0S_AE/X6?]"O_P"5"Z_^
M.T?\,I_"S_H5_P#RH77_ ,=H_MS#?RR^Y?YA_JQC/YX_>_\ Y$_/.BOT,_X9
M3^%G_0K_ /E0NO\ X[1_PRG\+/\ H5__ "H77_QVC^W,-_++[E_F'^K&,_GC
M][_^1/SSHK]#/^&4_A9_T*__ )4+K_X[1_PRG\+/^A7_ /*A=?\ QVC^W,-_
M++[E_F'^K&,_GC][_P#D3\\Z*_0S_AE/X6?]"O\ ^5"Z_P#CM'_#*?PL_P"A
M7_\ *A=?_':/[<PW\LON7^8?ZL8S^>/WO_Y$_/.BOT,_X93^%G_0K_\ E0NO
M_CM'_#*?PL_Z%?\ \J%U_P#':/[<PW\LON7^8?ZL8S^>/WO_ .1/SSHK]#/^
M&4_A9_T*_P#Y4+K_ ..T?\,I_"S_ *%?_P J%U_\=H_MS#?RR^Y?YA_JQC/Y
MX_>__D3\\Z*_0S_AE/X6?]"O_P"5"Z_^.T?\,I_"S_H5_P#RH77_ ,=H_MS#
M?RR^Y?YA_JQC/YX_>_\ Y$_/.BOT,_X93^%G_0K_ /E0NO\ X[1_PRG\+/\
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ME]R_S#_5C&?SQ^]__(GYTT5^BW_#)OPI_P"A5_\ *C=__':/^&3?A3_T*O\
MY4;O_P".T?VYAOY9?<O\P_U8QG\\?O?_ ,B?G317Z+?\,F_"G_H5?_*C=_\
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MC#5_$OP:T2/Q,_C&_FU'Q/\ V]<P[+,K(9(_LX\R$@'[1<9!\P_(G3^+U_\
MX5CX97QO?^,(M,^S^)[^%8+K4[>>6*66,*BA258<8CC_ .^174[C]E^S,S/%
ML\LB0EB5QCDGDG'<G-+VT82O!:/=/;_ANP_J\JD.6H]5LUO_ ,.UN</:^(/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N.^%'_(HI_P!=Y?\ T*NQKCOA1_R**?\ 7>7_ -"H [&BBB@
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MXFTJZA\17 %U&DJG[/=12.ZE3LE5L<$ '^+ U/VV'\>+_P %*O@_'\,UT_\
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M_&?P;G^+VK?!SPSX8MH'T_3_  [.+/4M;E>))&=)\AC@.3M&1M ^7[S#H_\
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M?>59R]Z,9IZ22:]//S_X<J.DI0MJFT_^ %%%%06%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!!??\>-Q_US;^1KG/A=_P B
M+IG_ &T_]&O71WW_ !XW'_7-OY&N<^%W_(BZ9_VT_P#1KT ?!'[47_)49?\
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M_2C]FG_DF%G_ -L__1$5?+Y[\%/U9]QPM_%J^B/5J***^//T4**** "BBB@
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MAK20V]K>PB">8^ -\C?>=L #<Q)X'-=;115-N3NR4DM$%%%%(84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $%]_QXW'_7-O
MY&N<^%W_ "(NF?\ ;3_T:]='??\ 'C<?]<V_D:YSX7?\B+IG_;3_ -&O0!\$
M?M1?\E1E_P"N!_\ 1TM>15Z[^U%_R5&7_K@?_1TM>15^D9?_ +K3]#\9S?\
MW^KZA1117H'D!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7_T-@_\  %*/^$;\5_\ 0V#_ , 4KL:* .._X1OQ7_T-@_\  %*/^$;\5_\
M0V#_ , 4KL:* .._X1OQ7_T-@_\  %*/^$;\5_\ 0V#_ , 4KL:* .._X1OQ
M7_T-@_\  %*/^$;\5_\ 0V#_ , 4KL:* .._X1OQ7_T-@_\  %*/^$;\5_\
M0V#_ , 4KL:* .._X1OQ7_T-@_\  %*/^$;\5_\ 0V#_ , 4KL:* .._X1OQ
M7_T-@_\  %*/^$;\5_\ 0V#_ , 4KL:* .._X1OQ7_T-@_\  %*/^$;\5_\
M0V#_ , 4KL:* .._X1OQ7_T-@_\  %*/^$;\5_\ 0V#_ , 4KL:* .._X1OQ
M7_T-@_\  %*/^$;\5_\ 0V#_ , 4KL:* .._X1OQ7_T-@_\  %*/^$;\5_\
M0V#_ , 4KL:* .._X1OQ7_T-@_\  %*/^$;\5_\ 0V#_ , 4KL:* .._X1OQ
M7_T-@_\  %*/^$;\5_\ 0V#_ , 4KL:* .._X1OQ7_T-@_\  %*/^$;\5_\
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M^ *5V-% 'E'B[1M>MK[0UN]>%V\EUMA;[*J>4W'S<=?I6K_PC_B7_H9A_P"
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MB@#G5\.^*-HQXI &/^?)*7_A'?%'_0TC_P  DKK(_P#5K]*=0!R/_".^*/\
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M-(_\ DH_X1WQ1_T-(_\  )*ZZB@#D?\ A'?%'_0TC_P"2C_A'?%'_0TC_P
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M% ''?\(WXK_Z&P?^ *4SX2JR^$5W-N_TB3MCO_G\Z[2N.^%'_(HI_P!=Y?\
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M **** "BBB@ HHHH **** "OTH_9I_Y)A9_]L_\ T1%7YKU^E'[-/_),+/\
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M15\P* I=7AE4L ,@*3SDG[(K:4>6UG=-)KT:NB(N]TU9IV?R"BBBH*"BBB@
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MJ_\ ]HH_X;S_ .I&_P#*O_\ :*/[*QG\GXK_ ##^WLN_Y^_A+_(^LZ*^3/\
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M1]<T5\C?\-^?]2)_Y6/_ +11_P -^?\ 4B?^5C_[11_96,_D_%?YA_;V7?\
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M_P"I&_\ *O\ _:*/[*QG\GXK_,/[>R[_ )^_A+_(^LZ*^3/^&\_^I&_\J_\
M]HH_X;S_ .I&_P#*O_\ :*/[*QG\GXK_ ##^WLN_Y^_A+_(^LZ*^3/\ AO/_
M *D;_P J_P#]HH_X;S_ZD;_RK_\ VBC^RL9_)^*_S#^WLN_Y^_A+_(^LZ*^3
M/^&\_P#J1O\ RK__ &BC_AO/_J1O_*O_ /:*/[*QG\GXK_,/[>R[_G[^$O\
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MBC_AO/\ ZD;_ ,J__P!HH_LK&?R?BO\ ,/[>R[_G[^$O\CZSHKY,_P"&\_\
MJ1O_ "K_ /VBC_AO/_J1O_*O_P#:*/[*QG\GXK_,/[>R[_G[^$O\CZSHKY,_
MX;S_ .I&_P#*O_\ :*/^&\_^I&_\J_\ ]HH_LK&?R?BO\P_M[+O^?OX2_P C
MZSHKY,_X;S_ZD;_RK_\ VBC_ (;S_P"I&_\ *O\ _:*/[*QG\GXK_,/[>R[_
M )^_A+_(^N+?_6'Z58KY"C_;V\ML_P#""Y_[B_\ ]HJ3_AOS_J1/_*Q_]HH_
MLK&?R?BO\P_M[+O^?OX2_P CZYHKY&_X;\_ZD3_RL?\ VBC_ (;\_P"I$_\
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MA_\ )3=1_P"P>O\ Z$M '<T444 %%%% !1110 444E "T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<=\*/^
M113_ *[R_P#H5=C7'?"C_D44_P"N\O\ Z%0!V-%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!!??\>-Q_US;^1KG/A=_R(NF?]M/_ $:]='??
M\>-Q_P!<V_D:YSX7?\B+IG_;3_T:] 'P1^U%_P E1E_ZX'_T=+7D5>N_M1?\
ME1E_ZX'_ -'2UY%7Z1E_^ZT_0_&<W_W^KZA1117H'D!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Z4?LT_\
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M"\^'&M^';,VMO/9::;B4-YC.)$D6XB*$;V'?\*X#_AWS\=O^CS?&W_@#<_\
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M*** "BBB@ HHHH X[3?^2H:Q_P!>47\Q78UQVF_\E0UC_KRB_F*[&@ HHHH
M***^._VC/^"B6F_#/XC#X8?#3P??_%CXE;S%-INF,P@M'QDJ[*KL[J.650 H
MSN=2"*ERU4>K*46TWT1]B45\!1_M!?MXZ:W]IZE^SUX5NM&4>8]I8WR"[*=<
M#%^[;O\ MD3[5](?LJ?M(77[1W@_5[[5O!&K?#[Q%HE__9VIZ'JX.^*7RUD!
M4LJ,05=3\R*1GN,$Z)7O;H0W:WF>VT5^;W[2G_!3WQO\ ?VKM;\"KX2T75?
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M'/4.'[R?)'?_ (%_R6P2]R#G+8_0BBBBD 4444 %%%% !1110 4444 %%%%
M'%?$+_D*>%_^OX?R%?G'\7?^2L>-?^PW>_\ H]Z_1SXA?\A3PO\ ]?P_D*_.
M/XN_\E8\:_\ 8;O?_1[U]-D7\2?H?$<4_P &EZO\CDJ***^R/SD**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"OHO]A?_ )*WJ_\ V YO_2BWKYTKZ+_87_Y*WJ__ & YO_2BWKSLP_W6IZ'K
MY1_O]+U/NBBBBOS@_9@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BN/
M]6/K4M17'^K'UH KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/:'_ ,E-U'_L
M'K_Z$M=#7/:'_P E-U'_ +!Z_P#H2T =S1110 4444 %%%% !7Y_?'SXB:CJ
MWQ>UZ>PU.ZMK>VF%K$+>X9%Q& I(P>Y!/XU^@##<I&2,C&17S]KW[&?A'49K
MBZBUC5K.>5VD9I)(Y$R3DG!0'J?6OK>'<=@\!7G5Q?566E^NI^><:97F6;86
MG0R^VDKO6VRLOS9\R:+\=?'N@,GV7Q1?LB](YW\U/R;->H>%?VU/$NG,D>NZ
M59ZQ#_%)#FWE^O&5_P#'14^O?L7:A#N.B>*=/U ]1%=(86/L""PS^5>4^+?@
M7XX\%J\FHZ!<M;KUN+4>='^:YQ^-?HB_L'-/=M!M_P#;K_1GXRUQ;D/OWJ**
M\^>/_MT3[%\"?M->!_'#1P"_;1[]^!:ZD!'D^@?)4_GGVKU56610RD,I&00<
M@U^5)'4$5ZI\)_VB/$OPQN(;=IWU?0\@2:?<.3M7N8V/*GVZ>U?/9CP>N5U,
M!+7^5_H_\_O/L<E\2&Y*CFT-/YX_K'_+[C]!**P?!'C;2OB!X<M=:T>?SK2<
M8(/#1L.J,.Q%;U?F52G*E)PFK-;H_<Z56G7IQJTI7C)736S04445!J%%9/BK
MQ9I'@G0;O6M=U"#3-,M5W2W-PVU5]O<GL!R:^?+[]OSP%:1B\BT3Q1=:$9?)
M&M1Z9MM2V>S,P)_*NJCA:^(5Z4&R)5(P^)GTS17-_#_XA:!\4/"]KX@\-WZ:
MCIEQD"1059&'WD93RK#N#725SRC*$G&2LT4G=704445(PHHHH **** "BL35
M?''AS0O$&DZ%J6OZ7I^N:MO_ +.TRZO(XKF]V#+^3$S!I-HY.T''>MNCI</(
M***Q?%/C;P]X'M+:Z\2:]IGA^VNKA+2";5+R.V26=\[(D9V 9S@X4<G!H VJ
M*** "BBB@ KCOA1_R**?]=Y?_0J[&N.^%'_(HI_UWE_]"H [&BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH @OO\ CQN/^N;?R-<Y\+O^1%TS
M_MI_Z->NCOO^/&X_ZYM_(USGPN_Y$73/^VG_ *->@#X(_:B_Y*C+_P!<#_Z.
MEKR*O7?VHO\ DJ,O_7 _^CI:\BK](R__ '6GZ'XSF_\ O]7U"BBBO0/("BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "OTH_9I_Y)A9_P#;/_T1%7YKU^E'[-/_ "3"S_[9_P#HB*OE\]^"GZL^
MXX6_BU?1'JU%%%?'GZ*%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!QVF_\ )4-8_P"O*+^8KL:X
M[3?^2H:Q_P!>47\Q78T %%%% 'FO[2OQ&N?A'\ ?'_C&RQ]OTC1KBXM2PR!/
ML(B)]MY6OEC_ ()%?"'3]#^ =Q\3;Q!?>+/&=_<R3ZE/\\PMXIFC$>X\_-(D
MCM_>+#.=HKZA_:A^'MW\5_V=_B)X2T]/,U'5-%N8;1,XW3A"T:_BZJ/QKY>_
MX)"_&/2_$W[/+_#F65;7Q1X/O+A9M/E^65K>:9I5E"GG =W0^A49ZBBA_$JV
MWY8_==\WZ?*]PK?PZ=]N9_EI?]//8^J]?_:0^$OA36;O2-;^*/@O1]6LW\JY
ML-0\0VD$\+_W7C>0,I]B*Z7P5\1/"GQ*TV;4?"/B?1O%6GPRF"2ZT6_BO(DD
M !*,\;, V"#@G."*\6^)'[!/P%^(&N:]XJU_X>VM_K^HM)=W5Y]ONXS+*1DN
M528*"2.P%?.?_!%-1'\%_B(JC"KXFP!_V[14J7O*2ENDGY;V'4]VTH[-V_!O
M]#F1\)]&^.7_  4O_:/\#:]'NTW6?!2V[2  M"^W33'*O^TCA6'NM=S_ ,$Q
M_BMK?@?5_&/[-'CZ0Q>*/!5S+)I1D8_O[/?\Z)GJJEED3U2;T6F?!7_E,%\:
M_P#L58__ $'3:9_P4J^&6M?"OQEX+_:A\ P;=?\ "ES#;ZY''D"XM2VU'?'\
M.&:%SUVRKV6JIR5*EAW+X90L_+WI<K^3T?DRZT75G4C'XHM->?NQNOFOQ18\
M,?\ *9'Q7_V)J_\ HJVK[ _: ^*UI\$/@OXQ\<W93;HNG2W$,;G EGQMAC_X
M%(R+^-?"OP%^)&C_ !?_ ."IEUXST";S])UKP##=PG(+)NAMMR-Z,K94CL5-
M;7_!6SQIK?C"S^'7P'\'6SZIXE\7Z@+V73X951I8HSMA1BQ"JK2%FW,0!Y&2
M<"N>49JA3HKXG>/SYY7^Y7?R*A*$JTJK^%*+^2A'\]OF>:?#7]D&[^(7_!,C
MQIK^I6SWGCWQ3=R^-[>>1=T[F MY:Y[F2+SR/^OBOL/_ ()S_&K_ (7=^RCX
M1OKFX\_6-$C.A:B6.6\R !48^[1&)C[L:\M\._%']LGPMX:TW0=/_9B\-PZ7
MI]I'96\ \4V6U8D0(JX^T_W0!7C/_!-OQ#XG^ /[67Q!^#7CO0%\&W?B>(ZQ
M9:&+F.>*VG4&58XI$9E<&!VY!/\ J0#R#7=&TJM2G#X9)6]8*W_I'XHXY<WL
MH5)_$F[^DWK]TOS.@_;\@_X7A^WM\!O@YJ+-)X:18M1O;0L0DWF32&4$=\Q6
MNT'J-[>M?I7:6D%A:PVUM#';VT*+'%#$H5$4# 50.  !C K\S_V[KY?@K_P4
M1^ WQ4U4^1X;GAAL;B[8?)%Y<TJ3$GMMCNE;\#Z5^F<<B31I)&ZR1N RLIR"
M#T(-84?]V7^.?YK^D;5O]X_[=C;\;_COYGQY_P %7/AEIOCG]D/Q#K4]K')J
MWAB>WU&QN2!OC#3)%*H/HR.<CN54]0*]4_8?\=7?Q(_9-^&.NZA,US?2:0EM
M/-(26D>!FA+$GJ3Y>2?>O)?^"L'Q4TSP)^R7K?A^:ZC76O%4\&GV-KD&215E
M269PO]U43!/8NHZD5[)^QE\/;SX5_LL_#7PWJ,+6VHVNCQS74+C#12RDS.A]
MU,A!^E%'^'6?3FC]_*[_ (6"M\5&^]I?=>-OQO\ U8^:O^"HGB*^^)&L?";]
MGK0)F&I^-M9BNM0$1YCM(WVJS#^[N+R?]N]?='A_PSI_AGPOIWA_3X%@TK3[
M..Q@@7@+"B!%7C_9 KX&_977_AI[_@H%\6/C-,/M7AOP8G_".>'Y&^9-^&C+
MH?=%F?\ [>17Z'4J:7U=7^W[S]'I%/\ [=5_F%3^.[?8]U>N\OQT^1\7?MS?
M"+P;\%_^"?/Q)T#P1X=LO#FE*ED[0VB'=*_VZW&^1R2\CXQ\SDGCK7J?[ __
M "9O\)O^P)'_ .A-7-_\%-O^3'OB9_URLO\ TNMZZ3]@?_DS?X3?]@2/_P!"
M:JIMN-5OO'_TECJ?\NO^W_\ W&>F^/O@_P"#/BE?Z!=^+O#MEXAET&Y:[TY-
M00R10S,NTOY9.QSCIN!P0",'FO@_XB@+_P %H?AN , >'V  _P"O&]K](:_-
M_P"(W_*:+X<?]@!O_2&]HI:5Z?K+_P!-R%4_@5?\/ZH_2"BBBD 4444 %%%%
M !1110 4444 %%%% '%?$+_D*>%_^OX?R%?G'\7?^2L>-?\ L-WO_H]Z_1SX
MA?\ (4\+_P#7\/Y"OSC^+O\ R5CQK_V&[W_T>]?39%_$GZ'Q'%/\&EZO\CDJ
M***^R/SD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "OHO]A?_DK>K_\ 8#F_]*+>OG2OHO\ 87_Y*WJ__8#F
M_P#2BWKSLP_W6IZ'KY1_O]+U/NBBBBOS@_9@HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *BN/]6/K4M17'^K'UH KT444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7/:'_P E-U'_ +!Z_P#H2UT-<]H?_)3=1_[!Z_\ H2T =S1110 4444
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MZABI^F<5>U"Z%C87-R>D,32'\ 37BU'[--RZ'3%.3274^'?@+<#]HK_@H?\
M%?X@W.;G1/AK:IX5T-6Y2.X8NL\B_P"UE+@9])!Z"O<OVF_VIH?@*^A^'=#\
M+:IX\^(WB02#0_#>EQ-^]V8WRS28(CC7(R>3[  L/ O^"/*/JGP-\>^)K@A[
M[6_&%U/++W?$,)Y_X$[_ )U]W_9(#="Z,,9N0AC$VP;PI.2N>N,@''M52IRA
M"G2EI:*OWU7,]?\ $^VPN92J5)K75I=K)\J_!?>?%'[ ?[0'QB^+/Q>^-/AK
MXMW]F;[PQ-:Q1:186T"0:?([3B2-)$&Z0#8HR[O]W@\YKVS]MCX1Q?&S]F'Q
MYX=\GSM033WU#3R!\RW5N/-CVGL6*;/HYKY\_87_ .3UOVN/^PS;_P#HVYK[
MPGA6XADBD4,DBE64]"",$5C43JX:FXZ2<$_G:]_O-8OV.*J)ZJ,OPTT/#/V'
M?C-+\>/V7_ _BB\F\_5UM/[/U%R<LUS 3$[GW?:'_P"!U[O7P-_P2%F;3/AO
M\5O"ZR-);:+XRN(X=W0*8T7C_OUG\:^^:ZJDXU6JL=I)2_\  DG^IS4X>S3I
MWORMK[FU^@4445D:!7'?"C_D44_Z[R_^A5V-<=\*/^113_KO+_Z%0!V-%%%
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M9X@_9I'A/P[X!T/3O$GCOQ 9[E+74ED>&WLX5W22,D;HQSS@[@ $<G.*[?\
M8;_:&UW]I[]G_3?''B33]/TW6)KVYM)H=*61+<^6^%95=W89!&06/(/TKX^\
M!,?VI_C3^TM\=[A?M/ACPMX<U'PQX6D;!3BUE5Y4_P" ;W_[>J]N_P""1/\
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MUK[OHJ*;]GMY?.W?N:5/WE[^>W2^]NVR^Y'C7[3GASXV^)/"^DP_ _Q5X?\
M"FN1WA>_N/$$/F1RV^Q@%3]Q-AMVT_=' Z]C\2:G^PS^V-K'QPTSXO77Q+^'
M4GC[3;?[+;:D/-"I'Y<D>/*&G^6?EE<9*YY]A7Z@45,5RRYEO_P+:?+\V-NZ
MY7L>.?LR>'?C7X;\)ZK!\</%&@>*]?DO=]C<^'XO+BCMO+4;'_<0Y;>&/W3P
M1SV'L=%%6WS.Y*5@HHHJ1A1110 4444 %%%% !1110!Q7Q"_Y"GA?_K^'\A7
MYQ_%W_DK'C7_ +#=[_Z/>OT<^(7_ "%/"_\ U_#^0K\X_B[_ ,E8\:_]AN]_
M]'O7TV1?Q)^A\1Q3_!I>K_(Y*BBBOLC\Y"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7\Q78UQVF_\ )4-8_P"O*+^8KL: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X
MKXA?\A3PO_U_#^0KY8\=?L=^,_$_C;Q#K%KJ>A1VNH:C<7<237$P=4DE9U#
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M=_\  F?_ .,T?\,/^.O^@MX=_P# F?\ ^,U]P44?VQBNZ^X/]7,!V?WGP_\
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M=_\  F?_ .,T?\,/^.O^@MX=_P# F?\ ^,U]P44?VQBNZ^X/]7,!V?WGP_\
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M^V,5W7W!_JY@.S^\^%_^&%O'O_07\.?^!-Q_\8H_X86\>_\ 07\.?^!-Q_\
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M^V,5W7W!_JY@.S^\^%_^&%O'O_07\.?^!-Q_\8H_X86\>_\ 07\.?^!-Q_\
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M .,U]P44?VQBNZ^X/]7,!V?WGP__ ,,/^.O^@MX=_P# F?\ ^,T?\,/^.O\
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M .,U]P44?VQBNZ^X/]7,!V?WGP__ ,,/^.O^@MX=_P# F?\ ^,T?\,/^.O\
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M .,U]P44?VQBNZ^X/]7,!V?WGP__ ,,/^.O^@MX=_P# F?\ ^,T?\,/^.O\
MH+>'?_ F?_XS7W!11_;&*[K[@_U<P'9_>?#_ /PP_P".O^@MX=_\"9__ (S1
M_P ,/^.O^@MX=_\  F?_ .,U]P44?VQBNZ^X/]7,!V?WGQ"G[#?CN0X&K>'?
M_ F?_P",4_\ X86\>_\ 07\.?^!-Q_\ &*^X+?\ UA^E6*/[8Q7=?<'^KF [
M/[SX7_X86\>_]!?PY_X$W'_QBC_AA;Q[_P!!?PY_X$W'_P 8K[HHH_MC%=U]
MP?ZN8#L_O/A?_AA;Q[_T%_#G_@3<?_&*/^&%O'O_ $%_#G_@3<?_ !BONBBC
M^V,5W7W!_JY@.S^\^%_^&%O'O_07\.?^!-Q_\8H_X86\>_\ 07\.?^!-Q_\
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M% !1110 4444 %%%% !1110 5%<?ZL?6I:BN/]6/K0!7HHHH **** "BBB@
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M $+7A;_P7O\ _'*/^&HM?_Z%KPM_X+W_ /CE=WUFM_S[_'_@'F_V?0_Y_?\
MDK_S+-%5O^&HM?\ ^A:\+?\ @O?_ ..4?\-1:_\ ]"UX6_\ !>__ ,<H^LUO
M^??X_P# #^SZ'_/[_P E?^99HJM_PU%K_P#T+7A;_P %[_\ QRC_ (:BU_\
MZ%KPM_X+W_\ CE'UFM_S[_'_ ( ?V?0_Y_?^2O\ S+-%5O\ AJ+7_P#H6O"W
M_@O?_P".4?\ #46O_P#0M>%O_!>__P <H^LUO^??X_\  #^SZ'_/[_R5_P"9
M9HJM_P -1:__ -"UX6_\%[__ !RC_AJ+7_\ H6O"W_@O?_XY1]9K?\^_Q_X
M?V?0_P"?W_DK_P RS15;_AJ+7_\ H6O"W_@O?_XY1_PU%K__ $+7A;_P7O\
M_'*/K-;_ )]_C_P _L^A_P _O_)7_F6:*K?\-1:__P!"UX6_\%[_ /QRC_AJ
M+7_^A:\+?^"]_P#XY1]9K?\ /O\ '_@!_9]#_G]_Y*_\RS15;_AJ+7_^A:\+
M?^"]_P#XY1_PU%K_ /T+7A;_ ,%[_P#QRCZS6_Y]_C_P _L^A_S^_P#)7_F6
M:*K?\-1:_P#]"UX6_P#!>_\ \<H_X:BU_P#Z%KPM_P""]_\ XY1]9K?\^_Q_
MX ?V?0_Y_?\ DK_S+-%5O^&HM?\ ^A:\+?\ @O?_ ..4?\-1:_\ ]"UX6_\
M!>__ ,<H^LUO^??X_P# #^SZ'_/[_P E?^99HJM_PU%K_P#T+7A;_P %[_\
MQRC_ (:BU_\ Z%KPM_X+W_\ CE'UFM_S[_'_ ( ?V?0_Y_?^2O\ S+-%5O\
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MA_S^_P#)7_F6:*K?\-1:_P#]"UX6_P#!>_\ \<H_X:BU_P#Z%KPM_P""]_\
MXY1]9K?\^_Q_X ?V?0_Y_?\ DK_S+-%5O^&HM?\ ^A:\+?\ @O?_ ..4?\-1
M:_\ ]"UX6_\ !>__ ,<H^LUO^??X_P# #^SZ'_/[_P E?^99HJM_PU%K_P#T
M+7A;_P %[_\ QRC_ (:BU_\ Z%KPM_X+W_\ CE'UFM_S[_'_ ( ?V?0_Y_?^
M2O\ S+-%5O\ AJ+7_P#H6O"W_@O?_P".4?\ #46O_P#0M>%O_!>__P <H^LU
MO^??X_\  #^SZ'_/[_R5_P"99HJM_P -1:__ -"UX6_\%[__ !RC_AJ+7_\
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M%KPM_P""]_\ XY1]9K?\^_Q_X ?V?0_Y_?\ DK_S+-?I1^S3_P DPL_^V?\
MZ(BK\SO^&HM?_P"A:\+?^"]__CE?HE\!_#Z>-OAUIVJW%Y>:?+-'$[0Z?+Y4
M0+0QL<*0>[8Z] *^?S>K.I""E&WSN?5\/X:G0J5'"?-=+I8]UHKCO^%96O\
MT&=:_P# L?\ Q-'_  K*U_Z#.M?^!8_^)KY@^U.QHKCO^%96O_09UK_P+'_Q
M-'_"LK7_ *#.M?\ @6/_ (F@#L:*X[_A65K_ -!G6O\ P+'_ ,31_P *RM?^
M@SK7_@6/_B: .QHKCO\ A65K_P!!G6O_  +'_P 31_PK*U_Z#.M?^!8_^)H
M[&BN._X5E:_]!G6O_ L?_$T?\*RM?^@SK7_@6/\ XF@#L:*X[_A65K_T&=:_
M\"Q_\31_PK*U_P"@SK7_ (%C_P")H [&BN._X5E:_P#09UK_ ,"Q_P#$T?\
M"LK7_H,ZU_X%C_XF@#L:*X[_ (5E:_\ 09UK_P "Q_\ $T?\*RM?^@SK7_@6
M/_B: .QHKCO^%96O_09UK_P+'_Q-'_"LK7_H,ZU_X%C_ .)H [&BN._X5E:_
M]!G6O_ L?_$T?\*RM?\ H,ZU_P"!8_\ B: .QHKCO^%96O\ T&=:_P# L?\
MQ-'_  K*U_Z#.M?^!8_^)H [&BN._P"%96O_ $&=:_\  L?_ !-'_"LK7_H,
MZU_X%C_XF@#L:*X[_A65K_T&=:_\"Q_\31_PK*U_Z#.M?^!8_P#B: .QHKCO
M^%96O_09UK_P+'_Q-'_"LK7_ *#.M?\ @6/_ (F@#L:*X[_A65K_ -!G6O\
MP+'_ ,31_P *RM?^@SK7_@6/_B: .QHKCO\ A65K_P!!G6O_  +'_P 31_PK
M*U_Z#.M?^!8_^)H [&BN._X5E:_]!G6O_ L?_$T?\*RM?^@SK7_@6/\ XF@#
ML:*X[_A65K_T&=:_\"Q_\31_PK*U_P"@SK7_ (%C_P")H [&BN._X5E:_P#0
M9UK_ ,"Q_P#$T?\ "LK7_H,ZU_X%C_XF@#L:*X[_ (5E:_\ 09UK_P "Q_\
M$T?\*RM?^@SK7_@6/_B: .QHKCO^%96O_09UK_P+'_Q-'_"LK7_H,ZU_X%C_
M .)H [&BN._X5E:_]!G6O_ L?_$T?\*RM?\ H,ZU_P"!8_\ B: .QHKCO^%9
M6O\ T&=:_P# L?\ Q-'_  K*U_Z#.M?^!8_^)H [&BN._P"%96O_ $&=:_\
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M\30!'\0O^0IX7_Z_A_(5NUP'B[P3!I=]H<::EJ4XN;KRRTUP&*=.5XX-:O\
MPKVV_P"@MJW_ ($C_P")H ZJBN5_X5[;?]!;5O\ P)'_ ,31_P *]MO^@MJW
M_@2/_B: .JHKE?\ A7MM_P!!;5O_  )'_P 31_PKVV_Z"VK?^!(_^)H ZJBN
M5_X5[;?]!;5O_ D?_$T?\*]MO^@MJW_@2/\ XF@#JJ*Y7_A7MM_T%M6_\"1_
M\31_PKVV_P"@MJW_ ($C_P")H ZJBN5_X5[;?]!;5O\ P)'_ ,31_P *]MO^
M@MJW_@2/_B: .JHKE?\ A7MM_P!!;5O_  )'_P 31_PKVV_Z"VK?^!(_^)H
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M ZZBN1_X5O:_]!C6/_ H?_$T?\*WM?\ H,:Q_P"!0_\ B: .NHKD?^%;VO\
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M7MM_T%M6_P# D?\ Q- '545RO_"O;;_H+:M_X$C_ .)H_P"%>VW_ $%M6_\
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M (F@#KJ*Y'_A6]K_ -!C6/\ P*'_ ,31_P *WM?^@QK'_@4/_B: .NHKD?\
MA6]K_P!!C6/_  *'_P 31_PK>U_Z#&L?^!0_^)H ZZBN1_X5O:_]!C6/_ H?
M_$T?\*WM?^@QK'_@4/\ XF@#KJ*Y'_A6]K_T&-8_\"A_\31_PK>U_P"@QK'_
M (%#_P")H ZZBN1_X5O:_P#08UC_ ,"A_P#$T?\ "M[7_H,:Q_X%#_XF@#KJ
M*Y'_ (5O:_\ 08UC_P "A_\ $T?\*WM?^@QK'_@4/_B: .NHKD?^%;VO_08U
MC_P*'_Q-'_"M[7_H,:Q_X%#_ .)H ZZBN1_X5O:_]!C6/_ H?_$T?\*WM?\
MH,:Q_P"!0_\ B: .NJ*X_P!6/K7+?\*WM?\ H,:Q_P"!0_\ B:9-\.;95!_M
M?5SSWNA_\30!TE%<K_PKVV_Z"VK?^!(_^)H_X5[;?]!;5O\ P)'_ ,30!U5%
M<K_PKVV_Z"VK?^!(_P#B:/\ A7MM_P!!;5O_  )'_P 30!U5%<K_ ,*]MO\
MH+:M_P"!(_\ B:/^%>VW_06U;_P)'_Q- '545RO_  KVV_Z"VK?^!(_^)H_X
M5[;?]!;5O_ D?_$T =517*_\*]MO^@MJW_@2/_B:/^%>VW_06U;_ ,"1_P#$
MT =517*_\*]MO^@MJW_@2/\ XFC_ (5[;?\ 06U;_P "1_\ $T =517*_P#"
MO;;_ *"VK?\ @2/_ (FC_A7MM_T%M6_\"1_\30!U5%<K_P *]MO^@MJW_@2/
M_B:/^%>VW_06U;_P)'_Q- '545RO_"O;;_H+:M_X$C_XFC_A7MM_T%M6_P#
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M17'?\*RM?^@SK7_@6/\ XFC_ (5E:_\ 09UK_P "Q_\ $T =C17'?\*RM?\
MH,ZU_P"!8_\ B:/^%96O_09UK_P+'_Q- '8T5QW_  K*U_Z#.M?^!8_^)H_X
M5E:_]!G6O_ L?_$T =C17'?\*RM?^@SK7_@6/_B:/^%96O\ T&=:_P# L?\
MQ- '8T5QW_"LK7_H,ZU_X%C_ .)H_P"%96O_ $&=:_\  L?_ !- '8T5QW_"
MLK7_ *#.M?\ @6/_ (FC_A65K_T&=:_\"Q_\30!V-%<=_P *RM?^@SK7_@6/
M_B:/^%96O_09UK_P+'_Q- '8T5QW_"LK7_H,ZU_X%C_XFC_A65K_ -!G6O\
MP+'_ ,30!V-%<=_PK*U_Z#.M?^!8_P#B:/\ A65K_P!!G6O_  +'_P 30!V-
M%<=_PK*U_P"@SK7_ (%C_P")H_X5E:_]!G6O_ L?_$T =C17'?\ "LK7_H,Z
MU_X%C_XFC_A65K_T&=:_\"Q_\30!V-%<=_PK*U_Z#.M?^!8_^)H_X5E:_P#0
M9UK_ ,"Q_P#$T =C17'?\*RM?^@SK7_@6/\ XFC_ (5E:_\ 09UK_P "Q_\
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M.M?^!8_^)H_X5E:_]!G6O_ L?_$T =C17'?\*RM?^@SK7_@6/_B:/^%96O\
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M^)H_X5E:_P#09UK_ ,"Q_P#$T =C17'?\*RM?^@SK7_@6/\ XFC_ (5E:_\
M09UK_P "Q_\ $T =C17'?\*RM?\ H,ZU_P"!8_\ B:/^%96O_09UK_P+'_Q-
M '8T5QW_  K*U_Z#.M?^!8_^)H_X5E:_]!G6O_ L?_$T =C17'?\*RM?^@SK
M7_@6/_B:/^%96O\ T&=:_P# L?\ Q- '57W_ !XW'_7-OY&N<^%W_(BZ9_VT
M_P#1KU3NOAK:QVLSC6-9)5&.&NA@\?[M6_A=_P B)IG_ &U_]&O0!^8O[<W_
M "6P?]> _P#2F>OGFOH;]N;_ )+8/^O ?^E,]?/-?=X+_=X>A^:YC_O=3U"B
MBBNT\X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *_8O\ 93_Y(WHW_7&#_P!)XJ_'2OV+_93_ .2-Z-_UQ@_]
M)XJ^>SCX(?,^IR'XZGHCV"BBBOF#[(***\1_;8\4:OX,_91^)NM:#J5UH^KV
M>D.]M?64IBFA8LHW(XY5L$X(Y':LJM14J<JCZ)O[BZ<?:34%U/;J*_*#_@G;
M^T5\2O"?QP\+>$OB=XTUGQ3X>^)&@_VCH=QKE]+=F*X5Y%55DE9BN3#.A4'!
M/EG'-?J_73*'*D_7[TVFODT81FI?@_DU=,**_/C_ (*.?&SQUJOQ&\,?!GX6
M^)]2\,:LFF7GB;Q!JFCW$D$T%K!"\B(9(R&4$12$@$9+1#H:]3_X)>^/O$GQ
M'_9+TC5O%>O:AXDU9=3O8#?ZK<O<7#(LGRAI')9L9(&2>,#M65)^U4FNGXJ_
M+^=U\F:5/W;BG]K\-+_E9_-'UI1113 **** "BBB@ HHHH **^5_VFOVK/%7
MP7_:2^"/P]T73='N]&\;WOV?4;B_BE:XB4SQQ@PLLBJIPY/S*W:OJBB/O4U4
M6UVOFMQ-\LW![V3^_8Y_PO\ $+PMXXNM4MO#GB71]?N-+F^S7\.EW\5R]I+D
MCRY0C$QME6^5L'@^E=!7YW_\$J_^2G_M.?\ 8TK_ .C[ROT0H7P0E_-&+^])
M_J%_>G'LVON84444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#CM-_Y*AK'_7E%_,5V
M-<=IO_)4-8_Z\HOYBNQH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#BOB%_P A
M3PO_ -?P_D*W:POB%_R%/"__ %_#^0K)O_C5\/=*OKFRO?'GAFSO+:1H9[>X
MUBW22*120R,I?*L"""#R"*J,92^%7)E.,?B=CLZ*X7_A?/PS_P"BB>$__!W;
M?_%T?\+Y^&?_ $43PG_X.[;_ .+J_95/Y7]QG[:G_,OO.ZHKA?\ A?/PS_Z*
M)X3_ /!W;?\ Q='_  OGX9_]%$\)_P#@[MO_ (NCV53^5_<'MJ?\R^\[JBN%
M_P"%\_#/_HHGA/\ \'=M_P#%T?\ "^?AG_T43PG_ .#NV_\ BZ/95/Y7]P>V
MI_S+[SNJ*X7_ (7S\,_^BB>$_P#P=VW_ ,71_P +Y^&?_11/"?\ X.[;_P"+
MH]E4_E?W![:G_,OO.ZHKA?\ A?/PS_Z*)X3_ /!W;?\ Q='_  OGX9_]%$\)
M_P#@[MO_ (NCV53^5_<'MJ?\R^\[JBN%_P"%\_#/_HHGA/\ \'=M_P#%T?\
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M_P#P=VW_ ,71_P +Y^&?_11/"?\ X.[;_P"+H]E4_E?W![:G_,OO.ZHKA?\
MA?/PS_Z*)X3_ /!W;?\ Q='_  OGX9_]%$\)_P#@[MO_ (NCV53^5_<'MJ?\
MR^\[JBN%_P"%\_#/_HHGA/\ \'=M_P#%T?\ "^?AG_T43PG_ .#NV_\ BZ/9
M5/Y7]P>VI_S+[SNJ*X7_ (7S\,_^BB>$_P#P=VW_ ,71_P +Y^&?_11/"?\
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MAC_T4;PE_P"#RU_^.4>RJ?RO[@]M3_F7WG>45P?_  OSX8_]%&\)?^#RU_\
MCE'_  OSX8_]%&\)?^#RU_\ CE'LJG\K^X/;4_YE]YWE%<'_ ,+\^&/_ $4;
MPE_X/+7_ ..4?\+\^&/_ $4;PE_X/+7_ ..4>RJ?RO[@]M3_ )E]YWE%<'_P
MOSX8_P#11O"7_@\M?_CE'_"_/AC_ -%&\)?^#RU_^.4>RJ?RO[@]M3_F7WG>
M45P?_"_/AC_T4;PE_P"#RU_^.4?\+\^&/_11O"7_ (/+7_XY1[*I_*_N#VU/
M^9?>=Y17!_\ "_/AC_T4;PE_X/+7_P".4?\ "_/AC_T4;PE_X/+7_P".4>RJ
M?RO[@]M3_F7WG>45P?\ POSX8_\ 11O"7_@\M?\ XY1_POSX8_\ 11O"7_@\
MM?\ XY1[*I_*_N#VU/\ F7WG>45P?_"_/AC_ -%&\)?^#RU_^.4?\+\^&/\
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M  =VW_Q='_"^?AG_ -%$\)_^#NV_^+H]E4_E?W![:G_,OO.ZHKA?^%\_#/\
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M  =VW_Q='_"^?AG_ -%$\)_^#NV_^+H]E4_E?W![:G_,OO.ZHKA?^%\_#/\
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MHH **** "BBB@ HHHH **** "BBB@ J*X_U8^M2U%<?ZL?6@"O1110 4444
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MC6-;^%?Q C\H:7JTPD\F9BR$@*%3>D@C;>JJ2KE2#C-?1'_!1S]IOQ'^S_\
M#'0M&\#$)X\\9W_]EZ9/M#-;*-OF2H#P7R\:+G@&3/:O-OVWO^3^OV3_ /K_
M )/_ $?%63_P5XTR^\.7GP.^)BVDEWH_A?7V^VK&,E2SP31Y] WV=UR>Y'K7
M/%^UH4O:O1U'%O\ NJ2LOQM?S-/@Q%106T%)+^]RO_*YIZ-_P2%\*^)]&@U;
MXE?$CQOXB^(5Q&);W5[?48]B3=<)YL4CL%/&6?)QG"YP(/V*/BE\0O@W^U)X
MP_9E^(OB2Z\8VEC;->^']9OV9Y_+5%D";F)8JT3YVECL:-E!P:^[/!_CSP_X
M]\(6/BG0-7M-3T"]@%S#?P2@Q%,9))SP1SD'D$$'&*_/7X,ZQ:?M(?\ !5SQ
M3X^\*2+J7A#P=HYLVU>W^:">7R/LX"MT(9WF*D<,L1(XYK>/,L1[.UE:5UT5
MDVG\G9?,SE:5#VE[M.-GWNTK?-7/)OVROV-?ASX'_:^^#/AS2X-373/B#J[O
MK:S7I=V,EU&&\MB,IQ(WKVK]%?V;_P!C[X=_LJMKS>!(-2A;6Q"+O[?>M/D1
M;]FT$ #_ %C?G7RM_P %#;R#1?VU/V4]3OY5M-/CU4![F4X1<7=OG)[8W#\Z
M_1,2HTAC#J74!BN>0#G!Q^!_*HP_N82/+I[TU\DU9>B*K7EB))[<L7\];L_'
M;]D3X,^/_CU\9/CQX5T?QM>^!/AV_B66;Q+=Z*XCU*](N+D0VT3]44@R%CC&
M  0V<5TO[17P&NO^"8OBSP!\3OA1XO\ $4WAR_U=;#7-&U:Z65+GY2^U@B(K
MJ\:RCYE)5@&!SC'J_P#P2K_Y*?\ M.?]C2O_ */O*T/^"T'_ ";CX0_[&RW_
M /2:XHH+V?U;EZJE?SNHII^5G:WZFJBJU2M"6UY_*UW=>=];_IH?2G[8'[0#
M?LW_ +._B7QY:P1W&J0Q1V^FPS#*-=3,$C+#NJY+D=PA%?&7PK_8[^&WQY\
MZ3X\^/?QGO\ Q-X]U^U6_>+_ (26W@CTH2C>D4:'.UE##*\(#P$ '/N/_!4[
MP/?^,_V*]9ET^&2XDT6ZL]5ECB&3Y*-LD;'HJR%CZ!2:X/\ 96_8E_91^/\
M\"?"/BVU\#P:IJ,]A#'JWE>(-1#PWRH!.CHMR-AWY(& ,$$#!%13CS.M)KX6
MDO)-=/5Z-^21GSODHZ_$FWZZ:?):V\VRE^QY\1M:^"'[7>O_ +.T_CR7XC^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "OK3_@FC_P EVUW_ +%N?_TJM:^2Z^M/^":/_)=M=_[%N?\ ]*K6
MN''?[M/T/1R[_>Z?J?I91117PI^E!1110 4444 %%%% !1110 4444 %%%%
M!1110 5%<?ZL?6I:BN/]6/K0!7HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N>T
M/_DINH_]@]?_ $):Z&N>T/\ Y*;J/_8/7_T): .YHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N.^%'_(HI_P!=Y?\ T*NQKCOA1_R**?\ 7>7_ -"H [&BBB@
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M,KC]J'XB>%9+/6)=,^QPZC>7*MMABDW[OM:8_P!;C:!QMK]9/$W_ "+>J_\
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ME\^_AP]3A:***^I/C HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *^M/^":/_ "7;7?\ L6Y__2JUKY+KZT_X
M)H_\EVUW_L6Y_P#TJM:X<=_NT_0]'+O][I^I^EE%%%?"GZ4%%%% !1110 44
M44 %%%% !1110 4444 %%%% !45Q_JQ]:EJ*X_U8^M %>BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *Y[0_^2FZC_V#U_\ 0EKH:Y[0_P#DINH_]@]?_0EH [FB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *X[X4?\BBG_ %WE_P#0J[&N.^%'_(HI
M_P!=Y?\ T*@#L:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"
M"^_X\;C_ *YM_(USGPN_Y$73/^VG_HUZZ.^_X\;C_KFW\C7.?"[_ )$73/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .*^(7_(4\+_\
M7\/Y"OR#^/7_ "7+XB_]C'J/_I5)7Z^?$+_D*>%_^OX?R%?D'\>O^2Y?$7_L
M8]1_]*I*]_)_XD_0^7S[^'#U.%HHHKZD^,"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]=Y?_0J[&N.^%'_(HI_UWE_]"H [&BBB@ HHHH **** "BBB@ HHHH ****
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MI676^$H?5Z,:?7KZ]3FQV(^M8B51;=/1;?UW"BBBNPX HHHH **** "BBB@
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MHM5UTW^9E#1-6M9OY:O3Y!1116984444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 <=IO_)4-8_Z\HOYBNQKCM-_Y*AK'_7E%_,5V- !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 <5\0O^0IX7_P"OX?R%?EM\:O@K\0]5
M^,GCR]LO ?B:\L[G7[^:"XM]'N'CEC:XD*NK!,,I!!!'!!K]2?B%_P A3PO_
M -?P_D*W:[L+BI863E%7N>=C<%'&Q49.UC\9O^%"_$S_ *)UXL_\$=U_\11_
MPH7XF?\ 1.O%G_@CNO\ XBOV9HKTO[8J?R(\C^P:?\[/QF_X4+\3/^B=>+/_
M  1W7_Q%'_"A?B9_T3KQ9_X([K_XBOV9HH_MBI_(@_L&G_.S\9O^%"_$S_HG
M7BS_ ,$=U_\ $4?\*%^)G_1.O%G_ (([K_XBOV9HH_MBI_(@_L&G_.S\9O\
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M_1./%O\ X([K_P"-T?\ "@_B=_T3CQ;_ .".Z_\ C=?M)11_;%3^1!_8-/\
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MO%G_ (([K_XBOV9HH_MBI_(@_L&G_.S\9O\ A0OQ,_Z)UXL_\$=U_P#$4?\
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M7BS_ ,$=U_\ $4?\*%^)G_1.O%G_ (([K_XBOV9HH_MBI_(@_L&G_.S\9O\
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M_P!6/K4M17'^K'UH KT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/Q,LEOI7QJMM3O+1G8E9)4NI74G/=6AE0#TD7UKT^+]I9[O_ () _:5F\SQ
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M,\UYUX%_8K^#^C_LZCPH?!>F:A'J>D>9?:KJ%K'/J%Q.\6XSM.R[A(&8LI!
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MK2D/!)&-H9E!P7!Y(Z5ZI^V9^U%X8_:*M?"L'AS3M6LAI3W#S-JD44>[S!&
M%"2/G[ASG':OF&BN>I0A5J0JRWCM^/\ F=E+%U:-*5&#TEN?<7[,_P"W1X(^
M#OP;T3PCKNC>(+C4-/:?=-IT$$D3J\SR @O,A!^?&,=NM>G2?\%-?AD$)C\/
M^+&?L&M;51^?V@U^9]%<U7+Z%:I*I.]V[LZZ6:8FC!4XM67D?6'Q[_X* ^)/
MBEHEWX>\,Z8/">BW2M%<SF?SKNXC/&W< !&I'4#)_P!K&<_/_P '_&UO\-_B
MCX7\3WEO+=6FE7\5U-# 1O9%;Y@N>,XSC)'U%<?1731P]/#JU-6.+$8FKBG>
MM*Y^F?\ P\T^%_\ T ?%W_@':_\ R345U_P4P^&$UK-&- \6,70J UG:X.1W
M_P!(Z5^:-%<#RK#-6L_O/36=8M.]U]Q]+_L<_M1:)\ =5\0VGB'2KFYT;7&B
M8W%B%=[9DWC!0D!E(?G!R-O .>/J_2OVHOV7]%U0Z[I\FC:=K3 L;NV\,31W
M63U!D6WSD_[U?ES16]?!4Z\^=MI[:/Y'/A\RK8>'(DFKWU6S>OD?8O[5G[=4
M?Q4\.W/@_P $6EWI^A71VWVI7F$FND!_U:("=J' )).2." ,YYG]B?\ :!\%
M?!JX\5:5XWMI#INNK;@72V@N(T\OS,K*G+%3O&,*><YKY@HJX8.E3HRHQ6DM
M^_\ 6AG4Q]>I7C7D]8[=C]0M/_:R_9G^'L5UJ/AA=.M;YT.^/0_#<EK//WV[
MC#&IY_O,!7QI^U-^U/J7[16MVL,-J^D>%M.=FLK!GW22.>/.EQQOQP .%!(R
M<DGPBBLJ6 I4IJI=MKN;5LSKUJ;I644][+<]*_9V\<>%OAK\6M&\3^+K"^U+
M3-,+3QV^GQQNYG Q&Q5V4$*3NZ@Y45[E^UU^VGH_QS\#V/A;PGI^K:=9/="Y
MU"34TBC,H0?NXU"2/D;CN.2.47K7R'1715P].M.-2>\=OS.2CBZM"G.E#:6_
M?L%%%%=1QA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7[%_LI_P#)&]&_ZXP?^D\5?CI7[!_L
MMZA:VGP?T9)[F&%C! 0LD@4X^SQ<\U\]G'P0^9]3D/QU/1'M%%4O[:T__G^M
MO^_R_P"-']M:?_S_ %M_W^7_ !KY@^R+M>+?M2?LH^$?VLO"&G:)XHN]3TR7
M2[DWEAJ&DSK'-!*5VGAE96!&,@C/'!%>N?VUI_\ S_6W_?Y?\:/[:T__ )_K
M;_O\O^-3**DK/^K%1DXNZ/@F7_@ESXWUR%M&\2?M3>/=<\%R#RY=!;SPKQ?W
M,O=O'^<1'M7V!\"?@+X-_9Q^']KX/\$Z:;'3(G,TTLS^9/=3$ --,^/F<@#L
M       .V_MK3_\ G^MO^_R_XT?VUI__ #_6W_?Y?\:T4FDTNI'*FT^Q\F_'
M7_@G'H'Q(^)EU\2/ 'CC7OA!X^O"6NM3\/L3%.Y^_(8U>-@[<;ML@#=2I)).
M'X)_X)CV-WXRTOQ-\9OBKXH^-MYI,GF6-EK;/'9)R#AXWEF9ER%)4.JMCY@P
MR*^SO[:T_P#Y_K;_ +_+_C1_;6G_ //];?\ ?Y?\:FG^[MR]-O+T[?(J?[R_
M-U_'U[G,?&3X<+\7/A+XN\#_ &_^R4U_2[C3/MJP^;]G\V,IOV;EW8SG&1G'
M45SW[+OP+7]FOX'>'/AVNM'Q$-'^T?\ $R-K]F\XRSR3?ZO>^W'F8^\>F:](
M_MK3_P#G^MO^_P O^-']M:?_ ,_UM_W^7_&FFU>W6U_E>WYL3U23Z;?,\'_9
M+_9)3]EN\^(<Z^*6\2_\)=JW]I[3I_V7[( 9"(_]:^__ %GWOEZ=*Y[]J/\
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MO!'BRU:[T358O+E\MMLD3 ADDC;!VNK ,#@C(Y!&173?VUI__/\ 6W_?Y?\
M&C^VM/\ ^?ZV_P"_R_XUI4_?-N>MR*:]BDH:6V/A'PU_P2NU32;1O"VH?M#>
M.;WX6%F'_"'6A>UC:(G/E,_G-&5)SD"$ DDX!YKV?]G#]B30?V9_C!X[\7^&
MM41-#\16MM9V?AV*Q,:Z='$!_P MC*QE+$9)*J<DDDDYKZ'_ +:T_P#Y_K;_
M +_+_C1_;6G_ //];?\ ?Y?\::DXOF6^J^_OW^>W04HJ2L]M']VIX+XZ_9%3
MQI^U]X(^.A\5-9GPUIQL/[!_L_?]IRMP _G^:-G_ !\=-C?=Z\\>J?&?X<CX
MO?"7Q?X(.H?V4/$&EW&F_;O)\[R/-0IOV;EW8SG&X9]173?VUI__ #_6W_?Y
M?\:/[:T__G^MO^_R_P"-9RBI4_9/X=?QW-.9\_M.NGX;'GW[-7P5'[._P2\,
M?#T:Q_;XT6*2/^T?LWV;SM\KR9\O>^W&_'WCTKB)_P!DE)OVS;?X^_\ "4L&
MATDZ9_PC_P#9_!/E-'YGVCS?1L[?+[=:]X_MK3_^?ZV_[_+_ (T?VUI__/\
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M_C6?*KM]R^9V2['GG[.O[.GA#]F'X<P^#O!T$XL_-:YNKR\D$EQ>3L &ED8
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MRFZA$36<8$AD&TG(XSFNM_MK3_\ G^MO^_R_XT 7:*I?VUI__/\ 6W_?Y?\
M&C^VM/\ ^?ZV_P"_R_XT 7:*I?VUI_\ S_6W_?Y?\:/[:T__ )_K;_O\O^-
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M +_+_C0!=HJE_;6G_P#/];?]_E_QH_MK3_\ G^MO^_R_XT 7:*I?VUI__/\
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MV_[^K_C0!<HJG_;%A_S_ %M_W]7_ !H_MBP_Y_K;_OZO^- %RBJ?]L6'_/\
M6W_?U?\ &C^V+#_G^MO^_J_XT 7**I_VQ8?\_P!;?]_5_P :/[8L/^?ZV_[^
MK_C0!<HJG_;%A_S_ %M_W]7_ !H_MBP_Y_K;_OZO^- %RBJ?]L6'_/\ 6W_?
MU?\ &C^V+#_G^MO^_J_XT 7**I_VQ8?\_P!;?]_5_P :/[8L/^?ZV_[^K_C0
M!<HJG_;%A_S_ %M_W]7_ !H_MBP_Y_K;_OZO^- %RBJ?]L6'_/\ 6W_?U?\
M&C^V+#_G^MO^_J_XT 7**I_VQ8?\_P!;?]_5_P :/[8L/^?ZV_[^K_C0!<HJ
MG_;%A_S_ %M_W]7_ !H_MBP_Y_K;_OZO^- %RBJ?]L6'_/\ 6W_?U?\ &C^V
M+#_G^MO^_J_XT 7**I_VQ8?\_P!;?]_5_P :/[8L/^?ZV_[^K_C0!<HJG_;%
MA_S_ %M_W]7_ !H_MBP_Y_K;_OZO^- %RBJ?]L6'_/\ 6W_?U?\ &C^V+#_G
M^MO^_J_XT 6I/]6WTJI0^L6&QO\ 3K;I_P ]5_QJI_:UC_S^6_\ W]7_ !H
MMT54_M:Q_P"?RW_[^K_C1_:UC_S^6_\ W]7_ !H MT54_M:Q_P"?RW_[^K_C
M1_:UC_S^6_\ W]7_ !H MT54_M:Q_P"?RW_[^K_C1_:UC_S^6_\ W]7_ !H
MMT54_M:Q_P"?RW_[^K_C1_:UC_S^6_\ W]7_ !H MT54_M:Q_P"?RW_[^K_C
M1_:UC_S^6_\ W]7_ !H MT54_M:Q_P"?RW_[^K_C1_:UC_S^6_\ W]7_ !H
MMT54_M:Q_P"?RW_[^K_C1_:UC_S^6_\ W]7_ !H MT54_M:Q_P"?RW_[^K_C
M1_:UC_S^6_\ W]7_ !H MT54_M:Q_P"?RW_[^K_C1_:UC_S^6_\ W]7_ !H
MMT54_M:Q_P"?RW_[^K_C1_:UC_S^6_\ W]7_ !H MT54_M:Q_P"?RW_[^K_C
M1_:UC_S^6_\ W]7_ !H MT54_M:Q_P"?RW_[^K_C1_:UC_S^6_\ W]7_ !H
MMT54_M:Q_P"?RW_[^K_C1_:UC_S^6_\ W]7_ !H MT54_M:Q_P"?RW_[^K_C
M1_:UC_S^6_\ W]7_ !H MT54_M:Q_P"?RW_[^K_C1_:UC_S^6_\ W]7_ !H
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M8?\ /];?]_5_QH N453_ +8L/^?ZV_[^K_C1_;%A_P _UM_W]7_&@"Y15/\
MMBP_Y_K;_OZO^-']L6'_ #_6W_?U?\: +E%4_P"V+#_G^MO^_J_XT?VQ8?\
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M_P"?ZV_[_+_C1_;6G_\ /];?]_E_QH NT52_MK3_ /G^MO\ O\O^-']M:?\
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MI+69HS'" X210=I*M@XP<&OLRBM^=^TJ5/YU;\;F2C:G"G_*[_@U^I\6Z?\
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MTQRJK>7^FS00L6Y4!W4#)[<\TW)1W8*,I;(YFBBN[B^ GQ-FC22/X=>+)(W
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 <U_P *X\-_] J+_OIO\:/^%<>&_P#H%1?]]-_C72T4 <U_PKCPW_T"HO\
MOIO\:/\ A7'AO_H%1?\ ?3?XU<TOQIX?US6M1T?3==TW4-7TT@7VGVMY'+<6
MI/02QJQ9,_[0%;-'F'D<U_PKCPW_ - J+_OIO\:/^%<>&_\ H%1?]]-_C72T
M4 <U_P *X\-_] J+_OIO\:/^%<>&_P#H%1?]]-_C72T4 <U_PKCPW_T"HO\
MOIO\:/\ A7'AO_H%1?\ ?3?XUTM% '-?\*X\-_\ 0*B_[Z;_ !H_X5QX;_Z!
M47_?3?XUTM% '-?\*X\-_P#0*B_[Z;_&C_A7'AO_ *!47_?3?XUTM% '-?\
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M;_&NEHH YK_A7'AO_H%1?]]-_C1_PKCPW_T"HO\ OIO\:Z6B@#FO^%<>&_\
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M] V/_OIO\:/^$"T#_H&Q_P#?3?XUT%% '/\ _"!:!_T#8_\ OIO\:/\ A M
M_P"@;'_WTW^-=!10!S__  @6@?\ 0-C_ .^F_P :/^$"T#_H&Q_]]-_C7044
M <__ ,(%H'_0-C_[Z;_&C_A M _Z!L?_ 'TW^-=!10!S_P#P@6@?] V/_OIO
M\:/^$"T#_H&Q_P#?3?XUT%% '/\ _"!:!_T#8_\ OIO\:/\ A M _P"@;'_W
MTW^-=!10!S__  @6@?\ 0-C_ .^F_P :/^$"T#_H&Q_]]-_C7044 <__ ,(%
MH'_0-C_[Z;_&C_A M _Z!L?_ 'TW^-=!10!DI\/?#Q53_9D?3^\W^-+_ ,*]
M\._] N/_ +Z;_&N@C_U:_2G4 <[_ ,*]\._] N/_ +Z;_&C_ (5[X=_Z!<?_
M 'TW^-=%10!SO_"O?#O_ $"X_P#OIO\ &C_A7OAW_H%Q_P#?3?XUT5% '._\
M*]\._P#0+C_[Z;_&C_A7OAW_ *!<?_?3?XUT5% '._\ "O?#O_0+C_[Z;_&C
M_A7OAW_H%Q_]]-_C7144 <[_ ,*]\._] N/_ +Z;_&C_ (5[X=_Z!<?_ 'TW
M^-=%10!SO_"O?#O_ $"X_P#OIO\ &C_A7OAW_H%Q_P#?3?XUT5% '._\*]\.
M_P#0+C_[Z;_&C_A7OAW_ *!<?_?3?XUT5% '._\ "O?#O_0+C_[Z;_&C_A7O
MAW_H%Q_]]-_C7144 <[_ ,*]\._] N/_ +Z;_&C_ (5[X=_Z!<?_ 'TW^-=%
M10!SO_"O?#O_ $"X_P#OIO\ &C_A7OAW_H%Q_P#?3?XUT5% '._\*]\._P#0
M+C_[Z;_&C_A7OAW_ *!<?_?3?XUT5% '._\ "O?#O_0+C_[Z;_&C_A7OAW_H
M%Q_]]-_C7144 <[_ ,*]\._] N/_ +Z;_&C_ (5[X=_Z!<?_ 'TW^-=%10!S
MO_"O?#O_ $"X_P#OIO\ &C_A7OAW_H%Q_P#?3?XUT5% '._\*]\._P#0+C_[
MZ;_&C_A7OAW_ *!<?_?3?XUT5% '._\ "O?#O_0+C_[Z;_&C_A7OAW_H%Q_]
M]-_C7144 <X_P]\/!6/]F1]/[S?XU5_X0+0/^@;'_P!]-_C75R?ZMOI52@#G
M_P#A M _Z!L?_?3?XT?\(%H'_0-C_P"^F_QKH** .?\ ^$"T#_H&Q_\ ?3?X
MT?\ "!:!_P! V/\ [Z;_ !KH** .?_X0+0/^@;'_ -]-_C1_P@6@?] V/_OI
MO\:Z"B@#G_\ A M _P"@;'_WTW^-'_"!:!_T#8_^^F_QKH** .?_ .$"T#_H
M&Q_]]-_C1_P@6@?] V/_ +Z;_&N@HH Y_P#X0+0/^@;'_P!]-_C1_P (%H'_
M $#8_P#OIO\ &N@HH Y__A M _Z!L?\ WTW^-'_"!:!_T#8_^^F_QKH** .?
M_P"$"T#_ *!L?_?3?XT?\(%H'_0-C_[Z;_&N@HH Y_\ X0+0/^@;'_WTW^-'
M_"!:!_T#8_\ OIO\:Z"B@#G_ /A M _Z!L?_ 'TW^-'_  @6@?\ 0-C_ .^F
M_P :Z"B@#G_^$"T#_H&Q_P#?3?XT?\(%H'_0-C_[Z;_&N@HH Y__ (0+0/\
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M?_?3?XT?\*]\._\ 0+C_ .^F_P :Z*B@#G?^%>^'?^@7'_WTW^-'_"O?#O\
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M10!S_P#P@6@?] V/_OIO\:/^$"T#_H&Q_P#?3?XUT%% '/\ _"!:!_T#8_\
MOIO\:/\ A M _P"@;'_WTW^-=!10!S__  @6@?\ 0-C_ .^F_P :/^$"T#_H
M&Q_]]-_C7044 <__ ,(%H'_0-C_[Z;_&C_A M _Z!L?_ 'TW^-=!10!S_P#P
M@6@?] V/_OIO\:/^$"T#_H&Q_P#?3?XUT%% '/\ _"!:!_T#8_\ OIO\:/\
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M - J+_OIO\:Z6B@#FO\ A7'AO_H%1?\ ?3?XT?\ "N/#?_0*B_[Z;_&NEHH
MYK_A7'AO_H%1?]]-_C1_PKCPW_T"HO\ OIO\:Z6B@#FO^%<>&_\ H%1?]]-_
MC1_PKCPW_P! J+_OIO\ &NEHH YK_A7'AO\ Z!47_?3?XT?\*X\-_P#0*B_[
MZ;_&NEHH YK_ (5QX;_Z!47_ 'TW^-'_  KCPW_T"HO^^F_QKI:* .:_X5QX
M;_Z!47_?3?XT?\*X\-_] J+_ +Z;_&NEHH YK_A7'AO_ *!47_?3?XT?\*X\
M-_\ 0*B_[Z;_ !KI:* .:_X5QX;_ .@5%_WTW^-'_"N/#?\ T"HO^^F_QKI:
M* .:_P"%<>&_^@5%_P!]-_C1_P *X\-_] J+_OIO\:Z6B@#FO^%<>&_^@5%_
MWTW^-'_"N/#?_0*B_P"^F_QKI:* .:_X5QX;_P"@5%_WTW^-'_"N/#?_ $"H
MO^^F_P :Z6B@#FO^%<>&_P#H%1?]]-_C5'X3(J>$5VC'^D2?SQ79UQWPH_Y%
M%/\ KO+_ .A4 =C1110 445XY^UE^T0G[+?P5U/X@/H+>)39W%O;KIRW?V7S
M#+($R9-CXQG/W3G&/>IE)05Y?U?0J,7)V1['17PI-_P4)^,.DZ'%XAUG]DOQ
M5:^&3$MS+J-CK!NS' 5W>;L%H/EV\Y)  ZD5]._L\?M$>#_VG/AS;^,?!MS,
M]DTC6]S:7:!+BSG4 M%*H) ;#*<@D$$$&M.5Z^6_D9\RT\]O,].HKQ#X(_&_
MQW\2OBA\1O#?B?X5ZIX(T3PY=^1I6NWID\K5T\QT#Q[HU5@517RC, ' )Z9]
MOJ5K%2Z-7*>DG'JM HHKY'^)_P >O''AO_@HM\*/A=I^LK#X&U[P_/>ZAI9M
M(6,LRI>E7$I3S%P8(^%8#CIR:<5S34%N[_@F_P D.WN2GTBK_BE^I]<4450U
M[7++PSH>H:QJ<_V;3M/MY+NYFVLWEQ(I9VPH). "< $U,I**;;LD"3D[+<OT
M5R7PK^*_A7XV>"+'Q?X+U4:UX=OFD6WO!;RP;RCE'&R55<892.0.E=;5-.+L
MT2FGJ@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** (+[_CQN/^N;?R-<Y\+O\ D1=,_P"VG_HUZZ.^_P"/&X_Z
MYM_(USGPN_Y$73/^VG_HUZ /S$_;F_Y+8/\ KP'_ *4SU\\U]#?MS?\ );!_
MUX#_ -*9Z^>:^[P7^[P]#\US'_>ZGJ%%%%=IYP5^M?P1U2V^#GP6^"GA^=%C
ME\0/';L&X*R36\UT?QW[5_X%7Y4^$]!E\4^*=&T6'B;4;R&T3ZR.$'\Z^[_V
MZ/B)'X#^*OP9T^VE,4'A^9-5EC0X&P2QHG3_ &8I!^->;C8^V=+#?SR_)/\
MST/9RZ7L%6Q7\D?_ $IJWY'S1^V=X3_X1']I+QE D7E07EPFH1<8#"9%=B/^
M!E_RKR?PKX7U+QIXDTW0M'MFN]3U"=;>WA7^)F..?0#J3V )KZY_X*;>&5M?
MB%X0\21<QZGICVI8="89-P/XB8?E5_\ 9 \"Z5\#_A;KGQX\90[2EN\6B6T@
MP[*?EW+G^*5OD4]EW'HU987$QIX&-66MM+=VG9+U=C3&85ULQE2A]IWOV35V
M_E?]#ZD^">AZ'\&9]$^$6A[;F_L=+;5]9O%7[TCNJ*6_VI&+$#LD0'I7YD?M
M*>*3XS^/7CK5=VY'U6:"-AWCB/E(?^^4%?8W[&WC"_U#PC\:OC+XBF\R]O)7
MDD?G"+;P-+L7/10)$4#T45^?=K;7OB+6(K>".2]U&^G")&HR\LKM@ >I)/ZU
MC@Z,UBYN>LE%7]9:Z>EK&^.K0>"A&FK0<GR^D=+OU;N>_P#[$/P-3XL_%)=6
MU:$-X7\-[;V\:3_5RR@YBB/ME2Q[80@]:^L_CEXXTS]HW]D/X@ZQHB[K33;R
M00/W=;6=&\SV#1Y8>S5YC\;KZV_9%_9>TGX8:5/&/&/B>-I=5N(3\P1@!.V<
M=#Q"OJJL>HI_[ ?E^-O@+\5_!$G/G;SM]KBV:/\ G%6.+;KPJ8I?#3MR^;4E
M=_?HO0Z,#%8:I3P<OBJWYO).+M']7Z^9\'PRM#*DB8#HP89 /(]C7T;I/[='
MQPU;4;/3[7Q';/<7,J01(-+MN68A5'^K]2*^<&4HQ5@58'!![5ZU^R;X5'C#
M]HKP+8,NZ./4%O7XXVP*9N?KY8'XU[\X4YV=6*:6NOX_D?,TZE:FVJ,G%O33
M\#[;_;A_:*\7? NR\&:?X6U..UU;4%FEO)Y+:*7<B!%'RLI RS,>/[M?%/Q'
M_:S^)WQ7\*W'ASQ)KT5WI%PZ22P164$1<HP9<LJ X# 'KV%>A?\ !1;Q4->_
M:#;34?='HVFV]J5[!WW3-^DB_E7R[7DY?AZ;H1J3BG)Z[>>GZ'M9IBJL<1*E
M";44DM_+6_XGU'_PWQXE\*^#])\,?#_PUI'A#3+"TC@\UD^U3O(% :3)"H"Q
MR3E&))SFOJ/]D[XO7_[5GPK\5Z/\0=.L]1%JZV<\R0!([F*1"067H'4J3E<=
M5( (K\S?#'AG5?&>OV.B:)8S:CJM]*(K>V@7+.Q_D ,DD\  D\"OOSQAKVE_
ML*_LVQ>#;&\CN_B+K\<DLCP'/ERN KSG/1(U 1,CYF4''WL+'T:2I.,8WJ3>
MG>][M^A66XC$2JQG.=J4%KVM:R7K>WF['Y]ZU9QZ;K%_:0R^?#;SR1)+_?56
M(#?B!7NW[%?P-7XQ_%>*ZU. /X8\/A;[4#(/DE8']U"?9F!)_P!E&]:\#L[.
M?4KR"TM87N+JXD6**&-2S.['"J!W)) K[N^+5U#^QW^RKIOP^TZ9$\<>*T=]
M1GA/S(K "=@?0+MA4\=V'(-=V(JSHTE&#O.6B]>K^6YY^&HPQ%:4YJU./O/T
MZ+Y['J7QD\=:1^T9^RC\4;S1 &LM(N9HH9 <^8+1XY?,&.S*"1[$5^7-?>7_
M  3OFC\7?"?XJ>"9QNCG ?;ZBX@>)O\ T6/SKX0FA>WF>*1=LB,593V(."*Y
M<'36&KU<.MDHO[UJ_P #LQ]5XK#T<3):MR7I9Z+_ "&4445ZYX(4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&=6\-V/]HV&H:3IT5M,OE,"R,Z*&=73<"&)Y(/4 U[!^PYXBO?'G['OPQO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% '%?$+_ )"GA?\ Z_A_(5NUA?$+_D*>%_\
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M_%T?\+Z^)G_11?%G_@[NO_BZ/['J?SH/[>I_R,_9FBOQF_X7U\3/^BB^+/\
MP=W7_P 71_POKXF?]%%\6?\ @[NO_BZ/['J?SH/[>I_R,_9FBOQF_P"%]?$S
M_HHOBS_P=W7_ ,71_P +Z^)G_11?%G_@[NO_ (NC^QZG\Z#^WJ?\C/V9HK\9
MO^%]?$S_ **+XL_\'=U_\71_POKXF?\ 11?%G_@[NO\ XNC^QZG\Z#^WJ?\
M(S]F:*_&;_A?7Q,_Z*+XL_\ !W=?_%T?\+Z^)G_11?%G_@[NO_BZ/['J?SH/
M[>I_R,_9FBOQF_X7U\3/^BB^+/\ P=W7_P 71_POKXF?]%%\6?\ @[NO_BZ/
M['J?SH/[>I_R,_9FBOQF_P"%]?$S_HHOBS_P=W7_ ,71_P +Z^)G_11?%G_@
M[NO_ (NC^QZG\Z#^WJ?\C/V9HK\9O^%]?$S_ **+XL_\'=U_\71_POKXF?\
M11?%G_@[NO\ XNC^QZG\Z#^WJ?\ (S]F:*_&;_A?7Q,_Z*+XL_\ !W=?_%T?
M\+Z^)G_11?%G_@[NO_BZ/['J?SH/[>I_R,_9FBOQF_X7U\3/^BB^+/\ P=W7
M_P 71_POKXF?]%%\6?\ @[NO_BZ/['J?SH/[>I_R,_9FBOQF_P"%]?$S_HHO
MBS_P=W7_ ,71_P +Z^)G_11?%G_@[NO_ (NC^QZG\Z#^WJ?\C/V9HK\9O^%]
M?$S_ **+XL_\'=U_\71_POKXF?\ 11?%G_@[NO\ XNC^QZG\Z#^WJ?\ (S]I
M(_\ 5K]*=7XM_P#"_/B=_P!%&\6_^#RZ_P#CE'_"_?B=_P!%'\6_^#RZ_P#C
ME']CU/YT']O4_P"1G[245^+?_"_?B=_T4?Q;_P"#RZ_^.4?\+]^)W_11_%O_
M (/+K_XY1_8]3^=!_;U/^1G[245^+?\ POWXG?\ 11_%O_@\NO\ XY1_POWX
MG?\ 11_%O_@\NO\ XY1_8]3^=!_;U/\ D9^TE%?BW_POWXG?]%'\6_\ @\NO
M_CE'_"_?B=_T4?Q;_P"#RZ_^.4?V/4_G0?V]3_D9^TE%?BW_ ,+]^)W_ $4?
MQ;_X/+K_ ..4?\+]^)W_ $4?Q;_X/+K_ ..4?V/4_G0?V]3_ )&?M)17XM_\
M+]^)W_11_%O_ (/+K_XY1_POWXG?]%'\6_\ @\NO_CE']CU/YT']O4_Y&?M)
M17XM_P#"_?B=_P!%'\6_^#RZ_P#CE'_"_?B=_P!%'\6_^#RZ_P#CE']CU/YT
M']O4_P"1G[245^+?_"_?B=_T4?Q;_P"#RZ_^.4?\+]^)W_11_%O_ (/+K_XY
M1_8]3^=!_;U/^1G[245^+?\ POWXG?\ 11_%O_@\NO\ XY1_POWXG?\ 11_%
MO_@\NO\ XY1_8]3^=!_;U/\ D9^TE%?BW_POWXG?]%'\6_\ @\NO_CE'_"_?
MB=_T4?Q;_P"#RZ_^.4?V/4_G0?V]3_D9^TE%?BW_ ,+]^)W_ $4?Q;_X/+K_
M ..4?\+]^)W_ $4?Q;_X/+K_ ..4?V/4_G0?V]3_ )&?M)17XM_\+]^)W_11
M_%O_ (/+K_XY1_POWXG?]%'\6_\ @\NO_CE']CU/YT']O4_Y&?M)17XM_P#"
M_?B=_P!%'\6_^#RZ_P#CE'_"_?B=_P!%'\6_^#RZ_P#CE']CU/YT']O4_P"1
MG[245^+?_"_?B=_T4?Q;_P"#RZ_^.4?\+]^)W_11_%O_ (/+K_XY1_8]3^=!
M_;U/^1G[245^+?\ POWXG?\ 11_%O_@\NO\ XY1_POWXG?\ 11_%O_@\NO\
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M* "BBB@"6W_UA^E6*KV_^L/TJQ0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %17'^K'
MUJ6HKC_5CZT 5Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KGM#_P"2FZC_ -@]
M?_0EKH:Y[0_^2FZC_P!@]?\ T): .YHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOB6XTO\ L;1_"^CS"=-.MMP),D@)5FX/W6;)D<\<*.'^-G_*7;X$?]BK=?\
MHO4JWII\]&,GK[U[?X9]>_+;;1.]B+_N\3);<JM]\;Z>M_D8'QL^)'[8W[*.
MBVGQ4\8^*O!_C?P?'=Q1ZQX7TO3UBCL4D8*!'+Y2RE<D*'+L0S+E6&:^@OVJ
M(?&_Q<_9K;Q'\,_'<7@S2KC0;C5M02XTJ&\;4K&2S+B &0'RB5)^9>1FJ?\
MP4W /[#_ ,3,C.(K(_\ D];UH^!$:7_@G;HB(K.[?#&,!5&23_9@KDK>]@Z[
M?V&K?.+=GWU77IHS>C&U>C)/XFT_DXZ^7Q=/4^:/^"9_PW^-FH_!3X?>(=&^
M,%KI'PVCU&XDF\'MX=MII)(DNI!-']J9?,'F$,<@_+NXZ5Z5XZ^-GQJ^.W[4
MWC/X._"+Q/HGPTTWP7;0S:GKVHV"7U[=22*K8BAD#)L!<#H.F=WS*M=#_P $
MH[J&?]B7P>D<JNT-WJ$<BJ<E&^UR-@^APRGZ$5M?'#]C+P%^T3XUF\?^%/&.
MI>!?B9IK-82>*/"%^/,6:-=GEW**W+(,*0&1\84G  '=B-*Z3UBKOSU2L[]4
MNU[:G#1UIR:=FW;RT;NO)M7UM?\ 3O\ ]G.U^-FC6^O:-\9+S0?$$EG+$=)\
M2:&GD'4(F#;Q-!@".1"%^ZH4[\#=@FO9*^-?V*?CI\2M5^,?Q2^"GQ,UFQ\9
MZIX'\I[?Q58VXA-S&YQLF"@+O 9.V05<$L1NK[*K.7O*,UJI)-/NOZW*CHY0
M>Z=GY!1114%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 07W_'C<?\ 7-OY&N<^%W_(BZ9_VT_]&O71WW_'C<?]<V_D:YSX
M7?\ (BZ9_P!M/_1KT ?F)^W-_P EL'_7@/\ TIGKYYKZ&_;F_P"2V#_KP'_I
M3/7SS7W>"_W>'H?FN8_[W4]0HHHKM/./</V*_"O_  EG[2G@^)H_,@L9I-0D
MSV\J-F4_]]A*U/V\O%1\3?M*>((@P>'2H;?3HR/]F,.P_P"^Y'KEOV:?CS%^
MSQXXO/$C^'?^$BEFL7LHX3>_9O*W.C%MWEOG[F,8[]:X#QUXKG\=>--=\1W,
M?E3ZK?37KQ!MP0R.6V@XY SC/M7%*G.6*C4M[L8O[V_\CT8580P<Z:?ORDO_
M  %+_,_2CQ)\)5_:V^!_P8NY[A(XX7M;G4YP?G\CR"MPB'^\TB*OL>>U?,7[
M=7QNM?%GBJS^'?ADQV_A'PGBW\JW $4ERJ[" !_#&OR#WW^U4OAS^W%K?PS^
M _\ PKW3-"4ZC%%/%:Z\U\0;<2NS9$/E\LN]L'?CIQQ@_,S.TC,S$LS')8G)
M)]:Y*6%FL1*4_@3;BO-]?DOQ.ZOC:;PL(T_XCBHR?DNGS?;IN?>L._X6_P#!
M-5VPL%]XB!^KBXN,?^B%_2N+_8!^#]G<:KJOQ8\3;+;P_P"&4<VDL_"&<)ND
ME.>T:'_OIAW6O-?C)^U(?BI\'O"'P^M/#/\ 8-CX?\C_ $C[>;@W'E0&)?E\
MM=OWB>IJ[XN_:W?5/V>]-^%/AWPJOABPACBBO+Z._P#.:[5?FD^7REVF23YF
M^8]QT-#I5U&LX+WIRT?:.U]^FNF^I,:V&<J"F_=IQNU;>6]OF_EIYGIWC']O
M?P)XNUR6\U;X#Z)XDE3,,-]JUS!+.T(8[ =]HQ7J3MW$ D\GK7KO['_[27A#
MXG>/-4\.>'OA7H_P]G;3S>27.ER1?Z2(W50C!((\X\PD$DXYXYK\SZ]*_9[^
M-,_P#^)5MXKBTP:PD=O+;2V)N/(\Q77'W]K8P0I^Z>E:SR^C[*48+6SMJ][:
M=;;_ ",Z>:5_;1G-JUU?1;7UZ7V^9D?&CP[_ ,(E\7/&>C^7Y26>KW44:XQA
M/-;9_P".XKZ*_P"":/A4ZI\8M<UQT#0Z3I3(&(^[),ZA<?\  4DKYX^-'Q(7
MXN_$[7O%Z:6-&&J2I+]A$_G>65C5#\^U<Y*YZ#K7HG[-G[4W_#.FA^*+2V\+
M+K5_K7E[;UK[R/(V*X4%/+;< 7)ZBK<:JP7(E[_+:WG:SU^\R52B\P]HW[G.
MW?R3NO/MT.%_: \5'QK\;?&^L;Q)'<:K.L3#H8T<I'_XZJUC_#?X:^(?BSXL
MM?#OAG3WO]1N.3CB.%!]Z21NBH,\D^P&20#S#NTCL['<S'))[FOHC]E_]K6U
M_9MT/6;-?!,?B"]U.Y69[[^T?LKB-5PL9'DOD ECU'WCQ6RC*A04*:NXI)+;
MR,)2AB<2YU9<L9-MOUU/<;G4_ /_  3^\)2V6GFV\7_&#4(-LLS#Y+4,,C=W
MCB'!V\/(0"<#!7XA\:>-=;^(?B:]U_Q#J$NIZK>/OEGE/Y* .%4#@*. *^K[
M[]O;P1J=Y-=WGP \/W=U,YDEGGO('>1B<EF8V>23ZFO//C9^U)X6^*7@2?P_
MHWPAT+P==S31R'5+5XI)556R57;;QD9X!.>F1CFN"A&O&?M*M.\GN[K1>2[+
M\3T\3+#SI^RHU4H+96EJ_-VW?X'9?L _!JUUKQ)J/Q.\1A(/#OA<,]O)<8$;
M7(3<TA)[1)\W^\RGL:W?&W[?'@/Q=KT]UJGP+T7Q082T%OJ&KW$$D[PAB4R'
MM'* Y)V[B 6/)ZUY;KW[6[S?LZV7PH\.^%5\.6JPQPWNI)?F5[L9W2G9Y:[3
M(_)^8\$KT-?/5;O#O$5I3K+1:1U^]Z=SG6*6%P\:>'?O/63MUZ+5=/\ ANI^
ME7[(G[2WA#XE_$6^\.>'OA1HWP^GET][I[S2Y(<W'EN@$;*EO'GAV.23C!XY
MKX2^/GAUO"?QL\<:44V+!K%R8U_Z9M(73_QUEJ?X _&&?X$_$W3_ !=#IPU=
M;:.6&2Q,_D>:KH5QOVMC!(/W3T_&JOQP^)R?&3XH:WXP321HG]IM&QLA<>?L
M*1)'G?M7.=F?NCK2AA?8XI3IKW7'77K?S?8*F,^L8-TZK]]2NM+:6\E;<X6B
MBBO3/'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\:_&NFRZ-J_Q'U(WMI83J5=+8R22F3!&0KO+\N>2L8;HPKG/V8?^4K7[0_\
MV"__ &:SK]$*Y_3?A[X6T7Q5J/B?3_#6CV'B34D$=]K%M811WETHQA99E4.X
M&U>&)^Z/2M8M0K1G%6C&,HI>J27^;[F4HN=.2D[RE)2;]'?_ ("/DG_@KU_R
M9O?_ /8:L/\ T)J^K?A7_P DP\(?]@>S_P#1"5?\7>"?#OQ T5](\4:!I?B3
M27=9&L-7LX[J LIRK&.12N1V..*U;6UALK:*WMXD@MX4$<<42A410,!0!P !
MQ@5E27LU47\TD_NC8NI[\H2_E37WNY^>7_!/O_D^#]K7_L-O_P"EUU7"?MD>
M/-;^%G_!3[P3XST+PQ=>,)M!\*I>76E6()F>TQ>)<.@'5DC=G'^[SQFOTMT'
MX>^%?"NMZOK.B^&M'T?6-8?S=2U"PL(H+B]?).Z:1%#2'+,<L3U/K3Y? OAJ
M?Q=#XKD\/:5)XHAMS:1:VUE$;U(3G,2S[=X3D_*#CDTX7A&BD]8*WKI)?=KK
MY%5&JDZTNE1_A=7^=EIYGQK\6O\ @J]\%+?X-ZO?^#M>NM:\87EB\5AH;:;<
M0RQ7#KM4RNR",!"<G:[9Q\NZNJ_X)=_ C6?@?^S+ ?$EG-I^O>);^36I[.X7
M;+!&R(D*..H8I&'(/(WX.",5]#V_P1^'-IXK/BB#P!X7A\2F0RG68]&MEO"Y
MZMYP3?GWS7;5<6H\\DM967DDG>R^?4B5Y<L;Z1N_5M6U^1^=_P#P2K_Y*?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y[0_^2FZC_P!@]?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7F0[LQ-QC&,<U^BW[)_QH'Q[_9$\/>*I9A-JATB2QU(Y&?M<"&.0D=MQ4/\
M1Q7@'_!%?_DV'Q1_V-MQ_P"DEI6L*<J=;$13VC'YKG_X9F?.IT:4FMY/Y/E_
MI' M9>./^"E'[3WP^\7_ /"#ZMX)^"_@B9;V"_UV'RIM1/F)*0@^ZQD,4:X0
MLJ*K$ODA3^G]%%1I&"IQ6BN_F]W_ %H5JYN<M]%\EL%%%%2,**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#BOB%_R%/"_P#U_#^0K\2:_;;XA?\
M(4\+_P#7\/Y"OQ)KZ3)_^7GR_4^2S_\ Y=?/] HHHKZ0^1"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M10 5%<?ZL?6I:BN/]6/K0!7HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N>T/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
M=/\ P3"_YJ5_W#/_ &[K[JKX5_X)A?\ -2O^X9_[=U]U5\3F/^]3^7Y(_1,I
M_P!RA\_S84445YIZX4444 %%%% !1110 4444 %%%% !1110 4444 2V_P#K
M#]*L57M_]8?I5B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BN/]6/K4M17'^K'UH
MKT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7/:'_P E-U'_ +!Z_P#H2UT-<]H?
M_)3=1_[!Z_\ H2T =S1110 4444 %>;_  %81^";_3)<?:M-UO4[6XCZ[6-Y
M+(OYI(C?\"KTBO*O&$=[\*_&%UXWL+6:^\-ZDL:>([&V0O+ R#;'?QH.6VH
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MO_H5 '8T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $%]_P >
M-Q_US;^1KG/A=_R(NF?]M/\ T:]='??\>-Q_US;^1KG/A=_R(NF?]M/_ $:]
M 'YB?MS?\EL'_7@/_2F>OGFOH;]N;_DM@_Z\!_Z4SU\\U]W@O]WAZ'YKF/\
MO=3U"BBBNT\X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *_8O]E/_ )(WHW_7&#_TGBK\=*_8O]E/_DC>C?\
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M0FHWEW?0_C%/,Z'\5KZ*TO2[+0]-MM/TVSM]/L+6-8H+6UB6**) ,!410 H
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M ,$=K_\ $4?\*%^&?_1.O"?_ (([7_XBN[HH]K4_F8>QI_RK[CA/^%"_#/\
MZ)UX3_\ !':__$4?\*%^&?\ T3KPG_X([7_XBN[HH]K4_F8>QI_RK[CA/^%"
M_#/_ *)UX3_\$=K_ /$4?\*%^&?_ $3KPG_X([7_ .(KNZ*/:U/YF'L:?\J^
MXX]/@'\,=B_\6Y\)=/\ H!VO_P ;I?\ A0?PQ_Z)QX2_\$=K_P#&Z[J/_5K]
M*=1[6I_,P]C3_E7W'!_\*#^&/_1./"7_ (([7_XW1_PH/X8_]$X\)?\ @CM?
M_C==Y11[6I_,P]C3_E7W'!_\*#^&/_1./"7_ (([7_XW1_PH/X8_]$X\)?\
M@CM?_C==Y11[6I_,P]C3_E7W'!_\*#^&/_1./"7_ (([7_XW1_PH/X8_]$X\
M)?\ @CM?_C==Y11[6I_,P]C3_E7W'!_\*#^&/_1./"7_ (([7_XW1_PH/X8_
M]$X\)?\ @CM?_C==Y11[6I_,P]C3_E7W'!_\*#^&/_1./"7_ (([7_XW1_PH
M/X8_]$X\)?\ @CM?_C==Y11[6I_,P]C3_E7W'!_\*#^&/_1./"7_ (([7_XW
M1_PH/X8_]$X\)?\ @CM?_C==Y11[6I_,P]C3_E7W'!_\*#^&/_1./"7_ (([
M7_XW1_PH/X8_]$X\)?\ @CM?_C==Y11[6I_,P]C3_E7W'!_\*#^&/_1./"7_
M (([7_XW1_PH/X8_]$X\)?\ @CM?_C==Y11[6I_,P]C3_E7W'!_\*#^&/_1.
M/"7_ (([7_XW1_PH/X8_]$X\)?\ @CM?_C==Y11[6I_,P]C3_E7W'!_\*#^&
M/_1./"7_ (([7_XW1_PH/X8_]$X\)?\ @CM?_C==Y11[6I_,P]C3_E7W'!_\
M*#^&/_1./"7_ (([7_XW1_PH/X8_]$X\)?\ @CM?_C==Y11[6I_,P]C3_E7W
M'!_\*#^&/_1./"7_ (([7_XW1_PH/X8_]$X\)?\ @CM?_C==Y11[6I_,P]C3
M_E7W'!_\*#^&/_1./"7_ (([7_XW1_PH/X8_]$X\)?\ @CM?_C==Y11[6I_,
MP]C3_E7W'!_\*#^&/_1./"7_ (([7_XW1_PH/X8_]$X\)?\ @CM?_C==Y11[
M6I_,P]C3_E7W'!_\*#^&/_1./"7_ (([7_XW1_PH/X8_]$X\)?\ @CM?_C==
MY11[6I_,P]C3_E7W'!_\*#^&/_1./"7_ (([7_XW1_PH/X8_]$X\)?\ @CM?
M_C==Y11[6I_,P]C3_E7W'!/\ _ACL;_BW/A+I_T [7_XW53_ (4+\,_^B=>$
M_P#P1VO_ ,17HTG^K;Z54H]K4_F8>QI_RK[CA/\ A0OPS_Z)UX3_ /!':_\
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MNQBMO-VYV[]BC=C<V,]-Q]:W:**S;<G=FJBHJR04444AA1110 4444 %%%%
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M "BBB@ HHHH **** (+[_CQN/^N;?R-<Y\+O^1%TS_MI_P"C7KH[[_CQN/\
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M$/\ \71_PSG\1O\ H69O_ B'_P"+KP?_ (3+7_\ H.:E_P"!<G^-'_"9:_\
M]!S4O_ N3_&CZ]7\ON?^8?ZK4/\ GX_P_P CWC_AG/XC?]"S-_X$0_\ Q='_
M  SG\1O^A9F_\"(?_BZ\'_X3+7_^@YJ7_@7)_C1_PF6O_P#0<U+_ ,"Y/\:/
MKU?R^Y_YA_JM0_Y^/\/\CWC_ (9S^(W_ $+,W_@1#_\ %T?\,Y_$;_H69O\
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M6O\ _0<U+_P+D_QH^O5_+[G_ )A_JM0_Y^/\/\CWC_AG/XC?]"S-_P"!$/\
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M_P"8?ZK4/^?C_#_(]X_X9S^(W_0LS?\ @1#_ /%T?\,Y_$;_ *%F;_P(A_\
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MX4?V39?\^=O_ -^E_P * ,/_ (67X:_Z"B?]^W_^)H_X67X:_P"@HG_?M_\
MXFMS^R;+_GSM_P#OTO\ A1_9-E_SYV__ 'Z7_"@##_X67X:_Z"B?]^W_ /B:
M/^%E^&O^@HG_ '[?_P")K<_LFR_Y\[?_ +]+_A1_9-E_SYV__?I?\* ,/_A9
M?AK_ *"B?]^W_P#B:/\ A9?AK_H*)_W[?_XFMS^R;+_GSM_^_2_X4?V39?\
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M)_W[?_XFMS^R;+_GSM_^_2_X4?V39?\ /G;_ /?I?\* ,/\ X67X:_Z"B?\
M?M__ (FC_A9?AK_H*)_W[?\ ^)K<_LFR_P"?.W_[]+_A1_9-E_SYV_\ WZ7_
M  H P_\ A9?AK_H*)_W[?_XFC_A9?AK_ *"B?]^W_P#B:W/[)LO^?.W_ ._2
M_P"%']DV7_/G;_\ ?I?\* ,/_A9?AK_H*)_W[?\ ^)H_X67X:_Z"B?\ ?M__
M (FMS^R;+_GSM_\ OTO^%']DV7_/G;_]^E_PH P_^%E^&O\ H*)_W[?_ .)H
M_P"%E^&O^@HG_?M__B:W/[)LO^?.W_[]+_A1_9-E_P ^=O\ ]^E_PH P_P#A
M9?AK_H*)_P!^W_\ B:/^%E^&O^@HG_?M_P#XFMS^R;+_ )\[?_OTO^%']DV7
M_/G;_P#?I?\ "@##_P"%E^&O^@HG_?M__B:/^%E^&O\ H*)_W[?_ .)K<_LF
MR_Y\[?\ []+_ (4?V39?\^=O_P!^E_PH \]L?&VB0^/M3U![Y19RVL<:2[&P
M6&,C&,UTW_"R_#7_ $%$_P"_;_\ Q-9VFZ?:M\3-7C-M"8ULXR$\L8!R.<5U
MO]DV7_/G;_\ ?I?\* ,/_A9?AK_H*)_W[?\ ^)H_X67X:_Z"B?\ ?M__ (FM
MS^R;+_GSM_\ OTO^%']DV7_/G;_]^E_PH P_^%E^&O\ H*)_W[?_ .)H_P"%
ME^&O^@HG_?M__B:W/[)LO^?.W_[]+_A1_9-E_P ^=O\ ]^E_PH P_P#A9?AK
M_H*)_P!^W_\ B:/^%E^&O^@HG_?M_P#XFMS^R;+_ )\[?_OTO^%']DV7_/G;
M_P#?I?\ "@##_P"%E^&O^@HG_?M__B:/^%E^&O\ H*)_W[?_ .)K<_LFR_Y\
M[?\ []+_ (4?V39?\^=O_P!^E_PH P_^%E^&O^@HG_?M_P#XFC_A9?AK_H*)
M_P!^W_\ B:W/[)LO^?.W_P"_2_X4?V39?\^=O_WZ7_"@##_X67X:_P"@HG_?
MM_\ XFC_ (67X:_Z"B?]^W_^)K<_LFR_Y\[?_OTO^%']DV7_ #YV_P#WZ7_"
M@##_ .%E^&O^@HG_ '[?_P")H_X67X:_Z"B?]^W_ /B:W/[)LO\ GSM_^_2_
MX4?V39?\^=O_ -^E_P * ,/_ (67X:_Z"B?]^W_^)H_X67X:_P"@HG_?M_\
MXFMS^R;+_GSM_P#OTO\ A1_9-E_SYV__ 'Z7_"@##_X67X:_Z"B?]^W_ /B:
M/^%E^&O^@HG_ '[?_P")K<_LFR_Y\[?_ +]+_A1_9-E_SYV__?I?\* ,/_A9
M?AK_ *"B?]^W_P#B:/\ A9?AK_H*)_W[?_XFMS^R;+_GSM_^_2_X4?V39?\
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M?V39?\^=O_WZ7_"@#SOQEXTT74]0T"2UOEE2VN_,E(1AM7CGD5J_\+ \/_\
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MAS_H)I_W[?\ ^)K:_LNR_P"?2#_OTO\ A1_9=E_SZ0?]^E_PH Q?^%C>'/\
MH)I_W[?_ .)H_P"%C>'/^@FG_?M__B:VO[+LO^?2#_OTO^%']EV7_/I!_P!^
ME_PH Q?^%C>'/^@FG_?M_P#XFC_A8WAS_H)I_P!^W_\ B:VO[+LO^?2#_OTO
M^%']EV7_ #Z0?]^E_P * ,7_ (6-X<_Z":?]^W_^)H_X6-X<_P"@FG_?M_\
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M_P!!%?\ OV_^%;/]FV?_ #Z0?]^U_P */[-L_P#GT@_[]K_A0!C?\+ \/_\
M017_ +]O_A1_PL#P_P#]!%?^_;_X5L_V;9_\^D'_ '[7_"C^S;/_ )](/^_:
M_P"% &-_PL#P_P#]!%?^_;_X4?\ "P/#_P#T$5_[]O\ X5L_V;9_\^D'_?M?
M\*/[-L_^?2#_ +]K_A0!C?\ "P/#_P#T$5_[]O\ X4?\+ \/_P#017_OV_\
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MV_\ A6S_ &;9_P#/I!_W[7_"C^S;/_GT@_[]K_A0!C?\+ \/_P#017_OV_\
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MAS_H)I_W[?\ ^)K:_LNR_P"?2#_OTO\ A1_9=E_SZ0?]^E_PH Q?^%C>'/\
MH)I_W[?_ .)H_P"%C>'/^@FG_?M__B:VO[+LO^?2#_OTO^%']EV7_/I!_P!^
ME_PH Q?^%C>'/^@FG_?M_P#XFHYOB)X=90!J2'G_ )YO_P#$UO?V79?\^D'_
M 'Z7_"H[C2[/8/\ 1(.O_/-?\* .>_X6!X?_ .@BO_?M_P#"C_A8'A__ *"*
M_P#?M_\ "MG^S;/_ )](/^_:_P"%']FV?_/I!_W[7_"@#&_X6!X?_P"@BO\
MW[?_  H_X6!X?_Z"*_\ ?M_\*V?[-L_^?2#_ +]K_A1_9MG_ ,^D'_?M?\*
M,;_A8'A__H(K_P!^W_PH_P"%@>'_ /H(K_W[?_"MG^S;/_GT@_[]K_A1_9MG
M_P ^D'_?M?\ "@#&_P"%@>'_ /H(K_W[?_"C_A8'A_\ Z"*_]^W_ ,*V?[-L
M_P#GT@_[]K_A1_9MG_SZ0?\ ?M?\* ,;_A8'A_\ Z"*_]^W_ ,*/^%@>'_\
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M_P"@BO\ W[?_  K9_LVS_P"?2#_OVO\ A1_9MG_SZ0?]^U_PH QO^%@>'_\
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M_P#OTO\ A0!A_P#"R_#7_043_OV__P 31_PLOPU_T%$_[]O_ /$UN?V39?\
M/G;_ /?I?\*/[)LO^?.W_P"_2_X4 8?_  LOPU_T%$_[]O\ _$T?\++\-?\
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M_"R_#7_043_OV_\ \36Y_9-E_P ^=O\ ]^E_PH_LFR_Y\[?_ +]+_A0!A_\
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MI?\ "@##_P"%E^&O^@HG_?M__B:/^%E^&O\ H*)_W[?_ .)K<_LFR_Y\[?\
M[]+_ (4?V39?\^=O_P!^E_PH P_^%E^&O^@HG_?M_P#XFC_A9?AK_H*)_P!^
MW_\ B:W/[)LO^?.W_P"_2_X4?V39?\^=O_WZ7_"@##_X67X:_P"@HG_?M_\
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M_P"2H:Q_UY1?S%=C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '%?$+_D*>%_^
MOX?R%;M87Q"_Y"GA?_K^'\A6[0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 6X_]6OTI
MU-C_ -6OTIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 V3_5M]*J5;D_U;?2JE !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 2V_^L/TJQ5>W_P!8?I5B@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *BN/]6/K4M17'^K'UH KT444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7/:'_R4W4?^P>O_H2UT-<]H?\ R4W4?^P>O_H2T =S1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %<=\*/^113_KO+_P"A5V-<=\*/^113_KO+_P"A4 =C
M1110 5\=?M[_ !^^('[-WB_X-^*-$UI;+X>WFN#3?$]B]I!()D9D93YCH73]
MVL_*,O*BOL6OFW_@HE\*O^%M_LB^/+"&$2ZAI=L-;L_ERPDMCYC!?=HQ(O\
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MC.5*J, JV>A"[!C&V(O"K57\F_3>]K+Y,YZ+4J<&WK*_X6O?[U_D?I+7P?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@"W'_JU^E.IL?^K7Z4Z@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M;)_JV^E5*MR?ZMOI52@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** );?_6'Z58J
MO;_ZP_2K% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5%<?ZL?6I:BN/]6/K0!7HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!?6H11_P VK\7H=>^)'QJUY-+CU+Q!XKU.Z/RV@N)9MWOMS@#WZ5[)HO\
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MDMO"/B6UZ/'=WA@N0/:2)"N?<@U]*Z%>7]]IL<NIZ<-+O<?O+=9UF4'_ &7
M&1]0#[5\[B,/[!VYXR7D[_\ !/5IU?:+X6O5&A1117(;A1110 4444 %%%%
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MW\C7.?"[_D1=,_[:?^C7KH[[_CQN/^N;?R-<Y\+O^1%TS_MI_P"C7H _)?\
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M6)6'4*">V[&0?G#X&?$"U^%7Q@\(^+KZUFO++1]0BNIX+<@2.@/S;<X&[!.
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MYH7DL;>W>W<M([*0S3*W1AGY?7K7"J4UA*L>LI)V\N5K^O456C.U**5[7O\
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M[J:]9K2<'3DX2W1G"2G%26S/S^_99_Y2@?M*_P#7A#_Z%;5Q_P ?K2;]@/\
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M!<V5Y$T4T$BPJ&1T8 JP/!!&13HZ4ZWG*/Y,=77V7_;WYH^,_P!NR&'XB?\
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M;VL-=VK^CWVUL[6./E<:3IS5KZ.WKTWZZW/I.BBBL#8**** ..TW_DJ&L?\
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M_P#Y<?\ ]R4?\/=_^J3_ /EQ_P#W)7YUT4>QI]@^K4NWYGZ*?\/=_P#JD_\
MY<?_ -R4?\/=_P#JD_\ Y<?_ -R5^==%'L:?8/JU+M^9^BG_  ]W_P"J3_\
MEQ__ ')1_P /=_\ JD__ )<?_P!R5^==%'L:?8/JU+M^9^BG_#W?_JD__EQ_
M_<E'_#W?_JD__EQ__<E?G711[&GV#ZM2[?F?HI_P]W_ZI/\ ^7'_ /<E'_#W
M?_JD_P#Y<?\ ]R5^==%'L:?8/JU+M^9^BG_#W?\ ZI/_ .7'_P#<E'_#W?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ]#_9S_Y.$^&'_8T:7_Z5Q5^[%?A/
M^SG_ ,G"?##_ +&C2_\ TKBK]V*X,3NCRL9\2"BBBN,\\**** "BBB@ HHHH
M **** "BBB@ HHHH **** );?_6'Z58JO;_ZP_2K% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5%<?ZL?6I:BN/]6/K0!7HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M>T/_ )*;J/\ V#U_]"6NAKGM#_Y*;J/_ &#U_P#0EH [FBBB@ HHHH ****
M"BBB@ HHHH _(K]O[P!?>#?VB=:U">-C9:\JW]M-CY6X"NH/J"HS]17S=7[5
M_M)?L[Z-^T5X%?1[YQ9:M:DS:;J2KEK>7'0^J-T8?CU K\UO!7[%_C[5_C;;
M^ ];TJ?2XHV\Z[U+:6@^S X,D;]&W= .N:_4LIS:A4PBC5E:4%KZ+JCXS'8&
MI&O>"NI/\6>C_P#!/O\ 9B_X6'XF7X@>(K4GP[H\P^PPR+Q=W0Y#>Z1\'W8C
MT-?ICJVEPZUI=WI]QN%O<Q-"_EG:VUA@X/8U2\'>$=*\!^%]-\/Z):K9Z7I\
M*P00J.BCN?4DY)/<DFO#_P!L[]I>+X"> 6M-,E1O%^KHT5A'D$P+T:=AZ+V]
M3BOB<57K9UC$H+?1+LOZU9]%1IT\OH7;VU;\_P"MCY,^)7@BT_X77HOP>^%^
MH:EK%];2;=2U":Y(6$]65F3&1&N-Q)^]\O6OT*^''PMT7X:Z+;6=A!YERD86
M:[E8N\K8Y;))QDU^8/[+_P"UAH/[/%OK%Y=>"[CQ+XGU68M<:Q)J0C;R^NP
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MI27VIO\ \E2C^=U\BJKO4A'^6/\ Z5)O\K/YBT444""N.^%'_(HI_P!=Y?\
MT*NQKCOA1_R**?\ 7>7_ -"H [&BBB@ KXW_ ."HGQM\0?"WX$Z;X<\(7,UG
MXG\<:FFB07%NQ26.$J3*48=&;*1Y'($A(Y%?9%?GM_P5\BFT'0?@OXU:)IM-
M\/\ BI6N0$W8W!9%SGCD0,.1WK*:4G"$MG**?HY),T@Y1YI1W49->JBVOQ/H
M;]G?]B'X6_ 7P#IFD1>$='UO7E@7^T==U.QCN+FZF(&\AW!*)D<(N  !U.2?
ME[_@HY^SSHO[/^D^'?V@OA'IMKX&\4^&M5@6^CT6%;:VN8I&*AGB0!<[R$;
M&]96#9P*_1K2M4M=;TNSU&QG2YLKN%+B":,Y62-E#*P/<$$&OC/_ (*Y>,;#
M0OV1;_0II%.I^(M4L[.RM\ O(8Y5F<@=<!8\9'=E]:O$3J1FIK22DK?^!)6M
M^%B</&$HN&\6G\]'K^IWO[1'[:EM\"?V<?!?Q9MO"_\ PE%MXEEL8XK :A]D
M\M;FV></YGE29P$QC;SGJ*^E(YO,MUEQC<@;'X9K\V?^"CWA.Y\"?\$[OA!X
M<NU876CWVBV4^?X7CT^9&S^(K](;5U?2X75@RM"I# Y!&WK6^(Y8QK2A]F<D
MO11BU^;,HWY*%_M0N_6]CYO_ &>_VQ-6_:.^ _C;Q_X<^',C:SH.HW.FV?AI
M=85FU&2***1<3M"HC+>;C!5L;>IS7Q9^S?\ ';XO^'?VL_C]K>A_ 6\\3>(M
M7N+=M7\-IXDAMVT=E+[0TS1%9<Y(RH&,5[O_ ,$;?^3=_&O_ &.=W_Z36M2_
ML:_\G^_M8?\ 7U9_^A25FXJ.,@EUIM_^2Q;^]O7M;2QM7M&G42V52W_DS2^Z
MW^=SVWXV?M?6?P$^'W@F_P#$?A#5;KQ_XN2.+3_ NDNMS=F[*(9(3(!@JCNJ
M%U!))&%/;)^$7[7'C#Q1\2M(\%?$CX'>)/A=?ZXLATK4)+I=1L)VCB>5HY)T
M1!')LC8A<$\<XJ7]L;]EG7_CQ-X*\7> _$\/A+XD^"+J2[T:]O(_,M9=^TM'
M*,-@$QI\VUAC<"IW<<5\,_VROB'X-^,7AOX2?M!> +?POXC\0,T.B^)M N/.
MTS4G!P!M))0D[1]XD%URB!@:=-J<VFO>;=ETM;2SZOR?W&=3W8)IZ):OK>^M
MUVVV^]'8_$#XT>%/#_[<_P .?AS>?#72=3\5:YHDUY:>.)?*^VZ?&JW1,"9A
M+[2(7Z2J/WAX/.>E_:H_:Z\*?LK:%I,FK65]XA\2:Y,;?1_#NDJ&N;V08!//
MW5!9%S@G+ !6-?/7QL_Y2[? C_L5;K_T7J55?BG'!K7_  5^^%MGK8#V=CX5
M>XTR*4Y0W 2\;< 1C<""?J@/:E&+G&C%.W,YW](N;T\[1L:5K4YU':]HP?S:
M2U\KNYSG[2'[=.L:]^SWX^\*?%+X+^*OA#>>(M$GM]#OK\/=V=W,R$B%Y/)C
M,4A ^Z5.,'<5[_4/["^H6VE?L4_"^]O;B.TL[;0%FFN)F"I&BERS,3P  "23
MZ5/^WMI]GJ7['GQ66]MH+I(M$FGC6XC5PDJX*.,]&# $$<@]*^<]9U#4M-_X
M(SPS:46%RWA."%RG7R7N52;\/+9_PK"53V=.M)+5<GI]NU_U\A1I^TK48-Z/
MF_.!W8_X*#>)_B%=ZC=?!?X!^)_BCX3L)'AD\1O>KIEO<,APWV8/$YE'MPW3
M*C->R?LS?M6>&/VFM)U@:98:EX;\3Z#.+76O#.M1>5>6$IR!N'=258 \'*D$
M*>*^5OV6M!_:[7]G?X?GP#K/P<M?![Z1#)IL6H1W_P!I6-AG]]LB*^9DG=@D
M;LUZ7^R[^R_\9/ ?[4'CCXO?%#6O!L\OB;2%LI[+PDUSL>=&@"2%9HDP D)R
M=Q)+GI78H*-1TY;)/5[W7X:[>7<PYG*"J1WTT6UG_EO?KV/LFOEKX]?MY:3\
M+_B0?AKX'\$ZY\6_B0D0FN-#\/C$=HIP?W\P5RAPRDX1@H(W%<BOJ6OS[_X)
M:K!JWQ _:1UW4563Q;/XM>*[ED_URQ>9.P7GD#?OX_V1Z5SJ\JG+?1)O[G%6
M_P#)OP-I-1AS6U;2^]-W_#\3NO ?_!1E(_B/I'@CXQ?"OQ%\%]8UJ40Z9=:I
M)]IL;AR0 #,8X\99E7*JR@D;BM<7_P %;OB#XUT_X&ZYX3L_A]<7?@F]BL9[
MSQJNJ1I':3"\4BW-MMWODH@W;@/W@XXK4_X+&:?ID_[*=G>W2QC5+3Q#:'3Y
M"<2!V60.%[\IN)'^R#VK2_X*127DW_!.O4Y-0W?V@\.BM<;_ +WF&XM]^??.
M:QJ252DW;6,XI]G>S7W7U^7FC6%Z=5+^:,GZ6NOQ_P _EV_[%OQ9^)/C#PKX
M;\/>*/@O<^ O#&G^&[3^S_$3ZY#=QWVR.)$ @6-6CWH2_).,8-?4-</\"_\
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M[_@?GM>_L]_%/3;:2XN_AKXPM;>,;GEFT&Z1% ZDDQX K@""I((P:^O?!?\
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M&,C.1V?_  48^!GA.\\#>'/C7X(M(;2VUAXAJ"VD0CBN4G0R17)4<!R>&/\
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MW1-7M&WV^H:=X?M+>XA;!&4D2,,IP2,@]ZNDU."J/:[7_@+L14O";IK>R?\
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MN>]>Y445O.;J2<F8PBH1Y4%%%%06%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 <5\0O^0IX7_Z_A_(5^(G[1G_ "<)\3_^QHU3_P!*Y:_;
MOXA?\A3PO_U_#^0K\1/VC/\ DX3XG_\ 8T:I_P"E<M=F&W9Z&#^)GGE%%%=Y
MZH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'H?[.?\ R<)\,/\ L:-+
M_P#2N*OW8K\)_P!G/_DX3X8?]C1I?_I7%7[L5P8G='E8SXD%%%%<9YX4444
M%%%% !1110 4444 %%%% !1110 4444 2V_^L/TJQ5>W_P!8?I5B@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *BN/]6/K4M17'^K'UH KT444 %%%% !1110 4444
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M6NT_\L=1FY^NYC4:_L)_ 70Q&MYHN64YS>:M*I;Z_.*Z/]9L&]HR^Y?YF/\
M9%?NOZ^1^2%3V.GW6IW"6]G;37<[G"Q0(79CZ #FOV5\._LB?!/2U6>P\":/
M=CM)<%KI3_WVS"O1=,T#PCX"ACM]/T_1?#T9&5CMX8K8'W  &:Y:G%%+:E2;
M?GI_F;QR:?VYI?U\C\COAW^Q?\6_B-)$UMX6N-)LWY^UZQ_HR ?1OF/X"OK[
MX.?\$S?#/AJ:#4/'NJOXFNT(;^S;0&&T!]&;[[C_ +Y'UK[&C\1Z3-($CU2S
M=ST5;A"3^M: 8%<@Y'K7S^*S_&UURQ?(O+?[_P#*QZ='+,/3U?O/S*6BZ'IW
MAO2[?3=*L;?3K"W4)%;6L8CC0#L .*O56M=2L[YY$MKJ"X>/AUBD#%?K@\5-
M)*D,;22.L:*,LS'  ]2:^:=V]=SUU:V@^BH+6^M[Z'S;:XBN(LXWQ.&7/U%-
ML]3L]09UM;N"Y,9PXAD5]OUP>*+,"6XMXKRWE@GC66&52CQN,JRD8((]"*\T
M_9\_9[\._LU>#;WPKX4OM6N="GU&;48+75)TF%D9<%H82J*1&",@-N.226.:
M]/HI+W6VNNGRW&]4D^FOZ!1110!Y9HG[.?AG1_V@-?\ C"]WJFI^+=5T^/2T
M2^FC:VT^W3;E+9%C#+N*Y8LS<DXQDUZG110M$HK9?\/^8=6^K_X;\@HHHH *
MX[X4?\BBG_7>7_T*NQKCOA1_R**?]=Y?_0J .QHHHH *XOXQ_"'PW\=OASK/
M@GQ9:-=Z+JD6R3RVVRQ."&26-L':ZL P.",CD$9%=I14RBI+ED5&3B[H^"_"
MO[*?[6/P!L4\-?"GXU^&==\$VX*V-CXTLG66S0G(162&8X XP'"]<(O2NE^&
MO["'BKQ1\5-&^)W[1'Q$'Q-\3Z*5?2M&L;86^EV,BMN#A0JA\$*<"-,E06W\
M8^SZ*T4FI*6[6SZ_\/Y[F<HIIQV3Z?U^6QY-^U'^SSI/[4'P:UCP'JMX^F&Z
M*7%GJ$<8D:UN(SF.3:2-PZJ5R,JS $'FOFCPO^R9^U-KGABV^'7CWXZZ5;?#
M:"(6<MQX;MF;6KVT7"B!YI(4\O*#!?>YY(;>,Y^\**SC%1;TT>ZZ.WD:.3=N
MZV?5?,^:_P!A']F#6OV4?AKXH\*ZS>Z;>K?>([G5+%M-FDE"6KQ0QQK(9(T/
MF 1'. 1R.37FWQ*_8]^-/A/]H[Q5\5?@)X^\/>'W\7PHFM:9XE@=HU=54;X]
ML,@;E=XR%()89(.*^W:*IWE*,V]4K7\K)?BEJ3I9QMHW?YWO^#/FSXJ?"']H
M&^T_P/K7P_\ B[I]CXPT?24L-;L=:L,Z3KDV%+W#(BMY+%@WW$SA@ 5 P>)\
M&_LC_%?XC?&_PE\3?V@/&^@:Q-X/=YM#\-^$K1TLHIFVGS7EE57/*JVT@Y*K
M\P *G[)HJHOEESK>[:\F^W;=V[=+"DN:/*^JL_->?]:]3YF^(7[,7B;Q=^W1
M\-OC3:ZCI,7ACPSHDVG75G-)*+V25UNU!C41E"O^D+R7!^4\=*B_;"_8\OOV
M@-6\*>-_!/BD^"/BCX2<OI6KM&7AE7=N$4N 2 &R0V&&&<%6#<?3U%1;W8K^
M5MKNFVW^K-')RDY/6Z2?:R5CX*\9?L9_M$_M$>"=6T?XT_%[1KJVALI?[+T#
MPO"UM8W5\$/D3WLWD([(K[6,81AD C&,'Z/^"OP#'A7]E?P_\(_&Z6.L)#H;
M:/JBV3NUO.KA@X1F56QAN#@&O9J*;LXRA;26_P"/^?Y=B%=2C.^L;V^=O\CX
M4\#?LI_M-_LSV\WAGX-_%+PCKOP_6626QTOQY:3++8;W+%5>"-RW7GYE4DDA
M%)-?0'[//@/XT>&;S6]3^+_Q(TWQA<7R1K9Z/HNEI:VFG;2Q8I)M5Y-V5'SC
M(V]3GCVNBJ4GN]7Y_P!?\$32Z:>@5\5_%#]B'XA>%?C5KOQ8_9X^(=GX'U_Q
M =VLZ#K5N9--O)"<O)D(^-QRV#&2&9RK+NQ7VI16=O>4ENOUW^3+O[KB]G_2
M^X^']&_8E^*WQJ^(7A[Q/^TM\1M*\5Z7X=N/M6G>$/#-L8]/:88(>5VCC+#(
MY4H20<;@N5/M?[:_P(UW]I']G7Q#X!\-7FG:?J^H36DD,VJ221VX$5Q'(P8Q
MH[#(0@84\XKW6BG)*45#HG?YZ:_@A1;C)SZ[?+^F<Y\-_#=QX.^'?A?0+N2*
M6[TK2K6QFDA),;/%"J,5) ."5.,@5T=%%:3FZDG.6[U,X05."A'9:!1114%A
M1110 4444 %%%% !1110 4444 %%%% !1110!!??\>-Q_P!<V_D:YSX7?\B+
MIG_;3_T:]='??\>-Q_US;^1KG/A=_P B+IG_ &T_]&O0!^2__!13_DOT7_8+
M7_TJN:^7J^H?^"BG_)?HO^P6O_I5<U\O5ZU+X$>]0_AQ"BBBM3<VO!/AN3QE
MXRT'0(21+JE_!8H1V,DBH/\ T*ONW_@K)XECL[KX;>"[60+!9VD]]) .P)2*
M(_E'*/SKY\_8'\'GQE^U5X*C:/S+?3I9=3ES_"(8V9#_ -_/+_.MK_@H]XP/
MBK]JCQ!;JVZ'1;6VTV/!STC$C?\ C\K#\*YZ^LJ5/S<ODM%]S.:'O8F3_EC^
M+>OX'S#7Z8JLG@'_ ().[-14+-J%B3%&V#D7-_NC(R/[CAO\YKX__9>_94\4
M?M'^,+.*WL[FQ\)0S#^TM=:,K%&@.62-CP\I' 49QD$X%>__ /!2;XZ:+-#H
M'P9\'R1?V1X<*/J(M3^[CEC3RX;8$'GRUR6'8E1U4BC$^]35#K)K[EO^?]=4
MI>TQ$.7:&K]>B.H_X)<Z=!X/^&7Q7^(=X0EO;A8-[<!4MX7GDY_[:)^5?GCJ
MVI3ZUJEYJ%T_F7-W,\\KG^)V8LQ_,FOT8\+Y^#__  2MU2]*>3?>)(IN.A;[
M5<" '_OR ?PK\W:'[V)F_P"5*/HTM?T'A=:<I_S2?S2T7X';?!'PA_PGWQB\
M%>'3$9XM2U>UMYD S^Z,J^8?H$W'\*^M?^"LWBX7_P 4O!OAE/\ 5Z5I+W;8
M/\4\I7'X+ OYUYU_P36\(CQ1^U-H]VPS'HEC=:DPQP3L\E?_ !Z8'\*Y3]NK
MQ@/&G[5'CNYCE,MO972:;%SPOD1K&X'_  -7/XTZVM2C#MS2_P#;0I^]B)RZ
M))?-N_Y'@E>U?LY_ 7PI\:5UQ_%/Q7T'X91Z>8E@&L&$O=E]V[8LD\7"[1D@
MG[PZ5X[IVFW>L:A;6%A:S7M]=2K#!;6\9DEED8@*B* 2S$D  <DFG:II=[HF
MH7%AJ-I/87UNYCFM;J)HY8F'565@"#[&M^ENYM).2M%V/U2_9\_9)\"_ _1[
MCXB>";T?'+Q?9PR+I[6%[:PVBRD$?N_WC*C$'!9G<@=!7YU_M#_%+Q7\7OBU
MKFN^,K=M/UE)39G3&5E%@D9*B *W(VG.<]6+'O7U#_P2H\$^*I/BIK?BB"&Z
MMO"$6FR6ES<-N6"YN&=#'&O9V4!F.,[<\XW#/@_[;?B+2O%/[4OC^_T:2.:R
M^V)!YL7W7DBACCE(]?G1N>^,UR23CB(J3O[M_37]3GPWQ5$]6K:]_+^NQX=7
MJO[,GP/O/V@OC!HWA2 /'I[-]JU.Y3_EA:(1YC9]3D(/]IUKRJOTT^ MMI/[
M!/[*<WQ*\3:8;[QCXI>!HM+:;R)71LF"W#%3LPF^5SM)&<8.T5U.:I1=273;
MU>P\1*5E3I_%+;]7\CQ3_@HU\;K+Q%XQTSX5^%S';^$O!B+!)#;8$37:ILVC
M':)/D'HQD'I7J/[24?\ PLC_ ()K?#7Q(K>9+HHT\ROU/RH]F_\ X^1^5>>W
MG[?'PJU"ZFNKK]EGP=<W,[M++--+:.\CL<LS,;#)))))-?0EOX^\/_M-_L!_
M$>7P_P"#++P18Z;!=I'H.FNC0PR6X2[#+LCC W$@D!>I/7-<$U.&&=UJFI-Z
M:V>OYV1"]VM12C9+W5UW]/O]3\\?V8_!Y\>?M"?#_1=F^.?6+>25<9S%&WFR
M?^.(U?0O_!5;Q@=9^/&BZ"D@>#1='0L@_AEF=G;_ ,<$597_  2\\'_\)#^T
MDVK21[HM"TFXNE?'"R.5A4?]\R/^5>2?MA>,/^$Y_::^(>IJVZ)=4DLHSG(V
MP 0 CZ^7G\:Z:VM6E#LI2_\ ;;%TO>KU)=DH_/?\CQROTS_:U+^!_P#@G/\
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M_NJ_QU/S'6_WI_X(?DS\[? ?_*9[XA?]BO'_ .DEE7T#_P %&/\ DROXI?\
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M0 4444 <=IO_ "5#6/\ KRB_F*[&N.TW_DJ&L?\ 7E%_,5V- !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 <5\0O^0IX7_Z_A_(5^(G[1G_ "<)\3_^QHU3_P!*
MY:_;OXA?\A3PO_U_#^0K\]?BQ_P37^)OCKXI>,?$MAKOA.&QUG6;S4;>.YN[
MI95CFG>10X%N0& 89P2,]S730DHMW.W"SC"3YF?!=%?97_#JWXL?]##X-_\
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M_P#(M'_#JWXL?]##X-_\#;O_ .1:/:P[A[>G_,?&M%?97_#JWXL?]##X-_\
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M]K#N'MZ?\Q\845]G_P##J7XM?]#%X+_\#;O_ .1:/^'4OQ:_Z&+P7_X&W?\
M\BT>UAW#V]/^8^,**^S_ /AU+\6O^AB\%_\ @;=__(M'_#J7XM?]#%X+_P#
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M !1110 4444 %%%% !1110 4444 %%%% $MO_K#]*L57M_\ 6'Z58H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "HKC_5CZU+45Q_JQ]: *]%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^"DVAZ+\+?#?@?5O@OI_B+3M&L;>S"WVKH\4K11A!)Y3VKA2<$]3C/6HYO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#BOB%_R%/"__7\/Y"MVL+XA?\A3PO\ ]?P_D*W:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@"W'_JU^E.IL?\ JU^E.H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** &R?ZMOI52K<G^K;Z54H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@"6W_UA^E6*KV_^L/TJQ0 4444 %%%% !1110 4444 %%%% !1110 4444
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M<JVL<E_PJ/P/_P!"?H7_ (+H?_B:VM8\,Z1XAM8K;5-+L]1MH6#1PW4"R(A
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M1_8WC/\ Z&&T_P# 1?\ "@#L:*X[^QO&?_0PVG_@(O\ A1_8WC/_ *&&T_\
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M  H [&BN._L;QG_T,-I_X"+_ (4?V-XS_P"AAM/_  $7_"@#L:*X[^QO&?\
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M/[)\6?\ 0<MO_ 9?\* .KHKE/[)\6?\ 0<MO_ 9?\*/[)\6?]!RV_P# 9?\
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MKHKE/[)\6?\ 0<MO_ 9?\*/[)\6?]!RV_P# 9?\ "@#JZ*Y3^R?%G_0<MO\
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M1!!C$2@*%.3\N,<FF^%/!^@^ ]$AT;PUHFG>'='@+-%I^DVD=K;QEB68K'&
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M17Z+6>@?#[]E?P$FHW-NB2+MBDOO)$EW>3$9VJ3TS@D+D* /J:M^%?&/P_\
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M KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI_VS_P#1,=?FY7Z1_LU_\DRM/^V?_HF.LYE1/5:***S+"BBB@ HHHH ****
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M;=VUBN<>6<9QTKT'XA?\A3PO_P!?P_D*^8?''_(Z:_\ ]A"X_P#1C4 >H?\
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M .UUX;10![E_PTU_U+?_ )/?_:Z/^&FO^I;_ /)[_P"UUX;10![E_P --?\
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M=_\ )[_[77BE% 'M?_#2/_4N_P#D]_\ :Z/^&D?^I=_\GO\ [77BE% 'M?\
MPTC_ -2[_P"3W_VNC_AI'_J7?_)[_P"UUXI10![7_P -(_\ 4N_^3W_VNC_A
MI'_J7?\ R>_^UUXI10![7_PTC_U+O_D]_P#:Z/\ AI'_ *EW_P GO_M=>*44
M >U_\-(_]2[_ .3W_P!KH_X:1_ZEW_R>_P#M=>*44 >U_P##2/\ U+O_ )/?
M_:Z/^&D?^I=_\GO_ +77BE% 'M?_  TC_P!2[_Y/?_:Z/^&D?^I=_P#)[_[7
M7BE% 'M?_#2/_4N_^3W_ -KKVNOBFOM:@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** );?_ %A^E6*KV_\ K#]*L4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !45Q_JQ]:EJ*X_U8^M %>BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y[0_
M^2FZC_V#U_\ 0EKH:Y[0_P#DINH_]@]?_0EH [FBBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7VM7Q37VM0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% $MO_ *P_2K%5[?\ UA^E6* "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ J*X_P!6/K4M17'^K'UH KT444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7/:'_R4W4?^P>O_ *$M=#7/:'_R4W4?^P>O_H2T =S1110 4444
M %%%% !2,P4$DX Y)-+7FOQ_UNYTGP#)#:N8WOIEMG=3@A"K,V/KMQ]":\[,
M<;#+L)4Q=174%?U\OF=F#PTL9B(8>+MS.Q5\3_M*^"O#-^UF;BZU.5#AVT^#
MS$4_[Q(!_ FL?_AKCP5_SZ:R/^W5/_CE>">&/A[J'C;5O[/TR%'G*EV,C;5
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MDXNIB'':\?SJ''%25"@I;W?_ *2CQW_@DE_R&/VAO^QJ7_T*XKEOAOX$TO\
M;(_X*2_%K4_B!9QZ_P"&/AV/[-T_0[X"2V+QRF% \9X9-R3R%3P689R.*ZG_
M ())?\AC]H;_ +&I?_0KBN(_X3Z#]@#_ (*'?$+6/'=O>67PW^)*27MOK45N
M\Z)*SB4L0H).R1ID95!8!T;&",\-"RGAW+;V:M_B]G&WSWL;RNZ5=1W]H_\
MP'VDK_+8]%_X*2_L;_"Z']GCQ)X_\.>&=/\ !GB7PY DL<WA^U2TBNXFD2-X
M9HXP%<$/D-C<-HYQD'Z"_8'_ .3-_A-_V!(__0FKY2_;B_;J\)?'+X%^+O /
MP<L[[X@/<6'VO7-:ALIK>RT>RB=9&D=I40LYV!5&,<]2V%/U;^P/_P F;_";
M_L"1_P#H35I2YE&IVO&W_DUWZ?A>_F34<7.GWM+_ -LM_7:WD>_5\_?M_?\
M)FOQ8_[ S?\ H:5] U\_?M_?\F:_%C_L#-_Z&E<F,_W:I_A?Y'5A_P"-#U7Y
ME/\ X)U_\F5_"K_L'2?^E$M>*_\ !9__ )-4T/\ [&NU_P#2:ZKVK_@G7_R9
M7\*O^P=)_P"E$M<)_P %7_AEK/Q)_9)OWT2TFOKCP_J=OK4UO NYV@1)(Y&
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M_P""K/PE\1SJ,WVO5O%.CK=17\3D!%:9D;8@P>3B)@=P8EC7ZD^/O&5G\.O
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M_P"RKIMMK/\ P4D_:DT^]A6XL[JRD@GA<95T:6%64^Q!(IW_  3EU:Z_9_\
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M% !1110 4444 %%%% !1110 4444 %17'^K'UJ6HKC_5CZT 5Z*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KGM#_P"2FZC_ -@]?_0EKH:Y[0_^2FZC_P!@]?\
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M!_:=^'G[,?ARWU?QYK?V#[6S)96%O&9KN\91EA'&.H&1ECA1D9(R*\8^'?\
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M\N[?PQ82:#X5D(NIHUC5&AA55#[5!*J6?@ <#=G'&*]9\>_M):'\"M8?P9X
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MK<.EAL<:QHJ(H1%& JC  ]!3J** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH X[3?^2H:Q_P!>47\Q78UQVF_\E0UC_KRB
M_F*[&@ HHHH 3KP:Y_P;\._"OPZM+JU\*>&='\,6MU,;BXAT:PBM$FE( +NL
M:J&;  R>>*Z&B@"&\L[?4K.>TNX([JUGC:*:"9 Z2(PPRLIX(()!!ZUE>$/
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M%/"__7\/Y"O/M<^ ']LZUJ&H?V]Y/VNXDG\O['NV[F+8SY@SC- '@]%>U_\
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M )(__;*/^&9?^ID_\D?_ +90!X;17N7_  S+_P!3)_Y(_P#VRC_AF7_J9/\
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M )(__;*/^&;O^IB_\D?_ +90!XI17M?_  S=_P!3%_Y(_P#VRC_AF[_J8O\
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M#'Q5XSO8'NK70=,N-2D@C.&E$4;/L![$XQGWK.I+E@Y-VLBX1<I**6Y\N_\
M"XOVR_'EG)KGA3X->"O!VCE/,MM)\9ZE++J=PO4<121K$Q&/ED"D'K7H_P"Q
MW^U7/^TIHGBBQU[PX?"'COPCJ']EZ[HXF\V..7+ .C?W2T<@P<X*'EA@GP?X
M)6/[4/[7W@&U^);_ !QL/A1H.LR22:7H&A^&H+_RX4=H\O)(RN"2K<%V['Y<
MX&1_P2[TO4M#^/G[4VG:QKA\3ZM::[;07>M- L)OIEGO@\QC4D)N(+;02!G&
M:Z81:E.$U:T;V>]TXK]7=?Y&4FG3]K%W]Y+39IW^?FF=1XR_X* >/?#O[3GQ
M)^#WA_X<Q>.M=L)+.#PO8Z8'@=R\"R7$M].\A18TWK@JJCL2/O!-(_;5^-OP
M=^,W@_P?^T/\.O#^@Z)XPN5LM+UWPQ<.T<,Q95"R;I90V&= WW" VX;@*@_9
MO4?\/3/VD3@9&D6>#_P"SI?^"N7[KX>_"&X3Y)X_'5ILD7AE_=2G@_4#\JSH
MKW,-)Z\_+?YRY?OZW^1-:7O8A+3DYK?*/-_P+'TC^U9^TQH7[*?PENO&>LVL
MFJ7#3+9Z;I4+A'O;IP2J;B#M4!69FP<!3@$X!^=M/_:D_:N\)Z&GCSQ]\"-)
ME^'31_:;JQ\/73?VY86IP?.>-YFWE5.2FQ#Q\WEX.,K_ (*K2QV'B+]G/4=6
MV#PI:^,5;4FE'[L#? PW<XQY:S=>P-?>NJ:G9Z7I-UJ%Y=0VMA!"TTUS-(%B
MCC"DEV8\!0.<USR_@U*CZ-KRLHIZ^M^^QT.W/""ZJ_GJVOPM^)\(_P#!&6=;
MK]F_QC,@(63QC=.,]<&UM37WU7P/_P $:I%D_9S\9NA#(WC*[(8="/LMKS7W
MQ7H8CXH_X8?^DHS=^>=W?WI?^E,SM#\.Z5X8L39Z-IEGI-F9&E-O8VZ0QEV)
M9FVJ ,DDDGN37YS?LVZ79ZM_P5F^,FJ^"84M_"VG:?+#J;V0 MVNF%NLBG'&
MYKA)6^L;GUKVC]K[]JCQ!!XHMO@3\$XAK7Q@UY/+N+J(_N?#]LP^:>5^BR;3
MN&?NC#$9**WJO[)7[+>@_LJ_#&/P]ITW]J:[>N+O6]<D7$M_<D<MR20BY(5<
M\#).2S$\U'X_;=$FEYMZ?<OQ>@5/@]EU;3?DD[_>_P K]SYC\(V%O\=O^"LG
MC:X\00KJ.F_#;0XDTBUG&Z.&X(A_>;3QN#SS,#C@A3_"#7KG_!3CX9Z9\0OV
M0/&=Y=6D4NI^'HX]6L+IDS) R2+YFT]0&C+J>W()Z5Y'\$[Q? '_  5J^,FC
M:FRVS^*=$CNM.,IQYY"6TA5/7A9O^_9]*]Q_X*0>-;+P3^QK\1I+N98Y=3M$
MTJVC)&Z66:14VJ.Y"[V^BDUS5M,!2:^+EO\ ]O\ ,_QYC>C?Z[.^UTO^W>5?
MA:Y\U>,/%FMWOPL_8V_:!U*ROO$.A>$D*>)IK2!KF6!)(DA>[=5R2%,+DG^]
MM]:[?0?BAX=_:6_;4\+_ !<\&SW$OPM^'GA:^&J^+KZRFL[1YY!(#"IF1"2B
MMO/&  ?;/T7^Q5X1NO O[*'PMT:^@:VO(M#@FFAD!#(\H,I4@]"#)R*\:_:4
MU[4_VK?C-;?LY>$;R6W\*:;Y6I?$76K5B/+M\AHM.5QTDE(!8>F.H5Q7?6YH
MXF4(;\TVO+F34F_)*[_#LCBHVEAHRGMRQ3\TG=)>;>G]-C/V=M)U#]KSXW3?
MM">*+26#P-H3RZ=\.M(N5(#*&*S:DZ'^-R"%STQ_L*Q^TZ_/K2?@WX5_:E_:
MZ^*?P]\=6MU<_#GX7Z9I>F>'?"-G>S6=E 98 QG*PNA+C:5!ST(!S@5Z+_P3
MQUK6-,_X7)\-+[6+S7M'\ ^+9]*T6\OI3-)'9G=L@,AY;9LZ'INP., 9QY90
MC&.BY>9>:NE=_P!YMI_.VEK&D[QFY2WNHOR?*VDO))-?CUN?6NK:M9Z#I5YJ
M>H7$=G86<+W%Q<2G"11HI9F8]@ "?PKX5T/]LS]HC]HRZU36OV?_ (3^'[CX
M?V-S):P:UXPNF234G0C/E(LT6S((X.X#H6!R!]'?MH0WMQ^R;\6X]/61KH^&
MKW"QCYBOE,7Q_P !W5Q7_!-74-+O_P!BGX;#2F0I!;7$-PJ$96X%S+Y@; &"
M6.?H1UZU$%S2FV_A2_'FU?I;\=2Y2Y5!)?$WKZ6T7F[_ '(ZSX*?M#:OXH^%
M?B?Q)\4_!MU\*]4\)SSP:W;7S^9;A8HEE:X@D ^>(JV01D9! +<$_/7AW]L+
M]I3]HV&[\1? KX0>'X? ,4TL%IJWC6[82ZB4;!,:)-%M]#]]001OR"![!_P4
M4:[OOV+_ (KPZ1+YEY#8PFX2%@62(3PO*&'8>5N)]C6]^PKJ&F:E^R#\)Y-)
MDADMH]!MX9/)Q@3(-LP./XA('S[YIQ_>.<GIR\JMYM.[]--%WOV!^Y&*7VG+
M[E:R_'?R.)_9>_;2U;XH?$S6OA)\4/!;?#OXK:1!]H:P2?S;6^C !9X6R<$!
M@P 9P5Y#'! H_%C]J[XG:Y\?M8^#?P)\&:)KOB+P_:Q7>N:YXIN9(["S$BJR
MQA(V5V.'3D-G)/RX4FO,OBMY>O?\%@OA5'H;+-=Z3X9D;6# >85\J]($F/\
M9EBX/]]?45ZQ\>OV+=?\1?%R?XP?!WXAW/PT^)4]LMO>^9 +C3]45%"H)HR#
MCA4!)61?D4[-PW47YHTZDMGS7MW3:3]--4OD-QY)3IQ>MHM7Z72;7K;9OO\
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MI&U^'_A>Z\(>*M%_M_PO<,S"- K/&&Y=-C?*ZD\X)&"3R>T*\HU':SD[_P#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:;_X K1_PU1XZ_YZ:;_X K1]6J>0?ZMXWO'[_P#@&M163_PU1XZ_YZ:;_P"
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MO^GO_P "&H_X53H7_3W_ .!#5RGE'8T5QW_"J="_Z>__  (:C_A5.A?]/?\
MX$-0!V-%<=_PJG0O^GO_ ,"&H_X53H7_ $]_^!#4 =C17'?\*IT+_I[_ / A
MJ/\ A5.A?]/?_@0U '8T5QW_  JG0O\ I[_\"&H_X53H7_3W_P"!#4 =C17'
M?\*IT+_I[_\  AJ/^%4Z%_T]_P#@0U '8T5QW_"J="_Z>_\ P(:C_A5.A?\
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M (5?HG_3U_W_ #1_PJ_1/^GK_O\ F@#KJ*Y'_A5^B?\ 3U_W_-'_  J_1/\
MIZ_[_F@#KJ*Y'_A5^B?]/7_?\T?\*OT3_IZ_[_F@#KJ*Y'_A5^B?]/7_ '_-
M'_"K]$_Z>O\ O^: .NHKD?\ A5^B?]/7_?\ -'_"K]$_Z>O^_P": .NHKD?^
M%7Z)_P!/7_?\T?\ "K]$_P"GK_O^: .NHKD?^%7Z)_T]?]_S1_PJ_1/^GK_O
M^: .NHKD?^%7Z)_T]?\ ?\T?\*OT3_IZ_P"_YH ZZBN1_P"%7Z)_T]?]_P T
M?\*OT3_IZ_[_ )H ZZBN1_X5?HG_ $]?]_S1_P *OT3_ *>O^_YH ZR3_5M]
M*J5SK?"_1 I/^E=/^>YJM_PK71O^GG_O^: .KHKE/^%:Z-_T\_\ ?\T?\*UT
M;_IY_P"_YH ZNBN4_P"%:Z-_T\_]_P T?\*UT;_IY_[_ )H ZNBN4_X5KHW_
M $\_]_S1_P *UT;_ *>?^_YH ZNBN4_X5KHW_3S_ -_S1_PK71O^GG_O^: .
MKHKE/^%:Z-_T\_\ ?\T?\*UT;_IY_P"_YH ZNBN4_P"%:Z-_T\_]_P T?\*U
MT;_IY_[_ )H ZNBN4_X5KHW_ $\_]_S1_P *UT;_ *>?^_YH ZNBN4_X5KHW
M_3S_ -_S1_PK71O^GG_O^: .KHKE/^%:Z-_T\_\ ?\T?\*UT;_IY_P"_YH Z
MNBN4_P"%:Z-_T\_]_P T?\*UT;_IY_[_ )H ZNBN4_X5KHW_ $\_]_S1_P *
MUT;_ *>?^_YH ZNBN4_X5KHW_3S_ -_S1_PK71O^GG_O^: .KHKE/^%:Z-_T
M\_\ ?\T?\*UT;_IY_P"_YH ZNBN4_P"%:Z-_T\_]_P T?\*UT;_IY_[_ )H
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MT]?]_P T ==17(_\*OT3_IZ_[_FC_A5^B?\ 3U_W_- '745R/_"K]$_Z>O\
MO^:/^%7Z)_T]?]_S0!UU%<C_ ,*OT3_IZ_[_ )H_X5?HG_3U_P!_S0!UU%<C
M_P *OT3_ *>O^_YH_P"%7Z)_T]?]_P T ==17(_\*OT3_IZ_[_FC_A5^B?\
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MC_A6NC?]//\ W_- '5T5RG_"M=&_Z>?^_P":/^%:Z-_T\_\ ?\T =717*?\
M"M=&_P"GG_O^:/\ A6NC?]//_?\ - '5T5RG_"M=&_Z>?^_YH_X5KHW_ $\_
M]_S0!U=%<I_PK71O^GG_ +_FC_A6NC?]//\ W_- '5T5RG_"M=&_Z>?^_P":
M/^%:Z-_T\_\ ?\T =717*?\ "M=&_P"GG_O^:/\ A6NC?]//_?\ - '5T5RG
M_"M=&_Z>?^_YH_X5KHW_ $\_]_S0!U=%<I_PK71O^GG_ +_FC_A6NC?]//\
MW_- '5T5RG_"M=&_Z>?^_P":/^%:Z-_T\_\ ?\T =717*?\ "M=&_P"GG_O^
M:/\ A6NC?]//_?\ - '5T5RG_"M=&_Z>?^_YH_X5KHW_ $\_]_S0!U=%<I_P
MK71O^GG_ +_FC_A6NC?]//\ W_- '5T5RG_"M=&_Z>?^_P":/^%:Z-_T\_\
M?\T =77/:'_R4W4?^P>O_H2U5_X5KHW_ $\_]_S61I?@73+GQO>:<_G_ &:.
MT65<2D-N+ =?3F@#UJBN._X53H7_ $]_^!#4?\*IT+_I[_\  AJ .QHKCO\
MA5.A?]/?_@0U'_"J="_Z>_\ P(:@#L:*X[_A5.A?]/?_ ($-1_PJG0O^GO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.EZL]AHHHKR3\_"OG[]O[_DS7XL?]@9O_0TKZ!KY^_;^_P"3-?BQ_P!@9O\
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MIO\ R5#6/^O*+^8KL:X[3?\ DJ&L?]>47\Q78T %%%% !1110 4444 %%%%
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MK@J*.6/8/J]'^1?<CO?^%_?$_P#Z*/XM_P#!Y=?_ !RC_A?WQ/\ ^BC^+?\
MP>77_P <K@J*.6/8/J]'^1?<CO?^%_?$_P#Z*/XM_P#!Y=?_ !RC_A?WQ/\
M^BC^+?\ P>77_P <K@J*.6/8/J]'^1?<CO?^%_?$_P#Z*/XM_P#!Y=?_ !RC
M_A?WQ/\ ^BC^+?\ P>77_P <K@J*.6/8/J]'^1?<CO?^%_?$_P#Z*/XM_P#!
MY=?_ !RC_A?WQ/\ ^BC^+?\ P>77_P <K@J*.6/8/J]'^1?<CO?^%_?$_P#Z
M*/XM_P#!Y=?_ !RC_A?WQ/\ ^BC^+?\ P>77_P <K@J*.6/8/J]'^1?<CO?^
M%_?$_P#Z*/XM_P#!Y=?_ !RC_A?WQ/\ ^BC^+?\ P>77_P <K@J*.6/8/J]'
M^1?<CO?^%_?$_P#Z*/XM_P#!Y=?_ !RC_A?WQ/\ ^BC^+?\ P>77_P <K@J*
M.6/8/J]'^1?<CO?^%_?$_P#Z*/XM_P#!Y=?_ !RC_A?WQ/\ ^BC^+?\ P>77
M_P <K@J*.6/8/J]'^1?<CO?^%_?$_P#Z*/XM_P#!Y=?_ !RC_A?WQ/\ ^BC^
M+?\ P>77_P <K@J*.6/8/J]'^1?<CO/^%^_$_P#Z*/XM_P#!Y=?_ !RD_P"%
M]?$W_HHOBS_P>77_ ,<KA**.6/8/J]'^1?<CN_\ A?7Q-_Z*+XL_\'EU_P#'
M*/\ A?7Q-_Z*+XL_\'EU_P#'*X2BCECV#ZO1_D7W([O_ (7U\3?^BB^+/_!Y
M=?\ QRC_ (7U\3?^BB^+/_!Y=?\ QRN$HHY8]@^KT?Y%]R.[_P"%]?$W_HHO
MBS_P>77_ ,<H_P"%]?$W_HHOBS_P>77_ ,<KA**.6/8/J]'^1?<CN_\ A?7Q
M-_Z*+XL_\'EU_P#'*/\ A?7Q-_Z*+XL_\'EU_P#'*X2BCECV#ZO1_D7W([O_
M (7U\3?^BB^+/_!Y=?\ QRC_ (7U\3?^BB^+/_!Y=?\ QRN$HHY8]@^KT?Y%
M]R.[_P"%]?$W_HHOBS_P>77_ ,<H_P"%]?$W_HHOBS_P>77_ ,<KA**.6/8/
MJ]'^1?<CN_\ A?7Q-_Z*+XL_\'EU_P#'*/\ A?7Q-_Z*+XL_\'EU_P#'*X2B
MCECV#ZO1_D7W([O_ (7U\3?^BB^+/_!Y=?\ QRC_ (7U\3?^BB^+/_!Y=?\
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M HHHH **** "BBB@ KGM#_Y*;J/_ &#U_P#0EKH:Y[0_^2FZC_V#U_\ 0EH
M[FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *X[X4?\ (HI_UWE_]"KL:X[X4?\
M(HI_UWE_]"H [&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M@OO^/&X_ZYM_(USGPN_Y$73/^VG_ *->NCOO^/&X_P"N;?R-<Y\+O^1%TS_M
MI_Z->@#\POVZ/^2V#_KP'_I3<5\\5]#_ +='_);!_P!> _\ 2FXKYXKZ&A_"
MB?L&4_[C2] HHHK<]4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *_8W]E/_DC>C?]<(/_ $GBK\<J_8W]E/\
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M?F<)1117KGZ$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?LW\
M!?\ DAGPZ_[%S3O_ $ECKNZX3X"_\D,^'7_8N:=_Z2QUW=?,R^)GXCB/XT_5
M_F%%%%28!1110 4444 %%%% !1110 4444 %%%% $MO_ *P_2K%5[?\ UA^E
M6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ J*X_P!6/K4M17'^K'UH KT444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7/:'_R4W4?^P>O_ *$M=#7/:'_R4W4?^P>O_H2T
M =S1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %<=\*/^113_ *[R_P#H5=C7'?"C
M_D44_P"N\O\ Z%0!V-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!!??\>-Q_US;^1KG/A=_R(NF?]M/_ $:]='??\>-Q_P!<V_D:YSX7?\B+
MIG_;3_T:] 'YA?MT?\EL'_7@/_2FXKYXKZ'_ &Z/^2V#_KP'_I3<5\\5]#0_
MA1/V#*?]QI>@4445N>J7M%T+4O$NJ0:;I&GW6JZC.2(K.R@:::3 ).U%!)P
M3P.@-:'BGP#XG\#-;KXD\.:MX?:X#&$:I8RVQEVXW;=ZC.,C./45Z]^PG_R=
M-X+_ .WS_P!(YZ^@/^"IG_'K\-O]_4/Y6U85JCIU*<%]I?J_\CR)8Z2S&&!Y
M=)1;OZ*3_0^+_#WPE\<^+M,34="\&>(-:T]V*K=Z?I<\\3$'! =$()!]ZT)/
M@'\3HE+/\.?%J*.K-H=T /\ R'7Z;?L*\?LK^"S[7G_I9/7BNF_\%1M-.K"#
M5OAY=6=BK%7GL]56XD&.XC:*,'_OH5G4JU%6G2A&_*SRHYICJU2K'#T5)4W9
MZ^;M]]GL?G]?6-SI=Y+:7EO+:74+;9()T*.C>A4\@_6BQL;G5+V"SL[>6[N[
MB18H;>!"\DCL<*JJ.222  .M?KSXJ\#?#;]LOX5V^IPK#>1W,3"PUB.+;=V,
MHX*GN,-]Z,\''T-?GG\ _".H> OVO?"WAS58Q'J&EZ]]EF SM+*6&Y<]5/!!
M[@BG1K>TG[.:M)'90S>-?#5:RC:=--N+\D_\OD<3_P ,_P#Q1_Z)MXN_\$5U
M_P#&Z9-\!?B;;PO++\.O%D<2*6=WT.Z"J!R23Y? K]4?VG?VAO\ AG'P;IFO
M?V!_PD/VV_%C]G^V_9=F8W?=N\M\_<QC Z]:^8[[_@J.UY8W$"_#,1M+&R!V
MU[<%)!&<?9AG\ZYXXBM4BW3A<Y,-F68XJ"J4Z"<7UNO\SX/KHO"_PY\6>.(I
MY?#GAC6?$$<#!97TO3Y;D1D\@,44X/UKT#]ECP'X&\??$R2V^(>K1:3X;L;"
M2^D::\6U2=T= (FD)! (9CA2&.."*_3+]G;XG>!OB%X?U2R^'>FC3_#.@W*V
M,+);B".5BH<LB=<<]6PQ.21W/56J^R6BN]_QL=.99K+!75.FY6M=O97_ #9^
M/&L:+J'AW4[C3M5L+G3-0MVVS6EY"T4L9QG#(P!!P1U'>J5>T_MF?\G.>/?^
MON/_ -$1UVW[ _P-L/BQ\3KS6-<MDO-#\.1I.UK*H9)[AR1$K C!4;78CU5>
MQ-52J<]%59::79Z5;&1H83ZU471.WKT^\\W\#?LK?%?XCZ3'JF@^"[ZXT^0!
MHKBZDBM$E4C(9#,Z;U(/WER/>LWXE?L\_$7X06,5[XM\+76E64K^6MTLD<\(
M;LI>)F52>P)&<'%?=W[5'[<TGP5\6/X/\):19ZKKEJB/>W6H%S;VY8!EB"(R
MEFVD$G< ,@<G./F7XQ_MR:[\;OA-=^#M;\,Z=:75S<0S-J-A-(J 1N&VB)]Q
MR2!SO]>*YHUJU2TX17*W^'<\W"8K,J\H5)THJG+SUMWW_0^9JZGPY\*?&WC#
M3_M^@>#]?UNPW%/M6FZ9/<1;AU&Y%(R/2O7/V0_!7PLUW4/$OB#XIZI;VNEZ
M!%!/;V%U<B-+MF,FX%!\\NW8N$3J6P01P?TJ^!WQ(T#XI_#^VUGPMI[:9X?C
MFDL[.W:)8L1Q-L!$:\(O'"^F.G0;5ZWLM$KO\#/,LXG@I.-.G>S2;>BNU>R[
MZ'XJW5K-8W,UM<PR6]Q"YCDAE4JZ,#@JP/((/&#45=7\6O\ DJGC/_L-7O\
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M_2J2OU^^(7_(4\+_ /7\/Y"OR!^/7_)<_B+_ -C'J/\ Z525Z."^)GV?#/\
M&J>B_,X2BBBO7/T(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;_?U#^5M7'BOX]#T_61\M+_D?TO\#_\ 29GNW["__)J_@OZ7G_I9/7Y*7O\
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M>@$G).GVY)/_ %S6O@[]B&1V_P""A'[5 +,1]J[GTN6 _(5]A_#?XL>$=0^
M_A[QTOB#3X/"@T>"YDU2XN%CAA58U#AV)PI5@5(/(((ZU\-_\$X?'6D?$S]M
M;]I#Q5H,SW.BZLWVJSFDC*&2)KIMK;3R,CG!YYYQ6LU_PHR\HU/QM;\C&/\
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MK$*2200/+&-NW*G/ZM:KJMEH>FW>HZE>6^GZ?:1-/<7=U*L44,:C+.[L0%4
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M %FH_P#/M_>C\9**_9O_ (4+\,O^B=>$_P#P1VO_ ,;H_P"%"_#+_HG7A/\
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MT3CPE_X([7_XW1]=CV#_ %FH_P#/M_>C\6**_:?_ (4#\,/^B<>$O_!':_\
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MGF7[3GQJ@_9Y^!/B_P ?2Q)<S:3:9M+>3.V6Y=A'"C8YVF1USCMFOD']D/\
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M2:X/]M/P;H7@7]B'XM:9X=TBST33FTZ>Y-I8PK%%YLDRO(P5> 68DG'K6?\
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M_P#1UU7WI7P7_P $R?\ DI7[4G_8]2_^CKJOO2H^Q3_P0_\ 2$3'XI_XI_\
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MA_\ 09L/_ E/\:IMR=V2DHJR->BLC_A+M#_Z#-A_X$I_C1_PEVA_]!FP_P#
ME/\ &D,UZ*R/^$NT/_H,V'_@2G^-'_"7:'_T&;#_ ,"4_P : ->BLC_A+M#_
M .@S8?\ @2G^-'_"7:'_ -!FP_\  E/\: ->BLC_ (2[0_\ H,V'_@2G^-'_
M  EVA_\ 09L/_ E/\: ->BLC_A+M#_Z#-A_X$I_C1_PEVA_]!FP_\"4_QH U
MZ*R/^$NT/_H,V'_@2G^-'_"7:'_T&;#_ ,"4_P : ->BLC_A+M#_ .@S8?\
M@2G^-'_"7:'_ -!FP_\  E/\: ->BLC_ (2[0_\ H,V'_@2G^-'_  EVA_\
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MXT :]%9'_"7:'_T&;#_P)3_&C_A+M#_Z#-A_X$I_C0!KT5D?\)=H?_09L/\
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M'\A6[7)^.?$&EWFI>'6@U&UF6&\WR-',K!%XY.#P*V/^$HT?_H*V7_@0G^-
M&I167_PE&C_]!6R_\"$_QH_X2C1_^@K9?^!"?XT :E%9?_"4:/\ ]!6R_P#
MA/\ &C_A*-'_ .@K9?\ @0G^- &I167_ ,)1H_\ T%;+_P "$_QH_P"$HT?_
M *"ME_X$)_C0!J45E_\ "4:/_P!!6R_\"$_QH_X2C1_^@K9?^!"?XT :E%9?
M_"4:/_T%;+_P(3_&C_A*-'_Z"ME_X$)_C0!J45E_\)1H_P#T%;+_ ,"$_P :
M/^$HT?\ Z"ME_P"!"?XT :E%9?\ PE&C_P#05LO_  (3_&C_ (2C1_\ H*V7
M_@0G^- &I167_P )1H__ $%;+_P(3_&C_A*-'_Z"ME_X$)_C0!J45E_\)1H_
M_05LO_ A/\:/^$HT?_H*V7_@0G^- &I167_PE&C_ /05LO\ P(3_ !H_X2C1
M_P#H*V7_ ($)_C0!J45E_P#"4:/_ -!6R_\  A/\:/\ A*-'_P"@K9?^!"?X
MT :E%9?_  E&C_\ 05LO_ A/\:/^$HT?_H*V7_@0G^- &I167_PE&C_]!6R_
M\"$_QH_X2C1_^@K9?^!"?XT :E%9?_"4:/\ ]!6R_P# A/\ &C_A*-'_ .@K
M9?\ @0G^- &I167_ ,)1H_\ T%;+_P "$_QH_P"$HT?_ *"ME_X$)_C0!J45
ME_\ "4:/_P!!6R_\"$_QH_X2C1_^@K9?^!"?XT ;\?\ JU^E.K)3Q7HNQ?\
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M5_PEFB?]!>Q_\"4_QH_X2S1/^@O8_P#@2G^- &K165_PEFB?]!>Q_P# E/\
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MQH_X2C1_^@K9?^!"?XT :E%9?_"4:/\ ]!6R_P# A/\ &C_A*-'_ .@K9?\
M@0G^- &I167_ ,)1H_\ T%;+_P "$_QH_P"$HT?_ *"ME_X$)_C0!J45E_\
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M_H*V7_@0G^-8>CZ_ID7Q#O[E]1M4MFL519FF4(6W+P#G&: /2**R/^$NT/\
MZ#-A_P"!*?XT?\)=H?\ T&;#_P "4_QH UZ*R/\ A+M#_P"@S8?^!*?XT?\
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M27W)+]!I6;?=M_>V_P!0HHHH&%%%% $%]_QXW'_7-OY&N<^%W_(BZ9_VT_\
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MI=V\MK=0.8Y8)D*/&P."K*>00>QJ8SC+X7<FG6I5E>E)2]'<@HHHJS8****
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M[/\ [\BMNB@#$_X0G0/^@/9_]^11_P (3H'_ $![/_OR*VZ* ,3_ (0G0/\
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M?] >S_[\BC_A"= _Z ]G_P!^16W10!B?\(3H'_0'L_\ OR*/^$)T#_H#V?\
MWY%;=% &)_PA.@?] >S_ ._(H_X0G0/^@/9_]^16W10!B?\ "$Z!_P! >S_[
M\BC_ (0G0/\ H#V?_?D5MT4 8G_"$Z!_T![/_OR*/^$)T#_H#V?_ 'Y%;=%
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M $"[7_OT*/\ A$=$_P"@7:_]^A6O10!D?\(CHG_0+M?^_0H_X1'1/^@7:_\
M?H5KT4 9'_"(Z)_T"[7_ +]"C_A$=$_Z!=K_ -^A6O10!D?\(CHG_0+M?^_0
MH_X1'1/^@7:_]^A6O10!D?\ "(Z)_P! NU_[]"C_ (1'1/\ H%VO_?H5KT4
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M^$-T+_H$VG_?H4?\(;H7_0)M/^_0K9HH QO^$-T+_H$VG_?H4?\ "&Z%_P!
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M(CHG_0+M?^_0H_X1'1/^@7:_]^A6O10!D?\ "(Z)_P! NU_[]"C_ (1'1/\
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M;_A#="_Z!-I_WZ%'_"&Z%_T";3_OT*V:* ,;_A#="_Z!-I_WZ%'_  ANA?\
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M_"(Z)_T"[7_OT*UZ* ,C_A$=$_Z!=K_WZ%'_  B.B?\ 0+M?^_0K7HH R/\
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M_"$Z!_T![/\ [\BC_A"= _Z ]G_WY%;=% &)_P (3H'_ $![/_OR*/\ A"=
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M^45\'1_&W]N6S\+VOBE_A1\.-?T>2V2]:RT>XG2\DA9 _P @>[/S;3T 8YX
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP!I7[.?_  5Q\+Z)X%M(= \.>,?#\UQ>:39+Y=NF8+AF5(QPJ^9:HX X!)P
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M^^)__11_%O\ X/+K_P".4?4I=P_U9K?\_%]S/VDD_P!6WTJI7XR_\+]^)_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *Y[0_^2FZC_V#U_\ 0EKH:Y[0_P#DINH_
M]@]?_0EH [FBBB@ HHHH ***\I^*?[2'A/X67#65U,^I:JH^:RL\%D_WF/"G
MVZU<82J.T5<Y<3BJ&#I^UQ$U&/=GJU%?*MG^W?IC7@6Z\-7"6V?O13@N/P(
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M+QE\6_#?Q9^)VH6@T]O^$5NHI;#2;7*GRXPAR<A5 )5<#/!+%CQWQL_Y2[?
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M+3F=HH[Q&>)M\;1L&"LI(VN>A%9?5Z7*U;I^FAQ8K)\-.A.-&FE*VGJ>A_M
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MGM+29P\^GSH)K:8C')1NAP -RX; QFO<#_P4R^*1B*?V-X3#8QYGV*YS]?\
MCXQ^E8QISHM^SUB];=CBP]''9?3^KTHJ<%?E;=FDW>ST/5O#7A_4?@)_P3S\
M4MK&G3Z1K>L)<>=:7*&.9#<R+;IN4\@^7M;!Y%?GG7I7Q7_:+^(/QJ5(?%7B
M":[L(Y/,CT^!%@MD;L=B ;B.Q;)&3SS7FM:4X2YI5)[O\EL>AE^%GAH3]JTY
M3DY.VVO37L%%%%=!Z84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC/5'1@593Z$8IGA[PYI/A'1;31]"TNRT72+1/+M[#3[=(((5R3M2- %49).
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M*** "BBB@ HHHH X[3?^2H:Q_P!>47\Q78UQVF_\E0UC_KRB_F*[&@ HHHH
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M^92?Y'@O[0G[>'A+]E_XN:3X2\>:!K5IH6JZ<EY;>*+.$SVXE\QUDB>/ ;Y
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M44 %%%% !45Q_JQ]:EJ*X_U8^M %>BBB@ HHHH **** "BBB@ HHHH ****
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M+'[H(XR3CX'^&OP%_:._:V2Z\1:,FO\ B&T:0AM5U/46B@=QU5'D8 X]%Z4
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MWFA/*'".<%\\=*]"HZ7Z?TOST#K8**** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5]8?\ !-G_ )+GKO\ V+D__I5:U\GU]8?\$V?^2YZ[_P!BY/\
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M_2=.\$_\%(OV@/"_@)%MOA]#8;YK.R ^R6]XLD'[M0.%VN]VH4= &'05T/\
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MXM_\$=U_\;H_X4#\3_\ HG'BW_P1W7_QNCGCW#ZQ1_G7WHX*BN\_X4%\3_\
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MOIK_ ()^_#/QAX,^,FLWOB#PIKFA64F@30I<:EITUO&TAN+8A SJ 6PK''7
M/I7/7E%TY69Y6:5J4L%52DKV[GZ T445X)^3!1110 4444 %%%% !1110 44
M44 %%%% !1110!+;_P"L/TJQ5>W_ -8?I5B@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *BN/\ 5CZU+45Q_JQ]: *]%%% !1110 4444 %%%% !1110 4444 %%%%
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MYA<QR12+AE8'!!%>I2A#&7E4>J/S?,,5B>%7'#8**=*6J<DV[]5=->1^@?\
MPU[\-/\ H*W7_@')_A2-^UW\,W!4ZI<L#P0;*3G]*_/6NR^$WPWU#XH^-+#1
MK*-O*9P]U.!\L,(/S,3].GJ<5M+!48J[;/-I<79K7J1I4X1<I.R5G_F>L6?[
M(?B7QEXBN=0LVM-,\,7L[7-E<329<VSMNC_=CD'81P<5]8_";X1:)\(?#_\
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MZ844 <K\4OAKH/Q@^'^M^#O$MHM[HVK6S6\R'[RY^ZZGLRG# ]B!7YN^"O\
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MMA91(2R*3OW D9.:]6FACN89(9HUEBD4H\;J"K*1@@@]16+35%4XO6,N9/\
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M:6&K?:YU\F(B0;?*5Q&W$LG+*3\W7@8[I33KTZG2/_R+C^9A"+C1J4WO)/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% #9/]6WTJI5N3_5M]*J4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!+;_ .L/TJQ5>W_UA^E6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,_[:?^C7H _/O]JSX+^*OB5\5'U30;.*YLH[;R&>2X2,[Q/,Q&&(/1UKQO\
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M /@;%_\ %5\S9HS1[.I_,ON_X(?ZR8S^6/W/_,^F?^&5_B)_T"K?_P #8O\
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M+_XJC_AE?XB?] JW_P# V+_XJOF;-&:/9U/YE]W_  0_UDQG\L?N?^9],_\
M#*_Q$_Z!5O\ ^!L7_P 51_PRO\1/^@5;_P#@;%_\57S-FC-'LZG\R^[_ ((?
MZR8S^6/W/_,^F?\ AE?XB?\ 0*M__ V+_P"*H_X97^(G_0*M_P#P-B_^*KYF
MS1FCV=3^9?=_P0_UDQG\L?N?^9],_P##*_Q$_P"@5;_^!L7_ ,51_P ,K_$3
M_H%6_P#X&Q?_ !5?,V:,T>SJ?S+[O^"'^LF,_EC]S_S/IG_AE?XB?] JW_\
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M_BJ^9LT9H]G4_F7W?\$/]9,9_+'[G_F?3/\ PRO\1/\ H%6__@;%_P#%4?\
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M_P"_+?X4?\+,T#_GZD_[\M_A74T4 <M_PLS0/^?J3_ORW^%'_"S- _Y^I/\
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MP[_S]2?]^6_PKKJ* .1_X6IX=_Y^I/\ ORW^%'_"U/#O_/U)_P!^6_PKKJ*
M.1_X6IX=_P"?J3_ORW^%'_"U/#O_ #]2?]^6_P *ZZB@#D?^%J>'?^?J3_OR
MW^%'_"U/#O\ S]2?]^6_PKKJ* .1_P"%J>'?^?J3_ORW^%'_  M3P[_S]2?]
M^6_PKKJ* .1_X6IX=_Y^I/\ ORW^%'_"U/#O_/U)_P!^6_PKKJ* .1_X6IX=
M_P"?J3_ORW^%'_"U/#O_ #]2?]^6_P *ZZB@#D?^%J>'?^?J3_ORW^%'_"U/
M#O\ S]2?]^6_PKKJ* .1_P"%J>'?^?J3_ORW^%'_  M3P[_S]2?]^6_PKKJ*
M .1_X6IX=_Y^I/\ ORW^%'_"U/#O_/U)_P!^6_PKKJ* .1_X6IX=_P"?J3_O
MRW^%'_"U/#O_ #]2?]^6_P *ZZB@#D?^%J>'?^?J3_ORW^%'_"U/#O\ S]2?
M]^6_PKKJ* .1_P"%J>'?^?J3_ORW^%'_  M3P[_S]2?]^6_PKKJ* .1_X6IX
M=_Y^I/\ ORW^%'_"U/#O_/U)_P!^6_PKKJ* .0;XI>'64C[5)T_YXM_A5?\
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M/Q/\/HQ)NI.G_/%O\*E_X6IX=_Y^I/\ ORW^%=+;_P"L/TJS0!R/_"U/#O\
MS]2?]^6_PH_X6IX=_P"?J3_ORW^%==10!R/_  M3P[_S]2?]^6_PH_X6IX=_
MY^I/^_+?X5UU% '(_P#"U/#O_/U)_P!^6_PH_P"%J>'?^?J3_ORW^%==10!R
M/_"U/#O_ #]2?]^6_P */^%J>'?^?J3_ +\M_A7744 <C_PM3P[_ ,_4G_?E
MO\*/^%J>'?\ GZD_[\M_A7744 <C_P +4\._\_4G_?EO\*/^%J>'?^?J3_OR
MW^%==10!R/\ PM3P[_S]2?\ ?EO\*/\ A:GAW_GZD_[\M_A7744 <C_PM3P[
M_P _4G_?EO\ "C_A:GAW_GZD_P"_+?X5UU% '(_\+4\._P#/U)_WY;_"C_A:
MGAW_ )^I/^_+?X5UU% '(_\ "U/#O_/U)_WY;_"C_A:GAW_GZD_[\M_A7744
M <C_ ,+4\._\_4G_ 'Y;_"C_ (6IX=_Y^I/^_+?X5UU% '(_\+4\._\ /U)_
MWY;_  H_X6IX=_Y^I/\ ORW^%==10!R/_"U/#O\ S]2?]^6_PH_X6IX=_P"?
MJ3_ORW^%==10!R/_  M3P[_S]2?]^6_PH_X6IX=_Y^I/^_+?X5UU% '(_P#"
MU/#O_/U)_P!^6_PH_P"%J>'?^?J3_ORW^%==10!R/_"U/#O_ #]2?]^6_P *
M/^%J>'?^?J3_ +\M_A7744 <C_PM3P[_ ,_4G_?EO\*9-\4?#SJ +J3K_P \
M6_PKL:BN/]6/K0!QO_"S- _Y^I/^_+?X4?\ "S- _P"?J3_ORW^%=310!RW_
M  LS0/\ GZD_[\M_A1_PLS0/^?J3_ORW^%=310!RW_"S- _Y^I/^_+?X4?\
M"S- _P"?J3_ORW^%=310!RW_  LS0/\ GZD_[\M_A1_PLS0/^?J3_ORW^%=3
M10!RW_"S- _Y^I/^_+?X4?\ "S- _P"?J3_ORW^%=310!RW_  LS0/\ GZD_
M[\M_A1_PLS0/^?J3_ORW^%=310!RW_"S- _Y^I/^_+?X4?\ "S- _P"?J3_O
MRW^%=310!RW_  LS0/\ GZD_[\M_A1_PLS0/^?J3_ORW^%=310!RW_"S- _Y
M^I/^_+?X4?\ "S- _P"?J3_ORW^%=310!RW_  LS0/\ GZD_[\M_A1_PLS0/
M^?J3_ORW^%=310!RW_"S- _Y^I/^_+?X4?\ "S- _P"?J3_ORW^%=310!RW_
M  LS0/\ GZD_[\M_A1_PLS0/^?J3_ORW^%=310!RW_"S- _Y^I/^_+?X4?\
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M1_$EA#-;V6K^.(+Z"*X $BQR7RNH8 D!L$9P2,]S7Z'?\%//^38I/^PS:?\
ML]76Q$J,*4FM9-)^7P_YFL8J564$]$F_S_R/R:T'P]JOBK5H-+T73+S6-3N"
M1#96$#SS2$ D[40%C@ G@=!6EXN^'/BSX?M;#Q1X7UKPV;K=Y U?3YK7S=N-
MVWS%&[&1G'3(K].?V"/V;K/X"_#>[^)7C01Z?K^J61N&:\ 0:9IX&_#9^ZS
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M110 4444 %%%% !7[B_LC_\ )$/#_P#UZVW_ *30U^'5?N+^R/\ \D0\/_\
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M9K>.2>U+;O)D9063/?!)'X5>JY+E;3(C)22DNH4444B@HHHH **** "BBB@
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M:-=)?:1JEK'>6ES']V6*10R,/J"*U*J2<6T]T0FI)-;!1112&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q7Q"_P"0IX7_
M .OX?R%;M87Q"_Y"GA?_ *_A_(5NT %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %N/\
MU:_2G4V/_5K]*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 -D_U;?2JE6Y/]6WTJI0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% $MO\ ZP_2K%5[?_6'Z58H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "HKC_5CZU+45Q_JQ]: *]%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5SVA_\ )3=1_P"P>O\ Z$M=#7/:'_R4W4?^P>O_ *$M '<T444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7'?"C_ )%%/^N\O_H5=C7'?"C_ )%%/^N\
MO_H5 '8T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPBNY426\:TMK=6QF27[3&V /7:C'Z U^,E<^!JSJ0DIN]G^B.JI%<D9]7?\
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M 3@X!ZXKTC_@K-:RWWC#X86UO&99YK>\CCC7JS&2$ #\363]M2Q5*ESWYO\
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MC4TWS*I%_9Y6GZW5O/:Z^9%1<O)-?:NG\DG?]-#ZOOKI+&SN+F3.R&-I&QZ
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MQ1#8C2-;LK@V&K::KEU@N H;<A/)1E8,,\CD'.W)]WED2&)Y)&5(U!9F8X
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M *5RUZ."IQJ2:DKB9]"_\/3?BO\ ]"_X-_\  *[_ /DFC_AZ;\5_^A?\&_\
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M "31_P /3?BO_P!"_P"#?_ *[_\ DFOCBBCZM1_E ^Q_^'IOQ7_Z%_P;_P"
M5W_\DT?\/3?BO_T+_@W_ , KO_Y)KXXHH^K4?Y0/L?\ X>F_%?\ Z%_P;_X!
M7?\ \DT?\/3?BO\ ]"_X-_\  *[_ /DFOCBBCZM1_E ^Q_\ AZ;\5_\ H7_!
MO_@%=_\ R31_P]-^*_\ T+_@W_P"N_\ Y)KXXHH^K4?Y0/L?_AZ;\5_^A?\
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M9T4?5J/\H'V9_P /5OBS_P!"]X,_\ KO_P"2J/\ AZM\6?\ H7O!G_@%=_\
MR57QG11]6H_R@?9G_#U;XL_]"]X,_P# *[_^2J/^'JWQ9_Z%[P9_X!7?_P E
M5\9T4?5J/\H'V9_P]6^+/_0O>#/_  "N_P#Y*H_X>K?%G_H7O!G_ (!7?_R5
M7QG11]6H_P H'V9_P]6^+/\ T+W@S_P"N_\ Y*H_X>K?%G_H7O!G_@%=_P#R
M57QG11]6H_R@?9G_  ]6^+/_ $+W@S_P"N__ )*H_P"'JWQ9_P"A>\&?^ 5W
M_P#)5?&=%'U:C_*!]EM_P54^++ C_A'O!G_@%=__ "54?_#TWXK_ /0O^#?_
M  "N_P#Y)KXXHH^K4?Y0/L?_ (>F_%?_ *%_P;_X!7?_ ,DT?\/3?BO_ -"_
MX-_\ KO_ .2:^.**/JU'^4#['_X>F_%?_H7_  ;_ . 5W_\ )-'_  ]-^*__
M $+_ (-_\ KO_P"2:^.**/JU'^4#['_X>F_%?_H7_!O_ (!7?_R31_P]-^*_
M_0O^#?\ P"N__DFOCBBCZM1_E ^Q_P#AZ;\5_P#H7_!O_@%=_P#R31_P]-^*
M_P#T+_@W_P  KO\ ^2:^.**/JU'^4#['_P"'IOQ7_P"A?\&_^ 5W_P#)-'_#
MTWXK_P#0O^#?_ *[_P#DFOCBBCZM1_E ^Q_^'IOQ7_Z%_P &_P#@%=__ "31
M_P /3?BO_P!"_P"#?_ *[_\ DFOCBBCZM1_E ^Q_^'IOQ7_Z%_P;_P" 5W_\
MDT?\/3?BO_T+_@W_ , KO_Y)KXXHH^K4?Y0/L?\ X>F_%?\ Z%_P;_X!7?\
M\DT?\/3?BO\ ]"_X-_\  *[_ /DFOCBBCZM1_E ^Q_\ AZ;\5_\ H7_!O_@%
M=_\ R37J?[+_ .WU\0?C5\<_#7@S7-'\-6NEZG]I\Z;3[6X2=?+M995VEYV4
M?-&H.5/!/UK\Y:^A?V /^3N/ ?\ V_\ _I!<5E5P]*-.34>C _8ZBBBOG2@H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH EM_]8?I5BJ]O_K#]*L4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+[6P P!Z'.,$<U],_M(?\%%M3^/7PQO/!EAX.7PK;WTL9O+K^U3=-+$C;O+
M$,>W+!<G)X!&.:^.Z*WJ485+<ZO;;^OD";4W46[_ *_4*]4_9R_:(\0_LV^/
M5\1:)&E];3Q_9[_2YW*Q7<.0<9'W6!Y5\'!SP02#Y716WD1**DK,_5&Q_P""
ML'PQDL8WO/"WBV"\*@O#!!:RQJW<!S.I(]]H^E?(W[6W[;6M_M+?9]%LM/;P
MYX.M)?.6Q,OF37<@R%DF8 #@'A!P"226X(^9Z*XXX2C&2DEL7&3BM#ZI_8Y_
M;>?]F?2;_P -ZKX=.N>&[Z]^W-+:2B.ZMY"BHQ ;Y9 1&GRDK@Y.[M7U1?\
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M!HHHKT" HHHH **** "BBB@ K]Q?V1_^2(>'_P#KUMO_ $FAK\.J_<7]D?\
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M27NPC36T7=?*W^2'S/VDJO5JS_'_ #9YM\;/AGJ/Q)_9\\7^ ]-N;6WU76-
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M1110!Q7Q"_Y"GA?_ *_A_(5^)?[17_)P7Q._[&C5/_2N6OVT^(7_ "%/"_\
MU_#^0K\2_P!HK_DX+XG?]C1JG_I7+7JY?\4A,\]HHHKVR0HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB[E[QW\0=.\!Z>LUV?.N9.(;5& 9_4^P'K7"6G[14=]<1P6_AZ>::1@J1QW
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M <@#3Y9-;K?NOZ_,RYDFNSV\SA_V%_VF?$O[3W@KQGJ_B?3]*T^ZT7Q'<:1
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M4I?A[\4+?264/_:4FA6_V=4/1RXNB,>XS7L7[?W_ "9K\6/^P,W_ *&E>?\
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MBBB@ HHHH **** "BO1O#O[._P 0O%GPSU/X@Z7X>:X\'Z:)6N=2:[@C"",
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M247'1_U?4E-2V_JV@4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^7>-DO5IZ_=IZF,KRY8]G=_<U^I\:_\ !(74;23X>?%BQ6YA:^B\9W,TEL)
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MY_RNCY[/[)O[1TT>/^&O]0=&'_0D6A!!_P"WBNQ_9I_8JTKX$_ #Q3\*=?\
M$#^.])\1W5U-?326?V(&.>%(GC5!(Y7A,[@V<MGBO/M'_85^,/A731X?\/\
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M(8DYRBA0N 1C7ZQ^YIU+:SV73:[U[+\>AK.-JCIQ>VK\O^#T/BSQ?^Q+\;?
MN@W&LZOX!O%T^W7?*]G=6UXZ+W8I#([8'4G& .37$_";X'^-_CEJU[IO@C0V
MUR\LX1<7""XA@6-"P4$M*ZKDD],YZ\<&OT1_8?\ #?QR\#W_ (C\3_&+7M6L
M/!(TTN(?%>IF:19 P;SL2.S0*J!]V[;G<.#C(^.OAMXEU'Q!^V$UM\.];U3P
M_H?B3Q81MTF\EM!-8FZ+X8(5ROE[CM/2JIU)RJ^R;3TO=='M9_F9S=J,JJZ/
M[^KL?:/[3W[.7CW7_P!E'X;?#3P-X?&K7VE-:MJ2)=V\ 0Q6S*QW22*&W2.3
M\N>E?F5\0?A[K_PL\77WACQ18?V9KECL^T6OG1S;-R*Z_-&S*<JP/!/6OMO_
M (*5?'KQCX4^,^C>'/"GBW6O#EM9:0DURFCZC-:^9-+(Y^?RV&XA%3&>FX^M
M><_L%_!]_P!HKX[:AXH\:SW'B&PT%$U"]DU*9IWO+ICM@65G)+CY'8Y//E@'
M(-<^$E*495YM*+<F_P OT_(NI^YIQAO9)+YZZ_>>8^!?V,_C/\2/#\&MZ#X$
MO)],G&Z&>[N(+/S5(R&19Y$9E(Z,!@]C5;2?V1?B_K7B/6]"M_!%['JFBPK<
MWL-W-#;*D3%@KJ\CJLBDH^"A8':?2O6_VG/V\O'_ (H^*6I6O@;Q-=>'/">D
MW1@L5TTA#=>62#-(XY<,<D+]W;MXSDGZB\#_ +07BKQ3_P $_?%WC[Q?- =;
M%A>Z?;:A#&(FN,_N(I&5< -YCD?* /ES@45,17C1=>*5K:)WOKM_PVY:A:K&
MC+=NW^?]=S\HJ**NZ'I-QX@UK3]+M%WW5[<1VT2^KNP51^9%>K%.3274QE)1
M3;/T1\?D?"'_ ();^']+60P7GB.*VQZO]IG-TP_[] CZ5^<-?K_^UQ9_ NW\
M'^"_ GQ9\5ZEX;LK)%N-.M],AF=I!%'Y(9C'!+@ ,0,XZGK7R]_PK[]AW_HI
MGBG_ ,!KK_Y!KR:-9.=6JDVI2;5ETVM\M2HWC2A!Z-+7U?7\COOV8L_"7_@G
M3\1/%Y?R+G6!?R6\O0@E5M(N?^N@)'UK\Y$1I'5$4LS' 51DD^E?IS^W)#H/
MP=_8G\+>"/"CW#:)J5[;06K761,\ #W)=P54Y+!"<J.6Z"O/O^"=_P $;'2_
M!OB/XVZWH5QXBN=*$T>@Z7;6YGFDDB3<\D2 $M(6(C3 X(<^A%4ZL>>OB9:)
M-+SLEI\]1)N-&G!:N3;6NFK[^5MSY\\-_L-_'/Q9I$.I6'P]O4M9AN07]U;6
M<I'J8YI$<?BM>7?$#X:^*/A7X@DT/Q;H=WH6J(N_R+I,!USC<C#*NN01N4D<
M'FOJG4)OVQ?CCX_DU&ULO&WA;?+F*U5Y]&L+5-V0,2%%< 'DG<S8[]*]#_X*
M@^(M+C\ _#?POJM_::K\0K-OM%[-;A0Z1^2%E8J/N+)(%8#C.P^E4Z]2+AS6
M]YVLM_Z74N*3DX;V3UZ:?Y]!O_!.6*/X<_L^_&'XE3+M,*.B,W&1:VS2X'U:
M8#\*^/OV>M#^)?B3XK65S\+(9+GQK8I)?PR*\"F-<;'<F<B,C]YC#==W2OL:
M_P _"/\ X)7V\6Y8+_Q.5QV+BYN=^/?-NGY"L7_@E)X=BM-6^(_C2Z39#IUA
M#9I,<<!RTLOY"%/SH<U&KB*[V@DOG%?E=HR5_8025W.3?JF[+\+^A\C?'?QC
MX^\8_$K4V^)6H/?^+--8Z;<[A !"8F(,:B$"/ 8M]WC)-:WPS_95^*_QATG^
MU/"?@N]U'3#]R]FDBM89>2#Y;S.@?!!!VDX(YKOOV5?A7'^U3^U!>76N1-)H
M@N;CQ!JL?.)5,NY82?\ :>10?]D-BO2OVR/VW/%MO\1-1\"?#?5W\*>%_#K_
M -G--I.(I;B:,A7PX&8T1@4"IC.TDD@@"^>4(PI1BE)J_DN_XFTO>J3Y7[L=
M+_DON/F/XJ?L]_$7X)_9V\:>%+W1(+AMD5TQ2:W9N3M$L3,F[ )V[LX&<5A_
M#WX9^*OBMKZ:+X1T*\U[4F&XPVJ9$:_WG<X5%SQN8@9(YKTGQU^V!\2_BM\*
M1\/?$^H0:Y9O>17(OYK<"];9]V(LN%9=V#DJ6)_BQQ7V)X^UV+_@GK^RKX?T
M3PU%;1_$GQ-@W-_(BR,LVP-/-@C#"+<L:*1C)!(/S9J52I2@W42;;LK=?\K=
M?^"1\4HPAO9M^5CXQ\??L<_&3X9>'Y=;\0^!;RVTN$;IKBUN(+P1+C)9Q!(Y
M51CEB !ZUROQ5^!GCCX(S:5#XUT,Z)+JD+3VD;74$S2(I )(B=MO+#AL'\J^
MF?V,/VLOB[XH^/WA[PMJOB6X\4:1KMQ(EY::MB7RT$;.SQMC<A4(<*#MZC'0
MC"_X*<>+U\1?M+'2TD)AT/2[:S9>RN^Z9B/PE3\JGGK1JTZ4K>]?[K?Y]=OF
M5&TN;^ZK_>[?YGB7PM_9L^)GQJM9;KP;X1O=7LHSM:\9H[>W+#JHEE949AW
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MD5E!],XZJ:^1JO#U'6I*;5K_ -?CN;U(\DK+^M HHHKH,@HHHH *_<7]D?\
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MOP^=2F^R6LLNJ37;-.D,,)$@C 9XXQ\R'[QYZ5P'Q$_;@_:J^$VCP_$3Q;\
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MGICQ;_@F]_R=E^UG_P!C!_[>7M'[2W_*6C]GS_L"#_T*_K.GJ\)%[-13_P#
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MH[>XBO+>*>"19895#I(IR&4C((]L5)5;:,E--704444AA1110 4444 %%%%
M'%?$+_D*>%_^OX?R%?B7^T5_R<%\3O\ L:-4_P#2N6OVT^(7_(4\+_\ 7\/Y
M"OSY^*W_  3;^)GCKXI>,?$EAKGA.&QUC6;S4;>.YN[E95CEG>10X%N0& 89
MP2,]S7HX*I&G)N3L)GP?17V/_P .LOBO_P!#!X-_\#;O_P"1:/\ AUE\5_\
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MW_\ (M'_  ZR^*__ $,'@W_P-N__ )%H^LT?Y@/CBBOL?_AUE\5_^A@\&_\
M@;=__(M'_#K+XK_]#!X-_P# V[_^1:/K-'^8#XXHK['_ .'67Q7_ .A@\&_^
M!MW_ /(M'_#K+XK_ /0P>#?_  -N_P#Y%H^LT?Y@/CBBOL?_ (=9?%?_ *&#
MP;_X&W?_ ,BT?\.LOBO_ -#!X-_\#;O_ .1:/K-'^8#XXHK['_X=9?%?_H8/
M!O\ X&W?_P BT?\ #K+XK_\ 0P>#?_ V[_\ D6CZS1_F ^.**^Q_^'67Q7_Z
M&#P;_P"!MW_\BT?\.LOBO_T,'@W_ ,#;O_Y%H^LT?Y@/CBBOL?\ X=9?%?\
MZ&#P;_X&W?\ \BT?\.LOBO\ ]#!X-_\  V[_ /D6CZS1_F ^.**^RU_X)5_%
ME@#_ ,)#X,_\#;O_ .1:7_AU3\6?^AA\&?\ @;=__(M'UFC_ # ?&=%?9G_#
MJGXL_P#0P^#/_ V[_P#D6C_AU3\6?^AA\&?^!MW_ /(M'UFC_,!\9T5]F?\
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M!\9T5]F?\.J?BS_T,/@S_P #;O\ ^1:/^'5/Q9_Z&'P9_P"!MW_\BT?6:/\
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MO_Y%H^LT?Y@/CBBOL?\ X=9?%?\ Z&#P;_X&W?\ \BT?\.LOBO\ ]#!X-_\
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M* "BBB@ HHHH EM_]8?I5BJ]O_K#]*L4 %%%% !1110 4444 %%%% !1110
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MDO613QF:38HQ["#_ ,>JI_P2A\)B^^*GC#Q-)CRM)TA;8$]FGD!S_P!\P/\
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M#JNWY20!M7'' Q710BXS7-!)=;?\,3)OD?*]>A]S_P#!2ZYB\!_!WX0_#BU
M6&VC\UE4]%MH$A3CW\UORJ3]GTCX3?\ !-?XA>*6<PW.O&]$,B\,#)MLH\?1
MPQ_$U\@?M"?M&>*/VE/%%AKGBB#3K.>QM!9PV^EQ21PA=[,6P\CG<2W)ST X
MXK3\0?M6>+O$/P"TSX0O8:-9^%[$QXFM8)5NIMCF0>8QE*G+G<<(.0*YG1J2
MP\H2^*<M?1O7YV2*C:$Z7+M!?BEM][>I]._\$CYK4>(OB3$S(+YK2R:-2?F,
M8>8.1[ E,_45\A?$#X1>/K#XHZWH5]X8UFZ\0/?3,88;"61[G,C?O(PJ_.K=
M0PX(-8OPP^*7B?X.>+[7Q-X2U.32M6@!3>H#)+&?O1R(<AU.!P1U (P0"/IR
MX_X*I?%^:S:!-)\(P2E=HN8["X,@/J UP5S_ ,!Q[5O4A-5O;05]+6)@W&,H
M=VG]RL>(:5\+-=^#_P <O &D^/\ 2FT62XO].OY;6>1&9;9[@#+A6.TX1LJV
M",<@5]9?\%6O"'B/6/%G@+4;+2[V_P!'6SFM5DM8&D1+AI%.T[0<,PVX!Z[3
MCH:^&/B%\1O$GQ5\57?B3Q5JLVL:S=;1)<RA5X485550%50.@4 5]%^"?^"F
M'Q@\%^%[/1'70?$'V6,11ZAK%I*]T5 PH9HYD#$# W%23W)/-34IU)^SJ.W-
M!MVZ:JP1]R<FM5))?=J?07_!.?\ 9-UGX?ZE/\1_&MA)I&J7%L]MI&E7:;+B
M.-L>9/(AY0D84 X.&8D<BOC_ .*/A_Q7^TE^TA\2[GPGI,_B&\2\O+SR+0J7
M^R0.(E902-QVB,!5RQ)  -=%X;_X*"?%K0?%VN>)+NZTW7]2U2U%FG]J6[^5
M81!BVVWCBD14R2,DABVQ<YQ7D/PG^,GBSX)^,D\3^$]2^P:KL:&4R1K(D\3,
M&:.16&"I*CW& 001FE&G5E6=6=E[K2_KY)OU=M@C[D)16K;3_#\.R]+L]3_9
MI^-'QL^$OCZR\)>#X=6U%C=".X\(7MN\D7+?.#&PS!RQ+.NW'5L@5[#_ ,%7
M=)\.V/Q(\&W=C!;0>)+S3YGU3R<!Y(U=%@:0#J?]:H8\D+CH!7-:C_P5.^,-
M]ILMK#IWA33YW0JMY;Z?,98SC[P#SLF1[J1[5\K>-/&VN_$3Q)>^(/$FJ7&L
M:Q>/OFN[ELLWH .BJ!P%   &  *'3J5*L)RBERWN^KNK?<BH6AS-=>GSN?J#
M^V%\4/B9\-?@O\-O$GPBOIK3P]]D4:A<V%C#=JL+01&W9@\;[$P'^88&2 3R
M*^'KK]H3]HCXX1RV%KXB\6Z^@!$MMX>MFC!4CD.MJBY&.QXJ[\%?V[_BG\#?
M#<7A_2[K3M<T2W&VUL]<MWF%LN22L;HZ/MY^Z6('8"NJ\9?\%-/C)XMT6XTZ
MW_L#PYYZE&NM(L7$P4C!"F:60#([@9'8@U#HRA*5H*5VVF_/OH33=H0@].56
MT/DY@58A@00><TE'7DT5Z(!1110(**** "OW%_9'_P"2(>'_ /KUMO\ TFAK
M\.J_<7]D?_DB'A__ *];;_TFAKR<P^&)2/9J***\485X-^UI\._C'XV\/^'K
M[X*>-[?PAXGT:\>XDM[XG[+J,31E3'(-CJV.H#H1DYRI ->\T5,H\RM_6A47
M8_/F[\6_\%#?%%K+X<_X07P)X8\]3 ?%45S"7B[>:%^URX/_ &P/TKW?]B/]
MD*#]DWP!J=K?ZL/$7C+Q!<+>ZWJP#!)) #MBCW?,44LYW-RQ=B0,A1]'T5HG
MRIV6KT?IO;[S-J]K[(_/'6_V3?CQ^RG\:/%?CO\ 9M;0_$OACQ1*;B^\&:W*
M(O+D+,V%W/&I5"[E&$J, VTA@,FMXN^ '[5/[;ESH^A_&N/P[\*?AQ8WBW5[
MI.@W GNK\KT^Y+,I/4#<ZJN[=L<J*_1>BHBE%1BU=1VOTMMZVZ7N7)N3<EHW
MO;KW^_R/(OCQ\+)]8_99\:?#SP5I<9GF\,7&CZ1IJ2+$O^H,<409R%4<*,L0
M/4USG[!GPK\3_!7]E7P7X.\9::-(\1Z?]L-U9BXBG\OS+N:1/GC9D.5=3P3U
MKZ HJ^9WFWKS6O\ *_\ F[D\JY8Q6T=ONL?&W_!/#]GOQ[\"-2^,DOC?1%T9
M/$'B$7NF$7D%Q]HA!F._]T[;?OKPV#[5RO[0W[*'Q>^'_P"TM-\?_P!GA]+U
M'7=3M_(UKPOJTJQ)=G:JL5+,BLC!$9@9$8.F03NP/O.BLU'EY.5V<4DO1)1U
M]4M2E]I-74FV_5N_X/8_.'XR? 7]K3]KSX7ZW%\2!H?@>QL;22?3? OAFY0R
MZQ?*,PBYG:9XUC#8(S)C('RJ<./L']D?P#KGPN_9K^'GA3Q-9#3M>TK2H[>\
MM1*DOE2 DE=Z$JV,]5)'O7KM%6GRII+>WWJ^OX_@K$./-)2;VO\ C;_+\6%>
M/_M?> =>^*7[-'Q"\)^&+'^TM?U73&M[.T\Y(O-DW*=N^1E5> >20*]@HK*I
M356$J<MFK?>:PDZ<E-=#Q;]C/X=>(/A+^S#\/_"/BJQ&F>(-+L6BO+031S>4
MYFD?&^-F4\,.A(IG[8G[.<7[4GP)UKP.M['ININ\=YIMY,I,<5U&24WX!.U@
M60D D!R0#C%>V45I7_VAR<^KO\[W_,SHKZO&,8=%;]#\\?A[IO[>VD>$++X8
M?V/X,T>PL;<:=!\0+Z[CN+B.!!M5U1)F+.% "E[?)P-W/S5TO["O[(?CO]FO
M]H?XLZEXB:ZUCP[JMI;1V/B:^NX9)]5GW>9/*T:R-(F7+G]X,].6ZU]TT5:D
M^?VCUE9I^=_ZZ?.Y+@G#V>RNG]W]?Y'QG\5_V>?'WB;_ (*/?"WXIZ;H:W'@
M71=&:UO]4^V0+Y,NR\&WRF<2-S-'RJD?-UX->_\ [3?@W5_B)^SQ\1_#'A^T
M^W:YJ^@WEE96OFI'YLSQ,J+N<A5R2.6('O7IM%92BI4O8O;7_P F=W^9MSOV
MJJ]=/_)=CPK]A_X9^)/@]^RWX%\(>+M._LKQ#IL$ZW=GY\<WEEKB5U&^-F4_
M*RG@GK7E=U^SWX]D_P""FMG\6ET13X C\/&R;5OMD&1-]G>/9Y._S?O$<[,>
M]?9-%:U)NI5]L][M_>FG^#9A&FHT_9+;3\&G^:/E?]N;]CF^_:7T[PSXC\':
MW%X9^)?A*X^TZ1J,Y98I!N5_+=E!92'165P#@@C'S9'E/_"8_P#!0;4M./AA
MO /@339W3[*?&1NX25XQ]H$8NF^;^+_4$?[':OOZBLHQY4X]'K;I?KZ7ZV-G
M*[3ZK2_];VZ7/F_]B;]D./\ 95\%ZNVK:N/$OCSQ)<B]U[6AN*R2#<1&A;YF
M52[G<V&9G8D#@#@_AS^SSX^T'_@I1\1/BM?:&L/@+5M#6TLM5^V0-YLWEVB[
M/*#F1>8I.64#Y>O(K[,HK7F?M%4[)KRLU;\%L1;W'#NTWZWO^9@>/K/Q!J/@
M?Q!:^$[^WTKQ1-83QZ7?72!XK>Z*$12.I5@5#[21M/ Z'I7QRWQ&_;QL;.70
M7^%'@34[_P#U$?BJ#5(TML=/.:!KD.3U/" 9_@[5]RT5ERZN^S+YM$NQ\W?L
M+_LKZC^RW\,M5L?$6L0:WXN\0ZBVK:M<V@(@21E $<9(!8#!);:,ECP !7TC
M116DI<W2W3Y+1?@9Q5OS^;U84445)04444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 <=IO_ "5#6/\ KRB_F*[&N.TW_DJ&L?\ 7E%_
M,5V- !1110 V0%HV ZD5\;_\$ROV>_'W[/'PY\<:9X_T-="OM2\0->VL(O(+
MGS(?)10^87<#D'@D'CI7V511'W92DNJM^-QMWCR^=_P:_4_./_@I%^PCX]^.
MWQ9\,>,_AA8+<76H6?\ 9'B!OML-J(HE8>7,^]U,BE'965=QQ&HP:^]/AA\/
M],^%/P[\.>#M&39IFB6$-C#QRP10"Q_VF.6)]2:ZBBB'[N#IK9N_Y_YO[Q3]
M^:F]TK?E_DON/C/]B?\ 9Y\??"']H3]H;Q/XLT-=+T3Q7K/VK1KD7D$QNHOM
M-S)NVQNS)\LJ<.%//3@U-^WA^R7XV^,'B+P-\3_A/J=MIWQ*\&29MH;N01K=
MQ!_,15<@J&5]WROA6$C D=_L:BE;2FD[.%K/KH6Y<TJDFK\][KIJ?G]K?P__
M &Q_VJ?"UUX4^)4'AOX0>$6A8:C'X=G674=8&TD0*RSS)&CD -EEX)R''RU[
M)_P3H^#/C#X#?LSZ=X4\<Z2-$U^/4KNX>S%S#<;4=P4.^)V7D#/!^M?3M%7%
M\KDTOB5G]]_ZZ>1E*/-RW?PNZ^ZW]=3\_P#XZ_LZ_'GX5_M@:G\=_@3HVC>,
M#X@T];+4]%U2ZC@VD)&CY#RQ J?)B<%9,A@01CKZS\2/@5\1OVLOV.;WP?\
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MR*68X&YF.2Q[L37HM%9U(JI2E1V4M_NM^6P1;C4C4W<=OS/E;_@FU\$?&GP
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M^0IX7_Z_A_(5NUA?$+_D*>%_^OX?R%;M !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!;
MC_U:_2G4V/\ U:_2G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #9/]6WTJI5N3_5M]
M*J4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!+;_ZP_2K%5[?_ %A^E6* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?\\9/^^37WW_ ,+9\3?\_P G_?B/_"C_ (6SXF_Y_D_[\1_X4?4<5VC][_\
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M>,G_ 'R:/LLW_/&3_ODU]]_\+9\3?\_R?]^(_P#"C_A;/B;_ )_D_P"_$?\
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M ._[_P"-'_"J/#7_ #Y/_P!_W_QH ZWS$_O+^='F)_>7\ZY+_A5'AK_GR?\
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M/_W^?_&@#I_,7^\/SH\Q?[P_.N8_X5IX?_Y]'_[_ #_XT?\ "M/#_P#SZ/\
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MY_\ &@#I_,7^\/SH\Q?[P_.N8_X5IX?_ .?1_P#O\_\ C1_PK3P__P ^C_\
M?Y_\: .G\Q?[P_.CS%_O#\ZYC_A6GA__ )]'_P"_S_XT?\*T\/\ _/H__?Y_
M\: .G\Q?[P_.CS%_O#\ZYC_A6GA__GT?_O\ /_C1_P *T\/_ //H_P#W^?\
MQH Z?S%_O#\Z/,7^\/SKF/\ A6GA_P#Y]'_[_/\ XT?\*T\/_P#/H_\ W^?_
M !H Z?S%_O#\Z/,7^\/SKF/^%:>'_P#GT?\ [_/_ (T?\*T\/_\ /H__ '^?
M_&@#I_,7^\/SH\Q?[P_.N8_X5IX?_P"?1_\ O\_^-'_"M/#_ /SZ/_W^?_&@
M#I_,7^\/SH\Q?[P_.N8_X5IX?_Y]'_[_ #_XT?\ "M/#_P#SZ/\ ]_G_ ,:
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M#I_,7^\/SH\Q?[P_.N8_X5IX?_Y]'_[_ #_XT?\ "M/#_P#SZ/\ ]_G_ ,:
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M_P"?-_\ O^_^-'_"K?#G_/F__?\ ?_&@#JO,3^\OYT>8G]Y?SKE?^%6^'/\
MGS?_ +_O_C1_PJWPY_SYO_W_ '_QH ZKS$_O+^='F)_>7\ZY7_A5OAS_ )\W
M_P"_[_XT?\*M\.?\^;_]_P!_\: .J\Q/[R_G1YB?WE_.N5_X5;X<_P"?-_\
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M/_W^?_&@#I_,7^\/SH\Q?[P_.N8_X5IX?_Y]'_[_ #_XT?\ "M/#_P#SZ/\
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MY_\ &@#I_,7^\/SH\Q?[P_.N8_X5IX?_ .?1_P#O\_\ C1_PK3P__P ^C_\
M?Y_\: .G\Q?[P_.CS%_O#\ZYC_A6GA__ )]'_P"_S_XT?\*T\/\ _/H__?Y_
M\: .G\Q?[P_.CS%_O#\ZYC_A6GA__GT?_O\ /_C1_P *T\/_ //H_P#W^?\
MQH Z?S%_O#\Z/,7^\/SKF/\ A6GA_P#Y]'_[_/\ XT?\*T\/_P#/H_\ W^?_
M !H Z?S%_O#\Z/,7^\/SKF/^%:>'_P#GT?\ [_/_ (T?\*T\/_\ /H__ '^?
M_&@#I_,7^\/SH\Q?[P_.N8_X5IX?_P"?1_\ O\_^-'_"M/#_ /SZ/_W^?_&@
M#I_,7^\/SH\Q?[P_.N8_X5IX?_Y]'_[_ #_XT?\ "M/#_P#SZ/\ ]_G_ ,:
M.G\Q?[P_.CS%_O#\ZYC_ (5IX?\ ^?1_^_S_ .-'_"M/#_\ SZ/_ -_G_P :
M .G\Q?[P_.CS%_O#\ZYC_A6GA_\ Y]'_ ._S_P"-'_"M/#__ #Z/_P!_G_QH
M Z?S%_O#\Z/,7^\/SKF/^%:>'_\ GT?_ +_/_C1_PK3P_P#\^C_]_G_QH Z?
MS%_O#\ZY_1'7_A9FHG(Q_9Z]_P#:6H/^%:>'_P#GT?\ [_/_ (UD:7X%T:Z\
M<7FG26S&TCLUE5/-8$,6 SG.>] 'JWF)_>7\Z/,3^\OYUR7_  JCPU_SY/\
M]_W_ ,:/^%4>&O\ GR?_ +_O_C0!UOF)_>7\Z/,3^\OYUR7_  JCPU_SY/\
M]_W_ ,:/^%4>&O\ GR?_ +_O_C0!UOF)_>7\Z/,3^\OYUR7_  JCPU_SY/\
M]_W_ ,:/^%4>&O\ GR?_ +_O_C0!UOF)_>7\Z/,3^\OYUR7_  JCPU_SY/\
M]_W_ ,:/^%4>&O\ GR?_ +_O_C0!UOF)_>7\Z/,3^\OYUR7_  JCPU_SY/\
M]_W_ ,:/^%4>&O\ GR?_ +_O_C0!UOF)_>7\Z/,3^\OYUR7_  JCPU_SY/\
M]_W_ ,:/^%4>&O\ GR?_ +_O_C0!UOF)_>7\Z/,3^\OYUR7_  JCPU_SY/\
M]_W_ ,:/^%4>&O\ GR?_ +_O_C0!UOF)_>7\Z/,3^\OYUR7_  JCPU_SY/\
M]_W_ ,:/^%4>&O\ GR?_ +_O_C0!UOF)_>7\Z/,3^\OYUR7_  JCPU_SY/\
M]_W_ ,:/^%4>&O\ GR?_ +_O_C0!UOF)_>7\Z/,3^\OYUR7_  JCPU_SY/\
M]_W_ ,:/^%4>&O\ GR?_ +_O_C0!UOF)_>7\Z/,3^\OYUR7_  JCPU_SY/\
M]_W_ ,:/^%4>&O\ GR?_ +_O_C0!UOF)_>7\Z/,3^\OYUR7_  JCPU_SY/\
M]_W_ ,:/^%4>&O\ GR?_ +_O_C0!UOF)_>7\Z/,3^\OYUR7_  JCPU_SY/\
M]_W_ ,:/^%4>&O\ GR?_ +_O_C0!UOF)_>7\Z/,3^\OYUR7_  JCPU_SY/\
M]_W_ ,:/^%4>&O\ GR?_ +_O_C0!UOF)_>7\Z/,3^\OYUR7_  JCPU_SY/\
M]_W_ ,:/^%4>&O\ GR?_ +_O_C0!UOF)_>7\Z/,3^\OYUR7_  JCPU_SY/\
M]_W_ ,:/^%4>&O\ GR?_ +_O_C0!UOF)_>7\Z/,3^\OYUR7_  JCPU_SY/\
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M (51X:_Y\G_[_O\ XT?\*H\-?\^3_P#?]_\ &@#K?,3^\OYT>8G]Y?SKDO\
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M .-'_"J/#7_/D_\ W_?_ !H ZWS$_O+^='F)_>7\ZY+_ (51X:_Y\G_[_O\
MXT?\*H\-?\^3_P#?]_\ &@#IKZ1?L-Q\R_ZMN_L:Y[X7?\B+IG_;3_T:]5;K
MX5^&XK69ULG#*C$?OWZ@?6K7PN_Y$73/^VG_ *->@#X>_:,_Y*1/_P!<V_\
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M*+^8KL:X[3?^2H:Q_P!>47\Q78T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q
M7Q"_Y"GA?_K^'\A6[6%\0O\ D*>%_P#K^'\A6[0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 6X_]6OTIU-C_P!6OTIU !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 V3_5M]*J5
M;D_U;?2JE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 2V_^L/TJQ5>W_UA^E6*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ J*X_U8^M2U%<?ZL?6@"O1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %<]H?\ R4W4?^P>O_H2UT-<]H?_ "4W4?\ L'K_ .A+
M0!W-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5QWPH_Y%%/^N\O_H5=C7'?"C_D
M44_Z[R_^A4 =C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?_&Z/^&F_B7_ -#)_P"2%M_\;KRZBCZEA?\ GU'[D']H8S_G]+_P)_YGJ/\
MPTW\2_\ H9/_ "0MO_C='_#3?Q+_ .AD_P#)"V_^-UY=11]2PO\ SZC]R#^T
M,9_S^E_X$_\ ,]1_X:;^)?\ T,G_ )(6W_QNC_AIOXE_]#)_Y(6W_P ;KRZB
MCZEA?^?4?N0?VAC/^?TO_ G_ )GJ/_#3?Q+_ .AD_P#)"V_^-T?\--_$O_H9
M/_)"V_\ C=>744?4L+_SZC]R#^T,9_S^E_X$_P#,]1_X:;^)?_0R?^2%M_\
M&Z/^&F_B7_T,G_DA;?\ QNO+J*/J6%_Y]1^Y!_:&,_Y_2_\  G_F>H_\--_$
MO_H9/_)"V_\ C='_  TW\2_^AD_\D+;_ .-UY=11]2PO_/J/W(/[0QG_ #^E
M_P"!/_,]4'[4'Q- P/$W_DA:_P#QJC_AJ+XG?]#-_P"2%K_\:KRNBCZEA?\
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M6;<:YJWPCN);C7[L7GA9F-IIEC8(K2P*#F,,6"Y C7&=S'/KUKL?%W@JS\2
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M3L;KACQDCFN2T?Q5KG@75K+2O&E\-7N]8G2*Q>PC39%\P5M^50XRZ] W0_B
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M44 %%%% !1110 4444 %%%% !1110 5%<?ZL?6I:BN/]6/K0!7HHHH ****
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M- BC\@*F$7#VKEO=1_\  =7^,DOD.4E-4E':SE]^B_*1F?$KX@Z/\*? .O\
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M<'KD4OBCXO>!/!.M6NC^(O&OAW0-7NL&WT_5-5@MKB;)P-D;N&;)]!7YR?\
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M "4K]J3_ +'J7_T==5]Z5/V*?^"'_I"(C\4_\4__ $MA1112- HHHH @OO\
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M1?#[X@Q&X=20&M72$IOQU42A5QZ3M4PDO:\L](JU_G)1_"YHX-TG*'Q7LO\
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M_P#+W_MW]3X#BK_EQ_V]_P"VA1117V1\"%%%% !1110 4444 %%%% !1110
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M99K=3&ZLA23 WK_N]N]<[I>L7'PKN6TS5TCLO!=LOE6&I2 R3RS,0^U@A/\
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M_&3X4V7Q&^!/BKX?Q1)%:ZCHDVFVR8XB;RBL)'^ZP0CZ5Z'17-R)X;ZN_O\
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MCK')L8[&_P!DX-;-( HKBOC/\6='^!?PQU_QWK\%Y<Z/HL(GN(=/C5YW!=4
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MX_[>_P#;0HHHK[(^!"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?,DM)I-*O"5:"X/EN=C]RC<?,H/!KD;C6M8^$EQ)=:]=K>>$]QLM-L+!%::
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M44 %%%% !1110 4444 %%%% !45Q_JQ]:EJ*X_U8^M %>BBB@ HHHH ****
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MV\9#PP/BIHYU3S/*\S9-]CW?]??E^1CW\S%?'G[;WPMMOC7_ ,%,?A=X'O\
M4KS2],UKP['!>S6#E)7MU>\DDB!SP'5"AZX#9P>E>Z_MH?L;?"'3/V0?&O\
MPC_@+0O#]_X9TA]1T[4K"R2*[1H%WD/,!ODWJI5MY.<Y/(!&#ERT?;RVUT]&
M]?NMWN[[:'2X7K>QCNU%W]4OUOZ+N?0OQC_:<^%WP L;.Z\?>,]/T 7B[[:
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M_P"%3^"/^A.\/_\ @K@_^(H_X5/X(_Z$[P__ ."N#_XBC_6"E_S[8?ZK5O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>N7^(?BK_A-O'&MZZ%=([ZZ>6-),;ECSA <=PH _"NV5*<\=&HU[L8O[V_\
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MLRS+%QQ=?FIJT8I15][(****]$\L**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]"?V<?\ DF]O_O)_
MZ)CK\]J_0G]G'_DF]O\ [R?^B8Z^2X@_AT_5GW'"W\6KZ(]2HHHKXD_10KPO
M]JO]JS3?V3=&\-:]KWAG5M<\.ZE?-97U]I(#-I_R;D<JV%;<WRX+KWQD\5[I
M4=Q;Q7EO)!/$D\,BE7CD4,K ]00>HJ97M[O]?\/L4K=3X_UW_@K'^SEI?AF?
M4K+Q5?ZSJ"1;X]'MM&NX[B1L<)ODC6('/<OBO/?^"5/P;\1V>B_%'XF>)M&E
M\.V7Q!O5DT[2YD*-]F#32&0 @'83/M0D#(0G&""?L33?V=_A3HNMIK.G_#+P
M=8ZPC^8NH6V@6D=P&_O"18PV??->A524?>;5VU;R2=K_ 'V1#<K**>B:?JUM
M]Q^4O[)?QHTW_@G'\4OB)\&_C%'>Z#X?O=1_M/1?$ LY)H)DQL$A$:LS)(BQ
M\J#M965L<XZS]MC]MCPM^TY\/4^"7P)-]\0/%'BZYA@GELK*>"*V@219&&94
M4DDHN6QL5-Y9AC%?HEXN\"^&OB!IG]G>*/#VE>)-/W;OLFKV45U%GUV2*1G\
M*J^"OAAX-^&L$T/A'PEH?A6&8YECT738;-9#ZL(U7/XTK>TC&-;6UOG;:_ZV
MW+YN23G2T;N_1OM\]5V/G_XI_"]?@M_P3A\5^!Q,MQ)H?@.YM)ID&%DE%LQD
M<>Q<L1]:A_X)<_\ )CGPZ^NH?^E]Q7U!K&CV'B'2KO3-5L;;4]-O(F@N;.\A
M66&>-AAD=&!#*0<$$8-5O#'A71?!.AVVB^'='L-!T>U#"#3]+M4MK>++%CMC
M0!5RQ).!U)-;>T<G4E+>=OPYO_DC+E2A3IQVC?\ )(^!O^"27_(8_:&_[&I?
M_0KBN(_X3Z#]@#_@H=\0M8\=V]Y9?#?XDI)>V^M16[SHDK.)2Q"@D[)&F1E4
M%@'1L8(S^DOA3X>^%O ;:BWAKPUH_AUM2F^TWK:3816INI>?WDOEJ-[<GYFR
M>35CQ5X-T#QYH\FD^)=#TWQ#I4A#/8ZK:1W4#$="4D!4G\*YX)TW3E'>,5'U
M7*HO\KHO24:D);2DY>CYG)?=>Q^=G[<7[=7A+XY? OQ=X!^#EG??$![BP^UZ
MYK4-E-;V6CV43K(TCM*B%G.P*HQCGJ6PI^K?V!_^3-_A-_V!(_\ T)J]4TOX
M4>"-#\)WGA?3?!WA_3_#-XK)<Z+:Z7!%9SJPPP>%4",".N1S6WH6@Z9X7T>T
MTG1M.M-(TJSC$5M8V,"P00(.BHB@*H'H!BM(VBI)?:M^%_PU5OGW)ES2E%OI
M?\>7_+\B_7S]^W]_R9K\6/\ L#-_Z&E?0-9^O>']+\5:/=Z1K>FV>L:3>)Y5
MS8W\"3P3(>JO&X*L/8BL*U-U:4J:ZIK[S>E/V=2,WT:/ O\ @G7_ ,F5_"K_
M +!TG_I1+7"?\%7_ (9:S\2?V2;]]$M)KZX\/ZG;ZU-;P+N=H$22.1@.X592
MY]D-?6_A_P .Z5X2T6TT?0],L]&TFT3R[>PT^W2""%<YVI&@"J,D\ =ZT*WQ
M7^T2E):7=_QN8X6^'C&+ULK?A9GPW\/O^"JWP0A^"NA7NH:GJ \80:?#;R^$
M[339Y+J2Z5 ACB?9Y1#,,JQ<<$9P>*\R_P"":^M:_P")OVR/V@]:\3Z!)X6U
MS5((;^XT68DR6?G3>8L;9YW!77.0#G.0#P/O[2?@I\/- \3OXDTOP%X8TWQ%
M(Q=]7M-'MXKMF/4F94#DGZUKZ5X$\-:%XBU7Q!IOAW2M/U[5=HU#5+6RBBNK
MS;]WSI54-)CMN)Q5\UZ_MY+5J2].;M_P2'#]RJ$7HG%_^ L^"OCI_P I@/@E
M_P!B^?\ T#4*^J_VT/\ DTKXO_\ 8KZA_P"B&KT>^^'GA74_%UCXKO/#.CW?
MBBQC,-IK<]A$][;QG<"D<Y7>B_._ ('S'U-:>LZ+I_B+2;O2]6L;;4],O(F@
MN;*\A6:&>-AAD=&!#*1P01@USSCS8?V/7WO_ "9MG3S_ +]5O*/_ )*CYP_X
M)I_\F2?#+_KWNO\ TKFKPV^_Y3/:=_V*I_\ 2.2OOOPWX8T?P;HEKHWA_2;'
M0](M05M]/TVV2WMX0220D: *HR2>!U)JDWP]\+-XR7Q<?#6CGQ6L/V8:Z;"+
M[<(L8\OS]N_;@GY<XKIJS]IB/;+:\G]\91_4Y(TW&A[+T_"2E^A\&?\ !2#P
MGXD^$OQX^$_[2F@:1/K>E^%F2RUR"W4DQ0K([!C_ '5=)IDWGA3LSUKU:Z_X
M*M?LY6_A!]9B\7WEQ?"#S5T--(NA>-)MSY.3'Y0;/&XOLS_%7UW)&LL;(ZAT
M8896&01Z&N L_P!GGX5Z?KPURU^&?@^VUI9/-&I0Z#:I<A\YW>8(]V<]\YK"
M*<8.E?2[?FK[^IT2:E-5+:V2\G;8^1O^":?PX\5>*/&WQ2_:&\8Z3-H<_CZZ
M)TBQN 0XM&D,I?D E#^Z5&(&X1D]""<?X1?\ICOBW_V+2_\ HFPK]$JY^T^'
MGA6P\87?BRU\,Z/;>*KR(07.N0V$2WT\8"@(\X7>R_(G!./E'H*UBU"<'%6C
M&+BEZJW_  61JXSYOBFTV_1I_DK"^/O&5G\.O ^O^*M1AN;G3]%L)]0N(;-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** .*^(7_ "%/"_\ U_#^0K=K"^(7_(4\+_\
M7\/Y"MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH MQ_P"K7Z4ZFQ_ZM?I3J "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH @OO^/&X_P"N;?R-<Y\+O^1%TS_MI_Z->NCOO^/&X_ZYM_(USGPN_P"1
M%TS_ +:?^C7H ^'OVC/^2D3_ /7-O_1TM>7U[;\;-4T"Q\=7,>K:/)J5UAB)
MDN&C&WS9., ^N3^-<%_PD/@S_H5[C_P-?_&OT+ 8IPPM./LY/3R_S/Q3.,5@
M(9A6C4Q,8ROJFIW7W1:_$X^BNP_X2'P9_P!"O<?^!K_XT?\ "0^#/^A7N/\
MP-?_ !KT/KC_ .?4O_)?_DCQOKF6_P#09#[I_P#R!Q]%=A_PD/@S_H5[C_P-
M?_&C_A(?!G_0KW'_ (&O_C1]<?\ SZE_Y+_\D'US+?\ H,A]T_\ Y X^BNP_
MX2'P9_T*]Q_X&O\ XT?\)#X,_P"A7N/_  -?_&CZX_\ GU+_ ,E_^2#ZYEO_
M $&0^Z?_ ,@<?178?\)#X,_Z%>X_\#7_ ,:/^$A\&?\ 0KW'_@:_^-'UQ_\
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M $&0^Z?_ ,@<?178?\)#X,_Z%>X_\#7_ ,:/^$A\&?\ 0KW'_@:_^-'UQ_\
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M $&0^Z?_ ,@<?178?\)#X,_Z%>X_\#7_ ,:/^$A\&?\ 0KW'_@:_^-'UQ_\
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M_P# U_\ &CZX_P#GU+_R7_Y(/KF6_P#09#[I_P#R!Q]?H3^SC_R3>W_WD_\
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M_L/QC_T,MO\ ^ :?X4 =C17'?V'XQ_Z&6W_\ T_PH_L/QC_T,MO_ . :?X4
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M / -/\*/[#\8_P#0RV__ (!I_A0!V-%<=_8?C'_H9;?_ , T_P */[#\8_\
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MJZ*Y3^Q_%?\ T,$'_@*O^%']C^*_^A@@_P# 5?\ "@#JZ*Y3^Q_%?_0P0?\
M@*O^%']C^*_^A@@_\!5_PH ZNBN4_L?Q7_T,$'_@*O\ A1_8_BO_ *&"#_P%
M7_"@#JZ*Y3^Q_%?_ $,$'_@*O^%']C^*_P#H8(/_  %7_"@#JZ*Y3^Q_%?\
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MO^%']C^*_P#H8(/_  %7_"@#JZ*Y3^Q_%?\ T,$'_@*O^%']C^*_^A@@_P#
M5?\ "@#MH_\ 5K]*=7(+HOBW:,>(H ,?\^:?X4O]B^+O^AC@_P# -/\ "@#K
MJ*Y'^Q?%W_0QP?\ @&G^%']B^+O^AC@_\ T_PH ZZBN1_L7Q=_T,<'_@&G^%
M']B^+O\ H8X/_ -/\* .NHKD?[%\7?\ 0QP?^ :?X4?V+XN_Z&.#_P  T_PH
M ZZBN1_L7Q=_T,<'_@&G^%']B^+O^AC@_P# -/\ "@#KJ*Y'^Q?%W_0QP?\
M@&G^%']B^+O^AC@_\ T_PH ZZBN1_L7Q=_T,<'_@&G^%']B^+O\ H8X/_ -/
M\* .NHKD?[%\7?\ 0QP?^ :?X4?V+XN_Z&.#_P  T_PH ZZBN1_L7Q=_T,<'
M_@&G^%']B^+O^AC@_P# -/\ "@#KJ*Y'^Q?%W_0QP?\ @&G^%']B^+O^AC@_
M\ T_PH ZZBN1_L7Q=_T,<'_@&G^%']B^+O\ H8X/_ -/\* .NHKD?[%\7?\
M0QP?^ :?X4?V+XN_Z&.#_P  T_PH ZZBN1_L7Q=_T,<'_@&G^%']B^+O^AC@
M_P# -/\ "@#KJ*Y'^Q?%W_0QP?\ @&G^%']B^+O^AC@_\ T_PH ZZBN1_L7Q
M=_T,<'_@&G^%']B^+O\ H8X/_ -/\* .NHKD?[%\7?\ 0QP?^ :?X4?V+XN_
MZ&.#_P  T_PH ZZBN1_L7Q=_T,<'_@&G^%']B^+O^AC@_P# -/\ "@#K)/\
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M ZZBN1_L7Q=_T,<'_@&G^%']B^+O^AC@_P# -/\ "@#KJ*Y'^Q?%W_0QP?\
M@&G^%']B^+O^AC@_\ T_PH ZZBN1_L7Q=_T,<'_@&G^%']B^+O\ H8X/_ -/
M\* .NHKD?[%\7?\ 0QP?^ :?X4?V+XN_Z&.#_P  T_PH ZZBN1_L7Q=_T,<'
M_@&G^%']B^+O^AC@_P# -/\ "@#KJ*Y'^Q?%W_0QP?\ @&G^%']B^+O^AC@_
M\ T_PH ZZBN1_L7Q=_T,<'_@&G^%']B^+O\ H8X/_ -/\* .NHKD?[%\7?\
M0QP?^ :?X4?V+XN_Z&.#_P  T_PH ZZHKC_5CZURW]B^+O\ H8X/_ -/\*9-
MHOBT*,^(H",_\^B?X4 =)17*?V/XK_Z&"#_P%7_"C^Q_%?\ T,$'_@*O^% '
M5T5RG]C^*_\ H8(/_ 5?\*/['\5_]#!!_P" J_X4 =717*?V/XK_ .A@@_\
M 5?\*/['\5_]#!!_X"K_ (4 =717*?V/XK_Z&"#_ ,!5_P */['\5_\ 0P0?
M^ J_X4 =717*?V/XK_Z&"#_P%7_"C^Q_%?\ T,$'_@*O^% '5T5RG]C^*_\
MH8(/_ 5?\*/['\5_]#!!_P" J_X4 =717*?V/XK_ .A@@_\  5?\*/['\5_]
M#!!_X"K_ (4 =717*?V/XK_Z&"#_ ,!5_P */['\5_\ 0P0?^ J_X4 =717*
M?V/XK_Z&"#_P%7_"C^Q_%?\ T,$'_@*O^% '5T5RG]C^*_\ H8(/_ 5?\*/[
M'\5_]#!!_P" J_X4 =717*?V/XK_ .A@@_\  5?\*/['\5_]#!!_X"K_ (4
M=717*?V/XK_Z&"#_ ,!5_P */['\5_\ 0P0?^ J_X4 =717*?V/XK_Z&"#_P
M%7_"C^Q_%?\ T,$'_@*O^% '5T5RG]C^*_\ H8(/_ 5?\*/['\5_]#!!_P"
MJ_X4 =717*?V/XK_ .A@@_\  5?\*/['\5_]#!!_X"K_ (4 =717*?V/XK_Z
M&"#_ ,!5_P */['\5_\ 0P0?^ J_X4 =717*?V/XK_Z&"#_P%7_"C^Q_%?\
MT,$'_@*O^% '5USVA_\ )3=1_P"P>O\ Z$M5?['\5_\ 0P0?^ J_X5D:7IOB
M%_&]Y#%K,4=^MHK/<&W4ADW#Y=N,>G- 'K5%<=_8?C'_ *&6W_\  -/\*/[#
M\8_]#+;_ /@&G^% '8T5QW]A^,?^AEM__ -/\*/[#\8_]#+;_P#@&G^% '8T
M5QW]A^,?^AEM_P#P#3_"C^P_&/\ T,MO_P" :?X4 =C17'?V'XQ_Z&6W_P#
M-/\ "C^P_&/_ $,MO_X!I_A0!V-%<=_8?C'_ *&6W_\  -/\*/[#\8_]#+;_
M /@&G^% '8T5QW]A^,?^AEM__ -/\*/[#\8_]#+;_P#@&G^% '8T5QW]A^,?
M^AEM_P#P#3_"C^P_&/\ T,MO_P" :?X4 =C17'?V'XQ_Z&6W_P# -/\ "C^P
M_&/_ $,MO_X!I_A0!V-%<=_8?C'_ *&6W_\  -/\*/[#\8_]#+;_ /@&G^%
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M3_"C^P_&/_0RV_\ X!I_A0!V-%<=_8?C'_H9;?\ \ T_PH_L/QC_ -#+;_\
M@&G^% '8T5QW]A^,?^AEM_\ P#3_  H_L/QC_P!#+;_^ :?X4 =C17'?V'XQ
M_P"AEM__  #3_"C^P_&/_0RV_P#X!I_A0!V-%<=_8?C'_H9;?_P#3_"C^P_&
M/_0RV_\ X!I_A0!V-%<=_8?C'_H9;?\ \ T_PH_L/QC_ -#+;_\ @&G^% '8
MT5QW]A^,?^AEM_\ P#3_  H_L/QC_P!#+;_^ :?X4 =C17'?V'XQ_P"AEM__
M  #3_"C^P_&/_0RV_P#X!I_A0!V-%<=_8?C'_H9;?_P#3_"C^P_&/_0RV_\
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M\SGGP0]6?M7AC_O.)_PQ_-GJ=%%%?('] A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <=IO_)4-
M8_Z\HOYBNQKCM-_Y*AK'_7E%_,5V- !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M <5\0O\ D*>%_P#K^'\A6[6%\0O^0IX7_P"OX?R%;M !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!;C_ -6OTIU-C_U:_2G4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #9/]6W
MTJI5N3_5M]*J4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!+;_ .L/TJQ5>W_U
MA^E6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ J*X_U8^M2U%<?ZL?6@"O1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %<]H?_ "4W4?\ L'K_ .A+70USVA_\E-U'_L'K
M_P"A+0!W-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5QWPH_P"113_KO+_Z%78U
MQWPH_P"113_KO+_Z%0!V-%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!!??\ 'C<?]<V_D:YSX7?\B+IG_;3_ -&O71WW_'C<?]<V_D:YSX7?
M\B+IG_;3_P!&O0!\-_M(?\E*G_ZYM_Z.EKRVO4OVD/\ DI4__7-O_1TM>6U^
MC9?_ +K3]#^0.*_^1YBO\04445WGR9ZI^R[_ ,ET\,?[T_\ Z3R5[3^W5_R!
M?"7_ %\7'_H*5XM^R[_R73PQ_O3_ /I/)7M/[=7_ "!?"7_7Q<?^@I7S^-_Y
M&.']/UD?K^1?\D=F'^+]('H_[*O_ "0GP_\ [US_ .CY*^$;S4[S2/$U[=6%
MW/97*7,A6:WD:-U^8]&!R*^[OV5?^2$^'_\ >N?_ $?)7P1KG_(;U#_KXD_]
M"-&#_P!_Q/J_S97%3<>'LJ:WY5_Z1$^YOV5_BOJ'Q*\&WEKK,QNM6TF18GN&
M'S31,"49O5OE8$]\ GDFO"-6\(P>"_VO--L+2,16<FL6UU"B]%60JY ] &+
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P ^T'^MF>?]!4CWO_AL[QM_T"] _P# >?\ ^/4?\-G>-O\ H%Z!_P" \_\
M\>KP2BC^S\+_ ,^T'^MF>?\ 05(][_X;.\;?] O0/_ >?_X]1_PV=XV_Z!>@
M?^ \_P#\>KP2BC^S\+_S[0?ZV9Y_T%2/>_\ AL[QM_T"] _\!Y__ (]1_P -
MG>-O^@7H'_@//_\ 'J\$HH_L_"_\^T'^MF>?]!4CWO\ X;.\;?\ 0+T#_P !
MY_\ X]1_PV=XV_Z!>@?^ \__ ,>KP2BC^S\+_P ^T'^MF>?]!4CWO_AL[QM_
MT"] _P# >?\ ^/4?\-G>-O\ H%Z!_P" \_\ \>KP2BC^S\+_ ,^T'^MF>?\
M05(][_X;.\;?] O0/_ >?_X]1_PV=XV_Z!>@?^ \_P#\>KP2BC^S\+_S[0?Z
MV9Y_T%2/>_\ AL[QM_T"] _\!Y__ (]1_P -G>-O^@7H'_@//_\ 'J\$HH_L
M_"_\^T'^MF>?]!4CWO\ X;.\;?\ 0+T#_P !Y_\ X]1_PV=XV_Z!>@?^ \__
M ,>KP2BC^S\+_P ^T'^MF>?]!4CWO_AL[QM_T"] _P# >?\ ^/4?\-G>-O\
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M;^29A)G"JV[.U?[WIVK/\'^,+K0[BZTCQ*D&CV=LZ6FD23*4>[C4LI)))#'
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M4M17'^K'UH KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/:'_ ,E-U'_L'K_Z
M$M=#7/:'_P E-U'_ +!Z_P#H2T =S1110 4444 %%%% !1110 4444 %%%%
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M#)-RA.<5HM%YOJEZ=7WT+:491@WO^"[OUZ+YGT317P!_P[A^-_\ T>A\0/\
MOB^_^65>$V_@GXQ_#W]N_P"'GPATO]HSQQ\198I[;5M>^U7UY!;6MNC>=)#+
M&;N4/NA09#8!\U!SFM()2J1IMVYG_P %_<M297C"4[;*_P#7S/UUHHHJ1A11
M10 4444 %%%% '%?$+_D*>%_^OX?R%?G[\5O^2H>,/\ L,WG_H]Z_0+XA?\
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MGQ>2E^(\/L<H0.BLN2&QN/':@#.O+._^%6J"\M'2T^']J-T]G'B64R.-H(+
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M$G[U %_2=8T'XN>%[Q5AEN-+:;R)8YLQ$LNQ^JG..5[US,U]/\']3F>[?R?
MFT6^GV< $DL<[ .Q)/S8)$QY8]1[8G\9:2?A],/%>ER_9-(T^)1-H%FOD07,
MCL4\QMIV[OG7DH3^['/3'1>&=1L/B;X/L-2O])MW@G9W6UNE6=497=,\KC.
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M10 4444 %%%% !45Q_JQ]:EJ*X_U8^M %>BBB@ HHHH **** "BBB@ HHHH
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MK1?*_JWT+C/WU*6R4DOGU?X?\$O^'?\ DFNF?]@B+_T2*^.O^".?_)KNM_\
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M/O*3^^3?ZA1112*"BBB@""^_X\;C_KFW\C7.?"[_ )$73/\ MI_Z->NCOO\
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MB^.D'[3G[;GPVE^.6EWWP/\ #GA:1+G0] U^SN%GO[HS*R^;*\:+&KO''EF
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MWRO?]/R.^_X*K_%.\\*_L]VG@30RTOB;X@:E%HMM;0M^\>'<&EP.X8^7$?\
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M7B+7HO%OQ;UC4)K>_P#-7#:-&3\L:*>GF(!AAP$ 1<;7S^AM?F7^T9X-UO\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /T#BTR_\
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M7Y 0X!* #.8Y.V>E2>-O!>H6]Q)K?@U([/Q+=2+'=74C[@\&WE=KY4?,L?0
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MC0O#FL>&?$=U96YC@\%10XL;0,&9)3M9B6(WGYC*>6/7Z5T] !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 2V_^L/TJQ5>W_P!8?I5B@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *BN/]6/K4M17'^K'UH KT444 %%%% !1110 4444
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MPQD+\_/4?G6M>?&O3=$T6;4=>TG5=!Q*L%O:WD \^[<_PQ*I.[_Z]<?\<O\
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M/^$\U*]\4Z#>#PS(DAL],LYG=HF+#8&?S%8@+NYSUKTO_A*?V;_^A/UK_O\
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M\FDZG=V4O^MMIGA?_>5B#_*O2/V;_AWI_P 2OB9!INKP-<Z7!;2W-Q"KLF\
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M8R?]YC-)])!7VQ532M*LM"TRUT[3;.WT_3[2)8+>TM8EBBAC485$10 J@
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MYO\ \_:?WR_^0/@FBOO;_AF'X9_]"U_Y/W/_ ,=H_P"&8?AG_P!"U_Y/W/\
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M_)^Z_P#CM'_#+?PP_P"A9_\ )^Z_^.T?VWA_Y9?<O\P_XAKF_P#S]I_?+_Y
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M% !1110 4444 %%%% !1110 4444 %%%% $MO_K#]*L57M_]8?I5B@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *BN/]6/K4M17'^K'UH KT444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+T6B_!'-24E#WMWJ_5ZL*X[X4?\ (HI_UWE_]"KL:X[X4?\ (HI_UWE_]"K
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M;OK>^O;U,3]F34O@I<?M ?'#3_AUX/U#P_XWT[4$3Q3J-V6,-],\DS;H 9Y
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MTV72+6"'P]HDB[)+6T8M)*O]UY#CY?90N1P<UY+JVHRZQJEY?S?ZZZF>=_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '':;_R5#6/^O*+^8KL:X[3?
M^2H:Q_UY1?S%=C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '%?$+_ )"GA?\
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MH_M/"?S_ (/_ "#_ %9S3_GVO_ Z?_R1R=%=9_PBWAS_ *';3_\ OV?\:/\
MA%O#G_0[:?\ ]^S_ (T?VGA/Y_P?^0?ZLYI_S[7_ ('3_P#DCDZ*ZS_A%O#G
M_0[:?_W[/^-'_"+>'/\ H=M/_P"_9_QH_M/"?S_@_P#(/]6<T_Y]K_P.G_\
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M)T5UG_"+>'/^AVT__OV?\:/^$6\.?]#MI_\ W[/^-']IX3^?\'_D'^K.:?\
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M $.VG_\ ?L_XT?VGA/Y_P?\ D'^K.:?\^U_X'3_^2.3HKK/^$6\.?]#MI_\
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MA0!V-%<=_P )IK/_ $*5]_W\'^%'_"::S_T*5]_W\'^% '8T5QW_  FFL_\
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M^$TUG_H4K[_OX/\ "@#L:*X[_A--9_Z%*^_[^#_"C_A--9_Z%*^_[^#_  H
M[&BN._X336?^A2OO^_@_PH_X336?^A2OO^_@_P * .QHKCO^$TUG_H4K[_OX
M/\*/^$TUG_H4K[_OX/\ "@#L:*X[_A--9_Z%*^_[^#_"C_A--9_Z%*^_[^#_
M  H [&BN._X336?^A2OO^_@_PH_X336?^A2OO^_@_P * .QHKCO^$TUG_H4K
M[_OX/\*/^$TUG_H4K[_OX/\ "@#L:*X[_A--9_Z%*^_[^#_"C_A--9_Z%*^_
M[^#_  H [&BN._X336?^A2OO^_@_PH_X336?^A2OO^_@_P * .QHKCO^$TUG
M_H4K[_OX/\*/^$TUG_H4K[_OX/\ "@#L:*X[_A--9_Z%*^_[^#_"C_A--9_Z
M%*^_[^#_  H [&BN._X336?^A2OO^_@_PH_X336?^A2OO^_@_P * .QHKCO^
M$TUG_H4K[_OX/\*/^$TUG_H4K[_OX/\ "@#L:*X[_A--9_Z%*^_[^#_"C_A-
M-9_Z%*^_[^#_  H C^(7_(4\+_\ 7\/Y"MVN!\7^)-1OK[0WFT"ZLVANMZ)(
MX)E/'RCCK6I_PEVJ_P#0L7G_ '\'^% '545RO_"7:K_T+%Y_W\'^%'_"7:K_
M -"Q>?\ ?P?X4 =517*_\)=JO_0L7G_?P?X4?\)=JO\ T+%Y_P!_!_A0!U5%
M<K_PEVJ_]"Q>?]_!_A1_PEVJ_P#0L7G_ '\'^% '545RO_"7:K_T+%Y_W\'^
M%'_"7:K_ -"Q>?\ ?P?X4 =517*_\)=JO_0L7G_?P?X4?\)=JO\ T+%Y_P!_
M!_A0!U5%<K_PEVJ_]"Q>?]_!_A1_PEVJ_P#0L7G_ '\'^% '545RO_"7:K_T
M+%Y_W\'^%'_"7:K_ -"Q>?\ ?P?X4 =517*_\)=JO_0L7G_?P?X4?\)=JO\
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MBN5_X2[5?^A8O/\ OX/\*/\ A+M5_P"A8O/^_@_PH ZJBN5_X2[5?^A8O/\
MOX/\*/\ A+M5_P"A8O/^_@_PH ZJBN5_X2[5?^A8O/\ OX/\*/\ A+M5_P"A
M8O/^_@_PH ZJBN5_X2[5?^A8O/\ OX/\*/\ A+M5_P"A8O/^_@_PH ZJBN5_
MX2[5?^A8O/\ OX/\*/\ A+M5_P"A8O/^_@_PH ZJBN5_X2[5?^A8O/\ OX/\
M*/\ A+M5_P"A8O/^_@_PH ZJBN5_X2[5?^A8O/\ OX/\*/\ A+M5_P"A8O/^
M_@_PH ZJBN5_X2[5?^A8O/\ OX/\*/\ A+M5_P"A8O/^_@_PH ZJBN5_X2[5
M?^A8O/\ OX/\*/\ A+M5_P"A8O/^_@_PH ZJBN5_X2[5?^A8O/\ OX/\*/\
MA+M5_P"A8O/^_@_PH ZJBN5_X2[5?^A8O/\ OX/\*/\ A+M5_P"A8O/^_@_P
MH ZJBN5_X2[5?^A8O/\ OX/\*/\ A+M5_P"A8O/^_@_PH ZJBN5_X2[5?^A8
MO/\ OX/\*/\ A+M5_P"A8O/^_@_PH ZJBN5_X2[5?^A8O/\ OX/\*/\ A+M5
M_P"A8O/^_@_PH ZJBN5_X2[5?^A8O/\ OX/\*/\ A+M5_P"A8O/^_@_PH ZJ
MBN5_X2[5?^A8O/\ OX/\*/\ A+M5_P"A8O/^_@_PH ZJBN5_X2[5?^A8O/\
MOX/\*/\ A+M5_P"A8O/^_@_PH Z^W_UA^E6*XR'Q?JRL<>%[P\?\]!_A4O\
MPF6K_P#0JWO_ '\'^% '745R/_"9:O\ ]"K>_P#?P?X4?\)EJ_\ T*M[_P!_
M!_A0!UU%<C_PF6K_ /0JWO\ W\'^%'_"9:O_ -"K>_\ ?P?X4 ==17(_\)EJ
M_P#T*M[_ -_!_A1_PF6K_P#0JWO_ '\'^% '745R/_"9:O\ ]"K>_P#?P?X4
M?\)EJ_\ T*M[_P!_!_A0!UU%<C_PF6K_ /0JWO\ W\'^%'_"9:O_ -"K>_\
M?P?X4 ==17(_\)EJ_P#T*M[_ -_!_A1_PF6K_P#0JWO_ '\'^% '745R/_"9
M:O\ ]"K>_P#?P?X4?\)EJ_\ T*M[_P!_!_A0!UU%<C_PF6K_ /0JWO\ W\'^
M%'_"9:O_ -"K>_\ ?P?X4 ==17(_\)EJ_P#T*M[_ -_!_A1_PF6K_P#0JWO_
M '\'^% '745R/_"9:O\ ]"K>_P#?P?X4?\)EJ_\ T*M[_P!_!_A0!UU%<C_P
MF6K_ /0JWO\ W\'^%'_"9:O_ -"K>_\ ?P?X4 ==17(_\)EJ_P#T*M[_ -_!
M_A1_PF6K_P#0JWO_ '\'^% '745R/_"9:O\ ]"K>_P#?P?X4?\)EJ_\ T*M[
M_P!_!_A0!UU%<C_PF6K_ /0JWO\ W\'^%'_"9:O_ -"K>_\ ?P?X4 ==17(_
M\)EJ_P#T*M[_ -_!_A1_PF6K_P#0JWO_ '\'^% '745R/_"9:O\ ]"K>_P#?
MP?X4?\)EJ_\ T*M[_P!_!_A0!UU17'^K'UKEO^$RU?\ Z%6]_P"_@_PIDWC#
M5V49\+7@Y_YZ#_"@#I**Y7_A+M5_Z%B\_P"_@_PH_P"$NU7_ *%B\_[^#_"@
M#JJ*Y7_A+M5_Z%B\_P"_@_PH_P"$NU7_ *%B\_[^#_"@#JJ*Y7_A+M5_Z%B\
M_P"_@_PH_P"$NU7_ *%B\_[^#_"@#JJ*Y7_A+M5_Z%B\_P"_@_PH_P"$NU7_
M *%B\_[^#_"@#JJ*Y7_A+M5_Z%B\_P"_@_PH_P"$NU7_ *%B\_[^#_"@#JJ*
MY7_A+M5_Z%B\_P"_@_PH_P"$NU7_ *%B\_[^#_"@#JJ*Y7_A+M5_Z%B\_P"_
M@_PH_P"$NU7_ *%B\_[^#_"@#JJ*Y7_A+M5_Z%B\_P"_@_PH_P"$NU7_ *%B
M\_[^#_"@#JJ*Y7_A+M5_Z%B\_P"_@_PH_P"$NU7_ *%B\_[^#_"@#JJ*Y7_A
M+M5_Z%B\_P"_@_PH_P"$NU7_ *%B\_[^#_"@#JJ*Y7_A+M5_Z%B\_P"_@_PH
M_P"$NU7_ *%B\_[^#_"@#JJ*Y7_A+M5_Z%B\_P"_@_PH_P"$NU7_ *%B\_[^
M#_"@#JJ*Y7_A+M5_Z%B\_P"_@_PH_P"$NU7_ *%B\_[^#_"@#JJ*Y7_A+M5_
MZ%B\_P"_@_PH_P"$NU7_ *%B\_[^#_"@#JJ*Y7_A+M5_Z%B\_P"_@_PH_P"$
MNU7_ *%B\_[^#_"@#JJ*Y7_A+M5_Z%B\_P"_@_PH_P"$NU7_ *%B\_[^#_"@
M#JJ*Y7_A+M5_Z%B\_P"_@_PH_P"$NU7_ *%B\_[^#_"@#JJY[0_^2FZC_P!@
M]?\ T):K?\)=JO\ T+%Y_P!_!_A61I?B/48?&]Y=IH-S+<-:*AM5<;E7</FS
MCI_C0!ZS17'?\)IK/_0I7W_?P?X4?\)IK/\ T*5]_P!_!_A0!V-%<=_PFFL_
M]"E??]_!_A1_PFFL_P#0I7W_ '\'^% '8T5QW_"::S_T*5]_W\'^%'_"::S_
M -"E??\ ?P?X4 =C17'?\)IK/_0I7W_?P?X4?\)IK/\ T*5]_P!_!_A0!V-%
M<=_PFFL_]"E??]_!_A1_PFFL_P#0I7W_ '\'^% '8T5QW_"::S_T*5]_W\'^
M%'_"::S_ -"E??\ ?P?X4 =C17'?\)IK/_0I7W_?P?X4?\)IK/\ T*5]_P!_
M!_A0!V-%<=_PFFL_]"E??]_!_A1_PFFL_P#0I7W_ '\'^% '8T5QW_"::S_T
M*5]_W\'^%'_"::S_ -"E??\ ?P?X4 =C17'?\)IK/_0I7W_?P?X4?\)IK/\
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M*^_[^#_"@#L:*X[_ (336?\ H4K[_OX/\*/^$TUG_H4K[_OX/\* .QHKCO\
MA--9_P"A2OO^_@_PH_X336?^A2OO^_@_PH [&BN._P"$TUG_ *%*^_[^#_"C
M_A--9_Z%*^_[^#_"@#L:*X[_ (336?\ H4K[_OX/\*/^$TUG_H4K[_OX/\*
M.QHKCO\ A--9_P"A2OO^_@_PH_X336?^A2OO^_@_PH [&BN._P"$TUG_ *%*
M^_[^#_"C_A--9_Z%*^_[^#_"@#L:*X[_ (336?\ H4K[_OX/\*/^$TUG_H4K
M[_OX/\* .QHKCO\ A--9_P"A2OO^_@_PH_X336?^A2OO^_@_PH [&BN._P"$
MTUG_ *%*^_[^#_"C_A--9_Z%*^_[^#_"@#L:*X[_ (336?\ H4K[_OX/\*/^
M$TUG_H4K[_OX/\* .QHKCO\ A--9_P"A2OO^_@_PH_X336?^A2OO^_@_PH [
M&BN._P"$TUG_ *%*^_[^#_"C_A--9_Z%*^_[^#_"@#L:*X[_ (336?\ H4K[
M_OX/\*/^$TUG_H4K[_OX/\* .QHKCO\ A--9_P"A2OO^_@_PH_X336?^A2OO
M^_@_PH [&BN._P"$TUG_ *%*^_[^#_"C_A--9_Z%*^_[^#_"@#L:*X[_ (33
M6?\ H4K[_OX/\*/^$TUG_H4K[_OX/\* .QHKCO\ A--9_P"A2OO^_@_PH_X3
M36?^A2OO^_@_PH [&BN._P"$TUG_ *%*^_[^#_"C_A--9_Z%*^_[^#_"@#L:
M*X[_ (336?\ H4K[_OX/\*/^$TUG_H4K[_OX/\* .JOO^/&X_P"N;?R-<Y\+
MO^1%TS_MI_Z->J=UXRUA[693X4O4!1@6,@XXZ]*M_"[_ )$33/\ MK_Z->@#
MX!_:J_Y*I+_U[G_T?-7CM>Q?M5?\E4E_Z]S_ .CYJ\=K1;'X#GO_ ",J_J%%
M%%,\(**U_"?A/5O''B"TT30[0WVJ7180VX=4W;5+'YF( P 3R>U;?Q"^#WB_
MX5K9-XHT=M+6\+"!OM$4P<KC<,QNV,;AU]:'I:_4Z(X>M4INK"#<5N[.R]6<
M;17H_@S]G?XA?$'0(=:T#PZU]IDS,L=PUW!$'*DJ<!Y%. 01G':MIOV1/BTB
MECX2.!Z:C:$_I+3>FC.B&7XRI%3A1DT^JB[?D>/45N>+/ WB#P+?"S\0:/>:
M1.V=@NHBHDQU*-T8<CD$BJ&B:+>^(]8L]+TVW:[O[R58((4(!=V. ,G@<]SQ
M2C[WPZG'.G.G+DG%I]GN4J*]C_X9!^+?_0I_^5*T_P#CM,F_9'^+,$+R/X3(
M1%+'&HVA.!["7FDY)*[9Z']EX_\ Z!Y_^ R_R/'Z*WO!?@37_B'K*Z5X=TN;
M5+XJ7,<6 $4?Q,Q(51VR2!D@=Z]OL_V#_B)<VR2R7WA^T=ADPS7<I=?8[8F7
M\C5/179GALOQ>,3>'IN279:?>?.5%=Q\3_@OXK^$-]%#XBT_RH)B1!>V[^9!
M-CJ%8=#[, ?:L[P#\-/$OQ0U2?3O#&F-J=W!%Y\B":.(*F0,EG91U(XSFE'W
MOA,9X6O3J^PG!J?:VOW',45['_PR#\6_^A3_ /*E:?\ QVN9\?? OQS\,-*A
MU+Q-H9TVQFF$"3"Z@F!<@L!B-V(X4]>.*5T;SR[&TXN<Z,DEU<7;\C@J**]+
M\*_LW?$GQIH\6JZ3X6N)K";F.6XGAM_,'4,JRNI*GL0,&JZ7.6C0JXB7)1@Y
M/LDW^1YI15G4M.N-'U&ZL+N/R;NUE>":/(.UU)5AD<'!!Z56I)IJZ,I1<6XR
M5F@HHHH)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *_33]F;_DEMC](_\ T1%7YEU^FG[,W_)+;'Z1
M_P#HB*ID?HW!G\:MZ+\V>KT445!^JA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/Q>\1> O#7A^TN/B%%8S:2]T(X%U#3S>)YVQB,($?!VA^<>HSS7SC\9/B+\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P!:\M[O[C[HHKX7_P"&Z?'O_0(\.?\ @-<?_'Z/^&Z?'O\ T"/#G_@-<?\
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MP_UKRWN_N/O"BO@__AO'Q_\ ] CPW_X#7'_Q^C_AO'Q__P! CPW_ . UQ_\
M'Z.5A_K7EO=_<?>%%?!__#>/C_\ Z!'AO_P&N/\ X_1_PWCX_P#^@1X;_P#
M:X_^/T<K#_6O+>[^X^\**^#_ /AO'Q__ - CPW_X#7'_ ,?H_P"&\?'_ /T"
M/#?_ (#7'_Q^CE8?ZUY;W?W'WA17P?\ \-X^/_\ H$>&_P#P&N/_ (_1_P -
MX^/_ /H$>&__  &N/_C]'*P_UKRWN_N/O"BO@_\ X;Q\?_\ 0(\-_P#@-<?_
M !^C_AO'Q_\ ] CPW_X#7'_Q^CE8?ZUY;W?W'WA17P?_ ,-X^/\ _H$>&_\
MP&N/_C]'_#>/C_\ Z!'AO_P&N/\ X_1RL/\ 6O+>[^X^\**^#_\ AO'Q_P#]
M CPW_P" UQ_\?KM_A'^V=KOBCQ)<VOB72-.%@EHTJ?V3%(DOF!T R9)6&W!;
MMG.*5F=.&XCP&*K1H4F^:6BT/KFBEO()C9S_ &1HQ=>6WDF8$H'Q\NX#G&<9
MQ7#Z1\1'7QI#X0U6W5]:.3)<V8VV_P#JS*,!B6^[@?6D?3G;T52U^WUAK6/^
MQ)+&.XW_ #G4$=DVX/380<YQ6/\ #[QY9?$.SN[BTMI[5;>01LLQ4DDC/&*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%-_B3%MN?E*2^2DTOP"BBBD6%%%% $%]_P >-Q_US;^1KG/A=_R(NF?]M/\
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M%%% !1110 4444 %%%% !7Z:?LS?\DML?I'_ .B(J_,NOTT_9F_Y);8_2/\
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M94445!84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '':;_R5#6/^O*+^8KL:X[3?
M^2H:Q_UY1?S%=C0 4444 %%5]0O[?2K"YO;N9;>TMHFFFFD.%1%!+,3Z  FO
MA'0?VVOCQ^TMJVK7/[.WPJT2Y\%:9<M:'Q)XTN61;MP ?DC26(J<$' +X!7<
M5)Q4WO+E6K6OHO,=K+F?I\S[VHKXK^!_[<WC@?'BQ^"OQY^'UOX%\<:E%YNF
M7^DW'FV-YD,R@ N^ P1@&$C?,"I"FOM2M+:*2U3)O[SB]&OZ7WA1114C"BO
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %17'^K'UJ6HKC_5CZT 5Z*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KGM#_Y*;J/_8/7_P!"6NAKGM#_ .2FZC_V#U_]"6@#
MN:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;MA7T!^U!^S-_9?_  3$TSPK;P;=:\#Z39ZVI489;B(;[MA]5DN#^54_C/\
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M&X_ZYM_(USGPN_Y$73/^VG_HUZZ.^_X\;C_KFW\C7.?"[_D1=,_[:?\ HUZ
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M.P+NXSG KX0_X)3_ /);OVI/^P_#_P"E-_7Z05^;_P#P2G_Y+=^U)_V'X?\
MTIOZ5+^+)?W)?^EP*J?P6_[T?U/T-\3^&].\9>&]5T#6+;[9I.J6DMC>6^]D
M\V&1"CKN4AAE6(R"",\&O@W_ (*I> ?#GPQ_8?T[P[X4T2R\/Z):>(+,0V-A
M"(XU^2;+$#JQ/)8Y)/))-?H+7PS_ ,%C/^318O\ L8K+_P! FKCQ.D-.KA_Z
M4CJP^L[/HI?^DL^KO@7_ ,D1^'O_ &+NG_\ I-'7<5P_P+_Y(C\/?^Q=T_\
M])HZ[BO5Q7^\5/5_F>7A/]WI_P"%?D%%%%<IU!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% '%?$+_D*>%_^OX?R%?E37ZK?$+_ )"GA?\
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M%% !7/:'_P E-U'_ +!Z_P#H2UT-<]H?_)3=1_[!Z_\ H2T =S1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %<=\*/\ D44_Z[R_^A5V-<=\*/\ D44_Z[R_^A4
M=C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB@ HHHH **** "BBB@ HHHH **** );?_6'Z58JO;_ZP_2K% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5%<?ZL?6I:BN/]6/K0!7HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:ZC<745ZNH3)&)(+J18CY08*<!%XQSCFLKXU2>$?BY^WIXO\!_M'^+]2\->
MK"RMG\):--?O8:5>EHU+2R2C"[BWF88D98%-WRA3V58I5E2BK-W]-%??JWVL
M<M-ODE.6R^_>VW9=S]/:*\7_ &:_V==/_9WT_6K#PWXQUOQ#X-U)X;C2M*U>
MZ%TFE@!MZV\O>-]R$+CC;G+$DU[16<DD]"DV]PHHHJ2@HHHH **** "BBB@
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ML^)GA?22GF)=:C DB_\ 3/>"_P#XZ#7H/[8NA_V+\>=:D PE_%!=K^,80_\
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M HHHH XKXA?\A3PO_P!?P_D*S?\ A3_@/_H2/#G_ (*;?_XBM+XA?\A3PO\
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M?PW_ ."BW_\ B*/^%-^ /^A'\-_^"BW_ /B*["B@/JN'_P"?:^Y''_\ "F_
M'_0C^&__  46_P#\11_PIOP!_P!"/X;_ /!1;_\ Q%=A10'U7#_\^U]R./\
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M%% !7/:'_P E-U'_ +!Z_P#H2UT-<]H?_)3=1_[!Z_\ H2T =S1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %<=\*/\ D44_Z[R_^A5V-<=\*/\ D44_Z[R_^A4
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MY@&V8120I? C X48JA\;/^4NWP(_[%6Z_P#1>I5R;?"OQE^UK^T9\,_%^E?
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M;_T KK_QW_&@/[/QG_/F7_@+_P CE**ZO_A5/BW_ * 5U_X[_C1_PJGQ;_T
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M*[01[HI.HQ#&#^H(_"ID?H'".'K4*M9U8.-TMTUU\SV>BN>_X6!X=_Z"UO\
MF?\ "C_A8'AW_H+6_P"9_P *@_3#H:*Y[_A8'AW_ *"UO^9_PH_X6!X=_P"@
MM;_F?\* .AHKGO\ A8'AW_H+6_YG_"C_ (6!X=_Z"UO^9_PH Z&BN>_X6!X=
M_P"@M;_F?\*/^%@>'?\ H+6_YG_"@#H:*Y[_ (6!X=_Z"UO^9_PH_P"%@>'?
M^@M;_F?\* .AHKGO^%@>'?\ H+6_YG_"C_A8'AW_ *"UO^9_PH Z&BN>_P"%
M@>'?^@M;_F?\*/\ A8'AW_H+6_YG_"@#H:*Y[_A8'AW_ *"UO^9_PH_X6!X=
M_P"@M;_F?\* .AHKGO\ A8'AW_H+6_YG_"C_ (6!X=_Z"UO^9_PH Z&BN>_X
M6!X=_P"@M;_F?\*/^%@>'?\ H+6_YG_"@#H:*Y[_ (6!X=_Z"UO^9_PH_P"%
M@>'?^@M;_F?\* .AHKGO^%@>'?\ H+6_YG_"C_A8'AW_ *"UO^9_PH Z&BN>
M_P"%@>'?^@M;_F?\*/\ A8'AW_H+6_YG_"@#H:*Y[_A8'AW_ *"UO^9_PH_X
M6!X=_P"@M;_F?\* .AHKGO\ A8'AW_H+6_YG_"C_ (6!X=_Z"UO^9_PH Z&B
MN>_X6!X=_P"@M;_F?\*/^%@>'?\ H+6_YG_"@#H:*Y[_ (6!X=_Z"UO^9_PH
M_P"%@>'?^@M;_F?\* .AHKGO^%@>'?\ H+6_YG_"C_A8'AW_ *"UO^9_PH Z
M&BN>_P"%@>'?^@M;_F?\*/\ A8'AW_H+6_YG_"@#H:*Y[_A8'AW_ *"UO^9_
MPH_X6!X=_P"@M;_F?\* .AHKGO\ A8'AW_H+6_YG_"C_ (6!X=_Z"UO^9_PH
M Z&BN>_X6!X=_P"@M;_F?\*/^%@>'?\ H+6_YG_"@#H:*Y[_ (6!X=_Z"UO^
M9_PH_P"%@>'?^@M;_F?\* .AHKGO^%@>'?\ H+6_YG_"C_A8'AW_ *"UO^9_
MPH Z&BN>_P"%@>'?^@M;_F?\*/\ A8'AW_H+6_YG_"@#H:*Y[_A8'AW_ *"U
MO^9_PH_X6!X=_P"@M;_F?\* .AHKGO\ A8'AW_H+6_YG_"C_ (6!X=_Z"UO^
M9_PH S]-_P"2H:Q_UY1?S%=C7F]AXNT>+X@:I?/J$*VDMI&B2Y."PQD5T_\
MPL#P[_T%K?\ ,_X4 =#17/?\+ \._P#06M_S/^%'_"P/#O\ T%K?\S_A0!T-
M%<]_PL#P[_T%K?\ ,_X4?\+ \._]!:W_ #/^% '0T5SW_"P/#O\ T%K?\S_A
M1_PL#P[_ -!:W_,_X4 =#17/?\+ \._]!:W_ #/^%'_"P/#O_06M_P S_A0!
MT-%<]_PL#P[_ -!:W_,_X4?\+ \._P#06M_S/^% '0T5SW_"P/#O_06M_P S
M_A1_PL#P[_T%K?\ ,_X4 =#17/?\+ \._P#06M_S/^%'_"P/#O\ T%K?\S_A
M0!T-%<]_PL#P[_T%K?\ ,_X4?\+ \._]!:W_ #/^% '0T5SW_"P/#O\ T%K?
M\S_A1_PL#P[_ -!:W_,_X4 =#17/?\+ \._]!:W_ #/^%'_"P/#O_06M_P S
M_A0!T-%<]_PL#P[_ -!:W_,_X4?\+ \._P#06M_S/^% '0T5SW_"P/#O_06M
M_P S_A1_PL#P[_T%K?\ ,_X4 =#17/?\+ \._P#06M_S/^%'_"P/#O\ T%K?
M\S_A0!T-%<]_PL#P[_T%K?\ ,_X4?\+ \._]!:W_ #/^% '0T5SW_"P/#O\
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M0!N45A_\)OH7_03A_,_X4?\ ";Z%_P!!.'\S_A0!N45A_P#";Z%_T$X?S/\
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M@_,_X4?\)YX?_P"@K!^9_P * -^HKC_5CZUB_P#">>'_ /H*P?F?\*CF\=:
MR@#5(#SZG_"@#6HK#_X3?0O^@G#^9_PH_P"$WT+_ *"</YG_  H W**P_P#A
M-]"_Z"</YG_"C_A-]"_Z"</YG_"@#<HK#_X3?0O^@G#^9_PH_P"$WT+_ *"<
M/YG_  H W**P_P#A-]"_Z"</YG_"C_A-]"_Z"</YG_"@#<HK#_X3?0O^@G#^
M9_PH_P"$WT+_ *"</YG_  H W**P_P#A-]"_Z"</YG_"C_A-]"_Z"</YG_"@
M#<HK#_X3?0O^@G#^9_PH_P"$WT+_ *"</YG_  H W**P_P#A-]"_Z"</YG_"
MC_A-]"_Z"</YG_"@#<HK#_X3?0O^@G#^9_PH_P"$WT+_ *"</YG_  H W**P
M_P#A-]"_Z"</YG_"C_A-]"_Z"</YG_"@#<HK#_X3?0O^@G#^9_PH_P"$WT+_
M *"</YG_  H W**P_P#A-]"_Z"</YG_"C_A-]"_Z"</YG_"@#<HK#_X3?0O^
M@G#^9_PH_P"$WT+_ *"</YG_  H W**P_P#A-]"_Z"</YG_"C_A-]"_Z"</Y
MG_"@#<HK#_X3?0O^@G#^9_PH_P"$WT+_ *"</YG_  H W**P_P#A-]"_Z"</
MYG_"C_A-]"_Z"</YG_"@#<HK#_X3?0O^@G#^9_PH_P"$WT+_ *"</YG_  H
MW*Y[0_\ DINH_P#8/7_T):E_X3?0O^@G#^9_PK$TGQ7I$'CZ^O9+^);5[)8U
ME.<%MP.* /3Z*Y[_ (6!X=_Z"UO^9_PH_P"%@>'?^@M;_F?\* .AHKGO^%@>
M'?\ H+6_YG_"C_A8'AW_ *"UO^9_PH Z&BN>_P"%@>'?^@M;_F?\*/\ A8'A
MW_H+6_YG_"@#H:*Y[_A8'AW_ *"UO^9_PH_X6!X=_P"@M;_F?\* .AHKGO\
MA8'AW_H+6_YG_"C_ (6!X=_Z"UO^9_PH Z&BN>_X6!X=_P"@M;_F?\*/^%@>
M'?\ H+6_YG_"@#H:*Y[_ (6!X=_Z"UO^9_PH_P"%@>'?^@M;_F?\* .AHKGO
M^%@>'?\ H+6_YG_"C_A8'AW_ *"UO^9_PH Z&BN>_P"%@>'?^@M;_F?\*/\
MA8'AW_H+6_YG_"@#H:*Y[_A8'AW_ *"UO^9_PH_X6!X=_P"@M;_F?\* .AHK
MGO\ A8'AW_H+6_YG_"C_ (6!X=_Z"UO^9_PH Z&BN>_X6!X=_P"@M;_F?\*/
M^%@>'?\ H+6_YG_"@#H:*Y[_ (6!X=_Z"UO^9_PH_P"%@>'?^@M;_F?\* .A
MHKGO^%@>'?\ H+6_YG_"C_A8'AW_ *"UO^9_PH Z&BN>_P"%@>'?^@M;_F?\
M*/\ A8'AW_H+6_YG_"@#H:*Y[_A8'AW_ *"UO^9_PH_X6!X=_P"@M;_F?\*
M.AHKGO\ A8'AW_H+6_YG_"C_ (6!X=_Z"UO^9_PH Z&N.^%'_(HI_P!=Y?\
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MC5#-7]>_Y#FH_P#7S)_Z$:H4 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44
M&:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T
M44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &
M:,T44 &:,T44 &:,T44 &:]@^#NEV=]X;NGN;2"X<7;*&EB5B!L3C)%>/U[3
M\$_^18N_^OQO_0$H [+_ (1_2_\ H&V?_?A/\*/^$?TO_H&V?_?A/\*T** ,
M_P#X1_2_^@;9_P#?A/\ "C_A']+_ .@;9_\ ?A/\*T** ,__ (1_2_\ H&V?
M_?A/\*/^$?TO_H&V?_?A/\*T** ,_P#X1_2_^@;9_P#?A/\ "C_A']+_ .@;
M9_\ ?A/\*T** ,__ (1_2_\ H&V?_?A/\*/^$?TO_H&V?_?A/\*T** ,_P#X
M1_2_^@;9_P#?A/\ "C_A']+_ .@;9_\ ?A/\*T** ,__ (1_2_\ H&V?_?A/
M\*/^$?TO_H&V?_?A/\*T** ,_P#X1_2_^@;9_P#?A/\ "C_A']+_ .@;9_\
M?A/\*T** ,__ (1_2_\ H&V?_?A/\*/^$?TO_H&V?_?A/\*T** ,_P#X1_2_
M^@;9_P#?A/\ "C_A']+_ .@;9_\ ?A/\*T** ,__ (1_2_\ H&V?_?A/\*/^
M$?TO_H&V?_?A/\*T** ,_P#X1_2_^@;9_P#?A/\ "C_A']+_ .@;9_\ ?A/\
M*T** ,__ (1_2_\ H&V?_?A/\*/^$?TO_H&V?_?A/\*T** ,_P#X1_2_^@;9
M_P#?A/\ "C_A']+_ .@;9_\ ?A/\*T** ,__ (1_2_\ H&V?_?A/\*/^$?TO
M_H&V?_?A/\*T** ,_P#X1_2_^@;9_P#?A/\ "C_A']+_ .@;9_\ ?A/\*T**
M ,__ (1_2_\ H&V?_?A/\*/^$?TO_H&V?_?A/\*T** ,_P#X1_2_^@;9_P#?
MA/\ "C_A']+_ .@;9_\ ?A/\*T** ,__ (1_2_\ H&V?_?A/\*/^$?TO_H&V
M?_?A/\*T** ,_P#X1_2_^@;9_P#?A/\ "C_A']+_ .@;9_\ ?A/\*T** ,__
M (1_2_\ H&V?_?A/\*/^$?TO_H&V?_?A/\*T** ,_P#X1_2_^@;9_P#?A/\
M"C_A']+_ .@;9_\ ?A/\*T** ,__ (1_2_\ H&V?_?A/\*/^$?TO_H&V?_?A
M/\*T** ,_P#X1_2_^@;9_P#?A/\ "C_A']+_ .@;9_\ ?A/\*T** ,__ (1_
M2_\ H&V?_?A/\*/^$?TO_H&V?_?A/\*T** ,_P#X1_2_^@;9_P#?A/\ "C_A
M']+_ .@;9_\ ?A/\*T** ,__ (1_2_\ H&V?_?A/\*/^$?TO_H&V?_?A/\*T
M** .#T[2+%OB1JT#65N8%LXV6,Q+M!R.0,5UG_"/Z7_T#;/_ +\)_A7/:;_R
M5#6/^O*+^8KL: ,__A']+_Z!MG_WX3_"C_A']+_Z!MG_ -^$_P *T** ,_\
MX1_2_P#H&V?_ 'X3_"C_ (1_2_\ H&V?_?A/\*ODX!)Z5\MW?_!3W]F:QNIK
M>7XF*)87:-]NAZDXW X.&%L01[@XI75[=1V=K]#Z5_X1_2_^@;9_]^$_PH_X
M1_2_^@;9_P#?A/\ "O+/A1^V%\&/C=J$6G^#/B'I&JZG,2(M/F9[2ZE(&3LA
MG5'; _NJ>AKV.J::W)33V,__ (1_2_\ H&V?_?A/\*/^$?TO_H&V?_?A/\*T
M**0S/_X1_2_^@;9_]^$_PH_X1_2_^@;9_P#?A/\ "H?%GBK2_ _A?5O$6MW2
MV.CZ5:RWMY<N"1'%&I9VP.3@ \"OCOX8_P#!1;Q3\8/$.FW7A7]GGQAJ7PXO
MM3CTU?%T<^XIND"-*UNL)78A/S$2D* <GC%$?>GR+?\ ST"7NQYWL?97_"/Z
M7_T#;/\ [\)_A1_PC^E_] VS_P"_"?X5QMG^T#\/-0^+UW\+K;Q39R^/;6'[
M1-HJA_,5=@?[VW86",&VAMP!SBO0J.B?1AU:[&?_ ,(_I?\ T#;/_OPG^%'_
M  C^E_\ 0-L_^_"?X5H44 9__"/Z7_T#;/\ [\)_A1_PC^E_] VS_P"_"?X5
MH44 9_\ PC^E_P#0-L_^_"?X4?\ "/Z7_P! VS_[\)_A6A10!G_\(_I?_0-L
M_P#OPG^%'_"/Z7_T#;/_ +\)_A7A4_[6R0_MFV_P"_X19F:;23J?_"0?;^ ?
M*:3R_L_E>BXW>9WZ5]"T+6*DMG?\&T_Q3%U<>J_5)_DT9_\ PC^E_P#0-L_^
M_"?X4?\ "/Z7_P! VS_[\)_A6A10,S_^$?TO_H&V?_?A/\*/^$?TO_H&V?\
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MAZ=_T#[7_ORO^%']AZ=_T#[7_ORO^%7J* */]AZ=_P! ^U_[\K_A1_8>G?\
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MJ_10!0_L'3/^@=:?]^%_PJ.XT'30@QIUJ.?^>"_X5IU%<?ZL?6@#)_L/3O\
MH'VO_?E?\*/[#T[_ *!]K_WY7_"KU% %'^P]._Z!]K_WY7_"C^P]._Z!]K_W
MY7_"KU% %'^P]._Z!]K_ -^5_P */[#T[_H'VO\ WY7_  J]10!1_L/3O^@?
M:_\ ?E?\*/[#T[_H'VO_ 'Y7_"KU% %'^P]._P"@?:_]^5_PH_L/3O\ H'VO
M_?E?\*O44 4?[#T[_H'VO_?E?\*/[#T[_H'VO_?E?\*O44 4?[#T[_H'VO\
MWY7_  H_L/3O^@?:_P#?E?\ "KU% %'^P]._Z!]K_P!^5_PH_L/3O^@?:_\
M?E?\*O44 4?[#T[_ *!]K_WY7_"C^P]._P"@?:_]^5_PJ]10!1_L/3O^@?:_
M]^5_PH_L/3O^@?:_]^5_PJ]10!1_L/3O^@?:_P#?E?\ "C^P]._Z!]K_ -^5
M_P *O44 4?[#T[_H'VO_ 'Y7_"C^P]._Z!]K_P!^5_PJ]10!1_L/3O\ H'VO
M_?E?\*/[#T[_ *!]K_WY7_"KU% %'^P]._Z!]K_WY7_"C^P]._Z!]K_WY7_"
MKU% %'^P]._Z!]K_ -^5_P */[#T[_H'VO\ WY7_  J]10!1_L/3O^@?:_\
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M@;9_]^$_PK0HH S_ /A']+_Z!MG_ -^$_P */^$?TO\ Z!MG_P!^$_PK0HH
MS_\ A']+_P"@;9_]^$_PH_X1_2_^@;9_]^$_PK0HH S_ /A']+_Z!MG_ -^$
M_P */^$?TO\ Z!MG_P!^$_PK0HH S_\ A']+_P"@;9_]^$_PH_X1_2_^@;9_
M]^$_PK0HH S_ /A']+_Z!MG_ -^$_P */^$?TO\ Z!MG_P!^$_PK0HH S_\
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M ._"?X4?\(_I?_0-L_\ OPG^%:%% &?_ ,(_I?\ T#;/_OPG^%'_  C^E_\
M0-L_^_"?X5H44 9__"/Z7_T#;/\ [\)_A1_PC^E_] VS_P"_"?X5H44 9_\
MPC^E_P#0-L_^_"?X4?\ "/Z7_P! VS_[\)_A6A10!G_\(_I?_0-L_P#OPG^%
M'_"/Z7_T#;/_ +\)_A6A10!G_P#"/Z7_ - VS_[\)_A1_P (_I?_ $#;/_OP
MG^%:%% &?_PC^E_] VS_ ._"?X4?\(_I?_0-L_\ OPG^%:%% &?_ ,(_I?\
MT#;/_OPG^%'_  C^E_\ 0-L_^_"?X5H44 9__"/Z7_T#;/\ [\)_A1_PC^E_
M] VS_P"_"?X5H44 9_\ PC^E_P#0-L_^_"?X4?\ "/Z7_P! VS_[\)_A6A10
M!G_\(_I?_0-L_P#OPG^%'_"/Z7_T#;/_ +\)_A6A10!G_P#"/Z7_ - VS_[\
M)_A1_P (_I?_ $#;/_OPG^%:%% &?_PC^E_] VS_ ._"?X4?\(_I?_0-L_\
MOPG^%:%% &?_ ,(_I?\ T#;/_OPG^%'_  C^E_\ 0-L_^_"?X5H44 9__"/Z
M7_T#;/\ [\)_A1_PC^E_] VS_P"_"?X5H44 9_\ PC^E_P#0-L_^_"?X4?\
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MI_\ OE?\:/\ A,++_GE/_P!\K_C7'44 =C_PF%E_SRG_ .^5_P :/^$PLO\
MGE/_ -\K_C7'44 =C_PF%E_SRG_[Y7_&C_A,++_GE/\ ]\K_ (UQU% '8_\
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M99)(W.5; !W$;5CZ*>IKJ]2TS0OBWX5MCY\MSI4LOFQR0[HB60LAX89Z[NU
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M:\LXT.V--WR$,,H<J\9X8]?KCJ* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!LG^K;Z54JW)_JV^E5* "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH EM_]
M8?I5BJ]O_K#]*L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !45Q_JQ]:EJ*X_U8^M
M%>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *Y[0_P#DINH_]@]?_0EKH:Y[0_\
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M)/6M(+VBE;[*3\K7MH_5DRO&SMN[>>S>WR9R/_!,J1V^)'[4:%F*CQW,0I/
M)FN<G]!^5?>5?!?_  3)_P"2E?M2?]CU+_Z.NJ^]*7V*?^"'_I"(C\4_\4__
M $MA1112- HHHH @OO\ CQN/^N;?R-<Y\+O^1%TS_MI_Z->NCOO^/&X_ZYM_
M(USGPN_Y$73/^VG_ *->@#PW7O\ D.:C_P!?,G_H1JA5_7O^0YJ/_7S)_P"A
M&J% !1110!>T/1KCQ!JD%A:E!/,2%,APHP"23^ KLO\ A2FN?\_6G_\ ?R3_
M .(K*^%W_(\Z;_VT_P#1;5Z%\5O%&I^&X]-.FW/V8S&0/^[5LXVX^\#ZFG+1
M+S!:MHX'6/A7KVCV[3^5%>1J,M]E<L0/H0"?P%8_A/1XM>\166GSN\<4S$,T
M>-PPI/&1[5[)\-?%EWXJTJX:]53/;R!#(@P'!&<X]>M<;'8Q:=\:4B@4+&9O
M,VKT!:(L?U)HVDDQ;Q;1F?$CP/9>#UL&LYKB47!<,)V4XV[<8P!ZUQ->L?'+
M_4Z/_O2_R2LKP7\*1XATV'4;V\:"WESLBA4%R <9)/ Z>AJ8W=RY65CSRBO9
MKCX):2T+""^O8Y<<-(491^ 4?SK@[?P#<MXR&@7$ZP,06%P$W!E"D@@9'7'K
MZT^MB>ES#_L'4_L?VO\ LZ[^R[=_G^0VS;Z[L8Q[U1KZ470=OA8:-Y__ "Z_
M9?.V?[.W=MS^F:\LU#X2FQUK2[ :H)!?>9^\\C&S8N>F[G/UHZV0=#3^'_PS
MT_4=%CU+5D:?SP6CAWE%5<\$D$')QZ]*QOB/H/A[2[:SGT.6)B[LDB0W'FC@
M#GJ<?_7KUF#03;^%AHZW'(M?LPN-G^SC=MS^F:\4\9>!9/"=[96T=R;][H'8
M%BV'.0,8R<]:4M79#CHKLY:BO5]#^"D;VJR:M>2),PSY-K@;/8L0<_E^=3:M
M\$K0VS'3;Z=9P,A;K:RM[94#'UYIO02U/(J*OPZ/.VN1:7.#;SM.L#;AG82V
M,^]=^WP3FCU*UC_M'SK1@S32B'84 Q@ ;CDG)^F*?F'D>8T5W_C3X=V>@ZAH
MUM97,Y^WS&%FN-K;>5 (P!_>JY<?!.ZCOK6*+45FMY-QFF:';Y8&,8&XY)S[
M=*0SS2BO8KSX):<;-A:7UTMUCY6F*LA/N H/ZUD>%_@[-?1O-K,LEHN2JPPX
MWG!QDD@@#\*!'FE%>C>-_A4F@Z8^H:;<2SPP\RQ38+!?[P( _+%><TKC"BBB
MF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *]I^"?_(L7?_7XW_H"5XM7M/P3_P"18N_^OQO_ $!* /0J*** "BBO
MCO\ X*J?%KQ-\)OV5[F7PM=7&FWFMZI!I$^H6KE);>!TD=]K#E2WEA,CLYY!
MQ652?LX\UNWXNQI3A[25O7\%<^B-7^/GPQ\/^(#H.J?$;PGINN!Q&=,O-<M8
MKG<>B^4T@;/MBNZCD66-71@Z,,JRG((]17P]\$O^"9?[.>N?!/PM=WOAYO%E
M]JFE07<OB$:M=1M.\D8<O&L<JHJ@MP-O0#=DYS]%_LS_ +/]I^S/\-F\$:;K
M^H^(-'AOY[JP?5"#+:PR$$09'!"D,<@*"6/RCOU2A[.4H2>J^YZVMW\SGC/G
MC&<%H_O6E[GK%%>;_&+]H[X:? &SAN/'_C'3?#9G7?#;3,TES,H."R01AI&
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MYG%_R\WX\O\ \C^)^>'@2)Q_P6;^(+;&V_\ "+1G..,?9;(9_.F_\%&8W?\
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M& ZMUSVJOX-\=&1I-+UO3SX=:V,=M9OJ$OEF_P 94F,.JYQA>!N^^/;(!?\
M#?B31?BQX;NI%LI9-.\_R)(+Y%&YE"/G 8C'*]^HKEM4NI_A#KESJUW*Q\'3
M 6EEI5@<M#*P#EMC;5 RDO(8GYAQR<:7CKPW=:;XFM?'%C'-J4^F6PMUT:WB
M.ZXW,ZE@XR1@2EONG[GOQT/A+Q=#XHL8A<Q1Z;J^UGGTB64-<0*&P"RD!@""
MIR5'WAZT +K&AV'C31[>[:TBDN?LYEL9;A?F@=U!5N,X.0O3/2N5\$^(-0\)
MZU;>$?$]Y-JNNW[-=074+>9"D.PX5F;:P.8G. I'S#GKBC:Z7??"#7+JXM[2
MX\16VO7'F7$L4;1)IZHQ.YR X(Q*3D[?N'\.Q\2:?8?$OPC?Z?IVK6[13LL9
MO+4K.J,K*^/E8<X XSWH S_'W@>_U1?MWAB6WTC7Y95%Q?LS1M)"$(*%E4D\
MB/C'\-3^!/&%KXMM[_2'2>6\TE$M+Z2=1LFD(96*D$D@E&Z@=1Q6-X-U4_#V
M7_A$]5C^S:5I\;-%XAO&\B"ZD=A)Y:AAMW#S&'#D_NR<=<7?B+X%'CA=(U2U
MOQ&NFA[F-(8O-%UNV, "&&,[.#S]Z@#-\1:/<?#O5X=>TUX[#PA91![W2[,D
M/-*Q9=X3&T_>CZL/N^U=3IL^B_%+PO9WTVG_ &G3YG:2.&]0;E969,D D9X;
MOT-5_!OCT>(X?*U:Q'AW57E*1:9>38GE0*#YBJRJQ!.X<#'R'GTY_P 3:3?^
M!?%U_P"--.LKCQ%+J"I9'2K6)E:%=BYDWJ&R,P@8VC[_ %XY *T7B"Y^$FL7
M$'B">:^T[5)]FD6]D=XM(D8C8P?;M&V2,#;G[I]!GL/&G@]=>M)KK3X[>W\1
M)$([34),JT.&SPP!(ZMV[U;TG6K3Q=H[+'-"EX8%%U:K())+21U.4<<$,"&&
M" <J:X/PM'<_!V\A\/36\NI:3=2&\GUYU,$%KN&S8V0R\>6#DN/OCCU -OX?
M^*)K?4&\&ZO--?>(]/A:>YO.&AD5F#*%8D,2%E0<J.A_&OXX\"ZM]KBOO"-U
M;Z&\CR3:DRNT;7)R"I.U3DC]YUQ]ZM+QUX3M?BIX9MH+'5H88/M G6\MU$ZO
MM#H5!# =2>_:JG@[Q>FC0R:%K<*Z'%I2QV-I>ZA+Y*ZB$RADC#@<?*IP"V/,
M'/3(!J^%O%.D?%+P[=S16DS6!E:VEAO44;B%5CP&(Q\P[UR>JR7/PEURXUBX
MF(\&,%MK72;$Y:*1E!+;&VJ 660\-_%TK0\?>"[C_A)+3QE:/)=3:5 H3288
M26N2K.<!@3@G?_=/2NB\)>,(/$UE"MU%'I>L,K/-H\TP-Q" Q +(0& (VMRH
MX84 /FTG1?'VD:9J%YIT=W%) MQ;BZ0%HQ(JMZG!^[G'I7'>%?%5]X%U2T\*
M^*KN?5M;U&836]U;GS(DC;Y%5F;:P(9'/"GJ*@NK74_A+KNJZAI^E7?BI?$%
MR]P\=K$R"RVLS $J'W9\T\X7[GY=QJT-AX^\,:C9Z?J=M-%<(UN;JU99UC8@
M'^$]0"#C(ZT 97CKP/<ZK%+?>'&M]+\12.N_4&+([1@8*EE!/0+V[5+\/O&$
M>O)=Z-)]HDU31%CM;ZXE V2S#<C,ASD@LC') /(XK"\'ZO)\.YT\)ZE;-%I%
MBC%?$=TQ@MYF<^9L 8;0<N5^^?N'Z"_\1OAQ%\4+?29K;5TLH8%>1)8H1,LR
MR!"""''&%Z\YS0!F^)/"^H^#=6@UC0KB'2_"EA&MS?Z;;,RM.RL2Y"8VDE H
MY8=*ZW2[S1_B=X5MKR2Q,^FW3,RP7B#.4=ER0"1U4]ZI>$?B%'KT'EZS:+X:
MU.2;RX=-OIPLTRX&'5656()+*, \J>:Y_P 4>&;WPCXPO/'-A#/KDTH2$:/;
M0L& ,:H6WC=TVY^[WH J2^(;KX.:E>R>(+B:^T:^E9-*M+$[_LL2,<*0^T+A
M60<$_=KN/%G@^T\003W45K;C74MV2ROI1AH)!DQL& )&&.>!5OP[XDL_$EE$
MZ20+?+$CW5BLJO+:N1S&XZJ0<CD Y!XKSOPZM_\ !NX@\/C3[C6],NIEN[C6
M]C0PVBMA&#\,N%6/>26'#=NM &QX'\9/I^JP>"=9EN+[Q);J[SWJX:!P<R+A
MB0QPC*.5ZC\:=XW^'VIW$BW/@ZXM="OYY7DO9][1M/GD9*J<\DG\:U_&'A^U
M^)GA)[2RU2%(+AU=+VW G4[6Y PP!Y!'7M61X1\9#0U?0M<M?[#M=*C6SMM2
MU"7R4O\ R_DWH' '(4-@,V-PY[T ;?A'Q?I?Q,T&\FMK6<61=K2:&\107R@+
M# 8\$-C\ZY#5[/4OACKTVO&Z$?@>VPJ:/9L=ZEU"Y"$!?]82WWN^?:M#X@_#
MV75/$-GXLM[IVET>%9DTV* LUTT3M*$#!N"WW?NG\>E=#X5\:VWB*SMH[Q8M
M)UJ7<9-&GG!N(L$XRA ;E0&^Z."/K0!8?3]'\>Z+IMY>Z?'=VLT27,,=T@)0
M.H(R,G!P?6N&\-^*[_X>:E9^'/%MY/J^K:I<(;:XMF\R-$=A& Q?:1\P)X!X
M-17FBZE\*?$&J:_IUA=>*FUF>0M9VL+(;8%R^2RA\CG'0=*[^\DT_P ;>'=3
MM-/U*UN([B"2U-S;.LPB9D(S\IZC(.,B@"R=!TZWU6;58[.)-2G41RW2K\[J
M ."?3Y5_(58KA_ *W_A>Z;P;+IUS-8:;"TL>N.C)%<,[!]@7! (\QA]\_</X
M=Q0 4444 %%%% !1110 4444 %%%% !1110 4444 -D_U;?2JE6Y/]6WTJI0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% $MO\ ZP_2K%5[?_6'Z58H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "HKC_5CZU+45Q_JQ]: *]%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5SVA_\ )3=1_P"P>O\ Z$M=#7/:'_R4W4?^P>O_ *$M '<T444
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M W' R<9.!75[3][5J?SJW_DUS!1M2IT_Y7?_ ,E:_4^*M+_Y3#ZQ_P!B(O\
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MK&.6XD$/F*<%0022/?C'XUP/B76HM:^*-D\#!X8+F&!6'0[7&3^9-==\:O\
MD5[;_KZ7_P!!:E_R[7K_ )%_;^1Y5X:F>3Q%I"L[,JW<>U2<@9<9Q7L/Q7UB
M[T?PP#:2F!YYA$SKPP4@DX/;I7C?A?\ Y&32O^ON+_T,5ZQ\:O\ D5[;_KZ7
M_P!!:JE\"]?\B8_$9GP0OII%U2U>1FA39(BDY"D[LX^N!^58/Q8UV]N/%$MD
M9V6VM=ACC0D#<5!W'U//6M;X&_\ 'UJ_^Y'_ #:N:^*/_(\:C_VS_P#0%I2W
M01VD>KI<2:A\-&FN&\V233&9V;JQ\L\FOGVO?M/_ .26I_V"V_\ 19KP&A_&
MP7\-?UV"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5[3\$_^18N_^OQO_0$KQ:O:?@G_ ,BQ=_\ 7XW_ * E
M 'H5%%% !7%_&+X1>&OCK\.=8\$^+;,WFB:G&$D$;;9(F!#)+&V#M=6 8'GD
M<@C(KM*\+_:K_:LTW]DW1O#6O:]X9U;7/#NI7S65]?:2 S:?\FY'*MA6W-\N
M"Z]\9/%9U.7EM/9V7WNR_$N'->\=U^A\8W7[//[4W[ <5UJ/P>\3)\4/AI;.
MUQ)X8O83)+%'EF;_ $;.>_+6SAF/)3%?7G[(?[97A[]K#X8:CXCL["30]:T5
MO*UC1Y)!*8&VEE=&P-T;!6P2 <JPQQD\#KO_  5C_9RTOPS/J5EXJO\ 6=02
M+?'H]MHUW'<2-CA-\D:Q Y[E\5Y[_P $J?@WXCL]%^*/Q,\3:-+X=LOB#>K)
MIVES(4;[,&FD,@! .PF?:A(&0A.,$$Z+VDHU([VCHWT=TDK];_A:YF^1.,MK
MO5+JNK\K?CL<-_P3V^%F@?MC^.OB;\=_BMIEKXRU&3638:9INK1BXM+1 @?'
ME-E6"H\2*&!"[2>IS7>_\%+/V2/A_I?[/>I_$7P7X7TOP7XN\)36][#>^'[6
M.P,T9F1&5Q$%#%=P=6/S I@'D@^3_LE_&C3?^"<?Q2^(GP;^,4=[H/A^]U'^
MT]%\0"SDF@F3&P2$1JS,DB+'RH.UE96QSCK/VV/VV/"W[3GP]3X)? DWWQ \
M4>+KF&">6RLIX(K:!)%D89E1222BY;&Q4WEF&,5%1<U.FL+VC;NGI>_SO>YM
M3]VM-XC:[OV:\O*UK'MWB'XE7WQ>_P""7.N>+]3D\[5-3\ 737DN,>9.D#QR
M/CW=&/XUJ?\ !+G_ ),<^'7UU#_TON*F^*?PO7X+?\$X?%?@<3+<2:'X#N;2
M:9!A9)1;,9''L7+$?6H?^"7/_)CGPZ^NH?\ I?<5VR<74Q#CM>/YU#CBI*A0
M4M[O_P!)1X[_ ,$DO^0Q^T-_V-2_^A7%<M\-_ FE_MD?\%)?BUJ?Q LX]?\
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MO_#+6?B3^R3?OHEI-?7'A_4[?6IK>!=SM B21R,!W"K*7/LAKLS+^)-_WO\
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MH **** "BBB@ HHHH **** "BBB@ HHHH X[3?\ DJ&L?]>47\Q78UQVF_\
M)4-8_P"O*+^8KL: "BBB@ HHKRZX_:I^"MI<2P3_ !?\!0SQ,4DCD\362LC
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ J*X_U8^M2U%<?ZL?6@"O1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %<]H?\ R4W4?^P>O_H2UT-<]H?_ "4W4?\
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M.C AE(."",&JWACPKHO@G0[;1?#NCV&@Z/:AA!I^EVJ6UO%EBQVQH JY8DG
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M-^$_[07P]\>ZO\0/"$/B+4;'Q"UK;SR7ES"8XO*1MN(I%!^9B<D9YK]:)?\
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MA3PO_P!?P_D*BNO"/VFZFF^U[?,<OM\O.,G..M ')T5T_P#PA?\ T^?^0O\
M[*C_ (0O_I\_\A?_ &5 ',45T_\ PA?_ $^?^0O_ +*C_A"_^GS_ ,A?_94
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MK4K/Y;!E8CY6ZX[9'6N=\'ZPWP_F/A75T,&EV$;-%XBO7\B&ZD=A)Y:[AMW
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M** "BBB@!LG^K;Z54JW)_JV^E5* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH E
MM_\ 6'Z58JO;_P"L/TJQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %17'^K'UJ6HKC
M_5CZT 5Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO%$S?V7>6,.L33W>U6DF*3(?)WA@W!'WMH!" U^IM?*?CC_@FS\*O%/C:_\
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M9-]_SY7'_?IO\*^H** /E_\ LF^_Y\KC_OTW^%']DWW_ #Y7'_?IO\*^H**
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M-_A1_9-]_P ^5Q_WZ;_"OJ"B@#Y?_LF^_P"?*X_[]-_A1_9-]_SY7'_?IO\
M"OJ"B@#Y?_LF^_Y\KC_OTW^%']DWW_/E<?\ ?IO\*^H** /E_P#LF^_Y\KC_
M +]-_A1_9-]_SY7'_?IO\*^H** /E_\ LF^_Y\KC_OTW^%']DWW_ #Y7'_?I
MO\*^H** /E_^R;[_ )\KC_OTW^%']DWW_/E<?]^F_P *^H** /E_^R;[_GRN
M/^_3?X4?V3??\^5Q_P!^F_PKZ@HH ^7_ .R;[_GRN/\ OTW^%']DWW_/E<?]
M^F_PKZ@HH ^7_P"R;[_GRN/^_3?X4?V3??\ /E<?]^F_PKZ@HH ^7_[)OO\
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M_P#7H_X6AI__ $#]4_\  7_Z]=C10!QW_"T-/_Z!^J?^ O\ ]>C_ (6AI_\
MT#]4_P# 7_Z]=C10!QW_  M#3_\ H'ZI_P" O_UZ/^%H:?\ ] _5/_ 7_P"O
M78T4 <=_PM#3_P#H'ZI_X"__ %Z/^%H:?_T#]4_\!?\ Z]=C10!QW_"T-/\
M^@?JG_@+_P#7H_X6AI__ $#]4_\  7_Z]=C10!QW_"T-/_Z!^J?^ O\ ]>C_
M (6AI_\ T#]4_P# 7_Z]=C10!QW_  M#3_\ H'ZI_P" O_UZ/^%H:?\ ] _5
M/_ 7_P"O78T4 <=_PM#3_P#H'ZI_X"__ %Z/^%H:?_T#]4_\!?\ Z]=C10!Q
MW_"T-/\ ^@?JG_@+_P#7H_X6AI__ $#]4_\  7_Z]=C10!QW_"T-/_Z!^J?^
M O\ ]>C_ (6AI_\ T#]4_P# 7_Z]=C10!QW_  M#3_\ H'ZI_P" O_UZ/^%H
M:?\ ] _5/_ 7_P"O78T4 <=_PM#3_P#H'ZI_X"__ %Z/^%H:?_T#]4_\!?\
MZ]=C10!QW_"T-/\ ^@?JG_@+_P#7H_X6AI__ $#]4_\  7_Z]=C10!QW_"T-
M/_Z!^J?^ O\ ]>C_ (6AI_\ T#]4_P# 7_Z]=C10!QW_  M#3_\ H'ZI_P"
MO_UZ/^%H:?\ ] _5/_ 7_P"O78T4 <=_PM#3_P#H'ZI_X"__ %Z/^%H:?_T#
M]4_\!?\ Z]=C10!QW_"T-/\ ^@?JG_@+_P#7H_X6AI__ $#]4_\  7_Z]=C1
M0!QW_"T-/_Z!^J?^ O\ ]>C_ (6AI_\ T#]4_P# 7_Z]=C10!QW_  M#3_\
MH'ZI_P" O_UZ/^%H:?\ ] _5/_ 7_P"O78T4 <=_PM#3_P#H'ZI_X"__ %Z/
M^%H:?_T#]4_\!?\ Z]=C10!QW_"T-/\ ^@?JG_@+_P#7H_X6AI__ $#]4_\
M 7_Z]=C10!QW_"T-/_Z!^J?^ O\ ]>C_ (6AI_\ T#]4_P# 7_Z]=C10!QW_
M  M#3_\ H'ZI_P" O_UZ/^%H:?\ ] _5/_ 7_P"O78T4 <=_PM#3_P#H'ZI_
MX"__ %Z/^%H:?_T#]4_\!?\ Z]=C10!QW_"T-/\ ^@?JG_@+_P#7H_X6AI__
M $#]4_\  7_Z]=C10!QW_"T-/_Z!^J?^ O\ ]>C_ (6AI_\ T#]4_P# 7_Z]
M=C10!Y;9^-+:#QMJ&IM8Z@;>:V2)5%O\X(QU&>G%=#_PM#3_ /H'ZI_X"_\
MUZ[&B@#CO^%H:?\ ] _5/_ 7_P"O1_PM#3_^@?JG_@+_ /7KL:* .._X6AI_
M_0/U3_P%_P#KT?\ "T-/_P"@?JG_ ("__7KL:* .._X6AI__ $#]4_\  7_Z
M]'_"T-/_ .@?JG_@+_\ 7KL:* .._P"%H:?_ - _5/\ P%_^O1_PM#3_ /H'
MZI_X"_\ UZ[&B@#CO^%H:?\ ] _5/_ 7_P"O1_PM#3_^@?JG_@+_ /7KL:*
M.._X6AI__0/U3_P%_P#KT?\ "T-/_P"@?JG_ ("__7KL:* .._X6AI__ $#]
M4_\  7_Z]'_"T-/_ .@?JG_@+_\ 7KL:* .._P"%H:?_ - _5/\ P%_^O1_P
MM#3_ /H'ZI_X"_\ UZ[&B@#CO^%H:?\ ] _5/_ 7_P"O1_PM#3_^@?JG_@+_
M /7KL:* .._X6AI__0/U3_P%_P#KT?\ "T-/_P"@?JG_ ("__7KL:* .._X6
MAI__ $#]4_\  7_Z]'_"T-/_ .@?JG_@+_\ 7KL:* .._P"%H:?_ - _5/\
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M_A85G_T#]3_\!O\ Z]>@T4 >??\ "PK/_H'ZG_X#?_7H_P"%A6?_ $#]3_\
M ;_Z]>@T4 >??\+"L_\ H'ZG_P" W_UZ/^%A6?\ T#]3_P# ;_Z]>@T4 >??
M\+"L_P#H'ZG_ . W_P!>C_A85G_T#]3_ / ;_P"O7H-% 'GW_"PK/_H'ZG_X
M#?\ UZ/^%A6?_0/U/_P&_P#KUZ#10!Y]_P +"L_^@?J?_@-_]>C_ (6%9_\
M0/U/_P !O_KUZ#10!Y]_PL*S_P"@?J?_ (#?_7H_X6%9_P#0/U/_ ,!O_KUZ
M#10!Y]_PL*S_ .@?J?\ X#?_ %Z/^%A6?_0/U/\ \!O_ *]>@T4 >??\+"L_
M^@?J?_@-_P#7H_X6%9_] _4__ ;_ .O7H-% 'GW_  L*S_Z!^I_^ W_UZ/\
MA85G_P! _4__  &_^O7H-% 'GW_"PK/_ *!^I_\ @-_]>C_A85G_ - _4_\
MP&_^O7H-% 'GW_"PK/\ Z!^I_P#@-_\ 7H_X6%9_] _4_P#P&_\ KUZ#10!Y
M]_PL*S_Z!^I_^ W_ ->C_A85G_T#]3_\!O\ Z]>@T4 >??\ "PK/_H'ZG_X#
M?_7H_P"%A6?_ $#]3_\  ;_Z]>@T4 >??\+"L_\ H'ZG_P" W_UZ/^%A6?\
MT#]3_P# ;_Z]>@T4 >??\+"L_P#H'ZG_ . W_P!>C_A85G_T#]3_ / ;_P"O
M7H-% 'GW_"PK/_H'ZG_X#?\ UZ/^%A6?_0/U/_P&_P#KUZ#10!PR_$BQ50/[
M/U3I_P ^O_UZ7_A9-A_T#]4_\!?_ *]=Q10!P_\ PLFP_P"@?JG_ ("__7H_
MX638?] _5/\ P%_^O7<44 </_P +)L/^@?JG_@+_ /7H_P"%DV'_ $#]4_\
M 7_Z]=Q10!P__"R;#_H'ZI_X"_\ UZ/^%DV'_0/U3_P%_P#KUW%% '#_ /"R
M;#_H'ZI_X"__ %Z/^%DV'_0/U3_P%_\ KUW%% '#_P#"R;#_ *!^J?\ @+_]
M>C_A9-A_T#]4_P# 7_Z]=Q10!P__  LFP_Z!^J?^ O\ ]>C_ (638?\ 0/U3
M_P !?_KUW%% '#_\+)L/^@?JG_@+_P#7H_X638?] _5/_ 7_ .O7<44 </\
M\+)L/^@?JG_@+_\ 7H_X638?] _5/_ 7_P"O7<44 </_ ,+)L/\ H'ZI_P"
MO_UZ/^%DV'_0/U3_ ,!?_KUW%% '#_\ "R;#_H'ZI_X"_P#UZ/\ A9-A_P!
M_5/_  %_^O7<44 </_PLFP_Z!^J?^ O_ ->C_A9-A_T#]4_\!?\ Z]=Q10!P
M_P#PLFP_Z!^J?^ O_P!>C_A9-A_T#]4_\!?_ *]=Q10!P_\ PLFP_P"@?JG_
M ("__7H_X638?] _5/\ P%_^O7<44 </_P +)L/^@?JG_@+_ /7H_P"%DV'_
M $#]4_\  7_Z]=Q10!P__"R;#_H'ZI_X"_\ UZ/^%DV'_0/U3_P%_P#KUW%%
M '#_ /"R;#_H'ZI_X"__ %Z/^%DV'_0/U3_P%_\ KUW%% '#-\2+%E(_L_5.
MG_/K_P#7JO\ \+"L_P#H'ZG_ . W_P!>O0:* //O^%A6?_0/U/\ \!O_ *]'
M_"PK/_H'ZG_X#?\ UZ]!HH \^_X6%9_] _4__ ;_ .O1_P +"L_^@?J?_@-_
M]>O0:* //O\ A85G_P! _4__  &_^O1_PL*S_P"@?J?_ (#?_7KT&B@#S[_A
M85G_ - _4_\ P&_^O1_PL*S_ .@?J?\ X#?_ %Z]!HH \^_X6%9_] _4_P#P
M&_\ KT?\+"L_^@?J?_@-_P#7KT&B@#S[_A85G_T#]3_\!O\ Z]'_  L*S_Z!
M^I_^ W_UZ]!HH \^_P"%A6?_ $#]3_\  ;_Z]'_"PK/_ *!^I_\ @-_]>O0:
M* //O^%A6?\ T#]3_P# ;_Z]'_"PK/\ Z!^I_P#@-_\ 7KT&B@#S[_A85G_T
M#]3_ / ;_P"O1_PL*S_Z!^I_^ W_ ->O0:* //O^%A6?_0/U/_P&_P#KT?\
M"PK/_H'ZG_X#?_7KT&B@#S[_ (6%9_\ 0/U/_P !O_KT?\+"L_\ H'ZG_P"
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MC_A9-A_T#]4_\!?_ *]=Q10!P_\ PLFP_P"@?JG_ ("__7H_X638?] _5/\
MP%_^O7<44 </_P +)L/^@?JG_@+_ /7H_P"%DV'_ $#]4_\  7_Z]=Q10!P_
M_"R;#_H'ZI_X"_\ UZ/^%DV'_0/U3_P%_P#KUW%% '#_ /"R;#_H'ZI_X"__
M %Z/^%DV'_0/U3_P%_\ KUW%% '#_P#"R;#_ *!^J?\ @+_]>C_A9-A_T#]4
M_P# 7_Z]=Q10!P__  LFP_Z!^J?^ O\ ]>C_ (638?\ 0/U3_P !?_KUW%%
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M6%9_] _4_P#P&_\ KUZ#10!Y]_PL*S_Z!^I_^ W_ ->C_A85G_T#]3_\!O\
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MZG_X#?\ UZR=-\86]KXTN]2>QU#R);18E5;?Y\A@<D9Z<5ZO10!QW_"T-/\
M^@?JG_@+_P#7H_X6AI__ $#]4_\  7_Z]=C10!QW_"T-/_Z!^J?^ O\ ]>C_
M (6AI_\ T#]4_P# 7_Z]=C10!QW_  M#3_\ H'ZI_P" O_UZ/^%H:?\ ] _5
M/_ 7_P"O78T4 <=_PM#3_P#H'ZI_X"__ %Z/^%H:?_T#]4_\!?\ Z]=C10!Q
MW_"T-/\ ^@?JG_@+_P#7H_X6AI__ $#]4_\  7_Z]=C10!QW_"T-/_Z!^J?^
M O\ ]>C_ (6AI_\ T#]4_P# 7_Z]=C10!QW_  M#3_\ H'ZI_P" O_UZ/^%H
M:?\ ] _5/_ 7_P"O78T4 <=_PM#3_P#H'ZI_X"__ %Z/^%H:?_T#]4_\!?\
MZ]=C10!QW_"T-/\ ^@?JG_@+_P#7H_X6AI__ $#]4_\  7_Z]=C10!QW_"T-
M/_Z!^J?^ O\ ]>C_ (6AI_\ T#]4_P# 7_Z]=C10!QW_  M#3_\ H'ZI_P"
MO_UZ/^%H:?\ ] _5/_ 7_P"O78T4 <=_PM#3_P#H'ZI_X"__ %Z/^%H:?_T#
M]4_\!?\ Z]=C10!QW_"T-/\ ^@?JG_@+_P#7H_X6AI__ $#]4_\  7_Z]=C1
M0!QW_"T-/_Z!^J?^ O\ ]>C_ (6AI_\ T#]4_P# 7_Z]=C10!QW_  M#3_\
MH'ZI_P" O_UZ/^%H:?\ ] _5/_ 7_P"O78T4 <=_PM#3_P#H'ZI_X"__ %Z/
M^%H:?_T#]4_\!?\ Z]=C10!QW_"T-/\ ^@?JG_@+_P#7H_X6AI__ $#]4_\
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M@#CO^%H:?_T#]4_\!?\ Z]'_  M#3_\ H'ZI_P" O_UZ[&B@#CO^%H:?_P!
M_5/_  %_^O1_PM#3_P#H'ZI_X"__ %Z[&B@#CO\ A:&G_P#0/U3_ ,!?_KT?
M\+0T_P#Z!^J?^ O_ ->NQHH X[_A:&G_ /0/U3_P%_\ KT?\+0T__H'ZI_X"
M_P#UZ[&B@#CO^%H:?_T#]4_\!?\ Z]'_  M#3_\ H'ZI_P" O_UZ[&B@#CO^
M%H:?_P! _5/_  %_^O1_PM#3_P#H'ZI_X"__ %Z[&B@#CO\ A:&G_P#0/U3_
M ,!?_KT?\+0T_P#Z!^J?^ O_ ->NQHH X[_A:&G_ /0/U3_P%_\ KT?\+0T_
M_H'ZI_X"_P#UZ[&B@#CO^%H:?_T#]4_\!?\ Z]'_  M#3_\ H'ZI_P" O_UZ
M[&B@#CO^%H:?_P! _5/_  %_^O1_PM#3_P#H'ZI_X"__ %Z[&B@#CO\ A:&G
M_P#0/U3_ ,!?_KT?\+0T_P#Z!^J?^ O_ ->NQHH X[_A:&G_ /0/U3_P%_\
MKT?\+0T__H'ZI_X"_P#UZ[&B@#CO^%H:?_T#]4_\!?\ Z]'_  M#3_\ H'ZI
M_P" O_UZ[&B@#CO^%H:?_P! _5/_  %_^O1_PM#3_P#H'ZI_X"__ %Z[&B@#
MCO\ A:&G_P#0/U3_ ,!?_KT?\+0T_P#Z!^J?^ O_ ->NQHH XFZ^)EA-;2QK
MI^J;F0J,VOJ/K5WX8JR>!M,5E*L/,X(P?]:]=310 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
3 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>idya-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-02-18T15:50:26.7835+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.ideayabio.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:idya="http://www.ideayabio.com/20241231" xmlns:srt="http://fasb.org/srt/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" namespace="http://xbrl.sec.gov/stpr/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" namespace="http://xbrl.sec.gov/cyd/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets" id="Role_StatementBalanceSheets">
        <link:definition>100010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" id="Role_StatementBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails3" id="DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails3">
        <link:definition>100030 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments under Operating Leases (Details) 3</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100040 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity" id="StatementStatementsOfStockholdersEquity">
        <link:definition>100050 - Statement - Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows" id="Role_StatementStatementsOfCashFlows">
        <link:definition>100060 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>100070 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganization" id="Role_DisclosureOrganization">
        <link:definition>995457 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995467 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecurities" id="Role_DisclosureFairValueMeasurementAndMarketableSecurities">
        <link:definition>995477 - Disclosure - Fair Value Measurement and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponents" id="Role_DisclosureBalanceSheetComponents">
        <link:definition>995487 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeases" id="Role_DisclosureOperatingLeases">
        <link:definition>995497 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>995507 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995517 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>995527 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>995537 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreements" id="Role_DisclosureSignificantAgreements">
        <link:definition>995547 - Disclosure - Significant Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognition" id="Role_DisclosureRevenueRecognition">
        <link:definition>995557 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholders">
        <link:definition>995567 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformation" id="DisclosureSegmentInformation">
        <link:definition>995577 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>995587 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995597 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesTables" id="Role_DisclosureFairValueMeasurementAndMarketableSecuritiesTables">
        <link:definition>995607 - Disclosure - Fair Value Measurement and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" id="Role_DisclosureBalanceSheetComponentsTables">
        <link:definition>995617 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesTables" id="Role_DisclosureOperatingLeasesTables">
        <link:definition>995627 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995637 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockTables" id="Role_DisclosureCommonStockTables">
        <link:definition>995647 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>995657 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognitionTables" id="Role_DisclosureRevenueRecognitionTables">
        <link:definition>995667 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
        <link:definition>995677 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>995687 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" id="Role_DisclosureOrganizationAdditionalInformationDetails">
        <link:definition>995697 - Disclosure - Organization - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995707 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails" id="Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails">
        <link:definition>995717 - Disclosure - Fair Value Measurement and Marketable Securities - Schedule of Financial Assets Measured and Recognized at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueParentheticalDetails" id="DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueParentheticalDetails">
        <link:definition>995727 - Disclosure - Fair Value Measurement and Marketable Securities - Schedule of Financial Assets Measured and Recognized at Fair Value (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementAndMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>995737 - Disclosure - Fair Value Measurement and Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" id="Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails">
        <link:definition>995747 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" id="Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails">
        <link:definition>995757 - Disclosure - Balance Sheet Components - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" id="Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails">
        <link:definition>995767 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails" id="Role_DisclosureOperatingLeasesAdditionalInformationDetails">
        <link:definition>995777 - Disclosure - Operating Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfOperatingLeaseInBalanceSheetAndOtherLeaseInformationDetails" id="DisclosureOperatingLeasesScheduleOfOperatingLeaseInBalanceSheetAndOtherLeaseInformationDetails">
        <link:definition>995787 - Disclosure - Operating Leases - Schedule of Operating Lease in Balance Sheet and Other Lease Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails" id="DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails">
        <link:definition>995797 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments under Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfOperatingLeaseDisclosuresDetails" id="DisclosureOperatingLeasesScheduleOfOperatingLeaseDisclosuresDetails">
        <link:definition>995807 - Disclosure - Operating Leases - Schedule Of Operating Lease Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>995817 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails">
        <link:definition>995827 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails" id="Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails">
        <link:definition>995837 - Disclosure - Income Taxes - Schedule of Tax Effects of Temporary Differences and Carryforwards of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanySUnrecognizedTaxBenefitsDetails" id="Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanySUnrecognizedTaxBenefitsDetails">
        <link:definition>995847 - Disclosure - Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" id="Role_DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>995857 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCommonStockScheduleOfAggregateWarrantsDetails" id="DisclosureCommonStockScheduleOfAggregateWarrantsDetails">
        <link:definition>995867 - Disclosure - Common Stock - Schedule of Aggregate Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCommonStockScheduleOfAggregateWarrantsParentheticalDetails" id="DisclosureCommonStockScheduleOfAggregateWarrantsParentheticalDetails">
        <link:definition>995877 - Disclosure - Common Stock - Schedule of Aggregate Warrants (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails" id="Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails">
        <link:definition>995887 - Disclosure - Common Stock - Schedule of Number of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>995897 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>995907 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails" id="Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails">
        <link:definition>995917 - Disclosure - Stock-Based Compensation - Summary of Activity under Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToCalculateFairValuesOfOptionsDetails" id="Role_DisclosureStockBasedCompensationAssumptionsUsedToCalculateFairValuesOfOptionsDetails">
        <link:definition>995927 - Disclosure - Stock-Based Compensation - Assumptions Used to Calculate Fair Values of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails" id="Role_DisclosureSignificantAgreementsAdditionalInformationDetails">
        <link:definition>995937 - Disclosure - Significant Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByResearchProgramDetails" id="Role_DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByResearchProgramDetails">
        <link:definition>995947 - Disclosure - Revenue Recognition - Summary of Revenue Disaggregated by Research Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" id="DisclosureRevenueRecognitionAdditionalInformationDetails">
        <link:definition>995957 - Disclosure - Revenue Recognition - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>995967 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
        <link:definition>995977 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Shares of Potentially Dilutive Securities Excluded From the Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" id="DisclosureSegmentInformationAdditionalInformationDetails">
        <link:definition>995987 - Disclosure - Segment Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesDetails" id="DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesDetails">
        <link:definition>995997 - Disclosure - Segment Information - Summary Of Disaggregated Research And Development Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails" id="DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails">
        <link:definition>996007 - Disclosure - Segment Information - Summary Of Disaggregated Research And Development Expenses (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" id="Role_DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>996017 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="idya-20241231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets" xlink:href="idya-20241231.xsd#Role_StatementBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:href="idya-20241231.xsd#Role_StatementBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:href="idya-20241231.xsd#Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity" xlink:href="idya-20241231.xsd#StatementStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:href="idya-20241231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="idya-20241231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganization" xlink:href="idya-20241231.xsd#Role_DisclosureOrganization" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="idya-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecurities" xlink:href="idya-20241231.xsd#Role_DisclosureFairValueMeasurementAndMarketableSecurities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponents" xlink:href="idya-20241231.xsd#Role_DisclosureBalanceSheetComponents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeases" xlink:href="idya-20241231.xsd#Role_DisclosureOperatingLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="idya-20241231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="idya-20241231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStock" xlink:href="idya-20241231.xsd#Role_DisclosureCommonStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="idya-20241231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreements" xlink:href="idya-20241231.xsd#Role_DisclosureSignificantAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognition" xlink:href="idya-20241231.xsd#Role_DisclosureRevenueRecognition" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:href="idya-20241231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformation" xlink:href="idya-20241231.xsd#DisclosureSegmentInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="idya-20241231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="idya-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesTables" xlink:href="idya-20241231.xsd#Role_DisclosureFairValueMeasurementAndMarketableSecuritiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" xlink:href="idya-20241231.xsd#Role_DisclosureBalanceSheetComponentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesTables" xlink:href="idya-20241231.xsd#Role_DisclosureOperatingLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="idya-20241231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:href="idya-20241231.xsd#Role_DisclosureCommonStockTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="idya-20241231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognitionTables" xlink:href="idya-20241231.xsd#Role_DisclosureRevenueRecognitionTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:href="idya-20241231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationTables" xlink:href="idya-20241231.xsd#DisclosureSegmentInformationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" xlink:href="idya-20241231.xsd#Role_DisclosureOrganizationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="idya-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails" xlink:href="idya-20241231.xsd#Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueParentheticalDetails" xlink:href="idya-20241231.xsd#DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesAdditionalInformationDetails" xlink:href="idya-20241231.xsd#Role_DisclosureFairValueMeasurementAndMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:href="idya-20241231.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:href="idya-20241231.xsd#Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" xlink:href="idya-20241231.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails" xlink:href="idya-20241231.xsd#Role_DisclosureOperatingLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfOperatingLeaseInBalanceSheetAndOtherLeaseInformationDetails" xlink:href="idya-20241231.xsd#DisclosureOperatingLeasesScheduleOfOperatingLeaseInBalanceSheetAndOtherLeaseInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails" xlink:href="idya-20241231.xsd#DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfOperatingLeaseDisclosuresDetails" xlink:href="idya-20241231.xsd#DisclosureOperatingLeasesScheduleOfOperatingLeaseDisclosuresDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="idya-20241231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:href="idya-20241231.xsd#Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails" xlink:href="idya-20241231.xsd#Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanySUnrecognizedTaxBenefitsDetails" xlink:href="idya-20241231.xsd#Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanySUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:href="idya-20241231.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCommonStockScheduleOfAggregateWarrantsDetails" xlink:href="idya-20241231.xsd#DisclosureCommonStockScheduleOfAggregateWarrantsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCommonStockScheduleOfAggregateWarrantsParentheticalDetails" xlink:href="idya-20241231.xsd#DisclosureCommonStockScheduleOfAggregateWarrantsParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails" xlink:href="idya-20241231.xsd#Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="idya-20241231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="idya-20241231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails" xlink:href="idya-20241231.xsd#Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToCalculateFairValuesOfOptionsDetails" xlink:href="idya-20241231.xsd#Role_DisclosureStockBasedCompensationAssumptionsUsedToCalculateFairValuesOfOptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails" xlink:href="idya-20241231.xsd#Role_DisclosureSignificantAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByResearchProgramDetails" xlink:href="idya-20241231.xsd#Role_DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByResearchProgramDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" xlink:href="idya-20241231.xsd#DisclosureRevenueRecognitionAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="idya-20241231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="idya-20241231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" xlink:href="idya-20241231.xsd#DisclosureSegmentInformationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesDetails" xlink:href="idya-20241231.xsd#DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails" xlink:href="idya-20241231.xsd#DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="idya-20241231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails3" xlink:href="idya-20241231.xsd#DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails3" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd#eedm1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SecondAmendmentMember" xlink:label="idya_SecondAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember" xlink:label="idya_TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:label="idya_AccruedResearchAndDevelopmentExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SignificantAgreementsAbstract" xlink:label="idya_SignificantAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_BiocytogenPharmaceuticalsBeijingCoLtdMember" xlink:label="idya_BiocytogenPharmaceuticalsBeijingCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ExerciseOfOutstandingOptionsMember" xlink:label="idya_ExerciseOfOutstandingOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MilestonePaymentReceivedClinicalEvaluation" xlink:label="idya_MilestonePaymentReceivedClinicalEvaluation"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_GlaxoSmithKlineMember" xlink:label="idya_GlaxoSmithKlineMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PayForExternalThirdPartyCostPercentage" xlink:label="idya_PayForExternalThirdPartyCostPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandTwentyThreeOctoberPublicOfferingMember" xlink:label="idya_TwoThousandTwentyThreeOctoberPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="idya_IncreaseDecreaseInOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_IncomeTaxDisclosureLineItems" xlink:label="idya_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_GlaxoSmithKlineCollaborationAgreementMember" xlink:label="idya_GlaxoSmithKlineCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ResearchAndExperimentalExpendituresAmortizePeriod" xlink:label="idya_ResearchAndExperimentalExpendituresAmortizePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CommonStockRemainingAvailableToBeSaleAmount" xlink:label="idya_CommonStockRemainingAvailableToBeSaleAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandNineteenEmployeeStockPurchasedPlanMember" xlink:label="idya_TwoThousandNineteenEmployeeStockPurchasedPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:label="us-gaap_IncomeTaxExaminationYearUnderExamination"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_UpfrontPayment" xlink:label="idya_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CloudComputingArrangementsPolicyTextBlock" xlink:label="idya_CloudComputingArrangementsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent" xlink:label="idya_ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MilestonePaymentsRelatingToFirstAndSecondTumorHistologies" xlink:label="idya_MilestonePaymentsRelatingToFirstAndSecondTumorHistologies"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents" xlink:label="idya_PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_UnpaidOfferingCosts" xlink:label="idya_UnpaidOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SanDiegoCaliforniaMember" xlink:label="idya_SanDiegoCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies" xlink:label="idya_DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AtTheMarketOfferingMember" xlink:label="idya_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_OperatingLeasesAdditionalAreaLeased" xlink:label="idya_OperatingLeasesAdditionalAreaLeased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_WernerHelicaseProgramMember" xlink:label="idya_WernerHelicaseProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="idya_SeriesBRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_RisksAndUncertaintiesPolicyTextBlock" xlink:label="idya_RisksAndUncertaintiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TaxCreditCarryForwardExpirationYear" xlink:label="idya_TaxCreditCarryForwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_JiangsuHengruiPharmaceuticalsCoLtdMember" xlink:label="idya_JiangsuHengruiPharmaceuticalsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AggregatePotentialMilestonePayments" xlink:label="idya_AggregatePotentialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_FairValueMeasurementsAndMarketableSecuritiesTextBlock" xlink:label="idya_FairValueMeasurementsAndMarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_NovartisInternationalPharmaceuticalsLimitedMember" xlink:label="idya_NovartisInternationalPharmaceuticalsLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_LaboratoryAndOfficeFacilitiesMember" xlink:label="idya_LaboratoryAndOfficeFacilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_LaboratoryEquipmentMember" xlink:label="idya_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ExternalClinicalDevelopmentExpenses" xlink:label="idya_ExternalClinicalDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CashCashEquivalentsAndMarketableSecurities" xlink:label="idya_CashCashEquivalentsAndMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CommonStockSubjectToOutstandingPreFundedWarrantsExercised" xlink:label="idya_CommonStockSubjectToOutstandingPreFundedWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ClassOfWarrantOrRightsIssueDate" xlink:label="idya_ClassOfWarrantOrRightsIssueDate"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies" xlink:label="idya_MilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AdditionalPaymentOfDevelopmentMilestoneToAchieve" xlink:label="idya_AdditionalPaymentOfDevelopmentMilestoneToAchieve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_GlaxoGroupLimitedMember" xlink:label="idya_GlaxoGroupLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_VestingOfEarlyExercisedOptionsAndRestrictedStock" xlink:label="idya_VestingOfEarlyExercisedOptionsAndRestrictedStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts" xlink:label="idya_ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SouthSanFranciscoCaliforniaMember" xlink:label="idya_SouthSanFranciscoCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="idya_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ScheduleOfOperatingLeaseInTheBalanceSheetAndOtherLeaseInformationTableTextBlock" xlink:label="idya_ScheduleOfOperatingLeaseInTheBalanceSheetAndOtherLeaseInformationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="idya_TwoThousandNineteenIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone" xlink:label="idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive" xlink:label="idya_EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_OrphanDrugCreditsMember" xlink:label="idya_OrphanDrugCreditsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ContingentDevelopmentAndSalesBasedMilestonePayments" xlink:label="idya_ContingentDevelopmentAndSalesBasedMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_JuneTwoThousandTwentyThreeSalesAgreementMember" xlink:label="idya_JuneTwoThousandTwentyThreeSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandFifteenAndNineteenEquityIncentivePlansMember" xlink:label="idya_TwoThousandFifteenAndNineteenEquityIncentivePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_IncomeTaxDisclosureTable" xlink:label="idya_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MarketableSecuritiesNonCurrentMember" xlink:label="idya_MarketableSecuritiesNonCurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ESPPMaximumSharesPurchasablePerPeriodPerEmployee" xlink:label="idya_ESPPMaximumSharesPurchasablePerPeriodPerEmployee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PersonnelRelatedAndStock-BasedCompensation" xlink:label="idya_PersonnelRelatedAndStock-BasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_IDE397Member" xlink:label="idya_IDE397Member"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ClinicalCombinationStudyWindDownMonthAndYear" xlink:label="idya_ClinicalCombinationStudyWindDownMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_BiocytogenOptionAndLicenseAgreementMember" xlink:label="idya_BiocytogenOptionAndLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember" xlink:label="idya_TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PercentageOfProfitShare" xlink:label="idya_PercentageOfProfitShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies" xlink:label="idya_DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_JanuaryTwoThousandTwentyOneSalesAgreementMember" xlink:label="idya_JanuaryTwoThousandTwentyOneSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CertainCommercialSalesMilestonesPaymentToBePaid" xlink:label="idya_CertainCommercialSalesMilestonesPaymentToBePaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PropertyPlantAndEquipmentUsefulLifeDescription" xlink:label="idya_PropertyPlantAndEquipmentUsefulLifeDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="idya_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants" xlink:label="idya_AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CommercialMilestonePaymentToBeReceived" xlink:label="idya_CommercialMilestonePaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies" xlink:label="idya_MilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_OtherResearchAndDevelopmentExpenseMember" xlink:label="idya_OtherResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_OperatingLeaseCommencementMonthAndYear" xlink:label="idya_OperatingLeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PolymeraseThetaProgramMember" xlink:label="idya_PolymeraseThetaProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock" xlink:label="idya_SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DeferredTaxAssetsLeaseLiability" xlink:label="idya_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_UpfrontPaymentFee" xlink:label="idya_UpfrontPaymentFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DeterminationPeriodOfCostsIncurred" xlink:label="idya_DeterminationPeriodOfCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation" xlink:label="idya_AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance" xlink:label="idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_OperatingLeasesAreaLeased" xlink:label="idya_OperatingLeasesAreaLeased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized" xlink:label="idya_RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PaymentOfOptionExerciseFee" xlink:label="idya_PaymentOfOptionExerciseFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_NetProceedsFromIssuanceOfCommonStock" xlink:label="idya_NetProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandTwentyThreeInducementPlanMember" xlink:label="idya_TwoThousandTwentyThreeInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ESPPDiscountedPurchasePricePercentage" xlink:label="idya_ESPPDiscountedPurchasePricePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DevelopmentMilestonePaymentToBeReceived" xlink:label="idya_DevelopmentMilestonePaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_JanuaryTwoThousandTwentyOneSalesAgreementAndJuneTwoThousandTwentyThreeSalesAgreementMember" xlink:label="idya_JanuaryTwoThousandTwentyOneSalesAgreementAndJuneTwoThousandTwentyThreeSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_UnvestedEarlyExercisedCommonStockOptionsMember" xlink:label="idya_UnvestedEarlyExercisedCommonStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AmgenClinicalTrialCollaborationAndSupplyAgreementMember" xlink:label="idya_AmgenClinicalTrialCollaborationAndSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_EffectiveIncomeTaxRateReconciliationSection162MLimitation" xlink:label="idya_EffectiveIncomeTaxRateReconciliationSection162MLimitation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent" xlink:label="idya_AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ReimbursementPeriodOfCostsIncurred" xlink:label="idya_ReimbursementPeriodOfCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SouthSanFranciscoMember" xlink:label="idya_SouthSanFranciscoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandTwentyThreeAprilPublicOfferingMember" xlink:label="idya_TwoThousandTwentyThreeAprilPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MarketableSecuritiesRemainingMaturityPeriod" xlink:label="idya_MarketableSecuritiesRemainingMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_HengruiPharmaLicenseAgreementMember" xlink:label="idya_HengruiPharmaLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DevelopmentAndRegulatoryMilestonePaymentToBePaid" xlink:label="idya_DevelopmentAndRegulatoryMilestonePaymentToBePaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_LesseeOperatingLeaseExistenceOfOptionToRenew" xlink:label="idya_LesseeOperatingLeaseExistenceOfOptionToRenew"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_UnpaidAtTheMarketOfferingProgramCosts" xlink:label="idya_UnpaidAtTheMarketOfferingProgramCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SharesIssuedWeightedAverageSalesPricePerShare" xlink:label="idya_SharesIssuedWeightedAverageSalesPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MethionineAdenosylTransferase2AProgramMember" xlink:label="idya_MethionineAdenosylTransferase2AProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="us-gaap_InvestmentOwnedAtCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SalesOfCommonStockAggregateOfferingPrice" xlink:label="idya_SalesOfCommonStockAggregateOfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived" xlink:label="idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="idya_MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PaymentOfOneTimeOptionExerciseFee" xlink:label="idya_PaymentOfOneTimeOptionExerciseFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_EmployeeStockPurchasePlanMember" xlink:label="idya_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_FollowOnPublicOfferingMember" xlink:label="idya_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_OperatingLeaseCommencementDescription" xlink:label="idya_OperatingLeaseCommencementDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement" xlink:label="idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CancerResearchTechnologyAndTheUniversityOfManchesterMember" xlink:label="idya_CancerResearchTechnologyAndTheUniversityOfManchesterMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_NumberOfPerformanceObligations" xlink:label="idya_NumberOfPerformanceObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_IDE161Member" xlink:label="idya_IDE161Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="idya_AccruedResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TotalMilestonePaymentToBeReceived" xlink:label="idya_TotalMilestonePaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_FairValueMeasurementsAndMarketableSecuritiesPolicyTextBlock" xlink:label="idya_FairValueMeasurementsAndMarketableSecuritiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DarovasertibMember" xlink:label="idya_DarovasertibMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SummaryOfSignificantAccountingPoliciesTable" xlink:label="idya_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:label="idya_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MarketableSecuritiesCurrentMember" xlink:label="idya_MarketableSecuritiesCurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_JefferiesLLCMember" xlink:label="idya_JefferiesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" xlink:label="idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_UpfrontFeePayment" xlink:label="idya_UpfrontFeePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CollaborationRevenue" xlink:label="idya_CollaborationRevenue"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_JanuaryTwoThousandTwentyFourSalesAgreementMember" xlink:label="idya_JanuaryTwoThousandTwentyFourSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_NumberOfCommonStockVotingRightsHeldPerShare" xlink:label="idya_NumberOfCommonStockVotingRightsHeldPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_UpfrontAndOptionLicenseExerciseFees" xlink:label="idya_UpfrontAndOptionLicenseExerciseFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_LeaseExpirationMonthAndYear" xlink:label="idya_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DevelopmentCostsSharingPercentage" xlink:label="idya_DevelopmentCostsSharingPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TenPercentStockholderMember" xlink:label="idya_TenPercentStockholderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="idya_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_OperatingLeasesDisclosuresTableTextBlock" xlink:label="idya_OperatingLeasesDisclosuresTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PresidentAndCEOMember" xlink:label="idya_PresidentAndCEOMember"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second amendment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Deferred Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Aggregate Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fifteen and nineteen equity incentive plans and two thousand twenty three inducement plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen and Nineteen Equity Incentive Plans and Two Thousand Twenty Three Inducement Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 and 2019 Plans and 2023 Inducement Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SignificantAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Agreements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SignificantAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_BiocytogenPharmaceuticalsBeijingCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Biocytogen Pharmaceuticals (Beijing) Co., Ltd. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_BiocytogenPharmaceuticalsBeijingCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Biocytogen Pharmaceuticals (Beijing) Co., Ltd.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_BiocytogenPharmaceuticalsBeijingCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biocytogen Pharmaceuticals (Beijing) Co., Ltd.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cliff Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ExerciseOfOutstandingOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ExerciseOfOutstandingOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Outstanding Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ExerciseOfOutstandingOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of outstanding options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Options, Weighted-Average Exercise Price, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum eligible rate of compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Plan Modification, Description and Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incentive award plan description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MilestonePaymentReceivedClinicalEvaluation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment received clinical evaluation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MilestonePaymentReceivedClinicalEvaluation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Received Clinical Evaluation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MilestonePaymentReceivedClinicalEvaluation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment received clinical evaluation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_GlaxoSmithKlineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GSK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_GlaxoSmithKlineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Glaxo Smith Kline [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_GlaxoSmithKlineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Glaxo Smith Kline.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PayForExternalThirdPartyCostPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pay for external third-party cost percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PayForExternalThirdPartyCostPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pay for External Third-party Cost Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PayForExternalThirdPartyCostPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pay for external third-party cost percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandTwentyThreeOctoberPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 October Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandTwentyThreeOctoberPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Three October Public Offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandTwentyThreeOctoberPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three October Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Examination, Penalties and Interest Accrued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Penalties or interest accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents, amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded Warrants Issued and Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Outstanding Options, Shares, Options canceled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_GlaxoSmithKlineCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GSK Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_GlaxoSmithKlineCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Glaxo Smith Kline Collaboration Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_GlaxoSmithKlineCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Glaxo Smith Kline collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in assets and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ResearchAndExperimentalExpendituresAmortizePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and experimental expenditures amortize period (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ResearchAndExperimentalExpendituresAmortizePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Experimental Expenditures Amortize Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ResearchAndExperimentalExpendituresAmortizePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and experimental expenditures amortize period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CommonStockRemainingAvailableToBeSaleAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock remained available to be sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CommonStockRemainingAvailableToBeSaleAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Remaining Available To Be Sale Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CommonStockRemainingAvailableToBeSaleAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock, remaining available to be sale, amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan (ESPP) purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandNineteenEmployeeStockPurchasedPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandNineteenEmployeeStockPurchasedPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Employee Stock Purchased Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandNineteenEmployeeStockPurchasedPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen employee stock purchased plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationYearUnderExamination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Year under Examination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationYearUnderExamination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Upfront payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Options, Aggregate Intrinsic Value, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CloudComputingArrangementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cloud Computing Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CloudComputingArrangementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cloud Computing Arrangements Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CloudComputingArrangementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cloud computing arrangements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Income and Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increased valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, option to extend, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, gross unrealized gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares outstanding under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement by Sharebased Payment Award of Shares Outstanding Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by sharebased payment award of shares outstanding percent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MilestonePaymentsRelatingToFirstAndSecondTumorHistologies_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments relating to first and second tumor histologies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MilestonePaymentsRelatingToFirstAndSecondTumorHistologies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Relating To First And Second Tumor Histologies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MilestonePaymentsRelatingToFirstAndSecondTumorHistologies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments relating to first and second tumor histologies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for achievement of specific development and regulatory approval events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Achievement Of Specific Development And Regulatory Approval Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments for achievement of specific development and regulatory approval events.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Receivables, Net, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables, Net, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding Options, Shares, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding Options, Shares, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares reserved for common stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, initially reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_UnpaidOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unpaid offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_UnpaidOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unpaid Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_UnpaidOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unpaid offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incentive award plan description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leased Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leased Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term contract liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SanDiegoCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">San Diego, California.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SanDiegoCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">San Diego, California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SanDiegoCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">San Diego, California</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Employee Stock Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gains (losses) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance as of December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance as of December 31, 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestone Payments Of Phase Two Relating To First And Second Tumor Histologies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestone payments of phase two relating to first and second tumor histologies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments of phase two relating to first and second tumor histologies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">At-the-market Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At The Market Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Shares subject to Outstanding Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_OperatingLeasesAdditionalAreaLeased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Additional Area Leased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_OperatingLeasesAdditionalAreaLeased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases additional area leased.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_OperatingLeasesAdditionalAreaLeased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional area of space leased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_WernerHelicaseProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WRN Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_WernerHelicaseProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Werner Helicase Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_WernerHelicaseProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Werner Helicase program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued salaries and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B redeemable convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income and other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Outstanding Shares of Potentially Dilutive Securities Excluded From the Computation of Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Uncertainties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks And Uncertainties Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Risks and uncertainties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carry forward expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carry Forward Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carry forward expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating lease liabilities, net of current position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-term lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal Income Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_JiangsuHengruiPharmaceuticalsCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jiangsu Hengrui Pharmaceuticals Co., Ltd [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_JiangsuHengruiPharmaceuticalsCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jiangsu Hengrui Pharmaceuticals Co., Ltd.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_JiangsuHengruiPharmaceuticalsCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jiangsu Hengrui Pharmaceuticals Co., Ltd</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AggregatePotentialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Potential Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AggregatePotentialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate potential milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AggregatePotentialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total potential milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_FairValueMeasurementsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement and Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_FairValueMeasurementsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements And Marketable Securities [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_FairValueMeasurementsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurements and marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Outstanding Options, Shares, Options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issues under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Options, Shares, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Financial Statement Error Correction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Issued, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid included in measurement of operating lease liabilities included in cash flow from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of common stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of pre-funded warrants for the purchase of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan (ESPP) purchase, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Receivable, after Allowance for Credit Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Receivable, after Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Options, Weighted-Average Exercise Price, Options canceled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_NovartisInternationalPharmaceuticalsLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Novartis International Pharmaceuticals Limited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_NovartisInternationalPharmaceuticalsLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Novartis International Pharmaceuticals Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_NovartisInternationalPharmaceuticalsLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Novartis international pharmaceuticals limited.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_LaboratoryAndOfficeFacilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory and Office Facilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_LaboratoryAndOfficeFacilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory And Office Facilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_LaboratoryAndOfficeFacilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory and office facilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ExternalClinicalDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">External clinical development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ExternalClinicalDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">External Clinical Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ExternalClinicalDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">External clinical development expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CashCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CashCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CashCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash cash equivalents and marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CommonStockSubjectToOutstandingPreFundedWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock subject to outstanding pre-funded warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CommonStockSubjectToOutstandingPreFundedWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock subject to outstanding pre-funded warrants Exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CommonStockSubjectToOutstandingPreFundedWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock subject to outstanding pre-funded warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset, In-Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research &amp; development expenditures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ClassOfWarrantOrRightsIssueDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or rights issue date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ClassOfWarrantOrRightsIssueDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Rights Issue Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ClassOfWarrantOrRightsIssueDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issue Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments of phase three relating to first and second tumor histologies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments of phase three relating to first and second tumor histologies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Of Phase Three Relating To First And Second Tumor Histologies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AdditionalPaymentOfDevelopmentMilestoneToAchieve_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional payment of development milestone to achieve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AdditionalPaymentOfDevelopmentMilestoneToAchieve_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional payment of development milestone to achieve.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AdditionalPaymentOfDevelopmentMilestoneToAchieve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Payment Of Development Milestone To Achieve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_GlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Glaxo Group Limited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_GlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Glaxo Group Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_GlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Glaxo Group Limited.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_VestingOfEarlyExercisedOptionsAndRestrictedStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of early exercised options and restricted stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_VestingOfEarlyExercisedOptionsAndRestrictedStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Early Exercised Options And Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_VestingOfEarlyExercisedOptionsAndRestrictedStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting of early exercised options and restricted stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Related To At Market Offering Program Net Of Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SouthSanFranciscoCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">South San Francisco, California</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SouthSanFranciscoCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">South San Francisco California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SouthSanFranciscoCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">South San Francisco, California.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Revenue Disaggregated by Research Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Lease Payments under Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ScheduleOfOperatingLeaseInTheBalanceSheetAndOtherLeaseInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of operating lease in the balance sheet and other lease information.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ScheduleOfOperatingLeaseInTheBalanceSheetAndOtherLeaseInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Operating Lease In The Balance Sheet And Other Lease Information [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ScheduleOfOperatingLeaseInTheBalanceSheetAndOtherLeaseInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Operating Lease in Balance Sheet and Other Lease Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized stock-based compensation expense, weighted-average period of recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Income Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Incentive Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen incentive award plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2019 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Received For Achievement Of Initial Preclinical Development Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment received for achievement of initial preclinical development milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment received for achievement of earlier preclinical development milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Milestone payment received for achievement of initial preclinical development milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Options, Weighted Average Remaining Contractual Term (Years), Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Early Clinical Development Milestone Payment Potential to Receive</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Early clinical development milestone payment potential to receive.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Early clinical development milestone payment potential to receive</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_OrphanDrugCreditsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Orphan Drug Credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_OrphanDrugCreditsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Orphan Drug Credits [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_OrphanDrugCreditsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Orphan Drug Credits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ContingentDevelopmentAndSalesBasedMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent development and sales based milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ContingentDevelopmentAndSalesBasedMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Development And Sales Based Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ContingentDevelopmentAndSalesBasedMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent development and sales-based milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issues under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net of valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Taxes Paid, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_JuneTwoThousandTwentyThreeSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">June Two Thousand Twenty Three Sales Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_JuneTwoThousandTwentyThreeSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">June Two Thousand Twenty Three Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_JuneTwoThousandTwentyThreeSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">June 2023 Sales Agreement | Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_JuneTwoThousandTwentyThreeSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">June 2023 Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandFifteenAndNineteenEquityIncentivePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 and 2019 Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandFifteenAndNineteenEquityIncentivePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen And Nineteen Equity Incentive Plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandFifteenAndNineteenEquityIncentivePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Fifteen And Nineteen Equity Incentive Plans Member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MarketableSecuritiesNonCurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities Non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MarketableSecuritiesNonCurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Non Current [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MarketableSecuritiesNonCurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities non current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Options, Shares, Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ESPPMaximumSharesPurchasablePerPeriodPerEmployee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of shares purchasable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ESPPMaximumSharesPurchasablePerPeriodPerEmployee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">E S P P Maximum Shares Purchasable Per Period Per Employee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ESPPMaximumSharesPurchasablePerPeriodPerEmployee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum number of shares purchasable by an employee under the ESPP per an offering period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumptions Used to Calculate Fair Values of Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PersonnelRelatedAndStock-BasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Personnel Related And Stock-based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PersonnelRelatedAndStock-BasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Personnel related and stock-based compensation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PersonnelRelatedAndStock-BasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Personnel related and stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_IDE397Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IDE397 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_IDE397Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">IDE397.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_IDE397Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IDE397</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ClinicalCombinationStudyWindDownMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical combination study wind down month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ClinicalCombinationStudyWindDownMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical combination study wind down month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_BiocytogenOptionAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biocytogen Option and License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_BiocytogenOptionAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Biocytogen Option and License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_BiocytogenOptionAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Biocytogen option and license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fifteen, nineteen and twenty three equity incentive plans.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen, Nineteen and Twenty Three Equity Incentive Plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015, 2019 and 2023 Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, operating loss carryforwards subject to do not expire</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decrease related to prior year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease related to prior year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Provision for Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202307Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2023-07 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202307Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2023-07</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PercentageOfProfitShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of profit share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PercentageOfProfitShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Profit Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PercentageOfProfitShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of profit share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestone Payments Of Phase Three Relating To First And Second Tumor Histologies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestone payments of phase three relating to first and second tumor histologies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments of phase two relating to first and second tumor histologies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_JanuaryTwoThousandTwentyOneSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">January two thousand twenty one sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_JanuaryTwoThousandTwentyOneSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">January 2021 Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_JanuaryTwoThousandTwentyOneSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">January Two Thousand Twenty One Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CertainCommercialSalesMilestonesPaymentToBePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Certain Commercial Sales Milestones Payment to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CertainCommercialSalesMilestonesPaymentToBePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Certain commercial sales milestones payment to be paid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CertainCommercialSalesMilestonesPaymentToBePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certain commercial sales milestones, agreed to make a payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other permanent differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PropertyPlantAndEquipmentUsefulLifeDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Property plant and equipment useful life description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PropertyPlantAndEquipmentUsefulLifeDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PropertyPlantAndEquipmentUsefulLifeDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment net, useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially dilutive securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities right of use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Exercise of Pre-Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital, exercise of pre-funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CommercialMilestonePaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial milestone payment eligible to receive</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CommercialMilestonePaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestone Payment To Be Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CommercialMilestonePaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestone payment to be received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments of phase two relating to first and second tumor histologies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments of phase two relating to first and second tumor histologies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Of Phase Two Relating To First And Second Tumor Histologies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_OtherResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_OtherResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other research and development expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_OtherResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_OperatingLeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Commencement Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_OperatingLeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease commencement month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_OperatingLeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term commencement month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PolymeraseThetaProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pol Theta Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PolymeraseThetaProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Polymerase Theta Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PolymeraseThetaProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Polymerase Theta program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Disaggregated Research And Development Expenses [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of disaggregated research and development expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Disaggregated Research And Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Options, Aggregate Intrinsic Value, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Marketable securities, gross unrealized losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized stock-based compensation expense for stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_UpfrontPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_UpfrontPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_UpfrontPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DeterminationPeriodOfCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Determination period of costs incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DeterminationPeriodOfCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Determination Period Of Costs Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DeterminationPeriodOfCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The period to determine an amount of reimbursable costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional milestone payment potentially received clinical evaluation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Milestone Payment Potentially Received Clinical Evaluation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional milestone payment potentially received clinical evaluation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in number of shares available for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement by Share Based Payment Award Increase in Number of Shares Available for Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement by Share Based Payment Award Increase in Number of Shares Available for Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_OperatingLeasesAreaLeased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to the area leased.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_OperatingLeasesAreaLeased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Area Leased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_OperatingLeasesAreaLeased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of space leased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Common Stock, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, dividends declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized income tax positions measured at percentage of likelihood of realization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recognized Income Tax Positions Measured At Percentage Of Likelihood To Be Realized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recognized income tax positions measured at percentage of likelihood to be realization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PaymentOfOptionExerciseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Option Exercise Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PaymentOfOptionExerciseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of option exercise fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PaymentOfOptionExerciseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of option exercise fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant-date fair value of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease right of use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial Liabilities Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities recognized at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Impairment [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_NetProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock net of underwriting discounts and commissions and other offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_NetProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds from issuance of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_NetProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds From Issuance Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Forecast</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, net of issuance costs, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period of options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandTwentyThreeInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty three inducement plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandTwentyThreeInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Inducement Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandTwentyThreeInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Inducement Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ESPPDiscountedPurchasePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of the fair value of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ESPPDiscountedPurchasePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">E S P P Discounted Purchase Price Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ESPPDiscountedPurchasePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The discounted percentage of the fair market value of the Company's common stock for stock purchase in employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DevelopmentMilestonePaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestone payment eligible to receive</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DevelopmentMilestonePaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestone Payment To Be Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DevelopmentMilestonePaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestone payment to be received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Options, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_JanuaryTwoThousandTwentyOneSalesAgreementAndJuneTwoThousandTwentyThreeSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">January two thousand twenty one sales agreement and june two thousand twenty three sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_JanuaryTwoThousandTwentyOneSalesAgreementAndJuneTwoThousandTwentyThreeSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">January Two Thousand Twenty One Sales Agreement and June Two Thousand Twenty Three Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_JanuaryTwoThousandTwentyOneSalesAgreementAndJuneTwoThousandTwentyThreeSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">January 2021 Sales Agreement and June 2023 Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived Intangible Assets, Major Class Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_UnvestedEarlyExercisedCommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested early exercised common stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_UnvestedEarlyExercisedCommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Early Exercised Common Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_UnvestedEarlyExercisedCommonStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Early Exercised Common Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-13</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-13 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of common shares outstanding used in computing net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted-average shares used in computing net loss per share attributable to common stock, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average shares used in computing net loss per share attributable to common stock, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AmgenClinicalTrialCollaborationAndSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amgen clinical trial collaboration and supply agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AmgenClinicalTrialCollaborationAndSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amgen Clinical Trial Collaboration and Supply Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AmgenClinicalTrialCollaborationAndSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amgen Clinical Trial Collaboration and Supply Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase related to prior year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Increase related to prior year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_EffectiveIncomeTaxRateReconciliationSection162MLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Section 162(m) Limitation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_EffectiveIncomeTaxRateReconciliationSection162MLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation section 162(m) limitation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_EffectiveIncomeTaxRateReconciliationSection162MLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Section 162(m) limitation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated useful lives of the assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment net, useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional payments for achievement of specific development and regulatory approval events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Payments For Achievement Of Specific Development And Regulatory Approval Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional payments for achievement of specific development and regulatory approval events.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock upon public offering, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock in public offering, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ReimbursementPeriodOfCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursement period of costs incurred for quarter ended</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ReimbursementPeriodOfCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursement Period Of Costs Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ReimbursementPeriodOfCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursement period of costs incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Options, Weighted-Average Exercise Price, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Options, Weighted-Average Exercise Price, Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SouthSanFranciscoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">South San Francisco</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SouthSanFranciscoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">South San Francisco [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SouthSanFranciscoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">South San Francisco.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandTwentyThreeAprilPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Three April Public Offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandTwentyThreeAprilPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three April Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TwoThousandTwentyThreeAprilPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 April Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Options, Weighted Average Remaining Contractual Term (Years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MarketableSecuritiesRemainingMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities remaining maturity period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MarketableSecuritiesRemainingMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Remaining Maturity Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MarketableSecuritiesRemainingMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities remaining maturity period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuances of pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities, estimated fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity under Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Operating Leased Assets [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Operating Leased Assets [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-current marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase related to current year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental non-cash investing and financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_HengruiPharmaLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hengrui Pharma License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_HengruiPharmaLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hengrui Pharma License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_HengruiPharmaLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hengrui pharma license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DevelopmentAndRegulatoryMilestonePaymentToBePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development and Regulatory Milestone Payment to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DevelopmentAndRegulatoryMilestonePaymentToBePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and regulatory milestone payment to be paid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DevelopmentAndRegulatoryMilestonePaymentToBePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certain clinical and regulatory development milestones, agreed to make a payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_LesseeOperatingLeaseExistenceOfOptionToRenew_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease existence of option to renew.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_LesseeOperatingLeaseExistenceOfOptionToRenew_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease Existence Of Option To Renew</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_LesseeOperatingLeaseExistenceOfOptionToRenew_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease existence of option to renew</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_UnpaidAtTheMarketOfferingProgramCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unpaid At The Market Offering Program Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_UnpaidAtTheMarketOfferingProgramCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unpaid At-the-market offering program costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_UnpaidAtTheMarketOfferingProgramCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unpaid at-the-market offering program costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Forfeiture [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal and professional fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SharesIssuedWeightedAverageSalesPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Weighted Average Sales Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SharesIssuedWeightedAverageSalesPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued weighted average sales price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SharesIssuedWeightedAverageSalesPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average sales price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Options, Weighted Average Remaining Contractual Term (Years), Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MethionineAdenosylTransferase2AProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MAT2A Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MethionineAdenosylTransferase2AProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Methionine Adenosyl Transferase2 A Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MethionineAdenosylTransferase2AProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Methionine Adenosyl Transferase 2A program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedAtCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedAtCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Owned, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SalesOfCommonStockAggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate offering price at which the Company may offer and sell its common stock under the sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SalesOfCommonStockAggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Of Common Stock Aggregate Offering Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SalesOfCommonStockAggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of common stock aggregate offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and regulatory milestone payment eligible to receive</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development And Regulatory Milestone Payment To Be Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and regulatory milestone payment to be received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of December 31, 2024 and December 31, 2023; no shares issued and outstanding as of December 31, 2024 and December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment in accounts payable and accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity Related to Company's Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carry forward amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum shares issues under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum share based compensation arrangement by share based payment award shares issued in period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PaymentOfOneTimeOptionExerciseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of one-time option exercise fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PaymentOfOneTimeOptionExerciseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of One Time Option Exercise Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PaymentOfOneTimeOptionExerciseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of one-time option exercise fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Follow-on Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow On Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow-on public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Sale Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary, Sale of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable securities, amortized cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Tax Effects of Temporary Differences and Carryforwards of Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_OperatingLeaseCommencementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease commencement, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_OperatingLeaseCommencementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Commencement Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_OperatingLeaseCommencementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease commencement description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of days of notice period for terminating agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of days of notice period for terminating agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Days Of Notice Period For Terminating Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of days of notice period for terminating collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Overallotment Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CancerResearchTechnologyAndTheUniversityOfManchesterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancer Research Technology and the University of Manchester</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CancerResearchTechnologyAndTheUniversityOfManchesterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cancer Research Technology and the University of Manchester [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CancerResearchTechnologyAndTheUniversityOfManchesterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cancer Research Technology and the University of Manchester [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from ESPP purchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Options, Weighted-Average Exercise Price, Options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_NumberOfPerformanceObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of performance obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_NumberOfPerformanceObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Performance Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_NumberOfPerformanceObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of performance obligations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_IDE161Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">IDE161.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_IDE161Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IDE161 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_IDE161Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IDE161</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of right of use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TotalMilestonePaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Totaling milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TotalMilestonePaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total Milestone Payment To Be Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TotalMilestonePaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total milestone payment to be received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_FairValueMeasurementsAndMarketableSecuritiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement and Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_FairValueMeasurementsAndMarketableSecuritiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements And Marketable Securities Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_FairValueMeasurementsAndMarketableSecuritiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurements and marketable securities policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DarovasertibMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Darovasertib [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DarovasertibMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Darovasertib.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DarovasertibMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Darovasertib</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, liability, to be paid, after year four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MarketableSecuritiesCurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MarketableSecuritiesCurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_MarketableSecuritiesCurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, operating loss carryforwards subject to expire</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_JefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jefferies LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_JefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jefferies L L C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_JefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jefferies LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value, 300,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 86,503,509 and 65,039,369 shares issued and outstanding as of December 31, 2024 and December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum offering period under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Maximum Offering Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The maximum offering period that could be set for the Employee Stock Purchase Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_UpfrontFeePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_UpfrontFeePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_UpfrontFeePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents, estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less:weighted-average shares of restricted stock that are subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities, net of current position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred tax assets, net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 6)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CollaborationRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total collaboration revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CollaborationRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_CollaborationRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_JanuaryTwoThousandTwentyFourSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">January two thousand twenty four sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_JanuaryTwoThousandTwentyFourSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">January Two Thousand Twenty Four Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_JanuaryTwoThousandTwentyFourSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">January 2024 Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average shares used in computing net loss per share attributable to common stock, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of common shares outstanding used in computing net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_NumberOfCommonStockVotingRightsHeldPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock voting rights held per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_NumberOfCommonStockVotingRightsHeldPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Common Stock Voting Rights Held Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_NumberOfCommonStockVotingRightsHeldPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock voting rights held per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Major Customer [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease renewal term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Options, Shares, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future minimum lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_UpfrontAndOptionLicenseExerciseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront And Option License Exercise Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_UpfrontAndOptionLicenseExerciseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront and option license exercise fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_UpfrontAndOptionLicenseExerciseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront and option license exercise fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Month and Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DevelopmentCostsSharingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development costs sharing percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DevelopmentCostsSharingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Costs Sharing Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_DevelopmentCostsSharingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development costs sharing percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets Measured and Recognized at Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net amortization (accretion) of premiums (discounts) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TenPercentStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">10% Stockholder</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TenPercentStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ten Percent Stockholder [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_TenPercentStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ten percent stockholder.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding Options, Weighted-Average Exercise Price, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding Options, Weighted-Average Exercise Price, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Number of Common Stock Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock reserved for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California State Income Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset obtained in exchange for a new operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive gain (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_OperatingLeasesDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of operating lease disclosures.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_OperatingLeasesDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Disclosures [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_OperatingLeasesDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Operating Lease Disclosures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PresidentAndCEOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">President and CEO.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="idya_PresidentAndCEOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">President and CEO [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_SecondAmendmentMember" xlink:to="idya_SecondAmendmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember" xlink:to="idya_TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:to="idya_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_SignificantAgreementsAbstract" xlink:to="idya_SignificantAgreementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_BiocytogenPharmaceuticalsBeijingCoLtdMember" xlink:to="idya_BiocytogenPharmaceuticalsBeijingCoLtdMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_ExerciseOfOutstandingOptionsMember" xlink:to="idya_ExerciseOfOutstandingOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_MilestonePaymentReceivedClinicalEvaluation" xlink:to="idya_MilestonePaymentReceivedClinicalEvaluation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_GlaxoSmithKlineMember" xlink:to="idya_GlaxoSmithKlineMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_PayForExternalThirdPartyCostPercentage" xlink:to="idya_PayForExternalThirdPartyCostPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_TwoThousandTwentyThreeOctoberPublicOfferingMember" xlink:to="idya_TwoThousandTwentyThreeOctoberPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="idya_IncreaseDecreaseInOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="idya_IncomeTaxDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_GlaxoSmithKlineCollaborationAgreementMember" xlink:to="idya_GlaxoSmithKlineCollaborationAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_ResearchAndExperimentalExpendituresAmortizePeriod" xlink:to="idya_ResearchAndExperimentalExpendituresAmortizePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_CommonStockRemainingAvailableToBeSaleAmount" xlink:to="idya_CommonStockRemainingAvailableToBeSaleAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_TwoThousandNineteenEmployeeStockPurchasedPlanMember" xlink:to="idya_TwoThousandNineteenEmployeeStockPurchasedPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:to="us-gaap_IncomeTaxExaminationYearUnderExamination_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_UpfrontPayment" xlink:to="idya_UpfrontPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_CloudComputingArrangementsPolicyTextBlock" xlink:to="idya_CloudComputingArrangementsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent" xlink:to="idya_ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_MilestonePaymentsRelatingToFirstAndSecondTumorHistologies" xlink:to="idya_MilestonePaymentsRelatingToFirstAndSecondTumorHistologies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents" xlink:to="idya_PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_UnpaidOfferingCosts" xlink:to="idya_UnpaidOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_SanDiegoCaliforniaMember" xlink:to="idya_SanDiegoCaliforniaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies" xlink:to="idya_DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_AtTheMarketOfferingMember" xlink:to="idya_AtTheMarketOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_OperatingLeasesAdditionalAreaLeased" xlink:to="idya_OperatingLeasesAdditionalAreaLeased_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_WernerHelicaseProgramMember" xlink:to="idya_WernerHelicaseProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="idya_SeriesBRedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_RisksAndUncertaintiesPolicyTextBlock" xlink:to="idya_RisksAndUncertaintiesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_TaxCreditCarryForwardExpirationYear" xlink:to="idya_TaxCreditCarryForwardExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_JiangsuHengruiPharmaceuticalsCoLtdMember" xlink:to="idya_JiangsuHengruiPharmaceuticalsCoLtdMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_AggregatePotentialMilestonePayments" xlink:to="idya_AggregatePotentialMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_FairValueMeasurementsAndMarketableSecuritiesTextBlock" xlink:to="idya_FairValueMeasurementsAndMarketableSecuritiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:to="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_NovartisInternationalPharmaceuticalsLimitedMember" xlink:to="idya_NovartisInternationalPharmaceuticalsLimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_LaboratoryAndOfficeFacilitiesMember" xlink:to="idya_LaboratoryAndOfficeFacilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_LaboratoryEquipmentMember" xlink:to="idya_LaboratoryEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_ExternalClinicalDevelopmentExpenses" xlink:to="idya_ExternalClinicalDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_CashCashEquivalentsAndMarketableSecurities" xlink:to="idya_CashCashEquivalentsAndMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_CommonStockSubjectToOutstandingPreFundedWarrantsExercised" xlink:to="idya_CommonStockSubjectToOutstandingPreFundedWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_ClassOfWarrantOrRightsIssueDate" xlink:to="idya_ClassOfWarrantOrRightsIssueDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_MilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies" xlink:to="idya_MilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_AdditionalPaymentOfDevelopmentMilestoneToAchieve" xlink:to="idya_AdditionalPaymentOfDevelopmentMilestoneToAchieve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_GlaxoGroupLimitedMember" xlink:to="idya_GlaxoGroupLimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_VestingOfEarlyExercisedOptionsAndRestrictedStock" xlink:to="idya_VestingOfEarlyExercisedOptionsAndRestrictedStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts" xlink:to="idya_ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_SouthSanFranciscoCaliforniaMember" xlink:to="idya_SouthSanFranciscoCaliforniaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="idya_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_ScheduleOfOperatingLeaseInTheBalanceSheetAndOtherLeaseInformationTableTextBlock" xlink:to="idya_ScheduleOfOperatingLeaseInTheBalanceSheetAndOtherLeaseInformationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_TwoThousandNineteenIncentiveAwardPlanMember" xlink:to="idya_TwoThousandNineteenIncentiveAwardPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone" xlink:to="idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive" xlink:to="idya_EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_OrphanDrugCreditsMember" xlink:to="idya_OrphanDrugCreditsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_ContingentDevelopmentAndSalesBasedMilestonePayments" xlink:to="idya_ContingentDevelopmentAndSalesBasedMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_JuneTwoThousandTwentyThreeSalesAgreementMember" xlink:to="idya_JuneTwoThousandTwentyThreeSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_TwoThousandFifteenAndNineteenEquityIncentivePlansMember" xlink:to="idya_TwoThousandFifteenAndNineteenEquityIncentivePlansMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_IncomeTaxDisclosureTable" xlink:to="idya_IncomeTaxDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_MarketableSecuritiesNonCurrentMember" xlink:to="idya_MarketableSecuritiesNonCurrentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_ESPPMaximumSharesPurchasablePerPeriodPerEmployee" xlink:to="idya_ESPPMaximumSharesPurchasablePerPeriodPerEmployee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_PersonnelRelatedAndStock-BasedCompensation" xlink:to="idya_PersonnelRelatedAndStock-BasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_IDE397Member" xlink:to="idya_IDE397Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_ClinicalCombinationStudyWindDownMonthAndYear" xlink:to="idya_ClinicalCombinationStudyWindDownMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_BiocytogenOptionAndLicenseAgreementMember" xlink:to="idya_BiocytogenOptionAndLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAgreementsMember" xlink:to="us-gaap_LeaseAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember" xlink:to="idya_TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202307Member" xlink:to="us-gaap_AccountingStandardsUpdate202307Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_PercentageOfProfitShare" xlink:to="idya_PercentageOfProfitShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies" xlink:to="idya_DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_JanuaryTwoThousandTwentyOneSalesAgreementMember" xlink:to="idya_JanuaryTwoThousandTwentyOneSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_CertainCommercialSalesMilestonesPaymentToBePaid" xlink:to="idya_CertainCommercialSalesMilestonesPaymentToBePaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_PropertyPlantAndEquipmentUsefulLifeDescription" xlink:to="idya_PropertyPlantAndEquipmentUsefulLifeDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="idya_DeferredTaxLiabilitiesRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants" xlink:to="idya_AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_CommercialMilestonePaymentToBeReceived" xlink:to="idya_CommercialMilestonePaymentToBeReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_MilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies" xlink:to="idya_MilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_OtherResearchAndDevelopmentExpenseMember" xlink:to="idya_OtherResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_OperatingLeaseCommencementMonthAndYear" xlink:to="idya_OperatingLeaseCommencementMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_PolymeraseThetaProgramMember" xlink:to="idya_PolymeraseThetaProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock" xlink:to="idya_SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_DeferredTaxAssetsLeaseLiability" xlink:to="idya_DeferredTaxAssetsLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_UpfrontPaymentFee" xlink:to="idya_UpfrontPaymentFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_DeterminationPeriodOfCostsIncurred" xlink:to="idya_DeterminationPeriodOfCostsIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation" xlink:to="idya_AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance" xlink:to="idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_OperatingLeasesAreaLeased" xlink:to="idya_OperatingLeasesAreaLeased_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized" xlink:to="idya_RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_PaymentOfOptionExerciseFee" xlink:to="idya_PaymentOfOptionExerciseFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentImpairment" xlink:to="us-gaap_PropertyPlantAndEquipmentImpairment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_NetProceedsFromIssuanceOfCommonStock" xlink:to="idya_NetProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_TwoThousandTwentyThreeInducementPlanMember" xlink:to="idya_TwoThousandTwentyThreeInducementPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_ESPPDiscountedPurchasePricePercentage" xlink:to="idya_ESPPDiscountedPurchasePricePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_DevelopmentMilestonePaymentToBeReceived" xlink:to="idya_DevelopmentMilestonePaymentToBeReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_JanuaryTwoThousandTwentyOneSalesAgreementAndJuneTwoThousandTwentyThreeSalesAgreementMember" xlink:to="idya_JanuaryTwoThousandTwentyOneSalesAgreementAndJuneTwoThousandTwentyThreeSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_UnvestedEarlyExercisedCommonStockOptionsMember" xlink:to="idya_UnvestedEarlyExercisedCommonStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201613Member" xlink:to="us-gaap_AccountingStandardsUpdate201613Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_AmgenClinicalTrialCollaborationAndSupplyAgreementMember" xlink:to="idya_AmgenClinicalTrialCollaborationAndSupplyAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_EffectiveIncomeTaxRateReconciliationSection162MLimitation" xlink:to="idya_EffectiveIncomeTaxRateReconciliationSection162MLimitation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent" xlink:to="idya_AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_ReimbursementPeriodOfCostsIncurred" xlink:to="idya_ReimbursementPeriodOfCostsIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_SouthSanFranciscoMember" xlink:to="idya_SouthSanFranciscoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_TwoThousandTwentyThreeAprilPublicOfferingMember" xlink:to="idya_TwoThousandTwentyThreeAprilPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_MarketableSecuritiesRemainingMaturityPeriod" xlink:to="idya_MarketableSecuritiesRemainingMaturityPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_HengruiPharmaLicenseAgreementMember" xlink:to="idya_HengruiPharmaLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_DevelopmentAndRegulatoryMilestonePaymentToBePaid" xlink:to="idya_DevelopmentAndRegulatoryMilestonePaymentToBePaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_LesseeOperatingLeaseExistenceOfOptionToRenew" xlink:to="idya_LesseeOperatingLeaseExistenceOfOptionToRenew_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_UnpaidAtTheMarketOfferingProgramCosts" xlink:to="idya_UnpaidAtTheMarketOfferingProgramCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:to="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_SharesIssuedWeightedAverageSalesPricePerShare" xlink:to="idya_SharesIssuedWeightedAverageSalesPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_MethionineAdenosylTransferase2AProgramMember" xlink:to="idya_MethionineAdenosylTransferase2AProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtCost" xlink:to="us-gaap_InvestmentOwnedAtCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_SalesOfCommonStockAggregateOfferingPrice" xlink:to="idya_SalesOfCommonStockAggregateOfferingPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived" xlink:to="idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="idya_MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_PaymentOfOneTimeOptionExerciseFee" xlink:to="idya_PaymentOfOneTimeOptionExerciseFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_EmployeeStockPurchasePlanMember" xlink:to="idya_EmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_FollowOnPublicOfferingMember" xlink:to="idya_FollowOnPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_OperatingLeaseCommencementDescription" xlink:to="idya_OperatingLeaseCommencementDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement" xlink:to="idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_CancerResearchTechnologyAndTheUniversityOfManchesterMember" xlink:to="idya_CancerResearchTechnologyAndTheUniversityOfManchesterMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_NumberOfPerformanceObligations" xlink:to="idya_NumberOfPerformanceObligations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_IDE161Member" xlink:to="idya_IDE161Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="idya_AccruedResearchAndDevelopmentExpensesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_TotalMilestonePaymentToBeReceived" xlink:to="idya_TotalMilestonePaymentToBeReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_FairValueMeasurementsAndMarketableSecuritiesPolicyTextBlock" xlink:to="idya_FairValueMeasurementsAndMarketableSecuritiesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_DarovasertibMember" xlink:to="idya_DarovasertibMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_SummaryOfSignificantAccountingPoliciesTable" xlink:to="idya_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="idya_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_MarketableSecuritiesCurrentMember" xlink:to="idya_MarketableSecuritiesCurrentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_JefferiesLLCMember" xlink:to="idya_JefferiesLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" xlink:to="idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_UpfrontFeePayment" xlink:to="idya_UpfrontFeePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_CollaborationRevenue" xlink:to="idya_CollaborationRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_JanuaryTwoThousandTwentyFourSalesAgreementMember" xlink:to="idya_JanuaryTwoThousandTwentyFourSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_NumberOfCommonStockVotingRightsHeldPerShare" xlink:to="idya_NumberOfCommonStockVotingRightsHeldPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_UpfrontAndOptionLicenseExerciseFees" xlink:to="idya_UpfrontAndOptionLicenseExerciseFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_LeaseExpirationMonthAndYear" xlink:to="idya_LeaseExpirationMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_DevelopmentCostsSharingPercentage" xlink:to="idya_DevelopmentCostsSharingPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_TenPercentStockholderMember" xlink:to="idya_TenPercentStockholderMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="idya_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_OperatingLeasesDisclosuresTableTextBlock" xlink:to="idya_OperatingLeasesDisclosuresTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="idya_PresidentAndCEOMember" xlink:to="idya_PresidentAndCEOMember_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorOpinionTextBlock" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_FollowOnPublicOfferingMember" xlink:label="idya_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AtTheMarketOfferingMember" xlink:label="idya_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants" xlink:label="idya_AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_13"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_14"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="idya_FollowOnPublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="idya_AtTheMarketOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="idya_AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_13" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_14" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_VestingOfEarlyExercisedOptionsAndRestrictedStock" xlink:label="idya_VestingOfEarlyExercisedOptionsAndRestrictedStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts" xlink:label="idya_ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_UnpaidOfferingCosts" xlink:label="idya_UnpaidOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_UnpaidAtTheMarketOfferingProgramCosts" xlink:label="idya_UnpaidAtTheMarketOfferingProgramCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="idya_IncreaseDecreaseInOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="idya_VestingOfEarlyExercisedOptionsAndRestrictedStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="idya_ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="idya_UnpaidOfferingCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="idya_UnpaidAtTheMarketOfferingProgramCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="idya_IncreaseDecreaseInOperatingLeaseLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganization" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecurities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_FairValueMeasurementsAndMarketableSecuritiesTextBlock" xlink:label="idya_FairValueMeasurementsAndMarketableSecuritiesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="idya_FairValueMeasurementsAndMarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SignificantAgreementsAbstract" xlink:label="idya_SignificantAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_SignificantAgreementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognition" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_RisksAndUncertaintiesPolicyTextBlock" xlink:label="idya_RisksAndUncertaintiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CloudComputingArrangementsPolicyTextBlock" xlink:label="idya_CloudComputingArrangementsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:label="idya_AccruedResearchAndDevelopmentExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_FairValueMeasurementsAndMarketableSecuritiesPolicyTextBlock" xlink:label="idya_FairValueMeasurementsAndMarketableSecuritiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="idya_RisksAndUncertaintiesPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentImpairment" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="idya_CloudComputingArrangementsPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="idya_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="idya_FairValueMeasurementsAndMarketableSecuritiesPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ScheduleOfOperatingLeaseInTheBalanceSheetAndOtherLeaseInformationTableTextBlock" xlink:label="idya_ScheduleOfOperatingLeaseInTheBalanceSheetAndOtherLeaseInformationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_OperatingLeasesDisclosuresTableTextBlock" xlink:label="idya_OperatingLeasesDisclosuresTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="idya_ScheduleOfOperatingLeaseInTheBalanceSheetAndOtherLeaseInformationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="idya_OperatingLeasesDisclosuresTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="idya_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="idya_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognitionTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock" xlink:label="idya_SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="idya_SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_JanuaryTwoThousandTwentyOneSalesAgreementMember" xlink:label="idya_JanuaryTwoThousandTwentyOneSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AtTheMarketOfferingMember" xlink:label="idya_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_GlaxoGroupLimitedMember" xlink:label="idya_GlaxoGroupLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_JuneTwoThousandTwentyThreeSalesAgreementMember" xlink:label="idya_JuneTwoThousandTwentyThreeSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_FollowOnPublicOfferingMember" xlink:label="idya_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_JefferiesLLCMember" xlink:label="idya_JefferiesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_JanuaryTwoThousandTwentyOneSalesAgreementAndJuneTwoThousandTwentyThreeSalesAgreementMember" xlink:label="idya_JanuaryTwoThousandTwentyOneSalesAgreementAndJuneTwoThousandTwentyThreeSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_JanuaryTwoThousandTwentyFourSalesAgreementMember" xlink:label="idya_JanuaryTwoThousandTwentyFourSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_NetProceedsFromIssuanceOfCommonStock" xlink:label="idya_NetProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SalesOfCommonStockAggregateOfferingPrice" xlink:label="idya_SalesOfCommonStockAggregateOfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CommonStockRemainingAvailableToBeSaleAmount" xlink:label="idya_CommonStockRemainingAvailableToBeSaleAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CashCashEquivalentsAndMarketableSecurities" xlink:label="idya_CashCashEquivalentsAndMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SharesIssuedWeightedAverageSalesPricePerShare" xlink:label="idya_SharesIssuedWeightedAverageSalesPricePerShare"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_JanuaryTwoThousandTwentyOneSalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="idya_AtTheMarketOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="idya_GlaxoGroupLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_JuneTwoThousandTwentyThreeSalesAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="idya_FollowOnPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="idya_JefferiesLLCMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_JanuaryTwoThousandTwentyOneSalesAgreementAndJuneTwoThousandTwentyThreeSalesAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_JanuaryTwoThousandTwentyFourSalesAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="idya_NetProceedsFromIssuanceOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="idya_SalesOfCommonStockAggregateOfferingPrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="idya_CommonStockRemainingAvailableToBeSaleAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="idya_CashCashEquivalentsAndMarketableSecurities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="idya_SharesIssuedWeightedAverageSalesPricePerShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="idya_TwoThousandNineteenIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="idya_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SummaryOfSignificantAccountingPoliciesTable" xlink:label="idya_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized" xlink:label="idya_RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_TwoThousandNineteenIncentiveAwardPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="idya_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202307Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_VestingAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_SummaryOfSignificantAccountingPoliciesTable" xlink:to="idya_SummaryOfSignificantAccountingPoliciesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="idya_RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MarketableSecuritiesCurrentMember" xlink:label="idya_MarketableSecuritiesCurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MarketableSecuritiesNonCurrentMember" xlink:label="idya_MarketableSecuritiesNonCurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="us-gaap_InvestmentOwnedAtCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="idya_MarketableSecuritiesCurrentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="idya_MarketableSecuritiesNonCurrentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentOwnedAtCost" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MarketableSecuritiesRemainingMaturityPeriod" xlink:label="idya_MarketableSecuritiesRemainingMaturityPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="idya_MarketableSecuritiesRemainingMaturityPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_LaboratoryEquipmentMember" xlink:label="idya_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PropertyPlantAndEquipmentUsefulLifeDescription" xlink:label="idya_PropertyPlantAndEquipmentUsefulLifeDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="idya_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="idya_PropertyPlantAndEquipmentUsefulLifeDescription" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="idya_AccruedResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="idya_AccruedResearchAndDevelopmentExpensesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SecondAmendmentMember" xlink:label="idya_SecondAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_OperatingLeasesAreaLeased" xlink:label="idya_OperatingLeasesAreaLeased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_LaboratoryAndOfficeFacilitiesMember" xlink:label="idya_LaboratoryAndOfficeFacilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SouthSanFranciscoCaliforniaMember" xlink:label="idya_SouthSanFranciscoCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_OperatingLeaseCommencementDescription" xlink:label="idya_OperatingLeaseCommencementDescription"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SouthSanFranciscoMember" xlink:label="idya_SouthSanFranciscoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SanDiegoCaliforniaMember" xlink:label="idya_SanDiegoCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_OperatingLeasesAdditionalAreaLeased" xlink:label="idya_OperatingLeasesAdditionalAreaLeased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_OperatingLeaseCommencementMonthAndYear" xlink:label="idya_OperatingLeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_LeaseExpirationMonthAndYear" xlink:label="idya_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_LesseeOperatingLeaseExistenceOfOptionToRenew" xlink:label="idya_LesseeOperatingLeaseExistenceOfOptionToRenew"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_SecondAmendmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="idya_OperatingLeasesAreaLeased" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeaseAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="idya_LaboratoryAndOfficeFacilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="idya_SouthSanFranciscoCaliforniaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="idya_OperatingLeaseCommencementDescription" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="idya_SouthSanFranciscoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="idya_SanDiegoCaliforniaMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="idya_OperatingLeasesAdditionalAreaLeased" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_OperatingLeasedAssetsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="idya_OperatingLeaseCommencementMonthAndYear" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="idya_LeaseExpirationMonthAndYear" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="idya_LesseeOperatingLeaseExistenceOfOptionToRenew" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_VariableLeaseCost" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfOperatingLeaseInBalanceSheetAndOtherLeaseInformationDetails" xlink:title="presentationLink" xlink:type="extended"/>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:label="idya_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="idya_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfOperatingLeaseDisclosuresDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_OrphanDrugCreditsMember" xlink:label="idya_OrphanDrugCreditsMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_IncomeTaxDisclosureLineItems" xlink:label="idya_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_IncomeTaxDisclosureTable" xlink:label="idya_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TaxCreditCarryForwardExpirationYear" xlink:label="idya_TaxCreditCarryForwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ResearchAndExperimentalExpendituresAmortizePeriod" xlink:label="idya_ResearchAndExperimentalExpendituresAmortizePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:label="us-gaap_IncomeTaxExaminationYearUnderExamination"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="idya_OrphanDrugCreditsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="idya_IncomeTaxDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_IncomeTaxDisclosureTable" xlink:to="idya_IncomeTaxDisclosureLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="stpr_CA" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="idya_TaxCreditCarryForwardExpirationYear" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="idya_ResearchAndExperimentalExpendituresAmortizePeriod" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationYearUnderExamination" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_EffectiveIncomeTaxRateReconciliationSection162MLimitation" xlink:label="idya_EffectiveIncomeTaxRateReconciliationSection162MLimitation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="idya_EffectiveIncomeTaxRateReconciliationSection162MLimitation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="idya_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DeferredTaxAssetsLeaseLiability" xlink:label="idya_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="idya_DeferredTaxLiabilitiesRightOfUseAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="idya_DeferredTaxAssetsLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanySUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_FollowOnPublicOfferingMember" xlink:label="idya_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_NumberOfCommonStockVotingRightsHeldPerShare" xlink:label="idya_NumberOfCommonStockVotingRightsHeldPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_NetProceedsFromIssuanceOfCommonStock" xlink:label="idya_NetProceedsFromIssuanceOfCommonStock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="idya_FollowOnPublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="idya_NumberOfCommonStockVotingRightsHeldPerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="idya_NetProceedsFromIssuanceOfCommonStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCommonStockScheduleOfAggregateWarrantsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ClassOfWarrantOrRightsIssueDate" xlink:label="idya_ClassOfWarrantOrRightsIssueDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="idya_ClassOfWarrantOrRightsIssueDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCommonStockScheduleOfAggregateWarrantsParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CommonStockSubjectToOutstandingPreFundedWarrantsExercised" xlink:label="idya_CommonStockSubjectToOutstandingPreFundedWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="idya_CommonStockSubjectToOutstandingPreFundedWarrantsExercised" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember" xlink:label="idya_TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="idya_TwoThousandNineteenIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandTwentyThreeInducementPlanMember" xlink:label="idya_TwoThousandTwentyThreeInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_EmployeeStockPurchasePlanMember" xlink:label="idya_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ExerciseOfOutstandingOptionsMember" xlink:label="idya_ExerciseOfOutstandingOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_TwoThousandNineteenIncentiveAwardPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_TwoThousandTwentyThreeInducementPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_EmployeeStockPurchasePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="idya_ExerciseOfOutstandingOptionsMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandTwentyThreeOctoberPublicOfferingMember" xlink:label="idya_TwoThousandTwentyThreeOctoberPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_FollowOnPublicOfferingMember" xlink:label="idya_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_UnvestedEarlyExercisedCommonStockOptionsMember" xlink:label="idya_UnvestedEarlyExercisedCommonStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TenPercentStockholderMember" xlink:label="idya_TenPercentStockholderMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandTwentyThreeAprilPublicOfferingMember" xlink:label="idya_TwoThousandTwentyThreeAprilPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="idya_TwoThousandNineteenIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandNineteenEmployeeStockPurchasedPlanMember" xlink:label="idya_TwoThousandNineteenEmployeeStockPurchasedPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandTwentyThreeInducementPlanMember" xlink:label="idya_TwoThousandTwentyThreeInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance" xlink:label="idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ESPPDiscountedPurchasePricePercentage" xlink:label="idya_ESPPDiscountedPurchasePricePercentage"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ESPPMaximumSharesPurchasablePerPeriodPerEmployee" xlink:label="idya_ESPPMaximumSharesPurchasablePerPeriodPerEmployee"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent" xlink:label="idya_ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" xlink:label="idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="idya_MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_TwoThousandTwentyThreeOctoberPublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="idya_FollowOnPublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="idya_UnvestedEarlyExercisedCommonStockOptionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="idya_TenPercentStockholderMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_TwoThousandTwentyThreeAprilPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_TwoThousandNineteenIncentiveAwardPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_TwoThousandNineteenEmployeeStockPurchasedPlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_TwoThousandTwentyThreeInducementPlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="idya_ESPPDiscountedPurchasePricePercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="idya_ESPPMaximumSharesPurchasablePerPeriodPerEmployee" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="idya_ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="idya_MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandFifteenAndNineteenEquityIncentivePlansMember" xlink:label="idya_TwoThousandFifteenAndNineteenEquityIncentivePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember" xlink:label="idya_TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_TwoThousandFifteenAndNineteenEquityIncentivePlansMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToCalculateFairValuesOfOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SignificantAgreementsAbstract" xlink:label="idya_SignificantAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_GlaxoSmithKlineCollaborationAgreementMember" xlink:label="idya_GlaxoSmithKlineCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_NovartisInternationalPharmaceuticalsLimitedMember" xlink:label="idya_NovartisInternationalPharmaceuticalsLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="idya_SeriesBRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_GlaxoSmithKlineMember" xlink:label="idya_GlaxoSmithKlineMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_UpfrontPayment" xlink:label="idya_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PolymeraseThetaProgramMember" xlink:label="idya_PolymeraseThetaProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CancerResearchTechnologyAndTheUniversityOfManchesterMember" xlink:label="idya_CancerResearchTechnologyAndTheUniversityOfManchesterMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_BiocytogenPharmaceuticalsBeijingCoLtdMember" xlink:label="idya_BiocytogenPharmaceuticalsBeijingCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_WernerHelicaseProgramMember" xlink:label="idya_WernerHelicaseProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AmgenClinicalTrialCollaborationAndSupplyAgreementMember" xlink:label="idya_AmgenClinicalTrialCollaborationAndSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_JiangsuHengruiPharmaceuticalsCoLtdMember" xlink:label="idya_JiangsuHengruiPharmaceuticalsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DevelopmentAndRegulatoryMilestonePaymentToBePaid" xlink:label="idya_DevelopmentAndRegulatoryMilestonePaymentToBePaid"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CertainCommercialSalesMilestonesPaymentToBePaid" xlink:label="idya_CertainCommercialSalesMilestonesPaymentToBePaid"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DevelopmentCostsSharingPercentage" xlink:label="idya_DevelopmentCostsSharingPercentage"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived" xlink:label="idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CommercialMilestonePaymentToBeReceived" xlink:label="idya_CommercialMilestonePaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone" xlink:label="idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MilestonePaymentReceivedClinicalEvaluation" xlink:label="idya_MilestonePaymentReceivedClinicalEvaluation"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive" xlink:label="idya_EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AdditionalPaymentOfDevelopmentMilestoneToAchieve" xlink:label="idya_AdditionalPaymentOfDevelopmentMilestoneToAchieve"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PercentageOfProfitShare" xlink:label="idya_PercentageOfProfitShare"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DevelopmentMilestonePaymentToBeReceived" xlink:label="idya_DevelopmentMilestonePaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement" xlink:label="idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ContingentDevelopmentAndSalesBasedMilestonePayments" xlink:label="idya_ContingentDevelopmentAndSalesBasedMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PayForExternalThirdPartyCostPercentage" xlink:label="idya_PayForExternalThirdPartyCostPercentage"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ClinicalCombinationStudyWindDownMonthAndYear" xlink:label="idya_ClinicalCombinationStudyWindDownMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PaymentOfOptionExerciseFee" xlink:label="idya_PaymentOfOptionExerciseFee"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PaymentOfOneTimeOptionExerciseFee" xlink:label="idya_PaymentOfOneTimeOptionExerciseFee"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents" xlink:label="idya_PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MilestonePaymentsRelatingToFirstAndSecondTumorHistologies" xlink:label="idya_MilestonePaymentsRelatingToFirstAndSecondTumorHistologies"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent" xlink:label="idya_AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies" xlink:label="idya_DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies" xlink:label="idya_DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AggregatePotentialMilestonePayments" xlink:label="idya_AggregatePotentialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_UpfrontPaymentFee" xlink:label="idya_UpfrontPaymentFee"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_UpfrontFeePayment" xlink:label="idya_UpfrontFeePayment"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TotalMilestonePaymentToBeReceived" xlink:label="idya_TotalMilestonePaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies" xlink:label="idya_MilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies" xlink:label="idya_MilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="idya_SignificantAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_GlaxoSmithKlineCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="idya_NovartisInternationalPharmaceuticalsLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="idya_SeriesBRedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="idya_GlaxoSmithKlineMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_UpfrontPayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_PolymeraseThetaProgramMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="idya_CancerResearchTechnologyAndTheUniversityOfManchesterMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="idya_BiocytogenPharmaceuticalsBeijingCoLtdMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_WernerHelicaseProgramMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="idya_AmgenClinicalTrialCollaborationAndSupplyAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="idya_JiangsuHengruiPharmaceuticalsCoLtdMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_DevelopmentAndRegulatoryMilestonePaymentToBePaid" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_CertainCommercialSalesMilestonesPaymentToBePaid" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_DevelopmentCostsSharingPercentage" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_CommercialMilestonePaymentToBeReceived" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_MilestonePaymentReceivedClinicalEvaluation" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_AdditionalPaymentOfDevelopmentMilestoneToAchieve" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_PercentageOfProfitShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_DevelopmentMilestonePaymentToBeReceived" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_ContingentDevelopmentAndSalesBasedMilestonePayments" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_PayForExternalThirdPartyCostPercentage" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_ClinicalCombinationStudyWindDownMonthAndYear" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_PaymentOfOptionExerciseFee" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_PaymentOfOneTimeOptionExerciseFee" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_MilestonePaymentsRelatingToFirstAndSecondTumorHistologies" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_AggregatePotentialMilestonePayments" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_UpfrontPaymentFee" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_UpfrontFeePayment" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_TotalMilestonePaymentToBeReceived" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_MilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_MilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByResearchProgramDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MethionineAdenosylTransferase2AProgramMember" xlink:label="idya_MethionineAdenosylTransferase2AProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CollaborationRevenue" xlink:label="idya_CollaborationRevenue"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PolymeraseThetaProgramMember" xlink:label="idya_PolymeraseThetaProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_WernerHelicaseProgramMember" xlink:label="idya_WernerHelicaseProgramMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_MethionineAdenosylTransferase2AProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="idya_CollaborationRevenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_PolymeraseThetaProgramMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_WernerHelicaseProgramMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_GlaxoSmithKlineCollaborationAgreementMember" xlink:label="idya_GlaxoSmithKlineCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_GlaxoSmithKlineMember" xlink:label="idya_GlaxoSmithKlineMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_NumberOfPerformanceObligations" xlink:label="idya_NumberOfPerformanceObligations"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PolymeraseThetaProgramMember" xlink:label="idya_PolymeraseThetaProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_WernerHelicaseProgramMember" xlink:label="idya_WernerHelicaseProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation" xlink:label="idya_AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone" xlink:label="idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MilestonePaymentReceivedClinicalEvaluation" xlink:label="idya_MilestonePaymentReceivedClinicalEvaluation"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ReimbursementPeriodOfCostsIncurred" xlink:label="idya_ReimbursementPeriodOfCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DeterminationPeriodOfCostsIncurred" xlink:label="idya_DeterminationPeriodOfCostsIncurred"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_GlaxoSmithKlineCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="idya_GlaxoSmithKlineMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="idya_NumberOfPerformanceObligations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_PolymeraseThetaProgramMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_WernerHelicaseProgramMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="idya_AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="idya_MilestonePaymentReceivedClinicalEvaluation" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="idya_ReimbursementPeriodOfCostsIncurred" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="idya_DeterminationPeriodOfCostsIncurred" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DarovasertibMember" xlink:label="idya_DarovasertibMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ExternalClinicalDevelopmentExpenses" xlink:label="idya_ExternalClinicalDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_IDE397Member" xlink:label="idya_IDE397Member"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PersonnelRelatedAndStock-BasedCompensation" xlink:label="idya_PersonnelRelatedAndStock-BasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_IDE161Member" xlink:label="idya_IDE161Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="idya_DarovasertibMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="idya_ExternalClinicalDevelopmentExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="idya_IDE397Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_EntityWideRevenueMajorCustomerLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="idya_PersonnelRelatedAndStock-BasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="idya_IDE161Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_HengruiPharmaLicenseAgreementMember" xlink:label="idya_HengruiPharmaLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_OtherResearchAndDevelopmentExpenseMember" xlink:label="idya_OtherResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_UpfrontPayment" xlink:label="idya_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_BiocytogenOptionAndLicenseAgreementMember" xlink:label="idya_BiocytogenOptionAndLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_UpfrontAndOptionLicenseExerciseFees" xlink:label="idya_UpfrontAndOptionLicenseExerciseFees"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_HengruiPharmaLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="idya_OtherResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_UpfrontPayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_BiocytogenOptionAndLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_UpfrontAndOptionLicenseExerciseFees" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_JanuaryTwoThousandTwentyFourSalesAgreementMember" xlink:label="idya_JanuaryTwoThousandTwentyFourSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AtTheMarketOfferingMember" xlink:label="idya_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_JefferiesLLCMember" xlink:label="idya_JefferiesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SouthSanFranciscoCaliforniaMember" xlink:label="idya_SouthSanFranciscoCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CommonStockRemainingAvailableToBeSaleAmount" xlink:label="idya_CommonStockRemainingAvailableToBeSaleAmount"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_OperatingLeasesAdditionalAreaLeased" xlink:label="idya_OperatingLeasesAdditionalAreaLeased"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_JanuaryTwoThousandTwentyFourSalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="idya_AtTheMarketOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeaseAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="idya_JefferiesLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="idya_SouthSanFranciscoCaliforniaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="idya_CommonStockRemainingAvailableToBeSaleAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="idya_OperatingLeasesAdditionalAreaLeased" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementGeographicalAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_FollowOnPublicOfferingMember" xlink:label="idya_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AtTheMarketOfferingMember" xlink:label="idya_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants" xlink:label="idya_AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="idya_FollowOnPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="idya_AtTheMarketOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="idya_AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_JanuaryTwoThousandTwentyOneSalesAgreementMember" xlink:label="idya_JanuaryTwoThousandTwentyOneSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AtTheMarketOfferingMember" xlink:label="idya_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_GlaxoGroupLimitedMember" xlink:label="idya_GlaxoGroupLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_JuneTwoThousandTwentyThreeSalesAgreementMember" xlink:label="idya_JuneTwoThousandTwentyThreeSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_FollowOnPublicOfferingMember" xlink:label="idya_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_JefferiesLLCMember" xlink:label="idya_JefferiesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_JanuaryTwoThousandTwentyOneSalesAgreementAndJuneTwoThousandTwentyThreeSalesAgreementMember" xlink:label="idya_JanuaryTwoThousandTwentyOneSalesAgreementAndJuneTwoThousandTwentyThreeSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_JanuaryTwoThousandTwentyFourSalesAgreementMember" xlink:label="idya_JanuaryTwoThousandTwentyFourSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_NetProceedsFromIssuanceOfCommonStock" xlink:label="idya_NetProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SalesOfCommonStockAggregateOfferingPrice" xlink:label="idya_SalesOfCommonStockAggregateOfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CommonStockRemainingAvailableToBeSaleAmount" xlink:label="idya_CommonStockRemainingAvailableToBeSaleAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CashCashEquivalentsAndMarketableSecurities" xlink:label="idya_CashCashEquivalentsAndMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SharesIssuedWeightedAverageSalesPricePerShare" xlink:label="idya_SharesIssuedWeightedAverageSalesPricePerShare"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_JanuaryTwoThousandTwentyOneSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="idya_AtTheMarketOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="idya_GlaxoGroupLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_JuneTwoThousandTwentyThreeSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="idya_FollowOnPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="idya_JefferiesLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_JanuaryTwoThousandTwentyOneSalesAgreementAndJuneTwoThousandTwentyThreeSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_JanuaryTwoThousandTwentyFourSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="idya_NetProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="idya_SalesOfCommonStockAggregateOfferingPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="idya_CommonStockRemainingAvailableToBeSaleAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="idya_CashCashEquivalentsAndMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="idya_SharesIssuedWeightedAverageSalesPricePerShare" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="idya_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SummaryOfSignificantAccountingPoliciesTable" xlink:label="idya_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="idya_TwoThousandNineteenIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized" xlink:label="idya_RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="idya_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_TwoThousandNineteenIncentiveAwardPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="idya_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202307Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="idya_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="idya_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="idya_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="idya_RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="idya_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MarketableSecuritiesCurrentMember" xlink:label="idya_MarketableSecuritiesCurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MarketableSecuritiesNonCurrentMember" xlink:label="idya_MarketableSecuritiesNonCurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="us-gaap_InvestmentOwnedAtCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="idya_MarketableSecuritiesCurrentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="idya_MarketableSecuritiesNonCurrentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentOwnedAtCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MarketableSecuritiesRemainingMaturityPeriod" xlink:label="idya_MarketableSecuritiesRemainingMaturityPeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="idya_MarketableSecuritiesRemainingMaturityPeriod" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_LaboratoryEquipmentMember" xlink:label="idya_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PropertyPlantAndEquipmentUsefulLifeDescription" xlink:label="idya_PropertyPlantAndEquipmentUsefulLifeDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="idya_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="idya_PropertyPlantAndEquipmentUsefulLifeDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SecondAmendmentMember" xlink:label="idya_SecondAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_OperatingLeasesAreaLeased" xlink:label="idya_OperatingLeasesAreaLeased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_LaboratoryAndOfficeFacilitiesMember" xlink:label="idya_LaboratoryAndOfficeFacilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SouthSanFranciscoCaliforniaMember" xlink:label="idya_SouthSanFranciscoCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_OperatingLeaseCommencementDescription" xlink:label="idya_OperatingLeaseCommencementDescription"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SouthSanFranciscoMember" xlink:label="idya_SouthSanFranciscoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SanDiegoCaliforniaMember" xlink:label="idya_SanDiegoCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_OperatingLeasesAdditionalAreaLeased" xlink:label="idya_OperatingLeasesAdditionalAreaLeased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_OperatingLeaseCommencementMonthAndYear" xlink:label="idya_OperatingLeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_LeaseExpirationMonthAndYear" xlink:label="idya_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_LesseeOperatingLeaseExistenceOfOptionToRenew" xlink:label="idya_LesseeOperatingLeaseExistenceOfOptionToRenew"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_SecondAmendmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="idya_OperatingLeasesAreaLeased" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeaseAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="idya_LaboratoryAndOfficeFacilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="idya_SouthSanFranciscoCaliforniaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="idya_OperatingLeaseCommencementDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="idya_SouthSanFranciscoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="idya_SanDiegoCaliforniaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="idya_OperatingLeasesAdditionalAreaLeased" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="idya_OperatingLeaseCommencementMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="idya_LeaseExpirationMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="idya_LesseeOperatingLeaseExistenceOfOptionToRenew" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_VariableLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_IncomeTaxDisclosureLineItems" xlink:label="idya_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_IncomeTaxDisclosureTable" xlink:label="idya_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_OrphanDrugCreditsMember" xlink:label="idya_OrphanDrugCreditsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TaxCreditCarryForwardExpirationYear" xlink:label="idya_TaxCreditCarryForwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ResearchAndExperimentalExpendituresAmortizePeriod" xlink:label="idya_ResearchAndExperimentalExpendituresAmortizePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:label="us-gaap_IncomeTaxExaminationYearUnderExamination"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="idya_IncomeTaxDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="idya_OrphanDrugCreditsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="idya_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="idya_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="stpr_CA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="idya_TaxCreditCarryForwardExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="idya_ResearchAndExperimentalExpendituresAmortizePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="idya_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationYearUnderExamination" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_FollowOnPublicOfferingMember" xlink:label="idya_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_NumberOfCommonStockVotingRightsHeldPerShare" xlink:label="idya_NumberOfCommonStockVotingRightsHeldPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_NetProceedsFromIssuanceOfCommonStock" xlink:label="idya_NetProceedsFromIssuanceOfCommonStock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="idya_FollowOnPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="idya_NumberOfCommonStockVotingRightsHeldPerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="idya_NetProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCommonStockScheduleOfAggregateWarrantsParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CommonStockSubjectToOutstandingPreFundedWarrantsExercised" xlink:label="idya_CommonStockSubjectToOutstandingPreFundedWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="idya_CommonStockSubjectToOutstandingPreFundedWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember" xlink:label="idya_TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ExerciseOfOutstandingOptionsMember" xlink:label="idya_ExerciseOfOutstandingOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="idya_TwoThousandNineteenIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandTwentyThreeInducementPlanMember" xlink:label="idya_TwoThousandTwentyThreeInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_EmployeeStockPurchasePlanMember" xlink:label="idya_EmployeeStockPurchasePlanMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="idya_ExerciseOfOutstandingOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_TwoThousandNineteenIncentiveAwardPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_TwoThousandTwentyThreeInducementPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandTwentyThreeOctoberPublicOfferingMember" xlink:label="idya_TwoThousandTwentyThreeOctoberPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_FollowOnPublicOfferingMember" xlink:label="idya_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_UnvestedEarlyExercisedCommonStockOptionsMember" xlink:label="idya_UnvestedEarlyExercisedCommonStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TenPercentStockholderMember" xlink:label="idya_TenPercentStockholderMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandTwentyThreeAprilPublicOfferingMember" xlink:label="idya_TwoThousandTwentyThreeAprilPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="idya_TwoThousandNineteenIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandNineteenEmployeeStockPurchasedPlanMember" xlink:label="idya_TwoThousandNineteenEmployeeStockPurchasedPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandTwentyThreeInducementPlanMember" xlink:label="idya_TwoThousandTwentyThreeInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance" xlink:label="idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ESPPDiscountedPurchasePricePercentage" xlink:label="idya_ESPPDiscountedPurchasePricePercentage"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ESPPMaximumSharesPurchasablePerPeriodPerEmployee" xlink:label="idya_ESPPMaximumSharesPurchasablePerPeriodPerEmployee"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent" xlink:label="idya_ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" xlink:label="idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="idya_MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_TwoThousandTwentyThreeOctoberPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="idya_FollowOnPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="idya_UnvestedEarlyExercisedCommonStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="idya_TenPercentStockholderMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_TwoThousandTwentyThreeAprilPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_TwoThousandNineteenIncentiveAwardPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_TwoThousandNineteenEmployeeStockPurchasedPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_TwoThousandTwentyThreeInducementPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="idya_ESPPDiscountedPurchasePricePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="idya_ESPPMaximumSharesPurchasablePerPeriodPerEmployee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="idya_ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="idya_MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandFifteenAndNineteenEquityIncentivePlansMember" xlink:label="idya_TwoThousandFifteenAndNineteenEquityIncentivePlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember" xlink:label="idya_TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_TwoThousandFifteenAndNineteenEquityIncentivePlansMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="idya_TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToCalculateFairValuesOfOptionsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_GlaxoSmithKlineCollaborationAgreementMember" xlink:label="idya_GlaxoSmithKlineCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_NovartisInternationalPharmaceuticalsLimitedMember" xlink:label="idya_NovartisInternationalPharmaceuticalsLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="idya_SeriesBRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_GlaxoSmithKlineMember" xlink:label="idya_GlaxoSmithKlineMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_UpfrontPayment" xlink:label="idya_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PolymeraseThetaProgramMember" xlink:label="idya_PolymeraseThetaProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CancerResearchTechnologyAndTheUniversityOfManchesterMember" xlink:label="idya_CancerResearchTechnologyAndTheUniversityOfManchesterMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_BiocytogenPharmaceuticalsBeijingCoLtdMember" xlink:label="idya_BiocytogenPharmaceuticalsBeijingCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_WernerHelicaseProgramMember" xlink:label="idya_WernerHelicaseProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AmgenClinicalTrialCollaborationAndSupplyAgreementMember" xlink:label="idya_AmgenClinicalTrialCollaborationAndSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_JiangsuHengruiPharmaceuticalsCoLtdMember" xlink:label="idya_JiangsuHengruiPharmaceuticalsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DevelopmentAndRegulatoryMilestonePaymentToBePaid" xlink:label="idya_DevelopmentAndRegulatoryMilestonePaymentToBePaid"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CertainCommercialSalesMilestonesPaymentToBePaid" xlink:label="idya_CertainCommercialSalesMilestonesPaymentToBePaid"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DevelopmentCostsSharingPercentage" xlink:label="idya_DevelopmentCostsSharingPercentage"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived" xlink:label="idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CommercialMilestonePaymentToBeReceived" xlink:label="idya_CommercialMilestonePaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone" xlink:label="idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MilestonePaymentReceivedClinicalEvaluation" xlink:label="idya_MilestonePaymentReceivedClinicalEvaluation"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive" xlink:label="idya_EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AdditionalPaymentOfDevelopmentMilestoneToAchieve" xlink:label="idya_AdditionalPaymentOfDevelopmentMilestoneToAchieve"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PercentageOfProfitShare" xlink:label="idya_PercentageOfProfitShare"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DevelopmentMilestonePaymentToBeReceived" xlink:label="idya_DevelopmentMilestonePaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement" xlink:label="idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ContingentDevelopmentAndSalesBasedMilestonePayments" xlink:label="idya_ContingentDevelopmentAndSalesBasedMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PayForExternalThirdPartyCostPercentage" xlink:label="idya_PayForExternalThirdPartyCostPercentage"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ClinicalCombinationStudyWindDownMonthAndYear" xlink:label="idya_ClinicalCombinationStudyWindDownMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PaymentOfOptionExerciseFee" xlink:label="idya_PaymentOfOptionExerciseFee"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PaymentOfOneTimeOptionExerciseFee" xlink:label="idya_PaymentOfOneTimeOptionExerciseFee"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents" xlink:label="idya_PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MilestonePaymentsRelatingToFirstAndSecondTumorHistologies" xlink:label="idya_MilestonePaymentsRelatingToFirstAndSecondTumorHistologies"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent" xlink:label="idya_AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies" xlink:label="idya_DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies" xlink:label="idya_DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AggregatePotentialMilestonePayments" xlink:label="idya_AggregatePotentialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_UpfrontPaymentFee" xlink:label="idya_UpfrontPaymentFee"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_UpfrontFeePayment" xlink:label="idya_UpfrontFeePayment"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_TotalMilestonePaymentToBeReceived" xlink:label="idya_TotalMilestonePaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies" xlink:label="idya_MilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies" xlink:label="idya_MilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_GlaxoSmithKlineCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="idya_NovartisInternationalPharmaceuticalsLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="idya_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="idya_GlaxoSmithKlineMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_UpfrontPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_PolymeraseThetaProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="idya_CancerResearchTechnologyAndTheUniversityOfManchesterMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="idya_BiocytogenPharmaceuticalsBeijingCoLtdMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_WernerHelicaseProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="idya_AmgenClinicalTrialCollaborationAndSupplyAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="idya_JiangsuHengruiPharmaceuticalsCoLtdMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_DevelopmentAndRegulatoryMilestonePaymentToBePaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_CertainCommercialSalesMilestonesPaymentToBePaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_DevelopmentCostsSharingPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_CommercialMilestonePaymentToBeReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_MilestonePaymentReceivedClinicalEvaluation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_AdditionalPaymentOfDevelopmentMilestoneToAchieve" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_PercentageOfProfitShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_DevelopmentMilestonePaymentToBeReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_ContingentDevelopmentAndSalesBasedMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_PayForExternalThirdPartyCostPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_ClinicalCombinationStudyWindDownMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_PaymentOfOptionExerciseFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_PaymentOfOneTimeOptionExerciseFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_MilestonePaymentsRelatingToFirstAndSecondTumorHistologies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_AggregatePotentialMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_UpfrontPaymentFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_UpfrontFeePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_TotalMilestonePaymentToBeReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_MilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_MilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByResearchProgramDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MethionineAdenosylTransferase2AProgramMember" xlink:label="idya_MethionineAdenosylTransferase2AProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CollaborationRevenue" xlink:label="idya_CollaborationRevenue"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PolymeraseThetaProgramMember" xlink:label="idya_PolymeraseThetaProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_WernerHelicaseProgramMember" xlink:label="idya_WernerHelicaseProgramMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_MethionineAdenosylTransferase2AProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="idya_CollaborationRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_PolymeraseThetaProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_WernerHelicaseProgramMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_GlaxoSmithKlineCollaborationAgreementMember" xlink:label="idya_GlaxoSmithKlineCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_GlaxoSmithKlineMember" xlink:label="idya_GlaxoSmithKlineMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_NumberOfPerformanceObligations" xlink:label="idya_NumberOfPerformanceObligations"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PolymeraseThetaProgramMember" xlink:label="idya_PolymeraseThetaProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_WernerHelicaseProgramMember" xlink:label="idya_WernerHelicaseProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation" xlink:label="idya_AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone" xlink:label="idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_MilestonePaymentReceivedClinicalEvaluation" xlink:label="idya_MilestonePaymentReceivedClinicalEvaluation"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ReimbursementPeriodOfCostsIncurred" xlink:label="idya_ReimbursementPeriodOfCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DeterminationPeriodOfCostsIncurred" xlink:label="idya_DeterminationPeriodOfCostsIncurred"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_GlaxoSmithKlineCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="idya_GlaxoSmithKlineMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="idya_NumberOfPerformanceObligations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_PolymeraseThetaProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_WernerHelicaseProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="idya_AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="idya_MilestonePaymentReceivedClinicalEvaluation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="idya_ReimbursementPeriodOfCostsIncurred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="idya_DeterminationPeriodOfCostsIncurred" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DarovasertibMember" xlink:label="idya_DarovasertibMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ExternalClinicalDevelopmentExpenses" xlink:label="idya_ExternalClinicalDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_IDE397Member" xlink:label="idya_IDE397Member"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PersonnelRelatedAndStock-BasedCompensation" xlink:label="idya_PersonnelRelatedAndStock-BasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_IDE161Member" xlink:label="idya_IDE161Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="idya_DarovasertibMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="idya_ExternalClinicalDevelopmentExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="idya_IDE397Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="idya_PersonnelRelatedAndStock-BasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="idya_IDE161Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_HengruiPharmaLicenseAgreementMember" xlink:label="idya_HengruiPharmaLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_OtherResearchAndDevelopmentExpenseMember" xlink:label="idya_OtherResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_UpfrontPayment" xlink:label="idya_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_BiocytogenOptionAndLicenseAgreementMember" xlink:label="idya_BiocytogenOptionAndLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_UpfrontAndOptionLicenseExerciseFees" xlink:label="idya_UpfrontAndOptionLicenseExerciseFees"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_HengruiPharmaLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="idya_OtherResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_UpfrontPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_BiocytogenOptionAndLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="idya_UpfrontAndOptionLicenseExerciseFees" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_JanuaryTwoThousandTwentyFourSalesAgreementMember" xlink:label="idya_JanuaryTwoThousandTwentyFourSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AtTheMarketOfferingMember" xlink:label="idya_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_JefferiesLLCMember" xlink:label="idya_JefferiesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_SouthSanFranciscoCaliforniaMember" xlink:label="idya_SouthSanFranciscoCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_CommonStockRemainingAvailableToBeSaleAmount" xlink:label="idya_CommonStockRemainingAvailableToBeSaleAmount"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_OperatingLeasesAdditionalAreaLeased" xlink:label="idya_OperatingLeasesAdditionalAreaLeased"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="idya_JanuaryTwoThousandTwentyFourSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="idya_AtTheMarketOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeaseAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="idya_JefferiesLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="idya_SouthSanFranciscoCaliforniaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="idya_CommonStockRemainingAvailableToBeSaleAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="idya_OperatingLeasesAdditionalAreaLeased" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PresidentAndCEOMember" xlink:label="idya_PresidentAndCEOMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="idya_PresidentAndCEOMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ReceivablesNetCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails3">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="idya_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:label="idya_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCash" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="idya_ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="5" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="6" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="7" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="8" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="9" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="idya_IncreaseDecreaseInOperatingLeaseLiabilities" order="10" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts" xlink:label="idya_ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="idya_IncreaseDecreaseInOperatingLeaseLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InvestmentOwnedAtCost" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InvestmentOwnedAtCost" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InvestmentOwnedAtCost" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="us-gaap_InvestmentOwnedAtCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="idya_AccruedResearchAndDevelopmentExpensesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="idya_AccruedResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="idya_EffectiveIncomeTaxRateReconciliationSection162MLimitation" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_EffectiveIncomeTaxRateReconciliationSection162MLimitation" xlink:label="idya_EffectiveIncomeTaxRateReconciliationSection162MLimitation"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="idya_DeferredTaxLiabilitiesRightOfUseAssets" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="2" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="idya_DeferredTaxAssetsLeaseLiability" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="6" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="idya_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_DeferredTaxAssetsLeaseLiability" xlink:label="idya_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="idya_ExternalClinicalDevelopmentExpenses" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="idya_PersonnelRelatedAndStock-BasedCompensation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_ExternalClinicalDevelopmentExpenses" xlink:label="idya_ExternalClinicalDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="idya-20241231.xsd#idya_PersonnelRelatedAndStock-BasedCompensation" xlink:label="idya_PersonnelRelatedAndStock-BasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="idya_MilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies" name="MilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="idya_SharesIssuedWeightedAverageSalesPricePerShare" name="SharesIssuedWeightedAverageSalesPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="idya_SouthSanFranciscoCaliforniaMember" name="SouthSanFranciscoCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_PropertyPlantAndEquipmentUsefulLifeDescription" name="PropertyPlantAndEquipmentUsefulLifeDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock" name="SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_FairValueMeasurementsAndMarketableSecuritiesTextBlock" name="FairValueMeasurementsAndMarketableSecuritiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_MarketableSecuritiesRemainingMaturityPeriod" name="MarketableSecuritiesRemainingMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived" name="DevelopmentAndRegulatoryMilestonePaymentToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="idya_CommonStockSubjectToOutstandingPreFundedWarrantsExercised" name="CommonStockSubjectToOutstandingPreFundedWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_CashCashEquivalentsAndMarketableSecurities" name="CashCashEquivalentsAndMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="idya_NumberOfCommonStockVotingRightsHeldPerShare" name="NumberOfCommonStockVotingRightsHeldPerShare" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="idya_ReimbursementPeriodOfCostsIncurred" name="ReimbursementPeriodOfCostsIncurred" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_AccruedResearchAndDevelopmentExpensesCurrent" name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="idya_CertainCommercialSalesMilestonesPaymentToBePaid" name="CertainCommercialSalesMilestonesPaymentToBePaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="idya_DevelopmentCostsSharingPercentage" name="DevelopmentCostsSharingPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_CloudComputingArrangementsPolicyTextBlock" name="CloudComputingArrangementsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_ClassOfWarrantOrRightsIssueDate" name="ClassOfWarrantOrRightsIssueDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember" name="TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_JanuaryTwoThousandTwentyOneSalesAgreementMember" name="JanuaryTwoThousandTwentyOneSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember" name="TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_TwoThousandNineteenEmployeeStockPurchasedPlanMember" name="TwoThousandNineteenEmployeeStockPurchasedPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_DarovasertibMember" name="DarovasertibMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_CommercialMilestonePaymentToBeReceived" name="CommercialMilestonePaymentToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="idya_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_UnvestedEarlyExercisedCommonStockOptionsMember" name="UnvestedEarlyExercisedCommonStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_TwoThousandTwentyThreeInducementPlanMember" name="TwoThousandTwentyThreeInducementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_UpfrontAndOptionLicenseExerciseFees" name="UpfrontAndOptionLicenseExerciseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="idya_OrphanDrugCreditsMember" name="OrphanDrugCreditsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_DeterminationPeriodOfCostsIncurred" name="DeterminationPeriodOfCostsIncurred" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_IDE397Member" name="IDE397Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_SalesOfCommonStockAggregateOfferingPrice" name="SalesOfCommonStockAggregateOfferingPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="idya_BiocytogenOptionAndLicenseAgreementMember" name="BiocytogenOptionAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents" name="PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="idya_DevelopmentMilestonePaymentToBeReceived" name="DevelopmentMilestonePaymentToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="idya_DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies" name="DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="idya_SignificantAgreementsAbstract" name="SignificantAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_ExternalClinicalDevelopmentExpenses" name="ExternalClinicalDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="idya_PercentageOfProfitShare" name="PercentageOfProfitShare" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_UnpaidAtTheMarketOfferingProgramCosts" name="UnpaidAtTheMarketOfferingProgramCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="idya_AdditionalPaymentOfDevelopmentMilestoneToAchieve" name="AdditionalPaymentOfDevelopmentMilestoneToAchieve" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="idya_UpfrontPayment" name="UpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="idya_WernerHelicaseProgramMember" name="WernerHelicaseProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_MilestonePaymentReceivedClinicalEvaluation" name="MilestonePaymentReceivedClinicalEvaluation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="idya_JiangsuHengruiPharmaceuticalsCoLtdMember" name="JiangsuHengruiPharmaceuticalsCoLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_MarketableSecuritiesNonCurrentMember" name="MarketableSecuritiesNonCurrentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_PersonnelRelatedAndStock-BasedCompensation" name="PersonnelRelatedAndStock-BasedCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="idya_LaboratoryAndOfficeFacilitiesMember" name="LaboratoryAndOfficeFacilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_CollaborationRevenue" name="CollaborationRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="idya_OperatingLeasesAreaLeased" name="OperatingLeasesAreaLeased" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="idya_GlaxoGroupLimitedMember" name="GlaxoGroupLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="idya_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_TwoThousandTwentyThreeAprilPublicOfferingMember" name="TwoThousandTwentyThreeAprilPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_JanuaryTwoThousandTwentyOneSalesAgreementAndJuneTwoThousandTwentyThreeSalesAgreementMember" name="JanuaryTwoThousandTwentyOneSalesAgreementAndJuneTwoThousandTwentyThreeSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone" name="MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="idya_TotalMilestonePaymentToBeReceived" name="TotalMilestonePaymentToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="idya_PaymentOfOptionExerciseFee" name="PaymentOfOptionExerciseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="idya_TenPercentStockholderMember" name="TenPercentStockholderMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies" name="DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="idya_TwoThousandTwentyThreeOctoberPublicOfferingMember" name="TwoThousandTwentyThreeOctoberPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_PresidentAndCEOMember" name="PresidentAndCEOMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_OperatingLeasesAdditionalAreaLeased" name="OperatingLeasesAdditionalAreaLeased" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="idya_VestingOfEarlyExercisedOptionsAndRestrictedStock" name="VestingOfEarlyExercisedOptionsAndRestrictedStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="idya_MilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies" name="MilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="idya_AmgenClinicalTrialCollaborationAndSupplyAgreementMember" name="AmgenClinicalTrialCollaborationAndSupplyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_TwoThousandFifteenAndNineteenEquityIncentivePlansMember" name="TwoThousandFifteenAndNineteenEquityIncentivePlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_OperatingLeaseCommencementDescription" name="OperatingLeaseCommencementDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent" name="AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="idya_ExerciseOfOutstandingOptionsMember" name="ExerciseOfOutstandingOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_GlaxoSmithKlineMember" name="GlaxoSmithKlineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_UpfrontFeePayment" name="UpfrontFeePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="idya_EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive" name="EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="idya_LeaseExpirationMonthAndYear" name="LeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_SanDiegoCaliforniaMember" name="SanDiegoCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation" name="AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="idya_MethionineAdenosylTransferase2AProgramMember" name="MethionineAdenosylTransferase2AProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_ESPPMaximumSharesPurchasablePerPeriodPerEmployee" name="ESPPMaximumSharesPurchasablePerPeriodPerEmployee" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="idya_JanuaryTwoThousandTwentyFourSalesAgreementMember" name="JanuaryTwoThousandTwentyFourSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_FairValueMeasurementsAndMarketableSecuritiesPolicyTextBlock" name="FairValueMeasurementsAndMarketableSecuritiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts" name="ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="idya_CancerResearchTechnologyAndTheUniversityOfManchesterMember" name="CancerResearchTechnologyAndTheUniversityOfManchesterMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_NovartisInternationalPharmaceuticalsLimitedMember" name="NovartisInternationalPharmaceuticalsLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_NetProceedsFromIssuanceOfCommonStock" name="NetProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="idya_GlaxoSmithKlineCollaborationAgreementMember" name="GlaxoSmithKlineCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_CommonStockRemainingAvailableToBeSaleAmount" name="CommonStockRemainingAvailableToBeSaleAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="idya_HengruiPharmaLicenseAgreementMember" name="HengruiPharmaLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_PolymeraseThetaProgramMember" name="PolymeraseThetaProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" name="MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement" name="NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_NumberOfPerformanceObligations" name="NumberOfPerformanceObligations" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_BiocytogenPharmaceuticalsBeijingCoLtdMember" name="BiocytogenPharmaceuticalsBeijingCoLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_ResearchAndExperimentalExpendituresAmortizePeriod" name="ResearchAndExperimentalExpendituresAmortizePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_ContingentDevelopmentAndSalesBasedMilestonePayments" name="ContingentDevelopmentAndSalesBasedMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="idya_AggregatePotentialMilestonePayments" name="AggregatePotentialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="idya_EffectiveIncomeTaxRateReconciliationSection162MLimitation" name="EffectiveIncomeTaxRateReconciliationSection162MLimitation" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_MilestonePaymentsRelatingToFirstAndSecondTumorHistologies" name="MilestonePaymentsRelatingToFirstAndSecondTumorHistologies" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="idya_ScheduleOfOperatingLeaseInTheBalanceSheetAndOtherLeaseInformationTableTextBlock" name="ScheduleOfOperatingLeaseInTheBalanceSheetAndOtherLeaseInformationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_SecondAmendmentMember" name="SecondAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_OtherResearchAndDevelopmentExpenseMember" name="OtherResearchAndDevelopmentExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_LesseeOperatingLeaseExistenceOfOptionToRenew" name="LesseeOperatingLeaseExistenceOfOptionToRenew" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_SeriesBRedeemableConvertiblePreferredStockMember" name="SeriesBRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_TwoThousandNineteenIncentiveAwardPlanMember" name="TwoThousandNineteenIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_DevelopmentAndRegulatoryMilestonePaymentToBePaid" name="DevelopmentAndRegulatoryMilestonePaymentToBePaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="idya_IDE161Member" name="IDE161Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_FollowOnPublicOfferingMember" name="FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" name="AccruedResearchAndDevelopmentExpensesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_TaxCreditCarryForwardExpirationYear" name="TaxCreditCarryForwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_ESPPDiscountedPurchasePricePercentage" name="ESPPDiscountedPurchasePricePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="idya_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="idya_PayForExternalThirdPartyCostPercentage" name="PayForExternalThirdPartyCostPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized" name="RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_PaymentOfOneTimeOptionExerciseFee" name="PaymentOfOneTimeOptionExerciseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="idya_JefferiesLLCMember" name="JefferiesLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_SouthSanFranciscoMember" name="SouthSanFranciscoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants" name="AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_MarketableSecuritiesCurrentMember" name="MarketableSecuritiesCurrentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_UpfrontPaymentFee" name="UpfrontPaymentFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="idya_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_OperatingLeasesDisclosuresTableTextBlock" name="OperatingLeasesDisclosuresTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="idya_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="idya_OperatingLeaseCommencementMonthAndYear" name="OperatingLeaseCommencementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_JuneTwoThousandTwentyThreeSalesAgreementMember" name="JuneTwoThousandTwentyThreeSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="idya_ClinicalCombinationStudyWindDownMonthAndYear" name="ClinicalCombinationStudyWindDownMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="idya_UnpaidOfferingCosts" name="UnpaidOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069716996816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 14, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IDYA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IDEAYA Biosciences, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001676725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,537,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-4268251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5000 Shoreline Court<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">443-6209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Jose, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the registrant&#8217;s definitive Proxy Statement relating to the 2025 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying balance sheets of IDEAYA Biosciences, Inc. (the "Company") as of December 31, 2024 and 2023, and the related statements of operations and comprehensive loss, of stockholders&#8217; equity and of cash flows for each of the three years in the period ended December 31, 2024, including the related notes (collectively referred to as the "financial statements"). We also have audited the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control - Integrated Framework </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control - Integrated Framework</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (2013) issued by the COSO.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069717707408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 84,378<span></span>
</td>
<td class="nump">$ 157,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term marketable securities</a></td>
<td class="nump">591,941<span></span>
</td>
<td class="nump">368,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">13,391<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">689,713<span></span>
</td>
<td class="nump">532,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="nump">405,832<span></span>
</td>
<td class="nump">107,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,966<span></span>
</td>
<td class="nump">6,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">18,775<span></span>
</td>
<td class="nump">2,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,124,091<span></span>
</td>
<td class="nump">649,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">15,421<span></span>
</td>
<td class="nump">6,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">30,352<span></span>
</td>
<td class="nump">18,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">1,747<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">46,071<span></span>
</td>
<td class="nump">27,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">18,873<span></span>
</td>
<td class="nump">1,125<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">64,944<span></span>
</td>
<td class="nump">28,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of December 31, 2024 and December 31, 2023; no shares issued and outstanding as of December 31, 2024 and December 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 300,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 86,503,509 and 65,039,369 shares issued and outstanding as of December 31, 2024 and December 31, 2023</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,681,167<span></span>
</td>
<td class="nump">968,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">812<span></span>
</td>
<td class="nump">562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(622,841)<span></span>
</td>
<td class="num">(348,364)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,059,147<span></span>
</td>
<td class="nump">621,090<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,124,091<span></span>
</td>
<td class="nump">$ 649,316<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069715220720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">86,503,509<span></span>
</td>
<td class="nump">65,039,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">86,503,509<span></span>
</td>
<td class="nump">65,039,369<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069715643040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 23,385<span></span>
</td>
<td class="nump">$ 50,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">294,673<span></span>
</td>
<td class="nump">129,508<span></span>
</td>
<td class="nump">89,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">39,302<span></span>
</td>
<td class="nump">28,306<span></span>
</td>
<td class="nump">23,897<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">333,975<span></span>
</td>
<td class="nump">157,814<span></span>
</td>
<td class="nump">113,433<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(326,975)<span></span>
</td>
<td class="num">(134,429)<span></span>
</td>
<td class="num">(62,502)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest income and other income, net</a></td>
<td class="nump">52,498<span></span>
</td>
<td class="nump">21,468<span></span>
</td>
<td class="nump">3,847<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(274,477)<span></span>
</td>
<td class="num">(112,961)<span></span>
</td>
<td class="num">(58,655)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains (losses) on marketable securities</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">3,433<span></span>
</td>
<td class="num">(2,159)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (274,227)<span></span>
</td>
<td class="num">$ (109,528)<span></span>
</td>
<td class="num">$ (60,814)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic</a></td>
<td class="num">$ (3.36)<span></span>
</td>
<td class="num">$ (1.96)<span></span>
</td>
<td class="num">$ (1.42)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted</a></td>
<td class="num">$ (3.36)<span></span>
</td>
<td class="num">$ (1.96)<span></span>
</td>
<td class="num">$ (1.42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares outstanding used in computing net loss per share, basic</a></td>
<td class="nump">81,678,069<span></span>
</td>
<td class="nump">57,519,929<span></span>
</td>
<td class="nump">41,444,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares outstanding used in computing net loss per share, diluted</a></td>
<td class="nump">81,678,069<span></span>
</td>
<td class="nump">57,519,929<span></span>
</td>
<td class="nump">41,444,696<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069716414752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Follow-on Public Offering</div></th>
<th class="th"><div>At-the-market Offering</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Follow-on Public Offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>At-the-market Offering</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Follow-on Public Offering</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>At-the-market Offering</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 301,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 478,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (712)<span></span>
</td>
<td class="num">$ (176,748)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,533,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,081<span></span>
</td>
<td class="nump">$ 8,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,080<span></span>
</td>
<td class="nump">$ 8,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,761,905<span></span>
</td>
<td class="nump">601,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">1,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan (ESPP) purchase</a></td>
<td class="nump">755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan (ESPP) purchase, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">11,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive gain (loss)</a></td>
<td class="num">(2,159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(58,655)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,655)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">349,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">587,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,871)<span></span>
</td>
<td class="num">(235,403)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,193,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,122<span></span>
</td>
<td class="nump">28,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,120<span></span>
</td>
<td class="nump">28,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,655,993<span></span>
</td>
<td class="nump">1,188,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrants for the purchase of common stock</a></td>
<td class="nump">42,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">9,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">931,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan (ESPP) purchase</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan (ESPP) purchase, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">18,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive gain (loss)</a></td>
<td class="nump">3,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(112,961)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(112,961)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">621,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">968,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">562<span></span>
</td>
<td class="num">(348,364)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,039,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,350<span></span>
</td>
<td class="nump">$ 379,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,349<span></span>
</td>
<td class="nump">$ 379,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,355,714<span></span>
</td>
<td class="nump">10,182,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrants for the purchase of common stock</a></td>
<td class="nump">9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants', window );">Exercise of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,749,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">12,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,118,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan (ESPP) purchase</a></td>
<td class="nump">1,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan (ESPP) purchase, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">34,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive gain (loss)</a></td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(274,477)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(274,477)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 1,059,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,681,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 812<span></span>
</td>
<td class="num">$ (622,841)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,503,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital, exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069716268704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (274,477)<span></span>
</td>
<td class="num">$ (112,961)<span></span>
</td>
<td class="num">$ (58,655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,387<span></span>
</td>
<td class="nump">2,476<span></span>
</td>
<td class="nump">2,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization (accretion) of premiums (discounts) on marketable securities</a></td>
<td class="num">(23,233)<span></span>
</td>
<td class="num">(11,553)<span></span>
</td>
<td class="num">(695)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">34,746<span></span>
</td>
<td class="nump">18,489<span></span>
</td>
<td class="nump">11,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right of use assets</a></td>
<td class="nump">1,447<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">1,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(6,174)<span></span>
</td>
<td class="num">(2,045)<span></span>
</td>
<td class="num">(2,119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">8,280<span></span>
</td>
<td class="nump">2,635<span></span>
</td>
<td class="nump">1,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">10,794<span></span>
</td>
<td class="nump">1,635<span></span>
</td>
<td class="nump">4,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,753)<span></span>
</td>
<td class="num">(46,479)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(1,369)<span></span>
</td>
<td class="num">(1,872)<span></span>
</td>
<td class="num">(1,699)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(247,584)<span></span>
</td>
<td class="num">(115,224)<span></span>
</td>
<td class="num">(87,175)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment, net</a></td>
<td class="num">(3,857)<span></span>
</td>
<td class="num">(2,368)<span></span>
</td>
<td class="num">(3,443)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(1,191,309)<span></span>
</td>
<td class="num">(595,980)<span></span>
</td>
<td class="num">(255,808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">692,607<span></span>
</td>
<td class="nump">439,892<span></span>
</td>
<td class="nump">225,847<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(502,559)<span></span>
</td>
<td class="num">(158,456)<span></span>
</td>
<td class="num">(33,404)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in public offering, net of issuance costs</a></td>
<td class="nump">274,350<span></span>
</td>
<td class="nump">281,165<span></span>
</td>
<td class="nump">86,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuances of pre-funded warrants</a></td>
<td class="nump">9,400<span></span>
</td>
<td class="nump">42,182<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts', window );">Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs</a></td>
<td class="nump">379,879<span></span>
</td>
<td class="nump">28,598<span></span>
</td>
<td class="nump">8,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
<td class="nump">12,483<span></span>
</td>
<td class="nump">9,559<span></span>
</td>
<td class="nump">1,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from ESPP purchases</a></td>
<td class="nump">1,439<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">755<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">677,551<span></span>
</td>
<td class="nump">362,717<span></span>
</td>
<td class="nump">97,165<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(72,592)<span></span>
</td>
<td class="nump">89,037<span></span>
</td>
<td class="num">(23,414)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, at beginning of period</a></td>
<td class="nump">157,775<span></span>
</td>
<td class="nump">68,738<span></span>
</td>
<td class="nump">92,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, at end of period</a></td>
<td class="nump">85,183<span></span>
</td>
<td class="nump">157,775<span></span>
</td>
<td class="nump">68,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">84,378<span></span>
</td>
<td class="nump">157,018<span></span>
</td>
<td class="nump">68,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">757<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">85,183<span></span>
</td>
<td class="nump">157,775<span></span>
</td>
<td class="nump">68,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for a new operating lease liability</a></td>
<td class="nump">17,976<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment in accounts payable and accrued liabilities</a></td>
<td class="nump">1,479<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_UnpaidOfferingCosts', window );">Unpaid offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_UnpaidAtTheMarketOfferingProgramCosts', window );">Unpaid at-the-market offering program costs</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_UnpaidAtTheMarketOfferingProgramCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid At-the-market offering program costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_UnpaidAtTheMarketOfferingProgramCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_UnpaidOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_UnpaidOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069716707296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy, and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity Risk Management and Strategy</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF). This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the NIST CSF as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.</span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk management program is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into our overall risk management program, and shares common methodologies, reporting channels and governance processes that apply across the risk management program to other legal, compliance, strategic, operational, and financial risk areas.</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Key elements of our cybersecurity risk management program include but are not limited to the following:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk assessments designed to help identify material risks from cybersecurity threats to our critical systems and information;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a security team principally responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a documented set of cybersecurity policies and procedures that specifies the manner in which security controls are implemented;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security processes</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity awareness training of our employees, including incident response personnel, and senior management; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a third-party risk management process for key service providers based on our assessment of their criticality to our operations and respective risk profile,, suppliers, and vendors who have access to our critical systems and information.</span></span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that our cybersecurity risk management program and processes, including our policies, controls or procedures, will be fully implemented, complied with or effective in protecting our systems and information.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face risks from cybersecurity threats that, if realized, are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For more information, see the section titled &#8220;Risk Factor&#8212; Our information technology systems, or those of our collaborators, CROs or other contractors or consultants, may fail or suffer security breaches, which could adversely affect our business. Security breaches, loss of data or financial assets, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity Governance</span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee, or the Committee, oversight of cybersecurity risks, including oversight of management&#8217;s implementation of our cybersecurity risk management program.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Committee is composed of members of our board of directors with diverse expertise, including risk management, public accounting, biotechnology, chief executive officer roles, and multiple public company directorships, which has prepared them to oversee our cybersecurity risks.</span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee receives quarterly reports from management on our cybersecurity risks. In addition, management updates the Committee where it deems appropriate, regarding any cybersecurity incidents it considers to be significant or potentially significant.</span></p></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee reports to our full board of directors regarding its activities, including those related to cybersecurity.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The full board of directors also receives briefings from management on our cybersecurity risk management program. Board members receive presentations on cybersecurity topics from our Senior Vice President, or SVP, Head of Finance and Investor Relations, Senior Vice President, General Counsel, internal security staff and external experts as part of the board of directors&#8217; continuing education on topics that impact public companies.</span></p></div><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Andres Briseno, our SVP, Head of Finance and Investor Relations and, Douglas Snyder, our Senior Vice President, General Counsel, are primarily responsible for assessing and managing our material risks from cybersecurity threats.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Mr. Briseno and Mr. Snyder have primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Briseno has served in a number of significant leadership roles at our company since 2016, including oversight of investor relations, business operations and corporate developments, and was appointed as SVP, Head of Finance and Investor Relations in 2023.</span></span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Mr. Snyder has served in a number of significant leadership roles in various companies in the healthcare industry, and provided an oversight to legal and compliance teams with his broad legal background. Prior to joining our company, Mr. Snyder served in senior leadership and operations roles across healthcare field, including biotechnology, pharmaceuticals and the FDA</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Further, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our management team&#8217;s experience includes monitoring the cybersecurity landscape for new risks and best practices, developing and executing cybersecurity strategies, overseeing related governance policies, testing compliance with applicable technical standards, remediating known risks and leading employee training programs.</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the information technology environment.</span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk management program is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into our overall risk management program, and shares common methodologies, reporting channels and governance processes that apply across the risk management program to other legal, compliance, strategic, operational, and financial risk areas.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee, or the Committee, oversight of cybersecurity risks, including oversight of management&#8217;s implementation of our cybersecurity risk management program.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Committee is composed of members of our board of directors with diverse expertise, including risk management, public accounting, biotechnology, chief executive officer roles, and multiple public company directorships, which has prepared them to oversee our cybersecurity risks.</span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee receives quarterly reports from management on our cybersecurity risks. In addition, management updates the Committee where it deems appropriate, regarding any cybersecurity incidents it considers to be significant or potentially significant.</span></p></div><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee reports to our full board of directors regarding its activities, including those related to cybersecurity.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The full board of directors also receives briefings from management on our cybersecurity risk management program. Board members receive presentations on cybersecurity topics from our Senior Vice President, or SVP, Head of Finance and Investor Relations, Senior Vice President, General Counsel, internal security staff and external experts as part of the board of directors&#8217; continuing education on topics that impact public companies.</span></p></div><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Andres Briseno, our SVP, Head of Finance and Investor Relations and, Douglas Snyder, our Senior Vice President, General Counsel, are primarily responsible for assessing and managing our material risks from cybersecurity threats.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Mr. Briseno and Mr. Snyder have primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Briseno has served in a number of significant leadership roles at our company since 2016, including oversight of investor relations, business operations and corporate developments, and was appointed as SVP, Head of Finance and Investor Relations in 2023.</span></span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Mr. Snyder has served in a number of significant leadership roles in various companies in the healthcare industry, and provided an oversight to legal and compliance teams with his broad legal background. Prior to joining our company, Mr. Snyder served in senior leadership and operations roles across healthcare field, including biotechnology, pharmaceuticals and the FDA</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Further, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our management team&#8217;s experience includes monitoring the cybersecurity landscape for new risks and best practices, developing and executing cybersecurity strategies, overseeing related governance policies, testing compliance with applicable technical standards, remediating known risks and leading employee training programs.</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the information technology environment.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee, or the Committee, oversight of cybersecurity risks, including oversight of management&#8217;s implementation of our cybersecurity risk management program.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee reports to our full board of directors regarding its activities, including those related to cybersecurity.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The full board of directors also receives briefings from management on our cybersecurity risk management program. Board members receive presentations on cybersecurity topics from our Senior Vice President, or SVP, Head of Finance and Investor Relations, Senior Vice President, General Counsel, internal security staff and external experts as part of the board of directors&#8217; continuing education on topics that impact public companies.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Andres Briseno, our SVP, Head of Finance and Investor Relations and, Douglas Snyder, our Senior Vice President, General Counsel, are primarily responsible for assessing and managing our material risks from cybersecurity threats.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Mr. Briseno and Mr. Snyder have primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Briseno has served in a number of significant leadership roles at our company since 2016, including oversight of investor relations, business operations and corporate developments, and was appointed as SVP, Head of Finance and Investor Relations in 2023.</span></span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Mr. Snyder has served in a number of significant leadership roles in various companies in the healthcare industry, and provided an oversight to legal and compliance teams with his broad legal background. Prior to joining our company, Mr. Snyder served in senior leadership and operations roles across healthcare field, including biotechnology, pharmaceuticals and the FDA</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Further, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our management team&#8217;s experience includes monitoring the cybersecurity landscape for new risks and best practices, developing and executing cybersecurity strategies, overseeing related governance policies, testing compliance with applicable technical standards, remediating known risks and leading employee training programs.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Andres Briseno, our SVP, Head of Finance and Investor Relations and, Douglas Snyder, our Senior Vice President, General Counsel, are primarily responsible for assessing and managing our material risks from cybersecurity threats.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Mr. Briseno and Mr. Snyder have primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Briseno has served in a number of significant leadership roles at our company since 2016, including oversight of investor relations, business operations and corporate developments, and was appointed as SVP, Head of Finance and Investor Relations in 2023.</span></span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Briseno has served in a number of significant leadership roles at our company since 2016, including oversight of investor relations, business operations and corporate developments, and was appointed as SVP, Head of Finance and Investor Relations in 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Mr. Snyder has served in a number of significant leadership roles in various companies in the healthcare industry, and provided an oversight to legal and compliance teams with his broad legal background. Prior to joining our company, Mr. Snyder served in senior leadership and operations roles across healthcare field, including biotechnology, pharmaceuticals and the FDA</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee receives quarterly reports from management on our cybersecurity risks. In addition, management updates the Committee where it deems appropriate, regarding any cybersecurity incidents it considers to be significant or potentially significant.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069715185568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (274,477)<span></span>
</td>
<td class="num">$ (112,961)<span></span>
</td>
<td class="num">$ (58,655)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069710177680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069718225120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069722058576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Organization</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Description of the Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDEAYA Biosciences, Inc. (the &#8220;Company&#8221;) is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The Company is headquartered in South San Francisco, California and was incorporated in the State of Delaware in June 2015. To date, the Company has been primarily engaged in business planning, research, development, recruiting and raising capital.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Follow-On Offering</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 11, 2024, the Company completed an underwritten public follow-on offering. The offering consisted of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,355,714</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (&#8220;common stock&#8221;), at an offering price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,127,142</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285,715</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.9999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, the Company received aggregate gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">302.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">283.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering expenses.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 27, 2023, the Company completed an underwritten public follow-on offering. The offering consisted of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,797,872</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at an offering price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">797,872</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">319,150</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.4999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, the Company received aggregate gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering expenses.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 27, 2023, the Company completed an underwritten public follow-on offering. The offering consisted of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,858,121</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at an offering price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,418,920</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,020,270</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.4999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, the Company received aggregate gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">201.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering expenses.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At-the-Market Offering</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 26, 2023, the Company filed a new Registration Statement on Form S-3 (File No. 333- 272936) under the Securities Act as an automatic shelf registration statement as a &#8220;well-known seasoned issuer,&#8221; as defined in Rule 405 under the Securities Act. On June 26, 2023, the Company also entered into an Open Market Sales Agreement (the &#8220;June 2023 Sales Agreement&#8221;), with Jefferies LLC (&#8220;Jefferies&#8221;), relating to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of our common stock, having aggregate gross proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million through Jefferies as sales agent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From January 1, 2024 through January 17, 2024, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,115,516</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock for aggregate net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">215.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million at a weighted average sales price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.39</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share under the at-the-market offering pursuant to the June 2023 Sales Agreement with Jefferies as sales agent.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 19, 2024, the Company entered into a new Open Market Sales Agreement (the &#8220;January 2024 Sales Agreement&#8221;), with Jefferies, relating to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of common stock having aggregate gross proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">350.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million through Jefferies as sales agent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, pursuant to the January 2024 Sales Agreement, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,066,866</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock for aggregate net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million at a weighted average sales price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41.28</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share under the at-the-market offering pursuant to the January 2024 Sales Agreement with Jefferies as sales agent. As of December 31, 2024, approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of common stock remained available to be sold under the ATM facility.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may cancel its at-the-market program at any time upon written notice, pursuant to its terms.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has incurred significant losses and negative cash flows from operations in all periods since inception and had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">622.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has financed its operations primarily through the sale and issuance of common stock and the upfront payment and certain milestone payments received from GSK.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, none of the Company&#8217;s product candidates have been approved for sale, and the Company has not generated any revenue from commercial products since inception. Management expects operating losses to continue and increase for the foreseeable future, as the Company progresses clinical development activities for its lead product candidates. The Company&#8217;s prospects are subject to risks, expenses and uncertainties frequently encountered by companies in the biotechnology industry as discussed under Risks and Uncertainties in Note 2. While the Company has been able to raise multiple rounds of financing, there can be no assurance that in the event the Company requires additional financing, such financing will be available on terms which are favorable or at all. Failure to generate sufficient cash flows from operations, raise additional capital or reduce certain discretionary spending would have a material adverse effect on the Company&#8217;s ability to achieve its intended business objectives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had cash, cash equivalents and marketable securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion. Management believes that the Company&#8217;s current cash, cash equivalents and marketable securities will be sufficient to fund its planned operations for at least 12 months from the date of the issuance of these financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069722049248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial statements and accompanying notes have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;).</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include useful lives of property and equipment, determination of the discount rate for operating leases, accruals for research and development activities, revenue recognition, stock-based compensation, and income taxes. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable and operating segment. Financial information about the Company&#8217;s operating segment and geographic areas is presented in Note 13 of the financial statements.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company operates in a dynamic and highly competitive industry and is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturers, contract research organizations and collaboration partners, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company believes that changes in any of the following areas could have a material</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse effect on the Company&#8217;s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials and collaboration activities; regulatory approval and market acceptance of the Company&#8217;s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company&#8217;s ability to attract and retain employees necessary to support its growth.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Products developed by the Company require approvals from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that the products will receive the necessary approvals, or that any approved products will be commercially viable. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval, it could have a materially adverse impact on the Company. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company may require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs which would materially and adversely affect its business, financial condition and operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. Substantially all the Company&#8217;s cash, cash equivalents and marketable securities are held by three financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s investment policy addresses credit ratings, diversification, and maturity dates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company invests its cash equivalents and marketable securities in money market funds, U.S. government securities, commercial paper, and corporate bonds. The Company limits its credit risk associated with cash equivalents and marketable securities by placing them with banks and institutions it believes are creditworthy and in highly rated investments and, by policy, limits the amount of credit exposure with any one commercial issuer. The Company has not experienced any credit losses on its deposits of cash, cash equivalents or marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents that are readily convertible to cash are stated at cost, which approximates fair value. The Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less at the date of purchase to be cash equivalents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash as of December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> consisted of cash balances held as security in connection with the Company&#8217;s facility lease agreements in South San Francisco, California and San Diego, California. The balances are classified as long-term assets on the Company&#8217;s balance sheet.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">securities are investments in marketable securities with maturities greater than three months at the time of purchase. The Company determines the appropriate classification of its investments in marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable securities as available-for-sale. After consideration of the Company&#8217;s risk versus reward objectives and liquidity requirements, the Company may sell these securities prior to their stated maturities. The Company classifies highly liquid securities with maturities beyond 12 months as long-term marketable securities in the balance sheet. These securities are carried at fair value as determined based upon quoted market prices or pricing models for similar securities. Unrealized gains and losses, if any, are excluded from earnings and are reported as a component of accumulated other comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income and other income (expense), net on the statements of operations and comprehensive loss. Realized gains and losses, if any, on available-for-sale securities are included in interest income and other income (expense),</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">net. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying amounts of the Company&#8217;s certain financial instruments, including cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities and market interest rates if applicable. Refer to Note 3 for details on the fair value of marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which is generally between </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d3a6b20e-57d6-4e14-ab8d-c3cbd58018ea;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Leasehold improvements are stated at cost and amortized over the shorter of the useful lives of the assets or the lease term. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations and comprehensive loss in the period realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount of the asset or asset group to the future net cash flows which the asset or asset group is expected to generate. If such asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group exceeds the fair value of the asset or asset group. There have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such impairments of long-lived assets for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if an arrangement is a lease, or contains a lease, at its inception. Operating leases are included in right-of-use (&#8220;ROU&#8221;) assets, lease liabilities, and long-term lease liabilities on the Company&#8217;s balance sheet.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ROU assets and lease liabilities are recognized based on the present value of the future lease payments over the lease term at commencement date. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The ROU asset also includes any lease payments made to the lessor at or before the commencement date, minus lease incentives received, and initial direct costs incurred. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company combines lease and nonlease components.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cloud Computing Arrangements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes certain implementation costs incurred under a cloud computing arrangement that is a service contract. Costs incurred during the application development stage related to the implementation of the hosting arrangement are capitalized and included within prepaid expenses and other current assets, and other non-current assets on the accompanying balance sheets. Amortization of capitalized implementation costs is recognized on a straight-line basis over the term of the associated hosting arrangement when it is ready for its intended use. Costs related to preliminary project activities and post-implementation activities are expensed as incurred.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company follows Accounting Standards Codification Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 606&#8221;). Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company applies the five-step model to contracts when (1) parties have approved the contract and are committed to performing respective obligations, (2) the Company can identify each party&#8217;s rights regarding the goods or services to be transferred, (3) the Company can identify the payment terms for the goods or services to be transferred, (4) the contract has commercial substance, and (5) it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines the performance obligations by assessing whether each promised good or service is distinct. Goods or services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligations when (or as) the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the &#8220;variable consideration constraint&#8221;) that a significant reversal of recognized revenue is not probable.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licenses of intellectual property:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> If a license to the Company&#8217;s intellectual property is determined to be distinct from the other promised goods or services identified in an arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license at the point in time when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other goods or services, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress toward satisfying the performance obligation for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Customer options for additional goods or services: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a contract contains customer options that allow the customer to acquire additional goods or services, including a license to the Company&#8217;s intellectual property, the goods and services underlying the customer options are evaluated to determine whether they are deemed to represent a material right. In determining whether the customer option has a material right, the Company assesses whether there is an option to acquire additional goods or services at a discount. If the customer option is determined not to represent a material right, the option is not considered to be a performance obligation. If the customer option is determined to represent a material right, the material right is recognized as a separate performance obligation. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until the option is exercised.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone payments:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> At the inception of each arrangement or amendment that includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 prescribes two methods to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the expected value method to estimate the amount of variable consideration related to the reimbursement of Pol Theta and WRN program costs which is consistently applied throughout the life of the contract: however, it is not necessary for the Company to use the same approach for all contracts. If it is probable that a significant revenue reversal would not occur when the uncertainty associated with the milestone is resolved, the associated milestone value is included in the transaction price. Milestone payments that are highly susceptible to factors outside the Company&#8217;s influence, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. If there is more than one performance obligation, the transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalties:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upfront payments and fees are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contractual cost sharing payments received from a customer or collaboration partner are accounted for as variable consideration. The Company includes an expected value in the transaction price. Contractual cost sharing payments made to a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">customer or collaboration partner are accounted for as a reduction to the transaction price if such payments are not related to distinct goods or services received from the customer or collaboration partner.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contracts may be amended to account for changes in contract specifications and requirements. Contract modifications exist when the amendment either creates new, or changes existing, enforceable rights and obligations. When contract modifications create new performance obligations and the increase in consideration approximates the standalone selling price for goods and services related to such new performance obligations as adjusted for specific facts and circumstances of the contract, the modification is accounted for as a separate contract. If a contract modification is not accounted for as a separate contract, the Company accounts for the promised goods or services not yet transferred at the date of the contract modification (the remaining promised goods or services) prospectively, as if it were a termination of the existing contract and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. The Company accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. In such case, the effect that the contract modification has on the transaction price, and on the entity&#8217;s measure of progress toward complete satisfaction of the performance obligation, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) at the date of the contract modification (the adjustment to revenue is made on a cumulative catch-up basis).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upfront payment contract liabilities resulting from the Company&#8217;s license and collaboration agreements do not represent a financing component as the payment is not financing the transfer of goods and services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company. As such, the Company does not adjust its revenues for the effects of a significant financing component. Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liability in the Company&#8217;s balance sheets. If the related performance obligation is expected to be satisfied within the next twelve (12) months, this will be classified and included within current contract liability.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of compensation costs, employee benefit costs, costs for contract manufacturing organizations (&#8220;CMOs&#8221;), costs for contract research organizations (&#8220;CROs&#8221;), costs for clinical trials, costs for sponsored research, consulting costs, costs for laboratory supplies, costs for product licenses, facility-related expenses and depreciation. All research and development costs are charged to research and development expenses as incurred and included within the statements of operations and comprehensive loss. Payments associated with licensing agreements to acquire exclusive licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternate commercial use are also expensed as incurred. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Research and Development Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into various agreements with CMOs and CROs. The Company&#8217;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CMOs and CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. Management&#8217;s process involves reviewing open contracts and purchase orders, communicating with applicable personnel to identify services that have been performed, and estimating the level of service performed and the associated costs incurred based on vendor estimates for the services when the Company has not yet been invoiced or otherwise notified of actual costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for stock-based compensation arrangements with employees and non-employees in accordance with ASC 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Compensation. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for stock-based compensation arrangements using a fair value method which requires the recognition of compensation expense related to all stock-based awards. The fair value method requires the Company to estimate the fair value of stock option awards on the date of grant using an option pricing model. The Company uses the Black-Scholes option pricing model to determine the fair value of options granted, which is expensed on a straight-line basis over the vesting period. Generally, the stock options granted by the Company to its employees have a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term and vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year period with </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year cliff vesting.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method whereby deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are currently in effect unless such rate is expected to be different when the deferred item reverses. Valuation allowances are established where necessary to reduce deferred tax assets to the amounts expected to be realized. Deferred tax assets and liabilities are classified as noncurrent on the balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that has a greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits in interest expense and other expense, respectively.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive Income and Loss</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive income and loss include net loss and certain changes in stockholders&#8217; equity that are excluded from net loss, primarily unrealized gains and losses from the Company&#8217;s marketable securities.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss per Share Attributable to Common Stockholders</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. Pre-funded warrants are included in the calculation of basic and diluted earnings per share. For purposes of the diluted net loss per share calculation, stock options, restricted stock and restricted stock that is subject to repurchase at the original purchase price are considered to be potentially dilutive securities. The Company considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of early exercised shares subject to repurchase do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) under its accounting standard codifications (&#8220;ASC&#8221;) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New Accounting Pronouncements Adopted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) under its accounting standard codifications (&#8220;ASC&#8221;) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. These amendments enhance interim disclosure requirements, require disclosure of the title and position of the chief operating decision maker (&#8220;CODM&#8221;), require disclosure of significant segment expenses that are regularly provided to the CODM, clarify circumstances for disclosure of more than one segment profit or loss measure and require that a public entity that has a single reportable segment provide all disclosures required by ASC 280 and amendments. This ASU update is effective for fiscal years beginning after December 15, 2023 for the Company&#8217;s annual report, and interim periods within fiscal years beginning after December 15, 2024. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company adopted this ASU for the annual report for the fiscal year beginning </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and evaluated the impact of the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adoption </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the ASU. It did </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t result in a material impact on the Company's financial statements and related disclosures. See Note 13. Segment Information.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New Accounting Pronouncements, Not yet Adopted</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative, which modifies the disclosure or presentation requirements related to variety of FASB Accounting Standard Codification topics. The effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K is effective. If by June 30, 2027, the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the associated amendment will be removed from the Codification and will not become effective for any entities. The Company is currently evaluating the effect of adopting this ASU.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 14, 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which amends the guidance in ASC 740, Income Taxes. The ASU is intended to improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The ASU&#8217;s amendments are effective for public business entities for annual periods beginning after December 15, 2024. Entities are permitted to early adopt the standard &#8220;for annual financial statements that have not yet been issued or made available for issuance.&#8221; Adoption is either prospectively or retrospectively; the Company will adopt this ASU on a prospective basis. The Company is currently evaluating the impact of the ASU, but does not expect any material impact upon adoption.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 2024, the FASB issued ASU 2024-03 - Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The ASU requires more detailed disclosures about the types of expenses in commonly presented expense captions such as cost of sales, selling, general and administrative expenses and research and development expenses. This includes separate footnote disclosure for expenses such as purchases of inventory, employee compensation, depreciation, and intangible asset amortization. Public business entities are required to apply the guidance prospectively and may apply it retrospectively. The ASU's amendments are effective for public business entities for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Public business entities are required to apply the guidance prospectively and may apply it retrospectively. The Company is currently evaluating the effect of adopting this ASU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069714975968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_FairValueMeasurementsAndMarketableSecuritiesTextBlock', window );">Fair Value Measurement and Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Fair Value Measurement and Marketable Securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Observable inputs, such as quoted prices in active markets for identical assets or liabilities at the measurement date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs which reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as consider counterparty credit risk in its assessment of fair value.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, financial assets measured and recorded at fair value are as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.986%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.002%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.562999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.681999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.521999999999998%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.222000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">552,008</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,214</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">353</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">552,869</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">363,197</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">357</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">419</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">363,135</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,109</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,122</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Subtotal</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,004,314</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,592</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">780</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,005,126</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,626</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,626</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,399</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,399</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total value of assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,081,339</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,592</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">780</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,082,151</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,379</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,378</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in marketable securities, current</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">591,089</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">928</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">591,941</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in marketable securities, non-current</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">405,871</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">664</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">703</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">405,832</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total value of assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,081,339</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,592</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">780</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,082,151</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of commercial paper was included in cash and cash equivalents on the balance sheet due to securities with purchase dates within 90 days of maturity dates.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s short-term marketable securities mature in one year or less.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s long-term marketable securities mature between one and three years.</span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023, financial assets measured and recognized at fair value are as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:30.58%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:9.1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">412,679</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">591</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">413,135</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,983</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">197</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,148</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126,601</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126,543</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Subtotal</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">593,263</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">788</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">593,826</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">480</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">480</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total value of assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">632,043</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">788</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">632,606</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,055</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,018</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in marketable securities, current</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">368,043</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">227</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">368,096</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in marketable securities, non-current</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106,945</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">557</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total value of assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">632,043</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">788</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">632,606</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37.8</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of U.S. government securities and $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80.4</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of commercial paper were included in cash and cash equivalents on the balance sheet due to securities with purchase dates within 90 days of maturity dates</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s short-term marketable securities mature in one year or less.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s long-term marketable securities mature between one and three years</span></div></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, all marketable securities had a remaining maturity of less than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> financial liabilities measured and recognized at fair value as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers available evidence in evaluating potential other-than-temporary impairments of its marketable securities, including the duration and extent to which fair value is less than cost, and the Company&#8217;s ability and intent to hold the investment. As of December 31, 2024 and December 31, 2023, the Company held certain securities in an unrealized loss position. These unrealized losses were considered to be temporary as the Company expects to recover the entire amortized cost basis on the securities in unrealized loss positions based on the creditworthiness of the underlying issuer, and the Company neither intends to sell these securities nor considers it more likely than not that the Company would be required to sell any such security before its anticipated recovery. As a result, the Company did not consider any of these investments to be other-than-temporarily impaired at December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_FairValueMeasurementsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurements and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_FairValueMeasurementsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069715139872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Balance Sheet Components</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.79%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:17.584%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.302000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.302000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Life</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In Years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,513</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,455</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">503</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">231</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">231</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of useful<br/>life or lease term</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,913</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,321</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,517</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">507</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,677</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,775</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,711</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,611</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,966</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,164</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024, 2023 and 2022, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:63.847%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.417%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.417%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,956</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,676</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued salaries and benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,233</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,974</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Legal and professional fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,213</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">959</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">950</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,352</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,756</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069820261664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Operating Leases</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2023, the Company entered into a lease agreement for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of laboratory and office facilities at 5000 Shoreline Court, South San Francisco, California. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The lease term is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120 months</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company has an option to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extend the lease term</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for a total of two consecutive five-year periods</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This lease agreement commenced in August 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, the Company amended its 5000 Shoreline Court facility lease agreement to expand the size of the original premises by adding approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,321</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> rentable square feet of additional space. The lease term for the expanded premises will not begin until the landlord makes certain improvements and offers to deliver possession of the expansion premises to the Company. The lease term for the expanded premises has not yet commenced as of December 31, 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's lease at 7000 Shoreline Court, South San Francisco, California, expired in September 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Company entered into a lease agreement for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,700</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of space at 11710 El Camino Real, San Diego, California for corporate office space. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The lease term commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 2028</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has an option to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">renew the lease</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future minimum lease payments under operating leases included on the Company's balance sheet are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.28%;box-sizing:content-box;"></td>
        <td style="width:3.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">386</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,705</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,389</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,224</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,263</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,790</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total future minimum lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,757</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,586</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,171</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes other information about the Company's operating leases:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.74%;box-sizing:content-box;"></td>
        <td style="width:2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:20.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.22%;box-sizing:content-box;"></td>
        <td style="width:22.44%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.4</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease costs were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024, 2023 and 2022, respectively. Variable lease costs were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024, 2023, and 2022, respectively. Variable lease costs represent additional costs incurred, related to administration, maintenance and property tax costs incurred, which are billed based on both usage and as a percentage of the Company's share of total square footage.</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024, 2023 and 2022, cash paid for amounts included in the measurement of lease liabilities and included within cash used in operating activities in the statement of cash flows was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069715189168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may be involved in litigation related to claims that arise in the ordinary course of its business activities. The Company accrues for these matters when it is probable that future expenditures will be made and these expenditures can be reasonably estimated. As of December 31, 2024, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company&#8217;s financial position, results of operations or cash flows.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company enters into standard indemnification arrangements in the ordinary course of business with vendors, clinical trial sites and other parties. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incurred </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs to defend lawsuits or settle claims related to these indemnification agreements. Accordingly, the Company has not recorded a liability related to such indemnification agreements as of December 31, 2024.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069722206784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Income Taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> provision for income taxes was recorded for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, December 31, 2023 and December 31, 2022. The Company has incurred net operating losses only in the United States since its inception. The Company has not reflected any benefit of such net operating loss carryforwards in the financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The provision for income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.342%;box-sizing:content-box;"></td>
        <td style="width:1.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.312999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.312999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.312999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other permanent differences</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 162(m) limitation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The tax effects of temporary differences and carryforwards of the deferred tax assets are presented below (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:60.328%;box-sizing:content-box;"></td>
        <td style="width:1.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.017%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.017%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,524</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,717</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credit carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,868</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,997</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,074</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">610</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,365</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,096</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,401</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,593</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,468</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,257</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research &amp; development expenditures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,271</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,267</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">168,971</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,537</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,876</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95,888</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,095</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">649</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,990</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">477</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">172</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on the Company&#8217;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#8217;s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during 2024, 2023, and 2022, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">147.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million available to reduce future taxable income, if any, for federal income tax purposes as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023, respectively. The Company had net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million available to reduce future taxable income, if any, for state income tax purposes. If not utilized, the federal carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the state carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2036</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. The federal net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">135.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million arising after December 31, 2017 do not expire.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also had federal and state research and development credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.8</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023, respectively. The Company had Orphan Drug Credits (&#8220;ODC&#8221;), related to the orphan drug designation of darovasertib in 2022, of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. The federal credits will expire starting in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if not utilized, and the state research credit can be carried forward indefinitely.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Tax Reform Act of 1986 limits the use of net operating loss carryforwards in certain situations where changes occur in the stock ownership of a company. The annual limitation may result in the expiration of net operating losses and credits before utilization. The Company performed a Section 382 analysis through December 31, 2024. The Company has not experienced ownership changes in the current year. Subsequent ownership changes may affect the limitation in future years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Related to unrecognized tax benefits noted below, the Company accrued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> penalties or interest during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, December 31, 2023 and December 31, 2022. The Company does not expect its unrecognized tax benefit balance to change materially over the next 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized tax benefits as of December 31, 2024 and December 31, 2023, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits (in thousands).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:72.675%;box-sizing:content-box;"></td>
        <td style="width:2.501%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:22.825%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance as of January 1, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,962</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase related to prior year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">372</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,488</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,822</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Decrease related to prior year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,290</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,927</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company files income tax returns in the U.S. federal jurisdiction and in the states of Arizona, California, New Jersey, North Carolina, Pennsylvania, Texas, Utah and Wisconsin. For jurisdictions in which tax filings have been filed, all tax years remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any net operating losses or credits.</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is under audit in California for tax years </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_338a4ed1-99c5-4700-8268-537e20e71a59;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2020-2021</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069714978096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company&#8217;s certificate of incorporation authorized the Company to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each share of common stock is entitled to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vote.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Company&#8217;s board of directors. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> dividends have been declared to date.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 11, 2024, the Company completed an underwritten public follow-on offering. The offering consisted of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,355,714</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at an offering price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,127,142</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285,715</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.9999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, the Company received aggregate gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">302.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">283.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 27, 2023, the Company completed an underwritten public follow-on offering. The offering consisted of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,797,872</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at an offering price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">797,872</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">319,150</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.4999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, the Company received aggregate gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering expenses.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 27, 2023, the Company completed an underwritten public follow-on offering. The offering consisted of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,858,121</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at an offering price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,418,920</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,020,270</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.4999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, the Company received aggregate gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">201.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering expenses.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, the following aggregate warrants to purchase shares of the Company&#8217;s common stock were issued and outstanding:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:22.324%;box-sizing:content-box;"></td>
        <td style="width:2.521%;box-sizing:content-box;"></td>
        <td style="width:21.904%;box-sizing:content-box;"></td>
        <td style="width:3.161%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.363%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:26.465%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Issue Date</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Expiration Date</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise Price per Share</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Shares subject to Outstanding Warrants</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">July 11, 2024</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">None</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285,715</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 27, 2023</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">None</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">319,150</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 27, 2023</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">None</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">270,270</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) In September 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,750,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock subject to outstanding pre-funded warrants were cashless exercised and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,749,993</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were issued.</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The warrants are classified as a component of Stockholders&#8217; Equity within Additional Paid-in-Capital. The warrants are classified as equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, are indexed to the Company&#8217;s common stock and meet the equity classification criteria. The warrants will not expire until they are fully exercised.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had reserved common stock for future issuance as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.673%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.403%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.403%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of outstanding options under the 2015, 2019 and 2023 Plans</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,737,595</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,269,975</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for grant under the 2019 Plan</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,910,589</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">964,622</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for grant under the 2023 Inducement Plan</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">593,592</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">524,300</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available under the Employee Stock Purchase Plan</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,911,011</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,317,974</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants issued and outstanding</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">875,135</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,339,420</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,027,922</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,416,291</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069713280656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2023 Inducement Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 24, 2023, the Company adopted the IDEAYA Biosciences, Inc. 2023 Employment Inducement Award Plan (the &#8220;2023 Inducement Plan&#8221;), pursuant to which the Company reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company as an inducement material to the individual&#8217;s entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The 2023 Inducement Plan was approved by the Company&#8217;s board of directors without stockholder approval in accordance with such rule. Options granted under the 2023 Inducement Plan have a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and generally vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year period with </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year cliff vesting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 25, 2024, the Company amended the 2023 Employment Inducement Award Plan, increasing the number of shares available for issuance by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the number of shares available for issuance under the 2023 Inducement Plan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">593,592</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2019 Incentive Award Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2019, the Company&#8217;s board of directors adopted and the Company&#8217;s stockholders approved the 2019 Incentive Award Plan (the &#8220;2019 Plan&#8221;), under which the Company may grant cash and equity-based incentive awards to the Company&#8217;s employees, consultants and directors. Following the effectiveness of the 2019 Plan, the Company will not make any further grants under the 2015 Equity Incentive Plan (the &#8220;2015 Plan&#8221;). However, the 2015 Plan continues to govern the terms and conditions of the outstanding awards granted under it. Shares of common stock subject to awards granted under the 2015 Plan that are forfeited or lapse unexercised and which following the effective date of the 2019 Plan are not issued under the 2015 Plan will be available for issuance under the 2019 Plan.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options granted under the 2019 Plan may be either incentive stock options (&#8220;ISOs&#8221;) or nonqualified stock options (&#8220;NSOs&#8221;). ISOs may be granted only to Company employees (including officers and directors who are also employees). NSOs may be granted to Company employees, directors and consultants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2019 Plan is subject to an annual increase on the first day of each year beginning in 2020 and ending in 2029, equal to the lesser of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the shares outstanding on the last day of the immediately preceding fiscal year, and such smaller number of shares as determined by the Company&#8217;s board of directors. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options granted under the 2019 Plan have a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years (or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if granted to a 10% stockholder) and generally vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year period with </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year cliff vesting.</span></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the number of shares available for issuance under the 2019 Plan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,910,589</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2015 Equity Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2015, the Company established its 2015 Plan which provides for the granting of stock options to employees, directors and consultants of the Company. Options granted under the 2015 Plan may be either ISOs or NSOs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2019 Employee Stock Purchase Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2019, the Company&#8217;s board of directors adopted and the Company&#8217;s stockholders approved the 2019 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP provides eligible employees with the opportunity to acquire an ownership interest in the Company through periodic payroll deductions up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of eligible compensation. The offering period is determined by the Company in its discretion but may not exceed </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months. The per-share purchase price on the applicable exercise date for an offering period is equal to the lesser of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the fair market value of the common stock at either the first business day or last business day of the offering period, provided that no more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock may be purchased by any one employee during each offering period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ESPP is intended to constitute an &#8220;employee stock purchase plan&#8221; under Section 423(b) of the Internal Revenue Code of 1986, as amended. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">195,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were initially reserved for issuance under the ESPP, subject to an annual increase on January 1 of each year, beginning on January 1, 2020, equal to the lesser of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the shares outstanding on the last day of the immediately preceding fiscal year and such smaller number of shares as may be determined by the Company&#8217;s board of directors, provided, however, that no more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares may be issued under the ESPP.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the number of shares available for issuance under the ESPP was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,911,011</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For the years ended December 31, 2024, 2023, and 2022 the Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million respectively, of compensation expense related to employee participation in the ESPP.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense recorded related to awards granted to employees and non-employees was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.642%;box-sizing:content-box;"></td>
        <td style="width:1.619%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.834%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.619%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.834%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.619%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.834%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,115</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,826</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,050</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,631</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,663</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,579</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,746</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,489</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,629</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Activity under the Company&#8217;s 2015 and 2019 Plans and 2023 Inducement Plan is set forth below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:37.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.68%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.68%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate    <br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance, January 1, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,269,975</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.53</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.82</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">128.49</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,247,538</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41.88</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,118,695</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.16</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options canceled</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">661,223</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.57</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance, December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,737,595</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.06</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.89</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43.01</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercisable as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,185,690</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.63</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.62</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.04</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vested and expected to vest as of<br/>&#160;&#160;&#160;December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,737,595</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.06</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.89</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43.01</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant-date fair value of options granted during the years ended December 31, 2024, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.93</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.98</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively. The aggregate intrinsic value of options exercised for the years ended December 31, 2024, 2023, 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. Intrinsic values are calculated as the difference between the exercise price of the underlying options and the fair value of the common stock on the date of exercise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and December 31, 2023, the total unrecognized stock-based compensation expense for stock options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.63</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.59</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Black-Scholes Assumptions</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair values of options were calculated using the assumptions set forth below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:37.852%;box-sizing:content-box;"></td>
        <td style="width:1.7%;box-sizing:content-box;"></td>
        <td style="width:19.016%;box-sizing:content-box;"></td>
        <td style="width:1.7%;box-sizing:content-box;"></td>
        <td style="width:19.016%;box-sizing:content-box;"></td>
        <td style="width:1.7%;box-sizing:content-box;"></td>
        <td style="width:19.016%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76.8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81.3</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81.8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86.9</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86.8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89.9</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The expected term represents the weighted-average period the stock options are expected to remain outstanding and is based on the options&#8217; vesting terms and contractual terms.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The expected volatility is based on the Company&#8217;s historical stock price volatility. The historical stock price volatility is calculated based on a period of time commensurate with the expected term assumption for each grant.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-Free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The risk-free rate assumption is based on U.S. Treasury instruments whose term was consistent with the expected term of the Company&#8217;s stock options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Dividend Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has not paid and does not anticipate paying any dividends in the near future. Accordingly, the Company has estimated the dividend yield to be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for forfeitures as they occur.</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the Company&#8217;s common stock is determined based on the market price on the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069715188912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_SignificantAgreementsAbstract', window );"><strong>Significant Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Significant Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Significant Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">GSK Collaboration, Option and License Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2020, the Company entered into the Collaboration, Option and License Agreement (the &#8220;GSK Collaboration Agreement&#8221;), with an affiliate of GSK plc, GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED (&#8220;GSK&#8221;), pursuant to which the Company and GSK have entered into a collaboration for its synthetic lethality programs targeting MAT2A, Pol Theta and Werner Helicase (&#8220;WRN&#8221;). On July 27, 2020, the Company and GSK received Hart-Scott-Rodino Antitrust Improvements Act clearance, and the GSK Collaboration Agreement became effective.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the GSK Collaboration Agreement, GSK paid the Company $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million on July 31, 2020. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, GSK has made aggregate payments in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the achievement of certain development and regulatory milestones with respect to Pol Theta and WRN products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">GSK Collaboration - Pol Theta Program</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the GSK Collaboration Agreement, GSK holds a global, exclusive license to develop and commercialize Pol Theta products arising out of the Pol Theta program. The Company and GSK collaborated on preclinical research for the Pol</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Theta program, and GSK is leading clinical development for the Pol Theta program. GSK is responsible for all research and development costs for the Pol Theta program.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will be eligible to receive total development and regulatory milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">485.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, with respect to each Pol Theta product, including as applicable, for multiple Pol Theta products that target certain alternative protein domains or are based on alternative modalities. Additionally, the Company will be eligible to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">475.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of commercial milestones with respect to each Pol Theta product. The Company is also entitled to receive tiered royalties on global net sales of Pol Theta products by GSK, its affiliates and their sublicensees ranging from high single digit to sub-teen double-digit percentages, subject to certain customary reductions.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2022, the Company announced the nomination of a Pol Theta Helicase Inhibitor development candidate (&#8220;DC&#8221;), and in August 2022, the Company announced the achievement of an initial preclinical development milestone in connection with ongoing investigational new drug (&#8220;IND&#8221;)-enabling studies to support evaluation of Pol Theta Helicase Inhibitor DC, triggering a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment, which the Company received in October 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An IND was submitted and was cleared by the FDA in August 2023 to enable clinical evaluation in combination with niraparib, triggering a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has the potential to achieve an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone upon initiation of Phase 1 clinical dose expansion, as well as potential further aggregate late-stage development and regulatory milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">465.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">GSK Collaboration - Werner Helicase Program</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the GSK Collaboration Agreement, GSK holds a global, exclusive license to develop and commercialize WRN products arising out of the WRN program. The Company and GSK are collaborating on ongoing preclinical research for the WRN program, and GSK will lead clinical development for the WRN program, with the Company responsible for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and GSK responsible for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of such global research and development costs. The cost-sharing percentages will be adjusted based on the actual ratio of U.S. to global profits for WRN products, as measured three and six years after global commercial launch thereof.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will be eligible to receive total development milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">485.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, with respect to each WRN product, including as applicable, for multiple WRN products that are based on alternative modalities. Additionally, the Company will be eligible to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">475.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of commercial milestones with respect to each WRN product. The Company will be entitled to receive </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of U.S. net profits and tiered royalties on global non-U.S. net sales of WRN products by GSK, its affiliates and their sublicensees ranging from high single digit to sub-teen double-digit percentages, subject to certain customary reductions. The Company will have a right to opt-out of the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% U.S. net profit share and corresponding research and development cost share for the WRN program, and would be eligible to receive tiered royalties on U.S. net sales of WRN products by GSK, its affiliates and their sublicensees at the same royalty rates as for global non-U.S. net sales thereafter, with economic adjustments based on the stage of the WRN program at the time of opt-out.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, the Company earned a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone from GSK in connection with IND-enabling studies for the Werner Helicase Inhibitor DC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, an IND was cleared by the FDA to enable clinical evaluation, triggering a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has the potential to earn up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million development milestone upon initiation of Phase 1 clinical dose expansion, as well as potential further aggregate late-stage development and regulatory milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">465.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">GSK Collaboration - General</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the GSK Collaboration Agreement, subject to certain exceptions, the Company and GSK will not, directly or through third parties, develop or commercialize other products whose primary and intended mechanism of action is the modulation of WRN or Pol Theta for an agreed upon period of time. The Company and GSK have formed a joint steering committee, joint development committees, and joint commercialization committees responsible for coordinating all activities under the GSK Collaboration Agreement. Ownership of intellectual property developed under the GSK Collaboration Agreement is allocated between or shared by the parties depending on development and subject matter.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GSK&#8217;s royalty obligations continue with respect to each country and each product until the later of (i) the date on which such product is no longer covered by certain intellectual property rights in such country and (ii) the 10th anniversary of the first commercial sale of such product in such country.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each party has the right to sublicense its rights under the GSK Collaboration Agreement subject to certain conditions.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The GSK Collaboration Agreement will continue in effect on a product-by-product and country-by-country basis until the expiration of the obligation to make payments under the GSK Collaboration Agreement with respect to such product in each country, unless earlier terminated by either party pursuant to its terms. Either party may terminate the GSK Collaboration Agreement for the other party&#8217;s insolvency or certain uncured breaches. The Company may terminate the GSK Collaboration Agreement if GSK or any of its sublicensees or affiliates challenge certain patents of the Company. GSK may terminate the GSK Collaboration Agreement in its entirety or on a target-by-target basis upon </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90-day</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> notice to the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Novartis License Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2018, the Company entered into a License Agreement with Novartis to develop and commercialize Novartis&#8217; LXS196 (also known as IDE196), a Phase 1 PKC inhibitor, for the treatment of cancers having GNAQ and GNA11 mutations. The Company renamed Novartis&#8217; LXS196 oncology as IDE196, and which has a non-proprietary name of darovasertib. Under the license agreement, Novartis granted to the Company a worldwide, exclusive, sublicensable license to research, develop, manufacture, and commercialize certain defined compounds and products, including IDE196 and certain other PKC inhibitors, as well as companion diagnostic products, collectively referred to as the licensed products, for any purpose.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid Novartis an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">263,615</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its Series B redeemable convertible preferred stock concurrently with the execution of the license agreement. Subject to completion of certain clinical and regulatory development milestones, the Company agreed to make milestone payments in the aggregate of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and subject to achievement of certain commercial sales milestones, the Company agreed to make milestone payments in the aggregate of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company also agreed to pay mid to high single-digit tiered royalty payments based on annual worldwide net sales of licensed products, payable on a licensed product-by-licensed product and country by country basis until the latest of the expiration of the last to expire exclusively licensed patent, the expiration of regulatory exclusivity, and the ten year anniversary of the first commercial sale of such product in such country. The royalty payments are subject to reductions for lack of patent coverage, loss of market exclusivity, and payment obligations for third-party licenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pfizer Clinical Trial Collaboration and Supply Agreements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2020, the Company entered into a Clinical Trial Collaboration and Supply Agreement with Pfizer, Inc. (as amended in September 2020, April 2021, September 2021 and May 2023 (the &#8220;Pfizer Agreement&#8221;). Pursuant to the Pfizer Agreement, Pfizer supplies the Company with their MEK inhibitor, binimetinib, and their cMET inhibitor, crizotinib, to evaluate combinations of darovasertib independently with each of the Pfizer compounds, in patients with tumors harboring activating GNAQ or GNA11 mutations. Under the Pfizer Agreement, the Company is the sponsor of the combination studies and will provide darovasertib and pay for the costs of the combination studies. Pfizer will provide binimetinib and crizotinib for use in the clinical trial at no cost to the Company. The Pfizer Agreement provides that the Company and Pfizer will jointly own clinical data generated from the clinical trial and will also jointly own inventions, if any, relating to the combined use of darovasertib and binimetinib, or independently, to the combined use of darovasertib and crizotinib. The Company and Pfizer have formed a joint development committee responsible for coordinating all regulatory and other activities under the agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2022, the Company and Pfizer entered into a Second Clinical Trial Collaboration and Supply Agreement (as amended in May 2023 (the &#8220;Second Pfizer Agreement&#8221;), pursuant to which the Company is evaluating darovasertib and crizotinib as a combination therapy in MUM in a planned Phase 2/3 potential registration-enabling clinical trial. Pursuant to the Second Pfizer Agreement, the Company is the sponsor of the combination trial and the Company will provide darovasertib and pay for the costs of the combination trial, and Pfizer will provide crizotinib for the planned combination trial at no cost to the Company for up to an agreed-upon number of MUM patients. The Company and Pfizer will jointly own clinical data from the planned combination trial and all inventions relating to the combined use of darovasertib and crizotinib. The Company and Pfizer have formed a joint development committee responsible for coordinating all regulatory and other activities under the Second Pfizer Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separately, in March 2022, the Company and Pfizer also entered into a Third Clinical Trial Collaboration and Supply Agreement (the &#8220;Third Pfizer Agreement&#8221;), pursuant to which the Company could, subject to preclinical validation and FDA feedback and guidance, evaluate darovasertib and crizotinib, as a combination therapy in cMET-driven tumors such as NSCLC and/or HCC in a Phase 1 clinical trial. Pursuant to the Third Pfizer Agreement, the Company was the sponsor of the planned combination trial, and the Company would provide darovasertib and pay for the costs of the combination trial. Pfizer would provide crizotinib for the planned combination trial at no cost to the Company. Pursuant to Amendment No. 1 to the Second Pfizer Agreement, as described below, the Company and Pfizer terminated the Third Pfizer Agreement.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2023, the Company continued its relationship with Pfizer by entering into Amendment No. 4 to the Pfizer Agreement relating to the supply of crizotinib in support of this Phase 2 clinical trial, pursuant to which Pfizer will continue to provide the Company with an additional defined quantity of crizotinib at no cost.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expanded its relationship with Pfizer in May 2023 under an Amendment No. 1 to the Second Pfizer Agreement to support the Phase 2/3 registrational trial to evaluate darovasertib and crizotinib as a combination therapy in MUM. Under the as-amended Second Pfizer Agreement, Pfizer will provide the Company with a first defined quantity of crizotinib at no cost, as well as an additional second defined quantity of crizotinib at a lump-sum cost. The Third Pfizer Agreement has been terminated by the Company and Pfizer under Amendment No. 1 to the Second Pfizer Agreement.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we entered into Amendment No. 5 to the Pfizer Agreement for the supply of crizotinib in the Phase 1/2 clinical trial for Pfizer to provide us a defined quantity of crizotinib at defined costs.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cancer Research UK and University of Manchester Exclusive Option and License Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2022, the Company exercised its option for an exclusive worldwide license covering a broad class of poly (ADP-ribose) glycohydrolase (&#8220;PARG&#8221;), inhibitors from Cancer Research Technology Ltd. (&#8220;CRT&#8221;), and the University of Manchester, and in connection therewith, paid a one-time option exercise fee of &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company will be obligated to make payments to CRT aggregating up to a total of &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of specific development and regulatory approval events for development of a PARG inhibitor in oncologic diseases. The Company will also pay low single-digit tiered royalties, and potentially also sales-based milestones, to CRT based on net sales of licensed products. In addition, in the event the Company sublicenses the intellectual property, it will also be obligated to pay CRT a specified percentage of any sublicense revenue.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2023, the Company incurred an obligation to pay milestone payments in an aggregate amount of &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">750,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to CRT based upon the achievement of certain milestones relating to first and second tumor histologies in connection with the Phase 1 portion of the Phase 1/2 clinical trial in oncologic diseases.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will be obligated to make additional payments to CRT aggregating up to &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of specific development and regulatory approval events for development of a PARG inhibitor in oncologic diseases, including an aggregate of up to &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and up to &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the achievement of certain Phase 2 and Phase 3 development milestones, respectively, in each case as relating to first and second tumor histologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amgen Clinical Trial Collaboration and Supply Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2022, the Company entered into a Clinical Trial Collaboration and Supply Agreement with Amgen Inc.(the &#8220;Amgen CTCSA&#8221;), to clinically evaluate IDE397 in combination with AMG 193, the Amgen investigational MTA-cooperative PRMT5 inhibitor, in patients having MTAP-null solid tumors, in a Phase 1/2 clinical trial. Under the mutually non-exclusive Amgen CTCSA, the Company will provide IDE397 drug supply to Amgen, who will be the sponsor of the Phase 1 clinical combination trial evaluating IDE397 and AMG 193. Each party will pay for fifty percent (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%) of the external third-party costs of the combination study. Each party will be responsible for its own internal costs and expenses in support of the combination study. The Company and Amgen will jointly oversee clinical development of the combination therapy through a Joint Oversight Committee responsible for coordinating all regulatory and other activities under the Amgen CTCSA. The parties will jointly own collaboration data and combination-related intellectual property, if any, arising from the combination clinical trial. The Company and Amgen each retain commercial rights to its respective compounds, including with respect to use as a monotherapy agent or combination agent. The Company and Amgen mutually agreed to wind down the IDE397 and AMG 193 clinical combination study in February 2025 and will not pursue dose expansion.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Gilead Clinical Study Collaboration and Supply Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Company entered into a Clinical Study Collaboration and Supply Agreement with Gilead Sciences, Inc. (&#8220;Gilead&#8221;), (&#8220;Gilead CSCSA&#8221;), to clinically evaluate IDE397 in combination with Trodelvy (sacacituzumab-govitecan-hziy), a Trop-2 directed ADC, in patients having MTAP-deletion urothelial cancer, in a Phase 1 clinical trial. Under the mutually non-exclusive Gilead CSCSA, the Company will receive Trodelvy drug supply from Gilead and will sponsor the Phase 1 clinical combination trial evaluating ID397 and Trodelvy. Gilead will bear internal or external costs incurred in connection with its supply of Trodelvy. The Company will bear all internal and external costs and expenses associated with the conduct of the combination study. The Company and Gilead will jointly oversee clinical development of the combination therapy through a Joint Steering Committee responsible for coordinating all regulatory and other activities under the Gilead CSCSA. The Company and Gilead each retain commercial rights to its respective compounds, including with respect to use as a monotherapy agent or combination agent.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 12, 2025, the Company entered into an additional Clinical Study Collaboration and Supply Agreement with Gilead, or the Second Gilead CSCSA, pursuant to which the Company and Gilead will collaborate on a portion of the Company&#8217;s Phase 1 study for the clinical evaluation of our IDE397 compound in combination with Trodelvy, or the Combination Study, in certain patients with advanced solid tumors in lungs. Pursuant to the Second Gilead CSCSA, the Company is the sponsor of the Combination Study and the Company will provide the IDE397 compound and pay for the costs of the Combination Study. Gilead will provide Trodelvy for the Combination Study at no cost to the Company. The Company and Gilead will jointly own clinical data from the Combination Study and all inventions relating to the combined use of IDE397 and Trodelvy. Each party retains commercial rights to its respective compounds, including with respect to use as a monotherapy or combination agent. The Company and Gilead will form a joint steering committee responsible for coordinating all regulatory and other activities under the Second Gilead CSCSA.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Merck Clinical Trial Collaboration and Supply Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, the Company entered into a Clinical Trial Collaboration and Supply Agreement (&#8220;Merck CTCSA&#8221;), with Merck (known as MSD outside of the United States and Canada) to evaluate the combination of IDE161 with Merck&#8217;s anti-PD-1 therapy, KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (pembrolizumab), in patients with high microsatellite instability (&#8220;MSI-High&#8221;) and microsatellite stable (&#8220;MSS&#8221;) endometrial cancer. Pursuant to the Merck CTCSA, the Company is the sponsor of the combination study, and the Company will provide the IDE161 compound and pay for the costs of the combination study. Merck will provide KEYTRUDA at no cost to the Company. The Company and Merck will jointly own clinical data from the combination. Each party retains commercial rights to its respective compounds, including with respect to use as a monotherapy or combination agent.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Biocytogen Option and License Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2024, the Company entered into an Option and License Agreement (the &#8220;Biocytogen Option and License Agreement&#8221;), pursuant to which Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (&#8220;Biocytogen&#8221;), granted us an option for an exclusive worldwide license from Biocytogen to develop and commercialize products in connection with a potential first-in-class B7H3/PTK7 topoisomerase-I-inhibitor-payload BsADC program (the &#8220;Option&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Biocytogen Option and License Agreement, the Company paid Biocytogen an upfront fee and, upon the Company&#8217;s potential exercise of the Option, an exercise fee totaling up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Option is exercisable by the Company within a specified time period after the Company obtains all data and results from certain non-GLP toxicology studies specified in the Biocytogen Option and License Agreement, which the Company will conduct at its own cost. Subject to the Company&#8217;s exercise of the Option, Biocytogen will be eligible to receive an option exercise fee, development and regulatory milestone payments and commercial milestone payments, as well as low to mid single-digit royalties on net sales. Total potential milestone payments equal an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">400.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, including development and regulatory milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Hengrui Pharma License Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, the Company entered into an exclusive License Agreement (the &#8220;Hengrui Pharma License Agreement&#8221;) with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (&#8220;Hengrui Pharma&#8221;), pursuant to which Hengrui Pharma granted the Company an exclusive worldwide license outside of Greater China, for IDE849 (SHR-4849), a potential first-in-class Phase 1 DLL3 TOP1i ADC. Under the terms of the Hengrui Pharma License Agreement, Hengrui Pharma is eligible to receive upfront and milestone payments totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.045</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion, including a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront fee, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in development and regulatory milestone payments, plus commercial success-based milestones. Hengrui Pharma is also eligible to receive mid-single to low-double digit royalties on net sales outside of Greater China.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_SignificantAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_SignificantAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069715477696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Revenue Recognition</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes revenue in accordance with ASC 606 for the GSK Collaboration Agreement (see No. 10, Significant Agreements).</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disaggregation of Revenue</span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents revenue disaggregated by research program (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.32%;box-sizing:content-box;"></td>
        <td style="width:1.98%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.98%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.98%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MAT2A</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,722</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,756</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pol Theta</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,002</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,894</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">WRN</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,661</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,281</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total collaboration revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,385</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,931</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company identified the following </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">six</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> performance obligations associated with the GSK Collaboration Agreement:</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preclinical and Phase 1 Monotherapy clinical research and development services under the MAT2A program (&#8220;MAT2A R&amp;D Services&#8221;)</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preclinical research services and the related license to IDEAYA-owned technology under the Pol Theta program (&#8220;Pol Theta R&amp;D Services&#8221;)</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preclinical research services and the related license to IDEAYA-owned technology under the WRN program (&#8220;WRN R&amp;D Services&#8221;)</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material right associated with the option to license IDEAYA-owned technology under the MAT2A program (&#8220;Option&#8221;)</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(v)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material right associated with the option to license to IDEAYA-owned technology under the MAT2A program to the extent necessary for preclinical activities in preparation for the MAT2A Combination Trial (&#8220;Preclinical MAT2A License&#8221;)</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(vi)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material right associated with the supply of MAT2A product for the MAT2A Combination Trial (&#8220;MAT2A Supply&#8221;) </span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to the Pol Theta and WRN programs, the Company identified two promises: (1) granting of the license to develop and commercialize Pol Theta and WRN products, respectively, and (2) the preclinical research services. The Company determined that these two promises are not distinct within the context of the contract.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized revenue related to amounts allocated to the MAT2A R&amp;D services as the underlying services were performed over the period through the delivery of the Option data package, which is generated from its conduct of the dose escalation portion of the MAT2A Phase 1 monotherapy clinical trial. The Company used its internal research and development capability and also engaged third-party clinical research organizations (&#8220;CROs&#8221;), for which the Company acted as a principal. The Company delivered the Option data package to GSK. Accordingly, the performance obligation related to the MAT2A R&amp;D services was fulfilled.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized revenue related to amounts allocated to the Pol Theta R&amp;D Services and WRN R&amp;D Services as the underlying services were performed over the period through the completion of the Pol Theta and WRN preclinical research programs, respectively. Within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days from the end of each calendar quarter, GSK reimbursed the Pol Theta program costs incurred by the Company. Within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days from the end of each calendar quarter, the Company and GSK determined the amounts of WRN program costs incurred by both parties and the net amount owed by GSK to the Company or by the Company to GSK, which was paid within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days from such determination by a reimbursing party. The Company used its internal research capability and could also engage third-party CROs in transferring the Pol Theta R&amp;D services and WRN R&amp;D services, for which the Company acts as a principal. The Company completed Pol Theta R&amp;D services during December 2022. Accordingly, the performance obligation related to the Pol Theta R&amp;D services was fulfilled. The Company completed WRN R&amp;D services during December 2023. Accordingly, the performance obligation related to the WRN R&amp;D services was fulfilled.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company completed all performance obligations related to the upfront payment under the GSK Collaboration Agreement as of December 31, 2023. Since December 31, 2023, the Company has no accounts receivable and no contract liabilities related to the GSK Collaboration Agreement. Because the Company completed all performance obligations, future collaboration revenue recognized under the GSK Collaboration Agreement is only related to milestone payments as they are earned.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Pol Theta product, the Company achieved and earned a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million payment for a milestone in August 2023 based on acceptance of the IND by the FDA. An earlier preclinical development $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment from GSK was achieved in August 2022 in connection with ongoing IND-enabling studies to support evaluation of GSK101. The Company has the potential to receive an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment upon initiation of Phase 1 clinical dose expansion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the WRN product, the Company achieved and earned a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million payment for a milestone in October 2024 based on the acceptance of the IND by the FDA. An earlier preclinical development $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million payment from GSK was achieved in October 2023 in connection with IND-enabling studies for the Werner Helicase Inhibitor DC. The Company has the potential to receive an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment upon initiation of Phase 1 clinical dose expansion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Significant judgments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In applying ASC 606 to the GSK Collaboration Agreement, the Company made the following judgment that significantly affect the timing and amount of revenue recognition.</span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(i) Determination of the transaction price, including whether any variable consideration is included at inception of the contract</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction price is the amount of consideration that the Company expects to be entitled to in exchange for transferring promised goods or services to the customer. The transaction price must be determined at inception of a contract and may include amounts of variable consideration. However, there is a constraint on inclusion of variable consideration in the transaction price, if there is uncertainty at inception of the contract as to whether such consideration will be recognized in the future.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The decision as to whether or not it is probable that a significant reversal of revenue will occur in the future, depends on the likelihood and magnitude of the reversal and is highly susceptible to factors outside the Company&#8217;s influence (for example, the Company cannot determine the outcome of clinical trials; the Company cannot determine if or when the counterparty will initiate or complete clinical trials; and the Company cannot determine if or when an regulatory agency provides any approval). In addition, the uncertainty is not expected to be resolved for a long period and finally, the Company has limited experience in the field. Therefore, at inception of the GSK Collaboration Agreement, development and regulatory milestones were fully constrained and were not included in the transaction price based on the factors noted above.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company constrains estimates of other variable consideration, such as reimbursable program costs, to amounts that are not expected to result in a significant revenue reversal in the future. The Company re-evaluates the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069715130160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Net Loss Per Share Attributable to Common Stockholders</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:54.091%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.902000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.902000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.902000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">274,477</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112,961</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,655</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used in computing net loss per share <br/>&#160;&#160;&#160;attributable to common stock, basic and diluted </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,678,069</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,519,929</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,444,696</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders, basic and<br/>&#160;&#160;&#160;diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.36</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.96</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.42</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) The shares underlying the pre-funded warrants to purchase shares of the Company's common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the years ended December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div style="font-size:12pt;font-family:Arial;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:54.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,737,595</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,269,975</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,097,263</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069722054720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. Segment Information</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company operates and manages its business as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating and reportable segment, which is the business of research and development for oncology-focused precision medicine. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_3b792965-e65d-4647-ad8c-bd3fa5a2dc19;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">President and CEO. The Company&#8217;s measure of segment profit or loss is net income. For purposes of evaluating performance and allocating resources, the CODM reviews the financial information and evaluates net income against comparable prior periods and the Company&#8217;s forecast. All of the Company's long-lived assets are located in the United States.</span></span></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the significant expense categories included within net income presented on the Company's statements of operations and comprehensive loss, see below for disaggregated research and development expenses:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.692%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.517%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.517%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.937000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External clinical development expenses </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Darovasertib</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,335</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,829</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,433</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">IDE397</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,629</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,985</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,426</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">IDE161</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,743</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,104</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,749</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel related and stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,543</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,948</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,717</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development expenses </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">:</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,423</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,642</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,211</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">294,673</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,508</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,536</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">         (1)          External clinical development expenses include manufacturing and clinical trial costs. These expenses are primarily for services provided by</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                        external consultants, CMOs and CROs.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">         (2)          IDE397 includes costs from the Amgen CTCSA</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">         (3)          Other research and development expenses include manufacturing and clinical trial costs for preclinical and earlier clinical stage programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                       These expenses are primarily for services provided by external consultants, CMOs and CROs.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069714487632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. Subsequent Events</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">At-the-Market Offering</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequent to December 31, 2024, from January 1, 2025 through January 6, 2025, the Company raised aggregate net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under the at-the-market offering pursuant to the January 2024 Sales Agreement with Jefferies as sales agent. As of January 6, 2025, approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">156.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of common stock remained available to be sold under the ATM facility.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commencement of Expansion Premises Office Lease - South San Francisco</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company commenced the First Amendment to the Lease Agreement by and between DW LSP 5000 Shoreline, LLC and the Company in January 2025. The Company added approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,321</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> rentable square feet of additional space to expand the size of the original premises.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Study Collaboration and Supply Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 12, 2025, the Company entered into the Second Gilead CSCSA with Gilead pursuant to which the Company and Gilead will collaborate on a portion of the Phase 1 study for the clinical evaluation of IDE397 in combination with Trodelvy, or the Combination Study, in certain patients with advanced solid tumors in lungs. Pursuant to the Second Gilead CSCSA, the Company is the sponsor of the Combination Study, and the Company will provide the IDE397 compound and pay for the costs of the Combination Study.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069717036944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial statements and accompanying notes have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include useful lives of property and equipment, determination of the discount rate for operating leases, accruals for research and development activities, revenue recognition, stock-based compensation, and income taxes. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable and operating segment. Financial information about the Company&#8217;s operating segment and geographic areas is presented in Note 13 of the financial statements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company operates in a dynamic and highly competitive industry and is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturers, contract research organizations and collaboration partners, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company believes that changes in any of the following areas could have a material</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse effect on the Company&#8217;s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials and collaboration activities; regulatory approval and market acceptance of the Company&#8217;s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company&#8217;s ability to attract and retain employees necessary to support its growth.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Products developed by the Company require approvals from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that the products will receive the necessary approvals, or that any approved products will be commercially viable. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval, it could have a materially adverse impact on the Company. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company may require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs which would materially and adversely affect its business, financial condition and operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. Substantially all the Company&#8217;s cash, cash equivalents and marketable securities are held by three financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s investment policy addresses credit ratings, diversification, and maturity dates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company invests its cash equivalents and marketable securities in money market funds, U.S. government securities, commercial paper, and corporate bonds. The Company limits its credit risk associated with cash equivalents and marketable securities by placing them with banks and institutions it believes are creditworthy and in highly rated investments and, by policy, limits the amount of credit exposure with any one commercial issuer. The Company has not experienced any credit losses on its deposits of cash, cash equivalents or marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents that are readily convertible to cash are stated at cost, which approximates fair value. The Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less at the date of purchase to be cash equivalents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash as of December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> consisted of cash balances held as security in connection with the Company&#8217;s facility lease agreements in South San Francisco, California and San Diego, California. The balances are classified as long-term assets on the Company&#8217;s balance sheet.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">securities are investments in marketable securities with maturities greater than three months at the time of purchase. The Company determines the appropriate classification of its investments in marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable securities as available-for-sale. After consideration of the Company&#8217;s risk versus reward objectives and liquidity requirements, the Company may sell these securities prior to their stated maturities. The Company classifies highly liquid securities with maturities beyond 12 months as long-term marketable securities in the balance sheet. These securities are carried at fair value as determined based upon quoted market prices or pricing models for similar securities. Unrealized gains and losses, if any, are excluded from earnings and are reported as a component of accumulated other comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income and other income (expense), net on the statements of operations and comprehensive loss. Realized gains and losses, if any, on available-for-sale securities are included in interest income and other income (expense),</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">net. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying amounts of the Company&#8217;s certain financial instruments, including cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities and market interest rates if applicable. Refer to Note 3 for details on the fair value of marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which is generally between </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d3a6b20e-57d6-4e14-ab8d-c3cbd58018ea;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Leasehold improvements are stated at cost and amortized over the shorter of the useful lives of the assets or the lease term. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations and comprehensive loss in the period realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount of the asset or asset group to the future net cash flows which the asset or asset group is expected to generate. If such asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group exceeds the fair value of the asset or asset group. There have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such impairments of long-lived assets for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if an arrangement is a lease, or contains a lease, at its inception. Operating leases are included in right-of-use (&#8220;ROU&#8221;) assets, lease liabilities, and long-term lease liabilities on the Company&#8217;s balance sheet.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ROU assets and lease liabilities are recognized based on the present value of the future lease payments over the lease term at commencement date. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The ROU asset also includes any lease payments made to the lessor at or before the commencement date, minus lease incentives received, and initial direct costs incurred. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company combines lease and nonlease components.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_CloudComputingArrangementsPolicyTextBlock', window );">Cloud Computing Arrangements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cloud Computing Arrangements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes certain implementation costs incurred under a cloud computing arrangement that is a service contract. Costs incurred during the application development stage related to the implementation of the hosting arrangement are capitalized and included within prepaid expenses and other current assets, and other non-current assets on the accompanying balance sheets. Amortization of capitalized implementation costs is recognized on a straight-line basis over the term of the associated hosting arrangement when it is ready for its intended use. Costs related to preliminary project activities and post-implementation activities are expensed as incurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company follows Accounting Standards Codification Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 606&#8221;). Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company applies the five-step model to contracts when (1) parties have approved the contract and are committed to performing respective obligations, (2) the Company can identify each party&#8217;s rights regarding the goods or services to be transferred, (3) the Company can identify the payment terms for the goods or services to be transferred, (4) the contract has commercial substance, and (5) it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines the performance obligations by assessing whether each promised good or service is distinct. Goods or services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligations when (or as) the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the &#8220;variable consideration constraint&#8221;) that a significant reversal of recognized revenue is not probable.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licenses of intellectual property:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> If a license to the Company&#8217;s intellectual property is determined to be distinct from the other promised goods or services identified in an arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license at the point in time when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other goods or services, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress toward satisfying the performance obligation for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Customer options for additional goods or services: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a contract contains customer options that allow the customer to acquire additional goods or services, including a license to the Company&#8217;s intellectual property, the goods and services underlying the customer options are evaluated to determine whether they are deemed to represent a material right. In determining whether the customer option has a material right, the Company assesses whether there is an option to acquire additional goods or services at a discount. If the customer option is determined not to represent a material right, the option is not considered to be a performance obligation. If the customer option is determined to represent a material right, the material right is recognized as a separate performance obligation. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until the option is exercised.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone payments:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> At the inception of each arrangement or amendment that includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 prescribes two methods to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the expected value method to estimate the amount of variable consideration related to the reimbursement of Pol Theta and WRN program costs which is consistently applied throughout the life of the contract: however, it is not necessary for the Company to use the same approach for all contracts. If it is probable that a significant revenue reversal would not occur when the uncertainty associated with the milestone is resolved, the associated milestone value is included in the transaction price. Milestone payments that are highly susceptible to factors outside the Company&#8217;s influence, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. If there is more than one performance obligation, the transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalties:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upfront payments and fees are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contractual cost sharing payments received from a customer or collaboration partner are accounted for as variable consideration. The Company includes an expected value in the transaction price. Contractual cost sharing payments made to a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">customer or collaboration partner are accounted for as a reduction to the transaction price if such payments are not related to distinct goods or services received from the customer or collaboration partner.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contracts may be amended to account for changes in contract specifications and requirements. Contract modifications exist when the amendment either creates new, or changes existing, enforceable rights and obligations. When contract modifications create new performance obligations and the increase in consideration approximates the standalone selling price for goods and services related to such new performance obligations as adjusted for specific facts and circumstances of the contract, the modification is accounted for as a separate contract. If a contract modification is not accounted for as a separate contract, the Company accounts for the promised goods or services not yet transferred at the date of the contract modification (the remaining promised goods or services) prospectively, as if it were a termination of the existing contract and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. The Company accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. In such case, the effect that the contract modification has on the transaction price, and on the entity&#8217;s measure of progress toward complete satisfaction of the performance obligation, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) at the date of the contract modification (the adjustment to revenue is made on a cumulative catch-up basis).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upfront payment contract liabilities resulting from the Company&#8217;s license and collaboration agreements do not represent a financing component as the payment is not financing the transfer of goods and services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company. As such, the Company does not adjust its revenues for the effects of a significant financing component. Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liability in the Company&#8217;s balance sheets. If the related performance obligation is expected to be satisfied within the next twelve (12) months, this will be classified and included within current contract liability.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of compensation costs, employee benefit costs, costs for contract manufacturing organizations (&#8220;CMOs&#8221;), costs for contract research organizations (&#8220;CROs&#8221;), costs for clinical trials, costs for sponsored research, consulting costs, costs for laboratory supplies, costs for product licenses, facility-related expenses and depreciation. All research and development costs are charged to research and development expenses as incurred and included within the statements of operations and comprehensive loss. Payments associated with licensing agreements to acquire exclusive licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternate commercial use are also expensed as incurred. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_AccruedResearchAndDevelopmentExpensesPolicyTextBlock', window );">Accrued Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Research and Development Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into various agreements with CMOs and CROs. The Company&#8217;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CMOs and CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. Management&#8217;s process involves reviewing open contracts and purchase orders, communicating with applicable personnel to identify services that have been performed, and estimating the level of service performed and the associated costs incurred based on vendor estimates for the services when the Company has not yet been invoiced or otherwise notified of actual costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for stock-based compensation arrangements with employees and non-employees in accordance with ASC 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Compensation. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for stock-based compensation arrangements using a fair value method which requires the recognition of compensation expense related to all stock-based awards. The fair value method requires the Company to estimate the fair value of stock option awards on the date of grant using an option pricing model. The Company uses the Black-Scholes option pricing model to determine the fair value of options granted, which is expensed on a straight-line basis over the vesting period. Generally, the stock options granted by the Company to its employees have a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term and vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year period with </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year cliff vesting.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method whereby deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are currently in effect unless such rate is expected to be different when the deferred item reverses. Valuation allowances are established where necessary to reduce deferred tax assets to the amounts expected to be realized. Deferred tax assets and liabilities are classified as noncurrent on the balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that has a greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits in interest expense and other expense, respectively.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income and Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive Income and Loss</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive income and loss include net loss and certain changes in stockholders&#8217; equity that are excluded from net loss, primarily unrealized gains and losses from the Company&#8217;s marketable securities.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss per Share Attributable to Common Stockholders</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. Pre-funded warrants are included in the calculation of basic and diluted earnings per share. For purposes of the diluted net loss per share calculation, stock options, restricted stock and restricted stock that is subject to repurchase at the original purchase price are considered to be potentially dilutive securities. The Company considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of early exercised shares subject to repurchase do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) under its accounting standard codifications (&#8220;ASC&#8221;) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New Accounting Pronouncements Adopted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) under its accounting standard codifications (&#8220;ASC&#8221;) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. These amendments enhance interim disclosure requirements, require disclosure of the title and position of the chief operating decision maker (&#8220;CODM&#8221;), require disclosure of significant segment expenses that are regularly provided to the CODM, clarify circumstances for disclosure of more than one segment profit or loss measure and require that a public entity that has a single reportable segment provide all disclosures required by ASC 280 and amendments. This ASU update is effective for fiscal years beginning after December 15, 2023 for the Company&#8217;s annual report, and interim periods within fiscal years beginning after December 15, 2024. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company adopted this ASU for the annual report for the fiscal year beginning </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and evaluated the impact of the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adoption </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the ASU. It did </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t result in a material impact on the Company's financial statements and related disclosures. See Note 13. Segment Information.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New Accounting Pronouncements, Not yet Adopted</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative, which modifies the disclosure or presentation requirements related to variety of FASB Accounting Standard Codification topics. The effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K is effective. If by June 30, 2027, the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the associated amendment will be removed from the Codification and will not become effective for any entities. The Company is currently evaluating the effect of adopting this ASU.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 14, 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which amends the guidance in ASC 740, Income Taxes. The ASU is intended to improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The ASU&#8217;s amendments are effective for public business entities for annual periods beginning after December 15, 2024. Entities are permitted to early adopt the standard &#8220;for annual financial statements that have not yet been issued or made available for issuance.&#8221; Adoption is either prospectively or retrospectively; the Company will adopt this ASU on a prospective basis. The Company is currently evaluating the impact of the ASU, but does not expect any material impact upon adoption.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 2024, the FASB issued ASU 2024-03 - Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The ASU requires more detailed disclosures about the types of expenses in commonly presented expense captions such as cost of sales, selling, general and administrative expenses and research and development expenses. This includes separate footnote disclosure for expenses such as purchases of inventory, employee compensation, depreciation, and intangible asset amortization. Public business entities are required to apply the guidance prospectively and may apply it retrospectively. The ASU's amendments are effective for public business entities for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Public business entities are required to apply the guidance prospectively and may apply it retrospectively. The Company is currently evaluating the effect of adopting this ASU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_FairValueMeasurementsAndMarketableSecuritiesPolicyTextBlock', window );">Fair Value Measurement and Marketable Securities</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Observable inputs, such as quoted prices in active markets for identical assets or liabilities at the measurement date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs which reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock', window );">Share Based Compensation Forfeiture</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for forfeitures as they occur.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_AccruedResearchAndDevelopmentExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_AccruedResearchAndDevelopmentExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_CloudComputingArrangementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cloud computing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_CloudComputingArrangementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_FairValueMeasurementsAndMarketableSecuritiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurements and marketable securities policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_FairValueMeasurementsAndMarketableSecuritiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (m)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069722169184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Schedule of Financial Assets Measured and Recognized at Fair Value</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, financial assets measured and recorded at fair value are as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.986%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.002%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.562999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.681999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.521999999999998%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.222000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">552,008</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,214</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">353</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">552,869</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">363,197</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">357</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">419</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">363,135</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,109</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,122</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Subtotal</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,004,314</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,592</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">780</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,005,126</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,626</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,626</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,399</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,399</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total value of assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,081,339</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,592</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">780</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,082,151</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,379</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,378</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in marketable securities, current</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">591,089</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">928</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">591,941</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in marketable securities, non-current</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">405,871</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">664</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">703</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">405,832</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total value of assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,081,339</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,592</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">780</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,082,151</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of commercial paper was included in cash and cash equivalents on the balance sheet due to securities with purchase dates within 90 days of maturity dates.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s short-term marketable securities mature in one year or less.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s long-term marketable securities mature between one and three years.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023, financial assets measured and recognized at fair value are as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:30.58%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:9.1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">412,679</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">591</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">413,135</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,983</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">197</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,148</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126,601</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126,543</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Subtotal</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">593,263</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">788</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">593,826</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">480</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">480</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total value of assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">632,043</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">788</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">632,606</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,055</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,018</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in marketable securities, current</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">368,043</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">227</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">368,096</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in marketable securities, non-current</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106,945</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">557</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total value of assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">632,043</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">788</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">632,606</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37.8</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of U.S. government securities and $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80.4</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of commercial paper were included in cash and cash equivalents on the balance sheet due to securities with purchase dates within 90 days of maturity dates</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s short-term marketable securities mature in one year or less.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s long-term marketable securities mature between one and three years</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069722169920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.79%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:17.584%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.302000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.302000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Life</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In Years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,513</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,455</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">503</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">231</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">231</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of useful<br/>life or lease term</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,913</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,321</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,517</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">507</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,677</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,775</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,711</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,611</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,966</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,164</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:63.847%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.417%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.417%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,956</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,676</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued salaries and benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,233</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,974</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Legal and professional fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,213</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">959</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">950</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,352</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,756</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069722124368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments under Operating Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future minimum lease payments under operating leases included on the Company's balance sheet are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.28%;box-sizing:content-box;"></td>
        <td style="width:3.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">386</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,705</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,389</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,224</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,263</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,790</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total future minimum lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,757</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,586</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,171</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_OperatingLeasesDisclosuresTableTextBlock', window );">Schedule of Operating Lease Disclosures</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes other information about the Company's operating leases:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.74%;box-sizing:content-box;"></td>
        <td style="width:2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:20.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.22%;box-sizing:content-box;"></td>
        <td style="width:22.44%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.4</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_OperatingLeasesDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of operating lease disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_OperatingLeasesDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069714979424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Provision for Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The provision for income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.342%;box-sizing:content-box;"></td>
        <td style="width:1.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.312999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.312999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.312999999999999%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other permanent differences</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 162(m) limitation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Tax Effects of Temporary Differences and Carryforwards of Deferred Tax Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The tax effects of temporary differences and carryforwards of the deferred tax assets are presented below (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:60.328%;box-sizing:content-box;"></td>
        <td style="width:1.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.017%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.82%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.017%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,524</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,717</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credit carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,868</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,997</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,074</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">610</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,365</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,096</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,401</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,593</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,468</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,257</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research &amp; development expenditures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,271</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,267</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">168,971</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,537</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,876</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95,888</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,095</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">649</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,990</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">477</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">172</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Summary of Activity Related to Company's Unrecognized Tax Benefits</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits (in thousands).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:72.675%;box-sizing:content-box;"></td>
        <td style="width:2.501%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:22.825%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance as of January 1, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,962</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase related to prior year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">372</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,488</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,822</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Decrease related to prior year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,290</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,927</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069715183360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Aggregate Warrants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, the following aggregate warrants to purchase shares of the Company&#8217;s common stock were issued and outstanding:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:22.324%;box-sizing:content-box;"></td>
        <td style="width:2.521%;box-sizing:content-box;"></td>
        <td style="width:21.904%;box-sizing:content-box;"></td>
        <td style="width:3.161%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.363%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:26.465%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Issue Date</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Expiration Date</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise Price per Share</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Shares subject to Outstanding Warrants</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">July 11, 2024</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">None</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285,715</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 27, 2023</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">None</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">319,150</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 27, 2023</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">None</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">270,270</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) In September 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,750,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock subject to outstanding pre-funded warrants were cashless exercised and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,749,993</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were issued.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Schedule of Number of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had reserved common stock for future issuance as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.673%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.403%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.26%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.403%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of outstanding options under the 2015, 2019 and 2023 Plans</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,737,595</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,269,975</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for grant under the 2019 Plan</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,910,589</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">964,622</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for grant under the 2023 Inducement Plan</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">593,592</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">524,300</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available under the Employee Stock Purchase Plan</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,911,011</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,317,974</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants issued and outstanding</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">875,135</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,339,420</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,027,922</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,416,291</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069713299632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense recorded related to awards granted to employees and non-employees was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.642%;box-sizing:content-box;"></td>
        <td style="width:1.619%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.834%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.619%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.834%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.619%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.834%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,115</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,826</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,050</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,631</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,663</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,579</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,746</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,489</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,629</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Activity under Plans</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Activity under the Company&#8217;s 2015 and 2019 Plans and 2023 Inducement Plan is set forth below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:37.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.68%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.68%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate    <br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance, January 1, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,269,975</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.53</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.82</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">128.49</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,247,538</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41.88</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,118,695</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.16</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options canceled</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">661,223</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.57</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance, December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,737,595</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.06</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.89</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43.01</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercisable as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,185,690</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.63</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.62</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.04</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vested and expected to vest as of<br/>&#160;&#160;&#160;December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,737,595</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.06</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.89</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43.01</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Calculate Fair Values of Options</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair values of options were calculated using the assumptions set forth below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:37.852%;box-sizing:content-box;"></td>
        <td style="width:1.7%;box-sizing:content-box;"></td>
        <td style="width:19.016%;box-sizing:content-box;"></td>
        <td style="width:1.7%;box-sizing:content-box;"></td>
        <td style="width:19.016%;box-sizing:content-box;"></td>
        <td style="width:1.7%;box-sizing:content-box;"></td>
        <td style="width:19.016%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76.8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81.3</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81.8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86.9</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86.8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89.9</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069722204784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Revenue Disaggregated by Research Program</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents revenue disaggregated by research program (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.32%;box-sizing:content-box;"></td>
        <td style="width:1.98%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.98%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.7%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.98%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MAT2A</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,722</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,756</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pol Theta</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,002</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,894</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">WRN</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,661</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,281</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total collaboration revenue</span></p></td>
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,385</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,931</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069715179168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:54.091%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.902000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.902000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.902000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">274,477</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112,961</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,655</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used in computing net loss per share <br/>&#160;&#160;&#160;attributable to common stock, basic and diluted </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,678,069</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,519,929</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,444,696</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders, basic and<br/>&#160;&#160;&#160;diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.36</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.96</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.42</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) The shares underlying the pre-funded warrants to purchase shares of the Company's common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the years ended December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Outstanding Shares of Potentially Dilutive Securities Excluded From the Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:54.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,737,595</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,269,975</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,097,263</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069858288640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock', window );">Summary Of Disaggregated Research And Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the significant expense categories included within net income presented on the Company's statements of operations and comprehensive loss, see below for disaggregated research and development expenses:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.692%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.517%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.517%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.937000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External clinical development expenses </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Darovasertib</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,335</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,829</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,433</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">IDE397</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,629</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,985</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,426</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">IDE161</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,743</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,104</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,749</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel related and stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,543</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,948</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,717</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development expenses </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">:</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,423</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,642</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,211</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">294,673</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,508</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,536</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">         (1)          External clinical development expenses include manufacturing and clinical trial costs. These expenses are primarily for services provided by</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                        external consultants, CMOs and CROs.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">         (2)          IDE397 includes costs from the Amgen CTCSA</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">         (3)          Other research and development expenses include manufacturing and clinical trial costs for preclinical and earlier clinical stage programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                       These expenses are primarily for services provided by external consultants, CMOs and CROs.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of disaggregated research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069716593872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 11, 2024</div></th>
<th class="th"><div>Jan. 19, 2024</div></th>
<th class="th"><div>Oct. 27, 2023</div></th>
<th class="th"><div>Jun. 26, 2023</div></th>
<th class="th"><div>Apr. 27, 2023</div></th>
<th class="th"><div>Jan. 17, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock upon public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,350<span></span>
</td>
<td class="nump">$ 281,165<span></span>
</td>
<td class="nump">$ 86,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">622,841<span></span>
</td>
<td class="nump">$ 348,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_CashCashEquivalentsAndMarketableSecurities', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="nump">285,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=idya_AtTheMarketOfferingMember', window );">At The Market Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,182,382<span></span>
</td>
<td class="nump">1,188,705<span></span>
</td>
<td class="nump">601,844<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=idya_AtTheMarketOfferingMember', window );">At The Market Offering | Jefferies LLC | Common Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_SalesOfCommonStockAggregateOfferingPrice', window );">Sale of common stock aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=idya_AtTheMarketOfferingMember', window );">At The Market Offering | Jefferies LLC | June 2023 Sales Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,115,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock upon public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_SharesIssuedWeightedAverageSalesPricePerShare', window );">Weighted average sales price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=idya_AtTheMarketOfferingMember', window );">At The Market Offering | Jefferies LLC | June 2023 Sales Agreement | Common Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_SalesOfCommonStockAggregateOfferingPrice', window );">Sale of common stock aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=idya_AtTheMarketOfferingMember', window );">At The Market Offering | Jefferies LLC | January 2024 Sales Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,066,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock upon public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_CommonStockRemainingAvailableToBeSaleAmount', window );">Common stock remained available to be sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_SharesIssuedWeightedAverageSalesPricePerShare', window );">Weighted average sales price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=idya_FollowOnPublicOfferingMember', window );">Follow On Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 34.9999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.4999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.4999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock upon public offering, net of issuance costs</a></td>
<td class="nump">$ 302,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_NetProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock net of underwriting discounts and commissions and other offering expenses</a></td>
<td class="nump">$ 283,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=idya_FollowOnPublicOfferingMember', window );">Follow On Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="nump">8,355,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,797,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,858,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,355,714<span></span>
</td>
<td class="nump">14,655,993<span></span>
</td>
<td class="nump">8,761,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock offering price</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="nump">285,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,020,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Overallotment Option | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="nump">1,127,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">797,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,418,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_CashCashEquivalentsAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_CashCashEquivalentsAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_CommonStockRemainingAvailableToBeSaleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, remaining available to be sale, amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_CommonStockRemainingAvailableToBeSaleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_NetProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_NetProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_SalesOfCommonStockAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate offering price at which the Company may offer and sell its common stock under the sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_SalesOfCommonStockAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_SharesIssuedWeightedAverageSalesPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued weighted average sales price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_SharesIssuedWeightedAverageSalesPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=idya_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=idya_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=idya_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=idya_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=idya_JuneTwoThousandTwentyThreeSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=idya_JuneTwoThousandTwentyThreeSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=idya_JanuaryTwoThousandTwentyFourSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=idya_JanuaryTwoThousandTwentyFourSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=idya_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=idya_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069717721792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member', window );">ASU 2023-07</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in Accounting Principle, Accounting Standards Update, Adoption Date</a></td>
<td class="text">Jan.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=idya_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of options</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=idya_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Equity Incentive Plan | Cliff Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized', window );">Recognized income tax positions measured at percentage of likelihood of realization</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognized income tax positions measured at percentage of likelihood to be realization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=idya_TwoThousandNineteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=idya_TwoThousandNineteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069717796432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement and Marketable Securities - Schedule of Financial Assets Measured and Recognized at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, amortized cost</a></td>
<td class="nump">$ 1,004,314<span></span>
</td>
<td class="nump">$ 593,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="nump">1,592<span></span>
</td>
<td class="nump">788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="num">(780)<span></span>
</td>
<td class="num">(225)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, estimated fair value</a></td>
<td class="nump">1,005,126<span></span>
</td>
<td class="nump">593,826<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Amortized Cost</a></td>
<td class="nump">1,081,339<span></span>
</td>
<td class="nump">632,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Estimated Fair Value</a></td>
<td class="nump">1,082,151<span></span>
</td>
<td class="nump">632,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, amortized cost</a></td>
<td class="nump">84,379<span></span>
</td>
<td class="nump">157,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, estimated fair value</a></td>
<td class="nump">84,378<span></span>
</td>
<td class="nump">157,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=idya_MarketableSecuritiesCurrentMember', window );">Marketable Securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, amortized cost</a></td>
<td class="nump">591,089<span></span>
</td>
<td class="nump">368,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="nump">928<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(174)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, estimated fair value</a></td>
<td class="nump">591,941<span></span>
</td>
<td class="nump">368,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=idya_MarketableSecuritiesNonCurrentMember', window );">Marketable Securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, amortized cost</a></td>
<td class="nump">405,871<span></span>
</td>
<td class="nump">106,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="nump">664<span></span>
</td>
<td class="nump">557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="num">(703)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, estimated fair value</a></td>
<td class="nump">405,832<span></span>
</td>
<td class="nump">107,492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, amortized cost</a></td>
<td class="nump">552,008<span></span>
</td>
<td class="nump">412,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="nump">1,214<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="num">(353)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, estimated fair value</a></td>
<td class="nump">552,869<span></span>
</td>
<td class="nump">413,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, amortized cost</a></td>
<td class="nump">363,197<span></span>
</td>
<td class="nump">53,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="num">(419)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, estimated fair value</a></td>
<td class="nump">363,135<span></span>
</td>
<td class="nump">54,148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, amortized cost</a></td>
<td class="nump">89,109<span></span>
</td>
<td class="nump">126,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, estimated fair value</a></td>
<td class="nump">89,122<span></span>
</td>
<td class="nump">126,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, amortized Cost</a></td>
<td class="nump">57,626<span></span>
</td>
<td class="nump">38,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, estimated Fair Value</a></td>
<td class="nump">57,626<span></span>
</td>
<td class="nump">38,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, amortized Cost</a></td>
<td class="nump">19,399<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, estimated Fair Value</a></td>
<td class="nump">$ 19,399<span></span>
</td>
<td class="nump">$ 480<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=idya_MarketableSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=idya_MarketableSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=idya_MarketableSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=idya_MarketableSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069715676944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement and Marketable Securities - Schedule of Financial Assets Measured and Recognized at Fair Value (Parenthetical) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 84,378<span></span>
</td>
<td class="nump">$ 157,018<span></span>
</td>
<td class="nump">$ 68,632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="nump">$ 80,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069721972208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement and Marketable Securities - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities recognized at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_MarketableSecuritiesRemainingMaturityPeriod', window );">Marketable securities remaining maturity period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_MarketableSecuritiesRemainingMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable securities remaining maturity period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_MarketableSecuritiesRemainingMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069718439488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Summary of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 20,677<span></span>
</td>
<td class="nump">$ 15,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(11,711)<span></span>
</td>
<td class="num">(9,611)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,966<span></span>
</td>
<td class="nump">6,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=idya_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 13,513<span></span>
</td>
<td class="nump">11,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment net, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 503<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment net, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 231<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment net, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 4,913<span></span>
</td>
<td class="nump">3,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_PropertyPlantAndEquipmentUsefulLifeDescription', window );">Property and equipment net, useful life</a></td>
<td class="text">Shorter of usefullife or lease term<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 1,517<span></span>
</td>
<td class="nump">$ 507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment net, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_PropertyPlantAndEquipmentUsefulLifeDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment useful life description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_PropertyPlantAndEquipmentUsefulLifeDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=idya_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=idya_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069718194400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069722046864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Summary of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_AccruedResearchAndDevelopmentExpensesCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 19,956<span></span>
</td>
<td class="nump">$ 10,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued salaries and benefits</a></td>
<td class="nump">8,233<span></span>
</td>
<td class="nump">6,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal and professional fees</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">950<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 30,352<span></span>
</td>
<td class="nump">$ 18,756<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069717217824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2024 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid included in measurement of operating lease liabilities included in cash flow from operating activities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreement | South San Francisco, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_OperatingLeasesAreaLeased', window );">Area of space leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_OperatingLeaseCommencementDescription', window );">Operating lease commencement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease term is 120 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease, option to extend, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company has an option to extend the lease term for a total of two consecutive five-year periods<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_OperatingLeasesAdditionalAreaLeased', window );">Additional area of space leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating lease option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreement | San Diego, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_OperatingLeasesAreaLeased', window );">Area of space leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_OperatingLeaseCommencementDescription', window );">Operating lease commencement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease term commenced in December 2023 and expires in March 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_OperatingLeaseCommencementMonthAndYear', window );">Operating lease term commencement month and year</a></td>
<td class="text">2023-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_LeaseExpirationMonthAndYear', window );">Lease expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2028-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_LesseeOperatingLeaseExistenceOfOptionToRenew', window );">Operating lease existence of option to renew</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_LeaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_LeaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_LesseeOperatingLeaseExistenceOfOptionToRenew">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease existence of option to renew.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_LesseeOperatingLeaseExistenceOfOptionToRenew</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_OperatingLeaseCommencementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease commencement description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_OperatingLeaseCommencementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_OperatingLeaseCommencementMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease commencement month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_OperatingLeaseCommencementMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_OperatingLeasesAdditionalAreaLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating leases additional area leased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_OperatingLeasesAdditionalAreaLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_OperatingLeasesAreaLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to the area leased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_OperatingLeasesAreaLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=idya_SouthSanFranciscoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=idya_SouthSanFranciscoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=idya_SanDiegoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=idya_SanDiegoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069715517152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Schedule of Future Minimum Lease Payments under Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">1,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">4,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">4,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">4,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">22,790<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">37,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(18,586)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 19,171<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, liability, to be paid, after year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069718322624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Schedule Of Operating Lease Disclosures (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">12.60%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069716919888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increased valuation allowance</a></td>
<td class="nump">69,000,000<span></span>
</td>
<td class="nump">32,100,000<span></span>
</td>
<td class="nump">14,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred tax assets, net operating loss carryforwards</a></td>
<td class="nump">37,524,000<span></span>
</td>
<td class="nump">34,717,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">30,868,000<span></span>
</td>
<td class="nump">19,997,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Penalties or interest accrued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">5,927,000<span></span>
</td>
<td class="nump">3,822,000<span></span>
</td>
<td class="nump">$ 1,962,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=idya_OrphanDrugCreditsMember', window );">Orphan Drug Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry forward amount</a></td>
<td class="nump">8,100,000<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal Income Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred tax assets, net operating loss carryforwards</a></td>
<td class="nump">147,500,000<span></span>
</td>
<td class="nump">135,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Deferred tax assets, operating loss carryforwards subject to expire</a></td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_TaxCreditCarryForwardExpirationYear', window );">Tax credit carry forward expiration year</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Deferred tax assets, operating loss carryforwards subject to do not expire</a></td>
<td class="nump">$ 135,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">19,800,000<span></span>
</td>
<td class="nump">12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">California State Income Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred tax assets, net operating loss carryforwards</a></td>
<td class="nump">93,500,000<span></span>
</td>
<td class="nump">89,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Deferred tax assets, operating loss carryforwards subject to expire</a></td>
<td class="nump">$ 93,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_TaxCreditCarryForwardExpirationYear', window );">Tax credit carry forward expiration year</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">$ 10,800,000<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_CA', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Tax years</a></td>
<td class="text">2020 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_TaxCreditCarryForwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carry forward expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_TaxCreditCarryForwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationYearUnderExamination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year being audited in the income tax examination, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationYearUnderExamination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=idya_OrphanDrugCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=idya_OrphanDrugCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069714543360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Provision for Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(25.10%)<span></span>
</td>
<td class="num">(29.10%)<span></span>
</td>
<td class="num">(23.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock-based compensation</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research tax credits</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other permanent differences</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_EffectiveIncomeTaxRateReconciliationSection162MLimitation', window );">Section 162(m) limitation</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(2.10%)<span></span>
</td>
<td class="num">(2.60%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for income taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_EffectiveIncomeTaxRateReconciliationSection162MLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation section 162(m) limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_EffectiveIncomeTaxRateReconciliationSection162MLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069717996528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Tax Effects of Temporary Differences and Carryforwards of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 37,524<span></span>
</td>
<td class="nump">$ 34,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">30,868<span></span>
</td>
<td class="nump">19,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">4,074<span></span>
</td>
<td class="nump">610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">18,365<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">7,401<span></span>
</td>
<td class="nump">2,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">1,468<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research &amp; development expenditures</a></td>
<td class="nump">69,271<span></span>
</td>
<td class="nump">36,267<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">168,971<span></span>
</td>
<td class="nump">96,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(164,876)<span></span>
</td>
<td class="num">(95,888)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">4,095<span></span>
</td>
<td class="nump">649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="num">(3,990)<span></span>
</td>
<td class="num">(477)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(105)<span></span>
</td>
<td class="num">(172)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069715061840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance</a></td>
<td class="nump">$ 3,822<span></span>
</td>
<td class="nump">$ 1,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase related to prior year tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decrease related to prior year tax positions</a></td>
<td class="num">(185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to current year tax positions</a></td>
<td class="nump">2,290<span></span>
</td>
<td class="nump">1,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance</a></td>
<td class="nump">$ 5,927<span></span>
</td>
<td class="nump">$ 3,822<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069718090800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 11, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 27, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 27, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of common stock is entitled to one vote.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_NumberOfCommonStockVotingRightsHeldPerShare', window );">Number of common stock voting rights held per share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Common stock, dividends declared | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="nump">285,715<span></span>
</td>
<td class="nump">319,150<span></span>
</td>
<td class="nump">270,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock upon public offering, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,350,000<span></span>
</td>
<td class="nump">$ 281,165,000<span></span>
</td>
<td class="nump">$ 86,105,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 23.5<span></span>
</td>
<td class="nump">$ 18.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=idya_FollowOnPublicOfferingMember', window );">Follow On Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock upon public offering, net of issuance costs | $</a></td>
<td class="nump">$ 302,400,000<span></span>
</td>
<td class="nump">$ 143,700,000<span></span>
</td>
<td class="nump">$ 201,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_NetProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock net of underwriting discounts and commissions and other offering expenses | $</a></td>
<td class="nump">$ 283,800,000<span></span>
</td>
<td class="nump">$ 134,600,000<span></span>
</td>
<td class="nump">$ 188,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=idya_FollowOnPublicOfferingMember', window );">Follow On Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">8,355,714<span></span>
</td>
<td class="nump">5,797,872<span></span>
</td>
<td class="nump">8,858,121<span></span>
</td>
<td class="nump">8,355,714<span></span>
</td>
<td class="nump">14,655,993<span></span>
</td>
<td class="nump">8,761,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="nump">$ 34.9999<span></span>
</td>
<td class="nump">$ 23.4999<span></span>
</td>
<td class="nump">$ 18.4999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="nump">285,715<span></span>
</td>
<td class="nump">319,150<span></span>
</td>
<td class="nump">2,020,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Overallotment Option | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">1,127,142<span></span>
</td>
<td class="nump">797,872<span></span>
</td>
<td class="nump">1,418,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_NetProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_NetProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_NumberOfCommonStockVotingRightsHeldPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock voting rights held per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_NumberOfCommonStockVotingRightsHeldPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=idya_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=idya_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069716810128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Schedule of Aggregate Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jul. 11, 2024</div></th>
<th class="th"><div>Oct. 27, 2023</div></th>
<th class="th"><div>Apr. 27, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_ClassOfWarrantOrRightsIssueDate', window );">Issue Date</a></td>
<td class="text">Jul. 11,  2024<span></span>
</td>
<td class="text">Oct. 27,  2023<span></span>
</td>
<td class="text">Apr. 27,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares subject to Outstanding Warrants</a></td>
<td class="nump">285,715<span></span>
</td>
<td class="nump">319,150<span></span>
</td>
<td class="nump">270,270<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_ClassOfWarrantOrRightsIssueDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights issue date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_ClassOfWarrantOrRightsIssueDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069858745312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Schedule of Aggregate Warrants (Parenthetical) (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,503,509<span></span>
</td>
<td class="nump">65,039,369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_CommonStockSubjectToOutstandingPreFundedWarrantsExercised', window );">Common stock subject to outstanding pre-funded warrants exercised</a></td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">1,749,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_CommonStockSubjectToOutstandingPreFundedWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock subject to outstanding pre-funded warrants Exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_CommonStockSubjectToOutstandingPreFundedWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069716875872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Schedule of Number of Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 24, 2023</div></th>
<th class="th"><div>May 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock reserved for future issuance</a></td>
<td class="nump">13,027,922<span></span>
</td>
<td class="nump">11,416,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Pre-funded Warrants Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock reserved for future issuance</a></td>
<td class="nump">875,135<span></span>
</td>
<td class="nump">2,339,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=idya_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock reserved for future issuance</a></td>
<td class="nump">1,910,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=idya_TwoThousandTwentyThreeInducementPlanMember', window );">2023 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock reserved for future issuance</a></td>
<td class="nump">593,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=idya_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock reserved for future issuance</a></td>
<td class="nump">1,911,011<span></span>
</td>
<td class="nump">1,317,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=idya_ExerciseOfOutstandingOptionsMember', window );">Outstanding Options | 2015, 2019 and 2023 Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock reserved for future issuance</a></td>
<td class="nump">7,737,595<span></span>
</td>
<td class="nump">6,269,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | 2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock reserved for future issuance</a></td>
<td class="nump">1,910,589<span></span>
</td>
<td class="nump">964,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | 2023 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock reserved for future issuance</a></td>
<td class="nump">593,592<span></span>
</td>
<td class="nump">524,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=idya_TwoThousandNineteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=idya_TwoThousandNineteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=idya_TwoThousandTwentyThreeInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=idya_TwoThousandTwentyThreeInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=idya_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=idya_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=idya_ExerciseOfOutstandingOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=idya_ExerciseOfOutstandingOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=idya_TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=idya_TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069717762672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 25, 2024</div></th>
<th class="th"><div>Feb. 24, 2023</div></th>
<th class="th"><div>May 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, initially reserved for issuance</a></td>
<td class="nump">13,027,922<span></span>
</td>
<td class="nump">11,416,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 34,746<span></span>
</td>
<td class="nump">$ 18,489<span></span>
</td>
<td class="nump">$ 11,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted</a></td>
<td class="nump">$ 29.93<span></span>
</td>
<td class="nump">$ 13.98<span></span>
</td>
<td class="nump">$ 10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="nump">$ 16,900<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized stock-based compensation expense for stock options</a></td>
<td class="nump">$ 90,200<span></span>
</td>
<td class="nump">$ 41,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Total unrecognized stock-based compensation expense, weighted-average period of recognition</a></td>
<td class="text">2 years 7 months 17 days<span></span>
</td>
<td class="text">2 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Estimated dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Maximum shares issues under ESPP</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=idya_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of options</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Incentive award plan description</a></td>
<td class="text">Options granted under the 2019 Plan have a term of 10 years (or five years if granted to a 10% stockholder) and generally vest over a 4-year period with 1-year cliff vesting.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, initially reserved for issuance</a></td>
<td class="nump">1,910,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=idya_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Equity Incentive Plan | Cliff Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=idya_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Equity Incentive Plan | 10% Stockholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of options</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=idya_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent', window );">Shares outstanding under ESPP</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=idya_TwoThousandNineteenEmployeeStockPurchasedPlanMember', window );">2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, initially reserved for issuance</a></td>
<td class="nump">1,911,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod', window );">Maximum offering period under ESPP</a></td>
<td class="text">27 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum eligible rate of compensation</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=idya_TwoThousandNineteenEmployeeStockPurchasedPlanMember', window );">2019 Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_ESPPDiscountedPurchasePricePercentage', window );">Percentage of the fair value of common stock</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_ESPPMaximumSharesPurchasablePerPeriodPerEmployee', window );">Maximum number of shares purchasable</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent', window );">Shares outstanding under ESPP</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=idya_TwoThousandTwentyThreeInducementPlanMember', window );">2023 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of options</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance', window );">Increase in number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, initially reserved for issuance</a></td>
<td class="nump">593,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=idya_TwoThousandTwentyThreeInducementPlanMember', window );">2023 Inducement Plan | Cliff Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_ESPPDiscountedPurchasePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The discounted percentage of the fair market value of the Company's common stock for stock purchase in employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_ESPPDiscountedPurchasePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_ESPPMaximumSharesPurchasablePerPeriodPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares purchasable by an employee under the ESPP per an offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_ESPPMaximumSharesPurchasablePerPeriodPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum share based compensation arrangement by share based payment award shares issued in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement by Share Based Payment Award Increase in Number of Shares Available for Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum offering period that could be set for the Employee Stock Purchase Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by sharebased payment award of shares outstanding percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=idya_TwoThousandNineteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=idya_TwoThousandNineteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=idya_TenPercentStockholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=idya_TenPercentStockholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=idya_TwoThousandNineteenEmployeeStockPurchasedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=idya_TwoThousandNineteenEmployeeStockPurchasedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=idya_TwoThousandTwentyThreeInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=idya_TwoThousandTwentyThreeInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069710055872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 34,746<span></span>
</td>
<td class="nump">$ 18,489<span></span>
</td>
<td class="nump">$ 11,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">21,115<span></span>
</td>
<td class="nump">10,826<span></span>
</td>
<td class="nump">6,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 13,631<span></span>
</td>
<td class="nump">$ 7,663<span></span>
</td>
<td class="nump">$ 5,579<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069715746784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Activity under Plans (Details) - 2015 and 2019 Plans and 2023 Inducement Plan - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding Options, Shares, Beginning balance</a></td>
<td class="nump">6,269,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Outstanding Options, Shares, Options granted</a></td>
<td class="nump">3,247,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Outstanding Options, Shares, Options exercised</a></td>
<td class="num">(1,118,695)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Outstanding Options, Shares, Options canceled</a></td>
<td class="num">(661,223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding Options, Shares, Ending balance</a></td>
<td class="nump">7,737,595<span></span>
</td>
<td class="nump">6,269,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Outstanding Options, Shares, Exercisable</a></td>
<td class="nump">3,185,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Outstanding Options, Shares, Vested and expected to vest</a></td>
<td class="nump">7,737,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding Options, Weighted-Average Exercise Price, Beginning balance</a></td>
<td class="nump">$ 15.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Outstanding Options, Weighted-Average Exercise Price, Options granted</a></td>
<td class="nump">41.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Outstanding Options, Weighted-Average Exercise Price, Options exercised</a></td>
<td class="nump">11.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Outstanding Options, Weighted-Average Exercise Price, Options canceled</a></td>
<td class="nump">29.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding Options, Weighted-Average Exercise Price, Ending balance</a></td>
<td class="nump">26.06<span></span>
</td>
<td class="nump">$ 15.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Outstanding Options, Weighted-Average Exercise Price, Exercisable</a></td>
<td class="nump">15.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Outstanding Options, Weighted-Average Exercise Price, Vested and expected to vest</a></td>
<td class="nump">$ 26.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding Options, Weighted Average Remaining Contractual Term (Years)</a></td>
<td class="text">7 years 10 months 20 days<span></span>
</td>
<td class="text">7 years 9 months 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Outstanding Options, Weighted Average Remaining Contractual Term (Years), Exercisable</a></td>
<td class="text">6 years 7 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Outstanding Options, Weighted Average Remaining Contractual Term (Years), Vested and expected to vest</a></td>
<td class="text">7 years 10 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding Options, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 43,010.00<span></span>
</td>
<td class="nump">$ 128,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Outstanding Options, Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">31,040.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Outstanding Options, Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">$ 43,010.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=idya_TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=idya_TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069716683392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions Used to Calculate Fair Values of Options (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">76.80%<span></span>
</td>
<td class="nump">81.80%<span></span>
</td>
<td class="nump">86.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">81.30%<span></span>
</td>
<td class="nump">86.90%<span></span>
</td>
<td class="nump">89.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069709453776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>GBP (&#163;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">License Agreement | Novartis International Pharmaceuticals Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">License Agreement | Cancer Research Technology and the University of Manchester</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_PaymentOfOneTimeOptionExerciseFee', window );">Payment of one-time option exercise fee | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents', window );">Payments for achievement of specific development and regulatory approval events | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 19,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_MilestonePaymentsRelatingToFirstAndSecondTumorHistologies', window );">Milestone payments relating to first and second tumor histologies | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">License Agreement | Amgen Clinical Trial Collaboration and Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_PayForExternalThirdPartyCostPercentage', window );">Pay for external third-party cost percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive', window );">Early clinical development milestone payment potential to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | License Agreement | Novartis International Pharmaceuticals Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_DevelopmentAndRegulatoryMilestonePaymentToBePaid', window );">Certain clinical and regulatory development milestones, agreed to make a payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_CertainCommercialSalesMilestonesPaymentToBePaid', window );">Certain commercial sales milestones, agreed to make a payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | License Agreement | Cancer Research Technology and the University of Manchester</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent', window );">Additional payments for achievement of specific development and regulatory approval events | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 18,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies', window );">Milestone payments of phase two relating to first and second tumor histologies | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies', window );">Milestone payments of phase two relating to first and second tumor histologies | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=idya_BiocytogenPharmaceuticalsBeijingCoLtdMember', window );">Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived', window );">Development and regulatory milestone payment eligible to receive</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_PaymentOfOptionExerciseFee', window );">Payment of option exercise fee</a></td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_AggregatePotentialMilestonePayments', window );">Total potential milestone payments</a></td>
<td class="nump">$ 400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=idya_JiangsuHengruiPharmaceuticalsCoLtdMember', window );">Jiangsu Hengrui Pharmaceuticals Co., Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived', window );">Development and regulatory milestone payment eligible to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_UpfrontFeePayment', window );">Upfront fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_TotalMilestonePaymentToBeReceived', window );">Totaling milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,045.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=idya_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock | License Agreement | Novartis International Pharmaceuticals Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=idya_GlaxoSmithKlineCollaborationAgreementMember', window );">GSK Collaboration Agreement | GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived', window );">Development and regulatory milestone payment eligible to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=idya_GlaxoSmithKlineCollaborationAgreementMember', window );">GSK Collaboration Agreement | GSK | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement', window );">Number of days of notice period for terminating agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=idya_PolymeraseThetaProgramMember', window );">Pol Theta Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone', window );">Milestone payment received for achievement of initial preclinical development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_MilestonePaymentReceivedClinicalEvaluation', window );">Milestone payment received clinical evaluation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_AdditionalPaymentOfDevelopmentMilestoneToAchieve', window );">Additional payment of development milestone to achieve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=idya_PolymeraseThetaProgramMember', window );">Pol Theta Program | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived', window );">Development and regulatory milestone payment eligible to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 485.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_CommercialMilestonePaymentToBeReceived', window );">Commercial milestone payment eligible to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_DevelopmentMilestonePaymentToBeReceived', window );">Development milestone payment eligible to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">465.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=idya_WernerHelicaseProgramMember', window );">WRN Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_DevelopmentCostsSharingPercentage', window );">Development costs sharing percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone', window );">Milestone payment received for achievement of initial preclinical development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_MilestonePaymentReceivedClinicalEvaluation', window );">Milestone payment received clinical evaluation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_PercentageOfProfitShare', window );">Percentage of profit share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=idya_WernerHelicaseProgramMember', window );">WRN Program | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_CommercialMilestonePaymentToBeReceived', window );">Commercial milestone payment eligible to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_DevelopmentMilestonePaymentToBeReceived', window );">Development milestone payment eligible to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 485.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=idya_WernerHelicaseProgramMember', window );">WRN Program | GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_DevelopmentCostsSharingPercentage', window );">Development costs sharing percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_AdditionalPaymentOfDevelopmentMilestoneToAchieve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional payment of development milestone to achieve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_AdditionalPaymentOfDevelopmentMilestoneToAchieve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional payments for achievement of specific development and regulatory approval events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_AggregatePotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_AggregatePotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_CertainCommercialSalesMilestonesPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain commercial sales milestones payment to be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_CertainCommercialSalesMilestonesPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_CommercialMilestonePaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial milestone payment to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_CommercialMilestonePaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_DevelopmentAndRegulatoryMilestonePaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development and regulatory milestone payment to be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_DevelopmentAndRegulatoryMilestonePaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development and regulatory milestone payment to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_DevelopmentCostsSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development costs sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_DevelopmentCostsSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_DevelopmentMilestonePaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development milestone payment to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_DevelopmentMilestonePaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development milestone payments of phase three relating to first and second tumor histologies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development milestone payments of phase two relating to first and second tumor histologies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Early clinical development milestone payment potential to receive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_MilestonePaymentReceivedClinicalEvaluation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received clinical evaluation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_MilestonePaymentReceivedClinicalEvaluation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received for achievement of initial preclinical development milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_MilestonePaymentsRelatingToFirstAndSecondTumorHistologies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments relating to first and second tumor histologies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_MilestonePaymentsRelatingToFirstAndSecondTumorHistologies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of days of notice period for terminating collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_PayForExternalThirdPartyCostPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pay for external third-party cost percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_PayForExternalThirdPartyCostPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_PaymentOfOneTimeOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of one-time option exercise fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_PaymentOfOneTimeOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_PaymentOfOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of option exercise fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_PaymentOfOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for achievement of specific development and regulatory approval events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_PercentageOfProfitShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of profit share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_PercentageOfProfitShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_TotalMilestonePaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total milestone payment to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_TotalMilestonePaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_UpfrontFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront fee payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_UpfrontFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=idya_NovartisInternationalPharmaceuticalsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=idya_NovartisInternationalPharmaceuticalsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=idya_CancerResearchTechnologyAndTheUniversityOfManchesterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=idya_CancerResearchTechnologyAndTheUniversityOfManchesterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=idya_AmgenClinicalTrialCollaborationAndSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=idya_AmgenClinicalTrialCollaborationAndSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=idya_BiocytogenPharmaceuticalsBeijingCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=idya_BiocytogenPharmaceuticalsBeijingCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=idya_JiangsuHengruiPharmaceuticalsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=idya_JiangsuHengruiPharmaceuticalsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=idya_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=idya_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=idya_GlaxoSmithKlineCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=idya_GlaxoSmithKlineCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=idya_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=idya_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=idya_PolymeraseThetaProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=idya_PolymeraseThetaProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=idya_WernerHelicaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=idya_WernerHelicaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069715805616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Summary of Revenue Disaggregated by Research Program (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_CollaborationRevenue', window );">Total collaboration revenue</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 23,385<span></span>
</td>
<td class="nump">$ 50,931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=idya_MethionineAdenosylTransferase2AProgramMember', window );">MAT2A Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_CollaborationRevenue', window );">Total collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,722<span></span>
</td>
<td class="nump">29,756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=idya_PolymeraseThetaProgramMember', window );">Pol Theta Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_CollaborationRevenue', window );">Total collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,002<span></span>
</td>
<td class="nump">13,894<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=idya_WernerHelicaseProgramMember', window );">WRN Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_CollaborationRevenue', window );">Total collaboration revenue</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 16,661<span></span>
</td>
<td class="nump">$ 7,281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_CollaborationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_CollaborationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=idya_MethionineAdenosylTransferase2AProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=idya_MethionineAdenosylTransferase2AProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=idya_PolymeraseThetaProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=idya_PolymeraseThetaProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=idya_WernerHelicaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=idya_WernerHelicaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069708205312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Obligation</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_ReimbursementPeriodOfCostsIncurred', window );">Reimbursement period of costs incurred for quarter ended</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">75 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=idya_GlaxoSmithKlineMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_ReimbursementPeriodOfCostsIncurred', window );">Reimbursement period of costs incurred for quarter ended</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">75 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=idya_GlaxoSmithKlineCollaborationAgreementMember', window );">GSK Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_NumberOfPerformanceObligations', window );">Number of performance obligations | Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=idya_PolymeraseThetaProgramMember', window );">Pol Theta Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation', window );">Additional milestone payment potentially received clinical evaluation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone', window );">Milestone payment received for achievement of earlier preclinical development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_MilestonePaymentReceivedClinicalEvaluation', window );">Milestone payment received clinical evaluation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_ReimbursementPeriodOfCostsIncurred', window );">Reimbursement period of costs incurred for quarter ended</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=idya_WernerHelicaseProgramMember', window );">WRN Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation', window );">Additional milestone payment potentially received clinical evaluation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone', window );">Milestone payment received for achievement of earlier preclinical development milestone</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_MilestonePaymentReceivedClinicalEvaluation', window );">Milestone payment received clinical evaluation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_ReimbursementPeriodOfCostsIncurred', window );">Reimbursement period of costs incurred for quarter ended</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">75 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_DeterminationPeriodOfCostsIncurred', window );">Determination period of costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">75 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment potentially received clinical evaluation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_DeterminationPeriodOfCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period to determine an amount of reimbursable costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_DeterminationPeriodOfCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_MilestonePaymentReceivedClinicalEvaluation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received clinical evaluation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_MilestonePaymentReceivedClinicalEvaluation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received for achievement of initial preclinical development milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_ReimbursementPeriodOfCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement period of costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_ReimbursementPeriodOfCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=idya_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=idya_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=idya_GlaxoSmithKlineCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=idya_GlaxoSmithKlineCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=idya_PolymeraseThetaProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=idya_PolymeraseThetaProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=idya_WernerHelicaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=idya_WernerHelicaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069716932176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (274,477)<span></span>
</td>
<td class="num">$ (112,961)<span></span>
</td>
<td class="num">$ (58,655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to common stock, basic</a></td>
<td class="nump">81,678,069<span></span>
</td>
<td class="nump">57,519,929<span></span>
</td>
<td class="nump">41,444,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to common stock, diluted</a></td>
<td class="nump">81,678,069<span></span>
</td>
<td class="nump">57,519,929<span></span>
</td>
<td class="nump">41,444,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic</a></td>
<td class="num">$ (3.36)<span></span>
</td>
<td class="num">$ (1.96)<span></span>
</td>
<td class="num">$ (1.42)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="num">$ (3.36)<span></span>
</td>
<td class="num">$ (1.96)<span></span>
</td>
<td class="num">$ (1.42)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069722033568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Shares of Potentially Dilutive Securities Excluded From the Computation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">7,737,595<span></span>
</td>
<td class="nump">6,269,975<span></span>
</td>
<td class="nump">5,097,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069722160128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">President and CEO [Member]<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069716302176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Summary Of Disaggregated Research And Development Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_PersonnelRelatedAndStock-BasedCompensation', window );">Personnel related and stock-based compensation</a></td>
<td class="nump">$ 54,543<span></span>
</td>
<td class="nump">$ 38,948<span></span>
</td>
<td class="nump">$ 26,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other research and development expenses</a></td>
<td class="nump">158,423<span></span>
</td>
<td class="nump">45,642<span></span>
</td>
<td class="nump">37,211<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense, Total</a></td>
<td class="nump">294,673<span></span>
</td>
<td class="nump">129,508<span></span>
</td>
<td class="nump">89,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=idya_DarovasertibMember', window );">Darovasertib</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_ExternalClinicalDevelopmentExpenses', window );">External clinical development expenses</a></td>
<td class="nump">55,335<span></span>
</td>
<td class="nump">25,829<span></span>
</td>
<td class="nump">13,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=idya_IDE397Member', window );">IDE397</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_ExternalClinicalDevelopmentExpenses', window );">External clinical development expenses</a></td>
<td class="nump">16,629<span></span>
</td>
<td class="nump">11,985<span></span>
</td>
<td class="nump">9,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=idya_IDE161Member', window );">IDE161</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_ExternalClinicalDevelopmentExpenses', window );">External clinical development expenses</a></td>
<td class="nump">$ 9,743<span></span>
</td>
<td class="nump">$ 7,104<span></span>
</td>
<td class="nump">$ 2,749<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_ExternalClinicalDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>External clinical development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_ExternalClinicalDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_PersonnelRelatedAndStock-BasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Personnel related and stock-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_PersonnelRelatedAndStock-BasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=idya_DarovasertibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=idya_DarovasertibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=idya_IDE397Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=idya_IDE397Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=idya_IDE161Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=idya_IDE161Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45069715973600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 06, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2025 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>May 31, 2024 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock upon public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,350<span></span>
</td>
<td class="nump">$ 281,165<span></span>
</td>
<td class="nump">$ 86,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=idya_SouthSanFranciscoCaliforniaMember', window );">South San Francisco, California | Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_OperatingLeasesAdditionalAreaLeased', window );">Additional area of space leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | South San Francisco, California | Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_OperatingLeasesAdditionalAreaLeased', window );">Additional area of space leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=idya_AtTheMarketOfferingMember', window );">At The Market Offering | Jefferies LLC | January 2024 Sales Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock upon public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_CommonStockRemainingAvailableToBeSaleAmount', window );">Common stock remained available to be sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=idya_AtTheMarketOfferingMember', window );">At The Market Offering | Subsequent Event | Jefferies LLC | January 2024 Sales Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock upon public offering, net of issuance costs</a></td>
<td class="nump">$ 25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_idya_CommonStockRemainingAvailableToBeSaleAmount', window );">Common stock remained available to be sold</a></td>
<td class="nump">$ 156,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_CommonStockRemainingAvailableToBeSaleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, remaining available to be sale, amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_CommonStockRemainingAvailableToBeSaleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_idya_OperatingLeasesAdditionalAreaLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating leases additional area leased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">idya_OperatingLeasesAdditionalAreaLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>idya_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=idya_SouthSanFranciscoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=idya_SouthSanFranciscoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=idya_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=idya_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=idya_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=idya_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=idya_JanuaryTwoThousandTwentyFourSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=idya_JanuaryTwoThousandTwentyFourSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MU$%MSMTW-T:NFZ/K:VF,+)O+%6> WAK ]TL)NF-[8T_#=[]^S/X'4$L#!!0
M   ( !. 4EI60#O[U (  -@)   8    >&PO=V]R:W-H965T<R]S:&5E=#,N
M>&ULK9;1;ILP%(9?Q6+3M$E=,!!(TA&D-M6T74R*&FV[F';AP$FP:C"SG:3;
MT\\&RD)#$E(M%V";\_]\QSG&#G=</,@40*''C.5R:J5*%=>V+>,4,B('O(!<
M/UEQD1&ENV)MRT( 24I1QFP7X\#.",VM*"S'YB(*^48QFL-<(+G),B)^WP+C
MNZGE6$\#]W2=*C-@1V%!UK  ];68"]VS&Y>$9I!+RG,D8#6U;ISKF8.-H(SX
M1F$G]]K(I++D_,%T/B=3"QLB8! K8T'T;0LS8,PX:8Y?M:G5O-,(]]M/[A_+
MY'4R2R)AQMEWFJAT:HTME,"*;)BZY[M/4"?D&[^8,UE>T:Z*'0XM%&^DXEDM
MU@09S:L[>:PG8D_@'!.XM<#M*_!J@5<F6I&5:=T11:)0\!T2)EJ[F48Y-Z5:
M9T-S\S<NE-!/J=:IZ)8PDL> %L9!HK=S(B!7*2@:$_8.O4>OD8UDJD=E:"O]
M0B.SX]K\MC)WCYC?03Q GG.%7.P..^2S_G*O+;=UFDVN;I.K6_IY1_P6BBC0
M):@07Z&/-->)4\+0G$M:EM2/FZ540A?6SZY4*^]AM[=9;=>R(#%,+;V<)(@M
M6-&;5TZ /W0E_I_,6M/@-=/@G7*/YGJA@!"0(%U=\<,5*HA 6\(VT)5VY34N
MO<PW81OA <;8">WM?D)GPUJHPP9U>!EJ58F(;%3*!?T#21=RY>GOL3BX^CV#
M[A'8PO8;;/]%V%3*33>R?T#RG/541 LR:""#%T'J;[U4)$]HONXB#<Z2GHIH
MD8X:TM%)TAG/,KT\^U3KJ%^UG@UK<8X;SO$%G+U*=7PP5Q[NKM4^D2WJ24,]
MN9SZ>*5.#CC&@8\]'T^> 1\&FKB)%TRZ>1W\;\O"EQ.?*=O:L@=W1^01<'MO
MVS5GGB]$K&DN$8.5EN+!2'N(ZAA1=10ORIUXR97>U\MFJH]>($R ?K[B7#UU
MS.;>'.:BOU!+ P04    "  3@%):"%4=N=P$  !N$@  &    'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;+586W.C-A3^*QJZT]F=V00D<4UMSR1V+YGIMIED
MTWWH] $;V3 +R(N$G?;7]P@PQB!H'M*7!/!WCO2=NS0[\N*KB!F3Z"5+<S$W
M8BGW-Z8I-C'+0G'-]RR'7[:\R$()K\7.%/N"A5$EE*4FL2S7S,(D-Q:SZMM#
ML9CQ4J9)SAX*),HL"XN_[UC*CW,#&Z</C\DNENJ#N9CMPQU[8O)Y_U# F]EJ
MB9*,Y2+A.2K8=F[<XIL5]I1 A?@C84?1>4:*RIKSK^KE/IH;EMH12]E&*A4A
M_#NP)4M3I0GV\:U1:K1K*L'N\TG[3Q5Y(+,.!5OR]$L2R7AN^ :*V#8L4_G(
MC[^PAI"C]&UX*JJ_Z-A@+0-M2B%YU@C##K(DK_^'+XTA.@+8'1$@C0#I"]@C
M K01H*\5L!L!N[),3:6RPRJ4X6)6\",J%!JTJ8?*F)4TT$]RY?<G6<"O"<C)
MQ9,,)0,_2H'X%OV^9T6H_"%0F$=HR3,(IEAY^<#0KUP(=(6>GU;H_;L/Z!U*
M<O0YYJ4 J)B9$G:C=)J;9N6[>F4RLC(FZ!//92S0CWG$HDL%)M!HN9 3ESLR
MJ7'%-M>(XH^(6,36;&CY>G&J$5^]7IQ,L*&M9VBECX[HN\\W/&.H=1#Z\W8M
M9 &)\I?.V+4R6Z],58\;L0\W;&Z 1P4K#LQ8?/\==JT?=(9Z2V6K-U)V842[
M-:(]I7T!Y2 -U[P.:JA3!Y:73&>^6HU7J5&U\K#P+,N:F8>N688@0JGO7*)6
M0Y1C!12WJ LB3DO$F8R&)C/S'6(O4/,%TV:<\Y9!\);*5F^D[,)V;FL[=S((
M'D%C6&SBJJ9%$ ,IWZN,TEFPUN1T71S8KD=[D3"$81(XEM\+A2',#QSJZD/!
M:^EXDW1^9CG$0EJQ"2/H"8DJ"ZI]Z@AY@RW0@%JDQV>((CZUW!X=#8KZ@:>G
MX[=T_$DZG[D$,OQ5\>T/R5 :>+T,7 YAV/%\;/?H:&"8VI3J^00MGV"23]4F
MMP7/3IR@F^JX!(/5KRAQAV0T.-BE38(>&PW.)4['TQ=LL'4>$*Q)/O>Y9)"3
M$MI]U9!4V'$9LZ+Y\!'E3)M*C=[NCAQB![T<66I@!-MN/Y4T,.K;([&'.^,/
MGF3W&XS6*7A,2P /34H\V_:\/@4-$$-!<'&?A ;H^*[CC- @9QIDDL9S#D-_
MFOS#(K2#85^@]XH4$Q\0M#T8Z+\R&:Y3A@3;E$4B$WUZ-8M<N,+I-T$-Z")I
M&J9#U!7!3C!"]#P4X<EQ87$YDHYZC@YZL/(<(0//:8#8"APR"#\-T+6Z->62
MT'E P=,3RBD $10+!/F4@<-$'!:05W">239:>K7*X*)V7%.W3TX#P]=!OZKK
M8?98X3A/+'BRJ4\QBY*TE/V9O^'FO(Z;!J;CIH6-<CM/%'AZI/A2G2=9=!4>
MH,;O&,K+; TTX0S590J'JE(*"253=;920'K"H0D0^[+J=7G71/_I=<TT@5W/
MM]R@;YPATO$<' 2#IJ%!VMBV;3<8&5+P>4K!TV/*_VBBJ? 9SBAC1AHBQXPT
M1(X8R>P<Q#-6[*H+#0%LRES6Y]CV:WMI<EM=%?2^WZG+E.J ?U93W\1\"HN=
M*O IVX)*Z]J#;17UY4;](OF^.NZON90\JQYC%D:L4 #X?<NY/+VH!=HKIL6_
M4$L#!!0    ( !. 4EI.-V:#@ L  %6*   8    >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&ULM9W=<IM(&H9OA=).[4ZJHHCNYC=KNVIB\<_NN,8SN\=$PA85
M26@ Q<G=#\BR$$VK#9XW)XDET\_7T/VJD7F$KI[RXDNY2M-*^;99;\OKR:JJ
M=A]GLW*Q2C=)^2'?I=OZ-P]YL4FJ^F'Q."MW19HL#XTVZQE556.V2;+MY.;J
M\-Q=<7.5[ZMUMDWO"J7<;S9)\?U3NLZ?KB=D\O+$;]GCJFJ>F-U<[9+']#ZM
M_MC=%?6CV8FRS#;IMLSRK5*D#]>37\C'F-E-@\,6_\O2I_+L9Z79E<]Y_J5Y
M$"RO)VK3HW2=+JH&D=3_?4UOT_6Z(=7]^/,(G9QJ-@W/?WZANX>=KW?F<U*F
MM_GZ_]FR6EU/K(FR3!^2_;KZ+7_RT^,.Z0UOD:_+P[_*T_.VACY1%ONRRC?'
MQG4/-MGV^?_DV_% G#4@[$(#>FQ N0;4N-" '1LPOL&E"MJQ@3:T2_JQ@<XU
MJ =+W, X-C#X!I?VP3PV,/E],"\TL(X-+*Z!?FD?[&,#FV^@7AHX]67D5*Z)
M=FDOR&FP^=&F%ZN\##<YC/?L>6(=9N4\J9*;JR)_4HIF^YK7_'"8VH?V]63,
MMDT*[ZNB_FU6MZMN[JND2NM45:62/RCW5;[XLLK7R[0H_Z4X?^ZSZKLR5?ZX
MGRL___1.^4G)MLKOJWQ?)MME>36KZ@XTF-GB6.S3<S%ZH=CO>96L!<UNY<W<
M?%V_6$SKS-[M/Z^SA?+KPT-:9-M' 6HN1_U23:M5.JU?<+[4KW 2CB/GW.:;
M3=V?P_$2M':'MU;&[)TW@CMX5_U7#MERF34OF,E:N4NRY338*K?)+A./9/!6
MUJC#$+ZYRN"#$KU28K'8;_;K.CM+Y=>:6"CUL:^7P56S/GU-E6"[R#>I\G.<
ME^4[ 3X>CI^G#]DBJ[J061WS4];I*>OT0-4N4#^EC]EV6^]OO6ZMD^TB59*J
MQB\^*(R\5ZA*B2C2STSSP&S6]*\W3"4ZT:YF7\\C+"W=G$M\+'?)(KV>U$>I
M3(NOZ>3FG_\@AOIO48B1,*>_ US?760Y#PGS!7TW+=M4NSL0(&N&2%C4WX&I
M26BW^[%@(V(:IF:=MNO,=W::[VS<?'^OE*ND[O2@>2]ECSP,MTC8' ESGF'Z
M>;PMG3%5T[F0(*MZ2)B/A 5(6(B$14A8#()U<JF=<JE)<QF4Y?ZP_-1GG(OG
M4Y:R.65YKVSK1;E^,GO98)&7E2B;4O[8;&J]5Q_+4"W2G?YSP5:6QKV0.<A^
MN?V*7)\\9#D?"0O$QY1;ML(AQS1"]BL&P3K37C]->QTX[<N7Q4HT_Z6%QLY_
M)&R.A#E(F*OW%CK+-(BM<NN<U]_.4(FE<>>,/K)O 1(6(F$1$A:#8)WT&:?T
M&6]*G[+?U3^FW])BD96'WSX_G>^:MY#"]!F]&4*TLW/5YU1)>S,V54B8@X2Y
M2)B'A/E#1BE 5@R1L @)BT&P3O#,4_#,'Q$\V?(G+3AV^4/"YDB88_9F,"6:
MH3'NC1FRIH>$^4A8@(2%2%B$A,4@6">JUBFJEC2JSF:WSK^GZ3&)NWVQ6"5U
M-G?K9*O\[-S?W;T[/2G*I=6;L*;.G5[=2GLP-FY(F(.$N4B8AX3Y P8I0!8,
MD; ("8M!L$[6[%/6;%C69&NAM,K8M1 )FR-ACMU_]T9,_F\%+K*DAX3Y2%B
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M\V(R]#J;,U6P6:VE<UD;^_-,RR%WF&1M+NLQ@^>/.H]!#R*@RXVH@#")F;<
M*$[P1%3@@05VLKB5_,CRK<>?==+R-BA$O>?2$>J=S7$-01$U:0$P[-/ ) ;!
M$)K(8C0H/>24/D,''=G+9.\0VZDX]DTB-@J'Q.)AHU <3N7M(+&06V,I&O*D
MZNK0,6_E++6_PX\2JW< &$#*1M$@F@J[074AI\!8;]0<12KM]":7P'J]U3DV
M9(E(9(U[$(Z&-)J*LT'-(+><^2M7X]Z;1&SEH;XR3$PR$"R.S!$"A(7)%)5!
MR:"WI<Q_)701I%%H%,16U,$J!6-J4@2 <82B":6"!JF"XG?- //RD5>74'1*
MH'</A7-:2^>R-G;I()B06S'=GF2V9WKT:.2N#IKZI2E8_/=3?M2SJT]Z$@6Z
MU58[2Q('IG""8)B$L1DUD#5*"1PT>!!/V"DFQ@PO%NZ=42/8$T1\,^\A9) $
MB3D4I1 0!T'LQQ,4!SV#W7KF&ZL[*N_C:,N2,,&A;W8@@*,D.5<P'4$;A[&J
M(]$$OT'I8+?2L6K;I8F/ 7T2^,KI5B<"0*0^/3!GH1"0$.I/: 4\2![\OM6M
M75ZR,KN XJS+6[-:2^>R-G;I(+^P6W[=2I%QOGT=+*KJI#S*=8JHB>Y!S1 K
M/??5\70\W1=YIG[9<:E<WE0\C>O;9**"]32V11:.* E,J0/A8C7C-44;@(M#
MY$\,G7A0;=BMVF!?=%6?+W<GO>3L/3$I63G!U!9A"?4MGC:*8A1;I<(E#L<4
M!S&'W6+NPNZ6O&"UXEH+C]5+I<J7;<'L>U\/@P^2'=X3!;:H(U$21U:9 1:Q
M8C54F-ZQ8?'YN#IVT" 1L5LBCAW$G[G,\LIVD#CJY1.8IZWL$*:QN9P%P!*K
MYJ:0,4JG!L-!)&+W@M:8Y:]WM[<JO3L) '("5J+4\&92 E 8F1,5 !5-+7/C
M0:-AMT;KAS\5F(^YSM/[E\O'!UM6A9'Z*&02M'$DQ$JUFQ1M7!*=U['QWLX@
MTXA;IFF2'[8\DWI*]E$5Y?9*5V?-_5/K 2U*'UG1K/EKD:J&C5KFF<YG_3NX
M_0/(K@@'IGK9 +@X\8G)'S*'R>0B'QE$''&+N,W%+#^IPN7=\X>\+'7_ZQ*N
M"I?8@NRA-:PHBLQU+  7QA$Q*Q, 2[": TZ0'Q0><2N\=Y+G>D'%2=N6:7&
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M965T,3$N>&ULU5EM<]LV$OXK&+7326=H6:1>+">V9^RXODLNJ3-Q>YV;F_L
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M"'@C/]0RPYH[2Z[",5EM*<B=7&J9RY0F*U!;A+I"D^-1:%$IMV(YJFL7@LG
M8<W!'O99%*CD06G "P>95,6FHNR.=U<\\"]-ZX(.!$7F=^E45H%&LR39-NOD
MI/N<,KR#/O>GQ)2BH&L/T?:HK@T_,CXYWJ.ADH'FW:UZ=1;JZA(ZTO$EWX0:
MA"HN82OXF$ *C$;2;;ZZ;3'J+?.7J[_UCA(UC7S@* UNI5*/_)[183ALCCPC
MPG&C)Z 7BA DZ%$'KV\">)Z!RB(<=(;2^$;H6@0PI![U%5RUJ]UQT! )72,<
MO*94.*9;8R+:&C* 4&B>\*9N;*B1,JF\)W@$BFII)X3G?EY7-?4!P-?'ZVDL
MO+A420VRJ9TC97\U%$HSDDI.50+,N6NG'2KT[>D"?,HCKE[\&P^$W$IWC?VE
MK8J] K5N/!K6L^)##0S^=-?7V7[K6[1'XS2F.45>2%.)=*7#R;G468VJ=>,+
M3^PC-=1K(_X]+>L7^W5G,0CZ&3)8,F2_K:ATOO>\N<TB=%(L6$%=!;I?!C[K
MD'T#^]O6R%*,:LHY&KLG&&X]Q:L5[71-BWE#5MYMHY 8*/?S#.D!9(!'>F)=
MC;VU>T8N19AC@6V2HPV.4DRS#9/9<WYC;/AH?<)2=+B-"6 $J=.2%<)SR@ $
MZ>'D$C7J]_ U)^8DWE*K)+K0W.[CM!V "MKWX&M3JRQ$%F>4T"V% \^P/4$R
M;0VI[V?N"U&^\+G:5R3I2L*"GI9P9-BFN_-_X\F&+. >V51V_9QYO:.@/3GB
M!E'>-G@A\WL[NFW'$O9<;$2+D"IW8G<A% %TP>?WGMU3KF_L_;O6;3W?\QDL
M0B<,WAS^\H,.5;8I. _>1_RZBL4)*\+]9"C$Z&*IJ4+H=S\?XYF22G?]US6"
M;GC?/=U^[\H5B6[I+Y:IAD$$A]O7[FUW=WT:KFRWP\/%-\K:I=24<G),'0T/
MI@,D#G^9'!XJ4_H+W(6IT+GZGW0])2P-P/?<(*B;!UJ@N]$_^2]02P,$%
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M6HO/7.'TM,;+O>E@*\6#/_[A^XN+Q\__?'GY@?YY_OSA6?')&WSHG>_MGM[
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M2>'U %90QR0[DJ&3X 5Z#_V(%*1>8 >DI]"ZPE:9F<"A/A!2@&$-.ALMA0G
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M]3@9DXSEM"WU=V+S;];Y$QM]J2B5_4\V;FXT'Y.T55I4G3 05+QVW_2QB\-
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MA&\S23B?JBU,2Z)A$A-++ ']9#S6QFK1XVR+[A90*G"Y*[-H*I$LSTP0PL^
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MJX8B['<@5Q#W@,;DJ#@+7 ! "M57JJ!G+F8:X/0=_L2UL.5]#884*I5&M!C
MJ$#?PKH?)5Q6. /WV'3(/FW '[*E7.,T48TQMF\*37A  8!S1FC4RBYCZJ5\
MK$(J,<U$OL'<!-(2P+N0-U:'T=="IP?5+.E9CUMQ4$!*'HVKP='IJ\S!L )L
MTNO'#-$+=%&(=B(08IW1> S]8#P*YI7+F*3"Z$M1%?OR&?U RV<$0UH"$A6U
M3\$\$\5BH-0"3?$@S.QL;+1KDS(IU3YI,%^F?6E>.CJD:GL"J2W-T,=-=,YE
MFODN0AG&460G5W7H(;N@N7)\N\5"E\_++$>9T$BWFZ';6 6F>H]+]#U.V. L
MAF!"A6LBD78R@]EV8.>E"07-"7^VFH/,*3//A "Y,G5QCK^4'H*BKO@7KP:]
MVTSK[E37M^]> 8P)X)QABHDE#@X BT&JO4-(#69D#K_;@>HG+ :#^?>L^+8<
MXE%);6I6Y0@N8F22J?A!)"&!L#49+$)HZ3)+<1:B1@*?]G:IFT($I>2UU(+Q
MB11>*MD6@#5$" 20DV;-<[*+,9T10^>R)\J2T-LQT:8BIRF39^FJ*GJ0J:\:
M!T+$?WDXB. ED+! 8+O2=S+<J <$K:R]3S>%1*A;(./#T8N>9AUO>9X<S(W?
M6QBP=QFSLJM_34<OG[-]*I]^2=0F08IQ>7X!OV*9SS&3VX]G((!A:('SE!SL
MGKO>"G:;8,T*:0TA^?W-Y#]UJKN9C$:P!LQYRT(A!=Z&^:]#,I6$*E:+;2F6
M8?0$J8A(G'@S0F0J(1=#4.. *$_$4Q@T ^>0LZ%'6BQF\9*=..T!4TYRO9JK
M4!+<KA!'&QD)KQ@3E.Y)W-.KS=CEBB,F 7A@4LRQ4)":EES5-&5G:BZ1<L/5
M-8!"I)<59<6@7&AK?>BAS,,Z<BO&RBKL,:0)$3F5?)' V@G6$N7@6//1_;\8
M33,7::J58:#?S-"79VX"%N!H#=2J:EUJ"3KE<F3-L&  =S$8:AIWPQ/'F8F1
M95D![Q@_/PJ>CTYT[L\L(DR!'L&_WN'2$\RG2;]*'LC,,5([*S9PW/ +7@.,
M C=#_NB*2N*K" L?YQM.,613+T7!?&)A[W<)R]+U&L%N+Z_42*[FBC:G-)8A
M98?3L7N/K+_TBS,^V2DKK_6.9RWS9W^39'X3ML9Z$6/*P6$TN(_^]"H3I@!1
M69-ORS>7E:(D06;DHK*Z6&]Q4QB"7(5@O'X= ;W^FT\9B)EU4 9D?9FK:30)
M1,PSS2+QBBC! [RQ?"4EKJ!E!,^K[),RWY8M?7B.*H7?D?&AS1J*Q_**YV-E
MV8?B/^80:#"PGH?FL[ (#8#@9F006&Q] 0,UIN!@P./A.K? XFZ@.8S1$N2-
MVSD 9<K.;-C=ISBK:@['4:?%>@WJ];;.0(J]INK1(WMA^-,'UYBB10O@1>$0
MTBDH;*47E;*:W/'M$\A4,?X]"JK71O2":P@,:N?X&VW,U!N[:YK;-.IW!O87
M[';%4A>5O#J=!D29LNN+CWZ*GX$>5KC!!9M#964KO+ZX]V\+4_FG,G>AE^NJ
MB_!;35D]&</S>N7F@3*Q8+L=00OL,B F/?0M2;;4(A<K150C!>/0"A:SEE[,
M$O$ )VKPCI("-)7D*\4L^FF]K%(KE=\\L\4LHB*X%,'--PA#E6D:#W=L26]$
MZ![.>7AE2,\0&I.<QFG@(A,6D%T^RLEW>8YK3*J/UMGH?8L.[ OM!H):P<(7
MC<H-6([9>$D05KN<+:A$A R*"H-M4EF543[P1\)^;F+J01+;Q  2J8BU4<T,
MM-:PG) U.!X-77%;W,?ENUJP\S"EDINE&Z.)MNI-:XWF\=*+A_+X LWB6NLQ
M'CWQ,:W1?G=2UN!MB@7DZ!M0KH9IK2!E!N_"JL<VZ$'8V:(MZ*7')-1BJ@00
M*HROMR39YVO\'V?K&'(B2*N7,..#(Z]T"@J7N)$4'RY+U%5/;4)KQ_R>"AYE
M'#0Z67\-1FC@H!&M=M :<% AS>BH1;PN\-"@XXK?Q.<&M !."DID(!C:P.)U
M9_P\@B0./WIDA,$P?$K@>#I>_*B!WN%K0V0,'!$6T4SN! %V;Y2/ _=4/?\&
M&/#"78_QK=$>8D^NTA?P]Q4 #N#N(RL']GCFX&@S))KXPZ* R[2YU3&.'M,&
MO8B!E&80I4"?$\LKB!'#,S?3LZLS'.P K/GA[$PC2Z-=TX$7[0JJ-;!Y*UYT
M.GW0! YJ;GX'Y"CI1V7$[P,;5>U,,).00]VH(6CR,8#E6.O/0)(9M05BM>GT
M=J]BVFT#DSVW+1U/6U2.=$U;Z+8/=3D\ID_56 PIO1&M,:7C+CK>0*A,AQBN
MU$M%TZ),;TXC:T%2,6FLYG1M4>;CJRN14WQI@S;X?[6):0M0?^"HN.6]*EII
MX2I@4K<R>DQM/G708 <O?YHW^#OW2,,NO_M9W?%-?U'R%SB%OWK@V<!2H4Z/
M;4O 3<6;-?K.*J_4\JIFR[0DCP_%65RLUH.L6'E6; \3*K#.L 57[4-TA)XV
MZ-.L29'H#@#H7O^F=CZC.N))9VA9>.H*J=);1@?U0**'+824L5*@5SRNT[)H
M2SO)SJ@2SN[LGI7/'TE-GW6)QHQP#3<M188]PPNWO>_1 ST\*;#$TTSXXBM6
M>3(3@&KM3K+PQ-L^6!;,;,&3BC5Z9\0L5;1%C^NBS5J!$O<GY[<#P%V5B6=L
M$6]#M=Q&J8K],RVWD[OW9=HO*\^:P]65<2_"9:*+^E=Y-'2CG-W=5S<8X^RZ
M5.:V('M[3C!@!<95H.O.G*E$#/1^%ZT.JR/D$C@>GOXZ>L7&)X?!X>$A:]_A
M96I37DG45<7@!Y#:%4)1BX89FXUVY3M&+[TB-]%E0I)JK19[A'CPJV_W!E^C
M;](&%Y)A7MNXK;=Y@T5*0Z">3",%QP8%\*S>JRN7Y$@8(,'V%&2EW7;@%E2Q
M*>]2!7:@J[25^K)6E"O?]E=K"1,LM 4V<FF^%9<OFX.:0[4VS7&7EC>[ND%Q
MMF1#JWR4PVU_T]O5_3>!*4".0I",KI)7XQ!2MQQP[W:M@:RKWFT5=5I,V8)Z
M>:S)N,^I<=&*(KO<R);\O8T^/NO0.8>Z!AJ3B?0R(!DYN8C(VC9S>>#),/=Z
M)>Y.3-W5[UJCS,MMCP><C;(7P],?+,PJ6V.3MJ:)E;W6!:M<' _'Y=5'SK99
MIDB9F?X^ZFQ)F7T)U(\(RMT(^!!_JM<,(5$O@"L\?55Y:<]!-K/:=ZG.:[FP
M-N^O7XVT]V?329EXL-EG7@+C..9X>7YQ]/*T]0S%Y/H]H+M! #UF_63*]?UD
M$"K$([VW^?;N^O[$KZ+[]6W3/H=G;@=) =&1J5@:=>M2..^,.)^EK@K$P7A+
M_?&2 7BS;ME*;7F/F2\=IS%TBH@8/(M'6I2+VY:U:V-YW%PF>G4^\R8TGM%D
M9=.1ELJL8>=RCDTI#<]LGW80/RM;;[1Y/*XTCWI+[MOFFV;-(@[1J8W>DD7C
MZS%I(]C7M<X^]?5:Z[OJY25MB6H9#,F.$.W')-K6[6:-8C=%<O8KE:<^$6G"
M;5IG?T=QRO,A/2V[(:]9TZM$*!7VS-8'.X<!@8P.\=;L;3H!]AA+V5?P]%"/
M@G95$[:EHMX.-_O6S#:J$A&K#2B+X?7M7(6&2LY6*E'6'D =T&!I14CZL4LV
M%ZUEAWPC<3V'6L3I-N.D/<#(V= A?Q&SU*X53LJV"PBI:P:BMLMXR-Y+.J/C
M0'9*0^V&WS=X^+QC#WD'AN\\/*G<"#<- 25#3%VZU6J_ T!72QBO_L[.IG\1
MY.^!FHKX =9#&0]Y*//BSV+%9X,%P&4N0IX,EG_*+6V9@EO7@['9LPS3GN"9
MP2Z AT'UMI(B1>>)T1_U/JHJTC\=Y_V9MP"]/?W@)N9#O=[4KP=PCF-1_EL@
MWGJN?9OS-0.Z/"WA%5[AH%Q#K:/3+;14;Q*TZ_UR_!:.R5/3+3"#:P3O!G58
M!JM0$C8Y!HS,!W=-[([R_D2_-\Q/[6;QOP7E?0_JG->/@:F?/+@;C>DC$B=]
M(%2IG/TE0 J8JC1LJF&WPQ=)//?POJ]@-C)7UUGF.;<GUT:AAGQ7Y&\Y^XOG
M?8K4 IRU02_2N8F=>7>0A@B9O#VWWK8,'CUP.O;M<U:\/2Z21=;94>W&JO9N
M:D.D_FZJES[=U'M;(XWQJWAEQW78.>]2U6-[,!X%BNZV:+L.GM@.]4A%"9T>
M)]:!G?W-D;T;3_+U@]W8GB,S?T,CM@J&UZ",+]^VT'4-V^/OO-*UE,?(5EW6
MDAWTE7VWS_MZ>HZGPC/T9>/YGQ.)^6Z:NP.-9SSA$7]6Z:/4\Y/VI-'SD?<>
MAU)8,Q_<G@]&-HT%[./%O^_O/I]/L+IQ>OR*[:^!.Z8 &42JGK7L]Z(MHBL9
MIBK#WG<,4N*1A)S/)'V6R4U^>CGX /?:F=,4:L_A4['P'IFZNT42J970!$;3
ML"9F>?K]EFUCVY8.;@M8H3)W ZL6#J)%K SK5/X$1/*&V0&0/#E^& QY)U6X
MS14NL![_5)HN0/6&Y2/#^-6E'5_=MUW"&P)2?;KBH2ARU'S&]M\)^3LHYQD(
M.@RJC93RL7)P>ZZAH+;A[MTALJXG1^_I$G?(LH6G<__@*I82!S(9Z%;3N],/
M1P>W]Q]/8?2UDAE$8 K$9G Y<!6R 7A_C,VI=QDLI]R19E_?6LGEOMB.0ZH[
MFJ7J!-1.\I[T#C+,]2<;@K+87&=IY;Q=^\G(H@4(M V\SA3UCLK:]D_L>5D:
MUE%J1,<=<_I!0K1:9Q;U3FO(LK-!S3!S-%5_6L)_0,UTI&*"=*4:"+PBSDTO
MS[(^7&J^O[H%Z;Y*<T#';HDM7V;Z-CMKO$F0[18&O1\_=Z4XW;?VSF>TZ;U+
MVYX\?5^/*,/$MTVPT\%J;]]\)4A:[JAT]+'MANT/&56[;Y5O$[C>&;@"-1E+
M!VL10/Q1T%*WVGCXB1W[7^;ST?9I\_-.?E2^]3=D'T2R2 MID*L=<VM]_S[<
M+4&J'W8?>ZU+]81*OTH.ZY*B)FP)LTUPK=[9A]XU2=S)LDJ2[05?CYN]QX-V
M>/8!(IKK0U= $EX<OV3[TP]W@V/XBXI/G2!KUXKG5U='[/[3[4AB8:H3)A]3
M8U"_ Z&H]1LL&B8U#6NXCT,Z<)_AX?$)FS4=DK[8X'_!Q8/>P#MWY']Y8<<O
M/'I1N 8K5,[*%&$HLF8ON^'8[N-S+;.'0!Z8+Z[D>-I[,]"?66%]8=UI]F';
M9VH/O*\)@^P+^F9RID_SZ \+NU_=9YDG^FO$Y>WZF\ZP,ED@_,=B#H\>#D]/
M]C13L_^ ]$S?)IZI/%<K^G,)BR*1X@UP?:[ ^\P_\ 7N8]5O_Q=02P,$%
M  @ $X!26C/M(C&V"@  ]B   !D   !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&ULS5I;;]LX%G[/KR \Q: !7,>7W-JD =QDNBUVVP9)=XO!8A]HB;:YI40-
M2<7Q_OK]#DG)4B([F:(+[$-;2R3/]3LWJN<K;;[;I1".W6<JMV][2^>*-P<'
M-EF*C-N!+D2.E;DV&7=X-(L#6QC!4W\H4P?CX?#X(.,R[UV<^W?7YN)<ET[)
M7%P;9LLLXV;]3BB]>ML;]:H7-W*Q=/3BX.*\X MQ*]S?BVN#IX.:2BHSD5NI
M<V;$_&UO.GKS[I#V^PW_D&)E&[\9:3+3^CL]?$S?]H8DD% B<42!XY\[<2F4
M(D(0XX](LU>SI(/-WQ7U]UYWZ#+C5EQJ]4VF;OFV=]ICJ9CS4KD;O?H@HCY'
M1"_1ROJ_V2KL/3SIL:2T3F?Q,"3(9![^Y??1#HT#I\,M!\;QP-C+'1AY*:^X
MXQ?G1J^8H=V@1C^\JOXTA),Y.>76&:Q*G',7-^).Y*5@-R+1BUR2I<X/' C3
M\D$2B;P+1,9;B(S&[)/.W=*RW_)4I&T"!Y"H%FM<B?5NO)/BE4@&;#+JL_%P
M?+B#WJ16<^+I39Y0<VYTQBXAJP$<8&JW9)?>R,*P?TYGUK__5Y<% OW#;OH4
M.F]LP1/QMH?8L,+<B=[%K[^,CH=G.Z0_K*4_W$7]N4[:360T&K .0NSK4L B
M6<'S-:+,O_^/L/@9MDJ*G$2;E.>)"!:;WEZRX^$Q0TI@#J?_<OM74%"*S[3A
MGN9T881 Z#KVT@K!/NL!&PW[[%:"^%PF' OU%KL_8%?2\@5>+,)Q/:\E)>GF
MH*U7,E\PQV=*,&]A'*QE3#?'1<IFI(<5W"1+;-4+PS/V$FJXI2XMSU.[_V;O
M=RP'L#) 360S^!]PVR.X$>8F]-=X[]/TZWC*7K!7^#/IGXS'^'?\NG]R=+QW
MC5"%<(YC<=(?#L=L-.F?OC[<^W;SF9W@Q9"-COO'QR,\C$]'>U^UXXHE+3-5
M\K^(!T!\TI^<'N''T;#_>C)J.4>F4!KF@\RN914K[UDAC,_0Y"0]4S)8TC)N
MK4ZDMXOWW1/^>@-+[;-KX #P@:,4@\'8]1)YCXTHR#4(&%ZL6;VAMC7M3*&1
MTH5W/46!3 "E$G8.2 GVK)WRZR^GX_'P++R]^95GQ=D5NXW'_.+H;!\2/1"I
MYEAS(-9$WPCE555XFT-DI]G'J]^FOT]?Z55.=A/),M=*+]8-H3:>?"C89F67
M</];Z0A.#^6B=SLDNMMGG\#(2)*&JE(G"G3A70\A*GF>%J;;?U\\I8T /\K_
M6?9HBX C]%+<.T)<CE"V%KV%3TU%$\54_)'OX UD JP4/$*_2F*!+F)M)O.P
M\M4K4&.A02WL_5L0NZ&W?);BMBP*M:8D5^N2EJA&SY4DK-]Z*C7S;T0=T"O0
M[516V<"7$-@ DNW[]:[$LM*T*9-66.2"T3[#?BPBRT!>.M1P5@QV3SW1&6HH
M5%6H'MV<24EPCD*B%U/KOE]_.=[WI(M=431HY<)4P,QHAWPNY(Z.DTP-Z1DW
M@B%=47& _+':^S(@(&WN@)E*IR0V!(/N8IC6B;J*8"C/,UU2#>+(PDGU<N.^
M*CPW2<#Z50]DM?9INUI:"8@:$SCHZ+L(=;R2FA0TNEP$[*1"P7!F74D>0H^E
MG+(73[ZCC^ZSU5+"<-*RA<B1K$DVW_=(B M5/=CB^53#;,+"X@%IA395!=[H
M4J7_K"O].\)FVW"E!4=B)F%ED^^J$0DO^$PJZ=9^B2NKF<@74(/TEB9]A4!U
M7=4&<PB'<V*9JV+C\N9+G0G[/J*",9IPAZ-!'?Z@A ]DR.*A M'*L=!VV)A\
MC2HZ8%/?&L&;A.7HLXXZW 3.#HRL(-2\5'.IE$A_"ABW5[ Z,A\O_!2D(B$4
M2C3!U)44.@)^DZ.:F6+@,QS"]_40GEC;@&B?^T$,' 3'61#"(UJ[/TK 1IB^
M[W6,D-FL-#;Z\W&]3[3U:$U*8T(#V<!+S?GDZ$]Q;D$..TF25MH2M=M I%GF
M'XLS0]PQB@39:"=RC.R! M.KL(]X1,]7K!$";7TB=JLT09@KN$RK]-C2TI;8
M40D=D QBO+8H@<,'Z+,3P(. 3W2I6F'?BGJ*9JK72,ZYG0MC_ S0"6N[#=;5
MPHYL8'<F@PAD:+2#:UIZV>I9@J:''\X.._CLR! ;.;O4[Y)P\L,2=G)XEFS(
M4%MGE0=,R@(8!+@+OO:U8M,#[AHXN0^GYE 75;V5Q._10CM04>G0-/B)MPP3
M9B+DG9\Z"5A8JGH%-$(!R%(\DGR'? /V3B2\I&;ES]H'""Y=:<26(;)1(9YG
M*30(.E?KIO"95,(ZG8O*Z%4U6/MV"B&<DVO?ZX[)B=J*!UDO64H(EWK3A;,(
M,PR[@R%Q4K[AB,ZEX.0-_HCZ:;DHK0O3.%V\(=GZNPA1N&":4%8^?KZJ,MS[
MJRD@G1,O)45[ FAV'1CF&R(\4CKD/C(=0;K6HB72F!Z!A3S>+OKN7N<+34$&
MD5Z)'*CQQ=.5*6$$YJ7.'PT6$W=<E?55!QB-AJ-VP"QC$2XT#3;4_>-X ",A
MD?$T];<W6'C!1L.=VI0%7DNZ[:E95AW=QCJ^#[P';[IMW7BXT;K_5-]^29R.
M6>APXUQ?$W^^@Y]T:T.:29=?._U9C6O?4.%P]@-ZQH2L^C%?RIET6+VZ_/]R
M:O/Z[=]EN@@!_A&,:90DW:J;O:?S6!L-&4_%@TNIBD&8S^R&-3(.G\_]F(H#
M3F:TVS?_L9>9/TQISDM/%U-7K58DXL-W!SRX"S4\P02$5*]**FLH^()&%D92
MWG',*I3*X5^+H3?J)&W<3Q!V]%L43?IUQO_:Q8R.;WHY.M.F7HVGM:W@$$$]
M!VP\HQ[22:="]@7RQ'VRY/E"!'0UVYXXUZ9LH75JJ:VK"V_T5A(OL@=;!,TH
M=<U$LPE]J"[?*$L>R?BZ,DVS5^VVXX!]0!MZ%UM?XPWCZ=&ENB33Y(&8C<RV
MN2/?ZM7YAG()L8TCNNO=3N/>/A4,?$/;YK="C)%9&O4SBA#*;3!G*A+I!6_3
M@QOHCD'Z:@H7S;Q"WN>\"7H/:6,1E UX>\XZ09O?YM@'MP+3A*URHI+?D5V6
M<'QT"P4%.24J6Q.G50BRE(LEPLR6UEO%BZ39'.;0!D1+1^HW04DC\^CDC )A
MKDI!R?<E(5#<<VI,VL$.??R]2@6C<)M7.C0Q7J+VU8 ]VWT83O5]N:AN9DJ:
M&4+_[PT4DYR@;56?])A'-10]AP^GIFE1HNO1!NA90-\U.>\.5K$^4R AXI&K
M_8%/CS$O]^-<O$&>M-[](:1#$'LD6:VHM(3"IS2%;YB02<PY\I>J^NUF;5#(
MA42%R!GIO5#A0@H56FHC0!0.Z<+\SG3=+(\D1<,"=76) SZ:>+7>1&XL\G[)
M@[U*EMLBM5W0*]CA*%&:Z3OQ<#B(C"R#&#*#KWV:\7=-6[)$/T0RM_4H&K\,
M-2;H?O-F)(1DU*#I+SBK5,Y_YGH4L*$&Q=CJ2 J;RYE7L:43]NF2Y*\.HJ+I
M]BSXE)'#?9EJ^REHV_>EA*XEC/ W>FT \D;Z9*2F"[>E-6X!VV#\4(S\#)Y(
MDY29]9V9#5EKT/5I\Z#Q+1K%:.&_N-L0U^&S=/VV_J@_#=^R-]O#_PCXQ,V"
M4*'$'$>'@Y.C7KA6KQZ<+OR7[9EVJ'S^YU*@%3&T >MS#<S%!V)0_U>'B_\"
M4$L#!!0    ( !. 4EI-$<M;]@,  (H)   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;*U6VV[C-A!]]U<,U*)- *UER9)\J6W 2;9H@6X:;-HNBJ(/
MM#2VA%"DEJ3B^.\[I"S'R3I&;R\V27'.G)DY0W*VE>I!%X@&GBHN]-PKC*FG
M0:"S BNF^[)&05_64E7,T%1M ETK9+DSJG@0#09I4+%2>(N96[M3BYEL#"\%
MWBG0354QM;M"+K=S+_2ZA8_EIC!V(5C,:K;!>S2_UG>*9L$!)2\K%+J4 A2N
MY]XRG%[%=K_;\%N)6WTT!AO)2LH'._DQGWL#2P@Y9L8B,/I[Q&ODW (1C<][
M3._@TAH>CSOT[UWL%,N*:;R6_%.9FV+NC3W(<<T:;C[*[0^XCR>Q>)GDVOW"
MMMV;)!YDC3:RVAL3@ZH4[3][VN?AR& \>,,@VAM$CG?KR+&\888M9DIN0=G=
MA&8'+E1G3>1*88MR;Q1]+<G.+&ZI[C])K>$.%=P73"$LC5'EJC%LQ1&,A&M9
M592_>R.SAT+R')6>!89\6X0@V_NY:OU$;_@)(_@@A2DTO!<YYB\! B)]8!YU
MS*^BLX@WF/5A&/H0#:+X#-[PD(FAPQN^@?>>*5&*S7$F_EBNM%$DG#]/!=S"
MQ:?A;#--=<TRG'O4+1K5(WJ+;[X*T\%W9\C&![+Q.?3_L6QG_9R.(HSZ\.\(
MP"\%PEIR.@HHU=!NU6@T+2I3@*'/F:QJ G$]*]>VY<H,F,@A+WEC, =!KKEU
M79-K[5RS5ZZSUK4^=GU1"L*7C28L[0,^95B;SI[@G]%R:J3+:>]W9*I5*Y#6
ML%K1!M);S^K-BFYH?Z+>;5.A8D:J:>^V8_9W^'P-%Q"-8C\>C>#2S<(P\B=I
MN)\E8S]-$KCLW:"0U/FMBT_NF,'\'7LDKQML*6MH--&D"-OLV>2>2--%> GC
MT$]'8W^03B 9^4DX\2?1!.+0C^/83R?I<Q#_*+W^4:$N8-@?IA0&A=2?=(,X
ML@-B8#70L:;L*KYS6J!5DMB[=>,ROF5*,4'"('=UH[*"3M[.BE1A=Y.^:B9V
MW^H7?*"@S, *45 Z,M[D;5Z<LAC/&GY0EEW:ODZG:%R=Z7/GK#':4%3$T?]2
MC+X5KD/:D5HTX!=R<<>3W^K%&EK-0/]5(QPY.0JRE@:%*1GGN]8?W5_4+5FC
M2E/2EBU2;4C';9!K):M3#?0?VZ:+CZQ*F6MPQX"P@"O,&,ENG^9]#2NZA1N>
M'U6!JEAV[*>]I8OL7#_]7%OF+PO_HL C?S0DY4X22/TH)?V.$DC\P61$LR&<
M.ER#H_N1FG7C7@%6-HTP[55Y6#T\-);M_?J\O7VE?&!J4Q([CFLR'?1'=*^K
M]N9O)T;6[K9=24-WMQL6]%A"93?0][6DJNXGUL'A^;7X"U!+ P04    "  3
M@%)::@<[XO,$  !1"P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6RU
M5MMN&S<0?==7#)0B=8"-I+WHYHL 6W;1/!@V[*1%4?2!VAVM"'-)A:0D^^\[
MPUUMU$)QW(>^2%QRYO"<X7 XYSMCG]P*T<-SI;2[Z*Z\7Y_V^RY?825<SZQ1
MT\K2V$IX^K1EWZTMBB(X5:J?# :C?B6D[L[.P]R]G9V;C5=2X[T%MZDJ85^N
M4)G=13?N[B<>9+GR/-&?G:]%B8_HOZSO+7WU6Y1"5JB=-!HL+B^ZE_'I5<;V
MP> WB3MW, 96LC#FB3\^%1?= 1-"A;EG!$%_6YRC4@Q$-+XVF-UV2W8\'._1
M?PG:2<M".)P;];LL_.JB.^E"@4NQ4?[!['[%1L^0\7*C7/B%76V;3+N0;YPW
M5>-,#"JIZW_QW,3AP&$R^(Y#TC@D@7>]46!Y+;R8G5NS \O6A,:#(#5X$SFI
M^5 >O:5527Y^]H@EA=C#)UT?,$7JO.\)F)?[>0-R58,DWP&)$[@UVJ\<W.@"
MBW\"](E12RO9T[I*7D6\QKP':1Q!,DBR5_#25F8:\-(?R'S M;%>ZA+^O%PX
M;RDI_CJFMT;+CJ/Q13EU:Y'C19=N@D.[Q>[L_;MX-#A[A6O6<LU>0W_KD;P*
M<IQBG/;@"#I\7B',3;46^@7HNEOAT8'0!26:IIOI0'H'BXVC/1PM.# :&T,.
M)5O:$%BQ4 BNWB&"W4KF*Y ./.&W[F8)3$A86F// K=4&M:!%%$B;,II4[Y\
M7!K*?RR ^.<R%($*"YD32N^0\?MWDR0>GSG(5Q*7![2*UDT\H843-DP&9_.[
MZ]LPC,\^,#G6=D^,9,$,F-'\YN[X#A4*M['($AJ11,XLI0?BK0R)(SQ-E522
MAHIH4N& ]<:NC<,@'+=";6IV1#,<@,XQ;"J4,GF]1&3,QN;HHA Y)DQS6RY(
M86(I-;E)H6B?;X?(( T^'K( 45)M=AYR5F/#$:VM9&9(?T5]TOZ(7,+&7#C?
M@TNEF/Z!T<^.!.ORHZ*:2N2=0PJCH-@$%30E=3#_HB5_/7IFU:.L U$4,A#V
M)E@X66JYE+F@:.(S/38.@2%*8R6GGL[5AHH*U46_(M #82&Q-<,;_2]NCO?C
M PIA;W+"Z%HK!\+BBE^6+89SB^@\*47YB0HY6$@GRM)B&:1\-UT;NNZT\P<9
MU,4/J'1AM:"$H_+5X?+%-2SEGZ1S\^S1:CJXG.XK259'X> D_@"GG6MAS98>
M'*I7"_@)AL,H38<T2(;1))G2($ZC+$T[GZYOTND83I(/$(^B$2W%<32=#&$:
M9<F(E^-13!_C+(5Q% ^($(VGG7NTSFB-B@2J()3UT8N3/WWDAZX.%#&J\VN8
M14-"2"?1-)M ,HK&\;AS1V&W/PX0G*2D".+AA"BED VC499 .HZ2..Y\-EZH
M-V"0\FD6C<8I2T^FT7 PH=&$!NDHA.R-T6TRBHO;9DD/P,;NBUCKYRW?KMPX
M:GBX$E!*MNZ<Y'1_J(61ZB5D"U=72=>5B\%6<@XL7LA^3X;2CEH$2F]*L_GM
M79V#\X<[@N8S:XZO8>7J76%I315R^K(J4</\\_SQ,D3QK1'_;RJ##BZT^[50
M3815DC9K)^E6E2S>E%94_V]DCKVC_8,VIT);AF:. [;1ONYXVMFV7[RLVZ1O
MYG6S>2ML2441%"[)== ;#[M@ZP:N_O!F'9JFA?'4@H7ABGI>M&Q ZTMC_/Z#
M-VB[Z-G?4$L#!!0    ( !. 4EKTI F<3P0  *X)   9    >&PO=V]R:W-H
M965T<R]S:&5E=#(T+GAM;(U647/:.!#^*SN^FWLB&!M(VQPP0TAR[4TR9>JT
M?;BY!]E>L":RY$@RA/OUMY*-X[0DTQ>05[N?OOVT6FFV5_K!%(@6GDHAS3PH
MK*TNPM!D!9;,#%6%DF8V2I?,TJ?>AJ;2R'(?5(HP'HW.PY)Q&2QFWK;6BYFJ
MK> 2UQI,799,'RY1J/T\B(*CX0O?%M89PL6L8EM,T'ZMUIJ^P@XEYR5*PY4$
MC9MYL(PN+B?.WSM\X[@WO3&X3%*E'MS'IWP>C!PA%)A9A\#H;X<K%,(!$8W'
M%C/HEG2!_?$1_<;G3KFDS.!*B>\\M\4\>!] CAM6"_M%[3]BF\_4X65*&/\+
M^\8W_A! 5ANKRC:8&)1<-O_LJ=6A%_!^]$I W ;$GG>SD&=YQ2Q;S+3:@W;>
MA.8&/E4?3>2X=)N26$VSG.+L(JE3@X\U2@O7._HUL] 2K)L,LQ;BLH&(7X&(
M8KA3TA8&KF6.^4N D/ATI.(CJ<OX3<0KS(8PC@80C^+)&WCC+LFQQQO_:I+P
MSS(U5E-)_'LJWP9M<AK-'9,+4[$,YP&= X-ZA\'BC]^B\]&?;W"==%PG;Z'_
MVH:\#1%-AO!SRDM[9@L\NV/Z@<[ZY\T&-9?;OJ-50,ICF:+NU!_ 1JL2_F:R
MIC,+C74*MM"JWA:=_;RQ#V@"8:7*BLD#:,8-YL"V6XU;9A$D+5QIE2'F!M0&
M?H=X.HRHK(5P)[2F\M$>@35<RX:K.G*M:FUJUC!U;L?5'5%(F$#*DM;"TF6S
MYY;XH8^E"6; > ]J-=(.8>D9_,2?543PB=-Q1W$@@M'T?'C>,:2(3)4EC>A@
M9@_4E5S?<SGN&!<L%>BHI0A&B;R7S_+^#C8LXX+;P]#I0PRSAB9!7C^17+[+
MK0F0-#-N>WB&<(O4<. ,$FJG!64HX48SF7&3*;CO*9VUB+E?[89K8V%)EKS$
M9[4:L&>!T@,PF1-;NT>4</4=;I,U3$>C$22%TNC*:@"WMROOUM]8+OO23X<O
MN+ \=X*\T#&*!N,X(KFD]2*91PI&V*#?71?"78]F OS!<HS1B=(L:_A_Z-S<
M6&F^Y<ZQ:J4B.8DHS\B4V#H_$ ]!.Z$T:[H^821U51&)Y\P_DXZ8ZJ:BXU.E
M2UZH*0TN6_$2S!1!_<4%W7RP2E;)LJFPUM(OS7W!L^(%''L.W5,IT7X=.5)&
M1!(JI6U;8"YN7;BMBJC*7$9T]7IK=DP4=TS4[!CPZ>IZ_.&=VQ0J@Y3$\1.>
MW+U6.8K=80 MQ*KGX>4:^#C4ENH8*IKPO<('LWS'?$U1,7/:B;I4VCAW4<LM
MZ;[^X32>D.BEJ-PTVUDI:8A/F^L)2C_6F]>,ZFG'<_03;<J4;Z7HE/F BO64
M4L::5Q<8GFK38>\.+5%O_4O!$%(M;7.==M;N,;)L[N!G]^8E0RV6:M2 P V%
MCH;OI@'HYG70?%A5^1LY59;N=S\L2#/4SH'F-TK9XX=;H'NB+?X'4$L#!!0
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M\0R3UX+T"#/<Y+:B:5#89V"ZXC1D90NN.V4%>4RP(QDZ<.R@]="/0$'L!79
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MM.^\09L4:HNCIH7:/:;B8P >0*E 06@K:;V*@W.3LL+#6-U8K5LIQ^_$_82
M#QX>\J,+X5-BAAEEIWC5-N12)7O]F/5R7.4&/23=#H,1 0\-8CON4,6CNL'!
MP>QAK_5'@SD0,":%\Y\0K9<8^JB<IA/,#V#Z>C/DW">SG2]FG[WZ$.:\O/4Y
M+[^:/HDAWY#+MC!%]B&9<I,P0$31#_@NF'!PSC9W;JB07YZ"@AS\;"GD?QCP
M.W1G;86GM3GF8I[@-H3.,[35Z5?-3"DG>4*D&)%F&O!8G[6V-OTMYKBQ\H4K
MVR!;/(* Z;+3[&?4I7?$@?84[1#[>+KE8%,F6!AA'OQ;5C*_.@USL/:.DO84
MM$U$SCH,!0.NB9C>Y>TV<"IW)*.!XM!5"ASP[\#A76X7"<B>G- :$KNU'>5%
M@6E-5@CK-WXKLX='8^TI\..B<['&1]]3. _=^7B *%;(  2A@O!OS09#5LQ5
MOT%BZ6><,Y:I"K%,9CX+\WPY?_+='L&LT92?4;7ZV>)^+PF<25);'#%-:G=,
M$^F)F@F6SGICI=D/A_$F##5AO$F\(T&"0)P79NL2A6<0RQPQ?U*A!)7(3T[_
MV+;-<" U&-TX:TZ"@RF5:\H?;)'"B>\!K<E7*#DV.>CA7DE/3.DH8SPG\W=-
M'D"MQV<9"(7/?FLY7E1P\H^+NU$,@<R9N:_4M.#OUD:@S:%4$\*>?Y:40&0%
MH\T'/C3XRZ_W:T# CM@N(7WF/M$@MD_JK1O>L5\ZD1X9$A6AH3 /#2DQ2^18
MVWW=',L$Z5-XSY<S<(D+I^GN/A_.V<R6$=N'TTBK9P[,Z2L-Q9:#AWDO=C3F
M@Y#H>C]*))THC2U)K69S KS?)2E\?/_))2FH=&+.'V@Y*U'$U;2;O' _7TL&
MDT59OI-AF*<[C(TT;<EIC%%,B(]' EU-T$>%GI=A+![W>_3P$H39&W )-"&:
M?FK] LFR(>:BL4TX*XN9406'#$QLD0_XA9P-F^R@C:Z;MN4$*';2AQN+DC]=
MJ#"U7CQ%11M51R9@$9 H,-B<<9#GB+"@14?2<02\?5ZJ[DKJ$](O4?':;#!B
MR-)YM+(5%H\, C#"RIK]&!+3+37KV%+HNP2.5;"^$JH*J;"-/T).'=8T[$:S
MT1O.6./T#,FX-L'IHPR21 C,/6LPX'MT!L,X<8:#Y>8+A@PZD46-4!@1L5-R
M-N1'CD!'4SCLI6!OK"URS#>!GF-7^'Y-C$$\J+"YNJGY#^=16$S:/??)S^?+
M.<Q753.4-/- S.,R".HG&=VW#Q?OD;,2 5+>>D.J8HHA8HC10Q(Y<["6<8K"
M31'R33HO8IZ2WN'25T]AYFBX(/=?["R:-(Q^<X(OF6\L;T7$AHL4SK%KNLEB
MV(FEVRPU[YX9,CK3K)2TV* DP7LG--= V;+_!9#A)/Y5>4E4/A-Q7V $ER/7
M4+BV-.B_$I^)T7KAK]'%%&QBJBR/SMU*AD;)]I.>67 " "_.8VB/R(\IEN[S
M)PE&8$CT)Z/]A*^TCH;+R%)9(B>?!']^1Q:\)$Y]]*4822KZZE$BXN%\VBZL
MH[O6Y%-XJ?1^J+\V!UMDS\Z>K;*/84[7E9"%>'6OJ!00@V^J&%Q>7^%GK@(J
M^T3D)X]CD>>0I'.)8W*^G109HN&Y9A6&"+*I)/UG;_$8MDU3DG6@25DK22@3
M'532@\A6ZT0"A2YVK[WJDEB[)O&@:468)/I%DM%8E\12DLG4P(H;KYRE:FO8
MSQHRMHD4"92[7"+2:F!J2DX2DJ##H3+0C;*FR170]>;0O<@>VD?J;#PJ*.@H
M'W:/)"3J@/X2WAZ_+E-P#O&ZDA1?9\GJ:/0I?.LA010.F^YR#@"2BQU?NWF$
M(=NF4+D[>4E9Y[VG1C)^",,ZQ(KQZB'9%(\BR&%Q4T?QBWQFGE%F'/)\B5<A
M>$\0O!PDX!0R1Q\TX_DCS?R3;$[-.0T7[H( J!_97ED6KX:4/X/^8JH_"?:_
MRAY>Q)O!%%]W:!3*PLG#V!&P8"2V+5"\2K$))HL)2,>Q,2T9B0^?+,Q$9\3*
MC&A<:G/=;^RGCV)P4'PMR&+F1*3"L"Q[^-TCD0  RC6GX26U,<R6UYRIF.[Y
M<UQ]7S&PIT2>6CQ\IROO%#F59D!.]GX+SL"*Z12E+F6&I,=WC$T(GXXPPI)1
MQ'2.,M8Z%1XR8"*)?T:(D'<&DU.VJT6!BSK/GZ?GIJD<:-'HB_1@#0I6I6D5
MK&@D(!>3:H;2IP*2XX^1KR50190R-YNE1"04Z3%-]DAJ@3#)O3R),WYFN(PJ
M?\*,G,H6D-T<H"=\9>Y%\K@*KRFG&2RH'M5L_ZDK>'[!WHDD6WN(_Q8!?).W
ME+ ^0GDW2>_L=C[2J!((P=9V><65KTZ%4VC:3@W:-?O)?H;ED/J)\?E4(O\+
MRFX%8YW>TV7?KP; 1B%;9AP.%YSK5A*^9U4"%V&3^N_(87*G/D+3H-X,6@2@
M*D=YA@,\1J\EEHU,L$;WJ@4*C47'3,WY"(0OX5NPR8 9CIF**VIQ#Q!/)7MJ
M$!MO;6JSL0%(9&RL-VGUCX""[T.P([8E0N\?0[E5)R'S%WJMSGLIRQ8C?TTG
MEB8%SCA6Y4!YTWT^Q&I+I2 Q'BC%@QP-^0C0E %H-_Z]U23%1&,P&_%O<L%_
MLVUI7PVE5O"$1^<U2:\,)<9A:#$4T86DP[+[GI@4,P6?IH+SB@-6E%]>(;'S
M<?FYV[>K?EE)G']^(([,L*F44%M/G9;OG">;.-U\@CU"]8[;.S]D,1Z)D1+U
MU1C-$<&*2:9^4M_7$.VW<9E5((JIN$39!KD-*G?RDY63/2B'5,XB]9'>*S&3
MK62C0AUO00$CJ654B!)ZZ2+2B&<G#6D\P(RF$0S3$KO!S,>#4N)]@,SDI6D?
MKA!JO*:87:.<6-PO+]=_BQ],HA3S.OF]%G&/!<3/1JZ+G#U"U"ACCOC'A3,L
M#;IYBR:><907HC%_*0JM,!49\[2D&0GJP"X(/,EG4L>P%WBN;X3*$1;=4A#I
M F8*Q+$3TS@?YJ7D4432;@Q1IQ_&(%2>PCI??.HZ&:A$O]@*5!_<L#I&7Z!*
MS:YNT::1;Q'?"WU"E+UDZC+PY*F?.O#*A>6C'!MQ!L9^,G-,2YX7AS3IOI)X
MML==9Y? :M>&A0 L6EQYOG-%H,%)4"X(NR3QYU3-?_+?%ZU=XS"WC<BR3M4"
M4C-D(N>M=&IP6D5\06^Y\"('!D1&*OI0T*.RGZEJA\?3C"7V\\P.L>(ZOQX1
MSZ=LDV=CV(LX4LP\N:6N54$C%NK,0"=.KS9@V$Q57'DY7,KL>A>6 _"JDE]^
MW2)"KC"HR9>&+A?/L=)_GY,:NY9;8_?KH>V,QN(_-!7.WW->]-\__JH%6>*@
M=2Q$T[BIXP%K>7C0;3-L=]I.I+*;0+=CB?XBVS6W7 S*MC12O2^X'=7Z*E82
M>/.]:&%(QJ1(2,DCN4V(L:>L^ZF=PFJ*V"M<88:K:(IB:+V>[5MQ'">5*Q$5
M,^OOFNI&@^+!Z_XM/KA1FN,,K4XYFE?")5NV&SIB;:+22S%[!K#'XYY18S:P
M!'*'2,@_5?G8K1PW7N1,< I88U,Z[HS.35^_+I%5BL6IT&4U8L]!/>K_,R<;
M5S-2T'9LLT?2A-T3:06;8@BQ;#Q)"$<.+)R.,D\F1EU.ZHU#D3F3?7!LQ+M@
M8BM>Q!-%$44PH;/*_#9PJY)8-Q\;FR>QCA^*9B0+/A@E:1K<HZ%/46).X,U[
MB9@F+8#0O>#2MRC1!3/!$\(&':2$8S2 SQU#H+:E!G<DTXIZ?^1]L3L9#MH,
M*JS_E#)/.056MUT>=)P019U(=,K3[&-SS"MTHKX@DW;J0]?H+I6:2_.J5C\*
MC82IJ(]UIPH5!M?V8N4$GYH67I-?&SDU4S886$(!T9L]_N3#"FX-<E!W^AM$
M(ZMRR;E#K[U#5#UL;LE!C([2/,A9?P<Z^W5UC1C-5:4HP,ODP@9*KO&$Z1YY
MTQO=7>34YLI4?8ZQ'C%G'6PI']&8$=+DG:>H,(V#\O&)VQQZ1Z&E-%\+B[=+
M3&IMU4TU#;20;JH)#8Q17OF<Q$RH,B]%]\@) U3S6K!F]\:&YF23B11A?TS3
MN@[4H#F$$+JJJ0^#5D"/*]K+QK#L%6^,ZJ=Y[$R/A:=OBN3+#*1I!.LGKAIF
MZL[FEE>$W>K?8OAJ'JK& 213;.+(4F>7HMZ"XV[L"W,]06I.YM**O%,7E1RH
M6AP4MVZ7LSM'$5%E&+MA\L!N;--=J.@PXZH> &1:'QO7]+HDF;&^-Z\JW+T#
MS:_YYK7G7.&O!#(CF26/T%.P,^F<RNE\L-,CB\$<&^@SB_5[YT0=M/KW',HG
M_P3;KYM1"J@BIM91!-FV8=&3'QQ#=,&+Y@O6Q3MB]/:CL41 '&? ID"WJS#]
ME+ZC;@H&TZ\*0]@@ECQE6GA&(CG,17H%/ .UAIJ-&0C-4$88)TB-K8VP0I;4
MZQFW 0$PX>4*CI7.?7$YHY(A5\,RU[)Q9#2(PR5,,[!="D^=Q\4GX<3^Q/$8
MQ 'O,<[(1:;L6<V5!5Z$,QQ-'_GJ1X7 D:(8K? A"V^M,)Z?YA'^IC&G"A4W
M2O($>^@6M>[<):H%&42*D7&<D!:#&"9OYG2R'@["[_VB$EZ_-A5N2;#I "3<
M\RO(^+L3."/W67@D<P<^!@HRDGEHW'.G<5BS9F6]I8VL<#5[-TVN+H(Y14O"
MB0D5Z=XH0\Y@(LB"TG9I:]HZ-^\7<(W;B*:YN^2"U6*TH//#J1^IP(#$0%R?
M(=Y'7H3H-V?X31VI=:#2LV>6%;>'PG+YG9#7$0YXH>65O4=?27OIB:T(U64;
M9JK6II577RSB:&62DZJ1P6DK/U_L+DG#H=\ZI;#E8C3*DH0)!OTN1[K6E/=[
MXR;HBS6*>KC@X1:&XOB0)%/--[IT&8D59^BYS,FX61XE42.*QTS9:[1T9M)E
M2"Q&9=1,"IU2XZ)JZ[5VIYRX$N=1="]E2A2M)1?WW1;,4=6[Q6SVSH4N5/3.
M1SO#4H]UX'@(\\)J\P60^M94@+@/SR\>24TU M4&#>WB:O5Q-JDFA4[WM)C=
MZ'LLG2\W6?H8(LN; %G>"K(D<QU_YYC9QSM1-.R/%+2Z9B_IRK5V<Q%V><Y.
MU(T46(R:WU*'M:C3K:9&7OWROM/DB^0@,YURW?<?9[Z/.X6&/W5  UW3$N%J
M?SCI4L=$,MJ/L"1T)&('S$I:!^G/VC9.V<+*->TX46R.$I+#PCN@PVJA/RY/
M,BH,O >3"3*S4Y@M.O'759-_<,;/R&',^R:WJ6?80125:OQY()=UT>C"5^@#
M7X5MDG4!0=.YN+,=I0RR-.#X4=S*>0."T@KO(0BQZ.!$PXH;AD:=C"AC!.?%
M8HYD,K/?NZ_G"-H7SOI&*#C"S6^3FD',\ISF)2(AGF/,:2>Y[MZ7$ZEPV&[7
MW)61[7LFG2\W3;J4JNUOXUW?T$[IWA-.6TA2!3@B/YP7NBB:H0LQE%.U@?O0
MD,A&TC4S"Y<&R-4"E/3@2I5G/*<NFY$1 ,,I3J441) FUZ%GEE"&^K1P<!95
M3HWXWDC)/9$+,TO#K2UD)WY-S$=(59S9C)1CE;Z=^I&JZ&\:6'6YFM2_I<KW
MFV0[$A'LXL;I[5ZZ;2:HP7<1;6/H<>M(.D43M ]VO:J<^S[1AE54)EX#G9A<
M=X+VRC%!VQ%._%_3]IUD/%>R<B=]9[^XKH!A>UL,=] Y5EQ!AA7'= *'P LC
MM1[:$PA7)QWG]T--1@.FWE ZO.NB$#0^QU1A37N.$U6#ZV8\W@?Q?J=2C^C$
MO^[T\4#LC&J9',4!1938G-,%<U0U=HL:.YI=RSK$=EJGHGQ<4@^OL*)(G6><
M0W*Y!<2%;V1VL=R&[)JN%WE-^[@*=*X4%_W&H>8]"G-WF\3H3J?O^X)+&=V)
M?Y*X1@C3,IZ??[_*:%'1<A8\'/=;#_>0R,-*:4D<X(".NXZ'R=#;+F.U5DL0
M Z<?!H'"5>1H\0M3G<X7S10$]Z/LA;B@FP;7A!\>7;FG&N]D6^HN77):U']I
M)IWB=97#RJ^+74,!L<2'<6+>='F:S2?V;9!=Y=2CN^O7;J2QLMX ]&?MSK$2
M8>=!X"WI4>MX9"QA-VEM_GU^=D*Q#BY&!E3$R7CJ/'N:\8\2@R%,/)=G8!5L
M-KJT)97HPO>KNUCN5_>.^Q[]%2__2=+K_3^?IXGPAJ&@?8I4(==E8&\[*@"I
ML#Y*5!#Q.O\R>RL410^G>7-\5Y AM[6&LL)FS1K))Q8-PZ]S2?5=N+$*YW*=
M$_Q.3,WJ"P[3NAN,JOPVR [QUY!@%0@[_H::NM*05Y"\VE,/@>XBB&PXH%!P
MFO-E,-?X;Y1Z0$2)V;>^.Z)KXVT$LO'%"-(E.@7KJ"9ALC;?X^3-/<\I;F\%
M+%C5A+3V-9/T$;A.J4A!L<O=_X'\" &]D>07_YP.$#W9D@=&V2Z48Z39,QWH
M6W0CP:G67%)1;&J2"!M<F!\LW:Z/RA4Y7ALU5OSN+/LW7H/=-9P=X=(*!:;!
M!5J1!&AU3E=9/&E=(\S#AN60OO>^2_FG=(-$;DU;=KX%%>E6@.!AS@,AP% '
MWF B(':I=%%;,M<(R&F&\F05U.)4BTZI"]^V[&*Y;=E59/F_\TW>?FZZ-'O[
M'>-E\:]!2SEI!\3Y*]@-AAZ0J2/E[4'<DT0)MG,"*A;5E[KH:#;OM-&@CDAW
M!.W!JJ"KC69[%LX[K]-]P99.PK<%NUAN"X:]N0A(@(K9]0XW<=ESPW]-L[CB
M.[2N@_TGC^@;.H9]V^P97E)9^ ,[<%M&?*VC,3"[,J\*:4&%X@F[^*D0\ <]
MFDK'"*<254&S8D]RS-@"\JP'ZE;#:I[[BI(',0R,<P7="C0)#;4$S.V<=!L-
M^\V7MAHXUR[H ?<&'V)N?[AIOUOM>?:OW"L7[B^N.X*'"_6*JO:A-2=8CH/"
MCI3N?MH AQBB'*6 :DV'S[T9&28ND<W!A,NOPK(@DL?S, SF6,5*([$_[=;L
M-SYYJ*''\%(ZX_O?]K$KP?W &0*C)':6VG?B1"@.1HG4N*F.NZ>7_OX4N@//
M%QF,3(2YM<MJT$-8V(/>9NC;VZ]-D:-W4]&HD3P6680X4FMLC;DQEC%0VVIJ
M^H8<-7F;J.!%?J98KB4U,<0]WGLP8;RS4N=.;RCRU3KO!%K;<<Z>D%<ZLL0\
M>Q1)<YB%%PTIR2&&ZD4E:<H[S5X+#,=. ]^:UH^MB=M,1\'-D:LTAH]9(R$(
MI8)W0DSSK_NF"S+;LBO"M\F[6&Z3!QJ;&5TJW39U,TB#HK2 ^88^>7?-D_U$
M,A>K%E&%IEI%S-:([B&./F @$ET)O_2M4).]/5XW&,AW-XQ=7K]V5<#L]4--
M+)A/KZ2#@PASEH(F'],KRMPWH-#3(.O&7628E\TA8?3Z.WHEEPC1E'1U9#/<
M($K,GJCG8S%T2&!KO+W]-/L58#4/W$N9^O^!_+N _ XOA+WA]GC8&H]Y#6Y2
M@71Y_8E^.3E[OLKDBENPBM1R?L@M92Z^/WOT(GL7-B.%\_CH+[W5+]^X^YY]
MXU/^2CF2Z*+\>G ]=)@ F$DQ"W"_74ZW=/@7.[DS-TP@T.'42:T]QEV"8*<C
ML=5B]W,SKWRV<G1S-<6[L.^$-AUROCHVO*S9!#?VEG!B'?Z.EVNW/A3\_LTO
M/A2<GFAI6UEP,P>6CJ#@TKB(RVJ&.59HA+?H[(XS^ZB+<#1;7 ZB\\&8&#?7
MSJF:9!2D:<I*0!D!L5=H259@"4NR5>+(75^]JHI.U=U7!H2 ?EE .>ENJV>(
MIPI""#%V.)3J2W$T@;O;6+RZ3)I&K@UH3)0\EE.C?M<H\OP[:10Y=[MA7M>#
M<R!I,SO&&Q6=$JG^J@F?CIS*0OF][DJ7$TWOG@93!3/])8=WVV.F'3$E>N%+
MG'?^WD$)=)7-(41>F!D8!=(B>LRS7G*BN'#.E8HF[R[\]V[^:G9U(P1G? IL
MPN@-U:>.9[SS+1'O$ LK_)A"(2H?@,&]+_KF/OSMV2K@3A$O>Q%WT;KT7 -@
M\-%0.H8K&[A^>^7P)!CO$V,DW6A"_2+=<.^H#2*BJ')$3G43+U=(D*UJ9%HP
M&+#$P"U#84:^ZX:VFI!K\8YZ9.(:=(V$"&$7U^:Z9&I-/_+>_M#)%.Z?.C+G
M4I"2]XDS9\_$1W?]<W9]\E^XS^C)?T:$3!%98 )_&8 E/3DCO'Z^TKE=0$R[
M01-*^Z!? +/[S;T2RY(M353I3=0'5V-Z4_A,^E%',$=,H#>Y4S%YCF)F147*
MR#DG)ID-K[066G:.:.<594*FQ\Q 3K/W=<!TGJ[NI(D_K29"W?O[4\*<H""-
MD 9;BDCE0-I3.*LP6L![PLELT.D/0R8\I<]V! O1U,5QY.H-I<-:RXA(*3E_
M%-3 8N:GV3:M*E3JA(7/\^T6NV8IMPM[KXIM)O>?XGU\M@H:Q6./KBBF0;9D
M,"0+JG^ *=N5MI#LWW'#5?4%LA88:",C(#B\J"7;(@T%!U OJ/R0Y$2,\$N$
MLU[.Z'!-D(]DC(JS>XBNM_IYSO59ON<9F]"$CIJZQ4Q(])Y@OJ2XB+.F?*2;
ML94N64.%P77+I8 3_(C8=RH*%4L$3<'DW.0H+9_O"^O#1R]3R1B\"9'(%$4,
MADF5JBX1:RQY841.7W'ILAQMR?ANGUC2DNM%9351=JC)/YVEZJ<G9T^R$R7$
M:X4R//):?=+I?:*I2DCW(>4$;"![>#VL>S8)+LY.GJ)5\&9"9Y.YWX9Z.2W4
MQ:1) ^6K+9)J/O&(XX%=<4X1MNK4(0U8G!@N$%'DSBO%E=;N?A<N#Y4:FY5>
MR"!VF+_7^\;$^2YW9C2*:NH(W]6P;)JFKU'A"45BT_KA=8GJ8A+R1V\6W9CN
MLEG#G(!5E*/I%-2\WE))ND1=H[LN/LPQ@]Q;0)Q; ++T&#/XF(ZTK)-?Q*[8
M,56Y0_[W?R%_>A9KZ>,B[KL'>/ZO!]'OEO9+_C3?Y?YBN5E]<#G/+V'0$;9P
M[YON[ICB9TJ>.B>I=?'R_1H];#2JK0\#:O5*!'*KEUSG9:63K]XK+9D&E,A%
M]X.[&TRB&#3SC#" RMW?>147<ZMP]WZ#,2P+UH6DEQ?>+99<RFJZ']U(U)>1
M-[GR[B)9D'NI\6O%+$M8(-UVW[8-Y7VS*A*\)%<,P;9S7F5T)S#9D@.V#H@;
M.$\WH#![(C#[5#<3J&DR$X6G@XM_?1T%A8B#[HBW?$,P7]RFH0'*X*)^ P-7
M$6D^D,\B"=9VG#_EJW$=]A;5*M=S!:_AL_6.TRU$![QQ2164J&U_D]KUV0_T
M?'A,3G5:HD7?GOUBN9\ZQS$3N7$_<0 $MIHDO^519Y-V-F[43BJ3CIPPD-S-
M8\K8> -(]>J'O6FWY@K$*,I6&._'!YB.Y)XB/F"N]HO+BP>/X4O_^JL?#H @
MP%BV&,&NS 8^/3M]#OR#PCGZ!Z@8.&2V;OJ^V=,_=P:4P!9?@-]1K.H?.,%M
MTWZFY;WZ7U!+ P04    "  3@%):%H-?U1H%   S#@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6S55VUOVS80_NY?<7"#(@%46R3UFB8&DO1E!58@
M2-KNP[ /M$3;0B71):FXV:_?D;1E=W'<M!LP[(,M\<1[[N'Q[I%XMI+JLUX(
M8>!K4[?Z?+@P9GDZ'NMB(1JN1W(I6GPRDZKA!H=J/M9+)7CIG)IZ3,,P&3>\
M:H>3,V>[5I,SV9FZ:L6U MTU#5?WEZ*6J_,A&6X,-]5\8:QA/#E;\KFX%>;C
M\EKA:-RCE%4C6EW)%I28G0\OR.EE9.>["9\JL=([]V!7,I7RLQV\*\^'H24D
M:E$8B\#Q<B>N1%U;(*3Q98TY[$-:Q]W[#?H;MW9<RY1K<27KWZK2+,Z'V1!*
M,>-=;6[DZA>Q7D]L\0I9:_</*S\W28=0=-K(9NV,#)JJ]5?^=9V''8<L?,2!
MKAVHX^T#.9:ON.&3,R57H.QL1+,W;JG.&\E5K=V46Z/P:85^9O*&5PH^\;H3
M\%YPW2F!&3? VQ+><_59&#ZM!=R*HE.5J82&XP_6HD_.Q@;#6Y!QL0YUZ4/1
M1T(1"N]E:Q8:7K>E*+\%&"/OGCS=D+^D!Q%?B6($C 1 0QH=P&-],IC#8]]/
MQJM*%[6T^=#P^\54&X7U\\>^17O(:#^D[:E3O>2%.!]BTVBA[L1P\OP92<*7
M!PA'/>'H$/KD%GNT['"#Y S>5"UOBXK7<*&U,'JSGZ7;S!M1R'E;_6F'!K8+
MW;>BPS$OM(V&J1?-5*@^_0',>@+<$VAV"2@DH$H??F;#W[D\<X4_#3-9HSQ@
M=54MF(7L-+KHD]/!@S"#BT8JX];Q5DFMU_^OM:FP144Y\(L??!S=CF N[X1J
M74'K;07_*NY$#12.((YI$(89WI& D@BOQ\!B!B?K9UF2#ZZD6DJ%T#"5R*GW
M9@D+2)[B_!2](I*CE[.Q&'V:1BB7BB5?(ON-4Y8'),R!$G3)T,&.*1W<=E,C
M#<XF2"<*&%(A09Q3G)5F(<ZS]ABG)@/L('&/ F!;$V;=EA&!. T2FL#S9QDE
M]&5_]>;!%=<+('G \OS!%&\>?' <_+[@%J]WT28GS$C 6.[N+:^CGIE_2@,2
MD\&[MJ@[N\6XB84-9_?=W8@O786XN!&XQ037C8M,MSR.D?W:F'V#TFPE:+N!
M >JB4G93C^D)Q+DED$-.,TLJ 6_*(_(4I%:V+WHT=@(1ICE+"21)9-%"6PO.
MQN@_38];^!&DHPAUO*[M*PE1BK^7R@J[H7I2(J5M%2Q+7F/;X;+<.[Q$<D;N
MEONJ,@M8=JI8X,L+2JQD;T/L/,3QO>MG;![K<.\GC%QJ/R ZEO*2M_=NI]*7
M&J-@^[TP0C7[4^J!A&6.E0KW@BN0"O"-84'9?M!:MO,G8$Z%60GA@6U&S$()
M'P*Q]\L2>XHL;77QYX6)_:O"%!$:)*DM**QE5TXH*ZZ<(K*1F/VR%+,@SQA8
M94(MH[8;HH!$V>.:A*H2)"'9:<;82I,UQQ';:E.<LX F# O;-AJEL>LT%F2'
M58EE 0O#!Y+CS5Z5HNSA<[0]VG )0]F.F&VF+'/9\6S\DR1,?D")",IC&,<0
M.1&'M8'\L RQ)'.<*+6))VD$:UN>_(P.D3!!"8OQ+>3@W#L@3(,H?UR&OIN5
MM0"Q=)3M*M"!@K19.X(L_)YD"=?P_[%F_=\D:]_GWWCG0QYS/'?'%8T9[UKC
MO^E[:W\BNO '@>UT?YS"K_=YU2)1,4/7<)3&0U#^B.('1B[=L6 J#1XRW.T"
M3W5"V0GX?":EV0QL@/Z<./D+4$L#!!0    ( !. 4EK"Z-H4NP,  &,(   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;)56;6_;-A#^KE]QT((A 83(
MDBS+]FP#3M)B!=(MB/N"8=@'6CI91"E2):DXW:_?4;*5%'"-[H,MOMUSS]T]
MU&FQ5_J+J1 M/-="FJ5?6=O,P]#D%=;,7*L&)>V42M?,TE3O0M-H9$5G5(LP
M'HTF8<VX]%>+;NU!KQ:JM8)+?-!@VKIF^ML-"K5?^I%_7'CDN\JZA7"U:-@.
M-V@_-@^:9N& 4O :I>%*@L9RZ:^C^4WJSG<'/G'<FU=C<)%LE?KB)N^*I3]R
MA%!@;AT"H\<3WJ(0#HAH?#U@^H-+9_AZ?$1_V\5.L6R9P5LE/O/"5DM_ZD.!
M)6N%?53[W_$03T<P5\)T_[#OSXY3'_+66%4?C(E!S67_9,^'/+PRF(Y^8! ?
M#.*.=^^H8WG'+%LMM-J#=J<)S0VZ4#MK(L>E*\K&:MKE9&=7-TPPF2-L.@7<
MJKI1$J4U</F!;06:JT5HR8T['.8'R)L>,OX!9!3#>R5M9>"-++#X'B D?@/)
M^$CR)CZ+>(?Y-211 /$H'I_!2X:@DPXO^:F@'U$PBP7<<9,+95J-!OY>;XW5
M))E_3L7?HX]/H[MK-#<-RW'ITSTQJ)_07_WZ2S09_7:&^WC@/CZ'OMKTMP=4
M"0^:[J:VWX#) MY\;7E#M\4&\ ?:4ZS/XIYF_9T'?/$@*6VYHIMI7.*(BJT0
M2B7HBG.Y@TLN:46UALS,U=S[:+!L!=SS$F%MW'FJ*-9;U*ZJWN4["7\AT^:J
M*[#[2[Q[ME6:646A#HXAA0N(DB"-$C>(@G&:>DZSK26HEV,)I*,$XDGD;51I
M]TPC+<5)Y'[>/=(EKI0H@->-5D]8=WK?5$H[%"+7]G3'P8S\)$$21][;5DMN
M21I=)DK^;#N9I! 1F8S<9=X'99F YF3&**1@DF40I4&6I43!F#FL\[RMVUY[
M!5+2<\[Z-Q69LIKH\'_[A4L7:Q9%<$7#63!Q(^]<;2Y@&LPF$WI.@F@RAC.Z
M2P?=I3^K.R*N6R)]S]F6"VXYFE-Z.XMW6F]'9/&"_']T=D);+X(Z8CMG3.=5
ME[<"GZ@O]37"9^ITACR2M&;!+'7IBUS=)H.MH1>'=J2<[18EEIRD,PWB)*%,
MS[(QE79'*G#;I(22ZDSUHX42R2@*8A+4+)UY?U(<FD8CB,:9=RKJ"TA&09+&
MCL,TR(C,J1J&KU[\->I=U]Y<REII^QXPK X==-TWCI?C??M]S_2.2P,"2S(=
M76=4/MVWM'YB5=.UD:VRU)2Z845? :C= =HOE;+'B7,P?%>L_@-02P,$%
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M1^%P3"-R(+,O;WA/R(&<T#ZI.P"?+<$;QO0\H+> K:^I183*EI9UIC OC(;
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M]Q!*8T#O-X*NE6YC O1?6//_ %!+ P04    "  3@%):!6$1/*($  #*"@
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MU57 I:QIUEK8=KW](A85ZG=G$T-AV'B2]Y 7'63P J0?P"?9F+6&ZZ; XK\
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M1K_;J?)-\]CQA[RJ\G6SN6+1@A5U _[^8YY7+SNU@^>\^-9T^^;_4$L#!!0
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MF ?T_81S]7QB&JCWIR;_ U!+ P04    "  3@%):?C/WYB0'  "J+P  &0
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MS-8BYTDU6"I(HG3S/_Q>!:(Q !++ %0-0-L.P-4 7$YTHZR<UMLP#R=G&7\
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M_Q6+55,K;>57@*9+D-I$4R=U6M6LV\.T!X<<P:K!S':2[K_?V1":)K3*PU[
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MZ.>=)QB@;"Z/9J)%;?OO7&CLYG98X'T+TAC@]UP(O9V8EM[=X.D_4$L#!!0
M   ( !. 4EI8+Q$JKP8  +$W   9    >&PO=V]R:W-H965T<R]S:&5E=#0S
M+GAM;+6;6V_;-A3'OPKA%4,+)+$D7Y,Y!A+KUJ'9BF;M'H8],!)M"Y5$CZ3C
M!.B''RG9EJ72M+6=OB26S//CY?S%RSG69$/95[XD1*"7+,WY;6<IQ.JFV^71
MDF287]$5R>4W<\HR+.0E6W3YBA$<%T99VG4L:]C-<))WII/BWD<VG="U2).<
M?&2(K[,,L]=[DM+-;<?N[&Y\2A9+H6YTIY,57I!'(CZO/C)YU=U3XB0C.4]H
MCAB9WW;N[)O0<91!4>)+0C;\X#-277FB]*NZ>!_?=BS5(I*22"@$EO^>R8RD
MJ2+)=ORSA7;V=2K#P\\[NE]T7G;F"7,RH^F?22R6MYUQ!\5DCM>I^$0W(=EV
M:*!X$4UY\1=MMF6M#HK67-!L:RQ;D"5Y^1^_; ?BP$!R] ;.UL!I&HR/&/2V
M!KUS#?I;@W[#X&@?!EN#0<- .DMO,-P:#,\U&&T-1LT^C(X8C+<&X\*[I3L*
M7[I8X.F$T0UBJK2DJ0^%( IKZ<(D5]I]%$Q^FT@[,?U]11@62;Y 'XB4 $>7
MZ"Z.$Z4KG*+W>?ET*)6]=8G 2<K?H3<HR=%#DJ;R-I]TA6R&@G6C;97W997.
MD2IM]$!SL>3(RV,2:^R]$_:. ="5_=\/@K,;A'O'2'1)=(5Z]@5R+*>G:=#,
M;/X;?9;F5FF.YN+GG^S1^!<-QS5S?EWGYW&\\[O31Y\?7?3VS3L-QF\Q*@9,
M<#[&,6!",^8!OU9]TH]-S?>]_0/0*[B]\QZ &-UQ3@1'?WV0!=%[03+^MT[C
M);6OIZH5YX:O<$1N.W))X80]D\Y4MGEHZ?PY@X2YD# /$N9#P@)(6 @$JRFP
MOU=@WT0_4&"J%(@BR@7ZAM[H5&<DM54=),R%A'DE;%C U.[K>6I?74^ZSX=B
MTI49U<L$9Y0)@1I><_U@[_J!T?5?,$OP4TK.\+P1U-;SD# 7$N:5,-NNN<QN
MN%Y;J-_P?5EH<%BFX7F@AM<\/]Q[?FCT_ SS)5KA))9[J2A=RWV,VE1E4@9K
M1N390" Z1[0Q,Z12+$DJ-V=RGW9H%BG87!Y#T)S1[,"L.!F4Y8_(RMC*MK*"
MA+F0,&]X>B+PRS*C@S).0U(G2X1 C:Y):K27U,@HJ6+_@NX6C)0"^H8>Y6%U
MB1YQCGR&\RCA$;U ,YPF<E>?)UBG!V,5;?4 "7,A81XDS(>$!9"P$ A6D^-X
M+\?Q#]E8CR$5" ES(6$>),R'A 60L! (5E/@]5Z!U\8)\8X1K);1HH9R"8WE
MK&@X6-\;@6W%!PESK[_;SO3[EF75UQ\/LDH?$A9 PD(@6$U5ME6%S*R6![9,
M+KA1L>I>H)CPB"4K%3/3QL:,[+82 Z6YH#3OQ"C^L=P=>P1A&4HXLAT+945D
M3Z=&T,8%H+00BE87Y$$,UVXE2#6@6NT9,:VU!TES3W31J T/M"D^*"T I850
MM+K2G$II3ANE7<BS9I$<$!21%T'R^/3\9ZR@M08A:2XHS3LQE$+.?S.:K7#^
MBI:8(WE*:PXF$O4Y4A[;$)9?"YRJ?8W84+GVY)Q$:Y4 1'/YY_*58(:DEQ(:
MZZ=1R#X&H+00BE87=Y4)L(UAWNE!X@NWWSJ:X:V%#9H2 *5YH#0?E!: TL(M
MK19$M'M.%4BL*ZV*^-OM0O[-!U^K+]#8/RC-/=%=P=9$*R3(1OB@M "4%D+1
MZGJKT@RV.<^@"0W*Y<9-R.)D0-!,;BT[T,P#*,T#I?F@M "4%D+1ZFJL4A_V
M\(=$!FW09 4HS06E>: T'Y06@-)"*%I=BE7*Q#;G3/Y#B-!,;*W"T7<[C,&H
M&=9S0>OT0&D^*"T I850M+JZJ@R(;0QO_\] (6@B!)3F@M*\$Z/8"!3N!K'(
M?+M$CN838>5OU+ \,I.75<**_#AZP"Q:JF_&6MV")DU :2$4K:[;*F]BFQ,G
MNGAB3;QE**X8;Q5OT,K77(7RUZ7M:*4*FC<!I7F@-!^4%H#20BA:_0>Y58[%
M,6<'RA-+\3#C8S.D&=%VACS1(#6-7%JZ7P>[H.WP0&D^*"T I850M+K$JJR)
MTRYK0EX2+M0,5_[T:A>1820G&ZW\0+,I)QI[)(3B@C;" Z7YH+0 E!9"T>K:
MJ_(H3JL\2BDRG![-W)EQK;5F;ERO6-1UV0,7M!T>*,T'I06@M!"*5LJM>_"^
M3T;8HGCWB\L=VCH7Y9L/^[O[]\ONBK>J&O?O[1O7UMSW[)N@?'NLPI<OL\D]
M]2+)N93M7%9E78WDR965[X>5%X*NBK>-GJ@0-"L^+@F."5,%Y/=S2L7N0E6P
M?TMO^B]02P,$%     @ $X!26K44,ZK5 @  _0<  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#0N>&ULC95K;]HP%(;_BI554R>MS8U<8!"I+:HVJ=50:;</
MTSX8<D*L.G%F.]#^^]E)FK'%P+X0W\[[O,?&Q],=X\\B!Y#HI:"EF%FYE-7$
MML4ZAP*+2U9!J68RQ@LL59=O;%%QP&D35%#;<YS0+C IK63:C"UX,F6UI*2$
M!4>B+@K,7Z^!LMW,<JVW@0>RR:4>L)-IA3>P!/E4+;CJV;U*2@HH!6$EXI#-
MK"MW<NTV <V*;P1V8J^-="HKQIYUYTLZLQSM""BLI9; ZK.%&Z!4*RD?OSI1
MJV?JP/WVF_IMD[Q*9H4%W##ZG:0RGUFQA5+(<$WE ]M]ABZA0.NM&17-+]IU
M:QT+K6LA6=$%*P<%*=LO?NDV8B_ \PX$>%V U_AN08W+.98XF7*V0URO5FJZ
MT:3:1"MSI-2GLI1<S1(5)Y.O%7 L2;E!=Z"2$^@"+=7)IS4%Q#)T6\N: [HG
M)2GJHEV#%OA5G8L4J"Y3X&@@<3X'B0D5'] 9(B5ZS%DM<)F*J2V58\VUUYV[
MZ]:==\#='-:7R'<_(L_Q1NAI.4?G9Q_^EK%5PGW67I^UU^CZ!W0[HS^N5D)R
M]<?X:;+62HS,$OJV3$2%US"SU'40P+=@)>_?N:'SZ8A!OS?H'U-/5+Z!R5,;
M%351^L)M$S\.I_;6@!KUJ-$I5&A"M5'!'LJ-G,#,"GI6<(H5F5C!@#7RX[&9
M%?:L\!0K-K'"(<OS1F96U+.B4ZRQB1496*%O9L4]*S[*>LQ!E=], C<1XP'1
M\Z*Q8T:.>^3X.)))3%'6UH*BJP6TJ0555PM,7L8#+WX4!9'9B^O\J5C.43=W
M(,0$D:*J):2JP*B= "&-Q<49.+APX^#0C7'WBJ;['QO"^L+7[@4E>$4HD03,
MI<X=7%YW[$;N/V;LO6*N'\9[S#>D%(J1J3CG,E+I\/:M:3N254U]7S&I7HNF
MF:OW&;A>H.8SQN1;1S\9_8N?_ 902P,$%     @ $X!26HX](VA: @  "08
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M+]#IN39\J>#*?LFV]9W<.B1ME!9E!\8(2E:U?_K:Y>$ X%^? /@=P+\4$'2
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MBB!#T9YDVH'B57,86',%1XOF<@>G/RJT 3S?<*Z>!_I\T9TGY_\!4$L#!!0
M   ( !. 4EKV>_:A^@(  .<(   9    >&PO=V]R:W-H965T<R]S:&5E=#0Y
M+GAM;*U66V^;,!3^*T>LVEII+0%RH5V"E,NF]:%2U;3;P[0'!TZ"5;"9;9)F
MOWXV$)K[VFXOX,OY/K[/Q_:AN^#B4<:("I[2A,F>%2N57=FV#&-,B;S@&3(]
M,^4B)4IWQ<R6F4 2%: TL=U&HVVGA#(KZ!9CMR+H\EPEE.&M )FG*1'+ 29\
MT;,<:S5P1V>Q,@-VT,W(#,>H'K);H7MVS1+1%)FDG(' :<_J.U=#W\07 =\H
M+N1:&XR3">>/IG,=]:R&$80)ALHP$/V:XQ"3Q!!I&;\J3JO^I &NMU?L7PKO
MVLN$2!SRY#N-5-RS? LBG)(\47=\\14K/RW#%_)$%D]85+$-"\)<*IY68*T@
MI:Q\DZ=J'=8 3OL P*T [C:@>0#@50"O,%HJ*VR-B")!5_ %"!.MV4RC6)L"
MK=U09K(X5D+/4HU3P34+>8IP3YY0PCF,RV0"GT+?+#!52[C#A"B,0'$8\C0C
M;/E!P@,3&/(9H[_UC$;# !E.J9)P.D)%:"+/--W#> 2G)V=P I3!?<QS25@D
MN[;2RLWW[;!2.2A5N@=4.B[<<*9B"9]9A-$F@:TMU[[=E>^!>Y1QA.$%>,Y'
M<!MN<X^@X<OAWA$Y7IT&K^#S_IH&&%$9)ESF N%'?R*5T#O]Y[XE*QF;^QG-
MZ;^2&0FQ9^GC+5',T0K>OW/:C4_[[/XGL@WSS=I\\QA[," )82'N\U@".P70
M7$CSP/-=MVO/U[7O!CF7[>>@#4VM6E/KJ":=$'TI2M0W5;W[,T&Y@"42 4HG
M*N.2FJMH[WX^RO[:Y)1DK?55Z!SPUZ[]M8_ZTQOXG_RU=R2=.WYK*S%');QQ
M4W5J@YU7)S#,A4"F7FBQLV/1=2\;6Q9W@YRF[^_/C5]+]]]Z'OR=K=ZZ=#M;
MFG:#-@Y-J<E>JQDIBEE12B6$/&>JO$;KT;I:]XLBM34^T%6\++K/-.4OP T1
M,\HD)#C5E(V+CEXF49;5LJ-X5E2F"5>ZSA7-6/^)H# !>G[*N5IUS ?J?YO@
M#U!+ P04    "  3@%):(89E$ ('   B-P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6R]FVMOVS84AO\*X15#"W2V2$F6G"4&6DO6,JQ+T*#MAV$?
M%(F.A4JB1]%.-_3'C[K$LF2:L;*#!47CRSD/*9Y7)/4JNGQD_&NQIE2@;UF:
M%U>CM1";B\FDB-8T"XLQV]!<?K-B/ N%?,L?)L6&TS"NDK)T0@QC.LG")!_-
M+ZO/;OG\DFU%FN3TEJ-BFV4A__L]3=GCU0B/GC[XF#RL1?G!9'ZY"1_H'16?
M-K=<OIOL*7&2T;Q(6(XX75V-WN&+@$S+A"KB<T(?BX/7J#R4>\:^EF^NXZN1
M4?:(IC02)2*4OW9T0=.T),E^_-5 1_LVR\3#UT_T977P\F#NPX(N6/HEB<7Z
M:N2.4$Q7X385']GC+[0Y(+OD12PMJO_18Q-KC%"T+03+FF39@RS)Z]_AMV8@
M#A*L4PFD22#G)IA-@GEN@M4D6+T$FYQ(L)L$N]^"?2)AVB1,>PED=B+!:1*<
MJECUZ%:E\4(1SB\Y>T2\C):T\D55WRI;5B3)2RG>"2Z_362>F"]8EDE%W D6
M?44_H7=QG)02"5-TG=="+P7SVJ,B3-+BS>5$R$;+U$G4-.#7#9 3#6""/K!<
MK ODYS&-NX")[.V^R^2IR^^)EOCK-ATCC-\B8A +?;KST.M7;] K-$'%.N2T
M:'XINKK0@V\B,4;$J<#F(+"G![_;\!>"?3W8H]$8F2\9BN7YX+;'GYF@9]&#
M\^ED3U?1.@(Q]YHV*[QY2M-I6!2(K1I5__&;_!Y="YH5?RKZ^KZ&66I8N11<
M%)LPHE<C.=<7E._H:/[C#WAJ_*Q2&"3,@X3YD+ E)"P @G6T8NVU8NGH3_-?
M42KE[9.NPZU8,Y[\TY^N:KUH@4/U @GS(&%^#;,K6+FAV<U-H_FYG.P.Q7!V
M9 #4P4ZE[7VE[0&5WH0<[<)T2]'W@QE-56XM=6BY(6$>),RO8>Y!$8VQ+"#N
MU?J\L "H:YU"3_>%G@XH](Z))'] O-R2*NNKA0VM+R3,@X3Y^C'SPVA=GP/E
MNAD=C"!*"D1SD8B4QD@PQ.1:*L>4CE7+ F2/ R!81T/.7D..=CQ^WV;WE!^-
M14=,:$W3&&UD6#UPWZO]D4IBVK:&2@P2YD'"?$C8TCE:5/IS#%!S'7VX>WVX
M ^:8.-DE,<WC0EX$1ZG40ERN*BHE:*E#E0 )\R!A?@US#E>)WCH"V5P !.LH
M8;97PDRKA"\AYV$N9P,Y-VZV/%J'!7W:1_:F#Y4@9D<R)Z[M8+L[7(OC,!//
ML-T;54]!<PSYKQOF:X]HZ(D*"0N 8)U*8J/U0@QM+6\YBRB5I_&*LTPN?,4V
MS*/C%7&[D2\WV_LTB>1W*\KEFO 6Y524D?NLB!52%2?F 7U'ADX$H#0/E.8W
M-*>C2<NT%=<1JE 7XZE]?"&A"'6GV.A$=D5P8(CA<Z;VNU-GK#Y]<.D@:1XH
MS0>E+4%I 12M*Q+2BH1 6DP-#4HSD#0/E.:#TI:@M "*UM5,ZTIBK9$UOVF6
M"K3AB5P?#B\<] Y$PSV<[,S^!J&)F1[.G>:X%^4IHK#;C_+UQS&XAJ!>(12M
M6\/6+<1ZNW#)TE3FW.3HME[_GXJJK!NH4PA*\T!I/BAM"4H+H&A=Q;2N([9!
M5PI0NQ&4YH'2?%#:$I060-&ZFFD-3*QWX_['ZY#I\=)B$$OAW2\4H=@R'46H
MIP@E!C85H;Y^) :K -2 A*)U5=!:D%CO09ZI@J;>VSRF_)$GE4$9)T7$MJ4K
M$>9Q%2[3$Y;7[YE85]YFLQVAWS8T+^AIC3B*RS+356KD.!2;UE2I$46HZZKD
MY.O':;!&(&D!%*VKD=:&Q'H?\N1^1!;SV0M94#,2E.:!TGQ0VA*4%D#1N@)J
MW4L\ ]V>0+I]"U":!TKS06E+4%H 1>O^^55KDQ*]3?K2.^D-]KF;QPM]\T-E
M 4KS06E+4%H 1>O*HC5.B=XXO3ZQ0SFQ)54J!!_=P'!-VW:PU9?(<:#MS!S7
M(;UMAHKHVBXF/='YYS:]5 1B:VK;LYG9,ZE52&>*9X:M]JA):S\2K57U<BNI
MX1Z>@J8UGLF?_@ ?!Q)S;!T%>HI ["H"??TA#3YS0)U!*%JWG*TS2/3.X'^\
MA]C0G[V)J(A3WD54\0RBN(^H/ZS!)04U"J%HW9*V1B'1&X4W.\I#N3<7&<T%
MNME4?T;]_)Y<3QVZOP*E>: T'Y2V!*4%4+2N=EK+D(!:A@34,@2E>: T'Y2V
M!*4%4+2N9EK+D.@M0XC-U_1X8X.)W "1_CIR'*C>>RF %G9GY&@= 34!06D!
M%*VNZ^3@29V,\H?J(:P"569=_03,_M/]@U[OJL>;>I_[^"*H']=J,?738Q]"
M_I#D!4KI2B*-L2/'G]</9-5O!-M4SP/=,R%85KU<TS"FO R0WZ\8$T]OR@;V
MC\7-_P502P,$%     @ $X!26GGK2:R] @  ] <  !D   !X;"]W;W)K<VAE
M971S+W-H965T-3$N>&ULK55=;]HP%/TK5C;M0]K(!U#:#B)1Z+1.6HN*MCY,
M>S#))?'JQ*GM /WWNW;2B'8A[4,EE-C./<<^A^M[QULA;U4*H,DNX[F:.*G6
MQ:GKJBB%C*J>*"#'+VLA,ZIQ*A-7%1)H;$$9=P//.W(SRG(G'-NUA0S'HM2<
MY;"01)591N7]&7"QG3B^\[!PS9)4FP4W'!<T@27HG\5"XLQM6&*60:Z8R(F$
M]<29^J?SH8FW ;\8;-7>F!@E*R%NS>0BGCB>.1!PB+1AH/C:P PX-T1XC+N:
MTVFV-,#]\0/[5ZL=M:RH@IG@-RS6Z<0Y=D@,:UIR?2VVWZ#68P\8":[LDVRK
MV*,3AT2ETB*KP7B"C.75F^YJ'_8 R-,."&I \%) OP;T7PH8U("!=::28GV8
M4TW#L11;(DTTLIF!-=.B43[+S=^^U!*_,L3I<":R#.U?:A'=DL]DB6D5EQR(
M6)-IDDA(J 9R0Z6DN5;DPQPT95Q]Q-"WQ"4JI1+4V-5X$L/G1O6N9]6NP8%=
MOY>\1WS_$PF\8- "GW7#KR+=(\'(POLM\'DW?%K(0W 7[6L\#!H/ \O7/\!G
MS4L%CT&J]^3\KF3ZGEP*-.[W=*6TQ-S^T^91Q3IH9S7W_505-(*)@Q=:@=R
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M0@?@^)ISM>OH"9I:W/L/4$L#!!0    ( !. 4EI4*TCL"@4  '0G   9
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M(7$U_S,G)/"W73J;]219QT"N%M179$@81<(8"*:(S#0:L\'0YL/+BS 6W49
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MJH-LGU,J]@4U0/$?C='_4$L#!!0    ( !. 4EITC\\WV@,  #L3   9
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M8(6WJ7BD^T]0"=()QC3E^AOMJUC'0O&6"YI58)E!1O+R%[]61C0 GM\!\"J
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MUA>JN6YZX7]IFL[\*^8;0@4J8*THQZ-()1]ONMUF(EEE^K\5DZJ;-,-<_4$
MK@'J^9HQN9_H#;J_'/-_ %!+ P04    "  3@%):X89GXO("  "B"   &0
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M"DT\UL%$<&6?9-?8>@Y)*J5%WH#1@YP5]9O>-SIT +W! 8#? /SG@/  (&@
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M8X#[:X%Z-A-S0/M;$OT%4$L#!!0    ( !. 4EK KD#4C@(  ",&   9
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( !. 4EK686K)%P4  "<K   /
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M$&%//:J983\K3W>UWNYUD!@B[.D&5 ;\B$),R!,1LB? ,J"-"9DB0C;%H3*
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M9VN7?QP_///6U-TAGPW__YJ] 5!+ 0(4 Q0    ( !. 4EH'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ $X!26A6\WQSN    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ $X!26IE<G",0!@  G"<  !,
M     ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  3@%):
MBA3&B=4*  # /   &               @($-"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ $X!26FBU<J//!0  "1D  !@
M     ("!&!,  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M !. 4EI60#O[U (  -@)   8              " @1T9  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    "  3@%):"%4=N=P$  !N$@  &
M            @($G'   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ $X!26DXW9H. "P  58H  !@              ("!.2$  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( !. 4EJ,["F#V @  %XL
M   8              " @>\L  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    "  3@%): #I\3?8,  !-1@  &               @(']-0
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ $X!26ESH7/%G
M @  B@8  !@              ("!*4,  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( !. 4EHL=6B^0P(  (H&   8              "
M@<9%  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  3@%):
M/*4S.!$"  #=!   &0              @($_2   >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( !. 4EJ:]'E.(@H  -T?   9
M      " @8=*  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ $X!26IR\V/9*)P  ;(0  !D              ("!X%0  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  3@%):$MD2:_P(  "_&0
M&0              @(%A?   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( !. 4EKD\.HAW@,  (T(   9              " @92%  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ $X!26JKXP,3V
M!0  TPX  !D              ("!J8D  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    "  3@%):E9H:TE4$   N"@  &0
M@('6CP  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( !.
M4EH@R#&0_@D  -@:   9              " @6*4  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ $X!26B5(JK@"!P  H!8  !D
M         ("!EYX  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    "  3@%):"1/P3&T,  "](P  &0              @('0I0  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( !. 4EIE@-'_^Q<  +A:
M   9              " @72R  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ $X!26C/M(C&V"@  ]B   !D              ("!ILH
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  3@%):31'+
M6_8#  "*"0  &0              @(&3U0  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( !. 4EIJ!SOB\P0  %$+   9
M  " @<#9  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
M$X!26O2D"9Q/!   K@D  !D              ("!ZMX  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    "  3@%):[V;.^=DI  "$E   &0
M            @(%PXP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( !. 4EH6@U_5&@4  #,.   9              " @8 - 0!X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ $X!26L+HVA2[ P
M8P@  !D              ("!T1(! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    "  3@%):G-)]?4D#  ",!P  &0              @('#
M%@$ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( !. 4EJ"
M4)QF= 4  % -   9              " @4,: 0!X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ $X!26I &:$D4!   ;0D  !D
M     ("![A\! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !. 4EH,0;K<" L  !Z    9              "
M@:<T 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ $X!2
M6I9OU);X!   JQH  !D              ("!YC\! 'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    "  3@%):?C/WYB0'  "J+P  &0
M        @($510$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( !. 4EI(M]XI10,  #0.   9              " @7!, 0!X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ $X!26AN3.E[X @  *PD
M !D              ("![$\! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    "  3@%):$%/MUJ\$  !:&0  &0              @($;4P$
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( !. 4EHM+3ZZ
MAP(  +\&   9              " @0%8 0!X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ $X!26N:*K([2 @  S0<  !D
M ("!OUH! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  3
M@%):6"\1*J\&  "Q-P  &0              @('(70$ >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( !. 4EJU%#.JU0(  /T'   9
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M970T."YX;6Q02P$"% ,4    "  3@%):]GOVH?H"  #G"   &0
M    @($F> $ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M !. 4EHAAF40 @<  "(W   9              " @5=[ 0!X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ $X!26GGK2:R] @  ] <  !D
M             ("!D((! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    "  3@%):T+L\B08#  "7"P  &0              @(&$A0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( !. 4EI4*TCL"@4
M '0G   9              " @<&( 0!X;"]W;W)K<VAE971S+W-H965T-3,N
M>&UL4$L! A0#%     @ $X!26GA^^*PL"@   F4  !D              ("!
M HX! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    "  3@%):
MB<Q"R6X#  !7#@  &0              @(%EF $ >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;%!+ 0(4 Q0    ( !. 4EJ*9ZZ>[P0  -T8   9
M      " @0J< 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%
M  @ $X!26G2/SS?: P  .Q,  !D              ("!,*$! 'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    "  3@%): K?ROTP3   12 $
M&0              @(%!I0$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+
M 0(4 Q0    ( !. 4EKBBI,T?@,  #01   9              " @<2X 0!X
M;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ $X!26ENL-'*2
M!0  ;"X  !D              ("!>;P! 'AL+W=O<FMS:&5E=',O<VAE970V
M,"YX;6Q02P$"% ,4    "  3@%):$YB(^W4#  !^#   &0
M@(%"P@$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( !.
M4EKAAF?B\@(  *((   9              " @>[% 0!X;"]W;W)K<VAE971S
M+W-H965T-C(N>&UL4$L! A0#%     @ $X!26L"N0-2. @  (P8  !D
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M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  3@%):EXJ[',     3 @  "P
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52P4&     $D 20#V$P  T^,!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>228</ContextCount>
  <ElementCount>372</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity</Role>
      <ShortName>Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy, and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995457 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995467 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995477 - Disclosure - Fair Value Measurement and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecurities</Role>
      <ShortName>Fair Value Measurement and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995487 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995497 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995507 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995517 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995527 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995537 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995547 - Disclosure - Significant Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreements</Role>
      <ShortName>Significant Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995557 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995567 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995577 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995587 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995597 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995607 - Disclosure - Fair Value Measurement and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesTables</Role>
      <ShortName>Fair Value Measurement and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecurities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995617 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponents</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995627 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995637 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995647 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStock</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995657 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995667 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognition</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995677 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995687 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995697 - Disclosure - Organization - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails</Role>
      <ShortName>Organization - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995707 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995717 - Disclosure - Fair Value Measurement and Marketable Securities - Schedule of Financial Assets Measured and Recognized at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails</Role>
      <ShortName>Fair Value Measurement and Marketable Securities - Schedule of Financial Assets Measured and Recognized at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995727 - Disclosure - Fair Value Measurement and Marketable Securities - Schedule of Financial Assets Measured and Recognized at Fair Value (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueParentheticalDetails</Role>
      <ShortName>Fair Value Measurement and Marketable Securities - Schedule of Financial Assets Measured and Recognized at Fair Value (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995737 - Disclosure - Fair Value Measurement and Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurement and Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995747 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Summary of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995757 - Disclosure - Balance Sheet Components - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Components - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995767 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Summary of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995777 - Disclosure - Operating Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails</Role>
      <ShortName>Operating Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995797 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments under Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails</Role>
      <ShortName>Operating Leases - Schedule of Future Minimum Lease Payments under Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995807 - Disclosure - Operating Leases - Schedule Of Operating Lease Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfOperatingLeaseDisclosuresDetails</Role>
      <ShortName>Operating Leases - Schedule Of Operating Lease Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995817 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995827 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995837 - Disclosure - Income Taxes - Schedule of Tax Effects of Temporary Differences and Carryforwards of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule of Tax Effects of Temporary Differences and Carryforwards of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995847 - Disclosure - Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanySUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995857 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995867 - Disclosure - Common Stock - Schedule of Aggregate Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCommonStockScheduleOfAggregateWarrantsDetails</Role>
      <ShortName>Common Stock - Schedule of Aggregate Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995877 - Disclosure - Common Stock - Schedule of Aggregate Warrants (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCommonStockScheduleOfAggregateWarrantsParentheticalDetails</Role>
      <ShortName>Common Stock - Schedule of Aggregate Warrants (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995887 - Disclosure - Common Stock - Schedule of Number of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Common Stock - Schedule of Number of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995897 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995907 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995917 - Disclosure - Stock-Based Compensation - Summary of Activity under Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Activity under Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995927 - Disclosure - Stock-Based Compensation - Assumptions Used to Calculate Fair Values of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToCalculateFairValuesOfOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Assumptions Used to Calculate Fair Values of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995937 - Disclosure - Significant Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails</Role>
      <ShortName>Significant Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995947 - Disclosure - Revenue Recognition - Summary of Revenue Disaggregated by Research Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByResearchProgramDetails</Role>
      <ShortName>Revenue Recognition - Summary of Revenue Disaggregated by Research Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995957 - Disclosure - Revenue Recognition - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails</Role>
      <ShortName>Revenue Recognition - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995967 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995977 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Shares of Potentially Dilutive Securities Excluded From the Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Shares of Potentially Dilutive Securities Excluded From the Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>995987 - Disclosure - Segment Information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails</Role>
      <ShortName>Segment Information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>995997 - Disclosure - Segment Information - Summary Of Disaggregated Research And Development Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesDetails</Role>
      <ShortName>Segment Information - Summary Of Disaggregated Research And Development Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="idya-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="idya-20241231.htm">idya-20241231.htm</File>
    <File>idya-20241231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img42081897_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="727">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>90
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "idya-20241231.htm": {
   "nsprefix": "idya",
   "nsuri": "http://www.ideayabio.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "idya-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "idya-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 299,
   "keyCustom": 73,
   "axisStandard": 25,
   "axisCustom": 0,
   "memberStandard": 31,
   "memberCustom": 33,
   "hidden": {
    "total": 10,
    "http://fasb.org/us-gaap/2024": 7,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 228,
   "entityCount": 1,
   "segmentCount": 65,
   "elementCount": 701,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 727,
    "http://xbrl.sec.gov/dei/2024": 40,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets",
     "longName": "100010 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheetsParenthetical",
     "longName": "100020 - Statement - Balance Sheets (Parenthetical)",
     "shortName": "Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100040 - Statement - Statements of Operations and Comprehensive Loss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity",
     "longName": "100050 - Statement - Statements of Stockholders' Equity",
     "shortName": "Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_6fb07cd5-fdda-41ce-bad2-075ecef88512",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fb07cd5-fdda-41ce-bad2-075ecef88512",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows",
     "longName": "100060 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "100070 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy, and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_eb642f77-00cf-4cd5-89ff-cfa0d9ff7eb3",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb642f77-00cf-4cd5-89ff-cfa0d9ff7eb3",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganization",
     "longName": "995457 - Disclosure - Organization",
     "shortName": "Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995467 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecurities",
     "longName": "995477 - Disclosure - Fair Value Measurement and Marketable Securities",
     "shortName": "Fair Value Measurement and Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "idya:FairValueMeasurementsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "idya:FairValueMeasurementsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponents",
     "longName": "995487 - Disclosure - Balance Sheet Components",
     "shortName": "Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeases",
     "longName": "995497 - Disclosure - Operating Leases",
     "shortName": "Operating Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "995507 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995517 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStock",
     "longName": "995527 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "longName": "995537 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreements",
     "longName": "995547 - Disclosure - Significant Agreements",
     "shortName": "Significant Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognition",
     "longName": "995557 - Disclosure - Revenue Recognition",
     "shortName": "Revenue Recognition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders",
     "longName": "995567 - Disclosure - Net Loss Per Share Attributable to Common Stockholders",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformation",
     "longName": "995577 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEvents",
     "longName": "995587 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995597 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesTables",
     "longName": "995607 - Disclosure - Fair Value Measurement and Marketable Securities (Tables)",
     "shortName": "Fair Value Measurement and Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables",
     "longName": "995617 - Disclosure - Balance Sheet Components (Tables)",
     "shortName": "Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesTables",
     "longName": "995627 - Disclosure - Operating Leases (Tables)",
     "shortName": "Operating Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995637 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockTables",
     "longName": "995647 - Disclosure - Common Stock (Tables)",
     "shortName": "Common Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "longName": "995657 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognitionTables",
     "longName": "995667 - Disclosure - Revenue Recognition (Tables)",
     "shortName": "Revenue Recognition (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables",
     "longName": "995677 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationTables",
     "longName": "995687 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "idya:SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "idya:SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
     "longName": "995697 - Disclosure - Organization - Additional Information (Details)",
     "shortName": "Organization - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "idya:CashCashEquivalentsAndMarketableSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-8",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995707 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentImpairment",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails",
     "longName": "995717 - Disclosure - Fair Value Measurement and Marketable Securities - Schedule of Financial Assets Measured and Recognized at Fair Value (Details)",
     "shortName": "Fair Value Measurement and Marketable Securities - Schedule of Financial Assets Measured and Recognized at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueParentheticalDetails",
     "longName": "995727 - Disclosure - Fair Value Measurement and Marketable Securities - Schedule of Financial Assets Measured and Recognized at Fair Value (Parenthetical) (Details)",
     "shortName": "Fair Value Measurement and Marketable Securities - Schedule of Financial Assets Measured and Recognized at Fair Value (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_251008aa-c1a9-42db-be7d-38cbbc1eb46d",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesAdditionalInformationDetails",
     "longName": "995737 - Disclosure - Fair Value Measurement and Marketable Securities - Additional Information (Details)",
     "shortName": "Fair Value Measurement and Marketable Securities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
     "longName": "995747 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Details)",
     "shortName": "Balance Sheet Components - Summary of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails",
     "longName": "995757 - Disclosure - Balance Sheet Components - Additional Information (Details)",
     "shortName": "Balance Sheet Components - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails",
     "longName": "995767 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Details)",
     "shortName": "Balance Sheet Components - Summary of Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "idya:AccruedResearchAndDevelopmentExpensesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "idya:AccruedResearchAndDevelopmentExpensesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails",
     "longName": "995777 - Disclosure - Operating Leases - Additional Information (Details)",
     "shortName": "Operating Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails",
     "longName": "995797 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments under Operating Leases (Details)",
     "shortName": "Operating Leases - Schedule of Future Minimum Lease Payments under Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfOperatingLeaseDisclosuresDetails",
     "longName": "995807 - Disclosure - Operating Leases - Schedule Of Operating Lease Disclosures (Details)",
     "shortName": "Operating Leases - Schedule Of Operating Lease Disclosures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "idya:OperatingLeasesDisclosuresTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "idya:OperatingLeasesDisclosuresTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "995817 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails",
     "longName": "995827 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails",
     "longName": "995837 - Disclosure - Income Taxes - Schedule of Tax Effects of Temporary Differences and Carryforwards of Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Schedule of Tax Effects of Temporary Differences and Carryforwards of Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "idya:DeferredTaxAssetsLeaseLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanySUnrecognizedTaxBenefitsDetails",
     "longName": "995847 - Disclosure - Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_99b1a732-1279-4f63-b48e-5b56395593f1",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
     "longName": "995857 - Disclosure - Common Stock - Additional Information (Details)",
     "shortName": "Common Stock - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCommonStockScheduleOfAggregateWarrantsDetails",
     "longName": "995867 - Disclosure - Common Stock - Schedule of Aggregate Warrants (Details)",
     "shortName": "Common Stock - Schedule of Aggregate Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_bb829766-4720-419f-b5f8-c1559b6f88fb",
      "name": "idya:ClassOfWarrantOrRightsIssueDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_bb829766-4720-419f-b5f8-c1559b6f88fb",
      "name": "idya:ClassOfWarrantOrRightsIssueDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCommonStockScheduleOfAggregateWarrantsParentheticalDetails",
     "longName": "995877 - Disclosure - Common Stock - Schedule of Aggregate Warrants (Parenthetical) (Details)",
     "shortName": "Common Stock - Schedule of Aggregate Warrants (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0178d793-324f-4f5d-8dfc-49181bd85b1e",
      "name": "idya:CommonStockSubjectToOutstandingPreFundedWarrantsExercised",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails",
     "longName": "995887 - Disclosure - Common Stock - Schedule of Number of Common Stock Reserved for Future Issuance (Details)",
     "shortName": "Common Stock - Schedule of Number of Common Stock Reserved for Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "idya:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ecf66199-2c61-4da1-b565-ea15c7525705",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "idya:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "longName": "995897 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "idya:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails",
     "longName": "995907 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_78c6497a-ce12-4868-8a73-d11183d394be",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails",
     "longName": "995917 - Disclosure - Stock-Based Compensation - Summary of Activity under Plans (Details)",
     "shortName": "Stock-Based Compensation - Summary of Activity under Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_4b10675f-0784-4fa3-8f18-4c914a58c0d5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_55abfe7d-fa2b-408a-b618-f79551bab538",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToCalculateFairValuesOfOptionsDetails",
     "longName": "995927 - Disclosure - Stock-Based Compensation - Assumptions Used to Calculate Fair Values of Options (Details)",
     "shortName": "Stock-Based Compensation - Assumptions Used to Calculate Fair Values of Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_99b1a732-1279-4f63-b48e-5b56395593f1",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_99b1a732-1279-4f63-b48e-5b56395593f1",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails",
     "longName": "995937 - Disclosure - Significant Agreements - Additional Information (Details)",
     "shortName": "Significant Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_b3327635-f95d-42dd-9385-6f262bcd38d3",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_017e85c7-1596-4e8e-927b-df535668349a",
      "name": "idya:UpfrontPayment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByResearchProgramDetails",
     "longName": "995947 - Disclosure - Revenue Recognition - Summary of Revenue Disaggregated by Research Program (Details)",
     "shortName": "Revenue Recognition - Summary of Revenue Disaggregated by Research Program (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "idya:CollaborationRevenue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "idya:CollaborationRevenue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails",
     "longName": "995957 - Disclosure - Revenue Recognition - Additional Information (Details)",
     "shortName": "Revenue Recognition - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "idya:ReimbursementPeriodOfCostsIncurred",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "idya:ReimbursementPeriodOfCostsIncurred",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "longName": "995967 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R62": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
     "longName": "995977 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Shares of Potentially Dilutive Securities Excluded From the Computation of Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Shares of Potentially Dilutive Securities Excluded From the Computation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_0e321b30-69e1-4345-9158-2fcb284b612c",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e321b30-69e1-4345-9158-2fcb284b612c",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
     "longName": "995987 - Disclosure - Segment Information - Additional Information (Details)",
     "shortName": "Segment Information - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R64": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesDetails",
     "longName": "995997 - Disclosure - Segment Information - Summary Of Disaggregated Research And Development Expenses (Details)",
     "shortName": "Segment Information - Summary Of Disaggregated Research And Development Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "idya:PersonnelRelatedAndStock-BasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "idya:SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "idya:PersonnelRelatedAndStock-BasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "idya:SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
     "longName": "996017 - Disclosure - Subsequent Events - Additional Information (Details)",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_29388ec7-4754-45f1-b582-afffea61e7ad",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b452a75e-2a3a-4c85-bb40-898b74dc7c1d",
      "name": "idya:OperatingLeasesAdditionalAreaLeased",
      "unitRef": "U_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate201613Member",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2016-13",
        "label": "Accounting Standards Update 2016-13 [Member]",
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_AccountingStandardsUpdate202307Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate202307Member",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2023-07 [Member]",
        "terseLabel": "ASU 2023-07",
        "documentation": "Accounting Standards Update 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r859"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net amortization (accretion) of premiums (discounts) on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accrued liabilities",
        "terseLabel": "Accrued liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal and professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "idya_AccruedResearchAndDevelopmentExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development expenses",
        "label": "Accrued Research And Development Expenses Current",
        "documentation": "Accrued research and development expenses current."
       }
      }
     },
     "auth_ref": []
    },
    "idya_AccruedResearchAndDevelopmentExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "AccruedResearchAndDevelopmentExpensesPolicyTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Research and Development Expenses",
        "label": "Accrued Research And Development Expenses Policy [Text Block]",
        "documentation": "Accrued research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "negatedLabel": "Less: Accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r136",
      "r649"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r72",
      "r142",
      "r645",
      "r677",
      "r681"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9",
      "r16",
      "r490",
      "r493",
      "r559",
      "r672",
      "r673",
      "r1017",
      "r1018",
      "r1019",
      "r1026",
      "r1027",
      "r1028",
      "r1030"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "idya_AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional milestone payment potentially received clinical evaluation",
        "label": "Additional Milestone Payment Potentially Received Clinical Evaluation",
        "terseLabel": "Additional milestone payment potentially received clinical evaluation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r694",
      "r1026",
      "r1027",
      "r1028",
      "r1030",
      "r1103",
      "r1160"
     ]
    },
    "idya_AdditionalPaymentOfDevelopmentMilestoneToAchieve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "AdditionalPaymentOfDevelopmentMilestoneToAchieve",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional payment of development milestone to achieve",
        "documentation": "Additional payment of development milestone to achieve.",
        "label": "Additional Payment Of Development Milestone To Achieve"
       }
      }
     },
     "auth_ref": []
    },
    "idya_AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional payments for achievement of specific development and regulatory approval events",
        "label": "Additional Payments For Achievement Of Specific Development And Regulatory Approval Event",
        "documentation": "Additional payments for achievement of specific development and regulatory approval events."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r176",
      "r177",
      "r178",
      "r179",
      "r190",
      "r242",
      "r243",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r311",
      "r312",
      "r315",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r526",
      "r527",
      "r536",
      "r537",
      "r538",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r600",
      "r601",
      "r602",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681"
     ]
    },
    "idya_AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Exercise of Pre-Funded Warrants",
        "documentation": "Adjustments to additional paid in capital, exercise of pre-funded warrants.",
        "terseLabel": "Exercise of pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r380"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of pre-funded warrants for the purchase of common stock",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r37",
      "r91"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "idya_AggregatePotentialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "AggregatePotentialMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Potential Milestone Payments",
        "documentation": "Aggregate potential milestone payments.",
        "terseLabel": "Total potential milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r907",
      "r918",
      "r928",
      "r961"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r910",
      "r921",
      "r931",
      "r964"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r911",
      "r922",
      "r932",
      "r956",
      "r965",
      "r969",
      "r977"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r415"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "idya_AmgenClinicalTrialCollaborationAndSupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "AmgenClinicalTrialCollaborationAndSupplyAgreementMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amgen clinical trial collaboration and supply agreement.",
        "terseLabel": "Amgen Clinical Trial Collaboration and Supply Agreement",
        "label": "Amgen Clinical Trial Collaboration and Supply Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByResearchProgramDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r107",
      "r138",
      "r168",
      "r205",
      "r214",
      "r230",
      "r233",
      "r278",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r478",
      "r482",
      "r528",
      "r641",
      "r732",
      "r816",
      "r817",
      "r859",
      "r885",
      "r1062",
      "r1063",
      "r1116"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r143",
      "r168",
      "r278",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r478",
      "r482",
      "r528",
      "r859",
      "r1062",
      "r1063",
      "r1116"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "idya_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "At-the-market Offering",
        "terseLabel": "At The Market Offering",
        "label": "At The Market Offering [Member]",
        "documentation": "At-the-market offering."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r890",
      "r891",
      "r914"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r890",
      "r891",
      "r914"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r890",
      "r891",
      "r914"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, gross unrealized gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Marketable securities, gross unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Marketable securities, amortized cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r297",
      "r640"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "verboseLabel": "Marketable securities, estimated fair value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r297",
      "r510",
      "r634",
      "r847",
      "r851",
      "r1040",
      "r1107",
      "r1108",
      "r1109"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "idya_BiocytogenOptionAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "BiocytogenOptionAndLicenseAgreementMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biocytogen Option and License Agreement",
        "label": "Biocytogen Option and License Agreement [Member]",
        "documentation": "Biocytogen option and license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "idya_BiocytogenPharmaceuticalsBeijingCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "BiocytogenPharmaceuticalsBeijingCoLtdMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Biocytogen Pharmaceuticals (Beijing) Co., Ltd. [Member]",
        "documentation": "Biocytogen Pharmaceuticals (Beijing) Co., Ltd.",
        "terseLabel": "Biocytogen Pharmaceuticals (Beijing) Co., Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "CA",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "California"
       }
      }
     },
     "auth_ref": []
    },
    "idya_CancerResearchTechnologyAndTheUniversityOfManchesterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "CancerResearchTechnologyAndTheUniversityOfManchesterMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancer Research Technology and the University of Manchester",
        "label": "Cancer Research Technology and the University of Manchester [Member]",
        "documentation": "Cancer Research Technology and the University of Manchester [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of property and equipment in accounts payable and accrued liabilities",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueParentheticalDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r134",
      "r801"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents, estimated Fair Value",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1105",
      "r1106"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r99"
     ]
    },
    "idya_CashCashEquivalentsAndMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "CashCashEquivalentsAndMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and marketable securities",
        "label": "Cash Cash Equivalents And Marketable Securities",
        "documentation": "Cash cash equivalents and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "totalLabel": "Cash, cash equivalents and restricted cash",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r77",
      "r165"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r77"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash Equivalents, at Carrying Value, Total",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents, amortized Cost",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1127"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental non-cash investing and financing activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "idya_CertainCommercialSalesMilestonesPaymentToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "CertainCommercialSalesMilestonesPaymentToBePaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Certain Commercial Sales Milestones Payment to be Paid",
        "documentation": "Certain commercial sales milestones payment to be paid.",
        "terseLabel": "Certain commercial sales milestones, agreed to make a payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in accounting principle, accounting standards update, adopted",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r130",
      "r175",
      "r242",
      "r280",
      "r281",
      "r282",
      "r288",
      "r289",
      "r311",
      "r315",
      "r450",
      "r459",
      "r460",
      "r468",
      "r469",
      "r471",
      "r485",
      "r486",
      "r498",
      "r499",
      "r526",
      "r527",
      "r537",
      "r554",
      "r555",
      "r600",
      "r601",
      "r670",
      "r671"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r130",
      "r242",
      "r280",
      "r281",
      "r282",
      "r288",
      "r289",
      "r290",
      "r311",
      "r315",
      "r450",
      "r459",
      "r460",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r484",
      "r485",
      "r486",
      "r487",
      "r498",
      "r499",
      "r500",
      "r503",
      "r526",
      "r527",
      "r537",
      "r554",
      "r555",
      "r600",
      "r601",
      "r670",
      "r671",
      "r1004"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r189",
      "r285"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r139",
      "r140",
      "r141",
      "r168",
      "r194",
      "r195",
      "r197",
      "r199",
      "r207",
      "r208",
      "r278",
      "r324",
      "r326",
      "r327",
      "r328",
      "r331",
      "r332",
      "r337",
      "r338",
      "r341",
      "r344",
      "r351",
      "r528",
      "r687",
      "r688",
      "r689",
      "r690",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r720",
      "r741",
      "r759",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r1000",
      "r1023",
      "r1031"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCommonStockScheduleOfAggregateWarrantsParentheticalDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r207",
      "r337",
      "r338",
      "r339",
      "r341",
      "r344",
      "r349",
      "r351",
      "r687",
      "r688",
      "r689",
      "r690",
      "r828",
      "r1000",
      "r1023"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCommonStockScheduleOfAggregateWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise Price per Share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCommonStockScheduleOfAggregateWarrantsDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of Shares subject to Outstanding Warrants",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase shares of common stock",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "idya_ClassOfWarrantOrRightsIssueDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "ClassOfWarrantOrRightsIssueDate",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCommonStockScheduleOfAggregateWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or rights issue date.",
        "label": "Class Of Warrant Or Rights Issue Date",
        "terseLabel": "Issue Date"
       }
      }
     },
     "auth_ref": []
    },
    "idya_ClinicalCombinationStudyWindDownMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "ClinicalCombinationStudyWindDownMonthAndYear",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical combination study wind down month and year",
        "documentation": "Clinical combination study wind down month and year."
       }
      }
     },
     "auth_ref": []
    },
    "idya_CloudComputingArrangementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "CloudComputingArrangementsPolicyTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cloud Computing Arrangements",
        "label": "Cloud Computing Arrangements Policy [Text Block]",
        "documentation": "Cloud computing arrangements."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "idya_CollaborationRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "CollaborationRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByResearchProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total collaboration revenue",
        "label": "Collaboration Revenue",
        "documentation": "Collaboration revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r112",
      "r123"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "idya_CommercialMilestonePaymentToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "CommercialMilestonePaymentToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial milestone payment eligible to receive",
        "label": "Commercial Milestone Payment To Be Received",
        "documentation": "Commercial milestone payment to be received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueParentheticalDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r323",
      "r879",
      "r880",
      "r881",
      "r882"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 6)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r101",
      "r642",
      "r719"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r317",
      "r318",
      "r785",
      "r1057",
      "r1059"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares reserved for common stock options",
        "verboseLabel": "Common stock, initially reserved for issuance",
        "terseLabel": "Number of common stock reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r875",
      "r876",
      "r877",
      "r879",
      "r880",
      "r881",
      "r882",
      "r1026",
      "r1027",
      "r1030",
      "r1103",
      "r1158",
      "r1160"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "idya_CommonStockRemainingAvailableToBeSaleAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "CommonStockRemainingAvailableToBeSaleAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock remained available to be sold",
        "label": "Common Stock Remaining Available To Be Sale Amount",
        "documentation": "Common stock, remaining available to be sale, amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r720"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCommonStockScheduleOfAggregateWarrantsParentheticalDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r66",
      "r720",
      "r738",
      "r1160",
      "r1161"
     ]
    },
    "idya_CommonStockSubjectToOutstandingPreFundedWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "CommonStockSubjectToOutstandingPreFundedWarrantsExercised",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCommonStockScheduleOfAggregateWarrantsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock subject to outstanding pre-funded warrants Exercised",
        "documentation": "Common stock subject to outstanding pre-funded warrants Exercised.",
        "terseLabel": "Common stock subject to outstanding pre-funded warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value, 300,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 86,503,509 and 65,039,369 shares issued and outstanding as of December 31, 2024 and December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r644",
      "r859"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, voting rights",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r94"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r148",
      "r150",
      "r155",
      "r635",
      "r655",
      "r656"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income and Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer Equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r114"
     ]
    },
    "idya_ContingentDevelopmentAndSalesBasedMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "ContingentDevelopmentAndSalesBasedMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent development and sales based milestone payments.",
        "label": "Contingent Development And Sales Based Milestone Payments",
        "terseLabel": "Contingent development and sales-based milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance as of December 31, 2022",
        "periodStartLabel": "Balance as of December 31, 2021",
        "terseLabel": "Contract liabilities",
        "totalLabel": "Contract with Customer, Liability, Total",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355",
      "r367"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liability",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355",
      "r367"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term contract liability",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355",
      "r367"
     ]
    },
    "us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerReceivableAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Contract with Customer, Receivable, after Allowance for Credit Loss, Total",
        "terseLabel": "Accounts receivable",
        "label": "Contract with Customer, Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r356",
      "r367",
      "r784"
     ]
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Bonds",
        "label": "Corporate Bond Securities [Member]",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r333",
      "r339",
      "r560",
      "r580",
      "r639",
      "r802",
      "r804"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r899",
      "r988"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r899",
      "r988"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r901",
      "r990"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r901",
      "r990"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r903",
      "r992"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r901",
      "r990"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r894",
      "r983"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r895",
      "r984"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r895",
      "r984"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r982"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r982"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r982"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r896",
      "r985"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r898",
      "r987"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r898",
      "r987"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r899",
      "r988"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r902",
      "r991"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r900",
      "r989"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r897",
      "r986"
     ]
    },
    "idya_DarovasertibMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "DarovasertibMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Darovasertib [Member]",
        "documentation": "Darovasertib.",
        "terseLabel": "Darovasertib"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "terseLabel": "Capitalized research &amp; development expenditures",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "idya_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets Lease Liability",
        "documentation": "Deferred tax assets lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "verboseLabel": "Deferred tax assets, net operating loss carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, operating loss carryforwards subject to do not expire",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, operating loss carryforwards subject to expire",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credit carryforwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total",
        "terseLabel": "Accruals and reserves",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Property and equipment",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "idya_DeferredTaxLiabilitiesRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use assets",
        "label": "Deferred Tax Liabilities Right Of Use Assets",
        "documentation": "Deferred tax liabilities right of use assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "terseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r34"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r205",
      "r217",
      "r233",
      "r816",
      "r817"
     ]
    },
    "idya_DeterminationPeriodOfCostsIncurred": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "DeterminationPeriodOfCostsIncurred",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Determination period of costs incurred",
        "label": "Determination Period Of Costs Incurred",
        "documentation": "The period to determine an amount of reimbursable costs."
       }
      }
     },
     "auth_ref": []
    },
    "idya_DevelopmentAndRegulatoryMilestonePaymentToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "DevelopmentAndRegulatoryMilestonePaymentToBePaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development and Regulatory Milestone Payment to be Paid",
        "documentation": "Development and regulatory milestone payment to be paid.",
        "terseLabel": "Certain clinical and regulatory development milestones, agreed to make a payment"
       }
      }
     },
     "auth_ref": []
    },
    "idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "DevelopmentAndRegulatoryMilestonePaymentToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and regulatory milestone payment eligible to receive",
        "label": "Development And Regulatory Milestone Payment To Be Received",
        "documentation": "Development and regulatory milestone payment to be received."
       }
      }
     },
     "auth_ref": []
    },
    "idya_DevelopmentCostsSharingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "DevelopmentCostsSharingPercentage",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development costs sharing percentage",
        "label": "Development Costs Sharing Percentage",
        "documentation": "Development costs sharing percentage."
       }
      }
     },
     "auth_ref": []
    },
    "idya_DevelopmentMilestonePaymentToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "DevelopmentMilestonePaymentToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development milestone payment eligible to receive",
        "label": "Development Milestone Payment To Be Received",
        "documentation": "Development milestone payment to be received."
       }
      }
     },
     "auth_ref": []
    },
    "idya_DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development Milestone Payments Of Phase Three Relating To First And Second Tumor Histologies",
        "documentation": "Development milestone payments of phase three relating to first and second tumor histologies.",
        "terseLabel": "Milestone payments of phase two relating to first and second tumor histologies"
       }
      }
     },
     "auth_ref": []
    },
    "idya_DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development Milestone Payments Of Phase Two Relating To First And Second Tumor Histologies",
        "documentation": "Development milestone payments of phase two relating to first and second tumor histologies.",
        "terseLabel": "Milestone payments of phase two relating to first and second tumor histologies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByResearchProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation Of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByResearchProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation Of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Revenue Disaggregated by Research Program",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r382",
      "r410",
      "r411",
      "r413",
      "r840"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Dividends, Common Stock, Total",
        "terseLabel": "Common stock, dividends declared",
        "label": "Dividends, Common Stock",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r91"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r890",
      "r891",
      "r914"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "terseLabel": "Document Financial Statement Error Correction",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r890",
      "r891",
      "r914",
      "r957"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Type",
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal Income Tax",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "idya_ESPPDiscountedPurchasePricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "ESPPDiscountedPurchasePricePercentage",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of the fair value of common stock",
        "label": "E S P P Discounted Purchase Price Percentage",
        "documentation": "The discounted percentage of the fair market value of the Company's common stock for stock purchase in employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "idya_ESPPMaximumSharesPurchasablePerPeriodPerEmployee": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "ESPPMaximumSharesPurchasablePerPeriodPerEmployee",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum number of shares purchasable",
        "label": "E S P P Maximum Shares Purchasable Per Period Per Employee",
        "documentation": "Maximum number of shares purchasable by an employee under the ESPP per an offering period."
       }
      }
     },
     "auth_ref": []
    },
    "idya_EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Early Clinical Development Milestone Payment Potential to Receive",
        "documentation": "Early clinical development milestone payment potential to receive.",
        "terseLabel": "Early clinical development milestone payment potential to receive"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share attributable to common stockholders, basic",
        "terseLabel": "Net loss per common share, basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r192",
      "r194",
      "r197",
      "r198",
      "r199",
      "r204",
      "r466",
      "r475",
      "r507",
      "r508",
      "r636",
      "r657",
      "r807"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share attributable to common stockholders, diluted",
        "terseLabel": "Net loss per common share, diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r194",
      "r197",
      "r198",
      "r199",
      "r204",
      "r466",
      "r475",
      "r507",
      "r508",
      "r636",
      "r657",
      "r807"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share Attributable to Common Stockholders",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r201"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r200",
      "r202",
      "r203"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Provision for income taxes",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r844"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal statutory income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r425",
      "r453",
      "r844"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r844",
      "r1025",
      "r1096"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r844",
      "r1025",
      "r1096",
      "r1098"
     ]
    },
    "idya_EffectiveIncomeTaxRateReconciliationSection162MLimitation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationSection162MLimitation",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation Section 162(m) Limitation",
        "documentation": "Effective income tax rate reconciliation section 162(m) limitation.",
        "terseLabel": "Section 162(m) limitation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1096",
      "r1097"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income taxes",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r844",
      "r1025",
      "r1096"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedLabel": "Research tax credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r844",
      "r1025",
      "r1096",
      "r1098"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "terseLabel": "Accrued salaries and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total unrecognized stock-based compensation expense, weighted-average period of recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total unrecognized stock-based compensation expense for stock options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "idya_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan",
        "documentation": "Employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Major Customer [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCommonStockScheduleOfAggregateWarrantsParentheticalDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r127",
      "r152",
      "r153",
      "r154",
      "r172",
      "r173",
      "r174",
      "r177",
      "r184",
      "r186",
      "r188",
      "r206",
      "r284",
      "r291",
      "r312",
      "r353",
      "r448",
      "r449",
      "r462",
      "r463",
      "r464",
      "r467",
      "r474",
      "r475",
      "r488",
      "r490",
      "r491",
      "r492",
      "r493",
      "r495",
      "r506",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r537",
      "r540",
      "r559",
      "r653",
      "r672",
      "r673",
      "r674",
      "r694",
      "r759"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r907",
      "r918",
      "r928",
      "r961"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r904",
      "r915",
      "r925",
      "r958"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "idya_ExerciseOfOutstandingOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "ExerciseOfOutstandingOptionsMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Options",
        "label": "Exercise Of Outstanding Options [Member]",
        "documentation": "Exercise of outstanding options."
       }
      }
     },
     "auth_ref": []
    },
    "idya_ExternalClinicalDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "ExternalClinicalDevelopmentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External clinical development expenses",
        "label": "External Clinical Development Expenses",
        "documentation": "External clinical development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueParentheticalDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r511",
      "r522",
      "r847"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueParentheticalDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r511",
      "r522",
      "r847"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r523",
      "r849"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r523",
      "r849"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets Measured and Recognized at Fair Value",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r509",
      "r511",
      "r512",
      "r513",
      "r514",
      "r521",
      "r522",
      "r524",
      "r567",
      "r568",
      "r569",
      "r826",
      "r827",
      "r836",
      "r837",
      "r838",
      "r847",
      "r851"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r370",
      "r375",
      "r511",
      "r522",
      "r567",
      "r836",
      "r837",
      "r838",
      "r847"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r370",
      "r375",
      "r511",
      "r512",
      "r522",
      "r568",
      "r826",
      "r827",
      "r836",
      "r837",
      "r838",
      "r847"
     ]
    },
    "idya_FairValueMeasurementsAndMarketableSecuritiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "FairValueMeasurementsAndMarketableSecuritiesPolicyTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement and Marketable Securities",
        "label": "Fair Value Measurements And Marketable Securities Policy [Text Block]",
        "documentation": "Fair value measurements and marketable securities policy."
       }
      }
     },
     "auth_ref": []
    },
    "idya_FairValueMeasurementsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "FairValueMeasurementsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement and Marketable Securities",
        "label": "Fair Value Measurements And Marketable Securities [Text Block]",
        "documentation": "Fair value measurements and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r509",
      "r511",
      "r512",
      "r513",
      "r514",
      "r521",
      "r522",
      "r524",
      "r567",
      "r568",
      "r569",
      "r826",
      "r827",
      "r836",
      "r837",
      "r838",
      "r847",
      "r851"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueParentheticalDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r335",
      "r349",
      "r496",
      "r525",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r654",
      "r824",
      "r847",
      "r849",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r860",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1104",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Financial Liabilities Fair Value Disclosure, Total",
        "terseLabel": "Financial liabilities recognized at fair value",
        "label": "Financial Liabilities Fair Value Disclosure",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": [
      "r1105",
      "r1106",
      "r1110"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r309",
      "r310",
      "r599",
      "r603",
      "r797"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r309",
      "r310",
      "r797"
     ]
    },
    "idya_FollowOnPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "FollowOnPublicOfferingMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Follow-on Public Offering",
        "terseLabel": "Follow On Public Offering",
        "label": "Follow On Public Offering [Member]",
        "documentation": "Follow-on public offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Income Tax",
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r911",
      "r922",
      "r932",
      "r965"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r911",
      "r922",
      "r932",
      "r965"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r911",
      "r922",
      "r932",
      "r965"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r911",
      "r922",
      "r932",
      "r965"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r911",
      "r922",
      "r932",
      "r965"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and Fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and Administrative Expense, Total",
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r743"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "idya_GlaxoGroupLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "GlaxoGroupLimitedMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Glaxo Group Limited",
        "label": "Glaxo Group Limited [Member]",
        "documentation": "Glaxo Group Limited."
       }
      }
     },
     "auth_ref": []
    },
    "idya_GlaxoSmithKlineCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "GlaxoSmithKlineCollaborationAgreementMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GSK Collaboration Agreement",
        "label": "Glaxo Smith Kline Collaboration Agreement [Member]",
        "documentation": "Glaxo Smith Kline collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "idya_GlaxoSmithKlineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "GlaxoSmithKlineMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GSK",
        "label": "Glaxo Smith Kline [Member]",
        "documentation": "Glaxo Smith Kline."
       }
      }
     },
     "auth_ref": []
    },
    "idya_HengruiPharmaLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "HengruiPharmaLicenseAgreementMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hengrui Pharma License Agreement",
        "label": "Hengrui Pharma License Agreement [Member]",
        "documentation": "Hengrui pharma license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "idya_IDE161Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "IDE161Member",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IDE161.",
        "label": "IDE161 [Member]",
        "terseLabel": "IDE161"
       }
      }
     },
     "auth_ref": []
    },
    "idya_IDE397Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "IDE397Member",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IDE397 [Member]",
        "documentation": "IDE397.",
        "terseLabel": "IDE397"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r890",
      "r891",
      "r914"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total",
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r33",
      "r84",
      "r848"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r316",
      "r516",
      "r520",
      "r523",
      "r667",
      "r669",
      "r744",
      "r797",
      "r850",
      "r1129"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r316",
      "r516",
      "r520",
      "r523",
      "r667",
      "r669",
      "r744",
      "r797",
      "r850",
      "r1129"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r425",
      "r426",
      "r433",
      "r445",
      "r844",
      "r1101"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r425",
      "r426",
      "r433",
      "r445",
      "r844",
      "r1101"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "idya_IncomeTaxDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "IncomeTaxDisclosureLineItems",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Line Items]",
        "label": "Income Tax Disclosure [Line Items]",
        "documentation": "Income tax disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "idya_IncomeTaxDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "IncomeTaxDisclosureTable",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Table]",
        "label": "Income Tax Disclosure [Table]",
        "documentation": "Income tax disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r420",
      "r425",
      "r430",
      "r431",
      "r432",
      "r437",
      "r443",
      "r454",
      "r456",
      "r457",
      "r458",
      "r692",
      "r844"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income Tax Examination, Penalties and Interest Accrued, Total",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Penalties or interest accrued",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "us-gaap_IncomeTaxExaminationYearUnderExamination": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationYearUnderExamination",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Year under Examination",
        "terseLabel": "Tax years",
        "documentation": "Tax year being audited in the income tax examination, in YYYY format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "terseLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r121",
      "r187",
      "r188",
      "r205",
      "r218",
      "r233",
      "r424",
      "r425",
      "r455",
      "r658",
      "r844"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r422",
      "r423",
      "r437",
      "r438",
      "r442",
      "r447",
      "r686"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income Taxes Paid, Net, Total",
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r164",
      "r444",
      "r445"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r1020"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "idya_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "documentation": "Increase (decrease) in operating lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r305",
      "r308",
      "r825"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r305",
      "r308",
      "r825"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r911",
      "r922",
      "r932",
      "r956",
      "r965",
      "r969",
      "r977"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r981"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r981"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r981"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r162",
      "r163"
     ]
    },
    "us-gaap_InvestmentOwnedAtCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentOwnedAtCost",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Investment Owned, Cost",
        "documentation": "Cost of the investment."
       }
      }
     },
     "auth_ref": [
      "r685",
      "r708",
      "r709",
      "r766",
      "r767",
      "r772",
      "r775",
      "r877",
      "r885",
      "r1159"
     ]
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Investments, Fair Value Disclosure, Total",
        "verboseLabel": "Estimated Fair Value",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r1105",
      "r1106",
      "r1110"
     ]
    },
    "idya_JanuaryTwoThousandTwentyFourSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "JanuaryTwoThousandTwentyFourSalesAgreementMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January two thousand twenty four sales agreement.",
        "label": "January Two Thousand Twenty Four Sales Agreement [Member]",
        "terseLabel": "January 2024 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "idya_JanuaryTwoThousandTwentyOneSalesAgreementAndJuneTwoThousandTwentyThreeSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "JanuaryTwoThousandTwentyOneSalesAgreementAndJuneTwoThousandTwentyThreeSalesAgreementMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January two thousand twenty one sales agreement and june two thousand twenty three sales agreement.",
        "label": "January Two Thousand Twenty One Sales Agreement and June Two Thousand Twenty Three Sales Agreement [Member]",
        "terseLabel": "January 2021 Sales Agreement and June 2023 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "idya_JanuaryTwoThousandTwentyOneSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "JanuaryTwoThousandTwentyOneSalesAgreementMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January two thousand twenty one sales agreement.",
        "terseLabel": "January 2021 Sales Agreement",
        "label": "January Two Thousand Twenty One Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "idya_JefferiesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "JefferiesLLCMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jefferies LLC",
        "label": "Jefferies L L C [Member]",
        "documentation": "Jefferies LLC."
       }
      }
     },
     "auth_ref": []
    },
    "idya_JiangsuHengruiPharmaceuticalsCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "JiangsuHengruiPharmaceuticalsCoLtdMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jiangsu Hengrui Pharmaceuticals Co., Ltd [Member]",
        "documentation": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.",
        "terseLabel": "Jiangsu Hengrui Pharmaceuticals Co., Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "idya_JuneTwoThousandTwentyThreeSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "JuneTwoThousandTwentyThreeSalesAgreementMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June Two Thousand Twenty Three Sales Agreement.",
        "label": "June Two Thousand Twenty Three Sales Agreement [Member]",
        "terseLabel": "June 2023 Sales Agreement | Common Stock",
        "verboseLabel": "June 2023 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "idya_LaboratoryAndOfficeFacilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "LaboratoryAndOfficeFacilitiesMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory and Office Facilities",
        "label": "Laboratory And Office Facilities [Member]",
        "documentation": "Laboratory and office facilities."
       }
      }
     },
     "auth_ref": []
    },
    "idya_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory Equipment",
        "label": "Laboratory Equipment [Member]",
        "documentation": "Laboratory equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseAgreementsMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Agreement",
        "label": "Lease Agreements [Member]",
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1052",
      "r1053",
      "r1055",
      "r1056"
     ]
    },
    "idya_LeaseExpirationMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "LeaseExpirationMonthAndYear",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expiration",
        "label": "Lease Expiration Month and Year",
        "documentation": "Lease expiration month and year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r553"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease option to extend",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "idya_LesseeOperatingLeaseExistenceOfOptionToRenew": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToRenew",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, operating lease existence of option to renew.",
        "label": "Lessee, Operating Lease Existence Of Option To Renew",
        "terseLabel": "Operating lease existence of option to renew"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments under Operating Leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "idya_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "documentation": "Lessee, operating lease, liability, to be paid, after year four.",
        "terseLabel": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Operating lease, option to extend, description",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r63",
      "r64",
      "r168",
      "r278",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r479",
      "r482",
      "r483",
      "r528",
      "r718",
      "r808",
      "r885",
      "r1062",
      "r1116",
      "r1117"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r102",
      "r647",
      "r859",
      "r1024",
      "r1046",
      "r1112"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r133",
      "r168",
      "r278",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r479",
      "r482",
      "r483",
      "r528",
      "r859",
      "r1062",
      "r1116",
      "r1117"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicensingAgreementsMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreement",
        "label": "Licensing Agreements [Member]",
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r419",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1095"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term marketable securities",
        "label": "Marketable Securities, Current",
        "verboseLabel": "Current marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "idya_MarketableSecuritiesCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "MarketableSecuritiesCurrentMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities Current [Member]",
        "documentation": "Marketable securities current.",
        "terseLabel": "Marketable Securities Current"
       }
      }
     },
     "auth_ref": []
    },
    "idya_MarketableSecuritiesNonCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "MarketableSecuritiesNonCurrentMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities Non-current",
        "label": "Marketable Securities Non Current [Member]",
        "documentation": "Marketable securities non current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term marketable securities",
        "label": "Marketable Securities, Noncurrent",
        "verboseLabel": "Non-current marketable securities",
        "documentation": "Amount of investment in marketable security, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "idya_MarketableSecuritiesRemainingMaturityPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "MarketableSecuritiesRemainingMaturityPeriod",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities remaining maturity period",
        "label": "Marketable Securities Remaining Maturity Period",
        "documentation": "Marketable securities remaining maturity period."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToCalculateFairValuesOfOptionsDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "verboseLabel": "Maximum",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r322",
      "r376",
      "r416",
      "r514",
      "r596",
      "r666",
      "r668",
      "r682",
      "r710",
      "r711",
      "r764",
      "r768",
      "r770",
      "r771",
      "r774",
      "r795",
      "r796",
      "r823",
      "r828",
      "r839",
      "r851",
      "r852",
      "r856",
      "r857",
      "r870",
      "r1064",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123"
     ]
    },
    "idya_MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum shares issues under ESPP",
        "label": "Maximum Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period",
        "documentation": "Maximum share based compensation arrangement by share based payment award shares issued in period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "idya_MethionineAdenosylTransferase2AProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "MethionineAdenosylTransferase2AProgramMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByResearchProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MAT2A Program",
        "label": "Methionine Adenosyl Transferase2 A Program [Member]",
        "documentation": "Methionine Adenosyl Transferase 2A program."
       }
      }
     },
     "auth_ref": []
    },
    "idya_MilestonePaymentReceivedClinicalEvaluation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "MilestonePaymentReceivedClinicalEvaluation",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment received clinical evaluation",
        "label": "Milestone Payment Received Clinical Evaluation",
        "terseLabel": "Milestone payment received clinical evaluation"
       }
      }
     },
     "auth_ref": []
    },
    "idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Payment Received For Achievement Of Initial Preclinical Development Milestone",
        "documentation": "Milestone payment received for achievement of initial preclinical development milestone.",
        "terseLabel": "Milestone payment received for achievement of earlier preclinical development milestone",
        "verboseLabel": "Milestone payment received for achievement of initial preclinical development milestone"
       }
      }
     },
     "auth_ref": []
    },
    "idya_MilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "MilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments of phase three relating to first and second tumor histologies",
        "documentation": "Milestone payments of phase three relating to first and second tumor histologies.",
        "label": "Milestone Payments Of Phase Three Relating To First And Second Tumor Histologies"
       }
      }
     },
     "auth_ref": []
    },
    "idya_MilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "MilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments of phase two relating to first and second tumor histologies",
        "documentation": "Milestone payments of phase two relating to first and second tumor histologies.",
        "label": "Milestone Payments Of Phase Two Relating To First And Second Tumor Histologies"
       }
      }
     },
     "auth_ref": []
    },
    "idya_MilestonePaymentsRelatingToFirstAndSecondTumorHistologies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "MilestonePaymentsRelatingToFirstAndSecondTumorHistologies",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments relating to first and second tumor histologies.",
        "label": "Milestone Payments Relating To First And Second Tumor Histologies",
        "terseLabel": "Milestone payments relating to first and second tumor histologies"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToCalculateFairValuesOfOptionsDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Minimum",
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r322",
      "r376",
      "r416",
      "r514",
      "r596",
      "r666",
      "r668",
      "r682",
      "r710",
      "r711",
      "r764",
      "r768",
      "r770",
      "r771",
      "r774",
      "r795",
      "r796",
      "r823",
      "r828",
      "r839",
      "r851",
      "r852",
      "r856",
      "r870",
      "r1064",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r79"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss",
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net loss attributable to common stockholders",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r79",
      "r103",
      "r131",
      "r146",
      "r149",
      "r154",
      "r168",
      "r176",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r187",
      "r188",
      "r196",
      "r278",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r466",
      "r475",
      "r508",
      "r528",
      "r652",
      "r740",
      "r757",
      "r758",
      "r883",
      "r1062"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "idya_NetProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "NetProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock net of underwriting discounts and commissions and other offering expenses",
        "documentation": "Net proceeds from issuance of common stock.",
        "label": "Net Proceeds From Issuance Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r911",
      "r922",
      "r932",
      "r956",
      "r965"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Nonoperating Income (Expense), Total",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Interest income and other income, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "idya_NovartisInternationalPharmaceuticalsLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "NovartisInternationalPharmaceuticalsLimitedMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novartis International Pharmaceuticals Limited",
        "label": "Novartis International Pharmaceuticals Limited [Member]",
        "documentation": "Novartis international pharmaceuticals limited."
       }
      }
     },
     "auth_ref": []
    },
    "idya_NumberOfCommonStockVotingRightsHeldPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "NumberOfCommonStockVotingRightsHeldPerShare",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common stock voting rights held per share",
        "label": "Number Of Common Stock Voting Rights Held Per Share",
        "documentation": "Number of common stock voting rights held per share."
       }
      }
     },
     "auth_ref": []
    },
    "idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of days of notice period for terminating agreement",
        "terseLabel": "Number of days of notice period for terminating agreement",
        "label": "Number Of Days Of Notice Period For Terminating Collaboration Agreement",
        "documentation": "Number of days of notice period for terminating collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r817",
      "r1034"
     ]
    },
    "idya_NumberOfPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "NumberOfPerformanceObligations",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of performance obligations",
        "label": "Number Of Performance Obligations",
        "documentation": "Number of performance obligations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r810",
      "r821",
      "r1034"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r809",
      "r1033",
      "r1035",
      "r1036",
      "r1037",
      "r1038"
     ]
    },
    "idya_OperatingLeaseCommencementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "OperatingLeaseCommencementDescription",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease commencement, description",
        "label": "Operating Lease Commencement Description",
        "documentation": "Operating lease commencement description."
       }
      }
     },
     "auth_ref": []
    },
    "idya_OperatingLeaseCommencementMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "OperatingLeaseCommencementMonthAndYear",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Commencement Month And Year",
        "documentation": "Operating lease commencement month and year.",
        "terseLabel": "Operating lease term commencement month and year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r858"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liabilities, net of current position",
        "label": "Total operating lease liabilities",
        "totalLabel": "Total lease liabilities",
        "terseLabel": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current operating lease liabilities",
        "terseLabel": "Operating lease liabilities, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, net of current position",
        "verboseLabel": "Long-term lease liabilities",
        "terseLabel": "Long-term operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid included in measurement of operating lease liabilities included in cash flow from operating activities",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r548"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease right of use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Amortization of right of use assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfOperatingLeaseDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r858"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureOperatingLeasesScheduleOfOperatingLeaseDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r858"
     ]
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasedAssetsLineItems",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leased Assets [Line Items]",
        "label": "Operating Leased Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "idya_OperatingLeasesAdditionalAreaLeased": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "OperatingLeasesAdditionalAreaLeased",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases Additional Area Leased",
        "documentation": "Operating leases additional area leased.",
        "terseLabel": "Additional area of space leased"
       }
      }
     },
     "auth_ref": []
    },
    "idya_OperatingLeasesAreaLeased": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "OperatingLeasesAreaLeased",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the area leased.",
        "label": "Operating Leases Area Leased",
        "terseLabel": "Area of space leased"
       }
      }
     },
     "auth_ref": []
    },
    "idya_OperatingLeasesDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "OperatingLeasesDisclosuresTableTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of operating lease disclosures.",
        "label": "Operating Leases Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r97",
      "r683",
      "r684"
     ]
    },
    "idya_OrphanDrugCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "OrphanDrugCreditsMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Orphan Drug Credits",
        "label": "Orphan Drug Credits [Member]",
        "documentation": "Orphan Drug Credits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total",
        "terseLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Other comprehensive gain (loss)",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r9",
      "r98",
      "r147",
      "r150",
      "r184"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gains (losses) on marketable securities",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r277"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Research and Development Expense",
        "terseLabel": "Other research and development expenses",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "idya_OtherResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "OtherResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Research and Development Expense [Member]",
        "documentation": "Other research and development expense.",
        "terseLabel": "Other Research and Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r909",
      "r920",
      "r930",
      "r963"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r912",
      "r923",
      "r933",
      "r966"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r912",
      "r923",
      "r933",
      "r966"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Overallotment Option",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "idya_PayForExternalThirdPartyCostPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "PayForExternalThirdPartyCostPercentage",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pay for external third-party cost percentage.",
        "label": "Pay for External Third-party Cost Percentage",
        "terseLabel": "Pay for external third-party cost percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "idya_PaymentOfOneTimeOptionExerciseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "PaymentOfOneTimeOptionExerciseFee",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of one-time option exercise fee",
        "label": "Payment Of One Time Option Exercise Fee",
        "documentation": "Payment of one-time option exercise fee."
       }
      }
     },
     "auth_ref": []
    },
    "idya_PaymentOfOptionExerciseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "PaymentOfOptionExerciseFee",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of Option Exercise Fee",
        "documentation": "Payment of option exercise fee.",
        "terseLabel": "Payment of option exercise fee"
       }
      }
     },
     "auth_ref": []
    },
    "idya_PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for achievement of specific development and regulatory approval events",
        "label": "Payments For Achievement Of Specific Development And Regulatory Approval Events",
        "documentation": "Payments for achievement of specific development and regulatory approval events."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r157",
      "r245"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "negatedLabel": "Purchases of property and equipment, net",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "idya_PercentageOfProfitShare": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "PercentageOfProfitShare",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of profit share",
        "label": "Percentage Of Profit Share",
        "documentation": "Percentage of profit share."
       }
      }
     },
     "auth_ref": []
    },
    "idya_PersonnelRelatedAndStock-BasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "PersonnelRelatedAndStock-BasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Personnel Related And Stock-based Compensation",
        "documentation": "Personnel related and stock-based compensation.",
        "terseLabel": "Personnel related and stock-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "idya_PolymeraseThetaProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "PolymeraseThetaProgramMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByResearchProgramDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pol Theta Program",
        "label": "Polymerase Theta Program [Member]",
        "documentation": "Polymerase Theta program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r337"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r720"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r337"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r720",
      "r738",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of December 31, 2024 and December 31, 2023; no shares issued and outstanding as of December 31, 2024 and December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r643",
      "r859"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from issuance of common stock upon public offering, net of issuance costs",
        "terseLabel": "Proceeds from issuance of common stock in public offering, net of issuance costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "idya_ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs",
        "label": "Proceeds From Issuance Of Common Stock Related To At Market Offering Program Net Of Issuance Costs",
        "documentation": "Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuances of pre-funded warrants",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of marketable securities",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r1041"
     ]
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of marketable securities",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r157",
      "r245",
      "r276"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of common stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from ESPP purchases",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r237",
      "r598",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r799",
      "r829",
      "r869",
      "r870",
      "r871",
      "r873",
      "r874",
      "r1060",
      "r1061",
      "r1065",
      "r1128",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r237",
      "r598",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r799",
      "r829",
      "r869",
      "r870",
      "r871",
      "r873",
      "r874",
      "r1060",
      "r1061",
      "r1065",
      "r1128",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r146",
      "r149",
      "r160",
      "r168",
      "r176",
      "r184",
      "r187",
      "r188",
      "r278",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r466",
      "r475",
      "r477",
      "r480",
      "r481",
      "r508",
      "r528",
      "r637",
      "r651",
      "r693",
      "r740",
      "r757",
      "r758",
      "r845",
      "r846",
      "r884",
      "r1019",
      "r1062"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r553"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "terseLabel": "Total property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r135",
      "r650"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentImpairment": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentImpairment",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Property, Plant and Equipment, Impairment [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r553",
      "r638",
      "r650",
      "r859"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r115",
      "r118",
      "r648"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r553"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Estimated useful lives of the assets",
        "terseLabel": "Property and equipment net, useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "idya_PropertyPlantAndEquipmentUsefulLifeDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescription",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property plant and equipment useful life description.",
        "label": "Property Plant And Equipment Useful Life Description",
        "terseLabel": "Property and equipment net, useful life"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToCalculateFairValuesOfOptionsDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r322",
      "r369",
      "r376",
      "r405",
      "r406",
      "r407",
      "r416",
      "r514",
      "r570",
      "r579",
      "r596",
      "r666",
      "r668",
      "r682",
      "r710",
      "r711",
      "r764",
      "r768",
      "r770",
      "r771",
      "r774",
      "r795",
      "r796",
      "r823",
      "r828",
      "r839",
      "r851",
      "r852",
      "r856",
      "r857",
      "r870",
      "r877",
      "r1058",
      "r1064",
      "r1108",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToCalculateFairValuesOfOptionsDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r322",
      "r369",
      "r376",
      "r405",
      "r406",
      "r407",
      "r416",
      "r514",
      "r570",
      "r579",
      "r596",
      "r666",
      "r668",
      "r682",
      "r710",
      "r711",
      "r764",
      "r768",
      "r770",
      "r771",
      "r774",
      "r795",
      "r796",
      "r823",
      "r828",
      "r839",
      "r851",
      "r852",
      "r856",
      "r857",
      "r870",
      "r877",
      "r1058",
      "r1064",
      "r1108",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123"
     ]
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Receivables, Net, Current, Total",
        "terseLabel": "Accounts receivable",
        "label": "Receivables, Net, Current",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "idya_RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized income tax positions measured at percentage of likelihood of realization",
        "label": "Recognized Income Tax Positions Measured At Percentage Of Likelihood To Be Realized",
        "documentation": "Recognized income tax positions measured at percentage of likelihood to be realization."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r904",
      "r915",
      "r925",
      "r958"
     ]
    },
    "idya_ReimbursementPeriodOfCostsIncurred": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "ReimbursementPeriodOfCostsIncurred",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursement period of costs incurred for quarter ended",
        "label": "Reimbursement Period Of Costs Incurred",
        "documentation": "Reimbursement period of costs incurred."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r333",
      "r339",
      "r560",
      "r580",
      "r639",
      "r803",
      "r804"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r797",
      "r816",
      "r1124"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "idya_ResearchAndExperimentalExpendituresAmortizePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "ResearchAndExperimentalExpendituresAmortizePeriod",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and experimental expenditures amortize period (in years)",
        "label": "Research and Experimental Expenditures Amortize Period",
        "documentation": "Research and experimental expenditures amortize period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r905",
      "r916",
      "r926",
      "r959"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r906",
      "r917",
      "r927",
      "r960"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r913",
      "r924",
      "r934",
      "r967"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restricted Cash, Total",
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1022",
      "r1125",
      "r1127"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r1014",
      "r1022"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r91",
      "r646",
      "r676",
      "r681",
      "r691",
      "r721",
      "r859"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r172",
      "r173",
      "r174",
      "r177",
      "r184",
      "r186",
      "r188",
      "r284",
      "r291",
      "r312",
      "r448",
      "r449",
      "r462",
      "r463",
      "r464",
      "r467",
      "r474",
      "r475",
      "r488",
      "r491",
      "r492",
      "r495",
      "r506",
      "r537",
      "r540",
      "r672",
      "r674",
      "r694",
      "r1160"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r205",
      "r215",
      "r216",
      "r229",
      "r233",
      "r237",
      "r239",
      "r241",
      "r365",
      "r366",
      "r598"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r368"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r798",
      "r805"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset obtained in exchange for a new operating lease liability",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r858"
     ]
    },
    "idya_RisksAndUncertaintiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks and Uncertainties",
        "label": "Risks And Uncertainties Policy [Text Block]",
        "documentation": "Risks and uncertainties."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock offering price",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "idya_SalesOfCommonStockAggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "SalesOfCommonStockAggregateOfferingPrice",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate offering price at which the Company may offer and sell its common stock under the sales agreement.",
        "label": "Sales Of Common Stock Aggregate Offering Price",
        "terseLabel": "Sale of common stock aggregate offering price"
       }
      }
     },
     "auth_ref": []
    },
    "idya_SanDiegoCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "SanDiegoCaliforniaMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "San Diego, California.",
        "label": "San Diego, California [Member]",
        "terseLabel": "San Diego, California"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r377",
      "r1029"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r190",
      "r377",
      "r1001",
      "r1029"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Accrued Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingSharesOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Outstanding Shares of Potentially Dilutive Securities Excluded From the Computation of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "idya_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Number of Common Stock Reserved for Future Issuance",
        "label": "Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]",
        "documentation": "Schedule of common stock reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Tax Effects of Temporary Differences and Carryforwards of Deferred Tax Assets",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Provision for Income Taxes",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r844",
      "r1096"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "documentation": "Disclosure of information about the extent of the entity's reliance on its major customers."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "idya_ScheduleOfOperatingLeaseInTheBalanceSheetAndOtherLeaseInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "ScheduleOfOperatingLeaseInTheBalanceSheetAndOtherLeaseInformationTableTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of operating lease in the balance sheet and other lease information.",
        "label": "Schedule Of Operating Lease In The Balance Sheet And Other Lease Information [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease in Balance Sheet and Other Lease Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Operating Leased Assets [Table]",
        "label": "Schedule of Operating Leased Assets [Table]",
        "documentation": "Disclosure of information about long-lived, depreciable assets that are subject to operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r553"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToCalculateFairValuesOfOptionsDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r381",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Activity under Plans",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r93"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assumptions Used to Calculate Fair Values of Options",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCommonStockScheduleOfAggregateWarrantsParentheticalDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r87",
      "r89",
      "r90",
      "r91",
      "r139",
      "r140",
      "r141",
      "r207",
      "r337",
      "r338",
      "r339",
      "r341",
      "r344",
      "r349",
      "r351",
      "r687",
      "r688",
      "r689",
      "r690",
      "r828",
      "r1000",
      "r1023"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Aggregate Warrants",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Company's Unrecognized Tax Benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r843"
     ]
    },
    "idya_SecondAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "SecondAmendmentMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Amendment",
        "label": "Second Amendment [Member]",
        "documentation": "Second amendment."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r706",
      "r707",
      "r709",
      "r765",
      "r769",
      "r773",
      "r776",
      "r783",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r800",
      "r830",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r872",
      "r877",
      "r1065",
      "r1128",
      "r1130",
      "r1131",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r815",
      "r822"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r205",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r219",
      "r220",
      "r221",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r237",
      "r238",
      "r241",
      "r810",
      "r813",
      "r814",
      "r816",
      "r818",
      "r820",
      "r821"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingExpenseInformationUsedByCodmDescription",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Description",
        "documentation": "Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r221",
      "r233"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r236",
      "r239",
      "r811",
      "r812",
      "r819"
     ]
    },
    "idya_SeriesBRedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "SeriesBRedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B redeemable convertible preferred stock.",
        "label": "Series B Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Redeemable Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period of options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incentive award plan description",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r46"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToCalculateFairValuesOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Estimated dividend yield",
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToCalculateFairValuesOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToCalculateFairValuesOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToCalculateFairValuesOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToCalculateFairValuesOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in number of shares available for issuance",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Increase in Number of Shares Available for Issuance",
        "documentation": "Share Based Compensation Arrangement by Share Based Payment Award Increase in Number of Shares Available for Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToCalculateFairValuesOfOptionsDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r381",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum eligible rate of compensation",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "idya_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum offering period under ESPP",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Offering Period",
        "documentation": "The maximum offering period that could be set for the Employee Stock Purchase Plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares issues under ESPP",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Options, Shares, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Options, Weighted-Average Exercise Price, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Outstanding Options, Shares, Options canceled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Options, Shares, Options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant-date fair value of options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Options, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding Options, Shares, Beginning balance",
        "periodEndLabel": "Outstanding Options, Shares, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding Options, Weighted-Average Exercise Price, Beginning balance",
        "periodEndLabel": "Outstanding Options, Weighted-Average Exercise Price, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Options, Aggregate Intrinsic Value, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Options, Shares, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Options, Weighted-Average Exercise Price, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Plan Modification, Description and Terms",
        "terseLabel": "Incentive award plan description",
        "documentation": "Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issues under ESPP",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "idya_ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares outstanding under ESPP",
        "label": "Share Based Compensation Arrangement by Sharebased Payment Award of Shares Outstanding Percent",
        "documentation": "Share based compensation arrangement by sharebased payment award of shares outstanding percent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Options, Weighted-Average Exercise Price, Options exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Options, Weighted-Average Exercise Price, Options canceled",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Options, Weighted-Average Exercise Price, Options granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cliff Vesting",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationForfeituresPolicyTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Forfeiture",
        "label": "Share-Based Payment Arrangement, Forfeiture [Policy Text Block]",
        "documentation": "Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r381",
      "r414"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock price per share",
        "label": "Share Price",
        "verboseLabel": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedToCalculateFairValuesOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Options, Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Options, Weighted Average Remaining Contractual Term (Years), Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Options, Weighted Average Remaining Contractual Term (Years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Options, Weighted Average Remaining Contractual Term (Years), Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Offering price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "idya_SharesIssuedWeightedAverageSalesPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "SharesIssuedWeightedAverageSalesPricePerShare",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued Weighted Average Sales Price Per Share",
        "documentation": "Shares issued weighted average sales price per share.",
        "terseLabel": "Weighted average sales price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r166"
     ]
    },
    "idya_SignificantAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "SignificantAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Agreements [Abstract]",
        "documentation": "Significant agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Software Development [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "idya_SouthSanFranciscoCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "SouthSanFranciscoCaliforniaMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "South San Francisco, California",
        "label": "South San Francisco California [Member]",
        "documentation": "South San Francisco, California."
       }
      }
     },
     "auth_ref": []
    },
    "idya_SouthSanFranciscoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "SouthSanFranciscoMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "South San Francisco",
        "label": "South San Francisco [Member]",
        "documentation": "South San Francisco."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California State Income Tax",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r139",
      "r140",
      "r141",
      "r168",
      "r194",
      "r195",
      "r197",
      "r199",
      "r207",
      "r208",
      "r278",
      "r324",
      "r326",
      "r327",
      "r328",
      "r331",
      "r332",
      "r337",
      "r338",
      "r341",
      "r344",
      "r351",
      "r528",
      "r687",
      "r688",
      "r689",
      "r690",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r720",
      "r741",
      "r759",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r1000",
      "r1023",
      "r1031"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCommonStockScheduleOfAggregateWarrantsParentheticalDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r66",
      "r69",
      "r70",
      "r127",
      "r152",
      "r153",
      "r154",
      "r172",
      "r173",
      "r174",
      "r177",
      "r184",
      "r186",
      "r188",
      "r206",
      "r284",
      "r291",
      "r312",
      "r353",
      "r448",
      "r449",
      "r462",
      "r463",
      "r464",
      "r467",
      "r474",
      "r475",
      "r488",
      "r490",
      "r491",
      "r492",
      "r493",
      "r495",
      "r506",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r537",
      "r540",
      "r559",
      "r653",
      "r672",
      "r673",
      "r674",
      "r694",
      "r759"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r706",
      "r707",
      "r709",
      "r765",
      "r769",
      "r773",
      "r776",
      "r783",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r800",
      "r830",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r872",
      "r877",
      "r1065",
      "r1128",
      "r1130",
      "r1131",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r206",
      "r540",
      "r598",
      "r685",
      "r705",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r720",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r739",
      "r742",
      "r743",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r759",
      "r878"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r190",
      "r377",
      "r1001",
      "r1002",
      "r1029"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r206",
      "r244",
      "r540",
      "r598",
      "r685",
      "r705",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r720",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r739",
      "r742",
      "r743",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r759",
      "r878"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r908",
      "r919",
      "r929",
      "r962"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock purchase plan (ESPP) purchase, shares",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r65",
      "r66",
      "r91"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock, net of issuance costs, shares",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r65",
      "r66",
      "r91",
      "r687",
      "r759",
      "r778"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Outstanding Options, Shares, Options exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options, shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r65",
      "r66",
      "r91",
      "r391"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock purchase plan (ESPP) purchase",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r65",
      "r66",
      "r91"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of issuance cost",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r65",
      "r66",
      "r91",
      "r694",
      "r759",
      "r778",
      "r884"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r66",
      "r69",
      "r70",
      "r91"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets",
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r69",
      "r70",
      "r82",
      "r722",
      "r738",
      "r760",
      "r761",
      "r859",
      "r885",
      "r1024",
      "r1046",
      "r1112",
      "r1160"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r167",
      "r336",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r350",
      "r353",
      "r497",
      "r762",
      "r763",
      "r782"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r562"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r562"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r562"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r562"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r562"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r563"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary Sale Of Stock [Line Items]",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "idya_SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Disaggregated Research And Development Expenses [Table Text Block]",
        "documentation": "Summary of disaggregated research and development expenses.",
        "terseLabel": "Summary Of Disaggregated Research And Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "idya_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "idya_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureBalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "idya_TaxCreditCarryForwardExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "TaxCreditCarryForwardExpirationYear",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carry forward expiration year",
        "label": "Tax Credit Carry Forward Expiration Year",
        "documentation": "Tax credit carry forward expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carry forward amount",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "idya_TenPercentStockholderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "TenPercentStockholderMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "10% Stockholder",
        "label": "Ten Percent Stockholder [Member]",
        "documentation": "Ten percent stockholder."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual",
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1039",
      "r1115"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual",
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "idya_TotalMilestonePaymentToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "TotalMilestonePaymentToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Totaling milestone payments",
        "label": "Total Milestone Payment To Be Received",
        "documentation": "Total milestone payment to be received."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueParentheticalDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r335",
      "r349",
      "r496",
      "r525",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r654",
      "r847",
      "r849",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r860",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1104",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "idya_TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen and nineteen equity incentive plans and two thousand twenty three inducement plan.",
        "label": "Two Thousand Fifteen and Nineteen Equity Incentive Plans and Two Thousand Twenty Three Inducement Plan [Member]",
        "terseLabel": "2015 and 2019 Plans and 2023 Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "idya_TwoThousandFifteenAndNineteenEquityIncentivePlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "TwoThousandFifteenAndNineteenEquityIncentivePlansMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityUnderPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 and 2019 Plans",
        "label": "Two Thousand Fifteen And Nineteen Equity Incentive Plans [Member]",
        "documentation": "Two Thousand Fifteen And Nineteen Equity Incentive Plans Member."
       }
      }
     },
     "auth_ref": []
    },
    "idya_TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen, nineteen and twenty three equity incentive plans.",
        "label": "Two Thousand Fifteen, Nineteen and Twenty Three Equity Incentive Plans [Member]",
        "terseLabel": "2015, 2019 and 2023 Plans"
       }
      }
     },
     "auth_ref": []
    },
    "idya_TwoThousandNineteenEmployeeStockPurchasedPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "TwoThousandNineteenEmployeeStockPurchasedPlanMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Employee Stock Purchase Plan",
        "label": "Two Thousand Nineteen Employee Stock Purchased Plan [Member]",
        "documentation": "Two thousand nineteen employee stock purchased plan."
       }
      }
     },
     "auth_ref": []
    },
    "idya_TwoThousandNineteenIncentiveAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "TwoThousandNineteenIncentiveAwardPlanMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Nineteen Incentive Award Plan [Member]",
        "documentation": "Two thousand nineteen incentive award plan.",
        "verboseLabel": "2019 Plan",
        "terseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "idya_TwoThousandTwentyThreeAprilPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "TwoThousandTwentyThreeAprilPublicOfferingMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Three April Public Offering.",
        "label": "Two Thousand Twenty Three April Public Offering [Member]",
        "terseLabel": "2023 April Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "idya_TwoThousandTwentyThreeInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "TwoThousandTwentyThreeInducementPlanMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty three inducement plan.",
        "label": "Two Thousand Twenty Three Inducement Plan [Member]",
        "terseLabel": "2023 Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "idya_TwoThousandTwentyThreeOctoberPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "TwoThousandTwentyThreeOctoberPublicOfferingMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 October Public Offering",
        "documentation": "Two Thousand Twenty Three October Public Offering.",
        "label": "Two Thousand Twenty Three October Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r176",
      "r177",
      "r178",
      "r179",
      "r190",
      "r242",
      "r243",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r311",
      "r312",
      "r315",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r526",
      "r527",
      "r536",
      "r537",
      "r538",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r600",
      "r601",
      "r602",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByResearchProgramDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueParentheticalDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementAndMarketableSecuritiesScheduleOfFinancialAssetsMeasuredAndRecognizedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Government Securities",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r806",
      "r836",
      "r1126"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "idya_UnpaidAtTheMarketOfferingProgramCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "UnpaidAtTheMarketOfferingProgramCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unpaid At The Market Offering Program Costs",
        "documentation": "Unpaid At-the-market offering program costs.",
        "terseLabel": "Unpaid at-the-market offering program costs"
       }
      }
     },
     "auth_ref": []
    },
    "idya_UnpaidOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "UnpaidOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unpaid offering costs.",
        "label": "Unpaid Offering Costs",
        "terseLabel": "Unpaid offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanySUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r434",
      "r843"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanySUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Decrease related to prior year tax positions",
        "terseLabel": "Decrease related to prior year tax positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r843"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanySUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase related to current year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r843"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanySUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase related to prior year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "negatedLabel": "Increase related to prior year tax positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r843"
     ]
    },
    "idya_UnvestedEarlyExercisedCommonStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "UnvestedEarlyExercisedCommonStockOptionsMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested early exercised common stock options.",
        "label": "Unvested Early Exercised Common Stock Options [Member]",
        "terseLabel": "Unvested Early Exercised Common Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "idya_UpfrontAndOptionLicenseExerciseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "UpfrontAndOptionLicenseExerciseFees",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront And Option License Exercise Fees",
        "terseLabel": "Upfront and option license exercise fees",
        "documentation": "Upfront and option license exercise fees."
       }
      }
     },
     "auth_ref": []
    },
    "idya_UpfrontFeePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "UpfrontFeePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront Fee Payment",
        "documentation": "Upfront fee payment.",
        "terseLabel": "Upfront fee payment"
       }
      }
     },
     "auth_ref": []
    },
    "idya_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "UpfrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureSegmentInformationSummaryOfDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Upfront payment",
        "terseLabel": "Upfront payment",
        "label": "Upfront Payment",
        "documentation": "Upfront payment."
       }
      }
     },
     "auth_ref": []
    },
    "idya_UpfrontPaymentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "UpfrontPaymentFee",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront Payment Fee",
        "documentation": "Upfront payment fee.",
        "terseLabel": "Upfront payment fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r111",
      "r113",
      "r116",
      "r117"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increased valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r858"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "idya_VestingOfEarlyExercisedOptionsAndRestrictedStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "VestingOfEarlyExercisedOptionsAndRestrictedStock",
     "crdr": "credit",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of early exercised options and restricted stock",
        "label": "Vesting Of Early Exercised Options And Restricted Stock",
        "documentation": "Vesting of early exercised options and restricted stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureCommonStockScheduleOfAggregateWarrantsParentheticalDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfNumberOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded Warrants Issued and Outstanding",
        "label": "Warrant [Member]",
        "verboseLabel": "Warrant",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r875",
      "r876",
      "r879",
      "r880",
      "r881",
      "r882"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average shares used in computing net loss per share attributable to common stock, diluted",
        "terseLabel": "Weighted-average number of common shares outstanding used in computing net loss per share, diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r199"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less:weighted-average shares of restricted stock that are subject to repurchase",
        "label": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation",
        "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Issued, Basic",
        "terseLabel": "Weighted-average shares outstanding, basic",
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of common shares outstanding used in computing net loss per share, basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted-average shares used in computing net loss per share attributable to common stock, basic",
        "verboseLabel": "Weighted-average shares used in computing net loss per share attributable to common stock, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r199"
     ]
    },
    "idya_WernerHelicaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ideayabio.com/20241231",
     "localname": "WernerHelicaseProgramMember",
     "presentation": [
      "http://www.ideayabio.com/20241231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureRevenueRecognitionSummaryOfRevenueDisaggregatedByResearchProgramDetails",
      "http://www.ideayabio.com/20241231/taxonomy/role/Role_DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WRN Program",
        "label": "Werner Helicase Program [Member]",
        "documentation": "Werner Helicase program."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-4"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-5"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0000950170-25-022183-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-022183-xbrl.zip
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M6YB6H),P$4BVT2M#'?Q_[ZK)?L;O^-PU]7O0+YM)Y;_)B].@31(B6>*CZ +
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MB-&8M2UUS-Y9GDU_[W>&RK)]PB20I)'S"**4 BORU()9Q0*Q)J7D@E0Z]2X
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MOL#+YY^>^&EUM@V0JZ=-2.WLXW%RL6,/@+%__5]%\6?XMV@GYR/@A*<N8I5
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MV"E^KNHV5&D<4OND>#D.6Y^W11YCS-KJ6,J/>V<N3#J@%W4N+H%=N+9H3U/
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MUFPY /O^N#B U[UHL(-(&^IOC_RDU](G&C'%CA)!=2#66$:4LD)81BGG;J7
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MUCK#^!TWF23LLX)H !B!39]A(>ZHRT:YJ&GOVA8,4?QJ@24)U,$N"G4\;[^
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MD>].NDKP[W+=O+LLN=:^FY6B?9?^-=VH@3(K4X]UIM_>K <W*QY<['45]9_
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M^_-E=I="N[!4?$\J?IFO-Z3!@OG.Q-:*+9BAL46_)=C0*GV08)<2C+U+"]&
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MZOD(]I3?.L((NQAQ[7GWF"GVJ<>:RN+'7PY^993]=-MSKF?/K;0WGX,X^9#
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MU*2Z@6,'"BM\B0U16ZS_<NEN"4!_[03(\QCFG[DGGBS\&Y<NA\Z[>V'E7N$
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M$CA(9J.Z*$WPH7UC>OB3;I=VN_3F=RE2G=#6\72FX;Z9Y6/%]6XV9\W4--J
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M37DHE/O>6$0^J N<44J-6 EQR@'V/3Z X*/V^'O%2,Z>UAB!LY<=G>Y]V.O
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M*%['+X4KSNN"' D$*<)7AKM3=4$<DF9 79RZ$\5[8U;<24:FLTL>B5UR2OD
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M,*H9J<>X!YXUZU=?NR:9O[":_%HS#M2PP$5*$$.]89V]V0]D@^LU,.= V7)
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M<I(OX/Y_)S&XXBBG!POV8PY@4.[C88 CD-E,=7+U6.3*#W^]?-8,?!FG>6=
MD:^GVDC_2KW^,G2]V>^7U48LR9%=KZ.?LHV)*9/>'J6C(%X_>-=H5M\,$E
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MSHM$79)R?_5N[V2%=N\'P[;W)27M7GHX44+!T<FPGZA($U78*S$W0-RO1*Q
M4S?Q:2QO3@SU/9QZ*?6LK[,9K"TQ[Q //Z+++71TK$#&]:?&QYL&2QFZLG0-
M'%UPFJ%J-_.X=_[AHP9^KK4'1"+,*<%J(*_3\0HK@2A6'0WA:8<=8S1$V'R[
M#$FJF#%8FH;99&V+1[KE&A)."8^T/M8ON>*\)N%'+:"5@FQ?Q[;ALUD,D8:R
MZ@<'Z]+I:)C@\FA]L<+<$-HP6^_4+O(=]OHQB.#CY!3X"A(!SS1'V :Z>[1*
M9&NAHF'J<]N?SZ7F<,_OM;:*<1?:J4P:\R"1=>?M@!K05R1]AM!YYFS),6"6
MC4FY'>7]8*!;MJ\@%]%VW-?=I0E5V%@3B!)H&QT#]*E:_\+XES #NC.K,% ?
MYT@O'R%R-DVE--]1P-+]_>I'10%X"O->6<_HD7>MU.Y/T*@+GSE-XT'B="2:
MI5^2($>2[H$-S_$5$:\.+_# \0(O.KS @[?2'A]>X"?4V==,<&A?QS.)?.>J
MU*:/C0P(C:/ORNTRB&$YH/XYPT2ADP-W4M\! B-JJ>,Q!B(5?[A8^8/3PX]B
M'Z*9U+@7K!A^!PP4\<W23:<U)-:<VXJZXW[0=GHA*9&/-I"E\8HCQ@C4G)']
M1&MK[#,GK)7][\'3E_ZMJS&V4=F,NV*EDV>E2J0U6@YD8UA-$ OI@F_41IX_
MGL&+->/YBOBUAFK0XW5Z?;"U324P,.F-YR]^W?2^C_@.49KV;-"!/R2]Y\6
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M9X.+K='1E$IM'LJ@2-[/ZZJ&EQ^A(O LEE:D#7,S\1YW'Y/A WY"A[USSW\
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M5TK#ID=7?<JH@=5I19W-O*&A1]3$1SQ]$6YMN<@>KY<L^7K(LZ?@=(Z(%.
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MGV5<Q*D;!#/8B:*M[X[V33K";]TKIF2;+4P6W.KN&CJ?2/'OU4TZ6E_7!DS
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M#2GJN89O8R1NH>:ZA_5I<VH.@>9YR(G9Y7']YL8'0V>E4#EN&<[WIHF&-"^
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MWWEMH1!N@U@;5CN<'#15>Z_/5%WITPYU=,G?I95O5*#]/^G?#.W../8WYS=
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MX+2UX,S5)NWUAH4U;)<NIBQ=!0TF0_&ZB:Q)Y$YHLF%@0DA*MJS(K\4$*I6
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MYMS)BW+B9GJ),ON)=ZE-08S^I!HE^@6\.KCNX@PNTT*T.>X$42]TS2QP:B_
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M14Q:CD AY"!I&RHP([JS$FYU57AH\,#SN<H+)!3"CZ-Y\,'3F.6*(S,&V3&
M8DN[H\^9#$%B/GXZU"*B..B:;L0! V]?@(H!,1?.VD!$%0MY_!$(!*XX!I*
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MC9=*D1H6A*I0E/.V#%N5RN/20N:HNB],42IDLYKXIYI$&?1\L!9M);440H/
MP0?RY.P/3"<]80*+3 %EI@_\3F2$T%216"N:YZ^>.>9M%8PJ;F_Z*QH./SKG
MNSR^/?OUQY. 2T7?FC '<XMLLNC492EE:NSPZZF@$Z$M:]-)<U4>-!EA(D@;
M4DB7>Z1LZL:MJ)EC,4>PE2$I(91(UFS\.SRA9",=&+:'- -+TQZ8UT*"!ZLR
M=[,6X]%\^FE^89EH?:27)=.?6984;K9G^QKZ8^Z(':VY\-;I4V8 XVTGW(>8
M69VE2;B?AZFS3S<=IKL;^VSVW!>I>U_7'0O3!45E(Z&%%R\%SP^<0P8>,.*V
M3V%-S$8#S-89:9RT<#D'4@.J5""D%A',CF261JV2:E(05*OJ?T+9'/%G$E_#
MH] E F7A<[$K.#(>S44"DUPP6BA::GU!/3MMVV[.NN&EO;K@@GX6^\:I4L O
MHIL5 QL_MM:VJ;W- 07:(K"8P1)SK-(G5Z_[^UF*34T]V<(J_4@BQ<V(/ PF
M\X/-G++_BY(Q"$:"80F5,VOV8=KF*THZ1)@1Z[DI"Z,?$I>N1%&=DR,<BUD3
M#(  $!L. 6CK+4,C30"]/DMT%YS"4MXP.8L9%5 H41_9&'0B(MPG*;0T6KL@
MGWAECSCRZ75[C7=)M]J2N@UF#>Q4XS4RL9O!WXQZ8ESWK7$;>EI6,K.,O.6S
MGS4B8N LJR3@6!EW@J9^UY-3M?#?.4+'NLG/]%?6'9U?@+=] 7;2'ZZVH+50
M%F;1<'1AUFP53[LTOA';0<@^X<7>.B/]GA598D_.-K/<9\:LP,OJX,(HZ-?^
MW0M,JV$RKG)0N"W.>N>\VII1)QQ6G7IR5%G>W+$_-1-4GSHSAO39<L BX9^X
M45D5>35>6#'KL?+_I%%UW6XX,+YST> &_$$[ ^<0#U?=$CE.),A-?K875A["
M\G0!C^#/+78<->)XPD,Z3^*2)B'B#3S2=*YAL8@'(C&?>]QRO,MA:V7#^0"3
M&Z:]T[N'X7#R$H'XF<1V"6W.">0M0>I8O:#JGQN,(+YBCPKDG@[\ECV-)=EQ
M6D@Y:I*]"&[=)P5"EU(-+J+DOJ1:88*+H%$<4']R55@92,+#2! 0?IKGP!H.
M+_DL>PW7\M=:MVB$/ET$3$\0.6*CA*#P"!E4028S<@;@\H/P$9O9J"%4@*YC
M1W:@PLU%'*<B 6O+3Q1)KD7!@IL+#+Y;J(2XA(V7KRP&TDTEC9N6;&6WY4@>
M2HVP[5UEH# ^PB^WU:4#]476*8$DTQ47#AD&5GF:+UZV("!>TD5*/42=A:%C
M[6 <U*,X&5&NB_H(;I<$<?AH!+>QZ9 <L]-*,,- 0\\+S!3%,V&<]7)#<OK=
MR_/W2=1"AM=#1\58&J1=],TB(3J2+..^XP#D"SHW[^J6T)8C:E:0AKPE_GJ'
M9Z6_1FV"-0-IP,C(S$&1J/N"Y@/-AD^P$D&OG(?=+%MTCQ,I-,A2?AUMH7_G
MFA^8N##$6"]%-R68!'I%F$$J4!D*$C\@JP*DS*9G\24A#> J^T.9L,J<NCQL
M MZ([F;:/P*D_-4@W'UCX1>KDF^FG6:B9B,'4[$A!G)T%+68F'J"#R?G/4("
M%4ZJY-G4'*+&-W)NH,P71IO"3L-_SF8MN.-EGI=7;,5VN!!&S3UJ[CV$$+T%
MV9+BK<,\Q A_&D_Q_MF?Y&Y1]!05Z[JMZI8+$];^[ 8K,3%=&L+9?J?<%"]!
M@H.AXU-M[UY2Z0>I:*)>!3]/NRVXRJ&9A&H?)^/Y!)A\O^[&++4KS5;+S48]
M+)TCPXJ9>M::NUC91]T>! 45E@M62, Z:X^6TM?J2G<%CJLR3V\5XBG<;F!X
M+/I":/ZW$SK4+:\#I:]6$UHAA:0(U6(:VF.33L4W$9M8A=>A9K)-.]_0\/3Z
MLK?OW_JV3EBTH\3*<14V&F?XU?A=8I%YVR!"I-<%.3S0%T>[:'&U<0)L$D2"
M)Z'_!7DT9/3S#LV)88G-'P&)22)<7B.;5G'3!HEM3S>FV8&QNW%1!$*7*!>[
M36$ $XB@P$UN^ (\Y0<=%LPR3]HU=4;B.DI<;'C4 )>,3^/#;S#MP7='D'(Y
M?AHX92)?(5&6$*0:D<;LB!5 ^[_Q;@$.'<?K,,\//DS1^+V4:JL(O4=4*3A4
M;H\/75]&N+,;U:UJM]>R)4Y8..$(MZ3CAGD<)K6IZ%SR"ZP#P4CG28,I@'LF
MO$<PWIT'XQV-8+P[;R_>/S#>>X<=%1N'>=\HO<MIKLEO4NO[3K0,$65&AD;F
M)*4AEDP:FVX9]FP@=)9/DL_%-MQ>L]:)2?ER5O]@8XOA;*7MLC*C"4=H[6-9
MJHH]1) ^U%II-)73H(^[2^;P(!H'X7>AXME@"4.%'ZKQG$#G?@D222%05\XK
M#<N1_EV7A&=\._0QHTRP10%N#$9@UBDE_4-TR'Z;C%,*FI$1@$:-!XVH,9TV
M#=BXGE IRGO%8*_P#"PHEKYCLEOX3OGW&YA!5G>G8FKYF%0OB@QB]47]42.<
M0B"TZ^P1CA'>&%J@7V L'#W_<GUSQT(65,3U2[5&:"@A*,^$& Y>WAC!N"L:
MZ3[IH@#_M<>6@A!6-;%;4_)72+;.P\DV&L@22A,C+F9,,.4LB;1):1(OIO(Z
M'?P"ZZQ4^E0LW)7"KH\?/DQ@GR@F 0*V-2#C7PM*XKUO"&:!_B-K0QUEQ9CH
MSQ@DX8 +8_*0!J(&<8VUX<R;D8:9<G* _4)Q\S7:(>BZ7I0E5)H/SE_UQN#N
M4$9GRL# 2T)/D[L' KY/@30TNA=5O1<:4.K"B:?X-''8 T#M<!*#>.B@U-M.
MBO1>DB(#G6-C2)'!]!8X!ZI^PZLI(U(-&)\G*O&?AZ+] $'9OC#8O$NWJ3U6
M'4,)Q8P9 ="WP<B(C9K$G(;X-O@F+%HB+('UI)\F,]CZ3/I>#3,9T*F0JD;Y
M A;E'2R<4U<]S-E,UZ,O>-ZD\-,YAMRP<TI&F:7Z F8HS;+FK1(T^0+_D"'J
M=/?D[!4"),?\S[CN_8!PD!1%OV6;IL'2'6Y+F6\"X",4%?UHP >[A6<()XNK
MQ)"IKJPR<6;K1MCY&<-;-=K*42!6=8)JT1C7O%$:#X/FBVN B2V)GN'I/_$3
MPW6AK?:*R<:EV-L.)H,%2=O*=@WFSNRE*==6JC@1(@$8UU+;>JHPB4E..&*[
M94,."3('?DRCSHB\M"B^.<] .5.E#O%!^=5V%AJB__(TG0&^/NN)(3IBRI'T
M[ED(6XH@>89TA,?;!W+D-&T^Z]$@Q=O0U<*3Z]4"(R 0"NC5:5[./JJ^#M 3
MH@CW^R5KJ'NAX"W'8JN=I<K["DG^1F$_KOOV -\#%IV/U*!T5.FP19R(+9_5
M :G$5YBIBSGY.:W*=*Z>PE8QDOF'A9D$X=_)(.H4G G+5.B2;W$[/. ,$8#H
M$&0!WX5!MVJP>J4R,1>K]*Y2')$0MPS25H:$P.<?49?"'K3LH1B$E:^)M0RM
M'2=!.;OQ,X2<U5$O$Y^9VRIHQDS2_5HWW)&3=97EX$H?'X> @;GC\Q0U%[@Z
M3385I+^]VJJ_HN8YOYY;#^P<_Y-*8AE=6SOW<:MY2,+ 5!+T];"6H+=X5;;[
MB=[Q6K8I!7-%O*#5UJ?.54<\$DH,Z?<[L2,*@GJ_P7SP>'_V>]VW%5%^^0G3
M%GB*SDQ'!KP40ACV5L#3XS[>]2/VU7HMH8N#7E_H >[\J9IW3I7$BCPD'\49
M-^G92$*J+U:[<5\ETMW5 3Z2@R,.Y9ZM^XWTZ8A)71W,D]I4$TD)<F(W53K[
M&&EG-GHWO1:6FG&XP=F+'63&PEF:?&Q)@_.4[B92L0=V]0KL8ZYZR,5&WA5F
M.IS\.+P$"OIPI;:4%$RS(HK=^@R!%'T.%)O&[@RZ/I;Z5*CC0KE(:O?3!C#Z
M4>Y%)9$AW-Z*B:^M!R!P/I>N,.9LA4)'EB"6;C;8D">.KVFJWK[]/L'+T *L
MKQ7]O"KSG M!F5<EL!!H/$X)$OCKO*;:S2)608*&(NI0A^/FI89<)Y3GQF6[
M9J59#(DP7!+U[,+-6YDQ?2<""](G_1D%6YN D5Q*PU1$0_/GX]UW./W#B3%?
M>STDYLC)?(FGJ=@$P*>G%&1,9G_2'(Z5R9BYC.&G<=VW&'X*Z= _06MLE3R$
M'51Z*\YN;KH)<[6^),\Y9("AP#.VE@^.73L\57\%-K;0>_I26AT,\!!8<6I5
MH242S5;DW^(T]_D:CT#>.P?D/1Z!O'<>-G7_@+S4!LL#,%D24UB]&*1HRC<1
M9PD<4VY[&9*R5MB&F*@3Z%(Y)>+.>:@E"GPJW:*B2!WX@O) -A(;TNCF@SF7
M8E 4JWW U'<YPD1Y :0M*?U!W&3!)2!EA87?5)0\=?#22%UB4I3FZ%NU'TD_
M'FWMFRHC#+&6:6F.5XH</!V,2L3ND0T5"[>!I\ &U<T\+B &JA'E,J[[MIFN
M!KQ@R5\.G.8T!EBDVX(A<#6^O8'-:2AH;^9J6^3+CJ^:8H->U,0WLHWDGK$B
M-1UC\C_X .+,5;)[;Y</VN"V&1?G9@U!B*]%H#"35%?6TL>X2_J:]%86(2(%
MT4,BT%.A((TL-=H!+R+]R!1EXO$6DI<U] Z&L^O&[*Y)6"%'7P*Q["!]["CE
MQG7?GI2+*"U]6%=;,4F(*ZNV%Z*C/$!90&',S\X@Q "SV<SEKDJ%,)L15%)!
MK,&P#G;;QD1A-WEJ'/VKVPK,)'2(U6SS>!./"$<*J8^.FS>N$1.,?KM::%(?
M1=6Z-&+PRJ,!I>D5R!O$;;"MERF:):M0-E8U"6,PS:;97/!N*VQLF),8N]&\
MHN7=8-A N]=?4</8=E@"12'+MI#P(@Y*4ZI2_G^1[FFN#1<Y?FK#\%0EQ:!X
M3R6;H\XC,GEX;0478WN5@:P^-0'G=!C\YL#+[_#6>D8J$^ADCG@LD8L,>$^G
MP#B$/*<SCP%A5#9EW1Q8OJ!BD6&)'36ME!K]<H([L=AHT3V1+/)20??,LC5-
M]$]Z(5L8PX0,/?=1W)IAH#$D=O#6H-2P($3/>D0L0@Q,JF.*,^F:R4TW4R%.
M:K*5X=@T-$IYVA;PTR[SF:G)#YR'=B)2=5)6-BGB41B!;F-X56ES<95N&':I
M'0M#1T%Y8SPANC2VC:#L-1AE6?2"R9/3/P9\EF<("#_P+;]M7)T.4^@(1)/B
MAD<M)IA XN/-P49A,WJ7\GK+DEFEJ7CGEU6134%NOG-TD)50Y,>S7]Z=)"!M
M4FYK&K<"1/@P!DXFI?P:Z:K(#ITRR?/D#!Y)J6,&^XA3.>=;3GN'CXM3P>#/
MZ9VV9I->;>[;2*T=@[9@^4TFT^ E#A;R=*-]7$TQHW](21=H>=%PMVJ5--0S
M<#%T3<?\\_U:MW*E!D>+,0Z: [4:P'/&W1@T$=?/*>@S)EC5YQ;E!%N;8==Y
MYZ3BV5@U 7ZA(J[LCX7ESQ/"Z+.A%5IS30Q):T07+)5#F"D&C?$&?;)POZ."
M+C3>AKU/[,1B,7Y,J^YSV<RK7F5_@+H N<(FH 7[$8=)!V/J(7\PV'NW;ORT
M'O6GU5R56Z9&0O;UV<NCIT<Q63-,MD)Z0FH.7E';[1G&KZP2 :/B-VF"RE5^
MW,2VPB+I:],OW!MD0.,0L#="1 H[)CPCI_(ZXH;1L]9/RY>M*OT!#$XJJ&AP
M8^&_1VFVW^N^+2SAV\C">&=X@,8"]?& [_&Z?Q$<42B7J@/11C/D*8CA[8NK
M=O"G:A2MULXKJS0KI!OF()UJZJN> _UT.KN08D1V!P\G/[/:SVHJT-ZP[P1*
MN6QK\(S:XF.!%&-^: GTVE0\]U2=4",1IJ!5NEK[;.3.NW1%@"+I'@SPARDC
MF,[Q)*(;2U@'(>D)=V:_2(MEP*EU.9A-/2$E4#N]N,$*TGKGN#6+#LM$@!ZP
M[SNM$ND@9J*XYERI^)28VA@WMJ#YD!T@6PQC68&=EKU(HLA3ZYL?:/_XP#AL
MF:>Y/'%K[WD.;L%[2J=Y5E^LXK(9[8V@.U(W%%)8,N._\-S%ZV5[#FR6MDB+
MH@0GF29-76#H''3:+@P/S87IP\UNE+3/[E.>7M5BTOH_[Z A!P>_Q*I\ RV.
MW=BXI4X_5F,=>B$5^!%/]*<43_,PYWDGZN)9SH-WJ 3H_3;"7>KQ <9SM,L,
M"7FW3>(U%.B6ASR-"J/V09#>5P5R7]>-G.<QSMJVWA)R<I9W3.7),7?T-3!"
M5* 0M7Q=ML:^]K5/1FKAH[.B9>RM2A CJLPM'>X0C80FU1Q6Y];=3BZ)D(!)
M'%'"C-S"#7NG."-P?1OORVQN(D3\A78])^<LOLH@*&8;RY*6\-;5*(J4RR52
M#_'D2,I2D00+69''X K.F@H$RDS6QB*&7<:V<IU12)3'(^&\?=A5U.8E.I%U
M=X="V)3MA=QSL\+>J()-[,^3SLCR,M0$L)QQ91%.$1?$58Z[*LSCE"?[[Z09
MZGY/M:XM,^^I[6!8-!>H70Q9'4/TX'Y*LQ\4VW8Q(K OLFEFYHSK*\P=$!Y5
M9LLO?#L!0UX<%H@&H4;MO='0U0G>2/!&S ,V[V -^*7CA]^7B\4!_16?3)\=
M??\-WH9YB^WG#R0-@:<R=">DDPE/4L0,)I@OR8Y)M#&A#\:'OXF-H\>>,#L%
MFGMG-S5&1?5AO)IZ5Y1R)$V[6@YJ8XYB6RN"R(3=9R4X8D;O'&;TT8@9'3&C
M=\X:&W+CH_:#J?7J;^S'1Z!-.&N<.IZ!-B!><%!=*V)-K\'C$8?NQQM)=@H:
MQ@H\T*9K\9>=F,V+",%8TJ,<HYQ$)_ @5*5D18:NKXP)B_@MJ!XO- ]@(HS?
MP9ZD7/*.-0>["2P*YHTCSAXREOR7X@Y'V".WEB) H6[2S*AM_)UT7I4)5"7!
M!;TH\SF]]=A![KFH5RF=)%Q%JZQ3W/^O3DS "3'%YH/:97\P@+>A!HJ&#[YN
MN?T0>]QKT[2VZC0NRHK?6]F)!.GQ')G<M =D#2[1>"CH[1(( EY*C>^N8',:
MC-M*V$FL@<H!B- -2JST>3E#8B@PLMTTK7#0A&S#K&E]4Z5E62T]IA=FCB3#
ME-#NOVA88IJC]3/ZV_LAWO=9L-]6 B9T_'H9B(W&W,N=4-[W==U\9B,F+@JK
M4*-X@[/Z\>STA!",<S!R-[UZYBI.R6!ZP6<'!G#2/I1Q>F)+IA>@7 X0KZ1P
MAQN1LP?*^)BJ2Q(;7*\<; [D>.Q0"/KPM&#V,=4QNW K 7$VBG!\<_H2\?/,
MAUP/?]$2@B':E-I'!6?<QQ("2Z2%L*O)1;1_*6O;59FY0$"921Z*,>[,%$;!
M*@HQ>"P_8^-LB39'N[@,"8%F9\' B]X^[7P<FK?LEIJ0DJ)T4U^/AM%TBO]!
M]D*A)!#FO=,NGE"9>^F+)D+%!!^W]U):_N3ADP?3;QX<?Z,KP.-"/PQ_H:'"
M %,,]VD3T-4:]YC>:&%VFK&XI50,#&_VX>15>87HM\38J[XR>&KZ+(NMN\"8
M*A%U2M6$*4G FV  /L2[QA42</8\_!//>58L\)TX+9HJ39LH^DT]R3,B;8Y2
M3Q)_A=-)^XFFJ*M&0VE<]RUS$X%P-[CN?!-$/0+^G=R7J".&E40LBSF?S$3T
M0W*44P&!^S9.4\<E1? H:46KMY=;LJE LIWX2@+2:P4H?0-NMD4.DO!7_PXN
M,WHW2_49->V!F/^L[,+>X2/TNQ4N+[U3!.!_A60F FCE+$Z('LM5#]J,N.><
M6X6_2=L/K .KZU"QU=7/9AAM[9;)BV$5;%\%Q971O<TWHGWF0:+%++HD8SW_
M9G@B:VBF6)''[]A Z<KM5']RS-^OS[#KXMM!C5+W% -G CBQWU&O(NR9DE[5
M95EE2W(V=Q^?4;".Z[ZU=?_H+61&WP_>5H\$WF:KQX46U&&0L!D#1D^AO3'9
MA/=?GEQ1+&T:XV4\##_0=#.;+CZI<L3%S; ,4[ ..Q;(R*6+%(?S=M3F=)O<
M%PZ#C\B)@GE$RW*R!= Q7N-QW;>'>(SS\,;'C2BQ)5!-;0#XFF]CSV;,P:<#
M*B >;H4V>4!->!&RV-;87B6=@E;_9D23[_>Z;R$&B!;6NP#O@0-Z2LXT_L=9
MEBZ+$@RUV8@J_]N\\+NR-7^V#/B-.T[!X\$Y*RLN3B=\ZMH#WO1/ JYEJV*)
M33,500<_.#W_I6:>BAAN3 [E9O(7F1I?^/;!2@/]4)5_U31O-*EYD#/4Q)(:
MBRTVG7HR\*,I=H!@\+HN9QQY],&Q!HXAT88TH0\9YM+%:]8V;A2,KK$*US\3
M'/A%0]W-L=TW&[=I+4%%HI&WWV78."/QJ/Y6:63A&=G,,<2Z%Z!.?%#3=T7+
M5A)_B!&649OVA9M352Z=+T*#X_^VC>LANR6C.XS$C*<H56Y2Q>[3_$EDG!-X
MT=O=BLN&;P@P<)8[I-2?.>MC) *BKT(%79[)3Z/*@<1 &.L&KMS215C&&!*7
M2#.\+FH3.WH@BM2C%*M&P'0!5AYAQ&_;_AESN']Q-TS.(G1N*.L!1 ERRV%B
MO/#A=PQ6TA\= SZ/CKZ?G.)_3UXG^H_7I ?DWZ_]U^9.,242 9L[Y/4E?SBK
M/_;$%MGHG;NIA?:PLP*6$$>8:*JE^[$0,IDFEM0?)@W :4P1B5K;ZA3K"J)]
M89QN"/-MK9$0AA-#3\(]:C@Q,[\P[C\X-1(4,$*N(VU_@E%1TIWR:CT/A5:*
M= M?.O@F I,;OF1+(?!?+5-MO-_4C5L9:Y?BP/_U_ETR <'$\=J>_%)4CI=C
M$7#]Y*54F:3Y(N!M?#$3U_""[*_:YF+1LE1%!W"5U2 _Z:AXG'$7!>PI.0[#
ML>N_*8]N-LC]_EX:5-E[+* >V&A\G^J$"GM*RO%JJ:E+B"*0FG/77LH."=G)
M.?9*&IRS+8KRJL24@ 6M8@+<G4SAT<,''Z,TX>$D7'CYJT>L=>K"*NZ)*JVT
M)5).E1!F/D494GB);:97+$.AOES7S*/"#>DCW 4?\6\$(.Z3&DS9*[\':X2B
M]]>,D?A!&*&WII:I,@5:T45ZZ4)^TY-W4)_5VK"?A$?S,749&0KQSQLWNRA
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M(B*EB^ P"XWOU$M1!B<BEM/IV94;;.^?TC"G$I32PT])7"H8'R!4@W-D[V+
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M_(%*\F_G@3LY.\D63JF.R/;66FT7R>^'<1%].&P=RR[GY;%V*PVVZS11GL0
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M.@+/0=,CG?J:#9$9]02N?G32WF;2E&9@_&TX-;-C7*J?P$E?\6KO(ONC+V,
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MS']-[FD%_>2^TQPM2MLA^?4K'929.O&2?9CJUY$S*VJ*T"(!>A^2I2L'F_\
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M ;W!#9,/,H(072@=_[ C"ZK@)##W;U18$.;5 7RWLB 0TIED9J55'5@^!X5
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M4!!$LWH;?$SY'IVSJZ;XWYJ<5-#A_]R _.E</,'__.Z_?W[]R\OG<&KV@A
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ML:.)B!W%@U9L\&ODJB3GEY\;RI9!%UL7DKRO1QW4\(P;0"C.1KW9)XN?)AD
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M.1_>PUH&;X6+D*]K%R4K@OO^ZJ,5G)!0E>9>GU".I0>]RT3[_]U%E]@[F94
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MBWQJVXZ=K!T'.5V)&7UDM6;!+44G1WKN4O8-S-JTSAE/DL. VD;Q,7T_'87
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MZ>+-\Y=OO60M=\CX-C!L*B\]\%]EJ@*9%XG6A)3&7VHR%FV 4!:8:BA.XVI
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M*8)I7_S>U7F#;0 LU806 -F0EUU>:'$S!O(E$?@@,<5/4^9$TL:@OQD;HEJ
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MP;_ABKJ-EWS; TG:^C:3< V5I90K!(G&4#04&^*R:-OGOD\QRQ&VBQB$JJ:
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MW@>/L156Y(OT,K&^/Z/2J,T>;Z2)@\ &&B->Z56*9IBNV[Y;1DM^F5=[A J
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M&-0.EOG#VZ!6!%=2^I43/C2, IL_/\S9<PUVL Z>'M8])7*D9D/-MOAH3(6
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M?'0W@2TV+1/3PD\IZ[0583TDJ<4 \[1WW-0Q'B]O\#2.C45<5OWYB-8+=6'
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MPP\S18_)\ZHRB=&RR:>2%"@2@C6"C.%N<%K][IHC>FG_5O"9J;A1C6]BE?T
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MH_9+F\BWUJ9;(5_5PV$-6Y/3N:--G;?GN<T< )PV1STA]BL)ZJ@C>:H;C8
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M/W<F+$KXB(1IK\Z&/=6_-O5]F A5.H0UDT^O9(KT+:E/> 8X2K6"TU>@]]:
M$76O9UJU,J4[90! %B ,!AW.S@8F)[4D4:'34P1;;)J>X@.<0$JGFETQSB9<
M.*40P<Y.@:O3PSM'RKG<,NQ.+F(5HX''S=N"^I9X"Y0(3&I+:EOB Y$EUT@,
MC9:%;?BZ*1MT 60#Z/-X^3-EEHM9NPEV%9S34*CR]*UI>P)N%=GY=F=C U7
MKX;$-F;]8,=0@I P.%%6LM.%F9G;! +4D!UE='\8AC%6DZ,)I'\K9>N(D\C3
MK_1$ GU4%A_O-GT)PBRX'2J:IQF_0Y\L"@-PTPM!V=VN,IF^G7)0E#>7S)K"
M$ML&S@"QD--\[;3/#.M]*,0D"C&I8DDV)6(8.G#2_+GHHF!81Z,].#EQ*+6-
MOPAGD@E1;"F':$VV^0U$1O+,=IVGL0G=2OH?&=9@\&M.IBTR17_QZH'5>9Y$
M_Z]<A-DX4ZWD&M8*"ZR&I/CV&I5%8HB9&DT'T_/Z(U&P>&_2._(6C8+=0M'[
MGP086J;F$C@#S<L%5Y0 !".](;]/@R-E<E:VDNBKCEH-4-*E<'+G&SDO+YH,
MK$*,JK,I'I=,HD!^IWX7#(^W&@GIZP*G>ACQW&-][M_8"^8B.:Q=#4?-]E-'
MS3B C9QB;C:?>7'O<3F"O8F8NBWJ'N508@:[Q+34,:XG^-N7I4BR>= +4S29
MGT?XHIRA*YZE('@;DI:%IQJ,2D_@%DC:%P*')3LB8;H5"&5>0*Z].>X/"7HE
M7VJZ;%3WP/S,AT;=QAU[U8,^(%3A*+G"%A97KTZ^L8"5RPL1T#@.?4P?B#T&
M<7^!,#IQP(4K[F-V9$S5%89P>%+!R?/$531G- Q8!_\GJ>3AAOW[YU=?//_Z
MD[C0:JS!ES#BR8(JU?^^H9W_!._8_7T-RQTK@",;$9X!;O;95Y]\/$;C\ZNO
MOH# ]^LO/__;\\^^^ORKYU]\\LVI:0LN6_[]M7-'&&?E9T=*G#1)%V8%JW-?
M/W_^I2_/F5HGW_C9TZ>?)%?]6$QG1-\BAD@Q4('%<021_":LR+B O*S,966^
MNY5)[#W&9;X <)Q% 5)FC/"),S((VSAQ2YY"R1F\Y&SD[U!"=MD(RT9XGR9Z
M6(?%9S!I@7B 3/>R&I?5>,^KL2CAQ9">V93B\E2W!M7/5>Z-=;43X>7):RYK
M>5G+[\&RLO+LOCRB636Z>)&.4P#'>RC9!J9-F0>9X''&OR#-^)6TFA#Q)$2L
M7JFV$H+VWYL28_YET2^+_KU%?(02' )Y*'=F"$AB,<3+FGRO:Y(8;05Z&$1T
MO:\;";I^LZS(947>ZXJ45!@+NQB8E^)B30( S>BR'I?U^(%.;0.OBW&5\*><
M$-Q2$B(TE2[;J[DE^UAJAH^U5OJ*.+ZZIAI"A>\<Z1;'-34MGP7<5=Z6'4/9
MACK"7@W4^_A>&6Q7OY ,>7@>OG^=MRV$;2<I^J[! KH;]T J>DL?Y</HH_QL
MZ:-<^B@?W@' X)"H[MM$()2(!7)6.CSA_\&&/Y<:7 &B$##;6WB/^I_.'_L[
MAP1R@Q0M<@>"G01*# ]E_Q/77R"KRW-_L.=.&W(4K,0DN[?CQ4\ND>O$1DW%
MCDZ0?VF3$6+'#L>\;-.F2=\IT(R;PRPPJR%B7'?L Z_1=!?"'9L:*#K1ELNI
MCMOY!K%I..YL6Y-YBFR$7-/Q^\ZGL<B1L9;>K!P"@1/SM&O3J#+S&,(CG@)L
MVU:5*VG1(.Y2ZK*5QU<H@G^Y_GX)VDX D$'CEGJ3#7H!&Z8%Z$"\K^#"O^Y&
MM#V&>'ZVG*&K#I_73VBGC4C;>4RB_*XYU0I49JD69>G%CIBRUO<<=V#/O4MJ
MN945H31I1B&[Q_;C.?!DO.QO[0_FP )5N5W[4%B'%NCUQS0UOZEQW""U3P0M
M"A1?HB@*^]7M&(+,^"56^3F4'74]'B&JUN*C]/B9W.24?Y3JP=W*'/AITTX-
M#)O#!/1<UD0@H !J3W\4=R%86HYNGM#N #-WEB:R;7QF0% ,8S.D9B'/0%I-
MS*@PUSMK[6S:CF_)KI<>AX?A,#W6YWXY1(R*LD.\E$W$&J@)MC$7QLCKF*6'
M[N80E>@T-$-O>HY3NW2Y"_ER0],V)47S8IOD=H'CD[>;?382N[;/P=;0H(V8
MFJ=V<'MJI9[JM38$(XH8'3^#>T,[BN"2PG2-5RP^D3SBMSR ] _C$7'_]\4[
MXJ.&UB_/A4".F; >6'M)H379T)@'5:2NQ[/J4,]37$YI$ ?[C(OIW R!^\8D
M;(L&H;29;SG!GR0=*<@CV@RU\//(PTZTTZEHRA*P+\_]P>PP[7I$)WC3PJV;
M;:Q7*]LL8-5MU"X-2MA\-(Z_7SND#H+_03<E0X$3ID,EP@0)W&$/SA& Q)']
M5*?WU>JZ8V:OLHDXH8NAZUNDEH5Y+CKQRUI#4(54$Z0CE D_2O?:)_^ZL/OG
MZ97&9I<"S>#C)E)"L\?"RT1-%^8=5@ZWI?U:4T_7+[TG1,G7;9,7&8L!P<78
M1:7W9N0:X>#<(:J/=-R47QE_3E\\$!V9$7=$D$K7B]2;5TG"5[-MJK)1T01E
M?+)$+%E8-T1\I634NH;XT"!^K8AQFK6?F9ZLD.]F,2F7D,,)L[0L,7N247EO
MBV)%/GDRM?R\HSQ+@48<%IB>R*-I"80<<$W)R63\<E3BFEH*^TZ98J+WA=GD
MFZ:Z"?0R!N5^&X_=>%&3$X/TS& 9!F9_D75>QAV!<J]H+2*7VD"J07[2F&^V
M.>I>(EH$Y+ 7@ C\^SV=3F\9-]"3T#Z"2WY,!ZE(U9*6FL-7(AYHT_5/J"-M
M-?$-X7&,=,L^)7^K%8TH NW&0F8D&>4\]Q(8R[H,9/3>#-+V'#HFZ>M<=%_8
M*411E$<&-B^PL@ ^UM7JGP,X3MB#;&/H7Z]^N8J4U1)1-GI>5]OU&!$!,N>W
MF@0F-[>L_)Q0\ZQ1\YM6DYP3W.*3XER2*E1/N?&5_8Y4[0^!:/  3G;#G.MI
M?E/^0IH*:&9IBQEF1N*6ZB07:GXZ3\*8ZD?@\^>GG'^4<\-7R_O2* 9:X3YL
MJ^GVCF@$?_KVU>JWEZOG3Y]]]>G3OWWY[,LO5M?/*!_IE<OH?76&[G#BFG:F
MC+ 6=SKX&]Z2@,S'S^OE"GZ\?O7\6H4*+O 6,J<0N]^>S,?G;#F5;!YB\:J7
MY_XXRF!1M<7O/=I2Z&YX&C**I76;!\"2-G3F)[[4J2U[%+LLRFY3-12KTDXP
MWD7P.$/"U'#*[L'L$N,<GA=T0_10G"H5@*%"%Y1QH21>[M ]!QM,SC:ZJCD8
MH'-7&K($-B4IVP0]AF9*I%2]<:,2E)@7^QCH$_K#(]*#U/DR?TA(7H-=GVVP
M+35O,*$@WSJ2B83+G_:.A2.F<]"S1YNP21*7K+6?V).N]7IZ^$RHC<,3<9OP
ML11 )*>CMU9K5,[+."K Z:*@P&=9B/JX(-]?[BBF%=X0>A-!I9W226Y'(!KD
M!0,'8G.1?%9*>Q>XA,5*,]:'0' #2;$%B3-V?EBW\X*+((P=>IJ+@S$KF_$Q
M[/W':O,>ZW-?>T+!ZIQ-+N+)'4LDU57G3EYHMS\?,:##@F_PXS -_4=YX$+P
MLZ^QL-3OX==;U0AE<="N%_D/(P/D.U"0M!H-$+II9([(2J8_)%.S=L+K#/<A
MJ2<($H7F,N]645\+?O]J]:W0WG L8)\ZA.^JK51BOG@V4A:YX(,PW7LR=7#M
M^K**34"J,_UVDXXW1+5HY\,JSJB<86I\+(;WPT.+,KZ1=#,ZIZP-;(6H$Z%H
MN0>:NQM7)(RUERR?4*^JN&M8$G#%+$H\R1N@W(C&+<B71)D?HJ%DTJ28<E)H
MS F7@Y8\SN?,)^-\6#,?QPA9DGT:@E=H*DJR^7&TF.G%::J(!I?R/LA\-373
MV>K=YH=('#A.#WW<Y\H"L7YP$.O/%XCU K%^@![.-+_W4/ODU%3FS1(;:QJ:
M0MQQ%391-<U6+[[[_K._?:4L QR73L5J$L%.298@6[>37.JV;#LZ*]$%,:&R
MB=A,XFXJ6=7,$34EG@@[+5N]ZN343(MX2I F0:NM8W40ZF.*%X_-M6,*?KD2
MPP<HVB:E SSI8-S%P-#,<JLY?G*'*,B4.@+X=[MPE&),B&E'>%)XW'Q-]2_-
M)/B[L\YJ!W_K-%0]N+R..7PXU+7<\R<EH V21%%90H)CRD+".GQRQ,ZM$@^Q
M4)<,WE#=A,G2]T3'_\ U'D55G?;"Z8U$]VDQBP;4[X?.7Y-B< )E<E,7A;'C
MA2[T%H?&EPZ3<I42Q$<KGF8JY( S7_J\[$@]TH#JL0:2$AK,Z>?B07VHP>'2
MZFE0T:+</U@8I'[Q&V"Z(#T&768!_..QE]T\8%I%%GX+(K.F1H%KG6K.4O/5
M"$<&$Y='.J)HAGV' <N0P&A,N55G(]+T%CTP?5J3^$MJ'-;48/F3CX5UVPR(
M9;<@3,J:R?YEX=F$<1_^BIG0EE#K#:P75AEFR)&!&TV -#\5P$/G$0&RWZ>R
MD!XI+UQI%.HIWAT>@1 /029J>\&L"JUN&'1^TY18AA0A /\U672;?8.%'=$G
M89VR>!WRYZ'RXBF$[$E'_0(TEX>FZU5D9T(XPU_%<7@9Y'/QSK L4Q'RM].H
MI@=!SBZ$H/@:HX#&3.]N,.!:$JSX8<8%J:O5]T'J@M:4MD2DQ:GI1A+?F1()
M2?A3UP#@<.F#X5 %^1B2O,-*;:+@0*TLG>]^HQ:)R=V\'#&/Z[FO*P2[[O;H
M\=CMBA(_ 9<NM:D9NQ(L)J8$X4O?@5D^K,&Z?/8L6SU_^OSSC(\309,U5:S@
M- :.*7IS*@;(+D8 VE<S*P3.UHFSFERVP(U[[:LI3_1$JMP.P3[<+60>D::"
MTZ.,-F4<D>\:<#52G5DHLP'J6D[U^8S:;(%*>W38_G//03#<DV#82"2L=6AJ
M=.#&4)F2(W+1EE7%K0D6*PP'<]/6SK2D.J<8,-'--">T6!I>32?"!EP$-P6#
MZ)&R:ZO[E(GFXX0*:CAYR(A.-9W=PT*Z@F6^97$++7G>0=2*3Q.MKUI8F9D[
M++#6@E#SQP]VDN#&[8:#MGG$N+2BQ -)@DR8AGP7Z"D=Q'+-V3F#^_,21UX$
MPQY?VN!LRZ>YI$P1'*^/XT'24B3U%5*OC85[&3O81 >3B\@;\2DE]8Q_T'?H
M_0$&<$3B>!I9F3.YN'3HCQLX49^*#OWPM,EIVYH+&@\0=M'01O/-J]XXL*DX
M(&U#?V$/?!PWK<;GMZF\BI8IOJ5=BPHG?*H87;^14_#D3WH%)L\PV^HH-XV5
MW\9:6_-Y&.V=*ARV=;R-)?1^:QS*P.OT,0&',0QA0U8JFDN<!5$J?A','Q9-
M]MB2)DT(03E68IBT[8RK6Z'^OH5':6E-0#R0A<5?.YX>S'M05QRFDL!)/QPU
M&Z1W$LPRN/CK 3SSFG&G>YAI2C'PKL"-+U8?.T7(IW=Y*T:XOH%%2DD2U"A$
M6$7NWZWTLJ6/9!^#=CDA2ACU6C?<^4  #=ZF&N]L917ASWZ'B*8C? 3"'-2\
M:>,<,8GZN'/JOA0X4M&&X<J"*.-9Z*+)PXD68"$-I(OBF*BG+KS."*IQT9&!
M5[#9-"2.@87;O/:T/GH\LGFF(^=W.%*5CB$O$*O!\LHW%D?I2UC8PSNT-A8(
MH6M0C'LKF<SX:/M31UHFE55J55?G3R:*("B"ON]6>P<#14H*=A+H=>.?N/=%
M$UV"'Y4E4^6G-#<Z:5TLJCH^24OT,H8>UP(#S#GUJ0:32Z*;4O@[*%'I$5&T
M9DT-N40YZ(/<QD.D8&)1Y*X@&=,+F;AYV^CS!45)BX(*M!:L6YT_ZB+B8PE\
M'NMSQ^ 4=@@T:RB:M9RTLXUZ5"CW*.SP Y<VNFDJAK<#V(; MM%J@@[O>9OH
M&UZ'4N$)7,_LVB"FM#HA:5LG+=LPD5$<$J+*WUUS1.VC?W.34=S=/<L#-'=[
M@F:C.K2J'X=[XJ_&49F'>F3)E',;3&B!?+,.4@O:FQL0]QE,C.BZZAJ;C!*6
M$>]]1])>70!,1 ^064'2;J!^'Q9,U; _2E93PQ'F (A6!%M7R+[;!DYDX/-D
MY-.S$64@B(+<JH:2G[!K&+K$A'WMX6V501=AT/\DEHIE:FXG\- $!;EPVB1F
M"'3(^-54$;'4&.IV^7]N8PWE.")=.TET4*P:IS=X;PUU\.F-]21S'9=:395F
MJ OKD0ZU#)2R ! ?^LB@6!@Q'H;+\EB?^U5\S,_*<W,HI*J:6M^S;ID>EDFM
M=X8"8F)_W9$-HI4NL'3C7ZU>-3ZNC;NA<8?F _RLA=DKN"]\NMQ-4!UOC.@A
MX7BF 6O :]L7;S=5%Y[H8S[+%YCG@X-Y?K' /!>8Y\,[@-BL>Z^-&Q=F?;8)
ME\US&U%YH7?'SO-Y]OEK)YDW:G7)7Y/;9PWW,,DO8M$>PHC(9==@XY7DK8O!
M0&](-7=;GH*2F5K9V)3M9CA@;8BPE;T=IL 7N4+5IM6(+:'^TD>X>,Y2BCLS
M&MR4A/5C,0ECDN-J!3S#/2Z<8*"34_GQ)2O.7)X^4O8(&+8"\)KWY;'S,$AB
MX(2GVZ,A:07<Q4>\%KGX@=1CT4)OPLF9KW:8X*_)'2!XIU2>NKX=F*H)/U*<
MJ\3W1;.!YZKIWQW^GND&#H>AIL3&R[BK8^P!W-&E4?JQ*<(Q6J5Q >&%Q^\&
MA.[XNRWJ>#>^)Q*+#'TIW,_HU\&>%!=%.06X_-(*70/W0]7"9*IJY:6A-FOB
M]AT+OBTGABB<.UU7QH E7TA*26PB9HBF]9" */,U\7>#<8O']VH_!,B9;F]/
M*$NSE_J),"BNKX E65FGE@U->.O9';8RIH[*VO8!,8Z9JTEWWIE)LBFF/\""
MF: 8D$,7GNL@7!EWX:5;D%F/Z[F32MD,?M76&GVM;521!%.Y'I BY$"PU VW
M6U)%5R[*Q,5L>)\H%$-$HBF7DN&_XF2*@%CE6[[L-\-PG%89@IT8H9<Y522%
M>1_E,2 KHL^1TSTN\1IS[Q^/XQZ$LO6,V)\K[+&KPI4*;"C0IDA2M>1C,K"
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M?^NV@[0:8",%7E-2>V38:=,-OM/,DN )<]6JX16Q$\.1F.I;!R,>.?? )_>
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M=^T=U X\Z\4;5,443MG&W"P>\A"@'P&#PGE)+>>QO%%9_PYG&P%26J07V7H
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MF5OE$2D7JO&*2D]=_ 4Y'1396"]-*T5&0<*>5;[)@%NW#MS(F!9*IK?CZH>
M ?K[QWR0F=0F#.'P!,+*_HFKR%NG8<"3_Y\D788+Z^^?7WWQ_.M/XFRF6;5?
MPH@GLY:49/N&5N@3O&/W=V3 P#3;:"V'9X";??;5)Q_/XO[\ZJLOGC_[ZNLO
M/__;\\^^^ORKYU]\\LT)%C#G!O_^VKDCC+/RLR-Y1)JD"[."*;"OGS__TN?
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MUR. ]-FKG0MQ^JJ =09;$6*[IJ"Z3+,"I]+-C:Z3_LDL]26][&N2IO2_N%K
MI8^SLOI+B?6DLI?REZ=GCLJ+OP](TX/I<Y;_TU(H7&:'#'4,9C;=B"9(,O(U
M4MNZ6KVL5_\SU&[U[*ML]?SI\V=9*$G^,AQ1CF7U+?)<H]MW0+)I98+N2$O$
MD90)#RG<59.)< =P )'$F;3S.M350:U$CNRT'QY'13A9HDD>F![;LV3R44B/
M)15-/_:?E(1S>LC>'RR$XRB#7[B.SM'5?^'_:4,RI29U-@DWY^NT%/71"/$D
MI9PDF0;V2[DOX@>W;@?$C3_[@B?1LVY?#SOTJ?WG1"8ZM%B=YKHRP4KP)EP
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M5?]ES8KGK!J3YZ:TDROQADM&5+<_[4:MX\XU".#V+"FI9U#/.-B78Q.AZBX
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MJ6=99:'A./*B%_(="PNO/!T.?_14Z"[>BN@>_>$%V 5VML<_>SA?96D6__5
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M!N_1!<<%3X&+]WR>IT4_+P(A+78-KG943 =0LDYK2)D!GTX70I_[9]^$/KI
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MPPU5:9$TG$,,$9M3@VAIY<A";8XI,'@HHU72C^(3D1[09A.5W7+-^A:?&$6
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M3DK;U2;S6W"X]<Y')<0;VJD?SFGY6)_;-M=Q!4#==_ZOHGH\K,1OJ]:60DL
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M>W<X#0_@J#K-4^#1?H!T=UX(%_E'6#0APWU6-!<4'D;G^8K\]-%U!G/-TJ'
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M8 M9*'H SD+<ZV/9TUPYK-.9J$$]_ZMA3<:WBB\ZKXOD_8P&0J[CJ[B6,AM
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MS.T^O.B[=@*'_?S-F7_ZRA^6HBJ^N"@A*D#>4UP;E7FY37V&:U%:X-D_#$I
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M=6/JPK9F=HD^>AZ" P24*@-.M<X,=N9M\.H'K_[;9ZU><39U \[N$X6^N%V
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M[UV/Z^_&0Q!>Q+2!WY70#'BF@DVL@!GH!S  ,I26V N", IBER9A20)T]MO
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M>-;1MH"D=[9WGGJ<%BW\=S,*]_H B,C+?QIJ:UAO]VF]?>F'?^Y!14 W.:7
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M\Z69879>X5+*Y;FX:[/7D%_%(#(GF.C-P8<3XD&21#(NX,\TR<>2A)&C$)[
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MO#*A8SMCI!+=49\:VD]]L3HH-LFG4-H.)8T5[IGK3E\%N!P*/CPGT8<!\1A
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MUW/[/IQ*CJ"HMQO=?M$!-@!J>"CZT&WTX*+%@/'Z>WAMOGE.JOM:[SAGT7F
MHO,AQILSQ7V#FJX[#IUO-_ ]3MA5 !.9Z)GHJPK?O<%NPS[4M317VBSFV 7J
M)4MWMR']5D$:B5^^K/CVYGQ<_6C4WW>%@I$GT,PZ)\(2X#E<J?C>(*PH?!^
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M$8X6<<V -]*]7T/?^#86B4VE+7]>?3:F47@3V9.X87Q(DS3"U2ZCDD@XX4T
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M.ULBT=HBJ8V]&]G!1BTQ(@52:E:W\ 'I1T,@IF )SKO>K4%.$XQPWHBZRLQ
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M]$C91D%"7?&!T4QL*;YHUK,:V[Z6R#GT:4:'.#7C2>Z=O&[M>-T[QS(68\$
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MCQPD=VB6VX8,117373,\+-BS.E<$\4I=:=-YYKM7TCQ?U)(H9+0LN6:)$"Z
M!%\6 >&.I/=@#>#(<%[A(%8=[CPHD%NNAL&:^\-CS?9(613D ,'EUV32J7Z-
MK5UTJ^P LI+B91K\VHA"<6@B/L=6_C.A4Y!U$'$I;%"#"U>(TII.TY5.#?0]
M9BF:RS)#5.8+*GZ^2+1G1#U1JV0KW$&+T=R@8/T7&^>\5MQ57E-D:X0"N6#.
M-?(WCR2XY2_VE.)PO[N#C:[,Z%IN6N5MLK(:GBS?#;E_2;&Q=2^*6!LCQ2R!
M9<:&S$?.EJ 8>W[EO)VP*,]RST(BG'$ L+R9S2>69"EQ-U@R1)E0(TQ2B<M-
MYPI!G#ROWO8Q7WR6Y]>#.9.B<2>M'Y(OVO+*77:9QTR+'$G?L>8P]YI@QXF3
M3_2>O1-+9&'B32CI?;3 M59H,H^':+?R %T+?$M=Z)F0_W3QS;HPKO[+GDS?
MOC.N,Y+Z&OI8=9/8"]\1H?QY]7GQBT(&)E U-JJ)/>"ZH!B*,(W]F3:1E-H(
MAY).E JK$EKC4O4B]>TKG"8\-/?"D#:12379X6]]L;;!;5?*I<M)/P>?]#/@
MI)\32_HY$D%3"O[(MF69RD2F.7!N)#;[)M/I\W9G29@H]U^<YZJDND BX^7W
MQ'N/4V=:"_+?G@K*34I_].,)+!+4)2I&.G7E@LK9)L7S4P&#+&F#E )?!1WH
M4U0CU /HBG]3\4=14<?T*B])A)!UPGG#V-48!@L\4VIYKD@JR'C4DW:6I>*"
MWN)-IM+;4LAQ*B4*+,:1U!M0I9%O:*P -@'K/GA3ZI<\,U?N,/.L+ZY=F3LK
M#R@_%:Z!K&AW@2N!3++4(@&,]!#3G<BP/K;6"$<B_:Z%2H,3*LSD)5AQAPXX
MJ_GV.IU,,&T.2/6Z8/HOZ8-!'COK[4-80,\UWR*;R\NDPU7=&;*4ML=42<\7
M/WD!L>U2T5@5(,]&S\$;/5:3C9X3,WJ>N6G#<__^ I/$OO?L[[*OXO?(BW]4
M5:I_Q'RVWD7#^-_4QLB,#$6@[@<?^/!WI<4Z+?9=UN@&I 9U8/E$<#>N .Y/
ML+[V)/CWT,3B(S);L$2,*XQG78L N<>ME\P.!FC;L%@EU1I(M:!;C&7;'#7G
M(]=B/$R13O.<P(4+-"_.(TTJHA3BN_ *FNIBPWNR();M8G6!*&:7>/J,(IEG
M'8&9I4S)2#:SN:#8S;*VE,(8V^Y]XZF7=Z&5'9Y-W>&YIFLUE$TWM(,?.)\%
M]T>)MW*!]:'J>#,! ,\T%&D,3DUUWM5*G^JWA7[Y@$SE_.6U8E72U)YBG8?T
MRD?3D/(GAB$]<439E#H)=V1[D4KHNM,5)C)%7+KL"P"E% +9ZBM/!:8%E4'=
M,-Z#^:S#^(47H%DK*SR>M07*-UF^Q"6KJ:GT$&I")M-$*4Q?1$.=>Z@&JJ0J
M_53U^IUQP\V3:+CY3>*)-.N&_Y:9/(@OLK1'TV&Q\Z9'#CGB4A$E(DQ1E%!Y
M4(J9&Z4)5JKZ/0X!Y<4/6>C^TYM@% ^0$U/0LWA\D>K1:8:RF?J/(9LH55>A
MI#9^$8Y-T[/F;D574][3,QZ#05C'T"O-B4IUA%\M= SR4Q>!S+.9)**XW$P1
MX$1VC8%'AY$V4S,?5B!4]I;O =,$8W-6*_:2HW08=8-LL@</*)&L$B R;Z"P
MV4K;J,P3CI(G_#GV,'=?MD $LJ6D4=VDT=%I_"#@I>2 *VJJ$H"* 26%*;%R
M(T+LB9=DW?PFMA.%<'$03CS'0)\SJ@6Z<I"JPH*;$$G^CQ]85";J5VD<>Y1E
M-P*%-2FU HI!?5(=;?'6CW%D"[_^#WLB2RSHACRS!G418B8"RQB-VQ#7ZFMB
M5=DO)9K-]E-;T*6,D9]BNK?,,*7.H:@_E;-BE,]==0PLM(DLS/@C!U4PT[TM
M#:7_8=$-\ ?O2;V-GNU6SBW3_O=,2_V>.^,J;:'V&[KG/B#=M5ISM4U3J6%?
MI].I3P!&>?S.S@WJD[2M[NN+JTON1AXZJ*=IA-VU$UD7 6)4XH&LHYA.LZ1\
M^DZ6Q&*-J4'>,1G'#5<UXJ7^K:DTVNBQ9@?O^(J)MA__G[QYO4:=^R'@P7?7
MB_.4QN^H6WU7&<QVU4EYT# N,U.GTB1,!/RN"&D9^KW((8U848B%X TYG\H=
M4X?CA=IX^W_XDEL^'7X@Q.1 R.&;//L)A SL[Y3 '_KQ=QI(X:*KOMHRZD(5
MZX6^2H2IM*#*@'J,8N:)L8WWLAN*RJW.1?'<N1XUZ-;-P\<*-?)GJZR0PN@(
MIPBMG'IK.L_#Q@YC(^I-"?=?I=B_PFS9=;/S&LNEX":SXZJ_\L8WUWFPX;VV
MP"\<RE\S!ZTVY>FKPELRT_&>XH6UO*V1*] Z5PU^ NF)4W:^S@J9-S#4]O).
M2M)\R =&H 5"A7KI<.(EA767%@L6PFOS3=8QH2;!$U.KJYCR:K)9&-FL#-0?
M=<4Y-HG6'@)5OIHOZ;H\%#![\24F%<8Q["HKH8L(Z-27 G8L?WMMO<&21EE<
MIA:!48DT\+)V2.B_R(<F%#NHR+(%'6H0/V$MRHD\\AS5)R'_/C>QJ(]0K@VK
MR^5I%MI>8RFU;/(+(/!G<(2.%Y/C)!(W=N3*QG'JR')<E"-"\A7GY2.ZRU4P
M,]9 72.@WJS8AV4,B[@3OI]C$;F1R9.#Q^C8V=A$T/2I4B0;'X*.[$B/?Y+]
ME52:HQ?ECO<X<TP7%JZ;*7E9Z[.8,C*S[N: !*J;4]:!.*0(FVRO+I4: -C8
MFY9:LCV\^T/W/A]+:O27.>++,HVI>A<)2XNN31-CH6UU5OT'SPNP1$F][F$T
MTH6PJD59H<>*@^$6&=%\R(EB_$*9^12D)'>QR&1V;</;EMY<V(S*-\S"-VML
ME:J],SCIG2_E!#*>;,=9>!93F@]HTMH..MGG46[*/L$$3J61&5^P3B]WGUSI
M/G<GJYI]HXQ8PC^0684$ =W0GL"G\%:6.>:$D+<)E,CN+$[A^BL%9B-6#C:5
M-Q+E%(H.=,X"*6:ED5HSW3>TT/P<_I*D4WO<HIEHBCV*%T=;Y?R4R>AQLE:U
M79UB3A-R;PS6B1B3H#S0IY035UM$]+<+NBCJK>M3W.M%LTA;1:,W*^R)-\7^
MO7$ZQ?*86/=."=P=:@ASVJILVW:?OK ^8.SEN6KE!HTXA@V9AX%SS.%X8-^J
M4]NE+JFB@@4\PI"8V9?HQ@9#0(5?E4+R#=LCW-FS@LUDY#;N/-FH^@;\^(:T
M?^-#!";H71C]T+;N:ZMIMMYHM254A0H2/%*+*T!MB:ZQ/IAP%&Y!XU@.M%,O
M+-P.)N:=,L$65JEY7[&+S1U*M'&8QN(R1 LQ-G[__6M-]HYQ!04DR2:]P:[6
MU HY!9;B%"ELY$43LH8I%JEM?2]2RRJ,_,@*8R2OT#B[,A2^,MJL<7=I3'/?
M8<SA=YKY];W@JZFV6_B7AO$%5UQI;S!H!!DX.;VKBNE=>TCU_Q;9Y%?[ZMM/
MZ3ES%%EP_SV,SO[G76[^).-(8 _ (!G'JVP@\A9>J]I)LZN5)$K$E[%H[)Z_
MC!\\8@NP-.\GKOUS.@'%QR$6^>&[9;5&HFEUZTZS.ZJW1Z)7'SC-9KW='/:[
M([<_:KG."Y)T .\K,?K[B\OO8MAM6Z->K]YL.G"/XW;J_<%H5'=&=M.%7WIB
MV'IA!*#9_/V%<-QS5$W-YK!C7D31A1OBU.L/OGWSPI L!#CUSP3 ^%.XL'@_
M%BN6:H^:@X%IM^J@(<$"AX-!O=_ONG73<6W;M'OM_K#_W*5^#H,GK+8*B&?+
MI69D5X+@DK\KY*$%--\.<C=-NR\ :^HC:]2NMUW \&%WU*F[W5:KW6KUG$%G
ML$GD_A9-@N1)N-T=-FW'MMWZL#6$MW:';GW@CLQZLS\0[:YE"=-J;1BWUUML
M%1!$MT [3.S.IL#45"&-DPU&OXO0T R,*0K,O#]K&H'%'LOHH.UG=15Y]0]7
MV?!V]Z\Z[4'#O/2]@&H"KI/41:=+J?^F-DYGQH7.IMR7$?7$_>V[5(9!4SF#
MXDM@?!##*$5GBVF1P="1<_,"Z0+R M75_QKK8USC5\\7MFM<7E]>7Z@V4O*3
M8K:[&G,DJ_#5]U3:F;>T5<V#R9>5^X"_DF0R 2I(@%ID.9HN12DC"F_X^.Y]
M:]"3[5U5.KP<@5[L<T4+R.(.WZ)P:M4OWEW6\%=7^+>S+$/GLG O,8$:/5'5
MRJ*_.L^AMMU;C)BZ1ASZGFLDZ03M*+C,3X.;N&%\+:7_+P5@31<TD<-<.H.U
M[W?)4LB'+B0D=4X'51C- 8&\Y78!?M29:]5S]RWN#RAUXRCV7:1'C46:$#*4
M6< 23!K ""Y.$:'*;%E$.T??U$(.)&1X%^14Z]J)G;?%7?)D1%G?IX+9(%%9
M5+Y*'%+#:>@F=";'I+ JC,<[]=(;QGL:CF='"28YJ?GL>1F[&BJ!-:ZR-[6:
M$)"136D"%U&XNDB/8I0SR\. /+[V5 \@S79CWV!_Z65@H2;XMFJP%R="1*HG
MM0H%S0?SG##$'#() @1-<7@AYJO(MN]Y^7,I+W&>RS"!<]'&H19M6%RT<?AF
MYBZ+-JJ!N-]6*LQJ<"_5J6..K!Q-H@?+SDU75*)/]T[5:8I2#451Y"4R>T!E
M+FKIG4WJL:.)ODNJU LYN;GX4E(MTX75PB\PX(OSDQU,$J<<P2R/0SX3E(@D
M!$C+M&V<]ZB:QJOL#Q"?ZEEJ*1C,]@WL$U38E?Q0/E$&D[/M%%>2!CB+#@>E
M^AZ*O,QYAU%N-0]%Z@!%@X2:Q<*E4FN!QZI'8N/6[!$KS1R]CC!_>F9-@):!
MC7D#!P!':: I=@3&\<<J?<P8T@1Q?"D^1SXC3Y:7J6?*I-"&!J@8.&0J%_6E
M(5PLSD]JWZMX"5Y!2BX.#0S3.._29:ON$W<T,E,W= (DM:FO!:HN:2+DY.Y4
M=F46F,7EQ1-2@ETQ"?+"#87UFIQC-7Q/CRHOS$J*LQR-@/K2,*:>UKZI/4((
MM@JU2O%B67!BJU(BK)*)G<B;EH;-(%/6?RSUD+BAD V(@)^35) 54%FS=>I<
M%V,BL)^5'R&[1U,2S, 9RH4(1]/B./C[?3'2:Z5:D,D>#G*TEO@Y]H9>HDN.
M_E<F'</>%FL"_C>3%B,O1NNWD*&,4/E$$Y%4;+ZS90HA2^"9>N%#QD3EPP^%
M;"WG>UXL\3VKU/J.. O7?_]W&E4[>>NRH<I *YV]1:4H5UD=W <)7>.?:>3%
MKJ<D!:64?J7^_HGQ,9#>F%,>)O49AYQA)9V#%3G<<.+P?1<M]EVP[V(7J+MU
MCB[;2GW\N(]T_5Q\F\WO6;[B=YW%^!U[TGZ7'3+M:N=>FTT4WVH#->-]I85X
M5H+S1:>+HJ)]F34 _E5!W-F[E<?Y,[MJLH%UE-M)I1P-A.@,;+O>[73:];;3
MZ=0'0ZM;[_>MCMOJV\.>W9U/4+0&K7Y?.+UZNX?W=$9F?=CI6R 51R-A=TW1
ML]UB@N)'.>G]6^3J@3#8.N6!'-PD2JN2IV@\E(-;H:Q$3\(:G4-D TP5Q!=J
M\#.%5]O6;LX@PR+G$6#NAS,AVXC+'B>Z*>I<!6^QG0I.B0\3Y2WP<N?U_/I\
M^RY6;4XHT$HFBN[0^MF.7?LO@&GH_,C;K?JJG3QH;($+I@ZVL8?W3&=9/2/N
M>4:=&LF5H+SF]P\&LK&=C'0VF(.&>;I=][YE_O:E;7!T;P94##*7C?*(BFR4
M 16P>B3& !-^SO(.FJ5&G5D\X_K]I<P@"@)5+Y%]I<[LDQ!ZB, UX@/VZD84
M55UQ3*MIN*"-&Z2:+ZO%4,ZAK[2<K/:MIMU8V']<B5AWG4%21>?6GFOA3/-[
M5KC['0E.!''U"^),LP$4IY6=2UQVI?4R!=/39@Q/9 E+".\8Z,[Z+KLJ43?L
M\"X ?C3VIM6F.JNA^X/-C"]RR94F.]FEZE+%9W_)X*T63VCTJ=!P /Z\4NW@
M"W("+L&F74\)X3+U'BGUMKZKN0'?*;'@>UZ*[SS5\M@1#;<:&4%<R79NE29A
MZC47ETCS6R%V75.]LJ7Y87PL' .3*Y.K)M?V][P;QO>1J'@78+/=P-8?JF\.
MM7FO-HV2<?5!*$^!'K#-!%A= N3(Y.%%)ML<F3S\X -')K/(Y/_;<V"R\UUE
MB%5<&^@TM'<9U-V\!5>E58)<>%T[8^%BI_![1!">1QU=\W4ANXC14J<B>K&(
M$LUY?6&I)"&^]Y8.OHY/C\^QTQ]RONKJ$.U&I]5Z]?8.6*-DR.<_A)C"TOQ,
MPBKF38+VGGV_^)_7]AL-[@('E^\QF\U7<T^LBI"3N:C8HQTU2C=T]*#CJ)#:
MB19WEK,LBP[.,]PJB\5-X!CQ'$:R94AF'B22??CX^>+SY<>+WXWK;Q??WG]Z
M__G;]0K\.;'6EJM(+^L*&6(Y/?:"_E WL8U9F-Z,X?>6:=A)8B.GITF3.&@!
MRX-74NU&)]P=BVJ(VU4ST4NJ/"Y3ZNIE*PTW@Y?7@<3"5%V245\#Z$]=3_T;
MIK$XUQ5F&BA472WO>X&OA_=G=@36C0QII.FYOE]=!%>Y96(?=%X5E7NU1ZG=
MGZVXY\%;_OLLB>87I2P,.H4""Y/F"WZPG& 6UUVR9<!8N141#995F $?+QBR
M7K ;4T5JJ)DC$]YI&^,(LV?^)H5=."HT?LW]6MCD=34O&8V6@X9>[^(H&7)5
MG%--.G)KV2#C$?BLB7E4\,(FF%&N^])^E7UIU_%G;7^URF<%,#->?[V\^/*+
M\?&=8;7ZF40[LY6]EK@;PIZE]MDV\8G(^ZGR93U16G^.%;+6*\JUY.HP3I4W
M;!'.%ZKM]+(>S^?+SN!8".*9<%OBX=D'DM(N/>*YYV:KT8'G/QYOBPJ'>DCQ
MN<UY16B3B)T)N:'M8\K?]W@L1+)/@?:+7(AQC0N)62Y42RZTF>0V1G+YB/+O
M<@8=AM8I&S 28Q'$F!OHA_$]?M+M4V-AX@"HF%^R9:H*A\)2C=]AJ4RNU2+7
M#I/K-L@5["HA)N@%P%G'M!_\?4J!W^J0:S'K6C5A,=[_E7K)C.FT6G3:93K=
M!ITZ=CS^/O+#NPK)T$M8D_$!U\1$6"TB[#$1;HP(@S 1\?<DS(EQGQ3X&5>#
M94S+W"Q,AM4BP_Y]9 C_HMI5R2#5EKO_;"*JWN20^M*0NG60(75C24S=N+[\
MQ_MW?_S^GH/K_W/A^T:L$Z%T.[-\.F1<F*88"2.D!M,4-9<3OU7V<#&EV(MU
MWTQX2EZ/'6+//VHGF*<3+WO/-I*Q.%%F)56W#I*JW__?/S[^\I&38]3<5Y6#
M23T$<NK" /P$ECC#>++N H 1\)]+\U^HEKR4R5_J=(B#.VK%S#9.W#_\Q/VR
M[Y,3]P\R.XL3]U$B%/G;X8P!WSI<7MMOLAS]QG/LTNT/:>;\RBR_<F/IE,]+
MGFPTVX]/GS0??TN[TS#[C[^MWVCM9'F]7<'!;.[J3;TGO*71[#[IC![<T3W^
MX_Z3W<=1>(?T]?<7UHNEVL:BAU(RBF5.RDRUT/KG-%%3VC3?7,);EO"O?C5E
M\6,$;%'OV.P.S6FR[SU^3K&[UG92"N_!H1']UVQM&6L>)_2>F6+(-+@]&C3>
MY8,/&/8[PN6M$__Q@Q"(0Z)D9UV4?#PX*X2/V^4%'^<\=5?:4\<8?!@"K0K0
MVBZ*?D /\_84QKWO[Q] <-BH=>OA?N.163=/MYI6(+5VQ],J-\6C*^6E/0@5
MX=CL \8V!EZE@,>ZT*9!>.A&Y98UI#":[$=[8"I@*J@*%;P#&Y9QE'&TRCA:
M#@T<(Z]FXZ)"#31VVOIAFSU))I[K^F)]J'8/$:C;ZM%R[,!@Y&!X,+$P<C!R
M,'(P<C!R,')L 1C*]E,E%@NF.^/.CAL8Z+^I^4"S89Y,'T<)?_FSU3!W2<2'
M::L?##1T2XMQDDSC\[.SN[N[1BR<QDUX>W81.6/O5L1GPKVQHS/73NPSL]OK
M]JS.&2"5:0Y:IM4Q!V:GW[9Z9VZOW>VU.J[XV3(;XV2O?8,O)M@JV%4CWJA$
MV:41==X(0)\(V5%8IV&5IJANO$\&X_4I0N/)LF(]AWQ%B@/7:WE2_VWKO7[W
M!ZJ*8M=SLQ</"<$Z9U;_S&J: T8S1K/MH=G6--]*@(H1K%)0XVC? :FOQPX,
M1@Z&!Q/+LY%C/8FU*?A42,QO4@TZ?O P C$",0(Q C$"5<#FXF#B=H.)2T?Q
M<9CA(*&QG6"B5<E@XB\SW[Z+.6QX7!B\=VAPV)##ANQNY[ AH]G1H-G6=-Q*
M@(H1K%)0X[#A :FOQPX,1@Z&!Q,+^US9:<\(5 4(,0(Q C$",0)QV/# PX9M
MKD$\TJ#+1E'F*A^!&!L3VQ4X)56/U,KZ=1UI"62Q6L'>.ETFXRA,;\9;!NK>
M0\%%7^XV@=HX&H)F]K9W:+"W?-^J_S'"A[&*L8JQJAI08ZQBK.)X\4$H8QP"
M8^1@>#"QL+.]VFK0\8.'$8@1B!&($8@1J (V%\>+MQLOYC+3XPFH;"2VV&[W
M+//,[;9Z_;;EBI_MO<<6<:(@]J6]#">3,#"ND]#Y4>Q9R[6FQX7&>X?&P7M%
M-RHOKNOFV04[WAG%MEEP:K:XX)31;,MHMC5MMQ*@8@2K%-0X@'A .NRQ X.1
M@^'!Q,+>5W;?,P)5 4*,0(Q C$",0!Q //@ 8HMC#4<3>=$!1,^=V77QL_V]
MM>_8WSL1.Y$WQ:?,AP!W'_8S&?F.F12?S-"/VY')[G%VCS-650D^C%6,58Q5
MVXT5_Q_']"J DQRF8.1@>#"QL$.TVOK0\8.'$8@1B!&($8@1Z)AC>L]4*0\S
MAK?XL]UH<RAACZ9)!2L#+?AAF6;GS&WW^\V^B96!>V_EJBL#+Z:1YQM6TVH9
M7^$MHY3&4OYI1Y$=))N($[)MR;;EU@3S(;E%%V7%GJ=1'JA6P^BU)GJUSZS>
M&7)V1C)&LJTAV;;&)C!ZL>W*\4)64ZL #$8.A@<3"PLL]M8S E4!0HQ C$",
M0(Q '"\\@GAAA^.%'"\LQPNM;L?L],_<3K=I#0:5BA=^<9)P*"*.&.Y=6)\F
M,$[;V\X10T:OK:"7V9P/%F[MM:1H,@XS#G- \B31ZT AQ %)UH(K PQ&#H8'
M$PL++ X', )5 4*,0(Q C$",0(<<D'RXB4]U(FU;;$K:Y7#DT?2%W$ LLFWV
M>CVK>^;VF[WFH%JUB_],_1D&(MM;"D0R*C,TGB\>CM7ION=8Y&GV$:PRR#:*
M8[TST\1XY):Z*50"8(QC^\6Q/8<*3Q.[Y 9.#VI;CQ\>DOW*^BQ#@Z'!T#@(
M:!RVQE1A!#I=^#!*,4HQ2NT;9 P?-N8X,%G=P*0)FX4S:+59@3T>=?[Y,4ES
M8%I6I]\]<[NM7K]MN>*GV=Q[4/)W#WA0+(R+FTB("7QF#&>&';C&4"1W0@3&
MQW?O+_YU8?SBA;'CB< 1<<WX&#@-NNAS>&O#(<7P"?"Q@!9C^\;7L1U-8,$I
MG9^Z'L B7,..,01Z+::)F&!!ICFH&5;3['/@\[CH9>_0.&S%<J,"Z;K. 0/&
MKJV%H\ZL[AFP\ 'C&./8%E5J1B\VDX\DYEFUYB][QT5671D]&"!,+^P09_@P
M?!@^#!^&S\G"I^*-D#@Z>>C12>NU_88#E$>FA6\I0&G9^XY0OK^U_90>4C.^
M3/%?"CVN#%S:DS"X61FVK!F7-OP5&5<B%C; Q?@FG'$ &[J9&;\GKHQK_A$
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MEK,+UA(9O[:$7YTSL[6).2Q5!ACCV'YQ#)5B#ERRK7L\@<N3;,[+^BOW;F:
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ML%AG^#!\&#X,'X;/<<.'S2Z.'&X[<FAQY/ ([1(=.2ST-SW\N-]UDAKOP@A
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MIG=I0)1_PR"A_P\8)<!K6_ B</ D@&P'F4I8;0&92LA4CI2O 7L%>(! 8+Y
M@!=R!$.0#T (( 00 @@!A/KTO_R_.IVZ^E>;?XW,5%=5D-H7YYM96E?6;_=O
M\BT+%[0-^P?*9]9]/T;L139UWY'-2V?J=(DIILNSV0N;5_.I/C\.WUX3[Y'P
M @Z-;I.C^"@)G_Q]62WR['S5@?I>Y&;VQ;RH\OKAI9OJ1?[5O4B+[V$ @@3:
M9OI/[CA&A/J_>XG$7#3G1Z^_1]"&7EY<[@>H_1G&\W3M6;<=RF<AC86JA2X7
MQWJY*%Y<_L*+NOFX&?[:!]>9[^^QGG[3Y]6+)\_70+EI>M7#NH&,ZR/<[4#N
MB%9W/6HWS,K5D-63<=6BR_,O]"!\B_RL*I;M^#6/)Q@?X5]>M-=[,$[UO'+'
ME9OK4B]<&RW9B+1\S:L\S:?YXOQX=?4-(97FX>H(\U\VAZGM2#-.SV^YB]S_
M%BZ.B+S_;?*([:1YR:[D0/"NWI0\X"U'.'[0&/VT1[!V9E=K9]13_<SK(,8A
M)C*>"-$C%M%@)3!),.6$XCC96$3SF?2]@N;]/#R@7OSR-O?<Z\%+9_RGYGQ1
M?/'7?3C5Y9EO[[(>O"IZ^JO+_^Y;\BQZ61Q-HK<+ZW]>JDF^G)ZWZV@HAW4T
MXYHWO4L#<M"PC@;@M:-U-/QYT.& ,<#8%ODUP M6T8QD%<T^^<G 94$:( V0
MQEY(8[\ITX !=+CR 4@!I !2?8L,Y /.'!0/&'H"-(4$Z-@H_2H!NI&]5&G?
M^<L;2I0/(J7YRIFF/ "AD-8<XVSH71K[31T[-3D1<$C UEXHI\.5#T *(+5S
M2 U\\TFG1O!_('\Y1)H&T@!I@#1 &L"7!@*@PY4/0 H@!9#J6V0@'\A?0OYR
MT/E+BF$#Y_@H_>.KH%.,*8\%N]C R3\S)OK.@;[T=P4I1Y_*W/]\&0H.I.UC
MZT3FQ^5\/CU_8!;T0^9'HVS^OGQ&LY=91.I3FBF&].:X)DOOTMAO9@F[-@?
MEP!>=Q*@>$YHV+6) 6. L>V1:M@4#([R6'9M0BUGX*X #Q (S!<H&3LDP(!\
M $( (8 00&@0\CE4"$&B<G>)2MAH.3H^WDFB4C#!XXWCFC_'HO?CFB^V:;XK
MCB(2-FL^.G>YF9X,G]^:R[SY]&;*('\YQCG4NS0@^ _Y2X#7KDYOA@0F@&S;
M9!O*SD("<\M2&T$7( <+_'N T@!X@$!@OD#H&K(? *'AB @@!! "" &$( >[
MUSE8 SG8L?'Q#G*P!-,84[:9@^52#2L'2_O+P9[,RWP:R3K]2B#].J[IT[LT
M('4!Z5> UXZVC^*0?87T&& ,LJ]C@A>XSE T%[@L2 .D =+8#VELF3+Q_;1G
MP)( 48"HH<@'$ 6( D\.DJ!C2X):2(*.C<]WD@05L9)J,PE*2#*L)"CK,0FZ
M_+*L%I&"+.@8YT_OTH 4 F1! 5Z[VH0J( T*((,TZ-C@!<XSI$&!S((T0!H@
MC?V0QGY3I@$#Z'#E Y "2 &D^A89R.>QD#JTBD*0"=U])M1!)G1LE/X1F5"L
M!"8)I@QSPA2_R(1^)L-*@_+^TJ!_U><1H742E$$2=%Q3IW=I[#?/A"3H -@3
MP.M. I3M5E && .,00YT1/ "MQERH,!E01H@#9#&?DACORG3@ %TN/(!2 &D
M %)]BPSD \X<Y$"'G@/-( <Z-DJ_RH%>)# ISH:5PA3]I3!?.=.<*$KB.H_)
M(8TY*O3W+@V@BD 5 5)]BPSD Y "2 T,4@/?H=FI>_4_D*8<(CL#:8 T0!H@
M#>!+ P'0X<H'( 60 DCU+3*0#Z0I(4TY[#0E>:HA33DV2M]!T5J,F4K(1M%:
M]IDGN.]4YZ5$YB1Z/U\G--_F7D55[O:,YE^F^GOQ\2Q?G/YG_>HW_IG3J3.+
MI9Y&'\IB[@?P/'I:[P)]YA_GKPR)S;OF/O]CZ9])1)WWQ+!_<USSJ7=I[#?Y
MA/V; Z!4 *^[[M^D8?\F!HP!QK;'NV%[,/C2_?O2\B@677O30-Q &B -D 9(
MHT-I#'QUSQ!$!(P(( 00 @@!A(8LGT.%T$X3FH.E4IU&41IA;_YL\IGI,Z">
MHR'B'60R*2984;IQ_*;\'/.^,YF7-VV2>M/F8).;[\VB"/LZ*;LEOPD3 ]0$
M2&-O:$[7"=G_!-8,<.H(3NPYD2$!2P%3@*D."^9*P%.W>*I;E7L"/%L<)T<A
MC]@)PMK.UWG<YK&;+VH%M]="A<7-NUO<;&!Q\]BX?@?GT%",I>+QQCDT;%CQ
M 'HT[(# ?^C94I?G$2-U0(#"@N=QS;'>I;'WR[E@S?, F!8@[*XR%.VQ->!U
M \Q@Y?/($':0(H-Z4'T#$Z0!T@!I@#0.CC(-&$.'*Q] %: *4#4,J0&JP*6#
MQ.F $Z<4JD*-C]AO)7%*^DZ<]G/4S5^U%UBD(/LYQHG2NS3VGE5"]G, = D0
M!ME/@-F 8!:6(0/"P%6&[.<!<#B0!D@#I '2.#C*-& ,':Y\ %6 *D#5,*0&
MJ *7#K*?@\Y^II#]'!NQ[R#[R3 G3/&-["?M._MY4QFIGA*BYQ'!=3Z403IT
M5#.G=VGL/<V$=.@ ^!,@[*XRE&TZ%+;J <RV3+4!8> [[]!W]O_J=.KJ7VW^
M-3)3755!BE^<;V;I67C]=O\FW[)P0=NP?]3UI[X?(_8BF[KOR.:E,S5U]S-B
M>39[8?-J/M7GQ^';:^(]$E[ H=&MNXZ/DO#)WY?5(L_.5QVH[T6>SK^8%U5>
M/[QT4T_;O[H7:?$]#$"00-M,_\D=QXA0_W<O6N"B.3]Z_3T4!KU<Q,T/4/LS
MC.?I.BK2=BB?!9<*50M=+H[U<E&\N/R%%W7S<3/\=<Q$9[Z_QWKZ39]7+YX\
M7P/EINE6#^L&,JZ/<+<#N2,BW_6HW3 K5T-63\95BR[/O]"#\"WRLZI8MN/7
M/)Y@?(1_>=%>;X)_.Z_<<>7FVGNYKHUN;43)ON95GN;3?'%^O+KZAA!8\W!U
MA/DOF\/4=J09I^>WW$7N?PL71T3>_S9YQ';2O&17<O L8$=O2A[PEB,</VB,
M?MHC6*#3-U4":8 T0!H@C8-SX@>,H<.5#Z *4 6H&H;4 %409(0%.@->H,-@
M=<[(6'TGM0DHHS@956V"D[,O_N?]5N+\Q](_D<90FF",\Z1W:>P]HX2U. .@
M2H"P.R.,/(?CT !F4)I@C @[2)%!YK-O8((T0!H@#9#&P5&F 6/H<.4#J )4
M :J&(35 %;ATD/D<<.:30^9S9*R^@\PG#S\5VZQ+T/MYUNO4Y\?%TIX_(/7Y
MEWSJM+_L<J+SSEG0=\57=Y:Z,J+J<E&">TKD[CV.(-4ZJHG9NS3VGL)VG6K]
M3Z"S@+#M(8P^IW79 PXP YAM>0$C0 P<\RV*; 1=@'3Q4'@H2 .D =( :1P<
M[1LPA@Y7/H J0!6@:AA2 U2!5PKIX@&GB\53_0Q([&@H_59JV/>>*G[K=.5N
M3P2_^N_H[<</D?!MB3Z>%J4++YE$;]^^O,^>6-\NTB2"84OLN"9%[]+8>^X(
M6V('0(H 87>5(92G!YCM)D\+" .'&'*<A\#A0!H@#9 &2./@*-. ,72X\@%4
M :H 5<.0&J *7#K(<0XZQPFG=8^.V*\RG1M;6D7:=Z+RM[RL%M'%D=N+(MI!
M[G+C9&T.N<MQP;QW:0 G!$X(J!J&U !5@"I U?!0-621=>I-_0_D)H?(T4 :
M( V0!D@#^-)P,'2X\@%4 :H 5<.0&J!JS+X=Y";W/C<9 X,=#9_?3J%>T7=2
M\WV6Y<;]+)%Y<O(I^O3^]]]?_V]$&"+\GCG,=37><.>EK3N0QQS#W.A=&GO/
M'Z%6[@"($2#LKC*$6KD LQW5RA4 ,?"*81/F 9 XD 9( Z0!TC@XSC1@#!VN
M? !5@"I U3"D!J@"EPX2G0-.=":P W-DK/Z&'9A)[[G*^?KXT+>YUR4_REC>
MFI<,%_U'KF=?JF7T[V[VI5SFT8=379[Y1B]K^5?1R^)H$KU=6/]S,XWYRIGV
M4-$$]F..$?2]2P/H(=!#0-4PI :H E0!JH:'JB&+#/9CCI^C@31 &B -D ;P
MI>%@Z'#E Z@"5 &JAB$U0-68?3M(4^Y]FE)"FG)DK+Z379F"\SC>V)5)^DYT
MOO1W!1%'G\K<_WQ93*<Z;1];)S _+N?SZ?D#LY]__?C*_^$UW*Q^H'_!K\O*
M-[.JHK^<I?\^N5)^UDLQDDV^$]*=HYH\O4MC[VDF')TY /X$"+NK#,7S!'9M
M LJVOVN3 ,+ =89-FP= X4 :( V0!DCCX"C3@#%TN/(!5 &J %7#D!J@"EPZ
MR(8..!NJ@,&.AL\_(@]*B&*$BE"=EC >/[="$B65#:G0WC.A[^=N%G*0?[A%
M]%%/O5@>N./399DK<W__V[<O+V<X_T//EKH\CXB"39UCG!J]2V/OZ6.GED="
M;5H V%:IS7.B(,L),(,LYP@1=I B@RQGW\ $:8 T0!H@C8.C3 /&T.'*!U %
MJ )4#4-J@"IPZ2#+.=0LISHBL.5S9*3^:F5:U?]^S3>S*O?W1I]*'802O2S.
MYM-<SXR+/OA'F?/-E.+6T'ZTU\,*(!^4-( - AL$5 U#:H J0!6@:GBH&K+(
MH!+M^#D:2 .D =( :0!?&@Z&#E<^@"I %:!J&%(#5(W9MX.LY%YG)2G;ULKQ
M0R&P@Y+&E7PD9?WG(U\6LRKLD"RRZ(U_R-SY'_[/W]V7O/+ZQ-GHPS*=YB8Z
M,:98SA8A9_E;7I[!UL=Q0;-W:0![ _8&J!J&U !5@"I U?!0-621C2"+>$7:
M9[FU4W?(G P8*L #! +S!> !\ !X #P 'L,1",#C\. !2;>=)-TX)-U&I*I6
M2;<_S8MOKOQ<9)^UO[B<N?,^\VX?0F-"UNVD;4ST-)^9Z=(Z&Q6^2;X'>K$L
M73377URT**+%:5Y%)[/94D^CW]V\*!?ANM^*\BPB&/WG,TC(C0NVO4OC,4'N
M?3<!$4 '\B/#5#^'*Q] %: *LFZ0=1N[]00N ?  @<!\ 7@ //J#QR#HS1!$
M-&3Z-P3Y (0 0@ AR.<--IC+".3S1D2AKFRB8V0 F^B"?#(OH?"<D-1;G+KH
MY6GNLNCU=V>6B_RKB]YG_@I71O-E62WU;!&2>K\OIRXB3"/"G^IG]?&#S4?"
MMA_5C:J?]]$_J,P7X6#"U]_-J9Y]<=&)J7?N$<7X))Q1J&TQ#\<5;K[#WU<W
MBV&Z:MI'7:9ZYBKT_OO4G:^>0C&FD$4<UV3I71J0103H0+YG<.KG<.4#J )4
M0181LHACMY[ )0 >(!"8+P /@ ?$[WL7T9#IWQ#D Q "" &$((LXV& N(T<4
M2,-H*-3U+"(=<!;QMWRF9R;7TSW+(MY3E@])K4"><@S3L7=I0)X2H ,9I<&I
MG\.5#Z *4 5Y2LA3CMUZ I< >(! 8+X /  >D"'H741#IG]#D ] "" $$((\
MY6"#N8P>D?\'K&$T'.IJHI(.;;OC9I:0R.AO1Q^/7AZM\X6$"?S3I*+"\3VW
M)D(N!*;.\*4!246 #J1_!J=^#E<^@"I %205^THJ^G]U.G7UKS;_&IFIKJH@
MSB_.M[?T=+Q^L7^);V*XH&WA/U#NN?KW8\1>9%/W'=F\;(CSL6_[\FSVPN;5
M?*K/C\.WU^1\)+RD0WM;7QL?)>&3OR\K3^+/5VVO[T5N9E_,BRJO'UZZJ0Z5
M2UZDQ?<P$J'S;3/])W<<+$+]W[V,UT5S?O3ZNP\MH>K2X/H!:G^&\3Q=AS3:
M#N6SX%NA:J'+Q;%>+HH7E[_PHFX^;H:_#GCHS/?W6$^_Z?/JQ9/G:Z#<-._J
M8=U QO41[G8@=T2INAZU&S3::LCJR;AJT>7Y%WH0OD5^5A7+=OR:QQ.,C_ O
M+]KK/1BG>EZYX\K-M7>L71N:V@AQ?<VK/,VG^>+\>'7U#?&KYN'J"/-?-H>I
M[4@S3L]ON8O<_Q8NCHB\_VWRB.VD><FNY$#PKMZ4/. M1SA^T!C]M$>PS&68
M'/) I0'P (' ? %X #P@P0PQG"'(!R $$ ((P3*7P:8750*4830$:K7&Y72Q
MF%?'SY]_^_;MJ'+FZ$OQ]?E):4[SKZYZ[NP773ZW>J&?DSB)$RJ>!R I@4F"
M*0\_%7O>+I-12=^+9#[XZ\UYE!5E]+M_GI?W>5C)\KHL_5W%LIJ>1R??=!G.
M^WU9G,W=K*K?"%OG8?+LF30.>95+(['F9SB&^R>SMX-E-37# +@>\!J(3O%$
MGU/L_Z,<O"& V6[TY.;/;='X04APH+@[2)%M/>.Y3YXXD&:0!D@#I+$7TM@S
M]Q(0T[LT]IYZ#QA#ARL?0!6@"MPU2**.*'I-,#EZ\^XCL(U1<J].H?*FWK42
M_<^OO[^-WLRJA9X9%[TJS/+,?[_]K,=H!@4@VKLT]LRAA(DT#NB,F["!#P"H
M E0-23[[[5E"J>_Q64_@$@ /$ C,%X 'P -V'_4NHB'3OR'(!R $$ ((0?IN
ML,'<D+[[^/+?@3>,DD5M+7WW27\O9L79>?3ZN_^V"@6X/YI3=Z:C;_GB-'I]
MECH;MB6^S6=_I+JZ2/-5D.<#+.^/-"#/!]"!C,S@U,_AR@=0!:B"/!_D^<9N
M/8%+ #Q (#!? !X #XBP]RZB(=._(<@'( 00 @A!GF_0IG&OH]$$;ZF\V!A&
M%J0Q&IR_#&5>HP_ZBXO>!#VL33AV*WJE%SKZ+9^ZZ*E;)5?K5&LX\'@S,VO;
M1.LSP ?,EM[CPX<B()#&>-() P;0X<H'( 60 DCM*VON.V^[>6KR_"H>V@:3
MU7FQ'71]?3)N\_>1F"_:PQ_:*\LZOA''1W&<_/)P&UXW-=[>0;>7Y'6[<!YQ
M/O-C_*DMG//+^(OH0U&&4S2J<-3&XC2O(O?]-$_S172JO2.6.C>+BK-\L? >
MV'Q95DL]6T2+(OK=?5E.Z_,WHH_H/R?1FX4[BV),GJ;/GA+\+"K*R'CUHG/?
M3W/J['+JFZEG-M*+A3:G]>+8\)PN7JF?/17/CJ*/2W.ZOC&?945YUESMWS K
M%I'_RY6YGM;-^%8LIS::YG^XZ7ED]+)RD0F'BBSRV@$]U>59TSP7E>Y+7BW*
MT(H\\RU*I[GQ-]F\,M.B<O9G!Y#L=%2C^^.YE^A U_W^4_1F9KTQ6_C[_9WZ
MBPL0B\(%(:A0XW%U:$Q1GD?SJ?[IR3$P<#OH]_^+/ODY%G1%GH7Q"Q.VT1%^
M%NLJ>MWJ!D:/B)^.>A%I$T92SW+_QEI]G,QF2S^M?W=SK\LB?_]O?NI'X7"1
MU=2WSL/!1ED^W0PD?7S]LM8%[45^NJ?.*PY3E/-PFI&_-#WWLS]SI0NUN_*9
MOT+/SL-C?+>"PGSSZO7)_YY$O^9%9?)P4>75TLP<1?4I2,U+G%F67JGXQIX$
M'&8148Q-0M>TAZAU=A+ >>72U]_-J9Y]<1OW\,OW?#MU_I[2@]T&G>FUG0O/
MT=FB?;'U/5@K];5$)E%>EJZ:NR;0YK\//?KB9J[T(KSH?!@&/T6^+$-H+HR6
MU^2U6HVJH&8;$1S='[-$/M9Z1KG]\Q./SK//)/X<E/QG@O_X7"W/_)WG#P3U
MMR8#DQ93NQV4U[:*Q$=A(!ZC=;;>T';>?&S$^8 !_AD_VQ.U],Y_>6OOZS;G
M?A[.%L>('R5<_7+9O^)'@K%?.B/8CV/,W7+&'U!F$,NF6&S^-3)3757!]_KB
M4.LEA?;X!_JVA@O:IOZC%MOW8\1>9%/W'=F\# JZ\+YD,5V>S5YXLND9R_EQ
M^/::DWXDO)L>VM8FDO%1$C[Y^[+R-O5\U<[Z7N2MQXMY4>7UPTL7^/17YSVX
M[T$HH:-K9^[['3U]\@A_Z'&><M?#2!B^Y%;[ 6I_AO$\7>?KVP[E=1X*50M=
M+H[U<E&\N/R%%W7S<3/\=3:_-L_'>OI-GU<OGCQ? ^6FH$T]K!O(N#["W0[D
M6";?Q9 --\BS?<+Q[M7K_XD^O8\^_?OKZ+<W[T[>O7QS\C;Z^.GDT^N_OG[W
MZ6//[L;/\/$SI?)(Y5P'R*[,Y]I$U1/VLJH.G0F7(Z^ BV5[2?,F@O$1_F5U
MO1_\J9Y7[KAR<QT<B,OQK_J^)U<7_WS-*^_?3//%^?'J_AM6]C2O4_R7S1G>
M]K&9XL]ON8?<_Q;QLUMVNHCIWE'JBYFY35#78SJ(R#X(J!,!W1[%'D0&Y,&6
MY6YG+WN*,H2M8/=:2A"/;25!MS.Y*_'LVT0>MWP&:'MWY%ZLSKS_4UD'>HLL
M>$9S5\<;0DQX.5OXAF5YV>LI]JLH=!82$JOFA=Q57GDH.AM]J!-(T<FZQ=%O
MOLF;1\QO+6O<H.KIAY<G[W^-WKR*-B.1__:O^?=P][OEF2M]^T*4];?/VDJM
M)8L1810CGG".E%4ILFFL1:I2D>GL21T?]@+\/8S.R\]4,2F=2?SE@B,N,H)2
M(:GW?;/,Z9BX1-LGT4R?^>Y9EQ^?+&V^*,H@A3=VFTESRN1:S)<Z^V];+].S
MI?6I0.KV0D"=0NDWM'6T4J""XX+W?E(=D ]0P9]0P51/P[E:GZM3YQ9]TKY?
MFX9$'T-#JDTV-T:#-H(I#Q9_\Q4W[C8$B[^_\-Y/BP;R 8O_$XM?+?2B7MM9
M?2[FKK';U>>P(K!TIZ$X[U?W>5I459]DX..ZC2$.]'[=S'JUX<O-ID9O?5.!
M+0Q>70!;V'R% +8P+GCOIS4$^0!;N#M;*%W8!1 6\GBV,*N;&WZ?UPO\A\,6
M/BX*\\=I,?5/J_[Y3Y*2Y$7T^O^6^>(<:,+@]030A,U7Q$ 3Q@7O_32#(!^@
M"7>G"497IY^S:?%M0!&$E[Y-T6^A3< !!J\$@ -LOB(!#C N>.^GC0/Y  ?X
M"0>8%0M7?5X4%UR@3P+P+K0FE"3X+9_IF0EE2RXX ;" P:L!8 &;KY _TCDW
MEJO:XHR_&])@CSCL$>]\LG2^8QWVJ^^_(MC:?O5 13>ZW<[U;F?2O_S%%?Z=
M^E\FE2OS[!YRV&7!JY4.J7>U/&+[4+][^A^[M>B*G#>WO8LC*CJKS+(+W VV
MT)J\W/DAU33ZU-0S_+70I0TH>E4SB*)LUB5M)AY_5-OL!@ISLP!_U.@G-V\W
ML\+0)!,844%CQ)VT2*:$(,JPC(TT6BO5T7:S]_-\YDW1)_^@7Z>^YT\B5QD]
M]Q<MRJ6[(ZWY63>W!HW'Z)KZ5<?YPK?"W ,]K<"J4& OP.@FQ[0&4GV0P\Q_
M_M+?6Q;3J#[CX>+R1HWY]]VS'F]_TNYZ(OZW:TJ=Z@!%K[>#.%=5#<^#VFZW
M-43UMH8?SL;H:;CYR<OFWB?/0HW ,+6="0=GE!$CDXABRNN1\;^$RH,SV]8U
MG=9%#JM+N8;B\FK%2PLKH["P<A*NJFY8I>#J50KU7?Z*D$>)ZCQ*E!5EY'0H
MSIK5+UZ<ELY%YTY[19,W8/(OS0L;U;4-KS=^$@H33I>!:EYJ>1VRB9Z&NBE-
M/<-I6Z\Q&,-0K+&J+W^2K;&W$=QY=A3Y<=#3JK@^&*TX_R6TKP6SV03SQ0/+
M%9AO$_S$#V;E'^MGC2GSN@*MUS3!X\VKTZ:BXHX\B@?.^VO3&=4S_$M3(?.W
MTBO6;T7YQZYZ<:<V/Z68L&=17E7+IHIG.ZAU<>"ZZN7'N4=X48:!>U]^T;/\
M'WJC#+*+/GGWQWJOI[FKJD(]S*<OWW]\_^SH8-76FUE4+$NO(6I#,*GE=-/4
MNCP'4S]C(M^P*I#53.?E]#S,9S_SIA<EF=N2I-75AZX\QM6PM!/S7EJN6DX;
MU9:'?RZKM_!1EYHJ7.4%%LJ2!EU8EYJ]<"Z\&+PBR^>A%G9;<M5K+/^]FS<U
MJ^LW_&U6ZZ':JM;M/JDIDCZ*3H*RRF\8A958SG3>5FK]D8B=)T9-^5?0;G?4
M;D-2;M'-VLWKIDNJZ5J)@WM$&0Z*V/ZJJ[R9^BN*^X"RQJ-1\I\NT9^-4NIY
M5:L0+YZP;K:6E\===;,)F-3?K]114" /4#J-$@\/"FI:5Y6KJKHIK79>/W+F
MOZ@5_-V?W!#*1D/]==W)ELI6&[7$[^S-1'H^]X8B_-94_ZYK/JN3H^B]5]=K
MT=6E_H(PO6UTWX-=K%:Z?.U:M?)?M^9&(UOS[-F#Z>I:;P=C4G/?JB'$I?]_
M>\K!IND*@;'V*(0ZUK2NHMX&G58F:"/X]-Z_NPK3N0TY/+UDV9Y%32&:9\VQ
M$&4PU=Z#:&E#78G](LA5OZVU8*MS&59O#(;.O[2TM<NT;M??CCX>19FS=6'S
MZJ*T^E1_J];LP(^9;WQ=#+)<'U%1K@^:6-/!C=+LX8IU>?8-=KAZ9-VIAU1&
M'XT*^>^Z8KQ=FC#8%_"Z;: \IF?6XV,M[$:"T:?3HMK\MH5'<PC -U<?X5!+
MW5.R0+B: 6U>Y2%2I/7I(Y['5\6L'F&O099E_6Y/2I>+=0G]6WEL &56-@[#
MFD>%\5Y=<E&&WRY=/:/+TJLK_U]6^I8T"FQUR4-HUS==;9"Z6SG=0</M_07"
M6@#=.)AKC=_"I>'CA7%V639++1H+TW@->?5'=>NP_^@]=X+$+4T(P&X,A6V4
M7)@ =5/:TVTV+EYWQWWW IS51BUHH<BKUD70[GE@^E]S6Y]=X56:GT.K^(D^
M"RJZ467M,3;M,V_M5F/%6C'KQ@]9->"KGB[U8OWP&]V=9; VX7W>(,SJDSZ\
M&'U+\[/VR)9PBL7Y!M^H3[OXYCS:_;]77A&F2Y@'K5>I-SW$GS3^7C3AHH^-
M,JFM_*PQ[[5>RIMC0.[#:&J,K0-9?FS;0TTND/;-Z3]J1N.^>V-;M:YLD%7]
M^FL"MR[(M.$#C7>[2;=NY49K E /6MTL_W=HT0_&>@.X]3D@18WT#5C6@Q;>
M47GD!5L^\RYC5>GR?(4NDY=F>1;$Y[^H*4?JIKG[VBKV#7OA'QOPZV6SH<33
M-5O?\(+W2P'VX..\<AZ-320EX.1M?I8O+AC.0R+V@Y=RUV;F)#)7:/D]]$@5
M.'68)7XR-O.UH;DKB-_(4BXK[=+/$MVZ#W[,;@S2M!34"Z(N0-ZJQ1O-81WJ
M^MYV8+XLY][6W$C1;@A4W:CBCZ)'2:C1,%5K].:%Q_>*;5\UD4_S9T$1U?2N
M]05JCN1F=:M]C\NP!-,VE]>1L WY6N=OG$Y")Y8ARC-M4A9-9#*$+J>UCQ&B
M?WX8*FTNHH5AA54;D%QSC: Y+YA'*X 7OHVAD3\:W;HKEU]1^T"AY<W15Q>J
M,R#%A9#BG8;V$8.XBIO61,2X?-ZR!.^I>D\L7]2#<+FO=;-3%YY36_%B-KW1
M)]-+/[3E9IQ]([C02'>5CKXJS/"M%^C/)'HQ7[R4O.5KA.3YO9_SX< ^MV@6
MS(7G+V>K]M2B\)Y%,ZZ3P%3J$[DV!OM*@];P;L>^%I>I#Q1L,DD7MKPQPRLK
M>R,W@26!L"2PP]906!)X8$L"QT.Q?G7-2:QMKBZ?G8:C%Q?1](*N3N[!*<[T
M>7VP8VL-:J5>VX!+SGS5Y-4FP;;\W9FU=0JF;>5I-2;@LD_E;7*V# :Q30DV
M]KM:IG_?B%%>.'AM:ZNZ5:FW\F<A#N0-YO\MPT&-Z477F]!BU:82;=[VNXZW
MZT7K\GUIPU+!)'E>>"F@MB9/Q277++PX]-\W-O">[;M,G1WNUX/#]#)$>XV'
M4[U<+/JK7GC!'7QBR*RDTL12SFJI! R>+6?UX;LV.//%M\;A:;_6?A+4&82R
M:&*TGG?7T[I-I:_C,K>&[IJ(KV?$E]Y4E%<S!I>^;F=@\W2S7ONQYK?!BV@6
M$C7!OX8.5RWU6\?$FNA,Z2XX7?O@6Y,R-?7/9U^+Z=<V_EU':?.:?OO)/9VZ
MV9<Z&-0J"Z]1)JL#BCW9BOZ^M%]:S?3I=+-7K1ZZ<12\7UFXYB!;/0UB#Q3<
MJ["PAF4C4O(C*CJ)%OH/-ZN/F8V^G193UP:PFZR0?_0DQ.@VVM.ZIC?#HD;"
MI*7LM7L:K0[&NMJ:FQ\08CRSS9CB]<$I?#MS<^K-Q6HL]TBM;5^+G1A3AC4"
MO[O*Z=++*0SG*V\-I\6\]KM>![\N./Z_MTOJO$3K(% X,WM]UZ454H>L T_J
MZ(U':]HD8YI=FK06*_^18KB\3.<TA+1G31ZU/E7ZJ]>1Q=)/NV#6&TU26_/U
M\>7E:BB*2XO5GK[\_7WUK%$35Y/&NAW[<G/L[<;8N]78W[:8*FC<?Z+X"'N^
M-)W6SK&_KIEP.JI95C';U*'%/&B/*WT(3;RYA;>VK&ZZGC:,:I4DL)<CUM-P
M?;T4U95?<^,;T,:FP]HGKW.^E&W@NTDQ>KWBJJOK2.=^(-R%YEWSO*_-D#7K
M7YL1<.'7:J62+]I4?]B$G&[I3!NR\*U*EXM:/Y^[16T??*M#/JATEU8CK,9M
M%>VKB5S3YTO+@H^B-VT$RBS"\>>^16TZHEVF%H2Q"HBMA=0>-;Z6GN>T8:%#
M *#_=FVBBS+W,S($,%8IFLEFN.9;'O(R-H0*5OHY#%@;\_'-F)X?W;2L8A4"
M;:UC@,#7W'VKVQVPLY)V&_=;>GDV(Q02+I,KEJ>)*ETD\'V7JV(V<[6%#GFO
M$,:XZ'EMR.OX3.K\JS;04@>XFGZND'$571>77RP=J*K"S_(+$/A!7-:K'M<X
M]3BR(<RZ3G.UBV8N&O7MU,VNJ8851NIVKH!26\.0;?F65[4MSK/<U2NMV_%O
MX#FD4,0#=MJ,QU1\JN/P=5RU\57KA%C#X5;9J]H;\P]H/JT!>G-FN F.!&P6
M]]#KY89-]TJX(>4W4ZWZJU/O96VXEKK9*+-2$?GL1XV[(-P/MT-7V@M8'@J6
M3ZPM-[+6*\RL7)R;87$E4]W ;;T@H0ENS-J ?*W*5\^HO94VPW\'KZ6VR"%E
M=,/:B%76_,;5@NN(S(-FUR:7N/PD9W]"A"XW]E*"?1+69@09!$T?6&/;@7M/
MGG8Q2*4#L5DM!_'.V^9"AD WZO5#=3K?B]V/BRW,LF6L=8+?FZ.FB$F]+^FF
M+DVNV^G69E5-#NGKRL;F];IXW;+&YIN&<IA5-N\T+SV>=+DXO["\#7\J;_?L
MMK:1]<J4/.B-K >\>WQ(JOAY]?S&'17W>-DM>V^3C#A&G4"4&HYXDG&DE#'(
M\#CC#L<VB5E'>V_?^0\&(L\/7@#N6PCMG7H'W+TLPA*J*GK[]L-/CHKL"7>/
M'V>IB4I%S)"AUB"N,$,ZU@)ABYUPF;:&XX[&^6W1!"T',M8??1/^HPCI_9=>
MP-X6S7(]S%'N+97M4N_'E^<1D74,2/0LAY[+,QW*L*_VHP?*U2P]NM&1:_U!
M[P=X6D8Q26#M"JQ=Z;(U#-:N[+_BW%HYJPZGT=9+-=VQ>,[.:E[=\9S4?H76
MGJ'Z&(VT]39>/>!U=^.X-TMGGM:!'.]-Z9D->Y"^AP7'475:[RQM-C^M_FKV
M(3T[;)995S]=M>4R90IM#]\B3X2*96OFF@<3C(_P+R_:ZT,)'#VOW/%JA45;
MAGFCG//7?+7[^'AU]0VUFIN'"W848_7+ICUK.]$8M.>WW$>/6'S_N\@#;I%'
M<D>OVO\^_:"XM_+03K7YXTOI9Z)%K5;)ZO]U6/3[")/K%9:;Z7E3D>751V7+
MMNJ[;YC$-R@*^1@]T?Z]?BU6";WTO]L*0-]-FVRK>'47TNU?FKL_+\&C/7SS
MYR?QDR[DNF;\*Q<U6+U0]CU:F>E'X%KUCNL',XX[;E"\6'VT3?#_8) :K8=9
M;\/4GVH!"P$6 BS$#RP$!0O1MX4(2U+!,AR 2MDED$&E'+A*8:!2!D\VC1=4
M9K9--F\Y\&F/%-=V)\M)7>P ;,3^V8B]M@#[R6Q&K<!AON_W?/_AP86[E/1
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M # $LG K6= ZB4,A6V3C6"&N8HFTH1A)J6D6QY:DF>W"N?Q]K9FJ=V[1,4T
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M8",(,EAZQ\[)%$F%":)):I3DVBC3B3-XH9Y"'8EWQ<QT:O4E%F#Q]WB&@J$
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M2/*0GL0B19KQ%#E),1%,I>KZTJ2'%T_M*@\Y(91/\-!.!KF"R#$R$;!)8)/
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MM8B(6!LAE*+T6DWNA_CVF\?$O:ZU7&>+K[%0$\)[7WR]1QQE\/,<#!(8I+T
M*ABDK@U2K##AJ2%(\U#_S:8"R23)D+%9K)7B1*>=%#3<FD&*J3=)ZJ;";T.9
MXV,T1STDVK?I& _'OFW!\YWF.LVG^2(/%0AG%CSA R4>](@&K62+93IU0Z,>
M#XWC_5//'.0>0@46<BL+,5+%L;4I(BDVB$MAD!1$(!'*FVCI,H&OK?%[B%O\
M]D(5GLSL%IUD0KEG)0/+=%_!ZAAY"5@KL%9@K<!:;7='$U$9SK3V1H?0YA"
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M.HV\OIF9XLP%17AWUE'Y,?"__2P(2^,A!&&',OT?>HK>LV'H@0',>C!(8)#
M(.W8(*7"""YKKY=[@Q03B:30!!GC?R:8,R*S3N.PVS-(A/$)IPH,$A@D,$A#
M1"08)#!(/]_"X7 :2TE0HC#VW@XA2!&)48:%_T.*6":\TZCL]@Q23">B__V$
M0YG]G=JCCA?%PC$46SR&8G'JRBBO9]DHB@</GD5 B6LH<0V"&@WJ8#H#2D%0
MHT$=3&= Z1X=0 %5X/;$SWH38E.N6K2N5ET-KMCPO2;1S,%I%$-43["F=A#1
M7UA3V\&)%DY0K6.#-'46<2T<4BKAB"6))B+-K-;7THD/6=_RKI@5EP.XW98Z
M$'3"5>]5R@]M:2U8(K!$ %6P1)U40X]5EG%N4$*L01QG,=)2$R0R&J<,*RD%
M[F)AR[8M$243'H,E&M/T!DL$EFA/H J6J(,EECJQ<4()RGB<A%*D!*DDL\@Q
M;# W)$GB:]56'K*B9=N6B$TDA^IO.Y[=?51_.QSKUNGL?^<6T;2H8(<A\(E]
MUCC )P;#)WI;@TNH9R4B1I0ZC3C1&=(F88C%TA'GA-7NFN_\H"BN6VQO]2U-
M^(0G0%A@RPB8/#!Y8/+ Y/VX4KO0F F,,%72FR_&D-98(!=C[836L9+=A(NW
M:?((H1,5$S!Y8/+ Y(') Y,')N]'7AYWQF$L$<T2Z[T\3I!4UB*:TB0F,A-4
M=U+_;JLF3\A)+'HO0G.P%@_6$X]V/?'?9GY<IKY?-OJB\UD5/0W!;5<]B[P&
M\8W]PRUT.G51Y<RRS!<Y'%L"E @H$5"B+2;2J:%<IQ8I%@B+) PI@1F*J:!$
MQ]PZW$WQO+!KXF5QYAM^ZF95_M4U_.5"(_Y[,0UC]1>O%P.I>3_[N%:")V5>
M^:]>^3]G7SZX,B^L)T#OLT_Z>U<KP@0&OC,BU0!6#*S8GD 5K%@75LPYX4</
MI5IDB"M+D+(X0XQZ)SK1F!E[;3G8@RKN#=N*0>WZL2D'L&-@Q_8$JF#']B%
M+3(A)*_W[*0.<9-()..4(DM-S+U/IPA/.RD%V+NEO..*I@D1O9>WW2>3.>22
M@[ 2>WOJY-)<AC79XR=#](@&/62+9<A(#(T./50-_5//O.@>4@5FM%-FQ&TF
MB=0".<Y3Q*W$2 EGD,&:,><) Z>TBTCX#:1H:^0FX1-*![9<^\H,&#?! 7L(
M]G#0J 5["/;PEM7;@E,MDA2E1@2OGR7>MC&*F%:8JS1Q$E];RO:0F/H.[2'!
M:B+HP I_@#T$>PCV<"BH!7L(]O"6'+.C1F><(,-#Y%QIC+1.!!*)M3'31"O>
M2<F1'=K#&$\DX6 .]RC^#>>>]Q3_7E4BB>:N]+/\[,PKANI4EVX2I;K*35T;
MVN;3Y<)98#[ ?/9.00'S >9S,_.A"<.)4Q+IA&#OU;,$::<SA$F<*"FUDO;:
M\8$/B8R_UG43JP^N_!@TZZ]!KU[F//Y79S\N],)5[[.3,U=ZH+TJIE-=5O4M
M:T:$-QD1O2!$MW0QPT:G.J8HH:EOKK\5I91H)#$/R^,SP7DG-;:O=O%58S"Z
M[B0[8O$-M YX'H0]P/B#\0?C#\;_S@L&B4@5U0H920CB-$V1CC%')C.2XY2*
M5,LNT@"[,/X_CH;<$O91&,?$8$2I[Q 7+D.:^C\S(IVP*:'.7F,&7?1_.\S@
M)_F1(P6T 6@#T :@#4 ;@#8\AC8PF2KO"!O$)#/!!'*D8B:0U)(8Z92.S36S
M^9!LR5!I TVRV!(LD25US"0F2"96H,09GCB16I5<JWW71?_[H0V< FT8#FV
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M[8L61:07:''JD&_Z'_52JV;A530OBR^E/IO\<.55LS@K&N("K&&.+E -H!I
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M$8ME%MOD1L805)RSKY9!;S4G5C=K +U,ZZ^J1Z\ )#SL'9@H!2[G/D]8L!L
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M.6H(-_KI\@BI&%+$B&T3*0)A.  8CH<BCKZ&@H9@'9,:>(J%B$*VA5XLZ:9
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M:Q.Y88AY0W!1.&LY0%T*=>5!Z<J2.D6,]Y C22"$EF!5,F!M<B0:Q5EB^RB
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M@8#A67I-O-2!['M%ZV,2BE%32I!/#KH0%7L;#DO:W&RWGB"7AY3BY(-K&K=
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M:?5>MHIZ<KKBBDTU/?CJ3:0KU(>1P1"_R&"/Q6"ZI%@DR029DP3"F))ZQ<1
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M,,0(F8&&P$%(Z\''4)*?:%,FGG"J=KK&?(T&^R@,59(]9*BAJ[%85_H(:NP
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M[;!K/N'Z3H1!VEZH]WH6#H=J5'/EW*^]QB8;3@P?O(Y"W%=5^Q\^+!?K6Y^
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MO83C*NBF7?\DGQ(9W!>AV^C"]XKK?<A7,0G9M>_T+MQ?-@;I;64.++WW=F'
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M21QU9.VO:Q>(5[T+W31:YXKI]Y!J;M<4U'HSL^YUQJR;.X6P4W6S[\G3;H)
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MM<>C8:,KY-!6+=9BID>G8S^VC<V_C4#9?@!ED[K=4[<1I10+F ,!E56W>68
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M%W$#9E6] GJF'>O[A=SJY:MFH:JJ;V?\[HV9Z<]]:B"[P/]:UZO*W#4/\]>
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M,HJ3)GP)YW8$IS0!26+(!"2[QP$RAC/("#!8:$ $)(!#H@!GT B5:8U9^0Q
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MP5L=?N4)T5O-?+'L,62UFMB7T%;T_JEG=V'?YXN5^V$UN/^GQ=KNA*75TD4
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M$L>"!53 ! MC\>&DW)Y3^7#>+\SJ$U\^MOPNP?Q8L.L%>&Y(F6$E:0&@119
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M_.O?9G8!89JD&W[JIO\E[\YYG^B7KD D-?ZD:CR4HE"F% !!5 +"K!I/"V$
MPX4FI%16,=\:6E3DL$!84*"9A%82&P9XP03(2U8*;2C,J3Y)DCV9LE2C=1F'
M= 1',J%&8LB$&KM1(RN(R'($>)YG@'!FS?B,9$!04^9%!I7]9$L7E[K$F2$
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M$N,/?XZVB<U#6S$\9) /;<5PKKT\Q+"ZH6ZU(.]CVYR<24>R7\;5?\['L>T
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MYFX4"WIZ/GIZ!$%?*'[:CFX4MB1YBA$Q3""..:";*#&21&N<>%))Z?VE6_\
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MN ;(#92^H?QDL<1VT8T=^&!069\7'%XQNAZT(G\UG7RL6P[8)NK#*JN(;3H
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MY&E28&>]1\8'C$0"E>JL<LQT-CXME\!'7B%,P$!SY1(RB2L4L,<>G!FA4Z<
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MTBP&( -S@"X[75T(#WJ[XT&[GC'J0D(E11K!.7@"!V9]N#?_M,:61;F&0(
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M[&81;/U5)DQ;X#Z=S:;S13!18\Z,,J -A/R723+],H%UG1:S4!WOYL%S7%?
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MGR#7[M=M>6F>SN"VO$>>_Z6:11:]ELK"646YF,?1"/T1QSW]#H>J*-PP*';
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MQ337#-M>Q#@[>+/O&"?.CO)>U#GW128,(#6 U$"03P2;=D<=I?$F]<:B3#F
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M?#\%X7=^JY%DCV6^=%=F*I!RRZ#!!%W=K[:K'D=^GDR-6<[75/<;.Z.>T&3
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M[ZH!RKI4W(;Q"][OND"UDKE;+35O!UGQQJ,M9&ANN@%2L7"IWJ,=R[L(J"J
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M'GQIOP$[_#&$^ ^=<NZS]R^[XQA_XTNK26\]H!\%;77D63LL]+>/KP#W%V4
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MBMQ# LK@F[M'_GX_'8=^@0LU^.<&_US_Q<N ^X-;;B#61T"L@T =:+3O-/H
MAE1N"6-.8J2-3Q%S*D=290)1;FB64L'4MB%%;$Y9[N#,S!G$=$J1YLR@G&>2
M*IY+K\G#>>/2=/#&#7PY8,= HP.-/BQV\#RE5$J.; Z(P23#@ A&HU0:(S(I
MA*/I)G9D1N08VQPY;"1BAF=(: __%%B8//>98>RAL /3D9!L (^^..&&!+E]
M.>'^\>'MX'Y[C.ZW'J51/P:=X(;;.6@-':W!VE0(@2G"E%K$>$Z18#8+LRVT
M9UYPT!ZV>LIFBBO"4[!--5BI-B=(62V0PF!N<N&<$^ZAM 8.%N?%/6/[P=M[
M3<@?N+NOW#V@V$#G3X'.'\+V30D7QE$D\V#'JCA>@60H<ZG28.(*MYW%R+E5
MGM(,>6,98@+@3UJ7(J<!":D5GCV@[9N/\AP/,#:P]^&Q]P!C YT_!3I_"!@+
M &1HBJR/4VZU0T+J# DKE&:IP%YLP1AUCFC&*;(9F&",6XV$H@""6OE,8\FT
M># 8XR,B!A0[*"_OW:1:QE<,+84G]8/NTQ%9[V]L01L?UGUZNMG#^=%XA:O9
MO69MF,)\>P3 -3AL^&J/V+M,CDB0>O4\H+ZI-(=5 7+CG1VTFXYV0R2EN6)@
M<'.L$4LM:#?<YTB:#*QT8@C/M@+4UYE!\D1=S1OD^&CUFX'#!SM]@+6!Z/L&
M:\ZG&%N1H=2DH>11I4@))N MN:&,8)=RO EK4FJL."4($RY#P21%F@F',IWE
M5&:9I!X_6/$C'5%Q\3C?OG#Z@&L#BP^X-N#:0/0/A&M22RD]3Q%7GB)&N4""
M4(DX%CC/C$CI=BU*SABF0EKDE 6;+;.AJ-\2)*@DQ#J<69D_%*YEZ4C2'GJC
MGPJN=?W1\'>8"K9OP?6 @\*O,$K[B<TO;08)%\'C6_C"V3@A>#76=-?,QFNL
MYB$\6(PP201#A*4$Q!O62$B3(A"+S-A<>J^R;9&H!34$(Z9!RV=&221S01'(
M5F^X3;T,,;V.2'R[#(-RWOGW;A[EV\2X=QJ^:"2=<DTXKG[O2L8W;W]>$XVH
M=":(QQ#2*=WDN[^4Q=<+Q6(?J"69K5X]F:[>/5%E.35%'&\;ITU_8\+TVH#;
MSA17>(\S-"[*!7+C>&)\%WAHVRN[&ZR@1Y32[]<'MVYPZ,X!K7&"YXO(BR@\
ML7RN5>G"#,]MC:#="':44?Y]?]B8'>62,DI2B7-,&8>U=4*%?S@W@V6.V\VI
M9Y3&/;ID4[[[R[/BA^;C=*9;MH,BO]^X8U_DV/NY,[">@/J)FMCD_2E\T@0G
MOTTG4R!&>.YYTI[0CE\.9UK0;<;361Q\7KKYY\+ $I83T LB%<>>R*LYS?_U
M?P4AZ8OJUP__I<YF+UXE'^O+XD'\HMW SD39@<I[1N6'3^8M%;=4&\@YT&P<
M#PRB> R_3H -%M/DS:O7Q_\\1M,ODX#NSIQ.X U.SCN$WC88VB+VU9&!X ^8
MX >*WZ#X?WQXNT7KX;>!R@^7RC\?))'_!L0;!J(GT<6P4YN>SJ(*#83=T/BW
M"7RW[O(NWFD@ZH,AZB=$TU>2V^MD#9>$'X$*@@8_<2"P2S4_#W8VG-.Q"L"<
M_EPL"GB=8A*.Q.GVX?GAS-5]7T[/=#&ICGR*+]#J09V[5>?^6BU[X*7#X:7#
MU(*NP$SE<C8;GR=3O^(/NS2+*U-W=?QCO$M#T,DNBGYH3_'#[?*VV_RI>,7_
M$:@(U.N9 XJI)>K*[ M:=D=9+D?Q^"ZW\9=I..FL*%WY/'F&?TC@_.!>/PET
M&2[J"/K:\1+O;J9G9VX.)#V&%]O]Y$#,\.1ZD05<>SZ*QY^1'^*M9Y=9"D=)
MU]-M'; 3[$7T=*M%N#RLJ;/Z1,U=,IDN$I 'L'[8E<!H !SA2;4?N7FG\,_@
MK3WJE:MVGV0\L.S#1FZ \J<G$WB ;0H/6HL8&$V=39>3!9#T>#PUS8\K2&C,
MW9517<:C4>$:GP?F;0]]<< 6=1  [C/]7*MD\%,Q#<PTGRY/*CRRH'/ X?.&
M2RJS([$J>)B4^4.=N%$"VP5,6I3)B9NX>5R;!PY,"E@NO&H$L/IZ.P46=2'@
M7*'7;#J/_ZT/5^_2N'W/=KE]%P'OU@7!LH0GAH<5(:E@<IEOV*B9TL6X6)S'
M0VI<3A,W.8'7".]=@'(""N5BEY=Y.C]1\''J4$F#MR\_O&L]"Z.(TM5F=$4K
M"!6X.WR/X)0#*53,-E^@WN4Z9+=CC\.W_N7CWX^28V- @X*O&>1F_<UVQ'*Z
MA',)C7R!1?GEV!?CL;.#X!L$WT$)OHL]VJW&L7W@3J0B*#JSL>L*KEW*S@Y%
M9J5[=36@H^0?E5IRRQ!]&U=_NP0]K#!-UUN:2LFY1HH0B5C*%-(Y]LBG3"I!
M-#-^*]-(*2U3!2>9,'F*I<HAE1&&M!;2<TUXNM&#Z(,KSO1R7D:3^'W<LG?^
MY;1<E&\F9CF?AY%5FT%SNYQ;==X3@I1IRX9KF]BOT#WL5UF!:W27 *T! 3H%
MI!5RN"96S9/_70*"N?DHAN[GS6>Q%X2'3/A$ )S5-TKT>1>Z[IDPN1?:IX0C
MJW".F#$>24Q21 W'N:9>.T:WYMIHF0E,/6)9*A##UB-E@:Q][IQ),P-$^L@(
MDV>/C3#7E",X,Q#JFC'G6J$/-^D&>+:I%7 .Q"K<N.@$DB9N4=\AF7ZIS@O/
MJ'&C>30H:^OD7FM9C4(;M*.9*FQC--X/$U!.,2,R17FJ-&),4R0I=4#?3*1.
M6<JSK:8$UR[;NQ43[&3=S"A!@6LQ"6T1,"&P:FE@_=YK0YWDBMVZK]V=K]HI
MS:EP'F7,P%XK$P9I,8V<-LQSSU,KMTHDK[WJ5S4E1T7\D0F<;_V[EP*I7 (S
MV^Y7"7RO6FP,6F"T^JYL56Y8D6:Z'*_9DFNF9# 10[!B,5>3TKOY/#QOM_Y:
M7J2_-@<N,3'+2RW,6F.%-[KDJ4"%86VOG'$A1S(A*2$W-CDO><ZZV7G!.G>]
M_JX5TANO<.<3=IO$@Q7Z^*W0%>F!I7EACNP&#2UG(&) S9BI\^A?6L4W+TF<
M#9P*BDU+Q12/:DK^6(3G;1U85YE.X?()V,5 ]5%' D/3%9]# 4"4&W"H\64G
MXZ*24T$YVECY)>L[2GYR1BV#,_VZ^P,":KE8SMWN1BI=2_]J.U7 3DW&Y]W%
MPR=WY0*^:K/IC55_'MW](*$G@S-K$",/^8%_GN[(O@QN[PU;QYP6P @VLFE%
MIX#8?[JE7?$ A1E,DPSG0B$62BL8]RD"VUP@'*K/*#5.DRU#':<*3'N6@[9,
MX4)'0&4V!B/O,DZX$3:5ZW.3?FOX^GW%UA^B6'/V9>U%>_U9C9=U-<8%%6SY
M6@5;]JV&(T<7MQOI U4%23>.09(:7(+NISKR#Y3*X^7)LEQ$D$A"A@B8W9.
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M$?&!MH%,AE)PC'@4<$3C&#PYPGQ$PLB7(B(Q<Z.[B!A%,>:!1Q F081HPCQ
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MA<//>)I7M2F"YJ7AUDF9ZI%U]<OZSGK)=.'92O"J'CLG6;;8!B$KP'7(P V
MP5>5 H[2!=1F%K=-$-HN*T[;9N6V^'_^/Z_,F-BH 2TQCYDD#''FA@!OD43<
M]7PDO(!*CV(1>7(=&$CEE!^=-A= WZD^":+B9V>E.M-K_*W3:">Y_'BKSSY=
M3U0._/Y=<]I:QO5!6%2_@&2"EVU$M"Z,3.C^06F2"@[Z0[74<K30G!6E[F%P
MTT?D*JW/08QZHGS;::#([TACI27,P+*6U X0=,*7EFXM^J4ZAS?I?@E:4XU
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M^,F+@F$G\Y"WPT&1 6"&M6^&JRZM6;-3LR:6W%=>S)#/(H$HBV/$8Z*02X)
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MYO78.3'\N,#-? +L>@V4JQ7X('O K@%6?H"E1#@08/=)X:&("HZHAX-(),"
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MB-6A?\-V*!JA2]!P7L^)P:&4LG^X"LS/']2%!3PBN/I3^189F$?#-BH:O!M
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M5&ID[,^RXL\/\%/H"%-6V,X+98V1[<H&)1A$R;7PV8D$SHM4W<JN\R[=9_;
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M,%K:*#B>39<0?C=@<B3^5P2\*%[BE.8I3#7^_9N<'+UCQ"R(.FP&49$"J*=
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M$OMN&I0@T*HMP#J* L0)507:?1C2%&S6ARI([@BZ2CP'(CA)$A[L8#'MCY?
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MWV>R1X_,=&)C8D<N%0Y'7LB"@/H*=@NQUU) ,-.0L:_RI1D0Q4%"SAD5J\<
M'1M8UMSIG\K,E<P"8:ZB2O>P,<S#"6T>#=TD'C82Y?SBXT]_[.4TER3&\8SW
M&6X^6$:0&G8[]1ENQ@ HZ R++>E+I'#8XX]>(.;H/HK=W:]>X)ZSE^ S"R)T
MMF# [[Z."L4"=[?F ;L>F) 7#[U'P(9LD(_X'G; Z6!%S@.J=A=]V)UYZK'E
M+F)K&L@;%L14H'X6TQ52)NH>%\*-!AXXK*!^)QG'.1X'$S:WG0VA62JTKX1V
M!L\W2E\PCB&:#6!+)#AFEHF%\?NE0Q\/SE+X)1:K7QUTW44+?H<X>3J01R#$
M)W\,U5_#?0O.2!\(/!P405%A#BFFH4,2_MYH$R:-AD]P'&,J,F!M6:'1"G(_
M1J6"!Q A7,% 4$&F_-E;>L%ZL;KT,([?P\"R,.*QQ" &>F'YGWI90A."Q* X
MCB6TF&"B<SQ.,OEP@^::)*6O5W((1VD-;/QM)-,B(Y$6267205H;&ZMB#PS6
M/OXDJ8U1EHASE&;A%')&YY6J-/0DY9/4CF2&FDQ5^_!QV%0UTROBN9[#=YC6
MJ1)P^D9)(*DDW^9@)/!+!C]2E,,-C3!9_I:S9\^E[ND.S917P56 M>\0:WL)
M>TT$AEL!4,.\_)7/7D*RXFP#AY%B0YR$S^%+K)83,1"%P)H5NB^^%V9@+_B!
M) Q)RG%$(+:R_ *57- /!)OQZ#C"ZHJ;LO2" Q++UV[(DGR0!#KO@.3)9M7K
M9)9)5JD09IXFF;,PS(1_W[ (SMG?Z3)Z8!=?M]Y^B-69U+(R*%:6)-_[,()L
MT#T)Y0#0>^,R$K (JX1ZPVO8HT^3GYLA,S[?@"? &<K%Z -_<I].4SJ$X6/
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MJCE<4W&O.2'A=N,0WDAOB T!$D!#'N9$<6,Y-H?NS!F,_QVQ&KC1:D7B,=)
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M\#TLB;<.(QJ][&#C+=?D2QC 60BSV2U6GZ'EFB0@^.ZW!!_5D<,ZQ;AL)R+
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M.AN+@NT)-VA'9'H]YTN([CD9$\Y<W75+=+V-%6MF*.2:OQ:+LJJZQ6K?>_+
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M>NYXV4A$\ T100\^Z1O7$R$!AN^E11^;&&O(=&AN:<?6*DI[OA)E[[<L/G]
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M&TN4&-R(\&.1QQ[ZPKJEYK2W^W2[TK1&,/6* +!-TSA 6W]3Q0"34(ZE9X5
M\DPV\U54:F''I'F\+P\ EGK1KL7COU5'*U@T@WD>E>AD!W/L/?D3"5_B+'@
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M7'':F ]08]-1I7L34'B%P[ O46S>L^56HTY0Z[*N3;#<:MP)K@FE:,=P0[,
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M!C&UO'(^Z( 5,A\Z2KI9O>I/6DD90SD>:213"WV)L;O[,DFIM=$[F]^WS2&
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M B83:5$B^*\%02[3:P5RE+C]O.#&N&.+Z(M*O5],;FVL"($J%52+*81%5I<
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MP=@U94'%.9<N!.1DQZ,'S^O="H<NH66_@!!O\2;&(H@7G5\IB=%.!M],))+
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MC;D@/G3B_2#,L%GRDGG+%5FXW12?LZ_1.\(+^/<>#,]U/'S#-,UUJDN.L$0
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MXFEADP91.-^SR>M(!OL*I;].SH;%2+S#H%R?7CU0V$<R6D46NK=_%N=1J\U
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M-'KJ/YY3=E-SF_,4(!D\1&J#Q 9<^FA[SYF:KAN>6?G3UQLQ=$C-KXP.K9Q
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MDP;3%5J]?[5R:CZO<#=S^O/Q%,9G '(2*!ZM8&:VT]L;6P(97"HU7MW[9_(
MC+1=G5^TQI+BG)7ZPKD&[@\K.UWQ1UP]-%<N2;4GY&EPYK%I@%9'''FJ!YUR
M;#M$.-$;L27VTB^=6=A71KBQ6MDZW"V:!>HRBIGJNV06 *N^4_@T+,V.9[$/
M>@0AA;O!9F#+'MFP1T\F*@.:K6OW"O8X5K%1PFXZ=>W*M;V 4PQ3?J@.M;FY
M>*_2KK<^ 5PC(-J74Z3&?E';&U]"@2H^MX)K('0PIV5W*.,V]H^/D1^\!W[F
MA1M\&%:1_QPG^<%9PT\PSDYKB V-09H"@,5._+ARE 1H/?=1=@20%4FD[WO6
M0(AC?Z,$-%C,UP0_8(*7>@>2+0Q.$@")CF;)/<CA2ZTH!SH+F(?,T ,K$J^9
MA0->!BR-/$V'T].F5.,A, OS/1T>NRL0;9,]Z]>M6L]:58]:X3R%2XI8B:1%
M20B< KG/,/:S;;J&KP"^!UM:)5]BLU$K^98S2/)GV/(Y)-3*O?2VUH@:SHG]
M%SWY'NFSZ?DW=*[*A*J;\V?OCQA6><,)?O&MG'=UUXEY<OJ/K+IBG(>?Y$X
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M8?Z.0,(\(&HQ<>.D'-#(<)N]@;_4*''81]_(*1TH7,M7IJ6*:_.^Z^M66MC
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M#_KKW5T P18-GJS1M))@?T@WB,)OPNO7=_J.8G2!V#\3I"D :_B:O6VK?[V
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M+*43G5;QJ3SO3;\@Q/RZO?!2-1&1 $ E$"N<@;LP7P7XF4!:;A+N@DVXE$W
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M&<;/Q1,T;8;'$F9.C]"P&3S3VH9\OJW-U? M(D7-SX2,^'Z 5OJ3SI6V^34
M2\BOMQO59FQ-$ZI 2KS-+R580II$@[S-N%E$=A(U#G0@^N.T*)$;KV@SAJ:I
M4K1:A0X,?YH6'3+B-6Q&SS0%JJX_H@/K?TT<:U*M$QTX_CP1'(?47M%BAYZ*
MRU2^^(L6."=@UV?7H=&"V@0M:>,+1=]/Q1XTM'Z/%G"G8L/H53Q("Z)34<]%
MBQAI 7$RVF0H4UE)"Y1348M8A9ZT #<5'4>@$I46_*:BVZBJD:7%5SL5/6=
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M^1#WC[ _27.#T"3^7N].@FN.X:'^@GCMD>*&SGDNT5*<_^46/Y&(E9@+Y7R
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MH[3LZY%?Z-2^7MVI;1V+2&I>7VI(&S1!V5RS)74_WZ7WI2R<5:T1'IOW0I8
M"$EA79Z2]R.&S\.B%<S'X6$"\U#<9&.TJHS8F 02KF'B-!WQ/?.QZ2^VSDU@
M@1TKP&.R."_/+-5>&'3B1]B+06G%C,DZO3R7IJJZZB',,B$!2&<B86!$4QH$
MX@5].V.R;U]A>1ES[_5! 0@W+&0;'L^97+?9R-\FW^#A%-895S6"RFXU];FA
MV57R\MSY*/ T30!L%62=W)6M9;Q&]*O:?,JE8;7S$$*$;W_Z\>F1[WF<5L@T
MN]_0T<K=.5)WAM@/0(Q(1PW&@7JWD4FSI5U7&<R/UB%),\))'1G,&Y=?(<TN
M1R5D^&)R^AW2+#/I'X/Y8AB,-/$=ZL5@'K2/>>9PR0FZ03-V,GRPD?I/X)^:
MY@C^9ON#D)X\WG(L$F<@YW19M)3'C9 OGO0!JB$="?E:&M]6"D*TY!HU4!3<
M>#PFYN^WH'-T661M%%C06C@] :.RGD?-@/;5K819";X$62NZ/NFJSNNSP':U
M=_BM1DFW_=K/E9'*NF]X64;@]CQ-NI> ^Q-&QW"G1/^:J$N!E&OFN.4(W+<G
M[()W0O@O/,![$1_"&.P\5$MK G $[>=/DP.UO@9EHPWXDIIKD=FJTV52XVD]
M?E9.H;24GY4VK+);O" :D^?U!%YD#[3Q8'2G?GU$8R,0@4X,<PZ=L8TX&:>R
MY2G9Z$38C46'' <::'UX5R5$"S"=C^^RH.PHZACAS!XA6[NGZ?ZQQ*0S+=;^
M;](^;6>;Q8[$GE$HD&MGE/21:S7*Y3:9V:SHW%U&% H38F$M6 KPCB'H$'H6
MH\!Z-Y[\4Y099[01AK+&-!@=XNM&@1V5-2PZY/2J^W;T]0U#/T($^C(J9W,F
MU1Z<Q+'DJT0U*5N*4E/AG0C _HEP>R8Z_#7;8#^,-5+,@R1FON-0A&)(?RB+
MCOF3SZ"O;MG'9+]B<K919$2S)(Y F&,+>D6PR9SL' !;+3,_Q1U)M<1E.5):
M#(MD]2=;QTOQS X);" X V9RBKII$%33N5QOFGX=R3*(436QXC8&35(KB]R=
MRC(Z30+=UJP[!YS&)WBN%$?*@FWQ\'L(P?S2@B8O_@<@;[N5;(MUG-W5JH2.
MA\X/;2:N CLER*0I/.;PK0;:1G,,N%$.)W\DPI %::$N8*GU_'W[3<B.E7-T
M&9 AJ'RG'JQA5XN_V@4P_00W[X/IP#EW[I?-]FHZ(FS0SGT?B,-V:'ZP _9U
M"\:'K!@+1.LC+GV+_UD!:_3C7W^ [_S%.QPXG$+X*'T0AD);+^H9/F*!:L_\
M'?=3QC_Q@$6Q"/.2[]EFCD?P$IBF6Q" *K84]UQ&Z&U;8**@OTSV0K[G@!>(
MK>K-%GI[X/N9!M.3B//$?P$M 8Y&>7P H;6$YV^^BY)5%/,X0;K>29$<,M!4
MKJF_#^IVK:4:R$]DNNY"'JA><;^]B266 GLP$O8,_^W-Q@O4]"GDE>[I\]N;
MM7*NZLDQLZ^LS]44'NQ&%\TE7[/,1LS8Y(BDV>''\GO\*T+:U)L36,)#U++C
M?HYTD2Z2>+?PPGN)C;RCM9AZ 0<E*.3>$T-=+R>W'[!.HB_V'@\O/.?JWQT$
MMGJ:/T5LDP2/?,-N6;26_)#^DJ+6%:N\V/&BL7#[*DN]:V('Z*]+Y?< W?HF
M4#=#IC-_AI'J2R/.7EV;3::V]U%+W_L&9P8BDV6&Z;N?&6YB6-#I=51'?>5A
M?EBXH)1W2?;!UZ:YM'C5M05;/*Z%/-9/P:6X8?IJ&983/PSWS >C]2E0/Q=]
MMNH^%DWF?<FU,Y?L/D$C/+N(L'11EN;/"0-4!*H^::^\4 SWA+9L]9Q\!XS1
M+(K, U2:V]\%:H0J_2!ZSP*_KBDYH909P<.8;9F\LHKTS/A^E<A(/=:B#&F)
M,)2RQI91^7JW@:0H ]U:N6E:W7"H+.]^6V *:A^<7KA641AY@5+F<XD>E43Z
MW..%J'-%&P]'2O.JUC)N5)3>NEX2S!W#<=@&:+""\-VU-\ T$(FOXX1X_S>>
M1ENMS<U%P-?'AN;G@$!6VYL&7A3EUPC/I);&RJ"]5=7L&:D]8!6)!D^N3=?R
M12QW(HE R;CGFY@QS-KXR&&+P9]X%L=87 \HH(ZI"Q#A=0EG^0*OCLK9\1#Z
MR5H+<X"KVL.7_A62QO0'+TQ 3C7HF(7:YS$!ZU"A5'GEC$:2^.:,9],]J<RG
M:?+[UH[[2-19E&^%M!&JOF\T#0WZG?O)'I4D$VX]*3[#E\J8KZHTFMZ0)*%0
M8VS,8%MH*BI/KXWSZ*V$5)9\[O>K3F0' ,GY_*2NC6'^G2>#8VYEE^RQ],KJ
M*I6N6"1)/^ED'^<IG7=0*/(;EOK>74U@^_L!;FP__F5W1#4^62G-[U)$F=-M
M2YKWS;$ 2<7/!#/IG[POV!%YAKTBM#52<E^>>U2*UOVGPT8*Y:'4^_61K]$X
MSS8TMO'.=[P-*)G 7J\<G\G#S@MO9;)-^]Q4-WKK:Y*[^A9T(KGGH1JHTPUE
M TEQH3[<WOWCYW]6YZCZC.3$*!.FXMV<9%&R7#Q@+#B7.=;PX]EI-URLC['8
MLE +#FS=IF5'BTGH@$!RTK/<B'LA)^L=9Y_5^]EF<6!KON'KMM#0Y'! &R"X
M^XS8>;CY3*.163!.7D7'4-M78F1T4)1GW+P(U^2=<X]*A9T623Q\&^)>P82-
M3(1$DW387/9V [UZ&D>?F+'*'-2D68&2$1"]VZ.(&JCN^1L>5V**K:^)1A@^
MA0>/^Y-XN6,Z %P<]6(KO;U2SPK#VPJ8S&3V;\Z)#P J33@51MB@KRFIEB(]
M_O(HHS,>%8'5N\!36RNEJV:!Y4_)S'$O/7^ ]&'R/0M ^$0L7:E5I:\3A*2:
ME^>^E0^.M;I7!;<CQOK@F'SDH?)]Y!O8&8W>P6/RO3=]9;U@)&>UKAEEVF-V
M=-Y]SKI.M.5$=V&,1@)]X%ZXC9+W+-S*A(-N*/?>FL&7 4'15#S&?BV,9PU/
M<M9M?7VKNJ_/4-:8-Z5V<R,Z#4U4DS'EKWT489KJ4UTQ=K D5XM+)4RNDEIC
MC.=8+T)=Z!7>P%G&[KUUVL:E+2K6 4IRLJ<",84>Z!GTR# I\E^,[\A,8+_N
M7;OY<2*9I_[*?2L= /79 EGE73D=\UW@?1'JUU1;<U8[I%I?DUQX#R','[#Z
MENG_/X3FB^]*'AXG%#++M%?.V*G,E3BF$PKAT*8YX#PY2![,DQ50D9G_-G'J
M#C22.\ Z-PS.E ])R,Q4GR7[;, OD&1IF[%2CRX\A" EO& NV;KI,\P'Z3.!
MAHXZ'M&T%+%=(I0%X&B,P]S?IN-SI12 6M#*"$%F<OO5HR4+4Y.KU.FI)FF[
M0$B* )LPT)#:\/./2V5#6%:)#\D5RC2VA[#:/F?RV>/J&_%2X"A*=%_4$Q.3
MW'ZLHA6=6F9W#NW>?/C.UK$ 6MRUH4Y$DCL7SLV(^UH;F=[-JD2VO"1)2-VJ
MS",Y_0:H$92@*?H["$"\OG)3S9!-TV)5I@::&FNP0M7!D='KCC>B\_2,R0P4
M,Q@N&B7=;UF8A126$K3HBO,)B4P.A^#88N@,1B<I/YP+K$ZLSR+-C*J$5 47
MH<Y&-S0OL01^]9AC?QUR/=I_6D)<:Q+!J<..1V?-SA8PTHH(D['8PP:2Y-90
M#M_%GL>[_X#H8P9O</,E24+2U ^PG\TY(>475%9@KQM!:3B&E+3ZT3X7,<IB
M.+=$ZBS)%^8)(XR&34I2WWTY<+V,GF"ZL:7"?YE71->Z0,J$;O&1>GUM>;[P
MPEO.MNT]Q5K?D]R@Q3G2NO:"8W\NR<G#C&95/[%X!U\!@G<"1JN(CJ"5@J8%
M5C@LY1\GQAPQ-QR2Z^1N,9^G]6':]Y(F1N%H<R9U10[\-TN>RB6=,QXY]TU;
MK.5>)')(C*8=C^3,NS2$:^DL<M(0=::0Z37RS*._D(I/(#A4HYP.#MC!DB55
MW:[!_.A>BGWF:*U4>Z7I04LQB8W9W1_Q2899R0N_R-!D_"/]_>@0+F_!NV3K
M78A>'LPV6N[8IQ#.2QF!73_;/ 'D#FO7:X&<4T8@*7 ^@E4J8QX]A*KX([5R
MJYF9QC29 8@T&<#BWEV1TVP%.Y[]4#-NJ\X^\SGKA$)RPBO2+NTSFL>V,-:.
MZL)DCTE 10:? PH5Y;K?MU/)P^ZNMK4")3G=<.Z#:2157!GFPF@R=,.0)*NL
MY@^)\I:;CS^$]9:\EQB;G*F1A;=OO6,TVWP4L6ZW#K]Q+^0R:X 0;LTR+C\3
M3ARES!8J?10RFH .=9T-GG&K@&_5R%&=\C:H,F6G-V(]"V%%TX":IG+#^)]J
MDAHU*TXH)$5%J<,JUO%*CJ^]0-7TP@F18&['7H N]S>KRH$!B!17\U2H=%X5
MO2I'9Y1;0 FO1IBX./@'H)+1_RSBQ5G?D-QQV,H**U JND]_5 ',VC5&;O-6
M5L] VC-F &"]B6+X B%$^/:G'Y^4(5/QP9XP0%U(4"G+JD_GR<D67V6*Q0*L
M>C\),,Q9B9(_A* [WNAQ%CO&5 \LO/$G?9O?"]=R1\:YAR7KWM)K8 (/_::=
MT?*2Y+G:?Y]3K5N8-3Q)<A]9%#%679UW7V 7,^4"T9%^#)V&[*4(.;K@E*7
M2HB >5?7'18P()STS\P'?1W' (W@LVJ_&K"Y3&]&5HZ!^CIVQ2,YYX:>NGG.
MDS+UK-KPMJ.0)-KE4I9R!W]W/"KJ4O^I]W![]_:GMXW.>J5G)*?R'HQN\3(+
MN_*^NV%(DF5U=49+<&P8+EEM A1OW7MSZDEYO!<214R1Y%+.?[$";>3!7)M
M0Z_=1K>8;IB*XXU$:YC%?(Y?BOYRYN=-7]+K#FMW@E@"G]^H.H>+\38]Z6%J
M2E75Z@*,V>93Q":@'L6EVB@[Z/$<&W#BP3[+&LLM=QR.?T_&1XP<-Z?:%IJH
M 8W&_S;D?Z/3.]V/<Q'Q- %6Y6+XDQ(AL\TC_XL%?"?@,U2-IQ<@=N%^.]=X
M1!E6U'^&;,GWS*)0M!5P1!Z$#TSI&"QZ?)S6DI@,;T@J((V[7'NN>B5-S,3_
M,XEBY;%:BG*J/X>--_4.7/F\L^3VQIV#15;FB<.<-4!VL4Y-UFV:QM"CR= A
MLU81U0Y DJ!J]\>2"#6\&(\:43A'*YD8$9.Z?<1]@L&H+!VGS\$Z9 RR]D^M
M\K4P %KN8K:')TMR24W6&G&E:]'1H$V;P:BL?XO:CJ87-:<C\R9--J VH\&*
M&<]=_M<^3"IL<>U+5BY3-)6_V$(W/  D*F$&=B[Z&KH1914L,&6K]$Z219SX
MQS]XZ-^*%V.MDQL.S2G73;PSM</0W[OVBJ )].L/2%D$1^_>^_?_ %!+ P04
M    "  3@%):#6U!J2U1  #(X ( $    &ED>6$M97@Q,%\Q,BYH=&WM??MS
MVT:VYL]S_PIL=F=+JH(440_+EG)3)4MTHEW;<DG*9%*S4[>:0)/L! 0X>(CF
MU/WC]SRZ&PT0E&A'LD *KGLG$@4"W8W3I\_C.]_Y89Q/HA__P_MA+$4(__5^
MR%4>R1_[?]_I[>WV]G_XGG^'*[[7E_PP2,*YE^7S2/[G=U,1ABH>G;R>?CZ=
MB'2DXA-1Y,G_4)-IDN8BSD^_H[N&ZJ[VE9T\F9[L[1ZJ^/3?.RH.Y>>3G8/3
MB8IWQE*-QOE)#_XR33*5JR0^264D<G4G3P?)YYU,_1N?.4C24*8[\ D\Y(>I
MN?\PB7.\1)[T]J:Y'A4_[93^-A03%<U/;M5$9MY'.?.NDXF(S86#),^3R4EO
M'[Z;R\_YCHC4" : 8\+GX"W,HX(D2M*3_[E'_TYG8Y7+G6PJ GDR3>7.+!53
M?N*,9S1(HO"T-KS[1D1_^T.F,<XV3F))RS-383X^&:I\)X"_2UKB_N>Q&JC<
MT^\,O_CC#]]/X?]AX>D%//'R!# .F3[R^NP_VOI<7O3/?COSWEY>W9Q?]C^>
M]V]\[_+C^:ZS5-TB]3]\>G_UVX?^QUOO[*?K?A]_6K9 -"O<M7%^\FKWU:OC
MO]8%^Y'6[/<BR]5P_K6+]MAK=#M6F=>?3*-D/H%/O+-1*B7]M)6/I?>__^?G
M_;U><&J6[5N_9WK4B<IA[8(OF)6=Q9\9]V,O-:]E>+KMP9+3SI&AI^(\\08R
MGTD9>V97JR0+E(P#F<&NCH-=WQ/>!1P8,Y%*+TA2.(H$GB)K_8[.D\E4Q/-V
MOB$1A]Y-7G@720JW\+;6=(W[GV50H)G1QE7&1?:]/!E)D.+4FZE\[*$\:\'P
MO346[D\BS97,VKCLVYX<#F6 4N&)S$N&H%H".1G *^CYWO[>_N%:JY6^G=R%
MR%LI]]N[;1H5&$%K;A(]N1WYZ\_]Z_[939O>FO]<NW(UF6K34CE'BA?*3*5P
M'["Y1)858$VI/)/1$+4@7I?)]$Z!V86_V[/3&\S!7!L)D."1\RG<8RK3(1@(
MY== GX*U(,F<EM+<U3R]@+V4TB=@^TTR#TX]F0SI'.SVX!KN04<8',&:ILF=
M"AU9@L]<*0"SO2H"*C;?"1>.9KRR>J*UZ_#HY/:!%?IX]:OOW:+POKNZ[K?I
MW?G@>X(S&6<@>-J=U ('.DV.$KB!3WX0_.HE9**/DB2DC^Y$5(A!)*O?QSL&
M48'!4+H/;(BIEMP@N9.QB/.,OBZ,>Y[!+LGQ 6#Z#V24S'S]Q4"J:4[79L5P
MJ,@;GN/X8'V"L8=^,&X=T,PB^"-.9I$,1S+D;VO;FRY 18\/P^TT3")X0G92
MDUF,Y 81' ?_^1TL_60G4EF^(R,:'RT_:/GO5I+KO:I0:]$T2WXRC.1GL&IA
M=$TR7;XF?5]'R",Y?.Q0[6/)T2Q)PYU!*L4?)W](.84!1Z?N(NV=ABJ;1F)^
MHN)(Q7('5^%+!G+?*MH1[>\>_A46J&>5HQ.>YRMZ>WM_K0VEI2L*+HP-QY7Q
M7 Q[E\'OKY;9WL'NP<'!$PBMN?':J.9V".[A[FL4W"VQ_<222U,+9: CAR=D
MB^*]O"R)U!,)\D\RAJ,A:M.IM^MYMXXQEHWAO6N#W3'GBFG%2L-S"&X14NHN
M*ZTU;;VM8+0Y7G:WDS=Z)P\V<B=_TGEKV@H71=MBF["_^@]N0L=?._&VU+;>
M_.BGT9<<)XU#=6].LS\5R7AR0^%\K.00QSR1::!$Y%VAK2S3-KT:CNNC*X"N
MPD!%"H7']\*"_TO^0)&/DU3E<Z_("I@&Z5O8=/"H=$[^1U: U6_ $S[\.O@=
MWBRZUB'XW0&))C@#] II44I=KM>D'HQ9YQCW>?^J3:_8!K9/85O9?95*1,SH
M]Q/-;1BD?^4EJ?FQW&@801G%4E(X#.\#-R+7C<[;R11O0=ZH 'D:%A'?,8"_
MP$\D8_A0F&B&R6NZLL@QPC<%K1B0J*7R7P6,AAQ/^*V()!_MX.T6$2E3+8]P
MEF1)3 ZN%2]SZ;\*F>'7:^+$OG2L1;&>RRJG.2@R4-59!AKK+&^^1#_##2^Y
MFLI]*@SI>UA,A8YT,0!/7(E4Z5D)D/M(@=[+<'"T@=B+#P3(!.U"_ ."EVC,
M^OU8Y[^F$O48^#6Q27/)-I*\PQ7/QR)W1XQCY0=0S$OB2Y_ O7'A:##FP;#?
MRQ$YDRX7!%^RC#..4? PXB1'K0&"FJM H# ,)$8?\,V!888'51 D!8RKX7$Z
M,M<992_&* LVTRA+0>+5U)[[;3H3T"*KJ:^%;,G0G -&FRU1B G-+O.B) #%
M@Y@9[R8!D\&[$;'W+A6P"%F0^-XY; RX9ZP$J.?4OT<+8]@2QNGC(TD_D6($
M$0CD,DT.1P[HTXB@46YVR-';"9P7]6>>6F_1]\;)#'1EZK.N=&<^$6#FP"GG
MY;#@I(GQO_J\JN:<\E3<R0@<4P2D@K;G<Y G0 M$9]47'T>=)GP9FC#<2$W8
M_QQ$(,EWX$*T3@D&<IJ7.W":*M!Z,W!VX!H/]@]H!U#@QIH$XWB+4QSF5U0-
M(]!Q.1I0>)LQR"GN;P1NPD>X[S/4/&3S#>#'(D>S-0-;"%_ ]J(=&<J[))=-
M*FP =B>&L\!PS[0-#=>#!/]!.1U8"%29.#MRP_ *#/&-5)GF-!JE9B#[GN25
M"(N4C$O0>E.A,)44Z.23R3+!A04:<3 9Q$#BN:&2$"WFCTF.*P"R'=LDT\.*
M:RI&<D=CZ_&MPS>_JXB_ ]>GO6-M_A,0G&(2VTU!.]/ _;5Z8L1_#>;?N"5E
M'+8(___GL-N/O5-Z+L;_B6>^Y+AX8+*O']%=[KW:.WW^"7_1NWZ\Z?_W0CE'
MN6O'J1F<GI$^$NDTHT*<T^H?8$_QQ[S)\93=$4,0[!,1S<0\ZZIUEALXW[):
MYXOLR&]L,SYEKOBQ]:0#S2A/=3 1V-D!I\B[4PG**IV.8"'<:!>@!Y:?3U%O
MQ*C!T9ME^%45W\&1/R%?*)G%WK081"I GR(5F.'*X!FIC151((5\. SF"/ O
M4KS=3.F(C'%8*%QDO+R!FUA3'#)*IC7("5H4YBEL_]"SG,<CY -&*$,=9"1$
M'GMK8W"#<HK64> 8S,# $QCWIV^>XF YGEA^1SM\,LTH(K2X',X-""@C!0PG
M$!D80%D"CA;'QVB0BDHYLIS,L?)K7IC0HDS 9TT5Q:CHRB%<;(PED$=\%@>H
MZM_$YX)LJK"@+V.<CU=/C$8@!931*.](%J:QH68J0U/31.:D\;T%VE/-WBO'
MXW60LQJLISPGV?$5KQXM4Q'!:M@,BO F#"37;W60B#3$7]BB2E):(ONI".]4
M1A_"SS&_DB0=B5C]FX7#)EHI6T,13/?/(-X4!^0 (0A04H_R:UDIQTS(HCN*
M*3?:X>R$-WG*8(N[H>DE[^S!5U9_8U_T<@R %"9N*YQ\O>-E\[#)5H;UID7&
M''81D$3$GDU<8[#$2P6*#"YE/ 0-D#M@U:;H"5\#MS3";\/L("+O=%Q'W"4J
M-+,*DV*0^]:M&:.XT*K#ZVV,^8)&B M20:1(S'(EF:Q(@0LA YGX2O?OF;Q6
M/C;/VN2S^EJRS8Z@) N_"Y")7$6LN 2L#LI'XB4!Z&A\PUMB>S&M SHH":RJ
MK]YZ=2>61'1KH)4 !<>,]C7B8?=5]M@;:TEFN+ZS]);06RE[E+W4)L%X]&3)
MM\-/=@'"E2&4^YL!H;R5Z:1-FT?#SCB4M407R;(*NTD?Z>!=@&@/4FAQ \:%
M(=/ZPHK6OO^!]0P!VE:(?5,Q95RF19H5&(,$?6\\BB,SIW$*9O&Z0BG:)BAE
M<2R<2ADGNQKE()5#/G^-^Y2ZXN6\VGHID_.6'R7KHW4Q8M2-ZJW$2U?5Z:2J
M=_!YV<D )(KTR]HK^N/=WN'!_L&;XS?'^Z\/W[SY:Z.Z;U+P]RS5=S\>;(::
M/G>1':BZKC'0!E+_ ;,,:;LPAEV*=+,MH,W&XI_%,4(KW^)9?2,BD;8M4WK!
MB4$\GO!07DQ;ZM@-.%9X/'@93<* 1E(T?N"H^U]'>WL^C!W/0F\.;BJXI1F%
MJBH L06PQ5JS3;3[W5IX: 6W:U+9\'6..H828U,,PM0A8'KM\-XH40S?J<21
M$>"7<GC)6J\E:'@JYFE"@%",T04ZLCE-DP >D\IZ>AKD[P:C"8LK68XBE7=*
MSD!XC!'5O_*9PX1C6?#., C-DO36!#DORM#GY@"0:7:ME#$#B34K;:T+1,EC
ML-=6Y=,<? K:1HA7R,<";9"80K?=8?]"#OLO+=?Q5/B?WR61_"_X]8^>66'W
MPWWX<(V"T$;C)7'1+G-[$4 *.AB\PI'"3!^<!J4]4 :*R2+@&0UP1F0J$!Z\
M(?XA@K&2=])XR95H,9U3E"F2&>86538N-;]6'0B[7Z)C7"V$QP2%JGE$Q/?F
M@3B.)'HZ@I,7<WP\8G*\K<.]OVXO"1$U'$_K?(RT5?9*IB8/EGSNN>,LLU95
M85CQP*E)1LW&T<9L)M PI2R'(\LZ"6Z,(0.6TT*R8%^,N/@VFE?,KN6IMJ2H
M1 3S<9H4(S:K0FU<F\Q-5SGQ8L['S:R<> M[ SYIE=)9<N#%Q%=-.WZ*Q"98
M\$$P CY3+-<487'+."]/$$L:8NOZC%(QR>IE7<VE!\E01Y<-FQ'\B,==J6XJ
M6F5IJ;S)^=(XEB!X'4P3@D#P8UU8KS+*B<94/8%5H&95L'XC3PMB?$DL[,B=
M%HX7KE$Y)I+AJS8;PL!C7,@"SD\:&(%2>,%6L/L[.''[X<3[SX^N[>#$'9RX
M@Q.W 4[<F9GM-S,WLRSMK:F%ZG]&O[!UG"F+3$A@=DT&19JY1:=8ILM_,ZP(
MOA<F08&;C0RS(M])ACO3)/A#YJ8^%>U ]E!M09C4BX!IF")-V8->@(:OC-FK
MT6HNR0@L .[*0+T94#EI<GP-^*Z>,!#L?EO8[*+5W+G%+T9?R8W45W_3M9@M
M4U.ECJ!*DP6OV*TB754-V"_0=I]3#N^^K=V!7S=Y6VOPZ^%FH*KZ_RJ02^ML
MANATV#]>=RYMN@!O-G;I,@:_642>%NR?D ZA76?4Y2+?"@7$,)A)+9[JM266
MTXQ9J4TLU*"[34YRGA3I?3CME:.PC8?@_M[^@=O\ZQ++P_C9I#R\3Y'0- ^U
MQ]2)*S3<Y0MP%XN'.K%<8$8T]I*IH22;%FDPQG0G4HB-0=I2*@G#PD9,OR5%
M1C5YO6-"?1'WW"*ZIT(E-D$2L1R<E6KJ](8^NJ('.X@E9I:+,?"=!EQ5J9B3
M@A_ER7\57"5%KR]*,GJ5J:#P-E^,F3-]]4KCTLA^DW6C=2& T@I9/.PA< ^L
MW\WJ.9X05KWB>$,J*MT_^JMMB,'+R;M\;J3472M^?7@#,^ZA2C.D58IA?&F&
M.6I],S.A)64+O>\/7V,1'U^0)SFL:UR8>E(]$L6J()I_V9C@C,OA^78HL-C\
M**KKI=^(7[ <,_JNDF)_VE%>? #([)_;?;UENP_W'=WFWLHS78H]-&+#0[/D
M^KO=J?]"3OW-Y!Q^Q_R=;,:VZ[B_#YEDZ6HU_RBI[ZR^33,G0B;9K!$T4:^$
M*X>22[!J6!-/,WXV'[/=KG\INWXSH1GGR1TU1KW5U8>X5]JU^1= #' X,VS!
M6(%P<8HVA&:_M2>R)Q%+$0=--@L!'/!JK38J9WK)C>:H"L:<%419@C6:2>HR
MJBS<V]5)J]R\)-JUA:!E7P2+"/,:WA>57(1RR)H+V_IL>X,B)T"&%*%--4P$
M,K$4N;.0807A219<0T3/E*"^TBW4'&(",'"E,>]J)B@M0,-PGR!LWT7WVJ0P
M=73O:#.B>Z[DMDDQ>OI?9WYL]F[:[%#C6;[S*_KVI5_>ICU6R]GC>5FZ(DXG
MO!H;?R/E@\J:R"*X.D& +,,J4%;,'.3,2>$$C2(QH_' C2828:;T4)4;7JZA
M-FBP": :*C11+#^!!K>'7B!B*H<HN28JH !$9E8H"PQC-]=L&M(S0WXGPCNR
M$N#Q*I!E^T+B^$[A8Q?ZR7@& H>*(J.&!CD3FCG3:5C#WY.![5Y":4C3-,)A
M39OKC\@H \LFDG<2EA.9=+TL&,NPP*^YC0WX)AJ&FM'*SR2\F66-:9B[+I;1
M,L"";]S(8"SB$2PL+1;\W39E-/1?]56TJU<NM4%G$$E366ZS4-/HQ,/P]Q0$
M?JATII7L+QX,N[AC@:VV2*Q*BX[NZ,;*MXV0F4BM%D[+E %B4Z3+P"*.P%?,
MSB(VRZ()B3O@[R8 ?P^>'P?; 7\[X&\'_&T#\/<;>PSKQ"/<<%+"7_ 8K;6P
M1YL"SVHTZ$I;PK+Y4X0+@90I(CR13A7/4NKD5;/DB-D1#MMHOJ/;O?T;"W,;
MF[.A*?;0:6XMQLQ:>&"0#@N#4UWD#]%3<+%C7 PTUQW!2N,K%!/0 VB%<2R,
M"HB<:#O'RY@QP.D'NL#5U3('O7/-7X9KOIGYP(_DEJ"J<$)@;=I@321&Y$ Y
MH?$'O92:N\L.<*G*MAS5 W\P/NP0W'21C[?=$LG)I(A58'QJ0W7-SIVW)=:5
M-*#U8E!RT1",&(%+GP0R/&"R E-$G"7B%UGY"]*<(X%X8 C\I0F>!!4AH@,G
MTW#G&CLDF)@8:L%,C>\I)%:?^[HMI\SIMLR5#=]TVUS*7.@,RE $NOE/H-*@
MF&!V!OF3X(2 )0G=HF!BXE*ZD=N7"'E)B%Q.)4O,W-&^*)G6>04LSN="9Y[N
MSS?I0-D0)H5&36U3Y8E#&JXC&XUB174OVC99MB[,544Y/S7 :F.T*V ?,J@/
MOGR.T:6FG%AIELP$FTBPH7$_U<,JEG\?U0$(;Q 58;7<F20-3G#)X2;.]0GF
MHW:'2QCW&"9N<I JY4=62/X;EJ[2@^X;+MY/28*LD*3EOF8)RW$O7T2GU.DQ
ME[&SMEZ&M;69.(P&/=NF0U:WF9@6Z33)#."W"K%>4_NFY0MOP^ZL>C%5L@#N
M_2);8 &C7.:+,+K0?+9TRO6%*-?-+ R_0!V%=@TW4V_9%@?=^@L!O;YD&YL@
MW++H&^%9I78@*/.72ATG9*N+C,6AI6KE+E'<3RH;JVE6>C/4OF@LHW!1=YA<
M[Y 0L@+N%RF,$1JBUB4=II%!2&;YXJB9[TBR)6B*WFTM>"QAM PO2V%VF4J%
M1JYQ:K40YJMI^:8?O]=RAS9KD^;2:+-7FX$V.\=.Z; YR%MKKU72V0,;OJLV
M&W7V2>>@<(>=!0$RVWE7 Q .W>*.<-=X'KFH>#J3VPI3(P-"/)8)L05_:?HN
M2 G3^T5R)##SAWE(N!4EV6N\[-O-I(J:19A14.!P'.QAG2#:#C#VIH<V!B -
MOM[TQ2-OJ*SDT0R%%(BO(NBV3[@I*R8B2P#_:M2_\# TGTQ-YXIC)40_!YR1
M>9'X,W2$&$=A67J2F:R1[E>A6@>^#M 2*D\++<+\BY@:%S%/+<C0#IAUBW?#
M;]]M?VV_QCN,T 4BTAHT*T"/NRB3W;W#/>=?[_&[X+5AGXDZ-[&6"'X+S"AL
MZT\;9$&'V>_T.YPD!3:^3175,)-5WB!3)0LI)R!\ASY35PISVLMB""IDI+YE
M(N6*ES1%1 %KOP4!X_ P#RQSN9+GM'^6D+W<RT3ZQ:,B AH".^!:YJ:[;B4&
MKH><>:^P224M:K#-]3D&7E"!=Z*S$*1JX& &+ (2VVC:F5*B*([F2V[C+ 2U
M ;N3M89?+KRCHHF7JMV5JF$Z*&3[H9"'SX\,[*"0'12R@T*V 0K9N;;M=VTW
M$[5U T9)2O:9=7+)FVVJ&[XJ\HQQ)>>$,T6[YASNE":1]XEJA]ID?1-*U3?U
M(TU]Z]"72A7'SIHKI9,'9^QM$47- O1!A\'1! [9QC7 HA4L3M?8]*O)-[0\
M'^H8$LH("ZOG=0Y6*@@G($:JZY\B2=Q-0T8/94XI/#P!L12:S$<;L(;09IT:
M*!E-_;9-LJD199:_:EZMOD*4324,4>\*@:F:S,EOK'.7H6N6PC:]GA(B2$6&
M Q!9O)6TI%BX>U2:RKLD6.;IFCW<ZVV%V[[%Y+F\:MH?MA1S)T_4[[EB71SN
M[K]^U5D7;;$N]G=?'QT?]?;V]XX.WAP<O=E[1<:&>FICXTGVS2)A.1QVU2 E
MEF1P(,LR\ZT639T44:ZF!)X=S+V]W>,CTQ14WZ^!\\U1H@O]3-T@E8<1-=2T
MQ02\FF+B!2(;FX.ZRIN7RA$WIM$-3"F27"6)I(_P!ZW9'D%_/ YK5*<:-D(U
MK*=N<$HO-,^ )E,E)'&\%#Q.I$/,/Z2OBM%B7*00RC794)(2%$6G>GP'_1;K
M@'6IC>S.=-GAL)1,,%0DE;"2FO0Q0/] C$R>19")3+GWW$2MTU*#C=*DF(*9
M)Z*<VVMY6YIN"G3+>K>S_IC$.^>7Y][YU=OKLQ8Z?LT-K1M.F3N8.#)::4T+
M%UF>#7YQ :*(:N_=Z.7#-Z_WWIKDS25&EF,XL:XQQE_@*1B2)/?>O'[%B<X)
M]4E;:TL=)]7*%VVY6/ETYEQ/;J'^C2XT]J_#I%65,</WI*+"GZVS[0KKBM-H
MKUHTV^A_3R4=%-ER2!L]5R=S*:>U]7:[L;W+@\_0.JLBI#BS)@U$"+WM2A]3
MHCYQFRLLU\6GWRJ[^I7R:0I]?6^<S#"NU29A]37_SM#;ZFE  ;Z3*;SN0L2D
MHOATXE[$)BY$+65M 3,Q]W"],UJ66-NLDM3$>4"<5&I3B(;J$"28/[,RHL]?
MXA+"4G$XO4Q/C9)WVMS&ZKN]-V=:NFXQ%5G D7MMMUMIKN[BA2RGO=/>EMC>
M.@)%O+6_76T'Y.9JB]C@,MT=1\.M<@W=OP_N$7U.&V\=5 <1@/F0Y.76'I=9
M9\.U<Z>2B*O]:@$9.,VQ0HG:8IJ+(S51N<[<F_78/^Z],F_C4S& 6W@_\[AN
M9'J'R/FS(-?10M\P4G(PB.R$!G^) H[,DX,#LWH-S!$5&L>KY,>VW8LKJHL:
ME+HA/KZ]H=I&+DCX6*.>[G0U8-/)3^":<C0&):.ML>T.^;?A7LIFEUE]27I$
M>SANKF##TR/AXHRK$W;U6IO2(&YTI@OQ=AJR"_$^;8B7O(UBLCIV=HG7 RL[
MDGD%5-E%@3OHWYI!_XZ>'PG70?\ZZ%\'_6L#]*\SYC;"F%M/:^[QDG+Y3$9W
M75KN.;,S74K.3<E1!J[+"W5YH2XOU)Z\T$Z7$-JHA-!S)(,Z@WDS#.;UM)B9
M+12WE^WL5^D/BEM6ZP'>N6Y341^)AO)4!?@U_HOI*HKTZV:CZ\\<2PGD'VLO
M,"ZX,Q!8OJ];0OM,M%2E<K^_IIS4.]K7WK# ?:YG001,: A8M>:;KMK\"[<#
MHME3GQ:>B.V5JODUX6E@G9==P2LS@D='8IKIV"9VY#$AVI**]($.X>?<B9O;
M)]H5XG**KK?JIBN3S::=^YAX5^1DV*QSFPQ5S=EL&:%+4L^R.Q2;&D3W 4K*
M$!^HE"A=8(O.6<G9I+I)KC@W-19/>0V8:SYWT9I;'@B_;(OJD$%X:'CDPFW)
M;(PAV< 1 ?L>GEMKW]P!5EZ(#I&;JD.NF<V(V[ DW@>5(U&5//5N"G P[D34
M,JVRI!&,)66".4ST'-@19?<G&;K]84IG&,,>AL"^0KT_0*TB_Z"@)6D.AV0%
M>[:SXN$_P21BI%K_HF;2=8;C+^;:+>>O0&LI]K&,807ZSJ$<T[.G_@2=W?-2
M=-9P(W76!5;.*[-%R,-JF8JJ<)ES,&-M"<Q;M[Y-E.6DB6/+6%[BYXB.KT&+
M8MY*99F6(>JY(:.DI!P.4FZ3>I=$=TR?)@IP>&'#C.$YL )XX03$/O)R>-$J
MQ^X391^42,RL3_H+R"J<,S<Y=3<S771S?3RA;)PR7U_#,$6>8U15AM4!DSF[
MR-PF>)CTC(!./&>\8B0P*.=:N:>:\J_AP8I6&VXL(NP\"\>2@JGJ:&:Y:'R<
M<4>-D@QB(/.9E'$M^U C=M9WP(4H\@1.Q+# 5=7$@K51WC4.LHB=WG,8:4#>
M9I4%49+I%K*-,0$8]%"A-L8IJ9@B)3PI>'FI")$-#O,XV2D%?9N?/4J3+ -#
M(T-2NB+(N<U**-T#G"+U7\B:"2:!3AVA8<+A(Z>9+W]@">4F.%K7'2'+)*>X
M1]G?#H,@V"Y*4H"8PK\<'&Y.7JW@TG2PL?;#QEX]/XJJ@XUUL+$.-M8&V%CG
MK;7?6QN]!&^M7OG3)L]B<[M0M7K9ESIT-6?.R^=3_592 ;8M9Q/9Q2-X(-F8
M')O3/V<B(O-9?@[L"MC"#61YQXHUG86,J+>J>VMC65/J%>M 9%K/-.*O$^1=
MIQ:N0S4$'P;T+EJ"WM;1WE^WS?5W"?<@Y/SN<,$-VX9Q360ZXH:&L#BT)8UO
MIS$]-02,(!]PSFX*>7(,Q^)<+,_8UUY-G VY,3?E3M,:>,-)J&*_Q'QAFD1;
MB![FFFZ V_*UME'TMY$<7:92$R?>)W!J,I$A=D&*L!?!D&5/>LX$O3"AH'"*
M76#CRA<8T%.[WE\$\UA8WS1--"HGTZ2""J1H%G,7)Z)AOS\!7Y'[A\?N-^UB
M!E4%Z*Y7'KW2QLL3D!4,GPPHSZ?',TUF99]ZI.TT 7LS7O#14SBU%F9&VXG*
MTP)D4TPX5YG/?48L\_L+-$VFJ+X6MUB5]JNO<P)PWJ0V!*&3#737$LZW?&O"
M1*3=X2EUV\W*47#+BH;,!*O65(X2PH4(5_,YF0741# 2[)K55+>KAJQ_;1A!
M'YZHGA"#QU]@F79:"BZ(B8J=5= *<=D]P5ZCT>C*/$9Z8Q]@#+>8@CX4E'!%
MP=9J'K/0^.MLG#!,IAEQ6TI&@S@3?,5921-B4^Y*9LO60%%(:LHPOV0([U-Q
MWUQ:"OM@K?#OZ+9T#KCOCO&WV+(C56"N@X+BCL[C<B'ACF"4B=CTNRUE"8$V
M5,?(W7DY=%5+>9NP41DQVEY%OLS)L2!$]OR?@+4,1U&65*7.?+$\P@,M?=0A
MP;??=UAUX:(F>"G&"8Y/-;CT  1WZZBCG'@I_M7X)?I7+:SNV+0$V3K0=RSK
M\[M8QI6/P=EE'+=3%]!T]CM57;U]\PVV,.D87/A&IVE?B*9]<JQV&S3M(L%-
MFS;\IBG9=J_V,O7Z1:G?&@2UFO+%KFPN:A]-^I^2!+M.<WM%U,8.((RJ"F0M
M^QP6<BGYD0#+G_/G8J B\#T[;?U"M/7O+T!;.UNE37ICP[1T2U>Y63N+W%&G
M8T&8,&X8H+@[KX4]Z<JCK"1H,^_'F;#W*4TP(F@?ML4!73:(=5QBN\;ZE 1!
MD:;(F6?P4 M)#XIQ9&61:%,/3[+29REB?"@X@DUS=2=:=Q:(4_JBEK1;11S!
ME"K5Q0(3#/C'\GZZR,(M<1W)6*8<<4N6Q=%B'#6\2:&K,4POSVS;9#2PE#U*
M@OO.3YA[C""XR"..AUHS3!HO_X'+IF.,'N).:[@5B-#.3,S)&<+($YRW982Y
M\DM&+V6^,Z1NQL='VQY(J*0(.=-.U+KCKCI<-Z!H72_RI<IU<+(]C2]7Q4W/
M_3T9>-0EF6G,*#)(D#LEN<QP"E*CZ.#'R";5%S*VCJ]8LXK];S;@E8:G<8!E
M_!+?A@'".)7@E6OH;6U7:QRPCQ/67EK]L_C^K?I13+O"P6,9#3V]EQN$PXMA
M4BP+1!1@[AKI38Y5$J:LG\62+^X*"5Z*B?C'RS(1S5G>)B6B344GC;-)YF(;
M5WRIV8BD/E73D9MM@^4S=Y-FH()'.,6A8+N13H$.7+T)X.KCY\<:=^#J#ES=
M@:O; *[^QM;J.O'?- 1*[+&*E5-L?>$1JD,A&#AY6S]>P?U10XS,5(!P,84\
M-$*F)-NNQE3P<]?.*!^* 16XQZL]+X2-5[U'CM5_^.LBR21RT]@[5Y_%M%OF
M 3"1\_I$@B0!P2&@:=4XL)&EA3B)' Z3% - &/$7)F&+#B&Y<Q2/.-!S<.,'
MU4#3PFW!8I!JFMMAXQ+#+-:ZWQ@6_;4W];Y-7$I(M!#.#1> E92+;7P#%0 5
MO1;[]I?+L>&\(W"<_ R*ZI0\_ZV^*WTF#=0<^G)B4'5)-/O$R%@)(94<7J!K
MRZ7?]2ZK^$38(1KQUCQ^IZ6(<QN_<K4M>-01$!1_F.U8W-D]^/A,+)HM[M&U
MN\M"UX4B5B>&.\10Q/'N$T<BOL6*?O?C69;!BZ<-AWOUQJ")6^4 :PJG:O\.
M02,G *BF&J$PH\,UTLBF@I%X)JS3L&E#XW9/*<*@R. =9IG!7"\I3<#0O*V<
ML'1-VS3ZRABL%ADH5K'4FXG::L2H>72JPG!X5I_CM#KR33V[2DUNB.AH[$OT
M]2K!#PPJCF7$7XKDB**U\.(P24-&>D;,>0%6P>,W0W@=H*+ 2J#?\2D9,0_D
MJ1H4N<3K0WD'4\2?S$WY<^P<:I,P!,IE4H0&E=_,$\-P<3U\&;K%(ZFL$@?Z
M&JE.%LCR!R =H>G=Y% I,ZI=/\Y]1!(CFGI.0&YX!)E+.D(7B1F5LU18N2R1
M#Z?;GLMF66U#=4?4"SBB7F_&$?5!98&,(A'+I,@P/JLI]UIV0G4IJ,W>5"8%
M)38R!75M>''O)"%*8T196(NE;7OMB@K4G,J]OFU.AMS!_@(W'\7LD4QH&0@$
MG5TL*4(2'M0QTU3)'*$)EPXO#]HXE_$=$Q)YCNE<FG;K'+? ;O 1MK! ^ VN
M@4SS>>,TVR0.-HR7)R-)AB!%#DI.1)=FB0BO5^>'6NO&*FNTI6UH2GMZ#PS=
M\O4B+ZAL CC7G+XE34?NBS:94D4'2\8ASZULVP/W#R_@KZ"U_W#=H:[()<"6
MPUHVA)N7@FAF8GW+AQ;"R*OSI68NSX8_FCZ8J;P3JJN)>2GVRV C[1=L\7Z#
M7-NZ<0D%&PR.LTVJ3L-G; (%6XS!TLRE2)U428.R:FR*T,!!;%L^,1HCFKL4
M!O ;HG$S7BE2<M7"#TYH@62HL$#*1:<:WL><E,M@;L)B/GW+HF9]0OX6$8;2
MJ*^$;6UC:1HIH&3OD^D&,CJ"TL!MDAI(,K40&@Y5A,DEW0Q'.1-R!V+X2W@D
MJ]Z3FCU(H8^5*M6ROIO.])FN17K<S-9 ,\D66G<O>=BZ=*!JTP;RV[UD+>[5
M5;%(\% O$+M'Z'Q,T]$^LBA?M'OFC%O7&'I/A#"O7&72[(?,5;A;6LC'BM)H
M+E2?>ZG<]^UM#8NG%+N'D6PU!*N+</O4.YN![)R*-(JFNL&SSH)Y(19,L)$6
MS$]864KMQ]Z+69NTQSWYJQ&-&>L=B"@E+?!'I&Q.84@Y40!1;3YHG4#7,]4:
MQ>-Y*#]C%BIC/X6_4J95&K[#M$<Z5W=7);F^,>P^Y["OX+&Q$F7)TD@1A[9N
M#*DS@;H2)F*&)>.2T2\=1'83(+*OGQ\QVD%D.XAL!Y'M(+*MAL@2JF$VYACZ
M\N/4.K-TW>]%JK)0:<Y$/+J)/[+2CO'>1A3:-YDE110BB 6,>1,KK77N=6_3
M/(#. W@A'L!F]E'\&S:15_F\=<8_-:#1@_.H39DVZ35#B^UI9K 9U!9FL>%B
MW8.@.(,VQI&:V'E$\P-XRSN/64QXZ*;C8V[V.B'BV9A:QGIT1_9(Z*$=:./%
M*(S-;)IXC@T%P=>&.;<MQU&+&&A\)<-+-1\N=4I%1N1R$CXW!8)M[6[C$FY/
M/:"QE7P"1JNBGE"#(C=074U07,( HL@E<,4TB\F7$O6N'1Z,]P9VE,BI0B"4
MD6*2K\'<&XH@4TBJL3 6:2$G5!"#F51=#MV9(2]$JVQF6\,^]3QN)]A'FR/+
MX0X5#- *" J?B$:HRUQ8TDMC>U+%:;R!U.5XH&U,I+)T2)3;;J[>';Z>0!RZ
M57Q5CCTBS;/MIQF6H4Q#6 ,IT70XSMB-MV8HES"EFJ)63.5(I.&23++)MU:3
ME'IIS=2'14JWYJ4Q":0_O=JL11VMS 5HL$HRU[;9YR J,DIIHX-HEHX7FU^\
M, .*L= ,'AAG*O DIBHI2 Q_RA(\7LRYHY#VE0ED=+O<WXN0B/PK=0Y<3&#2
MTEPB,44^",F(G@1,U'1^+Z9&HX8>6(<-@ MY7F<]OY1S;C,;0IV!/(:T+TZ]
M7P6:?&M@1&L"KDD24B$ZJ*\)G5S<7L?4UI(6E5.-Z/$4Y>:8V:TL5M>5514V
M5SI@O+# ^K>RI6FU3*R&I(%QOKWW*; .(H4;&N/?12T1$JK^N&0XA.,IK3VG
M5E3FTW+,\+UIPD1*$.ISE34X=1DOX< 56 $C@JF8_YYX A\S!#NHW%(0^ "N
MU#5K[)O0./0#,0(B4\2.=R"?KT&LM'O-V@OR(5FE;9$Z43;-]D!;R/Q5MV\&
MDR&!$SFJFZ^^$W'3Q;'R7P7NB2&<_^ IDQ%C?N&:?YD&F+-'+0*F&3C2@N@Q
M]!^(61#N20DG7S,0< MIZH)DJS)+4T.31[L#,8:I?5HE-KCLWK7J3$UC'8D9
MHR,]F!I233^^37/P5#;-06?3?%UMY!M<M<UMPP*C1K\*7($D*MK&3X]&#2B*
MF/JBD[,!MXK8_X6%BI,)'L^HA?3@=?/XJ>Y6A<QUJ88%!5C.'E@*G05?9GG7
M=W*A]=VT\ZV]4G 3T0XDJEG8[DH[FW8$^'""_Q:YA@!S^IZ]P_H(2D)5@T"*
MP!K*33$9<0S($3:#<_O9(R1*0Z%LS)$6Y ZNQ#YD9KV,H\QUZARAP#\85@&1
M#E2NJ]:ICQ@LV@T8:N]2[+B5!:#BG;1N/DZ38C3V_L_9AQN]O&B]*&-!T=L:
MRWB'J%WP_G2E$^!PGY<6D<Q,-B9 WF)T;PM<Z;QRMG\14.81)7&<Y]/LY/OO
M9[/9[N]BDHDPW07[[7L:^$XYJQUG5M_;PZ%-.PJC-N[2KY!X<Z![["*$9<*-
M^]Q9["Z^]G<RI%#]F?.4,\J?73)#N3Y[#3WYL)K^0P/$?=P]M_27CM<"#)<A
M E=& :9R*)DJBTQV!^^'YD )!ZRN;**MDA-O2VP;<\(3(1@.^"SL08=3+ O'
MJCH,/]%:1+,B#;;!?\@*;(UAPG?N6X1S@Y:/R)I,%XV\,B"GD"W+N+X1M4 9
M*H3)D8J@IIGDV=5#:L0B%NK07WVJ_$?-MDQ1']SU[ $),$G@?<XS,X@.++D1
M8,DWSX\=[,"2'5BR TMN)%CR?I]UG<"20ZF[4\C/2)/@#:GP45$H8H7L#K?+
M#?Z(DUDDPY'4^2Q5]@U6$Q#Z3*$Y!@; A%K(DMLS@6&Q#16*"6RVS 50#K R
M OOUHITTK.0R,5!3#U(ZC5Y<\BUZ-E%@X9\FFDCM1CM;K\$ \LL<7%.FBH)0
M.C*$EX+'-4J51 >&><C*:::IG(J4&<MI/B&C2)6.7!&U(M[!6%J:N!*>#.8:
M+/69>9Z^,YDN/A?FXY+[!#R)J8T%%Y%)^0>,^O<BYD09Z!0EAZZW9@+%)H*+
MAB;98=I(U@'A<L5X.?CM>Y76U4CR1GY57D:9W#LY;Z!JMU=7.];\:>X+U1@W
M@>XPB0/8M7$F2T-7N,2N Y$IMLSQ&Y;7TW[)E@BFU-_ZOA5?[EB7Z6J^W<!E
MV\!Z&VUA\KS)P:XY&_#H<N9C;DP^KTD#6=>H22WU9GDW-)MU(E\@-IAK;Q%D
ME.8,%N)EPV2%%.&RKQMGV+'([YTXYR%TDI93V_ 5$9799#O@0:JK+S&X$"06
M:51/))><=KS#5.H49H-+C08T-S^!<5&R1UC:/! E.@CT0I04%H3QKM:!ZFBP
M=C&8(-7 +O&5@6L!^LT$0S+N8Z0P=\(ET'B8@'Z:#.@FC -%(%2*3^>_4IBD
MDD(JL^J[;7*FNXSVAD=_-[LQ;)\/E1:"MBX7 .(+D2F5<9"2,5<J(OB-;Y#G
M?@UW#KJ,K1*M5C@SA !."@3YVB2PS[.G,2+!YQI\"G<Y72'@5*EA!0VH-%7Y
M"F,L!S"&PR8F3!(:8!C#QG@,JLG&Y3BU1PR#V*FD_N' W@.(]UIS5L32TN=E
M7.Z+YL1)-(Q7\WIB3$TWZ'+'AI0GG+2;D#T&HP.+J["4[U_T3+90[%L")U)2
MB[@$.=HXM0^O"-'$33Q0SHW@*HU-H .60$^&8N"+1N0<N\9BIRB\]/1-]"UJ
M4=8.)?Q"SIK-;&O[*S@58WA_<&'+SII%JO": SC30V==12[;!(L04&W,G:-E
M@41N#FX^I2U\#J3['C;#C$@[H$&-?.2S<EU*XS\7GS5=R1C93#)3JN!V$<%6
M&. >IM4QKC*?%#. E%'TDBD<%7R>8%U%)B/CE?ZKD!E[]\+2$_&TV3RG1YO,
M@#L)G0K $ZM362]$96UFF\5?83_#GAE$A CZE"8Y1QHXD'>;BE!B\"&5K:NF
MJH<384-C+Y21V<C,JY92]"$7U/./<4X8.>(K*8A0T6<F2. T8F&-"+XZFJ5H
M<1J#Q@(4R/346M# IU(Y*C1\07.J5"J\=>X7GXD A9&, UWBF6.,84DZMVKL
MX@NBS#Q^/BDBAEQ6XY+[O7<V_POSX8[!&!OA5K9G :FVWIN#0WRZC3+MO;+?
M$NE Q#+;N?H<R;GYPO[>WKY?+7J?501I:@6I-NB,L]#I/>OE]-RM1+6H*Y(.
M?,XT+S&L5$E%;/%L93^+L;/0O,PP_^T&X[N^W+W7WB^[-[OGNQYFQ(Y/X8.#
M W^A#]!2H5L0+6[YW<!-R+48'NHY+O.K(V86_!-R"8-4(:XY8B[#0-TI_#%2
MSEGM',Z$5J2ESVE+9[2E:?&W/F_;_#QF[*.$HNHH8-6+#1O9!#_38!A=74*4
M:'4[ .Y)IH#["@C&K'@\])9LTMR@>,Q0=.$@CJ/<>_3"[_#0'C' 2,!+)H!%
M'3!DVE%LS;]R=H*3 AC5*VV6, D8S#U4D49=D&M=*.>B,H[G6[=XR#@!<W^-
MZ)0B.BUYYI1;"S7DGN7V[A2DE@C)Y2G6:J7XSV:9[E^5\B'HHNE%T<BSRHHT
M-DDW[XOEL@,X; + H;?W_ G_#N'0(1PZA,-&(APVAPX*#\RBZ:QTS5"=_*?T
M:MT86#C@X>RV1H5V5(SA6WE :3'PP1LFDD&D2\]OW]2[N<ED'A1MG:[?U4:'
M+72_JS>;T>_J$U7^]RT"O66QB');VYP^!U# 3TV1AYG=BR9S.L ]*G23XON:
M;^A>R]I1-#RRY"J5B)PE_03#@OS^LIC,@D?X;ES7!E>!,SFKU[^6G+"6&=]I
MYZ@A1I5%,.5H2Q>CR@1/:X,(\M4FXZ*R&F;$#@\#3QYJ:^/P9]$L2CK_D8C5
MOS7%OYTJ1V=.":=>WD@3= ^HDF-0HT*HCL("S! [KK!U6\-Z$I:<XAW#%!.7
M%']"9U3F=(PT]S#P2XDI6W,.3<KWH:=5T')Z!6MB0!X+1\T6RGIP,;\W!0[W
MLO[7RRB6$"MHMSC8;A* E>6],65A!47']RN2[E?;XK@=)$Q&01_O*P\B29TS
MNKD%@B.!3A"07V\1R&I.A.%$8%WCW= 8X8(KG>V85\T&^Y[=AD^:B<ZV\W*-
MEP3Y0?!%"TRI1$D\TM&M)5+KS+PS*%Z"00%.QD98%#_!G>$\^"12./^P.+3_
MF2JG;\7G=AD777YQL_?59O?0?"NS'#99V_A;SQX WM73.;6\CZEJ,-VSN?,F
M=R8OC0?#W\QI*PT"6V8*U1FSRFX/6VO::_&3:)VK9GLJZG>#*3F'=TW8MI93
M>RSH-VP[:J(8:!-P(@4%:YS*A/W7>S^5'#VA++,["+/G1)1":"".*. ZC*P8
M_.ZRX_$YE(O/MN8$['#S@,,W;]Y4'K#.S57;>>1:(:&J@)A=*"W,MD8'RT B
M\\JN)?/HG3%V:$L@8>J0( =H0\],"\\U?4W5Z;7Q596OA=O\;9UMZ_IW1);E
M54BQM"^SD64_3I9=OD6I#;@4EH,;= TD%PU5-G IU92 ?LM#D<P@JN^E62 (
M^ZP19WSS7/QA?6S$)-!?$&M6UJO4\^RH8CC1[H2/"%U']5O)1)K?3,#(&>$6
MDWQ,ID1!K!NBC4'$<-F<A[+EAS0D],Q8VFKYB?BL)L6D7!9"6FO8@?M\0WQA
MP@S)0,-R&'((6\;<P,0M&+%0SH]NL^WKEY7A@Q;\;B_C$W<*:\SX/UK8'=2G
M5._EFX'#:8N>KN58L2=X'>3!I"@1@RAP.DOD0R.>EXJ#QOQ75TK8K[MHQWJ8
M!&F?I ZL\-%A7V9-^2C4/4QZ5[L/-[>CO6&KZ^IW]36\W@R0XQ])$!2I"7S
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M;].G]5&ZJ[V!!WB !WB !WB !WB !WB !WB !WB !WB !WB !WB !WB !WB
M!WB !WB !WB !WB !WB !WB !WB !WB !WB !WB !WB !WB !WB !WB !WB
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M'+&,/WD'#_  #_  #_  #_  #_  #_  #_  #_  #_  #_  #_  #_  #_
M#_  #_  #_  #_  #_  #_  #_  #_  #_  #_  #_  #_  #_  #_  #_
M#_!8.P\<L7S#$<O(WK6V9 .KLG>=RXCZP)=Z6AU*CTQQ/?F\-C&;5T^P-*N^
MR?/C4:>?VS.^>E/6YVXDZ?'"9 (\/?Z#]>GWZ[)X]622K'1B3G^U1WN<7Y[5
M0?KJ2]<>!&(/:D2./ECYAN3HV]O(''W-"U>,;2;]Y @-FW8W6LZNORII<<YF
M PV3!'NK#\A*,G K,3(9RN+ '?)@D'H/^J(?TT6JPA5)2F-[ M8=\G0C#]\F
M."WDX4,>ON>CPXLCZHO)PU="'C[DX7LB/AOA"9Z<"/+P;4(8!WGX$!<%#_
M#_  #_  #_  #_  #_  #_  #_  #_  #_  #_  #_  #_  #_  #_  #_
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MB6=NB>;(?HDQ8Q>-$M9&H._8QUQ(9>PMY$)P!2W5UHC#EE'H$X:=#DY7T5'
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MBOY9/BDF:=11MSH7"B8,F"UX=S4+*=-M P.6 -[%V([63M9(L5IK6;5N(GA
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M$A.*V4ED!C:3<LKF'+-UTL1X=Z%[&S;NZ3)G<W\%TC613<9P81HV]GX]K4P
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M@N?;O7ZLA=JDR3C-=,9:E_1Y7=+1AK.F/NF"%=2DTP:*]KPDJ\G:,LH<.,0
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M<QMAW/>"GMCMQ77B+, ^6;":+."==(N=\B)?6MR&WC]W,,E"^)%M-VIL:[X
M!EX0X1:"MUYT%^8F*# T;D#B_/+YF%[S[B]'Y!"7J%<F5<>NIBB\KV%T%4C_
M@E07QH@L\L')\A-D.2 \HE/Q[6;F"XUHZO9^@TOL4Z/<2PPTY5VT_\ADHMMF
M%R/"CB!GZT40KYJ%Y./6L)YKM?#!+KXTY2SAGL$R1B1\,+=W7XZQJR0]9@UY
MPPBMK=QJZW73UN^IW=&OXG>)Z'*,%<Z;J:\WJ8&)CQ-T':M+N3 G\1W_J2+:
MM4IGN56OHW4\\ 38:TI-0@K,X#&*!A#K%/[&0K#E9K/EDK&CO*D'2+J.VJ!
M*8@Z]56Z*)R_8F-=D!X\^4",4)+$43;B=BPJ]#-\&K4]Z+<L'I%"Z8"PIR_
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MT*&5M&LG:6O#9^LDH]P*8N/E;$@P-ULBVPUIV(;X9I&-THL\J3YCEAA!6'_
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MD15/M#VAF.]A\WH2A:%4=O7ML'"+3_^.DOT_#-<+G_Y9S*<ZQE]*<:!^:!I
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M 0!\Y D $    &ED>6$M97@Q,%\R-RYH=&WLO7MSVTB6+_CW[*? [=F^5YJ
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M@7&<LE"*1A"93?I@[N>D$<<1OIXCG&[%$4Z!(RQBPPSHO@6+1G9K$*>.(VS
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M6<1!HD 62JXWI%>[LT%ZK8&2IAK9D>1;=4OZFBRZ,YFWK^JKV,N%_'99MPZ
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MG&X7%7DZ)-I 4$Y!*;YT4P='&S:B#;2:WB?Q97>IP]E@9%L^:0+JQ!SAB3&
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MXA S#?$5]6<M(?L&&ZD0\T4BN8(B@TNI;^"1V;+@Q3&MXU,:BPP^ZN8*56#
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M";/L-*[H45^---O!.IR?! 'F3"^#FZR4ZV*P>W(8=X)1,5G\+UC-/G*IAU=
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M", .$8#M$@_AO9H 8%1L)Z2S(P";$X!/L)B[??_'/7 :.K/R(YEMAH?;)5[
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M*"=*HDS@R,(&9*%6Z'I)'6H44-Y?6R:H]8>&IM6IDM8/.>%A=X2'[8K4P7M
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MQ/*>KAQ#0_Y,SS#K:9*-,7>H/;H)E4@WJ\>) IK:*KBE&W1><J"?F0+!"&9
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MGNYT*[7Z-(B)(K7"ZN(T@&.+LG(0SN+>(D0IDMRT5,'1_9''[EW!V$6?:,S
M>Y>5>#$Q@$>7ND:(81.1Q@%D<+,1,#LFI!,.JJ.,^]I)V>V$E@F!J4!;P-!
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M(3&WQ/^65WFVN+PB\4K9Q'?TYO%691Z#/P&NA(IS$']9?AFGR?\*MC^W5]C
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MQHE'-U^IBFELNRO5/1*?"#59LTE&^%?/E"JE<3EWE:6X<GW\^BYNTGB442H
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M%?/:[T!REYH+\BL=_FPR2;"U:C!1:,F[K0$GIEE<FBZX(9VF^ZB5\1,U D6
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M&)W<LBU#3),\1_YL$Q7O=$D9+@<LCP=37<?31:P#_J,XSRD8BA@K+&G@.2%
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M?&XI[R:3;8;2,*CF>ON79SA7_4&O_V'P3(JS_[Y=!PIDRMZ'W9T/_<$>_'>
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M,A_IGE4A%Q7 GJ:" -DRZTX>=QF0TG?65'F@0EHEO32&009,)\_EJ;$"XZY
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M1Q&.[XH '!C!A5>?@8K8^@<AR#WGU!\E.=8.[DA\/D<I,4W%E0R<X06K)O;
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M6."_\+I@*'R<O;Q9AL*YS$3*_91!!DZRL1@S%98Q$B)M2@3ENGK:/&7Y$-L
M]8#FI//J,%(T/A8YY^0P^S!2E6X7 S=/*;D2B9L<>Z0@\VLUT6K)':K26T9*
MFM09N RC.D550(4QNJLHZ%*= 2)SX8KQ(ES8(]%>,6V5_X*ATUAR#H_&PAP'
M-RKES%&A$-2 #4IR=%0,CN(V>P;T\0QK,G)=J':"4\- APC[Q"1T-"V!C5$)
M9J;H9D8L>!*;CRCPM$:C,MK"OM:]%>DJ+X^X?2=3IRG)D8$"[G'V4. "6E(D
MM-V\\CGD<Q091Q$"IUL0OR<6/T_AP0$";UE@)6$ZVO'*__)B+#+U+SZS@G &
MX?QL/&ED7JCL]SK(7)"YSR-SB9B*L30UW\@/OF1A!BD,4OC44JC*,1R[TKA?
M6#:D/<$@?4'Z/LNYBUTM2AN+9<>=."BB>L;.>"$E51YPO%5,,;V(W[.D1F-!
M?3%TT,*$+(+\!OG] O)KPEPNTFU0E[HRI>2 E7"2OK7>_3[4KJOC6H=9[T5S
M8BQM: NNZ?"[J#8G'RD :.ZW?<4BHS%A)$C;_'&O]W+_VQZ\C$YT?(S6T8 ,
M.["@A8(6>FHM9$+B3A&Y&+T5Q-+)_1])R$G0M_ZX[_[ *[G)NZH6VX&C/DCO
M9Y#>WX5*B0<.:YD](=U_$2VD*,K0TGT%AL@KYVTGOV)" #(/'Z7FL!ZV+EU,
MU9Q2M@3*86] 2K "7*2NHNZ>("'O6UVGMB+;A35B=#B;[ZF$K,+@!UM4"(0R
M2@TOZ%G&/+PK)<S@$":X*.<_=7)PCIW41H6HDW6R5T)U2JA.>93!?/M,P?WA
M5<.K;O2KANJ44)WR-1F?&M0578CX6E82++E!-DIKM."9K/DX+Y#^-SKS,OIE
MU(^K:.MB<'R&&'0$A6O\.QN.3',##\ET$3Q5.K=,VX 5_:@%>[=96-%+N!_Z
M$%>NTHG$ZH*H?BA.X7_U-H].P17Y152@$@-\M,TX5>K9Q!WKU8Y%.F"]%-BT
M3.Q=+-L^CS>1/!D?T\-C>@#/B?;9#*X="4CR3&'$ECBHJ(7 5*2I+#4#B"ER
MTS>8R0)QK&54Y'#OS!),E75Q(U6:(M4&/.]-D5\;)H5$BM0 _0M)[;4I+ M^
M([.VX@WM P@[OR N$2)O\+Q8ZC^9SY!8:L+*2J-2;X?;^OC6\1AY[F VTX6F
MBT7F<YA6>GMZ\UN@JT';?930_[19VL[OPQ"P\/><J*60ERBEA5%'MCJ6BE4J
MV(<"+JB\)A$/)%ZR=3R:(OH69B?-JY?JUA/4D,13FHWNL&X\S082HT)A5PM7
M.!,)PT$*'W:PQ^@Z'%WW8YIL?M)+>MU=W%NY$J$V1]*1#YAWS\![TE3(I*OW
MIWE0G-=%*5WA%=\ [W7DO9_I!DSJN%F3IT^-/+^.1'(#KX/@JGS4:\ZW_V33
M9Z11FA V7-MZ<,R+>)["B5N;]BN=^] [O.@8+-O7X%TFBQDN:$6M86#=:)5*
M.*HE5J7TR.90&35D2=C*&*5>'R+8W9C9\CC(P)QP_8":'&F4TS*\5YS:VMQ5
M_M(EWOIX>H!9LE[S]R3ST\^,HD79^QLZOX8FBU5?R56:MA>1Z5>CR5UA7IL7
MS159A3$RF\+)4 C46,CRB\5+YUC'9- +'=2M5LN:QW&%DAFA:=E<-I_9JES2
M)JR^J.=5E_:X9Y@MG_4 @YB?F6/C,?CWS):MW0/&Y=VC^6".$BB?GFQ%X6E'
M59B?U%K*>RN7/K.)<SQ 3-81?X"921C/6VFZ)'6WW.VU5L]X+UX.'IX-1]:T
ML1"\_);;35-VZ)D590=J:(-/IR^MM[@@.JBM^ZJM"K8Q%DZR'<KJJ_D+Q%LQ
M46BNM1 U[6,]I-MD,8,"/)&,<HP,@B%>2%93I#QT!S2O$9NA,T0:SEC4I586
M9B"YZSE_F_[B_7U#/)S:'O!U9$O+P.-^SQ45Q.K]1Z%''(9^KM%T)J]-GWJ$
MGJR\V :5 DW<)27)F>T'Z<5;'M76D_!<;[C$SXYZQ:-U["R<=::UJX/%7+S!
M"?10$R6RA(N'N(!#,/%#4.*CMMO/FQ64.#?X"D:K7N#CDS)Z!V)%GJP5'_Q$
M1I>(WB#G=6//J*>)9.M<QM[!UG![:W_;;.N]UP<O*1^B Y2ECB@0@5>3B]7^
M=(IU08)#K=B24&6:%G@(7F^I&P;P,K$OC$$%57(K 7LQ*N$$'HI!AW)15LB4
M,W+WTN1=C"(B"Z1LA7/+>C9CI)]D0P>1.S45<.J7X8X3R,F2Y#.Z%?;STU:P
M >Y$6WO;''EE2#2YXR,2KP5=HE^%C@<:T]+,D#IJ/A1?E:>9(Q_<QU/'/O@9
MIFLN/-I$<D'QXY-E#Z,*8+(S'Q'A*(EU5U9KU<\I (H"H.A1!O/JF>(QPJN&
M5]WH5PV H@ H^IK,Y-*X#Z9E@3;Y,&'6 0JB7]2)JKC).<7(7&NSDV.;>@!C
MDUNSE3:'L-2JC!(-]&!LKY'7!6>.EC)G77DH&DP<8]JAV53$ZYFR9)QSXDE;
MH;&CFYRBQ'F("MU!QO"!-KN<8/[/VJJFT7LKPV5[;Q'NP/;.6NG ?T9!HZ\)
MC(+#/:RQ8 A3N$=?K)[BMV[__%,&^F6P4U?]JY-?3DZOHK-WT?G%V?')VU\O
M3B[A/T]^@T\'IS]%@]/+P=N3B^CJHO\6_@X>^^J<)RB06"8U.NB$_2$Z6-A-
M C92.3%I9TK8#*5ULC4*4C+/')+G-<IMF.T#$4#5$KXQBDYN)'(AF=2+T3\N
M<=_*VV.LT<*<X,X\>,T*[L8?PG8?%R7?M+"=W#G&I*,)?6.3L2O"U:$0XE^N
M/=?;QM%V+ L*$)TT\"''#A\2]$1#3^1L72#:J"P5)P,9"$D[FUDQ18),NKC1
MF]5QM]'M<^R.ZLDYS 5GCEM0-670BZP67::1YOGG% G'\E/9PD1TH98^NB/S
M;=;R(R+.N2&HZWMPCSYQ6R[_BU.#R2JJ5A2<'?:23AHWJDKCN91^?S7**'$6
MW4QFXRM0P&4-NI?2P_(#V >*H4S\+89 X8[;YA#H#$WV#$[%(:>(#=Z!L[#$
M&C%4V:,MU)<Q3V(X-6N8Q<%:RUNTA;UEIXQ 8H,=[D46-?[;.\^Q'3/L3*U5
MMWO<'1>[RL*(8U3%<CVK4==RWIN&DMO6RS.]5I0DV,Z<%YM/ 8;-6ZN,&@)J
MQ5 N:09'5H*_![6N.>'@8^.XP27\W0[2'B26-0[=QB37>+F;/ 4+55B$_/T4
M?[2%/S"](L"UF:3HSIKAVOZO1%G3U'L\?BX3^-C'6[1_P<V:YX2$P1?Z9PV'
M_FAAR9,5#@K[;&*?R]VH7U*?"_.(66,!R.PM-?3) ^+@BAA?N'$!;5J"BA::
M4W]")#+EQ*[F@QN.$EC+?XBMIRADJB1.ENXI.J+D/3R.,_&ZDR173/#K8_*-
MDFAPTW=X,J0"R:Q[#SX4P38H:UV\(:(+U,1[+X;?[NPA[V"&U#HJGD1SU'Z(
MKKW1@&>'I<"\7\'&C0&AT86(.3"-:)%LQVF_S84M/4VD@1>)W3_:56!X.%R,
MZPDK*-&;XW[W5KFWXN1INX&,+S.-99=N8X)#?0JCP>W ,*JDW;%O<A@$_F%]
M!*2#&*UZ]H1@(B 84W)^$>\&%A?RGT>Q[XUTOU(79&[E3C63I:-O!'4$(X:B
M?#W7CYYF@.J8O!'81EA=@]#0=#L"4@D=]T!C /0#?( E2_/<EE81CL<+'7"0
M\!#LT&V>MXD [2*RU7/<@]_J'X/F* FVCFKA>*+D*#KY0+"=&S?M+:@S);^5
M6O&XAZST5?<RFW5JWPI+HW2?$7)8DAO%ZVVZ)5/;%D0Y9J5,EUI2T\SK!=</
MOY?.UHVC"=2PT!N*.A+8-M*="XWP!GM;U^0'8Z@85H6!X4EFFLM$V,ZD')F:
MN95; ",TRG?L>O=>]/NL=8^_NW5)0XCGHQ3RF\T*\;Q)17R]<P;>[#G2^B0;
M'I=Y<I>B;W'>7%JR'%K%K67\;NN(>P%6[7JS)68LY;Z+X'@Q,F<N9Y%S=>U-
M5W0 -U^;OWAWVP;@ID:5]"0?*SVP3 DV;T(]:*L2]AY_Q^;>HGT^)*8CN<2[
M@.B XH-%I2HUS#^QX8X=YJ4IM4F%KLLE:BBQ,$,9J1)K=\!&+Y@]<:V]R@"8
M"H"I1QG,=\\4;Q)>-;SJ1K]J $P%P-17;>6VXP"Z9'&%60<6(O;]&]6<5K/6
MG8M>>-6E()14B(K!/U/"FHA*4#B%;-*V-5@84]-57INGE#6X_1F%4+4-"OY3
M*@K'G&TX2=?IW->19WSC1VO1M_?B\_$@'^P>'!RL$0_RP>YW+P[\?UX%)N0?
M76GV/;(VAKW"YSG E,N]+FYB%1^=HCY(=I#LAF1_O;G/30H<8OIQK0[5SYPS
M#GHNZ+G/W3MGF&=@)ZMDO>I'QVI4W<=0>)(6(&'7/)]=\U"[]P$V+/6&;Z!9
MX&P>JBRQI>LBKGH1)IF1L "!]E516^;3>8$ITXS *XQI(:0+,?6H5#9PM(7)
MKA 54MG(\2)2IL[0)I$F-W(7+HA+!@AGX\;9&AX-"X$#4RF))"AMUKD;4I,1
M I:XFW<B1^!82X-*)G_:P_=H; &.U\/F^. >?S+IZ#P'6R3V8068*\=CEO+E
M!AT)HYWF"<RQOENVL+E]Y@S4P I%#'S-%+[!Y7)[#[SA5*?!^9:Z[FDH&]G_
M>PT[](U9$473YI#U H>43\95T &9&2^[)N>V,+ \2Q?1_?&9#(C056PF?.0>
M/FJBGRU4PC7(ZT9+6!A$\X?W![=L=K;\T8G!V]#F7B,&AZ F9%!="5WI% :L
MHTSSLBZX?E&O2+$".=,C2</BR.G4DDV5^90N8=*EVUA,>PV4O'$G2QUH3&S@
M\1[8R*$DQBE\19^.5>-!L?P+E=]":@6H7],AA71Y)?9-,N@EY$T=P9A9';.:
MRQBJM&./)MJ!N %-'1D\AO5INVX,!P(?+ AMV6)#,7>!YU\VO_&V'=S9\#CU
M:')!_Y;2#;*<6%^*F& )4%<7_BRY\]&+Y2H"GTJZ#;MGWIW,1.%X].K0F\PE
MSZI>*ID$EO]/VLS'FP5D.L_!8[@BS"@?\QZG_X:#FAY[JOYJ2KOL5N[&O7LV
MHL&^-^EYJ<(,[ZNRFO8CVK)4D/I0(#D1V+.!5WEKB $^61#^LQEE9OPP$8E:
M:"=KC8>AZK'Y:^;CY>WC]"@D'4O(/^AA>354U.JTN]Z.,:+Z-N[9#!:-\7#2
M(^/6LUD>I7DVAM&8X0<5]E&"_G:S5-C DXT+RMUCZK0A]_>1@ST=IW@&"[RW
M60O<M^0>WE*'LZE[BNX.?#!CK.]@N!K=;O84S>K><] #C(X4.048L#'HQ%$G
MVTZD#^Q[T&:,QP8/F90)K-/.=9;/HZ$H%17 ^$U7EUH9>!;OT&=NX3&96B]=
M$>$_D+,5!#KVB:6C+8TZ4-E:18\#F#: :1]C,-\_4RQB>-7PJAO]J@%,&\"T
M7Y,%BV2#16(34MV6*&5%,#3@"K1UA6DE;=H.I'J2%S"\)()7949M+QKN,<=X
MAN-VQ U=M(6(0VA&*,@BS6S+$_C/#NLT."6M(GN/.A'6ZD[?!!9@)?=.TT'H
MW2,KL>1C4#5Y):XQ&59(_;2)P/>F>^.*4E*LT:^L MU8-;KZM//((D$85+84
M;NL07%UVC=)+#2%6-$:[5^3J&44L]C<K8C'(, 2,ZTVYO:N)@N4^AY-8R1!4
M7S%3&DR-,S7CF=+NO<  =8+=ZQ &(=)%B3$')E35R6C3A5'K"*KO[2U'.KQ
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M07/9-HO3ZX_44;7Q()*C:(O#'MR1C$\]? R,G67$AD<6R*IO3F/ZOO;5_W;
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MXG*?@&5K56Q3S-L55M,5\WR'8N;$LL!A >U#6R[,H1PK:JE4U'C;2J7>^S3
M%&-%.(2"BK]R_S5=@$$;Q_2V7E=SLU8-M!(8^L2!Y.*YQIJ_V^9>SFZT%CKX
MM9T=+'6IGDDH:GR:;E[)Z2Y3@VAS?4LH 4;/-5VEXXF,KS%MYB(]YD:88L'2
MG#+JTT>T#_L]@N5I5PQE1 _"!+:.J1B>$'N&/X4)9K$&,1N+L2X,6N)(=8B9
M.Q Q/N;'Q$O<1NG=*XD&XS$YM!"?WFCJ*A_TXH'MED+4<0A1KP(WQ,OQ, /
M*RU4(!)#6,6ZDNF"P\53<4WA*@]HMRJ#C<="Y=?_87;/N\Z0 =J[Z-WJ\O#F
MI+7'7S[/(K_4&2^"JWN-Q" 'I,58(#+OMKLE,E6F,8HN*=89Q/TE/ 3>'<;/
M K:"E'!5@Y49\V+'!!29Z4RTSA68.FE#DF&_Q]"@WY>ZT<VZL8R[%CM6FE_!
M#9LK/<( =%R OL28M8V9AG.W$\[>.LD<+ER?>DRWMLAKP_NXL/UP?,(:Q^Z2
M.UQ6+^K(?I"T>%NC;3 &..C'.2.;=:AQF</+EX\.XWR>N]E.I^U4*V![C1!
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M;<//*Q6K&>V>W*)9$W]],GCAL#Z?O#XO<?^4ID?C2]Y!\,P9&(;)RDE]IK:
M]F-N-PD:='H-;HV)FVB$]S:FFMO6PP^\BG3Z02&G.-&N"YG?R\E"A5F3$1W+
ML/CQ;K["E2O[/ W?<ZN:^K ,9ZR/3HP^"KM@V2+V^8Y;^IM\OV:7P,8^"<;K
MHQJO7$X2#-<-6\U]9QCQ"C[<YHFVN LF;"[Q88<R!'PM=A/!Q$0CR+(=5NJC
M3=BOUD1Z\I/UFS=RA.P]5, D;1>/U@G"9/Y8C$'::SZ1%-8U-5EBCO\/9LP4
MN=RP=^1RBU3-'A13#0?H,*KAHN8W7NE?XU3"6F<NG/+;DMS5CP0U;7<TU,9O
M/Z4$P%^0+Y+HP.'$J439?JSW>))QXCK@7[JD_)[U.6L0 P[@H@T#%ZT7%')%
M*G?=TO\!G1)>-;QJP!P%S-%77MW3O[KJ'_],M1MO-B6H^$4FZB.J^M=MWIYD
M7C3OP9N_1__[#_//_ZTYJ_C_@O\IB\KP R12)"@^_W<?[V)G[]O=@^^_;<53
MGE'+R:NSPV_>YO48'([H,ELD")_XB4ETP&.K86;3,(_WF,=W%V>_''[SCY7_
MA$F\E_8Y_&9P>CEX>W(1F=H[IYBC\[/W@^._H[8V.+S!V>7QX 2^N^Q%@]/C
M>P44GM%\#AA!:)H_]>"_;I2<ZP0G';34V8 ;# SS&[E32(U-3$P_R^BJ8$H7
M+X##Q"[N+I6XEIS1Q#"0:U \76!LMD3_V&/QPV0&$;^0XTP1R*V<6WP/(C$E
M4 C2BVMRF)[-@AB.I>V50,P>MT6F=E*C.O6;2LV(-UQ3S7@43A2W4ADWT"BD
MRM95BIYAG=^7VCBK]?@_VCJ>4OR#GT[[8#B=?/.V?_6Y#<@@*NLJ*B@:I_U?
M@D $@7 "<36X>M^6B!#RW\B0_YMG&C$-K_HUONIGB8/_\.=AGBQ^_+<?_CRI
MINF/_Q]02P,$%     @ $X!26F%D]/UW P  Z@L   \   !I9'EA+65X,C-?
M,2YH=&WM5FUOVS80_MY?P:78N@*F+5F)K4I:@-11 K>9$]@IMGVDI)/%52(%
MDH[M_OH>);ESO+XL;3KLPP38)G7'N^=>>'ZBPE3EZ1,2%< R_"61X::$T_AW
M.O3Z;C1HMZ@PZ#2B1&9;HLVVA%^.:I9E7"P#O]Z$%5-++@*V,O('7M52&29,
M>-08S?C=P1%J9!TX_1,NPG>4BPPV ?7"B@M: %\6)G!14DO-#9<B4% RP^\@
M3.2&:O[.^DRDRD!1?(-.HGIGOX5!2\A-,/;ZGN?]&.92&'L, M>I38>T1=#*
M<E;Q<AO<\@HTF<&:S&7%Q$XQD<;("G4-; QE)5^*P-JW?NWQG>M4EE(%3YWF
M"=<%-T!US5((:@5TK5A]B.1SSAO96U#"!BND@"8[:YZ9(LBYH2G*H<DP:9]H
M8(]\':1UF_1$EMEWPAAO"IYP0]JV:I$.:OQ@;S0]\J&"GZ[6\/@+>.X7K%'?
MJUF*4$ ];M6>78)$G^Q93X/B^0,R,KF>+>+9+;F^(-/9>7P3XQ=NY_'E='$;
MS^-S<O/FY=5T0LXFD^LWL]OI[))<3.>_[B7O'Z;M(4T^NI^RQV_SKT_8;T *
M4)!L";[3^(X824P!A(M4*APXS,X*@G(%.2J*U(H:C3DLN3:=PL(P Y4]CYL+
MJ2JRH#[Y>2;ML,"QYX[]XQYIUV-O-.S6)\<C=]RM1][H9+<>.YZWTQ^/7?\%
M82)KM[[K.>[S9M_Y\1H_'PPZHYTCWS_>.S@>OO!&SXG,R?0\/OOCC+SD4J?<
MAJ1[9"K2OI7)E<)0[:0E&8:$3B!1*Z:VQ/5[9.@,3T@[.,5REZJ<"R92SDHL
M9I<%-&C]6BGD.:1VS@K0VGK@]L((U+954+(D\@[4GI'6.]KO$>R#M""LKH$I
MW>:=ZS9LUZ&O^]^W;;\XF_^]:?S34W?DA \/UQT^:+CY_]V+.M #<J-X"FML
M,57(E8:)E#5@7UQ=W7S+WU2+U'TTI%&B3K\=S^-E;L$$>24U],@$RYI+/,+^
MS]>G\?QMX!U<.\L[TY)I;7GG$FC'&2TTM(WQ[!'3/1J:E["A&5=V&"+[Q.A6
ME0@SKNN2;0,K/62J?ZZTX?EV!ZW1H2"RCU#8HX[S_,5\"G5 7KDHN< ,&J9,
M0ZC#^P(TW+YN@U+ WE*6XUT+6+EF6]VP[FA@F?KI$V3NEN._!U!+ P04
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MBE/ ;3^O(,/<6B+#\0[DM'20"&ZM/8MQB1$YQO(UCU>'Q]%*\K@SY+)PL8M
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MXF/C(M#A#GV-T+N?#G?<%Q#]'U!+ P04    "  3@%):Z/T-/%L)  ")1P
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M%#74[@R-##E?"1GVR$B @9 :V"*EJ03N*!RES/,P"%UFQA;<9S63%>R8E9C
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M#><@274H8.L5DY^4PDT[I +O#)M[=T,@R\.?F,](X?RB%[S0!,CJ1V,FP%Y
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M#"M'H/OJS_? [CK+>D YY[U:%&TRT1]9A.*Z I!QS@)Y>YUWH[?^WG58+U5
MPH)J[.?XO48$,ODM5N1UIE1V75).E,!V8*P6])T<L[@]T,;[YF_*=F"1;#(N
MW$5I$SP^;(D0Q*!#&#QS_6$VF1<;\NV;06X@253\,H(LX[A:K/*G+W7Q0;4M
M,+ML:UV+G7>3[Z**<LLKX J0[E4X_&_"]:!T;%_# 2[*%AOY$U]9.Q06NI^\
M_&X^X\88ZE<$0N!0Y6L'1R9K-ZR;479?J2IRM,J"ZEYXCRD6K4<N .2BNKE-
MQ4U0+>**1_N,5T.V705/0"_<CQ'T2<C0I#@>CHF#VS49L&L!](TCR[RI>XV;
MF$IC=V"97D%K*8 >[/O,S"HBBQ]4UZ6+6Q>_W<OE"A0S=@=RFX<'!_L'7X[]
M\S"77,Z=.G(*[%/8->P<A,8;KR/N%*;(47C:/P1/I8WOC1I_NO_LN\,O8X^@
M'WYP"3ZJTFM>?;)_<'#'5^_XVK/#_8/#[V[S+OQB^V0)+E%<WXU[8 D49N_K
M$?M@\8,-E.LX7W4Y7N 13F3N^4ZATS17:XYV>/!V'M:_B.5]\([>N% WT 8^
M?IB$^>J+PZ?/Q@-UAFWS083IRKL8O=)FX&.(%+_-S4KFG%>Z6:R./T;VW7T=
M!UX[')J!U]X;Z@S;9@NOQ50*Y)R^UCK9+KH44[QZ)9-4_M!'=G2Y,/F"'#I4
MNQ!-&U&@"ZP$HZ3B-*[+DNOB++3)F_0?L)H&3OR@=HX8SM3 B@=6_.D(4Y?
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MQN1?I^4^R'3T+>;?;V :=<]T7,[P7K! 9!.4$EOC6U*_5G\+9VE)5IM^L\=
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M4[GBBP''/@==;<M4QU?_D'U*O_^;MN4)/A8ZD2$&]9&!"HHBB<TG X((53(
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M/15D%G:*A0ZK.JNJQE;3'%=/?4$^I_W WW&T&^F\[Z]I#\6!D#T_QI]"3<E
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M&5E6HVYJ:1/P)VU/P%IH/:ZAGB9.F1*JR,";_2LG&@H>-;\I@_'8'QN-DUV
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M+2P9N-W9O05=P,?(/&JNP=!NORM^*"YU!LHM0R5-U_9"3R+(Z#V]E7ZC%E[
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MWSH7UP/T ZT48M-H*SI=]K\HRS73Z?$7<<H?]/+C(N_M0YP?5$=*SVD/Z@Z
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M!5\/RDT"X@]!H01.X0Z)R;B'Z/_!WGN&-=5U[:*Q@4@3I;<H15 $%*1(BZB
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M&,06+32\-CI%=.-@1@H8K=@9$[ _!!%A- D7L'/U!TNPG;ZWL]?90Z_2.&O
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MU2LM&DL3"WVRI\*-ZX:?QQKC2_GJ?M4'O75_(+TR_BR^@A&'6ES';J-S#A:
M[3-WVOUIP$C6C*['[D\;+_*8/UH_Z<"R>GS%'U4#->3.;JE?.(38CR#/4 )'
MD.PM>]<G]$J<T]]HI"$N1Z?=NB8 9A80/JO=SWQ_G!1/UN\CG.BT.S>*^GZN
M39YS)K:FCFR95 !9[>";4$Y\QQ%5!JWAL>E?MWV4WA3DJPG"1G6U$SZ1]>MI
M7;1N\DFO2YB: /(!S\W^SB[E<?<Y\)2X#;X_EBF[=)4 #9WZDJ".J/X@>86)
M:;>F'0CCA&6YK'RZ8K]5(OMZ?6L@@)1*MG&95?VS,N33IR#/B;;YFK"@\WE
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MM0*4G?YI#J:_$ _N/$I9%QS+]2RVN]:=X;'T5J!_5(3;"\K/$QL_!(ZN3,V
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M9*@,.#(0W Z.$30-O/H2\W"$5SVB=OK)W3;#4NXL/_SIE09<S%!6ZL7@#+'
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M(JS-T0$'6ZCW9E@^3'541[R>4=#E9F/5B'%[_J>1EZ_3CKX\#6XMY12"/2:
M.IZX/B=P%%-STJR1_6Q<>E4> &JG0/_@N*;,99F\YKZOD@+@'L2/HP5.CEG8
M+6I*-55*Q[0!63]4-B0]V18)G3&0,P)0WGB_SJI'R%$_P?A*H,S8OOZDLENU
MXVMY&O&"/RL!_%UZ5^[U!?"%ARA"!^9I66-J'$U*J1G*=,#%G(07CP-3S\E
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ME/T5A1\7Y: #LO#PN<=T0 3PGX<A <9Z_W6"4'@9?^+A ;"#RH#BR'J\/^6
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M\WI?7Y8PDW[NH\G+W7GV4^.D8S5.M[DQM[N+C;;?A/_+X>>3OFR_)7GM/@M
M2J/?E;9_(_[UMO?_WT_!_BB>D"/H&9EI^"X3U&E!?!1\E06\S@MG <M4^!D[
M(SQX[%A3Q@GRX8+L"9</*VG6(8/520WJI+=.\=T7S)YP"7,)[ZW)OEKB.R0]
MV:$H+JC/DURB> _CFX4*8/NS*9(28V\P.Q1Z\0M.7@)/?],^R (N(_CA4ZH@
M>F =NH(,V2!^A(Q2^79V$S/SD1GP?U,ED>K.MY<%_))JA5 /<;$ L6P:6) %
MZ/Z&0Z? \TNZ$?]?Z"2NT"WIM$<,Y L6@,C?%8G9F6>*AGU';QX@"S$YKK"
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MGAKT_Y.__,S6Y*$__>6?3/W)U'\M4SZ"';ME6W_H<5TP6UTO)_*S@"DU- L
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MC5S3A[7H+9?K(D\2[=48/R(K/3-]Z<_DYE@ 50K2EAB-.(4ZL@PYHGO6-3;
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M MS] M'W"_,Y/G]GN/8BO\.C-&)$P =<7?GH6Y$]X.3'Z/M-I#FKR&QAPGQ
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MU@@1A#=)T+W]\"8C#ZB!C'<35$/K^O[SC.L.Q=U@#A4E^G[44&EA7]R3'?5
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M\,\::+;C'VK0]T_624BW5Z!W\82=2;C8\_7.3<ZOAY7U=9:C&!]9@+/)8=@
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M%DCS_-G3N>'ZGRUL\B]O6S-42A#RF2*O1Y"U)2*TOIBYN%GC(&2;SEUF/:?
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MTV>IZ0:!]6/D,AKBOI@N>3B>A&D*Q,;0K_E0%([I5R6MKX;DQK2'20%>!@O
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M)CRMAY2[*:4?*Z],&([X@8OH"K@W/&'^N'F)A'Y_,A^_4L[T[S9:4VH*BM;
M5!ZK"Q*T"*K'O0LRWCFE, 3?T/$]&R=JK4D7XJ=HS^%<YQ+:&, !3+K"#>CA
M8Z#LG[>X[0LAFB0S9_6[Q^-#/,J"%=%JFNYN^S[0MGG/M'N!%W,2P.-7,#CR
MG7$R'013(N2$,DVV^=MYLRHO!E!N)(U8*IW#CC ')[I>A>XL37V0L@6A)S&
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MR=[[<@D'/ K+6AS262Y7>W/Y@4;])C$IDF52YCSR12+JEKB(K<K;524;B(9
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M-7@Z+?*W A+Y'M^ST+$8FDGNE\PRCD#N?<2)=I$=[QBTGX@+SW=5V;V0#L*
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M3<=.U"J91UG/1H[D.$1()2\1\G64569OLP#W:@/JJSJ>8%TYG^[<*_/.*&,
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M7VR(G"EGRQ_>$8M)\[\^_^I^%)O2-:DH-A;[00PO?+X0PT%C7?0U;G<T_;2
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M]*C^O]+6AV$)YAS;.\6#1RV^/S?&T3$U@]P4U1#:.\F33,#?4<21^4N+.P-
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M^?,_\H89LS(BERJ_EIO"^CRK:.^#LI<A=HE)19NSOF/(7<BMFE9Z;SX30!6
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MNU+RV5BUR&2]E-6'EMTJP:L? /[1(8:2[U%B"ZU.C/.(:1PC]C@V@BC<04Q
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M4AB5<<?96!:\C>[]$%R@@C2"2LF[J%3[XHV\B=E!*FA:TWDSU0YF8W:TFJ-
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ME6D\Z)X?NA[1K&Y>O7Y\SO\+;1 E),1">[N/:#N4'CX!K31K#7!K21/&+X7
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M>MB;,V)R=Y^OKYCX=5=LC T:S%;733F]-2(FB&LX\)L<VN@'C.FXU/23>*&
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MG(_UWE\ILT/)J@1G@CY?NP)?4-S78\IGZ0?*YN L)"WD7.4!\&1>6D6?I56
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M2AOC'#@1Y1U"O,?STDR:/G=S]K^ZSB"R0,Y6<BA&(R  ^(JKD4U/8;W 4.-
M-9RRW[7>2$>"E@'IN6NS9^OTUDK9O*^**2)8;:PS3LO*E D9=S.>DNH:.)$K
ME?>JMZG[^!L@<,[:C.A&T,B-JA=T<\)N!=5*U\[ &KF'K1L'?5Y;#&9I3WC*
M23AU]ETF<.\N99'3X:!V H[E#!!_BZ#B\&JY]VHZF.B15V-M\HRUZY-[K/=E
M&=[? Y]CM^KPB/EU,'L14U)DA1B%#TCSRWD[W#*Y,<=5_>&=J<5\N#G.\_;L
MT[>LD6W3^)OG=/QT?7,),AAT3I!#=X&)=3+P'',XJ(BI=_"&K]$BXTJOEBA>
MJ\9?8"/\XOK0HZD)&%M!5YR&T#=.B>@F ? %VU8XQ[P=[D7Z$3^0:?0="/;S
M*/$V:_.*8@ERGZ%_V:I37OU:[?.)'.E/T7[/Z?2HH$)G;]Y*=1%O2!N8#BX%
M0W"K*64Y0EF1C[0K$, =]T(+P:L."YTI2'DY&<VU^Z>WDSXW[H.5R[TE.VK!
M[5N,FCV'OC#8<[911==72<HJ2FWY.U;]]?(J\K6L/;ERU:"WQX885MP>($))
MRGZ./"-)DOZ59C9KJ('*77EU!=*%*L)>U%AUAN7X!$FSJH+S\"K*W<*R+TA!
M_&SZ-SHORKG]J-=@$$7&QH$B CFE]MS+K\1?]]>&4/W(WJ>6ALCES>\=[+=-
M;]\U8\W_">NI%@(9<N-_PJ!EO\N>XXG[!B@"(MC#*F:#!A'@:<$)\Y7+&JR?
MLKMB3V'*"YT=S,BOYFRE5U"\ZN=7H)7TK7IZ+LS ]_Z62:N1NAB;84&]D4^:
M0E$?Y+6_1K6]]>([WW&#5U=R8L0K:-(:!?T0_QH^%E>I4>]'29J:19?UDF!D
M).G99+T*JCG 2@\OO)E^HQT=)NJ3';8GSIV085MU7?YA93,%O)=ZY 5AH$AX
M:Q$+ -<BZXD5Y;ZO-WXFF\RDE;$+ZMYUK7/EB[X:*['??PM7 PFB@KB_XJVS
MEP+K_9S @4[^8A_L:TWK<*K-+]*$M(_?WK\BU1-T(5KTDL ]GY7$9<NDSM+
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M<JO'02K)I$V@N1A /@)"BU 1"R_&YE*+%R).:)TV?A4;W1VME7=]X0N:^<S
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MVX4F#TS+!,@B4Z6X7Z5]VWV+*:Q Y#:FD#1X#K:RJ5RT?) K\,2DSS*$W%<
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M]B]-_O^J"0Y+>W9H%G[ !IJ<['%C %K8D93_Y)3Q=,$=>HXQM1CQ;\M*E5Z
MDJ%]A[&@[;+_(HO*E'6. 9 &_MNBEL(/!/^VT3D,:.T>4[7._\Z0U66A=?ZA
MU;\5^-^.6.D+5"SF[UK]#Z #2IO,2S%&M*P1O6:8L?CD&$EY?,-VOX^"0#:X
MQ7Z;1IO,TQQ?9TRK%J\Y_"E\^/K+M>149E;OHMIQHDG;(-VP"\^D*Z+3$EGA
M.\;V_UYA7"GIF#V[=9-A,'"M<_2=]#^E[+U&)C,/,AI&;(A@#L^.W7U""F$
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MN^0ZD)/,OD(^ZK,"8B*B72 $OU-"Y8I_,,@:Y ;3K"\&%YW/(O\RN=H*2JF
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MM*?5/K/[NF8LZ35N@]9QZ%:FZ;ZFNC  0=,4";+.X=)\WZB"WN^@_"15Z$T
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M&FH;D:0MR!L?1.LM1#!,+L\'8?S^Z6 E167CZ7L?=K:+VK:@\:/H$[3$,;J
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MU'>V0B)2/4+7W86(Y1-/>JZ%N57<@7!<'TPY2ETSOWFW"AX]%D,?P);O?V0
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M^=S:%UY%<AN[JT"93+D7?J\<UTLWO>&!Z==250^LFY^-5>P-G<2.WX*0M=M
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M[ 9W+QPO\BOLGU#^AT')T]ETW/@4\[VXSNOF!SK@L,@'GYT#"=+(WP@LX&J
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M&)UIT!E=E$YI697_) XA"%C'M]%"A9_3 ;P[%.HU0)D&\^PXFLJA<X .C*U
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MN4YFT-HAD;&L^P2"W)QG$CLX.GE9::R7@7)DEG;#9;RO[R8D7^30J0TZP+S
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MY3]#&G>:E 0H-_Q$?(4\^!>7BM<;>!K/3A[JB+N'?"57)E74SK%R#6CUWB3
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MK3]L46&^SL&6VW$@O+1#QTCF]5Q]#CVE7@7,&$(>H-GET,X/%FWQW5UVU^\
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MR+TQ+,]"J/86\$FM&@EH7C?B"E<4=WPJ5R%0?Y]?+EW=Y$C6(RZY2L@%/!-
M2",Z3AE4IZLDT,+R%\6:;E8B#UD[6PB?D^ZYQ-<=O)>O]E!D"Y05AW$XT#-J
MV:; X>E:B301G)-T0];1OJT,#ZOE\V6)[1V''D4-\W'L+2RZ5Q1\0T+*+(R=
MJL-@1>]<-#UBM%E*L[/P(!2.!QT>.Y%31(EN)GN&!@?J+TBV![.KNRA_L<Y2
M-;E7^@KC*:J])N(^-U:-]M+Z41":'.]*?C'R(C.3NEG9UL=@ISS"86(8(F4D
MX..M0M!AC\#P5SY%KOQ&WZ<*VHPX(_+W2NT7(EJT5.6@F8"(#JCB2SO[;$3C
M@%K[#,=5Y0I^$[DWK"AO*E4315R;1A/DB(V-P8Y-#CR?N1-J$^T-/^'Q$O';
M\DD1H2M"K;#O8"Z_M40X\=I:-&S_T)K/2?5,ZR;+XNGO)K-=,O+H ?WS-5Q"
M!P06YLH3*^2_OAPP*]QI=-R%+'OM,6D56OPVJ64^6>BR8HJ@R+NO+$/P6(HQ
M$%^"H.?,!3O?-=:[OLKR"$M%(Z48;F>7%TPAKWR*;W]&O]2+"WZF_["Y(>E;
M?-3>^^<E6Z#S)#!9@'(&CXK8'7E<WAL-D^S+=S*X.+AE*JFKO::<?^V$CCY1
MOU4O7+DJ$?=LM"?8@L9'Q6OF3ZN,PC8N#,DEXV@J13WOQM7C[8MKC"7>IVW:
M!@("  >NSB+U0UKD9@8#J&N4 W:(D]6:(SD57WO)QRB!1.D&9U5*A58#5O N
MX_C0G6_#V.;32[?/O10XF?(B5KG/L"I0U&BE(S-G;HN\C!@#XB:0S007W-9(
M#(&@?SUG,=H>4U85:Y]=6<9FDC9_YW X>X$T[-Q9I6DP119,>\X$C/DR6E^P
M]/GVBWGX$<;^17"Y'$THVI;H\U0%Y56KIQD#"7P_-GJY/X-R"QU[WGME_S'1
M1@'L[#3G(;4XG^_GO>3S%U=]P[K6T%EYGB&#J:.IV#5Y.FM%X4GD*%;\P;&'
MGE5K."U+K$.T2)XPNSZ[?K5+D.2H-P]0[FH]=B_K%2S4K3[RA^9J^WC\? 74
ME!H":P<?.$9/AKK#WP3Q-DV*#M5JN=!S;KWWU/6S'51Y_N636G:4O]^/_;>#
MCVX!1C["FK*.UY'F5T*)K4R 8QJJI$3=IC+]NGW9Y=*RQH,"';)7[PRIA B@
M6\1#]"8GD0=7+T#+8D,O,P%*#HR:DM; >-!4-K L_Y&_B3K=&O\R5;G;'0)W
M'?^QM'__DM9XRW'R%LJ28D(:_ *2+-?1\&$+*K0@:3R7.8F]\U V_/64J0"
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MPHQ/-]0M6XY_\CJ4>"8<'N 8V"U<!KH%WSGK,S;-:-)D+;GF7&W;%":&H;S
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M<80")#/Z66[@Z :YA'*+:N8YIC&,QH7]-_;>.RZJ94T77BJ*@HA(DM@J($E
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M\%NPO(T+TS%,/[;DYR6>,[OU+7@L!Z'1(Q.PZB*A4ELK(BF%$ER,NWBE@[>
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MR5$^? >9CPI7U,7?</FPN.P:5Q(Y/+W<)W[$S=6& 2>@M6I3??2DZG7$=QK
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MS0^W<FP&3>RD >J5C]S^_95M:SLV TD/P>:[B/51Y-K[QYN35?Y_\AO=GM$
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M.U04M4F!TW(ROLND,:N2QJ5GU%,$F68C[I%XB4(#N<]!=^\%Z4'[@T(A$W@
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M,YI51FJOCE)5N5.:M(92QC'39,ED-Y5S^_.X]@I$A! QT<@;F-W4YAAD/C$
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M750B(=C"%^:8+"Q(BEMU_A04_<IH(=WZ\3E=Q:)2%=U5-R56*@?*'SLM@MZ
MQ3$4AQRS@1RHSP)I@ ^.!@3FM,W'2VVNEM  K Z5#;S5#[8E8"E;* )&</8D
M_!)^RISR\Z.&J,WYL*T40-(:=DR#J!M+WH1U. XV+P-0!WLKL6.8+09A"@FD
M'@^'S'RX8=LG@SBX*+S#0]+Q5JH7_)2E#C@CHO\L:G7*"2XEEBRRB_F_5^%W
M^Y$_%W+GYRJ4(//O8J>^X:@4*4B?$F5# Y1=:<#&#%C[Y!?07T!_ ?T%])\9
M:-M=+\=DU?$%O2N>/S@>##1QZ^1]-+46./SU$8Z03Y:!A_.+,$HX=WV/:WSZ
M0$G]UVO2COM"[XX?5<Q[\N!<@POVG]-NOX#^ OI/!I1983DV](R5WI7O@D55
M9@8#2U]>/;]1Y#X588XE?%1$PE3!ODT55#8<PM1"-0.Z(U0HPKVQGQWX/.YK
M ?87@ZLS]!32ML6<(-/M%0#O@F T<$$,R+'K[B#UF?AV%<CBMJ2S;53O(_"S
M'. *W.ZG 6VIB(T%V&"GL'_,* (C>SH&.R![,; -"#GH^4'DYIHOE8*!#1UO
M"QOZ)8@KVC96X\\Y83/3P[[!]#'LM@5JB\&"NS1@JH.91-PVLR.:O'4!+J 7
M-A7/SSG#_U3O?NK7 O@%:2*7!GZS\B^(OR#^OP9Q'0H=J\X\\#X!.06[X<MG
MEB#3$5[XJW'_PB2WE23;;M* Y N=5 \I"'9R;6!&@&%N$]@I<,S:_2'UF=V_
M\9=L '+Z^+\PRP"U-?_W4G\G(5?4=JF_<2;JYU*V.3-TK&UK7_IO;%:,S9_'
M;N/\C?>L8G_'N<U=G#^7@/RY_!S,?+G4;Y;=YMI8F]\M^QM?-OQ<0OB?4#J0
M)%M_?Y7;I/<+XB^(_Z]!/#F(EPU@^,@=]X@&)&[K]>X_D]>,8,<\479+D \Y
M%0D78O03)P#68&TU@090Z$RH%.SV5![C+EACK+&@2$18IE@@_XTS4OY(>SM"
M_Y13@WR"F9D&?%<#EV"QX@<3UA^(,?S?F._*'MF?<R)^$A'L!3\Q(_(/S'?^
M,.YGO?%3S8W;_DB,OS#^POC/A3&:N1[)+'[(18@7;).%&<,>_!.#:.,N%8R
M[4=F:(!B+UFLZ1<S_X+X"^+__1##G%XD\MD ]IH>_S+ ]VS\(;N80JADVW4:
M<-$70UZ%2SW@^<OI^07Q%\3_81 ;.RIL4BR@%2)5YX>%UHD>H2CKZQ^O.X?8
M%KFB_NU[V4P<C?U5@O8L\>XA-VLT57R!Q6O.YWF0?XKHM\.B0JH.M<:FMZTI
MR+KW_A#M2_DI@ C<@*O=2NBE[&:%U0@-8(65$Y8)_*Z/W)9#RS*E/P4VP_\8
M0=P1\*=2$'^>5YCZ*;+YAW#IE3V(GXHY _Y4!POT'\.:?XR5GC\,_H+Z"^HO
MJ+\58]E6U\9S)T[*OV> N'D=_2VBF,VZ1O$1^S3J#\6+1T 6-QR<QRYZ."9%
M5&SNF3JO-_*.2>J?9&KCGV8.YQ?07T#_'P5ZX/$J7L-_HN@-IZ'*EQ!@!9>+
M'$[WDJ0!$9R7:$ Q>DMF[C9))Y_#A,YLT/='"3D?I9=F_=/_IW>MH*@,HC1
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M0(="HQ1:IZ#D*_5=Z\AK5(/&]BG\ ]R\[JV]%8C-%\,EUA7C.R]*4/TZ"G3
M\]S1IFOKM]2NRL'FYO2(L)70/8W28,MZ0^2,>4@SN"+[-WDC@?*&1""4.8XQ
M\J+( N(4H[0 9B*E@O &0PNPM#/5ILK\>-E_\!?U!WT47F[;%D))')2/POMW
MU6,<*4G*.N_!M9]H[&!63>249O#;\Y%BS?D7)5<J/*73#^OA-":9R\7/K/.D
M#Q):H-G-QVKHTAUXG?]KFAJIRQ$O@KW0&EA, H*JQMF0DC$6<9$NF)VDMZ#9
M_O33OVZNG)K7\SNGBT2>9J11AM>+,.]-(GA,[? F,4M,K;;A-<^2J^1;:RB
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M'SEZ$+(T7^@P$9TU0P>LJS8NN3&@^ER9T_=U.N#UO2E2"T&8B*(F!1E#HI:
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MY]5EK]AZZ;GG/6?+4?@AEKF0]]A*CL+MN3B1YZL]1PHYD^3O)?S0@X7Y94C
MH]UHR U"UWU"5U@H;B1)I=4DRF=OU@Q'-74H]TT)J%]Y?SYNU2=S^:=W?+/
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MCN;Z9C">@H#F<FG]/^R]=U137[LN&A5%L"!-FA"1*E5$!*1$19J(2 U%B/Q
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MM:(1181CQ^X^_$&JTI%Y]USESJ:E7<]!Q $A\??J*OPWF8D&=A9R(7NVJK3
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M945TH^B.Z<.4^E0O$EY?Y\?._/#7DN2U+]C$QWI#71;CA3'<-.74 F"Z [3
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M6T"Z$-)A"N-P,/?=E+7LHKO?EB'3)CSJPN\Z_<+J&ST]VJIE6;.M$+P :[F
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M67AD<NS#PG%]H&UZG#VW0P- TJF\&M3,*3(]3L>ZSKR]RUA& S1IT@ #U31
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M^6FV 2>_.B4/ -9U%8Z!A.M_0CAIOY2X'\^\DMIWKJEI:Y-K.A,-C.6FL,-
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MN>NCF)UV.H#@,TP27RR*79J9VO+N;+*X!KZ-(K7'.?&_B/>_1>NGR4)PW^F
MUD1:;:!V&SB\:>?M0=],Q1.K*,>P/HB838_*N_W*3832(DKKA5ZZ"D>?+B9@
M5\'1:7SU4^8?%$B;U;B(LU[A48WU!(7#B" >)063RIMSS0A]Z/ZJ^?.C$VY.
M_">U*[S0?*0='.8RU*S),07"]BE],D(G5=HKQW"]GM!21Y&:^$$'Y#!L]X!K
M]["5'.$1HPXTH0/4Z "BB2WR N&TBM2 ;(.D6N.MU_/K.Q86-!9%W>07U>?*
M+L:5A3B_L1PT$'ZSU03]496O\NVI4<HO3\!!09;S%B[ T2=!Q/C7IN?E\P59
M1X@EEA[A15VQH1K=<X'&V=]G;UZK5(O,@RL?E^^I=3@\@[O;S(-QB69T0%_S
MVH8#;-PD=5'>=7X@9NC5L0Q)+7F]'B&(DG+QDSQ1N:U:)['2<>'&_$+Z5:[?
M)%!/NKKB)33"W?];1X>!ZHLG]8<:O;W(;/7+%,5FP@$^RX9X_%B*/$5@F/(;
MF@[XB2X:\9YQ%^SFD[AKQN9L[JJ5_Q;4C8:&[YW;N<MPV>[7[8F/\LM;%*;\
M-D@YE0%A?=\G#@)YT@R;_K; *+%/C9[1;A-"$AE2I+VI/EI5(U@P,\_%;-C6
MUE;G2KF1D.BGLZRJY]]R!@(,0A*F8YHGCY@_9R=7:3[WY^BQ%._$LKBHW\+/
MS4#^*M><7/FYMK7\MN_JWQD14T\.MW?)8;_'J2:&TH.O38S-K4Y=3NNB2)#Z
M%[#QEK;%7TGREC9V,X\Q&8];^E%UNU:S/?$$U.N\;\+"GY\3Q=*W^XYIE2#Y
MVO^EJ4'E0$'_4')[".O$08N\9@-!,+_X6;^?1_YTE86'PR/);[EGL?(7+C\7
M!#\<KO]:*%$S['M+2NR3N;K0!]K9.7R^3H0^^ ))OP<M2+ASUT)5+2!?J$G.
M:[?2D0EI, /^5IXXQ=.JKDZ:(C_S;R:F$>K#=U!L>;,N=,"4NL"0@L)-/Y%G
MFGLV.LS2H^(B@'Z9OJ1&4)"1*=_--[65=9N5Y33?D95''[R6T5F!?W>.)BGC
MA/.U%0S%J$('N(&C0E3'4!)E&XC3(=?MB$M/A]PI2\5S'M*P5AW3Z[IB1\_B
M^X1NZ1K7:B]ANH.PI)N%$^$A7!1A/#9*&']]?0A"RNB:3D-,;>7%R,)](T4X
MF:K=1>3EOC)=53CVT'Q\/?4%ZWHN%)8]'+RU*_WZ=6HQCY,4S;6_LO\SN%-&
MD&2_P-%>H=V9]:=];9X/?Q E3NXR>M##>7Z[Q_7KM@[R!#4^Y,H&6I%PNHJL
M2=&KEO6?Z;YX9M] VE8K/-\GXC)+_@_97_YWU4XX<>UC8U!\.#I T$5<GR =
M7D2*?;S'[5'E6I<\][#%T+1.Y^RRH$:WIMNM\"> 5G[ K3SLG5)]LWU;\[GC
MEA:9N:3%1F%#9=%CMQ9N6MUFB!]%E+2&0T["%R=ZD.RP9[Q%L3)1*!-0%$7-
MASO3ZXU@U;F%M 3N^"L>P%O9G8!?&JJ\Q!V2N'@'_ )%E9H=-R\^(GU'"MP9
M.+:-OO,I[:;H9Y/O1\X_ HQ-F=Q5XR>%^&..$V*>4KM6?^;OFE%LTK#IT>>+
M,1+[*Z^/FFF">R,$.8HI;L.#Q]_>_#=2B<W < !ZL^Y@ZOIEMR!<?(A;R""\
MYG0S'< \-WP >8_@I0@LLN"SBPKO3'/$>0>!U ><"U1B4G2NB/"TVJU;E]WH
MANYOQWPLOMK84UJ]9]Y$CO%-?>HX-!>@AKD<XDCQ)_4SN%";?H6W3#B"A2*\
MR 8\J5^B[;?(P0M-?S _=#UJ6=)!_C1YIBY%(.;KV=,&P=D$S&(-YCN6@<P<
M$&?:B0E5KWP+@].97DZXO[\R%!5CV>R"W^DX0J0NASZ%'<W>#ML<-87)>D5D
M^(5X:!Y)!"]33(QSZLQL(2,3RXEA* T&AW4D>2QZL,^MA;#@/>)5S9>L)D5"
M1SK"=$Z"[Y0 ]*NP?P9MW@VJJ:DQT5@+R:K^B40_:G9_8NQS,DN4PI:>@=V2
MP8_^+)17=[+B7?8ZV4Y?J82Q@W@N(U?^?@^1#_N&=,#'PH#797]KCZ9[Q G.
MW"33)=G3ND/_-CWD%Q:OFR9!ODR"" ,)LJ.@_<*-34L)96C*&\2>"'K5:Q ;
M)TRIP+0\DUA A-_&4-29EO@VW</:QA?J[JZHJ?#36':1+5_+PI:_EOH:0P+K
M%U3(*9%!(9S@?54.X@J)XRMM"%-M'J,*S'-3/MI%UHPFAY97M^,Z'5( \[E)
MEUHE6=<@2C &I(0B_#UP2ATM/&V(*ZBK2S)L%(W?;G;?<CI=K-"S=D]B"![>
M0@U//%NEP>>T%8[Y-!^91,I9Z?4?5\@<NDR*NKRNJXW?^GL,9*7]4&<BU'?#
MIQ.[$37U\3#Y@(46L>-69]K5(9]'-WW=N[OVLL^<TIH\1J <W1SOBW%P=V/Q
M)/@IQ9%ZV@6+>ST"TAL[RA(ZT^?YRW2*T >B93L!BDXW&DO>J#F,D#]#_EQ.
MC,<L5-Q'3%9W/@/N<8[0 ?NYT'%U87_QIZ1W9.X-6^[AYW(;RL6AO /C<PTR
M\A8O3'+>U[&HUV[?,1,<//1QP=3MK&U/3F2-N8S1'DU4UH/4, LYH#KQB!HL
M,TR==*J$!.WB!EWT'F\8>;4%,>A4;+.U@*U9?)23/F-\=EGI2H\"EJ)'Q:"Y
M21Z6!/#;$$5_#FL\H:XY9UK"!J))^SUR4.;C^ZSP_59'Y!.^<[E:FZ_<7J)_
MYM67B)ONZ?L%4<B^%#_Y8BY#U:HIRWDSRK'OS"A)AL;Z@9&,S(901H3$;F6/
M\%K(28HD0;'PW/R5WS[>SH6310\<GTUFEYK^/LG*\D5$#+JC=R.WUKG++<5F
M/GM2M+S@T!V#NI$7D_+OCU_YWSEZ)0SDLG-TZQ)\XA(=D%^(%$%:_8<Q_'JK
MJRWM,3>*A/ZWYKLV;9G@0#'[$.8I4M.AGB(-V#RU;%/;:1$\-?.>'?,9B*LT
MONN0;)-\=>STLZ_B3*-#8Y5M0^I+_^F3(_^'W0Z.&B$%\&H(Y8,$F.Q$!^39
MEZ\\!9OFQ4C(M3=@XB!G4 J$"=Q U0*">^I3_R63.)%0Q1F1QV<<TA7;IM=;
M955W[S$[F+O8\I!-:6-9'IN?\OVAMA,H^3)HCL H,NOG,5GWQ"?PD9)PFIO$
M*X^,4Q-H.?_R]=>[TT$J,BU3(:(=68<)&_OJMYNH.7!7C\GS$A7:"X?1'Q8C
M._2=H-&JMX-84Y[E]\G#\YW4CJ!.YWI2/B*1( ?0C$0'MC:R@UV[T]>7TSEP
M/&;>K"J_5RBU=49?(O_YJ_C0.E; GV?V<3DL-HS(K:(-6$(BG$;+4:;P\G56
M;M)^D#OOMDHT'[_8D?"S=X.O24@&$PQ]2N$C".3$$K07G:)K7& JCH33!PXC
M-8U)^<$?[PQ?!0@)O!^L966ZQMI]1EQS2Y0W>7YH")VP)AI23Y%ZH_3CLV/M
M?(F/#20-(Y# 1V/=PE??IU91? A*2Y@N=[F);LNXK-YO(W?F+&][N3B_8UKZ
MZ59V2COZLNPUWP^C*\V,[.VTF<SP<7UJS@$H"LV&1V<L8'C\]:!!DQXP$%3@
M79:\G+!$5&B$1(-RU=&[QTR]++UT@ ,FGM>#<BEQ,:,3' :_DM_R&P8*^DH'
MN/Q%"W&_-F#NC0]](&SV4O>B_1^-Z9\_)U<%G+:JR&[^5L3/I$ $,YKYTTZ4
MX V"SR]9L%1:*E[3_:3.=]E?7PM2C%Y/3I:@JL_9Y>6M%!N\"-*:&QD^/)H_
M5"S>'O_4Z>X7TA\08#FNUMP)XD2B9>!MTCZ#/.NO Z:+BA?8BE 95_;$=03O
M 06WX^"\HXRVM:8#>A-@RL?KP&.(EPG,A&2+.859^*PN@;^;^4KD-X7EC<N=
M'[+?]:0^_EB:;+13K^6@<*[2'K_!34P\H0.&R3%;'V)+HKRF"91U?B_CIS=N
M>OC1 07Y/?"%%,CN%6HN9M,50CV[V.@106,>9OAV(NFF3%<%>/'4YW^.V%,7
M2-R< SU$G]2W(_Q\<9^0<U5)9)=+E?O%YP2)$L;;Z<)_V!,CZ("J$OB^1,PB
M"*<>1@0P_H^$/1A7]?,(<,1C%_5T@SPJ-%_MY>D-B$H^"#7LY75P?/*,1:O[
MS" [VTW<;!W1%;M(]*H?#.+[N9WF(T#-9VB>X +D[N0^A/$RFQ[X)N#44F<.
M"+\:X4T'G/;/Z$@2J>K'D9_6Q&R+)0O[OTR0Y6KC2)J<54SP2@H)_=?!HK(_
M,C.QQ'5\1H_,NQ!I/$=;G\I.%(?7"V++&\N(G] @*<&?XA:\VBY&;/<FN;1N
M#QI/FAQX;'+0 6(>^$^TUF0ZX*^!I?&*4<DTH9YFX+=&LJ4YC'J]*9YG--:,
M%-6W/GEG;.]PB\IX $JPI[7V,T1_83 3!!2"Q>Z^Q'"#-L]ACWG-Q>2IT\4D
MR++/"SH@GL/T*)4.6,B&[SK"SV(V!<1IJ?JV$@RZ@* #/CS]30=L0FL9MH.6
M$I$D<0@E$]*.)+/HT@&%G!.LC+L@),=RBBXUQ0/[J";K>*GC.!M=JX!B:YQF
MUA5.?KO-Y2@=G#3QTI&BB]F!;_4H6E"4H2BIP^X?Q_6M=,"NJ#^<UD:D XZE
MH N#DW":\24R0]!-##$J+*HLQAU2N*P6WH-.>4O,/30998D3&L'59[3[9KGM
MVNAZ?[W0<VES-^KE53/IN\)W5<TSX6T*!Q7P3FR=]A9+A3_B_H?VZ9429J5#
M7LG.3$G*&JHKOGI@H;+Q!\N]'RSORC,4U?K=71&)!U3K=DK#E;:=?C#^I?96
M"[YN9@E"N=R#\WNW<R#1+_-X'*7"SU/][)ZN[9SMKNYU%E66IS<"%Q0] \V;
M:-/ JOIV 7FB!@%)$::=_(T"P7'9UPX$5(R_?=>I'/IBLZS:ZO$AL,1LWO#-
MAQ_,GB !T!]9(#-F$P(Z/IT+,644L.L"X6$TLCF#%#TTYP+[G9S&8N'>V>AM
M!!ZL3;,WWHU<3*/MK8!(8HR[$ M +MBIWR%B_JMZ88OB,2@-I@?5_GE<F(3V
M<1;GZ_7O1&=+3W:JNSFQ.+?'F<O@_=J./3;_Z3!U)G"$P?A>-6F'P[1QQ*9@
ML9GE^O X"44N98!(_,]WAX_>GSLO\9<.((DA*)GB'3+'ATT,&S26=7A@_LA/
M^U%CBND G67D TQCO%'"_/'1:P.:"_SQWLUF'%\0.9$.$(^A9+><1>"?]&W0
M 0G 6J<V\-3< 5\\J#VKN:<,>O,5F?UGIL@)W8-G"QD>SX>91L\>=V'LZ(!W
M[C@F'))D*GB)URF9&+RD%[MU=Z8>/JUXA'X)^E-$G5I5V"VF7 YK#Q$AZ1.6
M<*"MFU]<+FT$0L(S)6M_2(U^N"PA_,V>.N:=Y3#O;U*M!AVKQ"R40:K3,.^!
M%K%=AQD\[1P*WG>&I<.7=.O5#1^'/'$C-*!_T0%<7B9>Q\W@$!=(2TU]Y2>!
MVLLM35XSZ8I;P0$8@4%!!FPXS[E"6.@ 9V0" H!]DD/NF&8?S3@V_D5&%5J\
M=TA\L"8B&ODX=^F#;= B^)VRTQ87HYGM2-$X\(7Y.4V<?WF%CYJ)85U:/F^J
MYXRE6_WK EB$EI8:S5#64[L:WG:'QN]?UB6H2"HD/_3OT?WT$-$S\6B-6PD0
MR1U_+14CQ!EYJ!=W?U98/)=YB7*=#DCM@5DQH,T%OF\0[FT<EZ9W%ME=TGQ<
MZ'/H["3VV>L\HGVYXN\RDH3=4^_Z3F)=H ,B:4""#$7"@]59\,S$@92T_HV=
M.\'J$H\;M'9CCUR5W%^?-S0(>1W200=PHL^&# :^:L:7+3&^NYPB2N!?EP]&
MFA$,$^J-()W+S&:9R75";<N+8BR>=L\FUL&)*$<G_$;K,1T04WOEU2MO*G=[
M\(-%OCL<\CV</,]C=$Y%F;S5N;HML>P1#:S+V/0CS."R!REBT]L?*M<6N84-
M1FL^)6Z=$<A@?J#:LB9^%\OW'+C8HS#8WWNS'YIG$&#3HN[W=]NEK_]*UUK%
MR-YWR\/A^<A1$ OETH(,$TGA.LG=OG"29&6<>7!7*UHHZ)ZE]4N=NI1<':83
MZK9WN68FVH%X'2 '*5:;Q+2H_XGDPP8^Z\J[7R_(7S]:C=ELOGPGEM:GY-7F
M:*>\3,7:< G_'-Z%2'$CI.*$MA%E,Y5(2 Y.\[+9RW?_V9V9_G5 L/)?3W?_
MMW[8<QE4*RI[B#2M-><4M1AFOH#E!>/E%V4B4%>_]%3*0:8WTM=$4F:/7/U*
MH#=I-N':\_P)V1O$&,B!Q[["T2I#ACYGE*E-D*=UIS/BTG_=I6P,03*GI<:+
M;&G"H^%K\G)H,8HPM<6-QD<J7>H$\JFR!7_I*K11SX5Z.%Y(@7JQ7372&9XX
M9^()E%T^$(#^QBPD8'>=Q6G=$ECJ:=[C3TM82M)@%((HS<CM!J*P:D:5OHP$
MH $BWK9EI!W9,=R?G8G$0V$&\'^TXVEDZ,D0R+%&+^T':/>#Q[03K0%(!;(_
MI_T&XJ/[&(&@A5^D>"I"\0>J=SDBZ0"<T*T[^5XUJ[^P9,Q!SBL_KP9-!*YB
M9XJ%9NQ.9M#U"28&#\<A9:FE* T<G/$ _@G')3"AKU4)<0D%7.0X_] %-P?2
MG7KCXW+EC$5^Y"\MLSW.I979<B7.@E#H66!;F_IO.".-"7:GF)?$,3R:@B/Y
MW0$M%',CSB C.ZP\PM/GKS:1FI6BA*R>P:0$FOM%3ND8*7?*MO8M;W(,SO?P
ME6TB9X1UZQCYS@X>HZB8;M8$N^W_:B$X9T T1L2NT;WT"T!.EP)=!KW#UJQN
M,HS7[37G3 >P4;3QV&>J[)#.IL<3KZ<Y&ZY95$J+Q*79(R1?<R@<K&XE(UW0
M-ZG1(6(;O&K[O#EIP;CH2BD/*0>.RT/?3U:6WQ4* W,V>IIR;ORB'4!#>/:D
M/ZQTCGCH6P1N8)8\A%?A)#'X9A!^QH2:0U$C<'0%LB/B*0^1VC?B2*%3T@LC
M"PD!PL^>Q]S_B2JQF^R5U&:*6?5& EP@U0@*5T_[L?@[]VN_5>\M 3GZO0(*
MIF0R7F6&XC*-;[<C,UT3  N<GH!%-(-5A#*$1&\*3(X.0 8AJ1)9*/,E%DH1
MWP*&&K/','Z\5LNM:&W^O#I#Z)]>F8T)FP%E=>+Y@APB>/47!MEACP4Y@V8&
M<>:;?4M0^%G2]))9I%E.K\R06PTQ"W1S[C=LBNE>?$,%:*J'.$R"DDU<IP>R
M%ZSB#:$58F>VI36IL?=/JG!=N7?OGH#$W-_*&VL$*-796Q\2:8!90'RF [Y7
M?G(OIP/:=$&N!NI$KH;JIN\IK#BO-&^7%V8FFQK7LQF^^H>!^PSA,\VVQ+$Y
M43ZK]*$8JU[]):!<-X63QY>C[,'XSKLYA\,RX'<.2L$,,9,.J&1 NW:'!1!O
MDBW_C(J@W8%)4 M5Q5V_SZ]5"PB;Q'\7SOCSYL)K%55W50=BN]FS@-([LM49
M';=<959F8H_TL/Z&TA76C[G787W+:1,#2N1X1O 0,H!X8_AY?PW0,(H='X$E
MFQ@+V&4\$;UR;1.<N2S-02&D/K74IA2]L6 @^5/XFJ3I/..S)&F7U@6ODJZ5
M4'0(@FLH*X+PDP]630VI+Z;9^Y=7J8O#^ONI@>:G"N _G1009"YM6DJ7U0UE
MA1M#086*=$ G3HRVA7[T4Z_\UJB5^B-,>_%E-!7RZSB2B*1^@ F3K6"@Q(YY
MX8":K0>]T\$REC5/1BSTM#A8(K5:9]_'+3P//0&\"/%/)'YG>('7E*9TO2BF
M&Q)6)VI'?JAR)]US]>RY]P'C%'<FOT]GEV\LQQQW$-]34:JB9!F*]3!,=*F?
MR;+F=ZW-/1DIE)$3:\ZL_HIR[Z6>MUBAIW9/FD/PCMK,I/JM?SJ?;I-N+NZ$
MVM["9[P]D-@1]$=T3GL?*Q1E0POF'G!M"]]F>7/'Y?.K'T_/Z;;VW+OR1N_B
MF_RR8*5F2U<,)'.H[ZK>G0WG#-O>C7PJR&0#&48'\*+4R ]@5[X1L!&"D,T6
MPW&3Y5F :'VRGV3R7>:W/UL3SG,P>VK"&/2;F2$>4UB6D&3>/PSH=):88+!=
M!(CY@ YXR_ ML4]Y_CESFSXSQ*:Q2C<',A'MS"?\8BKT%K= M'!M  OEHA]-
M!YB V81FT &Z7RK_7.FN]0$N)])2*]'@A^ERJ=_PKVE^1WJ#*[6@!PQQOGKG
M?[H5!/+_86PT6.W?[^P'ZUA*/!)0H /(9ZSA?[N_G-/[;]JNXK]\D2W1-Y&U
M7__?ND=.6L$/(M?,;K5@CCOVR_[K [9/S8'K/>.%7RM!8XD5 //_(XN5@QXR
M?.830X%/JL'W12LC_L/!#F]5LO[]A^]Z3&O4D1Z"&09D*)>\^9:7*"OBUT:R
M3*AWW8#\UQMTP \/B'@78E>DDT'+#K1_>U($'@^_-S<_ED^B?IY42BCNH1QC
M]BR/[=!FU(\>ZD-+?>\8N)<'8OQ5A#)D:-CD6W3 9<S#\:4SR@'YL;1GGUDZ
ML7'<P'/2;M=:JAJ:E9RWB[B-ZEV8/E.AD:#:NO>@%38X'1!<3)KP(]CCU!!=
M4M+S-Z4MNX]'JT)QYIZ I=??!H46@F^3S/L@W.J7!O%U2^"8X <J2[YQ"]WA
MOEM"?L<3&9U'&1?_F);:R1*/O]=FYVT%2:AL-&Y[SD,ZC@IO>=_F.>YH&5M&
M0IO+7*H.S#N ,>F0RU(>Q=^K<X;<;8S>=PI,75WBVDWLSJS\M)@1A9X$9]6+
MW #-MDXQ!,(6TH&:-(;Y=D!LFWXE#""2BYHQ,4#F.Q[1*:*S*;U%ZU^;3\W>
MNJ),/%]<J?::W2FAS9Y4'>EYD"^R/M=;D5J;L@^N*N+@>8=+$$+JZ9::&:&W
MG!$5B;)XX)9\(0G:'O@J+:# 1E?A\X-+(G+2$TP8-0DXC7?D 1WP1>&02D0L
M6<^$_/";2<!>M$H;9)[Y!AKX0+MZZ<D_VX#/T"A*I(E/6L5\N+7NN)MKEU.&
M^:14<L)=87RV!:4#1=_]X$!(,D-P=U@Z0_9/H^D ] @%^EL=2+'%'W;:X==&
M5)6&*E>K&T\XS*S+ZKS8!UD2)':FQ)_65N<X'VQ8"-Z1OICWG(_I[J K0>8\
M*6&C75WL^VC%9&%_*HYF,L&R LF]"GSXA/0IZKN;@<Q6#'2JKS!M:ZR8IVE/
M,9+=P6) L)BHJ3T(5,(\&OE+243! G#52QPLZTW*#3'Z7Z]>'+P_]Q3A]@XB
M3&+2;2(%$=YHQ78:T0$.; &] =()/X@+\6V)S$$Q#.[>92L2V8Z^@AE_=1GE
MFW0UYF:;'<M9]>*3:,,ABLM7BC/I4\$S_Q0_A$Y#@Y#+D(HV)WOQE6F-P<:5
ME@2YA$L;I'M=F/(][;3@],:TQF:) _.@O_ZSPI+FHU6>*1#SZA6XB[I-0%"S
MMZ^5JPO%E410BEO)T!K*_/)[Z-MN N^&P&#>\7FJP1.2##YA9U$*W]+,[IY[
M?S+E5809L!4Q2CP>-^^6":NG \X=L#1$.S3_+O*8G;-7D1\"_B8?5H8M@+<
M\Q>R.#@V=G=^3VZ%+B1FC7[ CLG!S\^GX9/H -=%-B]YJ UZ\- \576<ZN=&
MCAXB6G HG1>54B+;>@R$@/\, 9^M-;E7)MJS9Z>R>KB??:^S= 5@FI7 NM04
M+A:AF7[SLIPR?P1+[ND"Y)J.UNV8.*Z429KOA]2"V?JSI%C:V>C%V'YH&QW
M3F-W>5/#@&].F+[[BWM@E)1PNMSJVHHNZ_%-9#UT 3P=:C:.62A&5-LF>A9,
M6TQ:0WI:0L"RU-R&>QL?A:DW"PHMT^Y)\:=1>5J.3_WA-775]N^:62W&!2%\
M2$$:W_%U845_IQW8H,4NXT/35AI7VGOX7;F><MP'($,Q'CL)(7<)D3$*\' ,
MJZHV'->HRI=KXX_L%A0:?B42:N40PXFWB+9__G/ =_FD^O'!V7;T5VHIR)D=
M1'0CR5?XH_]P;Y@ +-9X_421'@4_(H181)PD)U==:V$[.#@C5)^0),BG*'9C
ME&?=>XN0.!2H9 ,MADYE$I\6J4]./QDL?$Z+A2_SQ\*X3\$J;QK?\$V,A>4:
M#"V^"W$>?V]_U:0HHW-X/WX32YM&>^1N8/%@##?4]BXU*41@P_;Z&+)VSFY]
M?FEP5($O,B>@;D[O"RI!__;9+PXY8TL0-@^65@CI9D\G\&1W.P<'Q6!8F""0
MW8 S.Y;M?L#RN*ZO2!TC4Q@82;D$ICW^@,N@!LW!UZS'EK"U9&D&0SC%2\U0
M\+\<6U:M\#ZNY;'CSQ,,')UO.3O]\JS$EI[1T1TZ0.S#D6#P/7B5GC'YIOY*
M%E4:[82M,=)\G7WM'VEG[=>>>'39A-;,$#2YYO;_\O.?$UW^!R4XX?ZUY_?+
M(F,C _1;Y9@C!/$,M5A5G_R4(D'@B$89%;M8NA.S%]GB;]VHB?JC,RT2PV/V
M0B3![Z4Q*_-YEI/HCQ6B/'R04O"..>3C=,UGB-;$[.9E\U[@18:.0;"HLBVJ
MZ3\<>4[03O2H:124ND\"ZY(?F96_CY@30?(FG0')I?/[((VIG^%0> 0=4*N>
M'."WX&[F(B/I^VE._$GD#U0=^Z&^F([C7?*/7XU+]Q:+@"CKH3&XY?%9VZ6:
M&K7TF%WD- LQFQ1 ODUZC34GK-03.6JK1=/"42^AS=U&Z1>[E=\EI]\U2DZ1
MD^A6%V PUR<T=M)&MYGZU=$*"GB!CWJ_=*I_<4M!ZGF#I.<797VA)T'R6Y!
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M7+C53\TV?^;PE76[ _;N&EJ+7G?#_5R/DABA=6*?=/ZM!71)!?PU_.G&9\H
M;!P)1B#Q#"(A12>MXUL;U<2;^7AE;I[NE^<-J3"X2F)*?@I<\!"I0$<@%*>%
ML(=)/I!!IT75G&6!0;='(:'MCF]4?'Z$WX#>64XJMFJ !O&6QJFKX7F3U0N.
MO+B\N)+Q&K+OVH5[AE$N'V?$EQ]OC!X+6J3=KH5U.<!0FQ5M;JG$!L*]Y-2V
M-!)<NP\!RBA< 8WT_'S&DFF ,UPZ?FPXJ(!\W%K<B-2LD'ZYV$>G(!8E4]$4
M=M-"O-_?HYD40[B!2V?H?O8'@A-/=:H0?R:5O<1D]/-DKM A;17'$.[JEQ 6
M>0LBG(3#,;)-HMG9:+W"?OMM*0U1;0N;$W:"*YP[P<J1L>8_1&+NVZKVEFEN
M_OB0<88?FZU$!]Y&E35UCXKK^STJ7!*<'DZ5!I^,N)Y!V[T/Z_\UNL]&J*F6
MY\?3*]I"XN42*NXA/*C;&","R#=1MJ]:B'!#DW"QBJ=S[M/']5<2QA+5N7/&
M-DP?KNV^54T<<)QI;<I!!8.XI+?)Y_)/?G6;]A^5_)RBH7&5XWK40>-74XDE
M29(AYQM+Z8!SJ%+TQWDL'$,)_XRQ>8CB0'Y7W]^;6W;FHW^74E#(P7T324DY
M[%A=J$AV[!4@>A5Z%Z%&S595QG*L4D $[D9]6*E"I-@Q[1>1'3]/XQ,B1UZV
M TS>W3\V;);I0+%XXSH'R4JO#WG"C6W1<-2O.!:=A96X4" :HM K,%*NQ@IP
M*&_E)%4IM<%<G334S ^UK>1VM1+YOFI#.$C8QU?13FSWLW>8=+';8BBL_ ;,
MJZQ)N?%HU.228M^\[7FK6$/[UQQ:8K22)5 1IC6 ))Z']<INVQ;FTWU@_-[\
MB=@M/9=*JS<OOQ^ZTJ4IRK-0ABW.: 0?&3>%B>PGN<^ZQ3HTP^7Y+4)//3UT
M(5GXV\[#D8^)-NV3?4G.SS!HW>N4,#4XU:L52A!MW*#P4,-G\%MKW ]JW7#E
M8]WKEM&=D8[8(^F.JU )BBHI.(\B31 SFO1Y^75"XIW;K&G/=]\WND/E5X0O
MN4WYF"41=H@^A:22*0SKPJ#N$LBZ0!V9_,KKN/79A [6BGTR,V=O_'#FYW&M
M1YVH/3&) /=62Q.8ZWIMH2.OWMNM.TW56IQ_VOJ)4,@%N?+T\'S8N[C+[^8'
MZ8 ?1OH4N?IK@#9240U>K[SN0P=>2'$_+!JB7(Z'!EXX=7>)MXGO_MB;0JW7
MPVR<:V.BD4-E\;1F#[;[E.>#U3^U+/M>G+T]XL&[J<O*V0C>&5 TI&:H2DUA
M6<VL44<0IVDBBID&=G=(X4H>(2&R<4\.UUO-_!B*0)PE)6=2Q CIF+<71(U3
MLG^,&]]^6=0T/%ZQXL#$4L#\YC)KAJ5N24I)K<NX7I5?8O[RVBKUA6=&*,:6
MD_TQJ>.Q=I*OAS QR\Y=C#W3M%A'SH__R\^S[".,5-HS:!,=""T1#T&*VG!9
M-Z[$\P:?'"9ZV/)<SM@Q;1,+MQSE? G[H:I!R)E2#)-GSB'YX(A?]ZH;G=9M
M;]JNCD?%'2YGL,[P;'71#%\3E(54B;W71Q&>ZD"Q#3\N4C&]G#%J?QE@^M96
M-Y^CH+7Z*'-4XK(ARCM];>SNIN"YE#+9?WB]116EQM.!V0]&J#$PE5L8:?\/
M@P.58K@'K%."OG_](R90_B&+JO^SA4/R]PW/)W*E?QL XO)/OS&4:J7E(=\M
MO4 M#2W>^Z=U/=A&RZN-T<O[[Q]_R'S<_^M>N_Y_GLW[GUI?M)O;#:Y#B N0
MUV%Y5**]*JY?&M6U-GIW-?;\\9RLULRSQ0OIY[+$^8H$[2\N.TYS<M"!>B6$
MZ920"IK539883HCS1PJ8W.U"*,%MA$R:0D:<@C:_BQA,0R3YV\0B'!R7P(5)
M*\;)M#:D!,G;"U=C#UOE:\*:\^[9->W7>B;5>U7[[C.XTJ?TY^*V3#_8G/:4
M@\K;6HB>.0A&%GCZV;MB9(8/19$:&XU;7]4@2,Z *&)Y2-KEXC?]UECSC>;W
MH4\/5*]?VOVP$8"_*#L932RGQL81,_%87Z=8@@R^?4%P2[DGY@6RW^I06*V!
M:M/8)X:-^FB1C'9/>><U<"@O&>;^> )Y^MV#CV-D5\RG@:0I][+5 WB6!E0Q
MNM%X_8!;P^1CN=V)YV^61MY ;)1]"JW?OV%FB_QV\LVU_8*[.8U@O$Z-_?1H
M1R/F*$V=U-&*Y;@0M*M^3&4%%W/,^W9&='=$&W^=T%63)W:24+BN_O&4,5-4
M7NE%G3:Q/91QHA!9C-9!Q!3&^:AJX3JD7L)</$HQK_)NE':LI R(W>YYPOI3
M?2KEU.8S*[4#GKY!9@KWFP_SL]5HUB@'.>Q$!2]$[9ZQ)!VV7JM!4B'=4$:L
M7R]-$Z5<(2B^E5\_@NSS^!*8O5PD-^JW92; ^<I!NXBV<<,]=BY0[;)[L\=Z
M V8$,@/UIIVRCE]_B[&A.K88G0FA60[ZO$J^(#-YME=!EII.#(EP+-Y"YUAG
M\+7!G(;%R:WB%ZN25)#]F *H/\;&2_,FX83'SZPI.&CAAOV'Z4_LQ&ZN-X]U
M6ZY9&ISQ'S38_U'A,,OW+1!)G'T^L-HT%0850LJZ1<_()P9+=)NG0*^^6+GI
M4UVP6[B^^I%'ZC7_UV]@VYX[H"K7<$\*>?=2'(;@@:@Z,=1DC#JN-25LS[FO
M]@-\NJS8;:M"WL6I..CI)?39)I?1FI?'YP'73O>=E0RRBC&R"\QFJ)FX0X8W
M>Z0W+B%/#SV*];I.N_$!Y.CPP,IV_FN;@(59IP;KA%T^AA'4XFG!7]7T3#$X
M#$<BNF+3L!DZPF<ZI'X)BH"0C EWR#APL+/GN17YK-,]4P-2)8=FZD)#9'E8
M3P+LNZI,KY7$?Z"L("/KFM1/JMRN*8M[?C^KLFU=>Y<J6RJRCMK+"[7=WCSS
M\HIN'9/F526Q*$BV[DVOY@YAS-3D9-S@F,F9=17,LK87L9?Z-C_/O+8D?G1:
M+''RF4S;<1^)I5N'1,M/UX+@I+-AZ"GP4=L^A "),(WQ$SDQ<,8F7Q4,/USE
M+5"Y>U-'9!PX+GOP); ;ZM6A 9' *.I5?*J ")*.D:5(%E.NC9VN#5C[_NIG
MDZ*)QGF>>@0Q.F"3I!][\]BW9]U"=T(LHL/2$F'S),Q4O,=.8XWV?8@/N)@E
MN):/9$LSB#?=?QV>'/I^<RY)6:H<./=4 '_PT=!X\4,UR\[!P5V7K3,V(F9Q
MF.Z**7 1: 6& X]\F7\T=*I_&\)/6C;Y-2@Q:'L7,5;1<NT<9OQZG4S;<S'V
M[V.&)Y*:I(>[6\I0QTKH "]%AK0S#?</:.([N*[7,]HIK\(L\]# [:G[T5OW
M?FCMAI?S,R]EGXNK[D_2@,?!(2>-SE8M;ZXON2FN=)-%%Y**TN??.N]6W\@A
MS;0BQ9[9630+SB9D?)2^J3'_U.HC5ZOWIOD##M:9C!4^9P+KS#,,#TT$H3]8
MRT5JV1MXL:T=JC"V*C-Y*SM3':IP.</VI-*%M)1/R?Z0P?[[VS;$'J>^LHP(
MS8E*4]=-=1@IFBR\E*B(3WK-K4VJG^%D=]NL'V2W@$^3W;\707-VG^N["CQY
MSM9SOOZEFJL!YVN4N= ZR<B#LPD4C.65[PY1I@,!SS:+C3T[Y+Y^+8I^(\:[
MM,;Z)GODP#6)-!_O\-S,;+U7<9<G=[;@V:L;W%JM,:LP1#69TA!T+HO_[P=]
M'MBAN(VCAA1HMRJZ_; ;IQ>3B'UTX%:-DRN6,/.*#IB,[0K.J_.AO@5_08U!
MJ();3'BK534Z<.8Z?&\:M>54,ANSF%0";0GG0BB2,O?,0@:#86<JRN'%QH%"
MKQ(M51.'KYDQ\G5VW1GT[B(C2)DZ,H2XM/E.7Q-SXU3S4YN68L&B33KP&J;[
M&(P?$&&T+#$>3@/R0+\?0 >RW87H0([;)(',D"#8;P"AR&N&8>:_)#"J2FK^
MFP/&M2Q[9:'K( R-*4_C&1UH?."V3/.PP9#V%:-^^^YEE!&!^E/DGR+_%/E?
M4>3 /^R;V$('_#,)0Y2M/A3^ &S+8DK:/Y?BC)_7&=B&R$WJ'+]+N^DOWW%#
M2(2E2G ^[\Z#7@?5E>>&4&G=F.<E*YXE/*VHAJP?F,5U.K!/,)ST4)F/RC!C
M4S<,S\\)A_Y[)W^M4_ *B\]VDM[SI -U_JDTGGM^= ""(AWM9QKN,7&E2'QB
MI24R H!3F8P\7#\9U8>E[9<'7.0,A>G D8SK=" #0SED"\8]6(!N[= !;_:K
M?Z+]B?;_%QI@@]EX(!^^MQ&\&[0":U]!,*=WSGS2U($7>\4+/8M\)3,1'3([
MI/D[*+!BG:_RFXC?0%^K"$J&_:8PZ&^@GSE:@F8P?]-7\[<F,C+"\O6_Z:O[
M)]K_:C11$N/74Q!6.C"$IUTO@[TFN+[>JCE+OA'$66Q76;F1ACT/EA96D]2G
M\>2',NJ#=R@_6 PU')+P>4[P/7<Z@/D93C*H5*2JT@'LYE5A4YYV5$-)#V9Q
MGD8'XL$XHP7L%B-J0W4"SDZ&YQE:#=UB:)5$IEDSV@A+1?5U4^F '-- CTD&
M1=)4B):(6M]-_1/KC\6R ^V5[.GG1$#]]D[=1_56HKH=M1EB,#<98M ,,<SY
M*14@TL,]<:H:"KO)H!65FY:(6=_]S%$9-(O"&2XD;6W_P@?A<[8@>QZ_%'ZM
MO"09R8"'IJ#ZAG[!HQK0/>#%Y5\: \N9^9HT'F0@ Q^Z0^GY$^J/A,J-IAI[
M2:0[YN$Q-X] ]@PANVNV97^][Y\Y\H/F?J,,Z&\<>ZU<*?GN=\;\1C)@:2'_
MMR[>\SO)F'-2*B!_XZ?FGUC_B[!46/^R?J-D<  N,6CE&ODOMQK^5YI=%7;F
M^48'_D8;\-^(!CCW&XK^3IO?F<8TI&L2_E>.IOZ-:#]83#4<P'_C:/B?6'\L
MUE^>Z\-B?Q,D?P++YO3@ON9H)1WH=KPJ+/5_LI_Y$^MW+.??MX L,?R;P,%;
M<5.FE^=;=N(==^G \[ >2Y,[-^POL$#O63,/9OX7"0S_1/OCT&9JCZ.^I21M
M3T*I1WY_GJ T!6*R\5@/&%Q:7A6QB1G:<>3A9V$. K;O_-_\;_R)]L>@*>>L
MDPCE="#?CA+JF,2*F=7H Z]FT$(],ISQ93>#!JV@)?8/GH)[.<T-:'RH;X%?
M4&/07T_E=P/(3JBV%Z#M*?#6E^E:-W0R'; /WY7RH56ST-Z-&W;S;,F!_;B)
M;!G4EKC/NAH\%4M^?\0.N?]10;;0VE$;M[;@>S@66G0S-.PA68C,,-5M0CV8
M95_0'H3'O1SK+][\"HQ?]"@:MDX)VH!T-P1)UJ'@@;-EU##U"ZIZ<A!JT'(%
MO\^;I4.4:Z*$7-@#XH,YO:%"^)I<!J?-E<:J@O5^PQDHA;NL:31CI970@2N)
MS?JU6.,A2#.5%;'O5I,,]D*O)DA8,?#TR'*P7R>RW= $UQZ];1:J(K^AE*R.
MJ@!'&]X]A^[D))WGP&0A?R0)RF&\*]DI>.M$_A]HA/%T0"GJ'?_JZ&V+5TO
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M;3KQ+%R9?_"'MS.%,S(/WCB],S!9GRFO;&9%^5F4KM*\L@YCOP7'KK<5&<>
MCU E9YZ>LA[!V W>1]GXJL1<6F _J]959:$^O/N<(DZ5)+=3[AL2>2S@XV \
M9TB2%MKADX&!K?::_YC-D_V NI@S0ON?1]'4R(J$ 306TP)F(Y_K\JVK_NX]
M^DBK57KPZKEG UP33QZ63<@3052N=;H6)A9$DF< 5F*M]6Y8IK^IEZB'8TW
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MY#'YWL"/YW S]KU8'0A+525>865AO7GF9=#R#>-G<)YLTS["?/N'G"*%<&\
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MV7T35 &$V-4;.EV,2G^5EZV_0Z7C9X3=)-;ZAM@D-^9)/K27,$5J$%D2!XX
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M#B\0!:75W3K<2[0XYW9XF,L4\M7;7H=\T^!LND*>#"50,&C#5.<34]>-FL1
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M<.=,^Q0D>HH%"([W (L ]3D;'OM>=\_-8WR2>8#RH>% J#=T^7>U@8O:ETG
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MIQ9TEAV@GL@T_+L'XZYXKN2P '*>^BS )W[4HK85]0>L&%>"H<?52S*K+K,
M662;U&CJ':2-$ MP.#E?)PRM4"1'IX,ZP!Z]L:(L0*EK0ZP0=<-6<&VM303=
M-'QC-6U)GUNP0F.L^H6:!K[0J1+&@6IT^U 52X&1EO1[/AL24Q\I.(6+CLAQ
M4F/[/W_"A[VSAP5<GXRRS"FZ1AA/O8@;O4KA*V=\K-,2:R/@069#2-="WVR3
MH9BX$RM)I&8/VYW[;2=M.,)/'3F?ERXEZ/NS&\KD3I\N"D_3)!%B@CB7?5@
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M@HI 6EK;BXC8=#H7F;,9)417=B6"N9>M@XY^6^<X2[#ME(LN;K2(B>+;9WI
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MO%HS\[;@SA6^[8K=D59P,:013'7MI2HD14Y57V!DPJ<2JP9-B<VK7OA6N88
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M8^AG-UB NTM/2S GISB4ZB*K72(:Y/9;[WWXT%<V&#3+]^?/.IK-48;&MW_
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M %*9?Z4LF:\!E[H]=ZC8N:#N/E@4AH3%GF0!^O3(KDR^,SCJ#^!?".;)#UD
M:SBJMW7[ N4!FN[" H3^)*LST<J18)+?$Q:@7>&O%/8"A?]C??[SUR<%_!.^
ME6-#;*<K$R)8@"TS.O2?[6O,M@2-B&((HT39O<!?3>'^L8@M.XP@Q (L9%(K
M_\46?TOYW1@F>D%LV9N85 Q;=V K[O^QQM]2_F0-O >(+;W8KZ<N=A682K^9
MXR^DW^TQ8 9CXPN'E6>K;T#V_!_V^%O"G^V!IK,!%LH@@YEH<"3J7_#Z-Y3?
M\5HV:,-&F/+ZG^UG\%?*[XC]D($314VCD! V0&.)A/^!V+\A_ FQJZHBOR#V
MEU7YQT+]%UDH.;9Z!*-<6!2.A OZD^Y_#8?_B'[_/\].NW F-XU\H4WF K6C
M8-3W1:O_7.U=F><J'9ZY'A<<]$L.1=Z2 A5S?/YZ863O[O#CIDX!+T_G5)%7
M5DU]B:XJ@Y!O1Q0RJB")_]JC4B?8KFT;E'@G_Y]/3[GTZ]3J?]>E]XA9$.AA
MCYYAV.Y^V^?_[WV4Z]?UY[D]"_"T;RS [(<E,(4/QN!VXZS.0"L _ONU@4&C
MRL)#F*(.JHF#O;D>>;IPD+8H9/L/4LY8H<-MQ9@^&XU'%_/$-8-&!%3%MUWS
MS6"*H\R)76>G?36DH2:HZ[K>Q3/@/0 &G* K33<GK;=**Q5Y2PZ];6\97E/K
M$F !W -U=JT3TLU3ZN(:7_2<%=^A:>M8_AASI7Y?_IB!;J!<^5^=4O2GI_L_
MM?WIY?O#;;]NP:JQNX!R%J CB1K);+)',5\K!2; )%&-]FP[="'U6(#;2F 6
MP$BT^A%XS\]8YNOH!3JDCWEC\]=0LG)?4 .*ITSZS-AT;\Q^;,I]T2386%(2
M/C"TI4OPPXS&NY>Q%[4JO#4N%MUFW_V8V3UYG,I+ZFTYTAMUE^VO(?EM^%A*
M]] 'S/DNWH*[AC%GEXR*=R8BS&WF $)1([EPS $5< P+4+(:'HR\C)"BV.>$
M(S(,Y2YU>ZJ/CG2]N= 7][F!9A.,:CR-5?3P#V\&"M*/DV\4:$-)(Q8)QKY9
M=Z KV>/Z^_U#O!.Y,D**C&#M!9A60LW<\,2[%4)R^OP "^"3>8*TN(&L@>-'
MG+*+O@\0Q=!("YH#<U#S9#E1!VK3MQ7H-*FC#L'6Q[N=?MWQ\&!35(O^ :OI
M2U)\1C_TL\G*E'%&-O:4KX41%?.)#J(B2$MDE4R^4!>:6OI'Q[EKKNZ#88=J
MU*?BJP[LF2VU*OH.8T*@E"H6X',WCAE=7<1#(D328=,$?,!,;R12DJPU/=\H
M[>4I4!Y-"&8>'T\U1I@+<]VE;.]4:B@=W6BGEVF'ROI(@RY^FQO9=J<S!E/7
M:^F[TD.?<F#)!KV>285%2CC3G*NDF6GE%@QWT"29+D>&M;, $?X]"?O? "/*
M\C\B]1[N&W17Q)1.Z,G6)&J=L&[?"T!%<EI0OJ-DE.G"^5-T%,\(.[N$X#T/
M&>X+J?G878[=#(J_,8-+EM1Z_B+^/>)!.![GW!M,=J3;DI7;E"604!*A%1.!
M#WT_,,84@'[,_MR/\,KIBCK6\<4*D.C 0S(6U?9IZ]TQKFR(I8D\P&TY93OR
M1\ZGFT*LNE'T_9XHXY,C7=4IJ-J6;D1GX<:CQ>6GCU!E.4TL /X0Y2K)B.[>
MSP*XP01\UY:-:Y\M^\L42SAJVOZ(N_E'(;TM6NBQ8J+5WOVG"[+N8*,8676G
MY%=/T4!X:JTQN2BB3N"^MKKZ2^W8PX34)UC#TU'!D_/ Y>/S^P)F^U&-)KC9
M=NQ)U A(F7&FLA 6_O2Q!Y $@?#AQ_0''$Q(_>(ST?K&YP8 @( $A\3Z%9EC
MN)*ANB)1YG)6#_J<4;T$C(@ :UU<7G970;*SV=Y>1LH390&D,#60+ B.Q/&K
MY%]4E8SH#3FM^C36X)7>DZ,*W[P5:5[-U<Z.OW8VS'CB+2AC9$QC-5/9@\"E
M?6$ZT@T(&:!K72P=+*]VDHM[)__%^=GLJH3DI9V@S<.Q3&YG,KS1&ERB_H(.
M]B%VBW8Y1IK7EB#4EI@*GWCZ)ZZ3]8M+]]][N%S&T>/[:7M&O1DXFDG!CJA&
MJ[>D),4I1VNKRZ4$=J^FO3^MBM!Y]>KR1/!"@:'Y$GE>SN?3BGYB8CFZMK(#
MOC$0J'K1;=G4?K02S@*,]4+>I>&9\AE!/:B#S./(8Y4C93 )NF$5-3E]IU@W
M/##O:J5YY0WU5)&6MSMU*\>Z!(,>"-^R*;%IQ)$@L)>3[#HBM)?\8MJ5+I^,
M$M&5\;W1@%>.6#\I=O[44W#U9J/NK;;IP:@FHU ND>U$5V7_<RG^AB?KM>DL
MP'1G3/QKI3P$F,JA)VPI^O_%36$YW\"?8T,A[/+-W9.WVO';HKMNIKRTFKX5
MA$%9-&'4U%E.*C"RZTS3FQL_G#[B;;LBJ'H&O%[A3PS:1_<=0;D2A)R6L3*?
M^]<]/Q7RIJ(\KLJA7SK:KHX>Y_>*G*S"B?C&;[;IGAPJ7[V4CALZ\Z,>T[57
M^8UL\OT]IOL-VU5#IG[87UA(H*TS#1(AO."B7B&=:DL;@@_UC17%9H63%-:I
M5>A,W$9?&7.3D8J!%!L_/ !1O?GFWK; ATO+F^IY(VWE*S65JQ;$5>.IZ)RF
M+Z>] ^6;'[9**9_!["T>[\D;Z_VC[4I. +([5$)CY7I^?N\*/J=V8* 6=#83
M*F1R\\-*%F.>,5GQ\SM%&LX\B"#O*X^<R:*BFD]E[ZQ3K.K*J]Q#H#'=/QX
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MK;<7%!)WG8>3__"%CH])Q1]PR0DLP(G*>6<W2%*A$::[FYHOAM1B 8XSDUD
MIV+4PIXR]^*VSVT?T1_1:GD?&P#> (M\PZX44\<>_T>SP;&W,M"*A_ZM/Z9=
M7%5G&H6QZP@G,]0YQ^A'>$]Z(J\SLRZ#>:?VR#_M_7'!+1$6X)N]S .-;.>.
M);HRHI5^[2L?6?!QXOUUUHG/-"S<.MD:*TSJB9V.A.9&M[9HJH981ZAD 1R'
M56]V/]L/T38/KSUE7%-)?&/N$QR;@@I)7KJ#_)_LYJ%Y;?00S$O3^M<.K!6Z
M1F>D<+_2O!YUMK/3]VCP9:["N[Y7&YA2U(#,3W'3GGR+04?ZK?!FSIFC!NZ
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MXFC_&FCBW9.1)#LV9MS!6#+^>2%'YH;VQWI\)1&SX"ULIO<X!9@&_ILM6G9
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M+8;J/"N(]_\T;?[_(X4\I@,.,QA6RD(I'3!:!Z*E66*Z=G>C**<=:;HY#73
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M_?UH:H3VA;A2BB0$KRH.Y[;X*E/JH[7QP67TG+*GZ%?!H/?3B*M\^U&?/I<
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M$C4U9.OQ2]A[$+NPI.E*Y9KP7] VNV0P DBXCXBI9HSUVYO@F9H(BJELO)K
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MRAS)YT@9';;GZX8NCP_>)[2OKGG;>\J]\79=JP=-)=X>U63AV4UJ@81;2K0
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ML<Q6GOSBF*KZDT$34Z4F.YFG= #A#)IGS\JL=PAIG*.K*6(%G]'=@H?LE,V
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M"5T3Y'S!OKR>UL3KG?+ /:G<!K^QN+$/'B:JR6YF4#ZZ-,.)4HJTE"GSQ8C
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M@UNX=]ZGPW/G:-AF5BNB#+B*(8"U2%6^@?D]"@B7#WW^' W6^=DM5I#'%^^
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M2AD9L8]@5/*?GLGP[R" KSO$_UQ=AE\CHV>B#KKB:0^I?92^C_ _U>RGOX.
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MPOW[O#9ZW'\5_J]3N$^V7?9$T7-BX4UXWQF&D8))ECG"#!LL!&WTP"-\D^F
M8G#^S= ;P#\<!Q*J5)09EFT$QZ8S"JU\>G="DW:F( K^WU%(&YQ@&/:_V%;]
M\D5FQH4B"G'8_0.&8=;\S;\:MZ*W=R6H^Q!":7TLX!<<]RS _W<PAP@;%*HV
MPZBM*%*E'_X"\)\ P%%2/F[$2&U8PF ?C\69,CR0@Q/POUU@Q&#7;:?(Y[]J
M/_BK\']LX2'0:8I:O'9]:@%E$T(H_(-I\0S\RYSVBEM"27^PTJ0_.I^A!RRB
M?[#2W-\;N(TO-Q-#"?W>2B_^P<+-;=0!7J _=A/0'W!@#/]"\)\1P1O%=B#G
MS5"9O!4Z0(7A?,K^Y34WP!--J)#C_)T#NW[K_\4I]X!%^H^'@+_+;6[,@(']
MJ_C_#<6?.L-4?JY!(8&%VLIQVM)G>"#2,9-\0G8BPXL\?8N_7YAB]Y]"%_XG
MD:=_P?BG8)C?F %&"\B$X78K&VL#YD\UK#U\4RLA^E)J:"619/R[F)+@_U-K
MX"\8_X? *$;&3@NECSRU*F2_=@58YSZ[9$;CA7^+^0B? /]QDX/L/VUR\&N!
MPJU,T_T%)AX'4R_5(5^[+&W\Z=,D9I !-.S40T-UGH'SM# <U;C=L@J5\6&I
M)A-5X*$5V=W"DN-\[/#+3^_*OAXFW&2VA,F0O/%]46NNJ(N$C@I<=?WD(P$4
M0KHPPUW1;9O;O4/#<_!\4RZ-=8,.D/"=,2"'T $#DBM+8))4 25,C0^.<=.D
M V[7E ;MV@B\>I?13G.#1;ZR6Y.X2-2C=J'[27=;04<I\%D]27D09X!@6^9Z
MYNJWFDR'9$]/]BM*9V^>.QR&R1Q,)7J3RMAXX9$BU]2%+1I!?@ ZX)OO01T=
M<'AO'_X4Q P\H#'N.[;24LEH1"G;],Q9RQ4@A\SJJFARBFZ<\&-W>SZE;PGO
MXX'D53-Y*9.$P)\%@EOE9]\6DC6KUO;I@.3]AD_.F""]U1'_D0H+FY:)"S6U
M\9WG%7,E^5E6-! %4\\P(T0SA4%;6VNM+ZT0"'^*MDTBCZFF6,HM@)<WN))V
MF<#;TC>1A>- %;/=#N$9DJF'50G=EO59BCIBX&%:5G_-KYK%E@/F2.M#L0ZA
MA&#CL),$%)(OR6@ JE6=ZO9CY%*;NS7#6(Y?46WF"8!J5A6N?BP14[>XV)\6
M\"QC]T!(EG(=WHX^N("28QA:$*.V$P;%J=DPJ8F6K1Y"9X>AND"Z?\BAU4NA
MU[35P(?0MG2 "^>X.8T?_G7</!J-$Z(#PC/6QF.7Z  'LO^8@H.D&+:A)Q6T
MO!E_HBD ^4J6#I@IY0BT\SP$O<1565;. N%R9],252)?[!L\7R<:@S22,<$%
M!V9=+"YU>T,H"(<)D!KP@'HU7D)U%?ZV2\T:B];@Q_HM?T=W.D!:?W)-J<\:
MJ+.(QF71&/3@I_1F >TT!DYQ;[I+U*16Y%'3?9!<H\!CR!C\\'RD!W9<_.?[
MBY_SX$6I'LI1'Z\$+23ERL%)4CP+T?+!PK(&I%L8Q;V*_*I&23PH4UOX15'2
MCG[>2ZGZO&+)K8&$$01F^DE^KO<@O);D_8"*H%U<4E#DQ6 Y*#;V]FZ">JKM
M'1&^0I[GXRNN\Q'> ;0EGL?BW$KF&VMCIZ<E<@*M-84,"QW\))AN":48/*,.
M47-1YZR@2E0$]#%RA5WHE$R:&+L[,*BJK7 N[]%+18[UHYZ#$CR;LI13-3,E
MD0V? Z+P:H5NPH-+UV2R\V.XK\3ZV6QU,PE=T5!GH5:7/N,K,#1Y-?S*;8](
M06TMK _&IZ]-;#&ZX!Y0;1']A=&5@^]'TC"XM4F/^PW#$%DW-_OFW5@+TR'R
M28Y \S;92#4IDG%I=1)^[>C>[2'/NB<-28?4E^J$[&V\.^;$@C&+X#6& SIR
M<9AV!NHRI"*)0W,X!Y7&?+!FM[D3W"6V7?H4$!AW6NI(DO-DG3W,Y*T?TI'Z
M687S/>PGHCR!UN0,R F02\:K"JQ -HRY6'62]F:[D]>5GS]LM'G8(C_'PQ 7
MR![P]8>M>SD=X-.4OF_@8Q30ID$;Z_HY CJR"GY*S_W]?)+6E_2E#T8>[,>&
M9DYQ6B[]7:NC&)=YH<[HLG?Q<*K7(#J[W1_(!YHI !**8!(!&2U 0@FZ"E2&
M%!E<0TR@#+)K2-4A;ZJIUUR*JIQ;:LH^EJ[!>RC?G[Q]E?]3&<8ROQ>'XB>U
MXBA^??@D-A>8H.Z'EJ/#.TLE]_(]:\\E:ZP^=12^)I6%_,CH I ),X/QU-:#
MHRDJ(BB^.-WZE*4\V@#92N?[\UO ^B0GH8,%T8\W]E.J<R^E&(QK?*^S[/XN
MM5(23&,E>\Y@QSH@L;87-NO_'_;>,ZRIKEL7#J(BH&(#I$8%!*D*(B@E*M*E
M2A$0(KT30$J D*A(D18! 04A2D=*I",M($U0>I,:0N\DE!!(^_(\[RG[W>><
M?7W[V_O'N;YK_U@_<K%8<XPUQASCON>:8PZ7 Y_5F *!$Y59;4KS72][ED\K
M<=V'&[PO6X\=>TO[C3V;34(3UEML+F<<3PE,>ZTR>/.GR[63%N:$1[:DL1D@
MWA0K> >)'_HA>*XF $FVHVY?-U4\*>$'N$'$BJ-()QRC"\7$'J+:14D(<_+;
MW&W3BG$)S/HB"?5!?A5TFC%AZ8"WF,M2M"$<\.2:956J8I/X-ZM;+,<E!Y,?
M/EAC=FI$TECI /*MIY1@TJN08E+*Y*;J>?Q!RJ[5G8<SS^X\]@&:,.G>I /\
M_-S(NL0":DV#"EFFQQ7'P>'RSCU3Q,H?\DUCCEWOGB1\&SXP''N>=WYQ(;E[
M<:QT5?O)ZX:/-QLU#@.L$>BU(R# #?O-H+.$M\.J'AE9(\N(.8Z5F,K:=Z]6
M$G[_[OQSS+W5OX3#"#]3Z).W-A$ZFEHP6=U5O&WKXO2V[)/LS>/\@G--LW@4
MA3.]HWKB,^0B2>;!L-^@M_V@38CV>^?254'#J8#FO@*T,K6A"03E)D:--IPI
MA2KJR]@.+48:QV\-M]X6_IFGF/'=O+/7M[C9:WTB[V(;6:O#>V U7P](4?@]
MX%M)SFY5Y8%=)(QUZ*YZPGAP,9M!7^8LGM__]BB$)?FGNN@W23F;5W,R?\#S
MZ/"][Y!MN"!8%W+YEU3X2-5"+3&>Q[IO5F*?9^PQ]:^N>Q^]*L^<6_,F0;2M
M(JHBSU=-M4D?.CP_*]M6?^<L0/6E>6<F,\.S*Z") BX<O% 9W?I!@6:ISY7O
MGCW\N#!G[O]NOOJ):E8%-#I97.?V!3<5.B#GD?3JUT1+N=D5O\GZ# T553Z+
M7$RBT3'+'(?NP8N55PQEK93M2]VS"08_#/A)?/IZ:FV9IPD<D1L";;K^7UV?
M3#[J?7!5[1Y &T#8M,:&4\Q=YS&3%S4)(F_DK,;=:(JOCTZ5 BY(^H(E"IZS
M,GW3\-;J>P'^@L4_Z3N\<P.T(>=*!U2,C+;IQ-[0+G$8A(,Y#M,ZQ$T=C^]I
M8_HHR*X2EM8)='25R^U&[L<-H_)*KQ_=,3NGO*MU7WCST8EX@.BK?K/4F"9^
M4@6.;,5Q"0JVQ(_732^< 1NDC?5,QDW"VOG*$C[Y_40/H?X($;TJ2.SXF>TY
M\[CCP7#,5PN^"/?F<ZYI4#[\.+FXF<5CCTGS.#]%C>Q &U( 5B+;6E^X6 )9
M5_DV*T,"K(M_:F&5D-MW#7W&'\9_3O*J]Z?&<F[6;U(1*/M[<,JSF6EE1FA:
M?_&C<O/.]E-,3=FWJC0B$==F.&G5X9!H+LID>K]+F,@YP! 5%*_,8LMY\+:!
M;X[C[+CNE0BE#"O=S%$%7U8VWD> :B;%]1;T !WPZE[-!I4L[R9X$K\=(1K6
MCCU/,?&4RA\N6= M_+Q+3)&YHG3E 6K?=?<.=P!\WX4.:#$#+6#]@.3+7QC0
M(R2Z-^]&AT^L?78 IL<&"S6BKE<,Z=+.H)LZ%T6"03_ZQL?F-#L*EM);,B\T
MCGK:>B(#W[^>4O#?=71\.(5\S[^C6 Q^ V="S:':MD]#=4ZZ3#[%1(_D&"7Q
M>[2&T '-YB_@G$>K9"V8TR#"#O.J[B'4^6%5RH-KKI:J:6TY8@_E>(0G=V\R
M^7H_<+)-E-5SCRK9N%9<NK"!X=B]KO#I4&B @13!U^%@BAKU'>TF3*)_<12F
M.QLRJ2=]_F-I25X$X:JAK*4:<U,['>#Z366]LXBH0!2GED@CW/18VN[87!N4
M]-M$:-\Z)/R)(,O_OK#%UAW_V^1UKI9D<!B6>?<7,9]T(Q=VB_JUBH.U>3V;
MY&[46/.]YMV["Z,3LX4>S@!)#P=FE6-LO<ENF=@_IMH*-?M4?VF"WZ(\,9"&
M*>D[QP#3$?L0+K?^U6#!U)#BM1?.W15#FS-!.<U=$U&LBH#,$RZD>EQ?C"JP
MJH"@&;Z//I->TC'E=@0;;0J8\AI?$IN.C9W/4X>74$X00,V(,,R%VY@W*/;Y
M&"L"UQ?^N$+WE-X:E@,C.=K1<G:94-3\H4D*SH"E S1;BMI]#-H2H@.J]V4N
M33]]>&O0&MQ'B=17WM+> ^?VO54]2;E326HA/&FEG6D8>]+JL[8K7^<F:W6(
M$_[3SNVTU^7$I/G[KJU-'-D2_C,8M5%1L&*U7S9G+606;R!C:"7D7NX@Y/<X
M'4NRT%+Z?E@[UR"C-BI-42IYZE8M^T&FV$OH^VO3M42ADT](YR3VAXB_\/OY
MG:@_'8@+XQWE>I[VGG,AUVEK;\Z(TAX$@?C-/GQ-S/IBK&331Z$#5.HOZLX4
M;2R.N*Y3K0@@8$%6],:Y?RJ4WI+98+ 1834&E]E?]V0$G_XQW,C_9@?+W<C6
M"PD;PT;JT.S_V5%L%C%Y0&2 Z5=D<<IS_/(;"A!7PF)5UC 0@89.?.*^\-B\
M)_GIU6B34YQ7)9]&=+SH?[&_W8R-Y97I1(>K"A!&7](!!)F1S3=Y7,]M9HQV
MNMCM20FM-XZ<HD+P+^*[)G?!V0Q(&BC/ZC7"( Y'&=.<NQR=!A-A;73 :9"[
M01B8O;)'2;NV7]FA7.#ATM8-RS6IXN8@R?(3-F';$G#.?O@?.H '+@;CQ O&
M?:5(D((4VO1LUHVMW(NT/*6EXQKX>&(.O6&4=]R!#S*#HY-%Q,1CG*;@KI.[
M["%;*).D0WE$_\&:>'QDD'^!2UKHR#[Z#\2I)EY[4]=KQ\'Q1)(*7AL8;E.4
MN.@I*R0BG%,7?LE(Z_,_;_^-V-*^6I6F9;>[^,A)JR)N@X59I=Q5>R?OSV!]
MF3SG;N?&"T+%'*:CA*5= <&IRMN#G]LV&.8ZH\I3XB75\UM=6]1CJGKHU9),
M]V0M\\D&\"RRK8_;[>_SL&-IYYL(&F5!.-TSQ_5<OTR!=8AF?=6MR_$7)L]C
MH)27'+VA[EKMW5]S9Z3!OM_/FH6AG%+G(?WDIFBQ C&QK"9#:A$= "D1(B((
M7BC&S/J1R=M 2B"H&;+9X6EI;>RA\S>6DLWL-E1M>0M%@D0>'/^5G&9MTRY6
MG;Y2HXK.PH"LB#G4J@8.B&@4Q9ZLN%*7&FX+EK6R/K9-57DRYF;]#,2,W@IY
M$4UFG@5V;#(3HTCF6:3M5MT79],+)<(@T%?77YOX)FK,7I MSG&XP''<O^1"
MG:<?]F?$QECFC/,7!O44^I]^MLA!NK$<UZ#&D).H,;:/9%^O2XV4]QN6M-=3
MTZY/',5QYALV:_.<9N+G%U0/26T6,-Y]1N+&;QL->^4U8>KQ1)1*^TAK:J(K
M[\P=9R?E%.%$[36]2W1 $$]7:$KJ3.D-50L-T.]T<D8\,5KL\[_59I!%@($8
MNPQ'0>O=,DL29:7_7*7RWTY2&/,L: O@0:<@9E&8*G T'>"VS0S%6!)LTK-7
M:RQ5*R?\ZUSZ?_'>MC%6E!9.?&@E&72<PTUH6X%S $SX-E$95&>#55(XDEN+
MED@G)<^Y(T]0[A$,HJ2NQ;N7B.K4-47<?26V?>GQ&M]Q_@O9BM<:P$1V:G:#
M)MF8PB(H3]"+2,UW:S6I+;NY0NCB/R%TRF0S4=.#0J%,UQL!X<;1Y!L**].8
M6[I31I#-.ZE?S2G(;#'T2U4I^#BB\C:V:BR&=@8FB#<(@SV:$"@VCZ&6BVA/
M")V6$;H=L26,RP, Y) V[J V8 UR\R+YCHUK#1U0"6S1D^[[P7W [B&/8)T^
M>;/L^"=DI7[N-]93/8*;^2S11FXZLN.Z[JL+)EES4X'N(<'@'9#:2C&&'9K^
MF) ?48D^YS*F'9KCEE(V8_FL\\ Q6OUTK.KGZ.&OB3Z>*@.LA<*C+>J7C"__
M.PH#_JN.X?]?=0S_H4Y_G3 Q.B!!';3>@#GB#)#_IY^ @/^,(?[E]>#_=%2*
MM< !!3J%&+M#T_C>%X[=N;:*(@[1 1J- +@^HD4-L]#$8+_/V_\ZR"SM,*(I
MDT$:(A%=L!A:2PP=D&LNOWLF5!5(NB7"2#/6UU2C_RHY8X2B:>A%&A:Q%QU\
M9$YC6Z4#KO1% /<G&:^TWW-]"4T2Q5 RQEZ!-@_H *U\="Z"@65V3I-LZ0#K
M*B#UY$SM+<SV983!J 8)/-='D:$#M)TQ#-"JBECH;^!@Y ?LD94*_ XCX^QP
M-=(!I=L,J_!2DQA#PQ!=7TA &A:S5QU,P801S4FM<P87#%R=\7WMK,)#JETR
MM[][VI([DR2_%K ,#]99A(<<(-(YKS<5R1!DJ+5D"1HKL,2F!X>)FM!-N1=:
M-9TQ?)\Z(/Q6O$F%< F1ZPODDO0LQLP6S@BX^]:7R@O(NB9KX7KJSH;BOR)X
MCU#$NU24YD8%/F ?IAWB+E@1*N06W-CYX3C7U\)P9%"S>#2KU)#DG_F336?Q
MF#82_!9#IT>58"[+"QXR,%TV2Z[C%R&\45D>@A]-SL2/%\8F>W2F97;)=,FT
MTS3Y&Z<XG47J ACH2:9N>=5@DW66#@A7O8TO1;D2 N9U:_KM&B],5)<456?P
M?-^9 @A;V$]-LE.^*SO,1Y,FB8DD$%D,&CB;&NT//+9FPP/A:CEV)[,.$KW0
MF)&S:VAKJW"6[\HG2CZS:*Q#\#+ETECSC#!ANP5SQ@+JW'J4'[5]=2S156HO
M_897CA:M3W'&3%Y86HM'V2&:\N?O!<Y+'MOXU@Z7:-G?,\!Z --PTN(8%R]*
MF6_99PSS90(E$5-%!^#ZE-#E=,#L1^ )@_@FF6>D41H6GH![VOJP-]]]YN>I
MV+.==ML0^V\'Z#A37@VVKQ8?9L5XA(_,-P,WL/@#/6HRQDD)O-F8\L1R7+MD
MO>*=[/4;C2U"I>WLE_?_2(RVC9J(=8<&@,<2*1Z^.M(YV=K^-(Q HS2LD XX
M84;Z+5.%YJ#(?DN_]>=5D5N(@:#[L6\:H3^X[3@H>VHVXW3 \<;*:"S1.='$
M$*WZW6^'/W2.2X1EQ^C0?+&S72:*-[(=')5YA>"5US;C-H;T-?ETZ*9_X68H
MY\,"HA$X!XO7 7.V%,*X"=(OG<P:!O=3/K5GFMW(TLL7#,].VBG5&O#S?F+
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MJR=Z<*>.^U,VM5#TG<(J[Y@<P]4:1JY]H^:)U+Q[>5 G,'R>_ V:T[G(9V[
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M0T)U#6H3>VE]X++:FMHHW'R";ODWU<\OW7E'K"T5@WYI+!ZU6\-=L.,SQ?/
M12I?S8KWWP3Q/!2K0W+^XGKTV,;\-7I+Q^W \.(2CP;O9?"@7 0DP/#L306X
MU=BF: LH*I./,9V=V6/T@F=X2J4]>]-+_WQNB5@0NV;2&_ ZX&=DV?S=)^ D
M('\3ASOP&/RZ&^W<J$EE-;)N9MW5I*[&R_YCZ =_@2C;8;-:T)3^TR!T" *\
MGI_Z^VZRI9O/ZM 1&?6QC"S.P"I=,'D&U-O/I\5R'OWU0>(I'9 4VH_8L&/
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MLO K, 2U&&1+#6R=N4KJ*8(&SB%:2RSW/;:6!DHN\$B^/5%=)'SN'%F-<T;
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M@_ 6V\RE46H]^2X@@KP+'?"2&K^2P6#GK%>!T?TU['D,RNF:1YM\'A/X^<W
M[VG6>\%XE'$J\WI: 8W\9]>UIR?$%6[C6?_" GY59OI>]6BW%#A?07RL$8U0
M@[0) AEOY"5%J7\+!A9%PL[//RI[6[J,SZUZ$[)X7];H5-7;3Z\RCW_^])Q+
ML6\ 4X;<-,V'CV)/);4SB*6057GM'=[JM%+KY[5L?+X7NS3,3LO]7.#?[#H(
M<M"R"Q)VU!KF<K)_"5C3@_LB6J[BR,Y1=("+BO/CR_B2Y2A;:\7/;<X<OG2
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M\MG@U =RO> BV0 ^.B-.S9>/>5*HQA6'F^22<<R:^.ZG(712F__5DG:\W$O
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M+C!\I_^JRBO'C)] _$7P)?@@MJJZC*P!W6VE74E5K^KWK#Q/"[-+NKUPRS_
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M&,U#)I-PR(X0*4VMR%;!RX,V'3N]<Q;J&XGG_<-XH[H9&%-+OY2#)?[C4>B
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MQ21[(_8*>"]P96%'<1WY52!0B,,HVI\SW3R?U\"E2$8/\1M==6/?:_D7$&]
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M;8[(2O!P/B9C?38U2OO4]QKL5N7F^Q_NMF3\"A\%U_!V";L0TG$]6T>X$!K
M!%?9\&U]?F8F+ZY6P[E!Y7WHZHMK-V0&ZA3'38V_G7YIV_KHK]YR*#^Q&K>X
M,!2I#'P'%-[6EE@_U):JBY.[Z,6A4WSE/M^REYJC&E\VH!\."#W"@E^$CP*K
M'&)ZH()KP'.:6HMR=@NPS@IVA>II8KRACM1SGTZQ*D^'-B]O9.7M[QY(0# H
M"8'^1,_X/#5C"#P-T#UT+JB_YYQ]!R%D(O_)Z9P$J87")%:Q3S+\5T]X++UD
M_S.2O]V7E;9A"&_-GK3<=X0&5&YQ*UL8NPB*US77!1[1 !^3_X8 W6=3KS73
M -^[\VB ?.4P"!IRQ-D,HA=U) B%IW9YOK9G:P+D!HU4##I%C*>>AU[?G=LA
MW;0)@UTTE_1*7Y&T/YCM:0FAQG]-%-3_/CK^J\S]U$L6YG:/4MX;9!FIRH>V
M-(";(4Q7,/RIL971_#,YD-T?' )%HMZ=Q/10WOP5,3$ZVD3#R%SSZ/D>A:FA
MMD,K1Q[X2"BXC!@@F(S1D!8S?MOX?%?\<9-[PH$EG^AO-+2J%10J"12BLA&K
MV_0?4+L$#I)KJ+])H+PEYS>SR]L.L^J>0-LJW.V%3T1%7$R'-J, E%"/H^:P
MY]%Y@6CO'D%>=>L/RG>]?G$B_]9VT?$WU/(09$"@0;G7,WL>*H>0"*47V*=&
MB0L8('\0;Q>0E1SL,QJTM]#]><:D_Z[OE8G\C,O/0)T/"_QFQZ)N&<JEMM,C
M#K3-TT/X32GWHSAW$%,\7%VB)$$M[H]]?5,06Q@#=>^(UO%]QEC2I9X%,(KI
M(7$Y/ZBD9DJY17/:_2(_CV#*KDF<YK!JIHKP<.?4[I#,'W)W%>@Y=$KQ-G$
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MJ/?$!:24Y7CR89983,]C.]/2$JR,H:VAFO*L@^.\QO/' HX#M\Y/J!J/UM(
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M7)>+$.AL&4\_K<H!'\J@D?K1)J0=:$J=R*N%12.>SC/,;,Q4%!YOMY0:>=1
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M!\7=%_RU[FE$S  7M<V5=!#9H3AG?$FT:BFP/G7%T5FFXJ!(@>+^.!7D3HG
MW%>G 9P@3,MK!:XSS?5:!(GV+\.5[S\7)K WZX34/["47_"\^R8]@C%('1P&
M+N]!5 ")YW2;32*'QP2;IN3LM.T,Y:S7XM32U%(?UFEESE^?/W?1B7%NI1U5
M+E7D@ZRPU#R++AS$,)7R[@EK5F"+-O9?BX+*"4>RIN#';8G&5*P!X=K0B;8<
MK+T8K&@]DNMD;,XM'LZ*^ J\AF@RH=-?AX)^]&CN!P2G^T*5GA7N<!$_L9NI
M5+697,R$QLWN:(D)4#D&]^1X4N6+24K[%8:E6]ZK"B2997 9MDG.JJW9MED0
M&X76SJLJ*K@]=DA,7^ R5ZL>4U"#1%5TBA: *4#\.D]V3G??!,CP.E&@Q6YK
M_\NM_RLE?_\C97TO7+:]P)C/0\"03\CL^A'V5@GX!7H.@-A6_8&J5#BNNE9X
M>O,84@DH<1)TUYLQ#G9&5,-ZU,(4^-PL8;F(^--M4JO>FRQ(,?D.)I[C6Q6?
MP<9B>?T59\"AO,<\O/)LZ%0*]J)^G#TO4N+N7!=IXD:DZ:B-M4>SZWGHADDH
MD'.[)P3,0;XXM29PP>6MQ*L+YPF=AV\> ^Z^GHO8.5L;*16V/K54E(99H+IO
MG*3LYW_IJYZC&JZ#E"D1=,>*!/J?HKP'/W0_02S7ME>X1G HWRT2G'6XHE@;
MM::F]'A<J%RR4_H)SN22NJK:&HXD01R?80Y'LQ/ .%"N6ZZ_ ?[^FZK0]2N"
M$\W KNO68GE. 5@9W"V]K_'85==S=@8NFNJV/<4A-9X&V6\QE]9K70/A4#@G
M/7K"QW(;AQU.$I.90ZG'8=??W\UKPXT.V>O>$M(_+B.[=>;A+&#4:>I=&%#.
M3Y)\(FNJ)QK$&-AUX!VBY9D=<P*",*O[[*?HR=XZX,W$04Q/C5-N.!CNK[!L
MV:Q1J9=PWJ,[F5DGJ:VG$V3YE?7JG0$R#4!<(6F0?8C6I#NN<!'JX<4QM6C.
M<)6=LH%M>[-E]0MQ\5FS6J6'<K]%--@H\1_7T3CH:4:\@'!AH HC\WL--,#)
M_NOXW&:_/;7XMNP4/YF+6:^_U"IB3XEELL[9E'Z.?W>O/O=#V:QQ:IEO3G5*
M=?\\M(N26V&WL]4W1JX& ? \;6O]. CC$H9=#LT^E>:^.GZ_;\W?QR^_[8S+
M(;%K28UEJ<X -L4P9L:GHIX_J%_!99AFR&C/]'"K'U98TW7H[6H5PFGZHN2K
MJ@(QEPR?:*BX%EP%V<IP$56=5Y2$U<S;<5/!HG:H 6PUUI+EMM?M3$Q6R(AP
MC!MF%#F-"@>I^U\BSN$=V#4M"6$A4Z0S8Z LC49Y1[8Y/?GV'(-N:77YL,-N
M%Y?6(>7%I83JE@SFX<>!JC#H%?S'.I4UT?2<14^?]V*;7R=D(G+,6KZU"F4N
MRHPM%B99ER?+TZF+S(:COGZ':ZZE>WI5#0%+/@'<A1,65C?P42UO%9K9CS^T
M3=\+O_^E.LCABF?]B<-2P&?RRTJFGR6UGA7+3+>M1A 04Y@USB*R"R4-]2SJ
M&_JRP Z&><58/'+>ZM2[? G+9.3>NV]",LYLVL=!^Q^*C3H\,KIE_(O<6\>B
MLC_L&&$7_*@BG-\1(OXR%+IQ/BHZJW"8;-"/EL'#OYJ9"+]]W[?..S^_P_.2
MZ=#%^8E@!E9;Q3@628#UV$U_R1(\^*LF(BR0JV)SM;""I:((Q.Q1,]+8GO-Z
MZO&#B[)^I:J+%59>IS^9)8LD59.*]A]Q/585-_<6P2C/N1//#C< !?T!E+2V
M$+)/5@RG@T;W(':4:4"-/Z+YKC$Q?3@]-WJ>+A%T(PBD22<"QH'?,^3PK>&J
M"O1LW=(OW75UHH%OU%%Y_+-;[')/LWOC$2WK$16K]2RONW:%@M#9PGOY>7WI
M\@E?J(\7@@/[$P)_O#5:"*M$O2# H+95E;'/!M$7ISGC)I7YR;F1-S[V9>I=
M3&;N4G^,5::S?V62*?4G9,2!BYB%@[#[BQ/]'/-T\R"J.63OX>H;GSK#R37W
M141*.+ZR?),+DMDVB^PX)P.QTUQ9@6=\Z4X+4.D;"VCFY35UJ;JPF[)2=@PV
M)#5\L3$/P-ENL6UJ,9Y8)R'!<_]_>#JR[A;DOU7)MEK[#[WQ\#\:=@B*+>7<
MP @-,(CJ2__;1:79$REV =(Y=O_VYV]+]VL8NE-+*-(MUO]>__KO%ZG^H^#U
M0"5/VT'I3B;K]K] 1)Z>A_!-<R\@B1E%?57Y8_A/K2!_,'O^*ZJ)_P?ZOOT+
MQW^J"0L-0#ZI)'"&N"-P[0%P-*HC&#ZW/%_O2)+%;K6:D&:'E]I:>X1<J7R$
MP9:,M"<E=G%]/(H%GO/M&O&+3$\@^"I_(QH _(T&"!2G 5A)PF=/<)F]DCA9
M..Q-U>V:]ER5%ZS(ZS8@;$+F_5EV;3 +T<B];UFKY? > ?!&(B2 !F@<):C1
MHY(DA8@@2]$ (>73[OM4$Q(!2+2&#'C89^UAJ-?F:0";$DBG0@W\#5YR] $-
MD*$$QYY%E'73 %IT.EIO%+!' QQS;L9ND9%[TV!\%I6W)P*SL _>:(;C=/_+
M+."A1WR;G>O_"4E,=X2M'U)^'8'BW$EC(I>14O>1AP)2W/=G)"F;#_^KJK#P
MOZ@#C'M$3*/"$ZED7>K) %V>,3"=L\]J4QXTP&7KYZC.7Y%.:508'>W_%M2I
M1B8D4O=5][!D.>0)>,\F'!M.EPE!M /1,P(D_3IAN.A" 4U;GB,F:8#]X[]U
M\ELGOW7R6R>_=?+_L$XP[O14-(4%KWN9[3FR;/P)?&5,D+CQC^J W/'GP\>^
MF>%D:LIS+5'9NV'!9R.@T1KSX[A&*>J$2M-0%G]M/G04NZU;E#J?I,QBH&+>
MCR%K7LKM,ME06-!]C9R$?*]1(%J*"M*EDJ1+M4%5@3?FX8?)^V *#0 GH#(N
M)19MG2!U[O?.2^ZE;A4;4GET0S$+]&UND&B &"#^DY8J#0 RH8.QY(>,O[&_
ML;^QO['_ BS#6RB*+$NYL\Y/.AE :7DN>@_N ]?87 $"%LMA*V;]#J,Q[R[D
MGY9\.\KFD?ANOM;DSVZ,86@_@C)'7OQCP6$)N@//:H)LT3WO'MVQM2)^@W^#
M_S\,9FYF-O\$<V3C/'BRL2KCV079X/S^V80?QGF]S[U"JJCH#??R2D>2P*TY
MV$QBBRN\L0)/3\\/P!0JG)#)@?P#CE"$H\$:\V"<+0Q.#0!2Z52(V$M?MK^)
M!MA:I*^[3U\W2 /^!TRKA8HGK[RF<QH7')W/;,-)=/(UHTN6,>&D 7JR: #L
M @T@"%@B_\(M;O&1FK:*':D\N6$TP )]THVM/^R_2 M,MW\$W?Z1=%^1^P<L
MZP]A:A!$JPP@?8.Z] WV_"(IOR7^+?'_1.*.BR?ND3O[A]+_+=R8!O(1G^6=
M[3Z ]SC3EX40+>N%Z?^K]N\F,^CS#_8E0]]2=1-R:_Z_V==O\&_P_T[@ ?W3
MC]S?^/H.FOQABPWN(5015KWR0.36*!U=\+^]=?^6^+?$?U/B3A\^G_TP$]O2
M?PL0(& H2/2YV"C&9'^5+K,YO+$(OT#>Q_SQ)"23H^ ?'YK\)7K\AOZ&_J\)
M-;VM5\?<]24 ^I9NDG:XGOTM.(EN#S.FW?BFIKS,*+45&N#2+R-[_]LM_);X
M_X\2UU"XAJF\#SX\5:1D?*$!QFQ?_F6%^RZ!3+W%: ^?7/U'K7V:JLGFW7>T
M>1DO?O?[P5S@\[]$OO\;_!O\_Q9X)99HMES/?:,$B$G%D"PER=((=GA/(MUX
M]^C&.T]FF!+A<\!O3CB,JY2_L5=CL8$Q,P8]9!SP;Z9N4I_]83\K"7078(I#
M[6_^6W#2_?,<@)7?V-_8W]B_A5U"94-*?OIW4HOJ2((+]?]P:LMJ!0<)G:Y\
M,_2M25H1B G,#' =;MS8YWK60W*A ;(<@D"BE"SP;+;)KQ-?-("NH0/$X3U)
M!_Y-#TFMJ:;&IJ#K,3<[X3^7#H#1\_28N1-P-5(*=6/S4.0V<K1'MW2X7@GV
MO,VL/)C:897655T3K2\TS<+O9,(<QXES*"(YP=0NX[\@0G)Z*XS >C[9GVV,
M8LJTT0RB:FZ,ZM]65AR\;M]WN7<W%&HC@]V@ <2'FN;ZF^]*WQM(N+FT!W^S
MQ<2S2P.L]N-G&M\.-WSAI@',\$.)>9/?^]_(*\AFO=5I_IXU[R0) "B:V<&&
M=P,&%&(BQX@/SE6?! 6&BUW6O5W7?#+0J\G\PER!QLV<<T_K-$63M6(Z7LD,
M%/'G%\G[7[P>4$#0W#7!]T16^*@J'/GDHA&OK:+8=,K/L##Z1;#QSUUICQYM
MB(*_[ _'6F(U;D+<NIQ;QTM]JJ;BLP,'D"T:E'58<+5Q_J3'S:3W:&\3S^^M
M<\EXI<C\!SGE=L+V/ =",P%".'!3^@41[68'(3PUW5FE\>@LM5G_Z9RA(XN0
M:*3/4LN380@WQCFT\K5$2M#M+ !?4RR'Q\B^L.#6^W<&V3[Y/Q(=;#.*;H2J
M.'VS/G$4H^8X72LS1@,X(5\=>#>C^"9_KB@&Y!KT.>J+#KQCR7YZ509>OEDJ
M7@]8>GN@VPJL8 ZB<J[HX\(J/L?J\5R+6[(*/U5U^! C>^?(RQ#FR)66!QPQ
M[@5]'Q=D[+=+6UYVI)Q^V6+]*;]QUV@%WD[DB"0US3@WH=C\S8GV?M-NH#'L
M&F$D7:?3+/12@EYDVBX&$&<MSO[C+0$X:CA5G$XXM$N"#!>U3*;FMI<TN=(
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MNHULW7@%Q]=HJ3IETP!0^/V C+7'Z(UR'U));)W'%X^]K7>[J'?UIP/;Y:;
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MD-6(&W2O)5&188-6RUQAEXA^W/)*1S,B4U*R[G0SR\9<Y +H!%D4G]N"(LH
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M.*$6_!<1T+61H!SZ!I"FI#CX0T?PPC8&+TEUSJ-[DC\O /S+YAWLKP/-&FF
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MO=R0_&^[4"K;B #74M")0;GU5]CM%GO!J,VCD=(D5'_=((^W.)P$"(^U9DA
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M*-WT->)A/9,&U1D4*TZWW O;?[5>]V&>&72@\KC^W*#V9R=FP!)S-&\Y-F5
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M#]^'?E6K5\FU1@WSVHB\601LZ06,)ZC%JG0"/K7I=)65/(1N%H1-YV"4=4F
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MR3XM&^@X?R *]F]\$Z^=/JV;&$-3+RP/"8S3/NYPM$[ZTXE\RG&*7!98[X^
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M[N:;FIFP W];451=3H+OM[2BI4[[8KU:S;)%#9A$B#GSC>L,@FRX9:K+E^3
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M5OTMD$GP3'@GLYL,Y!A);=!+W$:M2HSIS6)9ND>(&YN5H#/_)V$&UL--$E1
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M_KG)B*^= <[N)53AL.ZY:6"EKE;)K .;?)C]W"&KD_O,T:WV2USTRY*_;Z8
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M.U_A.'/:8#FM^6LC.R')).(#2J$I#67A#[LE<?8#V5\5D?5K(P?-NI3 CU2
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MOY/V;XUMF/ R%7#1.\4'ZXP[W8JF\ZS$L[;U'T-/J&8T,_](9"F$!"AEW"C
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MZ-D7OQYTPE1U$F]QL5*B@(D>( #L@CV*B>3M->4RLKEZIB+^DFG7J:E'#[-
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MW*/[C)/L-FG06W.FIM$RWZP7( .4=#L5S:0YJ89R9B5>>=$W;V\:QQ-E2E+
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MS$TO4H+0WZ6W=H)VX:)H2M+VF+DD$=H17-)M%(&Z2!B/QGL,G5YKSBFPGO+
M!CK<CLU^?A^[XG,[P^BV-MR?@J FP%4I'"05_) X(Z6W@]T9IP.^O1B</4!D
MA4*7<:^GEA"NFC-M_IF_3/E5KNC?3]T^HO;T:HP;3^=]X3-?'&(0? D*E$0F
MF'>BSX!QE2@)5\A4_: W-6<98A,DF#0J[C(U&O#WEW]"W?$50D#[<4,7),).
MG/"K!5\V*^*.]42G>..Y[E]K;//LW@[]M9E]YI:_!K='\>.77DK3ZA:=RB8/
MC?^HA-!TG;3YS)S?_/]5ES')+?E<;0ZSH+OA0<B:5]B,QPT)D!(06"A>X%U"
M>GG;Z[J&,:^MLQW:*2][QNQU!^,_.<1\^%N(3_M!!\3'+M;>FEI+G\FB\F R
M0;L*M/,"?3P3,@<I)+\YM"CE00NIB3#;BP&Y\"\A153^RH\4/NK(F=$.Q#[X
MQ1E77A[(=0C_0RV!LY-*YI&O-VJ!K!3#<4V^M6N0HJEUX<L?!JZ[)Q3S+@YR
M>$K_01THO7V+S6O_JO5T&K6,G"8EHU395D;0LPVS)'&T-NP$'<"-(\W2 ;KY
M1"8:"44'+*8&#6WPT $<ZD^H=:W>^8/$])X\7@WFN4"9VC;4N,*60=WB 'R5
M[Z[4SI>+VA_*'!>T<U6??V4SA*6/#U)G1^X;-';E8FT5VB:HVI]19ZF?4-*!
M#=K_2#O . G%.?CXYUV=QPE)2S,K]9B=/I=7BTB=U0M<54/?L[^!7P6;3_]1
M/"S]FNL9VC/H\_0 6HT(;C2&G-(E@GN!A$,!@@M%6FV(<A$XH>ERP#)51.9F
M6./V[(+79$N >E7V(9+AT>Y<"O,!T;6S/*[ TRJW05WGW 7.<;ET8Y/+$TNF
MOCQ!/7HAXMLD>U,KOLU$_:O7]$T#A5C& GM3Y8%>CT/E2#WZ^PVE6WSF2XE]
M"I.1!XG4'+@8(Y;#U,F/224]#33@FSJ.:=#3<Q4UG:W?^T73>>_[Q^7$?900
M/?.2!S-;A>@;&,*:'/@1^A)4]%T]5;+>R%50_.?/"N&2"ESNIKR>X$J8JL)6
M7M%[.&2!7<<@\Y5@%1"7AH'\+?[E8T3?T GW6<$Z8'@:7$(_3]QM_#EM6R\!
MZ[#0>4]L4'Y(X6:2IBT99=_CEWN%*!WY%J9<YG%<ONY9[.:?/#/]J.]=S'7Y
M/@( TP4FZ".X9BEW6TAEY+N!$:=MK?NLQKY9''V\!'KPM^8J<&O;*9$VW7,5
MOJ\K'GV##KA,W28\\CUT*_7SE#Y"-\'E@*'&D+3,D@C:%=K(+.$Q3QR"9P^9
M,'.=Y%?@>JUBL5Q-)]_GF2F'5ZY59TKO5[;W];HF^X-VI#_YM!$(P<A V8 4
M[43,>D+JFPMO2Y@U'Z$\3E;O%<4%)5M:FB:*S/M=B'&RX#41DC',T5LI3H&H
M0G_Z&.6^C*A4IZ32 9)[!S%'NOC#3O!Y.%:<F^0WGQ<)%J$8$"(?-(^$SUNM
MK-\B6^0X^.UJE'V$.W;8!?C=[+M%RII?[D#',S 9I4:1(7G3 5SZ1"8K.N#=
MSHHUPHW:?#R[ 48]. R">$*5MY=%THNO'CEM\@N!]%!/6_?I@(M!!=_72K:*
M$$ED'FV8,0%]P$-JFP-'Y8H1SR/)%H%3/<%V&2%B?WY%!J;##?;<)Z^AR(>V
MY3=OZ1R;J78CH^WD1^F N?(\SE:@)S[>>;;3/%<LJ/*5('+16JAP1V$JI%W$
MX8:#5K+R#K+HZ?.BRSVW;1D<KPE^XUN6NW)J;0QZWF&;'30_.S5U4/,'+F"Q
MFL>A*<BF HE#*8 \[3V=F?I+.I>AN2&@W'LN;R)\.W?_4E2IV90 '!TP:47&
MT6J(+MT!P#-^L2XA>4)&H;<7>_-\)2!ID[G:WL+,V&MK>K*S5UYPIOB\6^;_
M/!R$*@WV"]V3*Q+2X=HFR6]C/A_EW1^& !!=C7!5.F!X!7:'#D IH(^<['BA
M<WF,U4=XT0&1>:ROT%CE/N!9IY@03VL[LNG^POGQ^I695^\'A%H^:*X\=KQQ
M8O>Q;^8(V\-"MP8O%SJ F3KPQ"FPTZ2>$?<P/ZE^GV.NZOS+9@#(_]-[Q'QY
MNP=Z=%7\&L.G!Y=IB<'4D_^JM N&@Q#]CXF1U @H>"\$,[* Z,[+)_5%H[<^
M0HG@[XM?/L>0F8XV_KNO%_XK'^HYPG:\"H3-_3Q6(;Z2ABES-_D\65>N]PUT
MYK7BX\:CMO@7@5WM(&^5&?2GNV+H.$VCB\=Z@E_W='Z(EARW=6T=[B\UP'1Q
M(> SV$$4QZLQ6%K"U&-7T\5Z'VZ,SAI[O>"S!.V7-%YB'282YN!!H)$&RZ;[
M6NNK-)9]EVY\=&*5>7V/NC5Y@/R1N%6#:*=IUF,J\^YE+*;;CN9/PI>N5=5^
MN??@:<+4;@(+_]NOI"=DW/280"[_SMX05Q<MM:S3>C#(F-L:^E%P^9ED&"B@
MAX$"Z59Q>I_M%")4!#X.W-Z/$Y'.%EVT3/J07<75KQ&3B)M-S"?E%Z[)W4BK
M_Z8S<_]]OT2&HYG=769=P7F^$T4N?I\I)H1HYS#]G$L$7,&'VA?^8+*,Y)+Q
M3./8^'Y>>,/H(!Y4!&4%J>1F>+C'[-P_\?-.]NF;\:S]#D,V^Z6ME@5_8;=:
M\GKJS7?DHQT%Q$4:?I[?@)SE[<!JNLP>JB7VMH3<W-#PQ+4I;3\>]=RZT!P&
MJFMHCG>VF'P/Q(O=>:X< RB95SB-#8Q1A*6M'2_&&1Y[=CWX<?$C['LW4^UK
MG-%/UOFBYX'J?0(WK(J0X1KZ+S&:E]^W9%R(OZ_MGV[W],2A;M'SB35L>F<.
M0O_W_FV=]1Z%2AN=:%]?99G)"$+DB=CE;9<OJ[8-L:T"+%'E6^*#GT?\FDY&
M[4?9 UVC3BHQA8FD,@?:=P&+ ,](93CJ>)8L%AWV1$Z]V]PWQ<_O>GA7]Z2+
M",0GS.;"''=N:@4.*>2*X+L^_03[1R;MMTR23\J51)_OY:RG1/=8BAQ@MTGA
METKQZFC6(:A4NK &CVCFAY0TC[3H<:6>!]]E#;=;$>)U"G$:HLW"VI4K 1SY
M5JN7#QN"X7D"R>EX#<V^RW=6RILN5#42L:^5D;+;-'[WL)WAD5$<]<OT[>S
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MFA"/=X?S[-1.N3EZY'B$',6K7>&\$<GU]JW"]-1A9/T-BMN<,OYRZ_2EO<
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M'.9UA ^_.4)%NN#GT]0MMCBEN@_3U5/_% :8WYQZ[QOV]9YIWL26$2]\ -C
M$H-P8:/H?PE,:3<7=G!7$UXSM-V,TL[P/S#Z\*.2C]GYSH08: 7Z_ZU*6[D6
M;=Q#OOGB:'2WUG&+LH4>R%_6,0ST"O)J\ES<[K$,LIS:5=LF75;M&Q*S($WA
MEML1X9DIKG:*Q+]E!Q7.ET!RJ04/')@%?3) ( '(1UE=J(SD22.2)/J-R".U
M2(HL4@P(?+&+P$EZ?(\BFX''@^!VU):FOJP6*FK_!WPZ,PS&@.JP,,HI4@T2
MI(UC.NF&$6@Q'/#7NV0IE$B^\@JY=J]>S7PE!Q-W'03D0$?+C+^X2-BQ#JVJ
M,VNZZWZA=UOYYZ_IQN5;/3XFQ@?<9;.9>JA^JYG,4').JLC!6K;_8JQ^2\CQ
M>DE:7P\CSAIL)\ZH$T^W$$7F&KJI#PV@/:B3S8I:7__>"JKT'->)[FI:/*@N
MY9Y5EGU[&[0\%)4+)"41.6CL?D27=C1WW2[.K56[&(M=%]YQ&1K=&VNH#;(3
MO7:AG_6M*(5JGB:>P0B.J\ZD#K(-[7>>\*L)*0@[Y"\JJ\16B=\Z?I?EE$MC
MPN6)A!GW/T/O(#L?MV,1!W(*M.AO%:4E3XK83.UV2V2DE[U07S';/M*NNF>%
M$>S)QGM+UL'J4W6MB5 2#UG8%5@%3Y]'GPD$6A-5H[?KN*X4JGDU>/.5R74_
MW"H/NSFZY*P>U+]< 0LE ^%#<"8J6D.UDC2$W^Y&G G,PMNC<IQ&)/Z8L8S8
M?]^9N?RPBEU/ZHQ&57R+3PFXS*JRS"E_M2$XH2@(6K)ZD'3]4"#@2;FQEG!<
M34O5B:< /:FY$Q!IBC]CN0(H$J1!Z:%$C5L!JEU#Y[^+&$?V: HUG[TSLBDK
MDW1B0@?^G/C!8:SM^>* S*VUY :27QL&.>#);MSZ]/G&%+HRK8;69N1/8B)$
M;,]!NQ8(.7UQ?GDB=SW]9-,"CG>/THVMJY@E7(9^\6:+<C<" ,S!VC![QM0V
MD'#SD+B\TQ0]MWE;&U+F?)?:@)M9KH2__.&WJ#\1RY*'X;XYRTL7,!H[\*&*
M-;O5AI"BP^L5N_5+UZH-K,:AVRWH^6_&VOP9G_ZK/07_11+7(V$4L?#% [B_
M*+#+/_%O#069I.D ,SI "Y*0QXBWV)!NQ$D*SWR\@@Y)81X:_=[.8]#GD"90
ME8P7\=])A96 1  3)ZIRWYEOV*#79E<\=H=HK!W_B+/C7:CQ<HQ(2AP;1=>5
MTA@N422I9SV!)"I0+[G$!\;.%P)KES>;"%A(@I7M83L=P!UH=;_I]QX7_!?.
M!=VL#%+( O7&"K?TB5N^?LSKY=-3MO\+K0F>JQ'&O*4#<'=7K&Y3ZGU(6(/G
M5VIC[2-:'M0WYK0#K\7%?PTY/_F7,S2/< EC7462F>. GA/BB;+_+>LP!AM-
M)]]IN'MI?KWE5MGGL2]ZTEYZUI@,6W3:T&)5JGYOK77 4N*TBP>\C6JD3FW2
M!,ML+))5207=OPVK/!H4$<ZN:\%936],GZEOV.Z$2E8JT]CR"/PH-OC/YMLS
M!5[#@5D]\=2FTNN?CEX_ 'N+N"35RQ6^'<Y97Q["IN'0+[:GR.WH4R\*/1)/
M!TKDZ'>KLRFVOI9- 7'G!?QX+3ZHC%F-\RY7+'?-/WO'U%00P/WZ24'1+=/U
MVP(D!@;TZS\E7_@S[EU$R403P3NVZC4[ZP<TXA*2T$=C5R3X]@CSO-MN]2U;
M18E;>E)N%Z<+")0[MSV)KKXE(J'H=;;19!_) .;(1!B#RQ0HD!C,+'06L5-?
M W:#'NGK;APQ@/@N'9 /P:RD&O#1*G-H# JF_$@+8N$^ZPP\UCM2)*M1GA!9
M& SLZF!>C(;1W&U]7#W2^[.!:"[P3UP$GE__XM>^GS&7NDXTPMZ^G4$;:LH%
MKAWB2KK:/+JQ >'[$*&956)YTDJPJ)W3XKCMTRC,J62F\S=/X0Q/(-\Q.,>'
M,3 U=I:<@&R!Z1%C.S1YB,5).+F [F.O>+R<W?D\HRIT]CW,0\$K9VOL+:M?
M\HGU97-SJ6P_+LPO<&?8:_LRPX*<".-?%K\:@@.DP+C$033V\&"3]);(BZ/,
MG$233/$\;VB"Q OGA?-B6SU+9C;U_4_UBWKW0;._B?BH)K.)F&_S,.#$ <)$
M4L#-;LS.#0JT:TI$]L!%$R:+#+S^4AI2U&L,+OW-B?PI>T/<1,1( J-/OK=N
MQSJLR1&(FL>+CBN2M/=6"]JL\2W29O=.7@8'];<_OB47YQM#8CA%F4/E%(6-
M6#0XEZ-QVQOI\LCR#=;2WEA=YLM0VLWYJ].[YMHEF\_22F7@Q]A9T*Q1YMK5
M!KL?MB+NC(,]2@*9QHXD&NYVHFNF2]Y<5QHA9>%/%YV/]?3D@!-Q?X5MN'&)
MZ6<9>>.?O08&G*4A3M&X2%KM!W<?!<OG\-<F7WPMG2649E3VP!8]9TKT6Z8X
M&5'XY6=.T-+GZ("W]>(.+X4OC2GQS'6Z0"C,*L=B)OH/->B 7]MT@%>%Y#$Z
MPQ0<VT^)F54M(Z>F?Z=4$13Z$D_"&72;8().S)Q-I-P%1KYJ:;GKQMR=MOM(
MW.3 ;"HJ*>K(-.%!'S_B8(E:I:%(M@Z\V#>':/^N0),@O>TV']_V]?9PN'ZM
M0_0)FV*&J;5Z*AOLA2FGONEL&&,E83)$$(T]A7QGE:9 0,7CRUA?:) J_-HT
M1;X7I-QX&UP>TWZ#34AT+I/*38!T05@IJG5I4YUV_,,P!<\K/]^O-+^ZX;H\
M%O7G;FD)OZR\"/;%Y]Q<@S:X_96;&&0_6GEV4.'W#Y( 81%U%B9", ^;\6O.
MNCLB5RZ=HURO=^Z:6$3(^7[Q/T3=S5TZ0.8/^3)BPABQ5\E./8/\10=,+=.,
MR@X8?.C;9SI@U8:_UG'-X=MN2!,M[H?WXTZSF%6>'?!]T [FH)-87T>8I;&'
MXH"\I("NT< RJQ$*K[>?1V%[AU6 M>W]0XW72MWR%N$7[DJQ4Q\B?PW%H'<R
M$M_-'LB":2GN*MG/%\W.QM; 9H_O#TX9%QG7^4'_\"(Z9&'2. 8?U,//)MI=
MQ'PF0GO:'!YGSM !@S8WXH7 LJXE)1]?VT>> &CW8H96/.%.M.%<KG%&_I9#
M!]3Z-?0E B8&?0D-/0(7IWHRN>IAC5+^ ]=L<%KGAD3$SQOTOZ\\014@*,3O
M0:+%>48TC'$#I+K;O*8-UF767PRU"KAI[WQ8&7Q6(P;E]"3;B=])1!NYZ%%2
M,!V@[-99^"'G;YT1PXM4:B1(2?/3(!ST->PN?M,+(O-P^$41JM%KT5@/>UM/
M J">#,(A2=+I;_R,HM1*NA%8]9[?:426>!6ABMH#6))8=7\S1 '<T2KE\-L:
MGT)CKR*"3(@0B@2PIN]=X:Z&]GRH#AO4X1Y<W_OR ]-VVOET>2/[$QL>FW1
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MY[%X%**?\/3$L)$[-+:5):A$_T;5W,>"*J+8W^5-<R6]1@V#-.]Z@Q]*.!Z
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MB[$>H>^O[7E,:UU8#I"(:!;+AQI@CLLDY[5/N-XW1/BS,J]Q2QYS!ZO8GID
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MYNAI!S/9^,1VG,KZ50)G&F7Z-Y&X9?]"+96HGRZ=2!>;1YCY0Q!G*_^,*@G
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M0FZS>SY4 V/_:R$D=!(8GB6FWIANTAREQ13[JJE:P8 B19%7*?17%#Z_"LE
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M/6@M05GHX].3?9[?L1P?A1N9S]IF?]WJ0;QU/_0,T+U0]1E3O>0[6@+]+C:
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MO0=1BZ=D+6P17]6TS*/EF#V@ M])@#8VXE]3VXX!RJ=1GNS& 3U/&R;N,.V
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MF18\*$?T&XITV3"/*3FC,TT[SN=*%AS."\I23%/*!G+-7AM4-!C<^,W[^E:
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M4_?Z/>QHJR Q4=[9;>MBL6NUN]85YEJV:5HMTU*1P.NP5&V@4_101Y"BM 9
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M5+>)(:/XE8;E5U\-=(KY^?1+]R6=PD7O;@1VYU(!_Q["4:!-4VWC>)^U-?*
M'[%GX+<KM;9[\A-TJF\VSV?=#:Q0]?,_&DY7^%_PQLO^"P!?4Q8K^KVA ?^N
M%:(A XD*"*$"+E !9EZ&!WLHG#*<E/ /&"QP F*X1 (>T/]IKO^7S/7/T?NO
M,GJ_CY58_OZQQDZ"5(G=8QA#\$2K-L*J^FN"MWNS"649@*7_3(]'TBNT&[5I
MGGJ-]##>C6?9*K*S!9\5OW-/7\S**!"\517@QM8);W&F#75_#FUR@=/_.AO
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M_XN[?E/IW^@UF%YJ'8U= , =(!Y_44B*I!@?3R.+9]&H/R#&936RT!#C\50
M#;+B7R%[ (&_08;_'C): TJ3G,;2@-$P>_P5\XPZZ!?F<-IP_@YT2Q0!1.'I
MI&&CH9[]GZCKH?!?J$]3 ;^''<:&@_]!8W@KY-=%AB_X>?X _)38'!7P!X7_
M".JO5C?#:MY,4_,/&O\1UE_MKOX*,H1F=W]0^O>X_FIY$",PC3W^0>G_XY&H
M@X?"JWSJ,/'G;"8(J=I#8<%6<@7D)-:74F_X -V)9CQ/K:N\HLR<#'@B<9R?
M!C[H-#H_KE"OR4K98HC-H (<'K>/I<SHO#GW K^U09?AQ-7^]%"K30O,?0M]
MVFP:;'5-QF8\EA;VK'S+/O+2H^[%[L? :Y,#)I7$P ?%]I2VQ X5&BF^-GQV
M7&%NY\>-7D\+*H"EWL\1S]R[@1F<"#"M?J79(WU/1T#U89"RE5@*/J6A$'+-
MW?MM^VL*7Q5#X\D!RJC>F1 F:Z?9^_[/^_Q_[EAW51;SMQK%VBEMS,6AC4J3
MF3\$J9/ZCPV;G_;$QFJUI&TD?X3$B5D7OC-SB)K0E[ \I_K9&!5PSN_!T$R=
M_L.9@XIES92]97AGREC4=PZCC+ +.WVWQEB/2+!U0D 803L!O/QFQ*,JR*Z:
MNB+QSO(+QEKE["?'4@ I77TN/_#>HX59$^\TN\:KWCF=G[+K?!KG".EWOW3I
MY)&J<.(X5SO@R8#%##W>M#I.CFU$XD/:C%!"]K@(3QE*MP4/CY$'1<P\RBG2
M<O;-Z@&-KV>5:EH'M;'?6TAWYC$M?S$<!5C/SZD/MG<"C7-+>R]4)SXZ]AX*
MK0M:XNKPM+%+QT:G@S@G(,96X2+>KF'.9IAFW:8S E>/24L@7E$>!JEP_1;(
MWB,$CYDE=FM&7\[PM:9XP>*ZR^F53M)Z_G!,$;?=F09ONY7/:&V=;NRX$+$=
M19K<M^>D IY2GA\9&+!05QA!DOAX:WNBG4F@)]%++9]F71X]^J%0Y8,5;]"Z
M'ECHVFH^.B/4_Z12^Y[%P]KX;R:O8IL",$&"634\?:PNZN='=XI5VD1<GT^T
M-U67NTE;'H/+%'(IEO8=MG6HL53Z*'<@(!//L_42CZ&P/:Y-OW5_\W)F1,F5
M(Z_-Y=%@SM/6[1R97 VAL58=YR7:VU%GU+FTNA@D2/;(#\5@#CX]K7+NL&BK
M=![M^<P]E3![@8[W"I<N!/$<:=S3]-R\SLUJIA4$-77$TVFE&U4&8T:5\ER?
M);$)OOHTCJW^!A+]AD=&2:D#NPY3\G@Y_'G+BAOJS:):YK5-JFQ*)\P78"&J
MR : MXG)2X;&03-,_UK:8]4NZ(:)M$W)FD\W5_LS*WB4^\XFQP^"M6T<5Z7>
MSPF,6.PUW:;2,*]P9CWW;VY#<5JTY^5,_/<0G^33X _UG/C&WBCR[/KHO[G6
M=)/9*WZT5)4!R^/!;>-2%<QPOV9P_-*[ESQ\W4]UO96^\C=F!2G^+ +QN*3.
MG G;#998['?+!E?<JFP<[OU>\>1)&)WX.ZU'>\52]*OLC=*X]=Q2#][^6YZH
M)\_.?G'S,<X(* 9897W9/ /YNME46UG<6,>J^'3%N,('-/[5--OT/DMZ_=;3
MY?U GHDZ6W/#6C?U![GU8H$O%N3[)=B?R7Z19+FS(W>$C\W:,(K"HS1D[.K;
MR+7-/6#Y<,4SJ"WS#<G+[#^D9T>M?UOT$&WX+0/H/Y^GT^2WG)\Y_[8$ C#_
M%Y!#0$D +7Q.3,^G GZHP7<NEX3_;G<O2"7M/[OJ][<%V\@*[\I"[,Z R:?J
MN/_V4Y *]Z\*VYM * S'T<K""]%KX;\R-J:#9XD64CB4+THIKYW6YC+V>!-I
MQ+QT8[N,C+8+ 3-1 <U6)!9?4!-M@H'J#@P+U<SQ^<_>C9MC>7LI8809M)Y?
M36,*J9>Y-'K0M88#=6R<-057-IT\3$H:R?$UA=\;^2D#*&:8*&2[G9\1AWR9
M-5*OCW[+K6;5+K$8,UG69?]$)>MCD)*H+CL .VR\1!CXF+=V2 6PL6M0.OEY
MU2\<RU1%E1\TPQH:*P^,B9P_7%$ ^./-%X@SN\3NTXB. 'U-QJK4(*'$!5+I
M9@VE"PO:[A\MC3[L_)R2,D29\5T JYO#$S(^-B+7LU>I /="+U#B8W(DWO#E
M#NH8P=44?Z(:D@:+SYGH#O#SOG#Y8;B\^-KU8QD ""!IHC[38U)E;@$5 N7!
MU-3;SQ,".CCB\WZF#CJG1J4:?\RT%CG!VT'GX/Y*%&?@^=W/@\2F@CE&.4-.
MVM5G,7RDW!F]RVA[8O3*@9\BZNVE%QL)9;2)=#627 5Z9+$#)PCS)Z,;E"\<
MIK86BO'IBMQU>]A?TI.''7%XV_>EZ-KP ]%$@OT59,H67'!LQ:WG^Q5CZVX=
M2@)Q 9YX@/ ?2W\,JO!H19PGW1^%L3MG7HY:[4Q3%0J8%K0VR!4\PM"6<^R)
MUINWI]IB=N8PB#4BWG\,8[XV.[<9J6B<U>G[H=,O4 AFL1"G:N- !90M"R^
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MB?OF^M,CR.X(X>!_L/?>04U^W=IP$!00!.DH2)"B% $5D$Y$?C3IH'2("(B
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MVN9?,XYZV9_DY^2]=?[2MVT]ST_*1)AZ$WCQC8M*D"5/;GRO;6-N_Q*(I4]
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ME<8Y3MP2'!7*F!9A3+_-NIMT^PS0RBNYV+Z,&CE,F8S8YH9EQ^L)9'OOORU
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M1J\.%AY]PIGE8&"3T"50[(%;N'_1QCQC"[(^E]$S7O?I[U<S$?+56F1Z[S/
M#07LYF89=#VD^Y4=W^CNP1!>2!GK>CUJB"C>T@1X%2$(*8+$D B.U:B_>]SO
MH5@N[K+U30[\F,*CO(?L-R5FH*</;[<MY /K;Z:$*FV KPC@D W-/R#0+H%^
MO7.##-"Z#KU.YYU4_Y#NE=J03>JC9%(E4AS?<D21(%%4!!6K]53(I\%9&S>[
M&^-&.IP%&6;\%\P>/S;7_VG<YW(NZOO:^S- A [TN\-1]!F@IAQZ(!Y?3& 8
MNE1 9%<Z*JP=ZQGP<FM:A;,!YWGL(5W;1]-':^OQ2Y]:B\H>6"NZ&@Z4:6QN
MS*%-74#.!E4:S65+B/3<K(6,+/5H$BS8D& :+$#*(UHO%B3&?2#J8%-BJT;&
M@RT7?W>QKIN>E/VN^]3)^M8]2FWO],O)?A3(+?3;&6"/(M+HV[;H@>37XY1X
M<_YZ2\3HD1@^USE;/KA?WL'P3L2.MS<GNW.Y:D8-@?H,T)=#O'$&^"($/64S
M>[OB^UAV O0VKJQ*S!U$B1(SLB?DF#;S(73C,?$]K#N%0"U'CLXXN!1,(D"A
M?=E$B@K^(@W][6+S;NC8M6 1FCH>0Y91,5\UI8#B2WEW!E&,\H1/P:FQA%<!
MUM0SA4^>E ]U)DEU(0$3T9$44< 0=$4RJ8A+(>I#WI3?SV3$.U2N<S)\G**N
M%<\ RS_('-!)14.22"8"3&903D37YL<_2./J-GO]1I&YSI8)>L>V*3'7=0#V
MQ]9D&[BH203T^QG@(#JD<S%H'0YB7.?*NH1<6AJ\4O0$T'_WG %M$RR-0DT*
MIMEZVUBA+SQ3YB_@.!L:R5Q8!$$F@<69!NQTSD\O(#8<S<^,'  _AEQP_(J5
MBA%.FM!&ZS<X^2HP,CY4NX"\2(K:^8B@##*</#9JW<^+DQU]JCUY-]?VMG+*
M2]>BJI27ZZ[9@59H?W7YQD,.U<926#5%_Y83P*'30)8VY]T9P8Y0-NPAO#>.
MJ%*&#W!,Z+B7^>4DZS1QZ!6[PKL>)Z-K3X7$?4Q[;S05).8KDII5+^ 5P0G9
M1RT++6U,4^]V9('GUR=T1&KBOMLH!3S0O*C-:+(8NYGV(;44-THVI<+JDKOW
MSP ?7#D.#;?+$FYNI>."[T8#L8G@W-M# IS\9-\!444(^ 52> "O0R*UWLJH
M]/M:_C0D'6\5LY1%!%4?JSIBA[8E"-JA,U:W_-'G9/($%\VCM@62)(GZ2\5<
MK+;S41<LW+-^9.BY=B7U2+^ANA6S7)USI$#ZK"J")OKCP-^DDHTF;2!K?S7(
M96;/Y[%V9=4D):J+19DV"6MI/C*@OF"D$<A%9#,DZZ4O9I&"YJ#K-H>+6?%<
M9 ;0DT< ZXZN7/\S@'IHVYOJ'ZF/7JEVNQ;</2G[8;XW[C[39D<W,-9),&]>
M(3H6PD* :'B*'ZD!](*6].Y A5H;.Q^/%,6G+E6DU#ZW4O*XDSE;L:K-'FW?
M-/S@' /G!D (\C.?@3)SD92]&,C&'*MZGJ Y!(=V\#6\="[9K3LI<"*@.\EM
MP(/15N\">$:'"Q3[V'!J9]_*GB_^R$CCQ3ZT8O\GZN$'O[E595 VP7R=P]O4
M9BRDZM K;<^FP3K47_&SJA6R_U,B&':O#<O\#FI?,,,*GL[I.#U,B:UWQ**[
M@ RS$B7PXBYN39U;-+&5NB*SR<7TP@\/%3CVA[H+9H(PP BHNV%LP46$H&.P
MD\I 557*:Z+JQ)M;G(UIZC2U-OHB#(("']_'.L^,*MW_GGYTQ0*>@A<IW9:M
M^&WAR524KB;>!?)#7?)3&&K14CA>K0X63+(F,US'.;U7$U^$BVG_#DZ@2L6S
M69G 78QS1O.9](/;+M5OA]"G';DB.!%I.G(;;4.K]<XMY"&_MGKS3B7HE4U@
M/5<"0F$I[QS*@!"2_ORVF,Z+[]=6'G#.\R:%.2@U[=JQ8 N6S+?="<Z_N<X
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MF%V-8QQJTYH/A,T]5D*H?[0.R)> Q]G7O?E^+DHJAL=B"R38AT*A..!+[A>
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M<.'<9P1"I7K#"(%? OY(2,&[),&QQQ+T$U1<>P94.,%4$"F!Y8/^-I<KH8@
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MNC4RI/[JQL):4H7Z<?1(?]-FDZG^T97C^_D5%0EBIQA;.-]Y?EN8)?]6](K
M_O,-S]J[Z*!F!<>1$)@MG/TQE$Z\3'YO".WNMG6Y^EJTL&G^!<]S8 FFUQ^Y
M4R5N^*_NB!*!GFL)-;Q>Q0>&./YC*)[\"1'8;H211-*O?= Z1N@%T\O01X[
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M06:%OQ*!D,N%L)YA.!& "?S<"5D8Z86+47#^8V&0HT4(VK2%$QXZ/W [R>W
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M4=N&818#%HKTU,8W> ]U2@24^HNMI\]R0:9C\NAK-LUO)ZE$HG4:#[P&[(F
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MCSM[!<9)D$>)%1Q4%M7R>SA_JHT1&'\C7.KHZGKZ3=GMF_AE,_^U?O1(\&:
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M_IZM'_5-,?1-!O5B56@S%9[^_\/<>T<U^:S[HU% >E.03E207A0I*B4@TD1
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M0G<;E%"BKEWMQJ*=CPUF8=LBEC$%ZK^:T2\.9".P;B87):#7F6'7O12NC^%
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M'PZ3\ZO\R?- O'ML T]\T,YW B!8')\).F A *P4.3N8QPB 5N+?.IFGU 3
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M>.3?N;$RZ)QDQUJ*@/<5B7E^PR[B->OMWBUZ7&%77U!<[/1Y(;\Q<\5>W8$
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M"?W5G7FQMA6WR@,/-(Y;QUSBUEZX39]VGT%F#T,PWIMIRY)3@5E(;BY'$TK
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M,2YH=&U02P$"% ,4    "  3@%):2[9EI 1^ 0"L"!8 $0
M@ $6:04 :61Y82TR,#(T,3(S,2YX<V102P$"% ,4    "  3@%):#6U!J2U1
M  #(X ( $               @ %)YP8 :61Y82UE>#$P7S$R+FAT;5!+ 0(4
M Q0    ( !. 4EIFKKZ)Q X  'A; 0 1              "  :0X!P!I9'EA
M+65X,3!?,3EB+FAT;5!+ 0(4 Q0    ( !. 4EI"2(U871$  -?'   1
M          "  9='!P!I9'EA+65X,3!?,C!F+FAT;5!+ 0(4 Q0    ( !.
M4EJDJV^HQ#@   4H @ 1              "  2-9!P!I9'EA+65X,3!?,C5B
M+FAT;5!+ 0(4 Q0    ( !. 4EJM,_BZIPT! 'SD"0 0              "
M 1:2!P!I9'EA+65X,3!?,C<N:'1M4$L! A0#%     @ $X!26L.4:S<C3@
MQ,L"  \              ( !ZY\( &ED>6$M97@Q.5\Q+FAT;5!+ 0(4 Q0
M   ( !. 4EIA9/3]=P,  .H+   /              "  3ON" !I9'EA+65X
M,C-?,2YH=&U02P$"% ,4    "  3@%):C>:JX3\)  "'2   #P
M    @ '?\0@ :61Y82UE>#,Q7S$N:'1M4$L! A0#%     @ $X!26NC]#3Q;
M"0  B4<   \              ( !2_L( &ED>6$M97@S,5\R+FAT;5!+ 0(4
M Q0    ( !. 4EIE;<UQ!@8  #,^   /              "  =,$"0!I9'EA
M+65X,S)?,2YH=&U02P$"% ,4    "  3@%):4CA,@_@9  #3P   #@
M        @ $&"PD :61Y82UE>#1?,RYH=&U02P$"% ,4    "  3@%):(#+G
MMC!_!P!^MPH $0              @ $J)0D :6UG-#(P.#$X.3=?,"YJ<&=0
52P4&      X #@!C P  B:00

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>idya-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:idya="http://www.ideayabio.com/20241231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="idya-20241231.xsd" xlink:type="simple"/>
    <context id="C_80a30d44-ed50-40c7-8625-d5e98146ade0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:PolymeraseThetaProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_83549ecb-3fd7-4381-8f30-327213eea05d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_847c9af8-88d2-45a3-91d6-dcdef630162c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">idya:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8a14eee6-aa6b-4583-9df1-42b202346a23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">idya:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_8aa43324-1520-4534-b3e2-3a693540bf81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8b100a11-1b65-4fec-ae5b-2257a2c5399e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:JuneTwoThousandTwentyThreeSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-17</instant>
        </period>
    </context>
    <context id="C_8b87a953-8e4e-49fe-b4a9-0b35f9a89796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">idya:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8c32f180-89d2-481f-bc80-3f77774ec456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">idya:SanDiegoCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8c4ee195-6613-4c9b-a476-c2df7fdfea67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8f3cffd2-a88d-4fe5-892e-4adcc9f5604d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_907e44ce-49c7-48a8-8a1c-69ad47564e17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_933a2b9d-bb76-4d41-8fb8-2901d19455b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_93b03c8e-0f95-4d58-98e5-1b1e2a78067e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_94217de2-f133-4daf-80d3-64910929d8e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_949ed0b5-4cbf-4fe7-81a6-07bd20fe4626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9597b477-72d9-47f9-a2b7-c96116c45490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_97b79519-0af1-4cce-8a6d-7911a10985ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_99b1a732-1279-4f63-b48e-5b56395593f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9c02d070-8681-4a68-9460-90f6386b903f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-11</startDate>
            <endDate>2024-07-11</endDate>
        </period>
    </context>
    <context id="C_9c98a97a-3cca-48ab-963f-645540e482b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-25</instant>
        </period>
    </context>
    <context id="C_9e083923-3902-4bc7-aab2-a290354677b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-11</instant>
        </period>
    </context>
    <context id="C_9f7c598b-0376-4cd2-bb63-5b1ddcee4a82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9fb9e960-f425-4a31-bc47-44faa05f376c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a08caba6-5fab-4b48-87ef-fe485515b9e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a0e7b3d3-6830-4717-90ea-44da053262f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-27</instant>
        </period>
    </context>
    <context id="C_a1506248-4546-46fa-a347-9575de765d3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a17848a4-d1a9-4d09-81d7-b191ed14dfd6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">idya:IDE161Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a2a77a38-375b-46dc-9258-d476935d3c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a37ca623-522c-4962-8cd1-5abe0ff44d5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:JuneTwoThousandTwentyThreeSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-26</startDate>
            <endDate>2023-06-26</endDate>
        </period>
    </context>
    <context id="C_a46184c7-01af-47bf-9f47-d0c0ccee58f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">idya:OrphanDrugCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a4955acc-673d-4246-a4cf-8af30b6dc428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a59c732f-c597-47eb-9ca9-3046723cbffb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a6ac4859-4009-41b4-9008-d4385ab189d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">idya:ExerciseOfOutstandingOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a6b8d688-85fc-4f28-b94d-adbdcc815d1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-11</startDate>
            <endDate>2024-07-11</endDate>
        </period>
    </context>
    <context id="C_a702b98c-ab89-4793-9842-f4bec0373771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="C_a7f64497-48a3-44cb-b7f9-5fe1d8d9ba6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_aaa793d3-6d40-4eb9-8f53-fe79e2aded7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_aab90a1f-cce5-40ae-a524-bb89f7b2708e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:PolymeraseThetaProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ac598710-34a2-44e0-b556-f784f9ca8469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:JanuaryTwoThousandTwentyFourSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ad7e94d4-33b0-49a5-8627-5b260d67b825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">idya:MarketableSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_af24a5ec-af73-4d40-8dd3-8e064854bf7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b08e0fb2-11c2-4fdf-a73e-de1ec106e6a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b29be823-d29d-4c0b-b5d4-dab37fe7947c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b3327635-f95d-42dd-9385-6f262bcd38d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b3aa4c0b-2b97-4391-af57-fe7af6cf0a24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:WernerHelicaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b452a75e-2a3a-4c85-bb40-898b74dc7c1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">idya:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="C_b6a91b55-3856-4d3e-9d9b-637a1fc4e083">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b82f7f69-7a56-4486-a04d-d1739f434a83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:JanuaryTwoThousandTwentyFourSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-06</endDate>
        </period>
    </context>
    <context id="C_b8560028-9f37-4ff3-9028-5dc8f0dd96db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b89b606e-379c-490c-b2c7-22e9477ad049">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:PolymeraseThetaProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b8fed8f4-659e-48c7-a3fc-ebd4660253a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">idya:IDE397Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b9f082f0-76fd-4961-ba1a-7e2f141962b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bb829766-4720-419f-b5f8-c1559b6f88fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
        </entity>
        <period>
            <startDate>2024-07-11</startDate>
            <endDate>2024-07-11</endDate>
        </period>
    </context>
    <context id="C_bbfe6a5e-e0cb-482c-8581-bd5e60a751e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:PolymeraseThetaProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bccc40ef-fa48-4336-b831-e54faeed80cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">idya:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bf017758-6c8e-4dda-9992-6c460c60b3fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bfa82174-2a92-4b37-a2b1-ccf30e752c5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c0a63604-9e4a-452e-bb59-d9e6b5170b43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-19</startDate>
            <endDate>2024-01-19</endDate>
        </period>
    </context>
    <context id="C_c19a5e53-23fd-4bc8-8462-f68e81fbfe48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c3f56777-d0fc-4e30-8e99-35ce57f4b839">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c495f084-6fcb-44de-808b-4aa3452ff136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c6ec1b34-88b5-403e-b14c-f9db680a80a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">idya:DarovasertibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c78e44e9-bd4d-4c0a-9c26-f931942fb9cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:GlaxoSmithKlineCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-31</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="C_cbbfcaff-64c2-4dd6-8836-3121afdff880">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cbd0ef8f-ad56-44d1-80e0-5de5d8d02ca8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cdf3bc15-99ed-4518-8a55-98939fdba747">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ce651b87-a2ee-4952-8dab-aa55bb0ac861">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cec1db68-704c-4a32-8899-82a806f8d2c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">idya:TenPercentStockholderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d0071ee7-da0d-4c80-b8f6-5f69ef5e6bea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenEmployeeStockPurchasedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d007c432-86f1-4c3b-b319-24effed11e62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d3d4e1da-83e6-4d41-ae1c-a616266a1832">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d400c976-b0bd-479d-aa74-c54c3f83c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-27</instant>
        </period>
    </context>
    <context id="C_d4a29fc9-5039-4781-aa51-00d8294b4d29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-27</instant>
        </period>
    </context>
    <context id="C_d536bcf1-3ec0-423d-b2dc-d793db2570c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">idya:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d61cade1-8268-42c8-9099-392bd152a976">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d65b61cb-05ca-4927-b54c-ce7d454a1633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d83f8cee-a2f2-4da8-9137-df95b7b83290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d9ee7a65-84e7-461b-a9c8-917f6e54722e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:GlaxoSmithKlineCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_dcda7935-3db6-4964-a858-3e928a1e6238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:JuneTwoThousandTwentyThreeSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-17</endDate>
        </period>
    </context>
    <context id="C_ddead929-9307-4f06-a8f6-718bdcb2cf0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e3597327-9749-4444-867d-4367f5e1a23a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:MethionineAdenosylTransferase2AProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e499769c-c222-47df-bc66-3631881a62b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">idya:IDE161Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e4f99219-ed58-4929-87e5-a993db32910d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-27</startDate>
            <endDate>2023-10-27</endDate>
        </period>
    </context>
    <context id="C_e56ae803-71fa-40b1-b315-c44f63fe65d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-27</startDate>
            <endDate>2023-10-27</endDate>
        </period>
    </context>
    <context id="C_e6119aea-4ad7-47ff-8b8a-db55f4f12c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="C_e7bea947-3207-4f35-a41f-9c2f685e82c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-27</instant>
        </period>
    </context>
    <context id="C_e952c7de-9670-4b9f-bbd9-0381bf16deb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">idya:AmgenClinicalTrialCollaborationAndSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_ea3cfd25-fdc0-4753-b6b9-64944718b206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_eb581dfe-56cb-4aba-ab2b-d96ee1f0e219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_eb642f77-00cf-4cd5-89ff-cfa0d9ff7eb3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_eb95813f-4508-41df-ad29-f6eec05c524e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:GlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ecf66199-2c61-4da1-b565-ea15c7525705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ed5d8c12-9405-4e8a-b68f-e1da9fa98a3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ede69319-7140-4c54-a59f-e3cd00f2c014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_eed81da0-8376-4317-a154-9ffbb5c0bf7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202307Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ef560538-beca-4fdb-9d65-b2ca89c607d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ef94d34b-8101-44d9-aaaf-b044579ff409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:WernerHelicaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_f02efd60-1311-4d54-8d9c-b1359814dbc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f222b075-c12f-4efc-8c81-d8aea1803872">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f401e5c8-9543-480b-b6f2-bdab7d05f204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">idya:MarketableSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f605952c-8fcd-4667-9e72-9bc4842bb390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f7361d23-b930-48a8-9c1b-395215d1e86d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f7b6061f-1a70-4f34-9ba6-8614c500e543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:PolymeraseThetaProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="C_fa12496f-6344-415f-a910-de2c2bf8a71f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
        </entity>
        <period>
            <instant>2023-10-27</instant>
        </period>
    </context>
    <context id="C_faad213a-ce5c-4221-b05a-2e531d08f6d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fada0950-b58a-4dd1-87c9-557dfba92f85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fb60d22d-1a0c-4b09-951c-98eeeac567e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fd99da48-95e7-4823-8ffd-92a6ffd6af51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fdb1e9d4-d4ba-4bfd-94d7-8c22b58dd404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">idya:SanDiegoCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="C_fe0af623-ced9-4295-b11c-a7901893dc7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0178d793-324f-4f5d-8dfc-49181bd85b1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_017e85c7-1596-4e8e-927b-df535668349a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">idya:NovartisInternationalPharmaceuticalsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_028bd853-e9b5-4c40-9a66-731769196cc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_04d43460-4b81-4f83-b2c2-02fb5a312c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_074141e9-fba5-404a-bcf9-4a845e4634ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_07e35c69-dfae-4e28-83b9-c956215e0274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="C_09973aa9-24e1-483b-99d4-30e070b0dbb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">idya:SanDiegoCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0d608e0d-30c3-491f-bc22-755d69e64cfd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:JanuaryTwoThousandTwentyFourSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-06</instant>
        </period>
    </context>
    <context id="C_0e321b30-69e1-4345-9158-2fcb284b612c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0f3b93c3-2bd5-4282-b511-d0be9bbb12b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0f9012d2-5d2a-4197-80a8-0c4c3a822d34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-24</instant>
        </period>
    </context>
    <context id="C_102bebb9-1268-4e37-90b3-15a47af627e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_10a02746-ad3a-4e28-acc1-fe5727c8d092">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:PolymeraseThetaProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="C_10ae45c4-8dc3-46cf-ab6d-19afaee6b186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_12cb1aba-8889-4b3b-885c-40f700ad3c6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_14486222-86aa-41d5-ae07-15df550cdd49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_15a7a270-9ab0-4d62-adb8-a1a7678eee8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:WernerHelicaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_15cd159b-08a9-48df-9fa1-4e164fd62eb7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_15e27b17-950f-4151-a11c-4aba882b2d8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_16c5e261-e767-47ab-9f42-00c92286082e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1707f298-031e-42ff-92b2-f2d35e7cb9fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1789f966-ab3e-40ee-add4-b0aaa08d3263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_17c6d71a-63e2-457f-a633-102c0bde4eb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-27</instant>
        </period>
    </context>
    <context id="C_1894684a-f942-4a64-aebe-705ed6473dad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:JiangsuHengruiPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1995fabd-2822-4d7e-89fa-1b6e278a87fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">idya:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1b2706bd-6978-4079-8e5c-6be28981766b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1b812d03-ff06-4951-b51d-8d95f0881594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:WernerHelicaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_1ce730f4-285b-4d18-9b94-24f179a1f447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1d6fd8be-e5c3-430b-802a-c42663370c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
        </entity>
        <period>
            <startDate>2023-10-27</startDate>
            <endDate>2023-10-27</endDate>
        </period>
    </context>
    <context id="C_1fa75d5d-f291-49dc-801d-19a66aa48744">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenEmployeeStockPurchasedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20bb6b78-a1c7-4e02-a061-317ab08cbf4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">idya:CancerResearchTechnologyAndTheUniversityOfManchesterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="C_21330ef1-face-41aa-bc1a-38277d6baec6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_21782d2d-3573-4395-b36b-0736994720e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
        </entity>
        <period>
            <instant>2025-02-14</instant>
        </period>
    </context>
    <context id="C_21d37c85-a2fd-4198-8e25-eada4c1b7d75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_22bc9e4b-b2f2-40b0-b055-d6de85aad84e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_22f94b97-85f3-4e83-8f04-ecf937a7a2ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">idya:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="C_2378e96a-3247-479e-b4ea-c4f63e5949db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_251008aa-c1a9-42db-be7d-38cbbc1eb46d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_26c750d2-8712-4a4a-a85d-4f7f7ab0f46b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">idya:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_27155058-a3b3-4ee4-8db6-19df70e8e552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_274ca130-dad0-4940-9133-f4b57bf70ddb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:WernerHelicaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_28484219-22fe-452a-8a69-2ba6d3d5a00e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:WernerHelicaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_29388ec7-4754-45f1-b582-afffea61e7ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2a9cefda-dc1e-448e-84a6-0e063d36ae4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2c520ba2-7d16-4246-9088-3fdbb269e8a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2d6346e6-95ec-4b03-b74c-67593a769fb2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:PolymeraseThetaProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2dd15ed5-ab2a-4718-85b6-49aa0ce8c31a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">idya:OrphanDrugCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2f75efad-f0a6-4830-98d3-294b93ab7d63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenEmployeeStockPurchasedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2f896155-5fb2-43f9-9ec7-58dfaea72f5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3062bf66-4396-4633-bd29-bdc943e6d16c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:JanuaryTwoThousandTwentyFourSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_32a22686-66c0-40db-bd68-392be3f3a5cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_32b3ac20-7005-4029-b9d5-0a08c767ed8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_34b68bd4-0003-4e5f-b72b-00f8d56f232d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3581a854-ba16-4bf6-95e9-e33f2a21a2e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_35bd050f-8213-4ced-a848-8e723be54545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">idya:DarovasertibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_364b5f8f-7b5f-4a54-aaa4-7b2b4312be72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_364d998d-4e55-404f-9c33-0ee5538a29c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_38305cf8-eda8-4b97-a281-f86a6e1d392c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenEmployeeStockPurchasedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_39360529-0ce4-46c5-8c50-c0b69f139d2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_398ec6fa-698e-497a-9e5f-057cc0f5a06c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="C_3a8b018a-8ca5-43cb-9db1-a7f041be1845">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_3ccc9e3e-a98d-4222-a5ff-8d2e28d0cadc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:GlaxoSmithKlineCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_3d9101a4-e405-4fd0-a74a-a22c9cf099bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3ee2b473-d5b8-47db-8a39-4baf5b194b84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:WernerHelicaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3fb19a67-7108-4959-9367-f31f87dee14d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">idya:NovartisInternationalPharmaceuticalsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_46c16141-586e-4130-9e68-98823b85e056">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">idya:IDE397Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4731288a-d1d1-4c3c-a9e6-91e059e7e20f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_47b63c45-ebe3-463d-93fb-502e26c0ae49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_49528f5e-068e-48f2-8643-656de2cfb1fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4a13cb3d-0ae0-44c8-9454-9eb34da39ecb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-27</startDate>
            <endDate>2023-10-27</endDate>
        </period>
    </context>
    <context id="C_4b10675f-0784-4fa3-8f18-4c914a58c0d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4e5c2597-3aa6-4e75-84f5-fcacb80ec75e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4e9c63ed-b84b-4dfc-8ce5-17fc94afdaed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:MethionineAdenosylTransferase2AProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_51602dc5-8082-4af9-ae8d-664968b23422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_528a15eb-04d7-4a77-882c-7e2e6baa5a16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">idya:ExerciseOfOutstandingOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandFifteenNineteenAndTwentyThreeEquityIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_532df7ab-49f7-48a9-8543-1497d27c4737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-11</instant>
        </period>
    </context>
    <context id="C_5461c8ef-2882-483f-a96f-317b9393242b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">idya:SanDiegoCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="C_54da252c-c145-4c7e-bec2-4a22f8d0c57c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">idya:IDE397Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_55abfe7d-fa2b-408a-b618-f79551bab538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandFifteenAndNineteenEquityIncentivePlansAndTwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_569cd832-f7fb-45d7-b394-66e1bc0a4298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenEmployeeStockPurchasedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5855cfe6-054d-4ae0-825a-83a7de5b18e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
        </entity>
        <period>
            <instant>2023-04-27</instant>
        </period>
    </context>
    <context id="C_5b17504e-2e08-477e-af4e-e1ad86f5b6e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-11</instant>
        </period>
    </context>
    <context id="C_5c35883b-fbec-4b73-845e-1e70a57f9790">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenEmployeeStockPurchasedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5c3703b4-36c2-48ab-aecf-7f7732bf9bb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:WernerHelicaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5c8611d6-e1c9-4c75-8bf6-e818c66f5c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:PolymeraseThetaProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5d624162-e14b-4855-a956-1c0a4448424b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5eba0c16-aaa5-49a4-a81d-b173390ca4d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">idya:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">idya:NovartisInternationalPharmaceuticalsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_63980d6b-b6c2-4f34-9482-a0495f116793">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-11</startDate>
            <endDate>2024-07-11</endDate>
        </period>
    </context>
    <context id="C_6441389d-ead7-45d4-86d2-83922de15d96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_64b83c21-4b63-4ca9-9683-99ffc7d0f98b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:GlaxoSmithKlineCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_650406b3-09c1-4d06-8663-ecb638592c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="C_651623b8-e9c1-43f9-a69b-5797bef8158e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_65d2c0cd-0252-4d0e-99da-bb88696b6445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_66c2d5d4-7a3c-49b2-bb70-145a6e9b9b23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">idya:CancerResearchTechnologyAndTheUniversityOfManchesterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_67f86cd1-0ddf-496c-b21f-48df8bce456d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:BiocytogenPharmaceuticalsBeijingCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="C_6814219a-6bb3-46e5-9d9a-753145524259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">idya:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_69622302-21de-4f4c-a022-d0681d928a7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
        </entity>
        <period>
            <instant>2024-07-11</instant>
        </period>
    </context>
    <context id="C_6d1a7946-4210-4f48-afb5-2b7ec9271ed6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">idya:BiocytogenPharmaceuticalsBeijingCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-31</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="C_6fb07cd5-fdda-41ce-bad2-075ecef88512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_708a6a15-ace7-419f-8285-9848a72f3257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7415a7a9-5eb5-4ea2-a045-27af19dae8bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">idya:CancerResearchTechnologyAndTheUniversityOfManchesterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_750fdeba-ea50-4e26-8f84-b154ebcc6f75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">idya:DarovasertibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_75dd9ba0-2dcb-4995-8704-30a44e45f791">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_761fc146-6272-4882-8bef-299b24f35235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_76c3f127-e221-49fe-8e31-8bd88d9f4e1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_77882837-0da6-42b6-aba3-1ef2b76bff1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_77a77c54-3d7a-48df-b0a2-b2ee4ac11347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_77daf335-fcd4-483d-9de0-eb33d3d8f444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:WernerHelicaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_78c6497a-ce12-4868-8a73-d11183d394be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7997c4a8-f7da-4956-8da0-38a0332faec7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="C_79faf38f-faf7-45d1-b17b-062ffafd4097">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7a6bc497-f228-42bb-8d0a-1e9eedd0706f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7bcd1912-41e8-4474-944c-32f938bcc64c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-27</instant>
        </period>
    </context>
    <context id="C_7bf84ed4-93bd-4eeb-804c-d7cf2b19b16a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">idya:WernerHelicaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_7c297d4e-8a0d-4d1f-80dc-8cc368231084">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">idya:IDE161Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7cd721db-73ca-47d3-bf8c-9b912b4a5d53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">idya:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7d833bb0-e665-4cf0-b5ef-b88aee6558e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>idya:Segment</measure>
    </unit>
    <unit id="U_GBP">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="U_Vote">
        <measure>idya:Vote</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Obligation">
        <measure>idya:Obligation</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_43ee73fe-c85b-4774-968b-97b304ed243e">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_fbb4715e-22bc-422d-b405-05d7e185daba">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_d7f428a3-5053-41f0-ac78-0f76a6fb3fa6">0001676725</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      id="F_a4436390-e215-4734-bf5f-6f7d9bb4566d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      id="F_db1f14ba-60eb-409c-bacf-2ea36e6fcc5e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      id="F_8b9de624-e845-40d7-a9f4-ea6904fdf1d8"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      id="F_cd9a8961-a8bc-4fc1-85bb-4c42f207ee7a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_cdf3bc15-99ed-4518-8a55-98939fdba747"
      id="F_d3a6b20e-57d6-4e14-ab8d-c3cbd58018ea">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="C_8aa43324-1520-4534-b3e2-3a693540bf81"
      id="F_338a4ed1-99c5-4700-8268-537e20e71a59">2020 2021</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_3b792965-e65d-4647-ad8c-bd3fa5a2dc19">http://www.ideayabio.com/20241231#PresidentAndCEOMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <dei:DocumentType
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_1200cfad-cff1-4145-842c-cea51b10b7b9">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_285b70d1-d87e-4cf1-8b3b-7c7c47bbf679">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_e124e4bd-9c91-49b7-91a5-987714a7b79c">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_004140e2-4543-4bc8-af8f-a883aaf78773">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_8a9506ca-447a-448f-b649-a364a07a2dec">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_0fc82ed9-0baf-4f7e-8161-f5a93907033e">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_f584e6e7-56a8-416f-861b-b2b24ef5fee5">001-38915</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_b54dff6f-f641-4cb6-9cb0-f0a25221dc5b">IDEAYA Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_166b30c0-6479-46f6-b94f-f91e0f52a9d4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_73bcaea7-f29a-4541-bd7f-edbece6ff4fd">47-4268251</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_f237e3fd-b58b-4909-b5bc-f88f25b56955">5000 Shoreline Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_8e84f01b-b9ad-4969-8416-03971b46cfbb">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_a279b063-94fb-4cda-9d4b-d5baf642fedf">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_5b75be0d-8420-407c-9891-66944910022a">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_350e30f5-edc5-4737-aa7d-9f40ed909cc3">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_d45c8529-8c01-4f73-90c8-186c799c62e8">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_e4281d1c-7843-4519-9bfe-948c48c076a8">443-6209</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_825b8a3d-dc7f-4a19-9fd2-32fd34e202ea">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_632f0200-d783-45f5-b720-6c9f78df6612">IDYA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_cc8978d7-0148-4d84-9b04-a2c37aa4ce4a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_6d7bb1e5-07d0-4cda-95d5-4fad36580695">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_9942d0b1-23ea-4752-a57c-d26e7d31923c">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_a4fa99be-00ae-4158-be05-8fb997c75a4f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_14b67083-f7fa-4d5f-9fd3-6438be94a44c">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_7043f743-f057-4e8b-bcf5-fe85364e3bcc">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_06bb90ee-86e6-4b4c-8f42-254cbccaef2e">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_9e98e18e-7581-49e5-a82b-49b24cab7d93">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_0dbfe475-5164-4528-9293-fc50661bd04d">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_e6d579de-3a7d-421e-9c51-bfc3feaace9f">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_bce4e0a2-4af4-43c7-aeb6-ad404aa8644d">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_398ec6fa-698e-497a-9e5f-057cc0f5a06c"
      decimals="-8"
      id="F_1eee0472-0b80-4228-9ed6-b3baf8d502b9"
      unitRef="U_USD">2700000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_21782d2d-3573-4395-b36b-0736994720e9"
      decimals="INF"
      id="F_a955d8ca-f5e7-4627-93dc-df1d18624d0d"
      unitRef="U_shares">87537391</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_ddd45e5f-f343-4c31-b6b2-8584ed283c2c">&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Portions of the registrant&#x2019;s definitive Proxy Statement relating to the 2025 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#x2019;s fiscal year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_fc327759-af26-4301-b57f-fc3504f522e9">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cybersecurity Risk Management and Strategy&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF). This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the NIST CSF as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk management program is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; into our overall risk management program, and shares common methodologies, reporting channels and governance processes that apply across the risk management program to other legal, compliance, strategic, operational, and financial risk areas.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Key elements of our cybersecurity risk management program include but are not limited to the following:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;risk assessments designed to help identify material risks from cybersecurity threats to our critical systems and information;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a security team principally responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a documented set of cybersecurity policies and procedures that specifies the manner in which security controls are implemented;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security processes&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;cybersecurity awareness training of our employees, including incident response personnel, and senior management; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a third-party risk management process for key service providers based on our assessment of their criticality to our operations and respective risk profile,, suppliers, and vendors who have access to our critical systems and information.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There can be no assurance that our cybersecurity risk management program and processes, including our policies, controls or procedures, will be fully implemented, complied with or effective in protecting our systems and information.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We face risks from cybersecurity threats that, if realized, are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. For more information, see the section titled &#x201c;Risk Factor&#x2014; Our information technology systems, or those of our collaborators, CROs or other contractors or consultants, may fail or suffer security breaches, which could adversely affect our business. Security breaches, loss of data or financial assets, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability.&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cybersecurity Governance&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee, or the Committee, oversight of cybersecurity risks, including oversight of management&#x2019;s implementation of our cybersecurity risk management program.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Committee is composed of members of our board of directors with diverse expertise, including risk management, public accounting, biotechnology, chief executive officer roles, and multiple public company directorships, which has prepared them to oversee our cybersecurity risks.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Committee receives quarterly reports from management on our cybersecurity risks. In addition, management updates the Committee where it deems appropriate, regarding any cybersecurity incidents it considers to be significant or potentially significant.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Committee reports to our full board of directors regarding its activities, including those related to cybersecurity.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The full board of directors also receives briefings from management on our cybersecurity risk management program. Board members receive presentations on cybersecurity topics from our Senior Vice President, or SVP, Head of Finance and Investor Relations, Senior Vice President, General Counsel, internal security staff and external experts as part of the board of directors&#x2019; continuing education on topics that impact public companies.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Andres Briseno, our SVP, Head of Finance and Investor Relations and, Douglas Snyder, our Senior Vice President, General Counsel, are primarily responsible for assessing and managing our material risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Mr. Briseno and Mr. Snyder have primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Mr. Briseno has served in a number of significant leadership roles at our company since 2016, including oversight of investor relations, business operations and corporate developments, and was appointed as SVP, Head of Finance and Investor Relations in 2023.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Mr. Snyder has served in a number of significant leadership roles in various companies in the healthcare industry, and provided an oversight to legal and compliance teams with his broad legal background. Prior to joining our company, Mr. Snyder served in senior leadership and operations roles across healthcare field, including biotechnology, pharmaceuticals and the FDA&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Further, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;our management team&#x2019;s experience includes monitoring the cybersecurity landscape for new risks and best practices, developing and executing cybersecurity strategies, overseeing related governance policies, testing compliance with applicable technical standards, remediating known risks and leading employee training programs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management team takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the information technology environment.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_1a0721a8-c5b4-45c0-9205-8bb4013fe55c">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk management program is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; into our overall risk management program, and shares common methodologies, reporting channels and governance processes that apply across the risk management program to other legal, compliance, strategic, operational, and financial risk areas.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_a64a12f2-25a8-41a1-91b6-c9c57b0e6b80">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_091ec5fb-ea10-497e-9298-1a3a3a767ed4">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_51e839bd-8a76-4689-83a0-6469e69b034d">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_810fb6bf-e0bc-49e6-a868-c5f499362790">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_fd56092b-7b63-4adb-913c-f9e857075c91">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee, or the Committee, oversight of cybersecurity risks, including oversight of management&#x2019;s implementation of our cybersecurity risk management program.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Committee is composed of members of our board of directors with diverse expertise, including risk management, public accounting, biotechnology, chief executive officer roles, and multiple public company directorships, which has prepared them to oversee our cybersecurity risks.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Committee receives quarterly reports from management on our cybersecurity risks. In addition, management updates the Committee where it deems appropriate, regarding any cybersecurity incidents it considers to be significant or potentially significant.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Committee reports to our full board of directors regarding its activities, including those related to cybersecurity.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The full board of directors also receives briefings from management on our cybersecurity risk management program. Board members receive presentations on cybersecurity topics from our Senior Vice President, or SVP, Head of Finance and Investor Relations, Senior Vice President, General Counsel, internal security staff and external experts as part of the board of directors&#x2019; continuing education on topics that impact public companies.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Andres Briseno, our SVP, Head of Finance and Investor Relations and, Douglas Snyder, our Senior Vice President, General Counsel, are primarily responsible for assessing and managing our material risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Mr. Briseno and Mr. Snyder have primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Mr. Briseno has served in a number of significant leadership roles at our company since 2016, including oversight of investor relations, business operations and corporate developments, and was appointed as SVP, Head of Finance and Investor Relations in 2023.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Mr. Snyder has served in a number of significant leadership roles in various companies in the healthcare industry, and provided an oversight to legal and compliance teams with his broad legal background. Prior to joining our company, Mr. Snyder served in senior leadership and operations roles across healthcare field, including biotechnology, pharmaceuticals and the FDA&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Further, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;our management team&#x2019;s experience includes monitoring the cybersecurity landscape for new risks and best practices, developing and executing cybersecurity strategies, overseeing related governance policies, testing compliance with applicable technical standards, remediating known risks and leading employee training programs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management team takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the information technology environment.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_9268d4a8-7360-498c-9260-ded91734c6c8">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee, or the Committee, oversight of cybersecurity risks, including oversight of management&#x2019;s implementation of our cybersecurity risk management program.&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_8c137812-6142-4e9f-84e2-74b477ae1b2e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Committee receives quarterly reports from management on our cybersecurity risks. In addition, management updates the Committee where it deems appropriate, regarding any cybersecurity incidents it considers to be significant or potentially significant.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_cf7856b9-c11f-4e68-b20e-410948970679">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Committee reports to our full board of directors regarding its activities, including those related to cybersecurity.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The full board of directors also receives briefings from management on our cybersecurity risk management program. Board members receive presentations on cybersecurity topics from our Senior Vice President, or SVP, Head of Finance and Investor Relations, Senior Vice President, General Counsel, internal security staff and external experts as part of the board of directors&#x2019; continuing education on topics that impact public companies.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_2cfbf585-b877-41bd-8f32-d26a01535f59">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_ec23686f-ec6c-4246-a2bb-256cc438a792">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Andres Briseno, our SVP, Head of Finance and Investor Relations and, Douglas Snyder, our Senior Vice President, General Counsel, are primarily responsible for assessing and managing our material risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Mr. Briseno and Mr. Snyder have primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Mr. Briseno has served in a number of significant leadership roles at our company since 2016, including oversight of investor relations, business operations and corporate developments, and was appointed as SVP, Head of Finance and Investor Relations in 2023.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Mr. Snyder has served in a number of significant leadership roles in various companies in the healthcare industry, and provided an oversight to legal and compliance teams with his broad legal background. Prior to joining our company, Mr. Snyder served in senior leadership and operations roles across healthcare field, including biotechnology, pharmaceuticals and the FDA&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Further, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;our management team&#x2019;s experience includes monitoring the cybersecurity landscape for new risks and best practices, developing and executing cybersecurity strategies, overseeing related governance policies, testing compliance with applicable technical standards, remediating known risks and leading employee training programs.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_4d523b56-e882-4f5c-aada-28d133f7d2b5">&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Andres Briseno, our SVP, Head of Finance and Investor Relations and, Douglas Snyder, our Senior Vice President, General Counsel, are primarily responsible for assessing and managing our material risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Mr. Briseno and Mr. Snyder have primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Mr. Briseno has served in a number of significant leadership roles at our company since 2016, including oversight of investor relations, business operations and corporate developments, and was appointed as SVP, Head of Finance and Investor Relations in 2023.&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_9bc934ec-7695-4fff-a675-d238207fc753">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_0544803a-100e-468a-817c-2ea0d35bdb4b">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Mr. Briseno has served in a number of significant leadership roles at our company since 2016, including oversight of investor relations, business operations and corporate developments, and was appointed as SVP, Head of Finance and Investor Relations in 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Mr. Snyder has served in a number of significant leadership roles in various companies in the healthcare industry, and provided an oversight to legal and compliance teams with his broad legal background. Prior to joining our company, Mr. Snyder served in senior leadership and operations roles across healthcare field, including biotechnology, pharmaceuticals and the FDA&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_eb642f77-00cf-4cd5-89ff-cfa0d9ff7eb3"
      id="F_223fe026-c06f-4fe7-9c00-40b86fd8f3dc">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_eb642f77-00cf-4cd5-89ff-cfa0d9ff7eb3"
      id="F_af0991a3-0130-4b99-886d-1cdaa1a748b8">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_eb642f77-00cf-4cd5-89ff-cfa0d9ff7eb3"
      id="F_01a8ef09-f2f4-4d6f-b6f5-d6334337c959">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_eb642f77-00cf-4cd5-89ff-cfa0d9ff7eb3"
      id="F_6b0acaad-b3bf-46bd-9df1-089e4622e123">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_f9ee59aa-6554-4c55-9b26-8825d38ab7a6">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorFirmId
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_ad8aa836-1320-4744-9d9b-db6a5b9b5faf">238</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_d5c27f50-2526-4e8d-8b11-23086c8caa99">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Opinions on the Financial Statements and Internal Control over Financial Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying balance sheets of IDEAYA Biosciences, Inc. (the "Company") as of December 31, 2024 and 2023, and the related statements of operations and comprehensive loss, of stockholders&#x2019; equity and of cash flows for each of the three years in the period ended December 31, 2024, including the related notes (collectively referred to as the "financial statements"). We also have audited the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Internal Control - Integrated Framework &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Internal Control - Integrated Framework&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (2013) issued by the COSO.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_7f1e32e5-22c4-47f4-99cc-c46f4e06d763">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_8a19b563-c2dc-4903-a6a5-0d0e5efadc40">San Jose, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_942247fc-391c-498a-a740-fdba3fb6c567"
      unitRef="U_USD">84378000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_73ad4007-3113-45ff-9a94-3fd61043d414"
      unitRef="U_USD">157018000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_fa8877af-e671-410d-99d3-c965f06a5ccc"
      unitRef="U_USD">591941000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_b169ca0f-d5a2-43df-ab13-bf75ec243c11"
      unitRef="U_USD">368096000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_aa76fadc-d669-4968-ac20-88a2f66d1bfd"
      unitRef="U_USD">3000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_ea6d83f0-3734-437c-bfca-edf8c1905cfd"
      unitRef="U_USD">18000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_e68ba48b-0090-492e-8870-cad37aaf068e"
      unitRef="U_USD">13391000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_5338298d-844c-41ad-8248-9c5165fd1a5d"
      unitRef="U_USD">7500000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_4ff50180-974e-4348-92f0-86b236bf922e"
      unitRef="U_USD">689713000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_b25ddf46-e72b-460b-ad9a-0c875d96fdc9"
      unitRef="U_USD">532632000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_82510c51-c08d-4e8b-8901-27bc984ac9ce"
      unitRef="U_USD">805000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_d03823b6-f9c1-4931-b282-610d835b9084"
      unitRef="U_USD">757000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_f5e9c9ec-f141-486e-82b0-9fe6bc972681"
      unitRef="U_USD">405832000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_0e4125a6-f49c-4a0d-858c-31928cb65892"
      unitRef="U_USD">107492000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_07cd3245-8250-422e-a787-b4624893f2f2"
      unitRef="U_USD">8966000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_c3b617c8-f92c-4d25-949e-2e3fab0d7667"
      unitRef="U_USD">6164000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_f0c60728-9e89-468e-a2eb-93940b09fd13"
      unitRef="U_USD">18775000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_87502054-0e93-4835-9ab7-540898300b97"
      unitRef="U_USD">2246000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_d1774230-911a-4329-88c9-9034e66e0190"
      unitRef="U_USD">25000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_dae76a36-8489-405b-a34b-e8201539b967"
      unitRef="U_USD">1124091000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_b4f23a03-a693-49ea-b5c2-3bf85c2a9e21"
      unitRef="U_USD">649316000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_f056fa42-e885-47c2-b65b-2153007704f2"
      unitRef="U_USD">15421000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_e6660b9b-e85a-442c-9adc-f7f6f72ed930"
      unitRef="U_USD">6598000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_a309b5b5-2303-4707-9ff7-ed71b2fd05a6"
      unitRef="U_USD">30352000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_965c5614-070b-409a-bd98-d55d5f3d7436"
      unitRef="U_USD">18756000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_a87236c4-55d5-4701-8b43-14f503cd8e4c"
      unitRef="U_USD">298000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_efe410b2-5445-45fd-ab48-21bd1a9cee1d"
      unitRef="U_USD">1747000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_3895a109-21fe-4d2d-a021-358890907a5e"
      unitRef="U_USD">46071000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_20eb0c98-db95-4a63-b9c0-aceecd04c59a"
      unitRef="U_USD">27101000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_53fce149-b612-4cde-95fc-3d1cd734fb68"
      unitRef="U_USD">18873000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_3b7cf583-51f3-4c13-9118-0611e7f9f758"
      unitRef="U_USD">1125000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_116b0850-6006-4839-9cd2-e21bbe6a69f4"
      unitRef="U_USD">64944000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_8cc9de67-04ab-43bc-b7dd-911372fd81af"
      unitRef="U_USD">28226000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="INF"
      id="F_c0dc1053-8cfa-45d4-8b97-262a75ff884f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="INF"
      id="F_0ab33a1c-ba1f-4807-8f3d-fd5d88e97ea0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="INF"
      id="F_3a74f2dc-dda2-4e93-9116-29c89d13a85f"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="INF"
      id="F_cd2fa7eb-cc17-4e5c-935c-c9b9647495d9"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="INF"
      id="F_ef3dbc84-b89f-4516-9e38-55f430fc2bf4"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="INF"
      id="F_bbf1105e-307c-4ecc-b8fe-e9fb2754f14c"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="INF"
      id="F_da02a650-80ae-4fb6-992e-cab389a31cdb"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="INF"
      id="F_82148dd4-eb4e-4059-8ed9-ef3b8ebd522e"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="INF"
      id="F_43240f2d-540f-47be-9e44-70e13a7f353e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="INF"
      id="F_c8731961-2340-44f4-af3a-1d9898f60fe9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="INF"
      id="F_f24abd84-cead-4d91-84db-88e2d14d51d1"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="INF"
      id="F_efeb7e0a-6b01-419f-aaf0-3171aa016dc7"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="INF"
      id="F_c472744f-c89f-4bc8-9d99-9c6cd4ef06e7"
      unitRef="U_shares">86503509</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="INF"
      id="F_b0a98cc9-b820-4ad1-9507-dbab9e71aac7"
      unitRef="U_shares">86503509</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="INF"
      id="F_4f98ebce-4d53-4569-abc0-0730e479de0c"
      unitRef="U_shares">65039369</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="INF"
      id="F_c9263377-c92d-49c4-9b1f-72ff3a0ec336"
      unitRef="U_shares">65039369</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_d646e103-a4d8-489b-b870-0518707a3130"
      unitRef="U_USD">9000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_3cd2ec24-87f1-414a-b3b7-0dbe8186bcea"
      unitRef="U_USD">7000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_4ba33dea-6609-452e-8220-c574b2b4234f"
      unitRef="U_USD">1681167000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_aac25bd3-ce8f-4052-b68a-83216c025b48"
      unitRef="U_USD">968885000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_10b43fb3-bc46-4b9d-a4b0-2a8b36457176"
      unitRef="U_USD">812000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_85ccc905-7d08-4d8f-b837-2d4a207ab59a"
      unitRef="U_USD">562000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_91bc8ede-c284-4888-8bab-45214e16ad5c"
      unitRef="U_USD">-622841000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_29f454b0-7ab0-4c51-b199-e6eafcaf0db0"
      unitRef="U_USD">-348364000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_2a833497-52bb-4f80-80bd-156ac559922b"
      unitRef="U_USD">1059147000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_69014bc1-a401-4db5-877f-cdf6a9941ab9"
      unitRef="U_USD">621090000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_c8966ddb-1b0c-485c-8515-5cd2ea8ef50a"
      unitRef="U_USD">1124091000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_119f0faa-4212-44f4-b80f-2b4b975c978a"
      unitRef="U_USD">649316000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_70ffdd70-e81b-4de7-aaa2-02a409a094a8"
      unitRef="U_USD">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_bb4b231e-eee5-4e33-90d0-efcfbc213d02"
      unitRef="U_USD">23385000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_f65f8cea-6f36-4bfc-9d59-a48d9c6cb861"
      unitRef="U_USD">50931000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_ad1357ac-510c-4a34-8a71-9b3b2da7144a"
      unitRef="U_USD">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_77b120f2-10b0-409c-b05e-7884c4a9239b"
      unitRef="U_USD">23385000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_a166775f-6247-49ce-ae1e-1aa06d216025"
      unitRef="U_USD">50931000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_882b81f1-c96b-4c22-887f-406b500fa4e2"
      unitRef="U_USD">294673000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_b64d7982-9697-4a24-a12c-188ade7f7193"
      unitRef="U_USD">129508000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_108e7438-f4a9-490a-bc8c-bbde0e7dddfb"
      unitRef="U_USD">89536000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_d50c012a-f7a2-4af1-90d4-969d8439f391"
      unitRef="U_USD">39302000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_9bd76de2-edbd-4e73-85f0-43427d5201d9"
      unitRef="U_USD">28306000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_7a455789-a60a-403a-a12c-d1334f2663fc"
      unitRef="U_USD">23897000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_da347b30-b058-48ad-b1ee-16fa6f68c415"
      unitRef="U_USD">333975000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_fb13dfa1-38e2-47b7-94c8-41d48aa91d2e"
      unitRef="U_USD">157814000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_5901c8ee-0563-42c6-bf5c-a10efb4432e6"
      unitRef="U_USD">113433000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_5e4e3014-89ef-4d43-abe2-6eef096498b7"
      unitRef="U_USD">-326975000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_b5c5485c-a14f-4618-85a1-cc5a1704318f"
      unitRef="U_USD">-134429000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_9e0b6881-7900-4511-9180-f05451856874"
      unitRef="U_USD">-62502000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_8e52aa6c-a2ed-4a5e-9974-377a15bfdaaf"
      unitRef="U_USD">52498000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_169ff44c-71dc-40f6-a8a1-5f26b3098850"
      unitRef="U_USD">21468000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_ba7d6721-f467-4341-97fd-e30c04c17765"
      unitRef="U_USD">3847000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_91217756-22ea-41af-ac73-368e1ee5dae0"
      unitRef="U_USD">-274477000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_7a5a0350-0298-4533-aa05-e60ae5aa6980"
      unitRef="U_USD">-112961000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_94ece008-2f7d-4141-89dd-2b27618f52a6"
      unitRef="U_USD">-58655000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_b2c24abd-937d-4813-9503-62521a64de07"
      unitRef="U_USD">250000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_b2ee5160-ba5f-49d1-9d0f-328397a03cd5"
      unitRef="U_USD">3433000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_5f5584a1-5fbe-4c78-86b2-d2c64ec7914b"
      unitRef="U_USD">-2159000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_4df818a5-e44b-4d80-95ec-c0a33edec422"
      unitRef="U_USD">-274227000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_7542a57b-bc57-4537-b532-3a9049b7e806"
      unitRef="U_USD">-109528000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_be2caf41-c4be-49a0-aa75-57dd63a1a945"
      unitRef="U_USD">-60814000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="2"
      id="F_27307e98-a710-4f37-aeaf-0167988a98d4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="2"
      id="F_f0caba62-72b4-4dec-b21a-80424abf544f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="2"
      id="F_515b92a9-c811-42bb-a604-cfc840b25ba8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="2"
      id="F_b90061c0-2232-45ef-a2c0-f18e5db12edf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="2"
      id="F_38b9affc-383c-4f64-9635-8a81c8e9a6cf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="2"
      id="F_27f6d108-d110-4f61-87d5-7ec47e5bd970"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="0"
      id="F_2381f0c7-2c63-4aba-b537-58a7f89177f7"
      unitRef="U_shares">81678069</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="0"
      id="F_07d7b007-c773-4bc1-9d04-79009db886fc"
      unitRef="U_shares">81678069</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="0"
      id="F_b754dc43-49df-4a89-81bd-6d338e62bb2d"
      unitRef="U_shares">57519929</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="0"
      id="F_5b5dc0fc-ee80-4f15-9525-2219d08998bd"
      unitRef="U_shares">57519929</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="0"
      id="F_a0f3570d-6382-42a3-a87d-2b385e8a7010"
      unitRef="U_shares">41444696</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="0"
      id="F_d0e10406-1792-4a12-8ba0-d16ee1477637"
      unitRef="U_shares">41444696</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_3d9101a4-e405-4fd0-a74a-a22c9cf099bd"
      decimals="INF"
      id="F_abd5835d-49c7-44dc-9643-2743bd2de774"
      unitRef="U_shares">38533045</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_3d9101a4-e405-4fd0-a74a-a22c9cf099bd"
      decimals="-3"
      id="F_15747893-6baa-45aa-98e8-7d305de91a31"
      unitRef="U_USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_15cd159b-08a9-48df-9fa1-4e164fd62eb7"
      decimals="-3"
      id="F_0533e5d5-3756-432d-8224-5b7f5c21fb87"
      unitRef="U_USD">478970000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_eb581dfe-56cb-4aba-ab2b-d96ee1f0e219"
      decimals="-3"
      id="F_cce7f3d1-9b29-42ee-b4c3-2b4ca93f87f4"
      unitRef="U_USD">-712000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_aaa793d3-6d40-4eb9-8f53-fe79e2aded7a"
      decimals="-3"
      id="F_2dc4774f-8dc0-4b25-999d-4b2f36bf9fe7"
      unitRef="U_USD">-176748000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6fb07cd5-fdda-41ce-bad2-075ecef88512"
      decimals="-3"
      id="F_59f9c539-a0e9-4b1d-9ab0-8a04245c7158"
      unitRef="U_USD">301514000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_a1506248-4546-46fa-a347-9575de765d3e"
      decimals="INF"
      id="F_a1f783c7-5d3f-4921-8b06-ada4fd130c94"
      unitRef="U_shares">8761905</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_a1506248-4546-46fa-a347-9575de765d3e"
      decimals="-3"
      id="F_85793e98-decf-4f8e-bfa2-b830fef8aca7"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_47b63c45-ebe3-463d-93fb-502e26c0ae49"
      decimals="-3"
      id="F_b0020916-ee5d-4330-a4a5-d5a1b0acf107"
      unitRef="U_USD">86080000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_94217de2-f133-4daf-80d3-64910929d8e1"
      decimals="-3"
      id="F_dccdc9d2-144b-4bb6-9f86-ad8cd8f06882"
      unitRef="U_USD">86081000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_79faf38f-faf7-45d1-b17b-062ffafd4097"
      decimals="INF"
      id="F_60b3ae80-02ec-4a96-ae41-6da2b65f5326"
      unitRef="U_shares">601844</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_3581a854-ba16-4bf6-95e9-e33f2a21a2e8"
      decimals="-3"
      id="F_c191c77b-3df6-48e8-8146-26857972d063"
      unitRef="U_USD">8842000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_ef560538-beca-4fdb-9d65-b2ca89c607d8"
      decimals="-3"
      id="F_02844538-1af2-4c0c-a0c4-01bc9bbbd092"
      unitRef="U_USD">8842000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_fd99da48-95e7-4823-8ffd-92a6ffd6af51"
      decimals="INF"
      id="F_2de61c6b-1646-4262-8dd6-98f800ca5da3"
      unitRef="U_shares">214643</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_fb60d22d-1a0c-4b09-951c-98eeeac567e1"
      decimals="-3"
      id="F_bbe2d06e-653d-4acc-9658-9bd9f926f88e"
      unitRef="U_USD">1448000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_e328e3ac-159b-47da-8108-5fda32079caa"
      unitRef="U_USD">1448000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_fd99da48-95e7-4823-8ffd-92a6ffd6af51"
      decimals="INF"
      id="F_953cc608-d488-4596-98d7-3aaed9b492ae"
      unitRef="U_shares">81742</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_fb60d22d-1a0c-4b09-951c-98eeeac567e1"
      decimals="-3"
      id="F_a4507b7a-28b2-48ab-bd7c-9a9142a7ca39"
      unitRef="U_USD">755000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_b65c1d72-a5b2-4f2a-ad1b-88953eba029a"
      unitRef="U_USD">755000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_fb60d22d-1a0c-4b09-951c-98eeeac567e1"
      decimals="-3"
      id="F_03cc3a21-ee00-41ef-ae64-9fad82d1e2b3"
      unitRef="U_USD">11629000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_86f02063-2eba-4aa4-a1f7-61e8534ca70f"
      unitRef="U_USD">11629000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_1707f298-031e-42ff-92b2-f2d35e7cb9fd"
      decimals="-3"
      id="F_e5a0a66c-7ff8-42a9-b6cc-ecee090e18f5"
      unitRef="U_USD">-2159000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_a105e678-82ea-479a-a962-7f90220cae5e"
      unitRef="U_USD">-2159000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_b8560028-9f37-4ff3-9028-5dc8f0dd96db"
      decimals="-3"
      id="F_2fa7bb32-96c1-421a-928c-bbcd58aef997"
      unitRef="U_USD">-58655000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_3cda611c-7689-4a3a-bfa1-44b27f7b38e5"
      unitRef="U_USD">-58655000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_77882837-0da6-42b6-aba3-1ef2b76bff1b"
      decimals="INF"
      id="F_96bca776-2414-460c-9bc1-acd01ad0ed82"
      unitRef="U_shares">48193179</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_77882837-0da6-42b6-aba3-1ef2b76bff1b"
      decimals="-3"
      id="F_e429b35b-0d69-4e14-b8de-5958d977e28b"
      unitRef="U_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_028bd853-e9b5-4c40-9a66-731769196cc4"
      decimals="-3"
      id="F_2daed2b7-6c39-497b-9704-c2cdc4906316"
      unitRef="U_USD">587724000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_51602dc5-8082-4af9-ae8d-664968b23422"
      decimals="-3"
      id="F_252de9ff-ad62-415c-9ce6-585f52e83a65"
      unitRef="U_USD">-2871000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4731288a-d1d1-4c3c-a9e6-91e059e7e20f"
      decimals="-3"
      id="F_a4247812-1b13-43c3-a9c4-c43df2537f32"
      unitRef="U_USD">-235403000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ce651b87-a2ee-4952-8dab-aa55bb0ac861"
      decimals="-3"
      id="F_eb0bd431-1e11-4561-a1b9-ec104b10be09"
      unitRef="U_USD">349455000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_faad213a-ce5c-4221-b05a-2e531d08f6d7"
      decimals="INF"
      id="F_942a6237-f27b-4f33-b7f5-9104ca625c82"
      unitRef="U_shares">14655993</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_faad213a-ce5c-4221-b05a-2e531d08f6d7"
      decimals="-3"
      id="F_378c227b-0035-40a7-be3c-0abe76eee299"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_12cb1aba-8889-4b3b-885c-40f700ad3c6e"
      decimals="-3"
      id="F_1ffb5edd-dc37-43c5-abca-a41f818a7d08"
      unitRef="U_USD">281120000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_7cd721db-73ca-47d3-bf8c-9b912b4a5d53"
      decimals="-3"
      id="F_4ed1f380-38f5-4a74-a3aa-b522dbce2533"
      unitRef="U_USD">281122000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_32a22686-66c0-40db-bd68-392be3f3a5cc"
      decimals="-3"
      id="F_b78b6232-2649-4797-aa3d-342737619691"
      unitRef="U_USD">42182000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_71fb6051-a8a8-42f1-a687-fcc92714c41b"
      unitRef="U_USD">42182000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ede69319-7140-4c54-a59f-e3cd00f2c014"
      decimals="INF"
      id="F_3e270669-241a-4e33-ad1c-21d3b52cacec"
      unitRef="U_shares">1188705</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_fada0950-b58a-4dd1-87c9-557dfba92f85"
      decimals="-3"
      id="F_f3476d59-d41c-48b8-b4cd-01219af2d795"
      unitRef="U_USD">28598000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_b29be823-d29d-4c0b-b5d4-dab37fe7947c"
      decimals="-3"
      id="F_653675c5-c3c8-4153-a52e-4de4909c72ec"
      unitRef="U_USD">28598000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_074141e9-fba5-404a-bcf9-4a845e4634ea"
      decimals="INF"
      id="F_03bc7d8a-6622-45c5-9976-62418908a4ae"
      unitRef="U_shares">931012</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_32a22686-66c0-40db-bd68-392be3f3a5cc"
      decimals="-3"
      id="F_8eea4381-ec17-4067-80e1-3f194fe034e8"
      unitRef="U_USD">9559000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_6d4a0820-6de3-4331-aa38-35881c930f48"
      unitRef="U_USD">9559000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_074141e9-fba5-404a-bcf9-4a845e4634ea"
      decimals="INF"
      id="F_6b14cbfb-b53f-44d3-b389-a0aab7e4eac1"
      unitRef="U_shares">70480</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_32a22686-66c0-40db-bd68-392be3f3a5cc"
      decimals="-3"
      id="F_0609ee7f-d623-441a-ae0a-052ea2b01b45"
      unitRef="U_USD">1213000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_b15b7638-4b1e-42e6-8b22-f3bd2b515725"
      unitRef="U_USD">1213000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_32a22686-66c0-40db-bd68-392be3f3a5cc"
      decimals="-3"
      id="F_b29590bd-fa05-4044-9cab-eababe4251b7"
      unitRef="U_USD">18489000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_c519b082-23ee-47fc-81b6-ece42fc303ba"
      unitRef="U_USD">18489000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_d3d4e1da-83e6-4d41-ae1c-a616266a1832"
      decimals="-3"
      id="F_87923c16-76e2-4ef2-9c84-8d2d244df759"
      unitRef="U_USD">3433000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_f6e804af-6e85-411a-844a-802a5c4eabdc"
      unitRef="U_USD">3433000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_39360529-0ce4-46c5-8c50-c0b69f139d2e"
      decimals="-3"
      id="F_da1d7ded-bcc7-4eed-93a8-6bf805018d0b"
      unitRef="U_USD">-112961000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_db199e8a-d337-4e84-b4b3-f0bb788a425c"
      unitRef="U_USD">-112961000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_b9f082f0-76fd-4961-ba1a-7e2f141962b2"
      decimals="INF"
      id="F_898b50f9-eaf0-4078-976e-aae8db6cbd2b"
      unitRef="U_shares">65039369</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b9f082f0-76fd-4961-ba1a-7e2f141962b2"
      decimals="-3"
      id="F_766ed3e4-7cbc-4334-b63d-55a36eb2bc83"
      unitRef="U_USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_af24a5ec-af73-4d40-8dd3-8e064854bf7c"
      decimals="-3"
      id="F_cd5e55b2-b274-452b-8b09-b335cab046f9"
      unitRef="U_USD">968885000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f222b075-c12f-4efc-8c81-d8aea1803872"
      decimals="-3"
      id="F_c86e55fc-10d5-4c84-8c12-426c5788a4d5"
      unitRef="U_USD">562000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d007c432-86f1-4c3b-b319-24effed11e62"
      decimals="-3"
      id="F_1cc9a257-3ed2-4cf9-8c90-976e4443b8a4"
      unitRef="U_USD">-348364000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_73fa3fa3-abe0-40b2-a363-729d28d9ae2f"
      unitRef="U_USD">621090000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0f3b93c3-2bd5-4282-b511-d0be9bbb12b0"
      decimals="INF"
      id="F_ba81a60a-bb37-403a-a8ca-b0386d3c1311"
      unitRef="U_shares">8355714</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0f3b93c3-2bd5-4282-b511-d0be9bbb12b0"
      decimals="-3"
      id="F_10b158ac-996d-4e17-a42d-16efb5f63ed8"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_77a77c54-3d7a-48df-b0a2-b2ee4ac11347"
      decimals="-3"
      id="F_641395da-6b90-4793-8892-3862e289c39d"
      unitRef="U_USD">274349000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_32b3ac20-7005-4029-b9d5-0a08c767ed8d"
      decimals="-3"
      id="F_dc6e8689-37e2-4a4c-9b52-591cecf14b52"
      unitRef="U_USD">274350000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_77a77c54-3d7a-48df-b0a2-b2ee4ac11347"
      decimals="-3"
      id="F_edeed76d-b696-4fe1-9c80-47fca91f7370"
      unitRef="U_USD">9400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_b801ef2a-b988-45f9-9820-43d6d6631845"
      unitRef="U_USD">9400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <idya:AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants
      contextRef="C_65d2c0cd-0252-4d0e-99da-bb88696b6445"
      decimals="INF"
      id="F_822d74bd-3d04-4e7c-ae23-108ee55a0e26"
      unitRef="U_shares">1749993</idya:AdjustmentsToAdditionalPaidInCapitalExerciseOfPreFundedWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_f605952c-8fcd-4667-9e72-9bc4842bb390"
      decimals="INF"
      id="F_df0fc906-3a61-43e6-b65f-db1a601961e0"
      unitRef="U_shares">10182382</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_f605952c-8fcd-4667-9e72-9bc4842bb390"
      decimals="-3"
      id="F_0a5e165b-1837-4acb-8254-b6dbc84b3da1"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_c3f56777-d0fc-4e30-8e99-35ce57f4b839"
      decimals="-3"
      id="F_2121202b-132f-43c6-abea-9f3af92a61a5"
      unitRef="U_USD">379865000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_933a2b9d-bb76-4d41-8fb8-2901d19455b0"
      decimals="-3"
      id="F_5977d0b4-6d60-46fb-9ca8-8c5721563582"
      unitRef="U_USD">379866000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_65d2c0cd-0252-4d0e-99da-bb88696b6445"
      decimals="INF"
      id="F_fe3f0ead-9fd5-49ea-819c-3bba27468f32"
      unitRef="U_shares">1118695</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_ea3cfd25-fdc0-4753-b6b9-64944718b206"
      decimals="-3"
      id="F_784affd0-998f-4ac1-84e9-0b82b0680fab"
      unitRef="U_USD">12483000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_5d7f1fd4-c96e-490f-a31f-0966007c9684"
      unitRef="U_USD">12483000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_65d2c0cd-0252-4d0e-99da-bb88696b6445"
      decimals="INF"
      id="F_5adbcdef-fac8-4d07-8332-19793b29a923"
      unitRef="U_shares">57356</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_ea3cfd25-fdc0-4753-b6b9-64944718b206"
      decimals="-3"
      id="F_96cbbdae-4c2e-41a3-aee4-73b0863f6e3e"
      unitRef="U_USD">1439000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_a14b4825-e79b-4234-979a-9e8806f40a39"
      unitRef="U_USD">1439000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ea3cfd25-fdc0-4753-b6b9-64944718b206"
      decimals="-3"
      id="F_2d47c2d5-e303-4cca-bd51-7204dd5ad83f"
      unitRef="U_USD">34746000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_d02f788d-cff4-493b-9ca6-786834ec08cd"
      unitRef="U_USD">34746000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_21330ef1-face-41aa-bc1a-38277d6baec6"
      decimals="-3"
      id="F_25054031-23ca-4dc6-bc35-50e572088766"
      unitRef="U_USD">250000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_16e122f4-75c9-4fca-90a2-7bc57a7305a9"
      unitRef="U_USD">250000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_a59c732f-c597-47eb-9ca9-3046723cbffb"
      decimals="-3"
      id="F_7b912cba-5dbd-4d2d-beb5-8ae0f9c384d7"
      unitRef="U_USD">-274477000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_efb5e469-bb72-4e37-8bf9-b085c023270b"
      unitRef="U_USD">-274477000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_76c3f127-e221-49fe-8e31-8bd88d9f4e1e"
      decimals="INF"
      id="F_a1908dab-d2fe-4d5e-a1c6-db48852f982f"
      unitRef="U_shares">86503509</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_76c3f127-e221-49fe-8e31-8bd88d9f4e1e"
      decimals="-3"
      id="F_9a7026f9-badc-45d9-a0ce-0dcd10081272"
      unitRef="U_USD">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a4955acc-673d-4246-a4cf-8af30b6dc428"
      decimals="-3"
      id="F_91437ce0-0294-4f0e-8f46-de8a96102a18"
      unitRef="U_USD">1681167000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7d833bb0-e665-4cf0-b5ef-b88aee6558e7"
      decimals="-3"
      id="F_f0b7ceb1-f68e-463a-bdda-1eced22de8b3"
      unitRef="U_USD">812000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8c4ee195-6613-4c9b-a476-c2df7fdfea67"
      decimals="-3"
      id="F_87b20a5f-1680-44e3-b79a-32ae35aef088"
      unitRef="U_USD">-622841000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_c0e0bec2-7f0a-448e-ad75-6e0cb5c7bfcc"
      unitRef="U_USD">1059147000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_ce25e6c8-57f7-435c-8b2d-50849b4ec38e"
      unitRef="U_USD">-274477000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_ec90b025-8a00-4f90-9bcb-317393954f96"
      unitRef="U_USD">-112961000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_f5b37ef8-eb76-4d57-825b-7db21862f6da"
      unitRef="U_USD">-58655000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_4ca5a3aa-9624-4efd-89e9-7e8c2f8f813d"
      unitRef="U_USD">2387000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_233dc159-e553-4ac4-9cac-38456fc88b27"
      unitRef="U_USD">2476000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_f03d466f-47e7-42e6-8541-f609bc729e7f"
      unitRef="U_USD">2101000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_76031451-e281-4420-83db-49d27e23c443"
      unitRef="U_USD">23233000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_d7071f2d-c8bf-4934-86c9-099b95c23d13"
      unitRef="U_USD">11553000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_cecd06ef-8894-4e26-8ba4-2fa8370c9a48"
      unitRef="U_USD">695000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_e83464e5-51d7-4fb3-bcdf-1c1763f04b23"
      unitRef="U_USD">34746000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_0915b808-a057-49ac-8ad5-84e82ae291c4"
      unitRef="U_USD">18489000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_1b0914e6-81b7-4778-b614-c1f64ecc27b9"
      unitRef="U_USD">11629000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_006370f6-f522-407b-b417-514edb62deec"
      unitRef="U_USD">1447000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_a61ecd6d-a39b-445f-812e-3d7e17907ac8"
      unitRef="U_USD">1532000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_d16ab440-28b6-4230-b732-51e02c9c2d3f"
      unitRef="U_USD">1414000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_51a608bb-fd0e-4475-96e8-99ea0d8632e2"
      unitRef="U_USD">-15000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_64734d3d-acc8-4f85-9e15-86fefb9c9458"
      unitRef="U_USD">-193000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_c44a71aa-462c-437e-8e11-5da48af7c13a"
      unitRef="U_USD">-892000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_54ace939-5dc4-4430-815e-c59a4b1d2dfb"
      unitRef="U_USD">6174000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_9b956994-a1bf-4e50-96af-5a0b218166ca"
      unitRef="U_USD">2045000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_3039826e-7410-4db0-8c1d-363480dccc76"
      unitRef="U_USD">2119000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_783eb46b-a3f4-4912-aacb-a5085d8f2c54"
      unitRef="U_USD">8280000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_20faacaa-b882-4f8a-898e-fc0451e1dc7b"
      unitRef="U_USD">2635000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_afad2341-0049-4d82-b9d2-561222922994"
      unitRef="U_USD">1864000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_70a9a842-3d1b-4263-accf-ac6564ecae7d"
      unitRef="U_USD">10794000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_c00a1f51-18d6-4cd1-8f25-05029391dba9"
      unitRef="U_USD">1635000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_525eee8f-ab0b-4163-9ae9-d94c6c49ac7c"
      unitRef="U_USD">4572000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_7a9c2948-57df-4ea3-ba32-bb0adeec9710"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_a9be6f06-bd60-41fc-be37-738501088b89"
      unitRef="U_USD">-13753000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_ab48b5d7-4bbf-4b95-a827-f14f2afa23fe"
      unitRef="U_USD">-46479000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <idya:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_f9f77658-0d39-4601-9d47-a4712604a28b"
      unitRef="U_USD">-1369000</idya:IncreaseDecreaseInOperatingLeaseLiabilities>
    <idya:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_5d2efcf8-7f27-4b16-9db8-11ca5a8d9395"
      unitRef="U_USD">-1872000</idya:IncreaseDecreaseInOperatingLeaseLiabilities>
    <idya:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_4a4efeaa-6641-477f-9644-490b2c09f732"
      unitRef="U_USD">-1699000</idya:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_2dc184b2-7d5a-407f-a396-ac8e31832b9f"
      unitRef="U_USD">-247584000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_23e1b200-ddd4-4884-a9b5-c76f10b4ab0c"
      unitRef="U_USD">-115224000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_143e5676-0e7f-43a8-bbf4-d9dcfe787b84"
      unitRef="U_USD">-87175000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_ca4065a4-8dfd-4a71-85ab-b4a4c82a0648"
      unitRef="U_USD">3857000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_cd9422f6-2ede-47bc-ba31-ce856b61e8de"
      unitRef="U_USD">2368000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_8ae68c2b-4814-45ff-90b2-004e6311fb1d"
      unitRef="U_USD">3443000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_c6638c79-d2e8-4ba5-89eb-1e74ffc1ed8b"
      unitRef="U_USD">1191309000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_ead8b96c-615c-4c1b-ba2e-8275364ec0e6"
      unitRef="U_USD">595980000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_663143db-fd28-4a53-92ad-ea314d632019"
      unitRef="U_USD">255808000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_b6a0cb51-1562-411a-bbdf-4982ed924c8b"
      unitRef="U_USD">692607000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_f73d1ecb-e953-4513-b451-292289626899"
      unitRef="U_USD">439892000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_8d216216-7814-467c-8c98-113ff4aa62b9"
      unitRef="U_USD">225847000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_b62aa5d6-a137-49ec-b834-479d698c8c09"
      unitRef="U_USD">-502559000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_ef79af9c-1f2e-4aeb-9fcc-8a699e8f470d"
      unitRef="U_USD">-158456000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_22bfada6-9469-4c21-a575-9be6698d3115"
      unitRef="U_USD">-33404000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_f3a3ab3c-4a9f-4476-9ccc-30cb1a4e7472"
      unitRef="U_USD">274350000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_6d2f91b5-a671-4c04-8e04-45bede20e4ac"
      unitRef="U_USD">281165000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_f9d7fa02-6736-4bb6-abc0-83f5b70b57c0"
      unitRef="U_USD">86105000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_e255180a-f2ef-429d-9b21-73c607311bfa"
      unitRef="U_USD">9400000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_a9d5ca19-fc11-4dbb-bdf9-312eef142825"
      unitRef="U_USD">42182000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_e71489de-2fe7-477b-b0c4-8a1c7ee29872"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <idya:ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_600fe333-8900-431f-aa19-27f50d5ac85f"
      unitRef="U_USD">379879000</idya:ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts>
    <idya:ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_63702039-a0b9-4b6b-aa19-eba75b6c0620"
      unitRef="U_USD">28598000</idya:ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts>
    <idya:ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_6d66adf1-8eeb-489f-9245-fc0c20e0a6dd"
      unitRef="U_USD">8857000</idya:ProceedsFromIssuanceOfCommonStockRelatedToAtMarketOfferingProgramNetOfIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_d937ca0c-8b48-4496-b3b1-9c32ff835116"
      unitRef="U_USD">12483000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_5ce17b35-4584-4dcb-a15d-f795bd0d20fa"
      unitRef="U_USD">9559000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_a7bfd2d6-677d-47bd-86fd-49bb5381c236"
      unitRef="U_USD">1448000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_36220957-e361-4f8b-971c-3904e0f9c1ed"
      unitRef="U_USD">1439000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_e824d756-8d32-4a19-8a1f-54ac684ce1aa"
      unitRef="U_USD">1213000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_d44619ea-6b15-4701-974c-8e41e9fa352a"
      unitRef="U_USD">755000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_0c0a2821-ab58-4928-98e9-a6af7e39fa99"
      unitRef="U_USD">677551000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_a4d85c55-2349-443c-a083-df236f7c597c"
      unitRef="U_USD">362717000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_79280e5e-f30e-4881-ade2-5501ce59048d"
      unitRef="U_USD">97165000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_d40c68be-730f-494c-a5f7-0cb807db625c"
      unitRef="U_USD">-72592000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_38a12d91-f2f4-477c-94ed-d64c8238abb6"
      unitRef="U_USD">89037000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_36184e3a-0053-4390-ae56-93d05fdcdc13"
      unitRef="U_USD">-23414000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_980205f0-a0bb-4d14-b89c-df9480ce6c30"
      unitRef="U_USD">157775000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_ce651b87-a2ee-4952-8dab-aa55bb0ac861"
      decimals="-3"
      id="F_89d0bb26-c75e-4c22-b763-477be4e8dcc3"
      unitRef="U_USD">68738000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_6fb07cd5-fdda-41ce-bad2-075ecef88512"
      decimals="-3"
      id="F_5feab512-d35b-4c15-95c3-0d6d053d39bb"
      unitRef="U_USD">92152000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_bb80aa6b-c8a1-4245-91c6-2c6c77125104"
      unitRef="U_USD">85183000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_9ae5f015-4510-4683-996b-82002ca820db"
      unitRef="U_USD">157775000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_ce651b87-a2ee-4952-8dab-aa55bb0ac861"
      decimals="-3"
      id="F_bc636307-d4b5-4e19-b1bd-62cf66fb661d"
      unitRef="U_USD">68738000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_224a4a04-f1b5-4b17-b0bc-3f4dcecbf7f7"
      unitRef="U_USD">84378000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_805b4b11-0caf-4dcd-860b-e0a4551d36a0"
      unitRef="U_USD">157018000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_ce651b87-a2ee-4952-8dab-aa55bb0ac861"
      decimals="-3"
      id="F_525048e1-e3b6-48dd-b4b4-8eddb68ee8d0"
      unitRef="U_USD">68632000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_f106adc9-a532-4727-84ac-fb6654013f92"
      unitRef="U_USD">805000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_02a258f5-3975-4c7f-8393-0444e655eebf"
      unitRef="U_USD">757000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_ce651b87-a2ee-4952-8dab-aa55bb0ac861"
      decimals="-3"
      id="F_0480845f-1cc3-459b-bdc5-6d9ef0b03164"
      unitRef="U_USD">106000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_52f1dd56-b81f-4003-ac75-c0dd0e26712e"
      unitRef="U_USD">85183000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_24faee44-8906-4cf1-909f-91c17b9866ce"
      unitRef="U_USD">157775000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_ce651b87-a2ee-4952-8dab-aa55bb0ac861"
      decimals="-3"
      id="F_6f522614-9cb1-4489-b4a8-aa298294dd8a"
      unitRef="U_USD">68738000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_2e17333d-0de3-42b0-ac45-0124ce5cbac1"
      unitRef="U_USD">25000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_d596f0ff-c96a-4f7d-8d63-f1139e164d4a"
      unitRef="U_USD">69000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_23229960-c38a-4883-9966-91ee0ec16d09"
      unitRef="U_USD">60000</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_d2cd8d45-337a-4abf-b702-e1f609e3c1fd"
      unitRef="U_USD">17976000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_4fd2a5c9-f343-472a-8134-8e01c051d0c5"
      unitRef="U_USD">1294000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_14dce24c-0828-42c5-971b-1e3ac5471fab"
      unitRef="U_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_22a3f9e3-f2cb-4b88-95f5-60851d4f36a7"
      unitRef="U_USD">1479000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_4d6936cd-000f-4951-9052-c49ddfca58f9"
      unitRef="U_USD">147000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_2d90c7f3-97e0-4c78-87a3-c8ba9d7cbf30"
      unitRef="U_USD">384000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <idya:UnpaidOfferingCosts
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_868a478d-20e2-439c-8eb0-6e850f1168c7"
      unitRef="U_USD">0</idya:UnpaidOfferingCosts>
    <idya:UnpaidOfferingCosts
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_6adbbf53-e7ff-499a-9fda-e066f38135f8"
      unitRef="U_USD">43000</idya:UnpaidOfferingCosts>
    <idya:UnpaidOfferingCosts
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_00f962e0-fe23-4a78-8684-15a76b7e40be"
      unitRef="U_USD">39000</idya:UnpaidOfferingCosts>
    <idya:UnpaidAtTheMarketOfferingProgramCosts
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_6f0ebe1c-c7c8-41c4-b3bc-4bd9b0287480"
      unitRef="U_USD">13000</idya:UnpaidAtTheMarketOfferingProgramCosts>
    <idya:UnpaidAtTheMarketOfferingProgramCosts
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_783d0991-a2b6-40f4-bec3-6ffbcb5f38e3"
      unitRef="U_USD">0</idya:UnpaidAtTheMarketOfferingProgramCosts>
    <idya:UnpaidAtTheMarketOfferingProgramCosts
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_2931bd1d-3f84-412e-910b-4430f253e62d"
      unitRef="U_USD">0</idya:UnpaidAtTheMarketOfferingProgramCosts>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_047f46bb-b014-41bf-8b12-a7841b9d771b">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. Organization&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Description of the Business&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;IDEAYA Biosciences, Inc. (the &#x201c;Company&#x201d;) is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The Company is headquartered in South San Francisco, California and was incorporated in the State of Delaware in June 2015. To date, the Company has been primarily engaged in business planning, research, development, recruiting and raising capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Follow-On Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On July 11, 2024, the Company completed an underwritten public follow-on offering. The offering consisted of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,355,714&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share (&#x201c;common stock&#x201d;), at an offering price to the public of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,127,142&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285,715&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.9999&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, the Company received aggregate gross proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;302.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;283.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions and other offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 27, 2023, the Company completed an underwritten public follow-on offering. The offering consisted of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,797,872&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at an offering price to the public of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;797,872&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;319,150&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.4999&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, the Company received aggregate gross proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;134.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions and other offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 27, 2023, the Company completed an underwritten public follow-on offering. The offering consisted of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,858,121&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at an offering price to the public of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,418,920&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,020,270&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.4999&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, the Company received aggregate gross proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;201.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions and other offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At-the-Market Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On June 26, 2023, the Company filed a new Registration Statement on Form S-3 (File No. 333- 272936) under the Securities Act as an automatic shelf registration statement as a &#x201c;well-known seasoned issuer,&#x201d; as defined in Rule 405 under the Securities Act. On June 26, 2023, the Company also entered into an Open Market Sales Agreement (the &#x201c;June 2023 Sales Agreement&#x201d;), with Jefferies LLC (&#x201c;Jefferies&#x201d;), relating to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of our common stock, having aggregate gross proceeds of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million through Jefferies as sales agent.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From January 1, 2024 through January 17, 2024, the Company sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,115,516&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock for aggregate net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;215.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million at a weighted average sales price of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36.39&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share under the at-the-market offering pursuant to the June 2023 Sales Agreement with Jefferies as sales agent.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 19, 2024, the Company entered into a new Open Market Sales Agreement (the &#x201c;January 2024 Sales Agreement&#x201d;), with Jefferies, relating to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of common stock having aggregate gross proceeds of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;350.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million through Jefferies as sales agent.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2024, pursuant to the January 2024 Sales Agreement, the Company sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,066,866&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock for aggregate net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million at a weighted average sales price of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41.28&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share under the at-the-market offering pursuant to the January 2024 Sales Agreement with Jefferies as sales agent. As of December 31, 2024, approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of common stock remained available to be sold under the ATM facility.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company may cancel its at-the-market program at any time upon written notice, pursuant to its terms.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has incurred significant losses and negative cash flows from operations in all periods since inception and had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;622.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has financed its operations primarily through the sale and issuance of common stock and the upfront payment and certain milestone payments received from GSK.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To date, none of the Company&#x2019;s product candidates have been approved for sale, and the Company has not generated any revenue from commercial products since inception. Management expects operating losses to continue and increase for the foreseeable future, as the Company progresses clinical development activities for its lead product candidates. The Company&#x2019;s prospects are subject to risks, expenses and uncertainties frequently encountered by companies in the biotechnology industry as discussed under Risks and Uncertainties in Note 2. While the Company has been able to raise multiple rounds of financing, there can be no assurance that in the event the Company requires additional financing, such financing will be available on terms which are favorable or at all. Failure to generate sufficient cash flows from operations, raise additional capital or reduce certain discretionary spending would have a material adverse effect on the Company&#x2019;s ability to achieve its intended business objectives.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company had cash, cash equivalents and marketable securities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion. Management believes that the Company&#x2019;s current cash, cash equivalents and marketable securities will be sufficient to fund its planned operations for at least 12 months from the date of the issuance of these financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9c02d070-8681-4a68-9460-90f6386b903f"
      decimals="INF"
      id="F_f8ea72d0-c2da-40af-a574-f6af419cf1c3"
      unitRef="U_shares">8355714</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_5b17504e-2e08-477e-af4e-e1ad86f5b6e1"
      decimals="INF"
      id="F_384eab77-8420-40ad-bc34-59321a772b2e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_5b17504e-2e08-477e-af4e-e1ad86f5b6e1"
      decimals="INF"
      id="F_11c752d6-17e8-4c38-81d7-549947d0ca44"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">35</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_63980d6b-b6c2-4f34-9482-a0495f116793"
      decimals="INF"
      id="F_b780e195-1524-43c5-86fc-f6ca33f7cdca"
      unitRef="U_shares">1127142</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_5b17504e-2e08-477e-af4e-e1ad86f5b6e1"
      decimals="INF"
      id="F_d3d00edc-fbd9-40bd-873e-8acabd9bc94b"
      unitRef="U_shares">285715</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="C_532df7ab-49f7-48a9-8543-1497d27c4737"
      decimals="INF"
      id="F_505f3349-f295-40dd-a331-b062f6c9ae06"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">34.9999</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_a6b8d688-85fc-4f28-b94d-adbdcc815d1b"
      decimals="-5"
      id="F_77b55240-df4c-437a-ba12-b978afb6b2a2"
      unitRef="U_USD">302400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <idya:NetProceedsFromIssuanceOfCommonStock
      contextRef="C_a6b8d688-85fc-4f28-b94d-adbdcc815d1b"
      decimals="-5"
      id="F_0daf3e1c-d7b0-49d3-a43e-721bd5d5ea91"
      unitRef="U_USD">283800000</idya:NetProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e4f99219-ed58-4929-87e5-a993db32910d"
      decimals="INF"
      id="F_d49ab2c3-ec34-4f4b-89b2-2414a41a3b15"
      unitRef="U_shares">5797872</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_17c6d71a-63e2-457f-a633-102c0bde4eb4"
      decimals="INF"
      id="F_0a9a93f8-f2dd-46af-8433-50ea7606e376"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.5</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_4a13cb3d-0ae0-44c8-9454-9eb34da39ecb"
      decimals="INF"
      id="F_9e89a3f7-2a9f-4c35-9906-d081f1346a1c"
      unitRef="U_shares">797872</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_17c6d71a-63e2-457f-a633-102c0bde4eb4"
      decimals="INF"
      id="F_a6dacbec-f476-4f4d-83bf-ecdcf1005388"
      unitRef="U_shares">319150</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="C_a0e7b3d3-6830-4717-90ea-44da053262f8"
      decimals="INF"
      id="F_64a9fdac-002f-4599-82cf-414f72f04965"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.4999</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_e56ae803-71fa-40b1-b315-c44f63fe65d8"
      decimals="-5"
      id="F_5effc8b8-8dee-405b-ad7d-5d0ec6d5458d"
      unitRef="U_USD">143700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <idya:NetProceedsFromIssuanceOfCommonStock
      contextRef="C_e56ae803-71fa-40b1-b315-c44f63fe65d8"
      decimals="-5"
      id="F_1076e596-7f56-4578-9404-d8819b18833b"
      unitRef="U_USD">134600000</idya:NetProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_07e35c69-dfae-4e28-83b9-c956215e0274"
      decimals="INF"
      id="F_a90fb1c6-1a81-42cd-b773-89c4bfaf535c"
      unitRef="U_shares">8858121</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_d400c976-b0bd-479d-aa74-c54c3f83c119"
      decimals="INF"
      id="F_48f1907c-e4af-4b7c-ae24-4a4d8341e7e0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.5</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e6119aea-4ad7-47ff-8b8a-db55f4f12c97"
      decimals="INF"
      id="F_e3f9f14a-c0a4-40e8-bfde-ee99e8131710"
      unitRef="U_shares">1418920</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_d400c976-b0bd-479d-aa74-c54c3f83c119"
      decimals="INF"
      id="F_ad203082-7f63-4236-9823-91fe28ba8741"
      unitRef="U_shares">2020270</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="C_e7bea947-3207-4f35-a41f-9c2f685e82c3"
      decimals="INF"
      id="F_cf65c3a9-f37a-4b37-b2e5-2773f945c2dd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.4999</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_7997c4a8-f7da-4956-8da0-38a0332faec7"
      decimals="-5"
      id="F_a2ad24c2-ebe2-4efc-9a06-c5cd3005f579"
      unitRef="U_USD">201300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <idya:NetProceedsFromIssuanceOfCommonStock
      contextRef="C_7997c4a8-f7da-4956-8da0-38a0332faec7"
      decimals="-5"
      id="F_20a3f371-f8f9-4087-97e7-c2af9758e82c"
      unitRef="U_USD">188700000</idya:NetProceedsFromIssuanceOfCommonStock>
    <idya:SalesOfCommonStockAggregateOfferingPrice
      contextRef="C_a37ca623-522c-4962-8cd1-5abe0ff44d5e"
      decimals="-5"
      id="F_d00b8d6c-4a85-4230-9169-764f41b411ea"
      unitRef="U_USD">250000000</idya:SalesOfCommonStockAggregateOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_dcda7935-3db6-4964-a858-3e928a1e6238"
      decimals="INF"
      id="F_cc131812-40c5-4bc0-8109-16cd296b0b9c"
      unitRef="U_shares">6115516</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_dcda7935-3db6-4964-a858-3e928a1e6238"
      decimals="-5"
      id="F_261397d8-7bd7-48d5-bbe5-c1cd50ca2a5a"
      unitRef="U_USD">215900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <idya:SharesIssuedWeightedAverageSalesPricePerShare
      contextRef="C_8b100a11-1b65-4fec-ae5b-2257a2c5399e"
      decimals="2"
      id="F_503bee54-39d9-4eb5-abdd-cfd2bfb71cde"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">36.39</idya:SharesIssuedWeightedAverageSalesPricePerShare>
    <idya:SalesOfCommonStockAggregateOfferingPrice
      contextRef="C_c0a63604-9e4a-452e-bb59-d9e6b5170b43"
      decimals="-5"
      id="F_60401f35-345f-4162-ba68-c7dfdbce4fd3"
      unitRef="U_USD">350000000</idya:SalesOfCommonStockAggregateOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ac598710-34a2-44e0-b556-f784f9ca8469"
      decimals="INF"
      id="F_00b6e87f-4e13-45cf-a8f3-fa5b977cd0ee"
      unitRef="U_shares">4066866</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_ac598710-34a2-44e0-b556-f784f9ca8469"
      decimals="-5"
      id="F_dd3c64a4-21a9-4b76-b463-007a68f99500"
      unitRef="U_USD">164000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <idya:SharesIssuedWeightedAverageSalesPricePerShare
      contextRef="C_3062bf66-4396-4633-bd29-bdc943e6d16c"
      decimals="2"
      id="F_60f492c1-4484-406a-bed8-dc56e6eb7a81"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">41.28</idya:SharesIssuedWeightedAverageSalesPricePerShare>
    <idya:CommonStockRemainingAvailableToBeSaleAmount
      contextRef="C_3062bf66-4396-4633-bd29-bdc943e6d16c"
      decimals="-5"
      id="F_1a33528e-3711-441e-9de0-b9d7230998f0"
      unitRef="U_USD">182100000</idya:CommonStockRemainingAvailableToBeSaleAmount>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-5"
      id="F_82dfb81c-d1d7-499b-97a7-65acf52caf91"
      unitRef="U_USD">-622800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <idya:CashCashEquivalentsAndMarketableSecurities
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-8"
      id="F_ac847aa3-5e5b-416f-b8d5-6fbcc05e029f"
      unitRef="U_USD">1100000000</idya:CashCashEquivalentsAndMarketableSecurities>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_7d285788-4fa0-4539-aa76-246d7e49d029">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The financial statements and accompanying notes have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include useful lives of property and equipment, determination of the discount rate for operating leases, accruals for research and development activities, revenue recognition, stock-based compensation, and income taxes. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable and operating segment. Financial information about the Company&#x2019;s operating segment and geographic areas is presented in Note 13 of the financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company operates in a dynamic and highly competitive industry and is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturers, contract research organizations and collaboration partners, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company believes that changes in any of the following areas could have a material&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adverse effect on the Company&#x2019;s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials and collaboration activities; regulatory approval and market acceptance of the Company&#x2019;s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company&#x2019;s ability to attract and retain employees necessary to support its growth.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Products developed by the Company require approvals from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained or maintained, that the products will receive the necessary approvals, or that any approved products will be commercially viable. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval, it could have a materially adverse impact on the Company. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company may require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs which would materially and adversely affect its business, financial condition and operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. Substantially all the Company&#x2019;s cash, cash equivalents and marketable securities are held by three financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s investment policy addresses credit ratings, diversification, and maturity dates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company invests its cash equivalents and marketable securities in money market funds, U.S. government securities, commercial paper, and corporate bonds. The Company limits its credit risk associated with cash equivalents and marketable securities by placing them with banks and institutions it believes are creditworthy and in highly rated investments and, by policy, limits the amount of credit exposure with any one commercial issuer. The Company has not experienced any credit losses on its deposits of cash, cash equivalents or marketable securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents that are readily convertible to cash are stated at cost, which approximates fair value. The Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less at the date of purchase to be cash equivalents.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted cash as of December 31, 2024 and December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; consisted of cash balances held as security in connection with the Company&#x2019;s facility lease agreements in South San Francisco, California and San Diego, California. The balances are classified as long-term assets on the Company&#x2019;s balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;securities are investments in marketable securities with maturities greater than three months at the time of purchase. The Company determines the appropriate classification of its investments in marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable securities as available-for-sale. After consideration of the Company&#x2019;s risk versus reward objectives and liquidity requirements, the Company may sell these securities prior to their stated maturities. The Company classifies highly liquid securities with maturities beyond 12 months as long-term marketable securities in the balance sheet. These securities are carried at fair value as determined based upon quoted market prices or pricing models for similar securities. Unrealized gains and losses, if any, are excluded from earnings and are reported as a component of accumulated other comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income and other income (expense), net on the statements of operations and comprehensive loss. Realized gains and losses, if any, on available-for-sale securities are included in interest income and other income (expense),&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;net. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The carrying amounts of the Company&#x2019;s certain financial instruments, including cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities and market interest rates if applicable. Refer to Note 3 for details on the fair value of marketable securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which is generally between &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d3a6b20e-57d6-4e14-ab8d-c3cbd58018ea;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Leasehold improvements are stated at cost and amortized over the shorter of the useful lives of the assets or the lease term. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations and comprehensive loss in the period realized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount of the asset or asset group to the future net cash flows which the asset or asset group is expected to generate. If such asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group exceeds the fair value of the asset or asset group. There have been &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; such impairments of long-lived assets for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines if an arrangement is a lease, or contains a lease, at its inception. Operating leases are included in right-of-use (&#x201c;ROU&#x201d;) assets, lease liabilities, and long-term lease liabilities on the Company&#x2019;s balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ROU assets and lease liabilities are recognized based on the present value of the future lease payments over the lease term at commencement date. As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The ROU asset also includes any lease payments made to the lessor at or before the commencement date, minus lease incentives received, and initial direct costs incurred. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company combines lease and nonlease components.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cloud Computing Arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company capitalizes certain implementation costs incurred under a cloud computing arrangement that is a service contract. Costs incurred during the application development stage related to the implementation of the hosting arrangement are capitalized and included within prepaid expenses and other current assets, and other non-current assets on the accompanying balance sheets. Amortization of capitalized implementation costs is recognized on a straight-line basis over the term of the associated hosting arrangement when it is ready for its intended use. Costs related to preliminary project activities and post-implementation activities are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company follows Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 606&#x201d;). Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company applies the five-step model to contracts when (1) parties have approved the contract and are committed to performing respective obligations, (2) the Company can identify each party&#x2019;s rights regarding the goods or services to be transferred, (3) the Company can identify the payment terms for the goods or services to be transferred, (4) the contract has commercial substance, and (5) it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines the performance obligations by assessing whether each promised good or service is distinct. Goods or services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligations when (or as) the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the &#x201c;variable consideration constraint&#x201d;) that a significant reversal of recognized revenue is not probable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Licenses of intellectual property:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other promised goods or services identified in an arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license at the point in time when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other goods or services, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress toward satisfying the performance obligation for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Customer options for additional goods or services: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If a contract contains customer options that allow the customer to acquire additional goods or services, including a license to the Company&#x2019;s intellectual property, the goods and services underlying the customer options are evaluated to determine whether they are deemed to represent a material right. In determining whether the customer option has a material right, the Company assesses whether there is an option to acquire additional goods or services at a discount. If the customer option is determined not to represent a material right, the option is not considered to be a performance obligation. If the customer option is determined to represent a material right, the material right is recognized as a separate performance obligation. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until the option is exercised.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Milestone payments:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; At the inception of each arrangement or amendment that includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 prescribes two methods to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the expected value method to estimate the amount of variable consideration related to the reimbursement of Pol Theta and WRN program costs which is consistently applied throughout the life of the contract: however, it is not necessary for the Company to use the same approach for all contracts. If it is probable that a significant revenue reversal would not occur when the uncertainty associated with the milestone is resolved, the associated milestone value is included in the transaction price. Milestone payments that are highly susceptible to factors outside the Company&#x2019;s influence, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. If there is more than one performance obligation, the transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Royalties:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upfront payments and fees are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Contractual cost sharing payments received from a customer or collaboration partner are accounted for as variable consideration. The Company includes an expected value in the transaction price. Contractual cost sharing payments made to a&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;customer or collaboration partner are accounted for as a reduction to the transaction price if such payments are not related to distinct goods or services received from the customer or collaboration partner.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Contracts may be amended to account for changes in contract specifications and requirements. Contract modifications exist when the amendment either creates new, or changes existing, enforceable rights and obligations. When contract modifications create new performance obligations and the increase in consideration approximates the standalone selling price for goods and services related to such new performance obligations as adjusted for specific facts and circumstances of the contract, the modification is accounted for as a separate contract. If a contract modification is not accounted for as a separate contract, the Company accounts for the promised goods or services not yet transferred at the date of the contract modification (the remaining promised goods or services) prospectively, as if it were a termination of the existing contract and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. The Company accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. In such case, the effect that the contract modification has on the transaction price, and on the entity&#x2019;s measure of progress toward complete satisfaction of the performance obligation, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) at the date of the contract modification (the adjustment to revenue is made on a cumulative catch-up basis).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upfront payment contract liabilities resulting from the Company&#x2019;s license and collaboration agreements do not represent a financing component as the payment is not financing the transfer of goods and services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company. As such, the Company does not adjust its revenues for the effects of a significant financing component. Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liability in the Company&#x2019;s balance sheets. If the related performance obligation is expected to be satisfied within the next twelve (12) months, this will be classified and included within current contract liability.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses consist of compensation costs, employee benefit costs, costs for contract manufacturing organizations (&#x201c;CMOs&#x201d;), costs for contract research organizations (&#x201c;CROs&#x201d;), costs for clinical trials, costs for sponsored research, consulting costs, costs for laboratory supplies, costs for product licenses, facility-related expenses and depreciation. All research and development costs are charged to research and development expenses as incurred and included within the statements of operations and comprehensive loss. Payments associated with licensing agreements to acquire exclusive licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternate commercial use are also expensed as incurred. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has entered into various agreements with CMOs and CROs. The Company&#x2019;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CMOs and CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. Management&#x2019;s process involves reviewing open contracts and purchase orders, communicating with applicable personnel to identify services that have been performed, and estimating the level of service performed and the associated costs incurred based on vendor estimates for the services when the Company has not yet been invoiced or otherwise notified of actual costs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for stock-based compensation arrangements with employees and non-employees in accordance with ASC 718, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Compensation. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for stock-based compensation arrangements using a fair value method which requires the recognition of compensation expense related to all stock-based awards. The fair value method requires the Company to estimate the fair value of stock option awards on the date of grant using an option pricing model. The Company uses the Black-Scholes option pricing model to determine the fair value of options granted, which is expensed on a straight-line basis over the vesting period. Generally, the stock options granted by the Company to its employees have a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; term and vest over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-year period with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-year cliff vesting.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for income taxes using the asset and liability method whereby deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are currently in effect unless such rate is expected to be different when the deferred item reverses. Valuation allowances are established where necessary to reduce deferred tax assets to the amounts expected to be realized. Deferred tax assets and liabilities are classified as noncurrent on the balance sheet.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that has a greater than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits in interest expense and other expense, respectively.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Income and Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive income and loss include net loss and certain changes in stockholders&#x2019; equity that are excluded from net loss, primarily unrealized gains and losses from the Company&#x2019;s marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net Loss per Share Attributable to Common Stockholders&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. Pre-funded warrants are included in the calculation of basic and diluted earnings per share. For purposes of the diluted net loss per share calculation, stock options, restricted stock and restricted stock that is subject to repurchase at the original purchase price are considered to be potentially dilutive securities. The Company considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of early exercised shares subject to repurchase do not have a contractual obligation to share in the Company&#x2019;s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) under its accounting standard codifications (&#x201c;ASC&#x201d;) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;New Accounting Pronouncements Adopted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) under its accounting standard codifications (&#x201c;ASC&#x201d;) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. These amendments enhance interim disclosure requirements, require disclosure of the title and position of the chief operating decision maker (&#x201c;CODM&#x201d;), require disclosure of significant segment expenses that are regularly provided to the CODM, clarify circumstances for disclosure of more than one segment profit or loss measure and require that a public entity that has a single reportable segment provide all disclosures required by ASC 280 and amendments. This ASU update is effective for fiscal years beginning after December 15, 2023 for the Company&#x2019;s annual report, and interim periods within fiscal years beginning after December 15, 2024. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company adopted this ASU for the annual report for the fiscal year beginning &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 1, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and evaluated the impact of the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adoption &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of the ASU. It did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t result in a material impact on the Company's financial statements and related disclosures. See Note 13. Segment Information.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;New Accounting Pronouncements, Not yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative, which modifies the disclosure or presentation requirements related to variety of FASB Accounting Standard Codification topics. The effective date for each amendment will be the date on which the SEC&#x2019;s removal of that related disclosure from Regulation S-X or Regulation S-K is effective. If by June 30, 2027, the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the associated amendment will be removed from the Codification and will not become effective for any entities. The Company is currently evaluating the effect of adopting this ASU.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 14, 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which amends the guidance in ASC 740, Income Taxes. The ASU is intended to improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The ASU&#x2019;s amendments are effective for public business entities for annual periods beginning after December 15, 2024. Entities are permitted to early adopt the standard &#x201c;for annual financial statements that have not yet been issued or made available for issuance.&#x201d; Adoption is either prospectively or retrospectively; the Company will adopt this ASU on a prospective basis. The Company is currently evaluating the impact of the ASU, but does not expect any material impact upon adoption.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 2024, the FASB issued ASU 2024-03 - Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The ASU requires more detailed disclosures about the types of expenses in commonly presented expense captions such as cost of sales, selling, general and administrative expenses and research and development expenses. This includes separate footnote disclosure for expenses such as purchases of inventory, employee compensation, depreciation, and intangible asset amortization. Public business entities are required to apply the guidance prospectively and may apply it retrospectively. The ASU's amendments are effective for public business entities for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Public business entities are required to apply the guidance prospectively and may apply it retrospectively. The Company is currently evaluating the effect of adopting this ASU.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_8af901bc-9798-43d8-b0e0-30ec8984a15f">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The financial statements and accompanying notes have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_18a28408-1774-48e6-80d7-d7a1dff8a827">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include useful lives of property and equipment, determination of the discount rate for operating leases, accruals for research and development activities, revenue recognition, stock-based compensation, and income taxes. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_bb56694c-1495-48bd-8e91-f7940ff6a8cd">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable and operating segment. Financial information about the Company&#x2019;s operating segment and geographic areas is presented in Note 13 of the financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="INF"
      id="F_5cf5dc78-edc0-4502-9bb8-087032a3f1a2"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="INF"
      id="F_5ee9284d-087d-44a1-9d30-0455c0ecba3a"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <idya:RisksAndUncertaintiesPolicyTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_29c71d7d-46c7-432c-bca9-a1a4f9a3ea86">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company operates in a dynamic and highly competitive industry and is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturers, contract research organizations and collaboration partners, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company believes that changes in any of the following areas could have a material&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adverse effect on the Company&#x2019;s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials and collaboration activities; regulatory approval and market acceptance of the Company&#x2019;s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company&#x2019;s ability to attract and retain employees necessary to support its growth.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Products developed by the Company require approvals from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained or maintained, that the products will receive the necessary approvals, or that any approved products will be commercially viable. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval, it could have a materially adverse impact on the Company. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company may require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs which would materially and adversely affect its business, financial condition and operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</idya:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_c7990150-b6b8-4d9a-9329-7bcce9c5d469">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. Substantially all the Company&#x2019;s cash, cash equivalents and marketable securities are held by three financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s investment policy addresses credit ratings, diversification, and maturity dates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company invests its cash equivalents and marketable securities in money market funds, U.S. government securities, commercial paper, and corporate bonds. The Company limits its credit risk associated with cash equivalents and marketable securities by placing them with banks and institutions it believes are creditworthy and in highly rated investments and, by policy, limits the amount of credit exposure with any one commercial issuer. The Company has not experienced any credit losses on its deposits of cash, cash equivalents or marketable securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_3b8621fc-f563-416e-a0d3-92e214a2db5a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents that are readily convertible to cash are stated at cost, which approximates fair value. The Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less at the date of purchase to be cash equivalents.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_01d33524-6c2f-49eb-bf43-06eda5941a52">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted cash as of December 31, 2024 and December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; consisted of cash balances held as security in connection with the Company&#x2019;s facility lease agreements in South San Francisco, California and San Diego, California. The balances are classified as long-term assets on the Company&#x2019;s balance sheet.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_45adc29f-811f-428b-908c-460729104879">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;securities are investments in marketable securities with maturities greater than three months at the time of purchase. The Company determines the appropriate classification of its investments in marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable securities as available-for-sale. After consideration of the Company&#x2019;s risk versus reward objectives and liquidity requirements, the Company may sell these securities prior to their stated maturities. The Company classifies highly liquid securities with maturities beyond 12 months as long-term marketable securities in the balance sheet. These securities are carried at fair value as determined based upon quoted market prices or pricing models for similar securities. Unrealized gains and losses, if any, are excluded from earnings and are reported as a component of accumulated other comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income and other income (expense), net on the statements of operations and comprehensive loss. Realized gains and losses, if any, on available-for-sale securities are included in interest income and other income (expense),&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;net. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_5eb8274c-ad38-427f-99a1-236e55f75146">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The carrying amounts of the Company&#x2019;s certain financial instruments, including cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities and market interest rates if applicable. Refer to Note 3 for details on the fair value of marketable securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_6e9aa122-b000-40ce-98e6-f13af762693c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which is generally between &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d3a6b20e-57d6-4e14-ab8d-c3cbd58018ea;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Leasehold improvements are stated at cost and amortized over the shorter of the useful lives of the assets or the lease term. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations and comprehensive loss in the period realized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_4e5c2597-3aa6-4e75-84f5-fcacb80ec75e"
      id="F_4f7c6061-793e-4dc5-9a2f-547a4772c26a">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentImpairment
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_2848e7ac-d688-4730-95fe-8fd1758120ee">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount of the asset or asset group to the future net cash flows which the asset or asset group is expected to generate. If such asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group exceeds the fair value of the asset or asset group. There have been &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; such impairments of long-lived assets for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentImpairment>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_dfa63d63-f99b-4ae6-b844-82ea1e3a4493"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_978d2c8b-f453-4be4-a0da-f2e13b088ecc"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_d7b61219-5d1c-4f91-8034-e27ccfc26207">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines if an arrangement is a lease, or contains a lease, at its inception. Operating leases are included in right-of-use (&#x201c;ROU&#x201d;) assets, lease liabilities, and long-term lease liabilities on the Company&#x2019;s balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ROU assets and lease liabilities are recognized based on the present value of the future lease payments over the lease term at commencement date. As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The ROU asset also includes any lease payments made to the lessor at or before the commencement date, minus lease incentives received, and initial direct costs incurred. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company combines lease and nonlease components.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <idya:CloudComputingArrangementsPolicyTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_9642acfa-f6c4-4e50-be1a-cebaa0bbdea4">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cloud Computing Arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company capitalizes certain implementation costs incurred under a cloud computing arrangement that is a service contract. Costs incurred during the application development stage related to the implementation of the hosting arrangement are capitalized and included within prepaid expenses and other current assets, and other non-current assets on the accompanying balance sheets. Amortization of capitalized implementation costs is recognized on a straight-line basis over the term of the associated hosting arrangement when it is ready for its intended use. Costs related to preliminary project activities and post-implementation activities are expensed as incurred.&lt;/span&gt;&lt;/p&gt;</idya:CloudComputingArrangementsPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_964b97df-df66-44cc-b1f3-7539460047cb">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company follows Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 606&#x201d;). Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company applies the five-step model to contracts when (1) parties have approved the contract and are committed to performing respective obligations, (2) the Company can identify each party&#x2019;s rights regarding the goods or services to be transferred, (3) the Company can identify the payment terms for the goods or services to be transferred, (4) the contract has commercial substance, and (5) it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines the performance obligations by assessing whether each promised good or service is distinct. Goods or services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligations when (or as) the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the &#x201c;variable consideration constraint&#x201d;) that a significant reversal of recognized revenue is not probable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Licenses of intellectual property:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other promised goods or services identified in an arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license at the point in time when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other goods or services, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress toward satisfying the performance obligation for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Customer options for additional goods or services: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If a contract contains customer options that allow the customer to acquire additional goods or services, including a license to the Company&#x2019;s intellectual property, the goods and services underlying the customer options are evaluated to determine whether they are deemed to represent a material right. In determining whether the customer option has a material right, the Company assesses whether there is an option to acquire additional goods or services at a discount. If the customer option is determined not to represent a material right, the option is not considered to be a performance obligation. If the customer option is determined to represent a material right, the material right is recognized as a separate performance obligation. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until the option is exercised.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Milestone payments:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; At the inception of each arrangement or amendment that includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 prescribes two methods to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the expected value method to estimate the amount of variable consideration related to the reimbursement of Pol Theta and WRN program costs which is consistently applied throughout the life of the contract: however, it is not necessary for the Company to use the same approach for all contracts. If it is probable that a significant revenue reversal would not occur when the uncertainty associated with the milestone is resolved, the associated milestone value is included in the transaction price. Milestone payments that are highly susceptible to factors outside the Company&#x2019;s influence, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. If there is more than one performance obligation, the transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Royalties:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upfront payments and fees are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Contractual cost sharing payments received from a customer or collaboration partner are accounted for as variable consideration. The Company includes an expected value in the transaction price. Contractual cost sharing payments made to a&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;customer or collaboration partner are accounted for as a reduction to the transaction price if such payments are not related to distinct goods or services received from the customer or collaboration partner.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Contracts may be amended to account for changes in contract specifications and requirements. Contract modifications exist when the amendment either creates new, or changes existing, enforceable rights and obligations. When contract modifications create new performance obligations and the increase in consideration approximates the standalone selling price for goods and services related to such new performance obligations as adjusted for specific facts and circumstances of the contract, the modification is accounted for as a separate contract. If a contract modification is not accounted for as a separate contract, the Company accounts for the promised goods or services not yet transferred at the date of the contract modification (the remaining promised goods or services) prospectively, as if it were a termination of the existing contract and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. The Company accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. In such case, the effect that the contract modification has on the transaction price, and on the entity&#x2019;s measure of progress toward complete satisfaction of the performance obligation, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) at the date of the contract modification (the adjustment to revenue is made on a cumulative catch-up basis).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upfront payment contract liabilities resulting from the Company&#x2019;s license and collaboration agreements do not represent a financing component as the payment is not financing the transfer of goods and services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company. As such, the Company does not adjust its revenues for the effects of a significant financing component. Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liability in the Company&#x2019;s balance sheets. If the related performance obligation is expected to be satisfied within the next twelve (12) months, this will be classified and included within current contract liability.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_a1dec748-302f-4ae1-b1e3-4830754c25e0">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses consist of compensation costs, employee benefit costs, costs for contract manufacturing organizations (&#x201c;CMOs&#x201d;), costs for contract research organizations (&#x201c;CROs&#x201d;), costs for clinical trials, costs for sponsored research, consulting costs, costs for laboratory supplies, costs for product licenses, facility-related expenses and depreciation. All research and development costs are charged to research and development expenses as incurred and included within the statements of operations and comprehensive loss. Payments associated with licensing agreements to acquire exclusive licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternate commercial use are also expensed as incurred. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <idya:AccruedResearchAndDevelopmentExpensesPolicyTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_76eb1cc8-0955-4c1d-9dd7-d7d893766449">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has entered into various agreements with CMOs and CROs. The Company&#x2019;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CMOs and CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. Management&#x2019;s process involves reviewing open contracts and purchase orders, communicating with applicable personnel to identify services that have been performed, and estimating the level of service performed and the associated costs incurred based on vendor estimates for the services when the Company has not yet been invoiced or otherwise notified of actual costs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</idya:AccruedResearchAndDevelopmentExpensesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_14dbb7fc-daee-4bb8-bbcc-5c6f3897c7c4">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for stock-based compensation arrangements with employees and non-employees in accordance with ASC 718, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Compensation. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for stock-based compensation arrangements using a fair value method which requires the recognition of compensation expense related to all stock-based awards. The fair value method requires the Company to estimate the fair value of stock option awards on the date of grant using an option pricing model. The Company uses the Black-Scholes option pricing model to determine the fair value of options granted, which is expensed on a straight-line basis over the vesting period. Generally, the stock options granted by the Company to its employees have a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; term and vest over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-year period with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-year cliff vesting.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_93b03c8e-0f95-4d58-98e5-1b1e2a78067e"
      id="F_d2bfa8fa-0660-403a-a287-d56157599290">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_93b03c8e-0f95-4d58-98e5-1b1e2a78067e"
      id="F_82ca6b8e-20e5-4690-b970-ecb9c0dca863">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_9597b477-72d9-47f9-a2b7-c96116c45490"
      id="F_fdab4132-e59c-4532-9f73-7b7401e944b3">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_86d95657-ab93-4b72-8ea8-6522eeb8c3ac">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for income taxes using the asset and liability method whereby deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are currently in effect unless such rate is expected to be different when the deferred item reverses. Valuation allowances are established where necessary to reduce deferred tax assets to the amounts expected to be realized. Deferred tax assets and liabilities are classified as noncurrent on the balance sheet.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that has a greater than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits in interest expense and other expense, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <idya:RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized
      contextRef="C_97b79519-0af1-4cce-8a6d-7911a10985ed"
      decimals="INF"
      id="F_cf30acab-930a-49a6-8eb0-ee4e19f26e71"
      unitRef="U_pure">0.50</idya:RecognizedIncomeTaxPositionsMeasuredAtPercentageOfLikelihoodToBeRealized>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_a62f0163-20e5-49d8-982d-8273583c2054">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Income and Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive income and loss include net loss and certain changes in stockholders&#x2019; equity that are excluded from net loss, primarily unrealized gains and losses from the Company&#x2019;s marketable securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_70411431-3afd-45b9-9752-49f02174c015">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net Loss per Share Attributable to Common Stockholders&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. Pre-funded warrants are included in the calculation of basic and diluted earnings per share. For purposes of the diluted net loss per share calculation, stock options, restricted stock and restricted stock that is subject to repurchase at the original purchase price are considered to be potentially dilutive securities. The Company considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of early exercised shares subject to repurchase do not have a contractual obligation to share in the Company&#x2019;s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_7ec32e0a-ffe8-4960-86f7-cfc54f7edf99">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) under its accounting standard codifications (&#x201c;ASC&#x201d;) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;New Accounting Pronouncements Adopted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) under its accounting standard codifications (&#x201c;ASC&#x201d;) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. These amendments enhance interim disclosure requirements, require disclosure of the title and position of the chief operating decision maker (&#x201c;CODM&#x201d;), require disclosure of significant segment expenses that are regularly provided to the CODM, clarify circumstances for disclosure of more than one segment profit or loss measure and require that a public entity that has a single reportable segment provide all disclosures required by ASC 280 and amendments. This ASU update is effective for fiscal years beginning after December 15, 2023 for the Company&#x2019;s annual report, and interim periods within fiscal years beginning after December 15, 2024. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company adopted this ASU for the annual report for the fiscal year beginning &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 1, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and evaluated the impact of the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adoption &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of the ASU. It did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t result in a material impact on the Company's financial statements and related disclosures. See Note 13. Segment Information.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;New Accounting Pronouncements, Not yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative, which modifies the disclosure or presentation requirements related to variety of FASB Accounting Standard Codification topics. The effective date for each amendment will be the date on which the SEC&#x2019;s removal of that related disclosure from Regulation S-X or Regulation S-K is effective. If by June 30, 2027, the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the associated amendment will be removed from the Codification and will not become effective for any entities. The Company is currently evaluating the effect of adopting this ASU.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 14, 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which amends the guidance in ASC 740, Income Taxes. The ASU is intended to improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The ASU&#x2019;s amendments are effective for public business entities for annual periods beginning after December 15, 2024. Entities are permitted to early adopt the standard &#x201c;for annual financial statements that have not yet been issued or made available for issuance.&#x201d; Adoption is either prospectively or retrospectively; the Company will adopt this ASU on a prospective basis. The Company is currently evaluating the impact of the ASU, but does not expect any material impact upon adoption.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 2024, the FASB issued ASU 2024-03 - Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The ASU requires more detailed disclosures about the types of expenses in commonly presented expense captions such as cost of sales, selling, general and administrative expenses and research and development expenses. This includes separate footnote disclosure for expenses such as purchases of inventory, employee compensation, depreciation, and intangible asset amortization. Public business entities are required to apply the guidance prospectively and may apply it retrospectively. The ASU's amendments are effective for public business entities for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Public business entities are required to apply the guidance prospectively and may apply it retrospectively. The Company is currently evaluating the effect of adopting this ASU.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_eed81da0-8376-4317-a154-9ffbb5c0bf7e"
      id="F_1e37055a-f4e2-4c05-b05f-2e6a1a1cdfeb">2024-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_eed81da0-8376-4317-a154-9ffbb5c0bf7e"
      id="F_51bf1380-2091-4ab2-9f0a-9fdff7269773">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_eed81da0-8376-4317-a154-9ffbb5c0bf7e"
      id="F_9d397e36-c1bb-48ee-8581-cb37d2650d03">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <idya:FairValueMeasurementsAndMarketableSecuritiesTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_ea225c5e-1852-4f76-8bb1-ed96d8711823">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3. Fair Value Measurement and Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1&#x2014;Observable inputs, such as quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2&#x2014;Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs which reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as consider counterparty credit risk in its assessment of fair value.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, financial assets measured and recorded at fair value are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:28.986%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.002%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.562999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.681999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.521999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;552,008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;552,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;363,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;363,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Subtotal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,004,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,005,126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total value of assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,081,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,082,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in marketable securities, current&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;591,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;591,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in marketable securities, non-current&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;405,871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;405,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total value of assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,081,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,082,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of commercial paper was included in cash and cash equivalents on the balance sheet due to securities with purchase dates within 90 days of maturity dates.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s short-term marketable securities mature in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(3)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s long-term marketable securities mature between one and three years.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023, financial assets measured and recognized at fair value are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:30.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;412,679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;413,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126,601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Subtotal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;593,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;593,826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total value of assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;632,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;632,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in marketable securities, current&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;368,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;368,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in marketable securities, non-current&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total value of assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;632,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;632,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of U.S. government securities and $&lt;/span&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of commercial paper were included in cash and cash equivalents on the balance sheet due to securities with purchase dates within 90 days of maturity dates&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s short-term marketable securities mature in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(3)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s long-term marketable securities mature between one and three years&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, all marketable securities had a remaining maturity of less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; financial liabilities measured and recognized at fair value as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers available evidence in evaluating potential other-than-temporary impairments of its marketable securities, including the duration and extent to which fair value is less than cost, and the Company&#x2019;s ability and intent to hold the investment. As of December 31, 2024 and December 31, 2023, the Company held certain securities in an unrealized loss position. These unrealized losses were considered to be temporary as the Company expects to recover the entire amortized cost basis on the securities in unrealized loss positions based on the creditworthiness of the underlying issuer, and the Company neither intends to sell these securities nor considers it more likely than not that the Company would be required to sell any such security before its anticipated recovery. As a result, the Company did not consider any of these investments to be other-than-temporarily impaired at December 31, 2024 and December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</idya:FairValueMeasurementsAndMarketableSecuritiesTextBlock>
    <idya:FairValueMeasurementsAndMarketableSecuritiesPolicyTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_2e5f6ef7-165b-4bb5-b21b-3eaede15a6f5">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1&#x2014;Observable inputs, such as quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2&#x2014;Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs which reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.&lt;/span&gt;</idya:FairValueMeasurementsAndMarketableSecuritiesPolicyTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_b0a9eb60-ba70-4a79-b163-0372587b3edd">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, financial assets measured and recorded at fair value are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:28.986%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.002%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.562999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.681999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.521999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;552,008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;552,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;363,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;363,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Subtotal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,004,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,005,126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total value of assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,081,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,082,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in marketable securities, current&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;591,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;591,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in marketable securities, non-current&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;405,871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;405,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total value of assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,081,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,082,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of commercial paper was included in cash and cash equivalents on the balance sheet due to securities with purchase dates within 90 days of maturity dates.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s short-term marketable securities mature in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(3)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s long-term marketable securities mature between one and three years.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023, financial assets measured and recognized at fair value are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:30.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;412,679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;413,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126,601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Subtotal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;593,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;593,826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total value of assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;632,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;632,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in marketable securities, current&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;368,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;368,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in marketable securities, non-current&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total value of assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;632,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;632,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of U.S. government securities and $&lt;/span&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of commercial paper were included in cash and cash equivalents on the balance sheet due to securities with purchase dates within 90 days of maturity dates&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s short-term marketable securities mature in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(3)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s long-term marketable securities mature between one and three years&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_04d43460-4b81-4f83-b2c2-02fb5a312c66"
      decimals="-3"
      id="F_0300be4b-72ac-4b58-992b-1c7d2115da50"
      unitRef="U_USD">552008000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_04d43460-4b81-4f83-b2c2-02fb5a312c66"
      decimals="-3"
      id="F_47d66659-5486-47de-82e0-1b9523d3ebae"
      unitRef="U_USD">1214000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_04d43460-4b81-4f83-b2c2-02fb5a312c66"
      decimals="-3"
      id="F_674ca26e-de5f-4fb3-933e-ce5a13b551e6"
      unitRef="U_USD">353000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_04d43460-4b81-4f83-b2c2-02fb5a312c66"
      decimals="-3"
      id="F_2576e78d-43a7-4b0e-ab8d-07b2b59b6203"
      unitRef="U_USD">552869000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_16c5e261-e767-47ab-9f42-00c92286082e"
      decimals="-3"
      id="F_1ca5cf9d-94df-4c52-8bc7-d7da4211872d"
      unitRef="U_USD">363197000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_16c5e261-e767-47ab-9f42-00c92286082e"
      decimals="-3"
      id="F_efc434b0-87ab-42fc-b2d1-92dda692ae36"
      unitRef="U_USD">357000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_16c5e261-e767-47ab-9f42-00c92286082e"
      decimals="-3"
      id="F_5e7f0f03-027c-4f15-accd-ce609e6f745e"
      unitRef="U_USD">419000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_16c5e261-e767-47ab-9f42-00c92286082e"
      decimals="-3"
      id="F_afe22e20-7c7e-4f84-bbbd-5e96d7d7a6fd"
      unitRef="U_USD">363135000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ed5d8c12-9405-4e8a-b68f-e1da9fa98a3b"
      decimals="-3"
      id="F_7071fbb0-f62c-4812-8085-4ee06e265449"
      unitRef="U_USD">89109000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_ed5d8c12-9405-4e8a-b68f-e1da9fa98a3b"
      decimals="-3"
      id="F_3b168a8b-835b-4e2c-8af2-ff3b5a2d7470"
      unitRef="U_USD">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_ed5d8c12-9405-4e8a-b68f-e1da9fa98a3b"
      decimals="-3"
      id="F_48045723-0b14-40a3-ba85-014e79c2126b"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ed5d8c12-9405-4e8a-b68f-e1da9fa98a3b"
      decimals="-3"
      id="F_9e2f43e0-e3ae-440b-83dc-a86a49bf3c25"
      unitRef="U_USD">89122000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_7ce67f6e-74ef-4fbe-a284-d7babb457228"
      unitRef="U_USD">1004314000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_41ffc4de-0170-4c96-b6d0-8f87ddd8d344"
      unitRef="U_USD">1592000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_018cfeb8-51ff-4d2d-9403-6507b4358a16"
      unitRef="U_USD">780000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_fa817f8c-f942-49cd-80d3-231451c124e6"
      unitRef="U_USD">1005126000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_f7361d23-b930-48a8-9c1b-395215d1e86d"
      decimals="-3"
      id="F_6bd741cf-6d95-41bb-8833-d3196bdc99b2"
      unitRef="U_USD">57626000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_f7361d23-b930-48a8-9c1b-395215d1e86d"
      decimals="-3"
      id="F_5014cfd2-99b8-490a-87ff-6503d5c6d1ac"
      unitRef="U_USD">57626000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_d83f8cee-a2f2-4da8-9137-df95b7b83290"
      decimals="-3"
      id="F_e4626521-84ab-4e6b-9590-ecc02bce922b"
      unitRef="U_USD">19399000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_d83f8cee-a2f2-4da8-9137-df95b7b83290"
      decimals="-3"
      id="F_f63d5d54-0463-48c9-bf69-6f30d7e759ec"
      unitRef="U_USD">19399000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_28883b15-b1d3-4a0f-9e8e-37747aa61297"
      unitRef="U_USD">1081339000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_81c15ecc-4b0b-4df4-9fe0-3d61a416edc0"
      unitRef="U_USD">1592000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_b4c9e9e0-7700-4ece-89b8-75315c97eebf"
      unitRef="U_USD">780000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_35139051-88f1-4c52-a486-cdd188325fbb"
      unitRef="U_USD">1082151000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_2f896155-5fb2-43f9-9ec7-58dfaea72f5d"
      decimals="-3"
      id="F_c3c6d7ed-36bc-4c85-ac4c-9e3dc76ba94d"
      unitRef="U_USD">84379000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_2f896155-5fb2-43f9-9ec7-58dfaea72f5d"
      decimals="-3"
      id="F_f76ffc61-ed6d-4631-b899-454af2a72aae"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_2f896155-5fb2-43f9-9ec7-58dfaea72f5d"
      decimals="-3"
      id="F_d9572f42-ade5-43a0-9df1-4db43a7d8566"
      unitRef="U_USD">84378000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_8b87a953-8e4e-49fe-b4a9-0b35f9a89796"
      decimals="-3"
      id="F_182d5137-ed02-4d38-9f0e-c821a7f27a2a"
      unitRef="U_USD">591089000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_8b87a953-8e4e-49fe-b4a9-0b35f9a89796"
      decimals="-3"
      id="F_f25de3e3-fc6d-4c01-a774-3672c6829c04"
      unitRef="U_USD">928000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_8b87a953-8e4e-49fe-b4a9-0b35f9a89796"
      decimals="-3"
      id="F_18584b34-e8f3-4842-aea2-7a74172521e5"
      unitRef="U_USD">76000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8b87a953-8e4e-49fe-b4a9-0b35f9a89796"
      decimals="-3"
      id="F_ce2bcd4f-7944-46b9-a871-c1afc1eba3c5"
      unitRef="U_USD">591941000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ad7e94d4-33b0-49a5-8627-5b260d67b825"
      decimals="-3"
      id="F_ac21e0c7-1dab-4155-87f7-70e24a06ba2e"
      unitRef="U_USD">405871000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_ad7e94d4-33b0-49a5-8627-5b260d67b825"
      decimals="-3"
      id="F_e528a597-a0ce-4a00-babc-526f66a8d40f"
      unitRef="U_USD">664000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_ad7e94d4-33b0-49a5-8627-5b260d67b825"
      decimals="-3"
      id="F_4fcd94dd-a496-46eb-b0aa-b231509feb7c"
      unitRef="U_USD">703000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ad7e94d4-33b0-49a5-8627-5b260d67b825"
      decimals="-3"
      id="F_6b42f9e7-3ffe-43ae-a21a-89e85a77dd75"
      unitRef="U_USD">405832000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_c0777f34-8404-4e2a-b315-1165e7b5ca18"
      unitRef="U_USD">1081339000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_50fda0ac-93e3-4b85-adbc-97bf2e9d4a50"
      unitRef="U_USD">1592000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_1b12b64e-6dd4-4181-9580-7abb6127bf89"
      unitRef="U_USD">780000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_3dabb627-1e51-4cbc-844b-aa65c455f763"
      unitRef="U_USD">1082151000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_b08e0fb2-11c2-4fdf-a73e-de1ec106e6a4"
      decimals="-5"
      id="F_03ce6fb1-2ff2-4753-bdcb-0246c508e0d3"
      unitRef="U_USD">7400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_102bebb9-1268-4e37-90b3-15a47af627e2"
      decimals="-3"
      id="F_8c107c73-f072-465a-a8e8-588a73410584"
      unitRef="U_USD">412679000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_102bebb9-1268-4e37-90b3-15a47af627e2"
      decimals="-3"
      id="F_9c4dabd9-2605-4e26-9638-ce1936e4ac18"
      unitRef="U_USD">591000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_102bebb9-1268-4e37-90b3-15a47af627e2"
      decimals="-3"
      id="F_4a84789f-2e87-4119-beaf-6d2dd0a6a11b"
      unitRef="U_USD">135000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_102bebb9-1268-4e37-90b3-15a47af627e2"
      decimals="-3"
      id="F_dd96dae5-3094-41f5-b054-c3014155f4ce"
      unitRef="U_USD">413135000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_27155058-a3b3-4ee4-8db6-19df70e8e552"
      decimals="-3"
      id="F_df928b0f-1bc9-4709-96d3-3e6cdbf8e1a4"
      unitRef="U_USD">53983000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_27155058-a3b3-4ee4-8db6-19df70e8e552"
      decimals="-3"
      id="F_09930194-f3be-4b14-a14d-a91fbd0ee397"
      unitRef="U_USD">197000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_27155058-a3b3-4ee4-8db6-19df70e8e552"
      decimals="-3"
      id="F_56b523f0-014f-461e-88b3-988d5b029a87"
      unitRef="U_USD">32000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_27155058-a3b3-4ee4-8db6-19df70e8e552"
      decimals="-3"
      id="F_9c255008-75f0-4964-9937-f09c8d820440"
      unitRef="U_USD">54148000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d61cade1-8268-42c8-9099-392bd152a976"
      decimals="-3"
      id="F_7f46ef29-635f-4463-8224-75f269d424fb"
      unitRef="U_USD">126601000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_d61cade1-8268-42c8-9099-392bd152a976"
      decimals="-3"
      id="F_9de8607a-75fd-4012-8c4f-9249a3ef9621"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_d61cade1-8268-42c8-9099-392bd152a976"
      decimals="-3"
      id="F_d0d51988-952c-452a-b26b-f5af546a4332"
      unitRef="U_USD">58000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d61cade1-8268-42c8-9099-392bd152a976"
      decimals="-3"
      id="F_2f22c920-0031-42f2-bd8e-30d1060b08ae"
      unitRef="U_USD">126543000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_7c0454fb-b35c-49b2-95be-dac0426cac6b"
      unitRef="U_USD">593263000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_b15cc20b-27d3-43f9-9997-e22052bc76a3"
      unitRef="U_USD">788000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_29f801ff-e693-409e-b792-456c3e7d7e98"
      unitRef="U_USD">225000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_6a0497c0-3f64-463d-8ba5-b3a24b914d67"
      unitRef="U_USD">593826000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_cbd0ef8f-ad56-44d1-80e0-5de5d8d02ca8"
      decimals="-3"
      id="F_ae1bc0d3-d7e9-48fd-ae99-bbe4e0c6c04a"
      unitRef="U_USD">38300000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_cbd0ef8f-ad56-44d1-80e0-5de5d8d02ca8"
      decimals="-3"
      id="F_eacef13c-9230-4bca-a661-5e67d854211c"
      unitRef="U_USD">38300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_708a6a15-ace7-419f-8285-9848a72f3257"
      decimals="-3"
      id="F_934be7b9-70a2-4e54-a116-b0c029fb8570"
      unitRef="U_USD">480000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_708a6a15-ace7-419f-8285-9848a72f3257"
      decimals="-3"
      id="F_8ed2f0b6-178a-43dd-9b85-84dfd8ec68a3"
      unitRef="U_USD">480000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_9d4a77ae-cb46-495a-80e5-88bc3e926795"
      unitRef="U_USD">632043000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_e4cdedac-af5a-4370-97a0-e5b82e32a751"
      unitRef="U_USD">788000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_cc5996ae-7614-414b-954d-698791db371b"
      unitRef="U_USD">225000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_0f600eac-0cc6-496c-b328-ae77c15cd84d"
      unitRef="U_USD">632606000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_34b68bd4-0003-4e5f-b72b-00f8d56f232d"
      decimals="-3"
      id="F_2195f51d-aad4-4368-82ed-0477082d8e85"
      unitRef="U_USD">157055000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_34b68bd4-0003-4e5f-b72b-00f8d56f232d"
      decimals="-3"
      id="F_e42f05b3-b2a3-4698-8a2f-497cbaae6a93"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_34b68bd4-0003-4e5f-b72b-00f8d56f232d"
      decimals="-3"
      id="F_823f48a3-0504-433a-bd4d-2ecffeed7c71"
      unitRef="U_USD">41000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_34b68bd4-0003-4e5f-b72b-00f8d56f232d"
      decimals="-3"
      id="F_865c7ff5-2d7b-45ae-8dba-4fc0cb49f06b"
      unitRef="U_USD">157018000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_bccc40ef-fa48-4336-b831-e54faeed80cb"
      decimals="-3"
      id="F_8905e8e2-7b7d-4993-9a24-2334a5217829"
      unitRef="U_USD">368043000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_bccc40ef-fa48-4336-b831-e54faeed80cb"
      decimals="-3"
      id="F_7fb607ce-359e-46fd-bff2-c318bf356753"
      unitRef="U_USD">227000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_bccc40ef-fa48-4336-b831-e54faeed80cb"
      decimals="-3"
      id="F_2f4954d2-5412-410e-89ed-29ff923a99f8"
      unitRef="U_USD">174000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_bccc40ef-fa48-4336-b831-e54faeed80cb"
      decimals="-3"
      id="F_6cf28005-8585-42cf-b664-3231cdcfd98c"
      unitRef="U_USD">368096000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f401e5c8-9543-480b-b6f2-bdab7d05f204"
      decimals="-3"
      id="F_c97c0eed-a91f-4d27-96c6-2c2754cc1ea1"
      unitRef="U_USD">106945000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f401e5c8-9543-480b-b6f2-bdab7d05f204"
      decimals="-3"
      id="F_0be25175-0ce5-4a35-bb69-f75f0af8b436"
      unitRef="U_USD">557000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f401e5c8-9543-480b-b6f2-bdab7d05f204"
      decimals="-3"
      id="F_b88dde88-cd02-44f4-88a3-7e84e9840c3b"
      unitRef="U_USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f401e5c8-9543-480b-b6f2-bdab7d05f204"
      decimals="-3"
      id="F_cc12e577-c2e7-4821-86af-2f6ed5caf1c8"
      unitRef="U_USD">107492000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_a0c4a313-c0f2-4c00-842a-d07d26989916"
      unitRef="U_USD">632043000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_e8816331-e999-453e-970d-a57b226fafde"
      unitRef="U_USD">788000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_d77dfd5f-3384-4194-8734-01507ad0438f"
      unitRef="U_USD">225000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_cf2c3f6a-ba91-4495-8653-332a05275305"
      unitRef="U_USD">632606000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_251008aa-c1a9-42db-be7d-38cbbc1eb46d"
      decimals="-5"
      id="F_7c734cdf-e017-48ef-9f31-84561bbca0bb"
      unitRef="U_USD">37800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_83549ecb-3fd7-4381-8f30-327213eea05d"
      decimals="-5"
      id="F_20d9b401-081e-4f0a-a147-3972b6406abf"
      unitRef="U_USD">80400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <idya:MarketableSecuritiesRemainingMaturityPeriod
      contextRef="C_7a6bc497-f228-42bb-8d0a-1e9eedd0706f"
      id="F_bdb6e773-3b57-474c-bd27-29cce2ba2f21">P3Y</idya:MarketableSecuritiesRemainingMaturityPeriod>
    <idya:MarketableSecuritiesRemainingMaturityPeriod
      contextRef="C_75dd9ba0-2dcb-4995-8704-30a44e45f791"
      id="F_f9cddc40-08f0-4082-8c13-a057d8ec0105">P3Y</idya:MarketableSecuritiesRemainingMaturityPeriod>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_2ef77357-94a2-414d-b691-3aef7384d20f"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_36e8b12a-7d31-4e62-8181-9d0f45ebea5d"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_f21cb7e9-1e13-4d5a-ae69-a9007da52613">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. Balance Sheet Components&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.79%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.584%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.302000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.302000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of useful&lt;br/&gt;life or lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.847%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.417%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.417%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued salaries and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Legal and professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_023f6036-975d-458b-bf05-1d1b7f146442">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.79%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.584%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.302000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.302000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of useful&lt;br/&gt;life or lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_1995fabd-2822-4d7e-89fa-1b6e278a87fd"
      id="F_c371b3b1-1fe5-46d8-b1be-e806cf368993">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1995fabd-2822-4d7e-89fa-1b6e278a87fd"
      decimals="-3"
      id="F_d9f35fef-88ee-4440-a185-7ba9d2ff9623"
      unitRef="U_USD">13513000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d536bcf1-3ec0-423d-b2dc-d793db2570c0"
      decimals="-3"
      id="F_305bcaaf-c57f-41ed-a63b-b5dc0742ccb7"
      unitRef="U_USD">11455000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_c19a5e53-23fd-4bc8-8462-f68e81fbfe48"
      id="F_aa940907-1610-401d-a039-33a6afd96d30">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c19a5e53-23fd-4bc8-8462-f68e81fbfe48"
      decimals="-3"
      id="F_f2891de9-c44a-439e-86eb-3d4630d43286"
      unitRef="U_USD">503000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2378e96a-3247-479e-b4ea-c4f63e5949db"
      decimals="-3"
      id="F_2a71457f-0761-4627-a1b8-d0f899237b94"
      unitRef="U_USD">261000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_9fb9e960-f425-4a31-bc47-44faa05f376c"
      id="F_4703dc86-1a1b-404c-8f12-384a434fed66">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9fb9e960-f425-4a31-bc47-44faa05f376c"
      decimals="-3"
      id="F_e69ddcc0-5ea8-4e53-b61b-dd11fc577a0b"
      unitRef="U_USD">231000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_14486222-86aa-41d5-ae07-15df550cdd49"
      decimals="-3"
      id="F_65bae4b6-08d3-4b7c-bf4a-e4a6aab7d6b6"
      unitRef="U_USD">231000</us-gaap:PropertyPlantAndEquipmentGross>
    <idya:PropertyPlantAndEquipmentUsefulLifeDescription
      contextRef="C_1789f966-ab3e-40ee-add4-b0aaa08d3263"
      id="F_d9f3b61e-6fe5-433e-8ada-f5e31ef1121f">Shorter of usefullife or lease term</idya:PropertyPlantAndEquipmentUsefulLifeDescription>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_651623b8-e9c1-43f9-a69b-5797bef8158e"
      decimals="-3"
      id="F_1cb6df7b-2127-497c-86bf-936e447ddf5d"
      unitRef="U_USD">4913000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1ce730f4-285b-4d18-9b94-24f179a1f447"
      decimals="-3"
      id="F_1064b052-a550-4a9d-b040-b8f75601da9d"
      unitRef="U_USD">3321000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_c495f084-6fcb-44de-808b-4aa3452ff136"
      id="F_103b1c1b-e8f4-44d1-8670-32fe6b6ee71b">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c495f084-6fcb-44de-808b-4aa3452ff136"
      decimals="-3"
      id="F_38a7436e-a968-492b-a45b-4f7b4b1e56d8"
      unitRef="U_USD">1517000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d65b61cb-05ca-4927-b54c-ce7d454a1633"
      decimals="-3"
      id="F_bf3c8170-04d0-47fd-8c60-33abe7e49c8d"
      unitRef="U_USD">507000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_0212906b-3593-4a68-b653-a7742726c60d"
      unitRef="U_USD">20677000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_8f07c004-0e3e-41b6-b547-92ab2a302eb6"
      unitRef="U_USD">15775000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_23707035-c014-4162-90b3-93bcd9da0fb0"
      unitRef="U_USD">11711000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_4c6defd6-8902-4eb4-aa97-ad3945a238a7"
      unitRef="U_USD">9611000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_10711804-c7a1-4d9f-a807-e5b79f5a1314"
      unitRef="U_USD">8966000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_ecefc666-def8-4fe5-9293-158d1ff65f2b"
      unitRef="U_USD">6164000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-5"
      id="F_98e46306-319e-4dba-9cf1-fb6fe4cf10a0"
      unitRef="U_USD">2400000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-5"
      id="F_43f33b95-c7fc-40c7-b199-35751083f2f5"
      unitRef="U_USD">2500000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-5"
      id="F_89fd2945-19c7-499b-beeb-29a09b030d59"
      unitRef="U_USD">2100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_58758dcc-f1f8-4b59-846b-4b6aaea3c7a9">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.847%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.417%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.417%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued salaries and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Legal and professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <idya:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_71c269ba-ebf2-45f9-b876-028ec32d451a"
      unitRef="U_USD">19956000</idya:AccruedResearchAndDevelopmentExpensesCurrent>
    <idya:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_9bc231b2-592a-4a02-863c-1ca4a9b1874f"
      unitRef="U_USD">10676000</idya:AccruedResearchAndDevelopmentExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_59840193-8d39-49b9-974d-90430f3f8a69"
      unitRef="U_USD">8233000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_21914c70-d483-4f58-adc1-f3f9e31e4d9a"
      unitRef="U_USD">6974000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_741a3aa4-be44-4e5b-8bc8-5c49a50c0a24"
      unitRef="U_USD">1213000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_67a3d37d-add7-4bb9-a4ec-f979ea69309c"
      unitRef="U_USD">959000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_7c3008b1-453b-4df6-9578-00a533ea7888"
      unitRef="U_USD">950000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_e7031b67-ee9d-40ed-b8f2-3b397675c892"
      unitRef="U_USD">147000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_f58444de-0c39-44b0-9285-1112ebb85671"
      unitRef="U_USD">30352000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_fc71d166-c9f0-451f-acbe-d92b6288e610"
      unitRef="U_USD">18756000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_4ab202ec-9bd7-4525-b6fb-fdbe0d3aee5b">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2023, the Company entered into a lease agreement for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of laboratory and office facilities at 5000 Shoreline Court, South San Francisco, California. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The lease term is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;120 months&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the Company has an option to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;extend the lease term&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for a total of two consecutive five-year periods&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. This lease agreement commenced in August 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2024, the Company amended its 5000 Shoreline Court facility lease agreement to expand the size of the original premises by adding approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,321&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; rentable square feet of additional space. The lease term for the expanded premises will not begin until the landlord makes certain improvements and offers to deliver possession of the expansion premises to the Company. The lease term for the expanded premises has not yet commenced as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's lease at 7000 Shoreline Court, South San Francisco, California, expired in September 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the Company entered into a lease agreement for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,700&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of space at 11710 El Camino Real, San Diego, California for corporate office space. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The lease term commenced in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and expires in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 2028&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company has an option to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;renew the lease&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future minimum lease payments under operating leases included on the Company's balance sheet are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,171&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes other information about the Company's operating leases:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:20.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:22.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating lease costs were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, 2024, 2023 and 2022, respectively. Variable lease costs were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, 2024, 2023, and 2022, respectively. Variable lease costs represent additional costs incurred, related to administration, maintenance and property tax costs incurred, which are billed based on both usage and as a percentage of the Company's share of total square footage.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the years ended December 31, 2024, 2023 and 2022, cash paid for amounts included in the measurement of lease liabilities and included within cash used in operating activities in the statement of cash flows was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <idya:OperatingLeasesAreaLeased
      contextRef="C_8a14eee6-aa6b-4583-9df1-42b202346a23"
      decimals="INF"
      id="F_27582a0c-fdc9-4d9a-9f1b-e3809706ea47"
      unitRef="U_sqft">44000</idya:OperatingLeasesAreaLeased>
    <idya:OperatingLeaseCommencementDescription
      contextRef="C_847c9af8-88d2-45a3-91d6-dcdef630162c"
      id="F_2ae0f5ad-1933-4cc7-b627-659446c1a543">The lease term is 120 months</idya:OperatingLeaseCommencementDescription>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_8a14eee6-aa6b-4583-9df1-42b202346a23"
      id="F_8bd00d88-25cf-455b-a0bb-0a8743e238f7">P120M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_847c9af8-88d2-45a3-91d6-dcdef630162c"
      id="F_af3f4c52-090b-47c4-b5c3-24b80389dbe2">the Company has an option to extend the lease term for a total of two consecutive five-year periods</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_26c750d2-8712-4a4a-a85d-4f7f7ab0f46b"
      id="F_661fa099-669b-49de-bef5-a2c9aedfbe9d">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <idya:OperatingLeasesAdditionalAreaLeased
      contextRef="C_22f94b97-85f3-4e83-8f04-ecf937a7a2ac"
      decimals="INF"
      id="F_53ea7772-5e8a-4066-8054-064ffa32f1a2"
      unitRef="U_sqft">11321</idya:OperatingLeasesAdditionalAreaLeased>
    <idya:OperatingLeasesAreaLeased
      contextRef="C_fdb1e9d4-d4ba-4bfd-94d7-8c22b58dd404"
      decimals="INF"
      id="F_18e260ce-e54b-4dba-8374-b56fec363875"
      unitRef="U_sqft">5700</idya:OperatingLeasesAreaLeased>
    <idya:OperatingLeaseCommencementDescription
      contextRef="C_8c32f180-89d2-481f-bc80-3f77774ec456"
      id="F_d9e3d9e3-9f0b-4ee1-adb9-27c56d3c8c8c">The lease term commenced in December 2023 and expires in March 2028</idya:OperatingLeaseCommencementDescription>
    <idya:OperatingLeaseCommencementMonthAndYear
      contextRef="C_09973aa9-24e1-483b-99d4-30e070b0dbb0"
      id="F_c1c309c4-1d0a-4108-a27e-e8a496caffd3">2023-12</idya:OperatingLeaseCommencementMonthAndYear>
    <idya:LeaseExpirationMonthAndYear
      contextRef="C_5461c8ef-2882-483f-a96f-317b9393242b"
      id="F_8afb2456-7dcf-4372-8422-65ec0121d8da">2028-03</idya:LeaseExpirationMonthAndYear>
    <idya:LesseeOperatingLeaseExistenceOfOptionToRenew
      contextRef="C_5461c8ef-2882-483f-a96f-317b9393242b"
      id="F_cb450fa7-71ad-4081-b0b0-138c24e35699">true</idya:LesseeOperatingLeaseExistenceOfOptionToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_fdb1e9d4-d4ba-4bfd-94d7-8c22b58dd404"
      id="F_f082339b-4b3c-4bcc-823e-376a41a06400">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_08df0f95-9de2-4d91-8e35-914df5dccb4c">&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future minimum lease payments under operating leases included on the Company's balance sheet are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,171&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_2b83fc48-ce78-4468-b1ee-c80907eac40e"
      unitRef="U_USD">386000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_0b34ff4a-8f5b-41ba-9700-1c6d488bb66f"
      unitRef="U_USD">1705000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_08bca3c7-7028-498e-bb86-692ebe5e8f3e"
      unitRef="U_USD">4389000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_26f3d9ad-11c7-4dba-8c78-457d22feb88c"
      unitRef="U_USD">4224000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_63a68aa6-c3d2-49b9-99e7-07bf88b57430"
      unitRef="U_USD">4263000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <idya:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_9218055a-8aca-4427-bce5-3d95f3debaa9"
      unitRef="U_USD">22790000</idya:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_49c75f30-1bcf-4ca4-bb15-770436a6aad8"
      unitRef="U_USD">37757000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_cfb2a4e4-a26f-4050-a654-e3ab51ec690d"
      unitRef="U_USD">18586000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_f01ba43c-b279-4180-9754-0319827ea21c"
      unitRef="U_USD">19171000</us-gaap:OperatingLeaseLiability>
    <idya:OperatingLeasesDisclosuresTableTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_05d907d4-da25-43bb-9933-cd016867ce5d">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes other information about the Company's operating leases:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:20.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:22.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</idya:OperatingLeasesDisclosuresTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      id="F_e5a94bd0-2dd8-4c6d-ad83-3e1c1e6d7f0d">P9Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      id="F_163f6ab4-6e21-4cdc-b1da-71436562b344">P2Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="3"
      id="F_2e7cea99-dcb1-4a0e-a865-1d1769c35763"
      unitRef="U_pure">0.126</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="3"
      id="F_c31e3a7e-13ed-4200-bed3-8eb8703d80d1"
      unitRef="U_pure">0.08</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-5"
      id="F_9756db9a-fbb9-4b77-bf20-d9067af52d53"
      unitRef="U_USD">1900000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-5"
      id="F_fac5a83a-2c58-40e0-89aa-f4d163291cd8"
      unitRef="U_USD">1700000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-5"
      id="F_221180a6-9578-4847-8034-e3d6ab2d18de"
      unitRef="U_USD">1700000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-5"
      id="F_a153858f-b554-4ecf-b6da-256df81bf24b"
      unitRef="U_USD">1100000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-5"
      id="F_8a83e3f1-9250-45d8-b7e8-b3c89ae744aa"
      unitRef="U_USD">1400000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-5"
      id="F_d4fdfac3-3738-4398-8104-53a7a8f5728d"
      unitRef="U_USD">1000000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-5"
      id="F_234cb812-738b-4407-b7ef-8262df40d082"
      unitRef="U_USD">1700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-5"
      id="F_8cdda98b-b2f7-4cee-bc3e-ff6ae5444fc4"
      unitRef="U_USD">2000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-5"
      id="F_8f61f902-e278-4950-b3f0-d736c284cdd5"
      unitRef="U_USD">2000000</us-gaap:OperatingLeasePayments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_7fc66d88-cc99-4d6e-a0b2-144301ccf0ac">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, the Company may be involved in litigation related to claims that arise in the ordinary course of its business activities. The Company accrues for these matters when it is probable that future expenditures will be made and these expenditures can be reasonably estimated. As of December 31, 2024, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company&#x2019;s financial position, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Indemnification&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company enters into standard indemnification arrangements in the ordinary course of business with vendors, clinical trial sites and other parties. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;incurred &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;costs to defend lawsuits or settle claims related to these indemnification agreements. Accordingly, the Company has not recorded a liability related to such indemnification agreements as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_2fee3df8-0f05-47d8-84a0-927901a23918">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; provision for income taxes was recorded for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, December 31, 2023 and December 31, 2022. The Company has incurred net operating losses only in the United States since its inception. The Company has not reflected any benefit of such net operating loss carryforwards in the financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The provision for income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.342%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.312999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.312999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.312999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Section 162(m) limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The tax effects of temporary differences and carryforwards of the deferred tax assets are presented below (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.328%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.017%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.017%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research &amp;amp; development expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;168,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#x201c;more likely than not.&#x201d; Realization of the future tax benefits is dependent on the Company&#x2019;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#x2019;s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. The valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during 2024, 2023, and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company had net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;147.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million available to reduce future taxable income, if any, for federal income tax purposes as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and December 31, 2023, respectively. The Company had net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million available to reduce future taxable income, if any, for state income tax purposes. If not utilized, the federal carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and the state carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million will begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2036&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively. The federal net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;135.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million arising after December 31, 2017 do not expire.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company also had federal and state research and development credit carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023, respectively. The Company had Orphan Drug Credits (&#x201c;ODC&#x201d;), related to the orphan drug designation of darovasertib in 2022, of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively. The federal credits will expire starting in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; if not utilized, and the state research credit can be carried forward indefinitely.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Tax Reform Act of 1986 limits the use of net operating loss carryforwards in certain situations where changes occur in the stock ownership of a company. The annual limitation may result in the expiration of net operating losses and credits before utilization. The Company performed a Section 382 analysis through December 31, 2024. The Company has not experienced ownership changes in the current year. Subsequent ownership changes may affect the limitation in future years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Related to unrecognized tax benefits noted below, the Company accrued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; penalties or interest during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, December 31, 2023 and December 31, 2022. The Company does not expect its unrecognized tax benefit balance to change materially over the next 12 months.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of unrecognized tax benefits as of December 31, 2024 and December 31, 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits (in thousands).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:72.675%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.501%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:22.825%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balance as of January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Increase related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Decrease related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company files income tax returns in the U.S. federal jurisdiction and in the states of Arizona, California, New Jersey, North Carolina, Pennsylvania, Texas, Utah and Wisconsin. For jurisdictions in which tax filings have been filed, all tax years remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any net operating losses or credits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is under audit in California for tax years &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_338a4ed1-99c5-4700-8268-537e20e71a59;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2020-2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="INF"
      id="F_4db07650-b2ea-4a22-8fb1-005e5d1d16b9"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="INF"
      id="F_30050818-1400-41ab-bc69-5b3774a98314"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="INF"
      id="F_20f96056-7165-42bb-b5f1-f8ecd76839c2"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_3ce87b78-6309-4b1c-a569-e314658296cb">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The provision for income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.342%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.312999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.312999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.312999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Section 162(m) limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="INF"
      id="F_84721032-379e-45e6-af9b-3d880ad98b35"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="INF"
      id="F_aef348d0-121b-40c7-bde9-2ad75b154715"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="INF"
      id="F_f0746568-e8a6-4c7d-baf5-b3cddea0fb45"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="3"
      id="F_58087cbc-2800-4dbd-a8f7-af09bc2a0bc0"
      unitRef="U_pure">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="3"
      id="F_4d44cab2-5843-4481-9128-2cab5b5b94d6"
      unitRef="U_pure">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="3"
      id="F_8b6ea878-4174-4770-8797-03e90f6fce75"
      unitRef="U_pure">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="3"
      id="F_17fc6e75-26b7-4ba6-aadb-69f530f16d09"
      unitRef="U_pure">-0.251</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="3"
      id="F_a642768c-4b74-4323-a32e-ec3458d2557c"
      unitRef="U_pure">-0.291</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="3"
      id="F_09743046-36e8-4dab-b02e-a205d56bef43"
      unitRef="U_pure">-0.234</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="3"
      id="F_22eb25af-4446-4e74-af03-1f3ca6cc4f69"
      unitRef="U_pure">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="3"
      id="F_4e60c8e5-9f68-4184-9fd9-6db9564678b0"
      unitRef="U_pure">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="3"
      id="F_36c3d856-f477-4443-9ad1-ea8fd5cc3239"
      unitRef="U_pure">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="3"
      id="F_3cdd9b49-523b-4bd0-89cb-1a9986d3382f"
      unitRef="U_pure">-0.027</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="3"
      id="F_d934f446-739d-4e0c-9fc5-71b02fb7d74d"
      unitRef="U_pure">-0.083</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="3"
      id="F_e91bfd65-18ee-4902-a4ea-0bcc608ea729"
      unitRef="U_pure">-0.044</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="3"
      id="F_f9d17894-f153-45b2-9855-780ba010d33c"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="3"
      id="F_de0da4f7-4d2c-4b64-a134-e77beab04c95"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="3"
      id="F_6fea1ccd-d9a2-41fb-af05-e8f5e4794e16"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <idya:EffectiveIncomeTaxRateReconciliationSection162MLimitation
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="3"
      id="F_68e3f21c-2e41-476d-acda-75b7345f4852"
      unitRef="U_pure">-0.012</idya:EffectiveIncomeTaxRateReconciliationSection162MLimitation>
    <idya:EffectiveIncomeTaxRateReconciliationSection162MLimitation
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="3"
      id="F_af909175-adb1-4953-b0a8-9b171cfb2b93"
      unitRef="U_pure">-0.021</idya:EffectiveIncomeTaxRateReconciliationSection162MLimitation>
    <idya:EffectiveIncomeTaxRateReconciliationSection162MLimitation
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="3"
      id="F_08e1e547-db51-4525-b6e2-ece58f506a22"
      unitRef="U_pure">-0.026</idya:EffectiveIncomeTaxRateReconciliationSection162MLimitation>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="3"
      id="F_70a1fc20-1935-4045-be60-61880f4f7f78"
      unitRef="U_pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="3"
      id="F_2a295e37-aa12-4b96-a52a-900652704334"
      unitRef="U_pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="3"
      id="F_896b58d9-6b7e-40c9-b2b6-54c9328acf07"
      unitRef="U_pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_2c62cb67-2f87-42a1-9996-d4658c326936">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The tax effects of temporary differences and carryforwards of the deferred tax assets are presented below (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.328%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.017%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.017%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research &amp;amp; development expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;168,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_9bf6760a-a686-4d7b-a012-e15d9756781e"
      unitRef="U_USD">37524000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_580bc05f-d8d9-4e3e-8c5e-0d79f223f77c"
      unitRef="U_USD">34717000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_477428d7-496a-4530-beee-54528dfb8b98"
      unitRef="U_USD">30868000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_a30f0ab0-0380-4265-b6c4-8cff71e26438"
      unitRef="U_USD">19997000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <idya:DeferredTaxAssetsLeaseLiability
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_7d3f3da6-914a-4c4d-856e-4bd21da31e1f"
      unitRef="U_USD">4074000</idya:DeferredTaxAssetsLeaseLiability>
    <idya:DeferredTaxAssetsLeaseLiability
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_5f8bd430-896f-4157-854c-3acb46607e20"
      unitRef="U_USD">610000</idya:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_9be1ade3-775a-43aa-99de-276a90c6a68c"
      unitRef="U_USD">18365000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_4e270526-44c3-43a6-9461-4ac54222de19"
      unitRef="U_USD">1096000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_55fe3568-2c8e-4ddc-a39c-14fbbb52b762"
      unitRef="U_USD">7401000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_9c40291d-fb26-4055-973f-db9da4fea2bd"
      unitRef="U_USD">2593000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_5b782ce1-15e7-4ff5-a359-00d8b5ee9fd5"
      unitRef="U_USD">1468000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_007a2159-f222-4506-8c58-ca8d68dd1c57"
      unitRef="U_USD">1257000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_b1efe972-1406-4e15-aaf8-ea44586f1627"
      unitRef="U_USD">69271000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_8f45f74a-51fb-4e34-8fe3-feedf42aa2ec"
      unitRef="U_USD">36267000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_421c6e15-91b1-4386-8eed-9342d46e81fa"
      unitRef="U_USD">168971000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_fe56f997-d999-4242-8cc1-6be7cd02025c"
      unitRef="U_USD">96537000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_dd647a38-b587-4b61-870b-b5e0bb661fab"
      unitRef="U_USD">164876000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_52401a10-8aac-48f2-bbc5-caada2ccb2f3"
      unitRef="U_USD">95888000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_2b402c2d-7b7f-4847-9246-16704003477f"
      unitRef="U_USD">4095000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_e00132a0-850b-4f17-857c-8268d3df0f82"
      unitRef="U_USD">649000</us-gaap:DeferredTaxAssetsNet>
    <idya:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_b14d4f87-4ff4-4cf3-b936-439a31532e3c"
      unitRef="U_USD">3990000</idya:DeferredTaxLiabilitiesRightOfUseAssets>
    <idya:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_60d84e4b-5001-4845-a533-97d2ea0468e9"
      unitRef="U_USD">477000</idya:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_b71fd086-c90d-47e2-a324-b792477dbe61"
      unitRef="U_USD">105000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_aecc9063-6c9c-4094-b53f-8e67d8acd1a6"
      unitRef="U_USD">172000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_3d312ea2-fa90-4e4b-b689-db67ea7e4089"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_8d92c7d0-fca4-44c4-9b71-75aeffe4f91d"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-5"
      id="F_8b67ca9c-e692-435d-8e03-f2f28165ecdf"
      unitRef="U_USD">69000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-5"
      id="F_449a929f-8cad-4f74-9ef1-047af1c5ef26"
      unitRef="U_USD">32100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-5"
      id="F_0bbb70e3-7935-456d-bfb2-b76414b837f5"
      unitRef="U_USD">14200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_9f7c598b-0376-4cd2-bb63-5b1ddcee4a82"
      decimals="-5"
      id="F_d78ef02c-6eb4-4c25-ba32-e2416fd87c3d"
      unitRef="U_USD">147500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_22bc9e4b-b2f2-40b0-b055-d6de85aad84e"
      decimals="-5"
      id="F_0e4d9206-14a0-472e-b75d-83ed02bc55ec"
      unitRef="U_USD">135300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_bf017758-6c8e-4dda-9992-6c460c60b3fe"
      decimals="-5"
      id="F_87e92b05-245a-4c5a-99db-06cf7f685438"
      unitRef="U_USD">93500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_364b5f8f-7b5f-4a54-aaa4-7b2b4312be72"
      decimals="-5"
      id="F_37733c58-537b-4f4f-8b81-29be57b8de42"
      unitRef="U_USD">89600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="C_9f7c598b-0376-4cd2-bb63-5b1ddcee4a82"
      decimals="-5"
      id="F_66227a45-d724-43b0-bdd7-bccb720e8fcf"
      unitRef="U_USD">11600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="C_bf017758-6c8e-4dda-9992-6c460c60b3fe"
      decimals="-5"
      id="F_be23f1e5-d415-419a-affa-e0538ab913d1"
      unitRef="U_USD">93500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <idya:TaxCreditCarryForwardExpirationYear
      contextRef="C_10ae45c4-8dc3-46cf-ab6d-19afaee6b186"
      id="F_71acabec-2863-49c0-b01d-020706cd4a4f">2037</idya:TaxCreditCarryForwardExpirationYear>
    <idya:TaxCreditCarryForwardExpirationYear
      contextRef="C_364d998d-4e55-404f-9c33-0ee5538a29c1"
      id="F_9dd0b4bf-7234-47bb-aab7-f1d424d3c4f8">2036</idya:TaxCreditCarryForwardExpirationYear>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="C_9f7c598b-0376-4cd2-bb63-5b1ddcee4a82"
      decimals="-5"
      id="F_3c4837a3-fe13-4651-b6b4-0877284cb8e3"
      unitRef="U_USD">135900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_9f7c598b-0376-4cd2-bb63-5b1ddcee4a82"
      decimals="-5"
      id="F_07285f70-6bc3-4fd1-8d98-261c2c59b204"
      unitRef="U_USD">19800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_bf017758-6c8e-4dda-9992-6c460c60b3fe"
      decimals="-5"
      id="F_4e3bc040-2c70-4572-8984-0d1da0d2dfc5"
      unitRef="U_USD">10800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_22bc9e4b-b2f2-40b0-b055-d6de85aad84e"
      decimals="-5"
      id="F_713df2af-775c-4b8b-bba1-0f8bd4d2d3a6"
      unitRef="U_USD">12000000.0</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_364b5f8f-7b5f-4a54-aaa4-7b2b4312be72"
      decimals="-5"
      id="F_0b9ec81f-d515-40e3-9d0d-ac81a6edddf6"
      unitRef="U_USD">6400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_2dd15ed5-ab2a-4718-85b6-49aa0ce8c31a"
      decimals="-5"
      id="F_97877b6d-184b-4648-bc3b-e896b92abd90"
      unitRef="U_USD">8100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_a46184c7-01af-47bf-9f47-d0c0ccee58f3"
      decimals="-5"
      id="F_f24bef27-c2f7-4bcc-9cd0-5f6edba7b392"
      unitRef="U_USD">6300000</us-gaap:TaxCreditCarryforwardAmount>
    <idya:TaxCreditCarryForwardExpirationYear
      contextRef="C_10ae45c4-8dc3-46cf-ab6d-19afaee6b186"
      id="F_d26a20f9-ec8f-44bb-b496-f1e13539532f">2037</idya:TaxCreditCarryForwardExpirationYear>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="INF"
      id="F_5fa9d511-9007-477c-80d4-5107bdc17c1d"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="INF"
      id="F_7d8ac238-5f6d-4c2f-a880-e4bf8814ffb0"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_ce651b87-a2ee-4952-8dab-aa55bb0ac861"
      decimals="INF"
      id="F_3af41468-7898-4a99-86d9-6e458814c5ed"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-5"
      id="F_bf85dece-ba9b-4c83-ba20-09cff2027110"
      unitRef="U_USD">5900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-5"
      id="F_3550319e-8f7b-453a-9130-0345114f850a"
      unitRef="U_USD">3800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_cd3d3840-2ed5-40ee-b93c-ada321a04a5c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits (in thousands).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:72.675%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.501%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:22.825%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balance as of January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Increase related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Decrease related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_ce651b87-a2ee-4952-8dab-aa55bb0ac861"
      decimals="-3"
      id="F_ef809957-15ef-4d63-abf0-95e47e792c34"
      unitRef="U_USD">1962000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_20c4c2fd-c81b-4435-a9cd-eddd914eec32"
      unitRef="U_USD">372000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_a7fb1fee-7bbf-4d06-b543-58c1c06ad929"
      unitRef="U_USD">1488000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-3"
      id="F_43956ef2-5591-453d-bc15-eb8d9717ce1c"
      unitRef="U_USD">3822000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_6910e84e-45f0-4951-9fd4-09df2b06f6c1"
      unitRef="U_USD">185000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_72c568dc-54a3-4b14-936c-093e068bb49e"
      unitRef="U_USD">2290000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-3"
      id="F_3d2a82bc-43b4-4cb8-a4f7-5857d923ce7e"
      unitRef="U_USD">5927000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_5efa5253-11ea-4f3b-af26-dd73779a5560">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company&#x2019;s certificate of incorporation authorized the Company to issue &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at a par value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Each share of common stock is entitled to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; vote.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Company&#x2019;s board of directors. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; dividends have been declared to date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On July 11, 2024, the Company completed an underwritten public follow-on offering. The offering consisted of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,355,714&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at an offering price to the public of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,127,142&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285,715&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.9999&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, the Company received aggregate gross proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;302.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;283.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions and other offering expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 27, 2023, the Company completed an underwritten public follow-on offering. The offering consisted of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,797,872&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at an offering price to the public of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;797,872&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;319,150&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.4999&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, the Company received aggregate gross proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;134.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions and other offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 27, 2023, the Company completed an underwritten public follow-on offering. The offering consisted of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,858,121&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at an offering price to the public of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,418,920&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,020,270&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.4999&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, the Company received aggregate gross proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;201.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions and other offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, the following aggregate warrants to purchase shares of the Company&#x2019;s common stock were issued and outstanding:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:22.324%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.521%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:21.904%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3.161%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.363%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:26.465%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Issue Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercise Price per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Shares subject to Outstanding Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;July 11, 2024&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;October 27, 2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;319,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;April 27, 2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;270,270&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) In September 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,750,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock subject to outstanding pre-funded warrants were cashless exercised and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,749,993&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock were issued.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The warrants are classified as a component of Stockholders&#x2019; Equity within Additional Paid-in-Capital. The warrants are classified as equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, are indexed to the Company&#x2019;s common stock and meet the equity classification criteria. The warrants will not expire until they are fully exercised.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company had reserved common stock for future issuance as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.403%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.403%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercise of outstanding options under the 2015, 2019 and 2023 Plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,737,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,269,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for grant under the 2019 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,910,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;964,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for grant under the 2023 Inducement Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;593,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;524,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available under the Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,911,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,317,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pre-funded warrants issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;875,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,339,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,027,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,416,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="INF"
      id="F_cb110e91-c6a6-4ddd-a3d8-5a57f3d4f8c4"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="INF"
      id="F_3648c1c8-2bd3-47da-a307-f3dff849d39a"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="INF"
      id="F_8915f7c2-9703-4c16-823a-6571528d7df2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="INF"
      id="F_28dda432-ae8e-4a63-8a54-174d1466139d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockVotingRights
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_430e32ab-0272-4d09-b66f-bf2cbaf4c424">Each share of common stock is entitled to one vote.</us-gaap:CommonStockVotingRights>
    <idya:NumberOfCommonStockVotingRightsHeldPerShare
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="INF"
      id="F_4e4782ba-0075-4e17-850c-00e4b1017686"
      unitRef="U_Vote">1</idya:NumberOfCommonStockVotingRightsHeldPerShare>
    <us-gaap:DividendsCommonStock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="INF"
      id="F_0abbc197-b6e1-44b3-b5cb-fd189ef40ef8"
      unitRef="U_USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9c02d070-8681-4a68-9460-90f6386b903f"
      decimals="INF"
      id="F_f7d6f498-9211-48db-a6a4-df50fee5c9c3"
      unitRef="U_shares">8355714</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_9e083923-3902-4bc7-aab2-a290354677b9"
      decimals="INF"
      id="F_b8155150-ebf6-4ad4-9796-d405c74fc3a1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">35</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_63980d6b-b6c2-4f34-9482-a0495f116793"
      decimals="INF"
      id="F_8bb1b836-bcf4-4f04-bb50-b4ec0effc421"
      unitRef="U_shares">1127142</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_5b17504e-2e08-477e-af4e-e1ad86f5b6e1"
      decimals="INF"
      id="F_cbe31618-8e6a-440a-b406-c46cc6ce1258"
      unitRef="U_shares">285715</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_5b17504e-2e08-477e-af4e-e1ad86f5b6e1"
      decimals="INF"
      id="F_c18cd204-0107-4060-90fe-79f55c6ced10"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">34.9999</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_a6b8d688-85fc-4f28-b94d-adbdcc815d1b"
      decimals="-5"
      id="F_58c9e980-6866-4f8c-b6fa-d7761c445752"
      unitRef="U_USD">302400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <idya:NetProceedsFromIssuanceOfCommonStock
      contextRef="C_a6b8d688-85fc-4f28-b94d-adbdcc815d1b"
      decimals="-5"
      id="F_d86ac40e-5367-488b-a2dc-d5f1673136e8"
      unitRef="U_USD">283800000</idya:NetProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e4f99219-ed58-4929-87e5-a993db32910d"
      decimals="INF"
      id="F_22688874-155a-45ea-a42c-78edfdff8bfc"
      unitRef="U_shares">5797872</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_d4a29fc9-5039-4781-aa51-00d8294b4d29"
      decimals="INF"
      id="F_f81ffc01-c281-4f7d-97df-075325018e5e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_4a13cb3d-0ae0-44c8-9454-9eb34da39ecb"
      decimals="INF"
      id="F_05f7c63e-c292-4ed6-b115-314c4c56069c"
      unitRef="U_shares">797872</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_17c6d71a-63e2-457f-a633-102c0bde4eb4"
      decimals="INF"
      id="F_8d762d65-b761-4abb-adb9-8fafb81bae56"
      unitRef="U_shares">319150</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_17c6d71a-63e2-457f-a633-102c0bde4eb4"
      decimals="INF"
      id="F_27f7ca65-610d-4c40-8bc5-4cb899dc97cf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.4999</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_e56ae803-71fa-40b1-b315-c44f63fe65d8"
      decimals="-5"
      id="F_f3675798-5528-4f56-ba91-cdd92c7298d1"
      unitRef="U_USD">143700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <idya:NetProceedsFromIssuanceOfCommonStock
      contextRef="C_e56ae803-71fa-40b1-b315-c44f63fe65d8"
      decimals="-5"
      id="F_24b5a4fc-31ec-4f37-82cf-f1b9f33e1b4e"
      unitRef="U_USD">134600000</idya:NetProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_07e35c69-dfae-4e28-83b9-c956215e0274"
      decimals="INF"
      id="F_8cab3c7c-849d-4151-ac80-8f4611ae9264"
      unitRef="U_shares">8858121</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_7bcd1912-41e8-4474-944c-32f938bcc64c"
      decimals="INF"
      id="F_2d413959-68d3-4634-abb1-8a859707951c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e6119aea-4ad7-47ff-8b8a-db55f4f12c97"
      decimals="INF"
      id="F_720b8ea3-9ef2-4b32-9193-8e3821b11414"
      unitRef="U_shares">1418920</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_d400c976-b0bd-479d-aa74-c54c3f83c119"
      decimals="INF"
      id="F_445807f1-d1e2-46a3-b051-ad42c2c3cd90"
      unitRef="U_shares">2020270</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_d400c976-b0bd-479d-aa74-c54c3f83c119"
      decimals="INF"
      id="F_74ef83cc-bbfa-40a5-9490-907020ad6eb1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.4999</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_7997c4a8-f7da-4956-8da0-38a0332faec7"
      decimals="-5"
      id="F_3589f9c2-7538-4a86-b45f-3bcd98792cfd"
      unitRef="U_USD">201300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <idya:NetProceedsFromIssuanceOfCommonStock
      contextRef="C_7997c4a8-f7da-4956-8da0-38a0332faec7"
      decimals="-5"
      id="F_8c1bfec3-2bef-4296-bcb1-948e4763b85b"
      unitRef="U_USD">188700000</idya:NetProceedsFromIssuanceOfCommonStock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_67545a54-d34a-4308-90df-f3edefc153e1">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, the following aggregate warrants to purchase shares of the Company&#x2019;s common stock were issued and outstanding:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:22.324%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.521%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:21.904%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3.161%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.363%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:26.465%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Issue Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercise Price per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Shares subject to Outstanding Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;July 11, 2024&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;October 27, 2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;319,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;April 27, 2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;270,270&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) In September 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,750,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock subject to outstanding pre-funded warrants were cashless exercised and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,749,993&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock were issued.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <idya:ClassOfWarrantOrRightsIssueDate
      contextRef="C_bb829766-4720-419f-b5f8-c1559b6f88fb"
      id="F_b6d9ca13-abf9-4eca-b264-bc843d28eed2">2024-07-11</idya:ClassOfWarrantOrRightsIssueDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_69622302-21de-4f4c-a022-d0681d928a7a"
      decimals="INF"
      id="F_38554083-55fd-4ca7-8d1b-3aaca26c4d2d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_69622302-21de-4f4c-a022-d0681d928a7a"
      decimals="INF"
      id="F_533f9b09-c9a9-410b-97ba-e0911b5b2ddc"
      unitRef="U_shares">285715</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <idya:ClassOfWarrantOrRightsIssueDate
      contextRef="C_1d6fd8be-e5c3-430b-802a-c42663370c20"
      id="F_df7fef88-c00b-482b-941c-ece1fd5a7fb1">2023-10-27</idya:ClassOfWarrantOrRightsIssueDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_fa12496f-6344-415f-a910-de2c2bf8a71f"
      decimals="INF"
      id="F_4bd08f36-8050-4d2f-81e7-0ea5400df5d1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_fa12496f-6344-415f-a910-de2c2bf8a71f"
      decimals="INF"
      id="F_7d5838cd-a071-45d1-b2e3-18666302f54d"
      unitRef="U_shares">319150</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <idya:ClassOfWarrantOrRightsIssueDate
      contextRef="C_650406b3-09c1-4d06-8663-ecb638592c77"
      id="F_917aae1f-a632-4b1b-a88d-ab16ecef40b5">2023-04-27</idya:ClassOfWarrantOrRightsIssueDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_5855cfe6-054d-4ae0-825a-83a7de5b18e1"
      decimals="INF"
      id="F_e479c294-d497-4769-a219-7cad3acb678a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_5855cfe6-054d-4ae0-825a-83a7de5b18e1"
      decimals="INF"
      id="F_3e453748-e511-43ad-93eb-404fa56268cb"
      unitRef="U_shares">270270</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <idya:CommonStockSubjectToOutstandingPreFundedWarrantsExercised
      contextRef="C_0178d793-324f-4f5d-8dfc-49181bd85b1e"
      decimals="INF"
      id="F_605c1290-0c25-41c4-8865-bbc5d952fd04"
      unitRef="U_shares">1750000</idya:CommonStockSubjectToOutstandingPreFundedWarrantsExercised>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_3a8b018a-8ca5-43cb-9db1-a7f041be1845"
      decimals="INF"
      id="F_f2da8a04-9f80-4c8a-ad20-f00bbfdcb4af"
      unitRef="U_shares">1749993</us-gaap:CommonStockSharesIssued>
    <idya:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_ff4548ba-4d07-4a33-8e8f-345d2bf294a6">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company had reserved common stock for future issuance as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.403%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.403%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercise of outstanding options under the 2015, 2019 and 2023 Plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,737,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,269,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for grant under the 2019 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,910,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;964,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for grant under the 2023 Inducement Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;593,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;524,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available under the Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,911,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,317,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pre-funded warrants issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;875,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,339,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,027,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,416,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</idya:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a6ac4859-4009-41b4-9008-d4385ab189d1"
      decimals="INF"
      id="F_9cfc81ca-05f8-4d39-bbb8-3e7f2ea0e795"
      unitRef="U_shares">7737595</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_528a15eb-04d7-4a77-882c-7e2e6baa5a16"
      decimals="INF"
      id="F_772cf725-bb47-4bac-b915-ee835b371727"
      unitRef="U_shares">6269975</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2a9cefda-dc1e-448e-84a6-0e063d36ae4d"
      decimals="INF"
      id="F_cfcf3ff4-2882-4590-986e-9babd23be39f"
      unitRef="U_shares">1910589</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_cbbfcaff-64c2-4dd6-8836-3121afdff880"
      decimals="INF"
      id="F_412c4e69-cdbe-47d2-b58f-5d096fa5e5bc"
      unitRef="U_shares">964622</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_15e27b17-950f-4151-a11c-4aba882b2d8a"
      decimals="INF"
      id="F_e31e0c78-8065-4081-b3a4-a8cffe571749"
      unitRef="U_shares">593592</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_6814219a-6bb3-46e5-9d9a-753145524259"
      decimals="INF"
      id="F_df461a58-eb8e-490d-8c01-82e0c614556d"
      unitRef="U_shares">524300</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2c520ba2-7d16-4246-9088-3fdbb269e8a6"
      decimals="INF"
      id="F_3b5881db-4f1f-4bd2-a7c9-25130ea416e2"
      unitRef="U_shares">1911011</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f02efd60-1311-4d54-8d9c-b1359814dbc8"
      decimals="INF"
      id="F_fe8c5e55-03e8-4522-b6a6-a75f01995808"
      unitRef="U_shares">1317974</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_ecf66199-2c61-4da1-b565-ea15c7525705"
      decimals="INF"
      id="F_538554b7-cf98-495a-a50e-19610bc93a7b"
      unitRef="U_shares">875135</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_fe0af623-ced9-4295-b11c-a7901893dc7c"
      decimals="INF"
      id="F_9e30759e-6073-4aae-9e35-a852cd7c5cef"
      unitRef="U_shares">2339420</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="INF"
      id="F_9b835426-5660-44a5-bf90-fcec54e8027b"
      unitRef="U_shares">13027922</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="INF"
      id="F_91261ec3-a654-476d-9551-2e8c784b51ed"
      unitRef="U_shares">11416291</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_c27df491-c8c9-427f-9468-c12f740b982b">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9. Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2023 Inducement Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 24, 2023, the Company adopted the IDEAYA Biosciences, Inc. 2023 Employment Inducement Award Plan (the &#x201c;2023 Inducement Plan&#x201d;), pursuant to which the Company reserved &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company as an inducement material to the individual&#x2019;s entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The 2023 Inducement Plan was approved by the Company&#x2019;s board of directors without stockholder approval in accordance with such rule. Options granted under the 2023 Inducement Plan have a term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years and generally vest over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-year period with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-year cliff vesting.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On June 25, 2024, the Company amended the 2023 Employment Inducement Award Plan, increasing the number of shares available for issuance by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the number of shares available for issuance under the 2023 Inducement Plan was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;593,592&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2019 Incentive Award Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2019, the Company&#x2019;s board of directors adopted and the Company&#x2019;s stockholders approved the 2019 Incentive Award Plan (the &#x201c;2019 Plan&#x201d;), under which the Company may grant cash and equity-based incentive awards to the Company&#x2019;s employees, consultants and directors. Following the effectiveness of the 2019 Plan, the Company will not make any further grants under the 2015 Equity Incentive Plan (the &#x201c;2015 Plan&#x201d;). However, the 2015 Plan continues to govern the terms and conditions of the outstanding awards granted under it. Shares of common stock subject to awards granted under the 2015 Plan that are forfeited or lapse unexercised and which following the effective date of the 2019 Plan are not issued under the 2015 Plan will be available for issuance under the 2019 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Options granted under the 2019 Plan may be either incentive stock options (&#x201c;ISOs&#x201d;) or nonqualified stock options (&#x201c;NSOs&#x201d;). ISOs may be granted only to Company employees (including officers and directors who are also employees). NSOs may be granted to Company employees, directors and consultants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2019 Plan is subject to an annual increase on the first day of each year beginning in 2020 and ending in 2029, equal to the lesser of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the shares outstanding on the last day of the immediately preceding fiscal year, and such smaller number of shares as determined by the Company&#x2019;s board of directors. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Options granted under the 2019 Plan have a term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years (or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; if granted to a 10% stockholder) and generally vest over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-year period with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-year cliff vesting.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the number of shares available for issuance under the 2019 Plan was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,910,589&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2015 Equity Incentive Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In 2015, the Company established its 2015 Plan which provides for the granting of stock options to employees, directors and consultants of the Company. Options granted under the 2015 Plan may be either ISOs or NSOs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2019, the Company&#x2019;s board of directors adopted and the Company&#x2019;s stockholders approved the 2019 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The ESPP provides eligible employees with the opportunity to acquire an ownership interest in the Company through periodic payroll deductions up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of eligible compensation. The offering period is determined by the Company in its discretion but may not exceed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months. The per-share purchase price on the applicable exercise date for an offering period is equal to the lesser of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the fair market value of the common stock at either the first business day or last business day of the offering period, provided that no more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock may be purchased by any one employee during each offering period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The ESPP is intended to constitute an &#x201c;employee stock purchase plan&#x201d; under Section 423(b) of the Internal Revenue Code of 1986, as amended. A total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;195,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock were initially reserved for issuance under the ESPP, subject to an annual increase on January 1 of each year, beginning on January 1, 2020, equal to the lesser of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the shares outstanding on the last day of the immediately preceding fiscal year and such smaller number of shares as may be determined by the Company&#x2019;s board of directors, provided, however, that no more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,500,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares may be issued under the ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the number of shares available for issuance under the ESPP was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,911,011&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. For the years ended December 31, 2024, 2023, and 2022 the Company recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million respectively, of compensation expense related to employee participation in the ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense recorded related to awards granted to employees and non-employees was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.642%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.619%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.834%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.619%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.834%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.619%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.834%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Activity under the Company&#x2019;s 2015 and 2019 Plans and 2023 Inducement Plan is set forth below:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate    &lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balance, January 1, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,269,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.82&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;128.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,247,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,118,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;661,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balance, December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,737,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.89&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercisable as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,185,690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.62&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Vested and expected to vest as of&lt;br/&gt;&#160;&#160;&#160;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,737,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.89&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average grant-date fair value of options granted during the years ended December 31, 2024, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.93&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.98&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, respectively. The aggregate intrinsic value of options exercised for the years ended December 31, 2024, 2023, 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. Intrinsic values are calculated as the difference between the exercise price of the underlying options and the fair value of the common stock on the date of exercise.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and December 31, 2023, the total unrecognized stock-based compensation expense for stock options was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.63&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.59&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Black-Scholes Assumptions&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair values of options were calculated using the assumptions set forth below:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.852%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:19.016%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:19.016%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:19.016%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The expected term represents the weighted-average period the stock options are expected to remain outstanding and is based on the options&#x2019; vesting terms and contractual terms.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The expected volatility is based on the Company&#x2019;s historical stock price volatility. The historical stock price volatility is calculated based on a period of time commensurate with the expected term assumption for each grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The risk-free rate assumption is based on U.S. Treasury instruments whose term was consistent with the expected term of the Company&#x2019;s stock options.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected Dividend Rate&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company has not paid and does not anticipate paying any dividends in the near future. Accordingly, the Company has estimated the dividend yield to be &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of the Company&#x2019;s common stock is determined based on the market price on the date of grant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0f9012d2-5d2a-4197-80a8-0c4c3a822d34"
      decimals="INF"
      id="F_81140a40-7e13-44bb-9e6d-afb20a531bbc"
      unitRef="U_shares">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_907e44ce-49c7-48a8-8a1c-69ad47564e17"
      id="F_99029a07-856c-4ee9-aed1-c966a82afb65">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_907e44ce-49c7-48a8-8a1c-69ad47564e17"
      id="F_12bc15f3-64ab-43e9-b18d-773dbedb6bae">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_bfa82174-2a92-4b37-a2b1-ccf30e752c5b"
      id="F_beb188b6-508d-4b4b-9e16-f15afb779aab">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <idya:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance
      contextRef="C_9c98a97a-3cca-48ab-963f-645540e482b5"
      decimals="INF"
      id="F_f53a13f8-fe85-416e-b925-4fb04f196515"
      unitRef="U_shares">1000000</idya:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_49528f5e-068e-48f2-8643-656de2cfb1fd"
      decimals="INF"
      id="F_5dfec47c-e40c-496b-90ed-9979afc39642"
      unitRef="U_shares">593592</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <idya:ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent
      contextRef="C_a2a77a38-375b-46dc-9258-d476935d3c33"
      decimals="2"
      id="F_66fc1fa0-4616-47ee-b0e7-d435c5bcabf2"
      unitRef="U_pure">0.04</idya:ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_93b03c8e-0f95-4d58-98e5-1b1e2a78067e"
      id="F_941dc3c8-bcbc-45a3-8ba3-b225cc5f7b86">Options granted under the 2019 Plan have a term of 10 years (or five years if granted to a 10% stockholder) and generally vest over a 4-year period with 1-year cliff vesting.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_93b03c8e-0f95-4d58-98e5-1b1e2a78067e"
      id="F_f5966889-e31e-4d8c-a58f-e924b25e5286">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_cec1db68-704c-4a32-8899-82a806f8d2c7"
      id="F_9e4b5000-84b3-4eca-9544-68d240158ea0">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_93b03c8e-0f95-4d58-98e5-1b1e2a78067e"
      id="F_75210e08-9ef3-42e5-b5a1-eeb33d2dbd5d">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_9597b477-72d9-47f9-a2b7-c96116c45490"
      id="F_46bf4225-9ff0-417e-83b1-489c98f446d7">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_5d624162-e14b-4855-a956-1c0a4448424b"
      decimals="INF"
      id="F_30728ae9-5118-4433-9778-d1160866c75d"
      unitRef="U_shares">1910589</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_2f75efad-f0a6-4830-98d3-294b93ab7d63"
      decimals="2"
      id="F_57653990-08c1-4bdd-9325-8e8b352f937a"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <idya:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod
      contextRef="C_d0071ee7-da0d-4c80-b8f6-5f69ef5e6bea"
      id="F_55e16302-19de-4468-8d05-216af860f5ae">P27M</idya:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumOfferingPeriod>
    <idya:ESPPDiscountedPurchasePricePercentage
      contextRef="C_38305cf8-eda8-4b97-a281-f86a6e1d392c"
      decimals="INF"
      id="F_b33d8a76-4118-422d-92a2-a32726a1f664"
      unitRef="U_pure">0.85</idya:ESPPDiscountedPurchasePricePercentage>
    <idya:ESPPMaximumSharesPurchasablePerPeriodPerEmployee
      contextRef="C_38305cf8-eda8-4b97-a281-f86a6e1d392c"
      decimals="INF"
      id="F_5b86621e-218b-4c45-9754-39a58155b90a"
      unitRef="U_shares">4000</idya:ESPPMaximumSharesPurchasablePerPeriodPerEmployee>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a702b98c-ab89-4793-9842-f4bec0373771"
      decimals="INF"
      id="F_bd41d27b-0bbe-4ee2-a4cc-2f0cd6f559bd"
      unitRef="U_shares">195000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <idya:ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent
      contextRef="C_569cd832-f7fb-45d7-b394-66e1bc0a4298"
      decimals="INF"
      id="F_7d8365b4-e048-41e6-b14f-423e7deae78e"
      unitRef="U_pure">0.01</idya:ShareBasedCompensationArrangementBySharebasedPaymentAwardOfSharesOutstandingPercent>
    <idya:MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="INF"
      id="F_7d8e04b9-b5b7-47f0-ae27-49c68cde9665"
      unitRef="U_shares">2500000</idya:MaximumShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2f75efad-f0a6-4830-98d3-294b93ab7d63"
      decimals="INF"
      id="F_cd977400-c4f4-4a62-8f21-547fe90c4272"
      unitRef="U_shares">1911011</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d0071ee7-da0d-4c80-b8f6-5f69ef5e6bea"
      decimals="-5"
      id="F_0fe8d4f2-c276-4d6a-99b6-4277a4b254fe"
      unitRef="U_USD">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5c35883b-fbec-4b73-845e-1e70a57f9790"
      decimals="-5"
      id="F_dd192c31-7d86-47d1-91e6-4b2f59ba8d21"
      unitRef="U_USD">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1fa75d5d-f291-49dc-801d-19a66aa48744"
      decimals="-5"
      id="F_4d4a5c15-e5af-4c5d-b3a8-469bf88c25fc"
      unitRef="U_USD">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_f58d3033-1942-4461-a567-bce0af981c3a">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense recorded related to awards granted to employees and non-employees was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.642%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.619%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.834%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.619%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.834%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.619%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.834%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_78c6497a-ce12-4868-8a73-d11183d394be"
      decimals="-3"
      id="F_a391ac6d-17e3-4bfa-80b0-9d8b83b0a616"
      unitRef="U_USD">21115000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b6a91b55-3856-4d3e-9d9b-637a1fc4e083"
      decimals="-3"
      id="F_15d8d68e-e645-4530-a40c-aa6b0beda73b"
      unitRef="U_USD">10826000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8f3cffd2-a88d-4fe5-892e-4adcc9f5604d"
      decimals="-3"
      id="F_b4fea05a-ce75-45a0-a766-1431da4b651e"
      unitRef="U_USD">6050000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1b2706bd-6978-4079-8e5c-6be28981766b"
      decimals="-3"
      id="F_0d4dfc9d-7236-4733-892c-62e335ab4d53"
      unitRef="U_USD">13631000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a7f64497-48a3-44cb-b7f9-5fe1d8d9ba6e"
      decimals="-3"
      id="F_e0bc778d-1ba3-4f7f-84b9-15d9eed511fb"
      unitRef="U_USD">7663000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a08caba6-5fab-4b48-87ef-fe485515b9e7"
      decimals="-3"
      id="F_05d98571-0baf-4855-a925-710b53eaa16c"
      unitRef="U_USD">5579000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_df0a8190-8bf9-44f6-a6a6-fa741289d947"
      unitRef="U_USD">34746000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_0c5c60cb-4422-481c-bbf8-4d07869a1c7c"
      unitRef="U_USD">18489000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_816c21c4-7915-4bff-aab1-e5b612674112"
      unitRef="U_USD">11629000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_c38713c1-03ac-4080-ab09-5e3fdfe1140e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Activity under the Company&#x2019;s 2015 and 2019 Plans and 2023 Inducement Plan is set forth below:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate    &lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balance, January 1, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,269,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.82&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;128.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,247,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,118,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;661,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Balance, December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,737,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.89&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercisable as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,185,690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.62&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Vested and expected to vest as of&lt;br/&gt;&#160;&#160;&#160;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,737,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.89&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_4b10675f-0784-4fa3-8f18-4c914a58c0d5"
      decimals="INF"
      id="F_18eb1b36-9b6e-49ef-9ae7-c978dfd29dd0"
      unitRef="U_shares">6269975</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_4b10675f-0784-4fa3-8f18-4c914a58c0d5"
      decimals="2"
      id="F_6e0ee23b-b961-479d-97f2-0918f22f922e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_21d37c85-a2fd-4198-8e25-eada4c1b7d75"
      id="F_624d83a1-f458-4e69-96e9-097f9901cc69">P7Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_4b10675f-0784-4fa3-8f18-4c914a58c0d5"
      decimals="-1"
      id="F_cb1ecd74-e642-48f2-ab6f-1732d4acb0ef"
      unitRef="U_USD">128490</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_55abfe7d-fa2b-408a-b618-f79551bab538"
      decimals="INF"
      id="F_04f10dc3-7fb8-4b84-9601-973f0054e9a5"
      unitRef="U_shares">3247538</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_55abfe7d-fa2b-408a-b618-f79551bab538"
      decimals="2"
      id="F_04d9d257-dfd1-44d1-a909-0c62c56c5fb2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">41.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_55abfe7d-fa2b-408a-b618-f79551bab538"
      decimals="INF"
      id="F_2fc3d063-3f25-4e97-96b2-d1cdc853713e"
      unitRef="U_shares">1118695</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_55abfe7d-fa2b-408a-b618-f79551bab538"
      decimals="2"
      id="F_da8a2c41-697b-498f-9767-09d30317c84a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_55abfe7d-fa2b-408a-b618-f79551bab538"
      decimals="INF"
      id="F_6ed826dc-bcdd-4771-bf8a-035139c6fd8f"
      unitRef="U_shares">661223</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_55abfe7d-fa2b-408a-b618-f79551bab538"
      decimals="2"
      id="F_da6dd12f-a96f-4a28-b38f-26981d8b0801"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">29.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_ddead929-9307-4f06-a8f6-718bdcb2cf0c"
      decimals="INF"
      id="F_f1cd689b-fe6e-4232-a56b-e185fa6e79c9"
      unitRef="U_shares">7737595</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_ddead929-9307-4f06-a8f6-718bdcb2cf0c"
      decimals="2"
      id="F_d6baa338-e81a-432d-bb31-a8d0ddfde769"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">26.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_55abfe7d-fa2b-408a-b618-f79551bab538"
      id="F_12ff022c-fe5d-4961-942c-d19f84ae5516">P7Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_ddead929-9307-4f06-a8f6-718bdcb2cf0c"
      decimals="-1"
      id="F_40fd4290-5b26-4bc2-bf1f-5232699a865c"
      unitRef="U_USD">43010.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_ddead929-9307-4f06-a8f6-718bdcb2cf0c"
      decimals="INF"
      id="F_84dea0ea-4d98-4577-a1b7-75f108aac43f"
      unitRef="U_shares">3185690</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_ddead929-9307-4f06-a8f6-718bdcb2cf0c"
      decimals="2"
      id="F_d82e30f8-04c5-491b-bb0c-810d136b41d9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_55abfe7d-fa2b-408a-b618-f79551bab538"
      id="F_9cfc0fcd-5ae7-4364-a725-d98dcf40f5d0">P6Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_ddead929-9307-4f06-a8f6-718bdcb2cf0c"
      decimals="-1"
      id="F_e8f42a0b-841a-4ea1-99e9-10b9969ffe4c"
      unitRef="U_USD">31040.00</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_ddead929-9307-4f06-a8f6-718bdcb2cf0c"
      decimals="INF"
      id="F_db1b95c2-97a1-4697-a5ba-21878210fabd"
      unitRef="U_shares">7737595</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_ddead929-9307-4f06-a8f6-718bdcb2cf0c"
      decimals="2"
      id="F_2e464b65-0f79-4090-9fee-616d2910c4f7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">26.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_55abfe7d-fa2b-408a-b618-f79551bab538"
      id="F_c57af64b-5e92-47db-85ed-3f1693fc535b">P7Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_ddead929-9307-4f06-a8f6-718bdcb2cf0c"
      decimals="-1"
      id="F_e3983e64-844b-4ce1-8061-5b93361d89f3"
      unitRef="U_USD">43010.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="2"
      id="F_e6e0913b-bfa9-4a42-a0aa-9e08617f0e08"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">29.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="2"
      id="F_cd09f81d-da43-4102-a6ac-b603a60d27f1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="2"
      id="F_28b3587a-55a9-44ea-8d40-41a37dbd1019"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-5"
      id="F_5e8599bf-80e9-49c0-89d7-c81e6a7e296e"
      unitRef="U_USD">32000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-5"
      id="F_425c0e77-22b4-455b-b7da-b19493542dc4"
      unitRef="U_USD">16900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-5"
      id="F_8cf45095-068d-4a66-aa76-1742dab9de5c"
      unitRef="U_USD">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_b3327635-f95d-42dd-9385-6f262bcd38d3"
      decimals="-5"
      id="F_b7d54c24-7863-4c1d-bd73-7e7f243dad12"
      unitRef="U_USD">90200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_2dd7a8a7-7c58-4da0-aa18-cc7c5a4f15dd"
      decimals="-5"
      id="F_c4af6d59-4e1c-48c3-a33f-9d8abba2b7b5"
      unitRef="U_USD">41100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_58d8ccd1-1e5f-44f8-82ca-defe099955a8">P2Y7M17D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      id="F_5650d4b0-2161-48e6-80c5-86e70c674e5a">P2Y7M2D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_24650691-69b4-443c-a5fe-1cedef505c7b">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair values of options were calculated using the assumptions set forth below:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.852%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:19.016%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:19.016%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:19.016%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_97b79519-0af1-4cce-8a6d-7911a10985ed"
      id="F_255345f9-e94b-4959-964f-5504d142fffc">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_7a6bc497-f228-42bb-8d0a-1e9eedd0706f"
      id="F_3c26d0d0-3579-47da-8d5c-a5ea87dde343">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      id="F_2b057fc2-207b-4832-8895-31e1bb2e4db9">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      id="F_a3f6f47e-a5da-4b8d-b608-9eeef24725bb">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="3"
      id="F_bb326032-8f5f-41b3-8c12-4c0aa8eb72e4"
      unitRef="U_pure">0.768</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="3"
      id="F_99210ad7-7bdc-4cb7-be48-1c3577338fc6"
      unitRef="U_pure">0.813</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="3"
      id="F_64a23747-5a12-4604-b9b4-4322b2df952a"
      unitRef="U_pure">0.818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="3"
      id="F_eec63890-d55e-4818-a7b5-7b3037f7e998"
      unitRef="U_pure">0.869</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="3"
      id="F_d222937f-1b4b-4d71-a648-5634e6cefe3f"
      unitRef="U_pure">0.868</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="3"
      id="F_e03a594a-29a7-42e7-9fcb-7c9a9446494b"
      unitRef="U_pure">0.899</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="3"
      id="F_7b0dbd7c-352e-4316-b03b-14b391d08297"
      unitRef="U_pure">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="3"
      id="F_6dd8e6b3-d756-4aee-a528-a37f59db7bcc"
      unitRef="U_pure">0.047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="3"
      id="F_4433110f-3326-47ba-8279-8ddd9c337e6e"
      unitRef="U_pure">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="3"
      id="F_fb09d136-59a2-43f2-845f-82830f67f473"
      unitRef="U_pure">0.048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="3"
      id="F_1f4d4f2e-6f01-4e98-9829-d69b1fce88d1"
      unitRef="U_pure">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="3"
      id="F_a5f89dc2-f719-4cf6-94a0-5213d2ee3802"
      unitRef="U_pure">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="2"
      id="F_3d8ca389-63f5-4ef2-9907-f129a755eb7f"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="2"
      id="F_0e73aa34-877c-4ace-9c7b-a29011fa145b"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="2"
      id="F_45b088ce-7f6c-42ee-b13c-8da7d4f4e080"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="2"
      id="F_04c3e5ff-b7d2-4e87-83a1-2d54e9393743"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_6727c40e-7871-4bd9-8481-f197d8fa5773">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_844c441e-d0df-47ff-ad62-6049ced8846c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. Significant Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;GSK Collaboration, Option and License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2020, the Company entered into the Collaboration, Option and License Agreement (the &#x201c;GSK Collaboration Agreement&#x201d;), with an affiliate of GSK plc, GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED (&#x201c;GSK&#x201d;), pursuant to which the Company and GSK have entered into a collaboration for its synthetic lethality programs targeting MAT2A, Pol Theta and Werner Helicase (&#x201c;WRN&#x201d;). On July 27, 2020, the Company and GSK received Hart-Scott-Rodino Antitrust Improvements Act clearance, and the GSK Collaboration Agreement became effective.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the GSK Collaboration Agreement, GSK paid the Company $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million on July 31, 2020. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, GSK has made aggregate payments in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the achievement of certain development and regulatory milestones with respect to Pol Theta and WRN products.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;GSK Collaboration - Pol Theta Program&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the GSK Collaboration Agreement, GSK holds a global, exclusive license to develop and commercialize Pol Theta products arising out of the Pol Theta program. The Company and GSK collaborated on preclinical research for the Pol&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Theta program, and GSK is leading clinical development for the Pol Theta program. GSK is responsible for all research and development costs for the Pol Theta program.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company will be eligible to receive total development and regulatory milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;485.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, with respect to each Pol Theta product, including as applicable, for multiple Pol Theta products that target certain alternative protein domains or are based on alternative modalities. Additionally, the Company will be eligible to receive up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;475.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of commercial milestones with respect to each Pol Theta product. The Company is also entitled to receive tiered royalties on global net sales of Pol Theta products by GSK, its affiliates and their sublicensees ranging from high single digit to sub-teen double-digit percentages, subject to certain customary reductions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2022, the Company announced the nomination of a Pol Theta Helicase Inhibitor development candidate (&#x201c;DC&#x201d;), and in August 2022, the Company announced the achievement of an initial preclinical development milestone in connection with ongoing investigational new drug (&#x201c;IND&#x201d;)-enabling studies to support evaluation of Pol Theta Helicase Inhibitor DC, triggering a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone payment, which the Company received in October 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;An IND was submitted and was cleared by the FDA in August 2023 to enable clinical evaluation in combination with niraparib, triggering a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone payment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has the potential to achieve an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million development milestone upon initiation of Phase 1 clinical dose expansion, as well as potential further aggregate late-stage development and regulatory milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;465.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;GSK Collaboration - Werner Helicase Program&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the GSK Collaboration Agreement, GSK holds a global, exclusive license to develop and commercialize WRN products arising out of the WRN program. The Company and GSK are collaborating on ongoing preclinical research for the WRN program, and GSK will lead clinical development for the WRN program, with the Company responsible for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and GSK responsible for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of such global research and development costs. The cost-sharing percentages will be adjusted based on the actual ratio of U.S. to global profits for WRN products, as measured three and six years after global commercial launch thereof.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company will be eligible to receive total development milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;485.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, with respect to each WRN product, including as applicable, for multiple WRN products that are based on alternative modalities. Additionally, the Company will be eligible to receive up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;475.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of commercial milestones with respect to each WRN product. The Company will be entitled to receive &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of U.S. net profits and tiered royalties on global non-U.S. net sales of WRN products by GSK, its affiliates and their sublicensees ranging from high single digit to sub-teen double-digit percentages, subject to certain customary reductions. The Company will have a right to opt-out of the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% U.S. net profit share and corresponding research and development cost share for the WRN program, and would be eligible to receive tiered royalties on U.S. net sales of WRN products by GSK, its affiliates and their sublicensees at the same royalty rates as for global non-U.S. net sales thereafter, with economic adjustments based on the stage of the WRN program at the time of opt-out.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2023, the Company earned a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone from GSK in connection with IND-enabling studies for the Werner Helicase Inhibitor DC.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2024, an IND was cleared by the FDA to enable clinical evaluation, triggering a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone payment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has the potential to earn up to an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million development milestone upon initiation of Phase 1 clinical dose expansion, as well as potential further aggregate late-stage development and regulatory milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;465.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;GSK Collaboration - General&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the GSK Collaboration Agreement, subject to certain exceptions, the Company and GSK will not, directly or through third parties, develop or commercialize other products whose primary and intended mechanism of action is the modulation of WRN or Pol Theta for an agreed upon period of time. The Company and GSK have formed a joint steering committee, joint development committees, and joint commercialization committees responsible for coordinating all activities under the GSK Collaboration Agreement. Ownership of intellectual property developed under the GSK Collaboration Agreement is allocated between or shared by the parties depending on development and subject matter.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;GSK&#x2019;s royalty obligations continue with respect to each country and each product until the later of (i) the date on which such product is no longer covered by certain intellectual property rights in such country and (ii) the 10th anniversary of the first commercial sale of such product in such country.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Each party has the right to sublicense its rights under the GSK Collaboration Agreement subject to certain conditions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The GSK Collaboration Agreement will continue in effect on a product-by-product and country-by-country basis until the expiration of the obligation to make payments under the GSK Collaboration Agreement with respect to such product in each country, unless earlier terminated by either party pursuant to its terms. Either party may terminate the GSK Collaboration Agreement for the other party&#x2019;s insolvency or certain uncured breaches. The Company may terminate the GSK Collaboration Agreement if GSK or any of its sublicensees or affiliates challenge certain patents of the Company. GSK may terminate the GSK Collaboration Agreement in its entirety or on a target-by-target basis upon &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;90-day&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; notice to the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Novartis License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2018, the Company entered into a License Agreement with Novartis to develop and commercialize Novartis&#x2019; LXS196 (also known as IDE196), a Phase 1 PKC inhibitor, for the treatment of cancers having GNAQ and GNA11 mutations. The Company renamed Novartis&#x2019; LXS196 oncology as IDE196, and which has a non-proprietary name of darovasertib. Under the license agreement, Novartis granted to the Company a worldwide, exclusive, sublicensable license to research, develop, manufacture, and commercialize certain defined compounds and products, including IDE196 and certain other PKC inhibitors, as well as companion diagnostic products, collectively referred to as the licensed products, for any purpose.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company paid Novartis an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;263,615&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its Series B redeemable convertible preferred stock concurrently with the execution of the license agreement. Subject to completion of certain clinical and regulatory development milestones, the Company agreed to make milestone payments in the aggregate of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and subject to achievement of certain commercial sales milestones, the Company agreed to make milestone payments in the aggregate of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Company also agreed to pay mid to high single-digit tiered royalty payments based on annual worldwide net sales of licensed products, payable on a licensed product-by-licensed product and country by country basis until the latest of the expiration of the last to expire exclusively licensed patent, the expiration of regulatory exclusivity, and the ten year anniversary of the first commercial sale of such product in such country. The royalty payments are subject to reductions for lack of patent coverage, loss of market exclusivity, and payment obligations for third-party licenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Pfizer Clinical Trial Collaboration and Supply Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2020, the Company entered into a Clinical Trial Collaboration and Supply Agreement with Pfizer, Inc. (as amended in September 2020, April 2021, September 2021 and May 2023 (the &#x201c;Pfizer Agreement&#x201d;). Pursuant to the Pfizer Agreement, Pfizer supplies the Company with their MEK inhibitor, binimetinib, and their cMET inhibitor, crizotinib, to evaluate combinations of darovasertib independently with each of the Pfizer compounds, in patients with tumors harboring activating GNAQ or GNA11 mutations. Under the Pfizer Agreement, the Company is the sponsor of the combination studies and will provide darovasertib and pay for the costs of the combination studies. Pfizer will provide binimetinib and crizotinib for use in the clinical trial at no cost to the Company. The Pfizer Agreement provides that the Company and Pfizer will jointly own clinical data generated from the clinical trial and will also jointly own inventions, if any, relating to the combined use of darovasertib and binimetinib, or independently, to the combined use of darovasertib and crizotinib. The Company and Pfizer have formed a joint development committee responsible for coordinating all regulatory and other activities under the agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2022, the Company and Pfizer entered into a Second Clinical Trial Collaboration and Supply Agreement (as amended in May 2023 (the &#x201c;Second Pfizer Agreement&#x201d;), pursuant to which the Company is evaluating darovasertib and crizotinib as a combination therapy in MUM in a planned Phase 2/3 potential registration-enabling clinical trial. Pursuant to the Second Pfizer Agreement, the Company is the sponsor of the combination trial and the Company will provide darovasertib and pay for the costs of the combination trial, and Pfizer will provide crizotinib for the planned combination trial at no cost to the Company for up to an agreed-upon number of MUM patients. The Company and Pfizer will jointly own clinical data from the planned combination trial and all inventions relating to the combined use of darovasertib and crizotinib. The Company and Pfizer have formed a joint development committee responsible for coordinating all regulatory and other activities under the Second Pfizer Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Separately, in March 2022, the Company and Pfizer also entered into a Third Clinical Trial Collaboration and Supply Agreement (the &#x201c;Third Pfizer Agreement&#x201d;), pursuant to which the Company could, subject to preclinical validation and FDA feedback and guidance, evaluate darovasertib and crizotinib, as a combination therapy in cMET-driven tumors such as NSCLC and/or HCC in a Phase 1 clinical trial. Pursuant to the Third Pfizer Agreement, the Company was the sponsor of the planned combination trial, and the Company would provide darovasertib and pay for the costs of the combination trial. Pfizer would provide crizotinib for the planned combination trial at no cost to the Company. Pursuant to Amendment No. 1 to the Second Pfizer Agreement, as described below, the Company and Pfizer terminated the Third Pfizer Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2023, the Company continued its relationship with Pfizer by entering into Amendment No. 4 to the Pfizer Agreement relating to the supply of crizotinib in support of this Phase 2 clinical trial, pursuant to which Pfizer will continue to provide the Company with an additional defined quantity of crizotinib at no cost.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company expanded its relationship with Pfizer in May 2023 under an Amendment No. 1 to the Second Pfizer Agreement to support the Phase 2/3 registrational trial to evaluate darovasertib and crizotinib as a combination therapy in MUM. Under the as-amended Second Pfizer Agreement, Pfizer will provide the Company with a first defined quantity of crizotinib at no cost, as well as an additional second defined quantity of crizotinib at a lump-sum cost. The Third Pfizer Agreement has been terminated by the Company and Pfizer under Amendment No. 1 to the Second Pfizer Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2024, we entered into Amendment No. 5 to the Pfizer Agreement for the supply of crizotinib in the Phase 1/2 clinical trial for Pfizer to provide us a defined quantity of crizotinib at defined costs.&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cancer Research UK and University of Manchester Exclusive Option and License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In January 2022, the Company exercised its option for an exclusive worldwide license covering a broad class of poly (ADP-ribose) glycohydrolase (&#x201c;PARG&#x201d;), inhibitors from Cancer Research Technology Ltd. (&#x201c;CRT&#x201d;), and the University of Manchester, and in connection therewith, paid a one-time option exercise fee of &#xa3;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company will be obligated to make payments to CRT aggregating up to a total of &#xa3;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon the achievement of specific development and regulatory approval events for development of a PARG inhibitor in oncologic diseases. The Company will also pay low single-digit tiered royalties, and potentially also sales-based milestones, to CRT based on net sales of licensed products. In addition, in the event the Company sublicenses the intellectual property, it will also be obligated to pay CRT a specified percentage of any sublicense revenue.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In April 2023, the Company incurred an obligation to pay milestone payments in an aggregate amount of &#xa3;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;750,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to CRT based upon the achievement of certain milestones relating to first and second tumor histologies in connection with the Phase 1 portion of the Phase 1/2 clinical trial in oncologic diseases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company will be obligated to make additional payments to CRT aggregating up to &#xa3;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon the achievement of specific development and regulatory approval events for development of a PARG inhibitor in oncologic diseases, including an aggregate of up to &#xa3;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and up to &#xa3;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the achievement of certain Phase 2 and Phase 3 development milestones, respectively, in each case as relating to first and second tumor histologies.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Amgen Clinical Trial Collaboration and Supply Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2022, the Company entered into a Clinical Trial Collaboration and Supply Agreement with Amgen Inc.(the &#x201c;Amgen CTCSA&#x201d;), to clinically evaluate IDE397 in combination with AMG 193, the Amgen investigational MTA-cooperative PRMT5 inhibitor, in patients having MTAP-null solid tumors, in a Phase 1/2 clinical trial. Under the mutually non-exclusive Amgen CTCSA, the Company will provide IDE397 drug supply to Amgen, who will be the sponsor of the Phase 1 clinical combination trial evaluating IDE397 and AMG 193. Each party will pay for fifty percent (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%) of the external third-party costs of the combination study. Each party will be responsible for its own internal costs and expenses in support of the combination study. The Company and Amgen will jointly oversee clinical development of the combination therapy through a Joint Oversight Committee responsible for coordinating all regulatory and other activities under the Amgen CTCSA. The parties will jointly own collaboration data and combination-related intellectual property, if any, arising from the combination clinical trial. The Company and Amgen each retain commercial rights to its respective compounds, including with respect to use as a monotherapy agent or combination agent. The Company and Amgen mutually agreed to wind down the IDE397 and AMG 193 clinical combination study in February 2025 and will not pursue dose expansion.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Gilead Clinical Study Collaboration and Supply Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the Company entered into a Clinical Study Collaboration and Supply Agreement with Gilead Sciences, Inc. (&#x201c;Gilead&#x201d;), (&#x201c;Gilead CSCSA&#x201d;), to clinically evaluate IDE397 in combination with Trodelvy (sacacituzumab-govitecan-hziy), a Trop-2 directed ADC, in patients having MTAP-deletion urothelial cancer, in a Phase 1 clinical trial. Under the mutually non-exclusive Gilead CSCSA, the Company will receive Trodelvy drug supply from Gilead and will sponsor the Phase 1 clinical combination trial evaluating ID397 and Trodelvy. Gilead will bear internal or external costs incurred in connection with its supply of Trodelvy. The Company will bear all internal and external costs and expenses associated with the conduct of the combination study. The Company and Gilead will jointly oversee clinical development of the combination therapy through a Joint Steering Committee responsible for coordinating all regulatory and other activities under the Gilead CSCSA. The Company and Gilead each retain commercial rights to its respective compounds, including with respect to use as a monotherapy agent or combination agent.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 12, 2025, the Company entered into an additional Clinical Study Collaboration and Supply Agreement with Gilead, or the Second Gilead CSCSA, pursuant to which the Company and Gilead will collaborate on a portion of the Company&#x2019;s Phase 1 study for the clinical evaluation of our IDE397 compound in combination with Trodelvy, or the Combination Study, in certain patients with advanced solid tumors in lungs. Pursuant to the Second Gilead CSCSA, the Company is the sponsor of the Combination Study and the Company will provide the IDE397 compound and pay for the costs of the Combination Study. Gilead will provide Trodelvy for the Combination Study at no cost to the Company. The Company and Gilead will jointly own clinical data from the Combination Study and all inventions relating to the combined use of IDE397 and Trodelvy. Each party retains commercial rights to its respective compounds, including with respect to use as a monotherapy or combination agent. The Company and Gilead will form a joint steering committee responsible for coordinating all regulatory and other activities under the Second Gilead CSCSA.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Merck Clinical Trial Collaboration and Supply Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2024, the Company entered into a Clinical Trial Collaboration and Supply Agreement (&#x201c;Merck CTCSA&#x201d;), with Merck (known as MSD outside of the United States and Canada) to evaluate the combination of IDE161 with Merck&#x2019;s anti-PD-1 therapy, KEYTRUDA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (pembrolizumab), in patients with high microsatellite instability (&#x201c;MSI-High&#x201d;) and microsatellite stable (&#x201c;MSS&#x201d;) endometrial cancer. Pursuant to the Merck CTCSA, the Company is the sponsor of the combination study, and the Company will provide the IDE161 compound and pay for the costs of the combination study. Merck will provide KEYTRUDA at no cost to the Company. The Company and Merck will jointly own clinical data from the combination. Each party retains commercial rights to its respective compounds, including with respect to use as a monotherapy or combination agent.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Biocytogen Option and License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2024, the Company entered into an Option and License Agreement (the &#x201c;Biocytogen Option and License Agreement&#x201d;), pursuant to which Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (&#x201c;Biocytogen&#x201d;), granted us an option for an exclusive worldwide license from Biocytogen to develop and commercialize products in connection with a potential first-in-class B7H3/PTK7 topoisomerase-I-inhibitor-payload BsADC program (the &#x201c;Option&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the Biocytogen Option and License Agreement, the Company paid Biocytogen an upfront fee and, upon the Company&#x2019;s potential exercise of the Option, an exercise fee totaling up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Option is exercisable by the Company within a specified time period after the Company obtains all data and results from certain non-GLP toxicology studies specified in the Biocytogen Option and License Agreement, which the Company will conduct at its own cost. Subject to the Company&#x2019;s exercise of the Option, Biocytogen will be eligible to receive an option exercise fee, development and regulatory milestone payments and commercial milestone payments, as well as low to mid single-digit royalties on net sales. Total potential milestone payments equal an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;400.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, including development and regulatory milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Hengrui Pharma License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2024, the Company entered into an exclusive License Agreement (the &#x201c;Hengrui Pharma License Agreement&#x201d;) with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (&#x201c;Hengrui Pharma&#x201d;), pursuant to which Hengrui Pharma granted the Company an exclusive worldwide license outside of Greater China, for IDE849 (SHR-4849), a potential first-in-class Phase 1 DLL3 TOP1i ADC. Under the terms of the Hengrui Pharma License Agreement, Hengrui Pharma is eligible to receive upfront and milestone payments totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.045&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion, including a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upfront fee, up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in development and regulatory milestone payments, plus commercial success-based milestones. Hengrui Pharma is also eligible to receive mid-single to low-double digit royalties on net sales outside of Greater China.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <idya:UpfrontPayment
      contextRef="C_c78e44e9-bd4d-4c0a-9c26-f931942fb9cd"
      decimals="-5"
      id="F_8c3e18ed-d7b4-4cfc-b2e5-a9211b3a4f91"
      unitRef="U_USD">100000000</idya:UpfrontPayment>
    <idya:DevelopmentAndRegulatoryMilestonePaymentToBeReceived
      contextRef="C_d9ee7a65-84e7-461b-a9c8-917f6e54722e"
      decimals="-5"
      id="F_e5d99eb3-94ca-49b9-9719-d796ab928595"
      unitRef="U_USD">20000000</idya:DevelopmentAndRegulatoryMilestonePaymentToBeReceived>
    <idya:DevelopmentAndRegulatoryMilestonePaymentToBeReceived
      contextRef="C_80a30d44-ed50-40c7-8625-d5e98146ade0"
      decimals="-5"
      id="F_8003a83a-d11e-4b99-a165-d76b4743b01a"
      unitRef="U_USD">485000000</idya:DevelopmentAndRegulatoryMilestonePaymentToBeReceived>
    <idya:CommercialMilestonePaymentToBeReceived
      contextRef="C_80a30d44-ed50-40c7-8625-d5e98146ade0"
      decimals="-5"
      id="F_f1b38e9e-4b75-4d78-9f6a-91475ed30f53"
      unitRef="U_USD">475000000</idya:CommercialMilestonePaymentToBeReceived>
    <idya:MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone
      contextRef="C_f7b6061f-1a70-4f34-9ba6-8614c500e543"
      decimals="-5"
      id="F_7e7d8264-36eb-4fbd-8cb2-b5bf2b702ba4"
      unitRef="U_USD">3000000</idya:MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone>
    <idya:MilestonePaymentReceivedClinicalEvaluation
      contextRef="C_10a02746-ad3a-4e28-acc1-fe5727c8d092"
      decimals="-5"
      id="F_f262b159-2c4c-4ba4-a984-4a93769ca1d7"
      unitRef="U_USD">7000000</idya:MilestonePaymentReceivedClinicalEvaluation>
    <idya:AdditionalPaymentOfDevelopmentMilestoneToAchieve
      contextRef="C_b89b606e-379c-490c-b2c7-22e9477ad049"
      decimals="-5"
      id="F_aff19281-239c-4c53-abb7-1b3008a302c1"
      unitRef="U_USD">10000000</idya:AdditionalPaymentOfDevelopmentMilestoneToAchieve>
    <idya:DevelopmentMilestonePaymentToBeReceived
      contextRef="C_bbfe6a5e-e0cb-482c-8581-bd5e60a751e6"
      decimals="-5"
      id="F_9f99dbab-3917-4ab6-845e-02f2bc24ff48"
      unitRef="U_USD">465000000</idya:DevelopmentMilestonePaymentToBeReceived>
    <idya:DevelopmentCostsSharingPercentage
      contextRef="C_28484219-22fe-452a-8a69-2ba6d3d5a00e"
      decimals="2"
      id="F_a8519932-8b60-44d2-8b1a-5c112ece19c4"
      unitRef="U_pure">0.20</idya:DevelopmentCostsSharingPercentage>
    <idya:DevelopmentCostsSharingPercentage
      contextRef="C_ef94d34b-8101-44d9-aaaf-b044579ff409"
      decimals="2"
      id="F_b7dcc78b-0a07-47ba-b96c-286f5acfac1b"
      unitRef="U_pure">0.80</idya:DevelopmentCostsSharingPercentage>
    <idya:DevelopmentMilestonePaymentToBeReceived
      contextRef="C_1b812d03-ff06-4951-b51d-8d95f0881594"
      decimals="-5"
      id="F_b03eae25-d2f1-4ae8-8ce7-f614d486a976"
      unitRef="U_USD">485000000</idya:DevelopmentMilestonePaymentToBeReceived>
    <idya:CommercialMilestonePaymentToBeReceived
      contextRef="C_1b812d03-ff06-4951-b51d-8d95f0881594"
      decimals="-5"
      id="F_9399999a-a141-491d-8ef7-1c1aeb997b8e"
      unitRef="U_USD">475000000</idya:CommercialMilestonePaymentToBeReceived>
    <idya:PercentageOfProfitShare
      contextRef="C_28484219-22fe-452a-8a69-2ba6d3d5a00e"
      decimals="2"
      id="F_fefae537-a83f-45ca-b3c6-41eeaa605e0e"
      unitRef="U_pure">0.50</idya:PercentageOfProfitShare>
    <idya:PercentageOfProfitShare
      contextRef="C_28484219-22fe-452a-8a69-2ba6d3d5a00e"
      decimals="2"
      id="F_802eb252-cf44-456c-8ec4-4e24939e44bb"
      unitRef="U_pure">0.50</idya:PercentageOfProfitShare>
    <idya:MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone
      contextRef="C_7bf84ed4-93bd-4eeb-804c-d7cf2b19b16a"
      decimals="-5"
      id="F_80cd813e-ff9d-4092-afa4-f45d075578c4"
      unitRef="U_USD">3000000</idya:MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone>
    <idya:MilestonePaymentReceivedClinicalEvaluation
      contextRef="C_274ca130-dad0-4940-9133-f4b57bf70ddb"
      decimals="-5"
      id="F_f8f1d468-3459-44e0-aa61-28c3f11802c6"
      unitRef="U_USD">7000000</idya:MilestonePaymentReceivedClinicalEvaluation>
    <idya:EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive
      contextRef="C_4e5c2597-3aa6-4e75-84f5-fcacb80ec75e"
      decimals="-5"
      id="F_9ea88544-0268-41ed-a000-6b7524707fdc"
      unitRef="U_USD">10000000</idya:EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive>
    <idya:DevelopmentMilestonePaymentToBeReceived
      contextRef="C_5c3703b4-36c2-48ab-aecf-7f7732bf9bb6"
      decimals="-5"
      id="F_19917227-f47b-454c-a1ab-e67a16e33c59"
      unitRef="U_USD">465000000</idya:DevelopmentMilestonePaymentToBeReceived>
    <idya:NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement
      contextRef="C_3ccc9e3e-a98d-4222-a5ff-8d2e28d0cadc"
      id="F_b50c8ecf-ba75-42fc-bc84-2225cb7db106">P90D</idya:NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement>
    <idya:UpfrontPayment
      contextRef="C_017e85c7-1596-4e8e-927b-df535668349a"
      decimals="-5"
      id="F_bed24b04-64a5-4d50-b9f3-12724dea9086"
      unitRef="U_USD">2500000</idya:UpfrontPayment>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_5eba0c16-aaa5-49a4-a81d-b173390ca4d4"
      decimals="INF"
      id="F_d5e357be-c470-40da-b8d9-5b85a382222a"
      unitRef="U_shares">263615</us-gaap:PreferredStockSharesIssued>
    <idya:DevelopmentAndRegulatoryMilestonePaymentToBePaid
      contextRef="C_3fb19a67-7108-4959-9367-f31f87dee14d"
      decimals="-5"
      id="F_b4ef4e61-9efe-4c11-8f41-53472322b616"
      unitRef="U_USD">9000000</idya:DevelopmentAndRegulatoryMilestonePaymentToBePaid>
    <idya:CertainCommercialSalesMilestonesPaymentToBePaid
      contextRef="C_3fb19a67-7108-4959-9367-f31f87dee14d"
      decimals="-5"
      id="F_70e1c525-ba7e-4da8-a253-58a1adb4a80f"
      unitRef="U_USD">20000000</idya:CertainCommercialSalesMilestonesPaymentToBePaid>
    <idya:PaymentOfOneTimeOptionExerciseFee
      contextRef="C_7415a7a9-5eb5-4ea2-a045-27af19dae8bb"
      decimals="0"
      id="F_0d7c7374-26e6-44a0-8afb-c8212b81d7ef"
      unitRef="U_GBP">250000</idya:PaymentOfOneTimeOptionExerciseFee>
    <idya:PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents
      contextRef="C_7415a7a9-5eb5-4ea2-a045-27af19dae8bb"
      decimals="-5"
      id="F_f13c487a-e61d-499e-91a1-a39e9a1c43ce"
      unitRef="U_GBP">19500000</idya:PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents>
    <idya:MilestonePaymentsRelatingToFirstAndSecondTumorHistologies
      contextRef="C_20bb6b78-a1c7-4e02-a061-317ab08cbf4f"
      decimals="0"
      id="F_4e7c8415-d3be-497b-921f-80b866481d1a"
      unitRef="U_GBP">750000</idya:MilestonePaymentsRelatingToFirstAndSecondTumorHistologies>
    <idya:AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent
      contextRef="C_66c2d5d4-7a3c-49b2-bb70-145a6e9b9b23"
      decimals="-4"
      id="F_161e2a25-227f-4c0d-9f38-a91141a51f56"
      unitRef="U_GBP">18750000</idya:AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent>
    <idya:DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies
      contextRef="C_66c2d5d4-7a3c-49b2-bb70-145a6e9b9b23"
      decimals="-5"
      id="F_925843f1-6f81-4cce-a1e2-4c4dfe63ccc8"
      unitRef="U_GBP">1500000</idya:DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies>
    <idya:DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies
      contextRef="C_66c2d5d4-7a3c-49b2-bb70-145a6e9b9b23"
      decimals="2"
      id="F_ed855863-8f3b-4bde-bc3f-1050ebee99eb"
      unitRef="U_GBP">2.25</idya:DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies>
    <idya:PayForExternalThirdPartyCostPercentage
      contextRef="C_e952c7de-9670-4b9f-bbd9-0381bf16deb8"
      decimals="2"
      id="F_2a475eee-2c1b-4af5-a79b-4a43baf78a1f"
      unitRef="U_pure">0.50</idya:PayForExternalThirdPartyCostPercentage>
    <idya:PaymentOfOptionExerciseFee
      contextRef="C_6d1a7946-4210-4f48-afb5-2b7ec9271ed6"
      decimals="-5"
      id="F_ecda83c4-0c53-45da-a8b2-83264429f216"
      unitRef="U_USD">6500000</idya:PaymentOfOptionExerciseFee>
    <idya:AggregatePotentialMilestonePayments
      contextRef="C_67f86cd1-0ddf-496c-b21f-48df8bce456d"
      decimals="-5"
      id="F_189358fe-824b-461e-9453-61e1e46f46bc"
      unitRef="U_USD">400000000</idya:AggregatePotentialMilestonePayments>
    <idya:DevelopmentAndRegulatoryMilestonePaymentToBeReceived
      contextRef="C_67f86cd1-0ddf-496c-b21f-48df8bce456d"
      decimals="-5"
      id="F_adb6a0eb-071a-4873-bf01-0b30fb9f2941"
      unitRef="U_USD">100000000</idya:DevelopmentAndRegulatoryMilestonePaymentToBeReceived>
    <idya:TotalMilestonePaymentToBeReceived
      contextRef="C_1894684a-f942-4a64-aebe-705ed6473dad"
      decimals="-6"
      id="F_e995e9e8-9ca1-4f59-b8e0-0effe654e908"
      unitRef="U_USD">1045000000.000</idya:TotalMilestonePaymentToBeReceived>
    <idya:UpfrontFeePayment
      contextRef="C_1894684a-f942-4a64-aebe-705ed6473dad"
      decimals="-5"
      id="F_ce00a065-81dd-4e89-bd90-ed3a1bc523be"
      unitRef="U_USD">75000000</idya:UpfrontFeePayment>
    <idya:DevelopmentAndRegulatoryMilestonePaymentToBeReceived
      contextRef="C_1894684a-f942-4a64-aebe-705ed6473dad"
      decimals="-5"
      id="F_7ddfd232-621d-456d-bdcd-64feeba6bd99"
      unitRef="U_USD">200000000</idya:DevelopmentAndRegulatoryMilestonePaymentToBeReceived>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_e40856dd-f0cc-47e6-8193-50d7add41b3d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes revenue in accordance with ASC 606 for the GSK Collaboration Agreement (see No. 10, Significant Agreements).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents revenue disaggregated by research program (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;MAT2A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pol Theta&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;WRN&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total collaboration revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company identified the following &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;six&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; performance obligations associated with the GSK Collaboration Agreement:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(i)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Preclinical and Phase 1 Monotherapy clinical research and development services under the MAT2A program (&#x201c;MAT2A R&amp;amp;D Services&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(ii)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Preclinical research services and the related license to IDEAYA-owned technology under the Pol Theta program (&#x201c;Pol Theta R&amp;amp;D Services&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(iii)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Preclinical research services and the related license to IDEAYA-owned technology under the WRN program (&#x201c;WRN R&amp;amp;D Services&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(iv)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Material right associated with the option to license IDEAYA-owned technology under the MAT2A program (&#x201c;Option&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(v)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Material right associated with the option to license to IDEAYA-owned technology under the MAT2A program to the extent necessary for preclinical activities in preparation for the MAT2A Combination Trial (&#x201c;Preclinical MAT2A License&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(vi)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Material right associated with the supply of MAT2A product for the MAT2A Combination Trial (&#x201c;MAT2A Supply&#x201d;) &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;With respect to the Pol Theta and WRN programs, the Company identified two promises: (1) granting of the license to develop and commercialize Pol Theta and WRN products, respectively, and (2) the preclinical research services. The Company determined that these two promises are not distinct within the context of the contract.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognized revenue related to amounts allocated to the MAT2A R&amp;amp;D services as the underlying services were performed over the period through the delivery of the Option data package, which is generated from its conduct of the dose escalation portion of the MAT2A Phase 1 monotherapy clinical trial. The Company used its internal research and development capability and also engaged third-party clinical research organizations (&#x201c;CROs&#x201d;), for which the Company acted as a principal. The Company delivered the Option data package to GSK. Accordingly, the performance obligation related to the MAT2A R&amp;amp;D services was fulfilled.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognized revenue related to amounts allocated to the Pol Theta R&amp;amp;D Services and WRN R&amp;amp;D Services as the underlying services were performed over the period through the completion of the Pol Theta and WRN preclinical research programs, respectively. Within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; days from the end of each calendar quarter, GSK reimbursed the Pol Theta program costs incurred by the Company. Within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; days from the end of each calendar quarter, the Company and GSK determined the amounts of WRN program costs incurred by both parties and the net amount owed by GSK to the Company or by the Company to GSK, which was paid within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; days from such determination by a reimbursing party. The Company used its internal research capability and could also engage third-party CROs in transferring the Pol Theta R&amp;amp;D services and WRN R&amp;amp;D services, for which the Company acts as a principal. The Company completed Pol Theta R&amp;amp;D services during December 2022. Accordingly, the performance obligation related to the Pol Theta R&amp;amp;D services was fulfilled. The Company completed WRN R&amp;amp;D services during December 2023. Accordingly, the performance obligation related to the WRN R&amp;amp;D services was fulfilled.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company completed all performance obligations related to the upfront payment under the GSK Collaboration Agreement as of December 31, 2023. Since December 31, 2023, the Company has no accounts receivable and no contract liabilities related to the GSK Collaboration Agreement. Because the Company completed all performance obligations, future collaboration revenue recognized under the GSK Collaboration Agreement is only related to milestone payments as they are earned.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the Pol Theta product, the Company achieved and earned a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million payment for a milestone in August 2023 based on acceptance of the IND by the FDA. An earlier preclinical development $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone payment from GSK was achieved in August 2022 in connection with ongoing IND-enabling studies to support evaluation of GSK101. The Company has the potential to receive an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone payment upon initiation of Phase 1 clinical dose expansion.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the WRN product, the Company achieved and earned a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million payment for a milestone in October 2024 based on the acceptance of the IND by the FDA. An earlier preclinical development $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million payment from GSK was achieved in October 2023 in connection with IND-enabling studies for the Werner Helicase Inhibitor DC. The Company has the potential to receive an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone payment upon initiation of Phase 1 clinical dose expansion.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Significant judgments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In applying ASC 606 to the GSK Collaboration Agreement, the Company made the following judgment that significantly affect the timing and amount of revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;(i) Determination of the transaction price, including whether any variable consideration is included at inception of the contract&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The transaction price is the amount of consideration that the Company expects to be entitled to in exchange for transferring promised goods or services to the customer. The transaction price must be determined at inception of a contract and may include amounts of variable consideration. However, there is a constraint on inclusion of variable consideration in the transaction price, if there is uncertainty at inception of the contract as to whether such consideration will be recognized in the future.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The decision as to whether or not it is probable that a significant reversal of revenue will occur in the future, depends on the likelihood and magnitude of the reversal and is highly susceptible to factors outside the Company&#x2019;s influence (for example, the Company cannot determine the outcome of clinical trials; the Company cannot determine if or when the counterparty will initiate or complete clinical trials; and the Company cannot determine if or when an regulatory agency provides any approval). In addition, the uncertainty is not expected to be resolved for a long period and finally, the Company has limited experience in the field. Therefore, at inception of the GSK Collaboration Agreement, development and regulatory milestones were fully constrained and were not included in the transaction price based on the factors noted above.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company constrains estimates of other variable consideration, such as reimbursable program costs, to amounts that are not expected to result in a significant revenue reversal in the future. The Company re-evaluates the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_a72acbd1-0d8d-4054-97f5-15b785410bbe">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents revenue disaggregated by research program (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;MAT2A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pol Theta&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;WRN&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total collaboration revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <idya:CollaborationRevenue
      contextRef="C_4e9c63ed-b84b-4dfc-8ce5-17fc94afdaed"
      decimals="-3"
      id="F_1bb3b7f2-fe33-4da2-8ecb-b5a9f0ed83db"
      unitRef="U_USD">3722000</idya:CollaborationRevenue>
    <idya:CollaborationRevenue
      contextRef="C_e3597327-9749-4444-867d-4367f5e1a23a"
      decimals="-3"
      id="F_319f6071-c30e-4f68-8114-4950f4cb3012"
      unitRef="U_USD">29756000</idya:CollaborationRevenue>
    <idya:CollaborationRevenue
      contextRef="C_2d6346e6-95ec-4b03-b74c-67593a769fb2"
      decimals="-3"
      id="F_6d244e91-bcf0-4ea6-9a58-37c350384a12"
      unitRef="U_USD">3002000</idya:CollaborationRevenue>
    <idya:CollaborationRevenue
      contextRef="C_5c8611d6-e1c9-4c75-8bf6-e818c66f5c44"
      decimals="-3"
      id="F_76033997-d658-4941-95cb-09cc85988e30"
      unitRef="U_USD">13894000</idya:CollaborationRevenue>
    <idya:CollaborationRevenue
      contextRef="C_15a7a270-9ab0-4d62-adb8-a1a7678eee8e"
      decimals="-3"
      id="F_dd088813-133d-4763-84d5-bf0bf4f879cc"
      unitRef="U_USD">7000000</idya:CollaborationRevenue>
    <idya:CollaborationRevenue
      contextRef="C_77daf335-fcd4-483d-9de0-eb33d3d8f444"
      decimals="-3"
      id="F_70278ce3-96c9-4a59-b825-5e0ab8618edb"
      unitRef="U_USD">16661000</idya:CollaborationRevenue>
    <idya:CollaborationRevenue
      contextRef="C_3ee2b473-d5b8-47db-8a39-4baf5b194b84"
      decimals="-3"
      id="F_79de0c30-df10-4fbe-89b5-8d8ab4081f8b"
      unitRef="U_USD">7281000</idya:CollaborationRevenue>
    <idya:CollaborationRevenue
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_29336a45-f71b-40de-87f6-9c50ab2c2750"
      unitRef="U_USD">7000000</idya:CollaborationRevenue>
    <idya:CollaborationRevenue
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_ef011d85-0c04-49a0-a848-fa7c3421e071"
      unitRef="U_USD">23385000</idya:CollaborationRevenue>
    <idya:CollaborationRevenue
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_9b999f70-7af3-4378-8239-718165c80312"
      unitRef="U_USD">50931000</idya:CollaborationRevenue>
    <idya:NumberOfPerformanceObligations
      contextRef="C_64b83c21-4b63-4ca9-9683-99ffc7d0f98b"
      decimals="INF"
      id="F_24249284-2402-451b-89c0-2394cd69ffa5"
      unitRef="U_Obligation">6</idya:NumberOfPerformanceObligations>
    <idya:ReimbursementPeriodOfCostsIncurred
      contextRef="C_aab90a1f-cce5-40ae-a524-bb89f7b2708e"
      id="F_6309977b-a229-404a-b61f-f049a82b4cf2">P90D</idya:ReimbursementPeriodOfCostsIncurred>
    <idya:ReimbursementPeriodOfCostsIncurred
      contextRef="C_eb95813f-4508-41df-ad29-f6eec05c524e"
      id="F_7f8bf027-da16-4ccf-9120-3c716b3fbe43">P75D</idya:ReimbursementPeriodOfCostsIncurred>
    <idya:ReimbursementPeriodOfCostsIncurred
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_37314290-60ab-44b3-933e-45480ead375b">P75D</idya:ReimbursementPeriodOfCostsIncurred>
    <idya:ReimbursementPeriodOfCostsIncurred
      contextRef="C_15a7a270-9ab0-4d62-adb8-a1a7678eee8e"
      id="F_75ca8316-12b8-4122-939c-44ffbc3e97a4">P75D</idya:ReimbursementPeriodOfCostsIncurred>
    <idya:DeterminationPeriodOfCostsIncurred
      contextRef="C_15a7a270-9ab0-4d62-adb8-a1a7678eee8e"
      id="F_eab738ef-54cb-4ac8-814b-ebc4f7f70d90">P75D</idya:DeterminationPeriodOfCostsIncurred>
    <idya:MilestonePaymentReceivedClinicalEvaluation
      contextRef="C_10a02746-ad3a-4e28-acc1-fe5727c8d092"
      decimals="-5"
      id="F_4b25168a-4683-47f0-be48-186d233ceb23"
      unitRef="U_USD">7000000</idya:MilestonePaymentReceivedClinicalEvaluation>
    <idya:MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone
      contextRef="C_f7b6061f-1a70-4f34-9ba6-8614c500e543"
      decimals="-5"
      id="F_2f9d5b42-3abc-4267-bfd3-351e58e7586c"
      unitRef="U_USD">3000000</idya:MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone>
    <idya:AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation
      contextRef="C_b89b606e-379c-490c-b2c7-22e9477ad049"
      decimals="-5"
      id="F_7be2a354-ed7f-4d54-913f-bd1cefe048ea"
      unitRef="U_USD">10000000</idya:AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation>
    <idya:MilestonePaymentReceivedClinicalEvaluation
      contextRef="C_274ca130-dad0-4940-9133-f4b57bf70ddb"
      decimals="-5"
      id="F_f080e3e0-672e-4b5b-8abf-391c98cb6a5e"
      unitRef="U_USD">7000000</idya:MilestonePaymentReceivedClinicalEvaluation>
    <idya:MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone
      contextRef="C_7bf84ed4-93bd-4eeb-804c-d7cf2b19b16a"
      decimals="-5"
      id="F_7d5d00b0-9d4a-46da-b6d8-637b148873c1"
      unitRef="U_USD">3000000</idya:MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone>
    <idya:AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation
      contextRef="C_b3aa4c0b-2b97-4391-af57-fe7af6cf0a24"
      decimals="-5"
      id="F_57923a38-06ee-4ad5-abb3-a3c23a74a0b0"
      unitRef="U_USD">10000000</idya:AdditionalMilestonePaymentPotentiallyReceivedClinicalEvaluation>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_e184d64f-efd7-47ad-b95a-a046cef2f4fd">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12. Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.091%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.902000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.902000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.902000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;274,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average shares used in computing net loss per share &lt;br/&gt;&#160;&#160;&#160;attributable to common stock, basic and diluted &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,678,069&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,519,929&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,444,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share attributable to common stockholders, basic and&lt;br/&gt;&#160;&#160;&#160;diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) The shares underlying the pre-funded warrants to purchase shares of the Company's common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the years ended December 31, 2024, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,737,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,269,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,097,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_a7e246c7-c1d3-4f8d-b320-5ebb4c62c0e1">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.091%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.902000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.902000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.902000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;274,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average shares used in computing net loss per share &lt;br/&gt;&#160;&#160;&#160;attributable to common stock, basic and diluted &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,678,069&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,519,929&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,444,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share attributable to common stockholders, basic and&lt;br/&gt;&#160;&#160;&#160;diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) The shares underlying the pre-funded warrants to purchase shares of the Company's common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the years ended December 31, 2024, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_f7a6865e-3fb7-43ef-b43f-e45dd661b53a"
      unitRef="U_USD">-274477000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_76d8dca1-a97a-4bbd-b265-2895dc92b609"
      unitRef="U_USD">-112961000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_67108300-6512-4e45-9ae9-b9acd5a7382c"
      unitRef="U_USD">-58655000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="0"
      id="F_30269d97-26fb-48c7-b60a-9771d5a0fc11"
      unitRef="U_shares">81678069</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="0"
      id="F_7d80a458-b40f-4027-90b2-b299e9a44335"
      unitRef="U_shares">81678069</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="0"
      id="F_0bcc1d51-e60a-4934-95d0-dc1789a1a3fa"
      unitRef="U_shares">57519929</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="0"
      id="F_22f08a56-525c-41ef-8a1d-594dcc63f919"
      unitRef="U_shares">57519929</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="0"
      id="F_9b1db535-e52a-43ef-bc18-31e3ea053b17"
      unitRef="U_shares">41444696</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="0"
      id="F_4530e811-668f-4476-acba-b0f12573c004"
      unitRef="U_shares">41444696</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="2"
      id="F_dc68c207-9fb0-4a1f-965b-cf0b94ae6e25"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="2"
      id="F_cdcba9d4-d81b-42cb-925c-22f35c3e1515"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="2"
      id="F_f3075692-e932-4f61-a2e0-875025234793"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="2"
      id="F_065ff17d-6fc8-4a99-89d2-18fcab64f53c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="2"
      id="F_e551de3c-3d2e-4e95-8182-56a8d0473483"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="2"
      id="F_cd9013e6-5e31-4888-805d-18b0de68e91c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_2af500a6-3bd9-4ba4-aeee-c7149d4d7629">&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,737,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,269,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,097,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0e321b30-69e1-4345-9158-2fcb284b612c"
      decimals="0"
      id="F_208f127c-9478-449c-aa5e-30e5cbc65c22"
      unitRef="U_shares">7737595</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_761fc146-6272-4882-8bef-299b24f35235"
      decimals="0"
      id="F_9925c8eb-fe3e-429a-a860-037532817c95"
      unitRef="U_shares">6269975</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_949ed0b5-4cbf-4fe7-81a6-07bd20fe4626"
      decimals="0"
      id="F_d4d51568-c0c2-413c-b70e-bad8a0a1b40b"
      unitRef="U_shares">5097263</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_12d33bd3-3bc9-446d-bf2b-b2e6e1357fd8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13. Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company operates and manages its business as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating and reportable segment, which is the business of research and development for oncology-focused precision medicine. The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) is its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_3b792965-e65d-4647-ad8c-bd3fa5a2dc19;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;President and CEO. The Company&#x2019;s measure of segment profit or loss is net income. For purposes of evaluating performance and allocating resources, the CODM reviews the financial information and evaluates net income against comparable prior periods and the Company&#x2019;s forecast. All of the Company's long-lived assets are located in the United States.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition to the significant expense categories included within net income presented on the Company's statements of operations and comprehensive loss, see below for disaggregated research and development expenses:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:41.692%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.517%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.517%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.937000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;External clinical development expenses &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Darovasertib&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;IDE397&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;IDE161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,749&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel related and stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other research and development expenses &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;158,423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;294,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;         (1)          External clinical development expenses include manufacturing and clinical trial costs. These expenses are primarily for services provided by&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;                        external consultants, CMOs and CROs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;         (2)          IDE397 includes costs from the Amgen CTCSA&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;         (3)          Other research and development expenses include manufacturing and clinical trial costs for preclinical and earlier clinical stage programs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;                       These expenses are primarily for services provided by external consultants, CMOs and CROs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="INF"
      id="F_d55681f2-cc8e-48dc-95a0-01ac6c0df60f"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="INF"
      id="F_c84d50c1-d7ba-4c65-ad11-dbf553e82398"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <idya:SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_d1ab6d26-a608-489d-a035-c374d341c93d">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition to the significant expense categories included within net income presented on the Company's statements of operations and comprehensive loss, see below for disaggregated research and development expenses:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:41.692%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.517%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.517%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.937000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;External clinical development expenses &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Darovasertib&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;IDE397&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;IDE161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,749&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel related and stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other research and development expenses &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;158,423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;294,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;         (1)          External clinical development expenses include manufacturing and clinical trial costs. These expenses are primarily for services provided by&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;                        external consultants, CMOs and CROs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;         (2)          IDE397 includes costs from the Amgen CTCSA&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;         (3)          Other research and development expenses include manufacturing and clinical trial costs for preclinical and earlier clinical stage programs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;                       These expenses are primarily for services provided by external consultants, CMOs and CROs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</idya:SummaryOfDisaggregatedResearchAndDevelopmentExpensesTableTextBlock>
    <idya:ExternalClinicalDevelopmentExpenses
      contextRef="C_35bd050f-8213-4ced-a848-8e723be54545"
      decimals="-3"
      id="F_886dc366-3806-424f-a732-1681884a3a97"
      unitRef="U_USD">55335000</idya:ExternalClinicalDevelopmentExpenses>
    <idya:ExternalClinicalDevelopmentExpenses
      contextRef="C_c6ec1b34-88b5-403e-b14c-f9db680a80a0"
      decimals="-3"
      id="F_65e74421-e916-4fcc-92a1-a16359f68107"
      unitRef="U_USD">25829000</idya:ExternalClinicalDevelopmentExpenses>
    <idya:ExternalClinicalDevelopmentExpenses
      contextRef="C_750fdeba-ea50-4e26-8f84-b154ebcc6f75"
      decimals="-3"
      id="F_2dd9cbff-475e-48e3-8d4f-d66eb889a7d2"
      unitRef="U_USD">13433000</idya:ExternalClinicalDevelopmentExpenses>
    <idya:ExternalClinicalDevelopmentExpenses
      contextRef="C_b8fed8f4-659e-48c7-a3fc-ebd4660253a2"
      decimals="-3"
      id="F_bda5e3b6-569c-46bb-ab2e-0277cba29ff0"
      unitRef="U_USD">16629000</idya:ExternalClinicalDevelopmentExpenses>
    <idya:ExternalClinicalDevelopmentExpenses
      contextRef="C_54da252c-c145-4c7e-bec2-4a22f8d0c57c"
      decimals="-3"
      id="F_bc27938b-e85f-41c8-b004-90fa5e5f7d3e"
      unitRef="U_USD">11985000</idya:ExternalClinicalDevelopmentExpenses>
    <idya:ExternalClinicalDevelopmentExpenses
      contextRef="C_46c16141-586e-4130-9e68-98823b85e056"
      decimals="-3"
      id="F_ca9dfa7a-3164-4ded-9cc1-2f3d1c7eaba6"
      unitRef="U_USD">9426000</idya:ExternalClinicalDevelopmentExpenses>
    <idya:ExternalClinicalDevelopmentExpenses
      contextRef="C_e499769c-c222-47df-bc66-3631881a62b1"
      decimals="-3"
      id="F_7e850df9-6b18-479c-889b-80fbfc2ef56a"
      unitRef="U_USD">9743000</idya:ExternalClinicalDevelopmentExpenses>
    <idya:ExternalClinicalDevelopmentExpenses
      contextRef="C_7c297d4e-8a0d-4d1f-80dc-8cc368231084"
      decimals="-3"
      id="F_ff0f72ab-5621-4ab5-956f-b108cccb013a"
      unitRef="U_USD">7104000</idya:ExternalClinicalDevelopmentExpenses>
    <idya:ExternalClinicalDevelopmentExpenses
      contextRef="C_a17848a4-d1a9-4d09-81d7-b191ed14dfd6"
      decimals="-3"
      id="F_eb20379e-66e7-467b-aec8-b9934e6ff7b2"
      unitRef="U_USD">2749000</idya:ExternalClinicalDevelopmentExpenses>
    <idya:PersonnelRelatedAndStock-BasedCompensation
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_758e51fc-322e-47eb-9241-f3824f54361c"
      unitRef="U_USD">54543000</idya:PersonnelRelatedAndStock-BasedCompensation>
    <idya:PersonnelRelatedAndStock-BasedCompensation
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_a7d051a0-1eb6-4c25-8cc3-63facf7ec491"
      unitRef="U_USD">38948000</idya:PersonnelRelatedAndStock-BasedCompensation>
    <idya:PersonnelRelatedAndStock-BasedCompensation
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_9198b3e6-7a86-4e93-8ab7-1dafb684e007"
      unitRef="U_USD">26717000</idya:PersonnelRelatedAndStock-BasedCompensation>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_64a1f060-6e7d-42f6-acdb-c89a0a360d9b"
      unitRef="U_USD">158423000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_d8f1ad2f-df3e-429b-ba92-63664b145a1e"
      unitRef="U_USD">45642000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_1623d6e3-60ed-4daa-b1b6-1b6062ee0de9"
      unitRef="U_USD">37211000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      decimals="-3"
      id="F_f12714fc-c739-4a79-94a2-96ecf96c91ba"
      unitRef="U_USD">294673000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_99b1a732-1279-4f63-b48e-5b56395593f1"
      decimals="-3"
      id="F_9a29df52-d258-4b42-b594-d801527abced"
      unitRef="U_USD">129508000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_6441389d-ead7-45d4-86d2-83922de15d96"
      decimals="-3"
      id="F_3f2703dc-de74-46df-9140-8b60bbdcfa26"
      unitRef="U_USD">89536000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_29388ec7-4754-45f1-b582-afffea61e7ad"
      id="F_aaca54fe-961c-40c7-9fa5-b5193279a915">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;14. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;At-the-Market Offering&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Subsequent to December 31, 2024, from January 1, 2025 through January 6, 2025, the Company raised aggregate net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million under the at-the-market offering pursuant to the January 2024 Sales Agreement with Jefferies as sales agent. As of January 6, 2025, approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;156.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of common stock remained available to be sold under the ATM facility.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Commencement of Expansion Premises Office Lease - South San Francisco&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company commenced the First Amendment to the Lease Agreement by and between DW LSP 5000 Shoreline, LLC and the Company in January 2025. The Company added approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,321&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; rentable square feet of additional space to expand the size of the original premises.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Clinical Study Collaboration and Supply Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 12, 2025, the Company entered into the Second Gilead CSCSA with Gilead pursuant to which the Company and Gilead will collaborate on a portion of the Phase 1 study for the clinical evaluation of IDE397 in combination with Trodelvy, or the Combination Study, in certain patients with advanced solid tumors in lungs. Pursuant to the Second Gilead CSCSA, the Company is the sponsor of the Combination Study, and the Company will provide the IDE397 compound and pay for the costs of the Combination Study.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_b82f7f69-7a56-4486-a04d-d1739f434a83"
      decimals="-5"
      id="F_6817d24d-d7a7-40fe-af64-082e011d0d1b"
      unitRef="U_USD">25100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <idya:CommonStockRemainingAvailableToBeSaleAmount
      contextRef="C_0d608e0d-30c3-491f-bc22-755d69e64cfd"
      decimals="-5"
      id="F_71e571dd-17cc-4dc3-94ca-43179cf173b8"
      unitRef="U_USD">156600000</idya:CommonStockRemainingAvailableToBeSaleAmount>
    <idya:OperatingLeasesAdditionalAreaLeased
      contextRef="C_b452a75e-2a3a-4c85-bb40-898b74dc7c1d"
      decimals="INF"
      id="F_496ddac6-6ea0-4aed-b8d9-401cc1dba41a"
      unitRef="U_sqft">11321</idya:OperatingLeasesAdditionalAreaLeased>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
